PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Dossou-Yovo, F; Mamadou, G; Soudy, ID; Limas-Nzouzi, N; Miantezila, J; Desjeux, JF; Eto, B				Dossou-Yovo, Flore; Mamadou, Godefroy; Soudy, Imar Djibrine; Limas-Nzouzi, Nicolas; Miantezila, Joe; Desjeux, Jehan-Francois; Eto, Bruno			Metronidazole or Cotrimoxazole Therapy Is Associated with a Decrease in Intestinal Bioavailability of Common Antiretroviral Drugs	PLOS ONE			English	Article							MUCOUS GEL LAYER; P-GLYCOPROTEIN; MUCIN DYNAMICS; MUCUS; PERMEABILITY; TRANSPORT; LOPINAVIR/RITONAVIR; EXPRESSION; PARAMETERS; RESISTANCE	Metronidazole (MTZ) and Cotrimoxazole (CTX) are used in HIV/AIDS patients eligible for antiretroviral treatment. The objective of this animal study was to determine whether pre-treatment with antibiotics affects the intestinal bioavailability of Atazanavir (ATV) and Ritonavir (RTV). After oral administration of 1 mg MTZ and CTX for 7 days, the rat colonic mucosa were analyzed for mucus thickness or placed in Ussing chambers to measure ATV and RTV net transepithelial fluxes (J(net)). 1. In control rats, the mucus thickness was 43.3 +/- 7.6 mu m and 40.7 +/- 6.9 mu m, in proximal and distal colon, respectively. In proximal colon, the thickness was 57.2 +/- 8.8 and 58.2 +/- 6.9 mu m after MTZ and CTX, respectively whereas in distal colon, the thickness was 121.1 +/- 38.4 and 170.5 +/- 35.0 mu m (P<0.05) respectively. 2. Transepithelial conductance was reduced after MTZ or CTX in the proximal and distal colon. 3. In control, net ATV secretion was observed both in proximal (2 0.36 +/- 0.02 mu g.hr(-1) cm(-2)) and distal colon (-0.30 +/- 0.08 mu g.hr(-1) cm(-2)). After MTZ and CTX, it was increased in the proximal colon by two 2 fold and 4 fold, respectively and in the distal colon by 3 fold and 5 fold, respectively. 4. In control, there was no net active RTV transport either in proximal (+0.01 +/- 0.01 mu g.hr(-1) cm(-2)) or distal colon (+0.04 +/- 0.01 mu g.hr(-1) cm(-2)). After MTZ and CTX, secretion was increased 5 fold and 10 fold, respectively, in the proximal colon and two fold and 5 fold, respectively in the distal colon (p<0.001). In conclusion, after MTZ and CTX therapy, the mucus layer was enlarged, passive permeability was decreased and ATV and RTV were actively secreted by the colonic epithelium suggesting that, in rat, the intestinal bioavailability of ATV and RTV is impaired after antibiotic therapy.	[Dossou-Yovo, Flore] CNAM, Biol Lab, Paris, France; [Mamadou, Godefroy; Soudy, Imar Djibrine; Limas-Nzouzi, Nicolas; Miantezila, Joe; Eto, Bruno] Univ Paris 07, Fac Med Xavier Bichat, Lab TBC TransCell Lab, Paris, France; [Soudy, Imar Djibrine] Inst Univ Sci & Tech Abeche, Ndjamena, Chad; [Desjeux, Jehan-Francois] Acad Natl Med, Paris, France	heSam Universite; Conservatoire National Arts & Metiers (CNAM); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Eto, B (corresponding author), Univ Paris 07, Fac Med Xavier Bichat, Lab TBC TransCell Lab, Paris, France.	bruno.eto@paris7.jussieu.fr		ETO, Bruno/0000-0001-9397-2690	budget of training of the laboratory TBC-Transcell-lab, faculty of medicine Xavier Bichat. University of Paris Diderot - paris7, France	budget of training of the laboratory TBC-Transcell-lab, faculty of medicine Xavier Bichat. University of Paris Diderot - paris7, France	The study was support by the budget of training of the laboratory TBC-Transcell-lab, faculty of medicine Xavier Bichat. University of Paris Diderot - paris7, France. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Belkaid Y, 2013, SCIENCE, V342, P432, DOI 10.1126/science.1246252; Chiou WL, 1996, J PHARMACOKINET BIOP, V24, P433, DOI 10.1007/BF02353521; Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008; COOK HC, 1973, MED LAB TECHNOL, V30, P217; Crommentuyn KML, 2004, CLIN INFECT DIS, V38, pE73, DOI 10.1086/382675; DARMON N, 1993, J NUTR, V123, P1068; DAWSON DC, 1978, AM J PHYSIOL, V235, pE7, DOI 10.1152/ajpendo.1978.235.1.E7; DESAI MA, 1991, J PHARM PHARMACOL, V43, P124, DOI 10.1111/j.2042-7158.1991.tb06647.x; HEYMAN M, 1980, AM J PHYSIOL, V238, pG326, DOI 10.1152/ajpgi.1980.238.4.G326; Heyman M, 2000, ANN NY ACAD SCI, V915, P304; IIBOSHI Y, 1994, JPEN-PARENTER ENTER, V18, P346, DOI 10.1177/0148607194018004346; Iiboshi Y, 1996, JPEN-PARENTER ENTER, V20, P98, DOI 10.1177/014860719602000298; Iiboshi Y, 1996, JPEN-PARENTER ENTER, V20, P406, DOI 10.1177/0148607196020006406; Johansson MEV, 2011, P NATL ACAD SCI USA, V108, P4659, DOI 10.1073/pnas.1006451107; Kageyama M, 2005, BIOL PHARM BULL, V28, P130, DOI 10.1248/bpb.28.130; Kaplan Jonathan E., 2009, Morbidity and Mortality Weekly Report, V58, P1; Korjamo T, 2009, J PHARM SCI-US, V98, P4469, DOI 10.1002/jps.21762; Larsson JMH, 2011, INFLAMM BOWEL DIS, V17, P2299, DOI 10.1002/ibd.21625; Linden SK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003952; Mathieu J, 2008, METHOD FIND EXP CLIN, V30, P591, DOI 10.1358/mf.2008.30.8.1271096; McGuckin MA, 2011, NAT REV MICROBIOL, V9, P265, DOI 10.1038/nrmicro2538; McIsaac Warren J, 2008, Can J Infect Dis Med Microbiol, V19, P287; OTA H, 1992, HISTOCHEM J, V24, P86, DOI 10.1007/BF01082444; Pelissier MA, 2006, STEROIDS, V71, P240, DOI 10.1016/j.steroids.2005.10.009; Pelissier MA, 2010, FEMS MICROBIOL ECOL, V73, P601, DOI 10.1111/j.1574-6941.2010.00916.x; Perloff MD, 2001, J PHARM SCI-US, V90, P1829, DOI 10.1002/jps.1133; Rebiere H, 2007, J CHROMATOGR B, V850, P376, DOI 10.1016/j.jchromb.2006.12.007; Rodriguez-Novoa S, 2006, PHARMACOGENOMICS J, V6, P234, DOI 10.1038/sj.tpj.6500374; SHARMA R, 1995, GUT, V36, P209, DOI 10.1136/gut.36.2.209; Sharma R, 1995, DIGEST DIS SCI, V40, P2532, DOI 10.1007/BF02220438; TAI YH, 1981, J MEMBRANE BIOL, V59, P173, DOI 10.1007/BF01875423; THOMSON ABR, 1980, AM J PHYSIOL, V239, pG372, DOI 10.1152/ajpgi.1980.239.5.G372; USSING HH, 1949, ACTA PHYSIOL SCAND, V17, P1, DOI 10.1111/j.1748-1716.1949.tb00550.x; Varum FJO, 2012, J PHARM PHARMACOL, V64, P218, DOI 10.1111/j.2042-7158.2011.01399.x; Vertzoni M, 2011, INT J PHARMACEUT, V413, P81, DOI 10.1016/j.ijpharm.2011.04.028; Vogel M, 2004, LIVER TRANSPLANT, V10, P939, DOI 10.1002/lt.20165; Zembruski NCL, 2011, J ANTIMICROB CHEMOTH, V66, P802, DOI 10.1093/jac/dkq501	37	11	12	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2014	9	2							e89943	10.1371/journal.pone.0089943	http://dx.doi.org/10.1371/journal.pone.0089943			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC3BC	24587140	Green Submitted, Green Published, gold			2023-01-03	WOS:000332389000115
J	Kamata, H; Akagi, Y; Kayasuga-Kariya, Y; Chung, U; Sakai, T				Kamata, Hiroyuki; Akagi, Yuki; Kayasuga-Kariya, Yuko; Chung, Ung-il; Sakai, Takamasa			"Nonswellable" Hydrogel Without Mechanical Hysteresis	SCIENCE			English	Article							DOUBLE-NETWORK HYDROGELS; MODULUS	Hydrogels are three-dimensional polymer networks that contain a large amount of water inside. Certain hydrogels can be injected in solution and transformed into the gel state with the required shape. Despite their potential biomedical applications, the use of hydrogels has been severely limited because all the conventional hydrogels inevitably "swell" under physiological conditions, which drastically degrades their mechanical properties. We report the synthesis of injectable "nonswellable" hydrogels from hydrophilic and thermoresponsive polymers, in which two independently occurring effects (swelling and shrinking) oppose each other. The hydrogels can endure a compressive stress up to 60 megapascals and can be stretched more than sevenfold without hysteresis. Our results demonstrate that the suppression of swelling helps retain the mechanical properties of hydrogels under physiological conditions.	[Kamata, Hiroyuki; Akagi, Yuki; Kayasuga-Kariya, Yuko; Chung, Ung-il; Sakai, Takamasa] Univ Tokyo, Sch Engn, Dept Bioengn, Bunkyo Ku, Tokyo 1138656, Japan; [Chung, Ung-il] Univ Tokyo, Sch Med, Div Clin Biotechnol, Ctr Dis Biol & Integrat Med,Bunkyo Ku, Tokyo 1130033, Japan; [Chung, Ung-il] Tokyo Univ Hosp, Div Tissue Engn, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Sakai, T (corresponding author), Univ Tokyo, Sch Engn, Dept Bioengn, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	sakai@tetrapod.t.u-tokyo.ac.jp	Kamata, Hiroyuki/AAW-9435-2020	Kamata, Hiroyuki/0000-0002-5933-8677; Sakai, Takamasa/0000-0001-5052-0512	Japan Society for the Promotion of Science (JSPS); Center for Medical System Innovation (CMSI); Graduate Program for Leaders in Life Innovation (GPLLI); International Core Research Center for Nanobio; Core-to-Core Program; A. Advanced Research Networks; Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST program); Ministry of Education, Culture, Sports, Science, and Technology in Japan (MEXT) through the Center for NanoBio Integration (CNBI); MEXT [23700555, 24240069]; Japan Science and Technology Agency (JST) through the S-innovation program; COI STREAM	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Center for Medical System Innovation (CMSI); Graduate Program for Leaders in Life Innovation (GPLLI); International Core Research Center for Nanobio; Core-to-Core Program; A. Advanced Research Networks; Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST program)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science, and Technology in Japan (MEXT) through the Center for NanoBio Integration (CNBI)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Science and Technology Agency (JST) through the S-innovation program; COI STREAM	This work was supported by the Japan Society for the Promotion of Science (JSPS) through the Grants-in-Aid for Scientific Research, the Center for Medical System Innovation (CMSI), the Graduate Program for Leaders in Life Innovation (GPLLI), the International Core Research Center for Nanobio, Core-to-Core Program, A. Advanced Research Networks, and the Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST program); the Ministry of Education, Culture, Sports, Science, and Technology in Japan (MEXT) through the Center for NanoBio Integration (CNBI) and Grants-in-Aid for Scientific Research from MEXT (23700555 to T. S. and 24240069 to U. C.); the Japan Science and Technology Agency (JST) through the S-innovation program and COI STREAM.	Appel EA, 2012, CHEM SOC REV, V41, P6195, DOI 10.1039/c2cs35264h; Chung JE, 1998, J CONTROL RELEASE, V53, P119, DOI 10.1016/S0168-3659(97)00244-7; Cui J, 2012, MACROMOLECULES, V45, P6104, DOI 10.1021/ma300593g; Gong JP, 2003, ADV MATER, V15, P1155, DOI 10.1002/adma.200304907; Haraguchi K, 2002, ADV MATER, V14, P1120, DOI 10.1002/1521-4095(20020816)14:16<1120::AID-ADMA1120>3.0.CO;2-9; Haraguchi K, 2011, MACROMOL RAPID COMM, V32, P1253, DOI 10.1002/marc.201100248; Heskins M., 1968, J MACROMOL SCI CHEM, V2, P1441; Hoffman AS, 2002, ADV DRUG DELIVER REV, V54, P3, DOI 10.1016/j.addr.2012.09.010; JANMEY PA, 1994, J BIOL CHEM, V269, P32503; Lee KY, 2001, CHEM REV, V101, P1869, DOI 10.1021/cr000108x; Li J, 2006, BIOMATERIALS, V27, P4132, DOI 10.1016/j.biomaterials.2006.03.025; Mithieux SM, 2004, BIOMATERIALS, V25, P4921, DOI 10.1016/j.biomaterials.2004.01.055; Nakajima T, 2013, SOFT MATTER, V9, P1955, DOI 10.1039/c2sm27232f; Nicodemus GD, 2008, TISSUE ENG PT B-REV, V14, P149, DOI 10.1089/ten.teb.2007.0332; OBUKHOV SP, 1994, MACROMOLECULES, V27, P3191, DOI 10.1021/ma00090a012; Okumura Y, 2001, ADV MATER, V13, P485, DOI 10.1002/1521-4095(200104)13:7<485::AID-ADMA485>3.0.CO;2-T; Phadke A, 2012, P NATL ACAD SCI USA, V109, P4383, DOI 10.1073/pnas.1201122109; Reinicke S, 2009, SOFT MATTER, V5, P2648, DOI 10.1039/b900539k; Sakai T, 2008, MACROMOLECULES, V41, P5379, DOI 10.1021/ma800476x; Storm C, 2005, NATURE, V435, P191, DOI 10.1038/nature03521; Sun JY, 2012, NATURE, V489, P133, DOI 10.1038/nature11409; Wang Q, 2010, NATURE, V463, P339, DOI 10.1038/nature08693	22	427	436	54	976	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 21	2014	343	6173					873	875		10.1126/science.1247811	http://dx.doi.org/10.1126/science.1247811			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AB1LG	24558157				2023-01-03	WOS:000331552600042
J	Jang, M; Lee, MJ; Lee, JM; Bae, CS; Kim, SH; Ryu, JH; Cho, IH				Jang, Minhee; Lee, Min Jung; Lee, Jin Moo; Bae, Chun-Sik; Kim, Sung-Hoon; Ryu, Jong Hoon; Cho, Ik-Hyun			Oriental Medicine Kyung-Ok-Ko Prevents and Alleviates Dehydroepiandrosterone-Induced Polycystic Ovarian Syndrome in Rats	PLOS ONE			English	Article							DRIED REHMANNIAE RADIX; GENE-EXPRESSION; SYNDROME PCOS; T-CELLS; WOMEN; METFORMIN; MICE; INFLAMMATION; ADOLESCENTS; INFERTILITY	Kyung-Ok-Ko (KOK), a traditional herbal prescription composed of Rehmannia glutinosa Liboschitz var. purpurae, Lycium chinense, Aquillaria agallocha, Poria cocos, Panax ginseng, and honey, has been widely used in traditional Oriental medicine as a vitalizing medicine or as the prescription for patients with age-associated disorders such as amnesia and stroke. However, the potential protective value of KOK for the treatment of polycystic ovarian syndrome (PCOS) is largely unknown. We investigated whether pre-administration (daily from 2 hours before PCOS induction) and post-administration (daily after induction of PCOS) of KOK (0.5, 1.0, and 2.0 g/kg/day, p.o.) could have a protective effect in a dehydroepiandrosterone (DHEA, s. c.)-induced PCOS rat model. Pre-administration of KOK significantly decreased the elevated body weight and ovary weight, elevated size and number of follicular cysts, elevated level of serum glucose, and estradiol after DHEA injection. KOK reduced the elevated percentage of CD8 (+) T lymphocytes in lymph nodes, the elevated mRNA expression of CD11b and CD3 in ovaries, and infiltration of macrophages in ovarian tissue with PCOS. KOK diminished the increased mRNA expression of pro-inflammatory cytokines (IL-1 beta, IL-6, TNF-alpha), chemokines (IL-8, MCP-1), and iNOS in the ovaries, and increased the reduced mRNA expression of growth factors (EGF, TGF-b) by DHEA injection. Post-administration of KOK also improved the DHEA-induced PCOS-like symptoms, generally similar to those evident from pre-administration of KOK. KOK may effectively prevent and improve DHEA-induced PCOS via anti-inflammatory action, indicating its preventive and therapeutic potential for suppressing PCOS.	[Jang, Minhee; Lee, Min Jung; Cho, Ik-Hyun] Kyung Hee Univ, Dept Convergence Med Sci, Seoul, South Korea; [Jang, Minhee; Lee, Min Jung; Kim, Sung-Hoon] Kyung Hee Univ, Dept Canc Prevent Mat Dev, Seoul, South Korea; [Lee, Jin Moo] Kyung Hee Univ, Coll Korean Med, Dept Gynecol, Seoul, South Korea; [Bae, Chun-Sik] Chonnam Natl Univ, Coll Vet Med, Kwangju, South Korea; [Bae, Chun-Sik] Chonnam Natl Univ, Anim Med Inst, Kwangju, South Korea; [Cho, Ik-Hyun] Kyung Hee Univ, Inst Korean Med, Seoul, South Korea; [Ryu, Jong Hoon] Kyung Hee Univ, Coll Pharm, Dept Oriental Pharmaceut Sci, Seoul, South Korea; [Ryu, Jong Hoon] Kyung Hee Univ, Dept Life & Nanopharmaceut Sci, Seoul, South Korea	Kyung Hee University; Kyung Hee University; Kyung Hee University; Chonnam National University; Chonnam National University; Kyung Hee University; Kyung Hee University; Kyung Hee University	Cho, IH (corresponding author), Kyung Hee Univ, Dept Convergence Med Sci, Seoul, South Korea.	ihcho@khu.ac.kr	Cho, Ik-Hyun/A-9348-2014	kim, sunghoon/0000-0002-1570-3230; Lee, Minjung/0000-0003-4206-6713	Kwang Dong Pharmaceutical Co., Ltd; National Research Foundation of Korea (NRF); Korea government (MSIP) [2007-0054931]	Kwang Dong Pharmaceutical Co., Ltd; National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Korea government (MSIP)	Original study was supported by supported by grant from the Kwang Dong Pharmaceutical Co., Ltd. And study for revision was supported by supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2007-0054931). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amato G, 2003, OBSTET GYNECOL, V101, P1177, DOI 10.1016/S0029-7844(03)00233-3; Andrikopoulos S, 2008, AM J PHYSIOL-ENDOC M, V295, pE1323, DOI 10.1152/ajpendo.90617.2008; Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006-2952(99)00212-9; Benson S, 2008, BRAIN BEHAV IMMUN, V22, P177, DOI 10.1016/j.bbi.2007.07.003; Cai M, 2011, J ETHNOPHARMACOL, V138, P723, DOI 10.1016/j.jep.2011.10.016; Carmina E, 1999, J CLIN ENDOCR METAB, V84, P1897, DOI 10.1210/jc.84.6.1897; Cho IH, 2012, J GINSENG RES, V36, P342, DOI 10.5142/jgr.2012.36.4.342; Diamanti-Kandarakis E, 2007, Minerva Endocrinol, V32, P35; Elia E, 2006, MOL HUM REPROD, V12, P475, DOI 10.1093/molehr/gal057; Franks S, 2008, HUM REPROD UPDATE, V14, P367, DOI 10.1093/humupd/dmn015; Ropelato MG, 2009, J CLIN ENDOCR METAB, V94, P3602, DOI 10.1210/jc.2009-0402; Glintborg D, 2009, CLIN ENDOCRINOL, V71, P652, DOI 10.1111/j.1365-2265.2009.03523.x; Goodarzi MO, 2011, FERTIL STERIL, V95, P1736, DOI 10.1016/j.fertnstert.2011.01.015; Goodarzi MO, 2011, NAT REV ENDOCRINOL, V7, P219, DOI 10.1038/nrendo.2010.217; Hahn S, 2005, EUR J ENDOCRINOL, V153, P853, DOI 10.1530/eje.1.02024; Hatzirodos N, 2011, FASEB J, V25, P2256, DOI 10.1096/fj.11-181099; Huh J, 1610, DONGUIBOGAM; Ibanez L, 2006, FERTIL STERIL, V86, pS24, DOI 10.1016/j.fertnstert.2006.03.006; Jang M, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/237207; Johnson N, 2011, AUST NZ J OBSTET GYN, V51, P125, DOI 10.1111/j.1479-828X.2010.01274.x; 이소연, 2008, [The Korea Journal of Herbology, 대한본초학회지], V23, P123; Kousta E, 1997, HUM REPROD UPDATE, V3, P359, DOI 10.1093/humupd/3.4.359; Krinke G.J., 2000, LAB RAT; KUBO M, 1994, BIOL PHARM BULL, V17, P1282, DOI 10.1248/bpb.17.1282; Lee E. S., 2002, KOR J HERBOL, V17, P101; Lee JC, 2003, AM J CHINESE MED, V31, P885, DOI 10.1142/S0192415X03001636; Lee SM, 2012, J ETHNOPHARMACOL, V141, P368, DOI 10.1016/j.jep.2012.02.048; Legro RS, 2007, AM J OBSTET GYNECOL, V196, DOI 10.1016/j.ajog.2006.12.025; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu FX, 2002, CLIN EXP IMMUNOL, V128, P10, DOI 10.1046/j.1365-2249.2002.01780.x; Luchetti CG, 2004, J REPROD IMMUNOL, V64, P59, DOI 10.1016/j.jri.2004.04.002; Maharjan R, 2011, J AYURVEDA INTEGR ME, V1, P273; Manneras L, 2008, ENDOCRINOLOGY, V149, P3559, DOI 10.1210/en.2008-0053; Manneras L, 2007, ENDOCRINOLOGY, V148, P3781, DOI 10.1210/en.2007-0168; MARCONDES F. K., 2002, Braz. J. Biol., V62, P609, DOI 10.1590/S1519-69842002000400008; MEIKLE AW, 1992, J STEROID BIOCHEM, V42, P293, DOI 10.1016/0960-0760(92)90132-3; Musso C, 2005, CLIN ENDOCRINOL, V63, P73, DOI 10.1111/j.1365-2265.2005.02302.x; Nestler JE, 2002, FERTIL STERIL, V77, P209, DOI 10.1016/S0015-0282(01)02963-6; Norman RJ, 2006, ENDOCRINE, V30, P35, DOI 10.1385/ENDO:30:1:35; Obradovic S, 2001, PHARMAZIE, V56, P235; Park Hyun-Jung, 2011, Exp Neurobiol, V20, P137, DOI 10.5607/en.2011.20.3.137; Raja-Khan N, 2011, AM J PHYSIOL-ENDOC M, V301, pE1, DOI 10.1152/ajpendo.00667.2010; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Rios JL, 2011, PLANTA MED, V77, P681, DOI 10.1055/s-0030-1270823; Ross R, 2004, OBES RES, V12, P789, DOI 10.1038/oby.2004.95; Safadi FF, 2000, ENDOCRINE, V12, P81, DOI 10.1385/ENDO:12:1:81; Sander V, 2006, REPRODUCTION, V131, P591, DOI 10.1530/rep.1.00941; Sapino A, 2003, AM J PATHOL, V163, P1313, DOI 10.1016/S0002-9440(10)63490-6; Schindler AE, 2009, MATURITAS, V65, pS3, DOI 10.1016/j.maturitas.2009.10.011; Sekiya N, 2003, PHYTOTHER RES, V17, P160, DOI 10.1002/ptr.1097; Shin BumYoung, 2009, Journal of Traditional Medicines, V26, P35; Solano ME, 2011, J REPROD IMMUNOL, V92, P33, DOI 10.1016/j.jri.2011.09.003; Taylor AE, 1997, J CLIN ENDOCR METAB, V82, P2248, DOI 10.1210/jc.82.7.2248; Wu RJ, 2004, HUM REPROD UPDATE, V10, P119, DOI 10.1093/humupd/dmh011; Yan G, 2000, J WOMEN HEALTH GEN-B, V9, P275, DOI 10.1089/152460900318461; Ye Y, 2010, J ETHNOPHARMACOL, V129, P387, DOI 10.1016/j.jep.2010.04.009; Yokozawa T, 2004, AM J CHINESE MED, V32, P829, DOI 10.1142/S0192415X04002442; Zhang R, 2010, J ETHNOPHARMACOL, V130, P299, DOI 10.1016/j.jep.2010.05.007; Zhang Y, 2004, EUR J PHARMACOL, V504, P39, DOI 10.1016/j.ejphar.2004.09.051	59	34	36	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2014	9	2							e87623	10.1371/journal.pone.0087623	http://dx.doi.org/10.1371/journal.pone.0087623			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7CL	24520334	Green Published, Green Submitted, gold			2023-01-03	WOS:000331254600025
J	Grasmeijer, F; Lexmond, AJ; van den Noort, M; Hagedoorn, P; Hickey, AJ; Frijlink, HW; de Boer, AH				Grasmeijer, Floris; Lexmond, Anne J.; van den Noort, Maarten; Hagedoorn, Paul; Hickey, Anthony J.; Frijlink, Henderik W.; de Boer, Anne H.			New Mechanisms to Explain the Effects of Added Lactose Fines on the Dispersion Performance of Adhesive Mixtures for Inhalation	PLOS ONE			English	Article							DRY POWDER INHALATION; DRUG PARTICLE DETACHMENT; INTERACTIVE MIXTURES; SALMETEROL XINAFOATE; CARRIER SURFACE; MIXING TIME; DEPOSITION; FORMULATION; DEVICE; SIZE	Fine excipient particles or 'fines' have been shown to improve the dispersion performance of carrier-based formulations for dry powder inhalation. Mechanistic formulation studies have focussed mainly on explaining this positive effect. Previous studies have shown that higher drug contents may cause a decrease in dispersion performance, and there is no reason why this should not be true for fines with a similar shape, size and cohesiveness as drug particles. Therefore, the effects on drug detachment of 'fine lactose fines' (FLF, X-50 = 1.95 mu m) with a similar size and shape as micronised budesonide were studied and compared to those of 'coarse lactose fines' (CLF, X-50 = 3.94 mu m). Furthermore, interactions with the inhalation flow rate, the drug content and the mixing order were taken into account. The observed effects of FLF are comparable to drug content effects in that the detached drug fraction was decreased at low drug content and low flow rates but increased at higher flow rates. At high drug content the effects of added FLF were negligible. In contrast, CLF resulted in higher detached drug fractions at all flow rates and drug contents. The results from this study suggest that the effects of fines may be explained by two new mechanisms in addition to those previously proposed. Firstly, fines below a certain size may increase the effectiveness of press-on forces or cause the formation of strongly coherent fine particle networks on the carrier surface containing the drug particles. Secondly, when coarse enough, fines may prevent the formation of, or disrupt such fine particle networks, possibly through a lowering of their tensile strength. It is recommended that future mechanistic studies are based on the recognition that added fines may have any effect on dispersion performance, which is determined by the formulation and dispersion conditions.	[Grasmeijer, Floris; Lexmond, Anne J.; van den Noort, Maarten; Hagedoorn, Paul; Frijlink, Henderik W.; de Boer, Anne H.] Univ Groningen, Dept Pharmaceut Technol & Biopharm, Groningen, Netherlands; [Hickey, Anthony J.] RTI Int, Ctr Aerosol & Nanomat Engn, Res Triangle Pk, NC USA	University of Groningen; Research Triangle Institute	Grasmeijer, F (corresponding author), Univ Groningen, Dept Pharmaceut Technol & Biopharm, Groningen, Netherlands.	F.Grasmeijer@rug.nl	Frijlink, Henderik Willem/AAD-7382-2020	Frijlink, Henderik Willem/0000-0001-7901-8198				Adi H, 2006, PHARM RES, V23, P2556, DOI 10.1007/s11095-006-9082-6; Arnold K, 1995, POWDERS INHALATION; de Boer AH, 2012, ADV DRUG DELIVER REV, V64, P257, DOI 10.1016/j.addr.2011.04.004; de Boer AH, 2003, INT J PHARMACEUT, V260, P187, DOI 10.1016/S0378-5173(03)00250-3; Dickhoff BHJ, 2006, INT J PHARMACEUT, V327, P17, DOI 10.1016/j.ijpharm.2006.07.017; Dickhoff B.H.J., 2006, ADHESIVE MIXTURES PO; Dickhoff BHJ, 2002, EUR J PHARM BIOPHARM, V54, P245, DOI 10.1016/S0939-6411(02)00082-6; Dickhoff BHJ, 2003, EUR J PHARM BIOPHARM, V56, P291, DOI 10.1016/S0939-6411(03)00109-7; Donovan MJ, 2012, J PHARM SCI-US, V101, P1097, DOI 10.1002/jps.22824; Grasmeijer F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071339; Grasmeijer F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069263; Islam N, 2004, PHARM RES-DORDR, V21, P492, DOI 10.1023/B:PHAM.0000019304.91412.18; Jones MD, 2006, PHARM RES, V23, P1665, DOI 10.1007/s11095-006-9012-7; Jones MD, 2010, INT J PHARMACEUT, V391, P137, DOI 10.1016/j.ijpharm.2010.02.031; Kendall K, 2001, POWDER TECHNOL, V121, P223, DOI 10.1016/S0032-5910(01)00386-2; Louey MD, 2002, PHARM RES-DORDR, V19, P1524, DOI 10.1023/A:1020464801786; Lucas P, 1998, PHARMACEUT RES, V15, P562, DOI 10.1023/A:1011977826711; Shur J, 2008, PHARM RES-DORDR, V25, P1931, DOI 10.1007/s11095-008-9538-y; Thalberg K, 2012, INT J PHARMACEUT, V427, P224, DOI 10.1016/j.ijpharm.2012.02.009; Usmani OS, 2005, AM J RESP CRIT CARE, V172, P1497, DOI 10.1164/rccm.200410-1414OC; Zeng XM, 1999, INT J PHARMACEUT, V182, P133, DOI 10.1016/S0378-5173(99)00021-6	21	55	58	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2014	9	1							e87825	10.1371/journal.pone.0087825	http://dx.doi.org/10.1371/journal.pone.0087825			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301CJ	24489969	gold, Green Published, Green Submitted			2023-01-03	WOS:000330510000151
J	Hoffmann, CJ; Chaisson, RE; Martinson, NA				Hoffmann, Christopher J.; Chaisson, Richard E.; Martinson, Neil A.			Cotrimoxazole Prophylaxis and Tuberculosis Risk among People Living with HIV	PLOS ONE			English	Article							TRIMETHOPRIM-SULFAMETHOXAZOLE; MYCOBACTERIUM-TUBERCULOSIS; INFECTED ADULTS; COTE-DIVOIRE; MORTALITY; TRIAL; SUSCEPTIBILITY; COMBINATION; MORBIDITY; ABIDJAN	Objectives: Many randomized and cohort studies have reported a survival benefit with cotrimoxazole prophylaxis without detecting a difference in tuberculosis (TB) incidence by cotrimoxazole status. However, several in vitro studies have reported that cotrimoxazole possesses anti-TB activity. We sought to compare TB incidence and TB diagnostic yield by cotrimoxazole use among participants in a well characterized cohort of HIV-infected adults living in a high TB prevalence region. Methods: We analyzed prospective data from a long-term longitudinal cohort of adults receiving HIV care and TB investigations in Soweto, South Africa. Using longitudinal analysis, we compared total and laboratory confirmed TB incidence by cotrimoxazole status as well as all-cause mortality. In addition, we compared TB culture results by cotrimoxazole status. Results: In a multivariable analysis, adjusted for sex, body mass index, WHO clinical stage, time-updated CD4 count, and antiretroviral therapy status, we observed an association between cotrimoxazole and an increase in TB incidence (hazard ratio 1.7, 95% CI: 1.2, 2.2). However, when restricted to laboratory-confirmed TB, there was no association between cotrimoxazole and TB incidence (hazard ratio: 0.97, 95% CI: 0.39, 2.4). In TB cases, we found no difference in the proportion of positive sputum cultures or days to culture positivity by cotrimoxazole status. Cotrimoxazole was associated with a reduction in mortality. Conclusions: In this cohort with a mortality benefit from cotrimoxazole, we found an increased risk of all TB among individuals using cotrimoxazole, likely a result of residual confounding, but no association between use of cotrimoxazole and laboratory-confirmed TB. Cotrimoxazole did not compromise TB diagnosis.	[Hoffmann, Christopher J.; Chaisson, Richard E.; Martinson, Neil A.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA; [Hoffmann, Christopher J.; Chaisson, Richard E.; Martinson, Neil A.] Johns Hopkins Univ, Ctr TB Res, Baltimore, MD USA; [Martinson, Neil A.] Perinatal HIV Res Unit, Johannesburg, South Africa	Johns Hopkins University; Johns Hopkins University	Hoffmann, CJ (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.	choffmann@jhmi.edu		Hoffmann, Christopher/0000-0002-9422-0519	National Heart, Lung, and Blood Institute Lung Health [R01 HL90312]; Johns Hopkins University Center for AIDS Research [P30-AI094189-01A1]; National Institutes of Health [AI083099]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI094189, K23AI083099] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute Lung Health; Johns Hopkins University Center for AIDS Research; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was funded by a National Heart, Lung, and Blood Institute Lung Health research grant [R01 HL90312]. REC is partly supported by the Johns Hopkins University Center for AIDS Research [P30-AI094189-01A1]. CJH is supported by a National Institutes of Health K23 research grant [AI083099]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; [Anonymous], 2012, GLOBAL TUBERCULOSIS, P1; Ansari NA, 2002, INT J TUBERC LUNG D, V6, P55; Badri M, 2001, AIDS, V15, P1143, DOI 10.1097/00002030-200106150-00009; DUBAR V, 1990, J ANTIMICROB CHEMOTH, V26, P791, DOI 10.1093/jac/26.6.791; Forgacs P, 2009, ANTIMICROB AGENTS CH, V53, P4789, DOI 10.1128/AAC.01658-08; Hanrahan CF, 2010, AIDS, V24, P1501, DOI 10.1097/QAD.0b013e32833a2a4a; Huang TS, 2012, J ANTIMICROB CHEMOTH, V67, P633, DOI 10.1093/jac/dkr501; Lowrance D, 2007, JAIDS-J ACQ IMM DEF, V46, P56; Martinson Neil A, 2011, Proc Am Thorac Soc, V8, P288, DOI 10.1513/pats.201010-064WR; Mermin J, 2004, LANCET, V364, P1428, DOI 10.1016/S0140-6736(04)17225-5; Nunn AJ, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a257; Omar T, 2011, AIDS, V25, P87, DOI 10.1097/QAD.0b013e328340fd99; Ong W, 2010, ANTIMICROB AGENTS CH, V54, P2748, DOI 10.1128/AAC.00029-10; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Sesay M, 2006, GUIDELINES COTRIMOXA; Walker AS, 2010, LANCET, V375, P1278, DOI 10.1016/S0140-6736(10)60057-8; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; Zachariah R, 2003, AIDS, V17, P1053, DOI 10.1097/00002030-200305020-00015	19	11	11	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2014	9	1							e83750	10.1371/journal.pone.0083750	http://dx.doi.org/10.1371/journal.pone.0083750			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	291WL	24421903	Green Published, gold			2023-01-03	WOS:000329862500070
J	Cappa, P; Clerico, A; Nov, O; Porfiri, M				Cappa, Paolo; Clerico, Andrea; Nov, Oded; Porfiri, Maurizio			Can Force Feedback and Science Learning Enhance the Effectiveness of Neuro-Rehabilitation? An Experimental Study on Using a Low-Cost 3D Joystick and a Virtual Visit to a Zoo	PLOS ONE			English	Article							UPPER-LIMB; STROKE REHABILITATION; PATIENT MOTIVATION; ARM FUNCTION; THERAPY; CHILDREN; NEUROREHABILITATION; TECHNOLOGY; RECOVERY; ACCESS	In this paper, we demonstrate that healthy adults respond differentially to the administration of force feedback and the presentation of scientific content in a virtual environment, where they interact with a low-cost haptic device. Subjects are tasked with controlling the movement of a cursor on a predefined trajectory that is superimposed on a map of New York City's Bronx Zoo. The system is characterized in terms of a suite of objective indices quantifying the subjects' dexterity in planning and generating the multijoint visuomotor tasks. We find that force feedback regulates the smoothness, accuracy, and duration of the subject's movement, whereby converging or diverging force fields influence the range of variations of the hand speed. Finally, our findings provide preliminary evidence that using educational content increases subjects' satisfaction. Improving the level of interest through the inclusion of learning elements can increase the time spent performing rehabilitation tasks and promote learning in a new context.	[Cappa, Paolo; Clerico, Andrea] Univ Roma La Sapienza, Dept Mech & Aerosp Engn, I-00185 Rome, Italy; [Cappa, Paolo; Clerico, Andrea; Porfiri, Maurizio] NYU, Dept Mech & Aerosp Engn, Polytech Inst, Brooklyn, NY USA; [Cappa, Paolo] IRCCS Childrens Hosp Bambino Gesu, Movement Anal & Robot Lab MARLab, Neurorehabil Div, Rome, Italy; [Nov, Oded] NYU, Dept Technol Management & Innovat, Polytech Inst, Brooklyn, NY USA	Sapienza University Rome; New York University; New York University Tandon School of Engineering; IRCCS Bambino Gesu; New York University; New York University Tandon School of Engineering	Porfiri, M (corresponding author), NYU, Dept Mech & Aerosp Engn, Polytech Inst, Brooklyn, NY USA.	mporfiri@nyu.edu		Cappa, Paolo/0000-0002-4898-9589; Porfiri, Maurizio/0000-0002-1480-3539	National Science Foundation [BCS-1124795]; Italian Ministry of Health - Department of medical devices and drugs "Effectiveness of the robot mediated therapy for upper limb"; Honours Center of Italian Universities	National Science Foundation(National Science Foundation (NSF)); Italian Ministry of Health - Department of medical devices and drugs "Effectiveness of the robot mediated therapy for upper limb"; Honours Center of Italian Universities	This material is based upon work supported by the National Science Foundation under Grant # BCS-1124795, the Italian Ministry of Health - Department of medical devices and drugs "Effectiveness of the robot mediated therapy for upper limb" (Grant 2009), and the Honours Center of Italian Universities through a scholarship to Andrea Clerico. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Balasubramanian S, 2012, IEEE T BIO-MED ENG, V59, P2126, DOI 10.1109/TBME.2011.2179545; Barreca S, 2003, NEUROREHAB NEURAL RE, V17, P220, DOI 10.1177/0888439003259415; Bhattacherjee A, 2001, MIS QUART, V25, P351, DOI 10.2307/3250921; Bosecker C, 2010, NEUROREHAB NEURAL RE, V24, P62, DOI 10.1177/1545968309343214; Bovolenta F, 2011, J NEUROENG REHABIL, V8, P1, DOI [10.1186/1743-0003-8-1, DOI 10.1186/1743-0003-8-1.PUBMED:21226898]; Casadio M, 2009, MEASUREMENT, V42, P1176, DOI 10.1016/j.measurement.2008.09.012; Clark MS, 1998, CLIN REHABIL, V12, P73, DOI 10.1191/026921598669567216; Coles T, 2010, THIRD INTERNATIONAL CONFERENCE ON ADVANCES IN COMPUTER-HUMAN INTERACTIONS: ACHI 2010, P148, DOI 10.1109/ACHI.2010.20; Colombo R, 2007, J NEUROENG REHABIL, V4, DOI 10.1186/1743-0003-4-3; Coote S, 2008, CLIN REHABIL, V22, P395, DOI 10.1177/0269215507085060; de O Andrade K, 2013, BIOS BIOR C BRC 2013, P1, DOI DOI 10.1109/BRC.2013.6487455; De Pascale M, 2007, IEEE ROBOT AUTOM MAG, V14, P64, DOI 10.1109/M-RA.2007.905747; DIJKERS MP, 1991, J REHABIL RES DEV, V28, P33, DOI 10.1682/JRRD.1991.04.0033; Dipietro L, 2009, CORTEX, V45, P318, DOI 10.1016/j.cortex.2008.02.008; Frascarelli F, 2009, J REHABIL MED, V41, P988, DOI 10.2340/16501977-0412; Gouveia D, 2011, SERIOUS GAMING EXPER; Hogan N, 1992, WORKSTATION MANUAL T, P161; Krebs H I, 1998, IEEE Trans Rehabil Eng, V6, P75, DOI 10.1109/86.662623; Krebs HI, 2012, NEUROREHAB NEURAL RE, V26, P855, DOI 10.1177/1545968311433427; Krebs HI, 1999, P NATL ACAD SCI USA, V96, P4645, DOI 10.1073/pnas.96.8.4645; Lange B, 2009, PHYS THER REV, V14, P355, DOI 10.1179/108331909X12488667117258; Liebermann DG, 2006, CLIN BIOMECH, V21, P8, DOI 10.1016/j.clinbiomech.2005.08.006; Lin Y, 1374, FORCE CONTROL SYSTEM, P1379; Loureiro R, 2003, AUTON ROBOT, V15, P35, DOI 10.1023/A:1024436732030; Loureiro RCV, 2011, MED BIOL ENG COMPUT, V49, P1103, DOI 10.1007/s11517-011-0797-0; Lum PS, 2006, J REHABIL RES DEV, V43, P631, DOI 10.1682/JRRD.2005.02.0044; Maclean N, 2000, SOC SCI MED, V50, P495; Martin S, 2009, CHARACTERISATION NOV, P1; Masia L, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-28; Mehrholz J, 2008, COCHRANE DB SYST REV; Moritz E, 2005, CROSSROADS, V12, P5, DOI [10.1145/1144375.1144380., DOI 10.1145/1144375.1144380]; Nam CS, 2012, INT J HUM-COMPUT INT, V28, P784, DOI 10.1080/10447318.2012.661357; Nocchi F, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-49; Oujamaa L., 2009, Annals of Physical and Rehabilitation Medicine, V52, P269, DOI 10.1016/j.rehab.2008.10.003; Panarese A, 2011, MED ENG PHYS, V33, P386, DOI 10.1016/j.medengphy.2010.10.019; Patritti BL, 2010, PM&R, V2, P71, DOI 10.1016/j.pmrj.2009.10.012; Peter O, 2011, INT J REHABIL RES, V34, P196, DOI 10.1097/MRR.0b013e328346e8ad; Platz T, 2003, NERVENARZT, V74, P841, DOI 10.1007/s00115-003-1549-7; Pons JL, 2013, COMP INFLUENCE VISUA, P317; Prange GB, 2006, J REHABIL RES DEV, V43, P171, DOI 10.1682/JRRD.2005.04.0076; Riener R, 2005, MED BIOL ENG COMPUT, V43, P2, DOI 10.1007/BF02345116; Riener R, 2007, ACTA NEUROCHIR SUPPL, V97, P465; Rohrer B, 2002, J NEUROSCI, V22, P8297; TUPPER A, 1987, International Journal of Rehabilitation Research, V10, P119, DOI 10.1097/00004356-198700105-00024; van der Lee JH, 2001, CLIN REHABIL, V15, P20, DOI 10.1191/026921501677557755; VANVLIET P, 1991, PHYS THER, V71, P39, DOI 10.1093/ptj/71.1.39; Volpe BT, 2001, CURR OPIN NEUROL, V14, P745, DOI 10.1097/00019052-200112000-00011; Zhu SJ, 2011, INTERACT COMPUT, V23, P565, DOI 10.1016/j.intcom.2011.08.001; Zollo L, 2011, EUR J PHYS REHAB MED, V47, P223; Zollo L, 2011, MED BIOL ENG COMPUT, V49, P1131, DOI 10.1007/s11517-011-0808-1	50	19	20	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2013	8	12							e83945	10.1371/journal.pone.0083945	http://dx.doi.org/10.1371/journal.pone.0083945			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276FP	24349562	Green Submitted, gold, Green Published			2023-01-03	WOS:000328734200106
J	Delano, K; Gareri, J; Koren, G				Delano, Kaitlyn; Gareri, Joey; Koren, Gideon			Rates of Fetal Polydrug Exposures in Methadone-Maintained Pregnancies from a High-Risk Population	PLOS ONE			English	Article							NEONATAL OUTCOMES; DRUG; BUPRENORPHINE; MECONIUM; ABUSE; METABOLITES; CLEARANCE; WOMEN	Methadone maintenance treatment (MMT) is the standard of care during pregnancy for opioid-dependency, showing efficacy in improving prenatal care and reducing risk of relapse. By design, however, MMT is only intended to prevent withdrawal thus facilitating cognitive behavioural interventions. In order to maximize the benefits of MMT, it is essential that methadone is both properly prescribed and that additional addiction treatment is concurrently administered. This study aims to determine the effectiveness of MMT engagement in high-risk pregnant women in reducing polydrug use by objective laboratory examination of neonatal meconium. Patients and Methods: Over a 29-month period, the Motherisk Laboratory at the Hospital for Sick Children in Toronto analyzed meconium samples as per request by social services and hospitals for drugs of abuse. Results: Of the 904 meconium samples received, 273 were tested for methadone with 164 positive and 109 negative for methadone. Almost half of the methadone positive samples (46.34%) were also positive for at least one other opioid compound, which did not differ statistically from the methadone-negative control samples (46.79%; Chi square test, p=0.94). No differences were found between the methadone positive and negative groups in rates of concurrent amphetamines, cocaine, cannabis, and alcohol use indicating a similar risk of polydrug use between pregnant women taking or not taking methadone in this population. Discussion: The high rates of additional opioid and other drug use in the MMT group, suggest that MMT is failing this population of patients. It is possible that methadone doses during pregnancy are not appropriately adjusted for changes in pharmacokinetic parameters (e. g. blood volume, renal function) during the second and third trimesters. This may result in sub-therapeutic dosing creating withdrawal symptoms leading to additional substance use. Alternatively, these results may be demonstrating a substantial lack in delivery of addiction support services in this vulnerable population.	[Delano, Kaitlyn; Gareri, Joey; Koren, Gideon] Hosp Sick Children, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada; [Delano, Kaitlyn; Koren, Gideon] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON, Canada; [Gareri, Joey] Univ Toronto, Dept Pharmaceut Sci, Toronto, ON, Canada; [Koren, Gideon] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; Western University (University of Western Ontario)	Koren, G (corresponding author), Hosp Sick Children, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada.	gkoren@sickkids.ca	Koren, Gideon/AAG-7726-2019	Koren, Gideon/0000-0002-9234-0875	Research Leadership for Better Pharmacotherapy During Pregnancy and Lactation	Research Leadership for Better Pharmacotherapy During Pregnancy and Lactation	The source of funding for this study was the Research Leadership for Better Pharmacotherapy During Pregnancy and Lactation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aleksa K, 2012, FORENSIC SCI INT, V218, P31, DOI 10.1016/j.forsciint.2011.10.002; Bar-Oz B, 2003, ARCH DIS CHILD-FETAL, V88, pF98, DOI 10.1136/fn.88.2.F98; Bessa MA, 2010, ADDICT BEHAV, V35, P266, DOI 10.1016/j.addbeh.2009.10.007; Clancy Zoe, 2013, J Opioid Manag, V9, P121, DOI 10.5055/jom.2013.0153; Dickmann LJ, 2013, DRUG METAB DISPOS, V41, P270, DOI 10.1124/dmd.112.047118; Finnegan LP, 1971, CONTEMP DRUG PROBS, V1, P795; Gray TR, 2010, NICOTINE TOB RES, V12, P658, DOI 10.1093/ntr/ntq068; Hutson JR, 2011, ALCOHOL, V45, P193, DOI 10.1016/j.alcohol.2010.07.005; Jaffee WB, 2007, J SUBST ABUSE TREAT, V33, P33, DOI 10.1016/j.jsat.2006.11.008; Jarvis MAE, 1999, J ADDICT DIS, V18, P51, DOI 10.1300/J069v18n04_05; Kacinko SL, 2008, CLIN PHARMACOL THER, V84, P604, DOI 10.1038/clpt.2008.156; KANDALL SR, 1977, EARLY HUM DEV, V1, P159, DOI 10.1016/0378-3782(77)90017-2; Keegan J, 2010, J ADDICT DIS, V29, P175, DOI 10.1080/10550881003684723; Kelly L, 2011, CAN FAM PHYSICIAN, V57, pE441; Koren G, 2008, CLIN PHARMACOL THER, V83, P631, DOI 10.1038/sj.clpt.6100506; Kuczkowski KM, 2007, CURR OPIN OBSTET GYN, V19, P578, DOI 10.1097/GCO.0b013e3282f1bf17; Kwong TC, 1997, CLIN CHEM, V43, P235; Loudenburg R, 2003, NEUROTOXICOL TERATOL, V25, P737, DOI 10.1016/j.ntt.2003.07.009; McCarthy JJ, 2012, J MATERN-FETAL NEO M, V25, P109, DOI 10.3109/14767058.2011.600371; Miller V, 1974, GROWTH DEV ENDODERMA, P281; Moller Monique, 2010, Can J Clin Pharmacol, V17, pe177; Pepler D.J., 2002, BREAKING CYCLE EVALU; Poole N, 2000, EVALUATION REPORT SH; Welle-Strand GK, 2013, DRUG ALCOHOL DEPEN, V127, P200, DOI 10.1016/j.drugalcdep.2012.07.001; Wolff K, 2005, EUR J CLIN PHARMACOL, V61, P763, DOI 10.1007/s00228-005-0035-5	25	21	21	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2013	8	12							e82647	10.1371/journal.pone.0082647	http://dx.doi.org/10.1371/journal.pone.0082647			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	265IN	24312668	gold, Green Submitted, Green Published			2023-01-03	WOS:000327944500142
J	Jiang, ZB; Chen, YC; Yao, F; Chen, WZ; Zhong, SP; Zheng, FC; Shi, GG				Jiang, Zebin; Chen, Yicun; Yao, Fen; Chen, Weizhou; Zhong, Shuping; Zheng, Fuchun; Shi, Ganggang			Antioxidant, Antibacterial and Antischistosomal Activities of Extracts from Grateloupia livida (Harv). Yamada	PLOS ONE			English	Article							RADICAL SCAVENGING ACTIVITY; IN-VITRO; FATTY-ACIDS; SEAWEEDS; FRACTIONS; REDUCTASE; OIL	The present study was designated to evaluate the antioxidant, antibacterial and antischistosomal activities of Grateloupia livida (GL) extracts in vitro. A GL Ethanol extract (EE) was separated into petroleum ether (PE), ethyl acetate (EA), n-butyl alcohol (BuOH) and aqueous (AQ) fractions to fractionate the polar and non-polar compounds in the EE. Extracts antioxidant activities were evaluated in vitro by DPPH radical-scavenging, deoxyribose radical scavenging, and beta-carotene bleaching assays, all using butylated hydroxytoluene (BHT) as the reference antioxidant compound. The most effective antioxidant properties were observed in the PE fraction in all three assays. Antimicrobial testing showed that the PE fraction exhibited broad-spectrum antimicrobial activity, with the PE fraction also exhibiting strong activity against the human pathogenic trematode S. japonicum adult worm. In order to investigate the relationships between bioactivity and chemical composition, the chemical composition of the PE fraction was analyzed by gas chromatography-mass spectrometry (GC-MS). In total, 25 components were identified in the PE fraction, most of which have known antioxidant and antimicrobial activities. However, none of the compounds have reported activity against Schistosoma, suggesting that the schistosomicidal activity of the PE fraction may be related to minor constituents present in the extract, or governed by more intricate synergistic or additive relationships. Finally, fractions with the greatest biological activity displayed neither cellular cytotoxicity, at concentrations up to 100 ug/ml, or acute oral toxicity in mice, at doses up to 2000 mg/kg. Based on antioxidant, antimicrobial, antischistosomal activities, and low toxicity, the PE fraction possesses properties useful for food preservation and overall improvement of human health.	[Jiang, Zebin; Zheng, Fuchun] Shantou Univ, Affiliated Hosp 1, Coll Med, Dept Pharm, Shantou, Peoples R China; [Jiang, Zebin; Chen, Yicun; Yao, Fen; Shi, Ganggang] Shantou Univ, Coll Med, Dept Pharmacol, Shantou, Peoples R China; [Shi, Ganggang] Shantou Univ, Affiliated Hosp 1, Coll Med, Dept Cardiovasc Dis, Shantou, Peoples R China; [Chen, Weizhou] Shantou Univ, Inst Marine Biol, Shantou, Peoples R China; [Zhong, Shuping] Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	Shantou University; Shantou University; Shantou University; Shantou University; University of Southern California	Zheng, FC (corresponding author), Shantou Univ, Affiliated Hosp 1, Coll Med, Dept Pharm, Shantou, Peoples R China.	zhengfuchunsh@yahoo.com.cn; ggshi@stu.edu.cn	Chen, Weizhou/HIR-8601-2022		Guangdong Natural Science Foundation [9351503102000001]; Guangdong Province Administration of Traditional Chinese Medicine [2010408]; Doctoral Fund of Ministry of Education of China [20104402120006]; 211 project of Guangdong province; central government special funds supporting the development of local colleges and universities	Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Guangdong Province Administration of Traditional Chinese Medicine; Doctoral Fund of Ministry of Education of China(Ministry of Education, China); 211 project of Guangdong province(Guangdong University of Technology); central government special funds supporting the development of local colleges and universities	This study was undertaken and supported within the teamwork projects funded by the Guangdong Natural Science Foundation (9351503102000001), Guangdong Province Administration of Traditional Chinese Medicine (No. 2010408), Doctoral Fund of Ministry of Education of China (No. 20104402120006), the 211 project of Guangdong province and the central government special funds supporting the development of local colleges and universities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ainscow EK, 2000, DIABETES, V49, P1149, DOI 10.2337/diabetes.49.7.1149; Athukorala Y, 2003, J FOOD LIPIDS, V10, P251, DOI 10.1111/j.1745-4522.2003.tb00019.x; Banday MR, 2010, EUR J MED CHEM, V45, P1459, DOI 10.1016/j.ejmech.2009.12.052; Bangmei X, 2004, FLORA ALGARUM MARINA; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Blois M.S., 1958, ANTIOXIDANT DETERMIN; Chandini SK, 2008, FOOD CHEM, V107, P707, DOI 10.1016/j.foodchem.2007.08.081; Cho ML, 2011, FOOD CHEM, V127, P999, DOI 10.1016/j.foodchem.2011.01.072; Cho M, 2010, J MED FOOD, V13, P1232, DOI 10.1089/jmf.2010.1124; COOPPAN RM, 1986, AM J TROP MED HYG, V35, P765, DOI 10.4269/ajtmh.1986.35.765; de Melo NI, 2011, MOLECULES, V16, P762, DOI 10.3390/molecules16010762; Georgel P, 2005, INFECT IMMUN, V73, P4512, DOI 10.1128/IAI.73.8.4512-4521.2005; GUTTERIDGE JMC, 1987, BIOCHEM J, V243, P709, DOI 10.1042/bj2430709; Halliwell B, 2007, CARDIOVASC RES, V73, P341, DOI 10.1016/j.cardiores.2006.10.004; Han N, 2012, AFRICAN J BIOTECHNOL, V11; Hashem FA, 1999, PHYTOTHER RES, V13, P329, DOI 10.1002/(SICI)1099-1573(199906)13:4&lt;329::AID-PTR458&gt;3.0.CO;2-U; Kumar P. P., 2010, African Journal of Biochemistry Research, V4, P191; Kumaran A, 2006, FOOD CHEM, V97, P109, DOI 10.1016/j.foodchem.2005.03.032; LAMELA M, 1989, J ETHNOPHARMACOL, V27, P35, DOI 10.1016/0378-8741(89)90075-5; Lecanu L, 2004, STEROIDS, V69, P1, DOI 10.1016/j.steroids.2003.09.007; Liu F, 2010, J EXP MAR BIOL ECOL, V382, P82, DOI 10.1016/j.jembe.2009.11.005; Liu M, 2011, J BIOCHEM, V149, P27, DOI 10.1093/jb/mvq110; MACDONALD MJ, 1988, DIABETES, V37, P997, DOI 10.2337/diabetes.37.7.997; Magalhaes LG, 2010, PARASITOL RES, V106, P395, DOI 10.1007/s00436-009-1674-8; Mariod AA, 2009, FOOD CHEM, V116, P306, DOI 10.1016/j.foodchem.2009.02.051; Micallef MA, 2009, ATHEROSCLEROSIS, V204, P476, DOI 10.1016/j.atherosclerosis.2008.09.020; O'Sullivan AM, 2011, FOOD CHEM, V126, P1064, DOI 10.1016/j.foodchem.2010.11.127; OECD, 2001, AC OR T; OECD, 2002, GUID DOC REC ASS US; Preethi R., 2010, ADV BIOL RES, V4, P122; Rios AD, 2009, FOOD CHEM, V113, P1113, DOI 10.1016/j.foodchem.2008.08.084; Shao SQ, 2010, J AGR FOOD CHEM, V58, P11616, DOI 10.1021/jf102285b; Shon MY, 2003, FOOD CHEM, V82, P593, DOI 10.1016/S0308-8146(03)00015-3; Singh G, 2006, FOOD CONTROL, V17, P745, DOI 10.1016/j.foodcont.2005.03.010; Skrivanova E, 2005, LETT APPL MICROBIOL, V41, P77, DOI 10.1111/j.1472-765X.2005.01709.x; SLATER TF, 1963, BIOCHIM BIOPHYS ACTA, V77, P383, DOI 10.1016/0006-3002(63)90513-4; Song LJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031456; Wang SC, 2007, INT J BIOL MACROMOL, V41, P369, DOI 10.1016/j.ijbiomac.2007.05.008; Xiao SH, 2009, PARASITOL RES, V106, P237, DOI 10.1007/s00436-009-1656-x; Yan XJ, 1998, PLANT FOOD HUM NUTR, V52, P253, DOI 10.1023/A:1008007014659; Ye H, 2009, EUR FOOD RES TECHNOL, V230, P101, DOI 10.1007/s00217-009-1147-4; Yesilada E, 2000, J ETHNOPHARMACOL, V73, P471, DOI 10.1016/S0378-8741(00)00327-5; Yoon MA, 2006, BIOL PHARM BULL, V29, P735, DOI 10.1248/bpb.29.735; Zhang L., 2000, J JIMEI U NATURAL SC, V5, P35	44	18	19	0	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2013	8	11							e80413	10.1371/journal.pone.0080413	http://dx.doi.org/10.1371/journal.pone.0080413			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MX	24312216	Green Published, gold, Green Submitted			2023-01-03	WOS:000327670300012
J	Green, DS; Rupasinghe, C; Warburton, R; Wilson, JL; Sallum, CO; Taylor, L; Yatawara, A; Mierke, D; Polgar, P; Hill, N				Green, Daniel S.; Rupasinghe, Chamila; Warburton, Rod; Wilson, Jamie L.; Sallum, Christine O.; Taylor, Linda; Yatawara, Achani; Mierke, Dale; Polgar, Peter; Hill, Nicholas			A Cell Permeable Peptide Targeting the Intracellular Loop 2 of Endothelin B Receptor Reduces Pulmonary Hypertension in a Hypoxic Rat Model	PLOS ONE			English	Article							ET(B) RECEPTORS; ETB RECEPTORS; ACTIVATION; TRANSDUCTION; EXPRESSION; MIMICKING; KINASE; ET(A)	Cell permeable peptides (CPP) aid cellular uptake of targeted cargo across the hydrophobic plasma membrane. CPP-mediated cargo delivery of receptor signaling motifs provides an opportunity to regulate specific receptor initiated signaling cascades. Both endothelin-1 receptors, ETA and ETB, have been targets of antagonist therapies for individuals with pulmonary arterial hypertension (PAH). These therapies have had success but have been accompanied by adverse reactions. Also, unlike the CPP which target specific signaling cascades, the antagonists target the entire function of the receptor. Using the CPP strategy of biased antagonism of the ETB receptor's intracellular loop 2 (ICB2), we demonstrate blunting of hypoxic pulmonary hypertension (HPH) in the rat, including indices of pulmonary arterial pressure, right ventricular hypertrophy and pulmonary vascular remodeling. Further, ex vivo analysis of the pulmonary artery treated with the IC2B peptide upon injection manifests marked reductions in Akt and ERK activation. Both kinases have been intimately related to cell proliferation and vascular contraction, the hallmarks of PAH. These observations in sum illustrate an involvement of the ETB receptor in HPH and furthermore provide a basis for a novel, CPP-based, strategy in the treatment of PAH, ultimately able to target not only ET-1, but also other factors involved in the development of PAH.	[Green, Daniel S.; Wilson, Jamie L.; Sallum, Christine O.; Taylor, Linda; Polgar, Peter] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; [Rupasinghe, Chamila; Yatawara, Achani; Mierke, Dale] Dartmouth Coll, Dept Chem, Hanover, NH 03755 USA; [Warburton, Rod; Hill, Nicholas] Tufts Sch Med, Div Pulm Med, Boston, MA 02111 USA	Boston University; Dartmouth College	Hill, N (corresponding author), Tufts Sch Med, Div Pulm Med, Boston, MA 02111 USA.	nhill@tuftsmedicalcenter.org	Wilson, Jamie/J-5913-2019		NIH [HL025776]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025776] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was partially supported by NIH Grant number HL025776 to PP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200; Fisher Kimberly A., 2008, P145, DOI 10.1007/978-1-60327-075-5_8; FUKURODA T, 1994, BIOCHEM BIOPH RES CO, V199, P1461, DOI 10.1006/bbrc.1994.1395; Galie N, 2008, LANCET, V371, P2093, DOI 10.1016/S0140-6736(08)60919-8; Gomez-Arroyo JG, 2012, AM J PHYSIOL-LUNG C, V302, pL363, DOI 10.1152/ajplung.00212.2011; HIRATA Y, 1993, J CLIN INVEST, V91, P1367, DOI 10.1172/JCI116338; Hoeper MM, 2009, EUR RESPIR J, V34, P529, DOI 10.1183/09031936.00094409; Howell K, 2003, J PHYSIOL-LONDON, V547, P133, DOI 10.1113/jphysiol.2002.030676; Ivy DD, 2002, AM J PHYSIOL-LUNG C, V282, pL703, DOI 10.1152/ajplung.00272.2001; Kelland NF, 2010, J VASC RES, V47, P16, DOI 10.1159/000231717; Krymskaya VP, 2011, FASEB J, V25, P1922, DOI 10.1096/fj.10-175018; Liu G, 2011, J HYPERTENS, V29, P696, DOI 10.1097/HJH.0b013e328343c62b; McNamara PJ, 2008, AM J PHYSIOL-LUNG C, V294, pL205, DOI 10.1152/ajplung.00234.2007; Nishida M, 2004, EUR J PHARMACOL, V496, P159, DOI 10.1016/j.ejphar.2004.06.028; Pei YZ, 2011, EUR J PHARMACOL, V666, P165, DOI 10.1016/j.ejphar.2011.05.035; Rousselle C, 2001, J PHARMACOL EXP THER, V296, P124; Sallum CO, 2012, CHEM BIOL DRUG DES, V80, P374, DOI 10.1111/j.1747-0285.2012.01405.x; SATO K, 1995, AM J PHYSIOL-LUNG C, V269, pL668, DOI 10.1152/ajplung.1995.269.5.L668; Schermuly RT, 2005, J CLIN INVEST, V115, P2811, DOI 10.1172/JCI24838; Schneider MP, 2007, ANNU REV PHARMACOL, V47, P731, DOI 10.1146/annurev.pharmtox.47.120505.105134; SEO B, 1994, CIRCULATION, V89, P1203, DOI 10.1161/01.CIR.89.3.1203; STEWART DJ, 1991, ANN INTERN MED, V114, P464, DOI 10.7326/0003-4819-114-6-464; Tuder RM, 2001, CLIN CHEST MED, V22, P405, DOI 10.1016/S0272-5231(05)70280-X; Tykocki NR, 2009, J PHARMACOL EXP THER, V329, P875, DOI 10.1124/jpet.108.145953; Wagstaff KM, 2006, CURR MED CHEM, V13, P1371, DOI 10.2174/092986706776872871; Wilson JL, 2012, EXP CELL RES, V318, P1125, DOI 10.1016/j.yexcr.2012.03.029; Yang XM, 2009, INVEST OPHTH VIS SCI, V50, P1873, DOI 10.1167/iovs.08-2591; Yu J, 2013, J CELL PHYSIOL, V228, P322, DOI 10.1002/jcp.24132; Yu J, 2010, CHEM BIOL DRUG DES, V76, P70, DOI 10.1111/j.1747-0285.2010.00985.x; Zrelli H, 2011, PLANTA MED, V77, P1680, DOI 10.1055/s-0030-1271073	30	13	14	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 27	2013	8	11							e81309	10.1371/journal.pone.0081309	http://dx.doi.org/10.1371/journal.pone.0081309			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261GG	24312288	Green Published, Green Submitted, gold			2023-01-03	WOS:000327652100072
J	Neyrinck, AM; Alligier, M; Memvanga, PB; Nevraumont, E; Larondelle, Y; Preat, V; Cani, PD; Delzenne, NM				Neyrinck, Audrey M.; Alligier, Maud; Memvanga, Patrick B.; Nevraumont, Elodie; Larondelle, Yvan; Preat, Veronique; Cani, Patrice D.; Delzenne, Nathalie M.			Curcuma longa Extract Associated with White Pepper Lessens High Fat Diet-Induced Inflammation in Subcutaneous Adipose Tissue	PLOS ONE			English	Article							GUT-MICROBIOTA; INSULIN-RESISTANCE; OBESITY; TETRAHYDROCURCUMIN; ANGIOGENESIS; POMEGRANATE; POLYPHENOLS; MICROFLORA; MODULATION; PREVENTION	Background Supra-nutritional doses of curcumin, derived from the spice Curcuma longa, have been proposed as a potential treatm related to obesity. The aim of the present study was to test whether Curcuma longa extract rich in curcumin and asso doses compatible with human use, could modulate systemic inflammation in diet-induced obese mice. We questioned t and gut microbiota in the effect of Curcuma-P (R) in obesity. Methodology/Principal Findings Mice were fed either a control diet (CT), a high fat (HF) diet or a HF diet containing Curcuma longa extract (0.1 % of pepper (0.01 %) for four weeks. Curcumin has been usually combined with white pepper, which contain piperine, in or combination did not significantly modify body weight gain, glycemia, insulinemia, serum lipids and intestinal inflammato curcumin accumulated in the subcutaneous adipose tissue. Importantly, the co-supplementation in curcuma extract and pro-inflammatory cytokines expression in the subcutaneous adipose tissue, an effect independent of adiposity, immune of gut bacteria controlling inflammation. Conclusions/Significance These findings support that nutritional doses of Curcuma longa, associated with white pepper, is able to decrease infl tissue and this effect could be rather linked to a direct effect of bioactive metabolites reaching the adipose tissue, than composition.					Neyrinck, Audrey/AAE-7929-2019; D., Cani Patrice/M-8055-2016; Delzenne, Nathalie/AAC-4628-2019	Neyrinck, Audrey/0000-0002-9435-3338; D., Cani Patrice/0000-0003-2040-2448; Delzenne, Nathalie/0000-0003-2115-6082	Longevie SA	Longevie SA	P.D. Cani is Research Associate from the FRS-FNRS (Fonds de la Recherche Scientifique, http://www.f recipient of a grant from the SFD (Societe Francophone du Diabete). This work was supported by Longevie SA. T data collection and analysis, decision to publish, or preparation of the manuscript.	Aggarwal BB, 2006, BIOCHEM PHARMACOL, V71, P1397, DOI 10.1016/j.bcp.2006.02.009; Aggarwal BB, 2010, ANNU REV NUTR, V30, P173, DOI 10.1146/annurev.nutr.012809.104755; Ahn J, 2010, AM J PHYSIOL-CELL PH, V298, pC1510, DOI 10.1152/ajpcell.00369.2009; Alappat L, 2010, NUTR REV, V68, P729, DOI 10.1111/j.1753-4887.2010.00341.x; Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r; Babu PS, 1997, MOL CELL BIOCHEM, V166, P169, DOI 10.1023/A:1006819605211; Basu A, 2009, NUTR REV, V67, P49, DOI 10.1111/j.1753-4887.2008.00133.x; Bhandarkar SS, 2007, ADV EXP MED BIOL, V595, P185; Caesar R, 2010, J INTERN MED, V268, P320, DOI 10.1111/j.1365-2796.2010.02270.x; Cani PD, 2007, DIABETOLOGIA, V50, P2374, DOI 10.1007/s00125-007-0791-0; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; Delzenne NM, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-S1-S10; Delzenne NM, 2013, BRIT J NUTR, V109, pS81, DOI 10.1017/S0007114512004047; Delzenne NM, 2011, ANNU REV NUTR, V31, P15, DOI 10.1146/annurev-nutr-072610-145146; Delzenne NM, 2011, TARGETING GUT MICROB, P639, DOI [10.1038/nrendo.2011.126, DOI 10.1038/NREND0.2011.126]; Dewulf EM, 2011, J NUTR BIOCHEM, V22, P712, DOI 10.1016/j.jnutbio.2010.05.009; Diamant M, 2011, OBES REV, V12, P272, DOI 10.1111/j.1467-789X.2010.00797.x; Ejaz A, 2009, J NUTR, V139, P919, DOI 10.3945/jn.108.100966; El-Moselhy MA, 2011, FOOD CHEM TOXICOL, V49, P1129, DOI 10.1016/j.fct.2011.02.004; Finucane MM, 2011, LANCET, V377, P557, DOI 10.1016/S0140-6736(10)62037-5; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gonzales AM, 2008, NUTR METAB, V5, DOI 10.1186/1743-7075-5-17; Hassaninasab A, 2011, P NATL ACAD SCI USA, V108, P6615, DOI 10.1073/pnas.1016217108; Jang EM, 2008, METABOLISM, V57, P1576, DOI 10.1016/j.metabol.2008.06.014; Kemperman RA, 2010, MICROBIOL-SGM, V156, P3224, DOI 10.1099/mic.0.042127-0; Lansky EP, 2007, J ETHNOPHARMACOL, V109, P177, DOI 10.1016/j.jep.2006.09.006; Ley RE, 2010, CURR OPIN GASTROEN, V26, P5, DOI 10.1097/MOG.0b013e328333d751; Marczylo TH, 2009, J AGR FOOD CHEM, V57, P797, DOI 10.1021/jf803038f; Memvanga PB, 2013, ORAL MALARIA THERAPY, DOI DOI 10.1016/J.JC0NREL.2013.09.001; Murakami Y, 2008, ANTICANCER RES; Murugan Pidaran, 2006, Journal of Basic and Clinical Physiology and Pharmacology, V17, P231; Neyrinck AM, 2012, J NUTR BIOCHEM, V23, P51, DOI 10.1016/j.jnutbio.2010.10.008; Oner-Iyidogan Y, 2013, J PHYSIOL BIOCHEM, V69, P677, DOI 10.1007/s13105-013-0244-9; Osborn O, 2012, NAT MED, V18, P363, DOI 10.1038/nm.2627; Parkar SG, 2008, INT J FOOD MICROBIOL, V124, P295, DOI 10.1016/j.ijfoodmicro.2008.03.017; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Sandur SK, 2007, CARCINOGENESIS, V28, P1765, DOI 10.1093/carcin/bgm123; Selma MV, 2009, J AGR FOOD CHEM, V57, P6485, DOI 10.1021/jf902107d; Shao WJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028784; Sharma RA, 2005, EUR J CANCER, V41, P1955, DOI 10.1016/j.ejca.2005.05.009; Shehzad A, 2011, EUR J NUTR, V50, P151, DOI 10.1007/s00394-011-0188-1; Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552; Tzounis X, 2008, BRIT J NUTR, V99, P782, DOI 10.1017/S0007114507853384; Weisberg SP, 2008, ENDOCRINOLOGY, V149, P3549, DOI 10.1210/en.2008-0262; Woo HM, 2007, LIFE SCI, V80, P926, DOI 10.1016/j.lfs.2006.11.030; Yoysungnoen P, 2006, CLIN HEMORHEOL MICRO, V34, P109	47	33	36	2	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2013	8	11							e81252	10.1371/journal.pone.0081252	http://dx.doi.org/10.1371/journal.pone.0081252			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256LO	24260564	gold, Green Submitted, Green Published			2023-01-03	WOS:000327311900127
J	Boussi-Gross, R; Golan, H; Fishlev, G; Bechor, Y; Volkov, O; Bergan, J; Friedman, M; Hoofien, D; Shlamkovitch, N; Ben-Jacob, E; Efrati, S				Boussi-Gross, Rahav; Golan, Haim; Fishlev, Gregori; Bechor, Yair; Volkov, Olga; Bergan, Jacob; Friedman, Mony; Hoofien, Dan; Shlamkovitch, Nathan; Ben-Jacob, Eshel; Efrati, Shai			Hyperbaric Oxygen Therapy Can Improve Post Concussion Syndrome Years after Mild Traumatic Brain Injury - Randomized Prospective Trial	PLOS ONE			English	Article							EMISSION COMPUTED-TOMOGRAPHY; ACUTE ISCHEMIC-STROKE; MINOR HEAD-INJURY; DEAD-SEA; LOW-ALTITUDE; NEUROPSYCHOLOGICAL DEFICITS; MITOCHONDRIAL-FUNCTION; CEREBRAL OXYGENATION; CINGULATE GYRUS; TISSUE OXYGEN	Traumatic brain injury (TBI) is the leading cause of death and disability in the US. Approximately 70-90% of the TBI cases are classified as mild, and up to 25% of them will not recover and suffer chronic neurocognitive impairments. The main pathology in these cases involves diffuse brain injuries, which are hard to detect by anatomical imaging yet noticeable in metabolic imaging. The current study tested the effectiveness of Hyperbaric Oxygen Therapy (HBOT) in improving brain function and quality of life in mTBI patients suffering chronic neurocognitive impairments.	[Boussi-Gross, Rahav; Fishlev, Gregori; Bechor, Yair; Bergan, Jacob; Friedman, Mony; Efrati, Shai] Assaf Harofeh Med Ctr, Inst Hyperbar Med, IL-70300 Zerifin, Israel; [Ben-Jacob, Eshel; Efrati, Shai] Assaf Harofeh Med Ctr, Res & Dev Unit, IL-70300 Zerifin, Israel; [Golan, Haim; Volkov, Olga; Efrati, Shai] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Golan, Haim; Volkov, Olga] Assaf Harofeh Med Ctr, Inst Nucl Med, IL-70300 Zerifin, Israel; [Ben-Jacob, Eshel] Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, Sch Phys & Astron, IL-69978 Tel Aviv, Israel; [Hoofien, Dan] Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel; [Hoofien, Dan] Natl Inst Rehabil Brain Injured, Tel Aviv, Israel; [Shlamkovitch, Nathan] Assaf Harofeh Med Ctr, IL-70300 Zerifin, Israel; [Ben-Jacob, Eshel] Rice Univ, Ctr Theoret Biol Phys, Houston, TX USA; [Ben-Jacob, Eshel; Efrati, Shai] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel	Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Hebrew University of Jerusalem; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Rice University; Tel Aviv University	Ben-Jacob, E (corresponding author), Assaf Harofeh Med Ctr, Res & Dev Unit, IL-70300 Zerifin, Israel.	eshel@rice.edu; efratishai@013.net	Golan, Haim/K-2831-2019		Assaf-Harofeh medical center; Tauber Family Foundation; Maguy-Glass Chair in Physics of Complex Systems at Tel Aviv University	Assaf-Harofeh medical center; Tauber Family Foundation; Maguy-Glass Chair in Physics of Complex Systems at Tel Aviv University	The study was supported by the research fund of Assaf-Harofeh medical center, by the Tauber Family Foundation and by the Maguy-Glass Chair in Physics of Complex Systems at Tel Aviv University. None of the supporting bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abinader EG, 1999, AM J CARDIOL, V83, P250, DOI 10.1016/S0002-9149(98)00829-7; Vilela DSA, 2008, ACTA OTO-LARYNGOL, V128, P1048, DOI 10.1080/00016480701827525; ANDERSON DC, 1991, STROKE, V22, P1137, DOI 10.1161/01.STR.22.9.1137; Austin D, 1998, LANCET, V351, P1815, DOI 10.1016/S0140-6736(05)78781-X; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Calvert JW, 2007, NEUROL RES, V29, P132, DOI 10.1179/016164107X174156; Cao H, 2013, EXP THER MED, V5, P1609, DOI 10.3892/etm.2013.1043; Catafau AM, 1998, PSYCHIAT RES-NEUROIM, V83, P67, DOI 10.1016/S0925-4927(98)00031-6; Chang CC, 2009, J NEUROTRAUM, V26, P1263, DOI [10.1089/neu.2008.0619, 10.1089/neu.2008-0619]; Chen ZQ, 2008, NEURAL REGEN RES, V3, P117; Cifu DX, 2013, J HEAD TRAUMA REHABI; Cohen J., 2013, STAT POWER ANAL BEHA; Collet JP, 2001, LANCET, V357, P582, DOI 10.1016/S0140-6736(00)04054-X; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; de Frias CM, 2003, J GERONTOL B-PSYCHOL, V58, pP12, DOI 10.1093/geronb/58.1.P12; Doniger GM, 2007, MINDSTREAMS VALIDITY; Doniger GM, 2007, MINDSTREAMS COMPUTER; Doniger GM, 2012, GUIDE MINDSTREAMS NO; Doniger GM, 2007, CONSTRUCT VALIDITY M; Efrati S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053716; Falk B, 2006, PEDIATR PULM, V41, P234, DOI 10.1002/ppul.20342; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Gabizon I, 2011, ISR MED ASSOC J, V13, P402; Glisky EL, 2004, SCI PRACT NEUROPSYCH, P100; Goldbart AD, 2007, ISR MED ASSOC J, V9, P806; Golden Z, 2006, DISABIL REHABIL, V28, P1379, DOI 10.1080/09638280600638364; Golden ZL, 2002, INT J NEUROSCI, V112, P119, DOI 10.1080/00207450212027; GOLDING F C, 1960, Br J Ind Med, V17, P167; Gunther A, 2005, EUR J NEUROSCI, V21, P3189, DOI 10.1111/j.1460-9568.2005.04151.x; Harch PG, 2007, BRAIN RES, V1174, P120, DOI 10.1016/j.brainres.2007.06.105; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Hattori N, 2009, J NUCL MED, V50, P1054, DOI 10.2967/jnumed.108.060368; Imai K, 2006, NEUROL MED-CHIR, V46, P373, DOI 10.2176/nmc.46.373; Insel Thomas R, 2010, Sci Am, V302, P44; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; James PB, 2001, LANCET, V357, P2052, DOI 10.1016/S0140-6736(00)05137-0; JASZCZAK RJ, 1979, PHYS MED BIOL, V24, P1123, DOI 10.1088/0031-9155/24/6/003; Kan EM, 2012, BRAIN RES BULL, V87, P359, DOI 10.1016/j.brainresbull.2012.01.007; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kochanek PM, 2007, BRAIN INJURY MED PRI, P81; Kramer MR, 1998, CHEST, V113, P571, DOI 10.1378/chest.113.3.571; Kuffler DP, 2011, P R HEALTH SCI J, V30, P35; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Lin JW, 2008, ACTA NEUROCHIR SUPPL, V101, P145; Lo CP, 2007, EUR J NEUROL, V14, P777, DOI 10.1111/j.1468-1331.2007.01854.x; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mychaskiw G, 2013, J NEUROTRAUMA; Mychaskiw Ii G, 2012, J NEUROTRAUMA; Neubauer RA, 1998, NEUROL RES, V20, pS33; Neubauer RA, 2000, HYPERBARIC OXYGEN TH; NIGHOGHOSSIAN N, 1995, STROKE, V26, P1369, DOI 10.1161/01.STR.26.8.1369; Niklas A, 2004, J NEUROL SCI, V219, P77, DOI 10.1016/j.jns.2003.12.013; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Palzur E, 2008, BRAIN RES, V1221, P126, DOI 10.1016/j.brainres.2008.04.078; Posner MI, 2007, COGN AFFECT BEHAV NE, V7, P391, DOI 10.3758/CABN.7.4.391; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Rockswold SB, 2007, NEUROL RES, V29, P162, DOI 10.1179/016164107X181798; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Rusyniak DE, 2003, STROKE, V34, P571, DOI 10.1161/01.STR.0000050644.48393.D0; SCOVILLE WB, 1973, ACTA NEUROCHIR, V28, P251, DOI 10.1007/BF01405644; Sohlberg M., 2001, COGNITIVE REHABILITA; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Squire LR, 2004, NEUROBIOL LEARN MEM, V82, P171, DOI 10.1016/j.nlm.2004.06.005; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Vila JF, 2005, UNDERSEA HYPERBAR M, V32, P341; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Wolf G, 2012, J NEUROTRAUM, V29, P2606, DOI 10.1089/neu.2012.2549; Yang YJ, 2008, UNDERSEA HYPERBAR M, V35, P113; Zhang John H, 2005, Pathophysiology, V12, P63, DOI 10.1016/j.pathophys.2005.01.003; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	83	124	132	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2013	8	11							e79995	10.1371/journal.pone.0079995	http://dx.doi.org/10.1371/journal.pone.0079995			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255RX	24260334	gold, Green Published, Green Submitted			2023-01-03	WOS:000327258600052
J	Rusconi, S; Vitiello, P; Adorni, F; Colella, E; Foca, E; Capetti, A; Meraviglia, P; Abeli, C; Bonora, S; D'Annunzio, M; Di Biagio, A; Di Pietro, M; Butini, L; Orofino, G; Colafigli, M; d'Ettorre, G; Francisci, D; Parruti, G; Soria, A; Buonomini, AR; Tommasi, C; Mosti, S; Bai, F; Stuppino, SDN; Morosi, M; Montano, M; Tau, P; Merlini, E; Marchetti, G				Rusconi, Stefano; Vitiello, Paola; Adorni, Fulvio; Colella, Elisa; Foca, Emanuele; Capetti, Amedeo; Meraviglia, Paola; Abeli, Clara; Bonora, Stefano; D'Annunzio, Marco; Di Biagio, Antonio; Di Pietro, Massimo; Butini, Luca; Orofino, Giancarlo; Colafigli, Manuela; d'Ettorre, Gabriella; Francisci, Daniela; Parruti, Giustino; Soria, Alessandro; Buonomini, Anna Rita; Tommasi, Chiara; Mosti, Silvia; Bai, Francesca; Stuppino, Silvia Di Nardo; Morosi, Manuela; Montano, Marco; Tau, Pamela; Merlini, Esther; Marchetti, Giulia			Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial	PLOS ONE			English	Article							T-CELL RECOVERY; ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; VIROLOGICAL SUPPRESSION; HIV-1-INFECTED PATIENTS; VIRAL SUPPRESSION; ADDING MARAVIROC; INTERLEUKIN-7; ACTIVATION; RECONSTITUTION	Background: Immunological non-responders (INRs) lacked CD4 increase despite HIV-viremia suppression on HAART and had an increased risk of disease progression. We assessed immune reconstitution profile upon intensification with maraviroc in INRs. Methods: We designed a multi-centric, randomized, parallel, open label, phase 4 superiority trial. We enrolled 97 patients on HAART with CD4+<= 200/mu L and/or CD4+ recovery <= 25% and HIV-RNA<50 cp/mL. Patients were randomized 1: 1 to HAART+maraviroc or continued HAART. CD4+ and CD8+CD45+RA/RO, Ki67 expression and plasma IL-7 were quantified at W0, W12 and W48. Results: By W48 both groups displayed a CD4 increase without a significant inter-group difference. A statistically significant change in CD8 favored patients in arm HAART+maraviroc versus HAART at W12 (p=.009) and W48 (p=.025). The CD4>200/mu L and CD4>200/mu L + CD4 gain >= 25% end-points were not satisfied at W12 (p=.24 and p=.619) nor at W48 (p=.076 and p=.236). Patients continuing HAART displayed no major changes in parameters of T-cell homeostasis and activation. Maraviroc-receiving patients experienced a significant rise in circulating IL-7 by W48 (p=.01), and a trend in temporary reduction in activated HLA-DR+CD38+CD4+ by W12 (p=.06) that was not maintained at W48. Conclusions: Maraviroc intensification in INRs did not have a significant advantage in reconstituting CD4 T-cell pool, but did substantially expand CD8. It resulted in a low rate of treatment discontinuations.	[Rusconi, Stefano; Vitiello, Paola; Colella, Elisa; Stuppino, Silvia Di Nardo; Morosi, Manuela; Tau, Pamela] Univ Milan, DIBIC Luigi Sacco, Div Clin Malattie Infett, Milan, Italy; [Adorni, Fulvio] ITB CNR, Segrate, MI, Italy; [Foca, Emanuele] Univ Brescia, Clin Malattie Infett & Tropicali, Brescia, Italy; [Capetti, Amedeo] Osped L Sacco, Div Malattie Infett 1, Milan, Italy; [Meraviglia, Paola] Osped L Sacco, Div Malattie Infett 2, Milan, Italy; [Vitiello, Paola; Abeli, Clara] Osped L Sacco, Div Malattie Infett 2, Busto Arsizio, VA, Italy; [Bonora, Stefano] Univ Turin, Osped Amedeo Savoia, Clin Malattie Infett, Turin, Italy; [D'Annunzio, Marco] AO Univ Policlin, Clin Malattie Infett, Bari, Italy; [Di Biagio, Antonio] Univ Genoa, Osped San Martino, Clin Malattie Infett, Genoa, Italy; [Di Pietro, Massimo] Osped S Maria Annunziata, Div Malattie Infett, Florence, Italy; [Butini, Luca] AO Univ, Serv Immunol Clin & Tipizzazione, Torrette Di Ancona, Italy; [Orofino, Giancarlo] Osped Amedeo Savoia, Div A Malattie Infett, Turin, Italy; [Colafigli, Manuela] Univ Cattolica Sacro Cuore, Ist Clin Malattie Infett, Rome, Italy; [d'Ettorre, Gabriella] Univ Roma La Sapienza, UO Malattie Infett, Rome, Italy; [Francisci, Daniela] Monteluce Policlin, Clin Malattie Infett, Perugia, Italy; [Parruti, Giustino] Osped Santo Spirito, Div Clin Malattie Infett, Pescara, Italy; [Soria, Alessandro] Osped San Gerardo, Div Clin Malattie Infett, Monza, Italy; [Buonomini, Anna Rita; Montano, Marco] Policlin Tor Vergata, Clin Malattie Infett, Rome, Italy; [Tommasi, Chiara] III Div Malattie Infett INMI Lazzaro Spallanzani, Rome, Italy; [Mosti, Silvia] IV Div Malattie Infett INMI Lazzaro Spallanzani, Rome, Italy; [Bai, Francesca; Merlini, Esther; Marchetti, Giulia] Univ Milan, Polo Univ San Paolo, Dipartimento Sci Salute, Clin Malattie Infett, Milan, Italy	University of Milan; Luigi Sacco Hospital; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Brescia; University of Milan; Luigi Sacco Hospital; University of Milan; Luigi Sacco Hospital; University of Milan; Luigi Sacco Hospital; University of Turin; University of Genoa; IRCCS AOU San Martino IST; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Sapienza University Rome; San Gerardo Hospital; University of Rome Tor Vergata; Policlin Tor Vergata; University of Milan	Rusconi, S (corresponding author), Univ Milan, DIBIC Luigi Sacco, Div Clin Malattie Infett, Milan, Italy.	stefano.rusconi@unimi.it	Gori, Andrea/AAC-6078-2022; Bai, Francesca/K-4823-2018; Marchetti, Giulia/GPX-7655-2022; Di Biagio, Antonio/J-4901-2019; Adorni, Fulvio/P-7064-2018; Buonomini, Anna Rita/AAC-7325-2022; Adorni, Fulvio/GOH-0583-2022; Colafigli, Manuela/K-5167-2018; Rusconi, Stefano/H-9263-2012; d'Ettorre, Gabriella/K-4511-2016; MARCHETTI, GIULIA CARLA/K-4384-2018	Di Biagio, Antonio/0000-0003-1436-5089; Adorni, Fulvio/0000-0001-6264-6876; Buonomini, Anna Rita/0000-0001-7503-2742; Adorni, Fulvio/0000-0001-6264-6876; Colafigli, Manuela/0000-0003-1610-6347; Rusconi, Stefano/0000-0002-0375-9990; d'Ettorre, Gabriella/0000-0002-3571-5677; meraviglia, paola/0000-0002-3356-7199; MARCHETTI, GIULIA CARLA/0000-0002-4498-4828; SORIA, Alessandro/0000-0002-4447-2574; FOCA', Emanuele/0000-0003-4395-5379	Pfizer, Inc., New York, NY, USA; Anlaids Lombardy Onlus, Milan, Italy	Pfizer, Inc., New York, NY, USA(Pfizer); Anlaids Lombardy Onlus, Milan, Italy	This work has been funded by Pfizer, Inc., New York, NY, USA through an Investigator Initiated Research grant (to S. R.) and by Anlaids Lombardy Onlus, Milan, Italy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrams D, 2009, NEW ENGL J MED, V361, P1548, DOI 10.1056/NEJMoa0903175; AMOROSI EL, 1966, MEDICINE, V45, P139, DOI 10.1097/00005792-196603000-00003; Babiker A, 2000, AIDS RES HUM RETROV, V16, P1123; Cossarini F, 2012, J ANTIMICROB CHEMOTH, V67, P2474, DOI 10.1093/jac/dks216; Cuzin L, 2012, JAIDS-J ACQ IMM DEF, V61, P557, DOI 10.1097/QAI.0b013e318273015f; Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333; Gandhi RT, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000321; Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660; Gulick RM, 2007, AIDS, V21, P813, DOI 10.1097/QAD.0b013e32805e8753; Hammer SM, 2010, HIV CLIN TRIALS, V11, P312, DOI 10.1310/hct1105-312; Hunt PW, 2013, BLOOD, V121, P4635, DOI 10.1182/blood-2012-06-436345; Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786; LAPADULA G, 2012, 19 C RETR OPP INF SE; Levy Y, 2012, CLIN INFECT DIS, V55, P291, DOI 10.1093/cid/cis383; Marchetti G, 2006, AIDS, V20, P1727, DOI 10.1097/01.aids.0000242819.72839.db; MASSANELLA M, 18 C RETR OPP INF BO, P2011; Mazzucchelli R, 2007, NAT REV IMMUNOL, V7, P144, DOI 10.1038/nri2023; Monforte AD, 1999, AIDS, V13, P1669, DOI 10.1097/00002030-199909100-00010; NDHLOVU L, 2012, 19 C RETR OPP INF SE; Renaud M, 1999, AIDS, V13, P669, DOI 10.1097/00002030-199904160-00007; Robbins GK, 2009, CLIN INFECT DIS, V48, P350, DOI 10.1086/595888; Rossi R, 2011, CLIN EXP IMMUNOL, V166, P184, DOI 10.1111/j.1365-2249.2011.04409.x; Shalekoff S, 2001, J CLIN IMMUNOL, V21, P390, DOI 10.1023/A:1013121625962; Sieg SF, 2012, CURR HIV RES, V10, P341, DOI 10.2174/157016212800792432; Stepanyuk O, 2009, AIDS, V23, P1911, DOI 10.1097/QAD.0b013e32832f3c65; Street E, 2009, HIV MED, V10, P337, DOI 10.1111/j.1468-1293.2009.00692.x; Svicher V, 2012, NEW MICROBIOL, V35, P17; Tan RM, 2008, JAIDS-J ACQ IMM DEF, V47, P553, DOI 10.1097/QAI.0b013e31816856c5; Wilkin TJ, 2012, J INFECT DIS, V206, P534, DOI 10.1093/infdis/jis376; Zoufaly A, 2011, J INFECT DIS, V203, P364, DOI 10.1093/jinfdis/jiq055	30	33	35	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2013	8	11							e80157	10.1371/journal.pone.0080157	http://dx.doi.org/10.1371/journal.pone.0080157			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254DJ	24244635	Green Submitted, Green Published, gold			2023-01-03	WOS:000327143800129
J	Koeberl, DD; Austin, S; Case, LE; Smith, EC; Buckley, AF; Young, SP; Bali, D; Kishnani, PS				Koeberl, Dwight D.; Austin, Stephanie; Case, Laura E.; Smith, Edward C.; Buckley, Anne F.; Young, Sarah P.; Bali, Deeksha; Kishnani, Priya S.			Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease	FASEB JOURNAL			English	Article						mannose-6-phosphate receptor; acid -glucosidase; acid maltase; glycogen storage disease type II	ACID-ALPHA-GLUCOSIDASE; BECKER MUSCULAR-DYSTROPHY; MOUSE MODEL; EFFICACY; GLYCOGEN; MASS; RECOMBINANT; DUCHENNE; VECTOR; TRIAL	Effective dosages for enzyme replacement therapy (ERT) in Pompe disease are much higher than for other lysosomal storage disorders, which has been attributed to low cation-independent mannose-6-phosphate receptor (CI-MPR) in skeletal muscle. We have previously demonstrated the benefit of increased CI-MPR-mediated uptake of recombinant human acid--glucosidase during ERT in mice with Pompe disease following addition of albuterol therapy. Currently we have completed a pilot study of albuterol in patients with late-onset Pompe disease already on ERT for >2 yr, who were not improving further. The 6-min walk test (6MWT) distance increased in all 7 subjects at wk 6 (30 +/- 13 m; P=0.002), wk 12 (34 +/- 14 m; P=0.004), and wk 24 (42 +/- 37 m; P=0.02), in comparison with baseline. Grip strength was improved significantly for both hands at wk 12. Furthermore, individual subjects reported benefits; e.g., a female patient could stand up from sitting on the floor much more easily (time for supine to standing position decreased from 30 to 11 s), and a male patient could readily swing his legs out of his van seat (hip abduction increased from 1 to 2+ on manual muscle testing). Finally, analysis of the quadriceps biopsies suggested increased CI-MPR at wk 12 (P=0.08), compared with baseline. With the exception of 1 patient who succumbed to respiratory complications of Pompe disease in the first week, only mild adverse events have been reported, including tremor, transient difficulty falling asleep, and mild urinary retention (requiring early morning voiding). Therefore, this pilot study revealed initial safety and efficacy in an open label study of adjunctive albuterol therapy in patients with late-onset Pompe disease who had been stable on ERT with no improvements noted over the previous several years.Koeberl, D. D., Austin, S., Case, L. E., Smith, E. C., Buckley, A. F., Young, S. P., Bali, D., Kishnani, P. S. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease.	[Koeberl, Dwight D.; Austin, Stephanie; Young, Sarah P.; Bali, Deeksha; Kishnani, Priya S.] Duke Univ, Med Ctr, Dept Pediat, Div Med Genet, Durham, NC 27710 USA; [Case, Laura E.] Duke Univ, Med Ctr, Dept Community & Family Med, Div Phys Therapy, Durham, NC 27710 USA; [Smith, Edward C.] Duke Univ, Med Ctr, Dept Pediat, Div Pediat Genet, Durham, NC 27710 USA; [Buckley, Anne F.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University	Koeberl, DD (corresponding author), Duke Univ, Med Ctr, Box 103856, Durham, NC 27710 USA.	koebe001@mc.duke.edu		Case, Laura/0000-0002-2941-2186; Buckley, Anne/0000-0003-1209-5791	Duke University Medical Center	Duke University Medical Center	This study was funded by a Bridge Funding grant from the Duke University Medical Center. The authors express appreciation to Dr. Y.-T. Chen for discussions regarding study design and therapy in Pompe disease. In addition, the authors deeply appreciate Ms. Songtao Li and Ms. Jian Dai for their outstanding technical support of this project, and Ms. Carla Johnson for logistical support.	Amalfitano A, 1999, P NATL ACAD SCI USA, V96, P8861, DOI 10.1073/pnas.96.16.8861; Angelini EPC, 2004, BASIC APPL MYOL, V14, P71; Cardone Monica, 2008, Pathogenetics, V1, P6, DOI 10.1186/1755-8417-1-6; CARUSO JF, 1995, MED SCI SPORT EXER, V27, P1471; Fowler EG, 2004, NEUROLOGY, V62, P1006, DOI 10.1212/01.WNL.0000118530.71646.0F; Kissel JT, 2001, NEUROLOGY, V57, P1434, DOI 10.1212/WNL.57.8.1434; Koeberl DD, 2012, MOL GENET METAB, V105, P221, DOI 10.1016/j.ymgme.2011.11.005; Koeberl DD, 2011, MOL GENET METAB, V103, P107, DOI 10.1016/j.ymgme.2011.02.006; Li ST, 2013, FASEB J, V27, P34, DOI 10.1096/fj.12-207472; Matsumoto T, 2006, ARCH ORAL BIOL, V51, P603, DOI 10.1016/j.archoralbio.2006.01.003; McVie-Wylie AJ, 2008, MOL GENET METAB, V94, P448, DOI 10.1016/j.ymgme.2008.04.009; Raben N, 2005, MOL THER, V11, P48, DOI 10.1016/j.ymthe.2004.09.017; Raben N, 2003, MOL GENET METAB, V80, P159, DOI 10.1016/j.ymgme.2003.08.022; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Skura CL, 2008, NEUROLOGY, V70, P137, DOI 10.1212/01.WNL.0000287070.00149.a9; Sun BD, 2005, MOL THER, V11, P57, DOI 10.1016/j.ymthe.2004.10.004; van der Ploeg AT, 2010, NEW ENGL J MED, V362, P1396, DOI 10.1056/NEJMoa0909859; Young SP, 2009, GENET MED, V11, P536, DOI 10.1097/GIM.0b013e3181a87867; Young SP, 2003, ANAL BIOCHEM, V316, P175, DOI 10.1016/S0003-2697(03)00056-3; Zhu YX, 2009, MOL THER, V17, P954, DOI 10.1038/mt.2009.37	20	26	26	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2171	2176		10.1096/fj.13-241893	http://dx.doi.org/10.1096/fj.13-241893			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24443373	Green Submitted			2023-01-03	WOS:000335336000020
J	Sato, K; Iemitsu, M; Matsutani, K; Kurihara, T; Hamaoka, T; Fujita, S				Sato, Koji; Iemitsu, Motoyuki; Matsutani, Kenji; Kurihara, Toshiyuki; Hamaoka, Takafumi; Fujita, Satoshi			Resistance training restores muscle sex steroid hormone steroidogenesis in older men	FASEB JOURNAL			English	Article						aging; muscle strength; skeletal muscle; exercise	METABOLIC SYNDROME; TESTOSTERONE; EXERCISE; DHEA; DEHYDROEPIANDROSTERONE; STRENGTH; PATHWAY	Skeletal muscle can synthesize testosterone and 5 alpha-dihydrotestosterone (DHT) from dehydroepiandrosterone (DHEA) via steroidogenic enzymes in vitro, but hormone levels and steroidogenic enzyme expression decline with aging. Resistance exercise has been shown to increase in plasma sex steroid hormone levels. However, it remains unclear whether resistance training can restore impaired steroidogenic enzyme expressions in older individuals. Six young and 13 older men were recruited, and muscle biopsies were taken from the vastus lateralis at basal state. The same group of older subjects underwent resistance training involving knee extension and flexion exercises for 12 wk, and post-training biopsies were performed 4-5 d after the last exercise session. Muscular sex steroid hormone levels and sex steroidgenesis-related enzyme expressions were significantly lower in older subjects than younger ones at baseline, but 12 wk of resistance training significantly restored hormone levels (DHEA: 432 +/- 26 at baseline, 682 +/- 31 pg/mu g protein, DHT: 6.2 +/- 0.9 at baseline, 9.8 +/- 1.4 pg/mu g protein). Furthermore, the steroidogenesis-related enzymes such as 3 beta-hydroxysteroid dehydrogenase (HSD), 17 beta-HSD, and 5 alpha-reductase expressions were significantly restored by resistance training. We conclude progressive resistance training restores age-related declines in sex steroidogenic enzyme and muscle sex steroid hormone levels in older men.-Sato, K., Iemitsu, M., Matsutani, K., Kurihara, T., Hamaoka, T., Fujita, S. Resistance training restores muscle sex steroid hormone steroidogenesis in older men.	[Sato, Koji; Iemitsu, Motoyuki; Matsutani, Kenji; Kurihara, Toshiyuki; Hamaoka, Takafumi; Fujita, Satoshi] Ritsumeikan Univ, Fac Sport & Hlth Sci, Kusatsu, Shiga 5258577, Japan	Ritsumeikan University	Fujita, S (corresponding author), Ritsumeikan Univ, 1-1-1 Nojihigashi, Kusatsu, Shiga 5258577, Japan.	safujita@fc.ritsumei.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan [23700849, 24300235, 22680050]; Yamaha Motor Foundation for Sports; Grants-in-Aid for Scientific Research [25560378, 23300217] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Yamaha Motor Foundation for Sports; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors specially thank Dr. Noboru Mesaki for supporting this study. This work was supported by grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (23700849, 24300235, and 22680050). This work was also funded by the Yamaha Motor Foundation for Sports (to K. S., S. F., and M. I.). The authors declare no conflicts of interest.	Aizawa K, 2007, AM J PHYSIOL-ENDOC M, V292, pE577, DOI 10.1152/ajpendo.00367.2006; Aizawa K, 2010, STEROIDS, V75, P219, DOI 10.1016/j.steroids.2009.12.002; Akishita M, 2010, ATHEROSCLEROSIS, V210, P232, DOI 10.1016/j.atherosclerosis.2009.10.037; Belanger A., 2005, J CLIN ENDOCR METAB, V79, P1086; Caron Marc-Andre, 2011, BMC Res Notes, V4, P488, DOI 10.1186/1756-0500-4-488; Copeland JL, 2002, J GERONTOL A-BIOL, V57, pB158, DOI 10.1093/gerona/57.4.B158; Ferrando AA, 2002, AM J PHYSIOL-ENDOC M, V282, pE601, DOI 10.1152/ajpendo.00362.2001; Fujita S, 2009, DIABETOLOGIA, V52, P1889, DOI 10.1007/s00125-009-1430-8; Hawkins VN, 2008, MED SCI SPORT EXER, V40, P223, DOI 10.1249/mss.0b013e31815bbba9; Jubrias SA, 2001, J APPL PHYSIOL, V90, P1663, DOI 10.1152/jappl.2001.90.5.1663; Labrie F, 2005, J ENDOCRINOL, V187, P169, DOI 10.1677/joe.1.06264; Li CY, 2010, DIABETES CARE, V33, P1618, DOI 10.2337/dc09-1788; Lo JC, 2006, AM J MED, V119, P69, DOI 10.1016/j.amjmed.2006.07.009; Muller M, 2005, J CLIN ENDOCR METAB, V90, P2618, DOI 10.1210/jc.2004-1158; Pollanen E, 2011, AGING CELL, V10, P650, DOI 10.1111/j.1474-9726.2011.00701.x; Pollanen E, 2010, GROWTH HORM IGF RES, V20, P372, DOI 10.1016/j.ghir.2010.07.003; Sato K, 2008, AM J PHYSIOL-ENDOC M, V294, pE961, DOI 10.1152/ajpendo.00678.2007; Sato K, 2011, AM J PHYSIOL-ENDOC M, V301, pE274, DOI 10.1152/ajpendo.00564.2010; Sattler FR, 2009, J CLIN ENDOCR METAB, V94, P1991, DOI 10.1210/jc.2008-2338; Sheffield-Moore M, 2011, J CLIN ENDOCR METAB, V96, pE1831, DOI 10.1210/jc.2011-1262; Sinha-Hikim I., 2001, AM J PHYSIOL-ENDOC M, V283, pE154; Taekema DG, 2011, EUR J ENDOCRINOL, V164, P189, DOI 10.1530/EJE-10-0703; Villareal DT, 2006, AM J PHYSIOL-ENDOC M, V291, pE1003, DOI 10.1152/ajpendo.00100.2006; Vingren JL, 2010, SPORTS MED, V40, P1037, DOI 10.2165/11536910-000000000-00000; Vingren JL, 2008, J APPL PHYSIOL, V105, P1754, DOI 10.1152/japplphysiol.91235.2008; White JP, 2013, MOL CELL ENDOCRINOL, V365, P174, DOI 10.1016/j.mce.2012.10.019	26	47	49	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1891	1897		10.1096/fj.13-245480	http://dx.doi.org/10.1096/fj.13-245480			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24443372				2023-01-03	WOS:000335344300033
J	Andrew, KN; Hoshooley, J; Joanisse, MF				Andrew, Kathy N.; Hoshooley, Jennifer; Joanisse, Marc F.			Sign Language Ability in Young Deaf Signers Predicts Comprehension of Written Sentences in English	PLOS ONE			English	Article							PASSIVE VOICE; CHILDREN; ACQUISITION; READERS	We investigated the robust correlation between American Sign Language (ASL) and English reading ability in 51 young deaf signers ages 7; 3 to 19; 0. Signers were divided into 'skilled' and 'less-skilled' signer groups based on their performance on three measures of ASL. We next assessed reading comprehension of four English sentence structures (actives, passives, pronouns, reflexive pronouns) using a sentence-to-picture-matching task. Of interest was the extent to which ASL proficiency provided a foundation for lexical and syntactic processes of English. Skilled signers outperformed less-skilled signers overall. Error analyses further indicated greater single-word recognition difficulties in less-skilled signers marked by a higher rate of errors reflecting an inability to identify the actors and actions described in the sentence. Our findings provide evidence that increased ASL ability supports English sentence comprehension both at the levels of individual words and syntax. This is consistent with the theory that first language learning promotes second language through transference of linguistic elements irrespective of the transparency of mapping of grammatical structures between the two languages.	[Joanisse, Marc F.] Univ Western Ontario, Dept Psychol, London, ON, Canada; Univ Western Ontario, Brain & Mind Inst, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Joanisse, MF (corresponding author), Univ Western Ontario, Dept Psychol, London, ON, Canada.	marcj@uwo.ca	Joanisse, Marc/B-5772-2015	Joanisse, Marc/0000-0002-6352-291X	NSERC Canada Graduate Scholarship; NSERC	NSERC Canada Graduate Scholarship(Natural Sciences and Engineering Research Council of Canada (NSERC)); NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC))	This research was supported by an NSERC Canada Graduate Scholarship to KNM and an NSERC operating grant to MFJ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American National Standards Institute, 2004, S3212004 ANSI; BALDIE BJ, 1976, J CHILD LANG, V3, P331, DOI 10.1017/S0305000900007224; Beech J. R., 1997, J RES READ, V20, P105, DOI DOI 10.1111/1467-9817.00024; Brown L., 1997, TEST NONVERBAL INTEL; Chamberlain C, 2008, APPL PSYCHOLINGUIST, V29, P367, DOI 10.1017/S014271640808017X; Chomsky N., 1981, LECT GOVT BINDING PI; CUMMINS J, 1979, REV EDUC RES, V49, P222, DOI 10.3102/00346543049002222; DEUTSCH W, 1986, LINGUISTICS, V24, P203, DOI 10.1515/ling.1986.24.1.203; Friesen DC, 2012, READ WRIT, V25, P375, DOI 10.1007/s11145-010-9275-6; Goldin-Meadow S., 2001, LEARN DISABIL RES PR, V16, P222, DOI [DOI 10.1111/0938-8982.00022, 10.1111/0938-8982.00022]; HANSON VL, 1987, MEM COGNITION, V15, P199, DOI 10.3758/BF03197717; Hoffmeister R. J., 1999, AM SIGN LANGUAGE ASS; Hoffmeister RJ, 2000, LANGUAGE ACQUISITION BY EYE, P143; Isenhath JO, 1990, LINGUISTICS AM SIGN; Janzen T., 2001, SIGN LANG STUD, V1, P281, DOI [DOI 10.1353/SLS.2001.0009, 10.1353/sls.2001.0009]; Klima E.S., 1979, SIGNS LANGUAGE; MacWhinney B., 1989, CROSSLINGUISTIC STUD; MacWhinney B, 2005, NATURE NURTURE MAHWA, P79; Mayberry RI, 2011, J DEAF STUD DEAF EDU, V16, P164, DOI 10.1093/deafed/enq049; Mayberry RI, 2003, BRAIN LANG, V87, P369, DOI 10.1016/S0093-934X(03)00137-8; Mayberry RI, 2002, NATURE, V417, P38, DOI 10.1038/417038a; Morford JP, 2011, COGNITION, V118, P286, DOI 10.1016/j.cognition.2010.11.006; Nielsen DC, 2002, AM ANN DEAF, V147, P11, DOI 10.1353/aad.2012.0213; Padden C, 1998, TOP LANG DISORD, V18, P30, DOI 10.1097/00011363-199808000-00005; Pichler D. C., 2001, THESIS U CONNECTICUT; POWER DJ, 1973, J SPEECH HEAR RES, V16, P5, DOI 10.1044/jshr.1601.05; Semel E., 2006, CLIN EVALUATION LANG; Strong M, 1997, J Deaf Stud Deaf Educ, V2, P37; Transler C, 1999, J Deaf Stud Deaf Educ, V4, P124, DOI 10.1093/deafed/4.2.124; Traxler MJ, 2014, MEM COGNITION, V42, P97, DOI 10.3758/s13421-013-0346-1; vanderLely HKJ, 1997, COGNITION, V62, P245, DOI 10.1016/S0010-0277(96)00783-4; Vasilyeva M, 2006, DEV PSYCHOL, V42, P164, DOI 10.1037/0012-1649.42.1.164; Wexler Kenneth, 1990, LANG ACQUIS, V1, P225, DOI DOI 10.1207/S15327817LA0103_2; Wiederholt J. L., 2001, GRAY ORAL READING TE, V4th	34	17	18	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2014	9	2							e89994	10.1371/journal.pone.0089994	http://dx.doi.org/10.1371/journal.pone.0089994			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AC3DW	24587174	Green Published, gold, Green Submitted			2023-01-03	WOS:000332396200104
J	Ross, LL; Horton, J; Hasan, S; Brown, JR; Murphy, D; DeJesus, E; Potter, M; LaMarca, A; Melendez-Rivera, I; Ward, D; Uy, J; Shaefer, MS				Ross, Lisa L.; Horton, Joseph; Hasan, Samiul; Brown, James R.; Murphy, Daniel; DeJesus, Edwin; Potter, Martin; LaMarca, Anthony; Melendez-Rivera, Ivan; Ward, Douglas; Uy, Jonathon; Shaefer, Mark S.			HIV-1 Transmission Patterns in Antiretroviral Therapy-Naive, HIV-Infected North Americans Based on Phylogenetic Analysis by Population Level and Ultra-Deep DNA Sequencing	PLOS ONE			English	Article							TRANSMITTED DRUG-RESISTANCE; RITONAVIR-BOOSTED ATAZANAVIR; SUBTYPE B; NETWORKS; EPIDEMIC; CLUSTERS; SEX; MEN; ABACAVIR/LAMIVUDINE; SUPPRESSION	Factors that contribute to the transmission of human immunodeficiency virus type 1 (HIV-1), especially drug-resistant HIV-1 variants remain a significant public health concern. In-depth phylogenetic analyses of viral sequences obtained in the screening phase from antiretroviral-naive HIV-infected patients seeking enrollment in EPZ108859, a large open-label study in the USA, Canada and Puerto Rico (ClinicalTrials.gov NCT00440947) were examined for insights into the roles of drug resistance and epidemiological factors that could impact disease dissemination. Viral transmission clusters (VTCs) were initially predicted from a phylogenetic analysis of population level HIV-1 pol sequences obtained from 690 antiretroviral-naive subjects in 2007. Subsequently, the predicted VTCs were tested for robustness by ultra deep sequencing (UDS) using pyrosequencing technology and further phylogenetic analyses. The demographic characteristics of clustered and non-clustered subjects were then compared. From 690 subjects, 69 were assigned to 1 of 30 VTCs, each containing 2 to 5 subjects. Race composition of VTCs were significantly more likely to be white (72% vs. 60%; p = 0.04). VTCs had fewer reverse transcriptase and major PI resistance mutations (9% vs. 24%; p = 0.002) than non-clustered sequences. Both men-who-have-sex-with-men (MSM) (68% vs. 48%; p = 0.001) and Canadians (29% vs. 14%; p = 0.03) were significantly more frequent in VTCs than non-clustered sequences. Of the 515 subjects who initiated antiretroviral therapy, 33 experienced confirmed virologic failure through 144 weeks while only 3/33 were from VTCs. Fewer VTCs subjects (as compared to those with non-clustering virus) had HIV-1 with resistance-associated mutations or experienced virologic failure during the course of the study. Our analysis shows specific geographical and drug resistance trends that correlate well with transmission clusters defined by HIV sequences of similarity. Furthermore, our study demonstrates the utility of molecular and epidemiological analysis of VTCs for identifying population-specific risks associated with HIV-1 transmission and developing effective local healthcare strategies.	[Ross, Lisa L.; Shaefer, Mark S.] ViiV HealthCare, Res Triangle Pk, NC 27709 USA; [Horton, Joseph; Brown, James R.] GlaxoSmithKline, Res Triangle Pk, NC USA; [Hasan, Samiul] GlaxoSmithKline, Stevenage, Herts, England; [Murphy, Daniel] Clin Med Lactuel, Montreal, PQ, Canada; [DeJesus, Edwin] Orlando Immunol Ctr, Orlando, FL USA; [Potter, Martin] McGill Univ Hlth Ctr, Montreal, PQ, Canada; [LaMarca, Anthony] Therafirst Med Ctr, Ft Lauderdale, FL USA; [Melendez-Rivera, Ivan] Ctr Ararat, Ponce, PR USA; [Ward, Douglas] Dupont Circle Physicians Grp, Washington, DC USA; [Uy, Jonathon] Amicus Therapeut, Cranbury, NJ USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Orlando Immunology Center; McGill University	Ross, LL (corresponding author), ViiV HealthCare, Res Triangle Pk, NC 27709 USA.	Lisa.L.Ross@viivhealthcare.com		Shaefer, Mark/0000-0002-0545-7304; Brown, James/0000-0002-9368-627X	ViiV Healthcare, RTP, NC, USA	ViiV Healthcare, RTP, NC, USA	This ad hoc phylogenetic analysis used study data from EPZ108859, which was sponsored by ViiV Healthcare, RTP, NC, USA (http://www.viivhealthcare.com/). BristolMyers-Squibb supplied the atazanavir used by eligible participants in EPZ108859. L.L.R. and M.S.S. are employed by ViiV Healthcare and they had roles in the original study design, collection of data and analysis, as well as roles in the ad hoc phylogenetic analysis design and analysis as well as the decision to publish and the preparation of the manuscript; J.U. played a role in ad hoc analysis, the decision to publish and the preparation of the manuscript and was employed by BristolMyers-Squibb during the initial data collection. J.H., S.H. and J.B., employed by GlaxoSmithKline, were involved in the ad hoc phylogenetic analysis design and analysis and manuscript writing. D.M., E.D., M.P., A.L., I.M-R., and D.W. were involved with the clinical data collection and manuscript writing.	Ahumada-Ruiz S, 2009, INFECT GENET EVOL, V9, P933, DOI 10.1016/j.meegid.2009.06.013; Aldous JL, 2012, CLIN INFECT DIS, V55, P1135, DOI 10.1093/cid/cis612; Bezemer D, 2010, AIDS, V24, P271, DOI 10.1097/QAD.0b013e328333ddee; Brenner BG, 2007, J INFECT DIS, V195, P951, DOI 10.1086/512088; Brenner BG, 2011, J INFECT DIS, V204, P1115, DOI 10.1093/infdis/jir468; Brenner BG, 2008, AIDS, V22, P2509, DOI 10.1097/QAD.0b013e3283121c90; Cachay Edward R, 2007, Open AIDS J, V1, P5, DOI 10.2174/1874613600701010005; Callegaro A, 2011, INFECT GENET EVOL, V11, P624, DOI 10.1016/j.meegid.2011.01.019; Castro E, 2010, AIDS RES HUM RETROV, V26, P1233, DOI 10.1089/aid.2010.0083; Chalmet K, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-262; Chan PA, 2011, AIDS RES HUM RETROV, V27, P275, DOI 10.1089/aid.2010.0198; de Oliveira T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009311; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Eshleman SH, 2011, J INFECT DIS, V204, P1918, DOI 10.1093/infdis/jir651; Felsentein J, 2000, PHYLIP PHYLOGENETIC; Fisher M, 2010, AIDS, V24, P1739, DOI 10.1097/QAD.0b013e32833ac9e6; Frentz D, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-36; Han MV, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-356; Hollingsworth TD, 2008, J INFECT DIS, V198, P687, DOI 10.1086/590501; Jafa K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005416; Lai A, 2012, AIDS RES HUM RETROV, V28, P857, DOI [10.1089/aid.2011.0245, 10.1089/AID.2011.0245]; Lambert G, 2011, AIDS BEHAV, V15, P584, DOI 10.1007/s10461-009-9605-3; Lewis F, 2008, PLOS MED, V5, P392, DOI 10.1371/journal.pmed.0050050; Little SJ, 2008, J VIROL, V82, P5510, DOI 10.1128/JVI.02579-07; Martinez-Picado J, 2000, VIROLOGY, V275, P318, DOI 10.1006/viro.2000.0527; Pao D, 2005, AIDS, V19, P85, DOI 10.1097/00002030-200501030-00010; Paredes R, 2012, J INT AIDS SOC, V15, P7, DOI 10.7448/IAS.15.6.18309; Rumyantseva OA, 2009, AIDS RES HUM RETROV, V25, P931, DOI 10.1089/aid.2009.0075; Skoura L, 2011, J ANTIMICROB CHEMOTH, V66, P2831, DOI 10.1093/jac/dkr386; Smith DA, 2009, AIDS, V23, P225, DOI 10.1097/QAD.0b013e32831d2a81; Smith RJ, 2010, SCIENCE, V327, P697, DOI 10.1126/science.1180556; Squires KE, 2012, HIV CLIN TRIALS, V13, P233, DOI 10.1310/hct1305-233; Squires KE, 2010, AIDS, V24, P2019, DOI 10.1097/QAD.0b013e32833bee1b; Squires KE, 2010, HIV CLIN TRIALS, V11, P69, DOI 10.1310/hct1102-69; Yerly S, 2009, AIDS, V23, P1415, DOI 10.1097/QAD.0b013e32832d40ad	35	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2014	9	2							e89611	10.1371/journal.pone.0089611	http://dx.doi.org/10.1371/journal.pone.0089611			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC3BC	24586911	Green Submitted, Green Published, gold			2023-01-03	WOS:000332389000067
J	Sheu, MJ; Teng, YN; Chen, YY; Hung, CC				Sheu, Ming-Jyh; Teng, Yu-Ning; Chen, Ying-Yi; Hung, Chin-Chuan			The Functional Influences of Common ABCB1 Genetic Variants on the Inhibition of P-glycoprotein by Antrodia cinnamomea Extracts	PLOS ONE			English	Article							DRUG-DRUG INTERACTIONS; MULTIDRUG-RESISTANCE; FRUITING BODIES; CANCER; PHARMACOKINETICS; CELLS; LEUKEMIA; POLYMORPHISMS; DIGOXIN; TRANSPORTERS	Antrodia cinnamomea is a traditional healthy food that has been demonstrated to possess anti-inflammatory, antioxidative, and anticacer effects. The purpose of this study was to evaluate whether the ethanolic extract of A. cinnamomea (EEAC) can affect the efflux function of P-glycoprotein (P-gp) and the effect of ABCB1 genetic variants on the interaction between EEAC and P-gp. To investigate the mechanism of this interaction, Flp-In (TM)-293 cells stably transfected with various genotypes of human P-gp were established and the expression of P-gp was confirmed by Western blot. The results of the rhodamine 123 efflux assay demonstrated that EEAC efficiently inhibited wild-type P-gp function at an IC50 concentration of 1.51+/-0.08 mu g/mL through non-competitive inhibition. The IC50 concentrations for variant-type 1236T-2677T-3435T P-gp and variant-type 1236T-2677A-3435T P-gp were 5.56+/-0.49 mu g/mL and 3.33+/-0.67 mu g/mL, respectively. In addition, the inhibition kinetics of EEAC also changed to uncompetitive inhibition in variant-type 1236T-2677A-3435T P-gp. The ATPase assay revealed that EEAC was an ATPase stimulator and was capable of reducing verapamil-induced ATPase levels. These results indicate that EEAC may be a potent P-gp inhibitor and higher dosages may be required in subjects carrying variant-types P-gp. Further studies are required to translate this basic knowledge into clinical applications.	[Sheu, Ming-Jyh; Teng, Yu-Ning; Chen, Ying-Yi; Hung, Chin-Chuan] China Med Univ, Dept Pharm, Coll Pharm, Taichung, Taiwan; [Hung, Chin-Chuan] China Med Univ Hosp, Dept Pharm, Taichung, Taiwan	China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan	Hung, CC (corresponding author), China Med Univ, Dept Pharm, Coll Pharm, Taichung, Taiwan.	cc0206hung@gmail.com	Yu-Ning, Teng/AAS-8002-2021		National Science Council in Taiwan [NSC 102-2320-B-039-016]; Taiwan Department of Health Clinical Trial and Research Center of Excellence [DOH102-TD-B-111-004]; National Health Research Institutes in Taiwan [NHRI-102A1-PDCO-1312141]	National Science Council in Taiwan(Ministry of Science and Technology, Taiwan); Taiwan Department of Health Clinical Trial and Research Center of Excellence; National Health Research Institutes in Taiwan(National Health Research Institutes - Taiwan)	This work was supported by grants from the National Science Council in Taiwan (NSC 102-2320-B-039-016), Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004), and the National Health Research Institutes in Taiwan (NHRI-102A1-PDCO-1312141). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chang CY, 2008, J ETHNOPHARMACOL, V118, P387, DOI 10.1016/j.jep.2008.05.001; Chen YY, 2012, PHYTOMEDICINE, V19, P768, DOI 10.1016/j.phymed.2012.02.016; Dulucq S, 2008, BLOOD, V112, P2024, DOI 10.1182/blood-2008-03-147744; Eid SY, 2013, PHYTOMEDICINE, V21, P47, DOI 10.1016/j.phymed.2013.07.019; Falasca M, 2012, EXPERT OPIN INV DRUG, V21, P657, DOI 10.1517/13543784.2012.679339; Fenner KS, 2009, CLIN PHARMACOL THER, V85, P173, DOI 10.1038/clpt.2008.195; Gillet JP, 2011, CURR PHARM BIOTECHNO, V12, P686, DOI 10.2174/138920111795163931; Green H, 2008, J PHARM SCI-US, V97, P2045, DOI 10.1002/jps.21169; Hseu YC, 2004, NUTR CANCER, V48, P189, DOI 10.1207/s15327914nc4802_9; Hsu YL, 2007, FOOD CHEM TOXICOL, V45, P1249, DOI 10.1016/j.fct.2007.01.005; Hung CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059419; Hung CC, 2011, INVEST NEW DRUG, V29, P1337, DOI 10.1007/s10637-010-9496-1; Isla D, 2004, ANN ONCOL, V15, P1194, DOI 10.1093/annonc/mdh319; Jabir RS, 2012, PHARMACOGENOMICS, V13, P1979, DOI [10.2217/PGS.12.165, 10.2217/pgs.12.165]; Kafka A, 2003, INT J ONCOL, V22, P1117; Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308; Kishimoto W, 2014, DRUG METAB DISPOS, V42, P257, DOI 10.1124/dmd.113.053769; Liu FC, 2013, PHYTOMEDICINE, V20, P874, DOI 10.1016/j.phymed.2013.03.008; Liu YM, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/569737; Lu MC, 2013, PHARMACOL THERAPEUT, V139, P124, DOI 10.1016/j.pharmthera.2013.04.001; Mathijssen RHJ, 2003, CLIN CANCER RES, V9, P3246; Neuhoff S, 2013, J PHARM SCI-US, V102, P3145, DOI 10.1002/jps.23594; Neuhoff S, 2013, J PHARM SCI-US, V102, P3161, DOI 10.1002/jps.23607; Sissung TM, 2008, CLIN CANCER RES, V14, P4543, DOI 10.1158/1078-0432.CCR-07-4230; Tateishi T, 2008, BRIT J CLIN PHARMACO, V65, P693, DOI 10.1111/j.1365-2125.2008.03116.x; Ueda K, 2011, BIOSCI BIOTECH BIOCH, V75, P401, DOI 10.1271/bbb.100816; Wang HC, 2013, J AGR FOOD CHEM, V61, P8556, DOI 10.1021/jf402849b; Yasui-Furukori N, 2005, CLIN PHARMACOL THER, V77, P17, DOI 10.1016/j.clpt.2004.08.026; Yu M, 2013, CANCER METAST REV, V32, P211, DOI 10.1007/s10555-012-9402-8; Zhao Y, 2013, BRIT J PHARMACOL, V171, P1043	30	13	15	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2014	9	2							e89622	10.1371/journal.pone.0089622	http://dx.doi.org/10.1371/journal.pone.0089622			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC2ZX	24586917	gold, Green Submitted, Green Published			2023-01-03	WOS:000332385900059
J	Maltha, J; Guiraud, I; Kabore, B; Lompo, P; Ley, B; Bottieau, E; Van Geet, C; Tinto, H; Jacobs, J				Maltha, Jessica; Guiraud, Issa; Kabore, Berenger; Lompo, Palpouguini; Ley, Benedikt; Bottieau, Emmanuel; Van Geet, Chris; Tinto, Halidou; Jacobs, Jan			Frequency of Severe Malaria and Invasive Bacterial Infections among Children Admitted to a Rural Hospital in Burkina Faso	PLOS ONE			English	Article							SEVERE FEBRILE ILLNESS; FALCIPARUM-MALARIA; BACTEREMIA; SALMONELLA; PREVALENCE; DIAGNOSIS	Background: Although severe malaria is an important cause of mortality among children in Burkina Faso, data on community-acquired invasive bacterial infections (IBI, bacteremia and meningitis) are lacking, as well as data on the involved pathogens and their antibiotic resistance rates. Methods: The present study was conducted in a rural hospital and health center in Burkina Faso, in a seasonal malaria transmission area. Hospitalized children (<15 years) presenting with T >= 38.0 degrees C and/or signs of severe illness were enrolled upon admission. Malaria diagnosis and blood culture were performed for all participants, lumbar puncture when clinically indicated. We assessed the frequency of severe malaria (microscopically confirmed, according to World Health Organization definitions) and IBI, and the species distribution and antibiotic resistance of the bacterial pathogens causing IBI. Results: From July 2012 to July 2013, a total of 711 patients were included. Severe malaria was diagnosed in 292 (41.1%) children, including 8 (2.7%) with IBI co-infection. IBI was demonstrated in 67 (9.7%) children (bacteremia, n = 63; meningitis, n = 6), 8 (11.8%) were co-infected with malaria. Non-Typhoid Salmonella spp. (NTS) was the predominant isolate from blood culture (32.8%), followed by Salmonella Typhi (18.8%), Streptococcus pneumoniae (18.8%) and Escherichia coli (12.5%). High antibiotic resistance rates to first line antibiotics were observed, particularly among Gram-negative pathogens. In addition, decreased ciprofloxacin susceptibility and extended-spectrum beta lactamase (ESBL) production was reported for one NTS isolate each. ESBL production was observed in 3/8 E. coli isolates. In-hospital mortality was 8.2% and case-fatality rates for IBI (23.4%) were significantly higher compared to severe malaria (6.8%, p<0.001). Conclusions: Although severe malaria was the main cause of illness, IBI were not uncommon and had higher case-fatality rates. The high frequency, antibiotic resistance rates and mortality rates of community acquired IBI require improvement in hygiene, better diagnostic methods and revision of current treatment guidelines.	[Maltha, Jessica; Ley, Benedikt; Bottieau, Emmanuel; Jacobs, Jan] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Maltha, Jessica; Van Geet, Chris] Katholieke Univ Leuven, Ctr Mol & Vasc Biol, Louvain, Belgium; [Guiraud, Issa; Kabore, Berenger; Lompo, Palpouguini; Tinto, Halidou] IRSS Clin Res Unit Nanoro CRUN, Nanoro, Burkina Faso; [Van Geet, Chris] Katholieke Univ Leuven, Louvain, Belgium	Institute of Tropical Medicine (ITM); KU Leuven; KU Leuven	Maltha, J (corresponding author), Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium.	jessicamaltha@gmail.com	Jacobs, Jan/GRX-7316-2022; Issa, GUIRAUD/AGU-8073-2022; Kaboré, Bérenger/J-2773-2017	Kaboré, Bérenger/0000-0002-3719-7033; Ley, Benedikt/0000-0002-5734-0845; Tinto, Halidou/0000-0002-0472-3586	Steunfonds Margeurite-Marie Delacroix; Scientific Research-Flanders (F.W.O.-Vlaanderen, Belgium); Junior Mobility program of KU Leuven; McKinsey Company	Steunfonds Margeurite-Marie Delacroix; Scientific Research-Flanders (F.W.O.-Vlaanderen, Belgium)(FWO); Junior Mobility program of KU Leuven; McKinsey Company	The work of JM was funded by "Steunfonds Margeurite-Marie Delacroix''. For this study, JM received additional grants from the Fund for Scientific Research-Flanders (F.W.O.-Vlaanderen, Belgium), the Junior Mobility program of KU Leuven and McKinsey & Company. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Heart Association, 2006, PED ADV LIF SUPP; Bahwere P, 2001, Int J Infect Dis, V5, P180, DOI 10.1016/S1201-9712(01)90067-0; Bassat Q, 2009, TROP MED INT HEALTH, V14, P1011, DOI 10.1111/j.1365-3156.2009.02326.x; Beales PF, 2000, T ROY SOC TROP MED H, V94, pS1; Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275; Berkley JA, 2009, CLIN INFECT DIS, V49, P336, DOI 10.1086/600299; Bhutta ZA, 2006, BMJ-BRIT MED J, V333, P78, DOI 10.1136/bmj.333.7558.78; Blomberg B, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-43; Breiman RF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029119; Brent AJ, 2006, LANCET, V367, P482, DOI 10.1016/S0140-6736(06)68180-4; Bronzan RN, 2007, J INFECT DIS, V195, P895, DOI 10.1086/511437; CLSI, 2013, PERFORMANCE STANDARD; Crawley J, 2010, LANCET, V375, P1468, DOI 10.1016/S0140-6736(10)60447-3; Cunnington AJ, 2012, NAT MED, V18, P120, DOI 10.1038/nm.2601; Enwere G, 2006, PEDIATR INFECT DIS J, V25, P700, DOI 10.1097/01.inf.0000226839.30925.a5; European Committee on Antimicrobial Susceptibility Testing, 2013, BREAKP TABL INT MICS; Evans JA, 2004, QJM-INT J MED, V97, P591, DOI 10.1093/qjmed/hch093; Feasey NA, 2012, LANCET, V379, P2489, DOI 10.1016/S0140-6736(11)61752-2; Geiger C, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-27; Grimont F, 2007, J MED MICROBIOL, V56, P749, DOI 10.1099/jmm.0.46818-0; Gwer S, 2007, AM J TROP MED HYG, V77, P6, DOI 10.4269/ajtmh.2007.77.6; Hendriksen ICE, 2013, J INFECT DIS, V207, P351, DOI 10.1093/infdis/jis675; Institut National de la Statistique et de la Demographie (INSD) et ICF International, 2012, ENQ DEM SANT IND MUL; Lunguya Octavie, 2012, PLoS Negl Trop Dis, V6, pe1921, DOI 10.1371/journal.pntd.0001921; MABEY DCW, 1987, J INFECT DIS, V155, P1319, DOI 10.1093/infdis/155.6.1319; Mallewa M, 2013, LANCET GLOBAL HLTH, V1; Manyando C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056916; Marks F, 2010, EMERG INFECT DIS, V16, P1796, DOI 10.3201/eid1611.100388; Ministere de la Sante, 2012, PLANT ACT 2013 DISTR; Mtove G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009244; Nadjm B, 2012, T ROY SOC TROP MED H, V106, P688, DOI 10.1016/j.trstmh.2012.08.006; Nielsen MV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044063; Ouedraogo Abdoul-Salam, 2011, Sante, V21, P221, DOI 10.1684/san.2011.0273; Reddy EA, 2010, LANCET INFECT DIS, V10, P417, DOI 10.1016/S1473-3099(10)70072-4; Scott JAG, 2011, LANCET, V378, P1316, DOI 10.1016/S0140-6736(11)60888-X; Sigauque B, 2009, PEDIATR INFECT DIS J, V28, P108, DOI 10.1097/INF.0b013e318187a87d; Sjolund-Karlsson M, 2011, ANTIMICROB AGENTS CH, V55, P3985, DOI 10.1128/AAC.00590-11; WHO, 2012, WORLD MALARIA REPORT 2012, P1; WHO, 1991, BAS MAL MICR 1	39	52	53	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2014	9	2							e89103	10.1371/journal.pone.0089103	http://dx.doi.org/10.1371/journal.pone.0089103			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7IR	24551225	Green Published, Green Submitted, gold			2023-01-03	WOS:000331271500097
J	Benitez-Quiroz, CF; Gokgoz, K; Wilbur, RB; Martinez, AM				Benitez-Quiroz, C. Fabian; Goekgoez, Kadir; Wilbur, Ronnie B.; Martinez, Aleix M.			Discriminant Features and Temporal Structure of Nonmanuals in American Sign Language	PLOS ONE			English	Article							SYNTAX	To fully define the grammar of American Sign Language (ASL), a linguistic model of its nonmanuals needs to be constructed. While significant progress has been made to understand the features defining ASL manuals, after years of research, much still needs to be done to uncover the discriminant nonmanual components. The major barrier to achieving this goal is the difficulty in correlating facial features and linguistic features, especially since these correlations may be temporally defined. For example, a facial feature (e.g., head moves down) occurring at the end of the movement of another facial feature (e.g., brows moves up), may specify a Hypothetical conditional, but only if this time relationship is maintained. In other instances, the single occurrence of a movement (e.g., brows move up) can be indicative of the same grammatical construction. In the present paper, we introduce a linguistic-computational approach to efficiently carry out this analysis. First, a linguistic model of the face is used to manually annotate a very large set of 2,347 videos of ASL nonmanuals (including tens of thousands of frames). Second, a computational approach is used to determine which features of the linguistic model are more informative of the grammatical rules under study. We used the proposed approach to study five types of sentences - Hypothetical conditionals, Yes/no questions, Wh-questions, Wh-questions postposed, and Assertions - plus their polarities - positive and negative. Our results verify several components of the standard model of ASL nonmanuals and, most importantly, identify several previously unreported features and their temporal relationship. Notably, our results uncovered a complex interaction between head position and mouth shape. These findings define some temporal structures of ASL nonmanuals not previously detected by other approaches.	[Benitez-Quiroz, C. Fabian; Martinez, Aleix M.] Ohio State Univ, Columbus, OH 43210 USA; [Goekgoez, Kadir; Wilbur, Ronnie B.] Purdue Univ, W Lafayette, IN 47907 USA	University System of Ohio; Ohio State University; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Martinez, AM (corresponding author), Ohio State Univ, Columbus, OH 43210 USA.	martinez.158@osu.edu	Gökgöz, Kadir/AAL-7544-2021	Gökgöz, Kadir/0000-0003-2777-7656	National Institutes of Health [R21 DC011081, R01 EY 020834]; NATIONAL EYE INSTITUTE [R01EY020834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R21DC011081] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This work is supported by National Institutes of Health grants R21 DC011081 and R01 EY 020834. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aarons D, 1992, NORD J LINGUIST, V15; Aarons D, 1994, THESIS BOSTON U BOST; Abner N, 2010, P 28 W COAST C FORM, P24; ALLEN JF, 1984, ARTIF INTELL, V23, P123, DOI 10.1016/0004-3702(84)90008-0; Anderson D, 1998, SIGN LANGUAGE LINGUI, V2, P117, DOI DOI 10.1075/SLL.1.2.03AND; Bahan B, 1996, THESIS BOSTON U BOST; Baker C., 1978, UNDERSTING LANGUA, P27; Baker-Shenk Charlotte Lee, 1983, THESIS U CALIFORNIA; Barbera G., 2012, THESIS U POMPEU FABR; Battison R., 1978, LEXICAL BORROWING AM; Berwick RC, 2011, COGNITIVE SCI, V35, P1207, DOI 10.1111/j.1551-6709.2011.01189.x; Boyes Braem P., 2001, HANDS ARE HEAD MOUTH; Brentari D., 1998, PROSODIC MODEL SIGN; Brentari D., 2002, SIGN LANG LINGUIST, V5, P105, DOI [10.1075/sll.5.2.03bre, DOI 10.1075/SLL.5.2.03BRE]; Brugman H., 2004, P LREC 2004 4 INT C; Chomsky N., 1986, KNOWLEDGE LANGUAGE I; Churng S, 2009, THESIS U WASHINGTON; Churng S, 2006, P 25 W COAST C FORM, P114; Churng S, 2011, SIGN LANG LINGUIST, V14, P9, DOI 10.1075/sll.14.1.03chu; Coulter G, 1978, P 2 NAT S SIGN LANG; Dachkovsky S, 2008, SIGNS TIME; de Vos C, 2009, LANG SPEECH, V52, P315, DOI 10.1177/0023830909103177; Ding LY, 2010, IEEE T PATTERN ANAL, V32, P2022, DOI 10.1109/TPAMI.2010.28; Fitch WT, 2010, EVOLUTION OF LANGUAGE, PROCEEDINGS, P137; FRIEDMAN JH, 1989, J AM STAT ASSOC, V84, P165, DOI 10.2307/2289860; Geraci C., 2006, P N E LINGUISTIC SOC, P217; Gokgoz K, 2012, P FORM EXPT ADV SIGN; Gokgoz K, 2011, SIGN LANG LINGUIST, V14, P49, DOI 10.1075/sll.14.1.04gok; Gotardo PFU, 2011, IEEE T PATTERN ANAL, V33, P2051, DOI 10.1109/TPAMI.2011.50; Hrastinski I, 2010, THESIS PURDUE U W LA; Kelly D., 2009, PROC INT C MULTIMODA, P351; Lackner A, 2012, CODING MODALITY AUST; Liddell S.K., 1980, AM SIGN LANGUAGE SYN, DOI 10.1515/9783112418260; Liddell Scott K, 1986, SIGN LANG STUD, V52, P244; Lillo-Martin D, 1992, P 5 THEOR ISS SIGN L; Loeding BL, 2004, LECT NOTES COMPUT SC, V3118, P1079; Makaroglu B, 2012, THESIS ANKARA U; Martinez AM, 2005, IEEE T PATTERN ANAL, V27, P1934, DOI 10.1109/TPAMI.2005.250; Messing LS, 1999, GESTURE SPEECH SIGN; Nadolske MA, 2007, TRENDS LINGUIST-STUD, V188, P35; Neidle C., 2000, SYNTAX AM SIGN LANGU; Neidle C, 2002, FUNCTIONAL STRUCTURE, V1, P195; Neth D, 2010, VISION RES, V50, P1693, DOI 10.1016/j.visres.2010.05.024; Neth D, 2009, J VISION, V9, DOI 10.1167/9.1.5; Patschke C., 1999, SIGN LANGUAGE LINGUI, V2, P3, DOI [DOI 10.1075/SLL.2.1.03WIL, 10.1075/sll.2.1.03wil]; Pfau R., 2002, RIV GRAMM GEN, V27, P73; Pfau R., 2010, SIGNLANGUAGES, P381, DOI [DOI 10.1017/CBO9780511712203.018, 10.1017/CBO9780511712203.018]; Pitsikalis V, 2011, CVPRW, P1, DOI DOI 10.1109/CVPRW.2011.5981681; Porikli F, 2004, P COMP VIS PATT REC; Romero M, 2004, LINGUIST PHILOS, V27, P609, DOI 10.1023/B:LING.0000033850.15705.94; Sandler W, 2006, SIGN LANGUAGE AND LINGUISTIC UNIVERSALS, P1, DOI 10.2277/ 0521483956; Sandler W., 1989, PHONOLOGICAL REPRESE; Stokoe W., 1960, STUD LINGUISTICS, V8, P7; Stokoe W. C., 1965, DICT AM SIGN LANGUAG; Veinberg SC, 1990, SIGN LANGUAGE STUDIE, V68, P217, DOI DOI 10.1353/SLS.1990.0013; Watson K, 2010, THESIS PURDUE U W LA; Weast T, 2008, THESIS U TEXAS ARLIN; Wilbur R. B., 1994, SIGN LANGUAGE STUDY, V84, P221, DOI DOI 10.1353/SLS.1994.0019; Wilbur RB, 2000, SIGNS OF LANGUAGE REVISITED, P215; Wilbur RB, 1998, J PRAGMATICS, V30, P275, DOI 10.1016/S0378-2166(98)00003-4; Wilbur RB, 2011, P WORKSH SIGN LANG C; Wilbur RB, 2009, LANG SPEECH, V52; Wilbur RB, 2011, SIGN LANG LINGUIST, V14, P148, DOI 10.1075/sll.14.1.08wil; Zeshan U., 2004, LINGUIST TYPOL, V8, P1, DOI [10.1515/lity.2004.003, DOI 10.1515/LITY.2004.003]; Zhu ML, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-280	65	16	16	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2014	9	2							e86268	10.1371/journal.pone.0086268	http://dx.doi.org/10.1371/journal.pone.0086268			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA1BH	24516528	Green Published, gold, Green Submitted			2023-01-03	WOS:000330830700007
J	Kanyas, S; Aydin, D; Kizilel, R; Demirel, AL; Kizilel, S				Kanyas, Selin; Aydin, Derya; Kizilel, Riza; Demirel, A. Levent; Kizilel, Seda			Nanoparticle and Gelation Stabilized Functional Composites of an Ionic Salt in a Hydrophobic Polymer Matrix	PLOS ONE			English	Article							MACROPOROUS CERAMICS; SILICA; PARTICLES; EMULSIONS; FOAMS	Polymer composites consisted of small hydrophilic pockets homogeneously dispersed in a hydrophobic polymer matrix are important in many applications where controlled release of the functional agent from the hydrophilic phase is needed. As an example, a release of biomolecules or drugs from therapeutic formulations or release of salt in anti-icing application can be mentioned. Here, we report a method for preparation of such a composite material consisted of small KCOOH salt pockets distributed in the styrene-butadiene-styrene (SBS) polymer matrix and demonstrate its effectiveness in anti-icing coatings. The mixtures of the aqueous KCOOH and SBS-cyclohexane solutions were firstly stabilized by adding silica nanoparticles to the emulsions and, even more, by gelation of the aqueous phase by agarose. The emulsions were observed in optical microscope to check its stability in time and characterized by rheological measurements. The dry composite materials were obtained via casting the emulsions onto the glass substrates and evaporations of the organic solvent. Composite polymer films were characterized by water contact angle (WCA) measurements. The release of KCOOH salt into water and the freezing delay experiments of water droplets on dry composite films demonstrated their anti-icing properties. It has been concluded that hydrophobic and thermoplastic SBS polymer allows incorporation of the hydrophilic pockets/phases through our technique that opens the possibility for controlled delivering of anti-icing agents from the composite.	[Kanyas, Selin; Demirel, A. Levent; Kizilel, Seda] Koc Univ, Istanbul, Turkey; [Aydin, Derya; Kizilel, Seda] Koc Univ, Dept Chem & Biol Engn, Istanbul, Turkey; [Kizilel, Riza] Koc Univ, TUPRAS Energy Ctr KUTEM, Istanbul, Turkey; [Demirel, A. Levent] Koc Univ, Dept Chem, Istanbul, Turkey	Koc University; Koc University; Koc University; Tupras; Koc University	Kizilel, S (corresponding author), Koc Univ, Istanbul, Turkey.	skizilel@ku.edu.tr	Kizilel, Seda/P-3959-2014	Kizilel, Seda/0000-0001-9092-2698	Turkish Petroleum Oil Refineries (TUPRAS) Company	Turkish Petroleum Oil Refineries (TUPRAS) Company	This research was supported by Turkish Petroleum Oil Refineries (TUPRAS) Company. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akartuna I, 2008, LANGMUIR, V24, P7161, DOI 10.1021/la800478g; Akartuna I, 2009, LANGMUIR, V25, P12419, DOI 10.1021/la901916q; Akartuna I, 2009, POLYMER, V50, P3645, DOI 10.1016/j.polymer.2009.05.023; Akartuna I, 2008, ADV MATER, V20, P4714, DOI 10.1002/adma.200801888; Aranberri I, 2009, J POROUS MAT, V16, P429, DOI 10.1007/s10934-008-9215-x; Binks BP, 2002, ADV MATER, V14, P1824, DOI 10.1002/adma.200290010; Binks BP, 2002, CURR OPIN COLLOID IN, V7, P21, DOI 10.1016/S1359-0294(02)00008-0; Busby W, 2002, POLYM INT, V51, P871, DOI 10.1002/pi.934; Cayre OJ, 2004, J MATER CHEM, V14, P3351, DOI 10.1039/b411359d; Dai LL, 2005, LANGMUIR, V21, P2641, DOI 10.1021/la047256t; Dickinson E, 1997, J COLLOID INTERF SCI, V191, P166, DOI 10.1006/jcis.1997.4939; Duan HW, 2005, NANO LETT, V5, P949, DOI 10.1021/nl0505391; Dubois R, 1984, PROCESS PREVENTING F; French HK, 2001, J CONTAM HYDROL, V49, P23, DOI 10.1016/S0169-7722(00)00187-X; Haibach K, 2006, POLYMER, V47, P4513, DOI 10.1016/j.polymer.2006.03.114; Hellsten PP, 2005, ENVIRON SCI TECHNOL, V39, P5095, DOI 10.1021/es0482738; Ikem VO, 2010, ADV MATER, V22, P3588, DOI 10.1002/adma.201000729; Imhof A, 1998, CHEM ENG TECHNOL, V21, P682, DOI 10.1002/(SICI)1521-4125(199808)21:8<682::AID-CEAT682>3.0.CO;2-U; Imhof A, 1997, NATURE, V389, P948, DOI 10.1038/40105; Lee MN, 2012, LANGMUIR, V28, P3085, DOI 10.1021/la203384f; Lin Y, 2005, LANGMUIR, V21, P191, DOI 10.1021/la048000q; Locke C.E., 1987, TRANSP RES REC, V1113, P30; Melle S, 2005, LANGMUIR, V21, P2158, DOI 10.1021/la047691n; Menner A, 2006, POLYMER, V47, P7628, DOI 10.1016/j.polymer.2006.09.022; Pickering E C, 1907, Science, V25, P435, DOI 10.1126/science.25.637.435; Pulko I, 2008, CHEM COMMUN, P4481, DOI 10.1039/b807095d; Pulko I, 2010, CHEM-EUR J, V16, P2350, DOI 10.1002/chem.200903043; Qiao XY, 2012, COLLOID SURFACE A, V412, P20, DOI 10.1016/j.colsurfa.2012.06.026; Ramsden W, 1903, P R SOC, V72; Robidoux PY, 2001, ECOTOX ENVIRON SAFE, V48, P128, DOI 10.1006/eesa.2000.2035; RUCKENSTEIN E, 1991, J APPL POLYM SCI, V42, P2429, DOI 10.1002/app.1991.070420908; Velikov KP, 2007, COLLOID STABILITY AP; Wei ZX, 2002, ADV MATER, V14, P1314, DOI 10.1002/1521-4095(20020916)14:18<1314::AID-ADMA1314>3.0.CO;2-9; Zoldesi CI, 2005, ADV MATER, V17, P924, DOI 10.1002/adma.200401183	34	10	12	2	81	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2014	9	2							e88125	10.1371/journal.pone.0088125	http://dx.doi.org/10.1371/journal.pone.0088125			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA1BH	24516593	Green Published, Green Submitted, gold			2023-01-03	WOS:000330830700045
J	Hanmer, J; Lu, X; Rosenthal, GE; Cram, P				Hanmer, Janel; Lu, Xin; Rosenthal, Gary E.; Cram, Peter			Insurance Status and the Transfer of Hospitalized Patients An Observational Study	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; EMERGENCY-DEPARTMENT; CHEST-PAIN; PREFERENCES; TRIAGE; EMTALA; RACE; REVASCULARIZATION; CENTERS; NEED	Background: There is little objective evidence to support concerns that patients are transferred between hospitals based on insurance status. Objective: To examine the relationship between patients' insurance coverage and interhospital transfer. Design: Data analyzed from the 2010 Nationwide Inpatient Sample. Patients: All patients aged 18 to 64 years discharged alive from U.S. acute care hospitals with 1 of 5 common diagnoses (biliary tract disease, chest pain, pneumonia, septicemia, and skin or subcutaneous infection). Measurements: For each diagnosis, the proportion of hospitalized patients who were transferred to another acute care hospital based on insurance coverage (private, Medicare, Medicaid, or uninsured) was compared. Logistic regression was used to estimate the odds of transfer for uninsured patients (reference category, privately insured) while patient-and hospital-level factors were adjusted for. All analyses incorporated sampling and poststratification weights. Results: Among 315 748 patients discharged from 1051 hospitals with any of the 5 diagnoses, the percentage of patients transferred to another acute care hospital varied from 1.3% (skin infection) to 5.1% (septicemia). In unadjusted analyses, uninsured patients were significantly less likely to be transferred for 3 diagnoses (P < 0.05). In adjusted analyses, uninsured patients were significantly less likely to be transferred than privately insured patients for 4 diagnoses: biliary tract disease (odds ratio, 0.73 [95% CI, 0.55 to 0.96]), chest pain (odds ratio, 0.63 [CI, 0.44 to 0.89]), septicemia (odds ratio, 0.76 [CI, 0.64 to 0.91]), and skin infections (odds ratio, 0.64 [CI, 0.46 to 0.89]). Women were significantly less likely to be transferred than men for all diagnoses. Limitation: This analysis relied on administrative data and lacked clinical detail. Conclusion: Uninsured patients (and women) were significantly less likely to undergo interhospital transfer. Differences in transfer rates may contribute to health care disparities.	Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA; Univ Iowa, Carver Coll Med, Ctr Comprehens Access & Delivery Res & Evaluat, Iowa City, IA USA; Iowa City Vet Affairs Med Ctr, Iowa City, IA USA; Univ Toronto, Toronto, ON, Canada; [Cram, Peter] Univ Hlth Network, Mt Sinai Hosp, Toronto, ON M5G 2C4, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University Health Network Toronto	Hanmer, J (corresponding author), Univ Pittsburgh, Med Ctr, Montefiore Hosp, Suite W93,200 Lothrop St, Pittsburgh, PA 15213 USA.	hanmerjz@upmc.edu	Cram, Peter/K-4472-2014	Cram, Peter/0000-0002-1910-346X	National Institutes of Health; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000442] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K24AR062133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG033035] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	National Institutes of Health.	American Hospital Association, 2008, AM HOSP ASS ANN SURV; Babu MA, 2011, NEUROSURGERY, V69, P659, DOI 10.1227/NEU.0b013e31821bc667; Barnett H, 2010, PROF CASE MANAG, V15, P280, DOI 10.1097/NCM.0b013e3181e2d114; Boulware LE, 2005, AM J TRANSPLANT, V5, P1503, DOI 10.1111/j.1600-6143.2005.00860.x; Constantinescu F, 2009, ARTHRIT RHEUM-ARTHR, V61, P413, DOI 10.1002/art.24338; Cooke CR, 2011, MED CARE, V49, P662, DOI 10.1097/MLR.0b013e31821d98b2; Cram P, 2008, MED CARE, V46, P467, DOI 10.1097/MLR.0b013e31816c43d9; Durbin DR, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.3.e8; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Gurwitz JH, 2002, AM J MED, V112, P528, DOI 10.1016/S0002-9343(02)01072-0; HCUP Nationwide Inpatient Sample (NIS), HLTH CAR COST UT PRO; Healthcare Cost and Utilization Project (HCUP), HEALTHC COST UT PROJ; Healthcare Cost and Utilization Project National Institutes of Health, 2013, DESCR DAT EL HEALTHC; HIMMELSTEIN DU, 1984, AM J PUBLIC HEALTH, V74, P494, DOI 10.2105/AJPH.74.5.494; Houchens R, 2001, HCUP METHOD SERIES R; Kamoie B E, 2000, J Health Law, V33, P25; Kao DP, 2012, ARCH INTERN MED, V172, P891, DOI 10.1001/archinternmed.2012.1290; KELLERMANN AL, 1990, AM J PUBLIC HEALTH, V80, P864, DOI 10.2105/AJPH.80.7.864; KELLERMANN AL, 1988, AM J PUBLIC HEALTH, V78, P1287, DOI 10.2105/AJPH.78.10.1287; Koval KJ, 2006, J BONE JOINT SURG AM, V88A, P2124, DOI 10.2106/JBJS.F.00245; Lee Tiana Mayere, 2004, Ann Health Law, V13, P145; Lin DY, 1998, BIOMETRICS, V54, P948, DOI 10.2307/2533848; Lopez L, 2010, ACAD EMERG MED, V17, P801, DOI 10.1111/j.1553-2712.2010.00823.x; McCarthy JJ, 2013, COMMON PROBLEMS ACUT; Mumma BE, 2011, ANN EMERG MED, V57, P551, DOI 10.1016/j.annemergmed.2010.09.026; Nathens AB, 2001, J TRAUMA, V50, P776, DOI 10.1097/00005373-200105000-00002; Popescu I, 2007, JAMA-J AM MED ASSOC, V297, P2489, DOI 10.1001/jama.297.22.2489; Ravn-Fischer A, 2012, AM J EMERG MED, V30, P1515, DOI 10.1016/j.ajem.2011.12.020; Rosenbaum S, 2012, HEALTH AFFAIR, V31, P1749, DOI 10.1377/hlthaff.2012.0517; Rosenberg AL, 2003, ANN INTERN MED, V138, P882, DOI 10.7326/0003-4819-138-11-200306030-00009; SCHIFF RL, 1986, NEW ENGL J MED, V314, P552, DOI 10.1056/NEJM198602273140905; Smedley BD, 2003, UNEQUAL TREATMENT CO, DOI [10.17226/12875, DOI 10.17226/12875]; Smith JM, 2002, J NATL MED ASSOC, V94, P426; Strickler Jeffery, 2006, JONAS Healthc Law Ethics Regul, V8, P77, DOI 10.1097/00128488-200607000-00005; Thakur NA, 2010, J ORTHOP TRAUMA, V24, P336, DOI 10.1097/BOT.0b013e3181b18b89; White A.A., 2011, SEEING PATIENTS UNCO; Wong MD, 2004, AM J MED, V116, P613, DOI 10.1016/j.amjmed.2003.09.051	37	19	19	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 21	2014	160	2					81	+		10.7326/M12-1977	http://dx.doi.org/10.7326/M12-1977			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	297SQ	24592493	Green Accepted			2023-01-03	WOS:000330275600014
J	Campbell, C; Grapov, D; Fiehn, O; Chandler, CJ; Burnett, DJ; Souza, EC; Casazza, GA; Gustafson, MB; Keim, NL; Newman, JW; Hunter, GR; Fernandez, JR; Garvey, WT; Harper, ME; Hoppel, CL; Meissen, JK; Take, K; Adams, SH				Campbell, Caitlin; Grapov, Dmitry; Fiehn, Oliver; Chandler, Carol J.; Burnett, Dustin J.; Souza, Elaine C.; Casazza, Gretchen A.; Gustafson, Mary B.; Keim, Nancy L.; Newman, John W.; Hunter, Gary R.; Fernandez, Jose R.; Garvey, W. Timothy; Harper, Mary-Ellen; Hoppel, Charles L.; Meissen, John K.; Take, Kohei; Adams, Sean H.			Improved Metabolic Health Alters Host Metabolism in Parallel with Changes in Systemic Xeno-Metabolites of Gut Origin	PLOS ONE			English	Article							GLUCOSE-TOLERANCE TEST; INSULIN-RESISTANCE; MENSTRUAL-CYCLE; ACID CYCLE; PLASMA; PROFILES; MOUSE; SENSITIVITY; MICROBIOME; OBESITY	Novel plasma metabolite patterns reflective of improved metabolic health (insulin sensitivity, fitness, reduced body weight) were identified before and after a 14-17 wk weight loss and exercise intervention in sedentary, obese insulin-resistant women. To control for potential confounding effects of diet- or microbiome-derived molecules on the systemic metabolome, sampling was during a tightly-controlled feeding test week paradigm. Pairwise and multivariate analysis revealed intervention-and insulin-sensitivity associated: (1) Changes in plasma xeno-metabolites ("non-self'' metabolites of dietary or gut microbial origin) following an oral glucose tolerance test (e.g. higher post-OGTT propane-1,2,3-tricarboxylate [tricarballylic acid]) or in the overnight-fasted state (e.g., lower gamma-tocopherol); (2) Increased indices of saturated very long chain fatty acid elongation capacity; (3) Increased post-OGTT alpha-ketoglutaric acid (alpha-KG), fasting alpha-KG inversely correlated with Matsuda index, and altered patterns of malate, pyruvate and glutamine hypothesized to stem from improved mitochondrial efficiency and more robust oxidation of glucose. The results support a working model in which improved metabolic health modifies host metabolism in parallel with altering systemic exposure to xeno-metabolites. This highlights that interpretations regarding the origins of peripheral blood or urinary "signatures'' of insulin resistance and metabolic health must consider the potentially important contribution of gut-derived metabolites toward the host's metabolome.	[Campbell, Caitlin; Chandler, Carol J.; Burnett, Dustin J.; Souza, Elaine C.; Gustafson, Mary B.; Keim, Nancy L.; Newman, John W.; Adams, Sean H.] ARS, USDA, Western Human Nutr Res Ctr, Davis, CA USA; [Grapov, Dmitry; Fiehn, Oliver] Univ Calif Davis, West Coast Metabol Ctr, Davis, CA USA; [Fiehn, Oliver; Meissen, John K.; Take, Kohei] Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA; [Casazza, Gretchen A.] Univ Calif Davis, Sch Med, Sports Med Program, Sacramento, CA 95817 USA; [Keim, Nancy L.; Newman, John W.; Adams, Sean H.] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; [Hunter, Gary R.; Fernandez, Jose R.; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA; [Hunter, Gary R.] Univ Alabama Birmingham, Human Studies Dept, Birmingham, AL USA; [Harper, Mary-Ellen] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; [Hoppel, Charles L.] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	United States Department of Agriculture (USDA); University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Ottawa; Case Western Reserve University	Fiehn, O (corresponding author), Univ Calif Davis, West Coast Metabol Ctr, Davis, CA USA.	ofiehn@ucdavis.edu; sean.h.adams@ars.usda.gov	Casazza, Gretchen Ann/GPC-8610-2022; ADAMS, SEAN/N-9262-2018	ADAMS, SEAN/0000-0002-9515-2319; Newman, John/0000-0001-9632-6571; Harper, Mary-Ellen/0000-0003-3864-5886; Grapov, Dmitry/0000-0002-7204-3128	USDA-ARS intramural [5306-51530-016-00D, 5306-51530-019-00]; NIH-NIDDK [R01DK078328]; NIH [1 U24 DK097154, P20 HL113452]; West Coast Metabolomics Center; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024146] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P20HL113452] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK079626, R01DK078328, U24DK097154] Funding Source: NIH RePORTER	USDA-ARS intramural; NIH-NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); West Coast Metabolomics Center; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by USDA-ARS intramural Projects 5306-51530-016-00D and 5306-51530-019-00 (JWN, NLK, SHA), NIH-NIDDK R01DK078328 (OF, NLK, JWN, GH, JF, WTG, CLH, MEH, SHA), NIH 1 U24 DK097154 for the West Coast Metabolomics Center (OF, JWN), and NIH P20 HL113452 (OF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams SH, 2011, ADV NUTR, V2, P445, DOI 10.3945/an.111.000737; Adams SH, 2009, J NUTR, V139, P1073, DOI 10.3945/jn.108.103754; Aguer C, FASEB J IN PRESS; Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI [10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062, 10.2337/dc10-S062]; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bingley CA, 2008, HORM METAB RES, V40, P901, DOI 10.1055/s-0028-1082081; Bjom-Helge Mevik R.W., 2011, PLS PARTIAL LEAST SQ; Bostrom P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777; Bowtell JL, 2002, NUTRITION, V18, P222, DOI 10.1016/S0899-9007(01)00795-X; Brunengraber H, 2006, J INHERIT METAB DIS, V29, P327, DOI 10.1007/s10545-006-0320-1; Buse John B, 2003, Diabetes Technol Ther, V5, P355, DOI 10.1089/152091503765691839; Cao Y, 2008, BIOINFORMATICS, V24, P1733, DOI 10.1093/bioinformatics/btn307; Cheng SS, 2012, CIRCULATION, V125, P2222, DOI 10.1161/CIRCULATIONAHA.111.067827; Claus SP, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.56; Deo RC, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000692; Devaraj S, 2013, CLIN CHEM, V59, P617, DOI 10.1373/clinchem.2012.187617; Fiehn Oliver, 2007, V358, P3, DOI 10.1007/978-1-59745-244-1_1; Fiehn O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015234; Floegel A, 2013, DIABETES, V62, P639, DOI 10.2337/db12-0495; Gall WE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010883; GOODWIN BL, 1994, BIOCHEM PHARMACOL, V47, P2294, DOI 10.1016/0006-2952(94)90268-2; Grapov D, 2012, BIOINFORMATICS; Grapov D, 2012, APPL TARGETED METABO, P236; Hardt-Stremayr M, 2013, J SEP SCI, V36, P670, DOI 10.1002/jssc.201200768; Hardt-Stremayr M, 2012, J SEP SCI, V35, P2567, DOI 10.1002/jssc.201200251; Huffman KM, 2009, DIABETES CARE, V32, P1678, DOI 10.2337/dc08-2075; Hyotylainen T, 2012, MOL BIOSYST, V8, P2559, DOI 10.1039/c2mb25115a; Jakobsson A, 2006, PROG LIPID RES, V45, P237, DOI 10.1016/j.plipres.2006.01.004; Kernan WN, 2003, STROKE, V34, P1431, DOI 10.1161/01.STR.0000071108.00234.0E; Krug S, 2012, FASEB J, V26, P2607, DOI 10.1096/fj.11-198093; Laferrere B, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002043; LANOUE KF, 1971, METABOLISM, V20, P119, DOI 10.1016/0026-0495(71)90087-4; Marcobal A, 2013, ISME J; Martin FPJ, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb4100190; Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462; MCDEVITT J, 1991, FOOD CHEM TOXICOL, V29, P107, DOI 10.1016/0278-6915(91)90164-3; Messier V, 2010, OBESITY, V18, P911, DOI 10.1038/oby.2009.364; Messier V, 2010, METABOLISM, V59, P20, DOI 10.1016/j.metabol.2009.06.020; Mihalik SJ, 2010, OBESITY, V18, P1695, DOI 10.1038/oby.2009.510; NOBLE BJ, 1983, MED SCI SPORT EXER, V15, P523; Palermo Giuseppe, 2009, Adv Appl Bioinform Chem, V2, P57; Patel CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010746; PETTERSEN JE, 1972, CLIN CHIM ACTA, V41, P199, DOI 10.1016/0009-8981(72)90512-8; R DEVELOPMENT CORE TEAM, 2011, R LANG ENV STAT COMP; Ramos-Roman MA, 2012, METABOLISM, V61, P202, DOI 10.1016/j.metabol.2011.06.008; Romick-Rosendale LE, 2009, MAGN RESON CHEM, V47, pS36, DOI 10.1002/mrc.2511; RUSSELL JB, 1985, APPL ENVIRON MICROB, V49, P120, DOI 10.1128/AEM.49.1.120-126.1985; RUSSELL JB, 1986, BRIT J NUTR, V56, P153, DOI 10.1079/BJN19860095; Saeys Y, 2007, BIOINFORMATICS, V23, P2507, DOI 10.1093/bioinformatics/btm344; Salek RM, 2007, PHYSIOL GENOMICS, V29, P99, DOI 10.1152/physiolgenomics.00194.2006; Seifert EL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009834; Shah SH, 2012, DIABETOLOGIA, V55, P321, DOI 10.1007/s00125-011-2356-5; Shaham O, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.50; Suhre K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013953; Swann JR, 2011, J PROTEOME RES, V10, P3590, DOI 10.1021/pr200243t; Tai ES, 2010, DIABETOLOGIA, V53, P757, DOI 10.1007/s00125-009-1637-8; Toledo FG, 2013, MOL CELL ENDOCRINOL; Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552; Wang TJ, 2011, NAT MED, V17, P448, DOI 10.1038/nm.2307; Wang-Sattler R, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.43; Wierckx N, 2011, APPL MICROBIOL BIOT, V92, P1095, DOI 10.1007/s00253-011-3632-5; Wikoff WR, 2009, P NATL ACAD SCI USA, V106, P3698, DOI 10.1073/pnas.0812874106; WOLFFRAM S, 1993, EXP PHYSIOL, V78, P473, DOI 10.1113/expphysiol.1993.sp003699; Wopereis S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004525; Wurtz P, 2012, DIABETES CARE, V35, P1749, DOI 10.2337/dc11-1838; Wurtz P, 2012, DIABETES, V61, P1372, DOI 10.2337/db11-1355; Yap IKS, 2008, J PROTEOME RES, V7, P3718, DOI 10.1021/pr700864x; Yeung EH, 2010, J CLIN ENDOCR METAB, V95, P5435, DOI 10.1210/jc.2010-0702; Zhao XJ, 2010, METABOLOMICS, V6, P362, DOI 10.1007/s11306-010-0203-1; Zhao XJ, 2009, AM J PHYSIOL-ENDOC M, V296, pE384, DOI 10.1152/ajpendo.90748.2008	71	36	36	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2014	9	1							e84260	10.1371/journal.pone.0084260	http://dx.doi.org/10.1371/journal.pone.0084260			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	291WL	24416208	Green Submitted, Green Published, gold			2023-01-03	WOS:000329862500106
J	Irwin, CR; Favis, NA; Agopsowicz, KC; Hitt, MM; Evans, DH				Irwin, Chad R.; Favis, Nicole A.; Agopsowicz, Kate C.; Hitt, Mary M.; Evans, David H.			Myxoma Virus Oncolytic Efficiency Can Be Enhanced Through Chemical or Genetic Disruption of the Actin Cytoskeleton	PLOS ONE			English	Article							ENVELOPED VACCINIA VIRUS; F11L-MEDIATED INHIBITION; FIBROMA VIRUSES; RABBIT MYXOMA; CELL MOTILITY; LIM KINASES; RHOA; INFECTION; SPREAD; PROTEIN	Myxoma virus (MYXV) is one of many animal viruses that exhibit oncolytic properties in transformed human cells. Compared to orthopoxviruses like vaccinia (VACV), MYXV spreads inefficiently, which could compromise its use in treating tumors and their associated metastases. The VACV F11 protein promotes virus exit and rapid spread by inhibiting Rho signalling, which results in a disruption of cortical actin. We have previously shown that although MYXV lacks an F11 homolog, the F11L gene can be introduced into MYXV promoting the spread of this Leporipoxvirus in natural host cells. Here we show that the F11-encoding (F11L(+)) MYXV strain replicates to higher levels in a number of human cancer cells. We also show that F11L(+) MYXV induces better tumor control and prolonged survival of mice bearing MDA-MB-231 cancer cells. Furthermore, we show that this virus also spreads more efficiently from the site of growth in one injected tumor, to a second untreated tumor. While we focused mostly on the use of a modified MYXV we were able to show that the effects of F11 on MYXV growth in cancer cells could be mimicked through the use of pharmacological inhibition or siRNA-mediated silencing of key regulators of cortical actin (RhoA, RhoC, mDia1, or LIMK2). These data suggest that it may be possible to increase the oncolytic efficacy of wild-type MYXV using chemical inhibitors of RhoA/C or their downstream targets. Furthermore, since all viruses must overcome barriers to exit posed by structures like cortical actin, these findings suggest that the oncolytic activity of other viruses may be enhanced through similar strategies.	[Irwin, Chad R.; Favis, Nicole A.; Evans, David H.] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB, Canada; [Agopsowicz, Kate C.; Hitt, Mary M.] Univ Alberta, Dept Oncol, Edmonton, AB, Canada; [Hitt, Mary M.; Evans, David H.] Univ Alberta, Li Ka Shing Inst Virol, Edmonton, AB, Canada	University of Alberta; University of Alberta; University of Alberta	Evans, DH (corresponding author), Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB, Canada.	devans@ualberta.ca	Evans, David H/M-1912-2016	Evans, David H/0000-0001-5871-299X	Alberta Cancer Board Legacy program; Alberta Cancer Foundation; Canadian Institutes of Health Research; Li Ka Shing Institute for Virology; Canada Foundation for Innovation; Alberta Cancer Research Institute; Queen Elisabeth II Doctoral Award	Alberta Cancer Board Legacy program; Alberta Cancer Foundation; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Li Ka Shing Institute for Virology; Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Alberta Cancer Research Institute; Queen Elisabeth II Doctoral Award	This work was funded by operating grants from the Alberta Cancer Board Legacy program, Alberta Cancer Foundation, Canadian Institutes of Health Research, and the Li Ka Shing Institute for Virology. The authors also thank the Canada Foundation for Innovation and its partners for infrastructure support. CRI has been supported by a graduate studentship from the Alberta Cancer Research Institute, a Walter Johns 75th Anniversary Award, and a Queen Elisabeth II Doctoral Award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDREWES CH, 1957, VIROLOGY, V4, P346, DOI 10.1016/0042-6822(57)90068-5; Arakawa Y, 2007, CELL HOST MICROBE, V1, P227, DOI 10.1016/j.chom.2007.04.006; Arakawa Y, 2007, CELL HOST MICROBE, V1, P213, DOI 10.1016/j.chom.2007.04.007; Barry M, 1997, VIROLOGY, V239, P360, DOI 10.1006/viro.1997.8894; Bennett CJ, 2003, VIROLOGY, V315, P10, DOI 10.1016/S0042-6822(03)00512-9; BLASCO R, 1993, J VIROL, V67, P3319, DOI 10.1128/JVI.67.6.3319-3325.1993; CHAPRONIERE DM, 1957, VIROLOGY, V4, P351, DOI 10.1016/0042-6822(57)90069-7; Cordeiro JV, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008506; Doceul V, 2010, SCIENCE, V327, P873, DOI 10.1126/science.1183173; Duteyrat JL, 2006, ARCH VIROL, V151, P2161, DOI 10.1007/s00705-006-0791-2; Gauvin TJ, 2009, BIOCHEMISTRY-US, V48, P9327, DOI 10.1021/bi901354z; Gouin E, 2005, CURR OPIN MICROBIOL, V8, P35, DOI 10.1016/j.mib.2004.12.013; Handa Y, 2013, CELL HOST MICROBE, V14, P51, DOI 10.1016/j.chom.2013.06.006; Harrison BA, 2009, J MED CHEM, V52, P6515, DOI 10.1021/jm901226j; Horsington J, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003239; Ichihashi Y, 1996, VIROLOGY, V217, P478, DOI 10.1006/viro.1996.0142; Irwin CR, 2012, J VIROL, V86, P7167, DOI 10.1128/JVI.06936-11; Johnston JB, 2005, VIROLOGY, V332, P235, DOI 10.1016/j.virol.2004.11.030; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Kato SEM, 2004, J VIROL METHODS, V115, P31, DOI 10.1016/j.jviromet.2003.09.011; Kirn DH, 2008, CANCER RES, V68, P2071, DOI 10.1158/0008-5472.CAN-07-6515; Lun XQ, 2005, CANCER RES, V65, P9982, DOI 10.1158/0008-5472.CAN-05-1201; Mardilovich K, 2012, FUTURE ONCOL, V8, P165, DOI [10.2217/fon.11.143, 10.2217/FON.11.143]; McFadden G, 2005, NAT REV MICROBIOL, V3, P201, DOI 10.1038/nrmicro1099; McHenry PR, 2010, CURR DRUG TARGETS, V11, P1043, DOI 10.2174/138945010792006852; Morales I, 2008, TRAFFIC, V9, P1283, DOI 10.1111/j.1600-0854.2008.00762.x; OPGENORTH A, 1992, J VIROL, V66, P4720, DOI 10.1128/JVI.66.8.4720-4731.1992; PAYNE LG, 1982, ARCH VIROL, V74, P11, DOI 10.1007/BF01320778; Ridley AJ, 2013, J MICROSC; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Roberts KL, 2008, TRENDS MICROBIOL; Scott RW, 2007, J MOL MED, V85, P555, DOI 10.1007/s00109-007-0165-6; Scott RW, 2010, J CELL BIOL, V191, P169, DOI 10.1083/jcb.201002041; Shang X, 2012, CHEM BIOL, V19, P699, DOI 10.1016/j.chembiol.2012.05.009; Shmulevitz M, 2012, J VIROL, V86, P7403, DOI 10.1128/JVI.00304-12; Smallwood Sherin E, 2010, Curr Protoc Microbiol, VChapter 14, DOI 10.1002/9780471729259.mc14a01s17; Smith GL, 1998, ADV EXP MED BIOL, V440, P395; Smith GL, 2003, ANNU REV MICROBIOL, V57, P323, DOI 10.1146/annurev.micro.57.030502.091037; Smith GL, 2002, J GEN VIROL, V83, P2915, DOI 10.1099/0022-1317-83-12-2915; Sypula J., 2004, GENE THER MOL BIOL, V8, P103; Taylor MP, 2011, NAT REV MICROBIOL, V9, P427, DOI 10.1038/nrmicro2574; Teferi WM, 2013, J VIROL; Thirunavukarasu P, 2013, MOL THER, V21, P1024, DOI 10.1038/mt.2013.27; Valderrama F, 2006, SCIENCE, V311, P377, DOI 10.1126/science.1122411; Vanderplasschen A, 1998, P NATL ACAD SCI USA, V95, P7544, DOI 10.1073/pnas.95.13.7544; Vega FM, 2011, J CELL BIOL, V193, P655, DOI 10.1083/jcb.201011038; Wang F, 2004, NAT IMMUNOL, V5, P1266, DOI 10.1038/ni1132; Wang FA, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000099; Wang F, 2009, VIROLOGY, V387, P136, DOI 10.1016/j.virol.2009.02.013; Wang G, 2006, P NATL ACAD SCI USA, V103, P4640, DOI 10.1073/pnas.0509341103; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Zwilling J, 2010, VIROLOGY, V404, P231, DOI 10.1016/j.virol.2010.05.008	52	13	14	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2013	8	12							e84134	10.1371/journal.pone.0084134	http://dx.doi.org/10.1371/journal.pone.0084134			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	284MV	24391902	Green Published, Green Submitted, gold			2023-01-03	WOS:000329323900045
J	Hollis, A; Ahmed, Z				Hollis, Aidan; Ahmed, Ziana			Preserving Antibiotics, Rationally	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								With 51 tons of antibiotics consumed daily in the United States, the selective pressure in favor of antibiotic-resistant pathogens is strong. Given the critical public health threat, an economically rational solution is to impose a user fee on nonhuman antibiotic use. Antimicrobial resistance is a critical threat to public health. The value of antibiotics for human health is immeasurable, but were one to try to measure, a plausible estimate of the increase in life expectancy attributable to antibiotics might be 2 to 10 years.(1) If we multiply this increase by 300 million Americans and a dollar value of, say, $100,000 per life-year, we arrive at an estimate for the worth of the current stock of antibiotics of $60 trillion to $300 trillion in the United States alone. Unfortunately, this stock is being gradually depleted owing to genetic mutations in bacteria and ...	[Hollis, Aidan] Univ Calgary, Dept Econ, Calgary, AB T2N 1N4, Canada; [Hollis, Aidan] Incent Global Hlth, Washington, DC USA; [Ahmed, Ziana] Univ Toronto, Dept Econ, Toronto, ON M5S 1A1, Canada	University of Calgary; University of Toronto	Hollis, A (corresponding author), Univ Calgary, Dept Econ, Calgary, AB T2N 1N4, Canada.			Hollis, Aidan/0000-0001-5125-2193				Cogliani C, 2011, MICROBE, V6, P274, DOI [10.1128/microbe.6.274.1, DOI 10.1128/MICROBE.6.274.1]; Harrison EM, 2013, EMBO MOL MED, V5, P509, DOI 10.1002/emmm.201202413; MCDERMOTT W, 1982, JOHNS HOPKINS MED J, V151, P302; Outterson Kevin, 2013, GLOBALIZATION HLTH C, P318; Research Council N., 1999, USE DRUGS FOOD ANIMA, DOI DOI 10.17226/5137	5	99	101	2	42	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 26	2013	369	26					2474	2476		10.1056/NEJMp1311479	http://dx.doi.org/10.1056/NEJMp1311479			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	278BT	24369073				2023-01-03	WOS:000328863700004
J	Kato, T; Tanaka, M; Oba, M				Kato, Takuma; Tanaka, Masakazu; Oba, Makoto			Protein Transfection Study Using Multicellular Tumor Spheroids of Human Hepatoma Huh-7 Cells	PLOS ONE			English	Article							NONVIRAL GENE DELIVERY; IN-VIVO; DRUG; TISSUE; MODEL; TRANSCYTOSIS; TRAFFICKING; EXPRESSION; MICELLES; CAVEOLAE	Several protein transfection reagents are commercially available and are powerful tools for elucidating function of a protein in a cell. Here we described protein transfection studies of the commercially available reagents, Pro-DeliverIN, Xfect, and TuboFect, using Huh-7 multicellular tumor spheroid (MCTS) as a three-dimensional in vitro tumor model. A cellular uptake study using specific endocytosis inhibitors revealed that each reagent was internalized into Huh-7 MCTS by different mechanisms, which were the same as monolayer cultured Huh-7 cells. A certain amount of Pro-DeliverIN and Xfect was uptaken by Huh-7 cells through caveolae-mediated endocytosis, which may lead to transcytosis through the surface-first layered cells of MCTS. The results presented here will help in the choice and use of protein transfection reagents for evaluating anti-tumor therapeutic proteins against MCTS models.	[Kato, Takuma; Tanaka, Masakazu; Oba, Makoto] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 852, Japan	Nagasaki University	Oba, M (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 852, Japan.	moba@nagasaki-u.ac.jp		Oba, Makoto/0000-0002-3691-3608; Kato, Takuma/0000-0002-2561-8582	JSPS KAKENHI [25713008, 25560226]; Takeda Science Foundation; Mochida Memorial Foundation for Medical and Pharmaceutical Research; Grants-in-Aid for Scientific Research [25560226] Funding Source: KAKEN	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Mochida Memorial Foundation for Medical and Pharmaceutical Research; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was financially supported by JSPS KAKENHI Grant Number 25713008 and 25560226, by a Grant from the Takeda Science Foundation, and by a Grant from the Mochida Memorial Foundation for Medical and Pharmaceutical Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bae Y, 2005, BIOCONJUGATE CHEM, V16, P122, DOI 10.1021/bc0498166; Bromberg LE, 1998, ADV DRUG DELIVER REV, V31, P197, DOI 10.1016/S0169-409X(97)00121-X; De Clercq E, 2004, J CLIN VIROL, V30, P115, DOI 10.1016/j.jcv.2004.02.009; De Groot AS, 2007, TRENDS IMMUNOL, V28, P482, DOI 10.1016/j.it.2007.07.011; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Fiedrich J, 2009, NAT PROTC, V4, P309, DOI [10.1038/nprot.2008.226, DOI 10.1038/NPR0T.2008.226]; Han M, 2007, J CONTROL RELEASE, V121, P38, DOI 10.1016/j.jconrel.2007.05.012; Han M, 2009, MOL THER, V17, P1404, DOI 10.1038/mt.2009.119; Khalil IA, 2006, PHARMACOL REV, V58, P32, DOI 10.1124/pr.58.1.8; Kunz-Schughart LA, 2004, J BIOMOL SCREEN, V9, P273, DOI 10.1177/1087057104265040; Lee Y, 2009, ANGEW CHEM INT EDIT, V48, P5309, DOI 10.1002/anie.200900064; McIntosh DP, 2002, P NATL ACAD SCI USA, V99, P1996, DOI 10.1073/pnas.251662398; Mellert K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052473; Mellor HR, 2006, J GENE MED, V8, P1160, DOI 10.1002/jgm.947; Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Oba M, 2012, BIOL PHARM BULL, V35, P1064, DOI 10.1248/bpb.b12-00001; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236; Schnitzer JE, 2001, ADV DRUG DELIVER REV, V49, P265, DOI 10.1016/S0169-409X(01)00141-7; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; van der Gun BTF, 2007, J CONTROL RELEASE, V123, P228, DOI 10.1016/j.jconrel.2007.08.014; von Gersdorff K, 2006, MOL THER, V14, P745, DOI 10.1016/j.ymthe.2006.07.006	24	13	14	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2013	8	12							e82876	10.1371/journal.pone.0082876	http://dx.doi.org/10.1371/journal.pone.0082876			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273WD	24349384	Green Published, gold			2023-01-03	WOS:000328566100129
J	Liu, CH; Huang, CF; Liu, CJ; Dai, CY; Liang, CC; Huang, JF; Hung, PH; Tsai, HB; Tsai, MK; Chen, SI; Lin, JW; Yang, SS; Su, TH; Yang, HC; Chen, PJ; Chen, DS; Chuang, WL; Yu, ML; Kao, JH				Liu, Chen-Hua; Huang, Chung-Feng; Liu, Chun-Jen; Dai, Chia-Yen; Liang, Cheng-Chao; Huang, Jee-Fu; Hung, Peir-Haur; Tsai, Hung-Bin; Tsai, Meng-Kun; Chen, Shih-I; Lin, Jou-Wei; Yang, Sheng-Shun; Su, Tung-Hung; Yang, Hung-Chih; Chen, Pei-Jer; Chen, Ding-Shinn; Chuang, Wan-Long; Yu, Ming-Lung; Kao, Jia-Horng			Pegylated Interferon-alpha 2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							28B GENETIC POLYMORPHISMS; DIALYSIS PATIENTS; PLUS RIBAVIRIN; TREATMENT DURATION; KIDNEY-TRANSPLANTATION; ANTIVIRAL THERAPY; VIRAL KINETICS; HCV PATIENTS; INFECTION; ALPHA-2A	Background: Data are limited on the efficacy and safety of pegylated interferon plus ribavirin for patients with hepatitis C virus genotype 1 (HCV-1) receiving hemodialysis. Objective: To compare the efficacy and safety of combination therapy with pegylated interferon plus low-dose ribavirin and pegylated interferon monotherapy for treatment-naive patients with HCV-1 receiving hemodialysis. Design: Open-label, randomized, controlled trial. (ClinicalTrials.gov: NCT00491244) Setting: 8 centers in Taiwan. Patients: 205 treatment-naive patients with HCV-1 receiving hemodialysis. Intervention: 48 weeks of pegylated interferon-alpha 2a, 135 mu g weekly, plus ribavirin, 200 mg daily (n = 103), or pegylated interferon-alpha 2a, 135 mu g weekly (n = 102). Measurements: Sustained virologic response rate and adverse event-related withdrawal rate. Results: Compared with monotherapy, combination therapy had a greater sustained virologic response rate (64% vs. 33%; relative risk, 1.92 [95% CI, 1.41 to 2.62]; P < 0.001). More patients receiving combination therapy had hemoglobin levels less than 8.5 g/dL than those receiving monotherapy (72% vs. 6%; risk difference, 66% [CI, 56% to 76%]; P < 0.001). Patients receiving combination therapy required a higher dosage (mean, 13 946 IU per week [SD, 6449] vs. 5833 IU per week [SD, 1169]; P = 0.006) and longer duration (mean, 29 weeks [SD, 9] vs. 18 weeks [SD, 7]; P = 0.004) of epoetin-beta than patients receiving monotherapy. The adverse event-related withdrawal rates were 7% in the combination therapy group and 4% in the monotherapy group (risk difference, 3% [CI, -3% to 9%]). Limitation: Open-label trial; results may not be generalizable to patients on peritoneal dialysis. Conclusion: In treatment-naive patients with HCV-1 receiving hemodialysis, combination therapy with pegylated interferon plus low-dose ribavirin achieved a greater sustained virologic response rate than pegylated interferon monotherapy.	[Kao, Jia-Horng] Natl Taiwan Univ Hosp, Taipei 10002, Taiwan; Coll Med, Taipei, Taiwan; Far Easter Mem Hosp, Taipei, Taiwan; Kaohsiung Med Univ, Kaohsiung, Taiwan; Kaohsiung Municipal Tatung Hosp, Kaohsiung, Taiwan; Ditmanson Med Fdn, Chiayi Christian Hosp, Chiayi, Taiwan; Buddhist Tzu Chi Gen Hosp, Tzu, Chiayi County, Taiwan; Taichung Vet Gen Hosp, Taichung, Taiwan	National Taiwan University; National Taiwan University Hospital; Far Eastern Memorial Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Municipal Ta-Tung Hospital; Chia-Yi Christian Hospital; Buddhist Tzu Chi General Hospital; Taichung Veterans General Hospital	Kao, JH (corresponding author), Natl Taiwan Univ Hosp, 7 Chung Shan South Rd, Taipei 10002, Taiwan.	kaojh@ntu.edu.tw	Yu, Ming-Lung/AAZ-4306-2020; Kao, Jia-Horng/AAB-8947-2019; Huang, Jee-Fu/AAX-4622-2020; Chuang, Wan-Long/ABF-7427-2021; Liu, Chen-Hua/F-6608-2018; Tsai, Hung-Bin/G-3761-2011	Yu, Ming-Lung/0000-0001-8145-1900; Kao, Jia-Horng/0000-0002-2442-7952; Huang, Jee-Fu/0000-0002-2752-7051; Chuang, Wan-Long/0000-0002-2376-421X; Liu, Chen-Hua/0000-0003-3622-9707; CHEN, DING-SHINN/0000-0001-7791-6154; Yang, Sheng-Shun/0000-0001-5800-1901; Tsai, Hung-Bin/0000-0002-0689-8339; Chen, Pei-Jer/0000-0001-8316-3785; LIU, CHUN-JEN/0000-0002-6202-0993; TSAI, MENG-KUN/0000-0002-2962-8913; YANG, HUNG-CHIH/0000-0003-3864-9895; SU, TUNG-HUNG/0000-0002-6747-7941	National Center of Excellence for Clinical Trial and Research	National Center of Excellence for Clinical Trial and Research	National Center of Excellence for Clinical Trial and Research.	[Anonymous], 2011, PEG PACK INS; [Anonymous], 2013, INC PACK INS; [Anonymous], 2011, VECTR BOC CAPS; [Anonymous], 2011, COP PACK INS; Berenguer M, 2008, HEPATOLOGY, V48, P1690, DOI 10.1002/hep.22545; Bronowicki JP, 2006, GASTROENTEROLOGY, V131, P1040, DOI 10.1053/j.gastro.2006.07.022; Bruchfeld A, 2006, J VIRAL HEPATITIS, V13, P316, DOI 10.1111/j.1365-2893.2005.00680.x; Bruchfeld A, 2001, J VIRAL HEPATITIS, V8, P287, DOI 10.1046/j.1365-2893.2001.00300.x; Carriero D, 2008, INT J ARTIF ORGANS, V31, P295, DOI 10.1177/039139880803100404; Deltenre P, 2011, ALIMENT PHARM THER, V34, P454, DOI 10.1111/j.1365-2036.2011.04741.x; Di Martino V, 2011, HEPATOLOGY, V54, P789, DOI 10.1002/hep.24480; Dumortier J, 2013, J CLIN VIROL, V56, P146, DOI 10.1016/j.jcv.2012.10.009; Fabrizi F, 2008, J VIRAL HEPATITIS, V15, P79, DOI [10.1111/j.1365-2893.2007.00907.x, 10.1111/j.1365-2893.2008.01039.x]; Fabrizi F, 2007, J VIRAL HEPATITIS, V14, P697, DOI 10.1111/1365-2893.2007.00868.x; Fabrizi F, 2006, ALIMENT PHARM THER, V24, P1413, DOI 10.1111/j.1365-2036.2006.03151.x; Fabrizi F, 2011, J VIRAL HEPATITIS, V18, pE263, DOI 10.1111/j.1365-2893.2010.01405.x; Fabrizi F, 2008, INT J ARTIF ORGANS, V31, P1004, DOI 10.1177/039139880803101204; Pereira PDF, 2013, INT J INFECT DIS, V17, pE50, DOI 10.1016/j.ijid.2012.09.001; Gordon CE, 2008, AM J KIDNEY DIS, V51, P263, DOI 10.1053/j.ajkd.2007.11.003; Gordon CE, 2011, CLIN J AM SOC NEPHRO, V6, P2226, DOI 10.2215/CJN.00410111; Gupta SK, 2012, EUR J CLIN PHARMACOL, V68, P415, DOI 10.1007/s00228-011-1137-x; Hakim W, 2009, J CLIN GASTROENTEROL, V43, P477, DOI 10.1097/MCG.0b013e318180803a; Herrmann E, 2003, HEPATOLOGY, V37, P1351, DOI 10.1053/jhep.2003.50218; Huang CF, 2012, ANTIVIR RES, V93, P239, DOI 10.1016/j.antiviral.2011.12.002; Huraib S, 2001, AM J NEPHROL, V21, P435, DOI 10.1159/000046646; Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912; Kumada H, 2012, J HEPATOL, V56, P78, DOI 10.1016/j.jhep.2011.07.016; Liu CH, 2008, GUT, V57, P525, DOI 10.1136/gut.2007.133884; Liu CH, 2009, GUT, V58, P314, DOI 10.1136/gut.2008.165076; Liu CH, 2008, CLIN INFECT DIS, V47, P1260, DOI 10.1086/592579; Liu CH, 2012, ANTIVIR THER, V17, P1059, DOI 10.3851/IMP2322; Liu CH, 2012, ANTIVIR THER, V17, P477, DOI 10.3851/IMP2026; Liu CH, 2011, J GASTROEN HEPATOL, V26, P228, DOI 10.1111/j.1440-1746.2010.06488.x; Liu CH, 2010, CLIN INFECT DIS, V51, P541, DOI 10.1086/655682; Liu CH, 2010, KIDNEY INT, V78, P103, DOI 10.1038/ki.2010.74; Martin P, 2008, J HEPATOL, V49, P613, DOI 10.1016/j.jhep.2008.06.003; Mathurin P, 1999, HEPATOLOGY, V29, P257, DOI 10.1002/hep.510290123; Mousa DH, 2004, TRANSPLANT P, V36, P1831, DOI 10.1016/j.transproceed.2004.07.025; Poordad F, 2011, NEW ENGL J MED, V364, P1195, DOI 10.1056/NEJMoa1010494; Rendina M, 2007, J HEPATOL, V46, P768, DOI 10.1016/j.jhep.2006.12.016; Roth D, 2011, J AM SOC NEPHROL, V22, P1152, DOI 10.1681/ASN.2010060668; Russo MW, 2003, AM J GASTROENTEROL, V98, P1610, DOI 10.1111/j.1572-0241.2003.07526.x; Sherman KE, 2011, NEW ENGL J MED, V365, P1014, DOI 10.1056/NEJMoa1014463; Tan ACITL, 2001, NEPHROL DIAL TRANSPL, V16, P193, DOI 10.1093/ndt/16.1.193; Thompson AJ, 2010, GASTROENTEROLOGY, V139, P120, DOI 10.1053/j.gastro.2010.04.013; van Leusen R, 2008, NEPHROL DIAL TRANSPL, V23, P721, DOI 10.1093/ndt/gfm724; Yu ML, 2008, HEPATOLOGY, V47, P1884, DOI 10.1002/hep.22319	47	74	80	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 3	2013	159	11					729	+		10.7326/0003-4819-159-11-201312030-00005	http://dx.doi.org/10.7326/0003-4819-159-11-201312030-00005			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276EN	24297189				2023-01-03	WOS:000328731000002
J	Huang, J; Wang, JL; Gu, LJ; Bao, JF; Yin, J; Tang, ZH; Wang, L; Yuan, WJ				Huang, Juan; Wang, Jialin; Gu, Lijie; Bao, Jinfang; Yin, Jun; Tang, Zhihuan; Wang, Ling; Yuan, Weijie			Effect of a Low-Protein Diet Supplemented with Ketoacids on Skeletal Muscle Atrophy and Autophagy in Rats with Type 2 Diabetic Nephropathy	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; CHRONIC-RENAL-FAILURE; CHRONIC DIALYSIS PATIENTS; HEMODIALYSIS-PATIENTS; MELLITUS PATIENTS; AMINO-ACIDS; YOUNG MEN; LEUCINE; RESTRICTION; DEGRADATION	A low-protein diet supplemented with ketoacids maintains nutritional status in patients with diabetic nephropathy. The activation of autophagy has been shown in the skeletal muscle of diabetic and uremic rats. This study aimed to determine whether a low-protein diet supplemented with ketoacids improves muscle atrophy and decreases the increased autophagy observed in rats with type 2 diabetic nephropathy. In this study, 24-week-old Goto-Kakizaki male rats were randomly divided into groups that received either a normal protein diet (NPD group), a low-protein diet (LPD group) or a low-protein diet supplemented with ketoacids (LPD+KA group) for 24 weeks. Age-and weight-matched Wistar rats served as control animals and received a normal protein diet (control group). We found that protein restriction attenuated proteinuria and decreased blood urea nitrogen and serum creatinine levels. Compared with the NPD and LPD groups, the LPD+KA group showed a delay in body weight loss, an attenuation in soleus muscle mass loss and a decrease of the mean cross-sectional area of soleus muscle fibers. The mRNA and protein expression of autophagy-related genes, such as Beclin-1, LC3B, Bnip3, p62 and Cathepsin L, were increased in the soleus muscle of GK rats fed with NPD compared to Wistar rats. Importantly, LPD resulted in a slight reduction in the expression of autophagy-related genes; however, these differences were not statistically significant. In addition, LPD+KA abolished the upregulation of autophagy-related gene expression. Furthermore, the activation of autophagy in the NPD and LPD groups was confirmed by the appearance of autophagosomes or autolysosomes using electron microscopy, when compared with the Control and LPD+KA groups. Our results showed that LPD+KA abolished the activation of autophagy in skeletal muscle and decreased muscle loss in rats with type 2 diabetic nephropathy.	[Huang, Juan; Wang, Jialin; Gu, Lijie; Bao, Jinfang; Yin, Jun; Tang, Zhihuan; Wang, Ling; Yuan, Weijie] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 1, Dept Nephrol, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University	Yuan, WJ (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 1, Dept Nephrol, Shanghai 200030, Peoples R China.	ywj4169@163.com		gu, li jie/0000-0002-4351-7582; yuan, wei jie/0000-0002-6395-9994				Anthony JC, 2000, J NUTR, V130, P2413; Aparicio M, 2000, J AM SOC NEPHROL, V11, P708, DOI 10.1681/ASN.V114708; Aparicio M, 2012, J RENAL NUTR, V22, pS1, DOI 10.1053/j.jrn.2011.09.005; Aparicio M, 2012, J RENAL NUTR, V22, pS22, DOI 10.1053/j.jrn.2011.09.006; Aparicio M, 2009, J RENAL NUTR, V19, pS5, DOI 10.1053/j.jrn.2009.06.017; BARSOTTI G, 1988, CLIN NEPHROL, V29, P280; Barsotti G, 1987, Infusionsther Klin Ernahr, V14 Suppl 5, P12; Bernhard J, 2001, J AM SOC NEPHROL, V12, P1249, DOI 10.1681/ASN.V1261249; Blomstrand E, 2006, J NUTR, V136, p269S, DOI 10.1093/jn/136.1.269S; BRODSKY IG, 1992, J CLIN ENDOCR METAB, V75, P351, DOI 10.1210/jc.75.2.351; Carmignac V, 2011, HUM MOL GENET, V20, P4891, DOI 10.1093/hmg/ddr427; Carrero JJ, 2008, CLIN NUTR, V27, P557, DOI 10.1016/j.clnu.2008.04.007; Chang JH, 2009, NEPHROLOGY, V14, P750, DOI 10.1111/j.1440-1797.2009.01115.x; Chauveau P, 1999, AM J KIDNEY DIS, V34, P500, DOI 10.1016/S0272-6386(99)70078-8; Cianciaruso B, 2008, NEPHROL DIAL TRANSPL, V23, P636, DOI 10.1093/ndt/gfm576; Ciarambino T, 2011, NUTRITION, V27, P46, DOI 10.1016/j.nut.2009.10.017; de Mutsert R, 2008, NEPHROL DIAL TRANSPL, V23, P2957, DOI 10.1093/ndt/gfn167; De Santo Natale Gaspare, 2011, Front Biosci (Schol Ed), V3, P1432; Di Iorio BR, 2003, KIDNEY INT, V64, P1822, DOI 10.1046/j.1523-1755.2003.00282.x; DIAZ M, 1975, KIDNEY INT, V8, P349, DOI 10.1038/ki.1975.126; Dobrowolny G, 2008, CELL METAB, V8, P425, DOI 10.1016/j.cmet.2008.09.002; Doyle A, 2011, FASEB J, V25, P99, DOI 10.1096/fj.10-164152; Dussol B, 2005, J RENAL NUTR, V15, P398, DOI 10.1053/j.jrn.2005.07.003; Fanzani A, 2012, J CACHEXIA SARCOPENI, V3, P163, DOI 10.1007/s13539-012-0074-6; Fanzani A, 2011, TOXICOL APPL PHARM, V250, P312, DOI 10.1016/j.taap.2010.11.003; FOLLMANN P, 1993, DOC OPHTHALMOL, V83, P55, DOI 10.1007/BF01203570; Gao XA, 2011, KIDNEY INT, V79, P987, DOI 10.1038/ki.2010.539; Gao X, 2010, BRIT J NUTR, V103, P608, DOI 10.1017/S0007114509992108; Giordano M, 2008, DIABETOLOGIA, V51, P21, DOI 10.1007/s00125-007-0874-y; Glynn EL, 2010, J NUTR, V140, P1970, DOI 10.3945/jn.110.127647; GOODSHIP THJ, 1990, J AM SOC NEPHROL, V1, P66; Gros F, 2012, AUTOPHAGY, V8, P1113, DOI 10.4161/auto.20275; Hansen HP, 2002, KIDNEY INT, V62, P220, DOI 10.1046/j.1523-1755.2002.00421.x; Janssen U, 2004, J NEPHROL, V17, P769; Janssen U, 2003, KIDNEY INT, V63, P2162, DOI 10.1046/j.1523-1755.2003.00007.x; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kalantar-Zadeh K, 2005, NEPHROL DIAL TRANSPL, V20, P1880, DOI 10.1093/ndt/gfh941; Kalantar-Zadeh K, 2011, NAT REV NEPHROL, V7, P369, DOI 10.1038/nrneph.2011.60; Koya D, 2009, DIABETOLOGIA, V52, P2037, DOI 10.1007/s00125-009-1467-8; Lopez LV, 2008, NUTR HOSP, V23, P141; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Matsuda Sanae, 2004, Clin Exp Nephrol, V8, P322; Meloni C, 2004, J RENAL NUTR, V14, P208, DOI 10.1053/j.jm.2004.07.011; Mofarrahi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047265; MOTIL KJ, 1981, AM J PHYSIOL, V240, pE712, DOI 10.1152/ajpendo.1981.240.6.E712; NAIR KS, 1992, AM J PHYSIOL, V263, pE928, DOI 10.1152/ajpendo.1992.263.5.E928; Noori N, 2010, CLIN J AM SOC NEPHRO, V5, P2258, DOI 10.2215/CJN.02080310; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Pupim LB, 2005, KIDNEY INT, V68, P2368, DOI 10.1111/j.1523-1755.2005.00699.x; Pupim LB, 2005, KIDNEY INT, V68, P1857, DOI 10.1111/j.1523-1755.2005.00605.x; Robertson L, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002181.pub2; Sacheck JM, 2007, FASEB J, V21, P140, DOI 10.1096/fj.06-6604com; Sandri M, 2010, FEBS LETT, V584, P1411, DOI 10.1016/j.febslet.2010.01.056; Smuder AJ, 2011, J APPL PHYSIOL, V111, P1190, DOI 10.1152/japplphysiol.00429.2011; Sugawara T, 2009, AMINO ACIDS, V37, P609, DOI 10.1007/s00726-008-0180-0; Tassa A, 2003, BIOCHEM J, V376, P577, DOI 10.1042/BJ20030826; Walser M, 1975, Clin Nephrol, V3, P180; WALSER M, 1975, LIFE SCI, V17, P1011, DOI 10.1016/0024-3205(75)90320-3; Wang JL, 2012, NEPHRON CLIN PRACT, V121, pC102, DOI 10.1159/000345159; Yamamoto D, 2010, MUSCLE NERVE, V41, P819, DOI 10.1002/mus.21621; ZATZ R, 1985, P NATL ACAD SCI USA, V82, P5963, DOI 10.1073/pnas.82.17.5963; Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004	62	16	17	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 26	2013	8	11							e81464	10.1371/journal.pone.0081464	http://dx.doi.org/10.1371/journal.pone.0081464			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259SK	24303049	Green Submitted, gold, Green Published			2023-01-03	WOS:000327546400065
J	Zofou, D; Tematio, EL; Ntie-Kang, F; Tene, M; Ngemenya, MN; Tane, P; Titanji, VPK				Zofou, Denis; Tematio, Esther Laure; Ntie-Kang, Fidele; Tene, Mathieu; Ngemenya, Moses N.; Tane, Pierre; Titanji, Vincent P. K.			New Antimalarial Hits from Dacryodes edulis (Burseraceae) - Part I: Isolation, In Vitro Activity, In Silico "drug-likeness" and Pharmacokinetic Profiles	PLOS ONE			English	Article							NATURAL-PRODUCTS	The aims of the present study were to identify the compounds responsible for the anti-malarial activity of Dacryoedes edulis (Burseraceae) and to investigate their suitability as leads for the treatment of drug resistant malaria. Five compounds were isolated from ethyl acetate and hexane extracts of D. edulis stem bark and tested against 3D7 (chloroquine-susceptible) and Dd2 (multidrug-resistant) strains of Plasmodium falciparum, using the parasite lactate dehydrogenase method. Cytotoxicity studies were carried out on LLC-MK2 monkey kidney epithelial cell-line. In silico analysis was conducted by calculating molecular descriptors using the MOE software running on a Linux workstation. The "drug-likeness" of the isolated compounds was assessed using Lipinski criteria, from computed molecular properties of the geometry optimized structures. Computed descriptors often used to predict absorption, distribution, metabolism, elimination and toxicity (ADMET) were used to assess the pharmacokinetic profiles of the isolated compounds. Antiplasmodial activity was demonstrated for the first time in five major natural products previously identified in D. edulis, but not tested against malaria parasites. The most active compound identified was termed DES4. It had IC50 values of 0.37 and 0.55 mu g/mL, against 3D7 and Dd2 respectively. In addition, this compound was shown to act in synergy with quinine, satisfied all criteria of "Drug-likeness" and showed considerable probability of providing an antimalarial lead. The remaining four compounds also showed antiplasmodial activity, but were less effective than DES4. None of the tested compounds was cytotoxicity against LLC-MK2 cells, suggesting their selective activities on malaria parasites. Based on the high in vitro activity, low toxicity and predicted "Drug-likeness" DES4 merits further investigation as a possible drug lead for the treatment of malaria.	[Zofou, Denis; Ngemenya, Moses N.; Titanji, Vincent P. K.] Univ Buea, Biotechnol Unit, Fac Sci, Buea, Cameroon; [Tematio, Esther Laure; Tene, Mathieu; Tane, Pierre] Univ Dschang, Lab Nat Prod Chem, Dschang, Cameroon; [Ntie-Kang, Fidele] Univ Douala, CEPAMOQ, Douala, Cameroon; [Ntie-Kang, Fidele] Univ Buea, Chem & Bioact Informat Ctr, Fac Sci, Buea, Cameroon		Zofou, D (corresponding author), Univ Buea, Biotechnol Unit, Fac Sci, Buea, Cameroon.	zofden@yahoo.com	Ngemenya, Moses Njutain/GPW-7189-2022; Ntie-Kang, Fidele/B-5877-2013; Zofou, Denis/D-3538-2013	Ntie-Kang, Fidele/0000-0003-0795-394X; Zofou, Denis/0000-0002-3421-7609	International Foundation for Science, Stockholm, Sweden / Organisation for the Prohibition of Chemical Weapons, The Hague, The Netherlands (IFS/OPCW) [F/5122-1]	International Foundation for Science, Stockholm, Sweden / Organisation for the Prohibition of Chemical Weapons, The Hague, The Netherlands (IFS/OPCW)	This work was financially supported by a research grant awarded to Dr. Denis Zofou by the International Foundation for Science, Stockholm, Sweden / Organisation for the Prohibition of Chemical Weapons, The Hague, The Netherlands (IFS/OPCW) grant (number F/5122-1) (www.ifs.se). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ajibesin K. K., 2011, Research Journal of Medicinal Plant, V5, P32, DOI 10.3923/rjmp.2011.32.41; [Anonymous], 2005, ABSTRACT ACTA TROP S; Arhoghro E.M., 2009, EUR J SCI RES, V226, P122; Atawodi SE, 2009, J MED FOOD, V12, P1321, DOI 10.1089/jmf.2008.0215; Bell A, 2005, FEMS MICROBIOL LETT, V253, P171, DOI 10.1016/j.femsle.2005.09.035; BERENBAUM MC, 1978, J INFECT DIS, V137, P122, DOI 10.1093/infdis/137.2.122; Chemical Computing Group Inc, 2010, MOL OP ENV SOFTW; Comalada M, 2005, EUR J IMMUNOL, V35, P584, DOI 10.1002/eji.200425778; Darvas Ferenc, 2002, Current Topics in Medicinal Chemistry, V2, P1287, DOI 10.2174/1568026023392841; Delano W. L., 2002, PYMOL MOL GRAPHICS S; DESARR SO, 2011, MALARIA J, V10, P85, DOI DOI 10.1186/1475-2875-10-85.PUBMED:21481272; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; Efange S. M. N., 2002, Ethnomedicine and drug discovery, P61; Fivelman QL, 2004, ANTIMICROB AGENTS CH, V48, P4097, DOI 10.1128/AAC.48.11.4097-4102.2004; Grabowski K, 2008, NAT PROD REP, V25, P892, DOI 10.1039/b715668p; Hanson I., 2009, African Journal of Food, Agriculture, Nutrition and Development, V9, P1561; Harvey AL, 2008, DRUG DISCOV TODAY, V13, P894, DOI 10.1016/j.drudis.2008.07.004; LHUILLIER MA, 2007, THESIS I NATL POLYTE; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; Malebo H M, 2009, Tanzan J Health Res, V11, P226; Mpiana PT, 2007, PHYTOMEDICINE, V14, P192, DOI 10.1016/j.phymed.2006.05.008; Newman DJ, 2008, J MED CHEM, V51, P2589, DOI 10.1021/jm0704090; NOEDL H, 2002, HN NONLIN V1 1; Ntie-Kang F, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-88; Okwu D., 2006, INT J MOL MED ADV SC, V1, P1; Okwu D, 2005, INT J MOL MED ADV SC, V1, P375; Okwu DE, 2008, AFR J TRADIT COMPLEM, V5, P194; Okwu D. E., 2004, Journal of Sustainable Agriculture and the Environment, V6, P30; Omonhinmin C. A., 2012, Ethnobotany Research and Applications, V10, P175; Quinn RJ, 2008, J NAT PROD, V71, P464, DOI 10.1021/np070526y; Ramiarantsoa H., 2008, J SOC OUEST AFRICAIN, V26, P99; Schneider G, 2002, CURR MED CHEM, V9, P2095, DOI 10.2174/0929867023368755; SCHRODINGER P, 2011, QIK PROP 3 4; STEWART JJP, 1993, MOPAC MANUAL; Tane P, 2005, FITOTERAPIA, V76, P656, DOI 10.1016/j.fitote.2005.08.018; Teague SJ, 1999, ANGEW CHEM INT EDIT, V38, P3743, DOI 10.1002/(SICI)1521-3773(19991216)38:24<3743::AID-ANIE3743>3.0.CO;2-U; TL O, 2002, J COMPUT AID MOL DES, V16, P325; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465; Vivas L, 2007, J ANTIMICROB CHEMOTH, V59, P658, DOI 10.1093/jac/dkl563; WALKER AR, 1961, PLANTES UTILES GABON, P19; WATERMAN PG, 1987, PHYTOCHEMISTRY, V26, P1189, DOI 10.1016/S0031-9422(00)82376-6; Wetzel S, 2007, CHIMIA, V61, P355, DOI 10.2533/chimia.2007.355; Willcox ML, 2004, BMJ-BRIT MED J, V329, P1156, DOI 10.1136/bmj.329.7475.1156; ZOFOU D, 2011, IN VITRO ANTIPLASMOD; Zofou D, 2013, NAT PROD REP, V30, P1098, DOI 10.1039/c3np70030e; Zofou D, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-167; Zofou D, 2011, PARASITOL RES, V108, P1383, DOI 10.1007/s00436-011-2363-y	48	14	14	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2013	8	11							e79544	10.1371/journal.pone.0079544	http://dx.doi.org/10.1371/journal.pone.0079544			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255CG	24282507	gold, Green Published, Green Submitted			2023-01-03	WOS:000327216200074
J	Han, G; Liu, D; Gan, H; Denniston, KA; Li, SC; Tan, WY; Hu, DS; Zhen, WN; Wang, ZH				Han, Guang; Liu, Dong; Gan, Hua; Denniston, Kyle A.; Li, Sicong; Tan, Wenyong; Hu, Desheng; Zhen, Weining; Wang, Zhaohua			Evaluation of the Dosimetric Feasibility of Hippocampal Sparing Intensity-Modulated Radiotherapy in Patients with Locally Advanced Nasopharyngeal Carcinoma	PLOS ONE			English	Article							WHOLE-BRAIN RADIOTHERAPY; COGNITIVE DYSFUNCTION; RADIATION-THERAPY; IRRADIATION; NEUROGENESIS; CANCER; TRIAL	Purpose: The objective of this study was to evaluate the dosimetric feasibility of using hippocampus (HPC) sparing intensity-modulated radiotherapy (IMRT) in patients with locally advanced nasopharyngeal carcinoma (NPC). Materials/Methods: Eight cases of either T3 or T4 NPC were selected for this study. Standard IMRT treatment plans were constructed using the volume and dose constraints for the targets and organs at risk (OAR) per Radiation Therapy Oncology Group (RTOG) 0615 protocol. Experimental plans were constructed using the same criteria, with the addition of the HPC as an OAR. The two dose-volume histograms for each case were compared for the targets and OARs. Results: All plans achieved the protocol dose criteria. The homogeneity index, conformity index, and coverage index for the planning target volumes (PTVs) were not significantly compromised by the avoidance of the HPC. The doses to all OARs, excluding the HPC, were similar. Both the dose (D-max, D-2%, D-40%, D-mean, D-median, D-98% and D-min) and volume (V-5, V-10, V-15, V-20, V-30, V-40 and V-50) parameters for the HPC were significantly lower in the HPC sparing plans (p<0.05), except for D-min (P = 0.06) and V-5 (P = 0.12). Conclusions: IMRT for patients with locally advanced NPC exposes the HPC to a significant radiation dose. HPC sparing IMRT planning significantly decreases this dose, with minimal impact on the therapeutic targets and other OARs.	[Han, Guang; Liu, Dong; Tan, Wenyong; Hu, Desheng; Wang, Zhaohua] Hubei Canc Hosp, Dept Radiat Oncol, Wuhan, Peoples R China; [Gan, Hua; Denniston, Kyle A.; Li, Sicong; Zhen, Weining] Univ Nebraska Med Ctr, Dept Radiat Oncol, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center	Wang, ZH (corresponding author), Hubei Canc Hosp, Dept Radiat Oncol, Wuhan, Peoples R China.	hg7913@hotmail.com		Tan, Wenyong/0000-0002-2706-4149	Youth Science & Technology foundation from Hubei Provincial Health Department [QJX2012-29]	Youth Science & Technology foundation from Hubei Provincial Health Department	This study was financially supported by the Youth Science & Technology foundation from Hubei Provincial Health Department (QJX2012-29). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abayomi OK, 1996, ACTA ONCOL, V35, P659, DOI 10.3109/02841869609083995; Baujat B, 2006, INT J RADIAT ONCOL, V64, P47, DOI 10.1016/j.ijrobp.2005.06.037; Brown PD, 2013, NEURO-ONCOLOGY, V15, P1429, DOI 10.1093/neuonc/not114; Feuvret L, 2006, INT J RADIAT ONCOL, V64, P333, DOI 10.1016/j.ijrobp.2005.09.028; Gondi V, 2013, INT J RADIAT ONCOL, V87, P1186, DOI DOI 10.1016/J.IJR0BP.2013.10.005; Gondi V, 2013, INT J RADIAT ONCOL, V85, P348, DOI 10.1016/j.ijrobp.2012.11.031; Gondi V, 2010, RADIOTHER ONCOL, V97, P370, DOI 10.1016/j.radonc.2010.09.013; Gondi V, 2010, INT J RADIAT ONCOL, V78, P1244, DOI 10.1016/j.ijrobp.2010.01.039; Gondi V, 2010, RADIOTHER ONCOL, V95, P327, DOI 10.1016/j.radonc.2010.02.030; Gutierrez AN, 2007, INT J RADIAT ONCOL, V69, P589, DOI 10.1016/j.ijrobp.2007.05.038; Hsiao KY, 2010, INT J RADIAT ONCOL, V77, P722, DOI 10.1016/j.ijrobp.2009.06.080; Khodayari B, 2011, INT J RADIAT ONCOL, V81, pS508, DOI 10.1016/j.ijrobp.2011.06.1037; Lam LCW, 2003, J NEUROPSYCH CLIN N, V15, P90, DOI 10.1176/appi.neuropsych.15.1.90; Lee NY, 2012, LANCET ONCOL, V13, P172, DOI 10.1016/S1470-2045(11)70303-5; LEE PWH, 1989, J NEUROL NEUROSUR PS, V52, P488, DOI 10.1136/jnnp.52.4.488; LEUNG SF, 1992, BRIT J RADIOL, V65, P710, DOI 10.1259/0007-1285-65-776-710; Lin SJ, 2009, INT J RADIAT ONCOL, V75, P1071, DOI 10.1016/j.ijrobp.2008.12.015; Marsh JC, 2010, INT J RADIAT ONCOL, V78, P946, DOI 10.1016/j.ijrobp.2009.12.012; Mizumatsu S, 2003, CANCER RES, V63, P4021; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; Raber J, 2004, RADIAT RES, V162, P39, DOI 10.1667/RR3206; Shaw EG, 2006, J CLIN ONCOL, V24, P1415, DOI 10.1200/JCO.2005.03.3001; Taheri-Kadkhoda Z, 2008, RADIAT ONCOL, V3, DOI 10.1186/1748-717X-3-4; The International Commission on Radiation Units and Measurements Prescribing recording and reporting photon beam therapy, 1999, 62 ICRU; Van Esch A, 2006, MED PHYS, V33, P4130, DOI 10.1118/1.2358333; van Kesteren Z, 2012, RADIOTHER ONCOL, V102, P225, DOI 10.1016/j.radonc.2011.09.023; [吴晨彬 Wu Chenbin], 2012, [中华放射医学与防护杂志, Chinese Journal of Radiological Medicine and Protection], V32, P297	27	10	16	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2014	9	2							e90007	10.1371/journal.pone.0090007	http://dx.doi.org/10.1371/journal.pone.0090007			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC3DW	24587184	gold, Green Published, Green Submitted			2023-01-03	WOS:000332396200110
J	Wu, SK; Yang, MT; Kang, KH; Liou, HC; Lu, DH; Fu, WM; Lin, WL				Wu, Sheng-Kai; Yang, Ming-Tao; Kang, Kai-Hsiang; Liou, Houng-Chi; Lu, Dai-Hua; Fu, Wen-Mei; Lin, Win-Li			Targeted Delivery of Erythropoietin by Transcranial Focused Ultrasound for Neuroprotection against Ischemia/Reperfusion-Induced Neuronal Injury: A Long-Term and Short-Term Study	PLOS ONE			English	Article							BLOOD-BRAIN-BARRIER; MIDDLE CEREBRAL-ARTERY; CORTICAL INFARCTION; DRUG-DELIVERY; DISRUPTION; ISCHEMIA; RAT; STROKE; MODEL; OCCLUSION	Erythropoietin (EPO) is a neuroprotective agent against cerebral ischemia/reperfusion (I/R)-induced brain injury. However, its crossing of blood-brain barrier is limited. Focused ultrasound (FUS) sonication with microbubbles (MBs) can effectively open blood-brain barrier to boost the vascular permeability. In this study, we investigated the effects of MBs/FUS on extending the therapeutic time window of EPO and its neuroprotective effects in both acute and chronic phases. Male Wistar rats were firstly subjected to two common carotid arteries and right middle cerebral artery occlusion (three vessels occlusion, 3VO) for 50 min, and then the rats were treated with hEPO (human recombinant EPO, 5000 IU/kg) with or without MBs/FUS at 5 h after occlusion/reperfusion. Acute phase investigation (I/R, I/R+MBs/FUS, I/R+hEPO, and I/R+hEPO+MBs/FUS) was performed 24 h after I/R; chronic tests including cylinder test and gait analysis were performed one month after I/R. The experimental results showed that MBs/FUS significantly increased the cerebral content of EPO by bettering vascular permeability. In acute phase, both significant improvement of neurological score and reduction of infarct volume were found in the I/R+hEPO+MBs/FUS group, as compared with I/R and I/R+hEPO groups. In chronic phase, long-term behavioral recovery and neuronal loss in brain cortex after I/R injury was significantly improved in the I/R+hEPO+MBs/FUS group. This study indicates that hEPO administration with MBs/FUS sonication even at 5 h after occlusion/reperfusion can produce a significant neuroprotection.	[Wu, Sheng-Kai; Lin, Win-Li] Natl Taiwan Univ, Coll Med, Inst Biomed Engn, Taipei 10764, Taiwan; [Wu, Sheng-Kai; Lin, Win-Li] Natl Taiwan Univ, Coll Engn, Taipei 10764, Taiwan; [Yang, Ming-Tao; Kang, Kai-Hsiang; Liou, Houng-Chi; Lu, Dai-Hua; Fu, Wen-Mei] Natl Taiwan Univ, Coll Med, Inst Pharmacol, Taipei, Taiwan; [Lin, Win-Li] Natl Hlth Res Inst, Div Med Engn Res, Miaoli, Taiwan; [Yang, Ming-Tao] Far Eastern Mem Hosp, Dept Pediat, New Taipei City, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University; National Health Research Institutes - Taiwan; Far Eastern Memorial Hospital	Fu, WM (corresponding author), Natl Taiwan Univ, Coll Med, Inst Pharmacol, Taipei, Taiwan.	wenmei@ntu.edu.tw; winli@ntu.edu.tw	Wu, Sheng-Kai/GRF-1332-2022; Yang, Ming-Tao/K-2837-2019	Yang, Ming-Tao/0000-0001-5235-6912; FU, WEN-MEI/0000-0003-4157-8987; Kang, Kai-Hsiang/0000-0002-6529-4543	National Science Council of Taiwan [NSC 99-2221-E-002-005-MY3]; National Health Research Institutes of Taiwan [NHRI ME-100-PP-13]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); National Health Research Institutes of Taiwan(National Health Research Institutes - Taiwan)	This work was supported by research grants from the National Science Council of Taiwan (NSC 99-2221-E-002-005-MY3) and National Health Research Institutes of Taiwan (NHRI ME-100-PP-13). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aronowski J, 1997, J CEREBR BLOOD F MET, V17, P1048, DOI 10.1097/00004647-199710000-00006; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; CHEN ST, 1986, STROKE, V17, P738, DOI 10.1161/01.STR.17.4.738; Gan Y, 2012, STROKE, V43, P3071, DOI 10.1161/STROKEAHA.112.663120; Hamby AM, 2007, STROKE, V38, P632, DOI 10.1161/01.STR.0000250742.61241.79; Hynynen K, 2005, NEUROIMAGE, V24, P12, DOI 10.1016/j.neuroimage.2004.06.046; Hynynen K, 2001, RADIOLOGY, V220, P640, DOI 10.1148/radiol.2202001804; Hynynen K, 2006, J NEUROSURG, V105, P445, DOI 10.3171/jns.2006.105.3.445; Hynynen K, 2006, EUR J RADIOL, V59, P149, DOI 10.1016/j.ejrad.2006.04.007; Ishii T, 2010, BRAIN RES, V1321, P164, DOI 10.1016/j.brainres.2010.01.039; Jordao JF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010549; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Liu HL, 2010, RADIOLOGY, V255, P415, DOI 10.1148/radiol.10090699; Marquet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022598; McDannold N, 2006, PHYS MED BIOL, V51, P793, DOI 10.1088/0031-9155/51/4/003; MENZIES SA, 1993, J NEUROSURG, V78, P257, DOI 10.3171/jns.1993.78.2.0257; MENZIES SA, 1992, NEUROSURGERY, V31, P100, DOI 10.1227/00006123-199207000-00014; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; NAGAO M, 1992, BIOCHIM BIOPHYS ACTA, V1171, P99, DOI 10.1016/0167-4781(92)90146-Q; NAGASAWA H, 1989, STROKE, V20, P1037, DOI 10.1161/01.STR.20.8.1037; Park EJ, 2012, J CONTROL RELEASE, V163, P277, DOI 10.1016/j.jconrel.2012.09.007; Raymond SB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002175; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Sheikov N, 2004, ULTRASOUND MED BIOL, V30, P979, DOI 10.1016/j.ultrasmedbio.2004.04.010; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Treat LH, 2007, INT J CANCER, V121, P901, DOI 10.1002/ijc.22732; Vandeputte C, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-92; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Villa P, 2007, J CEREBR BLOOD F MET, V27, P552, DOI 10.1038/sj.jcbfm.9600370; Vykhodtseva N, 2008, ULTRASONICS, V48, P279, DOI 10.1016/j.ultras.2008.04.004; Wang YG, 2008, J CEREBR BLOOD F MET, V28, P1936, DOI 10.1038/jcbfm.2008.82; WEN D, 1993, BLOOD, V82, P1507; Weng JC, 2011, MAGN RESON MED, V65, P802, DOI 10.1002/mrm.22643; Yamamoto H, 2003, EXP NEUROL, V182, P261, DOI 10.1016/S0014-4886(03)00116-X; Yang FY, 2012, J CONTROL RELEASE, V160, P652, DOI 10.1016/j.jconrel.2012.02.023; Zhang F, 2010, TRANSL STROKE RES, V1, P113, DOI 10.1007/s12975-010-0019-3	40	96	103	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2014	9	2							e90107	10.1371/journal.pone.0090107	http://dx.doi.org/10.1371/journal.pone.0090107			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC3DW	24587228	Green Published, gold, Green Submitted			2023-01-03	WOS:000332396200127
J	Wolfe, SM				Wolfe, Sidney M.			THE WASHINGTON BRIEF Increased heart attacks in men using testosterone: the UK importantly lags far behind the US in prescribing testosterone	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							EVENTS		Publ Citizen, Hlth Res Grp, Washington, DC 20009 USA		Wolfe, SM (corresponding author), Publ Citizen, Hlth Res Grp, Washington, DC 20009 USA.	Swolfe@citizen.org						[Anonymous], 2014, COMMUNICATION; Avorn J, 2005, POWERFUL MED BENEFIT; Baillargeon J, 2013, JAMA INTERN MED, V173, P1465, DOI 10.1001/jamainternmed.2013.6895; Basaria S, 2010, NEW ENGL J MED, V363, P109, DOI 10.1056/NEJMoa1000485; Finkle WD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085805; Layton JB, 2014, J CLIN ENDOCR METAB; US Food and Drug Administration, 2014, FDA EV RISK STROK HE; Xu L, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-108	8	5	5	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 27	2014	348								g1789	10.1136/bmj.g1789	http://dx.doi.org/10.1136/bmj.g1789			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AC0UF	24578515	Green Published, Bronze			2023-01-03	WOS:000332210200003
J	Faigle, R; Sharrief, A; Marsh, EB; Llinas, RH; Urrutia, VC				Faigle, Roland; Sharrief, Anjail; Marsh, Elisabeth B.; Llinas, Rafael H.; Urrutia, Victor C.			Predictors of Critical Care Needs after IV Thrombolysis for Acute Ischemic Stroke	PLOS ONE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; AMERICAN-HEART-ASSOCIATION; ACUTE CEREBRAL INFARCTION; INTENSIVE-CARE; UNIT ADMISSION; DIABETES-MELLITUS; BLOOD-PRESSURE; RISK; MANAGEMENT; SMOKING	Background and Purpose: Intravenous (IV) tissue plasminogen activator (tPA) is the only Food and Drug Administration (FDA)-approved treatment for acute ischemic stroke. Post tPA patients are typically monitored in an intensive care unit (ICU) for at least 24 hours. However, rigorous evidence to support this practice is lacking. This study evaluates factors that predict ICU needs after IV thrombolysis. Methods: A retrospective chart review was performed for 153 patients who received intravenous tPA for acute ischemic stroke. Data on stroke risk factors, physiologic parameters on presentation, and stroke severity were collected. The timing and nature of an intensive care intervention, if needed, was recorded. Using multivariable logistic regression, we determined factors associated with requiring ICU care. Results: African American race (Odds Ratio [OR] 8.05, 95% Confidence Interval [CI] 2.65-24.48), systolic blood pressure, and National Institutes of Health Stroke Scale (NIHSS) (OR 1.20 per point increase, 95% CI 1.09-1.31) were predictors of utilization of ICU resources. Patients with an NIHSS >= 10 had a 7.7 times higher risk of requiring ICU resources compared to patients who presented with an NIHSS<10 (p<0.001). Most patients with ICU needs developed them prior to the end of tPA infusion (81.0%, 95% CI 68.8-93.1). Only 7% of patients without ICU needs by the end of the tPA infusion went on to require ICU care later on. These patients were more likely to have diabetes mellitus and had significantly higher NIHSS compared to patients without further ICU needs (mean NIHSS 17.3, 95% CI 11.5-22.9 vs. 9.2, 95% CI 7.7-9.6). Conclusion: Race, NIHSS, and systolic blood pressure predict ICU needs following tPA for acute ischemic stroke. We propose that patients without ICU needs by the end of the tPA infusion might be safely monitored in a non-ICU setting if NIHSS at presentation is low.	[Faigle, Roland; Sharrief, Anjail; Marsh, Elisabeth B.; Llinas, Rafael H.; Urrutia, Victor C.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Sharrief, Anjail] Univ Texas Hlth Sci Ctr Houston, Dept Neurol, Houston, TX 77030 USA	Johns Hopkins University; University of Texas System; University of Texas Health Science Center Houston	Urrutia, VC (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.	vurruti1@jhmi.edu	Faigle, Roland/ABB-9082-2020; Urrutia, Victor/AAH-6683-2021	Faigle, Roland/0000-0002-9074-1915; Urrutia, Victor/0000-0002-4995-6949; Marsh, Elisabeth/0000-0002-2385-5074; Llinas, Rafael/0000-0002-9161-2699	R25-NIH/NINDS Research Education Program for Residents and Fellows in Neurology and Neurosurgery	R25-NIH/NINDS Research Education Program for Residents and Fellows in Neurology and Neurosurgery	RF is supported by an R25 Grant-NIH/NINDS Research Education Program for Residents and Fellows in Neurology and Neurosurgery. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; BROTT T, 1989, STROKE, V20, P871, DOI 10.1161/01.STR.20.7.871; Bui JQH, 2011, J NEUROSURG, V115, P1236, DOI 10.3171/2011.8.JNS11105; Calhoun DA, 2008, HYPERTENSION, V51, P1403, DOI 10.1161/HYPERTENSIONAHA.108.189141; Demaerschalk BM, 2010, AM J MANAG CARE, V16, P525; Ernst R, 2000, STROKE, V31, P2552, DOI 10.1161/01.STR.31.11.2552; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; GOLDSTEIN LB, 1989, ARCH NEUROL-CHICAGO, V46, P660, DOI 10.1001/archneur.1989.00520420080026; Hacke W, 2004, LANCET, V363, P768; Howard G, 2013, JAMA INTERN MED, V173, P46, DOI 10.1001/2013.jamainternmed.857; HOWARD RS, 2003, J NEUROL NEUROSUR PS, V74, P2, DOI DOI 10.1136/JNNP.74.SUPPL_3.III2; Howard VJ, 2011, ANN NEUROL, V69, P619, DOI 10.1002/ana.22385; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; KITTNER SJ, 1990, JAMA-J AM MED ASSOC, V264, P1267, DOI 10.1001/jama.264.10.1267; Kufner A, 2013, STROKE, V44, P407, DOI 10.1161/STROKEAHA.112.662148; Lewandowski CA, 1999, STROKE, V30, P2598, DOI 10.1161/01.STR.30.12.2598; Lloyd-Jones D, 2010, CIRCULATION, V121, P948, DOI 10.1161/CIRCULATIONAHA.109.192666; Manolio TA, 1996, STROKE, V27, P1479, DOI 10.1161/01.STR.27.9.1479; Mensah G. A., 2004, ATLAS HEART DIS STRO; Nishijima DK, 2012, INJURY, V43, P1827, DOI 10.1016/j.injury.2011.07.020; OPPENHEIMER SM, 1985, BRIT MED J, V291, P1014, DOI 10.1136/bmj.291.6501.1014-a; Ovbiagele B, 2005, NEUROLOGY, V65, P293, DOI 10.1212/01.WNL.0000168163.72351.f3; Rocco A, 2013, STROKE, V44, P2134, DOI 10.1161/STROKEAHA.111.675918; Rockman CB, 2013, J VASC SURG, V57, P327, DOI 10.1016/j.jvs.2012.08.118; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Schneider AT, 2004, STROKE, V35, P1552, DOI 10.1161/01.STR.0000129335.28301.f5; Smith G, 1999, BRIT MED J, V318, P1544, DOI 10.1136/bmj.318.7197.1544; TAYLOR WAS, 1995, J NEUROSURG, V82, P48, DOI 10.3171/jns.1995.82.1.0048; Wang M Y, 2000, J Stroke Cerebrovasc Dis, V9, P64, DOI 10.1053/jscd.2000.0090064; Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025	31	30	31	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2014	9	2							e88652	10.1371/journal.pone.0088652	http://dx.doi.org/10.1371/journal.pone.0088652			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7FJ	24533130	Green Submitted, gold, Green Published			2023-01-03	WOS:000331262600088
J	Lee, H; Park, HJ; Park, CS; Oh, ET; Choi, BH; Williams, B; Lee, CK; Song, CW				Lee, Hyemi; Park, Heon Joo; Park, Chang-Shin; Oh, Eun-Taex; Choi, Bo-Hwa; Williams, Brent; Lee, Chung K.; Song, Chang W.			Response of Breast Cancer Cells and Cancer Stem Cells to Metformin and Hyperthermia Alone or Combined	PLOS ONE			English	Article							ANTIDIABETIC DRUG; IONIZING-RADIATION; PANCREATIC-CANCER; DIABETIC-PATIENTS; INITIATING CELLS; THERMAL THERAPY; IN-VITRO; GROWTH; CHEMOTHERAPY; KINASE	Metformin, the most widely prescribed drug for treatment of type 2 diabetes, has been shown to exert significant anticancer effects. Hyperthermia has been known to kill cancer cells and enhance the efficacy of various anti-cancer drugs and radiotherapy. We investigated the combined effects of metformin and hyperthermia against MCF-7 and MDA-MB-231 human breast cancer cell, and MIA PaCa-2 human pancreatic cancer cells. Incubation of breast cancer cells with 0.5-10 mM metformin for 48 h caused significant clonogenic cell death. Culturing breast cancer cells with 30 mM metformin, clinically relevant plasma concentration of metformin, significantly reduced the survival of cancer cells. Importantly, metformin was preferentially cytotoxic to CD44(high)/CD24(low) cells of MCF-7 cells and, CD44(high)/CD24(high) cells of MIA PaCa-2 cells, which are known to be cancer stem cells (CSCs) of MCF-7 cells and MIA PaCa-2 cells, respectively. Heating at 42 degrees C for 1 h was slightly toxic to both cancer cells and CSCs, and it markedly enhanced the efficacy of metformin to kill cancer cells and CSCs. Metformin has been reported to activate AMPK, thereby suppressing mTOR, which plays an important role for protein synthesis, cell cycle progression, and cell survival. For the first time, we show that hyperthermia activates AMPK and inactivates mTOR and its downstream effector S6K. Furthermore, hyperthermia potentiated the effect of metformin to activate AMPK and inactivate mTOR and S6K. Cell proliferation was markedly suppressed by metformin or combination of metformin and hyperthermia, which could be attributed to activation of AMPK leading to inactivation of mTOR. It is conclude that the effects of metformin against cancer cells including CSCs can be markedly enhanced by hyperthermia.	[Lee, Hyemi; Park, Heon Joo; Oh, Eun-Taex; Choi, Bo-Hwa] Inha Univ, Coll Med, Dept Microbiol, Inchon, South Korea; [Park, Chang-Shin] Inha Univ, Coll Med, Dept Pharmacol, Inchon, South Korea; [Williams, Brent; Lee, Chung K.; Song, Chang W.] Univ Minnesota, Sch Med, Dept Therapeut Radiol Radiat Oncol, Minneapolis, MN 55455 USA	Inha University; Inha University; University of Minnesota System; University of Minnesota Twin Cities	Park, HJ (corresponding author), Inha Univ, Coll Med, Dept Microbiol, Inchon, South Korea.	park001@inha.ac.kr; parkshin@inha.ac.kr			National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [2011-0015230, NRF-2013M2A2A7043703]; Komen for Cure from the University of Minnesota Cancer Center	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Komen for Cure from the University of Minnesota Cancer Center	This work was supported by grants from the R&D Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011-0015230 and NRF-2013M2A2A7043703), and the Komen for Cure from the University of Minnesota Cancer Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alimova IN, 2009, CELL CYCLE, V8, P909, DOI 10.4161/cc.8.6.7933; Atkinson RL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001447; Bao B, 2012, CANCER PREV RES, V5, P355, DOI 10.1158/1940-6207.CAPR-11-0299; Bao Qi, 2010, Cancers (Basel), V2, P1629, DOI 10.3390/cancers2031629; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419; Ben Sahra I, 2008, ONCOGENE, V27, P3576, DOI 10.1038/sj.onc.1211024; Ben Sahra I, 2010, MOL CANCER THER, V9, P1092, DOI 10.1158/1535-7163.MCT-09-1186; Bull JMC, 2008, INT J HYPERTHER, V24, P649, DOI 10.1080/02656730802104740; Burke AR, 2012, BIOMATERIALS, V33, P2961, DOI 10.1016/j.biomaterials.2011.12.052; Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447; Dewhirst MW, 2005, INT J HYPERTHER, V21, P779, DOI 10.1080/02656730500271668; Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008-5472.CAN-07-2310; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Eyler CE, 2008, STEM CELLS, V26, P3027, DOI 10.1634/stemcells.2007-1073; Frosina G, 2009, MOL CANCER RES, V7, P989, DOI 10.1158/1541-7786.MCR-09-0030; Gonzalez-Angulo AM, 2010, CLIN CANCER RES, V16, P1695, DOI 10.1158/1078-0432.CCR-09-1805; Hill R, 2009, J BIOL CHEM, V284, P11755, DOI 10.1074/jbc.R800071200; Hirsch HA, 2013, P NATL ACAD SCI USA, V110, P972, DOI 10.1073/pnas.1221055110; Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994; Iliopoulos D, 2011, CANCER RES, V71, P3196, DOI 10.1158/0008-5472.CAN-10-3471; Jiralerspong S, 2009, J CLIN ONCOL, V27, P3297, DOI 10.1200/JCO.2009.19.6410; Kourelis TV, 2012, MED ONCOL, V29, P1314, DOI 10.1007/s12032-011-9846-7; Li DH, 2009, GASTROENTEROLOGY, V137, P482, DOI 10.1053/j.gastro.2009.04.013; Liu BL, 2009, CELL CYCLE, V8, P2031, DOI 10.4161/cc.8.13.8814; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Lou H, 2007, ONCOGENE, V26, P1357, DOI 10.1038/sj.onc.1210200; Martin-Castillo B, 2010, CELL CYCLE, V9, P1057, DOI 10.4161/cc.9.6.10994; Memmott RM, 2010, CANCER PREV RES, V3, P1066, DOI 10.1158/1940-6207.CAPR-10-0055; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Park HJ, 2005, CLIN CANCER RES, V11, P8866, DOI 10.1158/1078-0432.CCR-05-0818; Pelicci PG, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2847; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Rattan R, 2011, J CELL MOL MED, V15, P166, DOI 10.1111/j.1582-4934.2009.00954.x; Rattan R, 2012, J ONCOL, V2012, DOI 10.1155/2012/928127; Rocha GZ, 2011, CLIN CANCER RES, V17, P3993, DOI 10.1158/1078-0432.CCR-10-2243; Sanli T, 2010, INT J RADIAT ONCOL, V78, P221, DOI 10.1016/j.ijrobp.2010.03.005; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Song CW, 2012, SCI REP-UK, V2, DOI 10.1038/srep00362; Sugahara T, 2008, INT J HYPERTHER, V24, P123, DOI 10.1080/02656730701883675; Tomimoto A, 2008, CANCER SCI, V99, P2136, DOI 10.1111/j.1349-7006.2008.00933.x; Vazquez-Martin A, 2011, BREAST CANCER RES TR, V126, P355, DOI 10.1007/s10549-010-0924-x; WILCOCK C, 1994, XENOBIOTICA, V24, P49, DOI 10.3109/00498259409043220; Witters LA, 2001, J CLIN INVEST, V108, P1105, DOI 10.1172/JCI14178; Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500; Zakikhani M, 2008, CANCER PREV RES, V1, P369, DOI 10.1158/1940-6207.CAPR-08-0081; Zannella VE, 2011, RADIOTHER ONCOL, V99, P293, DOI 10.1016/j.radonc.2011.05.049; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104	50	50	54	2	50	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2014	9	2							e87979	10.1371/journal.pone.0087979	http://dx.doi.org/10.1371/journal.pone.0087979			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA1AT	24505341	Green Published, Green Submitted, gold			2023-01-03	WOS:000330829200092
J	Xu, QD; Xu, FH; Fan, L; Xiong, LP; Li, HY; Cao, SR; Lin, XY; Zheng, ZH; Yu, XQ; Mao, HP				Xu, Qingdong; Xu, Fenghua; Fan, Li; Xiong, Liping; Li, Huiyan; Cao, Shirong; Lin, Xiaoyan; Zheng, Zhihua; Yu, Xueqing; Mao, Haiping			Serum Potassium Levels and Its Variability in Incident Peritoneal Dialysis Patients: Associations with Mortality	PLOS ONE			English	Article							RESIDUAL RENAL-FUNCTION; CHRONIC KIDNEY-DISEASE; HEMODIALYSIS-PATIENTS; CARDIAC DEATH; CAPD PATIENTS; RISK-FACTORS; HYPOKALEMIA; OUTCOMES; TRANSPORT; SURVIVAL	Background: Abnormal serum potassium is associated with an increased risk of mortality in dialysis patients. However, the impacts of serum potassium levels on short-and long-term mortality and association of potassium variability with death in peritoneal dialysis (PD) patients are uncertain. Methods: We examined mortality-predictability of serum potassium at baseline and its variability in PD patients treated in our center January 2006 through December 2010 with follow-up through December 2012. The hazard ratios (HRs) were used to assess the relationship between baseline potassium levels and short-term (<= 1 year) as well as long-term (>1 year) survival. Variability of serum potassium was defined as the coefficient of variation of serum potassium (CVSP) during the first year of PD. Results: A total of 886 incident PD patients were enrolled, with 248 patients (27.9%) presented hypokalemia (serum potassium <3.5 mEq/L). During a median follow-up of 31 months (range: 0.5-81.0 months), adjusted all-cause mortality hazard ratio (HR) and 95% confidence interval (CI) for baseline serum potassium of <3.0, 3.0 to <3.5, 3.5 to <4.0, 4.5 to <5.0, and >= 5.0 mEq/L, compared with 4.0 to <4.5 (reference), were 1.79 (1.02-3.14), 1.15 (0.72-1.86), 1.31 (0.82-2.08), 1.33 (0.71-2.48), 1.28 (0.53-3.10), respectively. The increased risk of lower potassium with mortality was evident during the first year of follow-up, but vanished thereafter. Adjusted all-cause mortality HR for CVSP increments of 7.5% to <12.0%; 12.0% to <16.7% and >= 16.7%, compared with <7.5% (reference), were 1.35 (0.67-2.71), 2.00 (1.05-3.83) and 2.18 (1.18-4.05), respectively. Similar association was found between serum potassium levels and its variability and cardiovascular mortality. Conclusions: A lower serum potassium level was associated with all-cause and cardiovascular mortality during the first year of follow-up in incident PD patients. In addition, higher variability of serum potassium levels conferred an increased risk of death in this population.	[Xu, Qingdong; Xu, Fenghua; Fan, Li; Xiong, Liping; Li, Huiyan; Cao, Shirong; Lin, Xiaoyan; Zheng, Zhihua; Yu, Xueqing; Mao, Haiping] Sun Yat Sen Univ, Affiliated Hosp 1, Key Lab Nephrol, Dept Nephrol,Minist Hlth China, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University	Mao, HP (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Key Lab Nephrol, Dept Nephrol,Minist Hlth China, Guangzhou 510275, Guangdong, Peoples R China.	haipingmao@126.com	cao, shirong/AAX-5688-2021	Mao, Haiping/0000-0002-3608-3851	National Key Technology Research and Development Program of the Ministry of Science and Technology of China [2011BAI10B05]; National Science Fund for Distinguished Young Scholars of China [30925019]; 5010 Clinical Program of Sun Yat-sen University [2007007]; Guangzhou Committee of Science and Technology of China [2010U1-E00831]	National Key Technology Research and Development Program of the Ministry of Science and Technology of China(National Key Technology R&D Program); National Science Fund for Distinguished Young Scholars of China(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); 5010 Clinical Program of Sun Yat-sen University; Guangzhou Committee of Science and Technology of China	This work was supported by grants from the National Key Technology Research and Development Program of the Ministry of Science and Technology of China (No. 2011BAI10B05), the National Science Fund for Distinguished Young Scholars of China (No. 30925019), 5010 Clinical Program of Sun Yat-sen University (No. 2007007) and the Guangzhou Committee of Science and Technology of China (No. 2010U1-E00831). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beddhu S, 2002, AM J MED, V112, P696, DOI 10.1016/S0002-9343(02)01097-5; Bleyer AJ, 1999, KIDNEY INT, V55, P1553, DOI 10.1046/j.1523-1755.1999.00391.x; Chan CT, 2008, NEPHROL DIAL TRANSPL, V23, P3061, DOI 10.1093/ndt/gfn280; Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624; Chuang YW, 2009, NEPHROL DIAL TRANSPL, V24, P1603, DOI 10.1093/ndt/gfn709; Davies SJ, 2001, J AM SOC NEPHROL, V12, P1046, DOI 10.1681/ASN.V1251046; Dekker FW, 2008, KIDNEY INT, V74, P994, DOI 10.1038/ki.2008.328; Di Iorio B, 2012, NEPHROL DIAL TRANSPL, V27, P4404, DOI 10.1093/ndt/gfs328; Fleischmann EH, 2001, ASAIO J, V47, P74, DOI 10.1097/00002480-200101000-00016; Gao HB, 1999, AM J NEPHROL, V19, P7, DOI 10.1159/000013418; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Harrison TR, 1930, J CLIN INVEST, V8, P325, DOI 10.1172/JCI100267; Jung Ji Yong, 2009, Electrolyte Blood Press, V7, P73, DOI 10.5049/EBP.2009.7.2.73; Kainz A, 2010, NEPHROL DIAL TRANSPL, V25, P3701, DOI 10.1093/ndt/gfq287; Kalantar-Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514; Kalantar-Zadeh K, 2003, KIDNEY INT, V63, P793, DOI 10.1046/j.1523-1755.2003.00803.x; Khan AN, 1996, PERITON DIALYSIS INT, V16, P652; Konings CJAM, 2003, NEPHROL DIAL TRANSPL, V18, P797, DOI 10.1093/ndt/gfg147; Korgaonkar S, 2010, CLIN J AM SOC NEPHRO, V5, P762, DOI 10.2215/CJN.05850809; Kovesdy CP, 2007, CLIN J AM SOC NEPHRO, V2, P999, DOI 10.2215/CJN.04451206; Kwan BCH, 2012, NAT REV NEPHROL, V8, P501, DOI 10.1038/nrneph.2012.159; Li PKT, 2003, ANN INTERN MED, V139, P105, DOI 10.7326/0003-4819-139-2-200307150-00010; Mcdonald SP, 2003, J AM SOC NEPHROL, V14, P2894, DOI 10.1097/01.ASN.0000091587.55159.5F; Newman L N, 2000, Adv Perit Dial, V16, P134; OREOPOULOS DG, 1982, NEPHRON, V30, P293, DOI 10.1159/000182504; ROCCO MV, 1994, J AM SOC NEPHROL, V5, P1333; ROSTAND SG, 1983, ARCH INTERN MED, V143, P377, DOI 10.1001/archinte.143.2.377; Royston P, 2000, STAT MED, V19, P1831, DOI 10.1002/1097-0258(20000730)19:14<1831::AID-SIM502>3.0.CO;2-1; Sica D A, 2002, J Clin Hypertens (Greenwich), V4, P198, DOI 10.1111/j.1524-6175.2002.01728.x; Szeto CC, 2005, AM J KIDNEY DIS, V46, P128, DOI 10.1053/j.ajkd.2005.03.015; Torlen K, 2012, CLIN J AM SOC NEPHRO, V7, P1272, DOI 10.2215/CJN.00960112; Tziviskou Effie, 2003, International Urology and Nephrology, V35, P429, DOI 10.1023/B:UROL.0000022867.93739.03; vanOlden RW, 1996, J AM SOC NEPHROL, V7, P745; Wang AYM, 2003, J AM SOC NEPHROL, V14, P159, DOI 10.1097/01.ASN.0000038685.95946.83	34	28	32	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2014	9	1							e86750	10.1371/journal.pone.0086750	http://dx.doi.org/10.1371/journal.pone.0086750			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301BI	24475176	Green Published, gold, Green Submitted			2023-01-03	WOS:000330507300107
J	Takahashi, Y; Soejima, Y; Kumagai, A; Watanabe, M; Uozaki, H; Fukusato, T				Takahashi, Yoshihisa; Soejima, Yurie; Kumagai, Arisa; Watanabe, Masato; Uozaki, Hiroshi; Fukusato, Toshio			Inhibitory Effects of Japanese Herbal Medicines Sho-saiko-to and Juzen-taiho-to on Nonalcoholic Steatohepatitis in Mice	PLOS ONE			English	Article							FATTY LIVER-DISEASE; ENZYME-ALTERED LESIONS; GROWTH-FACTOR-BETA; ACID-DEFINED DIET; METABOLIC SYNDROME; FIBROSIS; INFLAMMATION; KAMPO; RATS; HEPATOCARCINOGENESIS	Although Japanese herbal medicines (JHMs) are widely used in Japan, only a few studies have investigated their effects on nonalcoholic steatohepatitis (NASH). In the present study, we examined the effect of 4 kinds of JHMs [sho-saiko-to (TJ-9), inchin-ko-to (TJ-135), juzen-taiho-to (TJ-48), and keishi-bukuryo-gan (TJ-25)] on a mouse model of NASH. Db/db mice were divided into 6 groups: control diet (control), methionine-and choline-deficient diet (MCD), and MCD diet supplemented with TJ-9, TJ-135, TJ-48, and TJ-25 (TJ-9, TJ-135, TJ-48, and TJ-25, respectively). All mice were sacrificed after 4 weeks of treatment, and biochemical, pathological, and molecular analyses were performed. Serum alanine aminotransferase levels and liver histology, including necroinflammation and fibrosis, were significantly alleviated in the TJ-9 and TJ-48 groups compared with the MCD group. The expression level of transforming growth factor (TGF)-beta 1 mRNA in the liver was significantly suppressed by TJ-48. Although the differences were not statistically significant, the expression levels of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 were lower, and those of peroxisome proliferators-activated receptor (PPAR)gamma were higher in the TJ-9 and/or TJ-48 groups than in the MCD group. Similarly, even though the results were not statistically significant, malondialdehyde levels in liver tissues were lower in the TJ-9 and TJ-48 groups than in the MCD group. We showed that JHMs, especially TJ-9 and TJ-48, inhibited the necroinflammation and fibrosis in the liver of a mouse model of NASH, even though the mechanisms were not fully elucidated. Further studies are needed in the future to investigate the possibility of clinical application of these medicines in the treatment for NASH.	[Takahashi, Yoshihisa; Soejima, Yurie; Kumagai, Arisa; Watanabe, Masato; Uozaki, Hiroshi; Fukusato, Toshio] Teikyo Univ, Sch Med, Dept Pathol, Tokyo 173, Japan	Teikyo University	Takahashi, Y (corresponding author), Teikyo Univ, Sch Med, Dept Pathol, Tokyo 173, Japan.	ytakaha-tky@umin.ac.jp			Japan Society for the Promotion of Science (JSPS) [23790753]	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research Grant Number 23790753 (URL: http://www.jsps.go.jp/j-grantsinaid/). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anstee QM, 2006, INT J EXP PATHOL, V87, P1, DOI 10.1111/j.0959-9673.2006.00465.x; Asakawa T, 2012, PEDIATR SURG INT, V28, P379, DOI 10.1007/s00383-011-2974-5; Bissell DM, 2001, HEPATOLOGY, V34, P859, DOI 10.1053/jhep.2001.28457; Braunersreuther V, 2012, WORLD J GASTROENTERO, V18, P727, DOI 10.3748/wjg.v18.i8.727; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chowdhry S, 2010, FREE RADICAL BIO MED, V48, P357, DOI 10.1016/j.freeradbiomed.2009.11.007; Cohen JC, 2011, SCIENCE, V332, P1519, DOI 10.1126/science.1204265; Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2; Fujimoto M, 2008, EXP BIOL MED, V233, P328, DOI 10.3181/0707-RM-207; Fujimoto M, 2010, ANN NY ACAD SCI, V1190, P151, DOI 10.1111/j.1749-6632.2009.05265.x; Guo HX, 2009, ACTA PHARMACOL SIN, V30, P1505, DOI 10.1038/aps.2009.150; Iizuka A, 2000, J Atheroscler Thromb, V6, P49; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Kusunose M, 2002, BIOL PHARM BULL, V25, P1417, DOI 10.1248/bpb.25.1417; Larter CZ, 2008, J HEPATOL, V49, P407, DOI 10.1016/j.jhep.2008.03.026; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; Machado M, 2006, CURR OPIN CLIN NUTR, V9, P637, DOI 10.1097/01.mco.0000241677.40170.17; Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161; Mochiki E, 2010, SURG TODAY, V40, P1105, DOI 10.1007/s00595-010-4388-8; Motoo Y, 2011, CHIN J INTEGR MED, V17, P85, DOI 10.1007/s11655-011-0653-y; Nagai T, 2011, EVID-BASED COMPL ALT, V2011; POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114; Qin S, 2012, J ETHNOPHARMACOL, V140, P131, DOI 10.1016/j.jep.2011.12.046; RAMADORI G, 1991, VIRCHOWS ARCH B, V61, P147; Sakaida I, 2003, J HEPATOL, V38, P762, DOI 10.1016/S0168-8278(03)00094-1; Sakaida I, 1998, J HEPATOL, V28, P298, DOI 10.1016/0168-8278(88)80017-5; Shek FW, 2004, EUR J GASTROEN HEPAT, V16, P123, DOI 10.1097/00042737-200402000-00001; Shiota G, 2002, HEPATOLOGY, V35, P1125, DOI 10.1053/jhep.2002.33066; Tailleux A, 2012, BBA-MOL CELL BIOL L, V1821, P809, DOI 10.1016/j.bbalip.2011.10.016; Takahashi Y, 2012, WORLD J GASTROENTERO, V18, P2300, DOI 10.3748/wjg.v18.i19.2300; Tilg H, 2010, HEPATOLOGY, V52, P1836, DOI 10.1002/hep.24001; Tojima H, 1996, Nihon Kyobu Shikkan Gakkai Zasshi, V34, P904; Tomioka H, 1999, Nihon Kokyuki Gakkai Zasshi, V37, P1013; Tsuchiya M, 2008, INT J CANCER, V123, P2503, DOI 10.1002/ijc.23828; Warren A, 2005, EXP GERONTOL, V40, P807, DOI 10.1016/j.exger.2005.06.012; Yamaoka K, 1990, BYOUIN YAKUGAKU, V16, P168; Yamashiki M, 2000, CLIN SCI, V99, P421, DOI 10.1042/CS20000031; Younossi ZM, 2011, HEPATOLOGY, V53, P1874, DOI 10.1002/hep.24268	38	22	26	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2014	9	1							e87279	10.1371/journal.pone.0087279	http://dx.doi.org/10.1371/journal.pone.0087279			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297VL	24466347	Green Submitted, Green Published, gold			2023-01-03	WOS:000330283100253
J	Shehadah, A; Chen, JL; Pal, A; He, SY; Zeitlin, A; Cui, X; Zacharek, A; Cui, YS; Roberts, C; Lu, M; Hariri, R; Chopp, M				Shehadah, Amjad; Chen, Jieli; Pal, Ajai; He, Shuyang; Zeitlin, Andrew; Cui, Xu; Zacharek, Alex; Cui, Yisheng; Roberts, Cynthia; Lu, Mei; Hariri, Robert; Chopp, Michael			Human Placenta-Derived Adherent Cell Treatment of Experimental Stroke Promotes Functional Recovery after Stroke in Young Adult and Older Rats	PLOS ONE			English	Article							MARROW STROMAL CELLS; SENSORIMOTOR CORTEX LESIONS; CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; STEM-CELLS; SYNAPTIC PLASTICITY; EMBOLIC STROKE; GENE-EXPRESSION; INFARCT VOLUME; AGED RATS	Background: Human Placenta-Derived Adherent Cells (PDAC (R)) are a novel mesenchymal-like cell population derived from normal human placental tissue. PDA-001 is a clinical formulation of PDAC (R) developed for intravenous administration. In this study, we investigated the efficacy of PDA-001 treatment in a rat model of transient middle cerebral artery occlusion (MCAo) in young adult (2-3 month old) and older rats (10-12 months old). Methods: To evaluate efficacy and determine the optimal number of transplanted cells, young adult Wistar rats were subjected to MCAo and treated 1 day post MCAo with 1x10(6), 4x10(6) or 8x10(6) PDA-001 cells (i. v.), vehicle or cell control. 4x10(6) or 8x10(6) PDA-001 cells were also tested in older rats after MCAo. Treatment response was evaluated using a battery of functional outcome tests, consisting of adhesive-removal test, modified Neurological Severity Score (mNSS) and foot-fault test. Young adult rats were sacrificed 56 days after MCAo, older rats were sacrificed 29 days after MCAo, and lesion volumes were measured using H& E. Immunohistochemical stainings for bromodeoxyuridine (BrdU) and von Willebrand Factor (vWF), and synaptophysin were performed. Results: In young adult rats, treatment with 4x10(6) PDA-001 cells significantly improved functional outcome after stroke (p<0.05). In older rats, significant functional improvement was observed with PDA-001 cell therapy in both of the 4x10(6) and 8x10(6) treatment groups. Functional benefits in young adult and older rats were associated with significant increases in the number of BrdU immunoreactive endothelial cells, vascular density and perimeter in the ischemic brain, as well as significantly increased synaptophysin expression in the ischemic border zone (p<0.05). Conclusion: PDA-001 treatment significantly improved functional outcome after stroke in both young adult and older rats. The neurorestorative effects induced by PDA-001 treatment may be related to increased vascular density and synaptic plasticity.	[Shehadah, Amjad; Chen, Jieli; Cui, Xu; Zacharek, Alex; Cui, Yisheng; Roberts, Cynthia; Chopp, Michael] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; [Pal, Ajai; He, Shuyang; Zeitlin, Andrew; Hariri, Robert] Celgene Cellular Therapeut, Warren, NJ USA; [Lu, Mei] Henry Ford Hosp, Dept Biostat & Res Epidemiol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Oakland University	Chen, JL (corresponding author), Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA.	jieli@neuro.hfh.edu		Cui, Xu/0000-0002-6937-6191; Shehadah, Amjad/0000-0001-8679-3774	Celgene Cellular Therapeutics, New Jersey, USA	Celgene Cellular Therapeutics, New Jersey, USA	This work was funded by Celgene Cellular Therapeutics, New Jersey, USA. The funders had no role in study design, data collection, analysis or preparation of the manuscript. Study design and decision to publish were approved by the funders.	Adkins DL, 2008, EXP NEUROL, V212, P14, DOI 10.1016/j.expneurol.2008.01.031; BARTH TM, 1990, STROKE, V21, P153; Bohotin Catalina Roxana, 2004, Rom J Physiol, V41, P99; CHEN H, 1991, NEUROLOGY, V41, P1133, DOI 10.1212/WNL.41.7.1133; Chen J, 2006, NEUROSCIENCE, V141, P737, DOI 10.1016/j.neuroscience.2006.04.042; Chen J, 2012, CELL TRANSPLANT; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2002, J NEUROL SCI, V199, P17, DOI 10.1016/S0022-510X(02)00075-8; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Cramer SC, 2000, TRENDS NEUROSCI, V23, P265, DOI 10.1016/S0166-2236(00)01562-9; Cramer SC, 1997, STROKE, V28, P2518, DOI 10.1161/01.STR.28.12.2518; Cui X, 2010, STROKE, V41, P2044, DOI 10.1161/STROKEAHA.110.589333; Ding GL, 2011, STROKE, V42, P3537, DOI 10.1161/STROKEAHA.111.622092; FUTRELL N, 1991, STROKE, V22, P1582, DOI 10.1161/01.STR.22.12.1582; GARCIA JH, 1971, ACTA NEUROPATHOL, V18, P273, DOI 10.1007/BF00688441; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; He SY, 2013, BRAIN BEHAV IMMUN, V27, P185, DOI 10.1016/j.bbi.2012.10.015; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57; Kolb B, 1999, CAN J EXP PSYCHOL, V53, P62, DOI 10.1037/h0087300; Kranz A, 2010, BRAIN RES, V1315, P128, DOI 10.1016/j.brainres.2009.12.001; KRUPINSKI J, 1994, STROKE, V25, P1794, DOI 10.1161/01.STR.25.9.1794; Li X, 2011, STEM CELLS, V29, P263, DOI 10.1002/stem.572; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Lu M, 2003, J NEUROSCI METH, V128, P183, DOI 10.1016/S0165-0270(03)00188-2; Mayer L, 2013, INFLAMM BOWEL DIS, V19, P754, DOI 10.1097/MIB.0b013e31827f27df; Mochizuki N, 2008, EXP NEUROL, V211, P194, DOI 10.1016/j.expneurol.2008.01.027; Nichols RC, 2011, CLIN LUNG CANCER, V12, P252, DOI 10.1016/j.cllc.2011.03.027; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Pratt Phillip F, 2004, Curr Opin Investig Drugs, V5, P952; Rao MS, 2001, MECH AGEING DEV, V122, P713, DOI 10.1016/S0047-6374(01)00224-X; Rempe DA, 2002, NEUROLOGY, V59, P486, DOI 10.1212/WNL.59.4.486; Risau W, 1998, KIDNEY INT, V54, pS3, DOI 10.1046/j.1523-1755.1998.06701.x; SCHALLERT T, 1984, BEHAV NEUROSCI, V98, P518; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Takahashi K, 2008, BRAIN RES, V1234, P172, DOI 10.1016/j.brainres.2008.07.086; Ujike H, 2002, ANN NY ACAD SCI, V965, P55; Yoon YS, 2005, BIOL CELL, V97, P253, DOI 10.1042/BC20040099; Yu S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076329; Zacharek A, 2010, STROKE, V41, P524, DOI 10.1161/STROKEAHA.109.568881; Zhang L, 2005, STROKE, V36, P847, DOI 10.1161/01.STR.0000158923.19956.73; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	47	28	29	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2014	9	1							e86621	10.1371/journal.pone.0086621	http://dx.doi.org/10.1371/journal.pone.0086621			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297GT	24466174	Green Published, Green Submitted, gold			2023-01-03	WOS:000330244500266
J	van den Hoven, AF; Smits, MLJ; Rosenbaum, CENM; Verkooijen, HM; van den Bosch, MAAJ; Lam, MGEH				van den Hoven, Andor F.; Smits, Maarten L. J.; Rosenbaum, Charlotte E. N. M.; Verkooijen, Helena M.; van den Bosch, Maurice A. A. J.; Lam, Marnix G. E. H.			The Effect of Intra-Arterial Angiotensin II on the Hepatic Tumor to Non-Tumor Blood Flow Ratio for Radioembolization: A Systematic Review	PLOS ONE			English	Review							COLORECTAL LIVER METASTASES; INTERNAL RADIATION-THERAPY; Y-90 RESIN MICROSPHERES; HEPATOCELLULAR-CARCINOMA; PREDICTIVE DOSIMETRY; POTENTIAL METHOD; PHASE-I; CANCER; INFUSION; TRIAL	Purpose: Treatment efficacy of intra-arterial radioembolization for liver tumors depends on the selective targeting of tumorous tissue. Recent investigations have demonstrated that tumors may receive inadequate doses of radioactivity after radioembolization, due to unfavorable tumor to non-tumor (T/N) uptake ratios of radioactive microspheres. Hepatic arterial infusion of the vasoconstrictor angiotensin II (AT-II) is reported to increase the T/N blood flow ratio. The purpose of this systematic review was to provide a comprehensive overview of the effect of hepatic arterial AT-II on T/N blood flow ratio in patients with hepatic malignancies, and determine its clinical value for radioembolization. Methods: This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A structured search was performed in the PubMed, EMBASE and Cochrane databases. Only studies that presented data on T/N ratios before and after infusion of AT-II into the hepatic artery, in human patients with hepatic malignancies, were selected. Median T/N ratios before, during and after AT-II infusion, and the median T/N ratio improvement factor were extracted from the selected articles. All data on systemic blood pressure measurements and clinical symptoms were also extracted. Results: The search identified 524 titles of which 5 studies, including a total of 71 patients were considered relevant. Median T/N ratios before infusion of AT-II ranged from 0.4 to 3.4. All studies observed a substantial improvement of the T/N ratio after AT-II infusion, with median improvement factors ranging from 1.8 to 3.1. A transitory increase of systemic blood pressure was observed during AT-II infusion. Conclusions: Infusion of AT-II into the hepatic artery leads to an increase of the tumor to non-tumor blood flow ratio, as measured by T/N uptake ratios. Clinical trials are warranted to assess safety aspects, optimal administration strategy and impact on treatment efficacy during radioembolization.	[van den Hoven, Andor F.; Smits, Maarten L. J.; Rosenbaum, Charlotte E. N. M.; Verkooijen, Helena M.; van den Bosch, Maurice A. A. J.; Lam, Marnix G. E. H.] Univ Med Ctr Utrecht, Dept Radiol & Nucl Med, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	van den Hoven, AF (corresponding author), Univ Med Ctr Utrecht, Dept Radiol & Nucl Med, Utrecht, Netherlands.	a.f.vandenhoven@umcutrecht.nl		van den Hoven, Andor F./0000-0003-1218-0865				Ahn SS, 2010, RADIOLOGY, V255, P459, DOI 10.1148/radiol.10091388; Ashraf S, 1996, BRIT J CANCER, V73, P349, DOI 10.1038/bjc.1996.60; BIERMAN HR, 1951, J NATL CANCER I, V12, P107; Boppudi S, 2006, Australas Radiol, V50, P570, DOI 10.1111/j.1440-1673.2006.01630.x; Burke D, 2001, BRIT J CANCER, V85, P1640, DOI 10.1054/bjoc.2001.2152; Campbell AM, 2001, PHYS MED BIOL, V46, P487, DOI 10.1088/0031-9155/46/2/315; Cosimelli M, 2010, BRIT J CANCER, V103, P324, DOI 10.1038/sj.bjc.6605770; Dancey JE, 2000, J NUCL MED, V41, P1673; de Wit TC, 2006, PHYS MED BIOL, V51, P4773, DOI 10.1088/0031-9155/51/19/004; Dhabuwala Atul, 2005, BMC Nucl Med, V5, P7, DOI 10.1186/1471-2385-5-7; Elschot M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055742; Flamen P, 2008, PHYS MED BIOL, V53, P6591, DOI 10.1088/0031-9155/53/22/019; Flower MA, 2001, EUR J NUCL MED, V28, P99, DOI 10.1007/s002590000410; Garin E, 2012, J NUCL MED, V53, P255, DOI 10.2967/jnumed.111.094235; Gates VL, 2011, J NUCL MED, V52, P72, DOI 10.2967/jnumed.110.080986; GOLDBERG JA, 1991, BRIT J CANCER, V63, P308, DOI 10.1038/bjc.1991.71; GOLDBERG JA, 1991, BRIT J CANCER, V64, P114, DOI 10.1038/bjc.1991.252; Gray B, 2001, ANN ONCOL, V12, P1711, DOI 10.1023/A:1013569329846; Gulec SA, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-15; GYVES JW, 1984, J NUCL MED, V25, P972; HAFSTROM L, 1980, CANCER RES, V40, P481; He B, 2010, PHYS MED BIOL, V55, P3535, DOI 10.1088/0031-9155/55/12/017; Hendlisz A, 2010, J CLIN ONCOL, V28, P3687, DOI 10.1200/JCO.2010.28.5643; Ho S, 1997, BRIT J RADIOL, V70, P823, DOI 10.1259/bjr.70.836.9486047; Ishikawa T, 2007, WORLD J GASTROENTERO, V13, P3080, DOI 10.3748/wjg.v13.i22.3080; Kamaya A, 2009, SEMIN ULTRASOUND CT, V30, P387, DOI 10.1053/j.sult.2009.06.001; Kao YH, 2012, J NUCL MED, V53, P559, DOI 10.2967/jnumed.111.097469; Kao YH, 2013, EJNMMI RES, V3, DOI 10.1186/2191-219X-3-57; Kennedy AS, 2004, INT J RADIAT ONCOL, V60, P1552, DOI 10.1016/j.ijrobp.2004.09.004; Kojiro M, 2009, PATHOLOGY HEPATOCELL; Lam MG, 2013, J NUCL MED; LAU WY, 1994, BRIT J CANCER, V70, P994, DOI 10.1038/bjc.1994.436; LAWRENCE TS, 1995, INT J RADIAT ONCOL, V31, P1237, DOI 10.1016/0360-3016(94)00418-K; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Nijsen JFW, 2004, RADIOLOGY, V231, P491, DOI 10.1148/radiol.2312030594; Piana PM, 2013, HPB OXFORD; SASAKI Y, 1985, CANCER-AM CANCER SOC, V55, P311, DOI 10.1002/1097-0142(19850115)55:2<311::AID-CNCR2820550202>3.0.CO;2-M; Seevinck PR, 2012, INT J RADIAT ONCOL, V83, pE437, DOI 10.1016/j.ijrobp.2011.12.085; Shankar A, 1999, BRIT J SURG, V86, P453, DOI 10.1046/j.1365-2168.1999.01045.x; Smits MLJ, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-70; Smits ML, 2013, J NUCL MED; Smits ML, 2012, LANCET ONCOL; Stubbs RS, 2006, ANZ J SURG, V76, P696, DOI 10.1111/j.1445-2197.2006.03834.x; Stubbs RS, 2001, J GASTROINTEST SURG, V5, P294, DOI 10.1016/S1091-255X(01)80051-2; Taubman MB, 2003, CIRC RES, V92, P9, DOI 10.1161/01.RES.0000052920.70316.AE; Ulrich G, 2013, J NUCL MED, V54, P516, DOI 10.2967/jnumed.112.112508; Van de Wiele C, 2012, EUR J NUCL MED MOL I, V39, P1646, DOI 10.1007/s00259-012-2189-6; Van Hazel G, 2004, J SURG ONCOL, V88, P78, DOI 10.1002/jso.20141; Vente MAD, 2008, EUR J NUCL MED MOL I, V35, P1259, DOI 10.1007/s00259-008-0747-8; Vente MAD, 2009, EUR RADIOL, V19, P951, DOI 10.1007/s00330-008-1211-7; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Walrand S, 2012, EJNMMI RES, V2, DOI 10.1186/2191-219X-2-20; Wang XD, 2010, J GASTROINTEST SURG, V14, P858, DOI 10.1007/s11605-010-1180-4; Wissmeyer M, 2011, EUR J NUCL MED MOL I, V38, P1744, DOI 10.1007/s00259-011-1792-2; Wondergem M, 2013, J NUCL MED; Wright KC, 2011, RADIOLOGY, V260, P718, DOI 10.1148/radiol.11101868; Wu YP, 1996, ANN SURG ONCOL, V3, P24, DOI 10.1007/BF02409047	57	10	10	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2014	9	1							e86394	10.1371/journal.pone.0086394	http://dx.doi.org/10.1371/journal.pone.0086394			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297EA	24466071	gold, Green Published, Green Submitted			2023-01-03	WOS:000330237000097
J	Ding, H; Zhao, CJ; Cui, X; Gu, YF; Jia, WT; Rahaman, MN; Wang, Y; Huang, WH; Zhang, CQ				Ding, Hao; Zhao, Cun-Ju; Cui, Xu; Gu, Yi-Fei; Jia, Wei-Tao; Rahaman, Mohamed N.; Wang, Yang; Huang, Wen-Hai; Zhang, Chang-Qing			A Novel Injectable Borate Bioactive Glass Cement as an Antibiotic Delivery Vehicle for Treating Osteomyelitis	PLOS ONE			English	Article							CONTROLLABLE DEGRADATION BEHAVIOR; RESISTANT STAPHYLOCOCCUS-AUREUS; BONE SUBSTITUTE MATERIALS; CALCIUM-PHOSPHATE CEMENT; IN-VITRO; GLASS/CHITOSAN COMPOSITE; ADULT OSTEOMYELITIS; CARRIER MATERIAL; LOCAL-DELIVERY; DRUG-RELEASE	Background: A novel injectable cement composed of chitosan-bonded borate bioactive glass (BG) particles was evaluated as a carrier for local delivery of vancomycin in the treatment of osteomyelitis in a rabbit tibial model. Materials and Methods: The setting time, injectability, and compressive strength of the borate BG cement, and the release profile of vancomycin from the cement were measured in vitro. The capacity of the vancomycin-loaded BG cement to eradicate methicillin-resistant Staphylococcus aureus (MRSA)-induced osteomyelitis in rabbit tibiae in vivo was evaluated and compared with that for a vancomycin-loaded calcium sulfate (CS) cement and for intravenous injection of vancomycin. Results: The BG cement had an injectability of >90% during the first 3 minutes after mixing, hardened within 30 minutes and, after hardening, had a compressive strength of 18+/-2 MPa. Vancomycin was released from the BG cement into phosphate-buffered saline for up to 36 days, and the cumulative amount of vancomycin released was 86% of the amount initially loaded into the cement. In comparison, vancomycin was released from the CS cement for up 28 days and the cumulative amount released was 89%. Two months post-surgery, radiography and microbiological tests showed that the BG and CS cements had a better ability to eradicate osteomyelitis when compared to intravenous injection of vancomycin, but there was no significant difference between the BG and CS cements in eradicating the infection. Histological examination showed that the BG cement was biocompatible and had a good capacity for regenerating bone in the tibial defects. Conclusions: These results indicate that borate BG cement is a promising material both as an injectable carrier for vancomycin in the eradication of osteomyelitis and as an osteoconductive matrix to regenerate bone after the infection is cured.	[Jia, Wei-Tao; Wang, Yang; Zhang, Chang-Qing] Shanghai Jiao Tong Univ, Dept Orthoped Surg, Shanghai Peoples Hosp 6, Shanghai 200030, Peoples R China; [Zhao, Cun-Ju] Liaocheng Peoples Hosp, Dept Orthoped Surg, Liaocheng, Shandong, Peoples R China; [Cui, Xu; Gu, Yi-Fei; Huang, Wen-Hai] Tongji Univ, Inst Bioengn & Informat Technol Mat, Shanghai 200092, Peoples R China; [Rahaman, Mohamed N.] Missouri Univ Sci & Technol, Dept Mat Sci & Engn, Rolla, MO USA	Shanghai Jiao Tong University; Tongji University; University of Missouri System; Missouri University of Science & Technology	Huang, WH (corresponding author), Tongji Univ, Inst Bioengn & Informat Technol Mat, Shanghai 200092, Peoples R China.	whhuang@tongji.edu.cn; zcqgk@hotmail.com	Cui, Xu/P-1610-2015	zhang, changqing/0000-0002-7408-4126	National Natural Science Foundation of China [51072133, 81000788, 81201377]; Shanghai Science Committee [12JC1408500]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science Committee	This work was supported by the National Natural Science Foundation of China through the project 51072133, 81000788 and 81201377, and by the Shanghai Science Committee through the project 12JC1408500. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antoci V, 2007, CLIN ORTHOP RELAT R, P200, DOI 10.1097/BLO.0b013e31811ff866; Arcos D, 2001, BIOMATERIALS, V22, P701, DOI 10.1016/S0142-9612(00)00233-7; ASTM International C26699, 2007, C26699 ASTM INT; Brown RF, 2009, J BIOMED MATER RES A, V88A, P392, DOI 10.1002/jbm.a.31679; Buranapanitkit B, 2004, CLIN ORTHOP RELAT R, P244, DOI 10.1097/01.blo.0000130268.27024.c1; Cevher E, 2006, INT J PHARMACEUT, V317, P127, DOI 10.1016/j.ijpharm.2006.03.014; Chang W, 2007, ACTA ORTHOP BELG, V73, P238; Cierny G, 2003, CLIN ORTHOP RELAT R, P7, DOI 10.1097/01.blo.0000088564.81746.62; Englert C, 2007, UNFALLCHIRURG, V110, P408, DOI 10.1007/s00113-007-1229-3; Ginebra MP, 2001, J BIOMED MATER RES, V57, P113, DOI 10.1002/1097-4636(200110)57:1<113::AID-JBM1149>3.0.CO;2-5; GOLDSTEIN SA, 1987, J BIOMECH, V20, P1055, DOI 10.1016/0021-9290(87)90023-6; Haleem AA, 2004, CLIN ORTHOP RELAT R, P22, DOI 10.1097/01.blo.0000144477.43661.59; Hanssen AD, 2005, CLIN ORTHOP RELAT R, P91, DOI 10.1097/01.blo.0000175713.30506.77; Jia WT, 2010, INT J PHARMACEUT, V387, P184, DOI 10.1016/j.ijpharm.2009.12.002; Jia WT, 2010, ACTA BIOMATER, V6, P812, DOI 10.1016/j.actbio.2009.09.011; Jia WT, 2010, ANTIMICROB AGENTS CH, V54, P170, DOI 10.1128/AAC.01122-09; Jiang JL, 2012, INFLAMM RES, V61, P207, DOI 10.1007/s00011-011-0402-x; Joosten U, 2004, BIOMATERIALS, V25, P4287, DOI 10.1016/j.biomaterials.2003.10.083; Kanellakopoulou K, 2009, INT J ANTIMICROB AG, V33, P354, DOI 10.1016/j.ijantimicag.2008.09.008; Kluin OS, 2013, EXPERT OPIN DRUG DEL, V10, P341, DOI 10.1517/17425247.2013.751371; Liu H, 2006, ACTA BIOMATER, V2, P557, DOI 10.1016/j.actbio.2006.03.007; Marion NW, 2005, MECH ADV MATER STRUC, V12, P239, DOI 10.1080/15376490590928615; McCann SJ, 2002, J ANTIMICROB CHEMOTH, V50, P107, DOI 10.1093/jac/dkf067; McLaren AC, 2004, CLIN ORTHOP RELAT R, P101, DOI 10.1097/01.blo.0000143554.56897.26; MURAKAMI K, 1991, J CLIN MICROBIOL, V29, P2240, DOI 10.1128/JCM.29.10.2240-2244.1991; National Committee for Clinical Laboratory Standards NCCLS, 2000, M7A5 NCCLS; NORDEN CW, 1980, BRIT J EXP PATHOL, V61, P451; Patwardhan S, 2013, J BONE JOINT SURG AM, V95A, DOI 10.2106/JBJS.K.01338; Phaechamud T, 2008, AAPS PHARMSCITECH, V9, P829, DOI 10.1208/s12249-008-9117-x; Rauschmann MA, 2005, BIOMATERIALS, V26, P2677, DOI 10.1016/j.biomaterials.2004.06.045; Sanicola Shawn M, 2005, J Foot Ankle Surg, V44, P121, DOI 10.1053/j.jfas.2005.01.006; Simpson AHRW, 2001, J BONE JOINT SURG BR, V83B, P403, DOI 10.1302/0301-620X.83B3.10727; Smeltzer MS, 1997, J ORTHOPAED RES, V15, P414, DOI 10.1002/jor.1100150314; Tang H, 2009, ARCH ORTHOP TRAUM SU, V129, P1301, DOI 10.1007/s00402-008-0782-8; Xie ZP, 2009, J CONTROL RELEASE, V139, P118, DOI 10.1016/j.jconrel.2009.06.012; Yao AH, 2007, CHINESE SCI BULL, V52, P272, DOI 10.1007/s11434-007-0023-5; Yao AH, 2007, J AM CERAM SOC, V90, P303, DOI 10.1111/j.1551-2916.2006.01358.x; Yokoyama A, 2002, BIOMATERIALS, V23, P1091, DOI 10.1016/S0142-9612(01)00221-6; Zhang Y, 2002, J BIOMED MATER RES, V62, P378, DOI 10.1002/jbm.10312	39	35	40	0	57	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 10	2014	9	1							e85472	10.1371/journal.pone.0085472	http://dx.doi.org/10.1371/journal.pone.0085472			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	291YG	24427311	gold, Green Submitted, Green Published			2023-01-03	WOS:000329868200052
J	Liu, GFF; Bair, RJ; Bair, E; Liauw, SL; Koshy, M				Liu, Gene-Fu F.; Bair, Ryan J.; Bair, Eric; Liauw, Stanley L.; Koshy, Matthew			Clinical Outcomes for Gastric Cancer following Adjuvant Chemoradiation Utilizing Intensity Modulated versus Three-Dimensional Conformal Radiotherapy	PLOS ONE			English	Article							CHEMORADIOTHERAPY; DISPARITIES; RADIATION; THERAPY; CARE	Purpose/Objective(s): To determine if intensity modulated radiation therapy (IMRT) in the post-operative setting for gastric cancer was associated with reduced toxicity compared to 3D conformal radiation therapy (3DCRT). Materials/Methods: This retrospective study includes 24 patients with stage IB-IIIB gastric cancer consecutively treated from 2001-2010. All underwent surgery followed by adjuvant chemoradiation. Concurrent chemotherapy consisted of 5-FU/leucovorin (n = 21), epirubicin/cisplatin/5FU (n = 1), or none (n = 2). IMRT was utilized in 12 patients and 3DCRT in 12 patients. For both groups, the target volume included the tumor bed, anastomosis, gastric stump, and regional lymphatics. Results: Median follow-up for the entire cohort was 19 months (range 0.4-8.5 years), and 49 months (0.5-8.5 years) in surviving patients. The 3DCRT group received a median dose of 45 Gy, and the IMRT group received a median dose of 50.4 Gy (p = 0.0004). For the entire cohort, 3-year overall survival (OS) was 40% and 3-year disease free survival (DFS) was 41%. OS and DFS did not differ significantly between the groups. Acute toxicity was similar. Between 3DCRT and IMRT groups, during radiotherapy, median weight lost (3.2 vs. 3.3 kg, respectively; p = 0.47) and median percent weight loss were similar (5.0% vs. 4.3%, respectively; p = 0.43). Acute grade 2 toxicity was experienced by 8 patients receiving 3DCRT and 11 receiving IMRT (p = 0.32); acute grade 3 toxicity occurred in 1 patient receiving 3DCRT and none receiving IMRT (p = 1.0). No patients in either cohort experienced late grade 3 toxicity, including renal or gastrointestinal toxicity. At last follow up, the median increase in creatinine was 0.1 mg/dL in the IMRT group and 0.1 mg/dL in the 3DCRT group (p = 0.78). Conclusion: This study demonstrates that adjuvant chemoradiation for gastric cancer with IMRT to 50.4 Gy was well-tolerated and compared similarly in toxicity with 3DCRT to 45 Gy.	[Liu, Gene-Fu F.; Bair, Ryan J.; Liauw, Stanley L.; Koshy, Matthew] Univ Chicago, Med Ctr, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; [Bair, Eric] Univ N Carolina, Dept Endodont, Chapel Hill, NC USA; [Bair, Eric] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA; [Koshy, Matthew] Univ Illinois Hosp, Dept Radiat Oncol, Chicago, IL USA	University of Chicago; University of Chicago Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Illinois System; University of Illinois Chicago	Koshy, M (corresponding author), Univ Chicago, Med Ctr, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA.	mkoshy@radonc.uchicago.edu		Bair, Eric/0000-0001-8733-7869; Koshy, Matthew/0000-0001-6937-7058; Liauw, Stanley/0000-0002-4701-2469				Boda-Heggemann J, 2009, INT J RADIAT ONCOL, V75, P1187, DOI 10.1016/j.ijrobp.2008.12.036; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; Edge S., 2010, AJCC CANC STAGING MA; Hu WG, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-98; Jansen EPM, 2007, INT J RADIAT ONCOL, V67, P781, DOI 10.1016/j.ijrobp.2006.09.012; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Macdonald JS, 2001, NEW ENGL J MED, V345, P725, DOI 10.1056/NEJMoa010187; Milano MT, 2006, BRIT J RADIOL, V79, P497, DOI 10.1259/bjr/43441736; Minn AY, 2010, CANCER-AM CANCER SOC, V116, P3943, DOI 10.1002/cncr.25246; Ringash J, 2005, INT J RADIAT ONCOL, V63, P732, DOI 10.1016/j.ijrobp.2005.03.013; Ringash J, 2001, CAN MED ASSOC J, V164, P469; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Stessin AM, 2011, CANCER EPIDEM BIOMAR, V20, P223, DOI 10.1158/1055-9965.EPI-10-0158	13	13	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2014	9	1							e82642	10.1371/journal.pone.0082642	http://dx.doi.org/10.1371/journal.pone.0082642			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	291XP	24416146	gold, Green Published, Green Submitted			2023-01-03	WOS:000329866300011
J	Chevallier, M; Ego, A; Cans, C; Debillon, T				Chevallier, Marie; Ego, Anne; Cans, Christine; Debillon, Thierry		French Soc Neonatology	Adherence to Hypothermia Guidelines: A French Multicenter Study of Fullterm Neonates	PLOS ONE			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; AMPLITUDE-INTEGRATED EEG; WHOLE-BODY HYPOTHERMIA; MODERATE HYPOTHERMIA; SYSTEMIC HYPOTHERMIA; PERINATAL ASPHYXIA; NEWBORNS; OUTCOMES; INFANTS; RISK	Aim: The objective of this study was to describe the French practice of hypothermia treatment (HT) in full-term newborns with hypoxic-ischemic encephalopathy (HIE) and to analyze the deviations from the guidelines of the French Society of Neonatology. Materials and Methods: From May 2010 to March 2012 we recorded all cases of HIE treated by HT in a French national database. The population was divided into three groups, "optimal HT" (OHT), "late HT" (LHT) and "non-indicated" HT (NIHT), according to the guidelines. Results: Of the 311 newborns registered in the database and having HT, 65% were classified in the OHT group, 22% and 13% in the LHT and NIHT groups respectively. The severity of asphyxia and HIE were comparable between newborns with OHT and LHT, apart from EEG. HT was initiated at a mean time of 12 hours of life in the LHT group. An acute obstetrical event was more likely to be identified among newborns with LHT (46%), compared to OHT (34%) and NIHT (22%). There was a gradation in the rate of complications from the NIHT group (29%) to the LHT (38%) group and the OHT group (52%). Despite an insignificant difference in the rates of death or abnormal neurological examination at discharge, nearly 60% of newborns in the OHT group had an MRI showing abnormalities, compared to 44% and 49% in the LHT and NIHT groups respectively. Conclusion: The conduct of the HT for HIE newborns is not consistent with French guidelines for 35% of newborns, 22% being explained by an excessive delay in the start of HT, 13% by the lack of adherence to the clinical indications. This first report illustrates the difficulties in implementing guidelines for HT and should argue for an optimization of perinatal care for HIE.	[Chevallier, Marie; Debillon, Thierry] Grenoble Univ Hosp, Neonatol & Pediat Intens Care Unit, Grenoble, France; [Ego, Anne] Grenoble Univ Hosp, Clin Res Ctr CICO3, Grenoble, France; [Cans, Christine] Univ Grenoble 1, THEMAS Tech Evaluat & Modelisat Act Sante, Grenoble, France	CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Debillon, T (corresponding author), Grenoble Univ Hosp, Neonatol & Pediat Intens Care Unit, Grenoble, France.	TDebillon@chu-grenoble.fr	EGO, Anne/G-7071-2011; Cans, Christine/M-6153-2014; Debillon, Thierry/M-6929-2014	EGO, Anne/0000-0002-1025-910X; Cans, Christine/0000-0003-3071-9959; Beuchee, Alain/0000-0003-0064-7085; Marret, Stephane/0000-0002-2858-148X; CAMBONIE, GILLES/0000-0002-1360-7915; Meau-Petit, Virginie/0000-0002-2725-7522				Amiel-Tison C, 2002, PEDIATR NEUROL, V27, P196, DOI 10.1016/S0887-8994(02)00436-8; Austin T, 2012, COOL NOT COOL HYPOTH, DOI DOI 10.1136/ARCHDISCHILD-2012-302069.ACCESSED; Azzopardi D, 2009, ARCH DIS CHILD-FETAL, V94, pF260, DOI 10.1136/adc.2008.146977; Azzopardi D, 2013, ARCH DIS CHILD FETAL; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; BERGAMASCO B, 1984, EPILEPSIA, V25, P131, DOI 10.1111/j.1528-1157.1984.tb04168.x; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Glass HC, 2011, PEDIATR RES, V70, P535, DOI 10.1203/PDR.0b013e31822f24c7; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Graham EM, 2008, AM J OBSTET GYNECOL, V199, P587, DOI 10.1016/j.ajog.2008.06.094; Groenendaal F, 2013, NEONATOLOGY, V104, P15, DOI 10.1159/000348823; Inder TE, 2004, J PEDIATR-US, V145, P835, DOI 10.1016/j.jpeds.2004.07.034; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Kurinczuk JJ, 2010, EARLY HUM DEV, V86, P329, DOI 10.1016/j.earlhumdev.2010.05.010; Laptook A, 2013, LATE HYPOTHERMIA HYP; Lin ZL, 2006, J PERINATOL, V26, P180, DOI 10.1038/sj.jp.7211412; O'Reilly D, 2013, J PERINATOL, V33, P435, DOI 10.1038/jp.2012.138; Pfister RH, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-84; Pierrat V, 2005, ARCH DIS CHILD-FETAL, V90, P257, DOI 10.1136/adc.2003.047985; Pin TW, 2009, EUR J PAEDIATR NEURO, V13, P224, DOI 10.1016/j.ejpn.2008.05.001; Saliba E, 2010, ARCH PEDIATRIE, V17, pS67, DOI 10.1016/S0929-693X(10)70904-0; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Shah PS, 2010, SEMIN FETAL NEONAT M, V15, P238, DOI 10.1016/j.siny.2010.02.003; Shankaran S, 2002, PEDIATRICS, V110, P377, DOI 10.1542/peds.110.2.377; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shellhaas RA, 2007, PEDIATRICS, V120, P770, DOI 10.1542/peds.2007-0514; Simbruner G, 2010, PEDIATRICS, V126, pE771, DOI 10.1542/peds.2009-2441; Spitzmiller RE, 2007, J CHILD NEUROL, V22, P1069, DOI 10.1177/0883073807306258; Strohm B, 2011, PEDIATRICS, V128, pE450, DOI 10.1542/peds.2010-3508; Tagin MA, 2012, ARCH PEDIAT ADOL MED, V166, P558, DOI 10.1001/archpediatrics.2011.1772; Tao JD, 2010, J PERINATOL, V30, pS73, DOI 10.1038/jp.2010.93; THORNBERG E, 1995, ACTA PAEDIATR, V84, P927, DOI 10.1111/j.1651-2227.1995.tb13794.x; Walsh W, 2013, PILOT STUDY HEAD COO; Yates HL, 2012, ARCH DIS CHILD-FETAL, V97, DOI 10.1136/adc.2011.301240	34	14	14	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2013	8	12							e83742	10.1371/journal.pone.0083742	http://dx.doi.org/10.1371/journal.pone.0083742			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	284NF	24391817	Green Published, Green Submitted, gold			2023-01-03	WOS:000329325200115
J	Pivodic, L; Pardon, K; Van den Block, L; Van Casteren, V; Miccinesi, G; Donker, GA; Alonso, TV; Alonso, JL; Aprile, PL; Onwuteaka-Philipsen, BD; Deliens, L				Pivodic, Lara; Pardon, Koen; Van den Block, Lieve; Van Casteren, Viviane; Miccinesi, Guido; Donker, Ge A.; Vega Alonso, Tomas; Lozano Alonso, Jose; Aprile, Pierangelo Lora; Onwuteaka-Philipsen, Bregje D.; Deliens, Luc		EURO IMPACT	Palliative Care Service Use in Four European Countries: A Cross-National Retrospective Study via Representative Networks of General Practitioners	PLOS ONE			English	Article							OF-LIFE CARE; CANCER-PATIENTS; END; NETHERLANDS; HEALTH; POPULATION; PATIENT; DEATH	Background: Due to a rising number of deaths from cancer and other chronic diseases a growing number of people experience complex symptoms and require palliative care towards the end of life. However, population-based data on the number of people receiving palliative care in Europe are scarce. The objective of this study is to examine, in four European countries, the number of people receiving palliative care in the last three months of life and the factors associated with receiving palliative care. Methods: Cross-national retrospective study. Over two years (2009-2010), GPs belonging to representative epidemiological surveillance networks in Belgium, the Netherlands, Italy, and Spain registered weekly all deaths of patients (>= 18 years) in their practices and the care they received in the last three months of life using a standardized form. Sudden deaths were excluded. Results: We studied 4,466 deaths. GPs perceived to have delivered palliative care to 50% of patients in Belgium, 55% in Italy, 62% in the Netherlands, and 65% in Spain (p<.001). Palliative care specialists attended to 29% of patients in the Netherlands, 39% in Italy, 45% in Spain, and 47% in Belgium (p<.001). Specialist palliative care lasted a median (inter-quartile range) of 15 (23) days in Belgium to 30 (70) days in Italy (p<.001). Cancer patients were more likely than non-cancer patients to receive palliative care in all countries as were younger patients in Italy and Spain with regard to specialist palliative care. Conclusions: Although palliative care is established in the countries studied, there are considerable differences in its provision. Two potentially underserved groups emerge non-cancer patients in all countries and older people in Italy and Spain. Future research should examine how differences in palliative care use relate to both patient characteristics and existing national health care policies.	[Pivodic, Lara; Pardon, Koen; Van den Block, Lieve; Deliens, Luc] Vrije Univ Brussel, End Of Life Care Res Grp, Brussels, Belgium; [Pivodic, Lara; Pardon, Koen; Van den Block, Lieve; Deliens, Luc] Univ Ghent, Brussels, Belgium; [Van Casteren, Viviane] Sci Inst Publ Hlth, Hlth Serv Res Unit, Brussels, Belgium; [Miccinesi, Guido] Canc Prevent & Res Inst, Clin & Descript Epidemiol Unit, Florence, Italy; [Donker, Ge A.] Netherlands Inst Hlth Serv Res, NIVEL, Dutch Sentinel Gen Practice Network, Utrecht, Netherlands; [Vega Alonso, Tomas; Lozano Alonso, Jose] Reg Minist Hlth, Publ Hlth Gen Directorate, Valladolid, Spain; [Aprile, Pierangelo Lora] Italian Soc Gen Med, Florence, Italy; [Onwuteaka-Philipsen, Bregje D.; Deliens, Luc] Vrije Univ Amsterdam Med Ctr, EMGO Inst, Dept Publ & Occupat Hlth, Amsterdam, Netherlands	Vrije Universiteit Brussel; Ghent University; Netherlands Institute for Health Services Research; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Pivodic, L (corresponding author), Vrije Univ Brussel, End Of Life Care Res Grp, Brussels, Belgium.	lara.pivodic@vub.ac.be	miccinesi, guido/AAB-5476-2022; Caraceni, Augusto/C-1012-2017; Donker, Gé/AAX-8564-2021; Van den Block, Lieve/D-1247-2011; Pivodic, Lara/C-8588-2014	miccinesi, guido/0000-0002-7452-9594; Caraceni, Augusto/0000-0002-0375-6204; Van den Block, Lieve/0000-0002-7770-348X; Pivodic, Lara/0000-0002-8825-3699; Pardon, Koen/0000-0002-0571-709X; Harding, Richard/0000-0001-9653-8689; Deliens, Luc/0000-0002-8158-2422; Onwuteaka-Philipsen, Bregje/0000-0002-9440-1248; Lozano Alonso, Jose Eugenio/0000-0003-2589-0671; Donker, Ge/0000-0001-6314-9249	Institute for the Promotion of Innovation by Science and Technology in Flanders [SBO IWT 050158]; Italian Ministry of Health; European Union [264697]	Institute for the Promotion of Innovation by Science and Technology in Flanders(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); Italian Ministry of Health(Ministry of Health, Italy); European Union(European Commission)	Funding for the study came from the Institute for the Promotion of Innovation by Science and Technology in Flanders (http://www.iwt.be) as a Strategic Basic Research project (SBO) (contract SBO IWT 050158) (2006-2010), as part of the 'Monitoring Quality of End-of-Life Care (MELC) Study', a collaboration between the Vrije Universiteit Brussel, Ghent University, Antwerp University, the Scientific Institute for Public Health, Belgium, and VU University Medical Center Amsterdam, the Netherlands. Funding also came from the Italian Ministry of Health (http://www.salute.gov.it) through the 'Evaluation, testing and implementation of supportive care, care interventions, integrated programs and improving the quality of care for cancer patients' program ('Integrated Oncology Project no 6, years 2008-2011') led by Massimo Costantini (IRCCS AOU San Martino-IST, Genoa), from the annual budgets of the Autonomous Community of Castilla y Leon (http://www.jcyl.es) and Comunitat Valenciana (http://www.gva.es) and from EURO IMPACT: European Intersectorial and Multidisciplinary Palliative Care Research Training, funded by the European Union Seventh Framework Programme (FP7/2007-2013, under grant agreement no [264697], http://ec.europa.eu/research/fp7). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abarshi E, 2011, J PAIN SYMPTOM MANAG, V41, P436, DOI 10.1016/j.jpainsymman.2010.04.016; Abarshi E, 2010, AGE AGEING, V39, P716, DOI 10.1093/ageing/afq097; Addington-Hall J, 1998, SOC SCI MED, V46, P1011, DOI 10.1016/S0277-9536(97)10021-1; Addington-Hall J, 1998, PALLIATIVE MED, V12, P417, DOI 10.1191/026921698676924076; Ahmed N, 2004, PALLIATIVE MED, V18, P525, DOI 10.1191/0269216304pm921oa; [Anonymous], 2010, WHO DEF PALL CAR; Beccaro M, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-66; Beccaro M, 2013, J PAIN SYMPTOM MANAG, V46, P335, DOI 10.1016/j.jpainsymman.2012.08.020; Bilsen J, 2009, NEW ENGL J MED, V361, P1119, DOI 10.1056/NEJMc0904292; Borgsteede SD, 2006, PALLIATIVE MED, V20, P63, DOI 10.1191/0269216306pm1112oa; Brandt HE, 2005, ARCH INTERN MED, V165, P314, DOI 10.1001/archinte.165.3.314; Centeno C, 2007, PALLIATIVE MED, V21, P463, DOI 10.1177/0269216307081942; Clark D, 2000, PALLIATIVE MED, V14, P479, DOI 10.1191/026921600701536408; Clark D, 2007, J PAIN SYMPTOM MANAG, V33, P542, DOI 10.1016/j.jpainsymman.2007.02.010; Cohen J, 2011, J PAIN SYMPTOM MANAG, V42, P839, DOI 10.1016/j.jpainsymman.2011.02.017; Costantini M, 2006, ANN ONCOL, V17, P853, DOI 10.1093/annonc/mdl028; Currow DC, 2008, PALLIATIVE MED, V22, P43, DOI 10.1177/0269216307085182; DAVIES E, 2004, PALLIATIVE CARE SOLI; Deckers J, 2004, HLTH INFORM PRIMARY; Evans N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057965; Fleming DM, 2003, EUR J PUBLIC HEALTH, V13, P80, DOI 10.1093/eurpub/13.suppl_1.80; Francke A. L, 2003, PALLIATIVE CARE TERM; Francke AL, 2000, PATIENT EDUC COUNS, V41, P23, DOI 10.1016/S0738-3991(00)00112-9; Garcia-Armesto S, 2010, HLTH SYSTEMS TRANSIT; Gerkens S, 2010, HLTH SYSTEMS TRANSIT; Hall S., 2011, PALLIATIVE CARE OLDE; Hasselaar J, 2012, BMJ SUPPORT PALLIAT, V2, P334, DOI 10.1136/bmjspcare-2011-000162; Janssen DJA, 2008, PALLIATIVE MED, V22, P938, DOI 10.1177/0269216308096906; Keirse E, 2009, KCE REPORTS C, V115C; Ko W, 2013, EUR J CANCER, V49, P1967, DOI 10.1016/j.ejca.2013.01.006; Kuin A, 2004, J PAIN SYMPTOM MANAG, V27, P53, DOI 10.1016/j.jpainsymman.2003.06.001; Lo Scalzo ADA, 2009, HLTH SYST TRANSIT, V11, P1; Meeussen K, 2011, J CLIN ONCOL, V29, P4327, DOI 10.1200/JCO.2011.34.9498; Menaca A, 2012, CRIT REV ONCOL HEMAT, V82, P387, DOI 10.1016/j.critrevonc.2011.06.002; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; National Council for Palliative Care, 2011, NAT SURV PAT ACT DAT; Onwuteaka-Philipsen BD, 2012, LANCET, V380, P908, DOI 10.1016/S0140-6736(12)61034-4; Ottenbacher KJ, 2004, J CLIN EPIDEMIOL, V57, P1147, DOI 10.1016/j.jclinepi.2003.05.003; PIJNENBORG L, 1995, ARCH INTERN MED, V155, P286, DOI 10.1001/archinte.155.3.286; ROCAFORT J, 2008, EAPC REV PALLIATIVE; Rosenwax LK, 2005, PALLIATIVE MED, V19, P556, DOI 10.1191/0269216305pm1067oa; Schafer W., 2010, HLTH SYSTEMS TRANSIT; Rio-Valle JS, 2009, J PALLIAT CARE, V25, P191, DOI 10.1177/082585970902500306; Solano JP, 2006, J PAIN SYMPTOM MANAG, V31, P58, DOI 10.1016/j.jpainsymman.2005.06.007; The National Health System Palliative Care Strategy, 2007, NAT HLTH SYST PALL C; Van den Block L, 2008, ARCH INTERN MED, V168, P1747, DOI 10.1001/archinte.168.16.1747; Van den Block L, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-73; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6; Vega Alonso Agustin Tomas, 2006, Gac Sanit, V20 Suppl 3, P52, DOI 10.1157/13101090	49	65	67	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2013	8	12							e84440	10.1371/journal.pone.0084440	http://dx.doi.org/10.1371/journal.pone.0084440			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282SX	24386381	Green Published, Green Submitted, gold			2023-01-03	WOS:000329194700108
J	Ko, HK; Yu, WK; Lien, TC; Wang, JH; Slutsky, AS; Zhang, HB; Kou, YR				Ko, Hsin-Kuo; Yu, Wen-Kuang; Lien, Te-Cheng; Wang, Jia-Horng; Slutsky, Arthur S.; Zhang, Haibo; Kou, Yu Ru			Intensive Care Unit-Acquired Bacteremia in Mechanically Ventilated Patients: Clinical Features and Outcomes	PLOS ONE			English	Article							BLOOD-STREAM INFECTIONS; CRITICALLY-ILL PATIENTS; RISK-FACTORS; ATTRIBUTABLE MORTALITY; STAPHYLOCOCCUS-AUREUS; ANTIMICROBIAL THERAPY; EXCESS MORTALITY; EPIDEMIOLOGY; IMPACT; COSTS	Intensive care unit (ICU)-acquired bacteremia (IAB) is associated with high medical expenditure and mortality. Mechanically ventilated patients represent one third of all patients admitted to ICU, but the clinical features and outcomes in mechanically ventilated patients who develop IAB remain unknown. We conducted a 3-year retrospective observational cohort study, and 1,453 patients who received mechanical ventilation on ICU admission were enrolled. Among patients enrolled, 126 patients who had developed IAB >= 48 hours after ICU admission were identified. The study patients were divided into IAB and no IAB groups, and clinical characteristics of IAB based on specific bacterial species were further analyzed. The multivariate Cox regression analysis showed that ventilator support for chronic obstructive pulmonary disease and congestive heart failure, and patients admitted from nursing home were the independent risk factors for developing IAB. Patients with IAB were significantly associated with longer length of ICU stay, prolonged ventilator use, lower rate of successful weaning, and higher rate of ventilator dependence and ICU mortality as compared to those without IAB. IAB was the independent risk factor for ICU mortality (HR, 1.510, 95% CI 1.054-1.123; p = 0.010). The clinical characteristics of IAB related to specific bacterial species included IAB due to Pseudomonas aeruginosa being likely polymicrobial, lung source and prior antibiotic use; Escherichia coli developing earlier and from urinary tract source; methicillin-resistant Staphylococcus aureus related to central venous catheter and multiple sets of positive hemoculture; and Elizabethkingia meningoseptica significantly associated with delayed/inappropriate antibiotic treatment. In summary, IAB was significantly associated with poor patient outcomes in mechanically ventilated ICU patients. The clinical features related to IAB and clinical characteristics of IAB based on specific bacterial species identified in our study may be utilized to refine the management of IAB.	[Ko, Hsin-Kuo; Yu, Wen-Kuang; Kou, Yu Ru] Natl Yang Ming Univ, Sch Med, Inst Physiol, Taipei 112, Taiwan; [Ko, Hsin-Kuo; Yu, Wen-Kuang; Lien, Te-Cheng; Wang, Jia-Horng] Taipei Vet Gen Hosp, Dept Resp Therapy, Taipei, Taiwan; [Ko, Hsin-Kuo; Slutsky, Arthur S.; Zhang, Haibo] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada; [Slutsky, Arthur S.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada; [Zhang, Haibo] Univ Toronto, Dept Physiol, Interdept Div Crit Care Med, Dept Anesthesia, Toronto, ON, Canada; [Kou, Yu Ru] Natl Yang Ming Univ, Sch Med, Inst Emergency & Crit Care Med, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; National Yang Ming Chiao Tung University	Zhang, HB (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, 30 Bond St, Toronto, ON M5B 1W8, Canada.	zhangh@smh.ca; yrkou@ym.edu.tw	Slutsky, Arthur/M-3325-2019	Kou, Yu Ru/0000-0002-4681-9009	Taipei Veterans General Hospital, Taipei, Taiwan [VGH-97-A-024, VGH-98-A-065]; National Science Council, Taiwan [NSC 98-2320-B-010-016-MY3]	Taipei Veterans General Hospital, Taipei, Taiwan(Taipei Veterans General Hospital); National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported through Grants VGH-97-A-024 and VGH-98-A-065 from the Taipei Veterans General Hospital, Taipei, Taiwan and Grant NSC 98-2320-B-010-016-MY3 from the National Science Council, Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Blot S, 2003, J HOSP INFECT, V53, P18, DOI 10.1053/jhin.2002.1329; Blot S, 2003, INFECT CONT HOSP EP, V24, P912, DOI 10.1086/502159; Blot S, 2003, INTENS CARE MED, V29, P471, DOI 10.1007/s00134-003-1648-8; Blot SI, 2003, CHEST, V123, P1208, DOI 10.1378/chest.123.4.1208; Blot SI, 2002, EUR J CLIN MICROBIOL, V21, P471, DOI 10.1007/s10096-002-0746-9; Damas P, 2008, INTENS CARE MED, V34, P856, DOI 10.1007/s00134-008-1018-7; DiGiovine B, 1999, AM J RESP CRIT CARE, V160, P976, DOI 10.1164/ajrccm.160.3.9808145; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Garrouste-Orgeas M, 2006, CLIN INFECT DIS, V42, P1118, DOI 10.1086/500318; Hsu MS, 2011, EUR J CLIN MICROBIOL, V30, P1271, DOI 10.1007/s10096-011-1223-0; Ibrahim EH, 2000, CHEST, V118, P146, DOI 10.1378/chest.118.1.146; Kang CI, 2003, CLIN INFECT DIS, V37, P745, DOI 10.1086/377200; Kang CI, 2005, ANTIMICROB AGENTS CH, V49, P760, DOI 10.1128/AAC.49.2.760-766.2005; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kullar R, 2013, INFECT CONT HOSP EP, V34, P400, DOI 10.1086/669868; Kwon KT, 2007, J ANTIMICROB CHEMOTH, V59, P525, DOI 10.1093/jac/dkl499; Laupland KB, 2004, J HOSP INFECT, V58, P137, DOI 10.1016/j.jhin.2004.06.007; Laupland KB, 2002, CRIT CARE MED, V30, P2462, DOI 10.1097/00003246-200211000-00010; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Lu PL, 2012, INT J ANTIMICROB AG, V40, pS37, DOI 10.1016/S0924-8579(12)70008-0; Michalopoulos A, 2011, AM J INFECT CONTROL, V39, P396, DOI 10.1016/j.ajic.2010.06.017; Osmon S, 2004, CHEST, V125, P607, DOI 10.1378/chest.125.2.607; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; Renaud B, 2001, AM J RESP CRIT CARE, V163, P1584, DOI 10.1164/ajrccm.163.7.9912080; Richards MJ, 1999, CRIT CARE MED, V27, P887, DOI 10.1097/00003246-199905000-00020; ROBERTS FJ, 1989, REV INFECT DIS, V11, P1029; Suljagic V, 2005, AM J INFECT CONTROL, V33, P333, DOI 10.1016/j.ajic.2005.03.010; Thompson DS, 2008, J HOSP INFECT, V69, P56, DOI 10.1016/j.jhin.2008.01.012; Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754	30	6	7	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2013	8	12							e83298	10.1371/journal.pone.0083298	http://dx.doi.org/10.1371/journal.pone.0083298			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278IG	24376683	Green Published, gold, Green Submitted			2023-01-03	WOS:000328882000078
J	Cao, XB; Wu, ZY; Li, L; Pang, L; Rou, KM; Wang, CH; Luo, W; Yin, WY; Li, JH; McGoogan, JM				Cao, Xiaobin; Wu, Zunyou; Li, Li; Pang, Lin; Rou, Keming; Wang, Changhe; Luo, Wei; Yin, Wenyuan; Li, Jianhua; McGoogan, Jennifer M.		Natl Methadone Maintenance	Mortality among Methadone Maintenance Clients in China: A Six-Year Cohort Study	PLOS ONE			English	Article							ADMINISTERED ANTIRETROVIRAL THERAPY; HEROIN USERS; DRUG-USERS; RECEIVING METHADONE; TREATMENT OUTCOMES; HIV PREVENTION; TREATMENT MMT; RETENTION; ADHERENCE; SURVIVAL	Objective: To assess the overall mortality of methadone maintenance treatment (MMT) clients in China and its associated factors. Methods: A total of 1,511 MMT clients, all of whom enrolled in China's first eight MMT clinics between March and December 2004, were included in this cohort study and followed for approximately six years, until June 2010. Mortality and its predictors were examined using Cox proportional hazards regression models. Results: A total of 154 deaths were observed within 5,391 person-years (PY) of follow-up for an all-cause mortality rate of 28.6 per 1,000 PY. The leading causes of death were drug overdose (33.8%), HIV/AIDS-unrelated disease (21.4%), and HIV/AIDS (16.9%). The all-cause mortality rate of clients engaged in MMT for one year or less was roughly three times that of clients who stayed in MMT for four years or more (14.0 vs. 4.6, p<0.0001), HIV-positive subjects was nearly four times mortality rate than that of HIV-negative individuals (28.1 vs. 6.8, p<0.0001). ART-naive HIV-positive subjects had approximately two times higher mortality rate than those receiving ART (31.2 vs. 17.3, <0.0001). After adjusting for confounding variables, we found that being male (HR = 1.63, CI: 1.03-2.57, p = 0.0355) and being HIV-positive (HR = 5.16, CI: 3.70-7.10, p<0.0001) were both associated with higher risk of death whereas increased durations of methadone treatment were associated with a lower risk of death (HR = 0.26, CI: 0.18-0.38, p<0.0001 for two to three years, HR = 0.08, CI: 0.05-0.14, p<0.0001 for four or more years). Conclusion: Overall mortality was high among MMT clients in China. Specific interventions aimed at decreasing mortality among MMT clients are needed. Our study supports the need for keeping client at MMT longer and for expanding ART coverage and suggests the potential benefits of integrated MMT and ART services for drug users in China.	[Cao, Xiaobin; Wu, Zunyou; Pang, Lin; Rou, Keming; Wang, Changhe; Luo, Wei; Yin, Wenyuan; McGoogan, Jennifer M.] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China; [Li, Li] Univ Calif Los Angeles, Semel Inst Ctr Community Hlth, Los Angeles, CA USA; [Li, Jianhua] Yunnan Inst Drug Abuse, Kunming, Yunnan, Peoples R China	Chinese Center for Disease Control & Prevention; National Center for AIDS/STD Control & Prevention, Chinese Center for Disease Control & Prevention; University of California System; University of California Los Angeles	Wu, ZY (corresponding author), Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China.	wuzunyou@chinaaids.cn			Chinese National Methadone Maintenance Treatment Program; Fogarty International Center, National Institute on Drug Abuse of the US National Institutes of Health [5U2RTW006918-08]; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH058107] Funding Source: NIH RePORTER	Chinese National Methadone Maintenance Treatment Program; Fogarty International Center, National Institute on Drug Abuse of the US National Institutes of Health; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Support for this study was provided by the Chinese National Methadone Maintenance Treatment Program and the Fogarty International Center, National Institute on Drug Abuse of the US National Institutes of Health (Grant # 5U2RTW006918-08). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berg KM, 2011, CLIN INFECT DIS, V53, P936, DOI 10.1093/cid/cir537; Brugal MT, 2005, ADDICTION, V100, P981, DOI 10.1111/j.1360-0443.2005.01089.x; Brust JCM, 2011, AIDS RES HUM RETROV, V27, P535, DOI 10.1089/aid.2010.0181; Celentano DD, 2007, CLIN INFECT DIS, V45, pS318, DOI 10.1086/522557; China Ministry of Health UNAIDS WHO, 2011, 2011 EST HIV AIDS EP; Clausen T, 2008, DRUG ALCOHOL DEPEN, V94, P151, DOI 10.1016/j.drugalcdep.2007.11.003; Degenhardt L, 2006, SEX TRANSM INFECT, V82, pIII56, DOI 10.1136/sti.2005.019273; Degenhardt L, 2011, ADDICTION, V106, P32, DOI 10.1111/j.1360-0443.2010.03140.x; Dolan KA, 2005, ADDICTION, V100, P820, DOI 10.1111/j.1360-0443.2005.01050.x; Dou ZH, 2010, INT J EPIDEMIOL, V39, pII56, DOI 10.1093/ije/dyq215; Esteban J, 2003, DRUG ALCOHOL DEPEN, V70, P193, DOI 10.1016/S0376-8716(03)00002-4; Fareed A, 2009, J PSYCHIATR PRACT, V15, P227, DOI 10.1097/01.pra.0000351884.83377.e2; Gibson A, 2008, ADDICTION, V103, P462, DOI 10.1111/j.1360-0443.2007.02090.x; Gowing L, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004145.pub3; Gu J, 2012, ADDICTION; Hickman M, 2003, J URBAN HEALTH, V80, P274, DOI 10.1093/jurban/jtg030; Huang YF, 2011, ADDICTION, V106, P1437, DOI 10.1111/j.1360-0443.2011.03443.x; Hulse GK, 1999, ADDICTION, V94, P221, DOI 10.1046/j.1360-0443.1999.9422216.x; Langendam MW, 2001, AM J PUBLIC HEALTH, V91, P774, DOI 10.2105/AJPH.91.5.774; Li L, 2012, ADDICT BEHAV, V37, P264, DOI 10.1016/j.addbeh.2011.11.004; Lin CQ, 2011, DRUG ALCOHOL DEPEN, V117, P45, DOI 10.1016/j.drugalcdep.2011.01.004; Liu En-wu, 2011, Zhonghua Yu Fang Yi Xue Za Zhi, V45, P979; Lucas GM, 2006, CLIN INFECT DIS, V42, P1628, DOI 10.1086/503905; Maru DSR, 2009, JAIDS-J ACQ IMM DEF, V50, P176, DOI 10.1097/QAI.0b013e3181938e7e; Mathers BM, 2010, LANCET, V375, P1014, DOI 10.1016/S0140-6736(10)60232-2; Mattick RP, 2003, ADDICTION, V98, P387, DOI 10.1046/j.1360-0443.2003.00348.x; McCowan C, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2225; Metzger DS, 2010, JAIDS-J ACQ IMM DEF, V55, pS32, DOI 10.1097/QAI.0b013e3181f9c10b; Morgan OW, 2006, J PUBLIC HEALTH, V28, P318, DOI 10.1093/pubmed/fdl059; Nahvi S, 2012, DRUG ALCOHOL DEPEN, V120, P174, DOI 10.1016/j.drugalcdep.2011.07.025; Pang L, 2007, AIDS, V21, pS103, DOI 10.1097/01.aids.0000304704.71917.64; Peles E, 2010, DRUG ALCOHOL DEPEN, V107, P141, DOI 10.1016/j.drugalcdep.2009.09.013; Rosca P, 2012, DRUG ALCOHOL DEPEND; Sullivan S, 2013, ADDICTION UNPUB; Uhlmann S, 2010, ADDICTION, V105, P907, DOI 10.1111/j.1360-0443.2010.02905.x; Ward J, 1999, LANCET, V353, P221, DOI 10.1016/S0140-6736(98)05356-2; Wood E, 2008, AIDS, V22, P1247, DOI 10.1097/QAD.0b013e3282fbd1ed; World Health Organization, INT STAT CLASS DIS 1, P10; Wu ZY, 2007, LANCET, V369, P679, DOI 10.1016/S0140-6736(07)60315-8; Wu ZY, 2011, CHIN J AIDS STD, V17, P196; Xu HF, 2012, ADDICT BEHAV, V37, P657, DOI 10.1016/j.addbeh.2012.01.020; Yin WY, 2010, INT J EPIDEMIOL, V39, pII29, DOI 10.1093/ije/dyq210; Zhang FJ, 2007, AIDS, V21, pS143, DOI 10.1097/01.aids.0000304710.10036.2b; Zhang FJ, 2011, LANCET INFECT DIS, V11, P516, DOI 10.1016/S1473-3099(11)70097-4	44	17	18	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2013	8	12							e82476	10.1371/journal.pone.0082476	http://dx.doi.org/10.1371/journal.pone.0082476			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	276EU	24349294	Green Published, gold			2023-01-03	WOS:000328731800063
J	Zhang, YY; Xiao, Z; Wang, Y; Luo, S; Li, XH; Li, SW				Zhang, Yaoyao; Xiao, Zhun; Wang, Yan; Luo, Shan; Li, Xiaohong; Li, Shangwei			Gonadotropin-Releasing Hormone for Preservation of Ovarian Function during Chemotherapy in Lymphoma Patients of Reproductive Age: A Summary Based on 434 Patients	PLOS ONE			English	Article							BREAST-CANCER; FERTILITY PRESERVATION; PREMENOPAUSAL WOMEN; FEMALE FERTILITY; AGONIST; PREVENTION; FAILURE; DAMAGE; TRIPTORELIN; ANALOG	Background: Gonadotropin-releasing hormone agonists (GnRHa) might play a role in preserving ovarian function in lymphoma patients by inhibiting chemotherapy-induced ovarian follicular damage. However, studies of its clinical efficacy have reported conflicting results. Method: We conducted a meta-analysis to determine the effect of the preservation of ovarian function by administering GnRHa in young patients with lymphoma undergoing chemotherapy. Seven studies were identified that met inclusion criteria and comprised 434 patients assigned to GnRHa combined chemotherapy or chemotherapy alone. Results: The incidence of women with premature ovarian failure (POF) demonstrated a statistically significant difference in favor of the use of GnRHa (OR=0.32, 95% CI 0.13-0.77). In addition, the final level of FSH in the GnRH group was significantly lower than control group. (MD= -11.73, 95% CI,-22.25- -1.20), and the final level of AMH in the GnRH group was significantly higher than control group (MD=0.80; 95% CI, 0.61-0.98). However, there was no statistically significant difference between treatment and the control groups in the incidence of a spontaneous pregnancy (OR=1.11; 95% CI, 0.55-2.26). Conclusion: This meta-analysis suggests that GnRHa may be effective in protecting ovarian function during chemotherapy in lymphoma patients. More well-designed prospective studies are needed to carry out for further understanding of this topic.	[Zhang, Yaoyao; Xiao, Zhun; Wang, Yan; Luo, Shan; Li, Xiaohong; Li, Shangwei] Sichuan Univ, West China Univ Hosp 2, Dept Obstet & Gynecol, Reprod Med Ctr, Chengdu 610064, Sichuan, Peoples R China	Sichuan University	Li, SW (corresponding author), Sichuan Univ, West China Univ Hosp 2, Dept Obstet & Gynecol, Reprod Med Ctr, Chengdu 610064, Sichuan, Peoples R China.	lswivf0@sina.com	Zhang, Yaoyao/GWD-0693-2022; zhang, yaoyao/AAV-9742-2021; wang, yan/AAZ-4988-2021		National Science Foundation of China [31171442]	National Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Science Foundation of China (31171442). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Badawy A, 2009, FERTIL STERIL, V91, P694, DOI 10.1016/j.fertnstert.2007.12.044; Bedaiwy MA, 2011, FERTIL STERIL, V95, P906, DOI 10.1016/j.fertnstert.2010.11.017; Blumenfeld Z, 2008, FERTIL STERIL, V89, P166, DOI 10.1016/j.fertnstert.2007.02.010; Castelo-Branco C, 2007, FERTIL STERIL, V87, P703, DOI 10.1016/j.fertnstert.2006.10.004; Chen HX, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008018.pub2; Decanter C, 2010, REPROD BIOMED ONLINE, V20, P280, DOI 10.1016/j.rbmo.2009.11.010; Del Mastro L, 2011, JAMA-J AM MED ASSOC, V306, P269, DOI 10.1001/jama.2011.991; Demeestere I, 2013, J CLIN ONCOL, V31, P903, DOI 10.1200/JCO.2012.42.8185; Edmonds DK, 1996, BRIT J OBSTET GYNAEC, V103, P10; Gerber B, 2011, J CLIN ONCOL, V29, P2334, DOI 10.1200/JCO.2010.32.5704; Huser M, 2008, HUM REPROD, V23, P863, DOI 10.1093/humrep/den005; Loverro G, 2007, HEMATOLOGY, V12, P141, DOI 10.1080/10245330600954072; Lunardi FO, 2013, ZYGOTE, V21, P394, DOI 10.1017/S0967199412000573; Maltaris T, 2007, EUR J OBSTET GYN R B, V130, P148, DOI 10.1016/j.ejogrb.2006.08.006; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Munster PN, 2012, J CLIN ONCOL, V30, P533, DOI 10.1200/JCO.2011.34.6890; Nitzschke M, 2010, ARCH GYNECOL OBSTET, V282, P83, DOI 10.1007/s00404-009-1308-5; Salama M, 2013, ANN ONCOL, V24, P598, DOI 10.1093/annonc/mds514; Seli E, 2005, CURR OPIN OBSTET GYN, V17, P299, DOI 10.1097/01.gco.0000169108.15623.34; Shelling AN, 2010, REPRODUCTION, V140, P633, DOI 10.1530/REP-09-0567; Stern CJ, 2006, AUST NZ J OBSTET GYN, V46, P15, DOI 10.1111/j.1479-828X.2006.00507.x; WAXMAN JH, 1987, CANCER CHEMOTH PHARM, V19, P159; Yang B, 2013, BREAST, V22, P150, DOI 10.1016/j.breast.2012.12.008	23	15	15	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2013	8	11							e80444	10.1371/journal.pone.0080444	http://dx.doi.org/10.1371/journal.pone.0080444			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261IJ	24312222	Green Submitted, Green Published, gold			2023-01-03	WOS:000327657900009
J	Xiao, WD; Feng, YJ; Holst, JJ; Hartmann, B; Yang, H; Teitelbaum, DH				Xiao, Weidong; Feng, Yongjia; Holst, Jens J.; Hartmann, Bolette; Yang, Hua; Teitelbaum, Daniel H.			Glutamate prevents intestinal atrophy via luminal nutrient sensing in a mouse model of total parenteral nutrition	FASEB JOURNAL			English	Article						proliferation; epithelial barrier function; taste receptor; metabotropic glutamate receptor	BITTER TASTE RECEPTORS; RAT SMALL-INTESTINE; GASTROINTESTINAL-TRACT; BARRIER FUNCTION; EPITHELIAL-CELLS; GROWTH-FACTOR; UMAMI TASTE; MONOSODIUM GLUTAMATE; POTENTIAL MECHANISM; MULTIPLE RECEPTORS	Small intestine luminal nutrient sensing may be crucial for modulating physiological functions. However, its mechanism of action is incompletely understood. We used a model of enteral nutrient deprivation, or total parenteral nutrition (TPN), resulting in intestinal mucosal atrophy and decreased epithelial barrier function (EBF). We examined how a single amino acid, glutamate (GLM), modulates intestinal epithelial cell (IEC) growth and EBF. Controls were chow-fed mice, T1 receptor-3 (T1R3)-knockout (KO) mice, and treatment with the metabotropic glutamate receptor (mGluR)-5 antagonist MTEP. TPN significantly changed the amount of T1Rs, GLM receptors, and transporters, and GLM prevented these changes. GLM significantly prevented TPN-associated intestinal atrophy (2.5-fold increase in IEC proliferation) and was dependent on up-regulation of the protein kinase pAkt, but independent of T1R3 and mGluR5 signaling. GLM led to a loss of EBF with TPN (60% increase in FITC-dextran permeability, 40% decline in transepithelial resistance); via T1R3, it protected EBF, whereas mGluR5 was associated with EBF loss. GLM led to a decline in circulating glucagon-like peptide 2 (GLP-2) during TPN. The decline was regulated by T1R3 and mGluR5, suggesting a novel negative regulator pathway for IEC proliferation not previously described. Loss of luminal nutrients with TPN administration may widely affect intestinal taste sensing. GLM has previously unrecognized actions on IEC growth and EBF. Restoring luminal sensing via GLM could be a strategy for patients on TPN.Xiao, W., Feng, Y., Holst, J. J., Hartmann, B., Yang, H., Teitelbaum, D. H. Glutamate prevents intestinal atrophy via luminal nutrient sensing in a mouse model of total parenteral nutrition.	[Xiao, Weidong; Feng, Yongjia; Teitelbaum, Daniel H.] Univ Michigan, Pediat Surg Sect, Dept Surg, Sch Med, Ann Arbor, MI 48109 USA; [Xiao, Weidong; Feng, Yongjia; Teitelbaum, Daniel H.] Univ Michigan, CS Mott Childrens Hosp, Ann Arbor, MI 48109 USA; [Xiao, Weidong; Yang, Hua] Third Mil Med Univ, Xinqiao Hosp, Dept Gen Surg, Chongqing, Peoples R China; [Holst, Jens J.; Hartmann, Bolette] Univ Copenhagen, Panum Inst, Dept Biomed Sci, DK-2200 Copenhagen, Denmark	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Army Medical University; University of Copenhagen	Teitelbaum, DH (corresponding author), Univ Michigan, Pediat Surg Sect, Mott Childrens Hosp F3970, Ann Arbor, MI 48109 USA.	dttlbm@umich.edu	Holst, Jens/AAA-8022-2022	Holst, Jens Juul/0000-0001-6853-3805; Hartmann, Bolette/0000-0001-8509-2036	Ajinomoto Co. Inc. (Tokyo, Japan); U.S. National Institutes of Health [2R01AI-44076-14]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044076] Funding Source: NIH RePORTER	Ajinomoto Co. Inc. (Tokyo, Japan); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank P. J. Browner and Drs. R. Sueyoshi, M. W. Ralls, and R. S. Herman for assistance with mouse care, sample collection, and the Ussing chamber experiment, and H. K. Yoon for technical assistance. This work was supported by Ajinomoto Co. Inc. (Tokyo, Japan) and U.S. National Institutes of Health grant 2R01AI-44076-14. The authors declare no conflicts of interest.	Agency for Healthcare Research and Quality, 2010, DAT PN EN US; Akiba Y, 2011, ACTA PHYSIOL, V201, P77, DOI 10.1111/j.1748-1716.2010.02149.x; Akiba Y, 2011, DIGESTION, V83, P25, DOI 10.1159/000323401; Akiba Y, 2009, AM J PHYSIOL-GASTR L, V297, pG781, DOI 10.1152/ajpgi.90605.2008; Akiba Y, 2009, AM J CLIN NUTR, V90, p826S, DOI 10.3945/ajcn.2009.27462U; Amagase K, 2012, J PHARMACOL SCI, V118, P131, DOI 10.1254/jphs.11R03FM; Bezencon C, 2007, CHEM SENSES, V32, P41, DOI 10.1093/chemse/bjl034; Chance WT, 2006, PEPTIDES, V27, P883, DOI 10.1016/j.peptides.2005.09.012; Conigrave AD, 2006, AM J PHYSIOL-GASTR L, V291, pG753, DOI 10.1152/ajpgi.00189.2006; Delay ER, 2006, CHEM SENSES, V31, P351, DOI 10.1093/chemse/bjj039; Dockray G J, 2003, J Physiol Pharmacol, V54 Suppl 4, P9; Feng YJ, 2012, ANN NY ACAD SCI, V1258, P71, DOI 10.1111/j.1749-6632.2012.06572.x; Feng YJ, 2010, AM J PHYSIOL-GASTR L, V298, pG833, DOI 10.1152/ajpgi.00030.2010; Feng YJ, 2009, J PHYSIOL-LONDON, V587, P641, DOI 10.1113/jphysiol.2008.162719; Finger Thomas E, 2011, F1000 Biol Rep, V3, P20, DOI 10.3410/B3-20; Grossmann J, 1998, AM J PATHOL, V153, P53, DOI 10.1016/S0002-9440(10)65545-9; Janssen S, 2011, P NATL ACAD SCI USA, V108, P2094, DOI 10.1073/pnas.1011508108; Kaji I, 2009, AM J PHYSIOL-GASTR L, V296, pG971, DOI 10.1152/ajpgi.90514.2008; Kinnamon SC, 2009, AM J CLIN NUTR, V90, p753S, DOI 10.3945/ajcn.2009.27462K; Kondoh T, 2009, AM J CLIN NUTR, V90, p832S, DOI 10.3945/ajcn.2009.27462V; Krug SM, 2009, MOL BIOL CELL, V20, P3713, DOI 10.1091/mbc.E09-01-0080; Kubera C, 2012, NEUROSCIENCE, V219, P271, DOI 10.1016/j.neuroscience.2012.05.064; Li XD, 2009, AM J CLIN NUTR, V90, p733S, DOI 10.3945/ajcn.2009.27462G; Liu XW, 2006, AM J CLIN NUTR, V84, P1142, DOI 10.1093/ajcn/84.5.1142; Mace OJ, 2007, J PHYSIOL-LONDON, V582, P379, DOI 10.1113/jphysiol.2007.130906; Mace OJ, 2009, J PHYSIOL-LONDON, V587, P195, DOI 10.1113/jphysiol.2008.159616; Mayer EA, 2011, NAT REV NEUROSCI, V12, P453, DOI 10.1038/nrn3071; Negri R, 2011, J PEDIATR GASTR NUTR, V53, P601, DOI 10.1097/MPG.0b013e3182309641; Nelson DW, 2008, AM J PHYSIOL-REG I, V294, pR1175, DOI 10.1152/ajpregu.00238.2007; Newsholme P, 2003, CELL BIOCHEM FUNCT, V21, P1, DOI 10.1002/cbf.1003; Nguyen CA, 2012, CURR MED CHEM, V19, P28; Niswender CM, 2010, ANNU REV PHARMACOL, V50, P295, DOI 10.1146/annurev.pharmtox.011008.145533; Nochi R, 2012, EUR J NEUROSCI, V36, P2273, DOI 10.1111/j.1460-9568.2012.08128.x; Nose K, 2010, J INTERF CYTOK RES, V30, P67, DOI 10.1089/jir.2009.0046; Reeds PJ, 2000, J NUTR, V130, p978S, DOI 10.1093/jn/130.4.978S; Rozengurt E, 2006, AM J PHYSIOL-GASTR L, V291, pG171, DOI 10.1152/ajpgi.00073.2006; Schunemann DP, 2010, PATHOL ONCOL RES, V16, P285, DOI 10.1007/s12253-009-9223-4; Sharp CD, 2003, AM J PHYSIOL-HEART C, V285, pH2592, DOI 10.1152/ajpheart.00520.2003; Sheng H, 2003, GUT, V52, P1472, DOI 10.1136/gut.52.10.1472; Shin YJ, 2010, NEUROCHEM RES, V35, P1628, DOI 10.1007/s11064-010-0223-2; Sternini C, 2007, AM J PHYSIOL-GASTR L, V292, pG457, DOI 10.1152/ajpgi.00411.2006; Sun XY, 2008, AM J PHYSIOL-GASTR L, V294, pG139, DOI 10.1152/ajpgi.00386.2007; Sun XY, 2006, JPEN-PARENTER ENTER, V30, P474, DOI 10.1177/0148607106030006474; Swartz TD, 2012, BRIT J NUTR, V107, P621, DOI 10.1017/S0007114511003412; Vermeulen MAR, 2011, WORLD J GASTROENTERO, V17, P1569, DOI 10.3748/wjg.v17.i12.1569; Wang JH, 2011, J PHARMACOL EXP THER, V339, P464, DOI 10.1124/jpet.111.184788; Wauson EM, 2012, MOL CELL, V47, P851, DOI 10.1016/j.molcel.2012.08.001; Wildhaber BE, 2005, J SURG RES, V123, P8, DOI 10.1016/j.jss.2004.06.015; Wildhaber BE, 2002, PEDIATR SURG INT, V18, P570, DOI 10.1007/s00383-002-0869-1; Wildhaber BE, 2003, J SURG RES, V112, P144, DOI 10.1016/S0022-4804(03)00160-4; Yang H, 2003, AM J PHYSIOL-GASTR L, V284, pG629, DOI 10.1152/ajpgi.00290.2002; Yang H, 2008, ANN SURG, V248, P849, DOI 10.1097/SLA.0b013e31818a1522; Yang H, 2009, ANN NY ACAD SCI, V1165, P338, DOI 10.1111/j.1749-6632.2009.04026.x; Yasumatsu K, 2012, J PHYSIOL-LONDON, V590, P1155, DOI 10.1113/jphysiol.2011.211920; Yasumatsu K, 2009, AM J CLIN NUTR, V90, p747S, DOI 10.3945/ajcn.2009.27462J; Young RL, 2009, GUT, V58, P337, DOI 10.1136/gut.2008.148932; Zhang CJ, 2009, J NUTR, V139, P1315, DOI 10.3945/jn.108.096669; Zhang J, 2013, AMINO ACIDS, V45, P1169, DOI 10.1007/s00726-013-1573-2; Zhao GQ, 2003, CELL, V115, P255, DOI 10.1016/S0092-8674(03)00844-4; Zhao L, 2011, NEUROSCIENCE, V192, P185, DOI 10.1016/j.neuroscience.2011.06.044; Znalesniak EB, 2010, CELL PHYSIOL BIOCHEM, V25, P533, DOI 10.1159/000303057	61	31	35	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2073	2087		10.1096/fj.13-238311	http://dx.doi.org/10.1096/fj.13-238311			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24497581	Green Published, Green Submitted			2023-01-03	WOS:000335336000012
J	Means, AR; Weaver, MR; Burnett, SM; Mbonye, MK; Naikoba, S; McClelland, RS				Means, Arianna Rubin; Weaver, Marcia R.; Burnett, Sarah M.; Mbonye, Martin K.; Naikoba, Sarah; McClelland, R. Scott			Correlates of Inappropriate Prescribing of Antibiotics to Patients with Malaria in Uganda	PLOS ONE			English	Article							INTEGRATED MANAGEMENT; CHILDHOOD ILLNESS; FEBRILE ILLNESS; CHILDREN; BACTEREMIA; FACILITIES; QUALITY; PRESCRIPTION; PREVALENCE; PNEUMONIA	Background: In many rural areas of Uganda, febrile patients presenting to health facilities are prescribed both antimalarials and antibiotics, contributing to the overuse of antibiotics. We identified the prevalence and correlates of inappropriate antibiotic management of patients with confirmed malaria. Methods: We utilized individual outpatient data from 36 health centers from January to September 2011. We identified patients who were prescribed antibiotics without an appropriate clinical indication, as well as patients who were not prescribed antibiotics when treatment was clinically indicated. Multivariate logistic regression models were used to identify clinical and operational factors associated with inappropriate case management. Findings: Of the 45,591 patients with parasitological diagnosis of malaria, 40,870 (90%) did not have a clinical indication for antibiotic treatment. Within this group, 17,152 (42%) were inappropriately prescribed antibiotics. The odds of inappropriate prescribing were higher if the patient was less than five years old (aOR 1.96, 95% CI 1.75-2.19) and if the health provider had the fewest years of training (aOR 1.86, 95% CI 1.05-3.29). The odds of inappropriate prescribing were lower if patients had emergency triage status (aOR 0.75, 95% CI 0.59-0.96) or were HIV positive (aOR 0.31, 95% CI 0.20-0.45). Of the 4,721 (10%) patients with clinical indications for antibiotic treatment, 521 (11%) were inappropriately not prescribed antibiotics. Clinical officers were less likely than medical officers to inappropriately withhold antibiotics (aOR 0.54, 95% CI 0.29-0.98). Conclusion: Over 40% of the antibiotic treatment in malaria positive patients is prescribed despite a lack of documented clinical indication. In addition, over 10% of patients with malaria and a clinical indication for antibiotics do not receive them. These findings should inform facility-level trainings and interventions to optimize patient care and slow trends of rising antibiotic resistance.	[Means, Arianna Rubin; Weaver, Marcia R.; McClelland, R. Scott] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Means, Arianna Rubin; McClelland, R. Scott] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Burnett, Sarah M.] Accordia Global Hlth Fdn, Washington, DC USA; [Mbonye, Martin K.; Naikoba, Sarah] Makerere Coll Hlth Sci, Infect Dis Inst, Kampala, Uganda; [Burnett, Sarah M.; Mbonye, Martin K.; Naikoba, Sarah] Univ Antwerp, Dept Epidemiol & Social Med, B-2020 Antwerp, Belgium; [McClelland, R. Scott] Univ Washington, Dept Med, Seattle, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Antwerp; University of Washington; University of Washington Seattle	Means, AR (corresponding author), Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.	aerubin@u.washington.edu			Bill & Melinda Gates Foundation [94298]	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR)	This work was supported through grant number 94298 to Accordia Global Health Foundation from the Bill & Melinda Gates Foundation. The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation. The funder did not have any role in study design; data collection, analysis or interpretation; paper writing; or the decision to submit the paper for publication.	[Anonymous], 2003, IMPR DAT QUAL GUID D; Arifeen SE, 2009, LANCET, V374, P393, DOI 10.1016/S0140-6736(09)60828-X; Bassat Q, 2011, AM J TROP MED HYG, V85, P626, DOI 10.4269/ajtmh.2011.11-0223; Batwala V, 2011, MALARIA J, V10, DOI [10.1186/1475-2875-10-377, 10.1186/1475-2875-10-373]; Berkley J, 1999, T ROY SOC TROP MED H, V93, P283, DOI 10.1016/S0035-9203(99)90024-X; Berkley JA, 2009, CLIN INFECT DIS, V49, P336, DOI 10.1086/600299; Bronzan RN, 2007, J INFECT DIS, V195, P895, DOI 10.1086/511437; Bryce J, 2005, HEALTH POLICY PLANN, V20, pI5, DOI 10.1093/heapol/czi055; El Arifeen S, 2004, LANCET, V364, P1595, DOI 10.1016/S0140-6736(04)17312-1; Franco Beatriz Espinosa, 2009, Infect Drug Resist, V2, P1; Gouws E, 2004, B WORLD HEALTH ORGAN, V82, P509; Gwimile JJ, 2012, PAN AFR MED J, V12; Holloway KA, 2013, TROP MED INT HEALTH, V18, P656, DOI 10.1111/tmi.12123; Kajungu DK, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-311; Kallander K, 2004, ACTA TROP, V90, P211, DOI 10.1016/j.actatropica.2003.11.013; Koura KG, 2013, ACTA TROP, V127, P87, DOI 10.1016/j.actatropica.2013.04.004; Mbonye MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084945; Miceli A, 2012, INT J INFECT DIS, V16, pE708, DOI 10.1016/j.ijid.2012.07.003; MOH, 2010, NAT GUID MAN COMM CO; Opondo C, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-109; Pariyo GW, 2005, HEALTH POLICY PLANN, V20, pI58, DOI 10.1093/heapol/czi051; Peabody JW, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P1293; PMI, 2011, MAL OP PLAN FY 2012; Radyowijati A, 2003, SOC SCI MED, V57, P733, DOI 10.1016/S0277-9536(02)00422-7; Rubin D.B., 2004, MULTIPLE IMPUTATION, V81; Schellenberg JA, 2004, HEALTH POLICY PLANN, V19, P1, DOI 10.1093/heapol/czh001; Scott JAG, 2011, LANCET, V378, P1316, DOI 10.1016/S0140-6736(11)60888-X; Steinman MA, 2003, JAMA-J AM MED ASSOC, V289, P719, DOI 10.1001/jama.289.6.719; WHO, 2011, IMAI DISTR CLIN MAN; WHO, 2001, IMCI MULT EV MAIN FI; WHO, 2005, INT MAN CHILDH ILLN; WHO, 2010, RAT US MED; World Health Organization, 2010, MARK FOOD NONALC BEV; Yeka A, 2005, PLOS MED, V2, P654, DOI 10.1371/journal.pmed.0020190; Zurovac D, 2006, ANN TROP MED PARASIT, V100, P283, DOI 10.1179/136485906X105633	35	16	17	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2014	9	2							e90179	10.1371/journal.pone.0090179	http://dx.doi.org/10.1371/journal.pone.0090179			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC3DW	24587264	Green Published, gold, Green Submitted			2023-01-03	WOS:000332396200144
J	Lorgunpai, SJ; Grammas, M; Lee, DSH; McAvay, G; Charpentier, P; Tinetti, ME				Lorgunpai, Songprod Jonathan; Grammas, Marianthe; Lee, David S. H.; McAvay, Gail; Charpentier, Peter; Tinetti, Mary E.			Potential Therapeutic Competition in Community-Living Older Adults in the US: Use of Medications That May Adversely Affect a Coexisting Condition	PLOS ONE			English	Article							BENIGN PROSTATIC HYPERPLASIA; CLINICAL-PRACTICE GUIDELINES; MULTIPLE CHRONIC CONDITIONS; ASSOCIATION TASK-FORCE; BONE-MINERAL DENSITY; HEART-FAILURE; MYOCARDIAL-INFARCTION; ELDERLY-PATIENTS; CHOLINESTERASE-INHIBITORS; FOCUSED UPDATE	Objective: The 75% of older adults with multiple chronic conditions are at risk of therapeutic competition (i.e. treatment for one condition may adversely affect a coexisting condition). The objective was to determine the prevalence of potential therapeutic competition in community-living older adults. Methods: Cross-sectional descriptive study of a representative sample of 5,815 community-living adults 65 and older in the U. S, enrolled 2007-2009. The 14 most common chronic conditions treated with at least one medication were ascertained from Medicare claims. Medication classes recommended in national disease guidelines for these conditions and used by >= 2% of participants were identified from in-person interviews conducted 2008-2010. Criteria for potential therapeutic competition included: 1), well-acknowledged adverse medication effect; 2) mention in disease guidelines; or 3) report in a systematic review or two studies published since 2000. Outcomes included prevalence of situations of potential therapeutic competition and frequency of use of the medication in individuals with and without the competing condition. Results: Of 27 medication classes, 15 (55.5%) recommended for one study condition may adversely affect other study conditions. Among 91 possible pairs of study chronic conditions, 25 (27.5%) have at least one potential therapeutic competition. Among participants, 1,313 (22.6%) received at least one medication that may worsen a coexisting condition; 753 (13%) had multiple pairs of such competing conditions. For example, among 846 participants with hypertension and COPD, 16.2% used a nonselective beta-blocker. In only 6 of 37 cases (16.2%) of potential therapeutic competition were those with the competing condition less likely to receive the medication than those without the competing condition. Conclusions: One fifth of older Americans receive medications that may adversely affect coexisting conditions. Determining clinical outcomes in these situations is a research and clinical priority. Effects on coexisting conditions should be considered when prescribing medications.	[Lorgunpai, Songprod Jonathan] Yale Univ, Sch Med, New Haven, CT USA; [Grammas, Marianthe; McAvay, Gail; Charpentier, Peter; Tinetti, Mary E.] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; [Lee, David S. H.] Oregon Hlth & Sci Univ, Oregon State Univ, Coll Pharm, Portland, OR 97201 USA; [Tinetti, Mary E.] Sch Epidemiol & Publ Hlth, New Haven, CT USA	Yale University; Yale University; Oregon Health & Science University; Oregon State University	Tinetti, ME (corresponding author), Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA.	mary.tinetti@yale.edu			Yale Pepper Center [P30AG021342];  [5R03AG035146]; NATIONAL INSTITUTE ON AGING [P30AG021342, R03AG035146] Funding Source: NIH RePORTER	Yale Pepper Center; ; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	5R03AG035146, Yale Pepper Center (P30AG021342). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American College of Rheumatology Subcommittee on Osteoarthritis Guidelines, 2011, REC MED MAN OST HIP; American Thoracic Society/European Respiratory Society Task Force, 2004, STAND DIAGN MAN PAT; American Urological Association, 2010, PHARM MAN PREM EJ; Anderson G, 2010, CHRONIC CARE MAKING; Au DH, 2002, CHEST, V121, P846, DOI 10.1378/chest.121.3.846; Au DH, 2000, AM J RESP CRIT CARE, V161, P827, DOI 10.1164/ajrccm.161.3.9904006; Aubert RE, 2010, DIABETES OBES METAB, V12, P716, DOI 10.1111/j.1463-1326.2010.01225.x; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Bennett WL, 2012, ANN INTERN MED, V156, P27, DOI 10.7326/0003-4819-156-1-201201030-00005; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Brooks TWA, 2007, PHARMACOTHERAPY, V27, P684, DOI 10.1592/phco.27.5.684; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Chrischilles E, 2001, CLIN THER, V23, P727, DOI 10.1016/S0149-2918(01)80022-9; Cohen HW, 2000, AM J MED, V108, P2, DOI 10.1016/S0002-9343(99)00301-0; Degner D, 2004, PHARMACOPSYCHIATRY, V37, pS39, DOI 10.1055/s-2004-815509; deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403; Dungen HD, 2011, EUR J HEART FAIL, V13, P670, DOI 10.1093/eurjhf/hfr020; Ettinger B., 1998, J MANAGE CARE PHARM, V4, P488, DOI [10.18553/jmcp.1998.4.5.488, DOI 10.18553/jmcp.1998.4.5.488]; Eurich DT, 2007, BMJ-BRIT MED J, V335, P497, DOI 10.1136/bmj.39314.620174.80; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; Fortin M, 2004, HEALTH QUAL LIFE OUT, V2, P51, DOI [10.1186/1477-7525-2-51, DOI 10.1186/1477-7525-2-51]; Galatius S, 2004, CARDIOLOGY, V102, P160, DOI 10.1159/000080485; Garber JR, 2012, THYROID, V22, P1200, DOI 10.1089/thy.2012.0205; Gill SS, 2009, ARCH INTERN MED, V169, P867, DOI 10.1001/archinternmed.2009.43; GRADE Working Group, 2010, GRAD QUAL EV STRENGT; Graham DJ, 2006, JAMA-J AM MED ASSOC, V296, P1653, DOI 10.1001/jama.296.13.jed60058; Gray SL, 2010, ARCH INTERN MED, V170, P765, DOI 10.1001/archinternmed.2010.94; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Guthrie B, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6341; Hallas J, 2006, BMJ-BRIT MED J, V333, P726, DOI 10.1136/bmj.38947.697558.AE; Hawkins NM, 2011, J AM COLL CARDIOL, V57, P2127, DOI 10.1016/j.jacc.2011.02.020; Healthcare Cost and Utilization Project (HCUP), 2012, CLIN CLASS SYST; Hernandez RK, 2009, J AM GERIATR SOC, V57, P1997, DOI 10.1111/j.1532-5415.2009.02488.x; Hodgkinson JA, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X578034; Hsu PI, 2011, GASTROENTEROLOGY, V140, P791, DOI 10.1053/j.gastro.2010.11.056; Hunt SA, 2009, J AM COLL CARDIOL, V53, pE1, DOI 10.1016/j.jacc.2008.11.013; Ickowicz E, 2012, J AM GERIATR SOC, V60, pE1, DOI 10.1111/j.1532-5415.2012.04188.x; Johnell K, 2012, DRUG AGING, V29, P751, DOI 10.1007/s40266-012-0002-7; Johnson EM, 2006, AM J GERIAT PSYCHIAT, V14, P796, DOI 10.1097/01.JGP.0000204328.50105.b3; Jyrkka J, 2006, EUR J CLIN PHARMACOL, V62, P151, DOI 10.1007/s00228-005-0079-6; Kenneth RD, 2005, AM J GASTROENTEROL, V100, P190, DOI DOI 10.1111/j.1572-0241.2005.41217.x; Kirby RS, 2003, UROLOGY, V61, P119, DOI 10.1016/S0090-4295(02)02114-3; Klabunde CN, 2006, MED CARE, V44, P921, DOI 10.1097/01.mlr.0000223480.52713.b9; Lau YT, 2012, PHARMACOTHERAPY, V32, P67, DOI 10.1002/PHAR.1007; Lentine KL, 2009, CLIN J AM SOC NEPHRO, V4, P1213, DOI 10.2215/CJN.00670109; Lo A, 2002, P SURV RES SECT AM S, P2139; Loke YK, 2009, DRUG SAFETY, V32, P219, DOI 10.2165/00002018-200932030-00004; Marengoni A, 2011, AGEING RES REV, V10, P430, DOI 10.1016/j.arr.2011.03.003; Marengoni A, 2009, J AM GERIATR SOC, V57, P225, DOI 10.1111/j.1532-5415.2008.02109.x; Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337/dc08-9025; National Osteoporosis Foundation, 2010, CLIN GUID PREV TREAT; National Quality Forum, 2014, MULT CHRON COND MCC; Nissen SE, 2008, JAMA-J AM MED ASSOC, V299, P1561, DOI 10.1001/jama.299.13.1561; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761; Noyes K, 2011, PSYCHIAT SERV, V62, P1159, DOI 10.1176/ps.62.10.pss6210_1159; Padala KP, 2012, AM J GERIATR PHARMAC, V10, P296, DOI 10.1016/j.amjopharm.2012.08.002; Pantalone KM, 2012, DIABETES OBES METAB, V14, P803, DOI 10.1111/j.1463-1326.2012.01604.x; Park-Wyllie LY, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000157; Penning-van Beest FJA, 2006, CLIN THER, V28, P236, DOI 10.1016/j.clinthera.2006.01.002; Ray WA, 2009, CIRC-CARDIOVASC QUAL, V2, P155, DOI 10.1161/CIRCOUTCOMES.108.805689; Smith SC, 2011, CIRCULATION, V124, P2458, DOI 10.1161/CIR.0b013e318235eb4d; Solomon DH, 2004, HYPERTENSION, V44, P140, DOI 10.1161/01.HYP.0000136134.31846.83; Sowers JR, 2005, ARCH INTERN MED, V165, P161, DOI 10.1001/archinte.165.2.161; Tinetti ME, 2011, J AM GERIATR SOC, V59, P1686, DOI 10.1111/j.1532-5415.2011.03573.x; Tinetti ME, 2004, NEW ENGL J MED, V351, P2870, DOI 10.1056/NEJMsb042458; Wang CH, 2003, CIRCULATION, V107, P1350, DOI 10.1161/01.CIR.0000054675.30348.9A; Wann LS, 2011, J AM COLL CARDIOL, V57, P223, DOI 10.1016/j.jacc.2010.10.001; Winkelmayer WC, 2008, ARCH INTERN MED, V168, P2368, DOI 10.1001/archinte.168.21.2368; Wolff JL, 2002, ARCH INTERN MED, V162, P2269, DOI 10.1001/archinte.162.20.2269; Work Group on Alzheimer's Disease and Other Dementias, 2011, PRACT GUID TREATM PA; Work Group on Major Depressive Disorder, 2011, PRACT GUID TREATM PA; World Health Organization, 2012, AN THER CHEM CLASS S; Yang JC, 2001, J GEN INTERN MED, V16, P112; Yang YX, 2006, JAMA-J AM MED ASSOC, V296, P2947, DOI 10.1001/jama.296.24.2947	75	57	58	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2014	9	2							e89447	10.1371/journal.pone.0089447	http://dx.doi.org/10.1371/journal.pone.0089447			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AC2ZX	24586786	Green Submitted, Green Published, gold			2023-01-03	WOS:000332385900046
J	Maeyama, J; Takatsuka, H; Suzuki, F; Kubota, A; Horiguchi, S; Komiya, T; Shimada, I; Murata, E; Osawa, Y; Kitagawa, H; Matsuki, T; Isaka, M; Yamamoto, S; Iho, S				Maeyama, Jun-ichi; Takatsuka, Hisakazu; Suzuki, Fumiko; Kubota, Ayumi; Horiguchi, Satomi; Komiya, Takako; Shimada, Ichiroh; Murata, Eri; Osawa, Youko; Kitagawa, Harukazu; Matsuki, Takasumi; Isaka, Masanori; Yamamoto, Saburo; Iho, Sumiko			A Palindromic CpG-Containing Phosphodiester Oligodeoxynucleotide as a Mucosal Adjuvant Stimulates Plasmacytoid Dendritic Cell-Mediated T(H)1 Immunity	PLOS ONE			English	Article							INDUCED IFN-ALPHA; CUTTING EDGE; P38 MAPK; DNA; OLIGONUCLEOTIDES; RESPONSES; TOXIN; INDUCTION; SEQUENCES; VACCINES	Background: CpG oligodeoxynucleotides (ODNs), resembling bacterial DNA, are currently tested in clinical trials as vaccine adjuvants. They have the nuclease-resistant phosphorothioate bond; the immune responses elicited differ according to the CpG ODN sequence and vaccination method. To develop a CpG ODN that can induce plasmacytoid dendritic cell (pDC)mediated T(H)1 immunity through the mucosa, we constructed phosphodiester G9.1 comprising one palindromic CpG motif with unique polyguanosine-runs that allows degradation similar to naturally occurring bacterial DNA. Methods: T(H)1 and T(H)2 immunity activation was evaluated by cytokine production pattern and T-bet/GATA-3 ratio in human peripheral blood mononuclear cells and mouse bone marrow cells. Adjuvanticity was evaluated in mice administered G9.1 with diphtheria toxoid (DT) through nasal vaccination. Results: G9.1 exhibited stronger IFN-alpha-inducing activity than A-class CpG ODN2216 and increased T-bet/GATA-3 ratio by enhancing T-bet expression. Nasally administered G9.1 plus DT induced DT-specific mucosal IgA and serum IgG, but not IgE, responses with antitoxin activity in C57BL/6 and BALB/c mice, possibly due to IFN/BAFF production. Induction of T(H)1, but not T(H)2, -type Abs depended completely on pDCs, the first in vivo demonstration by CpG ODNs. Conclusions: G9.1 is a promising mucosal adjuvant for induction of pDC-mediated T(H)1 immunity.	[Maeyama, Jun-ichi] Natl Inst Infect Dis, Dept Safety Res Blood & Biol Prod, Musashimurayama, Tokyo, Japan; [Takatsuka, Hisakazu] Niigata Univ, Grad Sch Med & Dent Sci, Div Legal Med, Niigata, Japan; [Suzuki, Fumiko] Univ Fukui, Dept Ophthalmol, Fac Med Sci, Fukui, Japan; [Kubota, Ayumi; Iho, Sumiko] Univ Fukui, Dept Anat & Neurosci, Fac Med Sci, Fukui, Japan; [Horiguchi, Satomi] Natl Inst Infect Dis, Dept Bacterial Pathogenesis & Infect, Musashimurayama, Tokyo, Japan; [Shimada, Ichiroh; Murata, Eri; Osawa, Youko; Matsuki, Takasumi] Univ Fukui, Fac Med Sci, Fukui, Japan; [Shimada, Ichiroh; Matsuki, Takasumi; Iho, Sumiko] Univ Fukui, Res & Educ Program Life Sci & Translat Res Progra, Fukui 910, Japan; [Kitagawa, Harukazu] Emori & Co Ltd, Adm Control Off, Chem Subst Management, Fukui, Japan; [Isaka, Masanori] Nagoya City Univ, Sch Med, Dept Microbiol, Nagoya, Aichi 467, Japan; [Yamamoto, Saburo] Japan BCG Lab, Cent Lab, Kiyose, Tokyo, Japan	National Institute of Infectious Diseases (NIID); Niigata University; University of Fukui; University of Fukui; National Institute of Infectious Diseases (NIID); University of Fukui; University of Fukui; Nagoya City University	Iho, S (corresponding author), Univ Fukui, Fac Med Sci, Host Def Lab, Fukui, Japan.	ihosumik@u-fukui.ac.jp			Japan Society for the Promotion of Science [22591105, 19591962]; Japan Science and Technology Agency [AS231Z03382G, AS2314067G, AS2121188G, 09-08, 06-057]; Japan Health Sciences Foundation [KHC1021, SH54411]; Smoking Research Foundation; Fukui University	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan Science and Technology Agency(Japan Science & Technology Agency (JST)); Japan Health Sciences Foundation; Smoking Research Foundation; Fukui University	This work was supported in part by a Grant-in-Aid for Scientific Research [22591105 to SI, JIM, 19591962 to SI] from the Japan Society for the Promotion of Science; A-STEP [AS231Z03382G to SI, AS2314067G and AS2121188G to SY, SI, 09-08 and 06-057 to SI] from the Japan Science and Technology Agency; a grant for Research on Publicly Essential Drugs and Medical Devices [KHC1021 to JIM, MI, SY, SI, SH54411 to SY, SI] from The Japan Health Sciences Foundation; and Smoking Research Foundation [to SI, JIM]; and Fukui University [SI]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal T, 2009, CLIN MICROBIOL INFEC, V15, P50, DOI 10.1111/j.1469-0691.2008.02113.x; Baban B, 2011, J IMMUNOL, V187, P2329, DOI 10.4049/jimmunol.1100276; Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/ERV.10.174, 10.1586/erv.10.174]; Cerutti A, 2008, NAT REV IMMUNOL, V8, P421, DOI 10.1038/nri2322; Cooper CL, 2004, VACCINE, V22, P3136, DOI 10.1016/j.vaccine.2004.01.058; de Vries IJM, 2011, MOL IMMUNOL, V48, P810, DOI 10.1016/j.molimm.2010.12.022; Faquim-Mauro EL, 1999, J IMMUNOL, V163, P3572; Gonzalez-Navajas JM, 2012, NAT REV IMMUNOL, V12, P125, DOI 10.1038/nri3133; Hartmann E, 2006, CLIN VACCINE IMMUNOL, V13, P1278, DOI 10.1128/CVI.00172-06; Heikenwalder M, 2004, NAT MED, V10, P187, DOI 10.1038/nm987; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; Isaka M, 1999, VACCINE, V18, P743, DOI 10.1016/S0264-410X(99)00258-3; Kaetzel Charlotte S., 2007, P43, DOI 10.1007/978-0-387-72232-0_3; Kerkmann M, 2003, J IMMUNOL, V170, P4465, DOI 10.4049/jimmunol.170.9.4465; Klinman DM, 2009, ADV DRUG DELIVER REV, V61, P248, DOI 10.1016/j.addr.2008.12.012; Koyama S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000759; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059; KURAMOTO E, 1992, JPN J CANCER RES, V83, P1128, DOI 10.1111/j.1349-7006.1992.tb02734.x; Le Bon A, 2001, IMMUNITY, V14, P461, DOI 10.1016/S1074-7613(01)00126-1; Maeyama J, 2009, VACCINE, V27, P1166, DOI 10.1016/j.vaccine.2008.12.025; McCluskie MJ, 1998, J IMMUNOL, V161, P4463; MCGHEE JR, 1992, VACCINE, V10, P75, DOI 10.1016/0264-410X(92)90021-B; Mellor AL, 2005, J IMMUNOL, V175, P5601, DOI 10.4049/jimmunol.175.9.5601; MIYAMURA K, 1974, J BIOL STAND, V2, P189, DOI 10.1016/0092-1157(74)90015-8; Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777; Osawa Y, 2006, J IMMUNOL, V177, P4841, DOI 10.4049/jimmunol.177.7.4841; Pesce I, 2010, J INNATE IMMUN, V2, P144, DOI 10.1159/000254948; Sagara I, 2009, VACCINE, V27, P7292, DOI 10.1016/j.vaccine.2009.10.087; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; Stavnezer J, 2009, J IMMUNOL, V182, P5, DOI 10.4049/jimmunol.182.1.5; Sugai T, 2005, VACCINE, V23, P5450, DOI 10.1016/j.vaccine.2004.09.041; Swanson CL, 2010, J EXP MED, V207, P1485, DOI 10.1084/jem.20092695; Takauji R, 2002, J LEUKOCYTE BIOL, V72, P1011; Tezuka H, 2011, IMMUNITY, V34, P247, DOI 10.1016/j.immuni.2011.02.002; Vollmer J, 2009, ADV DRUG DELIVER REV, V61, P195, DOI 10.1016/j.addr.2008.12.008; Wingender G, 2006, EUR J IMMUNOL, V36, P12, DOI 10.1002/eji.200535602; Xin LJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034062; Yamamoto S, 1997, P NATL ACAD SCI USA, V94, P5267, DOI 10.1073/pnas.94.10.5267; YAMAMOTO S, 1992, J IMMUNOL, V148, P4072; YAMAMOTO T, 1994, ANTISENSE RES DEV, V4, P119, DOI 10.1089/ard.1994.4.119	41	13	18	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2014	9	2							e88846	10.1371/journal.pone.0088846	http://dx.doi.org/10.1371/journal.pone.0088846			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AB6EP	24586411	Green Published, gold, Green Submitted			2023-01-03	WOS:000331880700010
J	Mechanic, R				Mechanic, Robert			Post-Acute Care - The Next Frontier for Controlling Medicare Spending	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							COST		Brandeis Univ, Heller Sch Social Policy & Management, Waltham, MA 02454 USA	Brandeis University	Mechanic, R (corresponding author), Brandeis Univ, Heller Sch Social Policy & Management, Waltham, MA 02454 USA.							Chandra A, 2013, HEALTH AFFAIR, V32, P864, DOI 10.1377/hlthaff.2012.1262; Gage B., 2011, POSTACUTE CARE EPISO; Kramer A, 2011, COMMUNITY DISCHARGE; Newhouse JP, 2013, NEW ENGL J MED, V368, P1465, DOI 10.1056/NEJMp1302981; Taheri PA, 2000, J AM COLL SURGEONS, V191, P123, DOI 10.1016/S1072-7515(00)00352-5	5	177	177	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 20	2014	370	8					692	694		10.1056/NEJMp1315607	http://dx.doi.org/10.1056/NEJMp1315607			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AB1DO	24552315				2023-01-03	WOS:000331531900003
J	Reuben, DB; Tinetti, ME				Reuben, David B.; Tinetti, Mary E.			The Hospital-Dependent Patient	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Reuben, David B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA; [Tinetti, Mary E.] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; [Tinetti, Mary E.] Yale Univ, Sch Epidemiol & Publ Hlth, New Haven, CT USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Yale University; Yale University	Reuben, DB (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA.							Carson SS, 2012, RESP CARE, V57, P848, DOI 10.4187/respcare.01736; Jencks SF, 2011, NEW ENGL J MED, V364, P1582; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Mor V, 2010, HEALTH AFFAIR, V29, P57, DOI 10.1377/hlthaff.2009.0629; Robert Wood Johnson Foundation, 2013, REV DOOR REP US HOSP; Shepperd S, 2005, COCHRANE DB SYST REV, V3, DOI DOI 10.1056/NEJMP1315568	6	30	30	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 20	2014	370	8					694	697		10.1056/NEJMp1315568	http://dx.doi.org/10.1056/NEJMp1315568			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AB1DO	24552316	Green Published			2023-01-03	WOS:000331531900004
J	Wang, HQ; Wu, YH; Fu, R; Qu, W; Ruan, EB; Wang, GJ; Liu, H; Song, J; Xing, LM; Guan, J; Li, LJ; Liu, CY; Shao, ZH				Wang, Huaquan; Wu, Yuhong; Fu, Rong; Qu, Wen; Ruan, Erbao; Wang, Guojin; Liu, Hong; Song, Jia; Xing, Limin; Guan, Jing; Li, Lijuan; Liu, Chunyan; Shao, Zonghong			Granulocyte Transfusion Combined with Granulocyte Colony Stimulating Factor in Severe Infection Patients with Severe Aplastic Anemia: A Single Center Experience from China	PLOS ONE			English	Article							ANTITHYMOCYTE GLOBULIN; IMMUNOSUPPRESSIVE THERAPY; MARROW-TRANSPLANTATION; NEUTROPENIC PATIENTS; FOLLOW-UP; CYCLOSPORINE; CANCER	Objective: To investigate the efficacy and safety of granulocyte transfusion combined with granulocyte colony stimulating factor (G-CSF) in severe infection patients with severe aplastic anemia (SAA). Methods: Fifty-six patients in severe infections with SAA who had received granulocyte transfusions combined with G-CSF from 2006 to 2012 in our department were analyzed. A retrospective analysis was undertaken to investigate the survival rates (at 30 days, 90 days and 180 days), the responses to treatment (at 7 days and 30 days, including microbiological, radiographic and clinical responses), the neutrophil count and adverse events after transfusion. Results: All SAA patients with severe infections were treated with granulocyte transfusions combined with G-CSF. Forty-seven patients had received antithymocyte globulin/antilymphocyte globulin and cyclosporine A as immunosuppressive therapy. The median number of granulocyte components transfused was 18 (range, 3-75). The survival at 30 days, 90 days and 180 days were 50(89%), 39(70%) and 37(66%) respectively. Among 31 patients who had invasive fungal infections, the survival at 30 days, 90 days and 180 days were 27(87%), 18(58%) and 16(52%) respectively. Among the 25 patients who had refractory severe bacterial infections, the survival at 30 days, 90 days and 180 days were 23(92%), 21(84%) and 21(84%) respectively. Survival rate was correlated with hematopoietic recovery. Responses of patients at 7 and 30 days were correlated with survival rate. Common adverse effects of granulocyte transfusion included mild to moderate fever, chills, allergy and dyspnea. Conclusion: Granulocyte transfusions combined with G-CSF could be an adjunctive therapy for treating severe infections of patients with SAA.	[Wang, Huaquan; Wu, Yuhong; Fu, Rong; Qu, Wen; Ruan, Erbao; Wang, Guojin; Liu, Hong; Song, Jia; Xing, Limin; Guan, Jing; Li, Lijuan; Liu, Chunyan; Shao, Zonghong] Tianjin Med Univ, Gen Hosp, Dept Hematol, Tianjin, Peoples R China	Tianjin Medical University	Shao, ZH (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Hematol, Tianjin, Peoples R China.	shaozonghong@sina.com	li, li/GPX-3938-2022; Li, Li/AEM-3636-2022; Wang, Huaquan/AAN-6917-2021; LI, LI/GVS-5344-2022; li, li/HII-4157-2022; LI, LI QING/GRR-8855-2022; li, li/AAT-2097-2020		Natural Science Foundation of China [30971286, 30971285, 81170472]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This project is partly supported by Natural Science Foundation of China (No. 30971286, 30971285, 81170472) http://isisn.nsfc.gov.cn/egrantweb/. No additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BACIGALUPO A, 1988, BRIT J HAEMATOL, V70, P177, DOI 10.1111/j.1365-2141.1988.tb02460.x; Bacigalupo Andrea, 2007, Hematology Am Soc Hematol Educ Program, P23; Brodsky RA, 2010, BLOOD, V115, P2136, DOI 10.1182/blood-2009-06-225375; CAMITTA BM, 1976, BLOOD, V48, P63; Chinese Invasive Fungal Infection Working Group, 2010, ZHONGHUA NEI KE ZA Z, V49, P451; Drewniak A, 2009, BLOOD, V113, P5979, DOI 10.1182/blood-2008-10-182147; Gluckman E, 2002, BRIT J HAEMATOL, V119, P1075, DOI 10.1046/j.1365-2141.2002.03947.x; Kojima S, 2000, BLOOD, V96, P2049; Marsh JCW, 2009, BRIT J HAEMATOL, V147, P43, DOI 10.1111/j.1365-2141.2009.07842.x; Ofran Y, 2007, VOX SANG, V93, P363, DOI 10.1111/j.1423-0410.2007.00971.x; Peters C, 2009, VOX SANG, V96, P275, DOI 10.1111/j.1423-0410.2008.01159.x; Quillen K, 2009, HAEMATOL-HEMATOL J, V94, P1661, DOI 10.3324/haematol.2009.010231; Risitano AM, 2010, BRIT J HAEMATOL, V148, P791, DOI 10.1111/j.1365-2141.2009.08027.x; Rosenfeld S, 2003, JAMA-J AM MED ASSOC, V289, P1130, DOI 10.1001/jama.289.9.1130; Safdar A, 2004, CANCER, V101, P2859, DOI 10.1002/cncr.20710; Scheinberg P, 2009, HAEMATOL-HEMATOL J, V94, P348, DOI 10.3324/haematol.13829; Shao ZH, 1998, AM J HEMATOL, V59, P185, DOI 10.1002/(SICI)1096-8652(199811)59:3<185::AID-AJH2>3.0.CO;2-3; Teramura M, 2007, BLOOD, V110, P1756, DOI 10.1182/blood-2006-11-050526; Tichelli A, 2011, BLOOD, V117, P4434, DOI 10.1182/blood-2010-08-304071; Torres HA, 2003, CANCER, V98, P86, DOI 10.1002/cncr.11478; Walsh TJ, 2002, NEW ENGL J MED, V346, P225, DOI 10.1056/NEJM200201243460403; Wu YH, 2005, ZHONGHUA YI YUAN GAN, V15, P866; Wu Yu-hong, 2003, Zhonghua Xue Ye Xue Za Zhi, V24, P530; Young NS, 2006, BLOOD, V108, P2509, DOI 10.1182/blood-2006-03-010777	24	15	22	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2014	9	2							e88148	10.1371/journal.pone.0088148	http://dx.doi.org/10.1371/journal.pone.0088148			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA1AT	24505406	Green Published, Green Submitted, gold			2023-01-03	WOS:000330829200124
J	de Souza, RD; Batista, MT; Luiz, WB; Cavalcante, RCM; Amorim, JH; Bizerra, RSP; Martins, EG; Ferreira, LCD				de Souza, Renata Damasio; Batista, Milene Tavares; Luiz, Wilson Barros; Marques Cavalcante, Rafael Ciro; Amorim, Jaime Henrique; Pereira Bizerra, Raiza Sales; Martins, Eduardo Gimenes; de Souza Ferreira, Luis Carlos			Bacillus subtilis Spores as Vaccine Adjuvants: Further Insights into the Mechanisms of Action	PLOS ONE			English	Article							IMMUNE-RESPONSE; ENDOSPORES; DELIVERY	Bacillus subtilis spores have received growing attention regarding potential biotechnological applications, including the use as probiotics and in vaccine formulations. B. subtilis spores have also been shown to behave as particulate vaccine adjuvants, promoting the increase of antibody responses after co-administration with antigens either admixed or adsorbed on the spore surface. In this study, we further evaluated the immune modulatory properties of B. subtilis spores using a recombinant HIV gag p24 protein as a model antigen. The adjuvant effects of B. subtilis spores were not affected by the genetic background of the mouse lineage and did not induce significant inflammatory or deleterious effects after parenteral administration. Our results demonstrated that co-administration, but not adsorption to the spore surface, enhanced the immunogenicity of that target antigen after subcutaneous administration to BALB/c and C57BL/6 mice. Spores promoted activation of antigen presenting cells as demonstrated by the upregulation of MHC and CD40 molecules and enhanced secretion of pro-inflammatory cytokines by murine dendritic cells. In addition, in vivo studies indicated a direct role of the innate immunity on the immunomodulatory properties of B. subtilis spores, as demonstrated by the lack of adjuvant effects on MyD88 and TLR2 knockout mouse strains.	[de Souza, Renata Damasio; Batista, Milene Tavares; Luiz, Wilson Barros; Amorim, Jaime Henrique; Pereira Bizerra, Raiza Sales; Martins, Eduardo Gimenes; de Souza Ferreira, Luis Carlos] Univ Sao Paulo, Vaccine Dev Lab, Inst Biomed Sci, Dept Microbiol, Sao Paulo, Brazil; [Marques Cavalcante, Rafael Ciro] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo	Ferreira, LCD (corresponding author), Univ Sao Paulo, Vaccine Dev Lab, Inst Biomed Sci, Dept Microbiol, Sao Paulo, Brazil.	lcsf@usp.br	Luiz, Wilson/L-7575-2015; Luiz, Wilson/H-2073-2012; Amorim, Jaime Henrique/O-9222-2017; Ferreira, Luis/M-3954-2014	Luiz, Wilson/0000-0003-3265-8547; Luiz, Wilson/0000-0001-5219-6699; Amorim, Jaime Henrique/0000-0002-0623-2879; Ferreira, Luis/0000-0002-4883-1693	Foundation of the State of SApoundo Paulo(FAPESP); National Counsel of Technological and Scientific Development (CNPq)	Foundation of the State of SApoundo Paulo(FAPESP); National Counsel of Technological and Scientific Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by grants from the Foundation of the State of SA o pound Paulo(FAPESP) and the National Counsel of Technological and Scientific Development (CNPq). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U; Amorim JH, 2012, VACCINE, V30, P837, DOI 10.1016/j.vaccine.2011.12.034; Amuguni H, 2012, HUM VACC IMMUNOTHER, V8, DOI 10.4161/hv.20694; Barnes AGC, 2007, EUR J IMMUNOL, V37, P1538, DOI 10.1002/eji.200636875; Bozzacco L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041897; Breyhan H, 2009, ACTA NEUROPATHOL, V117, P677, DOI 10.1007/s00401-009-0539-7; Christmas P., 2010, NAT ED, V3, P85; Cutting SM, 2011, FOOD MICROBIOL, V28, P214, DOI 10.1016/j.fm.2010.03.007; DEUERLING E, 1995, J BACTERIOL, V177, P4105, DOI 10.1128/jb.177.14.4105-4112.1995; Fierens K, 2012, CURR PHARM DESIGN, V18, P2305, DOI 10.2174/138161212800166004; Heegaard PMH, 2011, ARCH VIROL, V156, P183, DOI 10.1007/s00705-010-0863-1; Huang JM, 2008, FEMS IMMUNOL MED MIC, V53, P195, DOI 10.1111/j.1574-695X.2008.00415.x; Huang JM, 2010, VACCINE, V28, P1021, DOI 10.1016/j.vaccine.2009.10.127; Lambrecht BN, 2009, CURR OPIN IMMUNOL, V21, P23, DOI 10.1016/j.coi.2009.01.004; Li XM, 2012, CLIN VACCINE IMMUNOL, V19, P723, DOI 10.1128/CVI.05700-11; Liard C, 2011, VACCINE, V29, P6379, DOI 10.1016/j.vaccine.2011.04.080; Marim FM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015263; Miyaji EN, 2011, BRAZ J MED BIOL RES, V44, P500, DOI 10.1590/S0100-879X2011007500064; Montomoli E, 2011, EXPERT REV VACCINES, V10, P1053, DOI [10.1586/erv.11.48, 10.1586/ERV.11.48]; Negri A, 2013, J MED MICROBIOL, V62, P1379, DOI 10.1099/jmm.0.057372-0; Nicholson WL, 2000, MICROBIOL MOL BIOL R, V64, P548, DOI 10.1128/MMBR.64.3.548-572.2000; O'Hagan DT, 2003, NAT REV DRUG DISCOV, V2, P727, DOI 10.1038/nrd1176; Paccez JD, 2007, VACCINE, V25, P4671, DOI 10.1016/j.vaccine.2007.04.021; Reed SG, 2009, TRENDS IMMUNOL, V30, P23, DOI 10.1016/j.it.2008.09.006; Rodrigues JF, 2011, J BIOL CHEM, V286, P5222, DOI 10.1074/jbc.M110.173682; Song M, 2012, VACCINE, V30, P3266, DOI 10.1016/j.vaccine.2012.03.016; Tagliamonte M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043318; Tavares MB, 2013, CURR MICROBIOL, V66, P279, DOI 10.1007/s00284-012-0269-2; Tavares MB, 2010, FEMS IMMUNOL MED MIC, V59, P131, DOI 10.1111/j.1574-695X.2010.00669.x; Visciano ML, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-4; Watanabe H, 2004, SHOCK, V22, P460, DOI 10.1097/01.shk.0000142249.08135.e9; Wehrl W, 2000, J BACTERIOL, V182, P3870, DOI 10.1128/JB.182.13.3870-3873.2000; Zanoni I, 2009, NATURE, V460, P264, DOI 10.1038/nature08118	33	32	34	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2014	9	1							e87454	10.1371/journal.pone.0087454	http://dx.doi.org/10.1371/journal.pone.0087454			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301BI	24475289	Green Published, Green Submitted, gold			2023-01-03	WOS:000330507300184
J	Ebeling, S; Naumann, K; Pollok, S; Wardecki, T; Vidal-y-Sy, S; Nascimento, JM; Boerries, M; Schmidt, G; Brandner, JM; Merfort, I				Ebeling, Sandra; Naumann, Katrin; Pollok, Simone; Wardecki, Tina; Vidal-y-Sy, Sabine; Nascimento, Juliana M.; Boerries, Melanie; Schmidt, Gudula; Brandner, Johanna M.; Merfort, Irmgard			From a Traditional Medicinal Plant to a Rational Drug: Understanding the Clinically Proven Wound Healing Efficacy of Birch Bark Extract	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; SELECTIVE CYCLOOXYGENASE-2 INHIBITION; MESSENGER-RNA; RHO-GTPASES; ACTIN CYTOSKELETON; COX-2 EXPRESSION; BINDING PROTEINS; CELL-MIGRATION; BETULINIC ACID; P38	Background: Birch bark has a long lasting history as a traditional medicinal remedy to accelerate wound healing. Recently, the efficacy of birch bark preparations has also been proven clinically. As active principle pentacyclic triterpenes are generally accepted. Here, we report a comprehensive study on the underlying molecular mechanisms of the wound healing properties of a well-defined birch bark preparation named as TE (triterpene extract) as well as the isolated single triterpenes in human primary keratinocytes and porcine ex-vivo wound healing models. Methodology/Principal Findings: We show positive wound healing effects of TE and betulin in scratch assay experiments with primary human keratinocytes and in a porcine ex-vivo wound healing model (WHM). Mechanistical studies elucidate that TE and betulin transiently upregulate pro-inflammatory cytokines, chemokines and cyclooxygenase-2 on gene and protein level. For COX-2 and IL-6 this increase of mRNA is due to an mRNA stabilizing effect of TE and betulin, a process in which p38 MAPK and HuR are involved. TE promotes keratinocyte migration, putatively by increasing the formation of actin filopodia, lamellipodia and stress fibers. Detailed analyses show that the TE components betulin, lupeol and erythrodiol exert this effect even in nanomolar concentrations. Targeting the actin cytoskeleton is dependent on the activation of Rho GTPases. Conclusion/Significance: Our results provide insights to understand the molecular mechanism of the clinically proven wound healing effect of birch bark. TE and betulin address the inflammatory phase of wound healing by transient up-regulation of several pro-inflammatory mediators. Further, they enhance migration of keratinocytes, which is essential in the second phase of wound healing. Our results, together with the clinically proven efficacy, identify birch bark as the first medical plant with a high potential to improve wound healing, a field which urgently needs effective remedies.	[Ebeling, Sandra; Naumann, Katrin; Wardecki, Tina; Merfort, Irmgard] Univ Freiburg, D-79106 Freiburg, Germany; [Pollok, Simone; Vidal-y-Sy, Sabine; Brandner, Johanna M.] Univ Hosp Hamburg Eppendorf, Dept Dermatol & Venerol, Hamburg, Germany; [Schmidt, Gudula] Univ Freiburg, Inst Expt & Clin Pharmacol & Toxicol, D-79106 Freiburg, Germany; [Nascimento, Juliana M.; Boerries, Melanie] Univ Freiburg, Inst Mol Med & Cell Res, D-79106 Freiburg, Germany; [Nascimento, Juliana M.; Boerries, Melanie] German Canc Consortium DKTK, Heidelberg, Germany; [Boerries, Melanie] German Canc Res Ctr, Heidelberg, Germany	University of Freiburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Merfort, I (corresponding author), Univ Freiburg, Hugstetter Str 55, D-79106 Freiburg, Germany.	Irmgard.Merfort@pharmazie.uni-freiburg.de	Nascimento, Juliana M/B-8764-2009; Boerries, Melanie/AAM-2602-2021	Nascimento, Juliana M/0000-0003-3126-4984; 	Aif; Birken AG; Albert-Ludwigs-University Freiburg	Aif; Birken AG; Albert-Ludwigs-University Freiburg	This study was funded by Aif and Birken AG. The article processing charge was funded by the open access publication fund of the Albert-Ludwigs-University Freiburg. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al Ghouleh I, 2012, SHOCK, V37, P433, DOI 10.1097/SHK.0b013e31824582e6; Ashcroft GS, 1999, MICROBES INFECT, V1, P1275, DOI 10.1016/S1286-4579(99)00257-9; Aspenstrom P, 2004, BIOCHEM J, V377, P327, DOI 10.1042/BJ20031041; Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524-475X.2008.00410.x; Behm B, 2012, J EUR ACAD DERMATOL, V26, P812, DOI 10.1111/j.1468-3083.2011.04415.x; Biname F, 2010, MOL BIOSYST, V6, P648, DOI 10.1039/b915591k; Blakytny R, 2006, DIABETIC MED, V23, P594, DOI 10.1111/j.1464-5491.2006.01773.x; Blomme EAG, 2003, BRIT J DERMATOL, V148, P211, DOI 10.1046/j.1365-2133.2003.05065.x; Busch H, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.36; Dauer DJ, 2005, ONCOGENE, V24, P3397, DOI 10.1038/sj.onc.1208469; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Di Mari JF, 2007, AM J PHYSIOL-GASTR L, V293, pG719, DOI 10.1152/ajpgi.00117.2007; Doller A, 2008, CELL SIGNAL, V20, P2165, DOI 10.1016/j.cellsig.2008.05.007; Eming SA, 2007, J INVEST DERMATOL, V127, P514, DOI 10.1038/sj.jid.5700701; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; Etienne-Manneville S, 2004, TRAFFIC, V5, P470, DOI 10.1111/j.1600-0854.2004.00196.x; Farooq F, 2009, HUM MOL GENET, V18, P4035, DOI 10.1093/hmg/ddp352; Fernandez MA, 2001, J PHARM PHARMACOL, V53, P1533, DOI 10.1211/0022357011777909; Fernau NS, 2010, J BIOL CHEM, V285, P3896, DOI 10.1074/jbc.M109.081430; FLECKENSTEIN A, 1977, ANNU REV PHARMACOL, V17, P149, DOI 10.1146/annurev.pa.17.040177.001053; Futagami A, 2002, LAB INVEST, V82, P1503, DOI 10.1097/01.LAB.0000035024.75914.39; Gallucci RM, 2000, FASEB J, V14, P2525, DOI 10.1096/fj.00-0073com; Geuijen CAW, 2002, MOL BIOL CELL, V13, P3845, DOI 10.1091/mbc.02-01-0601; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Goh WI, 2011, J BIOL CHEM, V286, P13681, DOI 10.1074/jbc.M110.182683; Goldman Robert, 2004, Adv Skin Wound Care, V17, P24, DOI 10.1097/00129334-200401000-00012; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hardy MM, 2003, J PHARMACOL EXP THER, V304, P959, DOI 10.1124/jpet.102.044545; Harper KA, 2008, BIOCHEM SOC T, V36, P543, DOI 10.1042/BST0360543; Hata K, 2005, J BIOCHEM, V138, P467, DOI 10.1093/jb/mvi151; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Hiller K., 2010, LEXIKON ARZNEIPFLANZ; Hoffmann C, 2004, J BIOL CHEM, V279, P16026, DOI 10.1074/jbc.M313556200; Ianaro A, 2001, FEBS LETT, V508, P61, DOI 10.1016/S0014-5793(01)03035-6; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jin M, 2005, J NEUROSCI, V25, P2338, DOI 10.1523/JNEUROSCI.4889-04.2005; Knust Z, 2010, TOXINS, V2, P116, DOI 10.3390/toxins2010116; Kondo T, 2010, FORENSIC SCI INT, V203, P93, DOI 10.1016/j.forsciint.2010.07.004; Kustermans G, 2008, BIOCHEM PHARMACOL, V76, P1310, DOI 10.1016/j.bcp.2008.05.028; Lafarga V, 2009, MOL CELL BIOL, V29, P4341, DOI 10.1128/MCB.00210-09; Laszczyk M, 2006, PLANTA MED, V72, P1389, DOI 10.1055/s-2006-951723; Laszczyk MN, 2009, PLANTA MED, V75, P1549, DOI 10.1055/s-0029-1186102; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Laulederkind SJF, 2002, LAB INVEST, V82, P919, DOI 10.1097/01.LAB.0000020407.98665.98; Lee JL, 2003, TOXICOL APPL PHARM, V192, P294, DOI 10.1016/S0041-008X(03)00301-6; Lee SH, 2010, MOL CELLS, V29, P311, DOI 10.1007/s10059-010-0053-8; Lerm M, 1999, INFECT IMMUN, V67, P496, DOI 10.1128/IAI.67.2.496-503.1999; Liao WL, 2011, J BIOL CHEM, V286, P35499, DOI 10.1074/jbc.M111.263582; Lin YC, 2009, AM J CHINESE MED, V37, P97, DOI 10.1142/S0192415X09006606; Lin ZQ, 2003, J LEUKOCYTE BIOL, V73, P713, DOI 10.1189/jlb.0802397; MANSBRIDGE JN, 1987, J INVEST DERMATOL, V89, P253, DOI 10.1111/1523-1747.ep12471216; Martin P, 2005, TRENDS CELL BIOL, V15, P599, DOI 10.1016/j.tcb.2005.09.002; Martin R, 2007, CANCER RES, V67, P3741, DOI 10.1158/0008-5472.CAN-06-4759; Martin R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005975; Masiero L, 1999, J CELL SCI, V112, P3205; Metelmann HR, 2011, J CRANIOMAXILLOFAC S, V40, P150; Mifflin RC, 2004, MOL PHARMACOL, V65, P470, DOI 10.1124/mol.65.2.470; Muller-Decker K, 2002, J INVEST DERMATOL, V119, P1189, DOI 10.1046/j.1523-1747.2002.19501.x; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nuutila K, 2012, WOUND REPAIR REGEN, V20, P830, DOI 10.1111/j.1524-475X.2012.00831.x; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pollok S, 2011, J CELL MOL MED, V15, P861, DOI 10.1111/j.1582-4934.2010.01057.x; Price LS, 2003, J BIOL CHEM, V278, P39413, DOI 10.1074/jbc.M302083200; RECIO MD, 1995, PLANTA MED, V61, P9, DOI 10.1055/s-2006-957988; Reipschlaeger S., 2012, J BIOL CHEM, V287, P11183; Remick DG, 2005, CRIT CARE MED, V33, pS466, DOI 10.1097/01.CCM.0000186783.34908.18; Rennekampff HO, 2000, J SURG RES, V93, P41, DOI 10.1006/jsre.2000.5892; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Roupe KM, 2010, J INVEST DERMATOL, V130, P1167, DOI 10.1038/jid.2009.284; Rys-Sikora KE, 2000, AM J PHYSIOL-CELL PH, V278, pC822, DOI 10.1152/ajpcell.2000.278.4.C822; Schafer C, 2009, EXP CELL RES, V315, P1212, DOI 10.1016/j.yexcr.2008.11.008; Schafer M, 2007, ANNU REV CELL DEV BI, V23, P69, DOI 10.1146/annurev.cellbio.23.090506.123609; Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034; Schempp C, 2005, MERKURSTAB, V5, P402; Schreml S, 2010, J AM ACAD DERMATOL, V63, P866, DOI 10.1016/j.jaad.2009.10.048; Singh A, 2012, BIOINFORMATICS, V28, pI495, DOI 10.1093/bioinformatics/bts410; Singh I, 2007, J BIOL CHEM, V282, P7833, DOI 10.1074/jbc.M608288200; Soboloff J, 2005, J BIOL CHEM, V280, P39786, DOI 10.1074/jbc.M506064200; Tudor C, 2009, FEBS LETT, V583, P1933, DOI 10.1016/j.febslet.2009.04.039; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; Velnar T, 2009, J INT MED RES, V37, P1528, DOI 10.1177/147323000903700531; Vockel M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019740; Wang XP, 2004, J INVEST DERMATOL, V123, P124, DOI 10.1111/j.0022-202X.2004.22736.x; Weckesser S, 2010, FORSCH KOMPLEMENTMED, V17, P271, DOI 10.1159/000320592; Widgerow AD, 2012, WOUND REPAIR REGEN, V20, P2, DOI 10.1111/j.1524-475X.2011.00754.x; Wiederholt T, 2009, EXP DERMATOL, V18, P969, DOI 10.1111/j.1600-0625.2009.00884.x; Woelfle U, 2010, J INVEST DERMATOL, V130, P113, DOI 10.1038/jid.2009.248; Wojciak-Kosior M, 2011, FOLIA HISTOCHEM CYTO, V49, P664, DOI 10.5603/FHC.2011.0050; Yun YH, 2003, ARCH PHARM RES, V26, P1087, DOI 10.1007/BF02994763; Zdzisinska B, 2003, POL J PHARMACOL, V55, P235; Zhao W, 2008, J BIOL CHEM, V283, P1778, DOI 10.1074/jbc.M707573200	95	57	59	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2014	9	1							e86147	10.1371/journal.pone.0086147	http://dx.doi.org/10.1371/journal.pone.0086147			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297VL	24465925	Green Submitted, Green Published, gold			2023-01-03	WOS:000330283100113
J	Zhao, GD; Guo, S; Somel, M; Khaitovich, P				Zhao, Guodong; Guo, Song; Somel, Mehmet; Khaitovich, Philipp			Evolution of Human Longevity Uncoupled from Caloric Restriction Mechanisms	PLOS ONE			English	Article							LIFE-SPAN EXTENSION; GENE-EXPRESSION; DIETARY RESTRICTION; OXIDATIVE STRESS; INCREASE LONGEVITY; RHESUS-MONKEYS; HUMAN-BEINGS; RESVERATROL; DISEASE; METABOLISM	Caloric restriction (CR) and chemical agents, such as resveratrol and rapamycin that partially mimic the CR effect, can delay morbidity and mortality across a broad range of species. In humans, however, the effects of CR or other life-extending agents have not yet been investigated systematically. Human maximal lifespan is already substantially greater compared to that of closely related primate species. It is therefore possible that humans have acquired genetic mutations that mimic the CR effect. Here, we tested this notion by comparing transcriptome differences between humans and other primates, with the transcriptome changes observed in mice subjected to CR. We show that the human transcriptome state, relative to other primate transcriptomes, does not match that of the CR mice or mice treated with resveratrol, but resembles the transcriptome state of ad libitum fed mice. At the same time, the transcriptome changes induced by CR in mice are enriched among genes showing age-related changes in primates, concentrated in specific expression patterns, and can be linked with specific functional pathways, including insulin signalling, cancer, and the immune response. These findings indicate that the evolution of human longevity was likely independent of CR-induced lifespan extension mechanisms. Consequently, application of CR or CR-mimicking agents may yet offer a promising direction for the extension of healthy human lifespan.	[Zhao, Guodong; Guo, Song; Somel, Mehmet; Khaitovich, Philipp] Chinese Acad Sci, Shanghai Inst Biol Sci, CAS MPG Partner Inst Computat Biol, Shanghai, Peoples R China; [Zhao, Guodong] Chinese Acad Sci, Grad Sch, Beijing, Peoples R China; [Khaitovich, Philipp] Max Planck Inst Evolutionary Anthropol, Leipzig, Germany; [Somel, Mehmet] Middle E Tech Univ, Dept Biol Sci, TR-06531 Ankara, Turkey	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Max Planck Society; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Max Planck Society; Middle East Technical University	Somel, M (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, CAS MPG Partner Inst Computat Biol, Shanghai, Peoples R China.	somel.mehmet@gmail.com; khaitovich@eva.mpg.de	Guo, Song/F-7572-2016; Khaitovich, Philipp/HGC-8520-2022; Somel, Mehmet/B-1471-2016	Guo, Song/0000-0002-7150-8528; Somel, Mehmet/0000-0002-3138-1307	Ministry of Science and Technology of the People's Republic of China [2012DFG31940]; National Natural Science Fund of China [31171232, 31050110128]; Max Planck-Society; Bundesministerum fuer Bildung und Forschung; 1000 Plan for Foreign Experts; Chinese Academy of Sciences [2009Y2BS12]; European Molecular Biology Organization [EMBO ALTF 1475-2010]	Ministry of Science and Technology of the People's Republic of China(Ministry of Science and Technology, China); National Natural Science Fund of China(National Natural Science Foundation of China (NSFC)); Max Planck-Society(Max Planck SocietyFoundation CELLEX); Bundesministerum fuer Bildung und Forschung; 1000 Plan for Foreign Experts; Chinese Academy of Sciences(Chinese Academy of Sciences); European Molecular Biology Organization(European Molecular Biology Organization (EMBO))	This work was supported by the Ministry of Science and Technology of the People's Republic of China (grant no. 2012DFG31940), National Natural Science Fund of China (grants no. 31171232 and 31050110128), the Max Planck-Society, and the Bundesministerum fuer Bildung und Forschung for financial support. PK was supported by 1000 Plan for Foreign Experts; MS was supported by fellowships from the Chinese Academy of Sciences (2009Y2BS12) and the European Molecular Biology Organization (EMBO ALTF 1475-2010). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen JS, 2005, AM J HUM BIOL, V17, P673, DOI 10.1002/ajhb.20439; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Barger JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002264; BARRETTCONNOR E, 1986, NEW ENGL J MED, V315, P1519, DOI 10.1056/NEJM198612113152405; Barzilai N, 2009, J GERONTOL A-BIOL, V64, P187, DOI 10.1093/gerona/gln061; Bass TM, 2007, MECH AGEING DEV, V128, P546, DOI 10.1016/j.mad.2007.07.007; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Blekhman R, 2010, GENOME RES, V20, P180, DOI 10.1101/gr.099226.109; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; Chouliaras L, 2011, BRAIN BEHAV IMMUN, V25, P616, DOI 10.1016/j.bbi.2010.11.016; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; CUTLER RG, 1979, MECH AGEING DEV, V9, P337, DOI 10.1016/0047-6374(79)90110-6; de Candia P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001670; de Magalhaes JP, 2009, AGING CELL, V8, P65, DOI 10.1111/j.1474-9726.2008.00442.x; de Magalhaes JP, 2002, EXP GERONTOL, V37, P769, DOI 10.1016/S0531-5565(02)00008-6; Dirks AJ, 2006, AGEING RES REV, V5, P179, DOI 10.1016/j.arr.2006.03.002; Finch CE, 2010, P NATL ACAD SCI USA, V107, P1718, DOI 10.1073/pnas.0909606106; Finch CE, 2004, Q REV BIOL, V79, P3, DOI 10.1086/381662; Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Guarente L, 2008, CELL, V132, P171, DOI 10.1016/j.cell.2008.01.007; HANSEN BC, 1993, DIABETES, V42, P1809, DOI 10.2337/diabetes.42.12.1809; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Hawkes K, 2003, AM J HUM BIOL, V15, P380, DOI 10.1002/ajhb.10156; Hawkes K, 2009, AM J HUM BIOL, V21, P578, DOI 10.1002/ajhb.20890; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; JONES M L, 1992, In Vivo (Attiki), V6, P363; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kaplan H, 2000, EVOL ANTHROPOL, V9, P156, DOI 10.1002/1520-6505(2000)9:4<156::AID-EVAN5>3.3.CO;2-Z; Kaplan HS, 2002, P NATL ACAD SCI USA, V99, P10221, DOI 10.1073/pnas.152502899; Kemnitz JW, 2011, ILAR J, V52, P66, DOI 10.1093/ilar.52.1.66; Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980; Khaitovich P, 2005, SCIENCE, V309, P1850, DOI 10.1126/science.1108296; Koga H, 2011, AGEING RES REV, V10, P205, DOI 10.1016/j.arr.2010.02.001; KRITCHEVSKY D, 1979, FED PROC, V38, P2001; Kuningas M, 2007, EUR J HUM GENET, V15, P294, DOI 10.1038/sj.ejhg.5201766; Lane MA, 2000, MECH AGEING DEV, V112, P185, DOI 10.1016/S0047-6374(99)00087-1; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Le Bourg E, 2006, BIOGERONTOLOGY, V7, P149, DOI 10.1007/s10522-006-9014-1; Le Bourg E, 2006, BIOGERONTOLOGY, V7, P123, DOI 10.1007/s10522-006-9010-5; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lefevre M, 2009, ATHEROSCLEROSIS, V203, P206, DOI 10.1016/j.atherosclerosis.2008.05.036; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Mattison JA, 2012, NATURE, V489, P318, DOI 10.1038/nature11432; MCCAY CM, 1989, NUTRITION, V5, P155; Merry BJ, 2004, AGING CELL, V3, P7, DOI 10.1046/j.1474-9728.2003.00074.x; Newton IG, 2008, NEUROBIOL AGING, V29, P1308, DOI 10.1016/j.neurobiolaging.2007.03.009; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011; Phelan JP, 2006, BIOGERONTOLOGY, V7, P161, DOI 10.1007/s10522-006-9005-2; Plank M, 2012, MOL BIOSYST, V8, P1339, DOI 10.1039/c2mb05255e; Powers RW, 2006, GENE DEV, V20, P174, DOI 10.1101/gad.1381406; Qin WP, 2006, J ALZHEIMERS DIS, V10, P417; Redman LM, 2011, ANTIOXID REDOX SIGN, V14, P275, DOI 10.1089/ars.2010.3253; ROBERTST.IC, 1974, LANCET, V2, P368; Rohrbach S, 2008, BIOGERONTOLOGY, V9, P169, DOI 10.1007/s10522-008-9126-x; Shanley DP, 2006, BIOGERONTOLOGY, V7, P165, DOI 10.1007/s10522-006-9006-1; Smith DL, 2010, EUR J CLIN INVEST, V40, P440, DOI 10.1111/j.1365-2362.2010.02276.x; Somel M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001504; Somel M, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001214; Somel M, 2010, GENOME RES, V20, P1207, DOI 10.1101/gr.106849.110; Spindler SR, 2010, AGEING RES REV, V9, P324, DOI 10.1016/j.arr.2009.10.003; Team. RDC, 2007, R LANG ENV STAT COMP; Timmers S, 2012, AGING-US, V4, P146, DOI 10.18632/aging.100445; Tokunaga C, 2004, BIOCHEM BIOPH RES CO, V313, P443, DOI 10.1016/j.bbrc.2003.07.019; Tsuchiya T, 2004, PHYSIOL GENOMICS, V17, P307, DOI 10.1152/physiolgenomics.00039.2004; Valdez G, 2010, P NATL ACAD SCI USA, V107, P14863, DOI 10.1073/pnas.1002220107; Valenzano DR, 2006, CURR BIOL, V16, P296, DOI 10.1016/j.cub.2005.12.038; van Heemst D, 2005, AGING CELL, V4, P79, DOI 10.1111/j.1474-9728.2005.00148.x; Videan EN, 2009, COMPARATIVE MED, V59, P287; Walker ARP, 2003, NUTRITION, V19, P169, DOI 10.1016/S0899-9007(02)00948-6; Walker R, 2006, AM J HUM BIOL, V18, P295, DOI 10.1002/ajhb.20510; Walker R, 2006, J HUM EVOL, V51, P480, DOI 10.1016/j.jhevol.2006.06.002; Wei M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040013; Willcox DC, 2006, BIOGERONTOLOGY, V7, P173, DOI 10.1007/s10522-006-9008-z; Wrangham R, 2003, COMP BIOCHEM PHYS A, V136, P35, DOI 10.1016/S1095-6433(03)00020-5; Wu X, 2009, BIOINFORMATICS, V25, P832, DOI 10.1093/bioinformatics/btp059; Yuan Y, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-347	82	9	9	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2014	9	1							e84117	10.1371/journal.pone.0084117	http://dx.doi.org/10.1371/journal.pone.0084117			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286IW	24400080	Green Published, gold			2023-01-03	WOS:000329462700014
J	Sattayasai, J; Chaonapan, P; Arkaravichie, T; Soi-ampornkul, R; Junnu, S; Charoensilp, P; Samer, J; Jantaravinid, J; Masaratana, P; Suktitipat, B; Manissorn, J; Thongboonkerd, V; Neungton, N; Moongkarndi, P				Sattayasai, Jintana; Chaonapan, Pongsatorn; Arkaravichie, Tarinee; Soi-ampornkul, Rungtip; Junnu, Sarawut; Charoensilp, Patcharakajee; Samer, Jutima; Jantaravinid, Jiraporn; Masaratana, Patarabutr; Suktitipat, Bhoom; Manissorn, Juthatip; Thongboonkerd, Visith; Neungton, Neelobol; Moongkarndi, Primchanien			Protective Effects of Mangosteen Extract on H2O2-Induced Cytotoxicity in SK-N-SH Cells and Scopolamine-Induced Memory Impairment in Mice	PLOS ONE			English	Article							ALZHEIMERS-DISEASE; ACETYLCHOLINESTERASE INHIBITORS; ANTIOXIDANT; TOXICITY; CLEAVAGE; PERICARP; BIOLOGY; AGE	Mangosteen extracts (ME) contain high levels of polyphenolic compounds and antioxidant activity. Protective effects of ME against beta-amyloid peptide (A beta), induced cytotoxicity have been reported. Here, we further studied the protective effects of ME against oxidative stress induced by hydrogen peroxide (H2O2) and polychlorinated biphenyls (PCBs), and demonstrated the protection against memory impairment in mice. The cytoprotective effects of ME were measured as cell viability and the reduction in ROS activity. In SK-N-SH cell cultures, 200 mu g/ml ME could partially antagonize the effects of 150 or 300 mu M H2O2 on cell viability, ROS level and caspase-3 activity. At 200, 400 or 800 mu g/ml, ME reduced AChE activity of SK-N-SH cells to about 60% of the control. In vivo study, Morris water maze and passive avoidance tests were used to assess the memory of the animals. ME, especially at 100 mg/kg body weight, could improve the animal's memory and also antagonize the effect of scopolamine on memory. The increase in ROS level and caspase-3 activity in the brain of scopolamine-treated mice were antagonized by the ME treatment. The study demonstrated cytoprotective effects of ME against H2O2 and PCB-52 toxicity and having AChE inhibitory effect in cell culture. ME treatment in mice could attenuate scopolamine-induced memory deficit and oxidative stress in brain.	[Sattayasai, Jintana; Chaonapan, Pongsatorn; Arkaravichie, Tarinee] Khon Kaen Univ, Fac Med, Dept Pharmacol, Khon Kaen, Thailand; [Soi-ampornkul, Rungtip; Junnu, Sarawut; Charoensilp, Patcharakajee; Jantaravinid, Jiraporn; Masaratana, Patarabutr; Suktitipat, Bhoom; Neungton, Neelobol] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Biochem, Bangkok 10700, Thailand; [Samer, Jutima; Moongkarndi, Primchanien] Mahidol Univ, Fac Pharm, Dept Microbiol, Bangkok 10700, Thailand; [Manissorn, Juthatip; Thongboonkerd, Visith] Mahidol Univ, Siriraj Hosp, Fac Med, Med Prote Unit,Off Res & Dev, Bangkok 10700, Thailand	Khon Kaen University; Mahidol University; Mahidol University; Mahidol University	Moongkarndi, P (corresponding author), Mahidol Univ, Fac Pharm, Dept Microbiol, Bangkok 10700, Thailand.	primchanien.moo@mahidol.ac.th	Thongboonkerd, Visith/C-6920-2009; Suktitipat, Bhoom/H-4239-2019	Thongboonkerd, Visith/0000-0001-7865-0765; Suktitipat, Bhoom/0000-0001-8034-7757; , Patarabutr/0000-0001-7228-7176	Graduate Research, Faculty of Medicine Siriraj Hospital; Mahidol University; Thai Traditional Medical Knowledge Fund; Ministry of Public Health, Thailand; Thailand Research Fund; Thai government	Graduate Research, Faculty of Medicine Siriraj Hospital; Mahidol University; Thai Traditional Medical Knowledge Fund; Ministry of Public Health, Thailand; Thailand Research Fund(Thailand Research Fund (TRF)); Thai government	This work was supported by Siriraj Grant for Graduate Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Thai Traditional Medical Knowledge Fund, Ministry of Public Health, Thailand, and the Thailand Research Fund. The grants belong to the Thai government support for scientific merit-study and had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Salam OME, 2013, EXCLI J, V12, P193; Ancelin ML, 2007, DEMENT GERIATR COGN, V24, P1, DOI 10.1159/000102567; [Anonymous], 2008, CMU J NATL SCI; BARTUS RT, 1985, PHARMACOL BIOCHEM BE, V23, P125, DOI 10.1016/0091-3057(85)90139-X; BECKER JT, 1988, ARCH NEUROL-CHICAGO, V45, P263, DOI 10.1001/archneur.1988.00520270037018; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Chantarasriwong O, 2010, CHEM-EUR J, V16, P9944, DOI 10.1002/chem.201000741; Chivapat S, 2011, THAI J VET MED, V41, P45; Cook A, 2007, ANNU REV BIOCHEM, V76, P647, DOI 10.1146/annurev.biochem.76.052705.161529; Deiana S, 2009, PSYCHOPHARMACOLOGY, V202, P53, DOI 10.1007/s00213-008-1394-2; Driver AS, 2000, NEUROTOXICOL TERATOL, V22, P175, DOI 10.1016/S0892-0362(99)00069-0; Fischbein A, 1979, Ann N Y Acad Sci, V320, P703, DOI 10.1111/j.1749-6632.1979.tb13188.x; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Giridharan VV, 2011, FOOD FUNCT, V2, P320, DOI 10.1039/c1fo10037h; Goverdhan Puchchakayala, 2012, Int J Alzheimers Dis, V2012, P974013, DOI 10.1155/2012/974013; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hasselmo ME, 2006, CURR OPIN NEUROBIOL, V16, P710, DOI 10.1016/j.conb.2006.09.002; Hatip-Al-Khatib I, 2005, BRIT J PHARMACOL, V145, P1035, DOI 10.1038/sj.bjp.0706288; Hutadilok-Towatana N, 2010, J MED PLANTS RES, V4, P969; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; Jung HA, 2006, J AGR FOOD CHEM, V54, P2077, DOI 10.1021/jf052649z; Kim DH, 2010, ARCH PHARM RES, V33, P1685, DOI 10.1007/s12272-010-1019-2; Kosem N, 2013, J NAT MED-TOKYO, V67, P255, DOI 10.1007/s11418-012-0673-8; Kosem Nuttavut, 2007, ScienceAsia, V33, P283, DOI 10.2306/scienceasia1513-1874.2007.33.283; Marquez-Valadez B, 2009, NUTR NEUROSCI, V12, P35, DOI 10.1179/147683009X388850; MOLCHAN SE, 1992, BRAIN RES REV, V17, P215, DOI 10.1016/0165-0173(92)90017-G; Moongkarndi P, 2010, J PROTEOME RES, V9, P2076, DOI 10.1021/pr100049v; Mukherjee PK, 2007, PHYTOMEDICINE, V14, P289, DOI 10.1016/j.phymed.2007.02.002; Ngawhirunpat T, 2010, PHARM BIOL, V48, P55, DOI 10.3109/13880200903046138; Onoue S, 2002, PEPTIDES, V23, P1471, DOI 10.1016/S0196-9781(02)00085-2; Pachauri SD, 2012, J ETHNOPHARMACOL, V139, P34, DOI 10.1016/j.jep.2011.09.057; Pedraza-Chaverri J, 2008, FOOD CHEM TOXICOL, V46, P3227, DOI 10.1016/j.fct.2008.07.024; Rogers SL, 1996, DEMENTIA, V7, P293, DOI 10.1159/000106895; RUSTED JM, 1988, PSYCHOPHARMACOLOGY, V96, P145; Sanchez-Perez Y, 2010, CHEM-BIOL INTERACT, V188, P144, DOI 10.1016/j.cbi.2010.06.014; Sekler Alejandra, 2008, Neuropsychiatr Dis Treat, V4, P715; Tabet N, 2006, AGE AGEING, V35, P336, DOI 10.1093/ageing/afl027; Vassar R, 2007, NEURON, V54, P671, DOI 10.1016/j.neuron.2007.05.018; WESNES K, 1988, HUMAN PSYCHOPHARMACO, V3, P27, DOI DOI 10.1002/HUP.470030106; World Health Organization, 2000, US; Yang Dongren, 2010, Curr Neurobiol, V1, P70	41	36	37	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2013	8	12							e85053	10.1371/journal.pone.0085053	http://dx.doi.org/10.1371/journal.pone.0085053			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281RE	24386444	Green Published, gold, Green Submitted			2023-01-03	WOS:000329117900120
J	Yoo, HG; Yoo, WH				Yoo, Han-Gyul; Yoo, Wan-Hee			Acupuncture with Gold Thread for Osteoarthritis of the Knee	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Yoo, Han-Gyul] Univ Rhode Isl, Kingston, RI 02881 USA; [Yoo, Wan-Hee] Chonbuk Natl Univ, Jeonju, South Korea	University of Rhode Island; Jeonbuk National University	Yoo, HG (corresponding author), Univ Rhode Isl, Kingston, RI 02881 USA.	ywhim@jbnu.ac.kr							0	10	11	1	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 26	2013	369	26					E37	E37		10.1056/NEJMicm1202540	http://dx.doi.org/10.1056/NEJMicm1202540			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278BT	24369089				2023-01-03	WOS:000328863700001
J	Laurent, C; Leduc, A; Pottier, I; Prevost, V; Sichel, F; Lefaix, JL				Laurent, Carine; Leduc, Alexandre; Pottier, Ivannah; Prevost, Virginie; Sichel, Francois; Lefaix, Jean-Louis			Dramatic Increase in Oxidative Stress in Carbon-Irradiated Normal Human Skin Fibroblasts	PLOS ONE			English	Article							HUMAN EPITHELIAL-CELLS; SPACE RADIATION; DIETARY-SUPPLEMENTS; ALPHA-TOCOPHEROL; ION IRRADIATION; DNA-DAMAGE; GAMMA-RAYS; PENTOXIFYLLINE; FIBROSIS; THERAPY	Skin complications were recently reported after carbon-ion (C-ion) radiation therapy. Oxidative stress is considered an important pathway in the appearance of late skin reactions. We evaluated oxidative stress in normal human skin fibroblasts after carbon-ion vs. X-ray irradiation. Survival curves and radiobiological parameters were calculated. DNA damage was quantified, as were lipid peroxidation (LPO), protein carbonylation and antioxidant enzyme activities. Reduced and oxidized glutathione ratios (GSH/GSSG) were determined. Proinflammatory cytokine secretion in culture supernatants was evaluated. The relative biological effectiveness (RBE) of C-ions vs. X-rays was 4.8 at D-0 (irradiation dose corresponding to a surviving fraction of 37%). Surviving fraction at 2 Gy (SF2) was 71.8% and 7.6% for X-rays and C-ions, respectively. Compared with X-rays, immediate DNA damage was increased less after C-ions, but a late increase was observed at D-10% (irradiation dose corresponding to a surviving fraction of 10%). LPO products and protein carbonyls were only increased 24 hours after C-ions. After X-rays, superoxide dismutase (SOD) activity was strongly increased immediately and on day 14 at D-0% (irradiation dose corresponding to a surviving fraction of around 0%), catalase activity was unchanged and glutathione peroxidase (GPx) activity was increased only on day 14. These activities were decreased after C-ions compared with X-rays. GSH/GSSG was unchanged after X-rays but was decreased immediately after C-ion irradiation before an increase from day 7. Secretion of IL-6 was increased at late times after X-ray irradiation. After C-ion irradiation, IL-6 concentration was increased on day 7 but was lower compared with X-rays at later times. C-ion effects on normal human skin fibroblasts seemed to be harmful in comparison with X-rays as they produce late DNA damage, LPO products and protein carbonyls, and as they decrease antioxidant defences. Mechanisms leading to this discrepancy between the two types of radiation should be investigated.	[Laurent, Carine; Leduc, Alexandre] ARCHADE Adv Resource Ctr Hadrontherapy Europe Pro, SAPHYN Sante Phys Nucl, Caen, France; [Pottier, Ivannah; Sichel, Francois] Univ Caen Basse Normandie, EA4651, Caen, France; [Pottier, Ivannah; Sichel, Francois] CLCC Ctr Lutte Canc Francois Baclesse, Caen, France; [Prevost, Virginie] Univ Caen Basse Normandie, INSERM, Canc & Prevent U1086, Caen, France; [Lefaix, Jean-Louis] IRCM, DSV, CEA, LARIA, Caen, France	Universite de Caen Normandie; UNICANCER; Centre Francois Baclesse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Caen Normandie; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Laurent, C (corresponding author), ARCHADE Adv Resource Ctr Hadrontherapy Europe Pro, SAPHYN Sante Phys Nucl, Caen, France.	c.laurent@mail.baclesse.fr	PREVOST, Virginie/ABE-4043-2020; leduc, alexandre/ABE-7968-2020; MOUTEL, Grégoire/N-8777-2015	PREVOST, Virginie/0000-0003-2873-6063; Leduc, Alexandre/0000-0002-4084-7041; Pottier, Ivannah/0000-0002-4186-0547	Conseil Regional de Basse-Normandie; FEDER; Electricite de France-Service de Radioprotection; Commissariat a l'Energie Atomique; Ligue contre le Cancer (Calvados, Orne, Manche, Eure, Seine-Maritime)	Conseil Regional de Basse-Normandie(Region Normandie); FEDER(European Commission); Electricite de France-Service de Radioprotection; Commissariat a l'Energie Atomique(French Atomic Energy Commission); Ligue contre le Cancer (Calvados, Orne, Manche, Eure, Seine-Maritime)	This work was supported by grants from the Conseil Regional de Basse-Normandie, FEDER, Electricite de France-Service de Radioprotection, the Commissariat a l'Energie Atomique and the Ligue contre le Cancer (Calvados, Orne, Manche, Eure, Seine-Maritime). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beuve M, 2008, INT J RADIAT ONCOL, V71, P635, DOI 10.1016/j.ijrobp.2007.10.050; Delanian S, 2005, J CLIN ONCOL, V23, P8570, DOI 10.1200/JCO.2005.02.4729; Fushimi K, 2008, RADIOTHER ONCOL, V89, P237, DOI 10.1016/j.radonc.2008.04.015; Guan J, 2006, RADIAT RES, V165, P373, DOI 10.1667/RR3523.1; Guan J, 2004, RADIAT RES, V162, P572, DOI 10.1667/RR3249; Haase O, 2004, RADIOTHER ONCOL, V73, pS144, DOI 10.1016/S0167-8140(04)80037-9; Imadome K, 2008, CANCER BIOL THER, V7, P208, DOI 10.4161/cbt.7.2.5255; Kennedy AR, 2007, RADIAT ENVIRON BIOPH, V46, P201, DOI 10.1007/s00411-007-0105-4; Kennedy AR, 2004, FREE RADICAL BIO MED, V36, P259, DOI 10.1016/j.freeradbiomed.2003.10.010; Laurent C, 2005, RADIAT RES, V164, P63, DOI 10.1667/RR3383; Laurent C, 2006, INT J RADIAT BIOL, V82, P309, DOI 10.1080/09553000600733150; MASUDA K, 1980, INT J RADIAT ONCOL, V6, P1539, DOI 10.1016/0360-3016(80)90012-7; Monzen S, 2009, J RADIAT RES, V50, P477, DOI 10.1269/jrr.09058; Paganetti H, 2002, INT J RADIAT ONCOL, V53, P407, DOI 10.1016/S0360-3016(02)02754-2; Pautard C, 2008, NUCL INSTRUM METH A, V588, P448, DOI 10.1016/j.nima.2008.01.098; PUCK TT, 1956, J EXP MED, V103, P273, DOI 10.1084/jem.103.2.273; Suit H, 2010, RADIOTHER ONCOL, V95, P3, DOI 10.1016/j.radonc.2010.01.015; Wan XS, 2006, INT J RADIAT ONCOL, V64, P1475, DOI 10.1016/j.ijrobp.2005.11.024; Wan XS, 2005, RADIAT RES, V163, P364, DOI 10.1667/0033-7587(2005)163[0364:DOOSIB]2.0.CO;2; Yanagi T, 2010, RADIOTHER ONCOL, V95, P60, DOI 10.1016/j.radonc.2009.08.041	20	17	17	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2013	8	12							e85158	10.1371/journal.pone.0085158	http://dx.doi.org/10.1371/journal.pone.0085158			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278IG	24376870	Green Submitted, gold, Green Published			2023-01-03	WOS:000328882000178
J	Parassol, N; Bienvenu, C; Boglio, C; Fiorucci, S; Cerezo, D; Yu, XM; Godeau, G; Greiner, J; Vierling, P; Noselli, S; Di Giorgio, C; Van De Bor, V				Parassol, Nadege; Bienvenu, Celine; Boglio, Cecile; Fiorucci, Sebastien; Cerezo, Delphine; Yu, Xiao-Min; Godeau, Guilhem; Greiner, Jacques; Vierling, Pierre; Noselli, Stephane; Di Giorgio, Christophe; Van De Bor, Veronique			In Vivo Characterization of Dynein-Driven nanovectors Using Drosophila Oocytes	PLOS ONE			English	Article							SINGLE-PARTICLE TRACKING; LIGHT-CHAIN LC8; INTRACELLULAR TRAFFICKING; LOCALIZATION SIGNALS; CARGO TRANSPORT; RNA; MOTOR; MICROTUBULES; COMPLEX; PROTEIN	Molecular motors transport various cargoes including vesicles, proteins and mRNAs, to distinct intracellular compartments. A significant challenge in the field of nanotechnology is to improve drug nuclear delivery by engineering nanocarriers transported by cytoskeletal motors. However, suitable in vivo models to assay transport and delivery efficiency remain very limited. Here, we develop a fast and genetically tractable assay to test the efficiency and dynamics of fluospheres (FS) using microinjection into Drosophila oocytes coupled with time-lapse microscopy. We designed dynein motor driven FS using a collection of dynein light chain 8 (LC8) peptide binding motifs as molecular linkers and characterized in real time the efficiency of the FS movement according to its linker's sequence. Results show that the conserved LC8 binding motif allows fast perinuclear nanoparticle's accumulation in a microtubule and dynein dependent mechanism. These data reveal the Drosophila oocyte as a new valuable tool for the design of motor driven nanovectors.	[Parassol, Nadege; Cerezo, Delphine; Noselli, Stephane; Van De Bor, Veronique] Univ Nice Sophia Antipolis, Inst Biol Valrose, UMR CNRS 7277, UMR INSERM 1091, F-06189 Nice, France; [Bienvenu, Celine; Boglio, Cecile; Fiorucci, Sebastien; Yu, Xiao-Min; Godeau, Guilhem; Greiner, Jacques; Vierling, Pierre; Di Giorgio, Christophe] Univ Nice Sophia Antipolis, ICN, UMR CNRS 7272, F-06189 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur	Di Giorgio, C (corresponding author), Univ Nice Sophia Antipolis, ICN, UMR CNRS 7272, F-06189 Nice, France.	Christophe.DI-GIORGIO@unice.fr; Veronique.VAN-DE-BOR@unice.fr	Godeau, Guilhem/AAE-3426-2022; Fiorucci, Sebastien/A-2060-2010	Godeau, Guilhem/0000-0002-2111-9858; Fiorucci, Sebastien/0000-0003-2245-0478; Noselli, stephane/0000-0002-7296-324X; Van De Bor, Veronique/0000-0001-7157-4456	Centre National de la Recherche Scientifique; Ministere de la Recherche et de l'Enseignement Superieur; Agence Nationale de la Recherche [ANR-09-BLAN-0113]; Association Francaise contre les Myopathies	Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Ministere de la Recherche et de l'Enseignement Superieur; Agence Nationale de la Recherche(French National Research Agency (ANR)); Association Francaise contre les Myopathies(Association Francaise contre les Myopathies)	The authors acknowledge research support from the "Centre National de la Recherche Scientifique", the "Ministere de la Recherche et de l'Enseignement Superieur", the "Agence Nationale de la Recherche" (program ANR-09-BLAN-0113), the "Association Francaise contre les Myopathies". The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akita H, 2013, MOL THER, V21, P309, DOI 10.1038/mt.2012.235; Amrute-Nayak M, 2012, NAT CELL BIOL, V14, P416, DOI 10.1038/ncb2446; Bacher CP, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-45; Benison G, 2007, J MOL BIOL, V371, P457, DOI 10.1016/j.jmb.2007.05.046; Bergen JM, 2007, MOL PHARMACEUT, V4, P119, DOI 10.1021/mp060086o; Bullock SL, 2001, NATURE, V414, P611, DOI 10.1038/414611a; Delanoue R, 2005, CELL, V122, P97, DOI 10.1016/j.cell.2005.04.033; Dick T, 1996, MOL CELL BIOL, V16, P1966; Dohner K, 2005, TRENDS MICROBIOL, V13, P320, DOI 10.1016/j.tim.2005.05.010; Fan JS, 2001, J MOL BIOL, V306, P97, DOI 10.1006/jmbi.2000.4374; Goodman BS, 2012, TRENDS CELL BIOL, V22, P644, DOI 10.1016/j.tcb.2012.09.005; Hall J, 2009, J BIOL CHEM, V284, P33115, DOI 10.1074/jbc.M109.048587; Hendricks AG, 2010, CURR BIOL, V20, P697, DOI 10.1016/j.cub.2010.02.058; Januschke J, 2006, DEVELOPMENT, V133, P129, DOI 10.1242/dev.02179; King SM, 2000, BBA-MOL CELL RES, V1496, P60, DOI 10.1016/S0167-4889(00)00009-4; KUSUMI A, 1993, BIOPHYS J, V65, P2021, DOI 10.1016/S0006-3495(93)81253-0; Lasko P, 1999, FASEB J, V13, P421, DOI 10.1096/fasebj.13.3.421; Leopold PL, 2006, TRAFFIC, V7, P516, DOI 10.1111/j.1600-0854.2006.00408.x; Martin KC, 2009, CELL, V136, P719, DOI 10.1016/j.cell.2009.01.044; Martinez-Moreno M, 2003, FEBS LETT, V544, P262, DOI 10.1016/S0014-5793(03)00516-7; Navarro C, 2004, NAT CELL BIOL, V6, P427, DOI 10.1038/ncb1122; Palacios IM, 2007, SEMIN CELL DEV BIOL, V18, P163, DOI 10.1016/j.semcdb.2007.01.008; Parton RM, 2011, J CELL BIOL, V194, P121, DOI 10.1083/jcb.201103160; Pfister KK, 2006, PLOS GENET, V2, P11, DOI 10.1371/journal.pgen.0020001; Rapali P, 2011, FEBS J, V278, P2980, DOI 10.1111/j.1742-4658.2011.08254.x; Rapali P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018818; Rodriguez-Crespo I, 2001, FEBS LETT, V503, P135, DOI 10.1016/S0014-5793(01)02718-1; Ross JL, 2008, CURR OPIN CELL BIOL, V20, P41, DOI 10.1016/j.ceb.2007.11.006; Saxton MJ, 1997, ANNU REV BIOPH BIOM, V26, P373, DOI 10.1146/annurev.biophys.26.1.373; Saxton MJ, 1997, BIOPHYS J, V72, P1744, DOI 10.1016/S0006-3495(97)78820-9; Saxton WM, 2001, CELL, V107, P707, DOI 10.1016/S0092-8674(01)00602-X; Schnorrer F, 2000, NAT CELL BIOL, V2, P185, DOI 10.1038/35008601; Silvanovich A, 2003, MOL BIOL CELL, V14, P1355, DOI 10.1091/mbc.E02-10-0675; Stelter P, 2007, NAT CELL BIOL, V9, P788, DOI 10.1038/ncb1604; Toledo MAS, 2012, J CONTROL RELEASE, V159, P222, DOI 10.1016/j.jconrel.2012.01.011; Van De Bor V, 2005, DEV CELL, V9, P51, DOI 10.1016/j.devcel.2005.04.012; Wang L, 2004, BIOCHEMISTRY-US, V43, P4611, DOI 10.1021/bi036328x; Wilkie GS, 2001, CELL, V105, P209, DOI 10.1016/S0092-8674(01)00312-9	38	3	3	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2013	8	12							e82908	10.1371/journal.pone.0082908	http://dx.doi.org/10.1371/journal.pone.0082908			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276EU	24349395	Green Published, gold, Green Submitted			2023-01-03	WOS:000328731800084
J	Hachmann, JT; Jeong, JH; Grahn, PJ; Mallory, GW; Evertz, LQ; Bieber, AJ; Lobel, DA; Bennet, KE; Lee, KH; Lujan, JL				Hachmann, Jan T.; Jeong, Ju Ho; Grahn, Peter J.; Mallory, Grant W.; Evertz, Loribeth Q.; Bieber, Allan J.; Lobel, Darlene A.; Bennet, Kevin E.; Lee, Kendall H.; Lujan, J. Luis			Large Animal Model for Development of Functional Restoration Paradigms Using Epidural and Intraspinal Stimulation	PLOS ONE			English	Article							SPINAL-CORD; MICROSTIMULATION; MOVEMENT; HINDLIMB	Restoration of movement following spinal cord injury (SCI) has been achieved using electrical stimulation of peripheral nerves and skeletal muscles. However, practical limitations such as the rapid onset of muscle fatigue hinder clinical application of these technologies. Recently, direct stimulation of alpha motor neurons has shown promise for evoking graded, controlled, and sustained muscle contractions in rodent and feline animal models while overcoming some of these limitations. However, small animal models are not optimal for the development of clinical spinal stimulation techniques for functional restoration of movement. Furthermore, variance in surgical procedure, targeting, and electrode implantation techniques can compromise therapeutic outcomes and impede comparison of results across studies. Herein, we present a protocol and large animal model that allow standardized development, testing, and optimization of novel clinical strategies for restoring motor function following spinal cord injury. We tested this protocol using both epidural and intraspinal stimulation in a porcine model of spinal cord injury, but the protocol is suitable for the development of other novel therapeutic strategies. This protocol will help characterize spinal circuits vital for selective activation of motor neuron pools. In turn, this will expedite the development and validation of high-precision therapeutic targeting strategies and stimulation technologies for optimal restoration of motor function in humans.	[Hachmann, Jan T.; Jeong, Ju Ho; Mallory, Grant W.; Bennet, Kevin E.; Lee, Kendall H.; Lujan, J. Luis] Mayo Clin, Dept Neurol Surg, Rochester, MN USA; [Hachmann, Jan T.; Grahn, Peter J.; Evertz, Loribeth Q.; Bieber, Allan J.] Mayo Clin, Mayo Grad Sch, Rochester, MN USA; [Jeong, Ju Ho] Kosin Univ, Dept Neurosurg, Coll Med, Pusan, South Korea; [Bieber, Allan J.] Mayo Clin, Dept Neurol, Rochester, MN USA; [Lobel, Darlene A.] Cleveland Clin, Dept Neurosurg, Cleveland, OH 44106 USA; [Bennet, Kevin E.] Mayo Clin, Div Engn, Rochester, MN USA; [Lee, Kendall H.; Lujan, J. Luis] Mayo Clin, Dept Physiol & Biomed Engn, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Cleveland Clinic Foundation; Mayo Clinic; Mayo Clinic	Lujan, JL (corresponding author), Mayo Clin, Dept Neurol Surg, Rochester, MN USA.	lujan.luis@mayo.edu	Hachmann, Jan/AFT-4474-2022	Hachmann, Jan/0000-0002-0625-6416	National Institutes of Health [K08 NS 52232, R01 NS 70872]; Grainger Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS052232, R01NS070872, R21NS087320] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Grainger Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the National Institutes of Health (K08 NS 52232 and R01 NS 70872 awards to KHL), The Grainger Foundation, and a gift from Louise Chapman. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bamford JA, 2005, J PHYSIOL-LONDON, V569, P873, DOI 10.1113/jphysiol.2005.094516; Bamford JA, 2010, BIOMATERIALS, V31, P5552, DOI 10.1016/j.biomaterials.2010.03.051; Busscher I, 2010, EUR SPINE J, V19, P1104, DOI 10.1007/s00586-010-1326-9; Chang SYK, 2013, J NEUROSURGERY; Courtine G, 2009, NAT NEUROSCI, V12, P1333, DOI 10.1038/nn.2401; Grahn PJ, 2013, WIRELESS CO IN PRESS; Harkema S, 2011, LANCET, V377, P1938, DOI 10.1016/S0140-6736(11)60547-3; Holinski BJ, 2011, IEEE ENG MED BIO, P5798, DOI 10.1109/IEMBS.2011.6091435; Jackson A, 2012, NAT REV NEUROL, V8, P690, DOI 10.1038/nrneurol.2012.219; JANKOWSKA E, 1992, PROG NEUROBIOL, V38, P335, DOI 10.1016/0301-0082(92)90024-9; Kiehn O, 2006, ANNU REV NEUROSCI, V29, P279, DOI 10.1146/annurev.neuro.29.051605.112910; Lemay MA, 2001, IEEE T NEUR SYS REH, V9, P12, DOI 10.1109/7333.918272; Lemay MA, 2009, IEEE T NEUR SYS REH, V17, P379, DOI 10.1109/TNSRE.2009.2023295; Mushahwar VK, 2000, EXP NEUROL, V163, P422, DOI 10.1006/exnr.2000.7381; Mushahwar VK, 2000, IEEE T REHABIL ENG, V8, P11, DOI 10.1109/86.830944; Mushahwar VK, 2004, CAN J PHYSIOL PHARM, V82, P702, DOI 10.1139/Y04-079; NICOLOPOULOSSTOURNARAS S, 1983, J COMP NEUROL, V217, P75, DOI 10.1002/cne.902170107; Nishimura Y, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00057; ROMANES GJ, 1951, J COMP NEUROL, V94, P313, DOI 10.1002/cne.900940209; Saigal R, 2004, IEEE T NEUR SYS REH, V12, P430, DOI 10.1109/TNSRE.2004.837754; Sunshine MD, 2013, J NEURAL ENG, V10, DOI 10.1088/1741-2560/10/3/036001; Tai C, 1999, IEEE Trans Rehabil Eng, V7, P46, DOI 10.1109/86.750551; Tai CF, 2003, EXP NEUROL, V183, P620, DOI 10.1016/S0014-4886(03)00210-3; van den Brand R, 2012, SCIENCE, V336, P1182, DOI 10.1126/science.1217416; Vanderhorst VGJM, 1997, J COMP NEUROL, V382, P46	25	26	26	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2013	8	12							e81443	10.1371/journal.pone.0081443	http://dx.doi.org/10.1371/journal.pone.0081443			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273WD	24339929	Green Submitted, Green Published, gold			2023-01-03	WOS:000328566100056
J	Canene-Adams, K; Sfanos, KS; Liang, CT; Yegnasubramanian, S; Nelson, WG; Brayton, C; De Marzo, AM				Canene-Adams, Kirstie; Sfanos, Karen S.; Liang, Chung-Tiang; Yegnasubramanian, Srinivasan; Nelson, William G.; Brayton, Cory; De Marzo, Angelo M.			Dietary Chemoprevention of PhIP Induced Carcinogenesis in Male Fischer 344 Rats with Tomato and Broccoli	PLOS ONE			English	Article							PROSTATE-CANCER; MEAT MUTAGENS; HETEROCYCLIC AMINES; COLON-CANCER; PREVENTION; RISK; EXPRESSION; VEGETABLES; CONSUMPTION; LYCOPENE	The heterocyclic amine, 2-amino-1-methyl-6-phenylimidazo[4,5-B] pyridine (PhIP), found in meats cooked at high temperatures, has been implicated in epidemiological and rodent studies for causing breast, prostate, and colorectal cancers. A previous animal study using a xenograft model has shown that whole tomato and broccoli, when eaten in combination, exhibit a marked effect on tumor reduction compared to when eaten alone. Our aim was to determine if PhIP-induced carcinogenesis can be prevented by dietary consumption of whole tomato + broccoli powders. Male Fischer 344 rats (n = 45) were randomized into the following treatment groups: control (AIN93G diet), PhIP (200 ppm in AIN93G diet for the first 20 weeks of the study), or tomato + broccoli + PhIP (mixed in AIN93G diet at 10% each and fed with PhIP for 20 weeks, and then without PhIP for 32 weeks). Study animals were monitored for 52 weeks and were euthanized as necessary based on a set of criteria for health status and tumor burden. Although there appeared to be some hepatic and intestinal toxicity due to the combination of PhIP and tomato + broccoli, these rodents had improved survival and reduced incidence and/or severity of PhIP-induced neoplastic lesions compared to the PhIP-alone treated group. Rats eating tomato + broccoli exhibited a marked decrease in the number and size of cribiform prostatic intraepitheilial neoplasia/carcinoma in situ (cribiform PIN/CIS) lesions and in the incidence of invasive intestinal adenocarcinomas and skin carcinomas. Although the apparent toxic effects of combined PhIP and tomato + broccoli need additional study, the results of this study support the hypothesis that a diet rich in tomato and broccoli can reduce or prevent dietary carcinogen-induced cancers.	[Canene-Adams, Kirstie; Sfanos, Karen S.; De Marzo, Angelo M.] Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD USA; [Liang, Chung-Tiang; Brayton, Cory] Johns Hopkins Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD USA; [Nelson, William G.; De Marzo, Angelo M.] Johns Hopkins Sch Med, Dept Urol, Baltimore, MD USA; [Yegnasubramanian, Srinivasan; Nelson, William G.; De Marzo, Angelo M.] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Canene-Adams, K (corresponding author), Texas State Univ, Sch Family & Consumer Sci, Nutr & Foods Program, San Marcos, TX 78666 USA.	ka26@txstate.edu	Brayton, Cory/AAW-4681-2021	Brayton, Cory/0000-0002-6666-6548; Canene-Adams, Kirstie/0000-0003-4617-448X	Ruth L. Kirschstein National Research Service Award Institutional Research Training Grant [T32 CA067751]; Prevent Cancer Foundation; Chris and Felicia Evensen Prostate Cancer Foundation Young Investigator [CB RR 007002-34]; Maryland Cigarette Restitution Fund at Johns Hopkins; NATIONAL CANCER INSTITUTE [T32CA067751] Funding Source: NIH RePORTER	Ruth L. Kirschstein National Research Service Award Institutional Research Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Prevent Cancer Foundation; Chris and Felicia Evensen Prostate Cancer Foundation Young Investigator; Maryland Cigarette Restitution Fund at Johns Hopkins; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	KCA was funded by a Ruth L. Kirschstein National Research Service Award Institutional Research Training Grant (T32 CA067751). KSS was funded by a Postdoctoral Fellowship Award from the Prevent Cancer Foundation and is currently supported as the Chris and Felicia Evensen Prostate Cancer Foundation Young Investigator (CB RR 007002-34). Support was also provided by the Maryland Cigarette Restitution Fund at Johns Hopkins. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bailey SA, 2004, TOXICOL PATHOL, V32, P448, DOI 10.1080/01926230490465874; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; Bogen KT, 2007, PROSTATE CANC PROSTA; Borowsky AD, 2006, NEOPLASIA, V8, P708, DOI 10.1593/neo.06373; Canene-Adams K, 2007, CANCER RES, V67, P836, DOI 10.1158/0008-5472.CAN-06-3462; Cerhan JR, 2004, CANCER EPIDEM BIOMAR, V13, P1114; Cross AJ, 2005, CANCER RES, V65, P11779, DOI 10.1158/0008-5472.CAN-05-2191; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; Di Paolo OA, 2005, INT J CANCER, V117, P8, DOI 10.1002/ijc.21152; Divisi Duilio, 2006, Acta Biomed, V77, P118; El-Zein R, 2006, MUTAT RES-FUND MOL M, V601, P1, DOI 10.1016/j.mrfmmm.2006.05.023; Enokida H, 2005, INT J CANCER, V116, P174, DOI 10.1002/ijc.21017; Etminan M, 2004, CANCER EPIDEM BIOMAR, V13, P340; Giovannucci E, 1998, P SOC EXP BIOL MED, V218, P129, DOI 10.3181/00379727-218-44277; Giovannucci E, 2003, CANCER EPIDEM BIOMAR, V12, P1403; Giovannucci E, 2002, JNCI-J NATL CANCER I, V94, P391, DOI 10.1093/jnci/94.5.391; GIOVANNUCCI E, 1995, J NATL CANCER I, V87, P1767, DOI 10.1093/jnci/87.23.1767; Gooderham NJ, 2002, MUTAT RES-FUND MOL M, V506, P91, DOI 10.1016/S0027-5107(02)00155-0; Harnack L, 2002, AM J CLIN NUTR, V76, P889, DOI 10.1093/ajcn/76.4.889; HASEGAWA R, 1993, CARCINOGENESIS, V14, P2553, DOI 10.1093/carcin/14.12.2553; Hikosaka A, 2004, CARCINOGENESIS, V25, P381, DOI 10.1093/carcin/bgh031; Hirose M, 2000, CANCER LETT, V155, P79, DOI 10.1016/S0304-3835(00)00411-0; Ikeda Y, 2005, CANCER LETT, V224, P23, DOI 10.1016/j.canlet.2004.10.040; Inaguma S, 2003, CANCER SCI, V94, P974, DOI 10.1111/j.1349-7006.2003.tb01387.x; John EM, 2011, NUTR CANCER, V63, P525, DOI 10.1080/01635581.2011.539311; Keating GA, 2004, J CHROMATOGR B, V802, P127, DOI 10.1016/j.jchromb.2003.10.047; Koh WP, 2005, EUR J CLIN NUTR, V59, P16, DOI 10.1038/sj.ejcn.1602027; Kristal AR, 2002, NUTR CANCER, V42, P1, DOI 10.1207/S15327914NC421_1; Lee Joanne, 2007, Cancer Control, V14, P78; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Li GX, 2012, CANCER PREV RES, V5, P963, DOI 10.1158/1940-6207.CAPR-12-0023; Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3; Mandimika T, 2012, FOOD CHEM, V131, P1272, DOI 10.1016/j.foodchem.2011.09.117; MILLS PK, 1989, CANCER, V64, P598, DOI 10.1002/1097-0142(19890801)64:3&lt;598::AID-CNCR2820640306&gt;3.0.CO;2-6; Nakagama H, 2005, CANCER SCI, V96, P627, DOI 10.1111/j.1349-7006.2005.00107.x; Nakai Y, 2007, CANCER RES, V67, P1378, DOI 10.1158/0008-5472.CAN-06-1336; Nelson CP, 2001, CANCER RES, V61, P103; Oba S, 2006, CANCER LETT, V244, P260, DOI 10.1016/j.canlet.2005.12.037; Panel WCRF, 1997, FOOD NUTR PREV CANC; Parsons JK, 2001, UROLOGY, V58, P619, DOI 10.1016/S0090-4295(01)01311-5; Parsons JK, 2001, PROSTATE, V49, P30, DOI 10.1002/pros.1115; Rautalahti M, 1997, CANCER LETT, V114, P235, DOI 10.1016/S0304-3835(97)04672-7; Rodriguez C, 2006, CANCER EPIDEM BIOMAR, V15, P211, DOI 10.1158/1055-9965.EPI-05-0614; Shirai T, 2002, MUTAT RES-FUND MOL M, V506, P129, DOI 10.1016/S0027-5107(02)00159-8; Shirai T, 1997, CANCER RES, V57, P195; Shirai T, 1999, CANCER LETT, V143, P217, DOI 10.1016/S0304-3835(99)00128-7; Smigel K, 1996, J NATL CANCER I, V88, P145, DOI 10.1093/jnci/88.3-4.145; Sonoda T, 2004, CANCER SCI, V95, P238, DOI 10.1111/j.1349-7006.2004.tb02209.x; Steinmetz KA, 1996, J AM DIET ASSOC, V96, P1027, DOI 10.1016/S0002-8223(96)00273-8; Stuart GR, 2000, CANCER RES, V60, P266; Tewari A, 2005, BJU INT, V96, P1247, DOI 10.1111/j.1464-410X.2005.05824.x; Van Horn L, 2010, J AM DIET ASSOC, V110, P1638, DOI 10.1016/j.jada.2010.08.018; Vaughn MP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025707; Wang R, 2008, CARCINOGENESIS, V29, P834, DOI 10.1093/carcin/bgn051; Wiseman MJ, 2005, J NUTR, V135, p3037S; Wong KY, 2005, NUTR CANCER, V52, P147, DOI 10.1207/s15327914nc5202_5; Wu K, 2006, CANCER EPIDEM BIOMAR, V15, P1120, DOI 10.1158/1055-9965.EPI-05-0782	57	10	10	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 27	2013	8	11							e79842	10.1371/journal.pone.0079842	http://dx.doi.org/10.1371/journal.pone.0079842			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261GG	24312188	Green Submitted, gold, Green Published			2023-01-03	WOS:000327652100016
J	Kang, MK; Lim, SS; Lee, JY; Yeo, KM; Kang, YH				Kang, Min-Kyung; Lim, Soon Sung; Lee, Jae-Yong; Yeo, Kyung Mok; Kang, Young-Hee			Anthocyanin-Rich Purple Corn Extract Inhibit Diabetes-Associated Glomerular Angiogenesis	PLOS ONE			English	Article							INDUCIBLE FACTOR-I; ENDOTHELIAL-CELLS; RENAL ALTERATIONS; NEPHROPATHY; HYPOXIA; ANGIOPOIETINS; MICE; REGULATOR; FIBROSIS; DISEASE	Diabetic nephropathy (DN) is one of the major diabetic complications and the leading cause of end-stage renal disease. Abnormal angiogenesis results in new vessels that are often immature and play a pathological role in DN, contributing to renal fibrosis and disrupting glomerular failure. Purple corn has been utilized as a daily food and exerts disease-preventive activities. This study was designed to investigate whether anthocyanin-rich purple corn extract (PCE) prevented glomerular angiogenesis under hyperglycemic conditions. Human endothelial cells were cultured in conditioned media of mesangial cells exposed to 33 mM high glucose (HG-HRMC-CM). PCE decreased endothelial expression of vascular endothelial growth factor (VEGF) and hypoxia inducible factor (HIF)-1 alpha induced by HG-HRMC-CM. Additionally, PCE attenuated the induction of the endothelial marker of platelet endothelial cell adhesion molecule (PECAM)-1 and integrin beta 3 enhanced in HG-HRMC-CM. Endothelial tube formation promoted by HG-HRMC-CM was disrupted in the presence of PCE. In the in vivo study employing db/db mice treated with 10 mg/kg PCE for 8 weeks, PCE alleviated glomerular angiogenesis of diabetic kidneys by attenuating the induction of VEGF and HIF-1 alpha. Oral administration of PCE retarded the endothelial proliferation in db/db mouse kidneys, evidenced by its inhibition of the induction of vascular endothelium-cadherin, PECAM-1 and Ki-67. PCE diminished the mesangial and endothelial induction of angiopoietin (Angpt) proteins under hypeglycemic conditions. The induction and activation of VEGF receptor 2 (VEGFR2) were dampened by treating PCE to db/db mice. These results demonstrate that PCE antagonized glomerular angiogenesis due to chronic hyperglycemia and diabetes through disturbing the Angpt-Tie-2 ligand-receptor system linked to renal VEGFR2 signaling pathway. Therefore, PCE may be a potent therapeutic agent targeting abnormal angiogenesis in DN leading to kidney failure.	[Kang, Min-Kyung; Lim, Soon Sung; Kang, Young-Hee] Hallym Univ, Dept Food & Nutr, Chunchon, South Korea; [Kang, Min-Kyung; Lim, Soon Sung; Kang, Young-Hee] Hallym Univ, Ctr Aging & Healthcare, Chunchon, South Korea; [Lee, Jae-Yong] Hallym Univ, Sch Med, Dept Biochem, Chunchon, South Korea; [Yeo, Kyung Mok] S&D Co Ltd, Chunchon, South Korea	Hallym University; Hallym University; Hallym University	Kang, YH (corresponding author), Hallym Univ, Dept Food & Nutr, Chunchon, South Korea.	yhkang@hallym.ac.kr			National Research Foundation of Korea through the Human Resource Training Project for Regional Innovation [2012-01-A-05-003-12-010100]; Ministry for Food, Agriculture, Forestry and Fisheries through the Korea Institute of Planning and Evaluation for Technology of Food, Agriculture, Forestry and Fisheries [109163-03-1-SB030]	National Research Foundation of Korea through the Human Resource Training Project for Regional Innovation(National Research Foundation of Korea); Ministry for Food, Agriculture, Forestry and Fisheries through the Korea Institute of Planning and Evaluation for Technology of Food, Agriculture, Forestry and Fisheries	This study was supported by the National Research Foundation of Korea through the Human Resource Training Project for Regional Innovation (2012-01-A-05-003-12-010100) and by a grant from the Ministry for Food, Agriculture, Forestry and Fisheries through the Korea Institute of Planning and Evaluation for Technology of Food, Agriculture, Forestry and Fisheries (109163-03-1-SB030). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Advani A, 2012, SEMIN NEPHROL, V32, P199, DOI 10.1016/j.semnephrol.2012.02.006; Ballermann BJ, 2007, NEPHRON PHYSIOL, V106, P19, DOI 10.1159/000101796; Bruns AF, 2010, TRAFFIC, V11, P161, DOI 10.1111/j.1600-0854.2009.01001.x; Choi S, 2013, NUTR RES PRACT, V7, P9, DOI 10.4162/nrp.2013.7.1.9; Costa PZ, 2013, LIFE SCI, V92, P1037, DOI 10.1016/j.lfs.2013.04.001; Crawford TN, 2009, CURR DIABETES REV, V5, P8, DOI 10.2174/157339909787314149; Dessapt-Baradez C, 2013, J AM SOC NEPHROL; Favot L, 2003, CARDIOVASC RES, V59, P479, DOI 10.1016/S0008-6363(03)00433-4; Fernandez PM, 2004, SEMIN THROMB HEMOST, V30, P31; Gu HF, 2013, DIABETES CARE, V36, P415, DOI 10.2337/dc12-1125; Hohenstein B, 2006, KIDNEY INT, V69, P1654, DOI 10.1038/sj.ki.5000294; Ichinose K, 2006, DIABETES, V55, P1232, DOI 10.2337/db05-1367; Kang MK, 2012, AM J PHYSIOL-RENAL, V303, pF1060, DOI 10.1152/ajprenal.00106.2012; Khoury CC, 2011, CONTRIB NEPHROL, V170, P83, DOI 10.1159/000324950; Kim TH, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/727143; Kolavennu V, 2008, DIABETES, V57, P714, DOI 10.2337/db07-1241; Lee HS, 2009, FEBS J, V276, P4622, DOI 10.1111/j.1742-4658.2009.07174.x; Li J, 2012, EUR J NUTR, V51, P961, DOI 10.1007/s00394-011-0274-4; Li J, 2012, J NUTR BIOCHEM, V23, P320, DOI 10.1016/j.jnutbio.2010.12.008; Lokmic Z, 2012, INT REV CEL MOL BIO, V296, P139, DOI 10.1016/B978-0-12-394307-1.00003-5; Long N, 2013, CANCER SCI, V104, P298, DOI 10.1111/cas.12078; Maeshima Yohei, 2005, Clin Exp Nephrol, V9, P271, DOI 10.1007/s10157-005-0388-1; Matsunaga N, 2010, PHYTOTHER RES, V24, pS42, DOI 10.1002/ptr.2895; Miyata T, 2010, NAT REV NEPHROL, V6, P83, DOI 10.1038/nrneph.2009.211; Nakagawa T, 2009, DIABETES, V58, P1471, DOI 10.2337/db09-0119; Nguyen Dung V, 2012, Front Endocrinol (Lausanne), V3, P170, DOI 10.3389/fendo.2012.00170; Saito D, 2011, AM J PHYSIOL-RENAL, V300, pF873, DOI 10.1152/ajprenal.00503.2010; Satchell SC, 2003, J NEPHROL, V16, P168; SAVAGE COS, 1994, KIDNEY INT, V45, P314, DOI 10.1038/ki.1994.40; Sid B, 2004, CRIT REV ONCOL HEMAT, V49, P245, DOI 10.1016/j.critrevonc.2003.09.009; Siddiqui IA, 2008, ONCOGENE, V27, P2055, DOI 10.1038/sj.onc.1210840; Sivaskandarajah GA, 2012, DIABETES, V61, P2958, DOI 10.2337/db11-1655; Smadja DM, 2011, ARTERIOSCL THROM VAS, V31, P551, DOI 10.1161/ATVBAHA.110.220624; Sun YM, 2013, BIOCHEM BIOPH RES CO, V433, P359, DOI 10.1016/j.bbrc.2013.02.120; Tait CR, 2004, J PATHOL, V204, P1, DOI 10.1002/path.1618; Tanaka J, 2012, PHYTOTHER RES, V26, P214, DOI 10.1002/ptr.3533; Tanaka T, 2013, NAT REV NEPHROL, V9, P211, DOI 10.1038/nrneph.2013.35; Westra J, 2010, CURR MED CHEM, V17, P254, DOI 10.2174/092986710790149783; Willard AL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/209538; Woolf AS, 2009, J AM SOC NEPHROL, V20, P239, DOI 10.1681/ASN.2008020243; Zent R, 2007, SEMIN NEPHROL, V27, P161, DOI 10.1016/j.semnephrol.2007.01.007	41	89	94	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 20	2013	8	11							e79823	10.1371/journal.pone.0079823	http://dx.doi.org/10.1371/journal.pone.0079823			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256LY	24278186	Green Published, Green Submitted, gold			2023-01-03	WOS:000327313100051
J	Uchino, K				Uchino, Ken			Strong stimulation acupuncture with needle manipulation improved recovery in Bell palsy	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Cleveland Clin, Cleveland, OH 44106 USA	Cleveland Clinic Foundation	Uchino, K (corresponding author), Cleveland Clin, Cleveland, OH 44106 USA.		Uchino, Ken/ABC-1611-2021	Uchino, Ken/0000-0001-9468-4172					0	3	3	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 19	2013	159	10							JC8	10.7326/0003-4819-159-10-201311190-02008	http://dx.doi.org/10.7326/0003-4819-159-10-201311190-02008			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276FB	24247698				2023-01-03	WOS:000328732700007
J	Rajapakse, BN; Neeman, T; Dawson, AH				Rajapakse, Bishan N.; Neeman, Teresa; Dawson, Andrew H.			The Effectiveness of a 'Train the Trainer' Model of Resuscitation Education for Rural Peripheral Hospital Doctors in Sri Lanka	PLOS ONE			English	Article							BASIC LIFE-SUPPORT; CARDIOPULMONARY-RESUSCITATION; CPR PERFORMANCE; MANAGEMENT; SKILLS; RELIABILITY; COMPETENCE; PATTERNS; FEEDBACK; STUDENTS	Background: Sri Lankan rural doctors based in isolated peripheral hospitals routinely resuscitate critically ill patients but have difficulty accessing training. We tested a train-the-trainer model that could be utilised in isolated rural hospitals. Methods: Eight selected rural hospital non-specialist doctors attended a 2-day instructor course. These "trained trainers" educated their colleagues in advanced cardiac life support at peripheral hospital workshops and we tested their students in resuscitation knowledge and skills pre and post training, and at 6- and 12-weeks. Knowledge was assessed through 30 multiple choice questions (MCQ), and resuscitation skills were assessed by performance in a video recorded simulated scenario of a cardiac arrest using a Resuci Anne Skill Trainer mannequin. Results/Discussion/Conclusion: Fifty seven doctors were trained. Pre and post training assessment was possible in 51 participants, and 6-week and 12-week follow up was possible for 43, and 38 participants respectively. Mean MCQ scores significantly improved over time (p<0.001), and a significant improvement was noted in "average ventilation volume", "compression count", and "compressions with no error", "adequate depth", "average depth", and "compression rate" (p<0.01). The proportion of participants with compression depth >= 40mm increased post intervention (p<0.05) and at 12-week follow up (p<0.05), and proportion of ventilation volumes between 400-1000mls increased post intervention (p<0.001). A significant increase in the proportion of participants who "checked for responsiveness", "opened the airway", "performed a breathing check", who used the "correct compression ratio", and who used an "appropriate facemask technique" was also noted (p<0.001). A train-the-trainer model of resuscitation education was effective in improving resuscitation knowledge and skills in Sri Lankan rural peripheral hospital doctors. Improvement was sustained to 12 weeks for most components of resuscitation knowledge and skills. Further research is needed to identify which components of training are most effective in leading to sustained improvement in resuscitation.	[Rajapakse, Bishan N.; Dawson, Andrew H.] Australian Natl Univ, Canberra, ACT, Australia; [Rajapakse, Bishan N.] Univ Peradeniya, South Asian Clin Toxicol Res Collaborat, Peradeniya, Sri Lanka; [Neeman, Teresa] Australian Natl Univ, Stat Consulting Unit, Canberra, ACT, Australia; [Dawson, Andrew H.] Univ Sydney, Royal Prince Alfred Hosp, Cent Clin Sch, Sydney, NSW 2006, Australia	Australian National University; University of Peradeniya; Australian National University; University of Sydney	Rajapakse, BN (corresponding author), Australian Natl Univ, Canberra, ACT, Australia.	bishan.rajapakse@gmail.com	Dawson, Andrew H/U-8041-2019	Dawson, Andrew H/0000-0002-8047-397X	international collaborative research Wellcome Trust/National Health and Medical Research Council [GR071669]	international collaborative research Wellcome Trust/National Health and Medical Research Council	This research was funded by an international collaborative research Wellcome Trust/National Health and Medical Research Council grant GR071669. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alirol E, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000603; Altintas KH, 2005, TOHOKU J EXP MED, V205, P157, DOI 10.1620/tjem.205.157; Arnold JL, 2005, EMERG MED CLIN N AM, V23, P133, DOI 10.1016/j.emc.2004.10.001; Aslan D, 2006, EUR J EMERG MED, V13, P9, DOI 10.1097/00063110-200602000-00003; Brennan RT, 1996, RESUSCITATION, V32, P85, DOI 10.1016/0300-9572(96)00967-7; Couper I D, 2005, Rural Remote Health, V5, P459; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Dawson AH, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000357; Delasobera BE, 2010, RESUSCITATION, V81, P217, DOI 10.1016/j.resuscitation.2009.10.013; Donnelly P, 2000, RESUSCITATION, V45, P195, DOI 10.1016/S0300-9572(00)00186-6; Eddleston M, 2000, QJM-INT J MED, V93, P715, DOI 10.1093/qjmed/93.11.715; Eddleston M, 2006, QJM-INT J MED, V99, P513, DOI 10.1093/qjmed/hcl065; Eddleston M, 2004, BMJ-BRIT MED J, V328, P42, DOI 10.1136/bmj.328.7430.42; Eddleston M, 2008, LANCET, V371, P597, DOI 10.1016/S0140-6736(07)61202-1; Enweronu-Laryea C, 2009, RESUSCITATION, V80, P1308, DOI 10.1016/j.resuscitation.2009.08.005; Finn J, 2010, RESUSCITATION, V81, P790, DOI 10.1016/j.resuscitation.2010.05.010; Gunnell D, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-357; Hazinski MF, 2005, CIRCULATION, V112, pIV206, DOI 10.1161/CIRCULATIONAHA.105.170809; Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218; Krautter M, 2011, TEACH LEARN MED, V23, P244, DOI 10.1080/10401334.2011.586917; KROMANN CB, 2009, ADV HLTH SCI ED THEO; Kromann CB, 2009, MED EDUC, V43, P21, DOI 10.1111/j.1365-2923.2008.03245.x; Kularatne SAM, 2002, POSTGRAD MED J, V78, P276, DOI 10.1136/pmj.78.919.276; Mpotos N, 2011, RESUSCITATION, V82, P896, DOI 10.1016/j.resuscitation.2011.02.024; Napier F, 2009, RESUSCITATION, V80, P1034, DOI 10.1016/j.resuscitation.2009.04.043; Nolan JP, 2010, RESUSCITATION, V81, pE1, DOI 10.1016/j.resuscitation.2010.08.002; O'Reilly GM, 2011, EMERG MED AUSTRALAS, V23, P632, DOI 10.1111/j.1742-6723.2011.01459.x; Opiyo N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001599; Perkins GD, 2008, RESUSCITATION, V77, P69, DOI 10.1016/j.resuscitation.2007.10.012; Perkins GD, 2006, INTENS CARE MED, V32, P1632, DOI 10.1007/s00134-006-0273-8; Perkins GD, 2010, RESUSCITATION, V81, P877, DOI 10.1016/j.resuscitation.2010.03.019; Perkins GD, 2002, INTENS CARE MED, V28, P698, DOI 10.1007/s00134-002-1291-9; Rajacich D, 2001, J Contin Educ Nurs, V32, P27; RAJAPAKSE BN, 2012, TXB EMERGENCY MED; Ringsted C, 2007, RESUSCITATION, V75, P153, DOI 10.1016/j.resuscitation.2007.03.003; Rosenthal ME, 2006, CHEST, V129, P1453, DOI 10.1378/chest.129.6.1453; Semeraro F, 2006, RESUSCITATION, V68, P101, DOI 10.1016/j.resuscitation.2005.06.011; Senarathna L, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-593; Senarathna L, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-373; Spooner BB, 2007, RESUSCITATION, V73, P417, DOI 10.1016/j.resuscitation.2006.10.017; Tweed M, 2001, RESUSCITATION, V51, P179, DOI 10.1016/S0300-9572(01)00404-X; WALKER M, 2004, POCKET GUIDE TEACHIN; Wayne DB, 2005, TEACH LEARN MED, V17, P210; Whitfield RH, 2003, RESUSCITATION, V59, P291, DOI 10.1016/S0300-9572(03)00246-6; 2010, CIRCULATION, V122, pS606, DOI DOI 10.1161/CIR.0B013E3181FE3E4C	45	9	10	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2013	8	11							e79491	10.1371/journal.pone.0079491	http://dx.doi.org/10.1371/journal.pone.0079491			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255CG	24255702	gold, Green Published, Green Submitted			2023-01-03	WOS:000327216200067
J	Ikeda, Y; Ozono, I; Tajima, S; Imao, M; Horinouchi, Y; Izawa-Ishizawa, Y; Kihira, Y; Miyamoto, L; Ishizawa, K; Tsuchiya, K; Tamaki, T				Ikeda, Yasumasa; Ozono, Iori; Tajima, Soichiro; Imao, Mizuki; Horinouchi, Yuya; Izawa-Ishizawa, Yuki; Kihira, Yoshitaka; Miyamoto, Licht; Ishizawa, Keisuke; Tsuchiya, Koichiro; Tamaki, Toshiaki			Iron Chelation by Deferoxamine Prevents Renal Interstitial Fibrosis in Mice with Unilateral Ureteral Obstruction	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; CHRONIC HEPATITIS-C; HYPOXIA PROMOTES FIBROGENESIS; SERUM AMINOTRANSFERASE LEVELS; DIVALENT METAL TRANSPORTER; NADPH OXIDASE ACTIVITY; OXIDATIVE STRESS; ANGIOTENSIN-II; RAT-KIDNEY; UP-REGULATION	Renal fibrosis plays an important role in the onset and progression of chronic kidney diseases (CKD). Although several mechanisms underlying renal fibrosis and candidate drugs for its treatment have been identified, the effect of iron chelator on renal fibrosis remains unclear. In the present study, we examined the effect of an iron chelator, deferoxamine (DFO), on renal fibrosis in mice with surgically induced unilateral ureter obstruction (UUO). Mice were divided into 4 groups: UUO with vehicle, UUO with DFO, sham with vehicle, and sham with DFO. One week after surgery, augmented renal tubulointerstitial fibrosis and the expression of collagen I, III, and IV increased in mice with UUO; these changes were suppressed by DFO treatment. Similarly, UUO-induced macrophage infiltration of renal interstitial tubules was reduced in UUO mice treated with DFO. UUO-induced expression of inflammatory cytokines and extracellular matrix proteins was abrogated by DFO treatment. DFO inhibited the activation of the transforming growth factor-beta 1 (TGF-beta 1)-Smad3 pathway in UUO mice. UUO-induced NADPH oxidase activity and p22(phox) expression were attenuated by DFO. In the kidneys of UUO mice, divalent metal transporter 1, ferroportin, and ferritin expression was higher and transferrin receptor expression was lower than in sham-operated mice. Increased renal iron content was observed in UUO mice, which was reduced by DFO treatment. These results suggest that iron reduction by DFO prevents renal tubulointerstitial fibrosis by regulating TGF-beta-Smad signaling, oxidative stress, and inflammatory responses.	[Ikeda, Yasumasa; Ozono, Iori; Tajima, Soichiro; Horinouchi, Yuya; Izawa-Ishizawa, Yuki; Kihira, Yoshitaka; Tamaki, Toshiaki] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Pharmacol, Tokushima 770, Japan; [Ozono, Iori] Univ Tokushima, Fac Med, Student Lab, Tokushima 770, Japan; [Imao, Mizuki; Miyamoto, Licht; Ishizawa, Keisuke; Tsuchiya, Koichiro] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Med Pharmacol, Tokushima 770, Japan	Tokushima University; Tokushima University; Tokushima University	Ikeda, Y (corresponding author), Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Pharmacol, Tokushima 770, Japan.	yasuike@tokushima-u.ac.jp		/0000-0003-2331-964X; Ikeda, Yasumasa/0000-0003-4318-7349	Osaka Foundation for Promotion of Fundamental Medical Research; JSPS KAKENHI Grant [24591203]; Grants-in-Aid for Scientific Research [25860063] Funding Source: KAKEN	Osaka Foundation for Promotion of Fundamental Medical Research; JSPS KAKENHI Grant(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The study was supported by Grants for the Regional Innovation Cluster Program and the Setsuro Fujii Memorial from the Osaka Foundation for Promotion of Fundamental Medical Research to T.T. and by a JSPS KAKENHI Grant, number 24591203, to Y.I. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALVAREZ RJ, 1992, KIDNEY INT, V41, P14, DOI 10.1038/ki.1992.3; Arosio P, 2009, BBA-GEN SUBJECTS, V1790, P589, DOI 10.1016/j.bbagen.2008.09.004; Azumi H, 1999, CIRCULATION, V100, P1494, DOI 10.1161/01.CIR.100.14.1494; BARRY M, 1974, BMJ-BRIT MED J, V2, P16, DOI 10.1136/bmj.2.5909.16; Cairo G, 2002, FREE RADICAL BIO MED, V32, P1237, DOI 10.1016/S0891-5849(02)00825-0; Camaschella C, 2005, BLOOD, V106, P3710, DOI 10.1182/blood-2005-05-1857; Canonne-Hergaux FS, 2002, KIDNEY INT, V62, P147, DOI 10.1046/j.1523-1755.2002.00405.x; Collins AJ, 2009, CLIN J AM SOC NEPHRO, V4, pS5, DOI 10.2215/CJN.05980809; Cooksey RC, 2010, AM J PHYSIOL-ENDOC M, V298, pE1236, DOI 10.1152/ajpendo.00022.2010; Cuajungco MP, 2000, ANN NY ACAD SCI, V920, P292; Facchini FS, 2002, GASTROENTEROLOGY, V122, P931, DOI 10.1053/gast.2002.32403; Ferguson CJ, 2003, KIDNEY INT, V64, P1755, DOI 10.1046/j.1523-1755.2003.00274.x; Ferguson CJ, 2001, AM J PHYSIOL-RENAL, V280, pF803, DOI 10.1152/ajprenal.2001.280.5.F803; FULLER SD, 1986, J CELL BIOL, V103, P1767, DOI 10.1083/jcb.103.5.1767; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Grande MT, 2009, NAT REV NEPHROL, V5, P319, DOI 10.1038/nrneph.2009.74; Grgic I, 2012, PEDIATR NEPHROL, V27, P183, DOI 10.1007/s00467-011-1772-6; Harmatz P, 2000, BLOOD, V96, P76, DOI 10.1182/blood.V96.1.76.013k22_76_79; HAYASHI H, 1995, J HEPATOL, V22, P268, DOI 10.1016/0168-8278(95)80278-9; HAYASHI H, 1994, AM J GASTROENTEROL, V89, P986; Higgins DF, 2007, J CLIN INVEST, V117, P3810, DOI 10.1172/JCI30487; Ikeda Y, 2013, AM J PHYSIOL-RENAL, V304, pF1028, DOI 10.1152/ajprenal.00473.2012; Ikeda Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040465; Inazaki K, 2004, KIDNEY INT, V66, P597, DOI 10.1111/j.1523-1755.2004.00779.x; Ishizaka N, 2005, ARTERIOSCL THROM VAS, V25, P2282, DOI 10.1161/01.ATV.0000181763.57495.2b; Ishizaka N, 2002, CIRCULATION, V106, P1840, DOI 10.1161/01.CIR.0000031161.77536.02; Ishizaka N, 2007, HYPERTENS RES, V30, P195, DOI 10.1291/hypres.30.195; Iwano M, 2004, CURR OPIN NEPHROL HY, V13, P279, DOI 10.1097/00041552-200405000-00003; Jung M, 2012, KIDNEY INT, V81, P969, DOI 10.1038/ki.2011.446; KANETO H, 1993, KIDNEY INT, V44, P313, DOI 10.1038/ki.1993.246; Kato J, 2001, CANCER RES, V61, P8697; Kawada N, 1999, KIDNEY INT, V56, P1004, DOI 10.1046/j.1523-1755.1999.00612.x; Kimura F, 2005, HEPATO-GASTROENTEROL, V52, P563; Kruszewski M, 2003, MUTAT RES-FUND MOL M, V531, P81, DOI 10.1016/j.mrfmmm.2003.08.004; Li LX, 2006, ARTERIOSCL THROM VAS, V26, P2638, DOI 10.1161/01.ATV.0000245820.34238.da; Li LX, 2009, ARTERIOSCL THROM VAS, V29, P732, DOI 10.1161/ATVBAHA.108.183210; Liu B, 2011, J BIOL CHEM, V286, P4248, DOI 10.1074/jbc.M110.158980; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Minamiyama Y, 2010, AM J PHYSIOL-ENDOC M, V298, pE1140, DOI 10.1152/ajpendo.00620.2009; Miyajima A, 2000, KIDNEY INT, V58, P2301, DOI 10.1046/j.1523-1755.2000.00414.x; Naito Y, 2013, J HYPERTENS, V31, P1203, DOI 10.1097/HJH.0b013e328360381d; Naito Y, 2012, J HYPERTENS, V30, P2192, DOI 10.1097/HJH.0b013e3283581a64; Naito Y, 2011, HYPERTENSION, V57, P497, DOI 10.1161/HYPERTENSIONAHA.110.159681; Neufeld EJ, 2006, BLOOD, V107, P3436, DOI 10.1182/blood-2006-02-002394; Norman JT, 2000, KIDNEY INT, V58, P2351, DOI 10.1046/j.1523-1755.2000.00419.x; Oberg BP, 2004, KIDNEY INT, V65, P1009, DOI 10.1111/j.1523-1755.2004.00465.x; Olivieri NF, 1998, NEW ENGL J MED, V339, P417, DOI 10.1056/NEJM199808133390701; Saito K, 2005, AM J PHYSIOL-HEART C, V288, pH1836, DOI 10.1152/ajpheart.00679.2004; Saito K, 2004, HYPERTENS RES, V27, P599, DOI 10.1291/hypres.27.599; Sartori M, 2001, DIGEST LIVER DIS, V33, P157, DOI 10.1016/S1590-8658(01)80072-4; Sato M, 2003, J CLIN INVEST, V112, P1486, DOI 10.1172/JCI200319270; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; Sugiyama H, 2005, NEPHROL DIAL TRANSPL, V20, P2670, DOI 10.1093/ndt/gfi045; Tajima S, 2012, AM J PHYSIOL-ENDOC M, V302, pE77, DOI 10.1152/ajpendo.00033.2011; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Vielhauer V, 2001, J AM SOC NEPHROL, V12, P1173, DOI 10.1681/ASN.V1261173; WANG GL, 1993, BLOOD, V82, P3610; Ward DT, 2005, BBA-MOL BASIS DIS, V1740, P79, DOI 10.1016/j.bbadis.2005.01.008; Wolff NA, 2011, J CELL MOL MED, V15, P209, DOI 10.1111/j.1582-4934.2009.00985.x; Yano M, 2002, AM J GASTROENTEROL, V97, P133, DOI 10.1111/j.1572-0241.2002.05436.x	61	58	60	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2014	9	2							e89355	10.1371/journal.pone.0089355	http://dx.doi.org/10.1371/journal.pone.0089355			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AB3TA	24586712	Green Published, gold			2023-01-03	WOS:000331711900131
J	Kirui, DK; Mai, JH; Palange, AL; Qin, GT; van de Ven, AL; Liu, XW; Shen, HF; Ferrari, M				Kirui, Dickson K.; Mai, Juahua; Palange, Anna-Lisa; Qin, Guoting; van de Ven, Anne L.; Liu, Xuewu; Shen, Haifa; Ferrari, Mauro			Transient Mild Hyperthermia Induces E-selectin Mediated Localization of Mesoporous Silicon Vectors in Solid Tumors	PLOS ONE			English	Article							ENDOTHELIAL-CELLS; NANOPARTICLE EXTRAVASATION; MULTISTAGE NANOVECTORS; IN-VIVO; DELIVERY; ACCUMULATION; PENETRATION; DOXORUBICIN; RECEPTORS; LIPOSOMES	Background: Hyperthermia treatment has been explored as a strategy to overcome biological barriers that hinder effective drug delivery in solid tumors. Most studies have used mild hyperthermia treatment (MHT) to target the delivery of thermo-sensitive liposomes carriers. Others have studied its application to permeabilize tumor vessels and improve tumor interstitial transport. However, the role of MHT in altering tumor vessel interfacial and adhesion properties and its relationship to improved delivery has not been established. In the present study, we evaluated effects of MHT treatment on tumor vessel flow dynamics and expression of adhesion molecules and assessed enhancement in particle localization using mesoporous silicon vectors (MSVs). We also determined the optimal time window at which maximal accumulation occur. Results: In this study, using intravital microscopy analyses, we showed that temporal mild hyperthermia (similar to 1 W/cm(2)) amplified delivery and accumulation of MSVs in orthotopic breast cancer tumors. The number of discoidal MSVs (1000x400 nm) adhering to tumor vasculature increased 6-fold for SUM159 tumors and 3-fold for MCF-7 breast cancer tumors. By flow chamber experiments and Western blotting, we established that a temporal increase in E-selectin expression correlated with enhanced particle accumulation. Furthermore, MHT treatment was shown to increase tumor perfusion in a time-dependent fashion. Conclusions: Our findings reveal that well-timed mild hyperthermia treatment can transiently elevate tumor transport and alter vascular adhesion properties and thereby provides a means to enhance tumor localization of non-thermally sensitive particles such as MSVs. Such enhancement in accumulation could be leveraged to increase therapeutic efficacy and reduce drug dosing in cancer therapy.	[Kirui, Dickson K.; Mai, Juahua; Palange, Anna-Lisa; Qin, Guoting; van de Ven, Anne L.; Liu, Xuewu; Shen, Haifa; Ferrari, Mauro] Houston Methodist Res Inst, Dept NanoMed, Houston, TX 77030 USA; [Shen, Haifa] Weill Cornell Med Coll, Dept Cell & Dev Biol, New York, NY USA; [Ferrari, Mauro] Weill Cornell Med Coll, Dept Internal Med, New York, NY USA	The Methodist Hospital System; The Methodist Hospital - Houston; Cornell University; Cornell University	Ferrari, M (corresponding author), Houston Methodist Res Inst, Dept NanoMed, Houston, TX 77030 USA.	mferrari@houstonmethodist.org	Qin, Guoting/A-7847-2010	van de Ven, Anne/0000-0002-0347-4004; Mai, Junhua/0000-0001-8374-4352; Qin, Guoting/0000-0001-8916-6311; Palange, Anna Lisa/0000-0002-2584-7297	Methodist Hospital Research Institute; Ernest Cockrell Jr. Distinguished Endowed Chair; National Institute of Health (NIH)'s Physical Sciences Oncology Center (PS-OC) [U54CA143837]; Department of Defense [W81XWH-09-1-0212]; NIH [U54CA151668]; NATIONAL CANCER INSTITUTE [U54CA143837, U54CA151668] Funding Source: NIH RePORTER	Methodist Hospital Research Institute; Ernest Cockrell Jr. Distinguished Endowed Chair; National Institute of Health (NIH)'s Physical Sciences Oncology Center (PS-OC); Department of Defense(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors gratefully acknowledge funding provided by the Methodist Hospital Research Institute, including the Ernest Cockrell Jr. Distinguished Endowed Chair and National Institute of Health (NIH)'s Physical Sciences Oncology Center (PS-OC) U54CA143837. Authors also acknowledge partial supports from the following funding sources: Department of Defense (W81XWH-09-1-0212) and NIH (U54CA151668). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adriani G, 2012, BIOMATERIALS, V33, P5504, DOI 10.1016/j.biomaterials.2012.04.027; Agarwal A, 2011, ACS NANO, V5, P4919, DOI 10.1021/nn201010q; Atkinson RL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001447; BICHER HI, 1980, RADIOLOGY, V137, P523, DOI 10.1148/radiology.137.2.7433686; Blanco E, 2013, CANCER LETT, V334, P245, DOI 10.1016/j.canlet.2012.07.027; Choi R, 2010, LANGMUIR, V26, P17520, DOI 10.1021/la1029728; Dreher MR, 2007, CANCER RES, V67, P4418, DOI 10.1158/0008-5472.CAN-06-4444; Dreher MR, 2006, JNCI-J NATL CANCER I, V98, P335, DOI 10.1093/jnci/djj070; Godin B, 2011, ACCOUNTS CHEM RES, V44, P979, DOI 10.1021/ar200077p; Grull H, 2012, J CONTROL RELEASE, V161, P317, DOI 10.1016/j.jconrel.2012.04.041; Hildebrandt B, 2002, CRIT REV ONCOL HEMAT, V43, P33, DOI 10.1016/S1040-8428(01)00179-2; Hu M, 2006, CHEM SOC REV, V35, P1084, DOI 10.1039/b517615h; Huang XH, 2006, J AM CHEM SOC, V128, P2115, DOI 10.1021/ja057254a; Jain PK, 2006, J PHYS CHEM B, V110, P7238, DOI 10.1021/jp057170o; Jain RK, 2013, J CLIN ONCOL, V31, P2205, DOI 10.1200/JCO.2012.46.3653; JANSEN W, 1990, PATHOL RES PRACT, V186, P247, DOI 10.1016/S0344-0338(11)80542-X; Joshi N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032067; Kapp D. S., 2000, PRINCIPLES HYPERTHER; Kaufmann JE, 2000, J CLIN INVEST, V106, P107, DOI 10.1172/JCI9516; Kim P, 2013, PROTOCOL EXCHANGE; Kirui D, 2013, NANOMED-NANOTECHNOL, DOI [10.1016/j.nano.2013.11.001, DOI 10.1016/J.NAN0.2013.11.001]; Kong G, 2001, CANCER RES, V61, P3027; Kong G, 2000, CANCER RES, V60, P4440; Kruskal JB, 2001, J VASC INTERV RADIOL, V12, P1193, DOI 10.1016/S1051-0443(07)61679-0; LEEUWENBERG JFM, 1992, IMMUNOLOGY, V77, P543; Li L, 2013, J CONTROL RELEASE, V167, P130, DOI 10.1016/j.jconrel.2013.01.026; Liu M, 2012, PLOS ONE, V7; Mann AP, 2011, ADV MATER, V23, pH278, DOI 10.1002/adma.201101541; Martinez JO, 2013, BIOMATERIALS, V34, P8469, DOI 10.1016/j.biomaterials.2013.07.049; Melancon MP, 2011, J CONTROL RELEASE, V156, P265, DOI 10.1016/j.jconrel.2011.06.030; Mitsunaga M, 2011, NAT MED, V17, P1685, DOI 10.1038/nm.2554; OVERGAARD J, 1995, LANCET, V345, P540, DOI 10.1016/S0140-6736(95)90463-8; Parodi A, 2013, NAT NANOTECHNOL, V8, P61, DOI 10.1038/nnano.2012.212; Pasut G, 2012, J CONTROL RELEASE, V161, P461, DOI 10.1016/j.jconrel.2011.10.037; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; ROVAINEN CM, 1993, J CEREBR BLOOD F MET, V13, P359, DOI 10.1038/jcbfm.1993.49; Shen HF, 2013, CLIN CANCER RES, V19, P1806, DOI 10.1158/1078-0432.CCR-12-2764; SONG CW, 1984, CANCER RES, V44, P4721; Tanaka T, 2010, CANCER RES, V70, P3687, DOI 10.1158/0008-5472.CAN-09-3931; Tasciotti E, 2008, NAT NANOTECHNOL, V3, P151, DOI 10.1038/nnano.2008.34; van de Ven AL, 2012, AIP ADV, V2, DOI 10.1063/1.3699060; van de Ven AL, 2012, J CONTROL RELEASE, V158, P148, DOI 10.1016/j.jconrel.2011.10.021; van der Zee J, 2002, ANN ONCOL, V13, P1173, DOI 10.1093/annonc/mdf280; Vertrees RA, 2005, CANCER BIOL THER, V4, P1144, DOI 10.4161/cbt.4.10.2074; Visaria RK, 2006, MOL CANCER THER, V5, P1014, DOI 10.1158/1535-7163.MCT-05-0381; von Maltzahn G, 2011, NAT MATER, V10, P545, DOI [10.1038/nmat3049, 10.1038/NMAT3049]; Xiaojing Z, 2009, NANOTECHNOLOGY; Xu R, 2013, SMALL, V9, P1799, DOI 10.1002/smll.201201510; Yokoi K, 2013, CANCER LETT, V334, P319, DOI 10.1016/j.canlet.2012.09.001; You J, 2012, CANCER RES, V72, P4777, DOI 10.1158/0008-5472.CAN-12-1003; Yudina A, 2012, J CONTROL RELEASE, V161, P90, DOI 10.1016/j.jconrel.2012.04.018; Zhu L, 2013, INTEGR BIOL-UK, V5, P96, DOI 10.1039/c2ib20135f	52	11	11	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2014	9	2							e86489	10.1371/journal.pone.0086489	http://dx.doi.org/10.1371/journal.pone.0086489			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AB3RA	24558362	Green Published, gold, Green Submitted			2023-01-03	WOS:000331706700008
J	Lang, E				Lang, Eddy			In out-of-hospital cardiac arrest, mechanical CPR did not improve survival compared with manual CPR	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Calgary, Calgary, AB, Canada	University of Calgary	Lang, E (corresponding author), Univ Calgary, Calgary, AB, Canada.		Lang, Eddy/AAS-2080-2020; Lang, Eddy/I-4759-2014	Lang, Eddy/0000-0003-0850-4337	Uppsala University and Physio-Control/Jolife AB	Uppsala University and Physio-Control/Jolife AB	Uppsala University and Physio-Control/Jolife AB.	Brooks SC, 2011, COCHRANE DB SYST REV, P1; Taniguchi D, 2012, EMERG MED CLIN N AM, V30, P1, DOI 10.1016/j.emc.2011.09.003; Westfall M, 2013, CRIT CARE MED, V41, P1782, DOI 10.1097/CCM.0b013e31828a24e3	3	0	0	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 18	2014	160	4							JC5	10.7326/0003-4819-160-4-201402180-02005	http://dx.doi.org/10.7326/0003-4819-160-4-201402180-02005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC8RF	24534939				2023-01-03	WOS:000350635100004
J	Mason, JM; Thomas, KS; Crook, AM; Foster, KA; Chalmers, JR; Nunn, AJ; Williams, HC				Mason, James M.; Thomas, Kim S.; Crook, Angela M.; Foster, Katharine A.; Chalmers, Joanne R.; Nunn, Andrew J.; Williams, Hywel C.			Prophylactic Antibiotics to Prevent Cellulitis of the Leg: Economic Analysis of the PATCH I & II Trials	PLOS ONE			English	Article							LOWER-LIMB CELLULITIS; RECURRENT ERYSIPELAS; PENICILLIN	Background: Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. We assessed the cost-effectiveness of prophylactic antibiotic treatment to prevent the recurrence of cellulitis using low dose penicillin V in patients following a first episode (6 months prophylaxis) and more recurrent cellulitis (12 months prophylaxis, or 6 months in those declining 12 months). Methods: Within-trial cost-effectiveness analysis was conducted using the findings of two randomised placebo-controlled multicentre trials (PATCH I and PATCH II), in which patients recruited in the UK and Ireland were followed-up for up to 3 years. Incremental cost, reduction in recurrence, cost per recurrence prevented and cost/QALY were estimated. National unit and reference costs for England in 2010 were applied to resource use, exploring NHS and societal perspectives. A total of 397 patients from the two trials contributed to the analysis. Results: There was a 29% reduction in the number of recurrences occurring within the trial (IRR: 0.71 95%CI: 0.53 to 0.90, p = 0.02), corresponding to an absolute reduction of recurrence of 0.31 recurrences/patient (95%CI: 0.05 to 0.59, p = 0.02). Incremental costs of prophylaxis suggested a small cost saving but were not statistically significant, comparing the two groups. If a decision-maker is willing to pay up to 25,000 pound/QALY then there is a 66% probability of antibiotic prophylaxis being cost-effective from an NHS perspective, rising to 76% probability from a secondary, societal perspective. Conclusion: Following first episode or recurrent cellulitis of the leg, prophylactic low dose penicillin is a very low cost intervention which, on balance, is effective and cost-effective at preventing subsequent attacks. Antibiotic prophylaxis reduces cellulitis recurrence by nearly a third but is not associated with a significant increase in costs.	[Mason, James M.] Univ Durham, Durham Clin Trials Unit, Stockton On Tees, England; [Thomas, Kim S.; Foster, Katharine A.; Chalmers, Joanne R.; Williams, Hywel C.] Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham NG7 2RD, England; [Crook, Angela M.; Nunn, Andrew J.] MRC, Clin Trials Unit, London, England	Durham University; University of Nottingham; Medical Research Council Clinical Trials Unit	Mason, JM (corresponding author), Univ Durham, Durham Clin Trials Unit, Queens Campus, Stockton On Tees, England.	j.m.mason@durham.ac.uk	Mason, James M/D-9904-2011	Mason, James M/0000-0001-9210-4082; williams, hywel/0000-0002-5646-3093; Thomas, Kim/0000-0001-7785-7465; Nunn, Andrew/0000-0002-9158-4595; Chalmers, Joanne/0000-0002-2281-7367	Action Medical Research; Bupa Foundation; National Institute for Health Research [NF-SI-0611-10246] Funding Source: researchfish; Alzheimer&quot;s Society [1651] Funding Source: researchfish	Action Medical Research; Bupa Foundation; National Institute for Health Research(National Institute for Health Research (NIHR)); Alzheimer&quot;s Society	PATCH I was funded by Action Medical Research; PATCH II was funded by the Bupa Foundation. Neither funder had any role in the study design; data collection, analysis, and interpretation of data; in the writing of this report; or in the decision to submit the article for publication.	[Anonymous], 2008, UPD GUID METH TECHN; Barber JA, 2000, STAT MED, V19, P3219, DOI 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P; BERNARD P, 1989, ARCH DERMATOL, V125, P779, DOI 10.1001/archderm.125.6.779; British Medical Association Royal Pharmaceutical Society of Great Britain, 2010, BRIT NATL FORMULARY; CHAKROUN M, 1994, MED MALADIES INFECT, V24, P894, DOI 10.1016/S0399-077X(05)80579-7; Cox NH, 2006, BRIT J DERMATOL, V155, P947, DOI 10.1111/j.1365-2133.2006.07419.x; Cox NH, 1998, J ROY SOC MED, V91, P634, DOI 10.1177/014107689809101206; CREST, 2005, GUID MAN CELL AD; Curtis L., 2012, UNIT COSTS HLTH SOCI; Department of Health, 2012, NHS HOSP TRUST REF C; Fenwick E, 2004, HEALTH ECON, V13, P405, DOI 10.1002/hec.903; FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; Goettsch WG, 2006, J EUR ACAD DERMATOL, V20, P834, DOI 10.1111/j.1468-3083.2006.01657.x; Hospital Episode Statistics, 2011, HESONLINE INP DAT PR; Jeng A, 2010, MEDICINE, V89, P217, DOI 10.1097/MD.0b013e3181e8d635; JORUPRONSTROM C, 1987, INFECTION, V15, P105, DOI 10.1007/BF01650206; Kind P, 1998, BMJ-BRIT MED J, V316, P736, DOI 10.1136/bmj.316.7133.736; KREMER M, 1991, J INFECTION, V22, P37, DOI 10.1016/0163-4453(91)90898-3; Levell NJ, 2011, BRIT J DERMATOL, V164, P1326, DOI 10.1111/j.1365-2133.2011.10275.x; NHS Information Centre, 2012, HRG4 2010 11 REF COS; Office of National Statistics, 2011, ANN SURV HOURS EARN; SJOBLOM AC, 1993, INFECTION, V21, P390, DOI 10.1007/BF01728920; Soo JK, 2008, BRIT J DERMATOL, V158, P1350, DOI 10.1111/j.1365-2133.2007.08423.x; Thomas KS, 2013, NEW ENGL J MED, V368, P1695, DOI 10.1056/NEJMoa1206300	24	11	11	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2014	9	2							e82694	10.1371/journal.pone.0082694	http://dx.doi.org/10.1371/journal.pone.0082694			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7IR	24551029	Green Submitted, Green Accepted, gold, Green Published			2023-01-03	WOS:000331271500002
J	Civaner, MM				Civaner, M. Murat			PERSONAL VIEW What should I tell my students now the law contravenes medical ethics?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Uludag Univ, Dept Med Eth, Sch Med, Bursa, Turkey	Uludag University	Civaner, MM (corresponding author), Uludag Univ, Dept Med Eth, Sch Med, Bursa, Turkey.	mcivaner@gmail.com	/S-4188-2019	/0000-0001-5376-3499				Civaner M, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3789; Hurriyet Daily News, 2013, HURRIYET DAILY  1211; Iacopino V, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4933; T urkish Medical Association, 2013, REP ASS HLTH PROBL P; Turkish Medical Association, PHYS PROF COD ETH; World Medical Association, DECL GEN; World Medical Association, INT COD MED ETH	7	0	0	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 13	2014	348								g1503	10.1136/bmj.g1503	http://dx.doi.org/10.1136/bmj.g1503			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AA9WZ	24525052				2023-01-03	WOS:000331445000008
J	Koo, HM; Kim, CH; Doh, FM; Lee, MJ; Kim, EJ; Han, JH; Han, JS; Oh, HJ; Park, JT; Han, SH; Yoo, TH; Kang, SW				Koo, Hyang Mo; Kim, Chan Ho; Doh, Fa Mee; Lee, Mi Jung; Kim, Eun Jin; Han, Jae Hyun; Han, Ji Suk; Oh, Hyung Jung; Park, Jung Tak; Han, Seung Hyeok; Yoo, Tae-Hyun; Kang, Shin-Wook			The Relationship of Initial Transferrin Saturation to Cardiovascular Parameters and Outcomes in Patients Initiating Dialysis	PLOS ONE			English	Article							CHRONIC HEART-FAILURE; CHRONIC KIDNEY-DISEASE; LEFT-VENTRICULAR HYPERTROPHY; IRON-OVERLOAD CARDIOMYOPATHY; C-REACTIVE PROTEIN; QUALITY-OF-LIFE; FERRIC CARBOXYMALTOSE; RISK-FACTOR; FOLLOW-UP; ANEMIA	Background: The prognostic importance of anemia for cardiovascular (CV) events and mortality has been extensively investigated. However, little is known about the impact of transferrin saturation (TSAT), a marker reflecting the availability of iron for erythropoiesis, on clinical outcome in dialysis patients. Methods: A total of 879 anemic incident dialysis patients were recruited from the Clinical Research Center for End-Stage Renal Disease in Korea and were divided into 3 groups according to baseline TSAT of <= 20%, 20-40%, and > 40%. Results: There were no differences in hemoglobin levels and the proportion of patients on erythropoiesis-stimulating agents or iron supplements among the 3 groups. During a mean follow-up duration of 19.3 months, 51 (5.8%) patients died. CV composite (11.71 vs. 5.55 events/100 patient-years, P = 0.001) and all-cause mortality rates (5.38 vs. 2.31 events/100 patient-years, P = 0.016) were significantly higher in patients with TSAT <= 20% compared to those with TSAT 20-40% (reference group). Cox regression analysis revealed that patients with TSAT <= 20% had 1.62- and 2.19-fold higher risks for CV composite outcome (P = 0.046) and all-cause mortality (P = 0.030). Moreover, TSAT <= 20% was significantly associated with left ventricular hypertrophy [odds ratio (OR) = 1.46], high-sensitivity C-reactive protein >= 3 mg/dL (OR = 2.09), N-terminal pro B-type natriuretic peptide >= 10000 pg/mL (OR = 2.04), and troponin-T >= 0.1 ng/mL (OR = 2.02), on logistic regression analysis. Conclusions: Low TSAT was a significant independent risk factor for adverse clinical outcome in incident dialysis patients with anemia, which may be partly attributed to cardiac dysfunction and inflammation.	[Koo, Hyang Mo; Kim, Chan Ho; Doh, Fa Mee; Lee, Mi Jung; Kim, Eun Jin; Han, Jae Hyun; Han, Ji Suk; Oh, Hyung Jung; Park, Jung Tak; Han, Seung Hyeok; Yoo, Tae-Hyun; Kang, Shin-Wook] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Kang, Shin-Wook] Yonsei Univ, Brain Korea PLUS Project Med Sci 21, Seoul 120749, South Korea	Yonsei University; Yonsei University Health System; Yonsei University	Kang, SW (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea.	kswkidney@yuhs.ac	Han, Seung Hyeok/K-4559-2018; Han, Seung Hyeok/W-8825-2019	Han, Seung Hyeok/0000-0001-7923-5635; Han, Seung Hyeok/0000-0001-7923-5635; doh, fa mee/0000-0002-4780-6728; Yoo, Tae-Hyun/0000-0002-9183-4507; Lee, Mi Jung/0000-0001-8888-029X; Kang, Shin-Wook/0000-0002-5677-4756; Park, Jung Tak/0000-0002-2325-8982	Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea [HI10C2020]	Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea	None of the authors received any significant primary financial arrangements with commercial companies that produce or sell products or with competitors of such companies. This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (HI10C2020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anand IS, 2008, J AM COLL CARDIOL, V52, P501, DOI 10.1016/j.jacc.2008.04.044; Anker SD, 2009, NEW ENGL J MED, V361, P2436, DOI 10.1056/NEJMoa0908355; Beutler E, 2006, BLOOD, V107, P1747, DOI 10.1182/blood-2005-07-3046; Cachofeiro V, 2008, KIDNEY INT, V74, pS4, DOI 10.1038/ki.2008.516; Comin-Colet J, 2013, EUR HEART J, V34, P30, DOI 10.1093/eurheartj/ehr504; DALLMAN PR, 1986, ANNU REV NUTR, V6, P13, DOI 10.1146/annurev.nu.06.070186.000305; Danesh J, 2004, NEW ENGL J MED, V350, P1387, DOI 10.1056/NEJMoa032804; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; Dong F, 2005, CLIN SCI, V109, P277, DOI 10.1042/CS20040278; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Ellervik C, 2011, CLIN CHEM, V57, P459, DOI 10.1373/clinchem.2010.156802; Franchini M, 2008, ANN HEMATOL, V87, P167, DOI 10.1007/s00277-007-0416-1; Han SS, 2010, PERITON DIALYSIS INT, V30, P300, DOI 10.3747/pdi.2009.00064; Jankowska EA, 2013, EUR HEART J, V34, P816, DOI 10.1093/eurheartj/ehs224; Jankowska EA, 2010, EUR HEART J, V31, P1872, DOI 10.1093/eurheartj/ehq158; Keane WF, 2003, KIDNEY INT, V63, P1499, DOI 10.1046/j.1523-1755.2003.00885.x; Kovesdy CP, 2006, KIDNEY INT, V69, P560, DOI 10.1038/sj.ki.5000105; Kremastinos DT, 2011, CIRCULATION, V124, P2253, DOI 10.1161/CIRCULATIONAHA.111.050773; Levin A, 2006, AM J KIDNEY DIS, V47, pS9, DOI 10.1053/j.ajkd.2006.04.023; Li SY, 2004, KIDNEY INT, V65, P626, DOI 10.1111/j.1523-1755.2004.00425.x; Liao YL, 1997, J AM COLL CARDIOL, V29, P641, DOI 10.1016/S0735-1097(96)00552-9; London GM, 2001, J AM SOC NEPHROL, V12, P2759, DOI 10.1681/ASN.V12122759; Maeder MT, 2011, J AM COLL CARDIOL, V58, P474, DOI 10.1016/j.jacc.2011.01.059; Mainous AG, 2004, ANN FAM MED, V2, P133, DOI 10.1370/afm.25; McClellan W, 2004, CURR MED RES OPIN, V20, P1501, DOI 10.1185/030079904X2763; Michels WM, 2010, CLIN J AM SOC NEPHRO, V5, P1003, DOI 10.2215/CJN.06870909; Murphy CJ, 2010, J CARD FAIL, V16, P888, DOI 10.1016/j.cardfail.2010.05.009; Naito Y, 2009, AM J PHYSIOL-HEART C, V296, pH585, DOI 10.1152/ajpheart.00463.2008; Nanas JN, 2006, J AM COLL CARDIOL, V48, P2485, DOI 10.1016/j.jacc.2006.08.034; Okonko DO, 2011, J AM COLL CARDIOL, V58, P1241, DOI 10.1016/j.jacc.2011.04.040; Park HJ, 2007, TOHOKU J EXP MED, V211, P321, DOI 10.1620/tjem.211.321; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Portoles J, 2007, NEPHROL DIAL TRANSPL, V22, P500, DOI 10.1093/ndt/gfl558; Robinson BE, 2006, J AM MED DIR ASSOC, V7, pS3, DOI 10.1016/j.jamda.2006.09.004; Robinson BM, 2009, CLIN J AM SOC NEPHRO, V4, pS12, DOI 10.2215/CJN.04720709; Silverberg DS, 2008, EUR J HEART FAIL, V10, P819, DOI 10.1016/j.ejheart.2008.06.015; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Steiber AL, 2004, J RENAL NUTR, V14, P191, DOI 10.1053/j.jrn.2004.08.004; Tang YD, 2006, CIRCULATION, V113, P2454, DOI 10.1161/CIRCULATIONAHA.105.583666; Toblli JE, 2007, J AM COLL CARDIOL, V50, P1657, DOI 10.1016/j.jacc.2007.07.029; van Veldhuisen DJ, 2011, NAT REV CARDIOL, V8, P485, DOI 10.1038/nrcardio.2011.77; Vlagopoulos PT, 2005, J AM SOC NEPHROL, V16, P3403, DOI 10.1681/ASN.2005030226; Wang JA, 2011, BIOCHEM J, V434, P365, DOI 10.1042/BJ20101825; Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809; Wish JB, 2006, CLIN J AM SOC NEPHRO, V1, pS4, DOI 10.2215/CJN.01490506; Zoccali C, 2004, KIDNEY INT, V65, P1492, DOI 10.1111/j.1523-1755.2004.00530.x	47	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2014	9	2							e87231	10.1371/journal.pone.0087231	http://dx.doi.org/10.1371/journal.pone.0087231			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA1AT	24505281	gold, Green Submitted, Green Published			2023-01-03	WOS:000330829200040
J	Leonard, SM; Perry, T; Woodman, CB; Kearns, P				Leonard, Sarah M.; Perry, Tracey; Woodman, Ciaran B.; Kearns, Pamela			Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia	PLOS ONE			English	Article							LOW-DOSE DECITABINE; DNA METHYLATION; PHASE-II; 5-AZA-2'-DEOXYCYTIDINE; MULTICENTER; COMBINATION; INHIBITORS; CELLS	The current interest in epigenetic priming is underpinned by the belief that remodelling of the epigenetic landscape will sensitise tumours to subsequent therapy. In this pre-clinical study, paediatric AML cells expanded in culture and primary AML xenografts were treated with decitabine, a DNA demethylating agent, and cytarabine, a frontline cytotoxic agent used in the treatment of AML, either alone or in combination. Sequential treatment with decitabine and cytarabine was found to be more effective in reducing tumour burden than treatment with cytarabine alone suggesting that the sequential delivery of these agents may a have real clinical advantage in the treatment of paediatric AML. However we found no evidence to suggest that this outcome was dependent on priming with a hypomethylating agent, as the benefits observed were independent of the order in which these drugs were administered.	[Leonard, Sarah M.; Perry, Tracey; Woodman, Ciaran B.] Univ Birmingham, Coll Med & Dent Sci, Sch Canc Sci, Birmingham, W Midlands, England; [Kearns, Pamela] Univ Birmingham, Sch Canc Sci, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England	University of Birmingham; Cancer Research UK; University of Birmingham	Woodman, CB (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Sch Canc Sci, Birmingham, W Midlands, England.	c.b.woodman@bham.ac.uk; p.r.kearns@bham.ac.uk	Kearns, Pamela/AAD-6011-2021	Kearns, Pamela/0000-0003-2756-5813	Leukemia and Lymphoma Research UK; Janssen Research and Development	Leukemia and Lymphoma Research UK(Leukemia and Lymphoma Society); Janssen Research and Development	This work was supported by Leukemia and Lymphoma Research UK and by Janssen Research and Development. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Salihi M, 2011, EPIGENETICS-US, V6, P1021, DOI 10.4161/epi.6.8.16064; Blum W, 2007, J CLIN ONCOL, V25, P3884, DOI 10.1200/JCO.2006.09.4169; BOEHM TLJ, 1982, CANCER RES, V42, P1537; Burnett A, 2011, J CLIN ONCOL, V29, P487, DOI 10.1200/JCO.2010.30.1820; Cashen AF, 2010, J CLIN ONCOL, V28, P556, DOI 10.1200/JCO.2009.23.9178; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Claus R, 2013, LEUKEMIA RES, V37, P190, DOI 10.1016/j.leukres.2012.10.015; Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397; Klco JM, 2013, BLOOD, V121, P1633, DOI 10.1182/blood-2012-09-459313; Link PA, 2008, CANCER RES, V68, P9358, DOI 10.1158/0008-5472.CAN-08-1860; Mims A, 2013, LEUKEMIA, V27, P871, DOI 10.1038/leu.2012.342; Negrotto S, 2012, LEUKEMIA, V26, P244, DOI 10.1038/leu.2011.207; Nyce JW, 1997, MUTAT RES-REV MUTAT, V386, P153, DOI 10.1016/S1383-5742(96)00051-8; Phillips CL, 2013, BRIT J HAEMATOL, V161, P406, DOI 10.1111/bjh.12268; Qin T, 2007, CLIN CANCER RES, V13, P4225, DOI 10.1158/1078-0432.CCR-06-2762; Ricart AD, 2011, CLIN CANCER RES, V17, P6417, DOI 10.1158/1078-0432.CCR-11-0486; Scandura JM, 2011, BLOOD, V118, P1472, DOI 10.1182/blood-2010-11-320093; Schuringa Jan Jacob, 2009, V538, P287, DOI 10.1007/978-1-59745-418-6_14; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; van Gosliga D, 2007, EXP HEMATOL, V35, P1538, DOI 10.1016/j.exphem.2007.07.001; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956	21	22	24	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2014	9	1							e87475	10.1371/journal.pone.0087475	http://dx.doi.org/10.1371/journal.pone.0087475			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301CJ	24489920	Green Submitted, Green Published, gold			2023-01-03	WOS:000330510000137
J	Chiu, HE; Hong, YC; Chang, KC; Shih, CC; Hung, JW; Liu, CW; Tan, TY; Huang, CC				Chiu, Hsienhsueh Elley; Hong, Yu-Chiang; Chang, Ku-Chou; Shih, Chun-Chuan; Hung, Jen-Wen; Liu, Chia-Wei; Tan, Teng-Yeow; Huang, Chih-Cheng			Favorable Circulatory System Outcomes as Adjuvant Traditional Chinese Medicine (TCM) Treatment for Cerebrovascular Diseases in Taiwan	PLOS ONE			English	Article							ACUPUNCTURE; STROKE	Background: This study searches the National Health Insurance Research Database (NHIRD) used in a previous project, aiming for reconstructing possible cerebrovascular disease-related groups (DRG), and estimating the costs between cerebrovascular disease and related diseases. Methods and Materials: We conducted a nationwide retrospective cohort study in stroke inpatients, we examined the overall costs in 3 municipalities in Taiwan, by evaluating the possible costs of the expecting diagnosis related group (DRG) by using the international classification of diseases version-9 (ICD-9) system, and the overall analysis of the re-admission population that received traditional Chinese medicine (TCM) treatment and those who did not. Results: The trend demonstrated that the non-participant costs were consistent with the ICD-9 categories (430 to 437) because similarities existed between years 2006 to 2007. Among the TCM patients, a wide variation and additional costs were found compared to non-TCM patients during these 2 years. The average re-admission duration was significantly shorter for TCM patients, especially those initially diagnosed with ICD 434 during the first admission. In addition, TCM patients demonstrated more severe general symptoms, which incurred high conventional treatment costs, and could result in re-admission for numerous reasons. However, in Disease 7 of ICD-9 category, representing the circulatory system was most prevalent in non-TCM inpatients, which was the leading cause of re-admission. Conclusion: We concluded that favorable circulatory system outcomes were in adjuvant TCM treatment inpatients, there were less re-admission for circulatory system events and a two-third reduction of re-admission within ICD-9 code 430 to 437, compared to non-TCM ones. However, there were shorter re-admission duration other than circulatory system events by means of unfavorable baseline condition.	[Chiu, Hsienhsueh Elley; Hong, Yu-Chiang; Huang, Chih-Cheng] Chang Gung Univ Coll Med, Dept TCM, Kaohsiung, Taiwan; [Chiu, Hsienhsueh Elley; Chang, Ku-Chou; Liu, Chia-Wei; Tan, Teng-Yeow] Chang Gung Univ Coll Med, Dept Neurol, Kaohsiung, Taiwan; [Hung, Jen-Wen] Chang Gung Univ Coll Med, Dept Rehabil, Kaohsiung, Taiwan; [Chiu, Hsienhsueh Elley; Hong, Yu-Chiang; Chang, Ku-Chou; Hung, Jen-Wen; Liu, Chia-Wei; Tan, Teng-Yeow] Chang Gung Univ Coll Med, Chang Gung Mem Hosp, Kaohsiung, Taiwan; [Shih, Chun-Chuan] I Shou Univ, Sch Chinese Med Post Baccalaureate, Kaohsiung, Taiwan	Chang Gung University; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; I Shou University	Chiu, HE (corresponding author), Chang Gung Univ Coll Med, Dept TCM, Kaohsiung, Taiwan.	elleychiu@hotmail.com			Chung Gung Research Project [CMRPG 890961]	Chung Gung Research Project	This study was supported by the Chung Gung Research Project, CMRPG 890961. The corresponding author and the first author had full access to all data in the study and had final responsibility for the decision to submit the paper for publication. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chen Z, 1997, J Stroke Cerebrovasc Dis, V6, P361, DOI 10.1016/S1052-3057(97)80219-4; Hackett ML, 2000, STROKE, V31, P440, DOI 10.1161/01.STR.31.2.440; HAN JS, 1982, ANNU REV PHARMACOL, V22, P193, DOI 10.1146/annurev.pa.22.040182.001205; Hess Dean R, 2004, Respir Care, V49, P1171; JANSEN G, 1989, NEUROSCI LETT, V97, P305, DOI 10.1016/0304-3940(89)90615-0; MAGNUSSON M, 1994, STROKE, V25, P1176, DOI 10.1161/01.STR.25.6.1176; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; NAESER MA, 1994, ACUPUNCTURE ELECTRO, V19, P227, DOI 10.3727/036012994816357231; O'Mahony PG, 1999, J PUBLIC HEALTH MED, V21, P166, DOI 10.1093/pubmed/21.2.166; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Southampton and South West Hampshire Health Commission, 1994, ANN REPORT; Sun H.L., 2001, CHIN ACUPUNCT MOXIBU, V21, P275; Wei YM, 2011, ENERGY ECONOMICS: CO2 EMISSIONS IN CHINA, P1, DOI 10.1155/2011/689813; Wu J N, 1996, J Altern Complement Med, V2, P19, DOI 10.1089/acm.1996.2.19	14	8	8	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2014	9	1							e86351	10.1371/journal.pone.0086351	http://dx.doi.org/10.1371/journal.pone.0086351			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301BI	24475108	Green Submitted, Green Published, gold			2023-01-03	WOS:000330507300056
J	Ye, L; Wei, SS; Zou, YF; Yang, XB; Abdullah, A; Zhong, XN; Ruan, YH; Lin, XQ; Li, MQ; Wu, DR; Jiang, JJ; Xie, PY; Huang, JG; Liang, BY; Zhou, B; Su, JM; Liang, H; Huang, AL				Ye, Li; Wei, Suosu; Zou, Yunfeng; Yang, Xiaobo; Abdullah, Abu S.; Zhong, Xiaoni; Ruan, Yuhua; Lin, Xinqin; Li, Mingqiang; Wu, Deren; Jiang, Junjun; Xie, Peiyan; Huang, Jiegang; Liang, Bingyu; Zhou, Bo; Su, Jinming; Liang, Hao; Huang, Ailong			HIV Pre-Exposure Prophylaxis Interest among Female Sex Workers in Guangxi, China	PLOS ONE			English	Article							TENOFOVIR DISOPROXIL FUMARATE; CONDOM USE; ANTIRETROVIRAL PROPHYLAXIS; LIMITED KNOWLEDGE; PREVENTION; RISK; WOMEN; INFECTION; INTERVENTIONS; TRANSMISSION	Objectives: Acceptability of pre-exposure prophylaxis (PrEP) and willingness to participate in a clinical trial for both safety and efficacy of PrEP were investigated among female sex workers (FSWs) in Guangxi, China. Methods: A cross-sectional study was performed in three cities in Guangxi. Structured, self-administered questionnaires were used to assess the acceptability of PrEP and the willingness to participate in a clinical trial. Multivariable logistic regression models were fitted to identify predictors. Results: Among 405 participants, 15.1% had heard of PrEP. If PrEP was deemed to be effective, safe and provided for free, 85.9% reported that they would accept it, and 54.3% of those who accepted PrEP said that they would participate in a clinical trial. The increased acceptability of PrEP was associated with working in male dominated venues, higher income, a poor family relationship, better HIV/AIDS knowledge, not realizing HIV risk from unfamiliar clients, not being forced to use condoms by the gatekeepers, consistent use of condoms, and use of drugs to prevent STD infection. The increased willingness to participate in a clinical trial was associated with a poor family relationship, better HIV/AIDS knowledge, not realizing HIV risk from unfamiliar clients, a willingness to adhere to daily PreP use, and not being concerned about discrimination by others. The main reason for rejecting PrEP or participating in a clinical trial was the concern about the side effects of PrEP. Conclusions: Acceptability of PrEP among Guangxi FSWs is relatively high, indicating that PrEP intervention programs may be feasible for Chinese FSWs. Given the fact that most of the participants had never heard of PrEP before, and that family, gatekeepers, and social discrimination could significantly affect its acceptability, a comprehensive mix of multiple interventions is necessary for the successful implementation of a PrEP program among this population in Guangxi.	[Ye, Li; Zou, Yunfeng; Yang, Xiaobo; Abdullah, Abu S.; Li, Mingqiang; Jiang, Junjun; Xie, Peiyan; Huang, Jiegang; Liang, Bingyu; Zhou, Bo; Su, Jinming; Liang, Hao] Guangxi Med Univ, Sch Publ Hlth, Guangxi Key Lab AIDS Prevent & Treatment, Nanning, Guangxi, Peoples R China; [Wei, Suosu] Peoples Hosp Guangxi Zhuang Autonomous Reg, Nanning, Guangxi, Peoples R China; [Abdullah, Abu S.] Boston Univ, Sch Med, Dept Med, Boston Med Ctr, Boston, MA 02118 USA; [Zhong, Xiaoni; Huang, Ailong] Chongqing Med Univ, Sch Publ Hlth, Chongqing, Peoples R China; [Ruan, Yuhua] Chinese Ctr Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing, Peoples R China; [Lin, Xinqin] Nanning Ctr Dis Control & Prevent, Nanning, Guangxi, Peoples R China; [Li, Mingqiang] Liuzhou Ctr Dis Control & Prevent, Liuzhou, Guangxi, Peoples R China; [Wu, Deren] Beihai Ctr Dis Control & Prevent, Beihai, Guangxi, Peoples R China	Guangxi Medical University; Boston Medical Center; Boston University; Chongqing Medical University; Chinese Center for Disease Control & Prevention	Liang, H (corresponding author), Guangxi Med Univ, Sch Publ Hlth, Guangxi Key Lab AIDS Prevent & Treatment, Nanning, Guangxi, Peoples R China.	haolphd@163.com; ahuang1964@yahoo.com.cn	Jiang, Kui/Z-2573-2019; Jiang, Junjun/AAH-9095-2020; Yang, Xiaobo/G-3854-2016	Jiang, Kui/0000-0002-4055-7503; wei, suosu/0000-0002-2022-7347	National Major Science and Technology Projects of the Twelfth Five-year Plan (China) [2012ZX10004910, 2012ZX10001-09]; Project for building of Talent Highland Innovative Team in Guangxi universities [[2010]38]	National Major Science and Technology Projects of the Twelfth Five-year Plan (China); Project for building of Talent Highland Innovative Team in Guangxi universities	This study was supported by National Major Science and Technology Projects of the Twelfth Five-year Plan (China, 2012ZX10004910 and 2012ZX10001-09), and the Project for building of Talent Highland Innovative Team in Guangxi universities (Guijiaoren [2010]38). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aaron E, 2013, AIDS, V27, pF1, DOI 10.1097/QAD.0b013e32835917b4; ABDOOL KQ, 2010, SCIENCE, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748; Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006; [Anonymous], 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003255, DOI 10.1002/14651858.CD003255]; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Baeten J, 2013, ANNU REV MED, V64, P219, DOI 10.1146/annurev-med-050911-163701; Barash EA, 2010, AIDS PATIENT CARE ST, V24, P689, DOI 10.1089/apc.2010.0173; Brown H, 2004, LANCET, V363, P1042, DOI 10.1016/S0140-6736(04)15881-9; CDC_Guangxi, 2009, WORKSH NIAAA VEN BAS; CDC_USA, 2010, CDC STAT RES IPREX T; Celum C, 2012, ANTIVIR THER, V17, P1483, DOI 10.3851/IMP2492; Celum C, 2012, CURR OPIN INFECT DIS, V25, P51, DOI 10.1097/QCO.0b013e32834ef5ef; Choi SYP, 2008, SEX TRANSM DIS, V35, P141, DOI 10.1097/OLQ.0b013e31815407c3; Choi SYP, 2007, CULT HEALTH SEX, V9, P489, DOI 10.1080/13691050701220446; Eisingerich AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028238; FRANK ML, 1995, WOMEN HEALTH, V23, P31, DOI 10.1300/J013v23n02_03; Galea JT, 2011, INT J STD AIDS, V22, P256, DOI 10.1258/ijsa.2009.009255; Galindo GR, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-116; Garcia-Lerma JG, 2008, PLOS MED, V5, P291, DOI 10.1371/journal.pmed.0050028; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Gupta GR, 2002, BRIT MED J, V324, P183, DOI 10.1136/bmj.324.7331.183; Gupta GR, 1993, WOMEN AIDS DEV NEW H; Hallett TB, 2006, SEX TRANSM INFECT, V82, pI1, DOI 10.1136/sti.2005.016014; Harcourt C, 2005, SEX TRANSM INFECT, V81, P201, DOI 10.1136/sti.2004.012468; Hayes RJ, 2000, STAT METHODS MED RES, V9, P95, DOI 10.1191/096228000670953670; Hesketh T, 2005, AIDS CARE, V17, P958, DOI 10.1080/09540120500100676; Hong Y, 2008, AIDS BEHAV, V12, P623, DOI 10.1007/s10461-007-9287-7; Hong Y, 2008, SEX TRANSM DIS, V35, P662, DOI 10.1097/OLQ.0b013e31816b322c; Hong Y, 2011, AIDS CARE, V23, P54, DOI 10.1080/09540121.2011.554526; Huang YY, 2004, SEX TRANSM DIS, V31, P695, DOI 10.1097/01.olq.0000143107.06988.ea; Jana S, 1998, AIDS, V12 Suppl B, pS101; Kar SB, 1999, SOC SCI MED, V49, P1431, DOI 10.1016/S0277-9536(99)00200-2; Kumwenda NI, 2008, NEW ENGL J MED, V359, P119, DOI 10.1056/NEJMoa0801941; Lau JTF, 2002, AIDS CARE, V14, P219, DOI 10.1080/09540120220104721; Li Q, 2010, SEX TRANSM DIS, V37, P700, DOI 10.1097/OLQ.0b013e3181e1a2b2; Liao SS, 2003, AIDS EDUC PREV, V15, P109, DOI 10.1521/aeap.15.3.109.23834; Liu AY, 2008, JAIDS-J ACQ IMM DEF, V47, P241, DOI 10.1097/QAI.0b013e31815e4041; Maman S, 2000, SOC SCI MED, V50, P459, DOI 10.1016/S0277-9536(99)00270-1; Mascolini M, 2012, 19 C RETR OPP INF SE; Mijiti P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067392; Mimiaga MJ, 2009, JAIDS-J ACQ IMM DEF, V50, P77, DOI 10.1097/QAI.0b013e31818d5a27; Ministry of Health of People's Republic of China Joint United Nations Programme on HIV/AIDS World Health Organization, 2012, EST HIV AIDS EP CHIN; Pirkle C, 2007, SEX TRANSM DIS, V34, P695, DOI 10.1097/01.olq.0000260989.70866.94; Rogers SJ, 2002, AIDS EDUC PREV, V14, P217, DOI 10.1521/aeap.14.3.217.23892; Schneider JA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011922; Severy LJ, 2005, AIDS BEHAV, V9, P121, DOI 10.1007/s10461-005-1687-y; STEIN ZA, 1990, AM J PUBLIC HEALTH, V80, P460, DOI 10.2105/AJPH.80.4.460; Subbarao S, 2006, J INFECT DIS, V194, P904, DOI 10.1086/507306; Swendeman D, 2009, SOC SCI MED, V69, P1157, DOI 10.1016/j.socscimed.2009.07.035; Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711; Turmen T, 2003, INT J GYNECOL OBSTET, V82, P411, DOI 10.1016/S0020-7292(03)00202-9; Van Damme L, 2012, 19 C RETR OPP INF MA; Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614; Van Rompay KKA, 2006, JAIDS-J ACQ IMM DEF, V43, P6, DOI 10.1097/01.qai.0000224972.60339.7c; Wang B, 2005, SEX TRANSM DIS, V32, P696, DOI 10.1097/01.olq.0000175403.68410.ec; Ware NC, 2012, JAIDS-J ACQ IMM DEF, V59, P463, DOI 10.1097/QAI.0b013e31824a060b; Whiteside YO, 2011, AIDS PATIENT CARE ST, V25, P365, DOI 10.1089/apc.2010.0224; Wong WCW, 2003, AIDS PATIENT CARE ST, V17, P417, DOI 10.1089/108729103322277439; Xia GM, 2005, AIDS EDUC PREV, V17, P143, DOI 10.1521/aeap.17.3.143.62904; Yang HM, 2005, SEX TRANSM DIS, V32, P572, DOI 10.1097/01.olq.0000175418.48665.95; Zhao Zhen, 2011, Zhejiang Da Xue Xue Bao Yi Xue Ban, V40, P281; Zhou F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032329	62	35	37	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2014	9	1							e86200	10.1371/journal.pone.0086200	http://dx.doi.org/10.1371/journal.pone.0086200			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	297VL	24465956	Green Published, gold, Green Submitted			2023-01-03	WOS:000330283100124
J	Van Parys, AS; Verhamme, A; Temmerman, M; Verstraelen, H				Van Parys, An-Sofie; Verhamme, Annelien; Temmerman, Marleen; Verstraelen, Hans			Intimate Partner Violence and Pregnancy: A Systematic Review of Interventions	PLOS ONE			English	Review							RANDOMIZED-CONTROLLED-TRIAL; DOMESTIC VIOLENCE; WOMEN; PREVALENCE; HEALTH; RISK; CARE; ASSOCIATIONS; DISCLOSURE; MANAGEMENT	Background: Intimate partner violence (IPV) around the time of pregnancy is a widespread global health problem with many negative consequences. Nevertheless, a lot remains unclear about which interventions are effective and might be adopted in the perinatal care context. Objective: The objective is to provide a clear overview of the existing evidence on effectiveness of interventions for IPV around the time of pregnancy. Methods: Following databases PubMed, Web of Science, CINAHL and the Cochrane Library were systematically searched and expanded by hand search. The search was limited to English peer-reviewed randomized controlled trials published from 2000 to 2013. This review includes all types of interventions aiming to reduce IPV around the time of pregnancy as a primary outcome, and as secondary outcomes to enhance physical and/or mental health, quality of life, safety behavior, help seeking behavior, and/or social support. Results: We found few randomized controlled trials evaluating interventions for IPV around the time of pregnancy. Moreover, the nine studies identified did not produce strong evidence that certain interventions are effective. Nonetheless, home visitation programs and some multifaceted counseling interventions did produce promising results. Five studies reported a statistically significant decrease in physical, sexual and/or psychological partner violence (odds ratios from 0.47 to 0.92). Limited evidence was found for improved mental health, less postnatal depression, improved quality of life, fewer subsequent miscarriages, and less low birth weight/prematurity. None of the studies reported any evidence of a negative or harmful effect of the interventions. Conclusions and implications: Strong evidence of effective interventions for IPV during the perinatal period is lacking, but some interventions show promising results. Additional large-scale, high-quality research is essential to provide further evidence about the effect of certain interventions and clarify which interventions should be adopted in the perinatal care context.	[Van Parys, An-Sofie; Verhamme, Annelien; Temmerman, Marleen; Verstraelen, Hans] Univ Ghent, Dept Obstet & Gynaecol, Int Ctr Reprod Hlth, Fac Med & Hlth Sci, B-9000 Ghent, Belgium	Ghent University	Van Parys, AS (corresponding author), Univ Ghent, Dept Obstet & Gynaecol, Int Ctr Reprod Hlth, Fac Med & Hlth Sci, B-9000 Ghent, Belgium.	ansofie.vanparys@ugent.be	Verstraelen, Hans/A-5602-2008; Verstraelen, Hans/AAA-8694-2019	Verstraelen, Hans/0000-0002-4070-1587; Verhamme, Anne/0000-0002-2201-1865	Research Foundation Flanders [69579]	Research Foundation Flanders(FWO)	ASVP received a PhD bursary for her studies from the Research Foundation Flanders (www.fwo.be, grant number 69579). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bacchus L, 2004, EUR J OBSTET GYN R B, V113, P6, DOI 10.1016/S0301-2115(03)00326-9; Bailey BA, 2010, INT J WOMENS HEALTH, V2, P183, DOI 10.2147/ijwh.s8632; Bair-Merritt MH, 2010, ARCH PEDIAT ADOL MED, V164, P16, DOI 10.1001/archpediatrics.2009.237; Campbell JC, 2001, CAN MED ASSOC J, V164, P1578; Chambliss LR, 2008, CLIN OBSTET GYNECOL, V51, P385, DOI 10.1097/GRF.0b013e31816f29ce; Charles P, 2007, J FAM VIOLENCE, V22, P609, DOI 10.1007/s10896-007-9112-0; Coker AL, 2004, PAEDIATR PERINAT EP, V18, P260, DOI 10.1111/j.1365-3016.2004.00569.x; Cripe SM, 2010, J INTERPERS VIOLENCE, V25, P2054, DOI 10.1177/0886260509354517; Curry MA, 2006, JOGNN-J OBST GYN NEO, V35, P181, DOI 10.1111/J.1552-6909.2006.00027.x; Daoud N, 2012, AM J PUBLIC HEALTH, V102, P1893, DOI 10.2105/AJPH.2012.300843; Devries KM, 2010, REPROD HEALTH MATTER, V18, P158, DOI 10.1016/S0968-8080(10)36533-5; Dunn LL, 2004, JOGNN, V33, P54, DOI 10.1177/0884217503261080; Fanslow JL, 2010, J INTERPERS VIOLENCE, V25, P929, DOI 10.1177/0886260509336963; Fisher J, 2012, B WORLD HEALTH ORGAN, V90, P139, DOI 10.2471/BLT.11.091850; Garcia-Moreno C, 2005, SCIENCE, V310, P1282, DOI 10.1126/science.1121400; Gazmararian JA, 1996, JAMA-J AM MED ASSOC, V275, P1915, DOI 10.1001/jama.275.24.1915; Hegarty K, 2013, LANCET, V382, P249, DOI 10.1016/S0140-6736(13)60052-5; Hegarty KL, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-2; Hellmuth JC, 2013, ARCH WOMEN MENT HLTH, V16, P19, DOI 10.1007/s00737-012-0309-8; Higgings JPT, 2013, COCHRANE HDB SYSTEMA; Humphreys J, 2011, WOMEN HEALTH ISS, V21, P136, DOI 10.1016/j.whi.2010.09.006; Jahanfar S, 2013, COCHRANE DATABASE SY; Jasinski Jana L, 2004, Trauma Violence Abuse, V5, P47, DOI 10.1177/1524838003259322; Johnson JK, 2003, BJOG-INT J OBSTET GY, V110, P272, DOI [10.1046/j.1471-0528.2003.02216.x, 10.1016/S1470-0328(02)02926-4]; Kan ML, 2010, VIOLENCE VICTIMS, V25, P319, DOI 10.1891/0886-6708.25.3.319; Kiely M, 2010, OBSTET GYNECOL, V115, P273, DOI 10.1097/AOG.0b013e3181cbd482; Krug EG, 2002, LANCET, V360, P1083, DOI 10.1016/S0140-6736(02)11133-0; Ludermir AB, 2010, LANCET, V376, P903, DOI 10.1016/S0140-6736(10)60887-2; MacMillan HL, 2009, JAMA-J AM MED ASSOC, V302, P493, DOI 10.1001/jama.2009.1089; Martin SL, 2004, J FAM VIOLENCE, V19, P201, DOI 10.1023/B:JOFV.0000032630.50593.93; McFarlane JM, 2006, NURS RES, V55, P52, DOI 10.1097/00006199-200601000-00007; Mechanic MB, 2008, VIOLENCE AGAINST WOM, V14, P634, DOI 10.1177/1077801208319283; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Nelson HD, 2012, ANN INTERN MED, V156, P796, DOI 10.7326/0003-4819-156-11-201206050-00447; O'Campo P, 2011, SOC SCI MED, V72, P855, DOI 10.1016/j.socscimed.2010.12.019; O'Reilly R, 2010, TRAUMA VIOLENCE ABUS, V11, P190, DOI 10.1177/1524838010378298; Olds DL, 2004, PEDIATRICS, V114, P1560, DOI 10.1542/peds.2004-0961; Ramsay J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005043.pub2; Rodrigues T, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.05.015; Roelens K, 2008, EUR J OBSTET GYN R B, V137, P37, DOI 10.1016/j.ejogrb.2007.04.013; Rose L, 2010, INT J QUAL METH, V9, P382; Saltzman Linda E, 2003, Matern Child Health J, V7, P31, DOI 10.1023/A:1022589501039; Shamu S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017591; Silverman JG, 2006, AM J OBSTET GYNECOL, V195, P140, DOI 10.1016/j.ajog.2005.12.052; Spangaro JM, 2010, HEALTH SOC CARE COMM, V18, P671, DOI 10.1111/j.1365-2524.2010.00943.x; Taft AJ, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-178; Taft AJ, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-159; Taillieu TL, 2010, AGGRESS VIOLENT BEH, V15, P14, DOI 10.1016/j.avb.2009.07.013; Tiwari A, 2005, BJOG-INT J OBSTET GY, V112, P1249, DOI 10.1111/j.1471-0528.2005.00709.x; Wathen CN, 2003, JAMA-J AM MED ASSOC, V289, P589, DOI 10.1001/jama.289.5.589; Zink T, 2004, ANN FAM MED, V2, P231, DOI 10.1370/afm.74; Zlotnick C, 2011, ARCH WOMEN MENT HLTH, V14, P55, DOI 10.1007/s00737-010-0195-x	52	80	81	2	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2014	9	1							e85084	10.1371/journal.pone.0085084	http://dx.doi.org/10.1371/journal.pone.0085084			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	297EA	24482679	Green Published, Green Submitted, gold			2023-01-03	WOS:000330237000023
J	Blanco, F; Barberia, I; Matute, H				Blanco, Fernando; Barberia, Itxaso; Matute, Helena			The Lack of Side Effects of an Ineffective Treatment Facilitates the Development of a Belief in Its Effectiveness	PLOS ONE			English	Article							CAUSAL JUDGMENT; CONTINGENCY; SUPERSTITION; COVARIATION; INFORMATION; ILLUSION; CUE	Some alternative medicines enjoy widespread use, and in certain situations are preferred over conventional, validated treatments in spite of the fact that they fail to prove effective when tested scientifically. We propose that the causal illusion, a basic cognitive bias, underlies the belief in the effectiveness of bogus treatments. Therefore, the variables that modulate the former might affect the latter. For example, it is well known that the illusion is boosted when a potential cause occurs with high probability. In this study, we examined the effect of this variable in a fictitious medical scenario. First, we showed that people used a fictitious medicine (i.e., a potential cause of remission) more often when they thought it caused no side effects. Second, the more often they used the medicine, the more likely they were to develop an illusory belief in its effectiveness, despite the fact that it was actually useless. This behavior may be parallel to actual pseudomedicine usage; that because a treatment is thought to be harmless, it is used with high frequency, hence the overestimation of its effectiveness in treating diseases with a high rate of spontaneous relief. This study helps shed light on the motivations spurring the widespread preference of pseudomedicines over scientific medicines. This is a valuable first step toward the development of scientifically validated strategies to counteract the impact of pseudomedicine on society.	[Blanco, Fernando; Barberia, Itxaso; Matute, Helena] Univ Deusto, Dept Fundamentos & Metodos Psicol, Bilbao, Spain	University of Deusto	Blanco, F (corresponding author), Univ Deusto, Dept Fundamentos & Metodos Psicol, Bilbao, Spain.	fernandoblanco@deusto.es	Blanco, Fernando/E-8941-2010; BARBERIA, ITXASO/L-8477-2014; Matute, Helena/A-8256-2011	Blanco, Fernando/0000-0003-1283-8313; BARBERIA, ITXASO/0000-0003-3045-2289; Matute, Helena/0000-0001-7221-1366	Direccion General de Investigacion of the Spanish Government [PSI2011-26965]; Departamento de Educacion, Universidades e Investigacion of the Basque Government [IT363-10]	Direccion General de Investigacion of the Spanish Government; Departamento de Educacion, Universidades e Investigacion of the Basque Government	Support for this research was provided by Direccion General de Investigacion of the Spanish Government (Grant PSI2011-26965) and Departamento de Educacion, Universidades e Investigacion of the Basque Government (Grant IT363-10). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALLAN LG, 1983, LEARN MOTIV, V14, P381, DOI 10.1016/0023-9690(83)90024-3; Barberia I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071303; Blanco F, 2013, LEARN BEHAV, V41, P333, DOI 10.3758/s13420-013-0108-8; Blanco F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046203; Blanco F, 2011, Q J EXP PSYCHOL, V64, P1290, DOI 10.1080/17470218.2011.552727; Buehner MJ, 2003, J EXP PSYCHOL LEARN, V29, P1119, DOI 10.1037/0278-7393.29.6.1119; Frankel MS, 1999, WORKSH CONV AM ASS A; Freckelton I, 2012, J LAW MED, V19, P454; Hannah SD, 2009, CAN J EXP PSYCHOL, V63, P59, DOI 10.1037/a0013403; Hayes A. F, 2012, PROCESS VERSATILE CO; KAO SF, 1993, J EXP PSYCHOL LEARN, V19, P1363, DOI 10.1037/0278-7393.19.6.1363; Killeen PR, 2013, LEARN BEHAV, V41, P1, DOI 10.3758/s13420-012-0095-1; Matute H, 1996, PSYCHOL SCI, V7, P289, DOI 10.1111/j.1467-9280.1996.tb00376.x; Matute H, 2011, BRIT J PSYCHOL, V102, P392, DOI 10.1348/000712610X532210; Perales JC, 2007, PSYCHON B REV, V14, P577, DOI 10.3758/BF03196807; Rescorta RA, 1972, CLASSICAL CONDITION, P64; Shang AJ, 2005, LANCET, V366, P726, DOI 10.1016/S0140-6736(05)67177-2; SKINNER BF, 1948, J EXP PSYCHOL, V38, P168, DOI 10.1037/h0055873; STADDON JER, 1971, PSYCHOL REV, V78, P3, DOI 10.1037/h0030305; WASSERMAN EA, 1990, PSYCHOL LEARN MOTIV, V26, P27, DOI DOI 10.1016/S0079-7421(08)60051-1; White PA, 2004, MEM COGNITION, V32, P353, DOI 10.3758/BF03195830; Yarritu I, 2014, EXP PSYCHOL, V61, P38, DOI 10.1027/1618-3169/a000225	22	15	15	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2014	9	1							e84084	10.1371/journal.pone.0084084	http://dx.doi.org/10.1371/journal.pone.0084084			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	291WL	24416194	Green Published, gold, Green Submitted			2023-01-03	WOS:000329862500095
J	Smith, AK; Lo, B; Aronson, L				Smith, Alexander K.; Lo, Bernard; Aronson, Louise			Elder Self-Neglect - How Can a Physician Help?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ABUSE; RISK	Clinicians often expend considerable effort caring for elderly patients who neglect their own needs. But there are some practical approaches to the clinical care of self-neglecting patients. Mr. L. is a 96-year-old widower with critical aortic stenosis and mild cognitive impairment who had become increasingly short of breath and exhausted over the course of several weeks and needed 3 hours to get dressed on the day of admission. A concerned neighbor brought him to the hospital. He is not a candidate for aortic-valve replacement owing to poor functional status and coexisting conditions, and after several days of gentle diuresis, he can barely walk across the room. At the request of the primary care physician, Mr. L.'s son flies in for a family meeting to discuss discharge options. ...	[Smith, Alexander K.; Aronson, Louise] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA; [Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA; [Lo, Bernard] Greenwall Fdn Bioeth, New York, NY USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Smith, AK (corresponding author), Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA.				NIA NIH HHS [P30 AG044281, K23 AG040772] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K23AG040772, P30AG044281] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Cogliani C, 2011, MICROBE, V6, P274, DOI [10.1128/microbe.6.274.1, DOI 10.1128/MICROBE.6.274.1]; Dong XQ, 2013, JAMA INTERN MED, V173, P911, DOI 10.1001/jamainternmed.2013.238; Dong XQ, 2012, GERONTOLOGY, V58, P258, DOI 10.1159/000334256; Dong XQ, 2009, JAMA-J AM MED ASSOC, V302, P517, DOI 10.1001/jama.2009.1109; Harrison EM, 2013, EMBO MOL MED, V5, P509, DOI 10.1002/emmm.201202413; Lachs MS, 2002, GERONTOLOGIST, V42, P734, DOI 10.1093/geront/42.6.734; MCDERMOTT W, 1982, JOHNS HOPKINS MED J, V151, P302; Outterson Kevin, 2013, GLOBALIZATION HLTH C, P318; Research Council N., 1999, USE DRUGS FOOD ANIMA, DOI DOI 10.17226/5137; Robine JM, 2007, BRIT MED J, V334, P570, DOI 10.1136/bmj.39129.397373.BE	10	8	8	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 26	2013	369	26					2476	2479		10.1056/NEJMp1310684	http://dx.doi.org/10.1056/NEJMp1310684			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	278BT	24369074	Green Accepted			2023-01-03	WOS:000328863700005
J	Marepally, S; Boakye, CHA; Shah, PP; Etukala, JR; Vemuri, A; Singh, M				Marepally, Srujan; Boakye, Cedar H. A.; Shah, Punit P.; Etukala, Jagan Reddy; Vemuri, Adithi; Singh, Mandip			Design, Synthesis of Novel Lipids as Chemical Permeation Enhancers and Development of Nanoparticle System for Transdermal Drug Delivery	PLOS ONE			English	Article							PENETRATION ENHANCERS; SKIN PENETRATION; STRATUM-CORNEUM; OLEIC-ACID; MECHANISMS; IMMUNE	In the present study, we designed and developed novel lipids that include (Z)-1-(Octadec-9-en-1-yl)-pyrrolidine (Cy5T), 1, 1-Di-((Z)-octadec-9-en-1-yl)pyrrolidin-1-ium iodide (Cy5), (Z)-1-(Octadec-9-en-1-yl)-piperidine (Cy6T), and 1, 1-Di-((Z)-octadec-9-en-1-yl) piperidin-1-ium iodide (Cy6) to enhance the transdermal permeation of some selected drugs. Firstly, we evaluated the transdermal permeation efficacies of these lipids as chemical permeation enhancers in vehicle formulations for melatonin, beta-estradiol, caffeine, alpha-MSH, and spantide using franz diffusion cells. Among them Cy5 lipid was determined to be the most efficient by increasing the transdermal permeation of melatonin, beta-estradiol, caffeine, alpha-MSH, and spantide by 1.5 to 3.26-fold more at the epidermal layer and 1.3 to 2.5-fold more at the dermal layer, in comparison to either NMP or OA. Hence we developed a nanoparticle system (cy5 lipid ethanol drug nanoparticles) to evaluate any further improvement in the drug penetration. Cy5 lipid formed uniformly sized nanoparticles ranging from 150-200 nm depending on the type of drug. Further, Cy5 based nanoparticle system significantly (p<0.05) increased the permeation of all the drugs in comparison to the lipid solution and standard permeation enhancers. There were about 1.54 to 22-fold more of drug retained in the dermis for the Cy5 based nanoparticles compared to OA/NMP standard enhancers and 3.87 to 66.67-fold more than lipid solution. In addition, epifluorescent microscopic analysis in rhodamine-PE permeation studies confirmed the superior permeation enhancement of LEDs (detection of fluorescence up to skin depth of 340 mu m) more than lipid solution, which revealed fluorescence up to skin depth of only 260 mu m. In summary the present findings demonstrate that i) cationic lipid with 5 membered amine heterocyclic ring has higher permeating efficacy than the 6 membered amine hertocyclic ring. ii) The nanoparticle system prepared with Cy5 showed significant (p<0.05) increase in the permeation of the drugs than the control penetration enhancers, oleic acid and NMP.	[Marepally, Srujan; Boakye, Cedar H. A.; Shah, Punit P.; Etukala, Jagan Reddy; Vemuri, Adithi; Singh, Mandip] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA	State University System of Florida; Florida A&M University	Singh, M (corresponding author), Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA.	mandip.sachdeva@gmail.com			National Center for Research Resources; National Institute of Minority Health and Health Disparities of the National Institutes of Health [8 G12 MD007582-28, 2 G12 RR003020]; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003020] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [G12MD007582] Funding Source: NIH RePORTER	National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute of Minority Health and Health Disparities of the National Institutes of Health; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This project was supported by the National Center for Research Resources and the National Institute of Minority Health and Health Disparities of the National Institutes of Health through Grant Number 8 G12 MD007582-28 and 2 G12 RR003020. The funders of the project had no role in the study design, data collection and analysis, decision to publish or the preparation of the manuscript.	AUNGST BJ, 1989, PHARM RES-DORDR, V6, P244, DOI 10.1023/A:1015921702258; Benson Heather A. E., 2005, Current Drug Delivery, V2, P23, DOI 10.2174/1567201052772915; Bos JD, 2000, EXP DERMATOL, V9, P165, DOI 10.1034/j.1600-0625.2000.009003165.x; Brychtova K, 2012, BIOORGAN MED CHEM, V20, P86, DOI 10.1016/j.bmc.2011.11.033; Ghafourian T, 2004, J CONTROL RELEASE, V99, P113, DOI 10.1016/j.jconrel.2004.06.010; GOODMAN M, 1989, INT J PHARM, V57, P29, DOI 10.1016/0378-5173(89)90260-3; Guo SQ, 2011, J CONTROL RELEASE, V151, P256, DOI 10.1016/j.jconrel.2011.01.014; Gwak HS, 2002, ARCH PHARM RES, V25, P392, DOI 10.1007/BF02976645; Heller LC, 2007, GENE THER, V14, P275, DOI 10.1038/sj.gt.3302867; Jampilek J, 2012, MED RES REV, V32, P907, DOI 10.1002/med.20227; Jungbauer FHW, 2001, CONTACT DERMATITIS, V45, P303, DOI 10.1034/j.1600-0536.2001.450514.x; Kanikkannan N, 2002, INT J PHARM, V248, P219, DOI 10.1016/S0378-5173(02)00454-4; Kanikkannan N, 2000, CURR MED CHEM, V7, P593, DOI 10.2174/0929867003374840; Kikwai L, 2005, AAPS PHARMSCITECH, V6; KIM CK, 1993, INT J PHARMACEUT, V95, P43, DOI 10.1016/0378-5173(93)90388-V; Kim DD, 1996, J PHARM SCI, V85, P1191, DOI 10.1021/js9601041; KUPPER TS, 1990, J CLIN INVEST, V86, P1783, DOI 10.1172/JCI114907; Mayes S, 2006, ANN PHARMACOTHER, V40, P2178, DOI 10.1345/aph.1H135; Menon GK, 1997, SKIN PHARMACOL, V10, P235; Novotny M, 2009, BIOORG MED CHEM LETT, V19, P344, DOI 10.1016/j.bmcl.2008.11.083; Oh HJ, 2001, INT J PHARM, V212, P63, DOI 10.1016/S0378-5173(00)00598-6; Park ES, 2001, DRUG DEV IND PHARM, V27, P975, DOI 10.1081/DDC-100107679; Prausnitz MR, 2008, NAT BIOTECHNOL, V26, P1261, DOI 10.1038/nbt.1504; Shah PP, 2012, J CONTROL RELEASE, V158, P336, DOI 10.1016/j.jconrel.2011.11.016; SOUTHWELL D, 1983, J INVEST DERMATOL, V80, P507, DOI 10.1111/1523-1747.ep12535090; Suhonen TM, 1999, J CONTROL RELEASE, V59, P149, DOI 10.1016/S0168-3659(98)00187-4; Tanojo H, 1999, J CONTROL RELEASE, V58, P97, DOI 10.1016/S0168-3659(98)00144-8; Thong HY, 2007, SKIN PHARMACOL PHYS, V20, P272, DOI 10.1159/000107575; TOUITOU EB, 2006, CHEM PERMEATION ENHA; Trommer H, 2006, SKIN PHARMACOL PHYS, V19, P106, DOI 10.1159/000091978; Williams AC, 2004, ADV DRUG DELIVER REV, V56, P603, DOI 10.1016/j.addr.2003.10.025; Williams IR, 1996, LIFE SCI, V58, P1485, DOI 10.1016/0024-3205(96)00042-2	32	32	32	2	46	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2013	8	12							e82581	10.1371/journal.pone.0082581	http://dx.doi.org/10.1371/journal.pone.0082581			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276EU	24349315	Green Published, gold			2023-01-03	WOS:000328731800068
J	Obreli-Neto, PR; Pereira, LRL; Guidoni, CM; Baldoni, AD; Marusic, S; de Lyra, DP; de Almeida, KL; Pazete, ACM; do Nascimento, JD; Kos, M; Girotto, E; Kenji, R; Cuman, N				Obreli-Neto, Paulo Roque; Leira Pereira, Leonardo Regis; Guidoni, Camilo Molino; Baldoni, Andre de Oliveira; Marusic, Srecko; de Lyra-Junior, Divaldo Pereira; de Almeida, Kelsen Luis; Montolezi Pazete, Ana Claudia; do Nascimento, Janaina Dutra; Kos, Mitja; Girotto, Edmarlon; Kenji, Roberto; Cuman, Nakamura			Use of Simulated Patients to Evaluate Combined Oral Contraceptive Dispensing Practices of Community Pharmacists	PLOS ONE			English	Article							ANTIEPILEPTIC DRUGS; WOMENS; KNOWLEDGE; PILLS; RISK; CONTRAINDICATIONS; PRESCRIPTION; CARBAMAZEPINE; ATTITUDES; PERSONNEL	Background: Combined oral contraceptive (COC) use is the most commonly used reversible method of birth control. The incorrect use of COCs is frequent and one of the most common causes of unintended pregnancies. Community pharmacists (CPs) are in a strategic position to improve COC use because they are the last health professional to interact with patients before drug use. Objective: To evaluate the COC dispensing practices of CPs in a developing country. Method: A cross-sectional study was conducted in community pharmacies of Assis and Ourinhos microregions, Brazil, between June 1, 2012, and October 30, 2012. Four simulated patients (SPs) (with counseled audio recording) visited community pharmacies with a prescription for Ciclo 21 (R) (a COC containing ethinyl estradiol 30 mcg + levonorgestrel 15 mcg). The audio recording of every SP visit was listened to independently by 3 researchers to evaluate the COC dispensing practice. The percentage of CPs who performed a screening for safe use of COCs (i.e., taking of patients' medical and family history, and measuring of blood pressure) and provided counseling, as well as the quality of the screening and counseling, were evaluated. Results: Of the 185 CPs contacted, 41 (22.2%) agreed to participate in the study and finished the study protocol. Only 3 CPs asked the SP a question (1 question asked by each professional), and all of the questions were closed-ended, viz., "do you smoke?" (n = 2) and "what is your age?" (n = 1). None of the CPs measured the patient's blood pressure. Six CPs provided counseling when dispensing COCs (drug dosing, 5 CPs; possible adverse effects, 2 CPs), and one CP provided counseling regarding both aspects. Conclusion: The CPs evaluated did not dispense COC appropriately and could influence in the occurrence of negatives therapeutic outcomes such as adverse effects and treatment failure.	[Obreli-Neto, Paulo Roque; Cuman, Nakamura] Univ Estadual Maringa, Dept Pharmacol & Therapeut, Maringa, Parana, Brazil; [Leira Pereira, Leonardo Regis; Baldoni, Andre de Oliveira] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Dept Pharmaceut Sci, BR-14049 Ribeirao Preto, SP, Brazil; [Guidoni, Camilo Molino; Girotto, Edmarlon] Univ Estadual Londrina, Dept Pharmaceut Sci, Londrina, Parana, Brazil; [Marusic, Srecko] Univ Hosp Dubrava, Dept Clin Pharmacol, Zagreb, Croatia; [de Lyra-Junior, Divaldo Pereira] Univ Fed Sergipe, Lab Teaching & Res Social Pharm, Sao Cristovao, Sergipe, Brazil; [de Almeida, Kelsen Luis; Montolezi Pazete, Ana Claudia; do Nascimento, Janaina Dutra] Fac Integradas Ourinhos, Dept Pharm, Sao Paulo, Brazil; [Kos, Mitja] Univ Ljubljana, Fac Pharm, Chair Social Pharm, Ljubljana, Slovenia	Universidade Estadual de Maringa; Universidade de Sao Paulo; Universidade Estadual de Londrina; Universidade Federal de Sergipe; University of Ljubljana	Obreli-Neto, PR (corresponding author), Univ Estadual Maringa, Dept Pharmacol & Therapeut, Maringa, Parana, Brazil.	paulorobreli@yahoo.com.br	Junior, Divaldo Lyra/AAU-9987-2020; AO BALDONI, AO BALDONI/B-3219-2016; Lyra, Divaldo P/G-4622-2012; Baldoni, André Oliveira/AAO-2675-2021; Kos, Mitja/C-7440-2019; Pereira, Leonardo R L/J-9322-2012	Junior, Divaldo Lyra/0000-0002-0266-0702; AO BALDONI, AO BALDONI/0000-0001-6379-0415; Lyra, Divaldo P/0000-0002-0266-0702; Kos, Mitja/0000-0002-6801-6450; Pereira, Leonardo R L/0000-0002-8609-1390				Adab N, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858, DOI 10.1002/14651858]; Alihonou E, 1997, CONTRACEPTION, V55, P97, DOI 10.1016/S0010-7824(96)00279-X; American College of Obstetrics and Gynecology, 2006, OBSTET GYNECOL, V73, P1453, DOI DOI 10.1097/00006250-200606000-00055.PUBMED:16738183; *ASHP, 1993, AM J HOSP PHARM, V50, P505; Beardsley RS KC, 2012, COMMUNICATION SKILLS; Becker D, 2004, CONTRACEPTION, V69, P295, DOI 10.1016/j.contraception.2003.11.014; BERGER BA, 2009, COMMUNICATION SKILLS; Berger K, 2005, J CLIN PHARM THER, V30, P45, DOI 10.1111/j.1365-2710.2004.00611.x; Blanchard K, 2005, INT FAM PLAN PERSPEC, V31, P172, DOI 10.1363/3117205; *BRAZ MIN HLTH, 2006, PESQ NAC DEM SAUD CR; Caamano F, 2002, PHARM WORLD SCI, V24, P217, DOI 10.1023/A:1021808923928; Chandra Ashish, 2003, Health Promot Pract, V4, P64, DOI 10.1177/1524839902238293; Chin-Quee DS, 2006, STUD FAMILY PLANN, V37, P99, DOI 10.1111/j.1728-4465.2006.00089.x; CHIRDAN OO, 2010, J MED TROPICS, V12, P18; Committee on Gynecologic Practice American College of Obstetricians and Gynecologists, 2012, Obstet Gynecol, V120, P1527, DOI 10.1097/01.AOG.0000423818.85283.bd; Curtis KM, 2006, CONTRACEPTION, V73, P179, DOI 10.1016/j.contraception.2005.08.005; Curtis KM, 2002, OBSTET GYNECOL, V99, P1100, DOI 10.1016/S0029-7844(02)01984-1; Dayal M, 2001, SEMIN REPROD MED, V19, P295, DOI 10.1055/s-2001-18637; de Oliveira DR, 2010, J MANAGE CARE PHARM, V16, P185, DOI 10.18553/jmcp.2010.16.3.185; Doose DR, 2003, EPILEPSIA, V44, P540, DOI 10.1046/j.1528-1157.2003.55602.x; Ehrle N, 2011, INT PERSPECT SEX R H, V37, P67, DOI 10.1363/3706711; Etminan M, 2005, BMJ-BRIT MED J, V330, P63, DOI 10.1136/bmj.38302.504063.8F; Frost JJ, 2007, PERSPECT SEX REPRO H, V39, P48, DOI 10.1363/3904807; Gardner JS, 2008, J AM PHARM ASSOC, V48, P212, DOI 10.1331/JAPhA.2008.07138; Grossman D, 2006, AM J PUBLIC HEALTH, V96, P791, DOI 10.2105/AJPH.2004.040774; Grossman D, 2008, OBSTET GYNECOL, V112, P572, DOI 10.1097/AOG.0b013e31818345f0; Grossman D, 2011, OBSTET GYNECOL, V117, P558, DOI 10.1097/AOG.0b013e31820b0244; HATCHER RA, 2007, CONTRACEPTIVE TECHNO; Institute of Medicine, 2009, IN NAT PRIOR COMP EF; Jensen JT, 2000, OBSTET GYN CLIN N AM, V27, P705, DOI 10.1016/S0889-8545(05)70169-8; Khader YS, 2003, CONTRACEPTION, V68, P11, DOI 10.1016/S0010-7824(03)00073-8; Landau SC, 2006, CONTRACEPTION, V74, P463, DOI 10.1016/j.contraception.2006.07.006; Machado RB, 2012, CONTRACEPTION, V86, P698, DOI 10.1016/j.contraception.2012.05.016; Matlow J, 2012, CAN FAM PHYSICIAN, V58, P163; McIntosh J, 2011, PHARMACOTHERAPY, V31, P424, DOI 10.1592/phco.31.4.424; Obreli-Neto PR, 2011, INT J CLIN PHARM-NET, V33, P642, DOI 10.1007/s11096-011-9518-x; ORTIZ M, 1989, J SOC ADMIN PHARM, V6, P39; Pharmaceutical Society of Australia, 2006, AUSTR PHARM FORM HDB; Ratanajamit C, 2001, PHARMACOEPIDEM DR S, V10, P149, DOI 10.1002/pds.573; Reddy Doodipala Samba, 2010, Expert Rev Clin Pharmacol, V3, P183, DOI 10.1586/ecp.10.3; Schwingl PJ, 1999, AM J OBSTET GYNECOL, V180, P241, DOI 10.1016/S0002-9378(99)70182-1; Shah MA, 2001, INT J GYNECOL OBSTET, V73, P243, DOI 10.1016/S0020-7292(01)00375-7; Shortridge E, 2007, CONTRACEPTION, V75, P355, DOI 10.1016/j.contraception.2006.12.022; Shorvon SD, 2002, J NEUROL NEUROSUR PS, V72, P114, DOI 10.1136/jnnp.72.1.114; Shotorbani S, 2006, CONTRACEPTION, V73, P501, DOI 10.1016/j.contraception.2005.12.001; Sonfield A, 2011, PERSPECT SEX REPRO H, V43, P94, DOI 10.1363/4309411; Tully MP, 2011, PATIENT EDUC COUNS, V83, P3, DOI 10.1016/j.pec.2010.04.029; *US PHARM, 2012, USP MED COUNS BEH GU; Van Riper KK, 2005, PERSPECT SEX REPRO H, V37, P19, DOI 10.1363/371905; Wang H, 2012, CONTRACEPTION, V85, P28, DOI 10.1016/j.contraception.2011.04.017; Watson MC, 2009, FAM PRACT, V26, P532, DOI 10.1093/fampra/cmp061; Watson MC, 2004, PHARM WORLD SCI, V26, P32, DOI 10.1023/B:PHAR.0000013467.61875.ce; WATSON MC, 2006, INT J PHARM PRACT, V14, P83; Weiss MC, 2010, PHARM WORLD SCI, V32, P353, DOI 10.1007/s11096-010-9375-z; Werner JB, 2008, AM J PHARM EDUC, V72, DOI 10.5688/aj7206136; Westhoff CL, 2007, AM J OBSTET GYNECOL, V196, DOI 10.1016/j.ajog.2006.12.015; World Health Organization, 2015, MED EL CRIT CONTR US, V5th	57	19	20	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2013	8	12							e79875	10.1371/journal.pone.0079875	http://dx.doi.org/10.1371/journal.pone.0079875			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	265KD	24324584	Green Submitted, gold, Green Published			2023-01-03	WOS:000327949300011
J	Engmann, C; Wall, S; Darmstadt, G; Valsangkar, B; Claeson, M				Engmann, Cyril; Wall, Stephen; Darmstadt, Gary; Valsangkar, Bina; Claeson, Mariam		Istanbul KMC Acceleration Meeting	Consensus on kangaroo mother care acceleration	LANCET			English	Editorial Material									[Engmann, Cyril; Darmstadt, Gary; Claeson, Mariam] Bill & Melinda Gates Fdn, Maternal Newborn & Child Hlth, Seattle, WA 98102 USA; [Wall, Stephen; Valsangkar, Bina] Save Children Saving Newborn Lives, Washington, DC USA	Bill & Melinda Gates Foundation; Save the Children	Engmann, C (corresponding author), Bill & Melinda Gates Fdn, Maternal Newborn & Child Hlth, Seattle, WA 98102 USA.	cyril.engmann@gatesfoundation.org	Valsangkar, Bina/CAF-1920-2022; Darmstadt, Gary/AAU-7488-2020	Darmstadt, Gary/0000-0002-7522-5824				UNICEF, 2017, LEVELS TRENDS CHILD	2	48	48	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 30	2013	382	9907					E26	E27		10.1016/S0140-6736(13)62293-X	http://dx.doi.org/10.1016/S0140-6736(13)62293-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259QF	24246562				2023-01-03	WOS:000327540700001
J	George, J; Majeed, W; Mackenzie, IS; MacDonald, TM; Wei, L				George, Jacob; Majeed, Waseem; Mackenzie, Isla S.; MacDonald, Thomas M.; Wei, Li			Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; MORTALITY; SALT; POTASSIUM; REDUCTION	Objective To determine whether patients taking formulations of drugs that contain sodium have a higher incidence of cardiovascular events compared with patients on non-sodium formulations of the same drugs. Design Nested case-control study. Setting UK Primary Care Patients registered on the Clinical Practice Research Datalink (CPRD). Participants All patients aged 18 or over who were prescribed at least two prescriptions of sodium-containing formulations or matched standard formulations of the same drug between January 1987 and December 2010. Main outcome measures Composite primary outcome of incident non-fatal myocardial infarction, incident non-fatal stroke, or vascular death. We performed 1: 1 incidence density sampling matched controls using the UK Clinical Practice Research Datalink (CPRD). For the secondary analyses, cases were patients with the individual components of the primary study composite endpoint of hypertension, incident heart failure, and all cause mortality. Results 1 292 337 patients were included in the study cohort. Mean follow-up time was 7.23 years. A total of 61 072 patients with an incident cardiovascular event were matched with controls. For the primary endpoint of incident non-fatal myocardial infarction, incident non-fatal stroke, or vascular death the adjusted odds ratio for exposure to sodium-containing drugs was 1.16 (95% confidence interval 1.12 to 1.21). The adjusted odds ratios for the secondary endpoints were 1.22 (1.16 to 1.29) for incident non-fatal stroke, 1.28 (1.23 to 1.33) for all cause mortality, 7.18 (6.74 to 7.65) for hypertension, 0.98 (0.93 to 1.04) for heart failure, 0.94 (0.88 to 1.00) for incident non-fatal myocardial infarction, and 0.70 (0.31 to 1.59) for vascular death. The median time from date of first prescription (that is, date of entry into cohort) to first event was 3.92 years. Conclusions Exposure to sodium-containing formulations of effervescent, dispersible, and soluble medicines was associated with significantly increased odds of adverse cardiovascular events compared with standard formulations of those same drugs. Sodium-containing formulations should be prescribed with caution only if the perceived benefits outweigh these risks.	[George, Jacob] Univ Dundee, Ninewells Hosp & Med Sch, Div Med Sci, Dundee DD1 9SY, Scotland; [Majeed, Waseem] Ninewells Hosp, NHS Tayside, Dundee DD1 9SY, Scotland; [Mackenzie, Isla S.; MacDonald, Thomas M.; Wei, Li] Univ Dundee, Ninewells Hosp & Med Sch, Med Monitoring Unit, Dundee DD1 9SY, Scotland; [Mackenzie, Isla S.; MacDonald, Thomas M.; Wei, Li] Univ Dundee, Ninewells Hosp & Med Sch, Hypertens Res Ctr, Dundee DD1 9SY, Scotland; [Wei, Li] UCL Sch Pharm, Dept Practice & Policy, London WC1H 9JP, England	University of Dundee; University of Dundee; University of Dundee; University of London; University College London	MacDonald, TM (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Med Monitoring Unit, Dundee DD1 9SY, Scotland.	tom@memo.dundee.ac.uk		Majeed, Waseem/0000-0001-7836-0610; MacDonald, Thomas/0000-0001-5189-6669; George, Jacob/0000-0001-8154-8278; Mackenzie, Isla/0000-0002-3680-7127	TENOVUS Scotland [T10/12]	TENOVUS Scotland	This study was funded by TENOVUS Scotland (ref T10/12). The funder had no role in the design, conduct or data interpretation of the study.	Aburto NJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1326; Alderman MH, 1998, LANCET, V351, P781, DOI 10.1016/S0140-6736(97)09092-2; Alderman MH, 2012, CURR HYPERTENS REP, V14, P193, DOI 10.1007/s11906-012-0275-6; Azoulay L, 2013, THROMB HAEMOSTASIS, V109, P431, DOI 10.1160/TH12-08-0542; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Barton P, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4044; DAHL LK, 1954, ARCH INTERN MED, V94, P525, DOI 10.1001/archinte.1954.00250040017003; Denny SD, 2006, AM J MED, V119, P327, DOI [10.1016/j.amjmed.2005.08.027, 10.1016/j.amjmed.2005.10.042]; ELLIOTT P, 1988, BRIT MED J, V297, P319; Essebag Vidal, 2005, BMC Med Res Methodol, V5, P5, DOI 10.1186/1471-2288-5-5; Food Standards Agency, 2002, HLTH IN WORTH ITS SA; Graudal NA, 1998, JAMA-J AM MED ASSOC, V279, P1383, DOI 10.1001/jama.279.17.1383; Gupta D, 2012, CIRCULATION, V126, P479, DOI 10.1161/CIRCULATIONAHA.111.062430; Haddy FJ, 2006, AM J PHYSIOL-REG I, V290, pR546, DOI 10.1152/ajpregu.00491.2005; Herrett E, 2010, BRIT J CLIN PHARMACO, V69, P4, DOI 10.1111/j.1365-2125.2009.03537.x; Institute of Medicine, 2010, STRAT RED SOD INT US; Li XY, 2012, CNS NEUROSCI THER, V18, P691, DOI 10.1111/j.1755-5949.2012.00355.x; Lim PO, 2001, HYPERTENSION, V37, P856, DOI 10.1161/01.HYP.37.3.856; Palar K, 2009, AM J HEALTH PROMOT, V24, P49, DOI 10.4278/ajhp.080826-QUAN-164; Pimenta E, 2009, HYPERTENSION, V54, P475, DOI 10.1161/HYPERTENSIONAHA.109.131235; Tzemos N, 2008, HYPERTENSION, V51, P1525, DOI 10.1161/HYPERTENSIONAHA.108.109868; Ubeda A, 2009, PHARMACOEPIDEM DR S, V18, P417, DOI 10.1002/pds.1701; Yang QH, 2011, ARCH INTERN MED, V171, P1183, DOI 10.1001/archinternmed.2011.257	23	41	43	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 26	2013	347								f6954	10.1136/bmj.f6954	http://dx.doi.org/10.1136/bmj.f6954			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263FN	24284017	hybrid, Green Published			2023-01-03	WOS:000327792500003
J	Oike, T; Suzuki, Y; Sugawara, K; Shirai, K; Noda, S; Tamaki, T; Nagaishi, M; Yokoo, H; Nakazato, Y; Nakano, T				Oike, Takahiro; Suzuki, Yoshiyuki; Sugawara, Ken-ichi; Shirai, Katsuyuki; Noda, Shin-ei; Tamaki, Tomoaki; Nagaishi, Masaya; Yokoo, Hideaki; Nakazato, Yoichi; Nakano, Takashi			Radiotherapy plus Concomitant Adjuvant Temozolomide for Glioblastoma: Japanese Mono-Institutional Results	PLOS ONE			English	Article							RADIATION-THERAPY; PHASE-II; SURVIVAL; MGMT; IMMUNOHISTOCHEMISTRY; MULTIFORME; EXPRESSION	This study was conducted to investigate the feasibility and survival benefits of combined treatment with radiotherapy and temozolomide (TMZ), which has been covered by the national health insurance in Japanese patients with glioblastoma since September 2006. Between September 2006 and December 2011, 47 patients with newly diagnosed and histologically confirmed glioblastoma received radiotherapy for 60 Gy in 30 fractions. Among them, 45 patients (TMZ group) received concomitant TMZ (75 mg/m(2)/day, every day) and adjuvant TMZ (200 mg/m(2)/day, 5 days during each 28-days). All 36 of the glioblastoma patients receiving radiotherapy between January 1988 and August 2006 were analyzed as historical controls (control group). All patients were followed for at least 1 year or until they died. The median survival was 15.8 months in the TMZ group and 12.0 months in the control group after a median follow-up of 14.0 months. The hazard ratio for death in the TMZ group relative to the control group was 0.52 (P < 0.01); the 2-year survival rate was 27.7% in the TMZ group and 14.6% in the control group. Hematologic toxicity of grade 3 and higher was observed in 20.4% in the TMZ group. Multivariate analysis showed that extent of surgery had the strongest impact on survival (P < 0.01), while the use of TMZ had the second largest impact on survival (P = 0.035). The results indicate that combined treatment with radiotherapy and TMZ has a significant survival benefit for Japanese patients with newly diagnosed glioblastoma with slightly higher toxicities than previously reported.	[Oike, Takahiro; Suzuki, Yoshiyuki; Shirai, Katsuyuki; Noda, Shin-ei; Tamaki, Tomoaki; Nakano, Takashi] Gunma Univ, Grad Sch Med, Dept Radiat Oncol, Maebashi, Gunma 371, Japan; [Sugawara, Ken-ichi] Gunma Univ, Grad Sch Med, Dept Neurosurg, Maebashi, Gunma 371, Japan; [Nagaishi, Masaya; Yokoo, Hideaki; Nakazato, Yoichi] Gunma Univ, Grad Sch Med, Dept Human Pathol, Maebashi, Gunma 371, Japan	Gunma University; Gunma University; Gunma University	Suzuki, Y (corresponding author), Gunma Univ, Grad Sch Med, Dept Radiat Oncol, Maebashi, Gunma 371, Japan.	syoshi@med.gunma-u.ac.jp	Tamaki, Tomoaki/AAU-2699-2020		Grants-in-Aid for Scientific Research [24591834] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Afra D, 2002, LANCET, V359, P1011; Athanassiou H, 2005, J CLIN ONCOL, V23, P2372, DOI 10.1200/JCO.2005.00.331; Brown DC, 2002, HISTOPATHOLOGY, V40, P2, DOI 10.1046/j.1365-2559.2002.01343.x; Chinot OL, 2007, J CLIN ONCOL, V25, P1470, DOI 10.1200/JCO.2006.07.4807; Colleoni M, 2003, BREAST, V12, P538, DOI 10.1016/S0960-9776(03)00163-2; Cunningham JM, 1997, J NEUROSURG, V86, P121, DOI 10.3171/jns.1997.86.1.0121; Gerson SL, 2004, NAT REV CANCER, V4, P296, DOI 10.1038/nrc1319; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Iuchi T, 2006, INT J RADIAT ONCOL, V64, P1317, DOI 10.1016/j.ijrobp.2005.12.005; Lai A, 2011, J CLIN ONCOL, V29, P142, DOI 10.1200/JCO.2010.30.2729; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Nagaishi M, 2011, NEUROPATHOLOGY, V31, P152, DOI 10.1111/j.1440-1789.2010.01143.x; Prados MD, 2009, J CLIN ONCOL, V27, P579, DOI 10.1200/JCO.2008.18.9639; Preusser M, 2008, BRAIN PATHOL, V18, P520, DOI 10.1111/j.1750-3639.2008.00153.x; Quillien V, 2012, CANCER-AM CANCER SOC, V118, P4201, DOI 10.1002/cncr.27392; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Suzuki Y, 2010, J RADIAT RES, V51, P343, DOI 10.1269/jrr.09109; Tanaka G, 2004, INT CONGR SER, V1259, P15, DOI 10.1016/S0531-5131(03)01668-6; Tang K, 2012, MED ONCOL, V29, P1292, DOI 10.1007/s12032-011-9901-4; Tsien CI, 2012, CLIN CANCER RES, V18, P273, DOI 10.1158/1078-0432.CCR-11-2073; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; Weller M, 2009, J CLIN ONCOL, V27, P5743, DOI 10.1200/JCO.2009.23.0805	23	62	72	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2013	8	11							e78943	10.1371/journal.pone.0078943	http://dx.doi.org/10.1371/journal.pone.0078943			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255PK	24265731	Green Published, gold			2023-01-03	WOS:000327252100064
J	Burdett, S; Rydzewska, LHM; Tierney, JF; Auperin, A; Le Pechoux, C; Le Chevalier, T; Pignon, JP				Burdett, Sarah; Rydzewska, Larysa H. M.; Tierney, Jayne F.; Auperin, Anne; Le Pechoux, Cecile; Le Chevalier, Thierry; Pignon, Jean-Pierre		NSCLC Meta-Anal Collaborative Grp	Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data	LANCET			English	Review							RANDOMIZED-TRIAL; PHASE-III; PERIOPERATIVE CHEMOTHERAPY; NEOADJUVANT THERAPY; PLUS SURGERY; CARBOPLATIN; CISPLATIN; FAILURE	Background Individual participant data meta-analyses of postoperative chemotherapy have shown improved survival for patients with non-small-cell lung cancer (NSCLC). We aimed to do a systematic review and individual participant data meta-analysis to establish the effect of preoperative chemotherapy for patients with resectable NSCLC. Methods We systematically searched for trials that started after January, 1965. Updated individual participant data were centrally collected, checked, and analysed. Results from individual randomised controlled trials (both published and unpublished) were combined using a two-stage fixed-effect model. Our primary outcome, overall survival, was defined as the time from randomisation until death (any cause), with living patients censored on the date of last follow-up. Secondary outcomes were recurrence-free survival, time to locoregional and distant recurrence, cause-specific survival, complete and overall resection rates, and postoperative mortality. Prespecified analyses explored any variation in effect by trial and patient characteristics. All analyses were by intention to treat. Findings Analyses of 15 randomised controlled trials (2385 patients) showed a significant benefit of preoperative chemotherapy on survival (hazard ratio [HR] 0.87, 95% CI 0.78-0.96, p=0.007), a 13% reduction in the relative risk of death (no evidence of a difference between trials; p=0.18, I-2 =25%). This finding represents an absolute survival improvement of 5% at 5 years, from 40% to 45%. There was no clear evidence of a difference in the effect on survival by chemotherapy regimen or scheduling, number of drugs, platinum agent used, or whether postoperative radiotherapy was given. There was no clear evidence that particular types of patient defined by age, sex, performance status, histology, or clinical stage benefited more or less from preoperative chemotherapy. Recurrence-free survival (HR 0.85, 95% CI 0.76-0.94, p=0.002) and time to distant recurrence (0.69, 0.58-0.82, p<0.0001) results were both significantly in favour of preoperative chemotherapy although most patients included were stage IB-IIIA. Results for time to locoregional recurrence (0.88, 0.73-1.07, p=0.20), although in favour of preoperative chemotherapy, were not statistically significant. Interpretation Findings, which are based on 92% of all patients who were randomised, and mainly stage IB-IIIA, show preoperative chemotherapy significantly improves overall survival, time to distant recurrence, and recurrence-free survival in resectable NSCLC. The findings suggest this is a valid treatment option for most of these patients. Toxic effects could not be assessed.	[Burdett, Sarah; Rydzewska, Larysa H. M.; Tierney, Jayne F.] UCL, MRC, Clin Trials Unit, Meta Anal Grp, London WC2B 6NH, England; [Auperin, Anne; Le Pechoux, Cecile] Inst Gustave Roussy, Serv Biostat & Epidemiol, Villejuif, France; [Le Chevalier, Thierry; Pignon, Jean-Pierre] Inst Gustave Roussy, Dept Lung Canc, Villejuif, France	Medical Research Council Clinical Trials Unit; University of London; University College London; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Burdett, S (corresponding author), UCL, MRC, Clin Trials Unit, Meta Anal Grp, Aviat House,125 Kingsway, London WC2B 6NH, England.	sarah.burdett@ucl.ac.uk	Rydzewska, Larysa/AAG-7228-2019; Rydzewska, Larysa/AAA-4242-2020; DAUTZENBERG, Bertrand/F-4104-2017	Rydzewska, Larysa/0000-0001-6205-7457; DAUTZENBERG, Bertrand/0000-0001-6937-8907; Tierney, Jayne/0000-0002-4734-3014; Stewart, Lesley/0000-0003-0287-4724; PIGNON, Jean-Pierre/0000-0003-2047-1582	Medical Research Council UK; MRC [MC_U122861323] Funding Source: UKRI; Medical Research Council [MC_U122861323] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [U10CA042777, U10CA180819, U10CA032102, U10CA180888, U10CA105409, U10CA038926] Funding Source: NIH RePORTER	Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Medical Research Council UK.	Allum WH, 2009, J CLIN ONCOL, V27, P5062, DOI 10.1200/JCO.2009.22.2083; American Cancer Society, 2007, CANC FACTS FIG 2007; Auperin A, 2010, LANCET, V375, P1267, DOI 10.1016/S0140-6736(10)60059-1; Berghmans T, 2005, LUNG CANCER, V49, P13, DOI 10.1016/j.lungcan.2005.01.002; Bunn P, PHASE 3 RANDOMIZED C; Burdett S, 2006, J THORAC ONCOL, V1, P611; Datta D, 2003, CHEST, V123, P2096, DOI 10.1378/chest.123.6.2096; DAUTZENBERG B, 1990, CANCER, V65, P2435, DOI 10.1002/1097-0142(19900601)65:11<2435::AID-CNCR2820651105>3.0.CO;2-2; de Boer RH, 1999, BRIT J CANCER, V79, P1514, DOI 10.1038/sj.bjc.6690241; Depierre A, 2002, J CLIN ONCOL, V20, P247, DOI 10.1200/JCO.20.1.247; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Felip E, 2010, J CLIN ONCOL, V28, P3138, DOI 10.1200/JCO.2009.27.6204; Fisher DJ, 2011, J CLIN EPIDEMIOL, V64, P949, DOI 10.1016/j.jclinepi.2010.11.016; Gilligan D, 2007, LANCET, V369, P1929, DOI 10.1016/S0140-6736(07)60714-4; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lefebvre C, 2008, COCHRANE HDB SYSTEMA, P95, DOI DOI 10.1002/9780470712184; Lim E, 2009, J THORAC ONCOL, V4, P1380, DOI 10.1097/JTO.0b013e3181b9ecca; Mattson KV, 2003, ANN ONCOL, V14, P116, DOI 10.1093/annonc/mdg009; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Nagai K, 2003, J THORAC CARDIOV SUR, V125, P254, DOI 10.1067/mtc.2003.15; Nakamura H, 2006, LUNG CANCER, V54, P325, DOI 10.1016/j.lungcan.2006.07.019; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; PASS HI, 1992, ANN THORAC SURG, V53, P992, DOI 10.1016/0003-4975(92)90373-C; Pisters KMW, 2010, J CLIN ONCOL, V28, P1843, DOI 10.1200/JCO.2009.26.1685; ROSELL R, 1994, NEW ENGL J MED, V330, P153, DOI 10.1056/NEJM199401203300301; ROTH JA, 1994, J NATL CANCER I, V86, P673, DOI 10.1093/jnci/86.9.673; Scagliotti GV, 2012, J CLIN ONCOL, V30, P172, DOI 10.1200/JCO.2010.33.7089; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; Song WA, 2010, J THORAC ONCOL, V5, P510, DOI 10.1097/JTO.0b013e3181cd3345; Sorensen JB, 2005, P AN M AM SOC CLIN, V23, P7146, DOI DOI 10.1200/JC0.2005.23.16_; Splinter TA, 2000, P AN M AM SOC CLIN, V19, P495; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; Waller D, 2004, EUR J CARDIO-THORAC, V26, P173, DOI 10.1016/j.ejcts.2004.03.041; Westeel V, 2013, EUR J CANCER, V49, P2654, DOI 10.1016/j.ejca.2013.04.013; Wu Y-L, 2002, ANN ONCOL, V13, P140; Yang X, 2005, LUNG CANCER-J IASLC, V49, pS288, DOI 10.1016/S0169-5002(05)81138-9; Yang X-N, 2013, ASCO ANN M, P7537; Yi Xianghua, 2003, Zhongguo Fei Ai Za Zhi, V6, P124, DOI 10.3779/j.issn.1009-3419.2003.02.09; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	41	375	391	11	60	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 3	2014	383	9928					1561	1571		10.1016/S0140-6736(13)62159-5	http://dx.doi.org/10.1016/S0140-6736(13)62159-5			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AG5YO	24576776	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000335495400027
J	Song, WS; Wang, F; Lotfi, P; Sardiello, M; Segatori, L				Song, Wensi; Wang, Fan; Lotfi, Parisa; Sardiello, Marco; Segatori, Laura			2-Hydroxypropyl-beta-cyclodextrin Promotes Transcription Factor EB- mediated Activation of Autophagy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						Apoptosis; Autophagy; Lipoprotein; Lysosomal Storage Disease; Lysosomes; Ceroid Lipopigment; Cyclodextrin; Neuronal Ceroid Lipofuscinosis; TFEB	CELL-DEATH; CHOLESTEROL; DISEASE; CYCLODEXTRINS; PROTEIN; LIFE; NEURODEGENERATION; RECOGNITION; DEGRADATION; HOMEOSTASIS	Background: The drug delivery vehicle 2-hydroxypropyl--cyclodextrin (HPCD) prevents cholesterol storage. Results: HPCD treatment induces TFEB mediated activation of autophagy and clearance of the autophagic substrate ceroid lipopigment. Conclusion: HPCD administration results in enhancement of the innate autophagic clearance capacity. Significance: Dissecting the cellular pathways impacted by HPCD is crucial to design HPCD-based therapeutic modalities. 2-Hydroxypropyl--cyclodextrin (HPCD) is a Food and Drug Administration-approved excipient used to improve the stability and bioavailability of drugs. Despite its wide use as a drug delivery vehicle and the recent approval of a clinical trial to evaluate its potential for the treatment of a cholesterol storage disorder, the cellular pathways involved in the adaptive response that is activated upon exposure to HPCD are still poorly defined. Here, we show that cell treatment with HPCD results in the activation of the transcription factor EB, a master regulator of lysosomal function and autophagy, and in enhancement of the cellular autophagic clearance capacity. HPCD administration promotes transcription factor EB-mediated clearance of proteolipid aggregates that accumulate due to inefficient activity of the lysosome-autophagy system in cells derived from a patient with a lysosomal storage disorder. Interestingly, HPCD-mediated activation of autophagy was found not to be associated with activation of apoptotic pathways. This study provides a mechanistic understanding of the cellular response to HPCD treatment, which will inform the development of safe HPCD-based therapeutic modalities and may enable engineering HPCD as a platform technology to reduce the accumulation of lysosomal storage material.	Rice Univ, Dept Chem & Biomol Engn, Houston, TX 77005 USA; [Segatori, Laura] Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; [Segatori, Laura] Rice Univ, Dept Bioengn, Houston, TX 77005 USA; [Lotfi, Parisa; Sardiello, Marco] Texas Childrens Hosp, Dept Mol & Human Genet, Baylor Coll Med, Jan & Dan Duncan Neurol Res Inst, Houston, TX 77030 USA	Rice University; Rice University; Rice University; Baylor College of Medicine	Segatori, L (corresponding author), Rice Univ, MS-362,6100 Main St, Houston, TX 77005 USA.	segatori@rice.edu			Welch Foundation [C-1824]; National Science Foundation [CBET 1254318]; Beyond Batten Disease Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS084005] Funding Source: NIH RePORTER	Welch Foundation(The Welch Foundation); National Science Foundation(National Science Foundation (NSF)); Beyond Batten Disease Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the Welch Foundation (C-1824; to L. S.), the National Science Foundation (CBET 1254318; to L. S.), and the Beyond Batten Disease Foundation (to M. S.).	Abi-Mosleh L, 2009, P NATL ACAD SCI USA, V106, P19316, DOI 10.1073/pnas.0910916106; Atger VM, 1997, J CLIN INVEST, V99, P773, DOI 10.1172/JCI119223; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Cao Y, 2006, J BIOL CHEM, V281, P20483, DOI 10.1074/jbc.M602180200; Cheng JL, 2006, BIOCHEM BIOPH RES CO, V351, P246, DOI 10.1016/j.bbrc.2006.10.042; Christian AE, 1997, J LIPID RES, V38, P2264; Davidson CD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006951; Davis ME, 2004, NAT REV DRUG DISCOV, V3, P1023, DOI 10.1038/nrd1576; Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738; Delgado M, 2009, IMMUNOL REV, V227, P189, DOI 10.1111/j.1600-065X.2008.00725.x; Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33; Futerman AH, 2004, NAT REV MOL CELL BIO, V5, P554, DOI 10.1038/nrm1423; Ghosh A, 2012, J BIOL CHEM, V287, P38922, DOI 10.1074/jbc.M112.365148; Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697; Gorski SM, 2003, CURR BIOL, V13, P358, DOI 10.1016/S0960-9822(03)00082-4; Hait WN, 2006, CLIN CANCER RES, V12, P1961, DOI 10.1158/1078-0432.CCR-06-0011; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kohlschutter A, 2009, BRAIN DEV-JPN, V31, P499, DOI 10.1016/j.braindev.2008.12.008; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kondo S, 2006, ONCOGENE, V25, P1099, DOI 10.1038/sj.onc.1209129; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Kundu M, 2008, ANNU REV PATHOL-MECH, V3, P427, DOI 10.1146/annurev.pathmechdis.2.010506.091842; Lee CY, 2003, CURR BIOL, V13, P350, DOI 10.1016/S0960-9822(03)00085-X; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Liu B, 2008, J LIPID RES, V49, P663, DOI 10.1194/jlr.M700525-JLR200; Liu B, 2009, P NATL ACAD SCI USA, V106, P2377, DOI 10.1073/pnas.0810895106; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Maxfield FR, 2010, CURR OPIN CELL BIOL, V22, P422, DOI 10.1016/j.ceb.2010.05.004; Medina DL, 2011, DEV CELL, V21, P421, DOI 10.1016/j.devcel.2011.07.016; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Mukhejee S, 2004, BBA-MOL CELL BIOL L, V1685, P28, DOI 10.1016/j.bbalip.2004.08.009; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Oh JE, 2012, YONSEI MED J, V53, P241, DOI 10.3349/ymj.2012.53.2.241; Palmieri M, 2011, HUM MOL GENET, V20, P3852, DOI 10.1093/hmg/ddr306; Persaud-Sawin DA, 2007, PEDIATR RES, V61, P146, DOI 10.1203/pdr.0b013e31802d8a4a; Pierret C, 2008, ACTA NEUROBIOL EXP, V68, P429; Rajewski RA, 1996, J PHARM SCI, V85, P1142, DOI 10.1021/js960075u; Rosenbaum AI, 2010, P NATL ACAD SCI USA, V107, P5477, DOI 10.1073/pnas.0914309107; Sardiello M, 2009, CELL CYCLE, V8, P4021, DOI 10.4161/cc.8.24.10263; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Settembre C, 2008, AUTOPHAGY, V4, P113, DOI 10.4161/auto.5227; Settembre C, 2011, AUTOPHAGY, V7, P1379, DOI 10.4161/auto.7.11.17166; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; Song WS, 2013, HUM MOL GENET, V22, P1994, DOI 10.1093/hmg/ddt052; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; Wang F, 2011, J BIOL CHEM, V286, P43454, DOI 10.1074/jbc.M111.274332; Wang F, 2011, CHEM BIOL, V18, P766, DOI 10.1016/j.chembiol.2011.04.008; Williams RE, 2012, NEUROLOGY, V79, P183, DOI 10.1212/WNL.0b013e31825f0547	57	80	83	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2014	289	14					10211	10222		10.1074/jbc.M113.506246	http://dx.doi.org/10.1074/jbc.M113.506246			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	AE2MK	24558044	Green Published, hybrid			2023-01-03	WOS:000333807000066
J	van Diepen, M; Schroijen, MA; Dekkers, OM; Rotmans, JI; Krediet, RT; Boeschoten, EW; Dekker, FW				van Diepen, Merel; Schroijen, Marielle A.; Dekkers, Olaf M.; Rotmans, Joris I.; Krediet, Raymond T.; Boeschoten, Elisabeth W.; Dekker, Friedo W.			Predicting Mortality in Patients with Diabetes Starting Dialysis	PLOS ONE			English	Article							STAGE RENAL-DISEASE; MULTIPLE IMPUTATION; PERITONEAL-DIALYSIS; PROGNOSTIC MODELS; HEMODIALYSIS; RISK; SURVIVAL; ADEQUACY; OUTCOMES; IMPACT	Background: While some prediction models have been developed for diabetic populations, prediction rules for mortality in diabetic dialysis patients are still lacking. Therefore, the objective of this study was to identify predictors for 1-year mortality in diabetic dialysis patients and use these results to develop a prediction model. Methods: Data were used from the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD), a multicenter, prospective cohort study in which incident patients with end stage renal disease (ESRD) were monitored until transplantation or death. For the present analysis, patients with DM at baseline were included. A prediction algorithm for 1-year all-cause mortality was developed through multivariate logistic regression. Candidate predictors were selected based on literature and clinical expertise. The final model was constructed through backward selection. The model's predictive performance, measured by calibration and discrimination, was assessed and internally validated through bootstrapping. Results: A total of 394 patients were available for statistical analysis; 82 (21%) patients died within one year after baseline (3 months after starting dialysis therapy). The final prediction model contained seven predictors; age, smoking, history of macrovascular complications, duration of diabetes mellitus, Karnofsky scale, serum albumin and hemoglobin level. Predictive performance was good, as shown by the c-statistic of 0.810. Internal validation showed a slightly lower, but still adequate performance. Sensitivity analyses showed stability of results. Conclusions: A prediction model containing seven predictors has been identified in order to predict 1-year mortality for diabetic incident dialysis patients. Predictive performance of the model was good. Before implementing the model in clinical practice, for example for counseling patients regarding their prognosis, external validation is necessary.	[van Diepen, Merel; Schroijen, Marielle A.; Dekkers, Olaf M.; Dekker, Friedo W.] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands; [Schroijen, Marielle A.; Dekkers, Olaf M.] Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, Leiden, Netherlands; [Rotmans, Joris I.] Leiden Univ, Med Ctr, Dept Nephrol, Leiden, Netherlands; [Krediet, Raymond T.] Univ Amsterdam, Acad Med Ctr, Dept Nephrol, NL-1105 AZ Amsterdam, Netherlands; [Boeschoten, Elisabeth W.] Hans Mak Inst, Naarden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam	Schroijen, MA (corresponding author), Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands.	m.a.schroijen@lumc.nl	Krediet, Raymond/AAP-3291-2021; Rotmans, Joris I./G-8866-2014; Dekker, Friedo W/B-6452-2011; Krediet, Raymond/GLT-2390-2022	Rotmans, Joris I./0000-0001-9682-6234; Dekker, Friedo W/0000-0002-2433-2494; Krediet, Raymond/0000-0002-9851-8507; Dekkers, Olaf/0000-0002-1333-7580	CTMM, the Center for Translational Molecular Medicine, project PREDICCt [01C-104]; Dutch Heart Foundation; Dutch Diabetes Research Foundation; Dutch Kidney Foundation [E.018]; Dutch National Health Insurance Board [OG97/005]	CTMM, the Center for Translational Molecular Medicine, project PREDICCt; Dutch Heart Foundation(Netherlands Heart Foundation); Dutch Diabetes Research Foundation; Dutch Kidney Foundation; Dutch National Health Insurance Board	This research was performed within the framework of CTMM, the Center for Translational Molecular Medicine (www.ctmm.nl), project PREDICCt (grant 01C-104), and supported by the Dutch Heart Foundation, Dutch Diabetes Research Foundation and Dutch Kidney Foundation. This study was supported by grants from the Dutch Kidney Foundation (E.018) and the Dutch National Health Insurance Board (OG97/005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akaike H, 1998, 2 INT S INFORM THEOR, P199, DOI 10.1007/978-1-4612-1694-0; Bazeley J, 2011, CLIN J AM SOC NEPHRO, V6, P2452, DOI 10.2215/CJN.00710111; Berhane AM, 2011, CLIN J AM SOC NEPHRO, V6, P2444, DOI 10.2215/CJN.00580111; Bos WJW, 2010, J HYPERTENS, V28, P439, DOI 10.1097/HJH.0b013e3283349a3c; Brotman DJ, 2005, ARCH INTERN MED, V165, P138, DOI 10.1001/archinte.165.2.138; COX DR, 1958, BIOMETRIKA, V45, P562, DOI 10.2307/2333203; de Goeij MCM, 2013, NEPHROL DIAL TRANSPL, V28, P2415, DOI 10.1093/ndt/gft221; Desai AS, 2011, AM J KIDNEY DIS, V58, P717, DOI 10.1053/j.ajkd.2011.05.020; Efron B., 1994, INTRO BOOTSTRAP, DOI DOI 10.1201/9780429246593; Forsblom C, 2011, J AM SOC NEPHROL, V22, P537, DOI 10.1681/ASN.2010020194; Goodkin DA, 2004, AM J KIDNEY DIS, V44, pS16, DOI 10.1053/j.akjd.2004.08.006; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; HARRELL FE, 2009, DESIGN PACKAGE R PAC; Hill CJ, 2014, AM J KIDNEY DIS, V63, P84, DOI 10.1053/j.ajkd.2013.06.020; Holme I, 2012, J INTERN MED, V271, P463, DOI 10.1111/j.1365-2796.2011.02435.x; Keane WF, 2006, CLIN J AM SOC NEPHRO, V1, P761, DOI 10.2215/CJN.01381005; Kenward MG, 2007, STAT METHODS MED RES, V16, P199, DOI 10.1177/0962280206075304; Liem YS, 2007, KIDNEY INT, V71, P153, DOI 10.1038/sj.ki.5002014; Moons KGM, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b606; Moons KGM, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b375; R Core Team, 2021, R LANG ENV STAT COMP; Royston P, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b604; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Sarnak MJ, 2003, AM J KIDNEY DIS, V41, pS11, DOI 10.1016/S0272-6386(03)00372-X; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Stel VS, 2011, CLIN KIDNEY J, V4, P1, DOI 10.1093/ndtplus/sfq191; Steyerberg E., 2012, CLIN PREDICTION MODE; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Termorshuizen F, 2003, J AM SOC NEPHROL, V14, P2851, DOI 10.1097/01.ASN.0000091585.45723.9E; Tripepi G, 2008, KIDNEY INT, V74, P1512, DOI 10.1038/ki.2008.416; van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463; Van Dijk PCW, 2005, KIDNEY INT, V67, P1489, DOI 10.1111/j.1523-1755.2005.00227.x; van Manen JG, 2002, AM J KIDNEY DIS, V40, P82, DOI 10.1053/ajkd.2002.33916; Villar E, 2007, DIABETES CARE, V30, P3070, DOI 10.2337/dc07-0895; Vonesh EF, 2004, KIDNEY INT, V66, P2389, DOI 10.1111/j.1523-1755.2004.66028.x; Vupputuri S, 2011, DIABETES RES CLIN PR, V91, P246, DOI 10.1016/j.diabres.2010.11.022; Wagner M, 2011, AM J KIDNEY DIS, V57, P894, DOI 10.1053/j.ajkd.2010.12.023	37	16	16	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2014	9	3							e89744	10.1371/journal.pone.0089744	http://dx.doi.org/10.1371/journal.pone.0089744			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC4FD	24594735	Green Submitted, gold, Green Published			2023-01-03	WOS:000332475500021
J	Khakwani, A; Rich, AL; Tata, LJ; Powell, HA; Stanley, RA; Baldwin, DR; Hubbard, RB				Khakwani, Aamir; Rich, Anna L.; Tata, Laila J.; Powell, Helen A.; Stanley, Rosamund A.; Baldwin, David R.; Hubbard, Richard B.			Small-Cell Lung Cancer in England: Trends in Survival and Chemotherapy Using the National Lung Cancer Audit	PLOS ONE			English	Article							CARCINOMA; OUTCOMES; METAANALYSIS; IRRADIATION; AGE; UK	Background: The purpose of this study was to identify trends in survival and chemotherapy use for individuals with small-cell lung cancer (SCLC) in England using the National Lung Cancer Audit (NLCA). Methods: We used data from the NLCA database to identify people with histologically proven SCLC from 2004-2011. We calculated the median survival by stage and assessed whether patient characteristics changed over time. We also assessed whether the proportion of patients with records of chemotherapy and/or radiotherapy changed over time. Results: 18,513 patients were diagnosed with SCLC in our cohort. The median survival was 6 months for all patients, 1 year for those with limited stage and 4 months for extensive stage. 69% received chemotherapy and this proportion changed very slightly over time (test for trends p = 0.055). Age and performance status of patients remained stable over the study period, but the proportion of patients staged increased (p-value<0.001), mainly because of improved data completeness. There has been an increase in the proportion of patients that had a record of receiving both chemotherapy and radiotherapy each year (from 19% to 40% in limited and from 9% to 21% in extensive stage from 2004 to 2011). Patients who received chemotherapy with radiotherapy had better survival compared with any other treatment (HR 0.24, 95% CI 0.23-0.25). Conclusion: Since 2004, when the NLCA was established, the proportion of patients with SCLC having chemotherapy has remained static. We have found an upward trend in the proportion of patients receiving both chemotherapy and radiotherapy which corresponded to a better survival in this group, but as it only applied for a small proportion of patients, it was not enough to change the overall survival.	[Khakwani, Aamir; Tata, Laila J.; Powell, Helen A.; Hubbard, Richard B.] Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG7 2RD, England; [Rich, Anna L.; Baldwin, David R.] Univ Nottingham Hosp, Dept Resp Med, Nottingham NG7 2UH, England; [Powell, Helen A.; Hubbard, Richard B.] Univ Nottingham, Nottingham Resp Res Unit, Nottingham NG7 2RD, England; [Stanley, Rosamund A.] Hlth & Social Care Informat Ctr, Leeds, W Yorkshire, England	University of Nottingham; University of Nottingham; University of Nottingham	Khakwani, A (corresponding author), Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG7 2RD, England.	mcxak14@nottingham.ac.uk	Tata, Laila/J-5227-2012	Tata, Laila/0000-0002-6404-8658	British Lung foundation chair of respiratory epidemiology; GSK; British Lung Foundation; British Lung Foundation [C05/01] Funding Source: researchfish	British Lung foundation chair of respiratory epidemiology; GSK(GlaxoSmithKline); British Lung Foundation; British Lung Foundation	RBH has a grant provided by the British Lung foundation chair of respiratory epidemiology and has a minor consultancy role with GSK concerning people with lung fibrosis where he was paid 350 pound. He is also a co-applicant on a grant for 500,000 pound from GSK to look at biomarkers for lung fibrosis. AK is also doing his PhD from the University of Nottingham on a studentship provided by the British Lung Foundation. The funders had no role in study design, data collection and analyses, decision to publish, or preparation of the manuscript.	Brown JS, 1996, THORAX, V51, P564, DOI 10.1136/thx.51.6.564; Coleman MP, 2011, LANCET, V377, P127, DOI 10.1016/S0140-6736(10)62231-3; Crawford SM, 2009, BRIT J CANCER, V101, P897, DOI 10.1038/sj.bjc.6605257; CRUK, 2012, STAT OUTL LUNG CANC; Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859; GREEN RA, 1969, AM J MED, V46, P516, DOI 10.1016/0002-9343(69)90071-0; Health and Social Care Information Centre, 2011, NAT LUNG CANC AUD RE; Health and Social Care Information Centre, 2010, NAT LUNG CANC AUD 20; Janssen-Heijnen MLG, 2012, ANN ONCOL, V23, P954, DOI 10.1093/annonc/mdr303; Li J, 2010, MED ONCOL, V27, P73, DOI 10.1007/s12032-009-9174-3; Ludbrook JJS, 2003, INT J RADIAT ONCOL, V55, P1321, DOI 10.1016/S0360-3016(02)04576-5; National Clinical Analysis and Specialised Application Team (NATCANSAT), 2013, NAT RAD DAT RTDS; National Institute for Health and Care Excellence, 2005, DIAGN TREATM LUNG CA; National Institute for Health and Clinical Excellence, 2011, LUNG CANC DIAGN TREA; PERRY MC, 1987, NEW ENGL J MED, V316, P912, DOI 10.1056/NEJM198704093161504; PIGNON JP, 1992, NEW ENGL J MED, V327, P1618, DOI 10.1056/NEJM199212033272302; Riaz SP, 2012, LUNG CANCER, V75, P280, DOI 10.1016/j.lungcan.2011.08.004; Rich AL, 2011, BRIT J CANCER, V105, P746, DOI 10.1038/bjc.2011.310; Rich AL, 2011, LUNG CANCER, V72, P16, DOI 10.1016/j.lungcan.2010.07.002; Slotman B, 2007, NEW ENGL J MED, V357, P664, DOI 10.1056/NEJMoa071780; Sobin LH, 2009, TNM CLASSIFICATION M, V7th, DOI DOI 10.1002/9780471420194.TNMC26.PUB2; Walters S, 2013, THORAX, V68, P551, DOI 10.1136/thoraxjnl-2012-202297; WARDE P, 1992, J CLIN ONCOL, V10, P890, DOI 10.1200/JCO.1992.10.6.890; Woolhouse I, 2011, CLIN MED, V11, P110, DOI 10.7861/clinmedicine.11-2-110	24	27	30	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2014	9	2							e89426	10.1371/journal.pone.0089426	http://dx.doi.org/10.1371/journal.pone.0089426			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AB3VI	24586771	gold, Green Published, Green Submitted			2023-01-03	WOS:000331717900095
J	Shin, IJ; Son, SU; Park, H; Kim, Y; Park, SH; Swanberg, K; Shin, JY; Ha, SK; Cho, Y; Bang, SY; Lew, JH; Cho, SH; Maeng, S				Shin, Im-Joon; Son, Sung Un; Park, Hyunwoo; Kim, Yoorim; Park, Sung Hyun; Swanberg, Kelley; Shin, Joo-Yeon; Ha, Sang-Kyu; Cho, Yoonju; Bang, Soo-Yong; Lew, Jae-Hwan; Cho, Seung-Hun; Maeng, Sungho			Preclinical Evidence of Rapid-Onset Antidepressant-Like Effect in Radix Polygalae Extract	PLOS ONE			English	Article							TAIL SUSPENSION TEST; CHRONIC MILD STRESS; AMPA RECEPTOR; ANIMAL-MODELS; TENUIFOLIA; KETAMINE; NMDA; ANTAGONIST; DEPRESSION; TENUIGENIN	Radix Polygalae (the root of Polygala tenuifolia) is a herb widely used in traditional Asian medicine that is thought to exert a variety of neuropsychiatric effects. Radix Polygalae extract can protect against N-methyl D-aspartate (NMDA) neurotoxicity and induce brain-derived neurotrophic factor (BDNF) expression, suggesting modulatory roles at glutamatergic synapses and possible antidepressant action. In accordance with this hypothesis, Radix Polygalae extract demonstrated antidepressant-like effects in 8-week-old male C57Bl/6 mice by decreasing behavioral despair in the forced swim and tail suspension tasks and increasing hedonic-like behavior in the female urine sniffing test 30 minutes after a single oral administration of 0.1 mg/kg. Reduced latency to acquire a food pellet in the novely suppressed feeding paradigm, without change in anxiety-like behaviors suggested a rapid-onset nature of the antidepressant-like effect. In addition, it decreased the number of failed escapes in the learned helplessness paradigm after two oral administrations 24 hours and 30 minutes before the first test. Finally, it reversed anhedonia as measured by saccharin preference in mice exposed to the chronic stress model after two administrations of 0.1 mg/kg, in contrast to the repeated administration generally needed for similar effect by monoamergic antidepressants. Immobility reduction in tail suspension task was blocked by the alpha-amino-3-hydroxy- 5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist NBQX, a pattern previously demonstrated by ketamine and other ketamine-like rapid-onset antidepressants. Also similarly to ketamine, Radix Polygalae appeared to acutely decrease phosphorylation of GluR1 serine-845 in the hippocampus while leaving the phosphorylation of hippocampal mTOR serine 2448 unchanged. These findings serve as preclinical evidence that Radix Polygalae extract exerts rapid-onset antidepressant effects by modulating glutamatergic synapses in critical brain circuits of depression and may be worthy of further evaluation as a safe substitute to other rapid-onset antidepressants known to have unacceptable side effects.	[Shin, Im-Joon; Cho, Yoonju] Kyung Hee Univ, Coll Oriental Med, Dept Appl Korean Med, Seoul, South Korea; [Son, Sung Un; Park, Hyunwoo; Kim, Yoorim; Park, Sung Hyun; Swanberg, Kelley; Shin, Joo-Yeon; Ha, Sang-Kyu; Bang, Soo-Yong; Lew, Jae-Hwan; Maeng, Sungho] Kyung Hee Univ, Grad Sch East West Med Sci, Dept East West Med, Yongin, South Korea; [Cho, Seung-Hun] Kyung Hee Univ, Coll Oriental Med, Dept Neuropsychiat, Seoul, South Korea	Kyung Hee University; Kyung Hee University; Kyung Hee University	Maeng, S (corresponding author), Kyung Hee Univ, Grad Sch East West Med Sci, Dept East West Med, Yongin, South Korea.	jethrot@hotmail.com	Cho, Seung-Hun/F-1294-2010; Swanberg, Kelley M./AAC-6427-2021; Maeng, Sungho/N-2905-2018	Cho, Seung-Hun/0000-0002-0627-768X; Swanberg, Kelley M./0000-0002-1254-190X; Maeng, Sungho/0000-0002-9347-7902	Kyung Hee University [KHU-20101838]; National Research Foundation of Korea (NRF); Korea government [MEST] [2012-0005755]	Kyung Hee University; National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Korea government [MEST](Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	This work was supported by a grant from the Kyung Hee University in 2010 (KHU-20101838) and by the National Research Foundation of Korea (NRF) grant funded by the Korea government [MEST] (No. 2012-0005755). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Auer DP, 2000, BIOL PSYCHIAT, V47, P305, DOI 10.1016/S0006-3223(99)00159-6; Autry AE, 2011, NATURE, V475, P91, DOI 10.1038/nature10130; Bai F, 2001, PHARMACOL BIOCHEM BE, V70, P187, DOI 10.1016/S0091-3057(01)00599-8; Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9; Bettio LE, 2012, BEHAV BRAIN RES; Black MD, 2005, PSYCHOPHARMACOLOGY, V179, P154, DOI 10.1007/s00213-004-2065-6; Bleakman D, 1998, NEUROPHARMACOLOGY, V37, P1187, DOI 10.1016/S0028-3908(98)00139-7; BORSINI F, 1988, PSYCHOPHARMACOLOGY, V94, P147; Bradley SR, 2012, PHARMACOL BIOCHEM BE, V101, P35, DOI 10.1016/j.pbb.2011.11.006; Burgdorf J, 2013, NEUROPSYCHOPHARMACOL, V38, P729, DOI 10.1038/npp.2012.246; Calabrese JR, 2000, J CLIN PSYCHIAT, V61, P841, DOI 10.4088/JCP.v61n1106; Chang H.M., 1986, WORLD SCI, P593, DOI [10.1142/9789814503143_0070, DOI 10.1142/9789814503143_0070]; Chen YJ, 2010, EUR J PHARMACOL, V645, P1, DOI 10.1016/j.ejphar.2010.06.034; Chen YJ, 2012, NEUROCHEM RES, V37, P771, DOI 10.1007/s11064-011-0671-3; Cheng MC, 2006, J NAT PROD, V69, P1305, DOI 10.1021/np060207r; Chung IW, 1992, J KOREAN NEUROPSYCHI, V31, P856; CORSSEN G, 1969, Proceedings of the Institute of Medicine of Chicago, V27, P341; Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P571, DOI 10.1016/j.neubiorev.2005.03.009; Cryan JF, 2002, TRENDS PHARMACOL SCI, V23, P238, DOI 10.1016/S0165-6147(02)02017-5; Denk MC, 2011, AM J PSYCHIAT, V168, P751, DOI 10.1176/appi.ajp.2011.11010128; Der-Avakian A, 2012, TRENDS NEUROSCI, V35, P68, DOI 10.1016/j.tins.2011.11.005; Dulawa SC, 2005, NEUROSCI BIOBEHAV R, V29, P771, DOI 10.1016/j.neubiorev.2005.03.017; Dwyer JM, 2012, INT J NEUROPSYCHOPH, V15, P429, DOI 10.1017/S1461145711001702; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Farber NB, 2003, ANN NY ACAD SCI, V1003, P119, DOI 10.1196/annals.1300.008; Ferrari AJ, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001547; Garcia-Gutierrez MS, 2010, BRIT J PHARMACOL, V160, P1773, DOI 10.1111/j.1476-5381.2010.00819.x; Gibbons RD, 2012, ARCH GEN PSYCHIAT; Gourley SL, 2012, PSYCHOPHARMACOLOGY, V219, P805, DOI 10.1007/s00213-011-2403-4; 이지용, 2004, [Journal of Physiology & Pathology in Korean Medicine, 동의생리병리학회지], V18, P544; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; Hu Y, 2010, PHARM BIOL, V48, P794, DOI 10.3109/13880200903280034; Hu Y, 2010, NEUROCHEM INT, V56, P461, DOI 10.1016/j.neuint.2009.12.004; Hu Y, 2009, PHARMAZIE, V64, P605, DOI 10.1691/ph.2009.9580; Ibrahim L, 2012, J CLIN PSYCHOPHARM, V32, P551, DOI 10.1097/JCP.0b013e31825d70d6; Jick H, 2004, JAMA-J AM MED ASSOC, V292, P338, DOI 10.1001/jama.292.3.338; Kawashima K, 2004, BIOL PHARM BULL, V27, P1317, DOI 10.1248/bpb.27.1317; KEITH SJ, 1993, PSYCHOPHARMACOL BULL, V29, P427; Lee HJ, 2004, AM J CHINESE MED, V32, P599, DOI 10.1142/S0192415X04002235; Lee HK, 2003, CELL, V112, P631, DOI 10.1016/S0092-8674(03)00122-3; Lee Young Jong, 2005, [The Korea Journal of Herbology, 대한본초학회지], V20, P115; Li NX, 2010, SCIENCE, V329, P959, DOI 10.1126/science.1190287; Liu P, 2010, PHYTOMEDICINE, V17, P794, DOI 10.1016/j.phymed.2010.01.004; Lv J, 2009, ACTA PHYSIOL, V196, P419, DOI 10.1111/j.1748-1716.2009.01961.x; Maeng Sungho, 2007, Curr Psychiatry Rep, V9, P467, DOI 10.1007/s11920-007-0063-1; Maeng S, 2008, BIOL PSYCHIAT, V63, P349, DOI 10.1016/j.biopsych.2007.05.028; Malkesman O, 2010, BIOL PSYCHIAT, V67, P864, DOI 10.1016/j.biopsych.2009.10.018; MATTHEWS K, 1995, PHYSIOL BEHAV, V57, P241, DOI 10.1016/0031-9384(94)00286-E; MORYL E, 1993, PHARMACOL TOXICOL, V72, P394, DOI 10.1111/j.1600-0773.1993.tb01351.x; Nestler EJ, 2010, NAT NEUROSCI, V13, P1161, DOI 10.1038/nn.2647; Palucha A, 2007, PHARMACOL THERAPEUT, V115, P116, DOI 10.1016/j.pharmthera.2007.04.007; Palucha-Poniewiera A, 2010, PSYCHOPHARMACOLOGY, V212, P523, DOI 10.1007/s00213-010-1978-5; Papp M, 1996, EUR J PHARMACOL, V316, P145, DOI 10.1016/S0014-2999(96)00675-9; Pomierny-Chamiolo L, 2010, PHARMACOL REP, V62, P1186, DOI 10.1016/S1734-1140(10)70381-9; Pryce CR, 2011, PHARMACOL THERAPEUT, V132, P242, DOI 10.1016/j.pharmthera.2011.06.006; Sanacora G, 2007, BIOL PSYCHIAT, V61, P822, DOI 10.1016/j.biopsych.2006.08.037; Shimazaki T, 2007, EUR J PHARMACOL, V575, P94, DOI 10.1016/j.ejphar.2007.08.006; STERU L, 1985, PSYCHOPHARMACOLOGY, V85, P367, DOI 10.1007/BF00428203; Sui Zhi-Yan, 2012, Clin Psychopharmacol Neurosci, V10, P155, DOI 10.9758/cpn.2012.10.3.155; Sun XL, 2007, BIOL PHARM BULL, V30, P1727, DOI 10.1248/bpb.30.1727; Sun Yan, 2009, Nan Fang Yi Ke Da Xue Xue Bao, V29, P1199; Wilkinson P, 2012, COCHRANE DB SYST REV, V11; Willner P, 1996, PHYSIOL BEHAV, V60, P129, DOI 10.1016/0031-9384(95)02256-2; Xie WB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045575; Yang C, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/175619; Zarate CA, 2004, AM J PSYCHIAT, V161, P171, DOI 10.1176/appi.ajp.161.1.171; Zarate CA, 2006, ARCH GEN PSYCHIAT, V63, P856, DOI 10.1001/archpsyc.63.8.856; Zhang H, 2008, PHYTOMEDICINE, V15, P587, DOI 10.1016/j.phymed.2007.12.004	68	44	46	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2014	9	2							e88617	10.1371/journal.pone.0088617	http://dx.doi.org/10.1371/journal.pone.0088617			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7CL	24520403	Green Published, gold, Green Submitted			2023-01-03	WOS:000331254600094
J	Chen, WW; Cheng, X; Chen, JZ; Yi, X; Nie, DK; Sun, XH; Qin, JB; Tian, ML; Jin, GH; Zhang, XH				Chen, Weiwei; Cheng, Xiang; Chen, Jinzhong; Yi, Xin; Nie, Dekang; Sun, Xiaohui; Qin, Jianbing; Tian, Meiling; Jin, Guohua; Zhang, Xinhua			Lycium barbarum Polysaccharides Prevent Memory and Neurogenesis Impairments in Scopolamine-Treated Rats	PLOS ONE			English	Article							ADULT HIPPOCAMPAL NEUROGENESIS; INDUCED OXIDATIVE STRESS; AMYLOID PEPTIDE NEUROTOXICITY; OCULAR HYPERTENSION MODEL; RETINAL GANGLION-CELLS; ANTIOXIDANT ACTIVITY; INDUCED AMNESIA; NEUROBLAST DIFFERENTIATION; ALZHEIMERS-DISEASE; PROTEIN COMPLEX	Lycium barbarum is used both as a food additive and as a medicinal herb in many countries, and L. barbarum polysaccharides (LBPs), a major cell component, are reported to have a wide range of beneficial effects including neuroprotection, anti-aging and anticancer properties, and immune modulation. The effects of LBPs on neuronal function, neurogenesis, and drug-induced learning and memory deficits have not been assessed. We report the therapeutic effects of LBPs on learning and memory and neurogenesis in scopolamine (SCO)-treated rats. LBPs were administered via gastric perfusion for 2 weeks before the onset of subcutaneous SCO treatment for a further 4 weeks. As expected, SCO impaired performance in novel object and object location recognition tasks, and Morris water maze. However, dual SCO- and LBP-treated rats spent significantly more time exploring the novel object or location in the recognition tasks and had significant shorter escape latency in the water maze. SCO administration led to a decrease in Ki67- or DCX-immunoreactive cells in the dentate gyrus and damage of dendritic development of the new neurons; LBP prevented these SCO-induced reductions in cell proliferation and neuroblast differentiation. LBP also protected SCO-induced loss of neuronal processes in DCX-immunoreactive neurons. Biochemical investigation indicated that LBP decreased the SCO-induced oxidative stress in hippocampus and reversed the ratio Bax/Bcl-2 that exhibited increase after SCO treatment. However, decrease of BDNF and increase of AChE induced by SCO showed no response to LBP administration. These results suggest that LBPs can prevent SCO-induced cognitive and memory deficits and reductions in cell proliferation and neuroblast differentiation. Suppression of oxidative stress and apoptosis may be involved in the above effects of LBPs that may be a promising candidate to restore memory functions and neurogenesis.	[Chen, Weiwei; Cheng, Xiang; Yi, Xin; Qin, Jianbing; Tian, Meiling; Jin, Guohua; Zhang, Xinhua] Nantong Univ, Dept Anat, Nantong, Jiangsu, Peoples R China; [Chen, Weiwei; Chen, Jinzhong] Southeast Univ, Affiliated Yancheng Hosp, Peoples Hosp Yancheng 3, Dept Radiotherapy, Yancheng, Jiangsu, Peoples R China; [Nie, Dekang] Nantong Univ, Affiliated Hosp, Dept Neurosurg, Nantong, Jiangsu, Peoples R China; [Sun, Xiaohui] Rehabil Hosp Agings, Cardiovasc Dept, Nantong, Jiangsu, Peoples R China	Nantong University; Southeast University - China; Nantong University	Jin, GH (corresponding author), Nantong Univ, Dept Anat, Nantong, Jiangsu, Peoples R China.	jguohua@ntu.edu.cn; zhangxinhua@ntu.edu.cn		Zhang, Xin-hua/0000-0002-5702-6733	National Natural Science Foundation of China [31171038]; Jiangsu Natural Science Foundation [BK2011385]; Jiangsu Natural College Foundation [11KJB180008]; Nantong University for Innovation Talent; Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Natural Science Foundation(Natural Science Foundation of Jiangsu Province); Jiangsu Natural College Foundation; Nantong University for Innovation Talent; Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions	This work was supported by grants from the National Natural Science Foundation of China (Grant No. 31171038), Jiangsu Natural Science Foundation (BK2011385), Jiangsu Natural College Foundation (11KJB180008), the Grant of Nantong University for Innovation Talent and a project funded by the Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amagase H, 2009, NUTR RES, V29, P19, DOI 10.1016/j.nutres.2008.11.005; Bromley-Brits K, 2011, JOVE-J VIS EXP, DOI 10.3791/2920; Chan HC, 2007, EXP NEUROL, V203, P269, DOI 10.1016/j.expneurol.2006.05.031; Chang RCC, 2008, CELL MOL NEUROBIOL, V28, P643, DOI 10.1007/s10571-007-9181-x; Cheng D, 2011, MOLECULES, V16, P2542, DOI 10.3390/molecules16032542; Chiu K, 2010, J CELL BIOCHEM, V110, P311, DOI 10.1002/jcb.22539; Chiu Kin, 2009, J Ocul Biol Dis Infor, V2, P47; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Cui BK, 2011, MOLECULES, V16, P9116, DOI 10.3390/molecules16119116; Deng HB, 2003, BIOMED ENVIRON SCI, V16, P267; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Deng W, 2009, J NEUROSCI, V29, P13532, DOI 10.1523/JNEUROSCI.3362-09.2009; Dodart JC, 1997, NEUROREPORT, V8, P1173, DOI 10.1097/00001756-199703240-00023; El-Sherbiny DA, 2003, PHARMACOL BIOCHEM BE, V76, P525, DOI 10.1016/j.pbb.2003.09.014; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gan L, 2004, INT IMMUNOPHARMACOL, V4, P563, DOI 10.1016/j.intimp.2004.01.023; Gan L, 2003, EUR J PHARMACOL, V471, P217, DOI 10.1016/S0014-2999(03)01827-2; Gao XM., 2000, TRADITIONAL CHINESE; Hancianu M, 2013, PHYTOMEDICINE, V20, P446, DOI 10.1016/j.phymed.2012.12.005; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Ho YS, 2007, BRAIN RES, V1158, P123, DOI 10.1016/j.brainres.2007.04.075; Ho YS, 2010, J ALZHEIMERS DIS, V19, P813, DOI 10.3233/JAD-2010-1280; Ho YS, 2009, CELL MOL NEUROBIOL, V29, P1233, DOI 10.1007/s10571-009-9419-x; Jacobs BL, 2000, MOL PSYCHIATR, V5, P262, DOI 10.1038/sj.mp.4000712; Jahanshahi M, 2013, ANAT SCI INT, V88, P217, DOI 10.1007/s12565-013-0188-8; Jeong EJ, 2008, EUR J PHARMACOL, V588, P78, DOI 10.1016/j.ejphar.2008.04.015; Jing LJ, 2009, AFR J TRADIT COMPLEM, V6, P579; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Konar A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027265; Kotani S, 2006, NEUROSCIENCE, V142, P505, DOI 10.1016/j.neuroscience.2006.06.035; Kotani S, 2008, CHEM-BIOL INTERACT, V175, P227, DOI 10.1016/j.cbi.2008.04.004; Kumar H, 2012, BIOSCI BIOTECH BIOCH, V76, P1518, DOI 10.1271/bbb.120247; Lau BWM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033374; LI QY, 2001, HLTH FUNCTIONS MED P, P1; Li SY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016380; Li XM, 2007, J ETHNOPHARMACOL, V111, P504, DOI 10.1016/j.jep.2006.12.024; Li XM, 2007, EUR POLYM J, V43, P488, DOI 10.1016/j.eurpolymj.2006.10.025; Lin CL, 2009, INT J BIOL MACROMOL, V45, P146, DOI 10.1016/j.ijbiomac.2009.04.014; Luo Q, 2004, LIFE SCI, V76, P137, DOI 10.1016/j.lfs.2004.04.056; Luo Q, 2006, LIFE SCI, V79, P613, DOI 10.1016/j.lfs.2006.02.012; Luo Q, 2011, PHYTOTHER RES, V25, P694, DOI 10.1002/ptr.3314; Ma M, 2009, FOOD CHEM, V113, P872, DOI 10.1016/j.foodchem.2008.03.064; Mao F, 2011, MED ONCOL, V28, P121, DOI 10.1007/s12032-009-9415-5; Marcus DL, 1998, EXP NEUROL, V150, P40, DOI 10.1006/exnr.1997.6750; Mi XS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045469; Mohapel P, 2005, NEUROBIOL AGING, V26, P939, DOI 10.1016/j.neurobiolaging.2004.07.015; Nade VS, 2011, INDIAN J PHARMACOL, V43, P137, DOI 10.4103/0253-7613.77347; Niu AJ, 2008, INT J BIOL MACROMOL, V42, P447, DOI 10.1016/j.ijbiomac.2008.02.003; Pandareesh MD, 2013, CELL MOL NEUROBIOL, V33, P875, DOI 10.1007/s10571-013-9952-5; Potterat O, 2010, PLANTA MED, V76, P7, DOI 10.1055/s-0029-1186218; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Shan XZ, 2011, INT J MOL SCI, V12, P1081, DOI 10.3390/ijms12021081; Tang Wai-Man, 2012, Inflammopharmacology, V20, P307, DOI 10.1007/s10787-011-0107-3; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wang CC, 2010, FOOD CHEM, V120, P184, DOI 10.1016/j.foodchem.2009.10.005; Wang YR, 2002, J ETHNOPHARMACOL, V82, P169, DOI 10.1016/S0378-8741(02)00169-1; WINTERBOURN CC, 1975, J LAB CLIN MED, V85, P337; Xiao J, 2012, J ETHNOPHARMACOL, V139, P462, DOI 10.1016/j.jep.2011.11.033; Xin YF, 2011, FOOD CHEM TOXICOL, V49, P259, DOI 10.1016/j.fct.2010.10.028; Yoo DY, 2013, NEUROL RES, V35, P813, DOI 10.1179/1743132813Y.0000000217; Yoo DY, 2011, NEUROCHEM INT, V59, P722, DOI 10.1016/j.neuint.2011.06.021; Yoo DY, 2011, PHYTOTHER RES, V25, P809, DOI 10.1002/ptr.3337; Yu MS, 2007, INT J MOL MED, V20, P261; Yu MS, 2005, EXP GERONTOL, V40, P716, DOI 10.1016/j.exger.2005.06.010; Zhang M, 2005, LIFE SCI, V76, P2115, DOI 10.1016/j.lfs.2004.11.009; Zhang ZP, 2011, CELL BIOL TOXICOL, V27, P107, DOI 10.1007/s10565-010-9174-2; Zhi Fei, 2004, Zhong Yao Cai, V27, P948	67	68	74	0	73	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2014	9	2							e88076	10.1371/journal.pone.0088076	http://dx.doi.org/10.1371/journal.pone.0088076			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA1AT	24505383	Green Published, gold, Green Submitted			2023-01-03	WOS:000330829200111
J	Cho, HW; Hwang, EH; Lim, B; Heo, KH; Liu, JP; Tsutani, K; Lee, MS; Shin, BC				Cho, Hyun-Woo; Hwang, Eui-Hyoung; Lim, Byungmook; Heo, Kwang-Ho; Liu, Jian-Ping; Tsutani, Kiichiro; Lee, Myeong Soo; Shin, Byung-Cheul			How Current Clinical Practice Guidelines for Low Back Pain Reflect Traditional Medicine in East Asian Countries: A Systematic Review of Clinical Practice Guidelines and Systematic Reviews	PLOS ONE			English	Review							EVIDENCE-INFORMED MANAGEMENT; ALTERNATIVE MEDICINE; CHINESE MEDICINE; ACUPUNCTURE; QUALITY; COMPLEMENTARY; FRAMEWORK; HEALTH; METAANALYSIS; VALIDITY	Objectives: The aims of this study were to investigate whether there is a gap between evidence of traditional medicine (TM) interventions in East-Asian countries from the current Clinical Practice Guidelines (CPGs) and evidence from current systematic reviews and meta-analyses (SR-MAs) and to analyze the impact of this gap on present CPGs. Methods: We examined 5 representative TM interventions in the health care systems of East-Asian countries. We searched seven relevant databases for CPGs to identify whether core CPGs included evidence of TM interventions, and we searched 11 databases for SR-MAs to re-evaluate current evidence on TM interventions. We then compared the gap between the evidence from CPGs and SR-MAs. Results: Thirteen CPGs and 22 SR-MAs met our inclusion criteria. Of the 13 CPGs, 7 CPGs (54%) mentioned TM interventions, and all were for acupuncture (only one was for both acupuncture and acupressure). However, the CPGs did not recommend acupuncture (or acupressure). Of 22 SR-MAs, 16 were for acupuncture, 5 for manual therapy, 1 for cupping, and none for moxibustion and herbal medicine. Comparing the evidence from CPGs and SR-MAs, an underestimation or omission of evidence for acupuncture, cupping, and manual therapy in current CPGs was detected. Thus, applying the results from the SR-MAs, we moderately recommend acupuncture for chronic LBP, but we inconclusively recommend acupuncture for (sub) acute LBP due to the limited current evidence. Furthermore, we weakly recommend cupping and manual therapy for both (sub) acute and chronic LBP. We cannot provide recommendations for moxibustion and herbal medicine due to a lack of evidence. Conclusions: The current CPGs did not fully reflect the evidence for TM interventions. As relevant studies such as SR-MAs are conducted and evidence increases, the current evidence on acupuncture, cupping, and manual therapy should be rigorously considered in the process of developing or updating the CPG system.	[Cho, Hyun-Woo; Hwang, Eui-Hyoung; Heo, Kwang-Ho; Shin, Byung-Cheul] Pusan Natl Univ, Korean Med Hosp, Spine & Joint Ctr, Dept Rehabil Med Korean Med, Yangsan, South Korea; [Hwang, Eui-Hyoung; Shin, Byung-Cheul] Pusan Natl Univ, Sch Korean Med, Div Clin Med, Yangsan, South Korea; [Lim, Byungmook] Pusan Natl Univ, Sch Korean Med, Div Humanities & Social Sci, Yangsan, South Korea; [Liu, Jian-Ping] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China; [Tsutani, Kiichiro] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Drug Policy & Management, Tokyo, Japan; [Lee, Myeong Soo] Korea Inst Oriental Med, Brain Dis Res Ctr, Taejon, South Korea	Pusan National University; Pusan National University; Pusan National University; Beijing University of Chinese Medicine; University of Tokyo; Korea Institute of Oriental Medicine (KIOM)	Shin, BC (corresponding author), Pusan Natl Univ, Korean Med Hosp, Spine & Joint Ctr, Dept Rehabil Med Korean Med, Yangsan, South Korea.	drshinbc@gmail.com	Lee, Myeong Soo/C-8147-2013	Lee, Myeong Soo/0000-0001-6651-7641; Liu, Jianping/0000-0002-0320-061X				Ammendolia C, 2008, SPINE J, V8, P160, DOI 10.1016/j.spinee.2007.10.014; Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140-6736(99)01312-4; Bidwell S, 2004, EXTEXT HLTH TECHNOLO; Cao HJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031793; Cheung F, 2011, NATURE, V480, pS82, DOI 10.1038/480S82a; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Cluzeau F, 2003, QUAL SAF HEALTH CARE, V12, P18; Dagenais S., 2011, EVIDENCE BASED MANAG; Dijkers M, 2013, TRY THIS KT UPDATE; Ernst E, 2005, Complement Ther Clin Pract, V11, P17, DOI 10.1016/j.ctnm.2004.09.005; Ernst E, 2002, SCHMERZ, V16, P129, DOI 10.1007/s004820100099; Field MJ, 1990, CLIN PRACTICE GUIDEL; Frass M, 2012, OCHSNER J, V12, P45; Furlan AD, 2005, SPINE, V30, P944, DOI 10.1097/01.brs.0000158941.21571.01; Furlan AD, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/953139; Furlan AD, 2009, SPINE, V34, P1669, DOI 10.1097/BRS.0b013e3181ad7bd6; Gagnier JJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004504; Goertz M, 2010, ADULT LOW BACK PAIN; Goertz MTD., 2012, I CLIN SYSTEMS IMPRO; Graham R, 2011, CLINICAL PRACTICE GUIDELINES WE CAN TRUST, P1; Hall H, 2008, CLIN EVID, V2008; Han Chnaghyun, 2007, Korean Journal of Acupuncture, V24, P17; Harbour R, 2001, BRIT MED J, V323, P334, DOI 10.1136/bmj.323.7308.334; Hegmann K, 2007, LOW BACK DISORDERS O; Henderson Helen, 2002, Br J Nurs, V11, P1395; Hesketh T, 1997, BRIT MED J, V315, P115, DOI 10.1136/bmj.315.7100.115; Hutchinson AJP, 2012, J ORTHOP SURG RES, V7, DOI 10.1186/1749-799X-7-36; Imamura M, 2008, SPINE J, V8, P121, DOI 10.1016/j.spinee.2007.10.016; Kim Jong-In, 2011, Evid Based Complement Alternat Med, V2011, P467014, DOI 10.1093/ecam/nep035; Kim YC, 2012, J MUSCULOSKELET PAIN, V20, P116, DOI 10.3109/10582452.2012.673543; Koes BW, 2010, EUR SPINE J, V19, P2075, DOI 10.1007/s00586-010-1502-y; Kong LJ, 2012, EVID-BASED COMPL ALT, V2012; Lu SC, 2011, EVID-BASED COMPL ALT, V2011; MacDermid JC, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-18; Manchikanti L, 2009, PAIN PHYSICIAN, V12, P699; Manheimer E, 2005, ANN INTERN MED, V142, P651, DOI 10.7326/0003-4819-142-8-200504190-00014; Michigan Quality Improvement Consortium, 2011, MAN AC LOW BACK PAIN; Moon TW, 2013, CHIN J INTEGR MED, V19, P228, DOI 10.1007/s11655-012-1238-0; Moret L, 2012, TRANSFUS CLIN BIOL, V19, P174, DOI 10.1016/j.tracli.2012.07.015; National Collaborating Centre for Primary Care, 2009, LOW BACK PAIN EARL M, P25; National Guideline Clearinghouse, 2009, OCC THER PRACT GUID; National Guideline Clearinghouse, 2011, LOW BACK LUMB THOR A; Park HL, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429103; Park JE, 2010, COMPLEMENT THER MED, V18, P215, DOI 10.1016/j.ctim.2010.07.001; Robinson N, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-88; Rubinstein SM, 2010, EUR SPINE J, V19, P1213, DOI 10.1007/s00586-010-1356-3; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; SCHIN - Sowerby Centre for Health Informatics at Newcastle, 2009, BACK PAIN LOW RAD PR; Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10; Smith LA, 2000, PAIN, V86, P119, DOI 10.1016/S0304-3959(00)00234-7; The Japanese Orthopaedic Association the Japanese Society of Lumbar Spine Disorders, 2012, CLIN PRACT GUID MAN; Toward Optimized Practice, 2009, GUID EV INF PRIM CAR; Trigkilidas D, 2010, ANN ROY COLL SURG, V92, P595, DOI 10.1308/003588410X12699663904196; University of Michigan Health System, 2010, ACT LOW BACK PAIN; van Tulder MW, 1999, SPINE, V24, P1113, DOI 10.1097/00007632-199906010-00011; van Tulder MW, 2005, BEST PRACT RES CL RH, V19, P639, DOI 10.1016/j.berh.2005.03.006; Waddell G, 1996, SPINE, V21, P2820, DOI 10.1097/00007632-199612150-00002; World Health Organization Media Centre, 2012, TRAD MED; Xu J, 2009, HEALTH POLICY, V90, P133, DOI 10.1016/j.healthpol.2008.09.003; Yu WY, 2011, J TRADIT CHIN MED, V31, P376, DOI 10.1016/S0254-6272(12)60021-1; Yuan J, 2008, SPINE, V33, pE887, DOI 10.1097/BRS.0b013e318186b276	61	10	11	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2014	9	2							e88027	10.1371/journal.pone.0088027	http://dx.doi.org/10.1371/journal.pone.0088027			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA1AT	24505363	gold, Green Published, Green Submitted			2023-01-03	WOS:000330829200101
J	Wang, LL; Chen, DD; Lee, JH; Gu, XH; Alaaeddine, G; Li, JM; Wei, L; Yu, SP				Wang, Li-Li; Chen, Dongdong; Lee, Jinhwan; Gu, Xiaohuan; Alaaeddine, Ghina; Li, Jimei; Wei, Ling; Yu, Shan Ping			Mobilization of Endogenous Bone Marrow Derived Endothelial Progenitor Cells and Therapeutic Potential of Parathyroid Hormone after Ischemic Stroke in Mice	PLOS ONE			English	Article							FOCAL CEREBRAL-ISCHEMIA; STEM-CELLS; ENHANCES ANGIOGENESIS; MYOCARDIAL-INFARCTION; FUNCTIONAL RECOVERY; BARREL CORTEX; NEUROGENESIS; RECEPTOR; BLOOD; BRAIN	Stroke is a major neurovascular disorder threatening human life and health. Very limited clinical treatments are currently available for stroke patients. Stem cell transplantation has shown promising potential as a regenerative treatment after ischemic stroke. The present investigation explores a new concept of mobilizing endogenous stem cells/progenitor cells from the bone marrow using a parathyroid hormone (PTH) therapy after ischemic stroke in adult mice. PTH 1-34 (80 mu g/kg, i.p.) was administered 1 hour after focal ischemia and then daily for 6 consecutive days. After 6 days of PTH treatment, there was a significant increase in bone marrow derived CD-34/Fetal liver kinase-1 (Flk-1) positive endothelial progenitor cells (EPCs) in the peripheral blood. PTH treatment significantly increased the expression of trophic/regenerative factors including VEGF, SDF-1, BDNF and Tie-1 in the brain peri-infarct region. Angiogenesis, assessed by co-labeled Glut-1 and BrdU vessels, was significantly increased in PTH-treated ischemic brain compared to vehicle controls. PTH treatment also promoted neuroblast migration from the subventricular zone (SVZ) and increased the number of newly formed neurons in the peri-infarct cortex. PTH-treated mice showed significantly better sensorimotor functional recovery compared to stroke controls. Our data suggests that PTH therapy improves endogenous repair mechanisms after ischemic stroke with functional benefits. Mobilizing endogenous bone marrow-derived stem cells/progenitor cells using PTH and other mobilizers appears an effective and feasible regenerative treatment after ischemic stroke.	[Wang, Li-Li; Chen, Dongdong; Lee, Jinhwan; Gu, Xiaohuan; Alaaeddine, Ghina; Wei, Ling; Yu, Shan Ping] Emory Univ Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA; [Wang, Li-Li; Li, Jimei] Capital Med Univ, Beijing Friendship Hosp, Dept Neurol, Beijing, Peoples R China; [Wei, Ling] Emory Univ Sch Med, Dept Neurol, Atlanta, GA USA	Emory University; Capital Medical University; Emory University	Yu, SP (corresponding author), Emory Univ Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA.	spyu@emory.edu	Alaaeddine, Ghina/HHN-7143-2022; wang, lili/HDL-7210-2022		NIH [NS0458710, NS075338, NS062097]; AHA Established Investigator Award; AHA [12GRNT12060222]; National Natural Science Foundation of China [81350012]; NIH from the Extramural Research Facilities Program of the National Center for Research Resources [C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062097, R21NS075338] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AHA Established Investigator Award(American Heart Association); AHA(American Heart Association); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NIH from the Extramural Research Facilities Program of the National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work is supported by NIH grants NS0458710 (SPY), NS075338 (LW), NS062097 (LW), AHA Established Investigator Award (LW), AHA Grant-in-Aid grant 12GRNT12060222 (SPY) and by a grant 81350012 (JL) from National Natural Science Foundation of China. This work was also supported by the NIH grant C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. The funders had no role in interfering with study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams GB, 2007, NAT BIOTECHNOL, V25, P238, DOI 10.1038/nbt1281; AKMAL M, 1984, P SOC EXP BIOL MED, V176, P434; Arai K, 2009, FEBS J, V276, P4644, DOI 10.1111/j.1742-4658.2009.07176.x; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Ballen KK, 2007, BIOL BLOOD MARROW TR, V13, P838, DOI 10.1016/j.bbmt.2007.03.007; Bensinger W, 2009, BONE MARROW TRANSPL, V43, P181, DOI 10.1038/bmt.2008.410; Bieglmayer C, 2002, CLIN CHEM, V48, P1731; Borlongan CV, 2011, PROG NEUROBIOL, V95, P213, DOI 10.1016/j.pneurobio.2011.08.005; Bouet V, 2007, EXP NEUROL, V203, P555, DOI 10.1016/j.expneurol.2006.09.006; Brines ML, 1999, NEUROSCI LETT, V274, P13, DOI 10.1016/S0304-3940(99)00664-3; Brunner S, 2008, EXP HEMATOL, V36, P1157, DOI 10.1016/j.exphem.2008.03.014; Brunner S, 2007, AM J PHYSIOL-ENDOC M, V293, pE1670, DOI 10.1152/ajpendo.00287.2007; CHAUBAL A, 1994, ACTA NEUROPATHOL, V88, P454; Chizh BA, 2007, J PSYCHOPHARMACOL, V21, P259, DOI 10.1177/0269881105062484; Coppolino G, 2011, J INVEST MED, V59, P823, DOI 10.2310/JIM.0b013e318214edf8; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Dunac A, 2007, J NEUROL, V254, P327, DOI 10.1007/s00415-006-0362-1; Espinera AR, 2013, NEUROSCIENCE, V247, P1, DOI 10.1016/j.neuroscience.2013.04.011; Fan YF, 2010, ANN NEUROL, V67, P488, DOI 10.1002/ana.21919; FEOLA M, 1986, SURG GYNECOL OBSTET, V163, P523; Freret T, 2009, BEHAV NEUROSCI, V123, P224, DOI 10.1037/a0014157; Ghani U, 2005, STROKE, V36, P151, DOI 10.1161/01.STR.0000149944.15406.16; Hess DC, 2008, CELL PROLIFERAT, V41, P94, DOI 10.1111/j.1365-2184.2008.00486.x; Horn T, 2010, NEUROCHEM INT, V57, P940, DOI 10.1016/j.neuint.2010.09.014; Huber BC, 2011, CARDIOVASC RES, V90, P529, DOI 10.1093/cvr/cvr014; Huber BC, 2010, AM J PHYSIOL-HEART C, V298, pH1466, DOI 10.1152/ajpheart.00033.2010; Kollet O, 2003, J CLIN INVEST, V112, P160, DOI 10.1172/JCI200317902; Lemoli RM, 2008, HAEMATOLOGICA, V93, P321, DOI 10.3324/haematol.12616; Lemoli RM, 2006, STEM CELLS, V24, P2817, DOI 10.1634/stemcells.2006-0333; Li WL, 2013, NEUROSCIENCE, V244, P16, DOI 10.1016/j.neuroscience.2013.03.045; Li WL, 2008, DEV NEUROBIOL, V68, P1474, DOI 10.1002/dneu.20674; Li Y, 2007, J CEREBR BLOOD F MET, V27, P1043, DOI 10.1038/sj.jcbfm.9600417; Liang Z, 2007, BIOCHEM BIOPH RES CO, V359, P716, DOI 10.1016/j.bbrc.2007.05.182; Lin TN, 2000, J CEREBR BLOOD F MET, V20, P387, DOI 10.1097/00004647-200002000-00021; Lubjuhn J, 2009, J NEUROSCI METH, V184, P95, DOI 10.1016/j.jneumeth.2009.07.029; Manzerra P, 2001, P NATL ACAD SCI USA, V98, P11055, DOI 10.1073/pnas.191353598; Misra V, 2012, NEUROLOGY, V79, pS207, DOI 10.1212/WNL.0b013e31826959d2; Moubarik C, 2011, STEM CELL REV REP, V7, P208, DOI 10.1007/s12015-010-9157-y; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Navarro-Sobrino M, 2010, MICROVASC RES, V80, P317, DOI 10.1016/j.mvr.2010.05.008; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; Ogle ME, 2012, NEUROBIOL DIS, V45, P733, DOI 10.1016/j.nbd.2011.10.020; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; Ovbiagele B, 2008, STROKE, V39, P2231, DOI 10.1161/STROKEAHA.107.513499; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Robin AM, 2006, J CEREBR BLOOD F MET, V26, P125, DOI 10.1038/sj.jcbfm.9600172; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050; Schwarzkopf TM, 2013, EXP BIOL MED, V238, P84, DOI 10.1258/ebm.2012.012261; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Sigler A, 2009, P NATL ACAD SCI USA, V106, P11759, DOI 10.1073/pnas.0812695106; Strong K, 2007, LANCET NEUROL, V6, P182, DOI 10.1016/S1474-4422(07)70031-5; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Taylor CW, 2012, BIOCHEM SOC T, V40, P147, DOI 10.1042/BST20110615; Usdin TB, 1997, ENDOCRINOLOGY, V138, P831, DOI 10.1210/en.138.2.831; Usdin TB, 2003, TRENDS ENDOCRIN MET, V14, P14, DOI 10.1016/S1043-2760(02)00002-4; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; WEI L, 1995, STROKE, V26, P1459, DOI 10.1161/01.STR.26.8.1459; Wei L, 2012, NEUROBIOL DIS, V46, P635, DOI 10.1016/j.nbd.2012.03.002; WEISS SW, 1993, AM J SURG PATHOL, V17, P1039, DOI 10.1097/00000478-199310000-00009; Whitaker VR, 2007, J CEREBR BLOOD F MET, V27, P57, DOI 10.1038/sj.jcbfm.9600318; Yang JJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020219; Zacharek A, 2007, J CEREBR BLOOD F MET, V27, P1684, DOI 10.1038/sj.jcbfm.9600475; Zaruba MM, 2008, CARDIOVASC RES, V77, P722, DOI 10.1093/cvr/cvm080; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460	65	30	32	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2014	9	2							e87284	10.1371/journal.pone.0087284	http://dx.doi.org/10.1371/journal.pone.0087284			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VA	24503654	gold, Green Submitted, Green Published			2023-01-03	WOS:000330631800026
J	Denegetu, AW; Dolamo, BL				Denegetu, Amenu Wesen; Dolamo, Bethabile Lovely			HIV Screening among TB Patients and Co-Trimoxazole Preventive Therapy for TB/HIV Patients in Addis Ababa: Facility Based Descriptive Study	PLOS ONE			English	Article							TUBERCULOSIS PATIENTS; PROPHYLAXIS; MORTALITY; SUSPECTS	Background: Collaborative TB/HIV management is essential to ensure that HIV positive TB patients are identified and treated appropriately, and to prevent tuberculosis (TB) in HIV positive patients. The purpose of this study was to assess HIV case finding among TB patients and Co-trimoxazole Preventive Therapy (CPT) for HIV/TB patients in Addis Ababa. Methods: A descriptive cross-sectional, facility-based survey was conducted between June and July 2011. Data was collected by interviewing 834 TB patients from ten health facilities in Addis Ababa. Both descriptive and inferential statistics were used to summarize and analyze findings. Results: The proportion of TB patients who (self reported) were offered for HIV test, tested for HIV and tested HIV positive during their anti-TB treatment follow-up were; 87.4%, 69.4% and 20.2%; respectively. Eighty seven HIV positive patients were identified, who knew their status before diagnosed for the current TB disease, bringing the cumulative prevalence of HIV among TB patients to 24.5%. Hence, the proportion of TB patients who knew their HIV status becomes 79.9%. The study revealed that 43.6% of those newly identified HIV positives during anti-TB treatment follow-up were actually treated with CPT. However, the commutative proportion of HIV positive TB patients who were ever treated with CPT was 54.4%; both those treated before the current TB disease and during anti-TB treatment follow-up. Conclusions: HIV case finding among TB patients and provision of CPT for TB/HIV co-infected patients needs boosting. Hence, routine offering of HIV test and provision of CPT for PLHIV should be strengthened in-line with the national guidelines.	[Denegetu, Amenu Wesen] WHO South Sudan, STOP Int Consultant, Addis Ababa, Ethiopia; [Dolamo, Bethabile Lovely] Univ S Africa, Dept Hlth Studies, ZA-0001 Pretoria, South Africa	University of South Africa	Denegetu, AW (corresponding author), WHO South Sudan, STOP Int Consultant, Addis Ababa, Ethiopia.	denegetu@gmail.com			University of South Africa (UNISA)	University of South Africa (UNISA)	Finally, the support of the University of South Africa (UNISA) financially and the UNISA Akaki (Ethiopia) Regional Learning Centre for administrative and library services deserve special acknowledgements. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Addis Ababa City Administration Health Bureau (AACAHB), 2010, ANN CIT ADM HLTH BUR; Adjei A A, 2006, West Afr J Med, V25, P38; Alemayehu YK, 2009, INT J QUAL HEALTH C, V21, P356, DOI 10.1093/intqhc/mzp030; [Anonymous], 2009, GUID MON EV COLL TB; Bipra B, 2013, PLOS ONE, V8; Deribew A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018614; Federal Ministry of Health of Ethiopia, 2007, IMPL GUID TB HIV COL; FHAPCO, 2007, GUID HIV COUNS TEST; Harries AD, 2010, LANCET, V375, P1906, DOI 10.1016/S0140-6736(10)60409-6; Kapata N, 2012, TROP MED INT HEALTH, V17, P760, DOI 10.1111/j.1365-3156.2012.02981.x; Kassa Aragie, 2012, BMC Res Notes, V5, P67, DOI 10.1186/1756-0500-5-67; Klein PW, 2013, J COMMUNITY HLTH; Kong DG, 2013, J PUBLIC HEALTH MAN, V19, P169, DOI 10.1097/PHH.0b013e3182550a83; Lowrance D, 2007, JAIDS-J ACQ IMM DEF, V46, P56; Mulenga V, 2007, AIDS, V21, P77, DOI 10.1097/QAD.0b013e3280114ed7; Munthali L, 2006, INT J TUBERC LUNG D, V10, P199; Nunn AJ, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a257; Odhiambo J, 2008, INT J TUBERC LUNG D, V12, pS63; Srikantiah P, 2007, INT J TUBERC LUNG D, V11, P168; UNAIDS, 2011, GLOB REP UNAIDS REP; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; WHO, 2020, WHO REPORT; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; World Health Organization, 2012, WHO POL COLL TB HIV; World Health Organization, 2007, GUID PROV IN HIV TES; World Health Organization, 2006, GLOB PLAN STOP TB 20; World Health Organization (WHO), 2006, GUID COTR PROPH HIV; World Health Organization (WHO), 2007, TB HIV MON ADV PROJ; Yadeta D, 2013, J INFECT PUBLIC HEAL, V6, P222, DOI 10.1016/j.jiph.2013.01.002	29	11	11	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2014	9	2							e86614	10.1371/journal.pone.0086614	http://dx.doi.org/10.1371/journal.pone.0086614			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302TD	24498278	Green Submitted, Green Published, gold			2023-01-03	WOS:000330626900024
J	Wang, F; Zhao, SC; Li, F; Zhang, B; Qu, Y; Sun, TL; Luo, T; Li, DP				Wang, Fei; Zhao, Shancang; Li, Feng; Zhang, Bo; Qu, Yi; Sun, Tianlei; Luo, Ting; Li, Dapeng			Investigation of Antioxidant Interactions between Radix Astragali and Cimicifuga foetida and Identification of Synergistic Antioxidant Compounds	PLOS ONE			English	Article							PHENOLIC-COMPOUNDS; LIQUID-CHROMATOGRAPHY; METHANOL EXTRACTS; IN-VITRO; ACID; MONGHOLICUS; FLAVONOIDS; LEAF	The medicinal plants of Huang-qi (Radix Astragali) and Sheng-ma (Cimicifuga foetida) demonstrate significantly better antioxidant effects when used in combination than when used alone. However, the bioactive components and interactional mechanism underlying this synergistic action are still not well understood. In the present study, 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay was employed to investigate the antioxidant capacity of single herbs and their combination with the purpose of screening synergistic antioxidant compounds from them. Chromatographic isolation was performed on silica gel, Sephadex LH-20 columns and HPLC, and consequently to yield formononetin, calycosin, ferulic acid and isoferulic acid, which were identified by their retention time, UV lambda(max), MS and MS/MS data. The combination of isoferulic acid and calycosin at a dose ratio of 1:1 resulted in significant synergy in scavenging DPPH radicals and ferric reducing antioxidant power (FRAP) assay. Furthermore, the protective effects of these four potential synergistic compounds were examined using H2O2-induced HepG2 Cells bioassay. Results revealed that the similar synergy was observed in the combination of isoferulic acid and calycosin. These findings might provide some theoretical basis for the purported synergistic efficiency of Huang-qi and Sheng-ma as functional foods, dietary supplements and medicinal drugs.	[Wang, Fei; Li, Feng; Zhang, Bo; Qu, Yi; Sun, Tianlei; Luo, Ting; Li, Dapeng] Shandong Agr Univ, Dept Food Sci, Tai An, Shandong, Peoples R China; [Zhao, Shancang] Shandong Acad Agr Sci, Shandong Prov Key Lab Test Technol Food Qual & Sa, Jinan, Shandong, Peoples R China; [Zhao, Shancang] Shandong Acad Agr Sci, Cent Lab, Jinan, Shandong, Peoples R China	Shandong Agricultural University; Shandong Academy of Agricultural Sciences; Shandong Academy of Agricultural Sciences	Li, DP (corresponding author), Shandong Agr Univ, Dept Food Sci, Tai An, Shandong, Peoples R China.	dpli73@sdau.edu.cn	li, dapeng/G-4166-2010; DaPeng, Li/G-4164-2010	li, dapeng/0000-0002-1816-3217; DaPeng, Li/0000-0002-1816-3217	National Key Technology R&D Program in the 12th five-year Plan of China [2012BAK17B05]; Shandong Provincial Natural Science Foundation [2009ZRB019PD]; National Natural Science Foundation of China [31201417]	National Key Technology R&D Program in the 12th five-year Plan of China(National Key Technology R&D Program); Shandong Provincial Natural Science Foundation(Natural Science Foundation of Shandong Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Key Technology R&D Program in the 12th five-year Plan of China (2012BAK17B05), Shandong Provincial Natural Science Foundation (2009ZRB019PD), and National Natural Science Foundation of China (31201417). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25; Cai YZ, 2006, LIFE SCI, V78, P2872, DOI 10.1016/j.lfs.2005.11.004; Costa RM, 2009, FOOD CHEM TOXICOL, V47, P860, DOI 10.1016/j.fct.2009.01.019; Dai F, 2008, BIOCHIMIE, V90, P1499, DOI 10.1016/j.biochi.2008.05.007; Facino RM, 1998, PLANTA MED, V64, P343, DOI 10.1055/s-2006-957448; Freeman BL, 2010, J FOOD SCI, V75, pC570, DOI 10.1111/j.1750-3841.2010.01717.x; Fridlender ZG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031524; Fu SF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019604; Goupy P, 2007, FREE RADICAL BIO MED, V43, P933, DOI 10.1016/j.freeradbiomed.2007.06.013; Guo FQ, 2006, J PHARMACEUT BIOMED, V40, P623, DOI 10.1016/j.jpba.2005.07.034; HUDSON BJF, 1983, FOOD CHEM, V10, P111, DOI 10.1016/0308-8146(83)90027-4; Jia Z, 1999, FOOD CHEM, V64, P555, DOI 10.1016/S0308-8146(98)00102-2; Kumaran A, 2007, LWT-FOOD SCI TECHNOL, V40, P344, DOI 10.1016/j.lwt.2005.09.011; Li HB, 2008, LWT-FOOD SCI TECHNOL, V41, P385, DOI 10.1016/j.lwt.2007.03.011; Li M, 2011, LWT FOOD SCI TECHNOL; Li XC, 2012, CHEM CENT J, V6, DOI 10.1186/1752-153X-6-140; Lin LZ, 2000, J CHROMATOGR A, V876, P87, DOI 10.1016/S0021-9673(00)00149-7; Liu DH, 2008, LWT-FOOD SCI TECHNOL, V41, P1344, DOI 10.1016/j.lwt.2007.08.001; Lopez-Alarcon C, 2012, ANAL CHIMICA ACTA; Palafox-Carlos H, 2012, MOLECULES, V17, P12657, DOI 10.3390/molecules171112657; Pan RL, 2009, ARCH PHARM RES, V32, P185, DOI 10.1007/s12272-009-1133-1; Peng ZF, 2003, PHYTOCHEMISTRY, V62, P219, DOI 10.1016/S0031-9422(02)00504-6; Peyrat-Maillard MN, 2003, J AM OIL CHEM SOC, V80, P1007, DOI 10.1007/s11746-003-0812-z; Prior R. L., 2013, AM J BIOMEDICAL SCI, V5, P126, DOI DOI 10.5099/AJ130200126; Rathee JS, 2006, J AGR FOOD CHEM, V54, P9046, DOI 10.1021/jf061679e; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; Wang CC, 2010, FOOD CHEM, V120, P184, DOI 10.1016/j.foodchem.2009.10.005; Wang XZ, 2011, NAT PROD COMMUN, V6, P1285; Williamson EM, 2001, PHYTOMEDICINE, V8, P401, DOI 10.1078/0944-7113-00060; Yang WJ, 2009, BIOL PHARM BULL, V32, P1021, DOI 10.1248/bpb.32.1021; Yu DH, 2005, BIOMED ENVIRON SCI, V18, P297	32	31	32	1	56	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2014	9	1							e87221	10.1371/journal.pone.0087221	http://dx.doi.org/10.1371/journal.pone.0087221			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302PJ	24498048	gold, Green Published, Green Submitted			2023-01-03	WOS:000330617100063
J	Zhang, ZL; Nix, CA; Ercan, UK; Gerstenhaber, JA; Joshi, SG; Zhong, YH				Zhang, Zhiling; Nix, Camilla A.; Ercan, Utku K.; Gerstenhaber, Jonathan A.; Joshi, Suresh G.; Zhong, Yinghui			Calcium Binding-Mediated Sustained Release of Minocycline from Hydrophilic Multilayer Coatings Targeting Infection and Inflammation	PLOS ONE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RESISTANT STAPHYLOCOCCUS-AUREUS; BIOMEDICAL APPLICATIONS; NITRIC-OXIDE; PH; BIOCOMPATIBILITY; TETRACYCLINES; ANTIBODIES; SURFACES; BIOFILMS	Infection and inflammation are common complications that seriously affect the functionality and longevity of implanted medical implants. Systemic administration of antibiotics and anti-inflammatory drugs often cannot achieve sufficient local concentration to be effective, and elicits serious side effects. Local delivery of therapeutics from drug-eluting coatings presents a promising solution. However, hydrophobic and thick coatings are commonly used to ensure sufficient drug loading and sustained release, which may limit tissue integration and tissue device communications. A calcium-mediated drug delivery mechanism was developed and characterized in this study. This novel mechanism allows controlled, sustained release of minocycline, an effective antibiotic and anti-inflammatory drug, from nanoscale thin hydrophilic polyelectrolyte multilayers for over 35 days at physiologically relevant concentrations. pH-responsive minocycline release was observed as the chelation between minocycline and Ca2+ is less stable at acidic pH, enabling 'smart' drug delivery in response to infection and/or inflammation-induced tissue acidosis. The release kinetics of minocycline can be controlled by varying initial loading, Ca2+ concentration, and Ca2+ incorporation into different layers, enabling facile development of implant coatings with versatile release kinetics. This drug delivery platform can potentially be used for releasing any drug that has high Ca2+ binding affinity, enabling its use in a variety of biomedical applications.	[Zhang, Zhiling; Nix, Camilla A.; Ercan, Utku K.; Gerstenhaber, Jonathan A.; Zhong, Yinghui] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA; [Joshi, Suresh G.] Drexel Univ, Coll Med, Surg Infect Program, Dept Surg, Philadelphia, PA 19104 USA; [Joshi, Suresh G.] Drexel Univ, Coll Med, Dept Microbiol & Immunol, Philadelphia, PA 19104 USA	Drexel University; Drexel University; Drexel University	Zhong, YH (corresponding author), Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA.	yz348@drexel.edu	Ercan, Utku Kursat/AAX-1924-2020; Ercan, Utku Kürşat/A-1658-2012; Joshi, Suresh G./AAT-1354-2021	Ercan, Utku Kürşat/0000-0002-9762-2265; Joshi, Suresh G./0000-0002-7838-4898; Gerstenhaber, Jonathan/0000-0002-8162-7977	Drexel University	Drexel University	This work was supported by the startup fund from Drexel University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amin AR, 1996, P NATL ACAD SCI USA, V93, P14014, DOI 10.1073/pnas.93.24.14014; Anderson JM, 1999, J CONTROL RELEASE, V57, P107, DOI 10.1016/S0168-3659(98)00178-3; Anderson JM, 2001, ANNU REV MATER RES, V31, P81, DOI 10.1146/annurev.matsci.31.1.81; Bernier C, 2001, ANN DERMATOL VENER, V128, P627; Bhatia S, 2010, STEREOT FUNCT NEUROS, V88, P147, DOI 10.1159/000303528; BJARNASON I, 1993, GASTROENTEROLOGY, V104, P1832, DOI 10.1016/0016-5085(93)90667-2; Boudou T, 2010, ADV MATER, V22, P441, DOI 10.1002/adma.200901327; Burke SE, 2004, MACROMOLECULES, V37, P5375, DOI 10.1021/ma049445o; Carlotti B, 2012, PHYS CHEM CHEM PHYS, V14, P823, DOI 10.1039/c1cp22703c; Chuang HF, 2008, BIOMACROMOLECULES, V9, P1660, DOI 10.1021/bm800185h; Coleman JW, 2001, INT IMMUNOPHARMACOL, V1, P1397, DOI 10.1016/S1567-5769(01)00086-8; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; Dejugnat C., 2006, FUNCTIONAL COATINGS, P67; Del Pace S, 2010, INTERN EMERG MED, V5, P121, DOI 10.1007/s11739-010-0350-4; Dunston CR, 2011, PROTEOMICS, V11, P42, DOI 10.1002/pmic.201000273; Ercan UK, 2013, PLASMA PROCESS POLYM, V10, P544, DOI 10.1002/ppap.201200104; Gupta AK, 2004, J NEUROTRAUM, V21, P678, DOI 10.1089/0897715041269722; Hetrick EM, 2006, CHEM SOC REV, V35, P780, DOI 10.1039/b515219b; Hezi-Yamit A, 2009, J BIOMED MATER RES A, V90A, P133, DOI 10.1002/jbm.a.32057; Huster D, 1998, BIOPHYS J, V75, P909, DOI 10.1016/S0006-3495(98)77579-4; Jin LH, 2007, BIOPHYS CHEM, V128, P185, DOI 10.1016/j.bpc.2007.04.005; Johnson MD, 2007, J NEUROSCI METH, V160, P276, DOI 10.1016/j.jneumeth.2006.09.023; Joshi SG, 2010, AM J INFECT CONTROL, V38, P293, DOI 10.1016/j.ajic.2009.11.002; Le Nga N, 2011, J Diabetes Sci Technol, V5, P605; LIEDBERG H, 1989, SCAND J UROL NEPHROL, P2; Lu Y, 2009, BIOMATERIALS, V30, P4143, DOI 10.1016/j.biomaterials.2009.04.030; Maragakis LL, 2008, CLIN INFECT DIS, V46, P1254, DOI 10.1086/529198; Menkin V, 1937, AM J PATHOL, V13, P25; Nieman GF, 2001, CURR MED CHEM, V8, P317, DOI 10.2174/0929867013373570; Novak MT, 2010, ANAL BIOANAL CHEM, V398, P1695, DOI 10.1007/s00216-010-4097-6; Onuki Yoshinori, 2008, J Diabetes Sci Technol, V2, P1003; Page J, 2000, ARCH INTERN MED, V160, P777, DOI 10.1001/archinte.160.6.777; Pautke C, 2011, ORAL ONCOL, V47, P425, DOI 10.1016/j.oraloncology.2011.03.022; PIRSON Y, 1986, AM J KIDNEY DIS, V8, P338, DOI 10.1016/S0272-6386(86)80108-1; Poelstra KA, 2002, J BIOMED MATER RES, V60, P206, DOI 10.1002/jbm.10069; Reis CP, 2008, J PHARM SCI-US, V97, P5290, DOI 10.1002/jps.21347; Satpute MG, 2011, AM J INFECT CONTROL, V39, pE21, DOI 10.1016/j.ajic.2010.10.034; Schwartz AB, 2004, ANNU REV NEUROSCI, V27, P487, DOI 10.1146/annurev.neuro.27.070203.144233; Shukla A, 2011, J CONTROL RELEASE, V155, P159, DOI 10.1016/j.jconrel.2011.06.011; Shukla A, 2010, SMALL, V6, P2392, DOI 10.1002/smll.201001150; Soliman GM, 2010, MACROMOL BIOSCI, V10, P278, DOI 10.1002/mabi.200900259; Telang NV, 2010, AM J INFECT CONTROL, V38, P165, DOI 10.1016/j.ajic.2009.07.007; Tendeloo HJC, 1936, J BIOL CHEM, V113, P333; THE TH, 1970, IMMUNOLOGY, V18, P865; Wu P, 2006, BIOMATERIALS, V27, P2450, DOI 10.1016/j.biomaterials.2005.11.031; Zhong YH, 2008, J R SOC INTERFACE, V5, P957, DOI 10.1098/rsif.2008.0071; Zimmerli W, 2011, SEMIN IMMUNOPATHOL, V33, P295, DOI 10.1007/s00281-011-0275-7	47	13	13	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2014	9	1							e84360	10.1371/journal.pone.0084360	http://dx.doi.org/10.1371/journal.pone.0084360			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286JC	24409292	Green Published, gold, Green Submitted			2023-01-03	WOS:000329463500016
J	Potiron, VA; Abderrahmani, R; Clement-Colmou, K; Marionneau-Lambot, S; Oullier, T; Paris, F; Supiot, S				Potiron, Vincent A.; Abderrahmani, Rym; Clement-Colmou, Karen; Marionneau-Lambot, Severine; Oullier, Thibauld; Paris, Francois; Supiot, Stephane			Improved Functionality of the Vasculature during Conventionally Fractionated Radiation Therapy of Prostate Cancer	PLOS ONE			English	Article							ENDOTHELIAL-CELLS; TUMOR RESPONSE; HYPOFRACTIONATED RADIOTHERAPY; INDUCED APOPTOSIS; OXYGEN-TENSION; HYPOXIA; IRRADIATION; DENSITY; DAMAGE; MICE	Although endothelial cell apoptosis participates in the tumor shrinkage after single high-dose radiotherapy, little is known regarding the vascular response after conventionally fractionated radiation therapy. Therefore, we evaluated hypoxia, perfusion and vascular microenvironment changes in an orthotopic prostate cancer model of conventionally fractionated radiation therapy at clinically relevant doses (2 Gy fractions, 5 fractions/week). First, conventionally fractionated radiation therapy decreased tumor cell proliferation and increased cell death with kinetics comparable to human prostate cancer radiotherapy. Secondly, the injection of Hoechst 33342 or fluorescent-dextrans showed an increased tumor perfusion within 14 days in irradiated tumors, which was correlated with a clear reduction of hypoxia. Improved perfusion and decreased hypoxia were not explained by increased blood vessel density, size or network morphology. However, a tumor vascular maturation defined by perivascular desmin+/SMA+ cells coverage was clearly observed along with an increase in endothelial, zonula occludens (ZO)-1 positive, intercellular junctions. Our results show that, in addition to tumor cell killing, vascular maturation plays an uncovered role in tumor reoxygenation during fractionated radiation therapy.	[Potiron, Vincent A.; Abderrahmani, Rym; Clement-Colmou, Karen; Paris, Francois; Supiot, Stephane] INSERM, UMR892, Nantes, France; [Potiron, Vincent A.; Abderrahmani, Rym; Clement-Colmou, Karen; Paris, Francois; Supiot, Stephane] Univ Nantes, Nantes, France; [Potiron, Vincent A.; Abderrahmani, Rym; Clement-Colmou, Karen; Paris, Francois; Supiot, Stephane] CNRS, UMR6299, Nantes, France; [Clement-Colmou, Karen; Paris, Francois; Supiot, Stephane] Inst Cancerol Ouest, Dept Radiat Oncol, St Herblain, France; [Marionneau-Lambot, Severine; Oullier, Thibauld] Canceropole Grand Ouest, Plate Forme Vivo, Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Institut de Cancerologie de l'Ouest (ICO)	Supiot, S (corresponding author), INSERM, UMR892, Nantes, France.	stephane.supiot@ico.unicancer.fr	Marionneau-Lambot, Séverine/AAY-1452-2020; Potiron, Vincent/L-6873-2015; Supiot, Stéphane/M-1586-2015; Paris, francois E/L-4915-2015	Marionneau-Lambot, Séverine/0000-0002-5041-8531; Potiron, Vincent/0000-0002-3693-6578; Supiot, Stéphane/0000-0003-2094-1708; Paris, francois E/0000-0002-0176-7348; Clement-Colmou, Karen/0000-0003-0986-2718	Institut National du Cancer (INCA PAIR-prostate); Association pour la Recherche sur le Cancer; Ligue Nationale Contre le Cancer; Region Pays de Loire	Institut National du Cancer (INCA PAIR-prostate)(Institut National du Cancer (INCA) France); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Region Pays de Loire(Region Pays de la Loire)	This work was supported by the Institut National du Cancer (INCA PAIR-prostate 2010), the Association pour la Recherche sur le Cancer, the Ligue Nationale Contre le Cancer and the Region Pays de Loire. The funding source was not involved in the collection, analysis and interpretation of data, preparation of the manuscript and decision to publish.	Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Baumann M, 2001, ACTA ONCOL, V40, P519, DOI 10.1080/028418601750288262; Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419; Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232; Bonnaud S, 2007, CANCER RES, V67, P1803, DOI 10.1158/0008-5472.CAN-06-2802; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Brizel DM, 1999, RADIOTHER ONCOL, V53, P113, DOI 10.1016/S0167-8140(99)00102-4; Bromfield GP, 2003, PROSTATE CANCER P D, V6, P73, DOI 10.1038/sj.pcan.4500628; Brurberg KG, 2005, RADIOTHER ONCOL, V77, P220, DOI 10.1016/j.radonc.2005.09.009; Burrell K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038366; Carlson DJ, 2011, INT J RADIAT ONCOL, V79, P1188, DOI 10.1016/j.ijrobp.2010.10.007; Chen FH, 2009, CLIN CANCER RES, V15, P1721, DOI 10.1158/1078-0432.CCR-08-1471; Chen FH, 2013, INT J RAD ONCOL BIOL; Corre I, 2010, MUTAT RES-REV MUTAT, V704, P61, DOI 10.1016/j.mrrev.2010.01.014; De Bock K, 2011, CURR OPIN GENET DEV, V21, P73, DOI 10.1016/j.gde.2010.10.008; Dreher MR, 2006, JNCI-J NATL CANCER I, V98, P335, DOI 10.1093/jnci/djj070; Fuks Z, 2005, CANCER CELL, V8, P89, DOI 10.1016/j.ccr.2005.07.014; Gabrys D, 2007, INT J RADIAT ONCOL, V69, P1553, DOI 10.1016/j.ijrobp.2007.08.039; Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504; Graves EE, 2010, CLIN CANCER RES, V16, P4843, DOI 10.1158/1078-0432.CCR-10-1206; Imaizumi N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011084; Killingsworth MC, 2011, PATHOBIOLOGY, V78, P24, DOI 10.1159/000322739; Kwak HJ, 2000, CIRCULATION, V101, P2317, DOI 10.1161/01.CIR.101.19.2317; Lan J, 2013, RADIAT RES, V179, P458, DOI 10.1667/RR3116.1; Laughlin KM, 1996, J PHARMACOL EXP THER, V277, P1049; LORD EM, 1993, CANCER RES, V53, P5721; Lyng H, 2000, INT J RADIAT ONCOL, V46, P935, DOI 10.1016/S0360-3016(99)00497-6; Maeda A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042133; Martin JM, 2011, DRUGS, V71, P1019, DOI 10.2165/11591500-000000000-00000; Milosevic M, 2012, CLIN CANCER RES, V18, P2108, DOI 10.1158/1078-0432.CCR-11-2711; Moeller BJ, 2005, CANCER CELL, V8, P99, DOI 10.1016/j.ccr.2005.06.016; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Park HJ, 2012, RADIAT RES, V177, P311, DOI 10.1667/RR2773.1; Penet MF, 2009, CANCER RES, V69, P8822, DOI 10.1158/0008-5472.CAN-09-1782; Potiron VA, 2013, RADIOTHER ONCOL, V106, P138, DOI 10.1016/j.radonc.2012.11.014; Roe K, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-75; Stewart GD, 2010, BJU INT, V105, P8, DOI 10.1111/j.1464-410X.2009.08921.x; Supiot S, 2013, CANCER RADIOTHER, V17, P349, DOI 10.1016/j.canrad.2013.05.005; Supiot S, 2012, CANCER RADIOTHER, V16, P11, DOI 10.1016/j.canrad.2011.10.006; Supiot S, 2008, RADIOTHER ONCOL, V88, P53, DOI 10.1016/j.radonc.2008.03.019; VANPUTTE.LM, 1968, J NATL CANCER I, V40, P441; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011; Yaromina A, 2011, INT J RADIAT ONCOL, V80, P1205, DOI 10.1016/j.ijrobp.2011.02.015; Zovein AC, 2010, DEV CELL, V18, P39, DOI 10.1016/j.devcel.2009.12.006; ZYWIETZ F, 1995, INT J RADIAT ONCOL, V32, P1391, DOI 10.1016/0360-3016(94)00653-3	45	41	41	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2013	8	12							e84076	10.1371/journal.pone.0084076	http://dx.doi.org/10.1371/journal.pone.0084076			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	284MV	24391887	Green Published, Green Submitted, gold			2023-01-03	WOS:000329323900030
J	Qi, ZY; Shao, C; Huang, YL; Hui, GZ; Zhou, YX; Wang, Z				Qi, Zhen-Yu; Shao, Chuan; Huang, Yu-Lun; Hui, Guo-Zhen; Zhou, You-Xin; Wang, Zhong			Reproductive and Exogenous Hormone Factors in Relation to Risk of Meningioma in Women: A Meta-Analysis	PLOS ONE			English	Article							GROWTH-FACTOR PROFILE; BRAIN-TUMORS; REPLACEMENT THERAPY; CANCER-RISK; INTRACRANIAL MENINGIOMA; SPINAL MENINGIOMAS; ASSOCIATION; COHORT; MORTALITY; RECEPTORS	Background and Objective: A number of studies have focused on the association between oral contraceptive (OC), hormonal replacement therapy (HRT) and reproductive factors and meningioma risk, but the results were inconsistent. Thus, a meta-analysis was performed to obtain more precise estimates of risk. Methods: We conducted a literature search using PubMed and EMBASE databases to July2013, without any limitations. Random effects models were used to summarize results. Results: Twelve case-control and six cohort studies were included in this meta-analysis. We found that an increased risk of meningioma was associated with HRT use(RR = 1.19, 95% CI = 1.01-1.40), postmenopausal women(RR = 1.32, 95% CI = 1.07-1.64) and parity(RR = 1.18, 95% CI = 1.00-1.40). No significant associations were observed for OC use (RR = 0.93, 95% CI = 0.83-1.03), age at menarche(RR = 1.06, 95% CI = 0.92-1.21), age at menopause(RR = 1.03, 95% CI = 0.81-1.30), or age at first birth(RR = 0.94, 95% CI = 0.80-1.10). Conclusion: In conclusion, the results of our study support the hypothesis that longer exposure to effect of female sex hormones may increase the risk of meningioma in women, yet additional studies are warranted to confirm our findings and identify the underlying biological mechanisms.	[Qi, Zhen-Yu; Shao, Chuan; Huang, Yu-Lun; Hui, Guo-Zhen; Zhou, You-Xin; Wang, Zhong] Soochow Univ, Dept Neurosurg, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China	Soochow University - China	Qi, ZY (corresponding author), Soochow Univ, Dept Neurosurg, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China.	qizhenyu@suda.edu.cn		Shao, Chuan/0000-0001-8260-4761				ADAMI HO, 1989, INT J CANCER, V44, P833, DOI 10.1002/ijc.2910440515; Aghi MK, 2007, NEUROSURGERY, V61, P754, DOI 10.1227/01.NEU.0000298903.63635.E3; Andersen L, 2013, EUR J CANCER, V49, P3303, DOI 10.1016/j.ejca.2013.05.026; [Anonymous], 2010, Prescrire Int, V19, P120; Basen-Engquist K, 2011, CURR ONCOL REP, V13, P71, DOI 10.1007/s11912-010-0139-7; Benson VS, 2008, BRIT J CANCER, V99, P185, DOI 10.1038/sj.bjc.6604445; Benson VS, 2010, INT J CANCER, V127, P1692, DOI 10.1002/ijc.25184; Blitshteyn S, 2008, J CLIN ONCOL, V26, P279, DOI 10.1200/JCO.2007.14.2133; CANTOR KP, 1993, CANCER CAUSE CONTROL, V4, P505, DOI 10.1007/BF00052425; Cea-Soriano L, 2012, CANCER EPIDEMIOL, V36, P198, DOI 10.1016/j.canep.2011.08.003; Chamoun R, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11220; Chiu HF, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-857; Claus EB, 2013, J NEUROSURG, V118, P649, DOI 10.3171/2012.9.JNS12811; Cowppli-Bony A, 2011, CANCER CAUSE CONTROL, V22, P697, DOI 10.1007/s10552-011-9742-7; Custer B, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-152; Custer BS, 2002, CANCER, V94, P1626, DOI 10.1002/cncr.10410; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dickson R B, 2000, J Natl Cancer Inst Monogr, P135; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fan ZX, 2013, CANCER CAUSE CONTROL, V24, P1517, DOI 10.1007/s10552-013-0228-7; Hannaford PC, 2007, BRIT MED J, V335, P651, DOI 10.1136/bmj.39289.649410.55; Hatch EE, 2005, INT J CANCER, V114, P797, DOI 10.1002/ijc.20776; Hatiboglu MA, 2008, SURG NEUROL, V69, P356, DOI 10.1016/j.surneu.2007.03.013; Henderson BE, 2000, CARCINOGENESIS, V21, P427, DOI 10.1093/carcin/21.3.427; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hsu DW, 1997, J NEUROSURG, V86, P113, DOI 10.3171/jns.1997.86.1.0113; HUNT K, 1990, BRIT J OBSTET GYNAEC, V97, P1080, DOI 10.1111/j.1471-0528.1990.tb02494.x; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; JAY JR, 1985, J NEUROSURG, V62, P757, DOI 10.3171/jns.1985.62.5.0757; Jhawar BS, 2003, J NEUROSURG, V99, P848, DOI 10.3171/jns.2003.99.5.0848; Johnson DR, 2011, NEURO-ONCOLOGY, V13, P1011, DOI 10.1093/neuonc/nor081; Korhonen K, 2010, CANCER CAUSE CONTROL, V21, P2149, DOI 10.1007/s10552-010-9634-2; Korhonen K, 2012, AM J EPIDEMIOL, V175, P309, DOI 10.1093/aje/kwr335; Lambe M, 1997, INT J CANCER, V72, P389; Lee E, 2006, INT J CANCER, V119, P1152, DOI 10.1002/ijc.21950; Maiuri F, 2011, CLIN NEUROL NEUROSUR, V113, P34, DOI 10.1016/j.clineuro.2010.08.017; McKinney PA, 2004, J NEUROL NEUROSUR PS, V75, P12, DOI 10.1136/jnnp.2004.040741; Michaud DS, 2010, CANCER EPIDEM BIOMAR, V19, P2562, DOI 10.1158/1055-9965.EPI-10-0447; Persson I, 1996, INT J CANCER, V67, P327, DOI 10.1002/(SICI)1097-0215(19960729)67:3<327::AID-IJC4>3.3.CO;2-J; PLESKO I, 1985, INT J CANCER, V36, P529, DOI 10.1002/ijc.2910360502; PRESTONMARTIN S, 1995, CANCER EPIDEM BIOMAR, V4, P333; Rao G, 2009, NEUROSURGERY, V65, P483, DOI 10.1227/01.NEU.0000350876.91495.E0; Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X; Roberts DL, 2010, ANNU REV MED, V61, P301, DOI 10.1146/annurev.med.080708.082713; RUBINSTEIN AB, 1994, J NEUROSURG, V81, P184, DOI 10.3171/jns.1994.81.2.0184; RYAN P, 1992, INT J CANCER, V51, P20, DOI 10.1002/ijc.2910510105; Sanson M, 2000, ACTA NEUROCHIR, V142, P493, DOI 10.1007/s007010050462; SCHLEHOFER B, 1992, J NATL CANCER I, V84, P1346, DOI 10.1093/jnci/84.17.1346; Schlehofer B, 1999, INT J CANCER, V82, P155, DOI 10.1002/(SICI)1097-0215(19990719)82:2<155::AID-IJC1>3.0.CO;2-P; Smith JS, 2005, CAN J NEUROL SCI, V32, P122, DOI 10.1017/S0317167100017017; Wiemels J, 2010, J NEURO-ONCOL, V99, P307, DOI 10.1007/s11060-010-0386-3; Wigertz A, 2008, CANCER EPIDEM BIOMAR, V17, P2663, DOI 10.1158/1055-9965.EPI-08-0406; Wigertz A, 2006, AM J EPIDEMIOL, V164, P629, DOI 10.1093/aje/kwj254; Wrensch M, 2002, NEURO-ONCOLOGY, V4, P278, DOI 10.1093/neuonc/4.4.278	56	44	45	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2013	8	12							e83261	10.1371/journal.pone.0083261	http://dx.doi.org/10.1371/journal.pone.0083261			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281RE	24386167	Green Published, gold, Green Submitted			2023-01-03	WOS:000329117900028
J	Dogovski, C; Gorman, MA; Ketaren, NE; Praszkier, J; Zammit, LM; Mertens, HD; Bryant, G; Yang, J; Griffin, MDW; Pearce, FG; Gerrard, JA; Jameson, GB; Parker, MW; Robins-Browne, RM; Perugini, MA				Dogovski, Con; Gorman, Michael A.; Ketaren, Natalia E.; Praszkier, Judy; Zammit, Leanne M.; Mertens, Haydyn D.; Bryant, Gary; Yang, Ji; Griffin, Michael D. W.; Pearce, F. Grant; Gerrard, Juliet A.; Jameson, Geoffrey B.; Parker, Michael W.; Robins-Browne, Roy M.; Perugini, Matthew A.			From Knock-Out Phenotype to Three-Dimensional Structure of a Promising Antibiotic Target from Streptococcus pneumoniae	PLOS ONE			English	Article							COLI DIHYDRODIPICOLINATE SYNTHASE; PNEUMOCOCCAL CONJUGATE VACCINE; PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM SPECTRA; SIZE-DISTRIBUTION ANALYSIS; HUMAN APOLIPOPROTEIN E3; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; CORYNEBACTERIUM-GLUTAMICUM; ALLOSTERIC INHIBITION	Given the rise in drug-resistant Streptococcus pneumoniae, there is an urgent need to discover new antimicrobials targeting this pathogen and an equally urgent need to characterize new drug targets. A promising antibiotic target is dihydrodipicolinate synthase (DHDPS), which catalyzes the rate-limiting step in lysine biosynthesis. In this study, we firstly show by gene knock out studies that S. pneumoniae (sp) lacking the DHDPS gene is unable to grow unless supplemented with lysine-rich media. We subsequently set out to characterize the structure, function and stability of the enzyme drug target. Our studies show that sp-DHDPS is folded and active with a k(cat) = 22 s(-1), K-M(PYR) = 2.55 +/- 0.05 mM and K-M(ASA) = 0.044 +/- 0.003 mM. Thermal denaturation experiments demonstrate sp-DHDPS exhibits an apparent melting temperature (T-M(app)) of 72 degrees C, which is significantly greater than Escherichia coli DHDPS (Ec-DHDPS) (T-M(app) = 59 degrees C). Sedimentation studies show that sp-DHDPS exists in a dimer-tetramer equilibrium with a K-D(4-2) = 1.7 nM, which is considerably tighter than its E. coli ortholog (K-D(4-2) = 76 nM). To further characterize the structure of the enzyme and probe its enhanced stability, we solved the high resolution (1.9 angstrom) crystal structure of sp-DHDPS (PDB ID 3VFL). The enzyme is tetrameric in the crystal state, consistent with biophysical measurements in solution. Although the sp-DHDPS and Ec-DHDPS active sites are almost identical, the tetramerization interface of the s. pneumoniae enzyme is significantly different in composition and has greater buried surface area (800 angstrom(2)) compared to its E. coli counterpart (500 angstrom(2)). This larger interface area is consistent with our solution studies demonstrating that sp-DHDPS is considerably more thermally and thermodynamically stable than Ec-DHDPS. Our study describe for the first time the knock-out phenotype, solution properties, stability and crystal structure of DHDPS from S. pneumoniae, a promising antimicrobial target.	[Dogovski, Con; Zammit, Leanne M.; Perugini, Matthew A.] La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem, Melbourne, Vic, Australia; [Dogovski, Con; Ketaren, Natalia E.; Griffin, Michael D. W.; Parker, Michael W.; Perugini, Matthew A.] Univ Melbourne, Dept Biochem & Mol Biol, Mol Sci & Biotechnol Inst Bio21, Melbourne, Vic 3010, Australia; [Gorman, Michael A.; Parker, Michael W.] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; [Praszkier, Judy; Yang, Ji; Robins-Browne, Roy M.] Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia; [Mertens, Haydyn D.] Australian Synchrotron, Clayton, Vic, Australia; [Bryant, Gary] RMIT Univ, Sch Appl Sci, Melbourne, Vic, Australia; [Pearce, F. Grant; Gerrard, Juliet A.] Univ Canterbury, Biomol Interact Ctr, Christchurch 1, New Zealand; [Pearce, F. Grant; Gerrard, Juliet A.] Univ Canterbury, Sch Biol Sci, Christchurch 1, New Zealand; [Gerrard, Juliet A.] Callaghan Innovat, Lower Hutt, New Zealand; [Jameson, Geoffrey B.] Massey Univ, Struct Biol Ctr, Inst Fundamental Sci, Palmerston North, New Zealand	La Trobe University; University of Melbourne; St. Vincent's Institute of Medical Research; University of Melbourne; Royal Melbourne Institute of Technology (RMIT); University of Canterbury; University of Canterbury; Callaghan Innovation; Massey University	Perugini, MA (corresponding author), La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem, Melbourne, Vic, Australia.	M.Perugini@latrobe.edu.au	Bryant, Gary/A-4186-2008; Parker, Michael W/F-9069-2013; Robinsbrowne, Roy/ABF-8434-2020	Bryant, Gary/0000-0001-5483-7592; Parker, Michael W/0000-0002-3101-1138; Robinsbrowne, Roy/0000-0001-9179-7884; Griffin, Michael/0000-0001-9845-7735; Pearce, Frederick/0000-0002-2683-0331; Mertens, Haydyn/0000-0002-5664-744X; Jameson, Geoffrey/0000-0003-4839-0784; Perugini, Matthew/0000-0001-8052-5584	Australian Research Council [FT0991245]; National Health & Medical Research Council (NHMRC) [628681I, APP1021645]	Australian Research Council(Australian Research Council); National Health & Medical Research Council (NHMRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)National Health and Medical Research Council (NHMRC) of Australia)	Funding provided by (1) Australian Research Council Future Fellowship FT0991245, (2) National Health & Medical Research Council (NHMRC) Project Grant 628681I (3) NHMRC Fellowship APP1021645. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; [Anonymous], [No title captured]; Atkinson SC, 2013, PLANT MOL BIOL, V81, P431, DOI 10.1007/s11103-013-0014-7; Atkinson SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038318; Blagova E, 2006, PROTEINS, V62, P297, DOI 10.1002/prot.20684; Blickling S, 1997, BIOCHEMISTRY-US, V36, P24, DOI 10.1021/bi962272d; Blickling S, 1997, J MOL BIOL, V274, P608, DOI 10.1006/jmbi.1997.1393; Burgess BR, 2008, J BIOL CHEM, V283, P27598, DOI 10.1074/jbc.M804231200; Cartwright K, 2002, EUR J PEDIATR, V161, P188, DOI 10.1007/s00431-001-0907-3; Chalker AF, 2001, J BACTERIOL, V183, P1259, DOI 10.1128/JB.183.4.1259-1268.2001; Davis AJ, 2004, J BIOL CHEM, V279, P12462, DOI 10.1074/jbc.M312365200; Devenish SRA, 2009, BBA-PROTEINS PROTEOM, V1794, P1168, DOI 10.1016/j.bbapap.2009.02.003; Dietrich C, 2009, MICROBIOL-SGM, V155, P1360, DOI 10.1099/mic.0.022004-0; Dobson RCJ, 2005, ACTA CRYSTALLOGR D, V61, P1116, DOI 10.1107/S0907444905016318; Dobson RCJ, 2004, J MOL BIOL, V338, P329, DOI 10.1016/j.jmb.2004.02.060; Dogovski C, 2012, BIOCHEMISTRY-US, P225, DOI DOI 10.85772/34121; Dogovski C., 2009, ENCY LIFE SUPPORT SY, V11, P116; Domigan LJ, 2009, BBA-PROTEINS PROTEOM, V1794, P1510, DOI 10.1016/j.bbapap.2009.06.020; DOWD SR, 1995, BBA-PROTEIN STRUCT M, V1252, P278, DOI 10.1016/0167-4838(95)00121-A; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; GARVIE EI, 1980, MICROBIOL REV, V44, P106, DOI 10.1128/MMBR.44.1.106-139.1980; Gerrard JA, 2007, MINI-REV MED CHEM, V7, P151, DOI 10.2174/138955707779802561; Girish TS, 2008, FEBS LETT, V582, P2923, DOI 10.1016/j.febslet.2008.07.035; Griffin MDW, 2008, J MOL BIOL, V380, P691, DOI 10.1016/j.jmb.2008.05.038; Griffin MDW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040318; Griffin MDW, 2010, ARCH BIOCHEM BIOPHYS, V494, P58, DOI 10.1016/j.abb.2009.11.014; Hayes DB, 2003, SEDIMENTATION INTERP; Hutton CA, 2007, MOL BIOSYST, V3, P458, DOI 10.1039/b705624a; Hutton CA, 2003, MINI-REV MED CHEM, V3, P115, DOI 10.2174/1389557033405359; Janssens JP, 2004, LANCET INFECT DIS, V4, P112, DOI 10.1016/S1473-3099(04)00931-4; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Kang BS, 2010, INT J BIOL MACROMOL, V46, P512, DOI 10.1016/j.ijbiomac.2010.03.005; Karsten WE, 1997, BIOCHEMISTRY-US, V36, P1730, DOI 10.1021/bi962264x; Kaur N, 2011, INT J BIOL MACROMOL, V48, P779, DOI 10.1016/j.ijbiomac.2011.03.002; Kefala G, 2008, BIOCHEM J, V411, P351, DOI 10.1042/BJ20071360; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Kyaw MH, 2006, NEW ENGL J MED, V354, P1455, DOI 10.1056/NEJMoa051642; LABER B, 1992, BIOCHEM J, V288, P691, DOI 10.1042/bj2880691; Laue TN, 1992, ANAL ULTRACENTRIFUGA, V224, P90; MACRINA FL, 1982, GENE, V19, P345, DOI 10.1016/0378-1119(82)90025-7; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McLennan N, 1998, NATURE, V392, P139, DOI 10.1038/32317; McPhillips TM, 2002, J SYNCHROTRON RADIAT, V9, P401, DOI 10.1107/S0909049502015170; MIRWALDT C, 1995, J MOL BIOL, V246, P227, DOI 10.1006/jmbi.1994.0078; Moscoso M, 2006, J BACTERIOL, V188, P7785, DOI 10.1128/JB.00673-06; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nordberg P, 2005, ANTIBACTERIAL RESIST; Novak R, 1999, NATURE, V399, P590, DOI 10.1038/21202; Nunes S, 2005, J CLIN MICROBIOL, V43, P1285, DOI 10.1128/JCM.43.3.1285-1293.2005; Ostendorp R, 1996, PROTEIN SCI, V5, P862; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Padmanabhan B, 2009, ACTA CRYSTALLOGR F, V65, P1222, DOI 10.1107/S174430910904651X; Pearce FG, 2006, BIOCHEM J, V400, P359, DOI 10.1042/BJ20060771; Perugini MA, 2000, J BIOL CHEM, V275, P36758, DOI 10.1074/jbc.M005565200; Perugini MA, 2005, EUR BIOPHYS J BIOPHY, V34, P469, DOI 10.1007/s00249-005-0491-y; Perugini MA, 2002, EUR J BIOCHEM, V269, P5939, DOI 10.1046/j.1432-1033.2002.03319.x; Pozzi G, 1996, J BACTERIOL, V178, P6087, DOI 10.1128/jb.178.20.6087-6090.1996; Reboul CF, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002537; Rice EA, 2008, ARCH BIOCHEM BIOPHYS, V480, P111, DOI 10.1016/j.abb.2008.09.018; Roberts SJ, 2003, BIOORG MED CHEM LETT, V13, P265, DOI 10.1016/S0960-894X(02)00923-X; Sambrook J., 1989, MOL CLONING LAB MANU; Schnell R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031133; Schrag SJ, 2004, ANTIMICROB AGENTS CH, V48, P3016, DOI 10.1128/AAC.48.8.3016-3023.2004; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Sibarani NE, 2010, ACTA CRYSTALLOGR F, V66, P32, DOI 10.1107/S174430910904771X; Sorum H, 2002, INT J FOOD MICROBIOL, V78, P43, DOI 10.1016/S0168-1605(02)00241-6; Sreerama N, 2000, ANAL BIOCHEM, V287, P243, DOI 10.1006/abio.2000.4879; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Stephens DS, 2005, LANCET, V365, P855, DOI 10.1016/S0140-6736(05)71043-6; Sun ZT, 2012, MICROBIOL-SGM, V158, P1350, DOI 10.1099/mic.0.055590-0; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980; Vistica J, 2004, ANAL BIOCHEM, V326, P234, DOI 10.1016/j.ab.2003.12.014; Voss JE, 2010, J BIOL CHEM, V285, P5188, DOI 10.1074/jbc.M109.038166; Wegener HC, 2003, CURR OPIN MICROBIOL, V6, P439, DOI 10.1016/j.mib.2003.09.009; Wei BPC, 2006, OTOL NEUROTOL, V27, P844, DOI 10.1097/01.mao.0000231603.25961.f1; Wells JA, 2007, NATURE, V450, P1001, DOI 10.1038/nature06526; Whitney CG, 2000, NEW ENGL J MED, V343, P1917, DOI 10.1056/NEJM200012283432603; YUGARI YASUMI, 1965, J BIOL CHEM, V240, P4710	81	18	18	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2013	8	12							e83419	10.1371/journal.pone.0083419	http://dx.doi.org/10.1371/journal.pone.0083419			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276FP	24349508	gold, Green Published			2023-01-03	WOS:000328734200087
J	Ponce, D; Abrao, JMG; Albino, BB; Balbi, AL				Ponce, Daniela; Gera Abrao, Juliana Maria; Albino, Bianca Ballarin; Balbi, Andre Luis			Extended Daily Dialysis in Acute Kidney Injury Patients: Metabolic and Fluid Control and Risk Factors for Death	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; RENAL REPLACEMENT THERAPY; LOW-EFFICIENCY DIALYSIS; INTERMITTENT HEMODIALYSIS; FAILURE; TRIAL; MANAGEMENT	Intermittent hemodialysis (IHD) and continuous renal replacement therapies (CRRT) are used as Acute Kidney Injury (AKI) therapy and have certain advantages and disadvantages. Extended daily dialysis (EDD) has emerged as an alternative to CRRT in the management of hemodynamically unstable AKI patients, mainly in developed countries. Objectives: We hypothesized that EDD is a safe option for AKI treatment and aimed to describe metabolic and fluid control of AKI patients undergoing EDD and identify complications and risk factors associated with death. Study Selection: This is an observational and retrospective study describing introduction of EDD at our institution. A total of 231 hemodynamically unstable AKI patients (noradrenalin dose between 0.3 and 1.0 ucg/kg/min) were assigned to 1367 EDD session. EDD consisted of 6-8 h of HD 6 days a week, with blood flow of 200 ml/min, dialysate flows of 300 ml/min. Data Synthesis: Mean age was 60.6 +/- 15.8 years, 97.4% of patients were in the intensive care unit, and sepsis was the main etiology of AKI (76.2). BUN and creatinine levels stabilized after four sessions at around 38 and 2.4 mg/dl, respectively. Fluid balance decreased progressively and stabilized around zero after five sessions. Weekly delivered Kt/V was 5.94 +/- 0.7. Hypotension and filter clotting occurred in 47.5 and 12.4% of treatment session, respectively. Regarding AKI outcome, 22.5% of patients presented renal function recovery, 5.6% of patients remained on dialysis after 30 days, and 71.9% of patients died. Age and focus abdominal sepsis were identified as risk factors for death. Urine output and negative fluid balance were identified as protective factors. Conclusions: EDD is effective for AKI patients, allowing adequate metabolic and fluid control. Age, focus abdominal sepsis, and lower urine output as well as positive fluid balance after two EDD sessions were associated significantly with death.	[Ponce, Daniela; Gera Abrao, Juliana Maria; Albino, Bianca Ballarin; Balbi, Andre Luis] Univ Sao Paulo State UNESP, Sao Paulo, Brazil	Universidade Estadual Paulista	Ponce, D (corresponding author), Univ Sao Paulo State UNESP, Sao Paulo, Brazil.	dponce@fmb.unesp.br	Ponce, Daniela/Q-4221-2019; Ponce, Daniela/M-8271-2015; Balbi, Andre/AAD-9859-2019; Balbi, André Luis/O-9278-2016	Ponce, Daniela/0000-0002-6178-6938; Ponce, Daniela/0000-0002-6178-6938; Balbi, Andre/0000-0001-8366-5064; Balbi, André Luis/0000-0001-8366-5064				Augustine JJ, 2004, AM J KIDNEY DIS, V44, P1000, DOI 10.1053/j.ajkd.2004.08.022; Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413; Berbece AN, 2006, KIDNEY INT, V70, P963, DOI 10.1038/sj.ki.5001700; CHUMLEA WC, 1985, J AM GERIATR SOC, V33, P116, DOI 10.1111/j.1532-5415.1985.tb02276.x; Costa e Silva VT, 2013, PLOS ONE; Daugirdas JT, 2007, HDB DIALYSIS, P23; Demirjian SG, 2011, CONTRIB NEPHROL, V174, P242, DOI 10.1159/000329402; DuBois D, 1915, ARCH INTERN MED, V15, P868; Eloot S, 2008, KIDNEY INT, V73, P765, DOI 10.1038/sj.ki.5002750; Faulhaber-Walter R, 2009, NEPHROL DIAL TRANSPL, V24, P2179, DOI 10.1093/ndt/gfp035; Fieghen HE, 2010, BMC NEPHROL, V11, DOI 10.1186/1471-2369-11-32; Fliser D, 2006, NAT CLIN PRACT NEPHR, V2, P32, DOI 10.1038/ncpneph0060; George J, 2011, PERITON DIALYSIS INT, V31, P422, DOI 10.3747/pdi.2009.00231; Himmelfarb J, 2007, KIDNEY INT, V71, P971, DOI 10.1038/sj.ki.5002224; Himmelfarb J, 2007, NAT CLIN PRACT NEPHR, V3, P120, DOI 10.1038/ncpneph0422; Kielstein JT, 2010, J NEPHROL, V23, P494; Kumar VA, 2000, AM J KIDNEY DIS, V36, P294, DOI 10.1053/ajkd.2000.8973; Levy MM, 2005, CRIT CARE MED, V33, P2194, DOI 10.1097/01.CCM.0000182798.39709.84; Lewis Charmaine A, 2004, Curr Opin Crit Care, V10, P13, DOI 10.1097/00075198-200402000-00003; LIANO F, 1993, NEPHRON, V63, P21, DOI 10.1159/000187139; Lima EQ, 2005, RENAL FAILURE, V27, P547, DOI 10.1080/08860220500198771; Marshall MR, 2004, NEPHROL DIAL TRANSPL, V19, P877, DOI 10.1093/ndt/gfg625; Marshall MR, 2002, AM J KIDNEY DIS, V39, P556, DOI 10.1053/ajkd.2002.31406; Marshall MR, 2001, KIDNEY INT, V60, P777, DOI 10.1046/j.1523-1755.2001.060002777.x; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Mehta RL, 2001, KIDNEY INT, V60, P1154, DOI 10.1046/j.1523-1755.2001.0600031154.x; Palevsky PM, 2008, NEW ENGL J MED, V10, P359; Pannu N, 2008, JAMA-J AM MED ASSOC, V299, P793, DOI 10.1001/jama.299.7.793; Payen D, 2008, CRIT CARE, V12, DOI 10.1186/cc6916; Ponce D, 2012, INT J UROL NEPHROL, P1; Ponce D, 2012, CLIN J AM SOC NEPHRO, V7, P887, DOI 10.2215/CJN.11131111; Ponce Daniela, 2011, Adv Perit Dial, V27, P118; Prowle JR, 2010, NAT REV NEPHROL, V6, P107, DOI 10.1038/nrneph.2009.213; Ricci Z, 2006, NEPHROL DIAL TRANSPL, V21, P690, DOI 10.1093/ndt/gfi296; Schiffl H, 2002, NEW ENGL J MED, V346, P305, DOI 10.1056/NEJMoa010877; Schiffl H, 2013, INT UROL NEPHROL, V45, P191, DOI 10.1007/s11255-011-0112-x; Schmidt JJ, 2012, BLOOD PURIFICAT, V34, P246, DOI 10.1159/000342631; Schortgen F, 2000, AM J RESP CRIT CARE, V162, P197, DOI 10.1164/ajrccm.162.1.9907098; Schrier RW, 2004, NEW ENGL J MED, V351, P159, DOI 10.1056/NEJMra032401; Schwenger V, 2012, CRIT CARE, V16, DOI 10.1186/cc11445; Silva TNV, 2013, INT UROL NEPHROL, V45, P1405, DOI 10.1007/s11255-012-0339-1; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; Uehlinger DE, 2005, NEPHROL DIAL TRANSPL, V20, P1630, DOI 10.1093/ndt/gfh880; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Vinsonneau C, 2006, LANCET, V368, P379, DOI 10.1016/S0140-6736(06)69111-3	45	9	11	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2013	8	12							e81697	10.1371/journal.pone.0081697	http://dx.doi.org/10.1371/journal.pone.0081697			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276EG	24349114	Green Published, gold, Green Submitted			2023-01-03	WOS:000328730300046
J	Megson, IL; Haw, SJ; Newby, DE; Pell, JP				Megson, Ian L.; Haw, Sally J.; Newby, David E.; Pell, Jill P.			Association between Exposure to Environmental Tobacco Smoke and Biomarkers of Oxidative Stress Among Patients Hospitalised with Acute Myocardial Infarction	PLOS ONE			English	Article							ACUTE CORONARY SYNDROMES; LOW-DENSITY-LIPOPROTEIN; PASSIVE SMOKING; SECONDHAND SMOKE; CIGARETTE-SMOKE; CARDIOVASCULAR-DISEASE; HEART-DISEASE; DNA-DAMAGE; RATS; NONSMOKERS	Objective: To determine whether exposure to environmental tobacco smoke was associated with oxidative stress among patients hospitalised for acute myocardial infarction. Design: An existing cohort study of 1,261 patients hospitalised for acute myocardial infarction. Setting: Nine acute hospitals in Scotland. Participants: Sixty never smokers who had been exposed to environmental tobacco smoke (admission serum cotinine >= 3.0 ng/mL) were compared with 60 never smokers who had not (admission serum cotinine <= 0.1 ng/mL). Intervention: None. Main outcome measures:Three biomarkers of oxidative stress (protein carbonyl, malondialdehyde (MDA) and oxidised low-density lipoprotein (ox-LDL)) were measured on admission blood samples and adjusted for potential confounders. Results: After adjusting for baseline differences in age, sex and socioeconomic status, exposure to environmental tobacco smoke was associated with serum concentrations of both protein carbonyl (beta coefficient 7.96, 95% Cl 0.76, 15.17, p=0.031) and MDA (beta coefficient 10.57, 95% Cl 4.32, 16.81, p=0.001) but not ox-LDL (beta coefficient 2.14, 95% Cl -8.94, 13.21, p = 0.703). Conclusions: Exposure to environmental tobacco smoke was associated with increased oxidative stress. Further studies are requires to explore the role of oxidative stress in the association between environmental tobacco smoke and myocardial infarction.	[Megson, Ian L.] Univ Highlands & Isl, Dept Diabet & Cardiovasc Sci, Free Rad Res Facil, Inverness, Scotland; [Haw, Sally J.] Univ Stirling, Sch Nursing Midwifery & Hlth, Stirling FK9 4LA, Scotland; [Newby, David E.] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh EH8 9YL, Midlothian, Scotland; [Pell, Jill P.] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland	UHI Millennium Institute; University of Stirling; University of Edinburgh; University of Glasgow	Pell, JP (corresponding author), Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland.	jill.pell@glasgow.ac.uk	Stefanadis, Christodoulos/ABH-2232-2020; Newby, David Ernest/AAB-1364-2019; Megson, Ian/K-2195-2012	Stefanadis, Christodoulos/0000-0001-5974-6454; Megson, Ian/0000-0001-8287-2459; Pell, Jill/0000-0002-8898-7035	NHS Health Scotland	NHS Health Scotland	Funded by an NHS Health Scotland project grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Arifi MN, 2012, J TOXICOL SCI, V37, P1083, DOI 10.2131/jts.37.1083; Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047; Aycicek A, 2005, EUR J PEDIATR, V164, P775, DOI 10.1007/s00431-005-1720-1; Aycicek A, 2008, EUR J PEDIATR, V167, P81, DOI 10.1007/s00431-007-0433-z; Celermajer DS, 1996, NEW ENGL J MED, V334, P150, DOI 10.1056/NEJM199601183340303; Chih-Ching Y, 2008, ENVIRON RES, V106, P219; Clark ML, 2013, NUTRITION, V29, P1304, DOI 10.1016/j.nut.2013.04.003; Ehara S, 2001, CIRCULATION, V103, P1955, DOI 10.1161/01.cir.103.15.1955; Gentner NJ, 2012, AM J PHYSIOL-HEART C, V302, pH818, DOI 10.1152/ajpheart.00852.2011; He J, 1999, NEW ENGL J MED, V340, P920, DOI 10.1056/NEJM199903253401204; Holvoet P, 1998, CIRCULATION, V98, P1487, DOI 10.1161/01.CIR.98.15.1487; Howard DJ, 1998, CANCER EPIDEM BIOMAR, V7, P141; Jaimes EA, 2004, ARTERIOSCL THROM VAS, V24, P1031, DOI 10.1161/01.ATV.0000127083.88549.58; Kapaki E, 2007, IN VIVO, V21, P523; Kato T, 2006, CAN J PHYSIOL PHARM, V84, P523, DOI 10.1139/Y06-030; Kim Kyoungwoo, 2009, Environmental Health and Preventive Medicine, V14, P60, DOI 10.1007/s12199-008-0060-y; Kosecik M, 2005, INT J CARDIOL, V100, P61, DOI 10.1016/j.ijcard.2004.05.069; Kostikas K, 2013, RESP MED, V107, P172, DOI 10.1016/j.rmed.2012.10.017; Lee R, 2012, CURR MED CHEM, V19, P2504, DOI 10.2174/092986712800493057; Panagiotakos DB, 2007, HEART, V93, P309, DOI 10.1136/hrt.2006.107367; Pell JP, 2009, HEART, V95, P1415, DOI 10.1136/hrt.2009.171702; Pell JP, 2008, NEW ENGL J MED, V359, P482, DOI 10.1056/NEJMsa0706740; Raji L, 2001, J HYPERTENS, V19, P891; Raupach T, 2006, EUR HEART J, V27, P386, DOI 10.1093/eurheartj/ehi601; SANDERSON KJ, 1995, ATHEROSCLEROSIS, V118, P45, DOI 10.1016/0021-9150(95)05591-J; Shermatov K, 2012, INDIAN PEDIATR, V49, P958, DOI 10.1007/s13312-012-0250-y; Tajika K, 2012, CIRC J, V76, P2211, DOI 10.1253/circj.CJ-12-0183; Torok J, 2000, PHYSIOL RES, V49, P135; Valenti VE, 2012, BMC CARDIOVASC DISOR, V12, DOI 10.1186/1471-2261-12-22; Zalata A, 2007, MUTAT RES-GEN TOX EN, V629, P140, DOI 10.1016/j.mrgentox.2007.02.001; ZHU BQ, 1994, CIRCULATION, V89, P1282, DOI 10.1161/01.CIR.89.3.1282	31	11	11	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2013	8	12							e81209	10.1371/journal.pone.0081209	http://dx.doi.org/10.1371/journal.pone.0081209			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273WD	24339911	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000328566100043
J	Lafontaine, MP; Theoret, H; Gosselin, F; Lippe, S				Lafontaine, Marc Philippe; Theoret, Hugo; Gosselin, Frederic; Lippe, Sarah			Transcranial Direct Current Stimulation of the Dorsolateral Prefrontal Cortex Modulates Repetition Suppression to Unfamiliar Faces: An ERP Study	PLOS ONE			English	Article							NONINVASIVE BRAIN-STIMULATION; HUMAN MOTOR CORTEX; WORKING-MEMORY; INTEGRATIVE THEORY; NEURAL MECHANISMS; DECISION-MAKING; INVERTED FACES; VISUAL-CORTEX; N170; HUMANS	Repeated visual processing of an unfamiliar face suppresses neural activity in face-specific areas of the occipito-temporal cortex. This "repetition suppression" (RS) is a primitive mechanism involved in learning of unfamiliar faces, which can be detected through amplitude reduction of the N170 event-related potential (ERP). The dorsolateral prefrontal cortex (DLPFC) exerts top-down influence on early visual processing. However, its contribution to N170 RS and learning of unfamiliar faces remains unclear. Transcranial direct current stimulation (tDCS) transiently increases or decreases cortical excitability, as a function of polarity. We hypothesized that DLPFC excitability modulation by tDCS would cause polarity-dependent modulations of N170 RS during encoding of unfamiliar faces. tDCS-induced N170 RS enhancement would improve long-term recognition reaction time (RT) and/or accuracy rates, whereas N170 RS impairment would compromise recognition ability. Participants underwent three tDCS conditions in random order at,72 hour intervals: right anodal/left cathodal, right cathodal/left anodal and sham. Immediately following tDCS conditions, an EEG was recorded during encoding of unfamiliar faces for assessment of P100 and N170 visual ERPs. The P3a component was analyzed to detect prefrontal function modulation. Recognition tasks were administered similar to 72 hours following encoding. Results indicate the right anodal/left cathodal condition facilitated N170 RS and induced larger P3a amplitudes, leading to faster recognition RT. Conversely, the right cathodal/left anodal condition caused N170 amplitude and RTs to increase, and a delay in P3a latency. These data demonstrate that DLPFC excitability modulation can influence early visual encoding of unfamiliar faces, highlighting the importance of DLPFC in basic learning mechanisms.	[Lafontaine, Marc Philippe; Theoret, Hugo; Gosselin, Frederic; Lippe, Sarah] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Lafontaine, Marc Philippe; Theoret, Hugo; Lippe, Sarah] St Justine Univ Hosp, Res Ctr, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal	Lafontaine, MP (corresponding author), Univ Montreal, Dept Psychol, CP 6128, Montreal, PQ H3C 3J7, Canada.	marc.philippe.lafontaine@umontreal.ca		Theoret, Hugo/0000-0002-7458-8797	Natural Sciences and Engineering Research Council of Canada (NSERC); Sainte-Justine UHC Foundation; Foundation of Stars scholarship	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Sainte-Justine UHC Foundation; Foundation of Stars scholarship	This work was supported by Natural Sciences and Engineering Research Council of Canada (NSERC) grant to SL; MPL is supported by a Sainte-Justine UHC Foundation and Foundation of Stars scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antal A, 2004, NEUROREPORT, V15, P1307, DOI 10.1097/01.wnr.0000127460.08361.84; Backhaus J, 2006, BIOL PSYCHIAT, V60, P1324, DOI 10.1016/j.biopsych.2006.03.051; Barcelo F, 2000, NAT NEUROSCI, V3, P399, DOI 10.1038/73975; Bentin S, 1996, J COGNITIVE NEUROSCI, V8, P551, DOI 10.1162/jocn.1996.8.6.551; Boggio PS, 2010, EUR J NEUROSCI, V31, P593, DOI 10.1111/j.1460-9568.2010.07080.x; Brunoni AR, 2011, INT J NEUROPSYCHOPH, V14, P1133, DOI 10.1017/S1461145710001690; Buchel C, 1999, SCIENCE, V283, P1538, DOI 10.1126/science.283.5407.1538; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Caharel S, 2011, BRAIN RES, V1387, P85, DOI 10.1016/j.brainres.2011.02.070; Caharel S, 2009, NEUROPSYCHOLOGIA, V47, P639, DOI 10.1016/j.neuropsychologia.2008.11.016; Campanella S, 2000, PSYCHOPHYSIOLOGY, V37, P796, DOI 10.1017/S0048577200991728; Chadick JZ, 2011, NAT NEUROSCI, V14, P830, DOI 10.1038/nn.2823; Daffner KR, 2000, BRAIN, V123, P927, DOI 10.1093/brain/123.5.927; Dale AM, 2000, NEURON, V26, P55, DOI 10.1016/S0896-6273(00)81138-1; Dering B, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00093; Desimone R, 1996, P NATL ACAD SCI USA, V93, P13494, DOI 10.1073/pnas.93.24.13494; Diekelmann S, 2010, NAT REV NEUROSCI, V11, P114, DOI 10.1038/nrn2762; Dockery CA, 2009, J NEUROSCI, V29, P7271, DOI 10.1523/JNEUROSCI.0065-09.2009; Elmer S, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-29; FABIANI M, 1990, ELECTROEN CLIN NEURO, V75, P22, DOI 10.1016/0013-4694(90)90149-E; FABIANI M, 1986, PSYCHOPHYSIOLOGY, V23, P298, DOI 10.1111/j.1469-8986.1986.tb00636.x; Faria P, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/6/066017; Fecteau S, 2007, J NEUROSCI, V27, P12500, DOI 10.1523/JNEUROSCI.3283-07.2007; Fecteau S, 2007, J NEUROSCI, V27, P6212, DOI 10.1523/JNEUROSCI.0314-07.2007; Fleuaris AV, 2008, BRAIN RES, V1194, P100, DOI 10.1016/j.brainres.2007.11.071; Floel A, 2008, J COGNITIVE NEUROSCI, V20, P1415, DOI 10.1162/jocn.2008.20098; Friedman D, 2001, NEUROSCI BIOBEHAV R, V25, P355, DOI 10.1016/S0149-7634(01)00019-7; Friedman D, 2011, NEUROPSYCHOLOGIA, V49, P3474, DOI 10.1016/j.neuropsychologia.2011.08.023; Friston KJ, 2005, PHILOS T R SOC B, V360, P815, DOI 10.1098/rstb.2005.1622; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Gonsalves BD, 2005, NEURON, V47, P751, DOI 10.1016/j.neuron.2005.07.013; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Grill-Spector K, 2006, TRENDS COGN SCI, V10, P14, DOI 10.1016/j.tics.2005.11.006; Habib R, 2003, TRENDS COGN SCI, V7, P241, DOI 10.1016/S1364-6613(03)00110-4; Heisz JJ, 2006, VISION RES, V46, P4604, DOI 10.1016/j.visres.2006.09.026; Heisz JJ, 2009, J COGNITIVE NEUROSCI, V21, P1127, DOI 10.1162/jocn.2009.21104; Heisz JJ, 2006, VISION RES, V46, P47, DOI 10.1016/j.visres.2005.09.028; Henson RNA, 2003, PROG NEUROBIOL, V70, P53, DOI 10.1016/S0301-0082(03)00086-8; Hillyard SA, 1998, P NATL ACAD SCI USA, V95, P781, DOI 10.1073/pnas.95.3.781; Hofer A, 2007, BRAIN COGNITION, V63, P174, DOI 10.1016/j.bandc.2006.11.005; Hsu TY, 2011, NEUROIMAGE, V56, P2249, DOI 10.1016/j.neuroimage.2011.03.059; Ishai A, 2008, NEUROIMAGE, V40, P415, DOI 10.1016/j.neuroimage.2007.10.040; Itier RJ, 2004, NEUROIMAGE, V21, P1518, DOI 10.1016/j.neuroimage.2003.12.016; Itier RJ, 2002, NEUROIMAGE, V15, P353, DOI 10.1006/nimg.2001.0982; Kadosh RC, 2010, CURR BIOL, V20, P2016, DOI 10.1016/j.cub.2010.10.007; Kanwisher N, 2006, PHILOS T R SOC B, V361, P2109, DOI 10.1098/rstb.2006.1934; Kim KH, 2008, NEUROSCI LETT, V445, P179, DOI 10.1016/j.neulet.2008.09.004; Kovacs G, 2006, CEREB CORTEX, V16, P742, DOI 10.1093/cercor/bhj020; Kovacs G, 2013, J NEUROSCI, V33, P9805, DOI 10.1523/JNEUROSCI.3423-12.2013; Kovacs G, 2012, NEUROIMAGE, V60, P2128, DOI 10.1016/j.neuroimage.2012.02.038; Kuo BC, 2011, NEUROPSYCHOLOGIA, V49, P1589, DOI 10.1016/j.neuropsychologia.2010.12.043; Luo WB, 2010, NEUROIMAGE, V49, P1857, DOI 10.1016/j.neuroimage.2009.09.018; Massicotte-Marquez J, 2008, NEUROLOGY, V70, P1250, DOI 10.1212/01.wnl.0000286943.79593.a6; Maurer D, 2002, TRENDS COGN SCI, V6, P255, DOI 10.1016/S1364-6613(02)01903-4; Mercure E, 2011, FRONT HUM NEUROSCI, V5, DOI [10.3389/fnhum.2011.00006, 10.3389/fnhum.2011.00062]; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Morgan HM, 2008, J COGNITIVE NEUROSCI, V20, P989, DOI 10.1162/jocn.2008.20072; Mulquiney PG, 2011, CLIN NEUROPHYSIOL, V122, P2384, DOI 10.1016/j.clinph.2011.05.009; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2005, J PHYSIOL-LONDON, V568, P291, DOI 10.1113/jphysiol.2005.092429; Pihlajamaki M, 2011, BRAIN IMAGING BEHAV, V5, P36, DOI 10.1007/s11682-010-9110-3; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Pourtois G, 2005, HUM BRAIN MAPP, V26, P65, DOI 10.1002/hbm.20130; Ranganath C, 2003, NAT REV NEUROSCI, V4, P193, DOI 10.1038/nrn1052; Rossion B, 1999, BIOL PSYCHOL, V50, P173, DOI 10.1016/S0301-0511(99)00013-7; Rossion B, 2000, NEUROREPORT, V11, P69, DOI 10.1097/00001756-200001170-00014; Rossion B, 2003, NEUROIMAGE, V20, P1609, DOI 10.1016/j.neuroimage.2003.07.010; Rossion B, 2008, NEUROIMAGE, V39, P1959, DOI 10.1016/j.neuroimage.2007.10.011; Rotshtein P, 2005, NAT NEUROSCI, V8, P107, DOI 10.1038/nn1370; Sadeh B, 2010, NEUROIMAGE, V53, P782, DOI 10.1016/j.neuroimage.2010.06.029; Sayres R, 2006, J NEUROPHYSIOL, V95, P995, DOI 10.1152/jn.00500.2005; Schacter DL, 1998, NEURON, V20, P185, DOI 10.1016/S0896-6273(00)80448-1; Schiltz C, 2006, CEREB CORTEX, V16, P574, DOI 10.1093/cercor/bhj005; Sergerie K, 2005, NEUROIMAGE, V24, P580, DOI 10.1016/j.neuroimage.2004.08.051; Sparing R, 2008, METHODS, V44, P329, DOI 10.1016/j.ymeth.2007.02.001; Summerfield C, 2008, NAT NEUROSCI, V11, P1004, DOI 10.1038/nn.2163; Taschereau-Dumouchel V, 2010, FRONT PSYCHOL, V1, DOI 10.3389/fpsyg.2010.00159; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; TULVING E, 1990, SCIENCE, V247, P301, DOI 10.1126/science.2296719; Vizioli L, 2010, P NATL ACAD SCI USA, V107, P20081, DOI 10.1073/pnas.1005751107; Wassermann EM, 2005, TRENDS COGN SCI, V9, P503, DOI 10.1016/j.tics.2005.09.001; Wiggs CL, 1998, CURR OPIN NEUROBIOL, V8, P227, DOI 10.1016/S0959-4388(98)80144-X; Willenbockel V, 2010, BEHAV RES METHODS, V42, P671, DOI 10.3758/BRM.42.3.671; Williams MA, 2007, CURR BIOL, V17, P1259, DOI 10.1016/j.cub.2007.06.042; WOODS DL, 1986, NEUROLOGY, V36, P212, DOI 10.1212/WNL.36.2.212; Zago L, 2005, CEREB CORTEX, V15, P1655, DOI 10.1093/cercor/bhi060; Zanto TP, 2011, NAT NEUROSCI, V14, P656, DOI 10.1038/nn.2773	88	22	24	1	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2013	8	12							e81721	10.1371/journal.pone.0081721	http://dx.doi.org/10.1371/journal.pone.0081721			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	265KD	24324721	Green Published, gold, Green Submitted			2023-01-03	WOS:000327949300107
J	Richards, T				Richards, Tessa			Journey of a patient editor	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												trichards@bmj.com						Treasure T, 2007, BMJ-BRIT MED J, V334, P831, DOI 10.1136/bmj.39161.403218.AD	1	3	3	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	2013	347								f6913	10.1136/bmj.f6913	http://dx.doi.org/10.1136/bmj.f6913			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258KF	24259330	Bronze			2023-01-03	WOS:000327457400011
J	Bonomo, LDF; Silva, DN; Boasquivis, PF; Paiva, FA; Guerra, JFD; Martins, TAF; Torres, AGD; de Paula, ITBR; Caneschi, WL; Jacolot, P; Grossin, N; Tessier, FJ; Boulanger, E; Silva, ME; Pedrosa, ML; Oliveira, RD				Bonomo, Larissa de Freitas; Silva, David Nunes; Boasquivis, Patricia Ferreira; Paiva, Franciny Aparecida; da Costa Guerra, Joyce Ferreira; Faria Martins, Talita Alves; de Jesus Torres, Alvaro Gustavo; Borges Raposo de Paula, Igor Thadeu; Caneschi, Washington Luiz; Jacolot, Philippe; Grossin, Nicolas; Tessier, Frederic J.; Boulanger, Eric; Silva, Marcelo Eustaquio; Pedrosa, Maria Lucia; Oliveira, Riva de Paula			Acai (Euterpe oleracea Mart.) Modulates Oxidative Stress Resistance in Caenorhabditis elegans by Direct and Indirect Mechanisms	PLOS ONE			English	Article							AMAZONIAN PALM BERRY; LIFE-SPAN EXTENSION; ANTIOXIDANT PROPERTIES; FACTOR SKN-1; RICH FRUIT; IN-VITRO; PULP; FLAVONOIDS; ACRYLAMIDE; EXTRACT	Acai (Euterpe oleracea Mart.) has recently emerged as a promising source of natural antioxidants. Despite its claimed pharmacological and nutraceutical value, studies regarding the effects of acai in vivo are limited. In this study, we use the Caenorhabditis elegans model to evaluate the in vivo antioxidant properties of acai on an organismal level and to examine its mechanism of action. Supplementation with acai aqueous extract (AAE) increased both oxidative and osmotic stress resistance independently of any effect on reproduction and development. AAE suppressed bacterial growth, but this antimicrobial property did not influence stress resistance. AAE-increased stress resistance was correlated with reduced ROS production, the prevention of sulfhydryl (SH) level reduction and gcs-1 activation under oxidative stress conditions. Our mechanistic studies indicated that AAE promotes oxidative stress resistance by acting through DAF-16 and the osmotic stress response pathway OSR-1/UNC-43/SEK-1. Finally, AAE increased polyglutamine protein aggregation and decreased proteasome activity. Our findings suggest that natural compounds available in AAE can improve the antioxidant status of a whole organism under certain conditions by direct and indirect mechanisms.	[Bonomo, Larissa de Freitas; Silva, David Nunes; Boasquivis, Patricia Ferreira; Paiva, Franciny Aparecida; da Costa Guerra, Joyce Ferreira; Borges Raposo de Paula, Igor Thadeu; Caneschi, Washington Luiz; Silva, Marcelo Eustaquio; Pedrosa, Maria Lucia; Oliveira, Riva de Paula] Univ Fed Ouro Preto, Nucl Pesquisa Ciencias Biol, Ouro Preto, Brazil; [Pedrosa, Maria Lucia] Univ Fed Ouro Preto, Dept Ciencias Biol, Ouro Preto, Brazil; [Faria Martins, Talita Alves; de Jesus Torres, Alvaro Gustavo; Oliveira, Riva de Paula] Univ Fed Ouro Preto, Dept Biodiversidade Evolucao & Meio Ambiente, Ouro Preto, Brazil; [Jacolot, Philippe; Tessier, Frederic J.] Inst Polytech LaSalle Beauvais, Beauvais, France; [Grossin, Nicolas; Boulanger, Eric] Univ Lille 2, Fac Med Pole Rech, Lille, France; [Silva, Marcelo Eustaquio] Univ Fed Ouro Preto, Dept Alimentos, Ouro Preto, Brazil	Universidade Federal de Ouro Preto; Universidade Federal de Ouro Preto; Universidade Federal de Ouro Preto; UniLaSalle; Universite de Lille - ISITE; Universite de Lille; Universidade Federal de Ouro Preto	Oliveira, RD (corresponding author), Univ Fed Ouro Preto, Nucl Pesquisa Ciencias Biol, Ouro Preto, Brazil.	rivaoliveira@nupeb.ufop.br	Tessier, Frederic J/G-3729-2018	Tessier, Frederic J/0000-0001-8096-5715; Paiva, Franciny Aparecida/0000-0002-2052-1079; de Paula Oliveira, Riva/0000-0002-6092-6142; BOULANGER, Eric/0000-0002-5204-2849; Ferreira Boasquivis, Patricia/0000-0002-6811-9978; Magalhaes, Talita/0000-0003-2818-369X	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [473015/2008 0]; Fundacao de Amparo a Pesquisa de Minas Gerais (FAPEMIG) [CBBAPQ- 01153-08, CBB-PPM-00491-10]; Universidade Federal de Ouro Preto (UFOP); CAPES; CNPq; FAPEMIG; UFOP	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa de Minas Gerais (FAPEMIG)(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); Universidade Federal de Ouro Preto (UFOP); CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPEMIG(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); UFOP	This work received financial support from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq Process 473015/2008 0), Fundacao de Amparo a Pesquisa de Minas Gerais (FAPEMIG Process CBBAPQ- 01153-08 and CBB-PPM-00491-10) and Universidade Federal de Ouro Preto (UFOP). Research fellowships were sponsored by CAPES (Bonomo, L. F.; Boasquivis, P. F.; de Paula, I. T. B. R; Guerra, J.F.C.), CNPq (Oliveira, R. P., Pedrosa, M. L., Silva, M. E.), FAPEMIG (Paiva, F. A.; Silva, D.N.) and UFOP (Caneschi, W. L.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	An JH, 2003, GENE DEV, V17, P1882, DOI 10.1101/gad.1107803; Boulanger E, 2007, KIDNEY INT, V71, P126, DOI 10.1038/sj.ki.5002016; BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25; BRENNER S, 1974, GENETICS, V77, P71; Buchter C, 2013, INT J MOL SCI, V14, P11895, DOI 10.3390/ijms140611895; Choe KP, 2007, FEBS J, V274, P5782, DOI 10.1111/j.1742-4658.2007.06098.x; Guerra JFD, 2011, J CLIN BIOCHEM NUTR, V49, P188, DOI 10.3164/jcbn.11-02; Del Pozo-Insfran D, 2004, J AGR FOOD CHEM, V52, P1539, DOI 10.1021/jf035189n; Garigan D, 2002, GENETICS, V161, P1101; Gems D, 2000, J GERONTOL A-BIOL, V55, pB215, DOI 10.1093/gerona/55.5.B215; Girones-Vilaplana A, 2012, J AGR FOOD CHEM, V60, P6571, DOI 10.1021/jf300873k; Giusti MM, 2001, CURRENT PROTOCOLS FO; Gonzalez-Manzano S, 2012, J AGR FOOD CHEM, V60, P8911, DOI 10.1021/jf3004256; Gordon A, 2012, FOOD CHEM, V133, P256, DOI 10.1016/j.foodchem.2011.11.150; Grunz G, 2012, MECH AGEING DEV, V133, P1, DOI 10.1016/j.mad.2011.11.005; Guha S, 2013, AGE, V35, P1559, DOI 10.1007/s11357-012-9459-x; Hasegawa K, 2004, TOXICOL LETT, V152, P183, DOI 10.1016/j.toxlet.2004.04.037; Hasegawa K, 2008, TOXICOL SCI, V101, P215, DOI 10.1093/toxsci/kfm276; Hasegawa K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011194; Heinrich M, 2011, PHYTOCHEM LETT, V4, P10, DOI 10.1016/j.phytol.2010.11.005; Hogan S, 2010, FOOD CHEM, V118, P208, DOI 10.1016/j.foodchem.2009.04.099; Honzel D, 2008, J AGR FOOD CHEM, V56, P8319, DOI 10.1021/jf800401d; Inoue H, 2005, GENE DEV, V19, P2278, DOI 10.1101/gad.1324805; Ishikado A, 2012, FREE RADIC BIOL MED; Jensen GS, 2008, J AGR FOOD CHEM, V56, P8326, DOI 10.1021/jf8016157; Jensen GS, 2011, J MED FOOD, V14, P702, DOI 10.1089/jmf.2010.0150; Kampkotter A, 2007, PHARMACOL RES, V55, P139, DOI 10.1016/j.phrs.2006.11.006; Kampkotter A, 2008, COMP BIOCHEM PHYS B, V149, P314, DOI 10.1016/j.cbpb.2007.10.004; Kampkotter A, 2007, TOXICOLOGY, V234, P113, DOI 10.1016/j.tox.2007.02.006; Kang J, 2011, FOOD CHEM, V128, P152, DOI 10.1016/j.foodchem.2011.03.011; Kisselev AF, 2005, METHOD ENZYMOL, V398, P364, DOI 10.1016/S0076-6879(05)98030-0; Lamitina T, 2006, P NATL ACAD SCI USA, V103, P12173, DOI 10.1073/pnas.0602987103; Liedo P, 2012, EXP GERONTOL, V47, P536, DOI 10.1016/j.exger.2012.05.001; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Montiel-Davalos A, 2010, TOXICOL IN VITRO, V24, P135, DOI 10.1016/j.tiv.2009.08.004; Mukhopadhyay A, 2006, EXP GERONTOL, V41, P928, DOI 10.1016/j.exger.2006.05.020; MunizMiret N, 1996, FOREST ECOL MANAG, V87, P163, DOI 10.1016/S0378-1127(96)03825-X; Murphy CT, 2006, EXP GERONTOL, V41, P910, DOI 10.1016/j.exger.2006.06.040; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Noratto GD, 2011, J AGR FOOD CHEM, V59, P7999, DOI 10.1021/jf201056x; Oh SW, 2005, P NATL ACAD SCI USA, V102, P4494, DOI 10.1073/pnas.0500749102; Oliveira RP, 2009, AGING CELL, V8, P524, DOI 10.1111/j.1474-9726.2009.00501.x; Pietsch K, 2009, BIOGERONTOLOGY, V10, P565, DOI 10.1007/s10522-008-9199-6; Reisner K, 2011, J BIOCHEM MOL TOXIC, V25, P269, DOI 10.1002/jbt.20386; Rufino MDM, 2011, FOOD RES INT, V44, P2100, DOI 10.1016/j.foodres.2010.09.011; Schauss AG, 2006, J AGR FOOD CHEM, V54, P8604, DOI 10.1021/jf0609779; Schauss AG, 2006, J AGR FOOD CHEM, V54, P8598, DOI 10.1021/jf060976g; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; Shi YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039515; Solomon A, 2004, GENETICS, V167, P161, DOI 10.1534/genetics.167.1.161; Song J, 2013, FOOD CHEM TOXICOL, V58, P306, DOI 10.1016/j.fct.2013.05.003; Spada PDS, 2009, J MED FOOD, V12, P1084, DOI 10.1089/jmf.2008.0236; Sun XP, 2010, EXP GERONTOL, V45, P243, DOI 10.1016/j.exger.2010.01.008; Tullet JMA, 2008, CELL, V132, P1025, DOI 10.1016/j.cell.2008.01.030; Udani JK, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-45; Wheeler JM, 2006, GENETICS, V174, P1327, DOI 10.1534/genetics.106.059089; Wilson MA, 2006, AGING CELL, V5, P59, DOI 10.1111/j.1474-9726.2006.00192.x; Wu GS, 2004, CANCER BIOL THER, V3, P156, DOI 10.4161/cbt.3.2.614; Wu ZX, 2002, CELL MOL BIOL, V48, P725; Xue YL, 2011, J AGR FOOD CHEM, V59, P5927, DOI 10.1021/jf104798n; Yu YB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009339	61	34	37	0	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2014	9	3							e89933	10.1371/journal.pone.0089933	http://dx.doi.org/10.1371/journal.pone.0089933			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC4CT	24594796	Green Published, Green Submitted, gold			2023-01-03	WOS:000332468900048
J	Murray, J; Bottle, A; Sharland, M; Modi, N; Aylin, P; Majeed, A; Saxena, S				Murray, Joanna; Bottle, Alex; Sharland, Mike; Modi, Neena; Aylin, Paul; Majeed, Azeem; Saxena, Sonia		Med Neonates Investigator Grp	Risk Factors for Hospital Admission with RSV Bronchiolitis in England: A Population-Based Birth Cohort Study	PLOS ONE			English	Article							SYNCYTIAL-VIRUS-INFECTION; YOUNG-CHILDREN; DISEASE; INFANTS; BURDEN	Objective: To examine the timing and duration of RSV bronchiolitis hospital admission among term and preterm infants in England and to identify risk factors for bronchiolitis admission. Design: A population-based birth cohort with follow-up to age 1 year, using the Hospital Episode Statistics database. Setting: 71 hospitals across England. Participants: We identified 296618 individual birth records from 2007/08 and linked to subsequent hospital admission records during the first year of life. Results: In our cohort there were 7189 hospital admissions with a diagnosis of bronchiolitis, 24.2 admissions per 1000 infants under 1 year (95% CI 23.7-24.8), of which 15% (1050/7189) were born preterm (47.3 bronchiolitis admissions per 1000 preterm infants (95% CI 44.4-50.2)). The peak age group for bronchiolitis admissions was infants aged 1 month and the median was age 120 days (IQR = 61-209 days). The median length of stay was 1 day (IQR = 0-3). The relative risk (RR) of a bronchiolitis admission was higher among infants with known risk factors for severe RSV infection, including those born preterm (RR = 1.9, 95% CI 1.8-2.0) compared with infants born at term. Other conditions also significantly increased risk of bronchiolitis admission, including Down's syndrome (RR = 2.5, 95% CI 1.7-3.7) and cerebral palsy (RR = 2.4, 95% CI 1.5-4.0). Conclusions: Most (85%) of the infants who are admitted to hospital with bronchiolitis in England are born at term, with no known predisposing risk factors for severe RSV infection, although risk of admission is higher in known risk groups. The early age of bronchiolitis admissions has important implications for the potential impact and timing of future active and passive immunisations. More research is needed to explain why babies born with Down's syndrome and cerebral palsy are also at higher risk of hospital admission with RSV bronchiolitis.	[Murray, Joanna; Bottle, Alex; Aylin, Paul; Majeed, Azeem; Saxena, Sonia] Univ London Imperial Coll Sci Technol & Med, Dept Primary Care & Publ Hlth, London, England; [Sharland, Mike] St Georges Hosp NHS Trust, Paediat Infect Dis Unit, London, England; [Modi, Neena] Univ London Imperial Coll Sci Technol & Med, Dept Med, Sect Neonatal Med, London, England	Imperial College London; St Georges University London; Imperial College London	Murray, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Primary Care & Publ Hlth, London, England.	joanna.murray@imperial.ac.uk	Saxena, Sonia/ABD-7737-2021; Saxena, Sonia K/G-4821-2013; Petrou, Stavros/ABD-8323-2021	Saxena, Sonia/0000-0003-3787-2083; Saxena, Sonia K/0000-0003-3787-2083; sharland, mike/0000-0001-8626-8291; Majeed, Azeem/0000-0002-2357-9858; Bottle, Alex/0000-0001-9978-2011; Petrou, Stavros/0000-0003-3121-6050; Aylin, Paul/0000-0003-4589-1743	National Institute for Health Research (NIHR) Programme Grant for Applied Research [RP-PG-0707-10010]; Neonatal Data Analysis Unit from Abbott International; Danone UK; Dr Foster Unit at Imperial by Dr Foster Intelligence, an independent healthcare information company; NIHR Collaboration for Leadership in Applied Health Research & Care (CLAHRC) for North West London; NIHR Imperial Biomedical Research Centre; NIHR Imperial Centre for Patient Safety and Service Quality; National Institute for Health Research (NIHR) [RP-PG-0707-10010]; Information Centre of the NHS; NIHR; National Institute for Health Research [RP-PG-0707-10010, CDF-2011-04-048] Funding Source: researchfish	National Institute for Health Research (NIHR) Programme Grant for Applied Research(National Institute for Health Research (NIHR)); Neonatal Data Analysis Unit from Abbott International; Danone UK(Danone Nutricia); Dr Foster Unit at Imperial by Dr Foster Intelligence, an independent healthcare information company; NIHR Collaboration for Leadership in Applied Health Research & Care (CLAHRC) for North West London; NIHR Imperial Biomedical Research Centre; NIHR Imperial Centre for Patient Safety and Service Quality; National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); Information Centre of the NHS; NIHR(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	JM was funded through a National Institute for Health Research (NIHR) Programme Grant for Applied Research (RP-PG-0707-10010) held by NM; JM and NM declare financial support from this award for the submitted work. Support for data analysis was received from the Neonatal Data Analysis Unit led by NM. Unrestricted support for the Neonatal Data Analysis Unit from Abbott International and Danone UK is acknowledged. The Dr Foster Unit at Imperial are principally funded via a research grant by Dr Foster Intelligence, an independent healthcare information company and joint venture with the Information Centre of the NHS. The Unit is affiliated with the NIHR Imperial Centre for Patient Safety and Service Quality at Imperial College Healthcare NHS Trust. The Department of Primary Care & Public Health at Imperial College is grateful for support from the NIHR Collaboration for Leadership in Applied Health Research & Care (CLAHRC) for North West London (a partnership between Chelsea and Westminster NHS Foundation Trust and Imperial College London), the NIHR Imperial Biomedical Research Centre (a partnership between Imperial College Healthcare NHS Trust and Imperial College London), and the NIHR Imperial Centre for Patient Safety and Service Quality. SS has an NIHR career development fellowship. This publication presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research scheme (RP-PG-0707-10010). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in the study design, collection, analysis, and interpretation of data, in the writing of the report or in the decision to submit the paper for publication.	Agency for Healthcare Research and Quality (AHRQ), 2003, CLIN CLASS SOFTW ICD; Audit Commission, 2011, EV 3 YEARS PBR DAT A; Aylin Paul, 2004, BMJ, V329, P1207; Barben J, 2008, THORAX, V63, P1103, DOI 10.1136/thx.2007.094706; Beck S, 2010, B WORLD HEALTH ORGAN, V88, P31, DOI 10.2471/BLT.08.062554; Bont L, 2011, PEDIATR INFECT DIS J, V30, P785, DOI 10.1097/INF.0b013e31821fef9e; Bottle A, 2009, QUAL SAF HEALTH CARE, V18, P303, DOI 10.1136/qshc.2007.026096; Bush A, 2007, BMJ-BRIT MED J, V335, P1037, DOI 10.1136/bmj.39374.600081.AD; Carbonell-Estrany XAVI, 2001, PEDIAT INFECT DIS J, V20; Deshpande SA, 2003, ARCH DIS CHILD, V88, P1065, DOI 10.1136/adc.88.12.1065; Figueras-Aloy J, 2004, PEDIAT INFECT DIS J, V23; Garcia CG, 2010, PEDIATRICS, V126, pE1453, DOI 10.1542/peds.2010-0507; Hall CB, 2010, LANCET, V375, P1500, DOI 10.1016/S0140-6736(10)60401-1; Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877; Houben ML, 2011, PEDIATRICS, V127, P35, DOI 10.1542/peds.2010-0581; Joint Committee on Vaccination and Immunisation - Respiratory Syncitial Virus (RSV) Subgroup, 2010, RSV SUBGR 8 JUN 2010; Koehoorn M, 2008, PEDIATRICS, V122, P1196, DOI 10.1542/peds.2007-2231; Ladhani S, 2010, PEDIATR INFECT DIS J, V29, P310, DOI 10.1097/INF.0b013e3181d73322; Law BJ, 2002, RESP MED, V96, pS1, DOI 10.1053/rmed.2002.1294; Manktelow BN, 2001, ARCH DIS CHILD-FETAL, V85, pF33, DOI 10.1136/fn.85.1.F33; Muller-Pebody B, 2002, EPIDEMIOL INFECT, V129, P99, DOI 10.1017/S095026880200729X; Murray J, 2013, J PUBLIC HEALTH-UK, V35, P298, DOI 10.1093/pubmed/fds077; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; *OFF NAT STAT, 2008, BIRTH STAT BIRTHS PA; Papadopoulos NG, 2002, AM J RESP CRIT CARE, V165, P1285, DOI 10.1164/rccm.200112-118BC; Patel H, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004878; Saxena S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007484; Scottish Intercollegiate Guidelines Network (SIGN), 2006, 91 SIGN; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Smyth RL, 2006, LANCET, V368, P312, DOI 10.1016/S0140-6736(06)69077-6; Spurling GKP, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005189.pub2; Stensballe LG, 2008, CLIN INFECT DIS, V46, P1165, DOI 10.1086/529438; The NHS Information Centre for Health and Social Care, 2009, HES ONL DAT DICT IMP; The NHS Information Centre for Health and Social Care HESonline Hospital Episode Statistic, 2010, NHS MAT STAT; Tregoning JS, 2010, CLIN MICROBIOL REV, V23, P74, DOI 10.1128/CMR.00032-09; Wang D, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15050; Wang D, 2008, HEALTH TECHNOL ASSES, V12, piii, DOI DOI 10.3310/HTA12020; Wang D, 2008, HEALTH TECHNOL ASSES, V12, pix; Wren C, 2000, HEART, V83, P414, DOI 10.1136/heart.83.4.414	39	116	120	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2014	9	2							e89186	10.1371/journal.pone.0089186	http://dx.doi.org/10.1371/journal.pone.0089186			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC3BC	24586581	Green Published, Green Accepted, gold			2023-01-03	WOS:000332389000030
J	Bao, S; Wu, DB; Wang, QG; Su, T				Bao, Song; Wu, Dongbei; Wang, Qigang; Su, Teng			Functional Elastic Hydrogel as Recyclable Membrane for the Adsorption and Degradation of Methylene Blue	PLOS ONE			English	Article							AQUEOUS-SOLUTION; DYE REMOVAL; NANOCOMPOSITE; WATER; CLAY; MODEL	Developing the application of high-strength hydrogels has gained much attention in the fields of medical, pharmacy, and pollutant removal due to their versatility and stimulus-responsive properties. In this presentation, a high-strength freestanding elastic hydrogel membrane was constructed by clay nanosheets, N, N-dimethylacrylamide and 2-acrylamide-2-methylpropanesulfonic acid for adsorption of methylene blue and heavy metal ions. The maximum values of elongation and Young's modulus for 0.5% AMPSNa hydrogel were 1901% and 949.4 kPa, respectively, much higher than those of traditional hydrogels. The adsorptions were confirmed to follow pseudo-second kinetic equation and Langmuir isotherm model fits the data well. The maximum adsorption capacity of hydrogel towards methylene blue was 434.8 mg g(-1). The hydrogel also exhibited higher separation selectivity to Pb2+ than Cu2+. The methylene blue adsorbed onto the hydrogel membrane can be photocatalytically degraded by Fenton agent and the hydrogel membrane could be recycled at least five times without obvious loss in mechanical properties. In conclusion, this presentation demonstrates a convenient strategy to prepare tough and elastic clay nanocomposite hydrogel, which can not only be applied as recyclable membrane for the photocatalytic degradation of organic dye, but also for the recovery of valuables.	[Bao, Song; Wu, Dongbei; Wang, Qigang; Su, Teng] Tongji Univ, Dept Chem, Shanghai 200092, Peoples R China; [Wang, Qigang; Su, Teng] Tongji Univ, Adv Res Inst, Shanghai 200092, Peoples R China	Tongji University; Tongji University	Wu, DB (corresponding author), Tongji Univ, Dept Chem, Shanghai 200092, Peoples R China.	wudongbei@tongji.edu.cn; wangqg66@tongji.edu.cn	Su, Teng/G-2709-2012; Wang, Qigang/G-1124-2010	Su, Teng/0000-0001-7888-0763; Wang, Qigang/0000-0002-4026-3337	National Natural Science Foundation of China [21274111]; Program for New Century Excellent Talents in University of Ministry of Education of China [NECT-11-0386]; Pujiang talents program [11PJ1409500]; Recruitment Program of Global Experts; Fundamental Research Funds for Central Universities	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University of Ministry of Education of China(Program for New Century Excellent Talents in University (NCET)); Pujiang talents program; Recruitment Program of Global Experts; Fundamental Research Funds for Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by the National Natural Science Foundation of China (No. 21274111), the Program for New Century Excellent Talents in University of Ministry of Education of China (NECT-11-0386), the Fundamental Research Funds for Central Universities, the Pujiang talents program (No. 11PJ1409500), and the Recruitment Program of Global Experts. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acarregui A, 2013, BIOMACROMOLECULES, V14, P322, DOI 10.1021/bm301690a; Ariga K, 2012, CHEM MATER, V24, P728, DOI 10.1021/cm202281m; Chatterjee S, 2011, ENVIRON TECHNOL, V32, P1503, DOI 10.1080/09593330.2010.543157; Chen DH, 2012, ADV FUNCT MATER, V22, P1966, DOI 10.1002/adfm.201102878; Chen YQ, 2013, J MATER CHEM A, V1, P1992, DOI 10.1039/c2ta00406b; Coskun R, 2012, POLYM BULL, V68, P1889, DOI 10.1007/s00289-011-0664-z; Do D.D., 1998, ADSORPTION ANAL EQUI; Dou XQ, 2012, SOFT MATTER, V8, P3231, DOI 10.1039/c2sm06927j; Feng YF, 2012, BIORESOURCE TECHNOL, V125, P138, DOI 10.1016/j.biortech.2012.08.128; Freundlich H, 1906, Z PHYS CHEM-STOCH VE, V57, P385; Geng ZG, 2012, J MATER CHEM, V22, P3527, DOI 10.1039/c2jm15544c; Gupta VK, 2012, J HAZARD MATER, V243, P179, DOI 10.1016/j.jhazmat.2012.10.018; Haraguchi K, 2002, ADV MATER, V14, P1120, DOI 10.1002/1521-4095(20020816)14:16<1120::AID-ADMA1120>3.0.CO;2-9; Haraguchi K, 2012, MACROMOLECULES, V45, P385, DOI 10.1021/ma202114z; Haraguchi K, 2011, POLYM J, V43, P223, DOI 10.1038/pj.2010.141; Kasgoz H, 2008, POLYM ADVAN TECHNOL, V19, P838, DOI 10.1002/pat.1045; Kredatusova J, 2012, APPL CLAY SCI, V62-63, P94, DOI 10.1016/j.clay.2012.04.009; Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004; Liu F, 2012, ACS APPL MATER INTER, V4, P922, DOI 10.1021/am201590z; Mahmoud GA, 2013, MONATSH CHEM, V144, P1097, DOI 10.1007/s00706-013-0957-z; MARGULIES L, 1988, CLAY CLAY MINER, V36, P270, DOI 10.1346/CCMN.1988.0360309; Ozay O, 2009, WATER RES, V43, P4403, DOI 10.1016/j.watres.2009.06.058; Parasuraman D, 2011, ACS APPL MATER INTER, V3, P4714, DOI 10.1021/am201132x; Ramirez E, 2011, J HAZARD MATER, V192, P432, DOI 10.1016/j.jhazmat.2011.04.109; Ren HY, 2011, MACROMOLECULES, V44, P8516, DOI 10.1021/ma201272j; Rytwo G, 2002, APPL CLAY SCI, V20, P273, DOI 10.1016/S0169-1317(01)00068-0; Shi YR, 2013, POLYM BULL, V70, P1163, DOI 10.1007/s00289-012-0898-4; Sun JY, 2012, NATURE, V489, P133, DOI 10.1038/nature11409; Luan VH, 2013, J MATER CHEM A, V1, P208, DOI 10.1039/c2ta00444e; Wang Q, 2010, NATURE, V463, P339, DOI 10.1038/nature08693; Yan L, 2013, J AM CHEM SOC, V135, P3748, DOI 10.1021/ja3114714; Yang XL, 2013, J MATER CHEM A, V1, P473, DOI 10.1039/c2ta00594h; Yi JZ, 2008, BIORESOURCE TECHNOL, V99, P2182, DOI 10.1016/j.biortech.2007.05.028; Zhang D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01399	34	15	15	2	104	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2014	9	2							e88802	10.1371/journal.pone.0088802	http://dx.doi.org/10.1371/journal.pone.0088802			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AB3UC	24586396	Green Published, gold, Green Submitted			2023-01-03	WOS:000331714700031
J	Santana, SS; Gennari-Cardoso, ML; Carvalho, FC; Roque-Barreira, MC; Santiago, AD; Alvim, FC; Pirovani, CP				Santana, Sanzio Silva; Gennari-Cardoso, Margareth Leitao; Carvalho, Fernanda Caroline; Roque-Barreira, Maria Cristina; Santiago, Andre da Silva; Alvim, Fatima Cerqueira; Pirovani, Carlos Priminho			Eutirucallin, a RIP-2 Type Lectin from the Latex of Euphorbia tirucalli L. Presents Proinflammatory Properties	PLOS ONE			English	Article							GALACTOSE-BINDING LECTIN; SHIGA TOXIN; PROTEINS; PLANTS; TREE; PURIFICATION; RECOGNITION; QUANTITIES; ACTIVATION; PRINCIPLES	Lectins are carbohydrate-binding proteins that recognize and modulate physiological activities and have been used as a toll for detection and identification of biomolecules, and therapy of diseases. In this study we have isolated a lectin present in the latex of Euphorbia tirucalli, and named it Eutirucallin. The latex protein extract was subjected to ion exchange chromatography and showed two peaks with haemagglutinating activity. Polypeptides of 32 kDa protein extract strongly interacted with immobilized galactose (alpha-lactose > D-N-acetylgalactosamine). The Eutirucallin was obtained with a yield of 5.6% using the a-lactose column. The lectin domain has 32 kDa subunits and at least two of which are joined by disulfide bridges. The agglutinating capacity for human erythrocytes A(+), B+ and O+ is inhibited by D-galactose. The haemagglutinating activity of Eutirucallin was independent of Ca2+ and maintained until the temperature of 55 degrees C. Eutirucallin presented biological activities such as neutrophils recruitment and cytokine prodution by macrophages. The analysis of the trypsin-digested Eutirucallin by ms/ms in ESI-Q-TOFF resulted in nine peptides similar to type 2 ribosome-inactivating protein (type-2 RIP). It's partial sequence showed a similarity of 67.4 - 83.1% for the lectin domain of type-2 RIP [Ricin and Abrin (83.1%), Viscumin, Ebulin, Pulchellin, Cinnamomin, Volkensin and type-2 RIP Iris hollandica]. Our data suggest that Eutirucallin is a new member of type 2 ribosome-inactivating protein and presents biotechnological potential.	[Santana, Sanzio Silva; Gennari-Cardoso, Margareth Leitao; Santiago, Andre da Silva; Alvim, Fatima Cerqueira; Pirovani, Carlos Priminho] Univ Estadual Santa Cruz, Ctr Biotecnol & Genet, Ilheus, BA, Brazil; [Carvalho, Fernanda Caroline; Roque-Barreira, Maria Cristina] Univ Sao Paulo, Med Sch Ribeirao Preto, Sao Paulo, Brazil	Universidade Estadual de Santa Cruz; Universidade de Sao Paulo	Pirovani, CP (corresponding author), Univ Estadual Santa Cruz, Ctr Biotecnol & Genet, Ilheus, BA, Brazil.	pirovani@uesc.br	Pirovani, Carlos P/J-3426-2017; Pirovani, Carlos Priminho/N-1153-2019; Ibrahim, Essam Hassan/G-1960-2018; Roque-Barreira, Maria-Cristina/A-4552-2008	Pirovani, Carlos P/0000-0002-6176-4069; Pirovani, Carlos Priminho/0000-0002-6176-4069; Ibrahim, Essam Hassan/0000-0003-0130-2257; Roque-Barreira, Maria-Cristina/0000-0001-7425-0908	Fundacao de Amparo Pesquisa of Bahia (FAPESB - PRONEM) [PNE0005/2011]	Fundacao de Amparo Pesquisa of Bahia (FAPESB - PRONEM)	Funding from Fundacao de Amparo Pesquisa of Bahia (FAPESB - PRONEM, TO No. no PNE0005/2011). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambrosi M, 2005, ORG BIOMOL CHEM, V3, P1593, DOI 10.1039/b414350g; BARBIERI L, 1983, BIOCHEM J, V215, P433, DOI 10.1042/bj2150433; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brasileiro Beatriz Gonçalves, 2006, Rev. Bras. Cienc. Farm., V42, P195, DOI 10.1590/S1516-93322006000200004; Coelho LCBB, 2000, PHYTOCHEM ANALYSIS, V11, P295, DOI 10.1002/1099-1565(200009/10)11:5&lt;295::AID-PCA517&gt;3.0.CO;2-S; Elifio-Esposito S, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-10; EMMERICH C, 1994, ACTA CRYSTALLOGR D, V50, P749, DOI 10.1107/S0907444994002143; FURSTENBERGER G, 1985, Z NATURFORSCH C, V40, P631; Goldstein J, 1989, Transfus Med Rev, V3, P206, DOI 10.1016/S0887-7963(89)70080-8; Hartley MR, 2004, BBA-PROTEINS PROTEOM, V1701, P1, DOI 10.1016/j.bbapap.2004.06.004; Konozy EHE, 2003, ARCH BIOCHEM BIOPHYS, V410, P222, DOI 10.1016/S0003-9861(02)00695-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g; Loris R, 2002, BBA-GEN SUBJECTS, V1572, P198, DOI 10.1016/S0304-4165(02)00309-4; Loyola W, 2012, INT IMMUNOPHARMACOL, V12, P378, DOI 10.1016/j.intimp.2011.12.010; Machuka JS, 1999, PHYTOCHEMISTRY, V51, P721, DOI 10.1016/S0031-9422(99)00136-3; MacNeil A, 2003, BRIT J CANCER, V88, P1566, DOI 10.1038/sj.bjc.6600929; OLSNES S, 1974, J BIOL CHEM, V249, P803; Pajic I, 2002, COMP BIOCHEM PHYS C, V132, P213, DOI 10.1016/S1532-0456(02)00068-6; Panunto-Castelo A, 2001, GLYCOBIOLOGY, V11, P1035, DOI 10.1093/glycob/11.12.1035; Rahuman AA, 2008, PARASITOL RES, V102, P867, DOI 10.1007/s00436-007-0839-6; Sandvig K, 1996, PHYSIOL REV, V76, P949, DOI 10.1152/physrev.1996.76.4.949; Sharon N, 2002, J AGR FOOD CHEM, V50, P6586, DOI 10.1021/jf020190s; Sharon N, 2001, ADV EXP MED BIOL, V491, P1; Souza MA, 2005, BRAZ ARCH BIOL TECHN, V48, P705, DOI 10.1590/S1516-89132005000600005; STIRPE F, 1983, BIOCHEM J, V216, P617, DOI 10.1042/bj2160617; Tiwari S, 2005, ENVIRON RES, V99, P378, DOI 10.1016/j.envres.2004.12.008; Turton K, 2004, GLYCOBIOLOGY, V14, P923, DOI 10.1093/glycob/cwh114; Valadares MC, 2006, INT IMMUNOPHARMACOL, V6, P294, DOI 10.1016/j.intimp.2005.07.013; Wititsuwannakul R, 1998, PHYTOCHEMISTRY, V47, P183, DOI 10.1016/S0031-9422(97)00329-4; Xu H, 2004, ACTA BIOCH BIOPH SIN, V36, P169, DOI 10.1093/abbs/36.3.169; Yamamoto Y, 1981, Plant Cell Rep, V1, P29, DOI 10.1007/BF00267653; Yamasaki C, 2004, BBA-GEN SUBJECTS, V1671, P44, DOI 10.1016/j.bbagen.2004.01.002	33	18	18	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2014	9	2							e88422	10.1371/journal.pone.0088422	http://dx.doi.org/10.1371/journal.pone.0088422			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AB3RA	24558388	Green Published, gold, Green Submitted			2023-01-03	WOS:000331706700034
J	Roehr, B				Roehr, Bob			FDA faces regulatory challenges with new approaches to medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												BobRoehr@aol.com						Dobbs D., 2014, NEW YORKER; Eichler HG, 2013, NAT REV DRUG DISCOV, V12, P907, DOI 10.1038/nrd4129; McCarthy M, 2013, BMJ-BRIT MED J, V347, pf5203, DOI [10.1136/bmj.f5203, DOI 10.1136/BMJ.F5203)]; Presidential Commission for the Study of Bioethical Issues, ANT COMM ETH MAN INC; Tabarrok A., 2013, MARGINAL REVOLUT NOV; U.S. Food and Drug Administration, GUID IND ENF POL REG; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037	7	1	1	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 14	2014	348								g1530	10.1136/bmj.g1530	http://dx.doi.org/10.1136/bmj.g1530			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AA9XG	24531207				2023-01-03	WOS:000331445700001
J	Finkle, WD; Greenland, S; Ridgeway, GK; Adams, JL; Frasco, MA; Cook, MB; Fraumeni, JF; Hoover, RN				Finkle, William D.; Greenland, Sander; Ridgeway, Gregory K.; Adams, John L.; Frasco, Melissa A.; Cook, Michael B.; Fraumeni, Joseph F., Jr.; Hoover, Robert N.			Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men	PLOS ONE			English	Article							CORONARY-HEART-DISEASE; OLDER MEN; CARDIOVASCULAR EVENTS; HORMONE-THERAPY; METAANALYSIS; THROMBOSIS; AUTOPSY; BLOOD	Background: An association between testosterone therapy (TT) and cardiovascular disease has been reported and TT use is increasing rapidly. Methods: We conducted a cohort study of the risk of acute non-fatal myocardial infarction (MI) following an initial TT prescription (N = 55,593) in a large health-care database. We compared the incidence rate of MI in the 90 days following the initial prescription (post-prescription interval) with the rate in the one year prior to the initial prescription (pre-prescription interval) (post/pre). We also compared post/pre rates in a cohort of men prescribed phosphodiesterase type 5 inhibitors (PDE5I; sildenafil or tadalafil, N = 167,279), and compared TT prescription post/pre rates with the PDE5I post/pre rates, adjusting for potential confounders using doubly robust estimation. Results: In all subjects, the post/pre-prescription rate ratio (RR) for TT prescription was 1.36 (1.03, 1.81). In men aged 65 years and older, the RR was 2.19 (1.27, 3.77) for TT prescription and 1.15 (0.83, 1.59) for PDE5I, and the ratio of the rate ratios (RRR) for TT prescription relative to PDE5I was 1.90 (1.04, 3.49). The RR for TT prescription increased with age from 0.95 (0.54, 1.67) for men under age 55 years to 3.43 (1.54, 7.56) for those aged >= 75 years (p(trend) = 0.03), while no trend was seen for PDE5I (p(trend) = 0.18). In men under age 65 years, excess risk was confined to those with a prior history of heart disease, with RRs of 2.90 (1.49, 5.62) for TT prescription and 1.40 (0.91, 2.14) for PDE5I, and a RRR of 2.07 (1.05, 4.11). Discussion: In older men, and in younger men with pre-existing diagnosed heart disease, the risk of MI following initiation of TT prescription is substantially increased.	[Finkle, William D.; Ridgeway, Gregory K.; Adams, John L.; Frasco, Melissa A.] Consolidated Res Inc, Los Angeles, CA 90045 USA; [Greenland, Sander] Univ Calif Los Angeles, Dept Epidemiol, Los Angeles, CA USA; [Greenland, Sander] Univ Calif Los Angeles, Dept Stat, Los Angeles, CA USA; [Cook, Michael B.; Fraumeni, Joseph F., Jr.; Hoover, Robert N.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Finkle, WD (corresponding author), Consolidated Res Inc, Los Angeles, CA 90045 USA.	bill@consolidated-research.com; hooverr@mail.nih.gov	Cook, Michael B/A-5641-2009	Cook, Michael B/0000-0002-0533-7302; Ridgeway, Greg/0000-0001-6911-0804; Frasco, Melissa/0000-0002-3437-1518	National Cancer Institute	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the Intramural Research Program of the National Cancer Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AJAYI AAL, 1995, CIRCULATION, V91, P2742, DOI 10.1161/01.CIR.91.11.2742; Baillargeon J, 2013, JAMA INTERN MED, P1; Bang H, 2005, BIOMETRICS, V61, P962, DOI 10.1111/j.1541-0420.2005.00377.x; Basaria S, 2010, NEW ENGL J MED, V363, P109, DOI 10.1056/NEJMoa1000485; Baskurt OK, 2012, SEMIN THROMB HEMOST, V38, P854, DOI 10.1055/s-0032-1325616; Bremner WJ, 2010, NEW ENGL J MED, V363, P189, DOI 10.1056/NEJMe1006197; Corona G, 2011, EUR J ENDOCRINOL, V165, P687, DOI 10.1530/EJE-11-0447; Greenland P, 2003, JAMA-J AM MED ASSOC, V290, P891, DOI 10.1001/jama.290.7.891; Hensen LG, 2010, HLTH RES DATA REAL W; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jackson G, 2006, UROLOGY, V68, P47, DOI 10.1016/j.urology.2006.05.047; JAMA, 1970, JAMA, V214, P1303, DOI DOI 10.1001/JAMA.1970.03180070069012; Lidegaard O, 2012, NEW ENGL J MED, V366, P2257, DOI 10.1056/NEJMoa1111840; Marchioli R, 2013, NEW ENGL J MED, V368, P22, DOI 10.1056/NEJMoa1208500; Fernandez-Balsells MM, 2010, J CLIN ENDOCR METAB, V95, P2560, DOI 10.1210/jc.2009-2575; O'Connor A, 2013, MENS USE HORMONES RI; Oliva A, 2011, ATHEROSCLEROSIS, V218, P28, DOI 10.1016/j.atherosclerosis.2011.05.012; Page ST, 2005, J CLIN ENDOCR METAB, V90, P1502, DOI 10.1210/jc.2004-1933; Peerschke EI, 2007, AM J CLIN PATHOL, V127, P422, DOI 10.1309/B29E2AHMTQA1KAKJ; Petersen LA, 1999, J GEN INTERN MED, V14, P555, DOI 10.1046/j.1525-1497.1999.10198.x; Roger VL, 2001, AM J MED, V110, P267, DOI 10.1016/S0002-9343(00)00709-9; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Rothman JK, 2008, MODERN EPIDEMIOLOGY, V3rd; Ruige JB, 2011, HEART, V97, P870, DOI 10.1136/hrt.2010.210757; Sandset PM, 2009, THROMB RES, V123, pS70, DOI 10.1016/S0049-3848(09)70015-5; Seeger JD, 2003, AM J CARDIOL, V92, P1447, DOI 10.1016/j.amjcard.2003.08.057; Spitzer M, 2013, NAT REV ENDOCRINOL, V9, DOI [10.1038/nrendo.2013.73-c2, 10.1038/nrendo.2013.73]; Swerdloff RS, 2000, J CLIN ENDOCR METAB, V85, P4500, DOI 10.1210/jc.85.12.4500; Urhausen A, 2003, J STEROID BIOCHEM, V84, P369, DOI 10.1016/S0960-0760(03)00105-5; Xu L, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-108	31	491	500	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2014	9	1							e85805	10.1371/journal.pone.0085805	http://dx.doi.org/10.1371/journal.pone.0085805			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301ZC	24489673	Green Published, Green Submitted, gold			2023-01-03	WOS:000330570000017
J	Soler, J; Cebolla, A; Feliu-Soler, A; Demarzo, MMP; Pascual, JC; Banos, R; Garcia-Campayo, J				Soler, Joaquim; Cebolla, Ausias; Feliu-Soler, Albert; Demarzo, Marcelo M. P.; Pascual, Juan C.; Banos, Rosa; Garcia-Campayo, Javier			Relationship between Meditative Practice and Self-Reported Mindfulness: The MINDSENS Composite Index	PLOS ONE			English	Article							ATTENTION AWARENESS SCALE; PSYCHOMETRIC PROPERTIES; 5 FACETS; COGNITIVE THERAPY; STRESS REDUCTION; QUESTIONNAIRE; VALIDATION; DEPRESSION; INTERNET	Mindfulness has been described as an inherent human capability that can be learned and trained, and its improvement has been associated with better health outcomes in both medicine and psychology. Although the role of practice is central to most mindfulness programs, practice-related improvements in mindfulness skills is not consistently reported and little is known about how the characteristics of meditative practice affect different components of mindfulness. The present study explores the role of practice parameters on self-reported mindfulness skills. A total of 670 voluntary participants with and without previous meditation experience (n = 384 and n = 286, respectively) responded to an internet-based survey on various aspects of their meditative practice (type of meditation, length of session, frequency, and lifetime practice). Participants also completed the Five Facets Mindfulness Questionnaire (FFMQ), and the Experiences Questionnaire (EQ). The group with meditation experience obtained significantly higher scores on all facets of FFMQ and EQ questionnaires compared to the group without experience. However different effect sizes were observed, with stronger effects for the Observing and Non-Reactivity facets of the FFMQ, moderate effects for Decentering in EQ, and a weak effect for Non-judging, Describing, and Acting with awareness on the FFMQ. Our results indicate that not all practice variables are equally relevant in terms of developing mindfulness skills. Frequency and lifetime practice - but not session length or meditation type - were associated with higher mindfulness skills. Given that these 6 mindfulness aspects show variable sensitivity to practice, we created a composite index (MINDSENS) consisting of those items from FFMQ and EQ that showed the strongest response to practice. The MINDSENS index was able to correctly discriminate daily meditators from non-meditators in 82.3% of cases. These findings may contribute to the understanding of the development of mindfulness skills and support trainers and researchers in improving mindfulness-oriented practices and programs.	[Soler, Joaquim; Feliu-Soler, Albert; Pascual, Juan C.] Hosp Santa Creu St Pau, Dept Psychiat, Barcelona, Spain; [Soler, Joaquim; Feliu-Soler, Albert; Pascual, Juan C.] Univ Autonoma Barcelona, CIBERSAM, IIB ST PAU, E-08193 Barcelona, Spain; [Cebolla, Ausias; Banos, Rosa] Ciber Fisiopatol Obesidad Nutr CIBERO, Santiago De Compostela, Spain; [Cebolla, Ausias] Univ Jaume 1, Dept Psicol Basica Clin Psicobiol, Castellon de La Plana, Spain; [Demarzo, Marcelo M. P.] Univ Fed Sao Paulo, Dept Prevent Med, Mente Aberta Brazilian Ctr Mindfulness & Hlth Pro, Sao Paulo, Brazil; [Banos, Rosa] Univ Valencia, Dept Personalitat Avaluacio Tractaments Psicol, Valencia, Spain; [Garcia-Campayo, Javier] Miguel Servet Hosp, Dept Psychiat, Zaragoza, Spain; [Garcia-Campayo, Javier] Univ Zaragoza, Inst Aragones Ciencias Salud, REDIAPP, Zaragoza, Spain	Hospital of Santa Creu i Sant Pau; Autonomous University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERSAM; University of Barcelona; Universitat Jaume I; Universidade Federal de Sao Paulo (UNIFESP); University of Valencia; Miguel Servet University Hospital; University of Zaragoza	Soler, J (corresponding author), Hosp Santa Creu St Pau, Dept Psychiat, Barcelona, Spain.	jsolerri@santpau.cat	Feliu-Soler, Albert/AAG-7555-2022; Feliu-Soler, Albert/X-4367-2018; Pascual, Juan/M-2559-2014; Marti, Ausias Cebolla/E-8410-2012; Feliu-Soler, Albert/AFL-7616-2022; BAÑOS, ROSA MARIA/C-6077-2011; Demarzo, Marcelo/A-7021-2010	Feliu-Soler, Albert/0000-0003-2810-7670; Feliu-Soler, Albert/0000-0003-2810-7670; Pascual, Juan/0000-0001-8039-9346; Marti, Ausias Cebolla/0000-0002-3456-9743; Feliu-Soler, Albert/0000-0003-2810-7670; BAÑOS, ROSA MARIA/0000-0003-0626-7665; Demarzo, Marcelo/0000-0002-7447-1839; Garcia-Campayo, Javier/0000-0002-3797-4218; Soler, Joaquim/0000-0001-8077-3641				Baer R.A., 2009, CLIN HDB MINDFULNESS, P153, DOI DOI 10.1007/978-0-387-09593-6_10; Baer RA, 2006, ASSESSMENT, V13, P27, DOI 10.1177/1073191105283504; Baer RA, 2004, ASSESSMENT, V11, P191, DOI 10.1177/1073191104268029; Baer RA, 2003, CLIN PSYCHOL-SCI PR, V10, P125, DOI 10.1093/clipsy/bpg015; Baer RA, 2008, ASSESSMENT, V15, P329, DOI 10.1177/1073191107313003; Bergomi C, 2013, MINDFULNESS, V4, P18, DOI 10.1007/s12671-012-0102-9; Bishop SR, 2004, CLIN PSYCHOL-SCI PR, V11, P230, DOI 10.1093/clipsy/bph077; Bodhi B., 1984, NOBLE EIGHTFOLD PATH; Brown KW, 2011, PSYCHOL ASSESSMENT, V23, P1023, DOI 10.1037/a0021338; Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822; Cardaciotto L, 2008, ASSESSMENT, V15, P204, DOI 10.1177/1073191107311467; Carmody J, 2008, J BEHAV MED, V31, P23, DOI 10.1007/s10865-007-9130-7; Cebolla A, 2012, EUR J PSYCHIAT, V26, P118, DOI 10.4321/S0213-61632012000200005; Chiesa A, 2011, PSYCHIAT RES, V187, P441, DOI 10.1016/j.psychres.2010.08.011; Creswell JD, 2007, PSYCHOSOM MED, V69, P560, DOI 10.1097/PSY.0b013e3180f6171f; de Bruin EI, 2012, ASSESSMENT, V19, P187, DOI 10.1177/1073191112446654; Dimidjian S, 2003, CLIN PSYCHOL-SCI PR, V10, P166, DOI 10.1093/clipsy/bpg019; Dobkin Patricia L, 2011, Complement Ther Clin Pract, V17, P22, DOI 10.1016/j.ctcp.2010.03.002; Feliu-Soler A, 2013, CLIN PSYCHOL PSYCHOT; Fennell MJV, 2004, BEHAV RES THER, V42, P1053, DOI 10.1016/j.brat.2004.03.002; Fjorback LO, 2011, ACTA PSYCHIAT SCAND, V124, P102, DOI 10.1111/j.1600-0447.2011.01704.x; Fresco DM, 2007, BEHAV THER, V38, P234, DOI 10.1016/j.beth.2006.08.003; Germer C., 2009, MINDFUL PATH SELF CO; Grossman P, 2011, PSYCHOL ASSESSMENT, V23, P1034, DOI 10.1037/a0022713; Hofmann SG, 2010, J CONSULT CLIN PSYCH, V78, P169, DOI 10.1037/a0018555; Kabat-Zinn J., 2013, FULL CATASTROPHE LIV; Khoury B, 2013, CLIN PSYCHOL REV, V33, P763, DOI 10.1016/j.cpr.2013.05.005; Kongsved SM, 2007, J MED INTERNET RES, V9, DOI 10.2196/jmir.9.3.e25; Leigh J, 2005, ADDICT BEHAV, V30, P1335, DOI 10.1016/j.addbeh.2005.01.010; Lilja JL, 2013, MINDFULNESS, V4, P203, DOI 10.1007/s12671-012-0111-8; Lilja Josefine L., 2011, Cognitive Behaviour Therapy, V40, P291, DOI 10.1080/16506073.2011.580367; Linehan M., 1993, DBT SKILLS TRAINING; Linehan M. M, 1993, COGNITIVE BEHAV THER; MacKillop J, 2007, J PSYCHOPATHOL BEHAV, V29, P289, DOI 10.1007/s10862-007-9045-1; Mitchell JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070253; Ritter P, 2004, J MED INTERNET RES, V6, P19, DOI 10.2196/jmir.6.3.e29; Sauer S, 2013, MINDFULNESS, V4, P3, DOI 10.1007/s12671-012-0122-5; Segal Z. V., 2013, MINDFULNESS BASED CO, V2nd; Soler J, 2012, BEHAV RES THER, V50, P150, DOI 10.1016/j.brat.2011.12.002; Teasdale JD, 2002, J CONSULT CLIN PSYCH, V70, P275, DOI 10.1037//0022-006X.70.2.275; TEASDALE JDS, 1995, BEHAV RES THER, V33, P1995; Vettese LC, 2009, J COGN PSYCHOTHER, V23, P198, DOI 10.1891/0889-8391.23.3.198; Wilson K. G, 1999, ACCEPTANCE COMMITMEN	43	76	77	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2014	9	1							e86622	10.1371/journal.pone.0086622	http://dx.doi.org/10.1371/journal.pone.0086622			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	297VL	24466175	gold, Green Published, Green Submitted			2023-01-03	WOS:000330283100191
J	Huang, Y; He, Q; Zhan, L; Yang, M				Huang, Yu; He, Qing; Zhan, Lei; Yang, Min			Sarcoplasmic Phospholamban Protein Is Involved in the Mechanisms of Postresuscitation Myocardial Dysfunction and the Cardioprotective Effect of Nitrite during Resuscitation	PLOS ONE			English	Article							ISCHEMIA-REPERFUSION INJURY; HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; IN-VIVO; IMPROVES OUTCOMES; OXIDE; RETICULUM; MICE; SURVIVAL; MODEL	Objectives: Sarcoplasmic reticulum (SR) Ca2+-handling proteins play an important role in myocardial dysfunction after acute ischemia/reperfusion injury. We hypothesized that nitrite would improve postresuscitation myocardial dysfunction by increasing nitric oxide (NO) generation and that the mechanism of this protection is related to the modulation of SR Ca2+-handling proteins. Methods: We conducted a randomized prospective animal study using male Sprague-Dawley rats. Cardiac arrest was induced by intravenous bolus of potassium chloride (40 mu g/g). Nitrite (1.2 nmol/g) or placebo was administered when chest compression was started. No cardiac arrest was induced in the sham group. Hemodynamic parameters were monitored invasively for 90 minutes after the return of spontaneous circulation (ROSC). Echocardiogram was performed to evaluate cardiac function. Myocardial samples were harvested 5 minutes and 1 hour after ROSC. Results: Myocardial function was significantly impaired in the nitrite and placebo groups after resuscitation, whereas cardiac function (i.e., ejection fraction and fractional shortening) was significantly greater in the nitrite group than in the placebo group. Nitrite administration increased the level of nitric oxide in the myocardium 5 min after resuscitation compared to the other two groups. The levels of phosphorylated phospholamban (PLB) were decreased after resuscitation, and nitrite increased the phosphorylation of phospholamban compared to the placebo. No significant differences were found in the expression of sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) and ryanodine receptors (RyRs). Conclusions: postresuscitation myocardial dysfunction is associated with the impairment of PLB phosphorylation. Nitrite administered during resuscitation improves postresuscitation myocardial dysfunction by preserving phosphorylated PLB protein during resuscitation.	[Huang, Yu; He, Qing] Chongqing Med Univ, Affiliated Hosp Chengdu 2, Peoples Hosp Chengdu 3, Chengdu, Peoples R China; [He, Qing; Zhan, Lei; Yang, Min] Sichuan Univ, West China Hosp, Dept Resp Dis, Chengdu 610064, Peoples R China; [Yang, Min] Anhui Med Univ, Hosp 2, Dept Intens Care Unit, Hefei, Anhui, Peoples R China	Chongqing Medical University; Sichuan University; Anhui Medical University	He, Q (corresponding author), Chongqing Med Univ, Affiliated Hosp Chengdu 2, Peoples Hosp Chengdu 3, Chengdu, Peoples R China.	kk555888@126.com			Natural Science Foundation of China [81071539]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The study was supported by the Natural Science Foundation of China (81071539). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdallah Y, 2005, CARDIOVASC RES, V66, P123, DOI 10.1016/j.cardiores.2005.01.007; Abdallah Y, 2006, CARDIOVASC RES, V70, P346, DOI 10.1016/j.cardiores.2006.02.020; Abella BS, 2004, CIRCULATION, V109, P2786, DOI 10.1161/01.CIR.0000131940.19833.85; Angelos MG, 2008, RESUSCITATION, V77, P101, DOI 10.1016/j.resuscitation.2007.10.017; Boucher JL, 1999, CELL MOL LIFE SCI, V55, P1015, DOI 10.1007/s000180050352; Champion HC, 2004, CIRC RES, V94, P657, DOI 10.1161/01.RES.0000119323.79644.20; Chang WT, 2007, INTENS CARE MED, V33, P88, DOI 10.1007/s00134-006-0442-9; Chohan PK, 2006, CARDIOVASC RES, V69, P152, DOI 10.1016/j.cardiores.2005.07.016; Dezfulian C, 2007, CARDIOVASC RES, V75, P327, DOI 10.1016/j.cardiores.2007.05.001; Dezfulian C, 2009, CIRCULATION, V120, P897, DOI 10.1161/CIRCULATIONAHA.109.853267; Elrod JW, 2006, ARTERIOSCL THROM VAS, V26, P1517, DOI 10.1161/01.ATV.0000224324.52466.e6; Gonzalez FM, 2008, CIRCULATION, V117, P2986, DOI 10.1161/CIRCULATIONAHA.107.748814; Hajnoczky G, 2010, CURR BIOL, V20, pR888, DOI 10.1016/j.cub.2010.09.035; Idris AH, 1996, RESUSCITATION, V33, P69, DOI 10.1016/S0300-9572(96)01055-6; Jung KH, 2006, STROKE, V37, P2744, DOI 10.1161/01.STR.0000245116.40163.1c; Kasseckert SA, 2009, CARDIOVASC RES, V83, P381, DOI 10.1093/cvr/cvp065; Kim SJ, 2001, CIRC RES, V89, P831, DOI 10.1161/hh2101.098547; Lim G, 2008, CARDIOVASC RES, V77, P256, DOI 10.1093/cvr/cvm012; Lundberg JO, 2008, NAT REV DRUG DISCOV, V7, P156, DOI [10.1038/nrd2466, 10.1038/nrd2466-c2]; Minamishima S, 2011, CIRCULATION, V124, P1645, DOI 10.1161/CIRCULATIONAHA.111.025395; Minamishima S, 2009, CIRCULATION, V120, P888, DOI 10.1161/CIRCULATIONAHA.108.833491; Modin A, 2001, ACTA PHYSIOL SCAND, V171, P9, DOI 10.1046/j.1365-201x.2001.171001009.x; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Nishida T, 2009, CRIT CARE MED, V37, P256, DOI 10.1097/CCM.0b013e318192face; Periasamy M, 2008, CARDIOVASC RES, V77, P265, DOI 10.1093/cvr/cvm056; Piper HM, 2008, CARDIOVASC RES, V77, P234, DOI 10.1093/cvr/cvm066; Piper HM, 2006, CARDIOVASC RES, V70, P170, DOI 10.1016/j.cardiores.2006.03.010; Prunier F, 2008, CIRCULATION, V118, P614, DOI 10.1161/CIRCULATIONAHA.108.770883; Seddon M, 2007, CARDIOVASC RES, V75, P315, DOI 10.1016/j.cardiores.2007.04.031; Singh RB, 2004, J MOL CELL CARDIOL, V37, P101, DOI 10.1016/j.yjmcc.2004.04.009; Tripatara P, 2007, J AM SOC NEPHROL, V18, P570, DOI 10.1681/ASN.2006050450; Valverde CA, 2010, CARDIOVASC RES, V85, P671, DOI 10.1093/cvr/cvp371; Yannopoulos D, 2011, CRIT CARE MED, V39, P1269, DOI 10.1097/CCM.0b013e31820ed8a6; Yellon DM, 2007, NEW ENGL J MED, V357, P1121, DOI 10.1056/NEJMra071667; Zhang T, 2010, CIRC RES, V106, P354, DOI 10.1161/CIRCRESAHA.109.207423; Zhong WL, 2010, DIABETES RES CLIN PR, V89, P38, DOI 10.1016/j.diabres.2010.03.013	38	6	7	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2013	8	12							e82552	10.1371/journal.pone.0082552	http://dx.doi.org/10.1371/journal.pone.0082552			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282SX	24386101	Green Published, Green Submitted, gold			2023-01-03	WOS:000329194700009
J	Poole, J; Mavromatis, K; Binongo, JN; Khan, A; Li, QN; Khayata, M; Rocco, E; Topel, M; Zhang, X; Brown, C; Corriere, MA; Murrow, J; Sher, S; Clement, S; Ashraf, K; Rashed, A; Kabbany, T; Neuman, R; Morris, A; Ali, A; Hayek, S; Oshinski, J; Yoon, YS; Waller, EK; Quyyumi, AA				Poole, Joseph; Mavromatis, Kreton; Binongo, Jose N.; Khan, Ali; Li, Qunna; Khayata, Mohamed; Rocco, Elizabeth; Topel, Matthew; Zhang, Xin; Brown, Charlene; Corriere, Matthew A.; Murrow, Jonathan; Sher, Salman; Clement, Stephanie; Ashraf, Khuram; Rashed, Amr; Kabbany, Tarek; Neuman, Robert; Morris, Alanna; Ali, Arshad; Hayek, Salim; Oshinski, John; Yoon, Young-sup; Waller, Edmund K.; Quyyumi, Arshed A.			Effect of Progenitor Cell Mobilization With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Peripheral Artery Disease A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANKLE BRACHIAL INDEX; ENDOTHELIAL-CELLS; LIMB ISCHEMIA; GM-CSF; BLOOD; STEM; WALKING; TRANSPLANTATION; REGENERATION; THERAPY	IMPORTANCE Many patients with peripheral artery disease (PAD) have walking impairment despite therapy. Experimental studies in animals demonstrate improved perfusion in ischemic hind limb after mobilization of bone marrow progenitor cells (PCs), but whether this is effective in patients with PAD is unknown. OBJECTIVE To investigate whether therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF) improves exercise capacity in patients with intermittent claudication. DESIGN, SETTING, AND PARTICIPANTS In a phase 2 double-blind, placebo-controlled study, 159 patients (median [SD] age, 64 [8] years; 87% male, 37% with diabetes) with intermittent claudication were enrolled at medical centers affiliated with Emory University in Atlanta, Georgia, between January 2010 and July 2012. INTERVENTIONS Participants were randomized (1:1) to received 4 weeks of subcutaneous injections of GM-CSF (leukine), 500 mu g/day 3 times a week, or placebo. Both groups were encouraged to walk to claudication daily. MAIN OUTCOMES AND MEASURES The primary outcome was peak treadmill walking time (PWT) at 3 months. Secondary outcomes were PWT at 6 months and changes in circulating PC levels, ankle brachial index (ABI), and walking impairment questionnaire (WIQ) and 36-item Short-Form Health Survey (SF-36) scores. RESULTS Of the 159 patients randomized, 80 were assigned to the GM-CSF group. The mean (SD) PWT at 3 months increased in the GM-CSF group from 296 (151) seconds to 405 (248) seconds (mean change, 109 seconds [95% CI, 67 to 151]) and in the placebo group from 308 (161) seconds to 376 (182) seconds (change of 56 seconds [95% CI, 14 to 98]), but this difference was not significant (mean difference in change in PWT, 53 seconds [95% CI, -6 to 112], P = .08). At 3 months, compared with placebo, GM-CSF improved the physical functioning subscore of the SF-36 questionnaire by 11.4 (95% CI, 6.7 to 16.1) vs 4.8 (95% CI, -0.1 to 9.6), with a mean difference in change for GM-CSF vs placebo of 7.5 (95% CI, 1.0 to 14.0; P = .03). Similarly, the distance score of the WIQ improved by 12.5 (95% CI, 6.4 to 18.7) vs 4.8 (95% CI, -0.2 to 9.8) with GM-CSF compared with placebo (mean difference in change, 7.9 [95% CI, 0.2 to 15.7], P = .047). There were no significant differences in the ABI, WIQ distance and speed scores, claudication onset time, or mental or physical component scores of the SF-36 between the groups. CONCLUSIONS AND RELEVANCE Therapy with GM-CSF 3 times a week did not improve treadmill walking performance at the 3-month follow-up. The improvements in some secondary outcomes with GM-CSF suggest that it may warrant further study in patients with claudication.	[Poole, Joseph; Khan, Ali; Khayata, Mohamed; Rocco, Elizabeth; Topel, Matthew; Sher, Salman; Ashraf, Khuram; Rashed, Amr; Kabbany, Tarek; Neuman, Robert; Morris, Alanna; Ali, Arshad; Hayek, Salim; Yoon, Young-sup; Waller, Edmund K.; Quyyumi, Arshed A.] Emory Univ, Sch Med, Div Cardiol, Emory Clin Cardiovasc Res Inst, Atlanta, GA 30322 USA; [Mavromatis, Kreton; Brown, Charlene; Corriere, Matthew A.] Atlanta Vet Affairs Med Ctr, Div Cardiol, Decatur, GA USA; [Binongo, Jose N.; Li, Qunna; Zhang, Xin] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA; [Clement, Stephanie; Oshinski, John] Emory Univ, Sch Med, Dept Radiol, Atlanta, GA 30322 USA; [Murrow, Jonathan] Univ Georgia, Georgia Regents Univ, Augusta, GA USA; [Corriere, Matthew A.] Emory Univ, Sch Med, Div Vasc & Endovasc Surg, Atlanta, GA 30322 USA; [Waller, Edmund K.] Emory Univ, Sch Med, Dept Hematol Oncol, Atlanta, GA 30322 USA	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Emory University; Rollins School Public Health; Emory University; University System of Georgia; Augusta University; University of Georgia; Emory University; Emory University	Quyyumi, AA (corresponding author), Emory Univ, Sch Med, Dept Med, Div Cardiol, 1462 Clifton Rd NE,Ste 507, Atlanta, GA 30322 USA.	aquyyum@emory.edu	Khayata, Mohamed/I-5288-2015; Waller, Edmund K/AAP-3055-2020; Hayek, Salim S./E-6932-2013	Hayek, Salim S./0000-0003-0180-349X; KHAYATA, MOHAMED/0000-0001-8116-4311	National Heart, Blood, and Lung Institute [1RC2HL101515-01]; National Institutes of Health [UL1 RR025008]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [RC2HL101515] Funding Source: NIH RePORTER	National Heart, Blood, and Lung Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the National Heart, Blood, and Lung Institute (1RC2HL101515-01) and by the National Institutes of Health (UL1 RR025008). The GM-CSF was supplied by sanofi-aventis.	Ahimastos AA, 2013, JAMA-J AM MED ASSOC, V309, P453, DOI 10.1001/jama.2012.216237; Arai M, 2006, CIRC J, V70, P1093, DOI 10.1253/circj.70.1093; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; BERENSON RJ, 1992, TRANSPL P, V24, P3032; Buschmann IR, 2001, ATHEROSCLEROSIS, V159, P343, DOI 10.1016/S0021-9150(01)00637-2; BUSSOLINO F, 1991, J CLIN INVEST, V87, P986, DOI 10.1172/JCI115107; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; Fischmeister G, 2000, CURR OPIN HEMATOL, V7, P150, DOI 10.1097/00062752-200005000-00004; Fischmeister G, 1999, ANN HEMATOL, V78, P117, DOI 10.1007/s002770050487; GARDNER AW, 1991, MED SCI SPORT EXER, V23, P402; Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; Hashimoto S, 2001, J IMMUNOL, V167, P3619, DOI 10.4049/jimmunol.167.7.3619; Heiss C, 2005, J AM COLL CARDIOL, V45, P1441, DOI 10.1016/j.jacc.2004.12.074; Hristov M, 2003, ARTERIOSCL THROM VAS, V23, P1185, DOI 10.1161/01.ATV.0000073832.49290.B5; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Krause DS, 1996, BLOOD, V87, P1; LANE TA, 1995, BLOOD, V85, P275, DOI 10.1182/blood.V85.1.275.bloodjournal851275; Lane TA, 1999, TRANSFUSION, V39, P39, DOI 10.1046/j.1537-2995.1999.39199116893.x; McDermott MM, 2007, J AM COLL CARDIOL, V50, P974, DOI 10.1016/j.jacc.2007.05.030; McDermott MM, 2013, JAMA-J AM MED ASSOC, V310, P57, DOI 10.1001/jama.2013.7231; McDermott MM, 2002, ANN INTERN MED, V136, P873, DOI 10.7326/0003-4819-136-12-200206180-00008; McDermott MM, 2001, JAMA-J AM MED ASSOC, V286, P1599; McDermott MM, 2004, JAMA-J AM MED ASSOC, V292, P453, DOI 10.1001/jama.292.4.453; Miraglia S, 1997, BLOOD, V90, P5013, DOI 10.1182/blood.V90.12.5013.5013_5013_5021; Norgren L, 2007, J ENDOVASC THER, V14, P743, DOI 10.1583/1545-1550(2007)14[743:TISFOR]2.0.CO;2; Ostchega Y, 2007, J AM GERIATR SOC, V55, P583, DOI 10.1111/j.1532-5415.2007.01123.x; Rauscher FM, 2003, CIRCULATION, V108, P457, DOI 10.1161/01.CIR.0000082924.75945.48; Rutherford RB, 1997, J VASC SURG, V26, P517, DOI 10.1016/S0741-5214(97)70045-4; Sacramento CB, 2009, J GENE MED, V11, P345, DOI 10.1002/jgm.1298; Seiler C, 2001, CIRCULATION, V104, P2012, DOI 10.1161/hc4201.097835; Shi Qun, 1998, Blood, V92, P362; Subramaniyam V, 2009, AM HEART J, V158, P53, DOI 10.1016/j.ahj.2009.04.014; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8; van Royen N, 2005, CIRCULATION, V112, P1040, DOI 10.1161/CIRCULATIONAHA.104.529552; Zbinden R, 2004, HEART, V90, P945, DOI 10.1136/hrt.2003.018259	40	26	26	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	2013	310	24					2631	2639		10.1001/jama.2013.282540	http://dx.doi.org/10.1001/jama.2013.282540			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277KN	24247554	Green Accepted			2023-01-03	WOS:000328818000015
J	Horanont, T; Phithakkitnukoon, S; Leong, TW; Sekimoto, Y; Shibasaki, R				Horanont, Teerayut; Phithakkitnukoon, Santi; Leong, Tuck W.; Sekimoto, Yoshihide; Shibasaki, Ryosuke			Weather Effects on the Patterns of People's Everyday Activities: A Study Using GPS Traces of Mobile Phone Users	PLOS ONE			English	Article								This study explores the effects that the weather has on people's everyday activity patterns. Temperature, rainfall, and wind speed were used as weather parameters. People's daily activity patterns were inferred, such as place visited, the time this took place, the duration of the visit, based on the GPS location traces of their mobile phones overlaid upon Yellow Pages information. Our analysis of 31,855 mobile phone users allowed us to infer that people were more likely to stay longer at eateries or food outlets, and (to a lesser degree) at retail or shopping areas when the weather is very cold or when conditions are calm (non-windy). When compared to people's regular activity patterns, certain weather conditions affected people's movements and activities noticeably at different times of the day. On cold days, people's activities were found to be more diverse especially after 10AM, showing greatest variations between 2PM and 6PM. A similar trend is observed between 10AM and midnight on rainy days, with people's activities found to be most diverse on days with heaviest rainfalls or on days when the wind speed was stronger than 4 km/h, especially between 10AM-1AM. Finally, we observed that different geographical areas of a large metropolis were impacted differently by the weather. Using data of urban infrastructure to characterize areas, we found strong correlations between weather conditions upon people's accessibility to trains. This study sheds new light on the influence of weather conditions on human behavior, in particular the choice of daily activities and how mobile phone data can be used to investigate the influence of environmental factors on urban dynamics.	[Horanont, Teerayut; Sekimoto, Yoshihide; Shibasaki, Ryosuke] Univ Tokyo, Sch Engn, Dept Civil Engn, Tokyo, Japan; [Phithakkitnukoon, Santi] Open Univ, Comp & Commun Dept, Milton Keynes MK7 6AA, Bucks, England; [Leong, Tuck W.] Univ Technol Sydney, Fac Engn & IT, Sydney, NSW 2007, Australia	University of Tokyo; Open University - UK; University of Technology Sydney	Horanont, T (corresponding author), Univ Tokyo, Sch Engn, Dept Civil Engn, Tokyo, Japan.	teerayut@iis.u-tokyo.ac.jp	Phithakkitnukoon, Santi/E-4204-2015; Leong, Tuck W/C-7936-2017	Phithakkitnukoon, Santi/0000-0002-5716-9363; Leong, Tuck W/0000-0002-1021-9001	DIAS (Data Integration and Analysis System); GRENE (Green Net- work of Excellence) project of Ministry of Education, Culture, Sports, Science and Technology	DIAS (Data Integration and Analysis System); GRENE (Green Net- work of Excellence) project of Ministry of Education, Culture, Sports, Science and Technology	This work was supported by the DIAS (Data Integration and Analysis System) and GRENE (Green Net- work of Excellence) project of Ministry of Education, Culture, Sports, Science and Technology (http://www.mext.go.jp/english/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal M, 2005, DOTF17007 IOW STAT U; Akhtari M, 2011, MICHIGAN J BUSINESS, V4, P51; [Anonymous], DOES IT FEEL; Calabrese F., 2010, 2010 13th International IEEE Conference on Intelligent Transportation Systems (ITSC 2010), P312, DOI 10.1109/ITSC.2010.5625119; CHARRY JM, 1981, J PERS SOC PSYCHOL, V41, P185, DOI 10.1037/0022-3514.41.1.185; COHN EG, 1990, BRIT J CRIMINOL, V30, P51, DOI 10.1093/oxfordjournals.bjc.a047980; Cools M, 2010, TRANSPORT RES REC, P22, DOI 10.3141/2157-03; Eagle N, 2010, SCIENCE, V328, P1029, DOI 10.1126/science.1186605; Edwards C, 2010, NEW ELECTRON, V43, P19; Gonzalez MC, 2009, NATURE, V458, DOI 10.1038/nature07850; HOWARTH E, 1984, BRIT J PSYCHOL, V75, P15, DOI 10.1111/j.2044-8295.1984.tb02785.x; Isaacman S, 2011, LECT NOTES COMPUT SC, V6696, P133, DOI 10.1007/978-3-642-21726-5_9; Maze TH, 2005, TRANSPORT RES REC, P1; Onnela JP, 2007, P NATL ACAD SCI USA, V104, P7332, DOI 10.1073/pnas.0610245104; Patz JA, 2000, ANNU REV PUBL HEALTH, V21, P271, DOI 10.1146/annurev.publhealth.21.1.271; Phithakkitnukoon S, 2012, PLOS ONE, V7; Phithakkitnukoon S, 2010, ACTIVITY AWARE MAP I, P14; Phithakkitnukoon S, 2012, PLOS ONE, V10; SAUNDERS EM, 1993, AM ECON REV, V83, P1337; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; Song CM, 2010, NAT PHYS, V6, P818, DOI 10.1038/NPHYS1760; Song CM, 2010, SCIENCE, V327, P1018, DOI 10.1126/science.1177170; Statistics Bureau Ministry of Internal and Communications, 2006, 2006 EST ENT CENS; Tokyo Metropolitan Archaeological Centre, 1998, OW SIT 3; Trenberth KE, 2002, EFFECTS CHANGING CLI; Tucker P, 2007, PUBLIC HEALTH, V121, P909, DOI 10.1016/j.puhe.2007.04.009; Wang P, 2009, SCIENCE, V324, P1071, DOI 10.1126/science.1167053; Zenrin: Maps to the Future, MAPS FUT TEL PACK	28	60	62	2	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2013	8	12							e81153	10.1371/journal.pone.0081153	http://dx.doi.org/10.1371/journal.pone.0081153			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	276HL	24367481	Green Accepted, Green Published, gold, Green Submitted			2023-01-03	WOS:000328740300003
J	Lee, HY; Lee, GH; Lee, MR; Kim, HK; Kim, NY; Kim, SH; Lee, YC; Kim, HR; Chae, HJ				Lee, Hwa-Young; Lee, Geum-Hwa; Lee, Mi-Rin; Kim, Hye-Kyung; Kim, Nan-Young; Kim, Seung-Hyun; Lee, Yong-Chul; Kim, Hyung-Ryong; Chae, Han-Jung			Eucommia ulmoides Oliver Extract, Aucubin, and Geniposide Enhance Lysosomal Activity to Regulate ER Stress and Hepatic Lipid Accumulation	PLOS ONE			English	Article							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED-PROTEIN RESPONSE; FATTY LIVER-DISEASE; INSULIN-RESISTANCE; SIGNALING PATHWAY; CHO-CELLS; DEGRADATION; APOPTOSIS; TEA; INHIBITION	Eucommia ulmoides Oliver is a natural product widely used as a dietary supplement and medicinal plant. Here, we examined the potential regulatory effects of Eucommia ulmoides Oliver extracts (EUE) on hepatic dyslipidemia and its related mechanisms by in vitro and in vivo studies. EUE and its two active constituents, aucubin and geniposide, inhibited palmitate-induced endoplasmic reticulum (ER) stress, reducing hepatic lipid accumulation through secretion of apolipoprotein B and associated triglycerides and cholesterol in human HepG2 hepatocytes. To determine how EUE diminishes the ER stress response, lysosomal and proteasomal protein degradation activities were analyzed. Although proteasomal activity was not affected, lysosomal enzyme activities including V-ATPase were significantly increased by EUE as well as aucubin and geniposide in HepG2 cells. Treatment with the V-ATPase inhibitor, bafilomycin, reversed the inhibition of ER stress, secretion of apolipoprotein B, and hepatic lipid accumulation induced by EUE or its component, aucubin or geniposide. In addition, EUE was determined to regulate hepatic dyslipidemia by enhancing lysosomal activity and to regulate ER stress in rats fed a high-fat diet. Together, these results suggest that EUE and its active components enhance lysosomal activity, resulting in decreased ER stress and hepatic dyslipidemia.	[Lee, Hwa-Young; Lee, Geum-Hwa; Lee, Mi-Rin; Kim, Hye-Kyung; Chae, Han-Jung] Chonbuk Natl Univ, Dept Pharmacol, Sch Med, Jeonju, Chonbuk, South Korea; [Lee, Hwa-Young; Lee, Geum-Hwa; Lee, Mi-Rin; Kim, Hye-Kyung; Chae, Han-Jung] Chonbuk Natl Univ, Inst Cardiovasc Res, Sch Med, Jeonju, Chonbuk, South Korea; [Kim, Nan-Young; Kim, Seung-Hyun] Yonsei Univ, Yonsei Inst Pharmaceut Sci, Coll Pharm, Inchon, South Korea; [Lee, Yong-Chul] Chonbuk Natl Univ, Dept Internal Med, Sch Med, Jeonju, Chonbuk, South Korea; [Kim, Hyung-Ryong] Wonkwang Univ, Sch Dent, Dept Dent Pharmacol, Iksan, Chonbuk, South Korea	Jeonbuk National University; Jeonbuk National University; Yonsei University; Jeonbuk National University; Wonkwang University	Chae, HJ (corresponding author), Chonbuk Natl Univ, Dept Pharmacol, Sch Med, Jeonju, Chonbuk, South Korea.	hjchae@chonbuk.ac.kr		Chae, Han-Jung/0000-0003-4190-9889	National Research Foundation [2012R1A2A1A3001907, 2008-0062279]; Korea Health Industry Development Institute [A121931-1211-0000200]	National Research Foundation; Korea Health Industry Development Institute(Korea Health Industry Development Institute (KHIDI))	This study was supported by the National Research Foundation (2012R1A2A1A3001907 and 2008-0062279) and Korea Health Industry Development Institute (A121931-1211-0000200). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bobrovnikova-Marjon E, 2008, P NATL ACAD SCI USA, V105, P16314, DOI 10.1073/pnas.0808517105; Cao J, 2012, MOL CELL BIOCHEM, V364, P115, DOI 10.1007/s11010-011-1211-9; Carabelli J, 2011, J CELL MOL MED, V15, P1329, DOI 10.1111/j.1582-4934.2010.01128.x; Choi MS, 2008, AM J CHINESE MED, V36, P81, DOI 10.1142/S0192415X08005606; Dunn Winston, 2008, Curr Gastroenterol Rep, V10, P67, DOI 10.1007/s11894-008-0011-1; Farrell GC, 2006, HEPATOLOGY, V43, pS99, DOI 10.1002/hep.20973; Feldstein AE, 2006, AM J PHYSIOL-GASTR L, V290, pG1339, DOI 10.1152/ajpgi.00509.2005; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Foufelle F, 2007, M S-MED SCI, V23, P291, DOI 10.1051/medsci/2007233291; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Fujita E, 2007, HUM MOL GENET, V16, P618, DOI 10.1093/hmg/ddm002; Gentile CL, 2008, J NUTR BIOCHEM, V19, P567, DOI 10.1016/j.jnutbio.2007.10.001; Hebert DN, 2007, PHYSIOL REV, V87, P1377, DOI 10.1152/physrev.00050.2006; Hsieh CL, 2000, LIFE SCI, V66, P1387, DOI 10.1016/S0024-3205(00)00450-1; Ishida Y, 2009, MOL BIOL CELL, V20, P2744, DOI 10.1091/mbc.E08-11-1092; Jung TW, 2012, BIOCHEM BIOPH RES CO, V422, P229, DOI 10.1016/j.bbrc.2012.04.129; Kawai A, 2007, AUTOPHAGY, V3, P154, DOI 10.4161/auto.3634; Kharroubi I, 2004, ENDOCRINOLOGY, V145, P5087, DOI 10.1210/en.2004-0478; Kurz T, 2008, HISTOCHEM CELL BIOL, V129, P389, DOI 10.1007/s00418-008-0394-y; Lai WL, 2008, EXP CELL RES, V314, P1667, DOI 10.1016/j.yexcr.2008.02.002; Lee GH, 2011, INT J BIOCHEM CELL B, V43, P1469, DOI 10.1016/j.biocel.2011.06.010; Li H, 2009, J AOAC INT, V92, P103; LI ZL, 1983, SCI SIN B-CHEM B A M, V26, P33; Lin J, 2011, J ZHEJIANG UNIV-SC B, V12, P47, DOI 10.1631/jzus.B1000057; Luo LF, 2010, J ETHNOPHARMACOL, V129, P238, DOI 10.1016/j.jep.2010.03.019; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; Miura Y, 2001, J NUTR, V131, P27, DOI 10.1093/jn/131.1.27; Nakamura T, 1997, MUTAT RES-GEN TOX EN, V388, P7, DOI 10.1016/S1383-5718(96)00096-4; Ota T, 2008, J CLIN INVEST, V118, P316, DOI 10.1172/JCI32752; Park S, 2011, J HEPATOL, V54, P984, DOI 10.1016/j.jhep.2010.08.019; Puri P, 2008, GASTROENTEROLOGY, V134, P568, DOI 10.1053/j.gastro.2007.10.039; Stangl V, 2006, MOL NUTR FOOD RES, V50, P218, DOI 10.1002/mnfr.200500118; Su QZ, 2009, HEPATOLOGY, V50, P77, DOI 10.1002/hep.22960; Temesvari LA, 1996, J CELL SCI, V109, P663; Tsai Yien Che, 2010, Genes Cancer, V1, P764; Zhang Q, 2013, MOLECULES, V18, P1857, DOI 10.3390/molecules18021857	37	19	21	0	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2013	8	12							e81349	10.1371/journal.pone.0081349	http://dx.doi.org/10.1371/journal.pone.0081349			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276EG	24349058	Green Published, Green Submitted, gold			2023-01-03	WOS:000328730300026
J	Sarangthem, V; Cho, EA; Bae, SM; Singh, TD; Kim, SJ; Kim, S; Jeon, WB; Lee, BH; Park, RW				Sarangthem, Vijaya; Cho, Eun A.; Bae, Sang Mun; Singh, Thoudam Debraj; Kim, Sun-Ji; Kim, Soyoun; Jeon, Won Bae; Lee, Byung-Heon; Park, Rang-Woon			Construction and Application of Elastin Like Polypeptide Containing IL-4 Receptor Targeting Peptide	PLOS ONE			English	Article							FREE-ENERGY TRANSDUCTION; PROTEIN-BASED POLYMERS; INTERLEUKIN-4 RECEPTOR; RECOMBINANT PROTEINS; CARCINOMA-CELLS; CANCER-THERAPY; DRUG-DELIVERY; TUMOR-CELLS; EXPRESSION; TEMPERATURE	Various human solid tumors highly express IL-4 receptors which amplify the expression of some of anti-apoptotic proteins, preventing drug-induced cancer cell death. Thus, IL-4 receptor targeted drug delivery can possibly increase the therapeutic efficacy in cancer treatment. Macromolecular carriers with multivalent targeting moieties offered great advantages in cancer therapy as they not only increase the plasma half-life of the drug but also allow delivery of therapeutic drugs to the cancer cells with higher specificity, minimizing the deleterious effects of the drug on normal cells. In this study we designed a library of elastin like polypeptide (ELP) polymers containing tumor targeting AP1 peptide using recursive directional ligation method. AP1 was previously discovered as an atherosclerotic plaque and breast tumor tissue homing peptide using phage display screening method, and it can selectively bind to the interleukin 4 receptor (IL-4R). The fluorescently labeled [AP1-V-12](6), an ELP polymer containing six AP1 enhanced tumor-specific targeting ability and uptake efficiency in H226 and MDA-MB-231 cancer cell lines in vitro. Surface plasmon resonance analysis showed that multivalent presentation of the targeting ligand in the ELP polymer increased the binding affinity towards IL-4 receptor compared to free peptide. The binding of [AP1-V-12](6) to cancer cells was remarkably reduced when IL-4 receptors were blocked by antibody against IL-4 receptor further confirmed its binding. Importantly, the Cy5.5-labeled [AP1-V-12](6) demonstrated excellent homing and longer retention in tumor tissues in MDA-MB-231 xenograft mouse model. Immunohistological studies of tumor tissues further validated the targeting efficiency of [AP1-V-12](6) to tumor tissue. These results indicate that designed [AP1-V-12](6) can serve as a novel carrier for selective delivery of therapeutic drugs to tumors.	[Sarangthem, Vijaya; Cho, Eun A.; Bae, Sang Mun; Kim, Sun-Ji; Kim, Soyoun; Lee, Byung-Heon; Park, Rang-Woon] Kyungpook Natl Univ, Sch Med, Cell & Matrix Res Inst, Dept Biochem & Cell Biol, Taegu, South Korea; [Singh, Thoudam Debraj] Kyungpook Natl Univ, Sch Med, Dept Nucl Med, Taegu, South Korea; [Jeon, Won Bae] Daegu Gyeongbuk Inst Sci & Technol, Lab Biochem & Cellular Engn, Div NanoBioTechnol, Taegu, South Korea	Kyungpook National University; Kyungpook National University; Daegu Gyeongbuk Institute of Science & Technology (DGIST)	Park, RW (corresponding author), Kyungpook Natl Univ, Sch Med, Cell & Matrix Res Inst, Dept Biochem & Cell Biol, Taegu, South Korea.	nwpark@knu.ac.kr	Sarangthem, Vijaya/AAX-7421-2020; Kim, Soyoun/Y-1276-2018	Vijaya Devi, Sarangthem/0000-0002-6924-0307; SINGH, THOUDAM DEBRAJ/0000-0003-0750-9136	Ministry of Knowledge Economy (MEK) [RTI04-01-01]; Regional Technology Innovation Program and R&D program of MOTIE/KEIT [10040393]	Ministry of Knowledge Economy (MEK)(Ministry of Trade, Industry & Energy (MOTIE), Republic of Korea); Regional Technology Innovation Program and R&D program of MOTIE/KEIT	This research was supported by the Ministry of Knowledge Economy (MEK) by grant no. RTI04-01-01 from the Regional Technology Innovation Program and R&D program of MOTIE/KEIT (10040393, Development and commercialization of molecular diagnostic technologies for lung cancer through clinical validation). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrews AL, 2006, J IMMUNOL, V176, P7456, DOI 10.4049/jimmunol.176.12.7456; Bidwell GL, 2007, BIOCHEM PHARMACOL, V73, P620, DOI 10.1016/j.bcp.2006.10.028; Bidwell GL, 2012, CANCER LETT, V319, P136, DOI 10.1016/j.canlet.2011.12.042; Bidwell GL, 2005, MOL CANCER THER, V4, P1076, DOI 10.1158/1535-7163.MCT-04-0253; Carlson KT, 2004, DESIGN SELECTION, V17; Conticello C, 2004, J IMMUNOL, V172, P5467, DOI 10.4049/jimmunol.172.9.5467; Dreher MR, 2003, J CONTROL RELEASE, V91, P31, DOI 10.1016/S0168-3659(03)00216-5; Duncan R, 2006, NAT REV CANCER, V6, P688, DOI 10.1038/nrc1958; Hassouneh W, 2012, BIOMACROMOLECULES, V13, P1598, DOI 10.1021/bm300321n; He XF, 2011, MOL PHARMACEUT, V8, P430, DOI 10.1021/mp100266g; Hong HY, 2008, J CELL MOL MED, V12, P2003, DOI 10.1111/j.1582-4934.2008.00189.x; Husain SR, 1997, MOL MED, V3, P327, DOI 10.1007/BF03401811; Jeon WB, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-61; Jeon WB, 2011, J BIOMED MATER RES A, V97A, P152, DOI 10.1002/jbm.a.33041; Kawakami K, 2000, CANCER RES, V60, P2981; Kawakami M, 2002, CLIN CANCER RES, V8, P3503; Li ZJ, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-S1-S1; Liu S, 2009, MACROMOLECULES, V42, P3, DOI 10.1021/ma801782q; Massodi I, 2005, J CONTROL RELEASE, V108, P396, DOI 10.1016/j.jconrel.2005.08.007; McElroy CA, 2009, STRUCTURE, V17, P54, DOI 10.1016/j.str.2008.10.019; Meyer DE, 2002, BIOMACROMOLECULES, V3, P357, DOI 10.1021/bm015630n; Meyer DE, 2004, BIOMACROMOLECULES, V5, P846, DOI 10.1021/bm034215n; Meyer DE, 1999, NAT BIOTECHNOL, V17, P1112, DOI 10.1038/15100; OBIRI NI, 1994, CLIN EXP IMMUNOL, V95, P148; OBIRI NI, 1993, J CLIN INVEST, V91, P88, DOI 10.1172/JCI116205; Park Y, 2008, J CONTROL RELEASE, V128, P217, DOI 10.1016/j.jconrel.2008.03.019; Raucher D, 2001, CANCER RES, V61, P7163; Roca H, 2012, J CELL BIOCHEM, V113, P1569, DOI 10.1002/jcb.24025; Ruoslahti E, 2010, J CELL BIOL, V188, P759, DOI 10.1083/jcb.200910104; Shamji MF, 2008, J CONTROL RELEASE, V129, P179, DOI 10.1016/j.jconrel.2008.04.021; Shamji MF, 2007, ARTHRITIS RHEUM-US, V56, P3650, DOI 10.1002/art.22952; Simnick AJ, 2011, J CONTROL RELEASE, V155, P144, DOI 10.1016/j.jconrel.2011.06.044; Tatham AS, 2000, TRENDS BIOCHEM SCI, V25, P567, DOI 10.1016/S0968-0004(00)01670-4; Todaro M, 2008, CELL DEATH DIFFER, V15, P762, DOI 10.1038/sj.cdd.4402305; Trabbic-Carlson K, 2004, PROTEIN SCI, V13, P3274, DOI 10.1110/ps.04931604; URRY DW, 1991, J BIOACT COMPAT POL, V6, P263, DOI 10.1177/088391159100600306; URRY DW, 1992, PROG BIOPHYS MOL BIO, V57, P23, DOI 10.1016/0079-6107(92)90003-O; URRY DW, 1991, J AM CHEM SOC, V113, P4346, DOI 10.1021/ja00011a057; Urry DW, 1997, J PHYS CHEM B, V101, P11007, DOI 10.1021/jp972167t; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Wu XL, 2010, BIOCONJUGATE CHEM, V21, P208, DOI 10.1021/bc9005283; YUAN F, 1995, CANCER RES, V55, P3752	42	29	31	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2013	8	12							e81891	10.1371/journal.pone.0081891	http://dx.doi.org/10.1371/journal.pone.0081891			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275VW	24339977	gold, Green Submitted, Green Published			2023-01-03	WOS:000328707400050
J	Brand, JS; Czene, K; Eriksson, L; Trinh, T; Bhoo-Pathy, N; Hall, P; Celebioglu, F				Brand, Judith S.; Czene, Kamila; Eriksson, Louise; Thang Trinh; Bhoo-Pathy, Nirmala; Hall, Per; Celebioglu, Fuat			Influence of Lifestyle Factors on Mammographic Density in Postmenopausal Women	PLOS ONE			English	Article							BREAST-CANCER RISK; RECREATIONAL PHYSICAL-ACTIVITY; HORMONE REPLACEMENT THERAPY; ALCOHOL-CONSUMPTION; PARENCHYMAL PATTERNS; CIGARETTE-SMOKING; ASSOCIATION; ESTROGENS; DIET	Background: Mammographic density is a strong risk factor for breast cancer. Apart from hormone replacement therapy (HRT), little is known about lifestyle factors that influence breast density. Methods: We examined the effect of smoking, alcohol and physical activity on mammographic density in a population-based sample of postmenopausal women without breast cancer. Lifestyle factors were assessed by a questionnaire and percentage and area measures of mammographic density were measured using computer-assisted software. General linear models were used to assess the association between lifestyle factors and mammographic density and effect modification by body mass index (BMI) and HRT was studied. Results: Overall, alcohol intake was positively associated with percent mammographic density (P trend = 0.07). This association was modified by HRT use (P interaction = 0.06): increasing alcohol intake was associated with increasing percent density in current HRT users (P trend = 0.01) but not in non-current users (P trend = 0.82). A similar interaction between alcohol and HRT was found for the absolute dense area, with a positive association being present in current HRT users only (P interaction = 0.04). No differences in mammographic density were observed across categories of smoking and physical activity, neither overall nor in stratified analyses by BMI and HRT use. Conclusions: Increasing alcohol intake is associated with an increase in mammography density, whereas smoking and physical activity do not seem to influence density. The observed interaction between alcohol and HRT may pose an opportunity for HRT users to lower their mammographic density and breast cancer risk.	[Brand, Judith S.; Czene, Kamila; Eriksson, Louise; Thang Trinh; Hall, Per] Karolinska Inst, Inst Med Epidemiol & Biostat, Stockholm, Sweden; [Bhoo-Pathy, Nirmala] Hosp Kuala Lumpur, Natl Clin Res Ctr, Kuala Lumpur, Malaysia; [Bhoo-Pathy, Nirmala] Univ Malaya, Fac Med, Julius Ctr Univ Malaya, Kuala Lumpur, Malaysia; [Celebioglu, Fuat] Sodersjukhuset KI SOS, Dept Clin Sci & Educ, Stockholm, Sweden	Karolinska Institutet; Universiti Malaya	Brand, JS (corresponding author), Karolinska Inst, Inst Med Epidemiol & Biostat, Nobels Vag 12A, Stockholm, Sweden.	judith.brand@ki.se	Pathy, Nirmala Bhoo/C-1228-2010	Pathy, Nirmala Bhoo/0000-0003-0568-8863; Brand, Judith S./0000-0002-3720-1274; Czene, Kamila/0000-0002-3233-5695	Marit and Hans Rausing's Initiative against Breast Cancer; Swedish Cancer Society [5128-B07-01PAF, CAN 2010/807]	Marit and Hans Rausing's Initiative against Breast Cancer; Swedish Cancer Society(Swedish Cancer Society)	This work was supported by Marit and Hans Rausing's Initiative against Breast Cancer and the Swedish Cancer Society [grant no: CAN 2010/807]. Kamila Czene was supported by the Swedish Cancer Society (grant number 5128-B07-01PAF). The funding resources had no role in the study design, data collection, analysis and interpretation of the data, writing of the manuscript or the decision to submit the manuscript for publication.	Beral V, 2002, BRIT J CANCER, V87, P1234, DOI 10.1038/sj.bjc.6600596; Boyd N, 2002, CANCER EPIDEM BIOMAR, V11, P1048; Bremnes Y, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1782; Butler LM, 2010, CANCER CAUSE CONTROL, V21, P301, DOI 10.1007/s10552-009-9462-4; BYNG JW, 1994, PHYS MED BIOL, V39, P1629, DOI 10.1088/0031-9155/39/10/008; Cabanes A, 2011, BREAST CANCER RES TR, V129, P135, DOI 10.1007/s10549-011-1414-5; Chen WY, 2002, ANN INTERN MED, V137, P798, DOI 10.7326/0003-4819-137-10-200211190-00008; Colditz GA, 1998, JNCI-J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814; Dorgan JF, 2001, JNCI-J NATL CANCER I, V93, P710, DOI 10.1093/jnci/93.9.710; Eriksson L, 2012, BREAST CANCER RES TR, V134, P859, DOI 10.1007/s10549-012-2127-0; Gapstur SM, 2003, CANCER EPIDEM BIOMAR, V12, P1074; Ginsburg ES, 1996, JAMA-J AM MED ASSOC, V276, P1747, DOI 10.1001/jama.276.21.1747; Irwin ML, 2006, BREAST CANCER RES TR, V95, P171, DOI 10.1007/s10549-005-9063-1; LANDS WEM, 1991, AM J CLIN NUTR, V54, P47, DOI 10.1093/ajcn/54.1.47; Li CI, 2010, J NATL CANCER I, V102, P1422, DOI 10.1093/jnci/djq316; Li Y, 2009, EUR J CANCER, V45, P843, DOI 10.1016/j.ejca.2008.11.001; Luo JH, 2011, AM J EPIDEMIOL, V174, P919, DOI 10.1093/aje/kwr192; Magnusson C, 1998, INT J CANCER, V76, P29, DOI 10.1002/(SICI)1097-0215(19980330)76:1<29::AID-IJC6>3.3.CO;2-1; Masala G, 2006, INT J CANCER, V118, P1782, DOI 10.1002/ijc.21558; Masala G, 2009, INT J CANCER, V124, P1654, DOI 10.1002/ijc.24099; Maskarinec G, 2006, INT J CANCER, V118, P2579, DOI 10.1002/ijc.21705; McCormack VA, 2006, CANCER EPIDEM BIOMAR, V15, P1159, DOI 10.1158/1055-9965.EPI-06-0034; McTiernan A, 2004, CANCER RES, V64, P2923, DOI 10.1158/0008-5472.CAN-03-3393; Modugno F, 2006, BREAST CANCER RES TR, V97, P157, DOI 10.1007/s10549-005-9105-8; Narod SA, 2011, NAT REV CLIN ONCOL, V8, P669, DOI 10.1038/nrclinonc.2011.110; Nielsen NR, 2008, INT J CANCER, V122, P1109, DOI 10.1002/ijc.23195; Onland-Moret NC, 2005, J CLIN ENDOCR METAB, V90, P1414, DOI 10.1210/jc.2004-0614; Peters TM, 2008, AM J EPIDEMIOL, V167, P579, DOI 10.1093/aje/kwm350; Qureshi SA, 2012, SPRINGERPLUS, V1, DOI 10.1186/2193-1801-1-75; Qureshi SA, 2012, BREAST CANCER RES TR, V131, P993, DOI 10.1007/s10549-011-1812-8; Reeves KW, 2007, CANCER EPIDEM BIOMAR, V16, P934, DOI 10.1158/1055-9965.EPI-06-0732; Royston P, 2009, STATA J, V9, P466, DOI 10.1177/1536867X0900900308; Rutter CM, 2001, JAMA-J AM MED ASSOC, V285, P171, DOI 10.1001/jama.285.2.171; Sala E, 2000, BRIT J CANCER, V83, P121, DOI 10.1054/bjoc.2000.1151; Shepherd JA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3081; Singletary KW, 2001, JAMA-J AM MED ASSOC, V286, P2143, DOI 10.1001/jama.286.17.2143; Siozon CC, 2006, INT J CANCER, V119, P1695, DOI 10.1002/ijc.22020; Slattery ML, 2007, ANN EPIDEMIOL, V17, P342, DOI 10.1016/j.annepidem.2006.10.017; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; Sterne Jonathan A C, 2009, BMJ, V338, pb2393, DOI 10.1136/bmj.b2393; Vachon CM, 2000, CANCER EPIDEM BIOMAR, V9, P151; Vachon CM, 2000, CANCER CAUSE CONTROL, V11, P653, DOI 10.1023/A:1008926607428; Westerterp Klaas R, 2004, Nutr Metab (Lond), V1, P5; Wu YL, 2013, BREAST CANCER RES TR, V137, P869, DOI 10.1007/s10549-012-2396-7; Xue F, 2011, ARCH INTERN MED, V171, P125, DOI 10.1001/archinternmed.2010.503; Yaghjyan L, 2012, BRIT J CANCER, V106, P996, DOI 10.1038/bjc.2012.1; Yaghjyan L, 2012, BREAST CANCER RES TR, V135, P367, DOI 10.1007/s10549-012-2152-z; Zhang SMM, 2007, AM J EPIDEMIOL, V165, P667, DOI 10.1093/aje/kwk054	48	33	33	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2013	8	12							e81876	10.1371/journal.pone.0081876	http://dx.doi.org/10.1371/journal.pone.0081876			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275VD	24349146	gold, Green Published, Green Submitted			2023-01-03	WOS:000328705200054
J	Wang, HL; Geng, Y; Han, B; Qiang, J; Li, XL; Sun, MY; Wang, Q; Wang, MW				Wang, Hualong; Geng, Yuan; Han, Bing; Qiang, Jing; Li, Xiaoli; Sun, Meiyu; Wang, Qian; Wang, Mingwei			Repetitive Transcranial Magnetic Stimulation Applications Normalized Prefrontal Dysfunctions and Cognitive-Related Metabolic Profiling in Aged Mice	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; CHROMATOGRAPHY/MASS SPECTROMETRY; RESONANCE-SPECTROSCOPY; SYNAPTIC PLASTICITY; AVOIDANCE-RESPONSE; BRAIN; RAT; CHOLESTEROL; HIPPOCAMPAL	Chronic high-frequency repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation technique that has recently received increasing interests as a therapeutic procedure for neurodegenerative diseases. To identify the metabolism mechanism underlying the improving effects of rTMS, we observed that high frequency (25Hz) rTMS for 14 days could reverse the decline of the performance of the passive avoidance task in aged mice. We further investigated the metabolite profiles in the prefrontal cortex (PFC) in those mice and found that rTMS could also reverse the metabolic abnormalities of gamma-aminobutyric acid, N-acetyl aspartic, and cholesterol levels to the degree similar to the young mice. These data suggested that the rTMS could ameliorate the age-related cognitive impairment and improving the metabolic profiles in PFC, and potentially can be used to improve cognitive decline in the elderly.	[Wang, Hualong; Han, Bing; Qiang, Jing; Li, Xiaoli; Sun, Meiyu; Wang, Qian; Wang, Mingwei] Hebei Med Univ, Hosp 1, Dept Neurol, Shijiazhuang, Hebei, Peoples R China; [Geng, Yuan; Wang, Mingwei] Brain Aging & Cognit Neurosci Lab Hebei Prov, Shijiazhuang, Hebei, Peoples R China	Hebei Medical University	Wang, MW (corresponding author), Hebei Med Univ, Hosp 1, Dept Neurol, Shijiazhuang, Hebei, Peoples R China.	wmwsjz@163.com	Li, Xiaoli/GYQ-7384-2022		973 special preliminary projects [2010CB535005]	973 special preliminary projects	This work was supported by grants from 973 special preliminary projects (2010CB535005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed MA, 2012, J NEUROL, V259, P83, DOI 10.1007/s00415-011-6128-4; Ahmed Z, 2006, BIOELECTROMAGNETICS, V27, P288, DOI 10.1002/bem.20211; Angelie E, 2001, AM J NEURORADIOL, V22, P119; Chen GH, 2004, PHYSIOL BEHAV, V83, P531, DOI 10.1016/j.physbeh.2004.09.012; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; Demougeot C, 2001, J NEUROCHEM, V77, P408, DOI 10.1046/j.1471-4159.2001.00285.x; Eckert GP, 2007, NEUROSCI LETT, V423, P47, DOI 10.1016/j.neulet.2007.05.063; Foster TC, 2012, PROG NEUROBIOL, V96, P283, DOI 10.1016/j.pneurobio.2012.01.007; Giovannini MG, 2005, NEUROSCIENCE, V136, P15, DOI 10.1016/j.neuroscience.2005.07.046; Guse B, 2010, J NEURAL TRANSM, V117, P105, DOI 10.1007/s00702-009-0333-7; Hallett M, 2007, NEURON, V55, P187, DOI 10.1016/j.neuron.2007.06.026; Hellmann J, 2012, EUR ARCH PSY CLIN N, V262, P87, DOI 10.1007/s00406-011-0217-3; Hirsch-Reinshagen V, 2009, MOL CELL BIOCHEM, V326, P121, DOI 10.1007/s11010-008-0012-2; Hooijmans CR, 2008, EUR J PHARMACOL, V585, P176, DOI 10.1016/j.ejphar.2007.11.081; Jansen D, 2012, J ALZHEIMERS DIS, V31, P813, DOI 10.3233/JAD-2012-120298; Jia LW, 2007, J PHARMACEUT BIOMED, V43, P646, DOI 10.1016/j.jpba.2006.07.040; Jonsson P, 2005, ANALYST, V130, P701, DOI 10.1039/b501890k; Keck ME, 2000, EUR J NEUROSCI, V12, P3713, DOI 10.1046/j.1460-9568.2000.00243.x; Kellert M, 2008, CHEM RES TOXICOL, V21, P761, DOI 10.1021/tx7004212; Kim J, 2009, NEURON, V63, P287, DOI 10.1016/j.neuron.2009.06.026; Kim SH, 2012, NEUROSCI RES, V74, P256, DOI 10.1016/j.neures.2012.08.008; Lasarge CL, 2009, NEUROSCIENCE, V164, P941, DOI 10.1016/j.neuroscience.2009.08.055; Ma J, 2013, NEUROCHEM INT, V62, P84, DOI 10.1016/j.neuint.2012.11.010; Marjanska M, 2013, MOVEMENT DISORD, V28, P201, DOI 10.1002/mds.25279; Meng JR, 2012, ANAL CHIM ACTA, V710, P125, DOI 10.1016/j.aca.2011.09.033; Michael N, 2003, EUR J NEUROSCI, V17, P2462, DOI 10.1046/j.1460-9568.2003.02683.x; Morrison JH, 2012, NAT REV NEUROSCI, V13, P240, DOI 10.1038/nrn3200; Paban V, 2010, EUR J NEUROSCI, V31, P1063, DOI 10.1111/j.1460-9568.2010.07126.x; Romanova GA, 2010, B EXP BIOL MED+, V149, P289, DOI 10.1007/s10517-010-0929-9; Tisserand DJ, 2003, CORTEX, V39, P1107, DOI 10.1016/S0010-9452(08)70880-3; Toman RE, 2000, J NEUROTRAUM, V17, P891, DOI 10.1089/neu.2000.17.891; Tremblay S, 2013, J NEUROPHYSIOL, V109, P1343, DOI 10.1152/jn.00704.2012; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4; Vlachos A, 2012, J NEUROSCI, V32, P17514, DOI 10.1523/JNEUROSCI.0409-12.2012; Wang L, 2002, P NATL ACAD SCI USA, V99, P13878, DOI 10.1073/pnas.172510899; Wang Y, 2008, ANAL CHEM, V80, P4680, DOI 10.1021/ac8002402; Wu H, 2009, J CHROMATOGR B, V877, P3111, DOI 10.1016/j.jchromb.2009.07.039; Yao H, 2010, MOL BIOSYST, V6, P1061, DOI 10.1039/b925612a; Yin PY, 2008, J CHROMATOGR B, V871, P322, DOI 10.1016/j.jchromb.2008.05.043; Yoshiike Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003029; Zhang XR, 2009, NEUROCHEM INT, V54, P481, DOI 10.1016/j.neuint.2009.02.004	41	13	15	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 22	2013	8	11							e81482	10.1371/journal.pone.0081482	http://dx.doi.org/10.1371/journal.pone.0081482			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259QP	24278445	Green Published, gold, Green Submitted			2023-01-03	WOS:000327541700065
J	Zimmermann, C; Swami, N; Krzyzanowska, M; Hannon, B; Leighl, N; Oza, A; Moore, M; Rydall, A; Rodin, G; Tannock, I; Donner, A; Lo, C				Zimmermann, Camilla; Swami, Nadia; Krzyzanowska, Monika; Hannon, Breffni; Leighl, Natasha; Oza, Amit; Moore, Malcolm; Rydall, Anne; Rodin, Gary; Tannock, Ian; Donner, Allan; Lo, Christopher			Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial	LANCET			English	Article							QUALITY-OF-LIFE; INTEGRATION; PEOPLE	Background Patients with advanced cancer have reduced quality of life, which tends to worsen towards the end of life. We assessed the effect of early palliative care in patients with advanced cancer on several aspects of quality of life. Methods The study took place at the Princess Margaret Cancer Centre (Toronto, ON, Canada), between Dec 1, 2006, and Feb 28, 2011. 24 medical oncology clinics were cluster randomised (in a 1:1 ratio, using a computer-generated sequence, stratified by clinic size and tumour site [four lung, eight gastrointestinal, four genitourinary, six breast, two gynaecological]), to consultation and follow-up (at least monthly) by a palliative care team or to standard cancer care. Complete masking of interventions was not possible; however, patients provided written informed consent to participate in their own study group, without being informed of the existence of another group. Eligible patients had advanced cancer, European Cooperative Oncology Group performance status of 0-2, and a clinical prognosis of 6-24 months. Quality of life (Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being [FACIT-Sp] scale and Quality of Life at the End of Life [QUAL-E] scale), symptom severity (Edmonton Symptom Assessment System [ESAS]), satisfaction with care (FAMCARE-P16), and problems with medical interactions (Cancer Rehabilitation Evaluation System Medical Interaction Subscale [CARES-MIS]) were measured at baseline and monthly for 4 months. The primary outcome was change score for FACIT-Sp at 3 months. Secondary endpoints included change score for FACIT-Sp at 4 months and change scores for other scales at 3 and 4 months. This trial is registered with ClinicalTrials.gov, number NCT01248624. Findings 461 patients completed baseline measures (228 intervention, 233 control); 393 completed at least one follow-up assessment. At 3-months, there was a non-significant difference in change score for FACIT-Sp between intervention and control groups (3 . 56 points [95% CI -0.27 to 7.40], p = 0.07), a significant difference in QUAL-E (2.25 [0.01 to 4.49], p = 0.05) and FAMCARE-P16 (3.79 [1.74 to 5.85], p = 0.0003), and no difference in ESAS (-1.70 [-5.26 to 1.87], p = 0.33) or CARES-MIS (-0.66 [-2.25 to 0.94], p = 0.40). At 4 months, there were significant differences in change scores for all outcomes except CARES-MIS. All differences favoured the intervention group. Interpretation Although the difference in quality of life was non-significant at the primary endpoint, this trial shows promising findings that support early palliative care for patients with advanced cancer.	[Zimmermann, Camilla; Krzyzanowska, Monika; Hannon, Breffni; Leighl, Natasha; Oza, Amit; Moore, Malcolm; Tannock, Ian] Univ Toronto, Dept Med, Div Med Oncol & Haematol, Toronto, ON, Canada; [Zimmermann, Camilla; Rodin, Gary; Lo, Christopher] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Zimmermann, Camilla; Swami, Nadia; Hannon, Breffni; Rydall, Anne; Rodin, Gary; Lo, Christopher] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Psychosocial Oncol & Palliat Care, Toronto, ON, Canada; [Krzyzanowska, Monika; Leighl, Natasha; Oza, Amit; Moore, Malcolm; Tannock, Ian] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med Oncol, Toronto, ON, Canada; [Zimmermann, Camilla; Rodin, Gary; Tannock, Ian] Univ Hlth Network, Princess Margaret Canc Ctr, Campbell Family Canc Res Inst, Toronto, ON, Canada; [Donner, Allan] Univ Western Ontario, London, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Western University (University of Western Ontario)	Zimmermann, C (corresponding author), Princess Margaret Canc Ctr, Dept Psychosocial Oncol & Palliat Care, Toronto, ON, Canada.	camilla.zimmermann@uhn.ca	Harding, Richard/G-9729-2012; Krzyzanowska, Monika K./ABG-3505-2020; Lo, Chris/AFJ-9787-2022	Krzyzanowska, Monika K./0000-0001-5533-7418; Lo, Chris/0000-0003-2171-6254; Rydall, Anne/0000-0002-4692-9101; Zimmermann, Camilla/0000-0003-4889-0244; Rodin, Gary/0000-0002-6626-6974; Oza, Amit/0000-0002-9510-8641	Canadian Cancer Society [017257, 020509]; Ontario Ministry of Health and Long Term Care; Rose Family Chair in Supportive Care, Faculty of Medicine, University of Toronto	Canadian Cancer Society(Canadian Cancer Society (CCS)); Ontario Ministry of Health and Long Term Care(Ministry of Health and Long-Term Care, Ontario); Rose Family Chair in Supportive Care, Faculty of Medicine, University of Toronto	Results of this study were presented, in part, at the American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; June 4, 2012; and at Best of ASCO, 2012. This study was funded by grants 017257 and 020509 from the Canadian Cancer Society (CZ) and by the Ontario Ministry of Health and Long Term Care. CZ is also supported by the Rose Family Chair in Supportive Care, Faculty of Medicine, University of Toronto. The views expressed in the study do not necessarily represent those of the sponsors. We thank the patients who participated in this study, and their caregivers. We thank the medical oncologists who referred patients to this study, and the clinical and administrative staff of the palliative care team at Princess Margaret Cancer Centre. We thank Debika Burman, Nanor Kevork, and Ashley Pope (Department of Psychosocial Oncology and Palliative Care, Princess Margaret Cancer Centre) for their assistance with preparation of study materials, recruitment of patients, and data entry and preparation.	Bakitas M, 2009, JAMA-J AM MED ASSOC, V302, P741, DOI 10.1001/jama.2009.1198; Bruera E, 1991, J Palliat Care, V7, P6; Campbell Marion K, 2012, BMJ, V345, pe5661, DOI 10.1136/bmj.e5661; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cohen J., 2013, STAT POWER ANAL BEHA; Craig Peter, 2008, BMJ, V337, pa1655, DOI 10.1136/bmj.a1655; de Raaf PJ, 2013, J CLIN ONCOL, V31, P716, DOI 10.1200/JCO.2012.44.4216; El Osta B, 2008, J PALLIAT MED, V11, P51, DOI 10.1089/jpm.2007.0103; Fairhurst K, 1996, J Health Serv Res Policy, V1, P77; Follwell M, 2009, J CLIN ONCOL, V27, P206, DOI 10.1200/JCO.2008.17.7568; Giesinger JM, 2011, J PALLIAT MED, V14, P904, DOI 10.1089/jpm.2011.0086; Gilbody S, 2002, BRIT J PSYCHIAT, V180, P13, DOI 10.1192/bjp.180.1.13; Glare P, 2003, BRIT MED J, V327, P195, DOI 10.1136/bmj.327.7408.195; Graham JW, 2007, PREV SCI, V8, P206, DOI 10.1007/s11121-007-0070-9; Harrison JD, 2009, SUPPORT CARE CANCER, V17, P1117, DOI 10.1007/s00520-009-0615-5; Hui D, 2010, JAMA-J AM MED ASSOC, V303, P1054, DOI 10.1001/jama.2010.258; Hwang SS, 2003, J PAIN SYMPTOM MANAG, V25, P225, DOI 10.1016/S0885-3924(02)00641-3; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Lamont EB, 2002, CANCER, V94, P2733, DOI 10.1002/cncr.10530; Lo C, 2009, QUAL LIFE RES, V18, P747, DOI 10.1007/s11136-009-9494-y; Lynch T, 2011, MAPPING LEVELS PALLI; Meier DE, 2008, J PALLIAT MED, V11, P823, DOI 10.1089/jpm.2008.9886; Morrison RS, 2000, ARCH INTERN MED, V160, P743, DOI 10.1001/archinte.160.6.743; Morrison RS, 2004, NEW ENGL J MED, V350, P2582, DOI 10.1056/NEJMcp035232; Morss S, 2008, J AM GERIATR SOC, V56, P124, DOI 10.1111/j.1532-5415.2007.01507.x; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Peterman AH, 2002, ANN BEHAV MED, V24, P49, DOI 10.1207/S15324796ABM2401_06; Rinck GC, 1997, J CLIN ONCOL, V15, P1697, DOI 10.1200/JCO.1997.15.4.1697; SCHAG CAC, 1990, HEALTH PSYCHOL, V9, P83, DOI 10.1037/0278-6133.9.1.83; Sepulveda C, 2002, J PAIN SYMPTOM MANAG, V24, P91, DOI 10.1016/S0885-3924(02)00440-2; Smith TJ, 2012, J CLIN ONCOL, V30, P880, DOI 10.1200/JCO.2011.38.5161; Steinhauser Karen E, 2004, Palliat Support Care, V2, P3; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Webster Kimberly, 2003, Health Qual Life Outcomes, V1, P79, DOI 10.1186/1477-7525-1-79; Wentlandt K, 2012, J CLIN ONCOL, V30, P4380, DOI 10.1200/JCO.2012.44.0248; Whitford HS, 2008, PSYCHO-ONCOLOGY, V17, P1121, DOI 10.1002/pon.1322; who, WHO DEF PALL CAR; Zimmermann C, 2008, JAMA-J AM MED ASSOC, V299, P1698, DOI 10.1001/jama.299.14.1698; Zimmermann C, 2006, SUPPORT CARE CANCER, V14, P982, DOI 10.1007/s00520-006-0093-y	40	1024	1038	16	165	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	2014	383	9930					1721	1730		10.1016/S0140-6736(13)62416-2	http://dx.doi.org/10.1016/S0140-6736(13)62416-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AH6UO	24559581				2023-01-03	WOS:000336267300025
J	Zimmermann, M; Armeanu-Ebinger, S; Bossow, S; Lampe, J; Smirnow, I; Schenk, A; Lange, S; Weiss, TS; Neubert, W; Lauer, UM; Bitzer, M				Zimmermann, Martina; Armeanu-Ebinger, Sorin; Bossow, Sascha; Lampe, Johanna; Smirnow, Irina; Schenk, Andrea; Lange, Sebastian; Weiss, Thomas S.; Neubert, Wolfgang; Lauer, Ulrich M.; Bitzer, Michael			Attenuated and Protease-Profile Modified Sendai Virus Vectors as a New Tool for Virotherapy of Solid Tumors	PLOS ONE			English	Article							TARGETED ONCOLYTIC POXVIRUS; C-PROTEINS; HOST-CELL; CANCER; ACTIVATION; DEFECTS; THERAPY; FUSION; GENERATION; INHIBITION	Multiple types of oncolytic viruses are currently under investigation in clinical trials. To optimize therapeutic outcomes it is believed that the plethora of different tumor types will require a diversity of different virus types. Sendai virus (SeV), a murine parainfluenza virus, displays a broad host range, enters cells within minutes and already has been applied safely as a gene transfer vector in gene therapy patients. However, SeV spreading naturally is abrogated in human cells due to a lack of virus activating proteases. To enable oncolytic applications of SeV we here engineered a set of novel recombinant vectors by a two-step approach: (i) introduction of an ubiquitously recognized cleavage-motive into SeV fusion protein now enabling continuous spreading in human tissues, and (ii) profound attenuation of these rSeV by the knockout of viral immune modulating accessory proteins. When employing human hepatoma cell lines, newly generated SeV variants now reached high titers and induced a profound tumor cell lysis. In contrast, virus release from untransformed human fibroblasts or primary human hepatocytes was found to be reduced by about three log steps in a time course experiment which enables the cumulation of kinetic differences of the distinct phases of viral replication such as primary target cell infection, target cell replication, and progeny virus particle release. In a hepatoma xenograft animal model we found a tumor-specific spreading of our novel recombinant SeV vectors without evidence of biodistribution into non-malignant tissues. In conclusion, we successfully developed novel tumor-selective oncolytic rSeV vectors, constituting a new tool for virotherapy of solid tumors being ready for further preclinical and clinical development to address distinct tumor types.	[Zimmermann, Martina; Smirnow, Irina; Schenk, Andrea; Lauer, Ulrich M.; Bitzer, Michael] Med Univ Hosp, Dept Internal Med 1, Tubingen, Germany; [Armeanu-Ebinger, Sorin] Univ Childrens Hosp, Tubingen, Germany; [Bossow, Sascha] Natl Ctr Tumor Dis, Dept Translat Oncol, Heidelberg, Germany; [Lampe, Johanna] Inst Mol Med Finland FIMM, Helsinki, Finland; [Lange, Sebastian] Tech Univ Munich, Med Klin, Klinikum Rechts Isar, D-80290 Munich, Germany; [Weiss, Thomas S.] Univ Regensburg Hosp, Ctr Liver Cell Res, Dept Pediat & Adolescent Med, Regensburg, Germany; [Neubert, Wolfgang] Max Planck Inst Biochem, Dept Mol Virol, D-82152 Martinsried, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; University of Hamburg; University Medical Center Hamburg-Eppendorf; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Technical University of Munich; University of Regensburg; Max Planck Society	Bitzer, M (corresponding author), Med Univ Hosp, Dept Internal Med 1, Tubingen, Germany.	michael.bitzer@uni-tuebingen.de	Lange, Sebastian/S-4635-2019; Weiss, Thomas S./G-3989-2012	Lange, Sebastian/0000-0003-0406-1401; Weiss, Thomas S./0000-0003-0336-0581	Deutsche Forschungsgemeinschaft [SFB 773, BI 669/3-6]; Federal Ministry for Education and Research of Germany [BMBF 01GU0506, 01GU0806]; Deutsche Forschungsgemeinschaft; Tuebingen University	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Federal Ministry for Education and Research of Germany; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Tuebingen University	This work was supported by grants from the Deutsche Forschungsgemeinschaft SFB 773 (B3) and BI 669/3-6, and from the Federal Ministry for Education and Research of Germany (BMBF 01GU0506 & 01GU0806). The authors acknowledge additional support by the "Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of Tuebingen University". The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armeanu S, 2008, CLIN CANCER RES, V14, P3520, DOI 10.1158/1078-0432.CCR-07-4744; Berchtold S, 2013, J VIROL, V87, P3484, DOI 10.1128/JVI.02106-12; Bitzer M, 2003, Z GASTROENTEROL, V41, P667; Bitzer M, 2003, J GENE MED, V5, P543, DOI 10.1002/jgm.426; Bitzer M, 2003, MOL THER, V7, P210, DOI 10.1016/S1525-0016(02)00052-7; Bitzer M, 1999, J VIROL, V73, P702, DOI 10.1128/JVI.73.1.702-708.1999; Blechacz B, 2006, HEPATOLOGY, V44, P1465, DOI 10.1002/hep.21437; Bourke MG, 2011, CANCER TREAT REV, V37, P618, DOI 10.1016/j.ctrv.2010.12.003; Breitbach CJ, 2011, NATURE, V477, P99, DOI 10.1038/nature10358; Cattaneo R, 2008, NAT REV MICROBIOL, V6, P529, DOI 10.1038/nrmicro1927; Chen NG, 2012, ADV VIROL, V2012, DOI 10.1155/2012/320206; Fontana JM, 2008, IMMUNOL REV, V225, P46, DOI 10.1111/j.1600-065X.2008.00669.x; Galanis E, 2010, CANC RES; Garcin D, 1999, J VIROL, V73, P6559, DOI 10.1128/JVI.73.8.6559-6565.1999; Gotoh B, 1999, FEBS LETT, V459, P205, DOI 10.1016/S0014-5793(99)01241-7; Haddad D, 2012, J NUCL MED, V53, P1933, DOI 10.2967/jnumed.112.105056; Hasegawa Y, 2010, MOL THER, V18, P1778, DOI 10.1038/mt.2010.138; Hawkins LK, 2002, LANCET ONCOL, V3, P17, DOI 10.1016/S1470-2045(01)00618-0; Karber G, 1931, N-S ARCH EX PATH PH, V162, P480, DOI 10.1007/BF01863914; Kato A, 2004, J VIROL, V78, P7443, DOI 10.1128/JVI.78.14.7443-7454.2004; Kelly E, 2007, MOL THER, V15, P651, DOI 10.1038/sj.mt.6300108; Keskinen P, 1999, VIROLOGY, V263, P364, DOI 10.1006/viro.1999.9983; KIDO H, 1992, J BIOL CHEM, V267, P13573; Kinoh H, 2004, GENE THER, V11, P1137, DOI 10.1038/sj.gt.3302272; Kinoh H, 2009, GENE THER, V16, P392, DOI 10.1038/gt.2008.167; Komatsu T, 2004, VIROLOGY, V325, P137, DOI 10.1016/j.virol.2004.04.025; Koyama S, 2008, CYTOKINE, V43, P336, DOI 10.1016/j.cyto.2008.07.009; Kurotani A, 1998, GENES CELLS, V3, P111, DOI 10.1046/j.1365-2443.1998.00170.x; Latorre P, 1998, J VIROL, V72, P5984, DOI 10.1128/JVI.72.7.5984-5993.1998; Laurie SA, 2006, CLIN CANCER RES, V12, P2555, DOI 10.1158/1078-0432.CCR-05-2038; Lech PJ, 2010, EXPERT REV VACCINES, V9, P1275, DOI 10.1586/ERV.10.124; Lemken ML, 2007, INT J ONCOL, V30, P1153; Li K, 2005, J BIOL CHEM, V280, P16739, DOI 10.1074/jbc.M414139200; LINGE C, 1995, CANCER RES, V55, P4099; Markwell M A, 1984, Adv Exp Med Biol, V174, P369; MARKWELL MAK, 1980, P NATL ACAD SCI-BIOL, V77, P5693, DOI 10.1073/pnas.77.10.5693; MARKWELL MAK, 1981, P NATL ACAD SCI-BIOL, V78, P5406, DOI 10.1073/pnas.78.9.5406; Marozin S, 2008, MOL THER, V16, P1789, DOI 10.1038/mt.2008.201; Naik S, 2009, EXPERT OPIN BIOL TH, V9, P1163, DOI 10.1517/14712590903170653; Park BH, 2008, LANCET ONCOL, V9, P533, DOI 10.1016/S1470-2045(08)70107-4; Patel MR, 2013, TRANSL RES, V161, P355, DOI 10.1016/j.trsl.2012.12.010; Persano L, 2009, CARCINOGENESIS, V30, P851, DOI 10.1093/carcin/bgp052; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Slobod KS, 2004, VACCINE, V22, P3182, DOI 10.1016/j.vaccine.2004.01.053; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Straehle L, 2007, J VIROL, V81, P12227, DOI 10.1128/JVI.01300-07; Stritzker J, 2013, P NATL ACAD SCI USA, V110, P3316, DOI 10.1073/pnas.1216916110; Takeuchi K, 2001, GENES CELLS, V6, P545, DOI 10.1046/j.1365-2443.2001.00442.x; Villar E, 2006, GLYCOCONJUGATE J, V23, P5, DOI 10.1007/s10719-006-5433-0; Wiegand MA, 2007, J VIROL, V81, P13835, DOI 10.1128/JVI.00914-07; Yonemitsu Y, 2013, MOL THER, V21, P707, DOI 10.1038/mt.2012.279; Yoshida A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049968	52	5	6	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2014	9	3							e90508	10.1371/journal.pone.0090508	http://dx.doi.org/10.1371/journal.pone.0090508			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC4GP	24598703	Green Published, Green Submitted, gold			2023-01-03	WOS:000332479400083
J	Hsieh, KP; Chen, LC; Cheung, KL; Chang, CS; Yang, YH				Hsieh, Kun-Pin; Chen, Li-Chia; Cheung, Kwok-Leung; Chang, Chao-Sung; Yang, Yi-Hsin			Interruption and Non-Adherence to Long-Term Adjuvant Hormone Therapy Is Associated with Adverse Survival Outcome of Breast Cancer Women - An Asian Population-Based Study	PLOS ONE			English	Article							ENDOCRINE THERAPY; ADHERENCE; TAMOXIFEN; RECURRENCE; MORTALITY; COHORT; RATES	This study aimed to evaluate the survival rate of women with breast cancer (BC) comparing persistence versus interruption and adherence versus non-adherence to adjuvant hormonal therapy (HT) in Asian population. Newly-diagnosed BC women from 2003 to 2010 were retrospectively identified from the Taiwan National Health Insurance Research Database. HT prescriptions were extracted to define treatment interruption and medication possession ratio. Their impacts on mortality were estimated by Cox regression with time dependent covariates. Interruption (HR: 1.32; 95% CI: 1.20, 1.46; P<0.0001) and non-adherence (HR: 1.45; 95% CI: 1.32, 1.59; P<0.0001) to adjuvant HT were significantly associated with increased mortality. Interruption to tamoxifen in younger patients and in patients receiving surgery (OP) with adjuvant chemotherapy (CT) was associated with increasing mortality rate when compared with their counterparts. Non-adherence to AIs in both younger and senior age groups and in OP with CT group also resulted in increasing risk. Treatment interruption and non-adherence to adjuvant HT were found to be associated with the increasing all-cause mortality of the Asian BC women; a greater impact of interruption and non-adherence on mortality was especially found in the younger BC population.	[Hsieh, Kun-Pin; Yang, Yi-Hsin] Kaohsiung Med Univ, Coll Pharm, Sch Pharm, Kaohsiung, Taiwan; [Hsieh, Kun-Pin] Kaohsiung Med Univ Hosp, Dept Pharm, Kaohsiung, Taiwan; [Chen, Li-Chia] Univ Nottingham, Sch Pharm, Div Social Res Med & Hlth, Nottingham NG7 2RD, England; [Cheung, Kwok-Leung] Univ Nottingham, Sch Grad Entry Med & Hlth, Div Breast Surg, Derby, England; [Chang, Chao-Sung] Kaohsiung Med Univ, Coll Hlth Sci, Dept Hlth Adm & Med Informat, Kaohsiung, Taiwan; [Yang, Yi-Hsin] Kaohsiung Med Univ Hosp, Ctr Canc, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; University of Nottingham; University of Nottingham; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Yang, YH (corresponding author), Kaohsiung Med Univ, Coll Pharm, Sch Pharm, Kaohsiung, Taiwan.	yihsya@kmu.edu.tw	Yang, Yi-Hsin/D-6471-2012; Thomas, Kendra/Y-2600-2019	Yang, Yi-Hsin/0000-0002-9581-2778; Hsieh, Kun-Pin/0000-0003-1565-2936; Cheung, Kwok-Leung/0000-0003-2973-0755; Chen, Li-Chia/0000-0002-6158-6645	National Science Council, Taiwan [NSC 101-2320-B-037-028]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by the National Science Council (NSC 101-2320-B-037-028), Taiwan. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Barron TI, 2007, CANCER-AM CANCER SOC, V109, P832, DOI 10.1002/cncr.22485; Bureau of Health Promotion, 2012, CANC REG ANN REP 200; Chlebowski RT, 2006, ONCOLOGY-BASEL, V71, P1, DOI 10.1159/000100444; Grymonpre R, 2006, MED CARE, V44, P471, DOI 10.1097/01.mlr.0000207817.32496.cb; Hershman DL, 2011, BREAST CANCER RES TR, V126, P529, DOI 10.1007/s10549-010-1132-4; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; Leong SPL, 2010, WORLD J SURG, V34, P2308, DOI 10.1007/s00268-010-0683-1; Makubate B, 2013, BRIT J CANCER, V108, P1515, DOI 10.1038/bjc.2013.116; McCowan C, 2008, BRIT J CANCER, V99, P1763, DOI 10.1038/sj.bjc.6604758; Murphy CC, 2012, BREAST CANCER RES TR, V134, P459, DOI 10.1007/s10549-012-2114-5; NCCN Clinical Practice Guidelines in Oncology, 2012, NCCN CLIN PRACT GUID; Nekhlyudov L, 2011, BREAST CANCER RES TR, V130, P681, DOI 10.1007/s10549-011-1703-z; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Partridge AH, 2008, J CLIN ONCOL, V26, P556, DOI 10.1200/JCO.2007.11.5451; Ruddy KJ, 2009, ANN ONCOL, V20, P401, DOI 10.1093/annonc/mdp039; Rutqvist LE, 1996, J NATL CANCER I, V88, P1543; Saphner T, 1996, J CLIN ONCOL, V14, P2738, DOI 10.1200/JCO.1996.14.10.2738; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012; Winer EP, 2005, J CLIN ONCOL, V23, P619, DOI 10.1200/JCO.2005.09.121	20	50	50	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2014	9	2							e87027	10.1371/journal.pone.0087027	http://dx.doi.org/10.1371/journal.pone.0087027			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AB3VI	24586261	Green Published, Green Submitted, gold			2023-01-03	WOS:000331717900007
J	Li, YH; Wang, FY; Feng, CQ; Yang, XF; Sun, YH				Li, Yan-hui; Wang, Feng-yun; Feng, Chun-qing; Yang, Xia-feng; Sun, Yi-hua			Massage Therapy for Fibromyalgia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	PLOS ONE			English	Review							CONNECTIVE-TISSUE MASSAGE; ALTERNATIVE MEDICINE; COMPLEMENTARY; MANAGEMENT; CLASSIFICATION; COSTS; WOMEN; PAIN	Background: Although some studies evaluated the effectiveness of massage therapy for fibromyalgia (FM), the role of massage therapy in the management of FM remained controversial. Objective: The purpose of this systematic review is to evaluate the evidence of massage therapy for patients with FM. Methods: Electronic databases (up to June 2013) were searched to identify relevant studies. The main outcome measures were pain, anxiety, depression, and sleep disturbance. Two reviewers independently abstracted data and appraised risk of bias. The risk of bias of eligible studies was assessed based on Cochrane tools. Standardised mean difference (SMD) and 95% confidence intervals (CI) were calculated by more conservative random-effects model. And heterogeneity was assessed based on the I 2 statistic. Results: Nine randomized controlled trials involving 404 patients met the inclusion criteria. The meta-analyses showed that massage therapy with duration >= 5 weeks significantly improved pain (SMD, 0.62; 95% CI 0.05 to 1.20; p = 0.03), anxiety (SMD, 0.44; 95% CI 0.09 to 0.78; p = 0.01), and depression (SMD, 0.49; 95% CI 0.15 to 0.84; p = 0.005) in patients with FM, but not on sleep disturbance (SMD, 0.19; 95% CI 20.38 to 0.75; p = 0.52). Conclusion: Massage therapy with duration >= 5 weeks had beneficial immediate effects on improving pain, anxiety, and depression in patients with FM. Massage therapy should be one of the viable complementary and alternative treatments for FM. However, given fewer eligible studies in subgroup meta-analyses and no evidence on follow-up effects, large-scale randomized controlled trials with long follow-up are warrant to confirm the current findings.	[Li, Yan-hui; Wang, Feng-yun; Feng, Chun-qing; Yang, Xia-feng; Sun, Yi-hua] Liaocheng Peoples Hosp, Dept Rehabil, Liaocheng, Shandong, Peoples R China		Wang, FY (corresponding author), Liaocheng Peoples Hosp, Dept Rehabil, Liaocheng, Shandong, Peoples R China.	fengyunwangdr@163.com						Alnigenis MNY, 2001, J MUSCULOSKELET PAIN, V9, P55, DOI 10.1300/J094v09n02_05; Bannwarth B, 2009, JOINT BONE SPINE, V76, P184, DOI 10.1016/j.jbspin.2008.06.002; Bennett RM, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-27; Branco JC, 2010, SEMIN ARTHRITIS RHEU, V39, P448, DOI 10.1016/j.semarthrit.2008.12.003; Brattberg G, 1999, EUR J PAIN, V3, P235, DOI 10.1016/S1090-3801(99)90050-2; Bronfort Gert, 2010, Chiropr Osteopat, V18, P3, DOI 10.1186/1746-1340-18-3; Carville SF, 2008, ANN RHEUM DIS, V67, P536, DOI 10.1136/ard.2007.071522; Citak-Karakaya I, 2009, J MANIP PHYSIOL THER, V29, P524; Da Silva GD, 2007, J ALTERN COMPLEM MED, V13, P1107, DOI 10.1089/acm.2007.0615; Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61; Ekici G, 2009, J MANIP PHYSIOL THER, V32, P127, DOI 10.1016/j.jmpt.2008.12.001; Ernst E, 2008, RHEUM DIS CLIN N AM, V34, P455, DOI 10.1016/j.rdc.2008.03.007; Field T, 2002, JCR-J CLIN RHEUMATOL, V8, P72, DOI 10.1097/00124743-200204000-00002; Field T.M., 1997, J CHRONIC FATIGUE SY, V3, P43, DOI [10.1300/J092v03n03_03, DOI 10.1300/J092V03N03_03]; Ge HY, 2010, J PAIN, V11, P644, DOI 10.1016/j.jpain.2009.10.006; GOATS GC, 1994, BRIT J SPORT MED, V28, P153, DOI 10.1136/bjsm.28.3.153; GOLDBERG J, 1992, PHYS THER, V72, P449, DOI 10.1093/ptj/72.6.449; Hauser W, 2010, EUR J PAIN, V14, P5, DOI 10.1016/j.ejpain.2009.01.006; Hauser W, 2009, DTSCH ARZTEBL INT, V106, P383, DOI 10.3238/arztebl.2009.0383; Imamura M., 2012, EVIDENCEBASED MANAGE, P216; Kalichman L, 2010, RHEUMATOL INT, V30, P1151, DOI 10.1007/s00296-010-1409-2; Kong LJ, 2011, ARTHRITIS RHEUM-US, V63, pS747; Lidbeck Jan, 2002, Pain Res Manag, V7, P81; Lund I, 2006, NEUROSCI LETT, V403, P166, DOI 10.1016/j.neulet.2006.04.038; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Castro-Sanchez AM, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/561753; Rossy LA, 1999, ANN BEHAV MED, V21, P180, DOI 10.1007/BF02908299; Sagar SM, 2008, CURR ONCOL, V15, P42, DOI 10.3747/co.2008.197; Stiller C, 2006, EFFECT THERAPEUTIC T; Sunshine W, 1996, J Clin Rheumatol, V2, P18, DOI 10.1097/00124743-199602000-00005; Terhorst L, 2011, J MANIP PHYSIOL THER, V34, P483, DOI 10.1016/j.jmpt.2011.05.006; Terry R, 2012, CLIN RHEUMATOL, V31, P55, DOI 10.1007/s10067-011-1783-5; Thompson JM, 2011, AM J PHYS MED REHAB, V90, P40, DOI 10.1097/PHM.0b013e3181fc7ff3; Topbas M, 2005, SCAND J RHEUMATOL, V34, P140, DOI 10.1080/03009740510026337; Wang CC, 2010, NEW ENGL J MED, V363, P743, DOI 10.1056/NEJMoa0912611; Wang J, 2010, CHIN J TRADIT MED SC, V17, P72; White LA, 2008, J OCCUP ENVIRON MED, V50, P13, DOI 10.1097/JOM.0b013e31815cff4b; Winkelmann A, 2012, SCHMERZ, V26, P276, DOI 10.1007/s00482-012-1171-3; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203	39	24	25	1	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2014	9	2							e89304	10.1371/journal.pone.0089304	http://dx.doi.org/10.1371/journal.pone.0089304			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AB3UC	24586677	gold, Green Published, Green Submitted			2023-01-03	WOS:000331714700097
J	Bibby, J; Tomkins, C				Bibby, Jo; Tomkins, Christine			Would criminalising healthcare professionals for wilful neglect improve patient care?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Bibby, Jo] Hlth Fdn, London WC2E 9RA, England; [Tomkins, Christine] Med Def Union, London SE1 8PJ, England		Bibby, J (corresponding author), Hlth Fdn, London WC2E 9RA, England.	Jo.Bibby@health.org.uk; christine.tomkins@themdu.com						Avineri E, 2010, INDIVIDUAL BEHAV CHA; Broughton J., 2003, 563 TRL; Department of Health, 2013, HARD TRUTHS JOURN PU, V1; Department of Health, 2013, MIDSTAFF NHS FDN TRU; Department of Health, 2013, HARD TRUTHS JOURN PU; Department of Health, 2013, BERW REV PAT SAF; General Medical Council, 2006, GOOD MED PRACT; Health Committee, FRANC MAK DIFF, P657; Horder J, BMJ QUALITY IN PRESS; Isle of Wight Country Press, CAR WORK FILM ATT EL; Office for National Statistics, 2013, REP DRINK DRIV ACC C; Vaughan D., 1996, CHALLENGER LAUNCH DE; Vincent C., 2013, MEASUREMENT MONITORI	13	5	5	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 23	2014	348								g133	10.1136/bmj.g133	http://dx.doi.org/10.1136/bmj.g133			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298BE	24458584				2023-01-03	WOS:000330298100003
J	Spence, D				Spence, Des			Bad medicine: the rise of duloxetine	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							TRIAL COMPARING DULOXETINE; DOUBLE-BLIND; PLACEBO; FIBROMYALGIA; MANAGEMENT; PAIN					destwo@yahoo.co.uk						[Anonymous], 2010, LILL PURS OK CYMB CH; Arnold LM, 2005, PAIN, V119, P5, DOI 10.1016/j.pain.2005.06.031; Arnold LM, 2004, ARTHRITIS RHEUM, V50, P2974, DOI 10.1002/art.20485; Bernardy K, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009796.pub2; Brennan F, 2007, ANESTH ANALG, V105, P205, DOI 10.1213/01.ane.0000268145.52345.55; Busch AJ, 2007, COCHRANE DB SYST REV, V4; Cymbalta sales data, 2013, TOP 100 STAT; Goldstein DJ, 2005, PAIN, V116, P109, DOI 10.1016/j.pain.2005.03.029; Gureje O, 1998, JAMA-J AM MED ASSOC, V280, P147, DOI 10.1001/jama.280.2.147; Health and Social Care Information Centre, 2013, PRESCR COST AN ENG 2; Kalso E, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7339; Lunn MPT, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007115.pub3; Raskin J, 2005, PAIN MED, V6, P346, DOI 10.1111/j.1526-4637.2005.00061.x; Russell IJ, 2008, PAIN, V136, P432, DOI 10.1016/j.pain.2008.02.024; Skljarevski V, 2010, J PAIN, V11, P1282, DOI 10.1016/j.jpain.2010.03.002; US Food and Drug Administration, 2010, EL LILL COR PRES CYM; US Food and Drug Administration, 2009, CYMB DUL DISC SYNDR; Williams ACD, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007407.pub3	18	2	2	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 17	2014	348								g139	10.1136/bmj.g139	http://dx.doi.org/10.1136/bmj.g139			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293MR	24443477				2023-01-03	WOS:000329976300001
J	Salas-Salvado, J; Bullo, M; Estruch, R; Ros, E; Covas, MI; Ibarrola-Jurado, N; Corella, D; Aros, F; Gomez-Gracia, E; Ruiz-Gutierrez, V; Romaguera, D; Lapetra, J; Lamuela-Raventos, RM; Serra-Majem, L; Pinto, X; Basora, J; Munoz, MA; Sorli, JV; Martinez-Gonzalez, MA				Salas-Salvado, Jordi; Bullo, Monica; Estruch, Ramon; Ros, Emilio; Covas, Maria-Isabel; Ibarrola-Jurado, Nuria; Corella, Dolores; Aros, Fernando; Gomez-Gracia, Enrique; Ruiz-Gutierrez, Valentina; Romaguera, Dora; Lapetra, Jose; Maria Lamuela-Raventos, Rosa; Serra-Majem, Lluis; Pinto, Xavier; Basora, Josep; Angel Munoz, Miguel; Sorli, Jose V.; Martinez-Gonzalez, Miguel A.			Prevention of Diabetes With Mediterranean Diets A Subgroup Analysis of a Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE INTERVENTION; METABOLIC SYNDROME; RISK-FACTORS; OLIVE OIL; REDUCTION; QUESTIONNAIRE; FREQUENCY; ADHERENCE; OXIDATION	Background: Interventions promoting weight loss can reduce the incidence of type 2 diabetes mellitus. Whether dietary changes without calorie restriction also protect from diabetes has not been evaluated. Objective: To assess the efficacy of Mediterranean diets for the primary prevention of diabetes in the Prevencion con Dieta Mediterranea trial, from October 2003 to December 2010 (median follow-up, 4.1 years). Design: Subgroup analysis of a multicenter, randomized trial. (Current Controlled Trials: ISRCTN35739639) Setting: Primary care centers in Spain. Participants: Men and women without diabetes (3541 patients aged 55 to 80 years) at high cardiovascular risk. Intervention: Participants were randomly assigned and stratified by site, sex, and age but not diabetes status to receive 1 of 3 diets: Mediterranean diet supplemented with extra-virgin olive oil (EVOO), Mediterranean diet supplemented with nuts, or a control diet (advice on a low-fat diet). No intervention to increase physical activity or lose weight was included. Measurements: Incidence of new-onset type 2 diabetes mellitus (prespecified secondary outcome). Results: During follow-up, 80, 92, and 101 new-onset cases of diabetes occurred in the Mediterranean diet supplemented with EVOO, Mediterranean diet supplemented with mixed nuts, and control diet groups, respectively, corresponding to rates of 16.0, 18.7, and 23.6 cases per 1000 person-years. Multivariate-adjusted hazard ratios were 0.60 (95% CI, 0.43 to 0.85) for the Mediterranean diet supplemented with EVOO and 0.82 (CI, 0.61 to 1.10) for the Mediterranean diet supplemented with nuts compared with the control diet. Limitations: Randomization was not stratified by diabetes status. Withdrawals were greater in the control group. Conclusion: A Mediterranean diet enriched with EVOO but without energy restrictions reduced diabetes risk among persons with high cardiovascular risk.			Salas-Salvado, J (corresponding author), Univ Rovira & Virgili, Fac Med & Hlth Sci, Human Nutr Unit, C St Llorenc 21, Reus 43201, Spain.	jordi.salas@urv.cat	perez, miguel/GXF-5077-2022; Salas-Salvado, Jordi/C-7229-2017; Sorlí, José V/L-8758-2014; Romaguera, Dora/ABE-7004-2020; Martinez-Gonzalez, Miguel A./AAE-7669-2019; Estruch, Ramon/AAZ-3723-2020; IBIS, ATENCION PRIMARIA/I-3524-2016; Serra-Majem, Lluis/I-6708-2019; Romaguera, Dora/AAB-2852-2020; Lapetra, Jose/F-2552-2015; Pintó, Xavier/AGI-4297-2022; Muñoz, Miguel Angel/X-3511-2019; Bulló, Mònica/F-2925-2016; Lamuela-Raventos, Rosa M/F-3986-2016	Salas-Salvado, Jordi/0000-0003-2700-7459; Sorlí, José V/0000-0002-0130-2006; Romaguera, Dora/0000-0002-5762-8558; Serra-Majem, Lluis/0000-0002-9658-9061; Pintó, Xavier/0000-0002-2216-2444; Muñoz, Miguel Angel/0000-0002-4083-3248; Bulló, Mònica/0000-0002-0218-7046; Ros, Emilio/0000-0002-2573-1294; Basora, Josep/0000-0003-0278-1149; Lamuela-Raventos, Rosa M/0000-0002-1287-4560; Martinez-Gonzalez, Miguel A./0000-0002-3917-9808	Instituto de Salud Carlos III	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission)	Instituto de Salud Carlos III.	Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS11, DOI 10.2337/dc13-S011; Martinez-Gonzalez MA, 2012, INT J EPIDEMIOL, V41, P377, DOI 10.1093/ije/dyq250; Bray GA, 2009, LANCET, V374, P1677, DOI 10.1016/S0140-6736(09)61457-4; Bullo M, 2011, CURR TOP MED CHEM, V11, P1797, DOI 10.2174/156802611796235062; Calder PC, 2011, BRIT J NUTR, V106, pS1, DOI 10.1017/S0007114511005460; Cole SR, 2008, AM J EPIDEMIOL, V168, P656, DOI 10.1093/aje/kwn164; Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140-6736(11)60679-X; ELOSUA R, 1994, AM J EPIDEMIOL, V139, P1197, DOI 10.1093/oxfordjournals.aje.a116966; Esfahani A, 2011, J AM COLL NUTR, V30, P285, DOI 10.1080/07315724.2011.10719971; Esposito K, 2010, METAB SYNDR RELAT D, V8, P471, DOI 10.1089/met.2010.0009; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Estruch R, 2006, ANN INTERN MED, V145, P1, DOI 10.7326/0003-4819-145-1-200607040-00004; Fernandez-Ballarth JD, 2010, BRIT J NUTR, V103, P1808, DOI 10.1017/S0007114509993837; Fito M, 2007, ARCH INTERN MED, V167, P1195, DOI 10.1001/archinte.167.11.1195; Gerstein HC, 2006, LANCET, V368, P1096, DOI 10.1016/S0140-6736(06)69420-8; Gillies CL, 2007, BMJ-BRIT MED J, V334, P299, DOI 10.1136/bmj.39063.689375.55; InterAct Project, 2011, DIABETES CARE, V34, P1913, DOI 10.2337/dc11-0891; Kastorini CM, 2011, J AM COLL CARDIOL, V57, P1299, DOI 10.1016/j.jacc.2010.09.073; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Lindstrom J, 2006, LANCET, V368, P1673, DOI 10.1016/S0140-6736(06)69701-8; Martinez-Gonzalez MA, 2008, BMJ-BRIT MED J, V336, P1348, DOI 10.1136/bmj.39561.501007.BE; Mena MP, 2009, AM J CLIN NUTR, V89, P248, DOI 10.3945/ajcn.2008.26094; Mortimer KM, 2005, AM J EPIDEMIOL, V162, P382, DOI 10.1093/aje/kwi208; Mozaffarian D, 2009, ARCH INTERN MED, V169, P798, DOI 10.1001/archinternmed.2009.21; Phung OJ, 2011, DIABETIC MED, V28, P948, DOI 10.1111/j.1464-5491.2011.03303.x; Riserus U, 2009, PROG LIPID RES, V48, P44, DOI 10.1016/j.plipres.2008.10.002; Rumawas ME, 2009, AM J CLIN NUTR, V90, P1608, DOI 10.3945/ajcn.2009.27908; Salas-Salvado J, 2011, NUTR METAB CARDIOVAS, V21, pB32, DOI 10.1016/j.numecd.2011.03.009; Salas-Salvado J, 2011, DIABETES CARE, V34, P14, DOI 10.2337/dc10-1288; Urpi-Sarda M, 2012, PHARMACOL RES, V65, P577, DOI 10.1016/j.phrs.2012.03.006; Viscogliosi G, 2013, METAB SYNDR RELAT D, V11, P210, DOI 10.1089/met.2012.0168	31	363	374	5	136	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 7	2014	160	1					1	+		10.7326/M13-1725	http://dx.doi.org/10.7326/M13-1725			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	297IS	24573661				2023-01-03	WOS:000330249700001
J	Liu, H; Qi, B; Guo, X; Tang, LQ; Chen, QY; Zhang, L; Guo, L; Luo, DH; Huang, PY; Mo, HY; Xiang, YQ; Qiu, F; Sun, R; Zhang, Y; Chen, MY; Hua, YJ; Lv, X; Wang, L; Zhao, C; Cao, KJ; Qian, CN; Hong, MH; Mai, HQ				Liu, Huai; Qi, Bin; Guo, Xiang; Tang, Lin-Quan; Chen, Qiu-Yan; Zhang, Lu; Guo, Ling; Luo, Dong-Hua; Huang, Pei-Yu; Mo, Hao-Yuan; Xiang, Yan-Qun; Qiu, Fang; Sun, Rui; Zhang, Ying; Chen, Ming-Yuan; Hua, Yi-Jun; Lv, Xing; Wang, Lin; Zhao, Chong; Cao, Ka-Jia; Qian, Chao-Nan; Hong, Ming-Huang; Mai, Hai-Qiang			Genetic Variations in Radiation and Chemotherapy Drug Action Pathways and Survival in locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy	PLOS ONE			English	Article							CELL LUNG-CANCER; PLATINUM-BASED CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; BREAST-CANCER; CONCURRENT CHEMORADIOTHERAPY; ERCC1 POLYMORPHISMS; CHINESE POPULATION; CLINICAL-OUTCOMES; RANDOMIZED-TRIAL; GASTRIC-CANCER	Background and Purpose: Treatment outcomes vary greatly in patients with nasopharyngeal carcinoma (NPC). The purpose of this study is to evaluate the influence of radiation and chemotherapy drug action pathway gene polymorphisms on the survival of patients with locoregionally advanced NPC treated with cisplatin-and fluorouracil-based chemoradiotherapy. Material and Methods: Four hundred twenty-one consecutive patients with locoregionally advanced NPC were prospectively recruited. We utilized a pathway approach and examined 18 polymorphisms in 13 major genes. Polymorphisms were detected using the LDR-PCR technique. Multifactor dimensionality reduction (MDR) analysis was performed to detect potential gene-gene interaction. Results: After adjustment for clinicopathological characteristics, overall survival was significantly decreased in patients with the MPO rs2243828 CT/CC genotype (HR=2.453, 95% CI, 1.687-3.566, P<0.001). The ERCC1 rs3212986 CC (HR=1.711, 95% CI, 1.135-2.579, P=0.010), MDM2 rs2279744 GT/GG (HR=1.743, 95% CI, 1.086-2.798, P=0.021), MPO rs2243828 CT/CC (HR=3.184, 95% CI, 2.261-4.483, P<0.001) and ABCB1 rs2032582 AT/AA (HR=1.997, 95% CI, 1.086-3.670, P=0.026) genotypes were associated with poor progression-free survival. Prognostic score models based on independent prognostic factors successfully classified patients into low-, intermediate-, and high-risk groups. Furthermore, MDR analysis showed no significant interaction between polymorphisms. Conclusions: Four single nucleotide polymorphisms were associated with survival in patients with locoregionally advanced NPC treated with cisplatin- and fluorouracil-based chemoradiotherapy. Combining clinical prognostic factors with genetic information was valuable in identifying patients with different risk.	[Liu, Huai; Guo, Xiang; Tang, Lin-Quan; Chen, Qiu-Yan; Zhang, Lu; Guo, Ling; Luo, Dong-Hua; Huang, Pei-Yu; Mo, Hao-Yuan; Xiang, Yan-Qun; Qiu, Fang; Sun, Rui; Zhang, Ying; Chen, Ming-Yuan; Hua, Yi-Jun; Lv, Xing; Wang, Lin; Zhao, Chong; Cao, Ka-Jia; Qian, Chao-Nan; Hong, Ming-Huang; Mai, Hai-Qiang] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Liu, Huai; Guo, Xiang; Tang, Lin-Quan; Chen, Qiu-Yan; Zhang, Lu; Guo, Ling; Luo, Dong-Hua; Huang, Pei-Yu; Mo, Hao-Yuan; Xiang, Yan-Qun; Qiu, Fang; Sun, Rui; Chen, Ming-Yuan; Hua, Yi-Jun; Lv, Xing; Wang, Lin; Zhao, Chong; Cao, Ka-Jia; Qian, Chao-Nan; Mai, Hai-Qiang] Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou 510275, Guangdong, Peoples R China; [Qi, Bin] Guangzhou Med Univ, Affilated Tumor Hosp, Dept Radiotherapy, Guangzhou, Guangdong, Peoples R China; [Zhang, Ying] Sun Yat Sen Univ, Ctr Canc, Tumor Resources Bank, Guangzhou 510275, Guangdong, Peoples R China; [Hong, Ming-Huang] Sun Yat Sen Univ, Ctr Canc, Clin Trial Study Ctr, Dept Epidemiol, Guangzhou 510275, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Guangzhou Medical University; Sun Yat Sen University; Sun Yat Sen University	Mai, HQ (corresponding author), State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China.	maihq@mail.sysu.edu.cn	Chen, Ming/GVU-8412-2022		National Natural Science Foundation of China [81072226]; 863 Project [2012AA02A501]; National Key Basic Research Program of China [2013CB910304]; Sci-Tech Project Foundation of Guangdong Province [2011B080701034]; Sci-Tech Project Foundation of Guangzhou City [2011J4300100]; Fundamental Research Funds for the central universities	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 863 Project(National High Technology Research and Development Program of China); National Key Basic Research Program of China(National Basic Research Program of China); Sci-Tech Project Foundation of Guangdong Province; Sci-Tech Project Foundation of Guangzhou City; Fundamental Research Funds for the central universities(Fundamental Research Funds for the Central Universities)	This research was supported by grants from the National Natural Science Foundation of China (No: 81072226, http://www.nsfc.gov.cn), the 863 Project (No: 2012AA02A501, http://www.863.gov.cn/), the National Key Basic Research Program of China (No: 2013CB910304, http://www.973.gov.cn), the Sci-Tech Project Foundation of Guangdong Province (No: 2011B080701034, http://gdsf.gdstc.gov.cn), the Sci-Tech Project Foundation of Guangzhou City (No: 2011J4300100, http://www.gzsi.gov.cn) and the Fundamental Research Funds for the central universities (http://www.sysu.edu.cn). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahn JY, 2004, CANCER RES, V64, P7634, DOI 10.1158/0008-5472.CAN-04-1843; Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; Ambrosone CB, 2009, J CLIN ONCOL, V27, P4973, DOI 10.1200/JCO.2009.21.8669; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Cao Su-Mei, 2011, Chin J Cancer, V30, P114; Chen PC, 2000, CANCER EPIDEM BIOMAR, V9, P843; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; Fung KL, 2009, BBA-PROTEINS PROTEOM, V1794, P860, DOI 10.1016/j.bbapap.2009.02.014; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Green H, 2006, CLIN CANCER RES, V12, P854, DOI 10.1158/1078-0432.CCR-05-0950; Gryshchenko I, 2008, J CLIN ONCOL, V26, P2252, DOI 10.1200/JCO.2007.11.5212; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Hahn LW, 2003, BIOINFORMATICS, V19, P376, DOI 10.1093/bioinformatics/btf869; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; HOFSTRA AH, 1993, TOXICOLOGY, V82, P221, DOI 10.1016/0300-483X(93)90066-2; Hrstka R, 2009, J CELL MOL MED, V13, P440, DOI 10.1111/j.1582-4934.2008.00634.x; Jin Y, 2012, EUR J CANCER, V48, P882, DOI 10.1016/j.ejca.2011.09.004; Khanna M, 1999, CLIN BIOCHEM, V32, P287, DOI 10.1016/S0009-9120(99)00020-X; Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697; Krivak TC, 2008, J CLIN ONCOL, V26, P3598, DOI 10.1200/JCO.2008.16.1323; Kumar AP, 2004, J BIOL CHEM, V279, P8300, DOI 10.1074/jbc.M311625200; Langer R, 2005, CLIN CANCER RES, V11, P7462, DOI 10.1158/1078-0432.CCR-05-0042; Lee AWM, 2010, JNCI-J NATL CANCER I, V102, P1188, DOI 10.1093/jnci/djq258; Liu L, 2013, MOL CARCINOGEN, V52, P923, DOI 10.1002/mc.21942; Liu L, 2011, J THORAC ONCOL, V6, P1793, DOI 10.1097/JTO.0b013e3182272273; Liu L, 2011, LUNG CANCER, V73, P110, DOI 10.1016/j.lungcan.2010.11.004; Lu WF, 2002, INT J CANCER, V102, P275, DOI 10.1002/ijc.10712; Lunn RM, 1999, CANCER RES, V59, P2557; Luo Jun-li, 2000, Hunan Yike Daxue Xuebao, V25, P18; Ma J, 2001, INT J RADIAT ONCOL, V50, P1181, DOI 10.1016/S0360-3016(01)01537-1; Martin DN, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-257; Miao XP, 2006, GASTROENTEROLOGY, V131, P420, DOI 10.1053/j.gastro.2006.05.050; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Moore JH, 2006, J THEOR BIOL, V241, P252, DOI 10.1016/j.jtbi.2005.11.036; Nakazato T, 2007, CLIN CANCER RES, V13, P5436, DOI 10.1158/1078-0432.CCR-07-0481; Oh SY, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-43; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; Orina JN, 2009, MOL CANCER THER, V8, P2057, DOI 10.1158/1535-7163.MCT-09-0256; Pander J, 2011, ANN ONCOL, V22, P1147, DOI 10.1093/annonc/mdq572; Park SR, 2011, BRIT J CANCER, V104, P1126, DOI 10.1038/bjc.2011.24; Pyaskovskaya O N, 2007, Exp Oncol, V29, P197; Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636; Reles A, 2001, CLIN CANCER RES, V7, P2984; Shiga H, 1999, CLIN CANCER RES, V5, P4097; Shiraishi K, 2010, J CLIN ONCOL, V28, P4945, DOI 10.1200/JCO.2010.30.5334; Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Sun JM, 2011, INT J RADIAT ONCOL, V80, P655, DOI 10.1016/j.ijrobp.2010.02.061; Thussbas C, 2006, J CLIN ONCOL, V24, P3747, DOI 10.1200/JCO.2005.04.8587; Wee J, 2005, J CLIN ONCOL, V23, P6730, DOI 10.1200/JCO.2005.16.790; Wee Joseph Tien Seng, 2010, Chin J Cancer, V29, P517; Weisberg I, 1998, MOL GENET METAB, V64, P169, DOI 10.1006/mgme.1998.2714; Wen YF, 2011, CLIN CANCER RES, V17, P2451, DOI 10.1158/1078-0432.CCR-10-2264; Winterbourn CC, 2000, CURR OPIN HEMATOL, V7, P53, DOI 10.1097/00062752-200001000-00010; Wu HZ, 2012, J CANCER RES CLIN, V138, P1449, DOI 10.1007/s00432-012-1209-z; Wu XF, 2006, J CLIN ONCOL, V24, P3789, DOI 10.1200/JCO.2005.03.6640; Xiao WW, 2011, CANCER-AM CANCER SOC, V117, P1874, DOI 10.1002/cncr.25754; Zhou GQ, 2007, CLIN CANCER RES, V13, P2627, DOI 10.1158/1078-0432.CCR-06-2281; Zhou W, 2004, CLIN CANCER RES, V10, P4939, DOI 10.1158/1078-0432.CCR-04-0247; ZWEIG MH, 1993, CLIN CHEM, V39, P561	60	12	12	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2013	8	12							e82750	10.1371/journal.pone.0082750	http://dx.doi.org/10.1371/journal.pone.0082750			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275VW	24340057	Green Submitted, Green Published, gold			2023-01-03	WOS:000328707400094
J	Curtis, JR; Back, AL; Ford, DW; Downey, L; Shannon, SE; Doorenbos, AZ; Kross, EK; Reinke, LF; Feemster, LC; Edlund, B; Arnold, RW; O'Connor, K; Engelberg, RA				Curtis, J. Randall; Back, Anthony L.; Ford, Dee W.; Downey, Lois; Shannon, Sarah E.; Doorenbos, Ardith Z.; Kross, Erin K.; Reinke, Lynn F.; Feemster, Laura C.; Edlund, Barbara; Arnold, Richard W.; O'Connor, Kim; Engelberg, Ruth A.			Effect of Communication Skills Training for Residents and Nurse Practitioners on Quality of Communication With Patients With Serious Illness A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-LIFE CARE; EARLY PALLIATIVE CARE; CELL LUNG-CANCER; DYING PATIENTS; PHYSICIAN COMMUNICATION; CHRONIC DISEASE; MENTAL-HEALTH; MEDICAL-CARE; END; PERSPECTIVES	IMPORTANCE Communication about end-of-life care is a core clinical skill. Simulation-based training improves skill acquisition, but effects on patient-reported outcomes are unknown. OBJECTIVE To assess the effects of a communication skills intervention for internal medicine and nurse practitioner trainees on patient- and family-reported outcomes. DESIGN, SETTING, AND PARTICIPANTS Randomized trial conducted with 391 internal medicine and 81 nurse practitioner trainees between 2007 and 2013 at the University of Washington and Medical University of South Carolina. INTERVENTION Participants were randomized to an 8-session, simulation-based, communication skills intervention (N = 232) or usual education (N = 240). MAIN OUTCOMES AND MEASURES Primary outcome was patient- reported quality of communication (QOC; mean rating of 17 items rated from 0-10, with 0 = poor and 10 = perfect). Secondary outcomes were patient- reported quality of end-of-life care (QEOLC; mean rating of 26 items rated from 0-10) and depressive symptoms (assessed using the 8-item Personal Health Questionnaire [PHQ-8]; range, 0-24, higher scores worse) and family-reported QOC and QEOLC. Analyses were clustered by trainee. RESULTS There were 1866 patient ratings (44% response) and 936 family ratings (68% response). The intervention was not associated with significant changes in QOC or QEOLC. Mean values for postintervention patient QOC and QEOLC were 6.5 (95% CI, 6.2 to 6.8) and 8.3 (95% CI, 8.1 to 8.5) respectively, compared with 6.3 (95% CI, 6.2 to 6.5) and 8.3 (95% CI, 8.1 to 8.4) for control conditions. After adjustment, comparing intervention with control, there was no significant difference in the QOC score for patients (difference, 0.4 points [95% CI, -0.1 to 0.9]; P = .15) or families (difference, 0.1 [95% CI, -0.8 to 1.0]; P = .81). There was no significant difference in QEOLC score for patients (difference, 0.3 points [95% CI, -0.3 to 0.8]; P = .34) or families (difference, 0.1 [95% CI, -0.7 to 0.8]; P = .88). The intervention was associated with significantly increased depression scores among patients of postintervention trainees (mean score, 10.0 [95% CI, 9.1 to 10.8], compared with 8.8 [95% CI, 8.4 to 9.2]) for control conditions; adjusted model showed an intervention effect of 2.2 (95% CI, 0.6 to 3.8; P = .006). CONCLUSIONS AND RELEVANCE Among internal medicine and nurse practitioner trainees, simulation-based communication training compared with usual education did not improve quality of communication about end-of-life care or quality of end-of-life care but was associated with a small increase in patients' depressive symptoms. These findings raise questions about skills transfer from simulation training to actual patient care and the adequacy of communication skills assessment.	[Curtis, J. Randall; Downey, Lois; Kross, Erin K.; Feemster, Laura C.; Engelberg, Ruth A.] Univ Washington, Harborview Med Ctr, Div Pulm & Crit Care, Dept Med, Seattle, WA 98104 USA; [Curtis, J. Randall; Shannon, Sarah E.; Doorenbos, Ardith Z.; Reinke, Lynn F.] Univ Washington, Sch Nursing, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98104 USA; [Back, Anthony L.] Univ Washington, Dept Med, Div Med Oncol, Seattle Canc Care Alliance, Seattle, WA 98104 USA; [Back, Anthony L.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; [Ford, Dee W.] Med Univ S Carolina, Dept Med, Div Pulm & Crit Care, Charleston, SC USA; [Reinke, Lynn F.; Feemster, Laura C.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA; [Edlund, Barbara] Med Univ S Carolina, Coll Nursing, Charleston, SC USA; [Arnold, Richard W.; O'Connor, Kim] Univ Washington, Dept Med, Seattle, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Seattle Cancer Care Alliance; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Medical University of South Carolina; University of Washington; University of Washington Seattle	Curtis, JR (corresponding author), Univ Washington, Harborview Med Ctr, Div Pulm & Crit Care, Box 359762, Seattle, WA 98104 USA.	jrc@u.washington.edu		Curtis, J. Randall/0000-0001-9529-845X; Shannon, Sarah E/0000-0001-8492-8743	National Institute of Nursing Research of the National Institutes of Health [R01NR009987]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL111116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR009987] Funding Source: NIH RePORTER	National Institute of Nursing Research of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	This study was supported by the National Institute of Nursing Research of the National Institutes of Health (R01NR009987).	Alexander SC, 2006, ACAD MED, V81, P1008, DOI 10.1097/01.ACM.0000242580.83851.ad; Au DH, 2012, CHEST, V141, P726, DOI 10.1378/chest.11-0362; Back AL, 2007, ARCH INTERN MED, V167, P453, DOI 10.1001/archinte.167.5.453; Bakitas M, 2009, JAMA-J AM MED ASSOC, V302, P741, DOI 10.1001/jama.2009.1198; Bays AM, 2014, J PALLIAT MED, V17, P159, DOI 10.1089/jpm.2013.0318; Carline JD, 2003, J PAIN SYMPTOM MANAG, V25, P19, DOI 10.1016/S0885-3924(02)00537-7; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Clayton JM, 2012, J PALLIAT MED, V15, P585, DOI 10.1089/jpm.2011.0292; Curtis JR, 2004, EUR RESPIR J, V24, P200, DOI 10.1183/09031936.04.00010104; Curtis JR, 2002, CHEST, V122, P356, DOI 10.1378/chest.122.1.356; Curtis JR, 2001, J GEN INTERN MED, V16, P41; Ell K, 2008, J CLIN ONCOL, V26, P4488, DOI 10.1200/JCO.2008.16.6371; Engelberg R, 2006, J PALLIAT MED, V9, P1086, DOI 10.1089/jpm.2006.9.1086; Engelberg RA, 2010, J PAIN SYMPTOM MANAG, V39, P951, DOI 10.1016/j.jpainsymman.2009.11.313; Fallowfield L, 2002, LANCET, V359, P650, DOI 10.1016/S0140-6736(02)07810-8; Fiscella K, 2007, ANN FAM MED, V5, P151, DOI 10.1370/afm.643; Frosch DL, 2010, J AM GERIATR SOC, V58, P1496, DOI 10.1111/j.1532-5415.2010.02980.x; Fryer-Edwards K, 2006, ACAD MED, V81, P638, DOI 10.1097/01.ACM.0000232414.43142.45; Greer JA, 2012, J CLIN ONCOL, V30, P394, DOI 10.1200/JCO.2011.35.7996; Gysels M, 2005, SUPPORT CARE CANCER, V13, P356, DOI 10.1007/s00520-004-0732-0; Haywood KL, 2005, QUAL LIFE RES, V14, P1651, DOI 10.1007/s11136-005-1743-0; Hopman WM, 2009, CHRONIC DIS CAN, V29, P108; Jackson VA, 2011, J PALLIAT MED, V14, P775, DOI 10.1089/jpm.2010.0493; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kroenke K, 2010, GEN HOSP PSYCHIAT, V32, P345, DOI 10.1016/j.genhosppsych.2010.03.006; Lowe B, 2004, MED CARE, V42, P1194, DOI 10.1097/00005650-200412000-00006; Lowe B, 2003, PSYCHOSOM MED, V65, P764, DOI 10.1097/01.PSY.0000079379.39918.17; Lowe B, 2004, J AFFECT DISORDERS, V78, P131, DOI 10.1016/S0165-0327(02)00237-9; Martin A, 2006, GEN HOSP PSYCHIAT, V28, P71, DOI 10.1016/j.genhosppsych.2005.07.003; McBurney CR, 2002, PHARMACOTHERAPY, V22, P1616, DOI 10.1592/phco.22.17.1616.34121; Reeder BA, 2008, J PHYS ACT HEALTH, V5, P74, DOI 10.1123/jpah.5.1.74; ROTER DL, 1995, ARCH INTERN MED, V155, P1877, DOI 10.1001/archinte.155.17.1877; Shilling V, 2003, PSYCHO-ONCOL, V12, P599, DOI 10.1002/pon.731; Szmuilowicz E, 2012, J PALLIAT MED, V15, P768, DOI 10.1089/jpm.2011.0446; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Weeks JC, 2012, NEW ENGL J MED, V367, P1616, DOI 10.1056/NEJMoa1204410; Wenrich MD, 2003, J PAIN SYMPTOM MANAG, V25, P236, DOI 10.1016/S0885-3924(02)00694-2; Wenrich MD, 2001, ARCH INTERN MED, V161, P868, DOI 10.1001/archinte.161.6.868; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Zhang BH, 2009, ARCH INTERN MED, V169, P480, DOI 10.1001/archinternmed.2008.587	41	274	278	7	102	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	2013	310	21					2271	2281		10.1001/jama.2013.282081	http://dx.doi.org/10.1001/jama.2013.282081			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	262OV	24302090	Green Accepted, Bronze			2023-01-03	WOS:000327746300012
J	Kwon, I; Hong, SY; Kim, YD; Nam, HS; Kang, S; Yang, SH; Heo, JH				Kwon, Il; Hong, Sung-Yu; Kim, Young Dae; Nam, Hyo Suk; Kang, Sungsoo; Yang, Seung-Hee; Heo, Ji Hoe			Thrombolytic Effects of the Snake Venom Disintegrin Saxatilin Determined by Novel Assessment Methods: A FeCl3-Induced Thrombosis Model in Mice	PLOS ONE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; ARTERIAL THROMBOSIS; STROKE; INTEGRINS; TIROFIBAN; ABCIXIMAB; ADHESION; BINDING; RECANALIZATION; INTRAARTERIAL	Saxatilin, a novel disintegrin purified and cloned from the venom of the Korean snake Gloydius saxatilis, strongly inhibits activation and aggregation of platelets. Glycoprotein (GP) IIb/IIIa receptor antagonists can resolve thrombus, so saxatilin might also have thrombolytic effects. We investigated the thrombolytic effects of saxatilin in mice using a ferric chloride-induced carotid arterial thrombosis model. Thrombotic occlusion and thrombus resolution were evaluated quantitatively by measuring blood flow in the carotid artery with an ultrasonic flow meter and calculating the degree of flow restoration on a minute-by-minute basis; results were confirmed by histological examination. Saxatilin dissolved thrombi in a dose-dependent manner. Saxatilin at 5 mg/kg restored blood flow to baseline levels. As saxatilin dose increased, time to recanalization decreased. A bolus injection of 10% of a complete dose with continuous infusion of the remaining dose for 60 minutes resulted in effective recanalization without reocclusion. The thrombolytic effect of saxatilin was also demonstrated in vitro using platelet aggregometry by administering saxatilin in preformed thrombi. Bleeding complications were observed in 2 of 71 mice that received saxatilin. Fibrin/fibrinogen zymography and platelet aggregometry studies indicated that saxatilin does not have fibrinolytic activity, but exerted its action on platelets. Integrin-binding assays showed that saxatilin inhibited multiple integrins, specifically alpha(2b)beta(3) (GP IIb/IIIa), alpha(5)beta(1), alpha(v)beta(3), alpha(v)beta(1), and alpha(v)beta(5), which act on platelet adhesion/aggregation. Saxatilin inhibited multiple integrins by acting on platelets, and was safe and effective in resolving thrombi in mice.	[Kwon, Il; Kim, Young Dae; Nam, Hyo Suk; Yang, Seung-Hee; Heo, Ji Hoe] Yonsei Univ, Coll Med, Dept Neurol, Seoul, South Korea; [Kwon, Il; Hong, Sung-Yu; Kim, Young Dae; Nam, Hyo Suk; Kang, Sungsoo; Yang, Seung-Hee; Heo, Ji Hoe] Yonsei Univ, Coll Med, Severance Integrat Res Inst Cerebral & Cardiovasc, Seoul, South Korea; [Kwon, Il; Heo, Ji Hoe] Yonsei Univ, Coll Med, Severance Biomed Sci Inst, Seoul, South Korea; [Hong, Sung-Yu; Kang, Sungsoo] Yonsei Univ, Coll Med, Cardiovasc Prod Evaluat Ctr, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Heo, JH (corresponding author), Yonsei Univ, Coll Med, Dept Neurol, Seoul, South Korea.	jhheo@yuhs.ac		NAM, HYO SUK/0000-0002-4415-3995; Heo, Ji Hoe/0000-0001-9898-3321; Kim, Young Dae/0000-0001-5750-2616; Kwon, Il/0000-0001-9449-5646	Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea [A085136]	Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea	This work was supported by a grant from the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (A085136). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abou-Chebl A, 2005, STROKE, V36, P2286, DOI 10.1161/01.STR.0000179043.73314.4f; Chen HS, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-88; Chopp M, 1999, ACT NEUR S, V73, P67; Eckert B, 2005, STROKE, V36, P1160, DOI 10.1161/01.STR.0000165918.80812.1e; Eckly A, 2011, J THROMB HAEMOST, V9, P779, DOI 10.1111/j.1538-7836.2011.04218.x; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Gruner S, 2003, BLOOD, V102, P4021, DOI 10.1182/blood-2003-05-1391; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hacke W, 2009, LANCET NEUROL, V8, P141, DOI 10.1016/S1474-4422(08)70267-9; Heo JH, 2003, NEUROLOGY, V60, P1684, DOI 10.1212/01.WNL.0000063323.23493.98; Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005; Hong SY, 2002, THROMB RES, V105, P79, DOI 10.1016/S0049-3848(01)00416-9; Hong SY, 2002, BIOCHEM BIOPH RES CO, V293, P530, DOI 10.1016/S0006-291X(02)00258-9; Jang YJ, 2007, J VASC RES, V44, P129, DOI 10.1159/000098519; Konstantinides S, 2001, CIRCULATION, V103, P576, DOI 10.1161/01.CIR.103.4.576; KORNINGER C, 1981, THROMB HAEMOSTASIS, V46, P561; Kroll MH, 1996, BLOOD, V88, P1525; KURZ KD, 1990, THROMB RES, V60, P269, DOI 10.1016/0049-3848(90)90106-M; Kwon I, 2009, J NEUROSCI RES, V87, P668, DOI 10.1002/jnr.21877; Lee KY, 2001, NEUROLOGY, V56, P1585, DOI 10.1212/WNL.56.11.1585; Lee KY, 2007, STROKE, V38, P192, DOI 10.1161/01.STR.0000251788.03914.00; Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6; LILIOM K, 1991, J IMMUNOL METHODS, V143, P119, DOI 10.1016/0022-1759(91)90280-S; Lu X, 2006, CURR PHARM DESIGN, V12, P2749, DOI 10.2174/138161206777947713; Marder VJ, 2010, STROKE, V41, pS45, DOI 10.1161/STROKEAHA.110.595157; Medcalf RL, 2012, INT J STROKE, V7, P419, DOI 10.1111/j.1747-4949.2012.00783.x; Moser M, 2003, J CARDIOVASC PHARM, V41, P586, DOI 10.1097/00005344-200304000-00011; Murray V, 2010, J INTERN MED, V267, P191, DOI 10.1111/j.1365-2796.2009.02205.x; Ni HY, 2003, TRANSFUS APHER SCI, V28, P257, DOI 10.1016/S1473-0502(03)00044-2; Niessen F, 2002, STROKE, V33, P2999, DOI 10.1161/01.STR.0000038096.60932.F4; Orosz F, 2002, J IMMUNOL METHODS, V270, P155, DOI 10.1016/S0022-1759(02)00295-8; PHILLIPS DR, 1988, BLOOD, V71, P831; Podolnikova NP, 2003, J BIOL CHEM, V278, P32251, DOI 10.1074/jbc.M300410200; Rha JH, 2007, STROKE, V38, P967, DOI 10.1161/01.STR.0000258112.14918.24; Seitz RJ, 2004, NEUROLOGY, V62, P2110, DOI 10.1212/01.WNL.0000129480.17345.4A; Seitz RJ, 2003, STROKE, V34, P1932, DOI 10.1161/01.STR.0000080535.61188.A6; Sohn YD, 2008, TOXICON, V51, P406, DOI 10.1016/j.toxicon.2007.10.019; Sugimori T, 1997, KIDNEY INT, V51, P1454, DOI 10.1038/ki.1997.199; Thijs VNS, 2009, STROKE, V40, P3789, DOI 10.1161/STROKEAHA.109.560201; Wang XK, 2005, THROMB RES, V115, P95, DOI 10.1016/j.thromres.2004.07.009; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; Yee KO, 1998, CIRC RES, V83, P241, DOI 10.1161/01.RES.83.3.241	42	19	22	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2013	8	11							e81165	10.1371/journal.pone.0081165	http://dx.doi.org/10.1371/journal.pone.0081165			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256KH	24260554	Green Published, gold, Green Submitted			2023-01-03	WOS:000327308500198
J	Goede, V; Fischer, K; Busch, R; Engelke, A; Eichhorst, B; Wendtner, CM; Chagorova, T; de la Serna, J; Dilhuydy, MS; Illmer, T; Opat, S; Owen, CJ; Samoylova, O; Kreuzer, KA; Stilgenbauer, S; Dohner, H; Langerak, AW; Ritgen, M; Kneba, M; Asikanius, E; Humphrey, K; Wenger, M; Hallek, M				Goede, Valentin; Fischer, Kirsten; Busch, Raymonde; Engelke, Anja; Eichhorst, Barbara; Wendtner, Clemens M.; Chagorova, Tatiana; de la Serna, Javier; Dilhuydy, Marie-Sarah; Illmer, Thomas; Opat, Stephen; Owen, Carolyn J.; Samoylova, Olga; Kreuzer, Karl-Anton; Stilgenbauer, Stephan; Doehner, Hartmut; Langerak, Anton W.; Ritgen, Matthias; Kneba, Michael; Asikanius, Elina; Humphrey, Kathryn; Wenger, Michael; Hallek, Michael			Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; ILLNESS RATING-SCALE; GENOMIC ABERRATIONS; ANTI-CD20 ANTIBODY; 1ST-LINE THERAPY; PROGRESSION-FREE; INITIAL THERAPY; IN-VITRO; RITUXIMAB; FLUDARABINE	Background The monoclonal anti-CD20 antibody rituximab, combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients with previously untreated chronic lymphocytic leukemia (CLL) but not in those with coexisting conditions. We investigated the benefit of the type 2, glycoengineered antibody obinutuzumab (also known as GA101) as compared with that of rituximab, each combined with chlorambucil, in patients with previously untreated CLL and coexisting conditions. Methods We randomly assigned 781 patients with previously untreated CLL and a score higher than 6 on the Cumulative Illness Rating Scale (CIRS) (range, 0 to 56, with higher scores indicating worse health status) or an estimated creatinine clearance of 30 to 69 ml per minute to receive chlorambucil, obinutuzumab plus chlorambucil, or rituximab plus chlorambucil. The primary end point was investigator-assessed progression-free survival. Results The patients had a median age of 73 years, creatinine clearance of 62 ml per minute, and CIRS score of 8 at baseline. Treatment with obinutuzumab-chlorambucil or rituximab-chlorambucil, as compared with chlorambucil monotherapy, increased response rates and prolonged progression-free survival (median progression-free survival, 26.7 months with obinutuzumab-chlorambucil vs. 11.1 months with chlorambucil alone; hazard ratio for progression or death, 0.18; 95% confidence interval [CI], 0.13 to 0.24; P<0.001; and 16.3 months with rituximab-chlorambucil vs. 11.1 months with chlorambucil alone; hazard ratio, 0.44; 95% CI, 0.34 to 0.57; P<0.001). Treatment with obinutuzumab-chlorambucil, as compared with chlorambucil alone, prolonged overall survival (hazard ratio for death, 0.41; 95% CI, 0.23 to 0.74; P = 0.002). Treatment with obinutuzumab-chlorambucil, as compared with rituximab-chlorambucil, resulted in prolongation of progression-free survival (hazard ratio, 0.39; 95% CI, 0.31 to 0.49; P<0.001) and higher rates of complete response (20.7% vs. 7.0%) and molecular response. Infusion-related reactions and neutropenia were more common with obinutuzumab-chlorambucil than with rituximab-chlorambucil, but the risk of infection was not increased. Conclusions Combining an anti-CD20 antibody with chemotherapy improved outcomes in patients with CLL and coexisting conditions. In this patient population, obinutuzumab was superior to rituximab when each was combined with chlorambucil.	[Goede, Valentin; Fischer, Kirsten; Engelke, Anja; Eichhorst, Barbara; Wendtner, Clemens M.; Kreuzer, Karl-Anton; Hallek, Michael] Univ Hosp Cologne, German CLL Study Grp, Ctr Integrated Oncol Cologne Bonn, Dept Internal Med 1, Cologne, Germany; [Goede, Valentin] St Marien Hosp, Dept Geriatr Med & Res, Cologne, Germany; [Goede, Valentin] Univ Cologne, D-50924 Cologne, Germany; [Busch, Raymonde] Tech Univ Munich, Inst Med Stat & Epidemiol, D-80290 Munich, Germany; [Wendtner, Clemens M.] Klinikum Schwabing, Munich, Germany; [Ritgen, Matthias; Kneba, Michael] Univ Schleswig Holstein, City Hosp Kiel, Dept Med 2, Kiel, Germany; [Stilgenbauer, Stephan; Doehner, Hartmut] Univ Ulm, Dept Internal Med 3, D-89069 Ulm, Germany; [Hallek, Michael] Univ Cologne, Cluster Excellence Cellular Stress Responses Agin, D-50924 Cologne, Germany; [Chagorova, Tatiana] Penza Reg Oncol Dispensary, Penza, Russia; [Samoylova, Olga] Reg Clin Hosp NA Semashko, Nizhnii Novgorod, Russia; [de la Serna, Javier] Hosp Univ 12 Octubre, Serv Hematol, Madrid, Spain; [Dilhuydy, Marie-Sarah] Hop Haut Leveque, Pessac, France; [Opat, Stephen] Monash Med Ctr, Dept Haematol, Clayton, Vic 3168, Australia; [Owen, Carolyn J.] Univ Calgary, Calgary, AB, Canada; [Langerak, Anton W.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Asikanius, Elina] F Hoffmann La Roche, Basel, Switzerland; [Humphrey, Kathryn] F Hoffmann La Roche, Welwyn Garden City, England; [Wenger, Michael] Genentech Inc, San Francisco, CA 94080 USA	University of Cologne; St. Marien Hospital; University of Cologne; Technical University of Munich; Munchen Klinik; University of Kiel; Schleswig Holstein University Hospital; Ulm University; University of Cologne; Hospital Universitario 12 de Octubre; CHU Bordeaux; Monash University; University of Calgary; Erasmus University Rotterdam; Erasmus MC; Roche Holding; Roche Holding; Roche Holding; Genentech	Hallek, M (corresponding author), Univ Cologne, German CLL Study Grp, D-50924 Cologne, Germany.	michael.hallek@uni-koeln.de	Opat, Stephen/AFR-0783-2022; Stilgenbauer, Stephan/ABE-6609-2020; Hallek, Michael/Y-3191-2019; DE LA SERNA, JAVIER/B-1735-2012; Döhner, Hartmut/C-8933-2016	Opat, Stephen/0000-0002-0308-6458; Hallek, Michael/0000-0002-7425-4455; DE LA SERNA, JAVIER/0000-0003-3904-1101; Döhner, Hartmut/0000-0003-2116-5536; Wendtner, Clemens-Martin/0000-0003-2866-2260	F. Hoffmann-La Roche	F. Hoffmann-La Roche(Hoffmann-La Roche)	Funded by F. Hoffmann-La Roche; ClinicalTrials.gov number, NCT01010061.; Supported by F. Hoffmann-La Roche.	Alduaij W, 2011, BLOOD, V117, P4519, DOI 10.1182/blood-2010-07-296913; Bottcher S, 2009, LEUKEMIA, V23, P2007, DOI 10.1038/leu.2009.140; Bottcher S, 2012, J CLIN ONCOL, V30, P980, DOI 10.1200/JCO.2011.36.9348; Byrd JC, 2005, BLOOD, V105, P49, DOI 10.1182/blood-2004-03-0796; Cartron G, 2004, BLOOD, V104, P2635, DOI 10.1182/blood-2004-03-1110; Catovsky D, 2007, LANCET, V370, P230, DOI 10.1016/S0140-6736(07)61125-8; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Dalle S, 2011, MOL CANCER THER, V10, P178, DOI 10.1158/1535-7163.MCT-10-0385; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Eichhorst BF, 2009, BLOOD, V114, P3382, DOI 10.1182/blood-2009-02-206185; Eichhorst BF, 2006, BLOOD, V107, P885, DOI 10.1182/blood-2005-06-2395; Flinn IW, 2007, J CLIN ONCOL, V25, P793, DOI 10.1200/JCO.2006.08.0762; Foa R, 2011, BLOOD, V118, P294; Goede V, 2013, LEUKEMIA, V27, P1172, DOI 10.1038/leu.2012.252; Hallek M, 2010, LANCET, V376, P1164, DOI 10.1016/S0140-6736(10)61381-5; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Herter S, 2013, MOL CANCER THER, V12, P2031, DOI 10.1158/1535-7163.MCT-12-1182; Hillmen P, 2010, ASH ANN M, V116, P697; Hillmen P, 2007, J CLIN ONCOL, V25, P5616, DOI 10.1200/JCO.2007.12.9098; Howlader N, 2013, SEER CANC STAT REV; Knauf WU, 2009, J CLIN ONCOL, V27, P4378, DOI 10.1200/JCO.2008.20.8389; Krober A, 2002, BLOOD, V100, P1410, DOI 10.1182/blood.V100.4.1410.h81602001410_1410_1416; MARTI GE, 1992, ANN NY ACAD SCI, V651, P480; Mossner E, 2010, BLOOD, V115, P4393, DOI 10.1182/blood-2009-06-225979; Morschhauser F, 2011, HAEMATOLOGICA S2, V96, P935; Morschhauser F, 2009, BLOOD, V114, P884; O'Brien SM, 2001, J CLIN ONCOL, V19, P2165, DOI 10.1200/JCO.2001.19.8.2165; OBRIEN S, 2005, ASH ANN M, V106, P2117; Owen C, 2012, EXPERT OPIN BIOL TH, V12, P343, DOI 10.1517/14712598.2012.657622; PARMELEE PA, 1995, J AM GERIATR SOC, V43, P130, DOI 10.1111/j.1532-5415.1995.tb06377.x; Patz M, 2011, BRIT J HAEMATOL, V152, P295, DOI 10.1111/j.1365-2141.2010.08428.x; Rai KR, 2000, NEW ENGL J MED, V343, P1750, DOI 10.1056/NEJM200012143432402; Rawstron AC, 2007, LEUKEMIA, V21, P956, DOI 10.1038/sj.leu.2404584; Ritgen M, 2008, LEUKEMIA, V22, P1377, DOI 10.1038/leu.2008.96; Robak T, 2013, FUTURE ONCOL, V9, P69, DOI [10.2217/fon.12.157, 10.2217/FON.12.157]; Salvi F, 2008, J AM GERIATR SOC, V56, P1926, DOI 10.1111/j.1532-5415.2008.01935.x; Tam CS, 2008, BLOOD, V112, P975, DOI 10.1182/blood-2008-02-140582; Thurmes P, 2008, LEUKEMIA LYMPHOMA, V49, P49, DOI 10.1080/10428190701724785; Woyach JA, 2013, J CLIN ONCOL, V31, P440, DOI 10.1200/JCO.2011.41.5646	39	1057	1091	1	51	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 20	2014	370	12					1101	1110		10.1056/NEJMoa1313984	http://dx.doi.org/10.1056/NEJMoa1313984			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AD2HA	24401022				2023-01-03	WOS:000333054000006
J	Hagen, S; Stark, D; Glazener, C; Dickson, S; Barry, S; Elders, A; Frawley, H; Galea, MP; Logan, J; McDonald, A; McPherson, G; Moore, KH; Norrie, J; Walker, A; Wilson, D				Hagen, Suzanne; Stark, Diane; Glazener, Cathryn; Dickson, Sylvia; Barry, Sarah; Elders, Andrew; Frawley, Helena; Galea, Mary P.; Logan, Janet; McDonald, Alison; McPherson, Gladys; Moore, Kate H.; Norrie, John; Walker, Andrew; Wilson, Don		POPPY Trial Collaborators	Individualised pelvic floor muscle training in women with pelvic organ prolapse (POPPY): a multicentre randomised controlled trial	LANCET			English	Article							SHORT-FORM; SYMPTOMS	Background Pelvic organ prolapse is common and is strongly associated with childbirth and increasing age. Women with prolapse are often advised to do pelvic floor muscle exercises, but evidence supporting the benefits of such exercises is scarce. We aimed to establish the effectiveness of one-to-one individualised pelvic floor muscle training for reducing prolapse symptoms. Methods We did a parallel-group, multicentre, randomised controlled trial at 23 centres in the UK, one in New Zealand, and one in Australia, between June 22, 2007, and April 9, 2010. Female outpatients with newly-diagnosed, symptomatic stage I, II, or III prolapse were randomly assigned (1:1), by remote computer allocation with minimsation, to receive an individualised programme of pelvic floor muscle training or a prolapse lifestyle advice leaflet and no muscle training (control group). Outcome assessors, and investigators who were gynaecologists at trial sites, were masked to group allocation; the statistician was masked until after data analysis. Our primary endpoint was participants' self-report of prolapse symptoms at 12 months. Analysis was by intention-to-treat analysis. This trial is registered, number ISRCTN35911035. Findings 447 eligible patients were randomised to the intervention group (n=225) or the control group (n=222). 377 (84%) participants completed follow-up for questionnaires at 6 months and 295 (66%) for questionnaires at 12 months. Women in the intervention group reported fewer prolapse symptoms (ie, a significantly greater reduction in the pelvic organ prolapse symptom score [POP-SS]) at 12 months than those in the control group (mean reduction in POP-SS from baseline 3.77 [SD 5.62] vs 2.09 [5.39]; adjusted difference 1.52, 95% CI 0.46-2.59; p=0.0053). Findings were robust to missing data. Eight adverse events (six vaginal symptoms, one case of back pain, and one case of abdominal pain) and one unexpected serious adverse event, all in women from the intervention group, were regarded as unrelated to the intervention or to participation in the study. Interpretation One-to-one pelvic floor muscle training for prolapse is effective for improvement of prolapse symptoms. Long-term benefits should be investigated, as should the effects in specific subgroups.	[Hagen, Suzanne; Dickson, Sylvia; Logan, Janet] Glasgow Caledonian Univ, Nursing Midwifery & Allied Hlth Profess Res Unit, Glasgow G4 0BA, Lanark, Scotland; [Stark, Diane] Leicester Royal Infirm, Clin 2, Leicester, Leics, England; [Glazener, Cathryn; Elders, Andrew] Univ Aberdeen, Hlth Serv Res Unit, Aberdeen, Scotland; [McDonald, Alison; McPherson, Gladys; Norrie, John] Univ Aberdeen, Hlth Serv Res Unit, Ctr Healthcare Randomised Trials, Aberdeen, Scotland; [Barry, Sarah; Walker, Andrew] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland; [Frawley, Helena] Univ Melbourne, Melbourne Sch Hlth Sci, Dept Physiotherapy, Melbourne, Vic 3010, Australia; [Galea, Mary P.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic 3010, Australia; [Moore, Kate H.] St George Hosp, Dept Urogynaecol, Pelv Floor & Bladder Unit, Kogarah, NSW, Australia; [Wilson, Don] Dunedin Sch Med, Dept Obstet & Gynaecol, Dunedin, New Zealand	Glasgow Caledonian University; University of Leicester; University of Aberdeen; University of Aberdeen; University of Glasgow; University of Melbourne; Royal Melbourne Hospital; University of Melbourne; St George Hospital; University of Otago	Hagen, S (corresponding author), Glasgow Caledonian Univ, Nursing Midwifery & Allied Hlth Profess Res Unit, Glasgow G4 0BA, Lanark, Scotland.	s.hagen@gcu.ac.uk	Galea, Mary/F-4242-2010; Frawley, Helena C/B-9840-2017; Walker, Andrew/ABF-6771-2020; Elders, Andrew/N-4195-2015	Galea, Mary/0000-0003-0045-7978; Frawley, Helena C/0000-0002-7126-6979; Elders, Andrew/0000-0003-4172-4702; Moore, Kate/0000-0001-6947-9839; Barry, Sarah J.E./0000-0003-3039-8729; HAGEN, SUZANNE/0000-0002-9741-9160	Chief Scientist Office of the Scottish Government Health and Social Care Directorates; New Zealand Lottery Board; National Health and Medical Research Council (Australia); Chief Scientist Office (CSO) of the Scottish Government [CZH/4/377]; CSO; Chief Scientist Office [NMAHP2, HSRU1, CZH/4/377] Funding Source: researchfish	Chief Scientist Office of the Scottish Government Health and Social Care Directorates; New Zealand Lottery Board; National Health and Medical Research Council (Australia)(National Health and Medical Research Council (NHMRC) of Australia); Chief Scientist Office (CSO) of the Scottish Government; CSO; Chief Scientist Office	Chief Scientist Office of the Scottish Government Health and Social Care Directorates, New Zealand Lottery Board, and National Health and Medical Research Council (Australia).; The UK component of the trial was funded by the Chief Scientist Office (CSO) of the Scottish Government (project number CZH/4/377) and is summarised online. The Nursing, Midwifery and Allied Health Professions Research Unit and the Health Services Research Unit are also funded by the CSO. The views expressed in this publication are those of the investigators and not necessarily those of the CSO. We also acknowledge funding for the international components from the National Health and Medical Research Council (Australia) and the New Zealand Lottery Board. We accept full responsibility for the research. We thank all the women who willingly participated in the POPPY trial and completed their questionnaires and attended physiotherapy and gynaecology appointments; the staff at each of our centres for recruiting, motivating and treating our participants; the POPPY trial office staff in the UK (Kim Stewart and Lucy Pyart); those who administered the trial in Dunedin (Gaye Ellis) and Sydney (Wendy Allen) and members of the trial steering committee and data monitoring committee for giving their time in advising the trial team throughout the work.	Abrams P, 2013, INCONTINENCE; Allahdin S, 2008, J OBSTET GYNAECOL, V28, P427, DOI 10.1080/01443610802150077; [Anonymous], 2012, R LANG ENV STAT COMP; Avery K, 2004, NEUROUROL URODYNAM, V23, P322, DOI 10.1002/nau.20041; Bo K., 1995, INT UROGYNECOL J, V6, P282, DOI [10.1007/BF01901527, DOI 10.1007/BF01901527]; Bradley CS, 2007, OBSTET GYNECOL, V109, P848, DOI 10.1097/01.AOG.0000255977.91296.5d; Braekken IH, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.02.037; Bump RC, 1996, AM J OBSTET GYNECOL, V175, P10, DOI 10.1016/S0002-9378(96)70243-0; C&G Medicare, 2010, CLUB PESS; Curtis L., 2009, UNIT COSTS HLTH SOCI; Diggle P., 2002, J R STAT SOC, DOI DOI 10.2307/2983303; Dumoulin C, 2010, COCHRANE DB SYST REV, V1; Ellerkmann RM, 2001, AM J OBSTET GYNECOL, V185, P1332, DOI 10.1067/mob.2001.119078; Ghroubi S., 2008, Annales de Readaptation et de Medecine Physique, V51, P96, DOI 10.1016/j.annrmp.2007.11.002; Hagen S, 2010, NEUROUROL URODYNAM, V29, P1055; Hagen S, 2009, BJOG-INT J OBSTET GY, V116, P25, DOI 10.1111/j.1471-0528.2008.01903.x; Hagen S, 2004, PHYSIOTHERAPY, V90, P19; Hagen S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003882.pub4; Hagen S, 2009, INT UROGYNECOL J, V20, P45, DOI 10.1007/s00192-008-0726-4; Handa VL, 2004, AM J OBSTET GYNECOL, V190, P27, DOI 10.1016/j.ajog.2003.07.017; Health and Social Care Information Centre, 2011, HOSP EP STAT ADM PAT; Hendrix SL, 2002, AM J OBSTET GYNECOL, V186, P1160, DOI 10.1067/mob.2002.123819; Information Services Division, 2010, SCOTT HLTH SERV COST; Joint Formulary Committee, 2011, BRIT NATL FORMULARY; Kashyap R, 2013, INT J GYNECOL OBSTET, V121, P69, DOI 10.1016/j.ijgo.2012.11.012; Laycock J., 2001, PHYSIOTHERAPY, V87, P631, DOI [10.1016/s0031-9406(05)61108-x, DOI 10.1016/S0031-9406(05)61108-X]; Miedel A, 2011, INT UROGYNECOL J, V22, P461, DOI 10.1007/s00192-010-1305-z; Miedel A, 2009, OBSTET GYNECOL, V113, P1089, DOI 10.1097/AOG.0b013e3181a11a85; Mouritsen L, 2003, INT UROGYNECOL J PEL, V14, P122, DOI 10.1007/s00192-002-1024-1; National Institute for Health & Clinical Excellence, 2006, UR INC MAN UR INC WO; Olsen AL, 1997, OBSTET GYNECOL, V89, P501, DOI 10.1016/S0029-7844(97)00058-6; Piya-Anant Manee, 2003, Journal of the Medical Association of Thailand, V86, P509; Rogers RG, 2003, INT UROGYNECOL J PEL, V14, P164, DOI 10.1007/s00192-003-1063-2; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; SLIEKERTENHOVE MC, 2009, AM J OBSTET GYNECOL, V200; Stupp L, 2011, INT UROGYNECOL J, V22, P1233, DOI 10.1007/s00192-011-1428-x; Su YS, 2011, J STAT SOFTW, V45, P1; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Wu JM, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.03.046	39	123	134	1	35	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 1	2014	383	9919					796	806		10.1016/S0140-6736(13)61977-7	http://dx.doi.org/10.1016/S0140-6736(13)61977-7			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AC3EV	24290404	Green Accepted, Green Submitted			2023-01-03	WOS:000332398700026
J	Fu, CY; Xia, RL; Zhang, TF; Lu, Y; Zhang, SF; Yu, ZQ; Jin, T; Mou, XZ				Fu, Cai-Yun; Xia, Rui-Long; Zhang, Teng-Fei; Lu, Yan; Zhang, Shi-Fu; Yu, Zhi-Qiang; Jin, Tao; Mou, Xiao-Zhou			Hemokinin-1(4-11)-Induced Analgesia Selectively Up-Regulates delta-Opioid Receptor Expression in Mice	PLOS ONE			English	Article							MAMMALIAN TACHYKININ PEPTIDE; IN-SITU HYBRIDIZATION; RAT/MOUSE HEMOKININ-1; MESSENGER-RNA; CARDIOVASCULAR-RESPONSES; PHARMACOLOGICAL PROFILE; FUNCTIONAL EXPRESSION; PERIAQUEDUCTAL GRAY; SUPRASPINAL LEVEL; ANESTHETIZED RATS	Our previous studies have shown that an active fragment of human tachykinins (hHK-1(4-11)) produced an opioid-independent analgesia after intracerebroventricular (i.c.v.) injection in mice, which has been markedly enhanced by a delta OR antagonist, naltrindole hydrochloride (NTI). In this study, we have further characterized the in vivo analgesia after i.c.v. injection of hHK-1(4-11) in mouse model. Our qRT-PCR results showed that the mRNA levels of several ligands and receptors (e. g. PPT-A, PPT-C, KOR, PDYN and PENK) have not changed significantly. Furthermore, neither transcription nor expression of NK1 receptor, MOR and POMC have changed noticeably. In contrast, both mRNA and protein levels of DOR have been up-regulated significantly, indicating that the enhanced expression of delta opioid receptor negatively modulates the analgesia induced by i.c.v. injection of hHK-1(4-11). Additionally, the combinatorial data from our previous and present experiments strongly suggest that the discriminable distribution sites in the central nervous system between hHK-1(4-11) and r/mHK-1 may be attributed to their discriminable analgesic effects. Altogether, our findings will not only contribute to the understanding of the complicated mechanisms regarding the nociceptive modulation of hemokinin-1 as well as its active fragments at supraspinal level, but may also lead to novel pharmacological interventions.	[Fu, Cai-Yun; Xia, Rui-Long; Zhang, Teng-Fei; Lu, Yan; Zhang, Shi-Fu] Zhejiang Sci Tech Univ, Coll Life Sci, Lab Prote & Mol Enzymol, Hangzhou, Zhejiang, Peoples R China; [Jin, Tao; Mou, Xiao-Zhou] Zhejiang Prov Peoples Hosp, Hangzhou, Zhejiang, Peoples R China; [Fu, Cai-Yun; Mou, Xiao-Zhou] Inst Cell Based Drug Dev Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China; [Yu, Zhi-Qiang] Arizona State Univ, Biodesign Inst, Ctr BioEnerget, Tempe, AZ USA; [Yu, Zhi-Qiang] Arizona State Univ, Dept Chem & Biochem, Tempe, AZ USA	Zhejiang Sci-Tech University; Zhejiang Provincial People's Hospital; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Fu, CY (corresponding author), Zhejiang Sci Tech Univ, Coll Life Sci, Lab Prote & Mol Enzymol, Hangzhou, Zhejiang, Peoples R China.	fucy03@126.com; zhiqiang.yu.1@asu.edu; mouxiaozhou@gmail.com		Fu, Caiyun/0000-0003-4090-885X	National Natural Science Foundation of China [31000496, 81201783]; 521 Talent Foundation of Zhejiang Sci-Tech University, Key Technologies R&D Program of Zhejiang Province [2012C13015-2]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 521 Talent Foundation of Zhejiang Sci-Tech University, Key Technologies R&D Program of Zhejiang Province	This work was supported by grants from the National Natural Science Foundation of China (No. 31000496, No. 81201783), the 521 Talent Foundation of Zhejiang Sci-Tech University, Key Technologies R&D Program of Zhejiang Province (No. 2012C13015-2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bellucci F, 2002, BRIT J PHARMACOL, V135, P266, DOI 10.1038/sj.bjp.0704443; Camarda V, 2002, LIFE SCI, V71, P363, DOI 10.1016/S0024-3205(02)01682-X; CHEN Y, 1993, MOL PHARMACOL, V44, P8; DELFS JM, 1994, J COMP NEUROL, V345, P46, DOI 10.1002/cne.903450104; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; Endo D, 2006, NEUROSCI LETT, V392, P114, DOI 10.1016/j.neulet.2005.09.005; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; Franklin K. B. J., 2013, PAXINOS FRANKLINS MO; Fu CY, 2008, BRAIN BEHAV IMMUN, V22, P850, DOI 10.1016/j.bbi.2007.12.010; Fu CY, 2007, BEHAV BRAIN RES, V184, P39, DOI 10.1016/j.bbr.2007.06.019; Fu CY, 2007, EUR J PHARMACOL, V572, P175, DOI 10.1016/j.ejphar.2007.06.014; Fu CY, 2006, BEHAV BRAIN RES, V170, P293, DOI 10.1016/j.bbr.2006.03.007; Fu CY, 2005, BRAIN RES, V1056, P51, DOI 10.1016/j.brainres.2005.07.020; Fueloep L, 2001, PEPT SCI, V7, P397; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; JENSEN TS, 1986, BRAIN RES, V372, P301, DOI 10.1016/0006-8993(86)91138-8; KAKIDANI H, 1982, NATURE, V298, P245, DOI 10.1038/298245a0; Kalyuzhny AE, 1996, J NEUROSCI, V16, P6490; Klassert TE, 2008, J NEUROIMMUNOL, V196, P27, DOI 10.1016/j.jneuroim.2008.02.010; Kong ZQ, 2008, EUR J PHARMACOL, V590, P310, DOI 10.1016/j.ejphar.2008.05.049; Kong ZQ, 2010, NEUROPEPTIDES, V44, P437, DOI 10.1016/j.npep.2010.04.006; KOTANI H, 1986, P NATL ACAD SCI USA, V83, P7074, DOI 10.1073/pnas.83.18.7074; Kurtz MM, 2002, GENE, V296, P205, DOI 10.1016/S0378-1119(02)00861-2; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Long Y, 2007, EUR J PHARMACOL, V569, P119, DOI 10.1016/j.ejphar.2007.04.049; MANSOUR A, 1994, J COMP NEUROL, V350, P412, DOI 10.1002/cne.903500307; Matsumura T, 2008, BRIT J PHARMACOL, V155, P767, DOI 10.1038/bjp.2008.301; MINAMI M, 1993, FEBS LETT, V329, P291, DOI 10.1016/0014-5793(93)80240-U; NAWA H, 1983, NATURE, V306, P32, DOI 10.1038/306032a0; NODA M, 1982, NATURE, V295, P202, DOI 10.1038/295202a0; Page NM, 2004, CELL MOL LIFE SCI, V61, P1652, DOI 10.1007/s00018-004-4035-x; Pennefather JN, 2004, LIFE SCI, V74, P1445, DOI 10.1016/j.lfs.2003.09.039; Severini C, 2002, PHARMACOL REV, V54, P285, DOI 10.1124/pr.54.2.285; URBAN MO, 1994, BRAIN RES, V652, P9, DOI 10.1016/0006-8993(94)90311-5; Walsh DA, 2006, CURR DRUG TARGETS, V7, P1031, DOI 10.2174/138945006778019291; Xia RL, 2013, PEPTIDES, V43, P113, DOI 10.1016/j.peptides.2013.02.020; Zhang Y, 2000, NAT IMMUNOL, V1, P392, DOI 10.1038/80826	37	16	16	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2014	9	2							e90446	10.1371/journal.pone.0090446	http://dx.doi.org/10.1371/journal.pone.0090446			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC3DW	24587368	Green Published, Green Submitted, gold			2023-01-03	WOS:000332396200202
J	Titov, N; Dear, BF; Johnston, L; McEvoy, PM; Wootton, B; Terides, MD; Gandy, M; Fogliati, V; Kayrouz, R; Rapee, RM				Titov, Nickolai; Dear, Blake F.; Johnston, Luke; McEvoy, Peter M.; Wootton, Bethany; Terides, Matthew D.; Gandy, Milena; Fogliati, Vincent; Kayrouz, Rony; Rapee, Ronald M.			Improving Adherence and Clinical Outcomes in Self-Guided Internet Treatment for Anxiety and Depression: A 12-Month Follow-Up of a Randomised Controlled Trial	PLOS ONE			English	Article							COGNITIVE-BEHAVIORAL THERAPY; SOCIAL PHOBIA; MEASURING RESPONSE; DISORDER; HEALTH; QUESTIONNAIRE; RELAPSE; PHQ-9; CARE	Background: A recent paper reported the outcomes of a study examining a new self-guided internet-delivered treatment, the Wellbeing Course, for symptoms of anxiety or depression. This study found the intervention resulted in significant symptom reductions. It also found that automated emails increased treatment completion and clinical improvements in a subsample with elevated anxiety and depression. Aims: To examine the clinical outcomes and the effect of automated emails at 12 months post-treatment. Method: Participants, who were randomly allocated to a Treatment Plus Automated Emails Group (TEG; n = 100), a standard Treatment Group (TG; n = 106) or delayed-treatment Waitlist Control Group (Control; n = 51), were followed up at 12 months post-treatment. Eighty-one percent, 78% and 87% of participants in the TEG, TG and treated Waitlist Control Group provided symptom data at 12-month follow-up, respectively. The primary outcome measures were the Patient Health Questionnaire-9 Item Scale (PHQ-9) and the Generalized Anxiety Disorder-7 Item Scale (GAD-7). Results: Significant improvements in symptoms of anxiety and depression were observed over time in both the TEG and TG (Fs > 69, ps < .001) these were sustained from post-treatment to 12-month follow-up (ps > .05), and were associated with large effect sizes. No statistically significant differences in symptoms were found between the TEG and TG at post-treatment, 3-month or 12-month follow-up. Previously reported symptom differences between TEG and TG participants with comorbid symptoms were no longer present at 12-month follow-up (ps > .70). Conclusions: The overall benefits of the Wellbeing Course were sustained at 12-month follow-up. Although automated emails facilitated Course completion and reductions in symptoms for participants with comorbid anxiety and depression from pre-post treatment, these differences were no longer observed at 12-month follow-up. The results indicate that automated emails promote more rapid treatment response for people with elevated and comorbid symptoms, but may not improve longer term outcomes.	[Titov, Nickolai; Dear, Blake F.; Johnston, Luke; Wootton, Bethany; Terides, Matthew D.; Gandy, Milena; Fogliati, Vincent; Kayrouz, Rony; Rapee, Ronald M.] Macquarie Univ, Ctr Emot Hlth, Dept Psychol, Sydney, NSW 2109, Australia; [McEvoy, Peter M.] UWA, Ctr Clin Intervent, Perth, WA, Australia; [McEvoy, Peter M.] UWA, Sch Psychol, Perth, WA, Australia	Macquarie University; University of Western Australia; University of Western Australia	Titov, N (corresponding author), Macquarie Univ, Ctr Emot Hlth, Dept Psychol, Sydney, NSW 2109, Australia.	nick.titov@mq.edu.au	Gandy, Milena/AAV-3617-2020	Gandy, Milena/0000-0003-2161-3298; Titov, Nickolai/0000-0002-7268-729X; Woottonb, Bethany/0000-0002-0751-8529; Wootton, Bethany/0000-0001-9036-0699; Rapee, Ronald/0000-0002-1724-1076; Dear, Blake/0000-0001-9324-3092; McEvoy, Peter/0000-0003-2924-6760	Australian National Health and Medical Research Council (NHMRC) Project [630560]; National Health and Medical Research Council (NHMRC) Australian Public Health Fellowship	Australian National Health and Medical Research Council (NHMRC) Project(National Health and Medical Research Council (NHMRC) of Australia); National Health and Medical Research Council (NHMRC) Australian Public Health Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	The authors gratefully acknowledge the participants for their involvement and helpful comments. This research was enabled by funding from the Australian National Health and Medical Research Council (NHMRC) Project Grant No. 630560. BFD is supported by a National Health and Medical Research Council (NHMRC) Australian Public Health Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersson Gerhard, 2009, Cognitive Behaviour Therapy, V38, P55, DOI 10.1080/16506070902916400; Berger Thomas, 2011, Cognitive Behaviour Therapy, V40, P251, DOI 10.1080/16506073.2011.616531; Carlbring P, 2009, BEHAV RES THER, V47, P848, DOI 10.1016/j.brat.2009.06.012; Christensen H, 2006, PSYCHOL MED, V36, P1737, DOI 10.1017/S0033291706008695; Clarke G, 2005, J MED INTERNET RES, V7, DOI 10.2196/jmir.7.2.e16; Clarke G, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.3.e14; Dear BF, 2011, BEHAV RES THER, V49, P830, DOI 10.1016/j.brat.2011.09.007; Dear Blake F., 2011, Cognitive Behaviour Therapy, V40, P216, DOI 10.1080/16506073.2011.582138; Farvolden P, 2009, J TECHNOL HUMAN SERV, V27, P5, DOI 10.1080/15228830802458889; Furmark T, 2009, BRIT J PSYCHIAT, V195, P440, DOI 10.1192/bjp.bp.108.060996; Gilbody S, 2007, J GEN INTERN MED, V22, P1596, DOI 10.1007/s11606-007-0333-y; Johnston L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028079; Klasnja P, 2012, J BIOMED INFORM, V45, P184, DOI 10.1016/j.jbi.2011.08.017; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kroenke K, 2007, ANN INTERN MED, V146, P317, DOI 10.7326/0003-4819-146-5-200703060-00004; Kroenke K, 2010, GEN HOSP PSYCHIAT, V32, P345, DOI 10.1016/j.genhosppsych.2010.03.006; Mackinnon A, 2008, BRIT J PSYCHIAT, V192, P130, DOI 10.1192/bjp.bp.106.032078; McEvoy PM, 2009, J COGN PSYCHOTHER, V23, P20, DOI 10.1891/0889-8391.23.1.20; Meyer B, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1151; Richards DA, 2009, BRIT J CLIN PSYCHOL, V48, P377, DOI 10.1348/014466509X405178; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Spek V, 2008, PSYCHOL MED, V38, P635, DOI 10.1017/S0033291707002590; Titov N, 2012, SPANISH J CLIN PSYCH, V17, P237, DOI DOI 10.5944/RPPC.V0L.17.NUM.3.2012; Titov N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062873; Titov Nickolai, 2011, Cognitive Behaviour Therapy, V40, P126, DOI 10.1080/16506073.2010.550059; Titov N, 2011, BEHAV RES THER, V49, P441, DOI 10.1016/j.brat.2011.03.007; Titov N, 2010, AUST NZ J PSYCHIAT, V44, P938, DOI 10.3109/00048674.2010.493859; Titov N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010885; Titov N, 2009, AUST NZ J PSYCHIAT, V43, P913, DOI 10.1080/00048670903179160; Titov N, 2008, AUST NZ J PSYCHIAT, V42, P1030, DOI 10.1080/00048670802512107; Titov N, 2009, AUST NZ J PSYCHIAT, V43, P36, DOI 10.1080/00048670802534424; Vittengl JR, 2007, J CONSULT CLIN PSYCH, V75, P475, DOI 10.1037/0022-006X.75.3.475; Yonkers KA, 2003, DEPRESS ANXIETY, V17, P173, DOI 10.1002/da.10106	33	45	45	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2014	9	2							e89591	10.1371/journal.pone.0089591	http://dx.doi.org/10.1371/journal.pone.0089591			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AC2ZX	24586897	Green Published, gold, Green Submitted			2023-01-03	WOS:000332385900056
J	Jung, K; LePendu, P; Chen, WS; Iyer, SV; Readhead, B; Dudley, JT; Shah, NH				Jung, Kenneth; LePendu, Paea; Chen, William S.; Iyer, Srinivasan V.; Readhead, Ben; Dudley, Joel T.; Shah, Nigam H.			Automated Detection of Off-Label Drug Use	PLOS ONE			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; GENE-EXPRESSION OMNIBUS; DOUBLE-BLIND; PPAR-GAMMA; SAFETY; EFFICACY; BEVACIZUMAB; VALIDATION; MIGRAINE; PATIENT	Off-label drug use, defined as use of a drug in a manner that deviates from its approved use defined by the drug's FDA label, is problematic because such uses have not been evaluated for safety and efficacy. Studies estimate that 21% of prescriptions are off-label, and only 27% of those have evidence of safety and efficacy. We describe a data-mining approach for systematically identifying off-label usages using features derived from free text clinical notes and features extracted from two databases on known usage (Medi-Span and DrugBank). We trained a highly accurate predictive model that detects novel off-label uses among 1,602 unique drugs and 1,472 unique indications. We validated 403 predicted uses across independent data sources. Finally, we prioritize well-supported novel usages for further investigation on the basis of drug safety and cost.	[Jung, Kenneth; Iyer, Srinivasan V.] Stanford Univ, Program Biomed Informat, Stanford, CA 94305 USA; [Dudley, Joel T.] Icahn Sch Med Mt Sinai, New York, NY USA; [LePendu, Paea; Chen, William S.; Shah, Nigam H.] Stanford Univ, Ctr Biomed Informat Res, Stanford, CA 94305 USA	Stanford University; Icahn School of Medicine at Mount Sinai; Stanford University	Jung, K (corresponding author), Stanford Univ, Program Biomed Informat, Stanford, CA 94305 USA.	kjung@stanford.edu		LePendu, Paea/0000-0001-7358-931X	National Institutes of Health [U54-HG004028]; Smith Stanford Graduate Fellowship; Bio-X Interdisciplinary Initiatives Program; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG004028] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM011369, T15LM007033] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Smith Stanford Graduate Fellowship; Bio-X Interdisciplinary Initiatives Program; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	The authors acknowledge support from National Institutes of Health grant U54-HG004028 for the National Center for Biomedical Ontology. KJ was supported by the Smith Stanford Graduate Fellowship. WC was funded by the Bio-X Interdisciplinary Initiatives Program (http://biox.stanford.edu/grant/iip_program.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; Avillach P, 2013, J AM MED INFORM ASSN, V20, P446, DOI 10.1136/amiajnl-2012-001083; Banko M, 2001, 39TH ANNUAL MEETING OF THE ASSOCIATION FOR COMPUTATIONAL LINGUISTICS, PROCEEDINGS OF THE CONFERENCE, P26, DOI 10.3115/1073012.1073017; Barrett T, 2006, METHOD ENZYMOL, V411, P352, DOI 10.1016/S0076-6879(06)11019-8; Bodenreider O, 2004, NUCLEIC ACIDS RES, V32, pD267, DOI 10.1093/nar/gkh061; Brown SH, 2004, STUD HEALTH TECHNOL, V107, P477; Chapman WW, 2011, J AM MED INFORM ASSN, V18, P540, DOI 10.1136/amiajnl-2011-000465; Chapman WW, 2001, J BIOMED INFORM, V34, P301, DOI 10.1006/jbin.2001.1029; Chen DT, 2009, PHARMACOEPIDEM DR S, V18, P1094, DOI 10.1002/pds.1825; Chen ES, 2008, J AM MED INFORM ASSN, V15, P87, DOI 10.1197/jamia.M2401; Chu D, 2007, BIONLP 2007 BIOL TRA, P81, DOI 10.3115/1572392.1572408; Dal Pan GJ, 2012, CLIN PHARMACOL THER, V91, P787, DOI 10.1038/clpt.2012.24; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Epstein RS, 2012, CLIN PHARMACOL THER, V91, P755, DOI 10.1038/clpt.2012.37; Flowers CM, 2006, NEW ENGL J MED, V354, P773, DOI 10.1056/NEJMc055301; Ginsberg J, 2009, NATURE, V457, P1012, DOI 10.1038/nature07634; Grip O, 2002, INFLAMM RES, V51, P58, DOI 10.1007/BF02684000; Hagenbeek A, 2008, BLOOD, V111, P5486, DOI 10.1182/blood-2007-10-117671; Halevy A, 2009, IEEE INTELL SYST, V24, P8, DOI 10.1109/MIS.2009.36; Hastie T., 2009, ELEMENTS STAT LEARNI, DOI [10.1007/978-0-387-84858-7, DOI 10.1007/978-0-387-84858-7]; Hayat SJ, 2007, CLIN RHEUMATOL, V26, P973, DOI 10.1007/s10067-006-0219-0; Iyer SV, 2013, AMIA SUMMITS TRANSL; Jung Kenneth, 2013, AMIA Jt Summits Transl Sci Proc, V2013, P94; Kimland E, 2012, CLIN PHARMACOL THER, V91, P796, DOI 10.1038/clpt.2012.26; Knox C, 2011, NUCLEIC ACIDS RES, V39, pD1035, DOI 10.1093/nar/gkq1126; Kuhn M, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2009.98; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lampl C, 2005, J NEUROL NEUROSUR PS, V76, P1730, DOI 10.1136/jnnp.2005.063750; Lependu P, 2013, CLIN PHARM THER; LePendu P, 2012, ANAL PATTERNS DRUG U; Li Ying, 2011, AMIA Annu Symp Proc, V2011, P768; Liu Yi, 2012, AMIA Jt Summits Transl Sci Proc, V2012, P47; Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673; Meltzer DO, 2011, MED DECIS MAKING, V31, pE1, DOI 10.1177/0272989X11412975; Merrill JT, 2010, ARTHRITIS RHEUM-US, V62, P3077, DOI 10.1002/art.27601; Merrill JT, 2010, ARTHRITIS RHEUM-US, V62, P222, DOI 10.1002/art.27233; Morris J, 2012, CLIN PHARMACOL THER, V91, P937, DOI 10.1038/clpt.2012.30; Nelson SJ, 2011, J AM MED INFORM ASSN, V18, P441, DOI 10.1136/amiajnl-2011-000116; Or R, 2003, BLOOD, V101, P441, DOI 10.1182/blood-2002-02-0535; Perren TJ, 2011, NEW ENGL J MED, V365, P2484, DOI 10.1056/NEJMoa1103799; Pizzolato R, 2011, J HEADACHE PAIN, V12, P521, DOI 10.1007/s10194-011-0338-0; Platt JC, 2000, ADV NEUR IN, P61; Platt R, 2012, PHARMACOEPIDEM DR S, V21, P1, DOI 10.1002/pds.2343; Poissant L, 2010, BMC MED INFORM DECIS, V10, DOI 10.1186/1472-6947-10-10; Poole SG, 2004, SUPPORT CARE CANCER, V12, P302, DOI 10.1007/s00520-004-0593-6; Radley DC, 2006, ARCH INTERN MED, V166, P1021, DOI 10.1001/archinte.166.9.1021; Rindflesch Thomas C, 2005, AMIA Annu Symp Proc, P634; Shakoor N, 2002, LANCET, V359, P579, DOI 10.1016/S0140-6736(02)07714-0; Sirota M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001318; Stafford RS, 2012, CLIN PHARMACOL THER, V91, P920, DOI 10.1038/clpt.2012.22; Tsentralfarband fun die bundistishe organisatsyonen in Amerika, 1905, KEMFER, V1, P1; Uzuner O, 2011, J AM MED INFORM ASSN, V18, P552, DOI 10.1136/amiajnl-2011-000203; Wei Wei-Qi, 2013, AMIA Jt Summits Transl Sci Proc, V2013, P172; Weiss-Smith S, 2011, ARCH INTERN MED, V171, P591, DOI 10.1001/archinternmed.2011.89; Xu R, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-181	55	40	41	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2014	9	2							e89324	10.1371/journal.pone.0089324	http://dx.doi.org/10.1371/journal.pone.0089324			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AB3TA	24586689	Green Submitted, Green Published, gold			2023-01-03	WOS:000331711900124
J	de Ronde, JJ; Bonder, MJ; Lips, EH; Rodenhuis, S; Wessels, LFA				de Ronde, Jorma J.; Bonder, Marc Jan; Lips, Esther H.; Rodenhuis, Sjoerd; Wessels, Lodewyk F. A.			Breast Cancer Subtype Specific Classifiers of Response to Neoadjuvant Chemotherapy Do Not Outperform Classifiers Trained on All Subtypes	PLOS ONE			English	Article							PATHOLOGICAL COMPLETE RESPONSE; GENE-EXPRESSION PROFILES; CYCLOPHOSPHAMIDE CHEMOTHERAPY; PREOPERATIVE CHEMOTHERAPY; DOXORUBICIN; PACLITAXEL; FLUOROURACIL; PREDICTOR; TRASTUZUMAB; RESISTANCE	Introduction: Despite continuous efforts, not a single predictor of breast cancer chemotherapy resistance has made it into the clinic yet. However, it has become clear in recent years that breast cancer is a collection of molecularly distinct diseases. With ever increasing amounts of breast cancer data becoming available, we set out to study if gene expression based predictors of chemotherapy resistance that are specific for breast cancer subtypes can improve upon the performance of generic predictors. Methods: We trained predictors of resistance that were specific for a subtype and generic predictors that were not specific for a particular subtype, i.e. trained on all subtypes simultaneously. Through a rigorous double-loop cross-validation we compared the performance of these two types of predictors on the different subtypes on a large set of tumors all profiled on the same expression platform (n = 394). We evaluated predictors based on either mRNA gene expression or clinical features. Results: For HER2+, ER- breast cancer, subtype specific predictor based on clinical features outperformed the generic, nonspecific predictor. This can be explained by the fact that the generic predictor included HER2 and ER status, features that are predictive over the whole set, but not within this subtype. In all other scenarios the generic predictors outperformed the subtype specific predictors or showed equal performance. Conclusions: Since it depends on the specific context which type of predictor - subtype specific or generic-performed better, it is highly recommended to evaluate both specific and generic predictors when attempting to predict treatment response in breast cancer.	[de Ronde, Jorma J.; Bonder, Marc Jan; Wessels, Lodewyk F. A.] Netherlands Canc Inst, Dept Mol Carcinogenesis, Amsterdam, Netherlands; [de Ronde, Jorma J.; Lips, Esther H.] Netherlands Canc Inst, Dept Mol Pathol, Amsterdam, Netherlands; [Lips, Esther H.] Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands; [Rodenhuis, Sjoerd] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands; [Wessels, Lodewyk F. A.] Delft Univ Technol, Fac EEMCS, Delft, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Delft University of Technology	de Ronde, JJ (corresponding author), Netherlands Canc Inst, Dept Mol Carcinogenesis, Amsterdam, Netherlands.	jorma.deronde@gmail.com		Bonder, Marc Jan/0000-0002-8431-3180	CTMM, the Center for Translational Molecular Medicine, project Breast CARE [03O-104]	CTMM, the Center for Translational Molecular Medicine, project Breast CARE	JR and EL were funded by CTMM, the Center for Translational Molecular Medicine (www.ctmm.nl), project Breast CARE (Grant 03O-104). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen JD, 2011, BRIEFINGS BIOINFORMA; [Anonymous], 2012, R LANG ENV STAT COMP; Ayers M, 2004, J CLIN ONCOL, V22, P2284, DOI 10.1200/JCO.2004.05.166; Bertucci F, 2004, CANCER RES, V64, P8558, DOI 10.1158/0008-5472.CAN-04-2696; Borst P, 2010, CELL CYCLE, V9, P4836, DOI 10.4161/cc.9.24.14326; Cleator S, 2006, BREAST CANCER RES TR, V95, P229, DOI 10.1007/s10549-005-9009-7; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fisher B, 1998, J CLIN ONCOL, V16, P2672, DOI 10.1200/JCO.1998.16.8.2672; Gyorffy B, 2006, INT J CANCER, V118, P1699, DOI 10.1002/ijc.21570; Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861; Horiguchi J, 2011, ANTICANCER RES, V31, P3041; Hornik K, 2009, COMPUTATION STAT, V24, P225, DOI 10.1007/s00180-008-0119-7; Kaufmann M, 2006, J CLIN ONCOL, V24, P1940, DOI 10.1200/JCO.2005.02.6187; Kuerer HM, 1999, J CLIN ONCOL, V17, P460, DOI 10.1200/JCO.1999.17.2.460; Miyake T, 2012, CANCER SCI, V103, P913, DOI 10.1111/j.1349-7006.2012.02231.x; Naoi Y, 2011, CANCER-AM CANCER SOC, V117, P3682, DOI 10.1002/cncr.25953; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Popovici V, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2468; Romanski P, 2009, FSELECTOR SELECTING; Sorlie T, 2006, MOL CANCER THER, V5, P2914, DOI 10.1158/1535-7163.MCT-06-0126; Tabchy A, 2010, CLIN CANCER RES, V16, P5351, DOI 10.1158/1078-0432.CCR-10-1265; Valachis A, 2011, BREAST, V20, P485, DOI 10.1016/j.breast.2011.06.009; Wessels LFA, 2005, BIOINFORMATICS, V21, P3755, DOI 10.1093/bioinformatics/bti429; Witten IH, 2011, MOR KAUF D, P1; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683	25	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2014	9	2							e88551	10.1371/journal.pone.0088551	http://dx.doi.org/10.1371/journal.pone.0088551			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AB3RA	24558399	gold, Green Published, Green Submitted			2023-01-03	WOS:000331706700045
J	Bazargani, YT; Ewen, M; de Boer, A; Leufkens, HGM; Mantel-Teeuwisse, AK				Bazargani, Yaser T.; Ewen, Margaret; de Boer, Anthonius; Leufkens, Hubert G. M.; Mantel-Teeuwisse, Aukje K.			Essential Medicines Are More Available than Other Medicines around the Globe	PLOS ONE			English	Article							ANTIEPILEPTIC DRUGS; AFFORDABILITY; PRICES; CHILDREN; CARE	Background: The World Health Organization (WHO) promotes the development of national Essential Medicines Lists (EMLs) in order to improve the availability and use of medicines considered essential within health care systems. However, despite over 3 decades of international efforts, studies show an inconsistent pattern in the availability of essential medicines. We evaluated and compared the availability of essential medicines, and medicines not included in national EMLs, at global and regional levels. Methods: Medicine availability in the public and private sector were calculated based on data obtained from national and provincial facility-based surveys undertaken in 23 countries using the WHO/HAI methodology. The medicines were grouped according to their inclusion ('essential') or exclusion (termed 'non-essential') in each country's EML current at the time of the survey. Availability was calculated for originator brands, generics and any product type (originator brands or generics) and compared between the two groups. Results were aggregated by WHO regions, World Bank country income groups, a wealth inequality measure, and therapeutic groups. Findings: Across all sectors and any product type, the median availability of essential medicines was suboptimal at 61.5% (IQR 20.6%-86.7%) but significantly higher than non-essential medicines at 27.3% (IQR 3.6%-70.0%). The median availability of essential medicines was 40.0% in the public sector and 78.1% in the private sector; compared to 6.6% and 57.1% for non-essential medicines respectively. A reverse trend between national income level categories and the availability of essential medicines was identified in the public sector. Interpretation: EMLs have influenced the provision of medicines and have resulted in higher availability of essential medicines compared to non-essential medicines particularly in the public sector and in low and lower middle income countries. However, the availability of essential medicines, especially in the public sector does not ensure equitable access.	[Bazargani, Yaser T.; de Boer, Anthonius; Leufkens, Hubert G. M.; Mantel-Teeuwisse, Aukje K.] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands; [Ewen, Margaret] Hlth Act Int Global, Amsterdam, Netherlands	Utrecht University	Mantel-Teeuwisse, AK (corresponding author), Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands.	A.K.Mantel@uu.nl	Mantel-Teeuwisse, Aukje/I-8902-2016					[Anonymous], WHO MED TERM STRAT P; Balasubramaniam R., 2011, CEYLON MEDICAL JOURNAL, V56, P101, DOI 10.4038/cmj.v56i3.3597; Bertoldi AD, 2012, GLOBALIZATION HEALTH, V8, DOI 10.1186/1744-8603-8-6; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Cameron A, 2012, VALUE HEALTH, V15, P664, DOI 10.1016/j.jval.2012.04.004; Cameron A, 2011, B WORLD HEALTH ORGAN, V89, P412, DOI 10.2471/BLT.10.084327; Carasso BS, 2009, TROP MED INT HEALTH, V14, P1394, DOI 10.1111/j.1365-3156.2009.02383.x; Chakma J, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-9; Chen W, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-211; Cheraghali AM, 2009, PHARM WORLD SCI, V31, P209, DOI 10.1007/s11096-009-9282-3; Chomba EN, 2010, AM J TROP MED HYG, V83, P571, DOI 10.4269/ajtmh.2010.10-0100; Dixit R, 2011, INDIAN J PHARMACOL, V43, P599, DOI 10.4103/0253-7613.84981; Gitanjali B, 2011, J PHARMACOL PHARMACO, V2, P95, DOI 10.4103/0976-500X.81900; Health Action International, 2008, MEAS MED PRIC AV AFF; Higuchi M, 2010, ASIA-PAC J PUBLIC HE, V22, p96S, DOI 10.1177/1010539510373005; *HLTH ACT INT, 2012, WHO HAI PROJ MED PRI; *HLTH ACT INT, 2003, MED PRIC NEW APPR ME; KANAVOS P, 2011, WORLDS MED SITUATION; Kaplan Warren Allan, 2011, South Med Rev, V4, P51, DOI 10.5655/smr.v4i2.1002; Mackey TK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051022; Madden JM, 2010, REV PANAM SALUD PUBL, V27, P291, DOI 10.1590/S1020-49892010000400008; Management Science for Health, 2012, MAN ACC MED HLTH TEC; *NORW I PUBL HLTH, 2012, AN THER CHEM ATC CLA; Odermatt P, 2007, NEUROEPIDEMIOLOGY, V28, P169, DOI 10.1159/000103270; Robertson J, 2007, CLIN PHARMACOL THER, V82, P498, DOI 10.1038/sj.clpt.6100392; Saouadogo Hamado, 2011, World Hosp Health Serv, V47, P8; Senarathna SMDKG, 2011, INDIAN J PHARMACOL, V43, P60, DOI 10.4103/0253-7613.75672; The World Bank, 2011, GINI IND; Twisselmann B, 2005, BRIT MED J, V330, P479, DOI 10.1136/bmj.330.7489.479-a; *UN, MILL DEV GOALS MDG8; *UN, UN DECL HUM RIGHTS A; van Mourik MSM, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-25; VANDENHAM R, 2011, WORLDS MED SITUATION; Voelker R, 2010, JAMA-J AM MED ASSOC, V304, P259, DOI 10.1001/jama.2010.962; VOLGER S, 2012, FARMECONOMIA HLTH EC, V13, P29; *WHO, 2012, WHO DAT NAT MED LIST; *WHO, 2012, HLTH TOP ESS MED; *WHO, 2012, 20 WAYS WHO HELPS CO; *WHO, 2012, WHO REG LOC REG OFF; *WORLD BANK, 2011, COUNTR CLASS; World Health Organization, 2011, LOC PROD ACC MED PRO; Yang H, 2010, HEALTH POLICY PLANN, V25, P219, DOI 10.1093/heapol/czp056	42	63	64	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2014	9	2							e87576	10.1371/journal.pone.0087576	http://dx.doi.org/10.1371/journal.pone.0087576			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7FJ	24533058	Green Published, gold, Green Submitted			2023-01-03	WOS:000331262600016
J	Rosenfeld, D; Sherwood, S; Wood, R; Donner, L				Rosenfeld, Daniel; Sherwood, Steven; Wood, Robert; Donner, Leo			Climate Effects of Aerosol-Cloud Interactions	SCIENCE			English	Editorial Material									[Rosenfeld, Daniel] Hebrew Univ Jerusalem, IL-91904 Jerusalem, Israel; [Sherwood, Steven] Univ New S Wales, Sydney, NSW 2052, Australia; [Wood, Robert] Univ Washington, Seattle, WA 98195 USA; [Donner, Leo] NOAA, Geophys Fluid Dynam Lab, Princeton, NJ 08540 USA	Hebrew University of Jerusalem; University of New South Wales Sydney; University of Washington; University of Washington Seattle; National Oceanic Atmospheric Admin (NOAA) - USA	Rosenfeld, D (corresponding author), Hebrew Univ Jerusalem, IL-91904 Jerusalem, Israel.	daniel.rosen-feld@huji.ac.il	Rosenfeld, Daniel/AAJ-4617-2021; Sherwood, Steven/B-5673-2008; Wood, Robert/A-2989-2008; Rosenfeld, Daniel/F-6077-2016	Rosenfeld, Daniel/0000-0002-0784-7656; Sherwood, Steven/0000-0001-7420-8216; Wood, Robert/0000-0002-1401-3828; Rosenfeld, Daniel/0000-0002-0784-7656	Div Atmospheric & Geospace Sciences [0968609] Funding Source: National Science Foundation	Div Atmospheric & Geospace Sciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))		ACKERMAN AS, 1993, SCIENCE, V262, P226, DOI 10.1126/science.262.5131.226; Anderson TL, 2003, SCIENCE, V300, P1103, DOI 10.1126/science.1084777; Andreae M. O., 2009, AEROSOLS CLOUDS PREC; Carslaw KS, 2013, NATURE, V503, P67, DOI 10.1038/nature12674; Goren T, 2012, J GEOPHYS RES-ATMOS, V117, DOI 10.1029/2012JD017981; IPCC, 2014, CONTRIBUTION WORKING; Isaksen ISA, 2009, ATMOS ENVIRON, V43, P5138, DOI 10.1016/j.atmosenv.2009.08.003; Koren I, 2010, ATMOS CHEM PHYS, V10, P5001, DOI 10.5194/acp-10-5001-2010; Renno NO, 2013, B AM METEOROL SOC, V94, P685, DOI 10.1175/BAMS-D-11-00239.1; Solomon S, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P1; Stevens B, 2009, NATURE, V461, P607, DOI 10.1038/nature08281; Wang M, 2011, ATMOS CHEM PHYS, V11, P5431, DOI 10.5194/acp-11-5431-2011; Winker DM, 2009, J ATMOS OCEAN TECH, V26, P2310, DOI 10.1175/2009JTECHA1281.1	13	268	274	5	215	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 24	2014	343	6169					379	380		10.1126/science.1247490	http://dx.doi.org/10.1126/science.1247490			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294IR	24458631				2023-01-03	WOS:000330039300035
J	[Anonymous]				[Anonymous]			WHO response to BMJ queries	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 14	2014	348								f7271	10.1136/bmj.f7271	http://dx.doi.org/10.1136/bmj.f7271			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293MN	24423892				2023-01-03	WOS:000329975900003
J	Elert, E				Elert, Emily			CALLING CELLS TO ARMS	NATURE			English	Editorial Material																			0	9	22	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 19	2013	504	7480					S2	S3		10.1038/504S2a	http://dx.doi.org/10.1038/504S2a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	273ZR	24352361	Bronze			2023-01-03	WOS:000328575300002
J	Chu, PHW; Li, HY; Chin, MP; So, KF; Chan, HHL				Chu, Patrick H. W.; Li, Hong-Ying; Chin, Man-Pan; So, Kwok-fai; Chan, Henry H. L.			Effect of Lycium Barbarum (Wolfberry) Polysaccharides on Preserving Retinal Function after Partial Optic Nerve Transection	PLOS ONE			English	Article							LUMINANCE-MODULATED ADAPTATION; GLOBAL FLASH MFERG; GANGLION-CELLS; SECONDARY DEGENERATION; MULTIFOCAL ELECTRORETINOGRAM; EXPERIMENTAL GLAUCOMA; UP-REGULATION; IN-VIVO; RATS; NEUROPROTECTION	Lycium Barbarum Polysaccharides (LBP) are the active components of Wolfberry (a traditional Chinese medicine) which has long been used for improving visual function. This study aims to investigate localized changes of retinal function in a partial optic nerve transection (PONT) model, and effects of LBP on visual function. The multifocal electroretinograms (mfERG) were obtained from 30 eyes of 30 Sprague-Dawley rats. The rats were divided into 6 groups (five treatment groups and one control group). Starting from the first day of the experiment, the rats in the (PONT+LBP) group and the (LBP) group were dosed with LBP; rats in the (PONT+PBS (phosphate buffered saline)) group and the (PBS) group were dosed with PBS via nasogastric tube every day until euthanized. The dorsal part of the optic nerve was transected in the (PONT), (PONT+LBP) and (PONT+PBS) groups at the end of week 1 (day 7 after LBP or PBS feeding began). The mfERG was measured at three time points: week 2, week 3 and week 5. Significant reduction of P1 and PhNR amplitudes of the mfERG were observed in all retinal regions a week after PONT. Feeding with LBP prior to PONT preserved retinal function. All mfERG responses returned to the normal range in the superior retina, which corresponds to the transected dorsal region of the optic nerve, while most of the inferior retinal responses were significantly increased at week 4 after PONT. The ventral part of the retina had secondary degeneration which was not only limited to the ganglion cell layer, but is a widespread effect affecting the outer retina. LBP altered the functional reduction caused by PONT by regulating the signal from the outer retina.	[Chu, Patrick H. W.; Chin, Man-Pan; Chan, Henry H. L.] Hong Kong Polytech Univ, Sch Optometry, Lab Expt Optometry Neurosci, Hong Kong, Hong Kong, Peoples R China; [Li, Hong-Ying; So, Kwok-fai] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Dept Anat, Res Ctr Heart Brain Hormone & Hlth Aging, Hong Kong, Hong Kong, Peoples R China; [Chan, Henry H. L.] Hong Kong Polytech Univ, Fac Hlth & Social Sci, Inst Act Ageing, Hong Kong, Hong Kong, Peoples R China	Hong Kong Polytechnic University; University of Hong Kong; Hong Kong Polytechnic University	So, KF (corresponding author), Univ Hong Kong, State Key Lab Brain & Cognit Sci, Dept Anat, Res Ctr Heart Brain Hormone & Hlth Aging, Hong Kong, Hong Kong, Peoples R China.	hrmaskf@hku.hk; henryhl.chan@polyu.edu.hk	Chu, Patrick HW/H-5532-2011; Li, Hong-Ying/AAH-2462-2019; Li, Hong-Ying/C-5762-2014; Li, Hongying/Q-1909-2016; Li, Hongying/AAU-2379-2021	Chu, Patrick HW/0000-0003-0547-2675; Li, Hong-Ying/0000-0002-1109-0799; Li, Hong-Ying/0000-0002-1109-0799; Li, Hongying/0000-0002-1109-0799; So, Kwok-Fai/0000-0003-4039-4246; CHAN, Henry HL/0000-0002-8516-4711	grant for Postdoctoral Fellowship [YX3C]; Internal Research Grants from The Hong Kong Polytechnic University [GU858]; Research Grants Council of the HKSAR, China [HKU 10208849]; Fundamental Research Funds for The Central Universities [21609101]; Azalea (1972) Foundation	grant for Postdoctoral Fellowship; Internal Research Grants from The Hong Kong Polytechnic University; Research Grants Council of the HKSAR, China(Hong Kong Research Grants Council); Fundamental Research Funds for The Central Universities(Fundamental Research Funds for the Central Universities); Azalea (1972) Foundation	This work was supported by a grant for Postdoctoral Fellowship (G-YX3C), Internal Research Grants (GU858) from The Hong Kong Polytechnic University, a grant from the Research Grants Council of the HKSAR, China (HKU 10208849), the Fundamental Research Funds for The Central Universities Grant 21609101 and the Azalea (1972) Foundation. The funders do not have any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ball SL, 2000, INVEST OPHTH VIS SCI, V41, P610; Blair M, 2005, INVEST OPHTH VIS SCI, V46, P884, DOI 10.1167/iovs.04-0731; Chan HHL, 2011, CLIN EXP OPTOM, V94, P247, DOI 10.1111/j.1444-0938.2010.00571.x; Chan HHL, 2005, J ALTERN COMPLEM MED, V11, P315, DOI 10.1089/acm.2005.11.315; Chan HC, 2007, EXP NEUROL, V203, P269, DOI 10.1016/j.expneurol.2006.05.031; Chan KC, 2011, NEUROIMAGE, V54, P389, DOI 10.1016/j.neuroimage.2010.07.015; Chiu K, 2010, J CELL BIOCHEM, V110, P311, DOI 10.1002/jcb.22539; Chiu Kin, 2009, J Ocul Biol Dis Infor, V2, P47; Chu PHW, 2008, VISION RES, V48, P1726, DOI 10.1016/j.visres.2008.05.006; Chu PHW, 2007, INVEST OPHTH VIS SCI, V48, P2626, DOI 10.1167/iovs.06-0962; Chu PHW, 2012, GRAEF ARCH CLIN EXP, V250, P261, DOI 10.1007/s00417-011-1790-x; Chu PHW, 2011, BRIT J OPHTHALMOL, V95, P1597, DOI 10.1136/bjophthalmol-2011-300263; Chu PHW, 2006, INVEST OPHTH VIS SCI, V47, P929, DOI 10.1167/iovs.05-0891; Fitzgerald M, 2009, INVEST OPHTH VIS SCI, V50, P5456, DOI 10.1167/iovs.09-3717; Fitzgerald M, 2009, EXP NEUROL, V216, P219, DOI 10.1016/j.expneurol.2008.11.026; Fortune B, 2012, INVEST OPHTH VIS SCI, V53, P3939, DOI 10.1167/iovs.12-9979; Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268; Ho YS, 2010, AGEING RES REV, V9, P354, DOI 10.1016/j.arr.2009.10.001; Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673; HUGHES A, 1979, VISION RES, V19, P569, DOI 10.1016/0042-6989(79)90143-3; Kielczewski JL, 2005, INVEST OPHTH VIS SCI, V46, P3188, DOI 10.1167/iovs.05-0321; Lalonde MR, 2006, J PHYSIOL-LONDON, V570, P325, DOI 10.1113/jphysiol.2005.098046; Lam KW, 1999, FOOD CHEM, V67, P173, DOI 10.1016/S0308-8146(99)00119-3; Levkovitch-Verbin H, 2001, INVEST OPHTH VIS SCI, V42, P975; Levkovitch-Verbin H, 2003, INVEST OPHTH VIS SCI, V44, P3388, DOI 10.1167/iovs.02-0646; Levkovitch-Verbin H, 2006, INVEST OPHTH VIS SCI, V47, P2491, DOI 10.1167/iovs.05-0996; Levkovitch-Verbin H, 2010, EXP EYE RES, V91, P127, DOI 10.1016/j.exer.2009.11.014; Li HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068881; Li L, 2007, BRAIN RES, V1159, P8, DOI 10.1016/j.brainres.2007.04.066; Li SY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016380; Machida S, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/397178; Mojumder DK, 2008, J PHYSIOL-LONDON, V586, P2551, DOI 10.1113/jphysiol.2008.150755; Ng YF, 2008, DOC OPHTHALMOL, V116, P165, DOI 10.1007/s10633-007-9076-7; Ortin-Martinez A, 2010, INVEST OPHTH VIS SCI, V51, P3171, DOI 10.1167/iovs.09-4861; Palmowski-Wolfe AM, 2007, DOC OPHTHALMOL, V114, P9, DOI 10.1007/s10633-006-9033-x; Selt M, 2010, BRAIN RES BULL, V81, P467, DOI 10.1016/j.brainresbull.2009.11.004; SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B; Yu MS, 2007, INT J MOL MED, V20, P261	38	33	35	0	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2013	8	12							e81339	10.1371/journal.pone.0081339	http://dx.doi.org/10.1371/journal.pone.0081339			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275VW	24339917	Green Published, gold, Green Submitted			2023-01-03	WOS:000328707400013
J	Micucci, M; Aldini, R; Cevenini, M; Colliva, C; Spinozzi, S; Roda, G; Montagnani, M; Camborata, C; Camarda, L; Chiarini, A; Mazzella, G; Budriesi, R				Micucci, Matteo; Aldini, Rita; Cevenini, Monica; Colliva, Carolina; Spinozzi, Silvia; Roda, Giulia; Montagnani, Marco; Camborata, Cecilia; Camarda, Luca; Chiarini, Alberto; Mazzella, Giuseppe; Budriesi, Roberta			Curcuma longa L. as a Therapeutic Agent in Intestinal Motility Disorders. 2: Safety Profile in Mouse	PLOS ONE			English	Article							IRRITABLE-BOWEL-SYNDROME; SALT EXPORT PUMP; INDUCED CHOLESTASIS; INHIBITION; ACTIVATION; SUPPRESSION; METABOLISM; EXPRESSION; SEROTONIN; APOPTOSIS	Background: Curcuma extract exerts a myorelaxant effect on the mouse intestine. In view of a possible use of curcuma extract in motor functional disorders of the gastrointestinal tract, a safety profile study has been carried out in the mouse. Methods: Thirty mice were used to study the in vitro effect of curcuma on gallbladder, bladder, aorta and trachea smooth muscular layers and hearth inotropic and chronotropic activity. The myorelaxant effect on the intestine was also thoroughly investigated. Moreover, curcuma extract (200 mg/Kg/day) was orally administered to twenty mice over 28 days and serum liver and lipids parameters were evaluated. Serum, bile and liver bile acids qualitative and quantitative composition was were also studied. Results: In the intestine, curcuma extract appeared as a not competitive inhibitor through cholinergic, histaminergic and serotoninergic receptors and showed spasmolytic effect on K+ induced contraction at the level of L type calcium channels. No side effect was observed on bladder, aorta, trachea and heart when we used a dose that is effective on the intestine. An increase in gallbladder tone and contraction was observed. Serum liver and lipids parameters were normal, while a slight increase in serum and liver bile acids concentration and a decrease in bile were observed. Conclusions: Although these data are consistent with the safety of curcuma extract as far as its effect on the smooth muscular layers of different organs and on the heart, the mild cholestatic effect observed in absence of alteration of liver function tests must be further evaluated and the effective dose with minimal side effects considered.	[Micucci, Matteo; Aldini, Rita; Camarda, Luca; Chiarini, Alberto; Budriesi, Roberta] Univ Bologna, Dipartimento Farm & Biotecnol, Bologna, Italy; [Cevenini, Monica; Roda, Giulia; Montagnani, Marco; Mazzella, Giuseppe] Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy; [Colliva, Carolina; Spinozzi, Silvia; Camborata, Cecilia] Univ Bologna, Dipartimento Chim G Ciamician, I-40126 Bologna, Italy	University of Bologna; University of Bologna; University of Bologna	Aldini, R (corresponding author), Univ Bologna, Dipartimento Farm & Biotecnol, Bologna, Italy.	rita.aldini@unibo.it; roberta.budriesi@unibo.it	Roda, Giulia/E-5521-2011; Micucci, Matteo/AAM-6126-2020; mazzella, giuseppe/A-1865-2016	MONTAGNANI, MARCO/0000-0003-0103-0327; MICUCCI, MATTEO/0000-0003-3525-1531; Mazzella, Giuseppe/0000-0001-8656-8112	Fondazione del Monte di Bologna e Ravenna; Alisal [Mazz100136-2010]; MINISTERO DELLE POLITICHE AGRICOLE, ALIMENTARI E FORESTALI [11008/7303/10]	Fondazione del Monte di Bologna e Ravenna(Fondazione del Monte di Bologna e Ravenna); Alisal; MINISTERO DELLE POLITICHE AGRICOLE, ALIMENTARI E FORESTALI	This work was supported by grants from Fondazione del Monte di Bologna e Ravenna and from Alisal (Mazz100136-2010). ALISAL is a project supported by the MINISTERO DELLE POLITICHE AGRICOLE, ALIMENTARI E FORESTALI, with D. M. 11008/7303/10, dated 17/05/2010. The title of the project is: Miglioramento delle proprieta igienico-sanitarie, salutistiche e funzionali di commodity per l'alimentazione dell'uomo e/o degli animali (Improvement of sanitary properties, healthy and functional food commodities for human and/or animals). Prof. GM was supported with materials, reagents, animals. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AHMED T, 2008, PHARM BIOCH BEHAV, V91, P554; Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r; Balestra B, 2012, NEUROGASTROENT MOTIL, V24, P1118, DOI 10.1111/nmo.12000; BHAVANISHANKAR TN, 1980, INDIAN J EXP BIOL, V18, P73; Budriesi R, 2011, J MED CHEM, V54, P3885, DOI 10.1021/jm200199r; Budriesi R, 2010, J MED FOOD, V13, P1104, DOI 10.1089/jmf.2009.0210; Carosati E, 2006, J MED CHEM, V49, P5206, DOI 10.1021/jm0604373; Chainani-Wu N, 2003, J ALTERN COMPLEM MED, V9, P161, DOI 10.1089/107555303321223035; Cremon C, 2011, AM J GASTROENTEROL, V106, P1290, DOI 10.1038/ajg.2011.86; Cuomo J, 2011, J NAT PROD, V74, P664, DOI 10.1021/np1007262; De Ponti F, 2004, GUT, V53, P1520, DOI 10.1136/gut.2003.035568; De Ponti F, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00007; Deters M, 2003, PLANTA MED, V69, P337, DOI 10.1055/s-2003-38870; Elguero J, 2009, BIOORGAN MED CHEM, V17, P8027, DOI 10.1016/j.bmc.2009.10.006; Ervin CM, 2013, REV RECENT CLIN TRIA, V8, P9, DOI 10.2174/1574887111308010003; Fan X, 2013, CURR PHARM DESIGN, V19, P2011; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Gupta SC, 2013, AAPS J, V15, P195, DOI 10.1208/s12248-012-9432-8; Hanai H, 2006, CLIN GASTROENTEROL H, V4, P1502, DOI 10.1016/j.cgh.2006.08.008; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Hurley LL, 2013, BEHAV BRAIN RES, V239, P27, DOI 10.1016/j.bbr.2012.10.049; ITTHIPANICHPONG C, 2003, J MED ASS THAI S2, V86, pS2999; Jitoe-Masuda A, 2013, CURR PHARM DESIGN, V19, P2084; Kaur CD, 2011, J COSMET DERMATOL-US, V10, P260, DOI 10.1111/j.1473-2165.2011.00586.x; Khaw AK, 2013, J CELL BIOCHEM, V114, P1257, DOI 10.1002/jcb.24466; Kim Darrick S H L, 2012, Recent Pat CNS Drug Discov, V7, P184; Kurapati Kesava Rao V., 2012, Journal of Basic and Clinical Physiology and Pharmacology, V23, P139, DOI 10.1515/jbcpp-2012-0021; Lao Christopher D, 2006, BMC Complement Altern Med, V6, P10, DOI 10.1186/1472-6882-6-10; Lee JH, 2012, BIOL PHARM BULL, V35, P777, DOI 10.1248/bpb.35.777; Leray V, 2011, BRIT J NUTR, V106, pS198, DOI 10.1017/S0007114511002492; Liju VB, 2013, FOOD CHEM TOXICOL, V53, P52, DOI 10.1016/j.fct.2012.11.027; Luo CF, 2011, INT J PHARMACEUT, V410, P138, DOI 10.1016/j.ijpharm.2011.02.064; Madkor HR, 2011, BRIT J NUTR, V105, P1210, DOI 10.1017/S0007114510004927; Marzio L, 2003, DIGEST LIVER DIS, V35, pS17, DOI 10.1016/S1590-8658(03)00088-4; Orellana-Paucar AM, 2012, EPILEPSY BEHAV, V24, P14, DOI 10.1016/j.yebeh.2012.02.020; Motulsky H, 2003, PRACTICAL GUIDE CURV; Moynihan R, 2002, BRIT MED J, V325, P592, DOI 10.1136/bmj.325.7364.592; Negi PS, 1999, J AGR FOOD CHEM, V47, P4297, DOI 10.1021/jf990308d; Noorafshan A, 2013, CURR PHARM DESIGN, V19, P2032; Pan MH, 1999, DRUG METAB DISPOS, V27, P486; Qin XY, 2012, NEUROSCI BULL, V28, P606, DOI 10.1007/s12264-012-1275-x; Rahimi R, 2012, WORLD J GASTROENTERO, V18, P589, DOI 10.3748/wjg.v18.i7.589; Rasyid A, 1999, ALIMENT PHARM THERAP, V13, P245; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Reuland DJ, 2013, FREE RADICAL BIO MED, V56, P102, DOI 10.1016/j.freeradbiomed.2012.11.016; RODA A, 1995, J CHROMATOGR B, V665, P281, DOI 10.1016/0378-4347(94)00544-F; Saelee C, 2011, MOLECULES, V16, P3908, DOI 10.3390/molecules16053908; SAHEBKAR A, 2012, BIOFACTORS, V39, DOI DOI 10.1002/BI0F.1062.PUBMED:23239418; Singh AK, 1996, CANCER LETT, V107, P109, DOI 10.1016/0304-3835(96)04357-1; *SOFTW INC, VERS 3 0 GRAPHPAD; STIEGER B, 1992, BIOCHEM J, V284, P67, DOI 10.1042/bj2840067; STIEGER B, 1994, GASTROENTEROLOGY, V107, P1781, DOI 10.1016/0016-5085(94)90821-4; Stieger B, 2000, GASTROENTEROLOGY, V118, P422, DOI 10.1016/S0016-5085(00)70224-1; Su J, 2010, J ETHNOPHARMACOL, V130, P70, DOI 10.1016/j.jep.2010.04.012; Sun XD, 2012, MOL MED REP, V6, P1267, DOI 10.3892/mmr.2012.1103; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA; Trendle MC, 1997, CANCER, V79, P830, DOI 10.1002/(SICI)1097-0142(19970215)79:4<830::AID-CNCR20>3.0.CO;2-#; Tsai YM, 2011, INT J PHARMACEUT, V416, P331, DOI 10.1016/j.ijpharm.2011.06.030; Venneman NG, 2006, BEST PRACT RES CL GA, V20, P1063, DOI 10.1016/j.bpg.2006.03.008; Wortelboer HM, 2003, CHEM RES TOXICOL, V16, P1642, DOI 10.1021/tx034101x; Xia Q, 2012, THROMB RES, V130, P409, DOI 10.1016/j.thromres.2012.04.005; Xu YX, 1997, EXP HEMATOL, V25, P413; Zhao JF, 2012, MOL NUTR FOOD RES, V56, P691, DOI 10.1002/mnfr.201100735	64	6	7	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2013	8	11							e80925	10.1371/journal.pone.0080925	http://dx.doi.org/10.1371/journal.pone.0080925			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256KH	24260512	Green Published, Green Submitted, gold			2023-01-03	WOS:000327308500183
J	Cui, JD; Li, LL; Bian, HJ				Cui, Jian Dong; Li, Lian Lian; Bian, Hong Jie			Immobilization of Cross-Linked Phenylalanine Ammonia Lyase Aggregates in Microporous Silica Gel	PLOS ONE			English	Article							CLEAS; STABILIZATION; BIOCATALYSTS; EFFICIENT; ENZYMES; LIPASES	A separable and highly-stable enzyme system was developed by adsorption of phenylalanine ammonia lyase (PAL) from Rhodotorula glutinis in amino-functionalized macroporous silica gel and subsequent enzyme crosslinking. This resulted in the formation of cross-linked enzyme aggregates (PAL-CLEAs) into macroporous silica gel (MSG-CLEAs). The effect of adsorptive conditions, type of aggregating agent, its concentration as well as that of cross-linking agent was studied. MSG-CLEAs production was most effective using ammonium sulfate (40%-saturation), followed by cross-linking for 1 h with 1.5% (v/v) glutaraldehyde. The resulting MSG-CLEAs extended the optimal temperature and pH range compared to free PAL and PAL-CLEAs. Moreover, MSG-CLEAs exhibited the excellent stability of the enzyme against various deactivating conditions such as temperature and denaturants, and showed higher storage stability compared to the free PAL and the conventional PAL-CLEAs. Such as, after 6 h incubation at 60 degrees C, the MSG-CLEAs still retained more than 47% of the initial activity whereas PAL-CLEAs only retained 7% of the initial activity. Especially, the MSG-CLEAs exhibited good reusability due to its suitable size and active properties. These results indicated that PAL-CLEAs on MSG might be used as a feasible and efficient solution for improving properties of immobilized enzyme in industrial application.	[Cui, Jian Dong; Li, Lian Lian] Hebei Univ Sci & Technol, Coll Biosci & Bioengn, Res Ctr Fermentat Engn Hebei, Shijiazhuang, Peoples R China; [Cui, Jian Dong] Chinese Acad Sci, Inst Proc Engn, Natl Key Lab Biochem Engn, Beijing, Peoples R China; [Cui, Jian Dong] Tianjin Univ Sci & Technol, Minist Educ, Key Lab Ind Microbiol, Tai Da Dev Area, Tianjin, Peoples R China	Hebei University of Science & Technology; Chinese Academy of Sciences; Institute of Process Engineering, CAS; Tianjin University Science & Technology	Cui, JD (corresponding author), Hebei Univ Sci & Technol, Coll Biosci & Bioengn, Res Ctr Fermentat Engn Hebei, Shijiazhuang, Peoples R China.	cjd007cn@163.com		cui, jian dong/0000-0002-2809-530X	National Natural Science Foundation of China (NSFC) [21072041]; National Key Laboratory of Biochemical Engineering [KF2010-12]; Foundation of Tianjin Key Laboratory of Industrial Microbiology (Tianjin University of Science and Technology), P. R. China [2012IM004]; Foundation of Hebei University of Science and technology for Distinguished Young Scientists	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); National Key Laboratory of Biochemical Engineering; Foundation of Tianjin Key Laboratory of Industrial Microbiology (Tianjin University of Science and Technology), P. R. China; Foundation of Hebei University of Science and technology for Distinguished Young Scientists	The authors are grateful for the financial support provided by the National Natural Science Foundation of China (NSFC, Project No. 21072041), Open Funding Project of the National Key Laboratory of Biochemical Engineering (NO. KF2010-12) and the Foundation (NO. 2012IM004) of Tianjin Key Laboratory of Industrial Microbiology (Tianjin University of Science and Technology), P. R. China, and Foundation of Hebei University of Science and technology for Distinguished Young Scientists. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bilkova Z, 2002, J CHROMATOGR B, V770, P177, DOI 10.1016/S1570-0232(02)00037-5; Cabana H, 2009, BIOTECHNOL BIOENG, V102, P1582, DOI 10.1002/bit.22198; Cao LQ, 2000, ORG LETT, V2, P1361, DOI 10.1021/ol005593x; Cowan DA, 2011, ENZYME MICROB TECH, V49, P326, DOI 10.1016/j.enzmictec.2011.06.023; Cui JD, 2013, APPL BIOCHEM BIOTECH, V170, P1827, DOI 10.1007/s12010-013-0317-9; Cui JD, 2012, APPL BIOCHEM BIOTECH, V167, P835, DOI 10.1007/s12010-012-9738-0; EVANS CT, 1987, APPL MICROBIOL BIOT, V25, P399; Garcia-Galan C, 2011, ADV SYNTH CATAL, V353, P2885, DOI 10.1002/adsc.201100534; Hernandez K, 2011, ENZYME MICROB TECH, V48, P510, DOI 10.1016/j.enzmictec.2011.02.005; Jung D, 2009, J MATER SCI, V44, P6747, DOI 10.1007/s10853-009-3917-6; Kim MI, 2007, BIOTECHNOL BIOENG, V96, P210, DOI 10.1002/bit.21107; Palomo JM, 2002, J MOL CATAL B-ENZYM, V19, P279, DOI 10.1016/S1381-1177(02)00178-9; Park JM, 2013, INT J BIOL MACROMOL, V54, P37, DOI 10.1016/j.ijbiomac.2012.11.025; Park JM, 2010, PROCESS BIOCHEM, V45, P259, DOI 10.1016/j.procbio.2009.09.015; Quinn AJ, 2011, BIOTECHNOL PROGR, V27, P1554, DOI 10.1002/btpr.687; Rees DG, 1996, ENZYME MICROB TECH, V19, P282; Reshmi R, 2013, J MOL CATAL B-ENZYM, V85-86, P111, DOI 10.1016/j.molcatb.2012.08.007; Rodrigues RC, 2013, CHEM SOC REV, V42, P6290, DOI 10.1039/c2cs35231a; Sangeetha K, 2008, INT J BIOL MACROMOL, V43, P314, DOI 10.1016/j.ijbiomac.2008.07.001; Schoevaart R, 2004, BIOTECHNOL BIOENG, V87, P754, DOI 10.1002/bit.20184; Sheldon RA, 2007, BIOCHEM SOC T, V35, P1583, DOI 10.1042/BST0351583; Talekar S, 2013, RSC ADV, V3, P12485, DOI 10.1039/c3ra40818c; Talekar S, 2012, BIORESOURCE TECHNOL, V123, P542, DOI 10.1016/j.biortech.2012.07.044; WADDELL TG, 1981, J AM CHEM SOC, V103, P5303, DOI 10.1021/ja00408a005; Wang MF, 2010, BIOCHEM ENG J, V52, P168, DOI 10.1016/j.bej.2010.08.003; Wilson L, 2004, BIOTECHNOL BIOENG, V86, P558, DOI 10.1002/bit.20107; Wilson L, 2006, ENZYME MICROB TECH, V39, P750, DOI 10.1016/j.enzmictec.2005.12.011; Yang XL, 2012, CHINESE J CATAL, V33, P878, DOI 10.3724/SP.J.1088.2012.11139; Zhang BZ, 2010, J AGR FOOD CHEM, V58, P2795, DOI 10.1021/jf9036744	29	26	28	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2013	8	11							e80581	10.1371/journal.pone.0080581	http://dx.doi.org/10.1371/journal.pone.0080581			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255RX	24260425	Green Published, gold, Green Submitted			2023-01-03	WOS:000327258600071
J	Wills, AM; Hubbard, J; Macklin, EA; Glass, J; Tandan, R; Simpson, EP; Brooks, B; Gelinas, D; Mitsumoto, H; Mozaffar, T; Hanes, GP; Ladha, SS; Heiman-Patterson, T; Katz, J; Lou, JS; Mahoney, K; Grasso, D; Lawson, R; Yu, H; Cudkowicz, M				Wills, Anne-Marie; Hubbard, Jane; Macklin, Eric A.; Glass, Jonathan; Tandan, Rup; Simpson, Ericka P.; Brooks, Benjamin; Gelinas, Deborah; Mitsumoto, Hiroshi; Mozaffar, Tahseen; Hanes, Gregory P.; Ladha, Shafeeq S.; Heiman-Patterson, Terry; Katz, Jonathan; Lou, Jau-Shin; Mahoney, Katy; Grasso, Daniela; Lawson, Robert; Yu, Hong; Cudkowicz, Merit		MDA Clinical Res Network	Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial	LANCET			English	Article							BODY-MASS INDEX; ALS PATIENTS; ENERGY-EXPENDITURE; SURVIVAL; DYSLIPIDEMIA; MANAGEMENT; PREDICTOR; NEUROLOGY; BENEFIT; DEATH	Background Amyotrophic lateral sclerosis is a fatal neurodegenerative disease with few therapeutic options. Mild obesity is associated with greater survival in patients with the disease, and calorie-dense diets increased survival in a mouse model. We aimed to assess the safety and tolerability of two hypercaloric diets in patients with amyotrophic lateral sclerosis receiving enteral nutrition. Methods In this double-blind, placebo-controlled, randomised phase 2 clinical trial, we enrolled adults with amyotrophic lateral sclerosis from participating centres in the USA. Eligible participants were aged 18 years or older with no history of diabetes or liver or cardiovascular disease, and who were already receiving percutaneous enteral nutrition. We randomly assigned participants (1:1:1) using a computer-generated list of random numbers to one of three dietary interventions: replacement calories using an isocaloric tube-fed diet (control), a high-carbohydrate hypercaloric tube-fed diet (HC/HC), or a high-fat hypercaloric tube-fed diet (HF/HC). Participants received the intervention diets for 4 months and were followed up for 5 months. The primary outcomes were safety and tolerability, analysed in all patients who began their study diet. This trial is registered with ClinicalTrials.gov, number NCT00983983. Findings Between Dec 14, 2009, and Nov 2, 2012, we enrolled 24 participants, of whom 20 started their study diet (six in the control group, eight in the HC/HC group, and six in the HF/HC group). One patient in the control group, one in the HC/HC group, and two in the HF/HC group withdrew consent before receiving the intervention. Participants who received the HC/HC diet had a smaller total number of adverse events than did those in the other groups (23 in the HC/HC group vs 42 in the control group vs 48 in the HF/HC group; overall, p=0.06; HC/HC vs control, p=0.06) and significantly fewer serious adverse events than did those on the control diet (none vs nine; p=0.0005). Fewer patients in the HC/HC group discontinued their study diet due to adverse events (none [0%] of eight in the HC/HC group vs three [50%] of six in the control group). During the 5 month follow-up, no deaths occurred in the nine patients assigned to the HC/HC diet compared with three deaths (43%) in the seven patients assigned to the control diet (log-rank p=0.03). Adverse events, tolerability, deaths, and disease progression did not differ significantly between the HF/HC group and the control group. Interpretation Our results provide preliminary evidence that hypercaloric enteral nutrition is safe and tolerable in patients with amyotrophic lateral sclerosis, and support the study of nutritional interventions in larger randomised controlled trials at earlier stages of the disease.	[Wills, Anne-Marie; Mahoney, Katy; Grasso, Daniela; Lawson, Robert; Yu, Hong; Cudkowicz, Merit] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Wills, Anne-Marie; Mahoney, Katy; Grasso, Daniela; Lawson, Robert; Yu, Hong; Cudkowicz, Merit] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurol Clin Res Inst, Boston, MA 02114 USA; [Hubbard, Jane] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Harvard Catalyst Massachusetts Gen Hosp,Clin Res, Boston, MA 02114 USA; [Macklin, Eric A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA; [Glass, Jonathan] Emory Univ, Sch Med, Atlanta, GA USA; [Tandan, Rup] Univ Vermont, Burlington, VT USA; [Simpson, Ericka P.] Methodist Neurol Inst, Houston, TX USA; [Brooks, Benjamin] Neuromuscular ALS MDA Ctr, Med Ctr, Charlotte, NC USA; [Gelinas, Deborah] St Marys Hlth Care, Grand Rapids, MI USA; [Mitsumoto, Hiroshi] Columbia Presbyterian Med Ctr, New York, NY 10032 USA; [Mozaffar, Tahseen] Univ Calif Irvine, Irvine, CA USA; [Hanes, Gregory P.] Sarasota Mem Hosp, Sarasota, FL USA; [Ladha, Shafeeq S.] St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Heiman-Patterson, Terry] Drexel Univ, Philadelphia, PA 19104 USA; [Katz, Jonathan] Univ Calif San Francisco, Calif Pacific Med Ctr, San Francisco, CA 94143 USA; [Lou, Jau-Shin] Oregon Hlth & Sci Univ, Portland, OR 97201 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Emory University; University of Vermont; The Methodist Hospital System; The Methodist Hospital - Houston; Columbia University; NewYork-Presbyterian Hospital; University of California System; University of California Irvine; Barrow Neurological Institute; St. Joseph's Hospital and Medical Center; Drexel University; California Pacific Medical Center; University of California System; University of California San Francisco; Oregon Health & Science University	Wills, AM (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA.	awills@partners.org	Ladha, Shafeeq S/A-4948-2010; Mozaffar, Tahseen/AAE-6971-2020; Ladha, Shafeeq/AAW-6829-2020; CUDKOWICZ, MERIT/GWM-6585-2022; Macklin, Eric A/E-2955-2013	Ladha, Shafeeq S/0000-0003-1955-4292; Ladha, Shafeeq/0000-0003-1955-4292; CUDKOWICZ, MERIT/0000-0002-7075-1681; Macklin, Eric A/0000-0003-1618-3502	Muscular Dystrophy Association; National Center for Research Resources; National Institutes of Health; Harvard NeuroDiscovery Center; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000170] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025758, M01RR000109] Funding Source: NIH RePORTER	Muscular Dystrophy Association(Muscular Dystrophy Association); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard NeuroDiscovery Center; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Muscular Dystrophy Association, National Center for Research Resources, National Institutes of Health, and Harvard NeuroDiscovery Center.	Aldrich T K, 1993, Monaldi Arch Chest Dis, V48, P327; Andersen PM, 2012, EUR J NEUROL, V19, P360, DOI 10.1111/j.1468-1331.2011.03501.x; Berry JD, AMYOTROPH LATERAL SC, V14, P162; BOUCHARD C, 1983, AM J CLIN NUTR, V37, P461, DOI 10.1093/ajcn/37.3.461; BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0; Silva LBD, 2010, ARQ NEURO-PSIQUIAT, V68, P263, DOI 10.1590/S0004-282X2010000200021; Desport JC, 1999, NEUROLOGY, V53, P1059, DOI 10.1212/WNL.53.5.1059; Dorst J, 2013, AMYOTROPH LAT SCL FR, V14, P533, DOI 10.3109/21678421.2013.823999; Dupuis L, 2008, NEUROLOGY, V70, P1004, DOI 10.1212/01.wnl.0000285080.70324.27; Dupuis L, 2004, P NATL ACAD SCI USA, V101, P11159, DOI 10.1073/pnas.0402026101; Dupuis L, 2011, LANCET NEUROL, V10, P75, DOI 10.1016/S1474-4422(10)70224-6; Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7; Gallo V, 2013, NEUROLOGY, V80, P829, DOI 10.1212/WNL.0b013e3182840689; Genton L, 2011, CLIN NUTR, V30, P553, DOI 10.1016/j.clnu.2011.06.004; Greenwood DI, 2013, NUTR CLIN PRACT, V28, P392, DOI 10.1177/0884533613476554; Ichihara N, 2012, AMYOTROPH LATERAL SC, V13, P544, DOI 10.3109/17482968.2012.699968; Kasarskis EJ, 2011, AMYOTROPH LATERAL SC, V12, P17, DOI 10.3109/17482968.2010.515225; Kasarskis EJ, 1996, NEUROLOGY, V47, pS118, DOI 10.1212/WNL.47.4_Suppl_2.118S; Kasarskis EJ, 1996, AM J CLIN NUTR, V63, P130, DOI 10.1093/ajcn/63.1.130; Kiernan MC, 2011, LANCET, V377, P942, DOI 10.1016/S0140-6736(10)61156-7; Mattson MP, 2007, NEUROMOL MED, V9, P17, DOI 10.1385/NMM:9:1:17; Miller RG, 2009, NEUROLOGY, V73, P1218, DOI 10.1212/WNL.0b013e3181bc0141; NAU KL, 1995, J NEUROL SCI, V129, P47, DOI 10.1016/0022-510X(95)00061-6; O'Reilly EJ, 2013, AMYOTROPH LAT SCL FR, V14, P205, DOI 10.3109/21678421.2012.735240; Otten JJ, 2006, DIETARY REFERENCE IN, DOI DOI 10.17226/11537; Paganoni S, 2011, MUSCLE NERVE, V44, P20, DOI 10.1002/mus.22114; Pedersen WA, 1999, BRAIN RES, V833, P117, DOI 10.1016/S0006-8993(99)01471-7; Pontes-Arruda A, 2006, CRIT CARE MED, V34, P2325, DOI 10.1097/01.CCM.0000234033.65657.B6; Reich-Slotky R, 2013, AMYOTROPH LAT SCL FR, V14, P212, DOI 10.3109/21678421.2013.770028; Shaw AS, 2006, AMYOTROPH LATERAL SC, V7, P16, DOI 10.1080/14660820510012013; Trumbo P, 2002, J AM DIET ASSOC, V102, P1621, DOI 10.1016/S0002-8223(02)90346-9	31	154	160	1	36	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2014	383	9934					2065	2072		10.1016/S0140-6736(14)60222-1	http://dx.doi.org/10.1016/S0140-6736(14)60222-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AI9VZ	24582471	Green Accepted, Green Published			2023-01-03	WOS:000337292400026
J	Herpertz-Dahlmann, B; Schwarte, R; Krei, M; Egberts, K; Warnke, A; Wewetzer, C; Pfeiffer, E; Fleischhaker, C; Scherag, A; Holtkamp, K; Hagenah, U; Buhren, K; Konrad, K; Schmidt, U; Schade-Brittinger, C; Timmesfeld, N; Dempfle, A				Herpertz-Dahlmann, Beate; Schwarte, Reinhild; Krei, Melanie; Egberts, Karin; Warnke, Andreas; Wewetzer, Christoph; Pfeiffer, Ernst; Fleischhaker, Christian; Scherag, Andre; Holtkamp, Kristian; Hagenah, Ulrich; Buehren, Katharina; Konrad, Kerstin; Schmidt, Ulrike; Schade-Brittinger, Carmen; Timmesfeld, Nina; Dempfle, Astrid			Day-patient treatment after short inpatient care versus continued inpatient treatment in adolescents with anorexia nervosa (ANDI): a multicentre, randomised, open-label, non-inferiority trial	LANCET			English	Article							EATING-DISORDER; WEIGHT; HOSPITALIZATION; PREDICTORS; PROGRAM; NEED	Background In-patient treatment (IP) is the treatment setting of choice for moderately-to-severely ill adolescents with anorexia nervosa, but it is costly, and the risks of relapse and readmissions are high. Day patient treatment (DP) is less expensive and might avoid problems of relapse and readmission by easing the transition from hospital to home. We investigated the safety and efficacy of DP after short inpatient care compared with continued IP. Methods For this multicentre, randomised, open-label, non-inferiority trial, we enrolled female patients (aged 11-18 years) with anorexia nervosa from six centres in Germany. Patients were eligible if they had a body-mass index (BMI) below the tenth percentile and it was their first admission to hospital for anorexia nervosa. We used a computer-generated randomisation sequence to randomly assign patients to continued IP or DP after 3 weeks of inpatient care (1:1; stratified for age and BMI at admission). The treatment programme and treatment intensity in both study groups were identical. The primary outcome was the increase in BMI between the time of admission and a 12-month follow-up adjusted for age and duration of illness (non-inferiority margin of 0.75 kg/m(2)). Analysis was done by modified intention to treat. This trial is registered with the International Standard Randomised Controlled Trial Number Register, number ISRCTN67783402, and the Deutsches Register Klinischer Studien, number DRKS00000101. Findings Between Feb 2, 2007, to April 27, 2010, we screened 660 patients for eligibility, 172 of whom we randomly allocated to treatment:85 to IP and 87 to DP. DP was non-inferior to IP with respect to the primary outcome, BMI at the 12-month follow-up (mean difference 0.46 kg/m(2) in favour of DP (95% CI, -0.11 to 1.02; p(non-inferiority) < 0.0001). The number of treatment-related serious adverse events was similar in both study groups (eight in the IP group, seven in the DP group). Three serious adverse events in the IP group and two in the DP group were related to suicidal ideation; one patient in the DP attempted suicide 3 months after she was discharged. Interpretation DP after short inpatient care in adolescent patients with non-chronic anorexia nervosa seems no less effective than IP for weight restoration and maintenance during the first year after admission. Thus, DP might be a safe and less costly alternative to IP. Our results justify the broad implementation of this approach.	[Herpertz-Dahlmann, Beate; Schwarte, Reinhild; Krei, Melanie; Hagenah, Ulrich; Buehren, Katharina] Rhein Westfal TH Aachen, Univ Hosp, Dept Child & Adolescent Psychiat Psychosomat & Ps, D-52074 Aachen, Germany; [Egberts, Karin; Warnke, Andreas] Univ Hosp Wurzburg, Dept Child & Adolescent Psychiat Psychosomat & Ps, Wurzburg, Germany; [Wewetzer, Christoph] Kliniken Stadt Koln, Dept Child & Adolescent Psychiat & Psychotherapy, Cologne, Germany; [Pfeiffer, Ernst] Charite, Dept Child & Adolescent Psychiat Psychosomat & Ps, Berlin, Germany; [Fleischhaker, Christian] Univ Med Ctr, Dept Child & Adolescent Psychiat & Psychotherapy, Freiburg, Germany; [Scherag, Andre] Univ Duisburg Essen, Inst Med Informat Biometry & Epidemiol, Essen, Germany; [Holtkamp, Kristian] DRK Fachklin Bad Neuenahr, Dept Child & Adolescent Psychiat Psychosomat & Ps, Bad Neuenahr Ahrweiler, Germany; [Konrad, Kerstin] Rhein Westfal TH Aachen, Univ Hosp, Child Neuropsychol Sect, Dept Child & Adolescent Psychiat Psychosomat & Ps, D-52074 Aachen, Germany; [Schmidt, Ulrike] Kings Coll London, Inst Psychiat, London WC2R 2LS, England; [Schade-Brittinger, Carmen] Univ Marburg, Coordinating Ctr Clin Trials, Marburg, Germany; [Timmesfeld, Nina; Dempfle, Astrid] Univ Marburg, Inst Med Biometry & Epidemiol, Marburg, Germany	RWTH Aachen University; RWTH Aachen University Hospital; University of Wurzburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Freiburg; University of Duisburg Essen; RWTH Aachen University; RWTH Aachen University Hospital; University of London; King's College London; Philipps University Marburg; Philipps University Marburg	Herpertz-Dahlmann, B (corresponding author), Rhein Westfal TH Aachen, Univ Hosp, Dept Child & Adolescent Psychiat Psychosomat & Ps, Neuenhofer Weg 21, D-52074 Aachen, Germany.	bherpertz-dahlmann@ukaachen.de	Konrad, Kerstin/H-7747-2013; Dempfle, Astrid/D-1513-2012; Egberts, Karin Maria/AAV-4042-2020; Dempfle, Astrid/ABB-8889-2020	Konrad, Kerstin/0000-0001-9039-2615; Dempfle, Astrid/0000-0002-2618-3920; Egberts, Karin Maria/0000-0002-0270-0954; Scherag, Andre/0000-0002-9406-4704	German Ministry for Education and Research	German Ministry for Education and Research(Federal Ministry of Education & Research (BMBF))	Funding German Ministry for Education and Research.	Agras WS, 2004, INT J EAT DISORDER, V35, P509, DOI 10.1002/eat.10261; American Psychiatric Association, 2006, AM J PSYCHIAT S, V163, P4; Bulik CM, 2007, INT J EAT DISORDER, V40, P310, DOI 10.1002/eat.20367; Byford S, 2007, BRIT J PSYCHIAT, V191, P436, DOI 10.1192/bjp.bp.107.036806; Carter JC, 2004, PSYCHOL MED, V34, P671, DOI 10.1017/S0033291703001168; Castro J, 2004, INT J EAT DISORDER, V36, P22, DOI 10.1002/eat.20009; Catalan Agency for Health Technology Assessment and Research, 2009, CLIN PRACT GUID EAT; Dancyger I, 2003, Eat Weight Disord, V8, P242; DANZIGER Y, 1989, J ADOLESCENT HEALTH, V10, P328, DOI 10.1016/0197-0070(89)90067-3; Delmo C., 2000, KIDDIE SADS PRESENT, V3rd ed.; Fichter MM, 1998, INT J EAT DISORDER, V24, P227, DOI 10.1002/(SICI)1098-108X(199811)24:3<227::AID-EAT1>3.3.CO;2-O; Franke G.H., 2000, BSI BRIEF SYMPTOM IN; German Institute for Federal Statistics, DIAGN KRANK AB 2000; Godart NT, 2005, AM J PSYCHIAT, V162, P2398, DOI 10.1176/appi.ajp.162.12.2398; Goldstein M, 2011, INT J EAT DISORDER, V44, P29, DOI 10.1002/eat.20789; Gowers SG, 2007, BRIT J PSYCHIAT, V191, P427, DOI 10.1192/bjp.bp.107.036764; Guarda AS, 2007, AM J PSYCHIAT, V164, P108, DOI 10.1176/appi.ajp.164.1.108; Halmi Katherine A, 2009, Dialogues Clin Neurosci, V11, P100; Health and Social Care Information Centre, PROV MONTHL HOSP EP; Hebebrand J, 2000, AM J PSYCHIAT, V157, P1024, DOI 10.1176/appi.ajp.157.6.1024; Herpertz S., 2011, S3 LEITLINIE DIAGNOS; Herpertz-Dahlmann B, 2009, CHILD ADOL PSYCH CL, V18, P131, DOI 10.1016/j.chc.2008.07.010; Kaplan AS, 2009, PSYCHOL MED, V39, P1037, DOI 10.1017/S003329170800442X; Krug I, 2013, J HEALTH PSYCHOL, V18, P26, DOI 10.1177/1359105311435946; Lievers LS, 2009, EUR CHILD ADOLES PSY, V18, P75, DOI 10.1007/s00787-008-0706-8; Lock J, 2010, ARCH GEN PSYCHIAT, V67, P1025, DOI 10.1001/archgenpsychiatry.2010.128; Marshall M, 2011, COCHRANE DB SYST REV, V12; MORGAN HG, 1988, BRIT J PSYCHIAT, V152, P367, DOI 10.1192/bjp.152.3.367; NICE, 2004, EAT DIS COR INT TREA; Olmsted M. P., 2010, The treatment of eating disorders: a clinical handbook, P198; Ornstein RM, 2012, EAT WEIGHT DISORD-ST, V17, pE170, DOI 10.1007/BF03325344; Paul T., 2005, EATING DISORDER INVE; Pavlova B, 2010, SOC PSYCH PSYCH EPID, V45, P541, DOI 10.1007/s00127-009-0092-7; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; Pinheiro AP, 2010, INT J EAT DISORDER, V43, P123, DOI 10.1002/eat.20671; Rosenberger WF, 2002, RANDOMIZATION CLIN T; Royal College of Psychiatrists, 2012, EAT DIS UK SERV DIST; SIGNORINI DF, 1993, STAT MED, V12, P2343, DOI 10.1002/sim.4780122410; Steinhausen HC, 2009, INT J EAT DISORDER, V42, P19, DOI 10.1002/eat.20577; Steinhausen HC, 2002, AM J PSYCHIAT, V159, P1284, DOI 10.1176/appi.ajp.159.8.1284; Striegel-Moore RH, 2000, INT J EAT DISORDER, V27, P381; Strober M, 2012, INT J EAT DISORDER, V45, P155, DOI 10.1002/eat.22005; Treat TA, 2008, INT J EAT DISORDER, V41, P564, DOI 10.1002/eat.20571; van Elburg AA, 2012, INT J EAT DISORDER, V45, P193, DOI 10.1002/eat.20918; Wentz E, 2009, BRIT J PSYCHIAT, V194, P168, DOI 10.1192/bjp.bp.107.048686; Willer MG, 2005, AM J PSYCHIAT, V162, P2374, DOI 10.1176/appi.ajp.162.12.2374; Zipfel S, 2002, INT J EAT DISORDER, V31, P105, DOI 10.1002/eat.10009	47	148	149	0	41	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	2014	383	9924					1222	1229		10.1016/S0140-6736(13)62411-3	http://dx.doi.org/10.1016/S0140-6736(13)62411-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AE6LO	24439238				2023-01-03	WOS:000334104600026
J	Ackerly, DC; Grabowski, DC				Ackerly, D. Clay; Grabowski, David C.			Post-Acute Care Reform - Beyond the ACA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Ackerly, D. Clay] Partners HealthCare, Boston, MA 02199 USA; [Ackerly, D. Clay] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Ackerly, D. Clay] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Ackerly, D. Clay; Grabowski, David C.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA	Partners Healthcare System; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Ackerly, DC (corresponding author), Partners HealthCare, Boston, MA 02199 USA.			Grabowski, David/0000-0003-2915-5770				Institute of Medicine, 2013, VAR HLTH CAR SPEND T; Jencks SF, 2011, NEW ENGL J MED, V364, P1582; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Lipsitz LA, 2013, JAMA-J AM MED ASSOC, V310, P1441, DOI 10.1001/jama.2013.254845; Medicare Payment Advisory Commission, 2013, MED POSTAC CAR REF; Mor V, 2010, HEALTH AFFAIR, V29, P57, DOI 10.1377/hlthaff.2009.0629	6	85	85	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 20	2014	370	8					689	691		10.1056/NEJMp1315350	http://dx.doi.org/10.1056/NEJMp1315350			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AB1DO	24552314				2023-01-03	WOS:000331531900002
J	Hong, CS; Chung, KM; Huang, PC; Wang, JJ; Yang, CM; Chu, CC; Chio, CC; Chang, FL; Chien, CC				Hong, Chon-Seng; Chung, Kun-Ming; Huang, Po-Chang; Wang, Jhi-Joung; Yang, Chun-Ming; Chu, Chin-Chen; Chio, Chung-Ching; Chang, Fu-Lin; Chien, Chih-Chiang			Epidemiology and Mortality of Liver Abscess in End-Stage Renal Disease Dialysis Patients: Taiwan National Cohort Study	PLOS ONE			English	Article							POLYCYSTIC KIDNEY-DISEASE; RISK-FACTORS; HEMODIALYSIS-PATIENTS; MAINTENANCE DIALYSIS; MORBIDITY; INFECTION; ESRD; PREDICTORS; SURVIVAL; THERAPY	Background and Objectives: To determine the incidence rates and mortality of liver abscess in ESRD patients on dialysis. Design, Setting, Participants, & Measurements: Using Taiwan's National Health Insurance Research Database, we collected data from all ESRD patients who initiated dialysis between 2000 and 2006. Patients were followed until death, end of dialysis, or December 31, 2008. Predictors of liver abscess and mortality were identified using Cox models. Results: Of the 53,249 incident dialysis patients identified, 447 were diagnosed as having liver abscesses during the followup period (224/100,000 person-years). The cumulative incidence rate of liver abscess was 0.3%, 1.1%, and 1.5% at 1 year, 5 years, and 7 years, respectively. Elderly patients and patients on peritoneal dialysis had higher incidence rates. The baseline comorbidities of diabetes mellitus, polycystic kidney disease, malignancy, chronic liver disease, biliary tract disease, or alcoholism predicted development of liver abscess. Overall in-hospital mortality was 10.1%. Conclusions: The incidence of liver abscess is high among ESRD dialysis patients. In addition to the well known risk factors of liver abscess, two other important risk factors, peritoneal dialysis and polycystic kidney disease, were found to predict liver abscess in ESRD dialysis patients.	[Hong, Chon-Seng] Chi Mei Med Ctr, Dept Internal Med, Tainan, Taiwan; [Chung, Kun-Ming] Chi Mei Med Ctr, Dept Gen Med, Tainan, Taiwan; [Huang, Po-Chang] Chi Mei Med Ctr, Dept Orthoped Med, Tainan, Taiwan; [Wang, Jhi-Joung; Chu, Chin-Chen] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Yang, Chun-Ming] Chi Mei Med Ctr, Dept Neurol, Tainan, Taiwan; [Chio, Chung-Ching] Chi Mei Med Ctr, Dept Neurol Surg, Tainan, Taiwan; [Chang, Fu-Lin] Chung Hwa Univ Med Technol, Dept Pharmaceut Sci & Technol, Tainan, Taiwan; [Chien, Chih-Chiang] Chi Mei Med Ctr, Dept Nephrol, Tainan, Taiwan; [Chien, Chih-Chiang] Chung Hwa Univ Med Technol, Dept Food Nutr, Tainan, Taiwan	Chi Mei Hospital; Chi Mei Hospital; Chi Mei Hospital; Chi Mei Hospital; Chi Mei Hospital; Chi Mei Hospital; Chung Hua University; Chi Mei Hospital; Chung Hua University	Wang, JJ (corresponding author), Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan.	400002@mail.chimei.org.tw; ccchien58@yahoo.com.tw		Chu, Chin-Chen/0000-0001-8745-239X	Chi Mei Hospital [CMFHR10242]; National Health Research Institutes in Taiwan [NHRI-NHIRD-99182]	Chi Mei Hospital; National Health Research Institutes in Taiwan(National Health Research Institutes - Taiwan)	This study was supported by grants CMFHR10242 from Chi Mei Hospital and NHRI-NHIRD-99182 from the National Health Research Institutes in Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bae KT, 2006, CLIN J AM SOC NEPHRO, V1, P64, DOI 10.2215/CJN.00080605; Chen HA, 2011, J RHEUMATOL, V38, P2390, DOI 10.3899/jrheum.110311; Chen SC, 2006, SWISS MED WKLY, V136, P119; Chien CC, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-43; Chien CC, 2012, AM J HYPERTENS, V25, P900, DOI 10.1038/ajh.2012.60; Chonchol M, 2006, SEMIN DIALYSIS, V19, P291, DOI 10.1111/j.1525-139X.2006.00175.x; Chou MT, 2013, INT J CARDIOL, V167, P2719, DOI 10.1016/j.ijcard.2012.06.108; Chuang FR, 2002, RENAL FAILURE, V24, P511, DOI 10.1081/JDI-120006778; Cigarran S, 2008, THER APHER DIAL, V12, P91, DOI 10.1111/j.1744-9987.2007.00548.x; Collins AJ, 2009, CLIN J AM SOC NEPHRO, V4, pS5, DOI 10.2215/CJN.05980809; GABRIEL R, 1984, J ROY SOC MED, V77, P595, DOI 10.1177/014107688407700713; Hansen PS, 1998, APMIS, V106, P396, DOI 10.1111/j.1699-0463.1998.tb01363.x; Kaplan GG, 2004, CLIN GASTROENTEROL H, V2, P1032, DOI 10.1016/S1542-3565(04)00459-8; Lee KT, 2001, DIGEST SURG, V18, P459, DOI 10.1159/000050194; Lee PW, 2013, J NEPHROL, V26, P755, DOI 10.5301/jn.5000224; Liu JN, 2010, KIDNEY INT, V77, P141, DOI 10.1038/ki.2009.413; Meddings L, 2010, AM J GASTROENTEROL, V105, P117, DOI 10.1038/ajg.2009.614; Molle I, 2001, GUT, V48, P260, DOI 10.1136/gut.48.2.260; Perrone RD, 2001, AM J KIDNEY DIS, V38, P777, DOI 10.1053/ajkd.2001.27720; Siu LK, 2012, LANCET INFECT DIS, V12, P881, DOI 10.1016/S1473-3099(12)70205-0; TELENTI A, 1990, MAYO CLIN PROC, V65, P933, DOI 10.1016/S0025-6196(12)65154-4; Tien KJ, 2013, DIABETES CARE, V36, P3027, DOI 10.2337/dc12-2148; Tsai FC, 2008, EMERG INFECT DIS, V14, P1592, DOI 10.3201/eid1410.071254; United States Renal Data System, 2006, AM J KIDNEY DIS S, pS1; United States Renal Data System, 2010, AM J KIDNEY DIS S, pS1; United States Renal Data System, 2009, EXC USRDS 2009 ANN D; VANHOLDER R, 1993, J AM SOC NEPHROL, V3, P1541; WOLFE RA, 1992, KIDNEY INT, V42, P991, DOI 10.1038/ki.1992.378; Yang WC, 2008, NEPHROL DIAL TRANSPL, V23, P3977, DOI 10.1093/ndt/gfn406; Yang YF, 2006, AM J KIDNEY DIS, V47, P856, DOI 10.1053/j.ajkd.2006.01.032; Zeier M, 1996, NEPHROL DIAL TRANSPL, V11, P18	31	7	8	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2014	9	2							e88078	10.1371/journal.pone.0088078	http://dx.doi.org/10.1371/journal.pone.0088078			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7IR	24551077	Green Submitted, gold, Green Published			2023-01-03	WOS:000331271500028
J	Helfer, M; Koppensteiner, H; Schneider, M; Rebensburg, S; Forcisi, S; Muller, C; Schmitt-Kopplin, P; Schindler, M; Brack-Werner, R				Helfer, Markus; Koppensteiner, Herwig; Schneider, Martha; Rebensburg, Stephanie; Forcisi, Sara; Mueller, Constanze; Schmitt-Kopplin, Philippe; Schindler, Michael; Brack-Werner, Ruth			The Root Extract of the Medicinal Plant Pelargonium sidoides Is a Potent HIV-1 Attachment Inhibitor	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; (-)-EPIGALLOCATECHIN GALLATE; ANTIRETROVIRAL THERAPY; CHEMOKINE RECEPTOR; ENTRY INHIBITORS; REPLICATION; INFECTION; SAFETY; PHARMACOKINETICS; IDENTIFICATION	Global HIV-1 treatment would benefit greatly from safe herbal medicines with scientifically validated novel anti-HIV-1 activities. The root extract from the medicinal plant Pelargonium sidoides (PS) is licensed in Germany as the herbal medicine EPs (R) 7630, with numerous clinical trials supporting its safety in humans. Here we provide evidence from multiple cell culture experiments that PS extract displays potent anti-HIV-1 activity. We show that PS extract protects peripheral blood mononuclear cells and macrophages from infection with various X4 and R5 tropic HIV-1 strains, including clinical isolates. Functional studies revealed that the extract from PS has a novel mode-of-action. It interferes directly with viral infectivity and blocks the attachment of HIV-1 particles to target cells, protecting them from virus entry. Analysis of the chemical footprint of anti-HIV activity indicates that HIV-1 inhibition is mediated by multiple polyphenolic compounds with low cytotoxicity and can be separated from other extract components with higher cytotoxicity. Based on our data and its excellent safety profile, we propose that PS extract represents a lead candidate for the development of a scientifically validated herbal medicine for anti-HIV-1 therapy with a mode-of-action different from and complementary to current single-molecule drugs.	[Helfer, Markus; Koppensteiner, Herwig; Schneider, Martha; Rebensburg, Stephanie; Schindler, Michael; Brack-Werner, Ruth] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Virol, Neuherberg, Germany; [Forcisi, Sara; Mueller, Constanze; Schmitt-Kopplin, Philippe] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Analyt BioGeoChem, Neuherberg, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Brack-Werner, R (corresponding author), German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Virol, Neuherberg, Germany.	brack@helmholtz-muenchen.de	Brack-Werner, Ruth/M-4615-2014; Schindler, Michael/C-1647-2015; Schmitt-Kopplin, Philippe/H-6271-2011	Brack-Werner, Ruth/0000-0002-8651-9318; Schindler, Michael/0000-0001-8989-5813; Schmitt-Kopplin, Philippe/0000-0003-0824-2664	Helmholtz Zentrum Munchen	Helmholtz Zentrum Munchen(Helmholtz Association)	Financial support for this study was provided by intramural funding of the Helmholtz Zentrum Munchen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AIDSinfo USDoHaHSH, 2012, HIV ITS TREATM FDA A; Alexandre KB, 2011, J VIROL, V85, P9039, DOI 10.1128/JVI.02675-10; Brendler T, 2008, J ETHNOPHARMACOL, V119, P420, DOI 10.1016/j.jep.2008.07.037; Cordell GA, 2012, J NAT PROD, V75, P514, DOI 10.1021/np200803m; Cos P, 2008, PLANTA MED, V74, P1323, DOI 10.1055/s-2008-1081314; Daelemans D, 2011, NAT PROTOC, V6, P925, DOI 10.1038/nprot.2011.330; DE CLERCQ E, 1994, ANTIMICROB AGENTS CH, V38, P668, DOI 10.1128/AAC.38.4.668; De Clercq E, 2009, REV MED VIROL, V19, P287, DOI 10.1002/rmv.624; Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005; Forcisi S, 2013, J CHROMATOGR A, V1292, P51, DOI 10.1016/j.chroma.2013.04.017; Francois K, 2010, MED RES REV, V32, P349; FREED EO, 1995, J VIROL, V69, P3949, DOI 10.1128/JVI.69.6.3949-3954.1995; Fuss IJ., 2009, CURRENT PROTOCOLS IM; Gertsch J, 2011, PLANTA MED, V77, P1086, DOI 10.1055/s-0030-1270904; Gibson RM, 2012, CURR HIV RES, V10, P19, DOI 10.2174/157016212799304616; Hamza A, 2006, J PHYS CHEM B, V110, P2910, DOI 10.1021/jp0550762; Hawkins T, 2010, ANTIVIR RES, V85, P201, DOI 10.1016/j.antiviral.2009.10.016; Hendrix CW, 2000, ANTIMICROB AGENTS CH, V44, P1667, DOI 10.1128/AAC.44.6.1667-1673.2000; Hendrix CW, 2004, JAIDS-J ACQ IMM DEF, V37, P1253, DOI 10.1097/01.qai.0000137371.80695.ef; Hertje M, 2010, CHEMMEDCHEM, V5, P1825, DOI 10.1002/cmdc.201000292; Huskens D, 2012, MAR DRUGS, V10, P1476, DOI 10.3390/md10071476; Jones J, 2007, BIOTECHNIQUES, V43, P589, DOI 10.2144/000112624; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kolodziej H, 2007, PHYTOMEDICINE, V14, P9, DOI 10.1016/j.phymed.2006.11.021; Koppensteiner H, 2012, J VIROL, V86, P2826, DOI 10.1128/JVI.05915-11; Kouokam JC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022635; Kremb S, 2010, ANTIMICROB AGENTS CH, V54, P5257, DOI 10.1128/AAC.00515-10; Krepstakies M, 2012, J INFECT DIS, V205, P1654, DOI 10.1093/infdis/jis273; Magalhaes PJ, 2010, J CHROMATOGR A, V1217, P3258, DOI 10.1016/j.chroma.2009.10.068; Marcus KA, 2012, CURR OPIN HIV AIDS, V7, P292, DOI 10.1097/COH.0b013e328354dcac; Michaelis M, 2011, PHYTOMEDICINE, V18, P384, DOI 10.1016/j.phymed.2010.09.008; Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200; Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000; Mukhtar M, 2008, VIRUS RES, V131, P111, DOI 10.1016/j.virusres.2007.09.008; Overy DP, 2008, NAT PROTOC, V3, P471, DOI 10.1038/nprot.2007.512; Parrish NF, 2013, P NATL ACAD SCI USA, V110, P6626, DOI 10.1073/pnas.1304288110; PEDEN K, 1991, VIROLOGY, V185, P661, DOI 10.1016/0042-6822(91)90537-L; Peters PJ, 2004, J VIROL, V78, P6915, DOI 10.1128/JVI.78.13.6915-6926.2004; Schnitzler P, 2008, PHYTOMEDICINE, V15, P1108, DOI 10.1016/j.phymed.2008.06.009; Singh IP, 2010, NAT PROD REP, V27, P1781, DOI 10.1039/c0np00025f; Sluis-Cremer N, 2008, VIRUS RES, V134, P147, DOI 10.1016/j.virusres.2008.01.002; Stadeli KM, 2012, ANTIVIRAL THERAPY; Tang MW, 2012, DRUGS, V72, pE1, DOI 10.2165/11633630-000000000-00000; Theisen LL, 2012, ANTIVIRAL RES; Timmer A, 2008, COCHRANE DATABASE SY, V3; Vella S, 2012, AIDS, V26, P1231, DOI 10.1097/QAD.0b013e32835521a3; Yamaguchi K, 2002, ANTIVIR RES, V53, P19, DOI 10.1016/S0166-3542(01)00189-9; Yang J, 2011, FITOTERAPIA	48	49	53	2	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2014	9	1							e87487	10.1371/journal.pone.0087487	http://dx.doi.org/10.1371/journal.pone.0087487			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301ZC	24489923	gold, Green Submitted, Green Published			2023-01-03	WOS:000330570000150
J	Maurya, SR; Mahalakshmi, R				Maurya, Svetlana Rajkumar; Mahalakshmi, Radhakrishnan			Influence of Protein - Micelle Ratios and Cysteine Residues on the Kinetic Stability and Unfolding Rates of Human Mitochondrial VDAC-2	PLOS ONE			English	Article							DEPENDENT ANION CHANNEL; OUTER-MEMBRANE PROTEIN; BETA-BARREL; THERMODYNAMIC STABILITY; STRUCTURAL STABILITY; LIPID INTERACTIONS; PARALLEL PATHWAYS; APOPTOSIS; ISOFORMS; DYNAMICS	Delineating the kinetic and thermodynamic factors which contribute to the stability of transmembrane beta-barrels is critical to gain an in-depth understanding of membrane protein behavior. Human mitochondrial voltage-dependent anion channel isoform 2 (hVDAC-2), one of the key anti-apoptotic eukaryotic beta-barrel proteins, is of paramount importance, owing to its indispensable role in cell survival. We demonstrate here that the stability of hVDAC-2 bears a strong kinetic contribution that is dependent on the absolute micellar concentration used for barrel folding. The refolding efficiency and ensuing stability is sensitive to the lipid-to-protein (LPR) ratio, and displays a non-linear relationship, with both low and high micellar amounts being detrimental to hVDAC-2 structure. Unfolding and aggregation process are sequential events and show strong temperature dependence. We demonstrate that an optimal lipid-to-protein ratio of 2600:1 - 13000:1 offers the highest protection against thermal denaturation. Activation energies derived only for lower LPRs are similar to 17 kcal mol(-1) for full-length hVDAC-2 and similar to 23 kcal mol(-1) for the Cys-less mutant, suggesting that the nine cysteine residues of hVDAC-2 impart additional malleability to the barrel scaffold. Our studies reveal that cysteine residues play a key role in the kinetic stability of the protein, determine barrel rigidity and thereby give rise to strong micellar association of hVDAC-2. Non-linearity of the Arrhenius plot at high LPRs coupled with observation of protein aggregation upon thermal denaturation indicates that contributions from both kinetic and thermodynamic components stabilize the 19-stranded beta-barrel. Lipid-protein interaction and the linked kinetic contribution to free energy of the folded protein are together expected to play a key role in hVDAC-2 recycling and the functional switch at the onset of apoptosis.	[Maurya, Svetlana Rajkumar; Mahalakshmi, Radhakrishnan] Indian Inst Sci Educ & Res, Dept Biol Sci, Mol Biophys Lab, Bhopal, Madhya Pradesh, India	Indian Institute of Science Education & Research (IISER) - Bhopal	Mahalakshmi, R (corresponding author), Indian Inst Sci Educ & Res, Dept Biol Sci, Mol Biophys Lab, Bhopal, Madhya Pradesh, India.	maha@iiserb.ac.in	Mahalakshmi, Radhakrishnan/B-3143-2008; Maurya, Svetlana/H-3664-2018	Mahalakshmi, Radhakrishnan/0000-0003-1549-7550; Maurya, Svetlana/0000-0002-4700-2711	Department of Biotechnology (DBT), Govt. of India [BT/01/IYBA/2009]; Council of Scientific and Industrial Research, India; DBT, Govt. of India	Department of Biotechnology (DBT), Govt. of India(Department of Biotechnology (DBT) India); Council of Scientific and Industrial Research, India(Council of Scientific & Industrial Research (CSIR) - India); DBT, Govt. of India(Department of Biotechnology (DBT) India)	This work is supported by the Department of Biotechnology (DBT), Govt. of India award number BT/01/IYBA/2009. S.R.M. is supported by a senior research fellowship from Council of Scientific and Industrial Research, India. R. M. is a recipient of the Ramalingaswami Fellowship from DBT, Govt. of India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen KK, 2012, BIOCHEMISTRY-US, V51, P8371, DOI 10.1021/bi300974y; Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Aram L, 2010, BIOCHEM J, V427, P445, DOI 10.1042/BJ20091690; Bauer AJ, 2011, BIOCHEMISTRY-US, V50, P3408, DOI 10.1021/bi2003247; Bayrhuber M, 2008, P NATL ACAD SCI USA, V105, P15370, DOI 10.1073/pnas.0808115105; Betaneli V, 2012, BIOPHYS J, V102, P523, DOI 10.1016/j.bpj.2011.12.049; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; Chaturvedi D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079351; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Colombini M, 1996, Ion Channels, V4, P169; Colombini M, 2004, MOL CELL BIOCHEM, V256, P107, DOI 10.1023/B:MCBI.0000009862.17396.8d; Colombini M, 2012, BBA-BIOMEMBRANES, V1818, P1457, DOI 10.1016/j.bbamem.2011.12.026; Corley SC, 2011, BIOPHYS J, V100, P2946, DOI 10.1016/j.bpj.2011.05.015; Curnow P, 2007, P NATL ACAD SCI USA, V104, P18970, DOI 10.1073/pnas.0705067104; De Pinto V, 2010, BBA-BIOENERGETICS, V1797, P1268, DOI 10.1016/j.bbabio.2010.01.031; Eddy MT, 2012, J AM CHEM SOC, V134, P6375, DOI 10.1021/ja300347v; Garbuzynskiy SO, 2013, P NATL ACAD SCI USA, V110, P147, DOI 10.1073/pnas.1210180110; Geula S, 2012, J BIOL CHEM, V287, P2179, DOI 10.1074/jbc.M111.268920; Greenfield NJ, 2006, NAT PROTOC, V1, P2527, DOI 10.1038/nprot.2006.204; HALTIA T, 1995, BBA-BIOENERGETICS, V1228, P1, DOI 10.1016/0005-2728(94)00161-W; Hiller S, 2008, SCIENCE, V321, P1206, DOI 10.1126/science.1161302; Horvath SE, 2013, PROG LIPID RES, V52, P590, DOI 10.1016/j.plipres.2013.07.002; Huysmans GHM, 2012, J MOL BIOL, V416, P453, DOI 10.1016/j.jmb.2011.12.039; Huysmans GHM, 2010, P NATL ACAD SCI USA, V107, P4099, DOI 10.1073/pnas.0911904107; Ignatova Z, 2004, P NATL ACAD SCI USA, V101, P523, DOI 10.1073/pnas.0304533101; Jackson SE, 1998, FOLD DES, V3, pR81, DOI 10.1016/S1359-0278(98)00033-9; Jayaraman S, 2005, BIOPHYS J, V88, P2907, DOI 10.1529/biophysj.104.055921; Jefferson RE, 2013, J AM CHEM SOC, V135, P15183, DOI 10.1021/ja407232b; Kleinschmidt JH, 2002, J MOL BIOL, V324, P319, DOI 10.1016/S0022-2836(02)01071-9; Kleinschmidt JH, 1999, PROTEIN SCI, V8, P2065, DOI 10.1110/ps.8.10.2065; Manning M, 2004, BIOCHEMISTRY-US, V43, P11248, DOI 10.1021/bi0491898; Maurya SR, 2013, J BIOL CHEM, V288, P25584, DOI 10.1074/jbc.M113.493692; Maurya SR, 2013, SCI REP-UK, V3, DOI 10.1038/srep01989; Messina A, 2012, BBA-BIOMEMBRANES, V1818, P1466, DOI 10.1016/j.bbamem.2011.10.005; Moon CP, 2013, P NATL ACAD SCI USA, V110, P4285, DOI 10.1073/pnas.1212527110; Palazzo G, 2010, BBA-PROTEINS PROTEOM, V1804, P137, DOI 10.1016/j.bbapap.2009.09.021; Perrett S, 1999, J MOL BIOL, V290, P331, DOI 10.1006/jmbi.1999.2872; Rodriguez-Larrea D, 2006, J MOL BIOL, V360, P715, DOI 10.1016/j.jmb.2006.05.009; Rostovtseva TK, 2006, J BIOL CHEM, V281, P37496, DOI 10.1074/jbc.M602548200; Rostovtseva TK, 2005, J BIOENERG BIOMEMBR, V37, P129, DOI 10.1007/s10863-005-6566-8; Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5; Saccone C, 2003, J MOL EVOL, V57, pS277, DOI 10.1007/s00239-003-0037-9; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; Sampson MJ, 1997, J BIOL CHEM, V272, P18966, DOI 10.1074/jbc.272.30.18966; Sanchez-Ruiz JM, 2010, BIOPHYS CHEM, V148, P1, DOI 10.1016/j.bpc.2010.02.004; SCHELLMAN JA, 1987, ANNU REV BIOPHYS BIO, V16, P115, DOI 10.1146/annurev.bb.16.060187.000555; Schlebach JP, 2013, BIOCHEMISTRY-US, V52, P3229, DOI 10.1021/bi301635f; Schlebach JP, 2012, PROTEIN SCI, V21, P97, DOI 10.1002/pro.766; Shanmugavadivu B, 2007, J MOL BIOL, V368, P66, DOI 10.1016/j.jmb.2007.01.066; Shoshan-Barmatz V, 2013, PROG MOL BIOL TRANSL, V117, P303, DOI 10.1016/B978-0-12-386931-9.00011-8; Shoshan-Barmatz V, 2009, BBA-BIOENERGETICS, V1787, P421, DOI 10.1016/j.bbabio.2008.11.009; Tan EHL, 1996, BIOPHYS J, V70, P2385, DOI 10.1016/S0006-3495(96)79806-5; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Xu X, 1999, J MEMBRANE BIOL, V170, P89, DOI 10.1007/s002329900540; Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859	56	17	18	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2014	9	1							e87701	10.1371/journal.pone.0087701	http://dx.doi.org/10.1371/journal.pone.0087701			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301ZC	24494036	gold, Green Published, Green Submitted			2023-01-03	WOS:000330570000171
J	Macrae, D; Grieve, R; Allen, E; Sadique, Z; Morris, K; Pappachan, J; Parslow, R; Tasker, RC; Elbourne, D				Macrae, Duncan; Grieve, Richard; Allen, Elizabeth; Sadique, Zia; Morris, Kevin; Pappachan, John; Parslow, Roger; Tasker, Robert C.; Elbourne, Diana		CHiP Investigators	A Randomized Trial of Hyperglycemic Control in Pediatric Intensive Care	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INSULIN THERAPY; STRESS HYPERGLYCEMIA; CRITICAL ILLNESS; GLYCEMIC CONTROL; GLUCOSE CONTROL; MORTALITY; RISK	BACKGROUND Whether an insulin infusion should be used for tight control of hyperglycemia in critically ill children remains unclear. METHODS We randomly assigned children (<= 16 years of age) who were admitted to the pediatric intensive care unit (ICU) and were expected to require mechanical ventilation and vasoactive drugs for at least 12 hours to either tight glycemic control, with a target blood glucose range of 72 to 126 mg per deciliter (4.0 to 7.0 mmol per liter), or conventional glycemic control, with a target level below 216 mg per deciliter (12.0 mmol per liter). The primary outcome was the number of days alive and free from mechanical ventilation at 30 days after randomization. The main prespecified subgroup analysis compared children who had undergone cardiac surgery with those who had not. We also assessed costs of hospital and community health services. RESULTS A total of 1369 patients at 13 centers in England underwent randomization: 694 to tight glycemic control and 675 to conventional glycemic control; 60% had undergone cardiac surgery. The mean between-group difference in the number of days alive and free from mechanical ventilation at 30 days was 0.36 days (95% confidence interval [CI], -0.42 to 1.14); the effects did not differ according to subgroup. Severe hypoglycemia (blood glucose, <36 mg per deciliter [12.0 mmol per liter]) occurred in a higher proportion of children in the tight-glycemic-control group than in the conventional-glycemic-control group (7.3% vs. 1.5%, P<0.001). Overall, the mean 12-month costs were lower in the tight-glycemic-control group than in the conventional-glycemic-control group. The mean 12-month costs were similar in the two groups in the cardiac-surgery subgroup, but in the subgroup that had not undergone cardiac surgery, the mean cost was significantly lower in the tight-glycemic-control group than in the conventional-glycemic-control group: -$13,120 (95% CI, -$24,682 to -$1,559). CONCLUSIONS This multicenter, randomized trial showed that tight glycemic control in critically ill children had no significant effect on major clinical outcomes, although the incidence of hypoglycemia was higher with tight glucose control than with conventional glucose control. (Funded by the National Institute for Health Research, Health Technology Assessment Program, U.K. National Health Service; CHiP Current Controlled Trials number, ISRCTN61735247.)	[Macrae, Duncan] Royal Brompton & Harefield NHS Fdn Trust, London SW3 6NP, England; [Grieve, Richard; Sadique, Zia] London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London WC1, England; [Allen, Elizabeth; Elbourne, Diana] London Sch Hyg & Trop Med, Dept Med Stat, London WC1, England; [Allen, Elizabeth; Elbourne, Diana] London Sch Hyg & Trop Med, Clin Trials Unit, London WC1, England; [Morris, Kevin] Birmingham Childrens Hosp, Birmingham, W Midlands, England; [Pappachan, John] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England; [Parslow, Roger] Univ Leeds, Fac Med & Hlth, Leeds Inst Genet & Therapeut, Div Epidemiol, Leeds, W Yorkshire, England; [Tasker, Robert C.] Boston Childrens Hosp, Dept Neurol & Anesthesia, Boston, MA USA; [Tasker, Robert C.] Harvard Univ, Sch Med, Boston, MA USA	Royal Brompton & Harefield NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of Birmingham; University of Southampton; University Hospital Southampton NHS Foundation Trust; University of Leeds; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Macrae, D (corresponding author), Royal Brompton & Harefield NHS Fdn Trust, Sydney St, London SW3 6NP, England.	d.macrae@rbht.nhs.uk	Macrae, Duncan/AAC-9564-2020; Parslow, Roger/AAV-1477-2020; Tasker, Robert C/R-5837-2019; Peters, Mark/AAD-7518-2019	Peters, Mark/0000-0003-3653-4808; Mok, Quen/0000-0003-4807-9275; Parslow, Roger/0000-0002-3945-5294; Tasker, Robert/0000-0003-3647-8113; Dunger, Professor David/0000-0002-2566-9304; Grieve, Richard/0000-0001-8899-1301; Inwald, David/0000-0001-9518-7821; Brierley, Joe/0000-0003-0919-6882; Macrae, Duncan/0000-0002-7158-6585; Sadique, Zia/0000-0001-5814-0258; Pathan, Nazima/0000-0001-7656-9453	NIHR-HTA, a research institute of the U.K. National Health Service; National Institute for Health Research [PDA/03/07/026, NF-SI-0508-10274, NF-SI-0513-10012] Funding Source: researchfish	NIHR-HTA, a research institute of the U.K. National Health Service; National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by a grant from the NIHR-HTA, a research institute of the U.K. National Health Service.	Agus MSD, 2012, NEW ENGL J MED, V367, P1208, DOI 10.1056/NEJMoa1206044; Branco Ricardo G, 2005, Pediatr Crit Care Med, V6, P470, DOI 10.1097/01.PCC.0000161284.96739.3A; Branco RG, 2011, PEDIATR CRIT CARE ME, V12, P265, DOI 10.1097/PCC.0b013e3181f52847; Branco RG, 2010, PEDIATR CRIT CARE ME, V11, P755, DOI 10.1097/PCC.0b013e3181f4d606; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Draper E, 2007, PAEDIAT INTENSIVE CA; Faustino EV, 2005, J PEDIATR-US, V146, P30, DOI 10.1016/j.jpeds.2004.08.076; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Finfer S, 2012, NEW ENGL J MED, V367, P1108, DOI 10.1056/NEJMoa1204942; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; Griesdale DEG, 2009, CAN MED ASSOC J, V180, P821, DOI 10.1503/cmaj.090206; Jenkins KJ, 2002, J THORAC CARDIOV SUR, V123, P110, DOI 10.1067/mtc.2002.119064; Kenward MG, 2007, STAT METHODS MED RES, V16, P199, DOI 10.1177/0962280206075304; Lacroix Jacques, 2005, Pediatr Crit Care Med, V6, pS126, DOI 10.1097/01.PCC.0000161287.61028.D4; Leteurtre S, 1999, MED DECIS MAKING, V19, P399, DOI 10.1177/0272989X9901900408; Macrae D, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-5; Mesotten D, 2012, JAMA-J AM MED ASSOC, V308, P1641, DOI 10.1001/jama.2012.12424; Mooney C. Z., 1993, BOOTSTRAPPING NONPAR; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Slater A, 2003, INTENS CARE MED, V29, P278, DOI 10.1007/s00134-002-1601-2; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; Tasker RC, 2012, JAMA-J AM MED ASSOC, V308, P1687, DOI 10.1001/jama.2012.14151; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vlasselaers D, 2009, LANCET, V373, P547, DOI 10.1016/S0140-6736(09)60044-1; Wiener RS, 2009, JAMA-J AM MED ASSOC, V301, P936; Yates AR, 2006, PEDIATR CRIT CARE ME, V7, P351, DOI 10.1097/01.PCC.0000227755.96700.98; Yung M, 2008, PEDIATR CRIT CARE ME, V9, P147, DOI 10.1097/PCC.0b013e3181668c22	30	138	144	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 9	2014	370	2					107	118		10.1056/NEJMoa1302564	http://dx.doi.org/10.1056/NEJMoa1302564			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AH4TA	24401049	Green Accepted			2023-01-03	WOS:000336119800006
J	Huiart, L; Bouhnik, AD; Rey, D; Rousseau, F; Retornaz, F; Meresse, M; Bendiane, MK; Viens, P; Giorgi, R				Huiart, Laetitia; Bouhnik, Anne-Deborah; Rey, Dominique; Rousseau, Frederique; Retornaz, Frederique; Meresse, Megane; Bendiane, Marc Karim; Viens, Patrice; Giorgi, Roch			Complementary or Alternative Medicine as Possible Determinant of Decreased Persistence to Aromatase Inhibitor Therapy among Older Women with Non-Metastatic Breast Cancer	PLOS ONE			English	Article							ADJUVANT HORMONAL-THERAPY; POSTMENOPAUSAL WOMEN; EARLY DISCONTINUATION; MEDICATION ADHERENCE; TAMOXIFEN THERAPY; ENDOCRINE THERAPY; CLINICAL-PRACTICE; RANDOMIZED-TRIAL; COHORT; LETROZOLE	Purpose: Aromatase inhibitor therapy (AI) significantly improves survival in breast cancer patients. Little is known about adherence and persistence to aromatase inhibitors and about the causes of treatment discontinuation among older women. Methods: We constituted a cohort of women over 65 receiving a first AI therapy for breast cancer between 2006 and 2008, and followed them until June 2011. Women were selected in the population-based French National Health Insurance databases, and data was collected on the basis of pharmacy refills, medical records and face-to-face interviews. Non-persistence to treatment was defined as the first treatment discontinuation lasting more than 3 consecutive months. Time to treatment discontinuation was studied using survival analysis techniques. Results: Overall among the 382 selected women, non-persistence to treatment went from 8.7% (95% CI: 6.2-12.1) at 1 year, to 15.6% (95% CI: 12.2-19.8) at 2 years, 20.8% (95% CI: 16.7-25.6) at 3 years, and 24.7% (95% CI: 19.5-31.0) at 4 years. In the multivariate analysis on a sub-sample of 233 women with available data, women using complementary or alternative medicine (CAM) (HR = 3.2; 95% CI: 1.5-6.9) or suffering from comorbidities (HR = 2.2; 95% CI: 1.0-4.8) were more likely to discontinue their treatment, whereas women with polypharmacy (HR = 0.4; 95% CI: 0.2-0.91) were less likely to discontinue. In addition, 13% of the women with positive hormonal receptor status did not fill any prescription for anti-hormonal therapy. Conclusion: AI therapy is discontinued prematurely in a substantial portion of older patients. Some patients may use CAM not as a complementary treatment, but as an alternative to conventional medicine. Improving patient-physician communication on the use of CAM may improve hormonal therapy adherence.	[Huiart, Laetitia] CHU La Reunion, Unite Soutien Methodol, St Denis, France; [Huiart, Laetitia; Bouhnik, Anne-Deborah; Rey, Dominique; Meresse, Megane; Bendiane, Marc Karim; Giorgi, Roch] INSERM, SESSTIM U912, F-13258 Marseille, France; [Huiart, Laetitia; Bouhnik, Anne-Deborah; Rey, Dominique; Meresse, Megane; Bendiane, Marc Karim; Giorgi, Roch] Univ Aix Marseille, IRD, UMR S912, Marseille, France; [Rey, Dominique; Bendiane, Marc Karim] ORS PACA, Marseille, France; [Rousseau, Frederique; Viens, Patrice] Inst J Paoli I Calmettes, Dept Med Oncol, F-13009 Marseille, France; [Retornaz, Frederique] Ctr Gerontol Dept, Marseille, France; [Viens, Patrice] Univ Aix Marseille, Ctr Rech Cancerol Marseille, INSERM U891, Marseille, France; [Giorgi, Roch] Hop Enfants La Timone, Assistance Publ Hop Marseille, Serv Biostat & Technol Informat & Commun, Marseille, France	CHU Reunion; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Huiart, L (corresponding author), CHU La Reunion, Unite Soutien Methodol, St Denis, France.	laetitia.huiart@mail.mcgill.ca	Bouhnik, Anne-Déborah/Q-9650-2017; Huiart, Laetitia/GQB-4064-2022; Bendiane, Marc-Karim K/F-5414-2010; Bouhnik, Anne-Deborah/M-2829-2019; Viens, Patrice/Q-8499-2018; Bendiane, Marc-Karim/M-7060-2019; GIORGI, Roch/A-6438-2009	Bouhnik, Anne-Déborah/0000-0002-5418-4592; Bendiane, Marc-Karim K/0000-0003-4329-8807; Bouhnik, Anne-Deborah/0000-0002-5418-4592; Viens, Patrice/0000-0003-1511-1048; GIORGI, Roch/0000-0001-6135-3078	French Ministry of Research; French National Institute of Cancer (INCa); cancer foundations (Fondation de France and Association pour la Recherche sur le Cancer); National Institute for Health Research [UMR912 INSERM]	French Ministry of Research(Ministry of Research, FranceEuropean Commission); French National Institute of Cancer (INCa)(Institut National du Cancer (INCA) France); cancer foundations (Fondation de France and Association pour la Recherche sur le Cancer); National Institute for Health Research(National Institute for Health Research (NIHR))	This study was funded by the French Ministry of Research, the French National Institute of Cancer (INCa), regional authorities (Conseil Regional Provence-Alpes Cote-d'Azur), cancer foundations (Fondation de France and Association pour la Recherche sur le Cancer), and the National Institute for Health Research (UMR912 INSERM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Almeida OP, 1999, INT J GERIATR PSYCH, V14, P858, DOI 10.1002/(SICI)1099-1166(199910)14:10<858::AID-GPS35>3.0.CO;2-8; Andrade SE, 2006, PHARMACOEPIDEM DR S, V15, P565, DOI 10.1002/pds.1230; Balkrishnan R, 1998, CLIN THER, V20, P764, DOI 10.1016/S0149-2918(98)80139-2; Borson S, 2000, INT J GERIATR PSYCH, V15, P1021, DOI 10.1002/1099-1166(200011)15:11<1021::AID-GPS234>3.0.CO;2-6; Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI [10.1200/JCO.2009.26.3756, 10.1200/JOP.000082]; Choo PW, 1999, MED CARE, V37, P846, DOI 10.1097/00005650-199909000-00002; Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331; Cramer JA, 2008, VALUE HEALTH, V11, P44, DOI 10.1111/j.1524-4733.2007.00213.x; Crivellari D, 2008, J CLIN ONCOL, V26, P1972, DOI 10.1200/JCO.2007.14.0459; Dezentje V, 2009, J CLIN ONCOL, V27; Eisenberg DM, 2001, ANN INTERN MED, V135, P344, DOI 10.7326/0003-4819-135-5-200109040-00011; FILLENBAUM GG, 1981, J GERONTOL, V36, P428, DOI 10.1093/geronj/36.4.428; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; Goldhirsch A, 2009, ANN ONCOL, V20, P1319, DOI 10.1093/annonc/mdp322; Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312; Hershman DL, 2011, BREAST CANCER RES TR, V126, P529, DOI 10.1007/s10549-010-1132-4; Hershman DL, 2010, J CLIN ONCOL, V28, P4120, DOI 10.1200/JCO.2009.25.9655; Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6; Huiart L, 2011, BRIT J CANCER, V104, P1558, DOI 10.1038/bjc.2011.140; Huiart L, 2013, BREAST CANCER RES TR, V138, P325, DOI 10.1007/s10549-013-2422-4; Huiart L, 2012, EUR J CANCER, V48, P1939, DOI 10.1016/j.ejca.2012.03.004; Jernewall N, 2005, AIDS CARE, V17, P601, DOI 10.1080/09540120512331314295; KATZ S, 1983, J AM GERIATR SOC, V31, P721, DOI 10.1111/j.1532-5415.1983.tb03391.x; Knippels HMA, 2000, AIDS CARE, V12, P435, DOI 10.1080/09540120050123837; Lash TL, 2006, BREAST CANCER RES TR, V99, P215, DOI 10.1007/s10549-006-9193-0; LOVE RR, 1990, J NATL CANCER I, V82, P18, DOI 10.1093/jnci/82.1.18; Maggiore RJ, 2012, CANCER-AM CANCER SOC, V118, P4815, DOI 10.1002/cncr.27427; Martin-Latry K, 2010, PHARMACOEPIDEM DR S, V19, P256, DOI 10.1002/pds.1912; McCowan C, 2008, BRIT J CANCER, V99, P1763, DOI 10.1038/sj.bjc.6604758; Murphy CC, 2012, BREAST CANCER RES TR, V134, P459, DOI 10.1007/s10549-012-2114-5; Nekhlyudov L, 2011, BREAST CANCER RES TR, V130, P681, DOI 10.1007/s10549-011-1703-z; Neugut AI, 2011, J CLIN ONCOL, V29, P2534, DOI 10.1200/JCO.2010.33.3179; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Owen-Smith A, 2007, AIDS CARE, V19, P589, DOI 10.1080/09540120701203279; Partridge AH, 2002, JNCI-J NATL CANCER I, V94, P652; Partridge AH, 2008, J CLIN ONCOL, V26, P556, DOI 10.1200/JCO.2007.11.5451; Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505; Ruddy K, 2009, CA-CANCER J CLIN, V59, P56, DOI 10.3322/caac.20004; Thomas-Schoemann A, 2011, B CANCER, V98, P645, DOI 10.1684/bdc.2011.1375; Williams N, 2008, LANCET ONCOL, V9, P45, DOI 10.1016/S1470-2045(07)70385-6; Ziller V, 2009, ANN ONCOL, V20, P431, DOI 10.1093/annonc/mdn646	42	14	14	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2013	8	12							e81677	10.1371/journal.pone.0081677	http://dx.doi.org/10.1371/journal.pone.0081677			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276HL	24367488	Green Published, Green Submitted, gold			2023-01-03	WOS:000328740300009
J	Saadatian-Elahi, M; Tristan, A; Laurent, F; Rasigade, JP; Bouchiat, C; Ranc, AG; Lina, G; Dauwalder, O; Etienne, J; Bes, M; Vanderesch, F				Saadatian-Elahi, Mitra; Tristan, Anne; Laurent, Frederic; Rasigade, Jean-Philippe; Bouchiat, Coralie; Ranc, Anne-Gaelle; Lina, Gerard; Dauwalder, Olivier; Etienne, Jerome; Bes, Michele; Vanderesch, Francois			Basic Rules of Hygiene Protect Health Care and Lab Workers from Nasal Colonization by Staphylococcus aureus: An International Cross-Sectional Study	PLOS ONE			English	Article							CARRIAGE; PREVALENCE; PERSISTENT; INFECTION; CARRIERS; RISK; MICROBIOLOGY; EPIDEMIOLOGY; POPULATION; BACTEREMIA	Acquisition of nasal Staphylococcus aureus (S. aureus) colonization by contaminated hands is likely an important determinant of its nasal carriage rate in health care and lab setting. The objective of our cross-sectional study was to assess the prevalence of nasal methicillin-sensitive (MSSA) or -resistant Staphylococcus aureus (MRSA) carriage among health care professionals (HCPs) attending an international symposium and to study the association between compliance with hygiene rules, individual-related parameters, and medical conditions with nasal S. aureus carriage in this population. After obtaining consent, two nasal swabs were collected. Nasal MSSA and MRSA carriage was measured by the: i) molecular approach targeting spa, mecA and mecA-orfX junction sequences, and ii) culture on selective S. aureus media combined with mecA molecular detection of isolated strains. Information on compliance with hygiene rules, demographic variables, sector of activity and long-term medication was collected by anonymous questionnaire. The participation rate was 32.3%. In total, 176 subjects from 34 countries were included in the analysis. S. aureus was isolated from the nasal swabs of 57 (32.4%) subjects, of whom 3 (5.3%) harbored MRSA strains. Overall, 123 subjects reported working in microbiology laboratories with direct manipulation of S. aureus, and 29 acknowledged regular contacts with patients. In this exposed population, hydro-alcoholic solutions appeared to have a significant protective effect against nasal S. aureus carriage (OR = 0.36; 95% CI: 0.15-0.85). Hospital work was associated with increased risk of nasal S. aureus carriage (OR = 2.38; 95% CI: 1.07-5.29). The results of this study showed that compliance with basic rules of hygiene, such as the use of hydro-alcoholic solutions, could reduce the risk of nasal S. aureus colonization. Hydro-alcoholic solution could interrupt auto-transmission of the pathogen, consequently decreasing the overall nasal carriage rate, specifically in transient carriers.	[Saadatian-Elahi, Mitra; Tristan, Anne; Laurent, Frederic; Rasigade, Jean-Philippe; Bouchiat, Coralie; Ranc, Anne-Gaelle; Lina, Gerard; Dauwalder, Olivier; Etienne, Jerome; Bes, Michele; Vanderesch, Francois] Hosp Civils Lyon, Ctr Natl References Staphylocoques, Lyon, France; [Tristan, Anne; Laurent, Frederic; Rasigade, Jean-Philippe; Bouchiat, Coralie; Lina, Gerard; Etienne, Jerome; Bes, Michele; Vanderesch, Francois] Univ Lyon, INSERM, U1111, Lyon, France	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)	Vanderesch, F (corresponding author), Hosp Civils Lyon, Ctr Natl References Staphylocoques, Lyon, France.	francois.vandenesch@univ-lyon1.fr	Lina, Gerard J/L-9352-2014; bouchiat, coralie/AAG-3339-2020; DAUWALDER, Olivier/L-9619-2014; Vandenesch, Francois/C-7209-2014; Rasigade, Jean-Philippe/AAE-1667-2021; Rasigade, Jean-Philippe/L-9320-2014; Tristan, Anne/L-9464-2014; TRISTAN, Anne/GSN-8306-2022; LAURENT, Frederic/AGM-0706-2022; ETIENNE, Jerome/C-5471-2014	Vandenesch, Francois/0000-0001-9412-7106; Rasigade, Jean-Philippe/0000-0002-8264-0452; TRISTAN, Anne/0000-0001-9471-2655; ETIENNE, Jerome/0000-0002-3348-3315; DAUWALDER, Olivier/0000-0003-1722-1582; Lina, Gerard/0000-0002-9236-7998; laurent, frederic/0000-0003-0609-9091				Acton DS, 2009, EUR J CLIN MICROBIOL, V28, P115, DOI 10.1007/s10096-008-0602-7; Albrich WC, 2008, LANCET INFECT DIS, V8, P289, DOI 10.1016/S1473-3099(08)70097-5; Amorim ML, 2009, MICROB DRUG RESIST, V15, P19, DOI 10.1089/mdr.2009.0881; Argudin MA, 2013, MICROB PATHOGENESIS, V54, P26, DOI 10.1016/j.micpath.2012.09.001; Bode LGM, 2010, NEW ENGL J MED, V362, P9, DOI 10.1056/NEJMoa0808939; Boisseau D, 2012, MED MALADIES INFECT, V42, P435, DOI 10.1016/j.medmal.2012.07.014; da Silva ECBF, 2008, BRAZ J INFECT DIS, V12, P504, DOI 10.1590/S1413-86702008000600012; Chen YT, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0017844, 10.1371/journal.pone.0017876, 10.1371/journal.pone.0027333, 10.1371/journal.pone.0021428, 10.1371/journal.pone.0027163, 10.1371/journal.pone.0024144]; Elie-Turenne MC, 2010, INFECT CONT HOSP EP, V31, P574, DOI 10.1086/652525; Farzana K, 2008, PAK J PHARM SCI, V21, P290; Herwaldt LA, 1998, J HOSP INFECT, V40, pS13, DOI 10.1016/S0195-6701(98)90200-6; Herwaldt LA, 2004, INFECT CONT HOSP EP, V25, P481, DOI 10.1086/502426; Ibarra M, 2008, PEDIATR INFECT DIS J, V27, P1109, DOI 10.1097/INF.0b013e31817eeefa; Jager MM, 2010, J HOSP INFECT, V74, P292, DOI 10.1016/j.jhin.2009.11.003; Johannessen M, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00056; Krebes J, 2011, J CLIN MICROBIOL, V49, P430, DOI 10.1128/JCM.02039-10; Lozano C, 2011, INT J MED MICROBIOL, V301, P500, DOI 10.1016/j.ijmm.2011.02.004; LUZAR MA, 1990, NEW ENGL J MED, V322, P505, DOI 10.1056/NEJM199002223220804; Mainous AG, 2006, ANN FAM MED, V4, P132, DOI 10.1370/afm.526; Mody L, 2008, CLIN INFECT DIS, V46, P1368, DOI 10.1086/586751; Monecke S, 2009, EUR J CLIN MICROBIOL, V28, P1159, DOI 10.1007/s10096-009-0752-2; Munckhof WJ, 2009, CLIN MICROBIOL INFEC, V15, P149, DOI 10.1111/j.1469-0691.2008.02652.x; Ng LSY, 2011, J HOSP INFECT, V78, P231, DOI 10.1016/j.jhin.2011.01.025; Nulens E, 2005, EUR J CLIN MICROBIOL, V24, P145, DOI 10.1007/s10096-004-1258-6; Olsen K, 2013, EPIDEMIOL INFECT, V141, P143, DOI 10.1017/S0950268812000465; Padoveze MC, 2008, AM J INFECT CONTROL, V36, P187, DOI 10.1016/j.ajic.2007.05.012; Rashid Z, 2012, ACTA POL PHARM, V69, P985; Rijnders MIA, 2010, BRIT J GEN PRACT, V60, P902, DOI 10.3399/bjgp10X544078; Rodriguez-Avial C, 2013, ENFERM INFEC MICR CL, V31, P516, DOI 10.1016/j.eimc.2012.09.017; Ruimy R, 2010, J INFECT DIS, V202, P924, DOI 10.1086/655901; Skramm I, 2011, APMIS, V119, P522, DOI 10.1111/j.1600-0463.2011.02758.x; Stiefel U, 2011, INFECT CONT HOSP EP, V32, P185, DOI 10.1086/657944; Stone SP, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3005; Tristan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051172; van Belkum A, 2007, MICROBES INFECT, V9, P1471, DOI 10.1016/j.micinf.2007.08.003; von Eiff C, 2001, NEW ENGL J MED, V344, P11, DOI 10.1056/NEJM200101043440102; Wertheim HFL, 2006, INFECT CONT HOSP EP, V27, P863, DOI 10.1086/506401; Wertheim HFL, 2005, LANCET INFECT DIS, V5, P751, DOI 10.1016/S1473-3099(05)70295-4; Wertheim HFL, 2004, LANCET, V364, P703, DOI 10.1016/S0140-6736(04)16897-9; Zanger P, 2012, CLIN INFECT DIS, V55, P1625, DOI 10.1093/cid/cis778; Zhang M, 2011, J HOSP INFECT, V78, P113, DOI 10.1016/j.jhin.2011.02.018	41	14	16	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2013	8	12							e82851	10.1371/journal.pone.0082851	http://dx.doi.org/10.1371/journal.pone.0082851			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276HL	24367562	gold, Green Submitted, Green Published			2023-01-03	WOS:000328740300075
J	Martinez-Garcia, MA; Capote, F; Campos-Rodriguez, F; Lloberes, P; de Atauri, MJD; Somoza, M; Masa, JF; Gonzalez, M; Sacristan, L; Barbe, F; Duran-Cantolla, J; Aizpuru, F; Manas, E; Barreiro, B; Mosteiro, M; Cebrian, JJ; de la Pena, M; Garcia-Rio, F; Maimo, A; Zapater, J; Hernandez, C; SanMarti, NG; Montserrat, JM				Martinez-Garcia, Miguel-Angel; Capote, Francisco; Campos-Rodriguez, Francisco; Lloberes, Patricia; Diaz de Atauri, Maria Josefa; Somoza, Maria; Masa, Juan F.; Gonzalez, Monica; Sacristan, Lirios; Barbe, Ferran; Duran-Cantolla, Joaquin; Aizpuru, Felipe; Manas, Eva; Barreiro, Bienvenido; Mosteiro, Mar; Cebrian, Juan J.; de la Pena, Monica; Garcia-Rio, Francisco; Maimo, Andres; Zapater, Jordi; Hernandez, Concepcion; SanMarti, Nuria Grau; Montserrat, Josep Maria			Effect of CPAP on Blood Pressure in Patients With Obstructive Sleep Apnea and Resistant Hypertension The HIPARCO Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITIVE AIRWAY PRESSURE; METAANALYSIS; DIAGNOSIS; HYPOPNEA; THERAPY; ASSOCIATION; PREVALENCE; PROGNOSIS; FEATURES; IMPACT	IMPORTANCE More than 70% of patients with resistant hypertension have obstructive sleep apnea (OSA). However, there is little evidence about the effect of continuous positive airway pressure (CPAP) treatment on blood pressure in patients with resistant hypertension. OBJECTIVE To assess the effect of CPAP treatment on blood pressure values and nocturnal blood pressure patterns in patients with resistant hypertension and OSA. DESIGN, SETTING, AND PARTICIPANTS Open-label, randomized, multicenter clinical trial of parallel groups with blinded end point design conducted in 24 teaching hospitals in Spain involving 194 patients with resistant hypertension and an apnea-hypopnea index (AHI) of 15 or higher. Data were collected from June 2009 to October 2011. INTERVENTIONS CPAP or no therapy while maintaining usual blood pressure control medication. MAIN OUTCOMES AND MEASURES The primary end point was the change in 24-hour mean blood pressure after 12 weeks. Secondary end points included changes in other blood pressure values and changes in nocturnal blood pressure patterns. Both intention-to-treat (ITT) and per-protocol analyses were performed. RESULTS A total of 194 patients were randomly assigned to receive CPAP (n = 98) or no CPAP (control; n = 96). The mean AHI was 40.4 (SD, 18.9) and an average of 3.8 antihypertensive drugs were taken per patient. Baseline 24-hour mean blood pressure was 103.4 mm Hg; systolic blood pressure (SBP), 144.2 mm Hg; and diastolic blood pressure (DBP), 83 mm Hg. At baseline, 25.8% of patients displayed a dipper pattern (a decrease of at least 10% in the average nighttime blood pressure compared with the average daytime blood pressure). The percentage of patients using CPAP for 4 or more hours per day was 72.4%. When the changes in blood pressure over the study period were compared between groups by ITT, the CPAP group achieved a greater decrease in 24-hour mean blood pressure (3.1 mm Hg [95% CI, 0.6 to 5.6]; P = .02) and 24-hour DBP (3.2 mm Hg [95% CI, 1.0 to 5.4]; P = .005), but not in 24-hour SBP (3.1 mm Hg [95% CI, -0.6 to 6.7]; P = .10) compared with the control group. Moreover, the percentage of patients displaying a nocturnal blood pressure dipper pattern at the 12-week follow-up was greater in the CPAP group than in the control group (35.9% vs 21.6%; adjusted odds ratio [OR], 2.4 [95% CI, 1.2 to 5.1]; P = .02). There was a significant positive correlation between hours of CPAP use and the decrease in 24-hour mean blood pressure (r = 0.29, P = .006), SBP (r = 0.25; P = .02), and DBP (r = 0.30, P = .005). CONCLUSIONS AND RELEVANCE Among patients with OSA and resistant hypertension, CPAP treatment for 12 weeks compared with control resulted in a decrease in 24-hour mean and diastolic blood pressure and an improvement in the nocturnal blood pressure pattern. Further research is warranted to assess longer-term health outcomes.	[Martinez-Garcia, Miguel-Angel] Hosp Univ & Politecnico La Fe, Resp Dept, Valencia, Spain; [Capote, Francisco] Hosp Univ Virgen Rocio, Resp Dept, Seville, Spain; [Campos-Rodriguez, Francisco] Hosp Univ Valme, Resp Dept, Seville, Spain; [Lloberes, Patricia] Hosp Univ Vall Hebron, Resp Dept, Barcelona, Spain; [Diaz de Atauri, Maria Josefa] Hosp Univ 12 Octubre, Resp Dept, Madrid, Spain; [Somoza, Maria] Consorcio Sanitario Terrassa, Resp Dept, Barcelona, Spain; [Masa, Juan F.] Hosp Univ San Pedro Alcantara, Resp Dept, Caceres, Spain; [Gonzalez, Monica] Hosp Univ Marques Valdecilla, Resp Dept, Santander, Spain; [Sacristan, Lirios] Hosp Villajoyosa, Resp Dept, Alicante, Spain; [Barbe, Ferran] IRB Lleida, Lleida, Spain; [Duran-Cantolla, Joaquin] BioAraba Res Inst, Vitoria, Spain; [Duran-Cantolla, Joaquin] Hosp Univ Araba, Clin Res Unit, Vitoria, Spain; [Manas, Eva] Hosp Univ Ramon & Cajal, Resp Dept, Madrid, Spain; [Barreiro, Bienvenido] Hosp Univ Mutua Terrassa, Resp Dept, Barcelona, Spain; [Mosteiro, Mar] Hosp Univ Xeral, Resp Dept, Vigo, Spain; [Mosteiro, Mar] Hosp Univ Xeral, Resp Dept, Vigo, Spain; [Cebrian, Juan J.] Hosp Costa Sol, Resp Dept, Malaga, Spain; [de la Pena, Monica] Hosp Univ Son Espases, Resp Dept, Palma de Mallorca, Spain; [Garcia-Rio, Francisco] Hosp Univ La Paz, Resp Dept, IdiPAZ, Madrid, Spain; [Maimo, Andres] Hosp Son Llatzer, Resp Dept, Palma de Mallorca, Spain; [Zapater, Jordi] Hosp Igualada, Resp Dept, Barcelona, Spain; [Hernandez, Concepcion] Hosp Univ Palmas, Resp Dept, Gran Canaria, Spain; [SanMarti, Nuria Grau] Hosp Mar, Resp Dept, Barcelona, Spain	Hospital Universitari i Politecnic La Fe; Virgen del Rocio University Hospital; Hospital Valme; Hospital Universitari Vall d'Hebron; Hospital Universitario 12 de Octubre; Hospital Universitario Marques de Valdecilla (HUMV); Bioaraba Health Research Institute; University Hospital of Araba; Hospital Universitario Ramon y Cajal; Hospital Universitario Mutua Terrassa; Hospital Universitari Son Espases; Hospital Universitario La Paz; Hospital Universitari Son Llatzer; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Martinez-Garcia, MA (corresponding author), Hosp Univ & Politecn La Fe, Serv Neumol, Bulevar Sur S-N, E-46026 Valenicia, Spain.	mianmartinezgarcia@gmail.com	Carmona-Bernal, Carmen/C-9429-2015; Mañas, Eva/AGV-9568-2022; Martinez-Garcia, Miguel/AAA-6349-2019; de la Torre, Manuel Sanchez/B-5578-2009; Cantolla, Joaquin Duran/B-6996-2015; Grilo-Reina, Antonio/S-8097-2018; mañas, pedro/F-1441-2015; IBIS, SUEÑO/I-2520-2016; Caballero Eraso, Candela/F-1455-2015; Barbé, Ferran/A-5988-2010; Garcia-Rio, Francisco/AAC-9981-2020; GONZALEZ, MONICA/AAM-4033-2021; Lloberes Canadell, Patricia/F-9707-2014; Capote, Francisco/E-9954-2015	Mañas, Eva/0000-0003-2107-3316; Martinez-Garcia, Miguel/0000-0002-7321-1891; de la Torre, Manuel Sanchez/0000-0002-5695-348X; Grilo-Reina, Antonio/0000-0002-3702-2540; Barbé, Ferran/0000-0002-2340-8928; GONZALEZ, MONICA/0000-0003-1516-0181; Lloberes Canadell, Patricia/0000-0002-1595-8225; Saracho, Ramon/0000-0002-7849-5440; Garcia-Rio, Francisco/0000-0002-7227-2238; de la Pena, Monica/0000-0003-3276-776X; EMBID, Cristina/0000-0002-3691-917X; Egea, Carlos/0000-0002-7618-7444; Campos-Rodriguez, Francisco/0000-0002-2632-3073; Gomez, Ricardo/0000-0001-9267-304X; MONTSERRAT, Josep Maria/0000-0003-3098-4605	Philips-Respironics; Sociedad Espanola de Neumologia; Instituto de Salud Carlos III; Sociedad Valenciana de Neumologia	Philips-Respironics; Sociedad Espanola de Neumologia; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Sociedad Valenciana de Neumologia	The study received a grant from Philips-Respironics, Sociedad Espanola de Neumologia, Instituto de Salud Carlos III, and Sociedad Valenciana de Neumologia.	Alajmi M, 2007, LUNG, V185, P67, DOI 10.1007/s00408-006-0117-x; Bazzano LA, 2007, HYPERTENSION, V50, P417, DOI 10.1161/HYPERTENSIONAHA.106.085175; Ben-Dov IZ, 2007, HYPERTENSION, V49, P1235, DOI 10.1161/HYPERTENSIONAHA.107.087262; Calhoun DA, 2008, HYPERTENSION, V51, P1403, DOI 10.1161/HYPERTENSIONAHA.108.189141; Campos-Rodriguez F, 2006, CHEST, V129, P1459, DOI 10.1378/chest.129.6.1459; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Daugherty SL, 2012, CIRCULATION, V125, P1635, DOI 10.1161/CIRCULATIONAHA.111.068064; de la Sierra A, 2011, HYPERTENSION, V57, P898, DOI 10.1161/HYPERTENSIONAHA.110.168948; Duran J, 2001, AM J RESP CRIT CARE, V163, P685, DOI 10.1164/ajrccm.163.3.2005065; Duran-Cantolla J, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5991; Eckert Danny J, 2008, Proc Am Thorac Soc, V5, P144, DOI 10.1513/pats.200707-114MG; Franklin SS, 1997, CIRCULATION, V96, P308; Grote L, 2000, J HYPERTENS, V18, P679, DOI 10.1097/00004872-200018060-00004; Gugger M, 1997, EUR RESPIR J, V10, P587; Haentjens P, 2007, ARCH INTERN MED, V167, P757, DOI 10.1001/archinte.167.8.757; HAYNES RB, 1976, LANCET, V1, P1265; Head GA, 2012, J HYPERTENS, V30, P253, DOI 10.1097/HJH.0b013e32834de621; Hein H, 2002, AM J RESP CRIT CARE, V165, P305, DOI 10.1164/ajrccm.165.2.correspondence_a; Hui DS, 2006, THORAX, V61, P1083, DOI 10.1136/thx.2006.064063; Lloberes P, 2010, J SLEEP RES, V19, P597, DOI 10.1111/j.1365-2869.2010.00839.x; Logan AG, 2003, EUR RESPIR J, V21, P241, DOI 10.1183/09031936.03.00035402; Logan AG, 2001, J HYPERTENS, V19, P2271, DOI 10.1097/00004872-200112000-00022; Lozano L, 2010, J HYPERTENS, V28, P2161, DOI 10.1097/HJH.0b013e32833b9c63; Mancia G, 2007, J HYPERTENS, V25, P1751, DOI 10.1097/HJH.0b013e3282f0580f; Marrone O, 2011, CLIN EXP HYPERTENS, V33, P373, DOI 10.3109/10641963.2010.531853; Martinez-Garcia MA, 2007, EUR RESPIR J, V29, P951, DOI 10.1183/09031936.00048606; Martinez-Garcia MA, 2006, ARCH BRONCONEUMOL, V42, P14, DOI 10.1157/13083275; Masa JF, 2004, AM J RESP CRIT CARE, V170, P1218, DOI 10.1164/rccm.200312-1787OC; Masa JF, 2011, THORAX, V66, P567, DOI 10.1136/thx.2010.152272; Montesi SB, 2012, J CLIN SLEEP MED, V8, P587, DOI 10.5664/jcsm.2170; Pavlova MK, 2008, SLEEP, V31, P241, DOI 10.1093/sleep/31.2.241; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; Persell SD, 2011, HYPERTENSION, V57, P1076, DOI 10.1161/HYPERTENSIONAHA.111.170308; Pickering Thomas G., 2005, Hypertension (Baltimore), V45, P142; Robinson GV, 2006, EUR RESPIR J, V27, P1229, DOI 10.1183/09031936.06.00062805; Sanders Mark H, 2008, Proc Am Thorac Soc, V5, P161, DOI 10.1513/pats.200709-150MG; Schwartz SW, 2012, SLEEP, V35, P1585, DOI 10.5665/sleep.2218; VERDECCHIA P, 1994, HYPERTENSION, V24, P793, DOI 10.1161/01.HYP.24.6.793; Weaver Terri E, 2008, Proc Am Thorac Soc, V5, P173, DOI 10.1513/pats.200708-119MG; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	40	412	433	1	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	2013	310	22					2407	2415		10.1001/jama.2013.281250	http://dx.doi.org/10.1001/jama.2013.281250			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266NN	24327037	Bronze, Green Published			2023-01-03	WOS:000328030900021
J	Chen, J; Qi, LH; Xia, Z; Shen, M; Shen, X; Mei, J; DeRiemer, K; Yuan, ZA				Chen, Jing; Qi, Lihong; Xia, Zhen; Shen, Mei; Shen, Xin; Mei, Jian; DeRiemer, Kathryn; Yuan, Zheng'an			Which Urban Migrants Default from Tuberculosis Treatment in Shanghai, China?	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; RISK-FACTORS; TB PATIENTS; EPIDEMIOLOGY; BARRIERS; IMPACT; DOT	Background: Migration is a major challenge to tuberculosis (TB) control worldwide. TB treatment requires multiple drugs for at least six months. Some TB patients default before completing their treatment regimen, which can lead to ongoing infectiousness and drug resistance. Methods: We conducted a retrospective analysis of 29,943 active TB cases among urban migrants that were reported between 2000 to 2008 in Shanghai, China. We used logistic regression models to identify factors independently associated with treatment defaults in TB patients among urban migrants during 2005-2008. Results: Fifty-two percent of the total TB patients reported in Shanghai during the study period were among urban migrants. Three factors increased the odds of a treatment default: case management using self-administered therapy (OR, 5.84, 95% CI, 3.14-10.86, p<0.0005), being a retreatment case (OR, 1.47, 95% CI, 1.25-1.71, p<0.0005), and age >= 60 years old (OR, 1.33, 95% CI, 1.05-1.67, p=0.017). The presence of a cavity in the initial chest radiograph decreased the odds for a treatment default (OR, 0.87, 95% CI, 0.77-0.97, p=0.015), as did migration from central China (OR, 0.85, 95% CI, 0.73-0.99, p=0.042), case management by family members (OR, 0.73, 95% CI 0.66-0.81, p<0.0005), and the combination of case detection by a required physical exam and case management by health care staff (OR, 0.64, 95% CI, 0.45-0.93, p=0.019). Conclusion: Among TB patients who were urban migrants in Shanghai, case management using self-administered therapy was the strongest modifiable risk factor that was independently associated with treatment defaults. Interventions that target retreated TB cases could also reduce treatment defaults among urban migrants. Health departments should develop effective measures to prevent treatment defaults among urban migrants, to ensure completion of therapy among urban migrants who move between cities and provinces, and to improve reporting of treatment outcomes.	[Chen, Jing; Xia, Zhen; Shen, Mei; Shen, Xin; Mei, Jian; Yuan, Zheng'an] Shanghai Municipal Ctr Dis Control & Prevent, Dept TB Control, Shanghai, Peoples R China; [Qi, Lihong; DeRiemer, Kathryn] Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, Davis, CA 95616 USA	Shanghai Center for Disease Control & Prevention; University of California System; University of California Davis	Yuan, ZA (corresponding author), Shanghai Municipal Ctr Dis Control & Prevent, Dept TB Control, Shanghai, Peoples R China.	zayuan@scdc.sh.cn	Qi, LI/AAF-3389-2019	DeRiemer, Kathryn/0000-0002-8375-7505	Key Project of Chinese National Programs [2013ZX10004903]; National Institutes of Health (NIH) [D43 TW007887]; Shanghai Public Health Key Discipline Construction Project [12GWZX0601]; FOGARTY INTERNATIONAL CENTER [D43TW007887] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD006452] Funding Source: NIH RePORTER	Key Project of Chinese National Programs; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Shanghai Public Health Key Discipline Construction Project; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was financially supported by the Key Project of Chinese National Programs (2013ZX10004903) and by National Institutes of Health (NIH) grant D43 TW007887. This work was also partly supported by the Shanghai Public Health Key Discipline Construction Project, 12GWZX0601. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chang KC, 2004, INT J TUBERC LUNG D, V8, P1492; Chiang CY, 2010, RESPIROLOGY, V15, P413, DOI 10.1111/j.1440-1843.2010.01738.x; Department of Disease Contorl Ministry of Health, 2009, GUID IMPL NAT CONTR; Gilbert RL, 2009, INT J TUBERC LUNG D, V13, P645; Hasker E, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-97; Jakubowiak WM, 2007, INT J TUBERC LUNG D, V11, P46; Kamolratanakul P, 1999, T ROY SOC TROP MED H, V93, P552, DOI 10.1016/S0035-9203(99)90379-6; Kim J, 2008, INT J TUBERC LUNG D, V12, P1128; Kirwan DE, 2009, TROP MED INT HEALTH, V14, P1442, DOI 10.1111/j.1365-3156.2009.02405.x; Long Q, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-202; Ministry of Health of the Peoples Republic of China, REP INC MORT MAND RE; Shanghai Municipal Statistic Bureau, SHANGHAI STAT YB 208; Shanghai Municipal Statistic Bureau, SHANGH CHIN SHANG MU; Shen X, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-95; The National Bureau of Statistics of China, 2010, RUR MIGR SURV REP 20; Walley JD, 2001, LANCET, V357, P664, DOI 10.1016/S0140-6736(00)04129-5; Wang Y, 2008, TROP MED INT HEALTH, V13, P927, DOI 10.1111/j.1365-3156.2008.02093.x; Wei XL, 2009, TROP MED INT HEALTH, V14, P754, DOI 10.1111/j.1365-3156.2009.02286.x; *WHO, PUBL WHO; World Health Organization, WHO PUBL; World Health Organization, 2012, WHO PUBL; Zhang LX, 2006, INT J TUBERC LUNG D, V10, P959	22	2	2	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2013	8	11							e81351	10.1371/journal.pone.0081351	http://dx.doi.org/10.1371/journal.pone.0081351			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261IJ	24312292	Green Submitted, Green Published, gold			2023-01-03	WOS:000327657900029
J	Yuan, F; Tabor, DE; Nelson, RK; Yuan, HJ; Zhang, YJ; Nuxoll, J; Bynote, KK; Lele, SM; Wang, D; Gould, KA				Yuan, Fang; Tabor, Dana E.; Nelson, Richard K.; Yuan, Hongjiang; Zhang, Yijia; Nuxoll, Jenny; Bynote, Kimberly K.; Lele, Subodh M.; Wang, Dong; Gould, Karen A.			A Dexamethasone Prodrug Reduces the Renal Macrophage Response and Provides Enhanced Resolution of Established Murine Lupus Nephritis	PLOS ONE			English	Article							SYSTEMIC-LUPUS; GLUCOCORTICOID TREATMENT; RHEUMATOID-ARTHRITIS; MICE; DISEASE; RECEPTOR; KIDNEY; GLOMERULONEPHRITIS; ERYTHEMATOSUS; PATHOGENESIS	We evaluated the ability of a macromolecular prodrug of dexamethasone (P-Dex) to treat lupus nephritis in (NZB x NZW)F1 mice. We also explored the mechanism underlying the anti-inflammatory effects of this prodrug. P-Dex eliminated albuminuria in most (NZB x NZW) F1 mice. Furthermore, P-Dex reduced the incidence of severe nephritis and extended lifespan in these mice. P-Dex treatment also prevented the development of lupus-associated hypertension and vasculitis. Although P-Dex did not reduce serum levels of anti-dsDNA antibodies or glomerular immune complexes, P-Dex reduced macrophage recruitment to the kidney and attenuated tubulointerstitial injury. In contrast to what was observed with free dexamethasone, P-Dex did not induce any deterioration of bone quality. However, P-Dex did lead to reduced peripheral white blood cell counts and adrenal gland atrophy. These results suggest that P-Dex is more effective and less toxic than free dexamethasone for the treatment of lupus nephritis in (NZB x NZW) F1 mice. Furthermore, the data suggest that P-Dex may treat nephritis by attenuating the renal inflammatory response to immune complexes, leading to decreased immune cell infiltration and diminished renal inflammation and injury.	[Yuan, Fang; Yuan, Hongjiang; Zhang, Yijia; Wang, Dong] Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA; [Tabor, Dana E.; Nelson, Richard K.; Nuxoll, Jenny; Bynote, Kimberly K.; Gould, Karen A.] Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE USA; [Lele, Subodh M.] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Wang, D (corresponding author), Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA.	dwang@unmc.edu; kagould@unmc.edu			National Institute of General Medical Sciences of the National Institutes of Health [P20GM103480]; NIH [R01 AR053325]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR021937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103480] Funding Source: NIH RePORTER	National Institute of General Medical Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20GM103480 (K.A.G. and D.W.). This study was also supported in part by NIH R01 AR053325 (http://www.nih.gov/) (D.W.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDREWS BS, 1978, J EXP MED, V148, P1198, DOI 10.1084/jem.148.5.1198; Benigni A, 2007, ARTHRITIS RHEUM, V56, P1569, DOI 10.1002/art.22524; Bergtold A, 2006, J IMMUNOL, V177, P7287, DOI 10.4049/jimmunol.177.10.7287; BUTLER WT, 1973, J CLIN INVEST, V52, P2629, DOI 10.1172/JCI107455; Bynote KK, 2008, GENES IMMUN, V9, P137, DOI 10.1038/sj.gene.6364458; Clynes R, 1998, SCIENCE, V279, P1052, DOI 10.1126/science.279.5353.1052; Da Silva JAP, 2006, ANN RHEUM DIS, V65, P285, DOI 10.1136/ard.2005.038638; Ferraccioli G, 2008, LUPUS, V17, P533, DOI 10.1177/0961203307088002; Fu YY, 2006, J IMMUNOL, V176, P632, DOI 10.4049/jimmunol.176.1.632; Hahn BH, 2012, ARTHRIT CARE RES, V64, P797, DOI 10.1002/acr.21664; Howie J B, 1968, Adv Immunol, V9, P215, DOI 10.1016/S0065-2776(08)60444-7; Hsieh C, 2011, ARTHRIT CARE RES, V63, P865, DOI 10.1002/acr.20441; Kielian T, 2008, J IMMUNOL, V180, P5004, DOI 10.4049/jimmunol.180.7.5004; LAMBERT PH, 1968, J EXP MED, V127, P507, DOI 10.1084/jem.127.3.507; Liu XM, 2008, PHARM RES-DORDR, V25, P2910, DOI 10.1007/s11095-008-9683-3; Manolides AS, 2010, J BONE MINER METAB, V28, P532, DOI 10.1007/s00774-009-0156-5; Mok CC, 2013, ARTHRITIS RHEUM-US, V65, P2154, DOI 10.1002/art.38006; Papadimitraki ED, 2009, LUPUS, V18, P831, DOI 10.1177/0961203309103054; Paragas N, 2011, NAT MED, V17, P216, DOI 10.1038/nm.2290; Pawar RD, 2012, ARTHRITIS RHEUM-US, V64, P1620, DOI 10.1002/art.33485; Ruiz-Irastorza G, 2012, RHEUMATOLOGY, V51, P1145, DOI 10.1093/rheumatology/ker410; Ryan MJ, 2007, AM J PHYSIOL-REG I, V292, pR736, DOI 10.1152/ajpregu.00168.2006; Ryan MJ, 2009, AM J PHYSIOL-REG I, V296, pR1258, DOI 10.1152/ajpregu.90864.2008; Schiffer L, 2008, J IMMUNOL, V180, P1938, DOI 10.4049/jimmunol.180.3.1938; SETTIPANE GA, 1978, J ALLERGY CLIN IMMUN, V62, P162, DOI 10.1016/0091-6749(78)90101-X; SLACK JH, 1984, J IMMUNOL, V132, P1271; STEWARD MW, 1976, CLIN EXP IMMUNOL, V26, P363; SUGISAKI T, 1991, CLIN IMMUNOL IMMUNOP, V61, P296, DOI 10.1016/S0090-1229(05)80002-9; Viau A, 2010, J CLIN INVEST, V120, P4065, DOI 10.1172/JCI42004; Yu F, 2010, KIDNEY INT, V77, P820, DOI 10.1038/ki.2010.13; Yuan F, 2012, ARTHRITIS RHEUM	31	15	15	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2013	8	11							e81483	10.1371/journal.pone.0081483	http://dx.doi.org/10.1371/journal.pone.0081483			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261IJ	24312306	Green Submitted, gold, Green Published			2023-01-03	WOS:000327657900034
J	Li, SS; Li, GF; Liu, L; Jiang, X; Zhang, B; Liu, ZG; Li, XL; Weng, LD; Zuo, T; Liu, Q				Li, Sha-Sha; Li, Guo-Feng; Liu, Li; Jiang, Xiao; Zhang, Bin; Liu, Zhi-Gang; Li, Xue-Ling; Weng, Li-Dong; Zuo, Ting; Liu, Qiang			Evaluation of Paeonol Skin-Target Delivery from Its Microsponge Formulation: In Vitro Skin Permeation and In Vivo Microdialysis	PLOS ONE			English	Article							TOPICAL DELIVERY; SIGNALING PATHWAYS; BENZOYL PEROXIDE; TNF-ALPHA; KAPPA-B; SYSTEM; RELEASE; PENETRATION; DESIGN; MODEL	The aim of the present study was to design a novel topical skin-target drug-delivery system, the paeonol microsponge, and to investigate its drug-release patterns in dosage form, both in vitro and in vivo. Paeonol microsponges were prepared using the quasi-emulsion solvent-diffusion method. In vitro release studies were carried out using Franz diffusion cells, while in vivo studies were investigated by microdialysis after the paeonol microsponges were incorporated into a cream base. In vitro release studies showed that the drug delivered via microsponges increased the paeonol permeation rate. Ex vivo drug-deposition studies showed that the microsponge formulation improved drug residence in skin. In addition, in vivo microdialysis showed that the values for the area under the concentration versus time curve (AUC) for the paeonol microsponge cream was much higher than that of paeonol cream without microsponges. Maximum time (T-max) was 220 min for paeonol microsponge cream and 480 min for paeonol cream, while the half-life (t(1/2)) of paeonol microsponge cream (935.1 min) was almost twice that of paeonol cream (548.6 min) in the skin (n = 3). Meanwhile, in the plasma, the AUC value for paeonol microsponge cream was half that of the paeonol cream. Based on these results, paeonol-loaded microsponge formulations could be a better alternative for treating skin disease, as the formulation increases drug bioavailability by lengthening the time of drug residence in the skin and should reduce side-effects because of the lower levels of paeonol moving into the circulation.	[Li, Sha-Sha; Li, Guo-Feng] Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China; [Liu, Li; Jiang, Xiao; Zhang, Bin; Liu, Zhi-Gang; Li, Xue-Ling; Weng, Li-Dong; Zuo, Ting; Liu, Qiang] Southern Med Univ, Sch Tradit Chinese Med, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China	Liu, Q (corresponding author), Southern Med Univ, Sch Tradit Chinese Med, Guangzhou, Guangdong, Peoples R China.	gzlq2002@163.com	Li, Sha-Sha/AHA-2014-2022; Li, Sha-Sha/AHA-4810-2022	Li, Sha-Sha/0000-0003-4346-7535	Guangdong Technology Research Center for Chinese Herbs Cosmetic of China [GCZX-A1007]	Guangdong Technology Research Center for Chinese Herbs Cosmetic of China	This project was supported by Guangdong Technology Research Center for Chinese Herbs Cosmetic of China (No. GCZX-A1007). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amrutiya N, 2009, AAPS PHARMSCITECH, V10, P402, DOI 10.1208/s12249-009-9220-7; Chadawar V, 2007, AAPS PHARMSCITECH, V4, P402; Desai PR, 2012, PHARM RES-DORDR, V29, P2587, DOI 10.1007/s11095-012-0789-2; Embil K, 1996, J MICROENCAPSUL, V13, P575, DOI 10.3109/02652049609026042; Fang JY, 1999, INT J PHARM, V180, P137, DOI 10.1016/S0378-5173(98)00287-7; Himaya SWA, 2012, TOXICOL IN VITRO, V26, P878, DOI 10.1016/j.tiv.2012.04.022; Hsieh CL, 2006, J ETHNOPHARMACOL, V106, P208, DOI 10.1016/j.jep.2005.12.027; Incecayir T, 2011, PHARM RES-DORDR, V28, P2165, DOI 10.1007/s11095-011-0444-3; Jain V, 2010, J PHARM SCI, P1545; Jain V, 2011, ARCH PHARM RES, V34, P733, DOI 10.1007/s12272-011-0506-4; Jalon EGd, 2001, J CONTROL RELEASE, P191; Jalon EGd, 2001, J CONTROL RELEASE, V75, P197; Jelvehgari M, 2006, INT J PHARM, V308, P124, DOI 10.1016/j.ijpharm.2005.11.001; Kim SH, 2004, INT IMMUNOPHARMACOL, V4, P279, DOI 10.1016/j.intimp.2003.12.013; Li YJ, 2010, VASC PHARMACOL, V53, P169, DOI 10.1016/j.vph.2010.07.001; Ma YL, 2006, EUR J PHARMACOL, V545, P87, DOI 10.1016/j.ejphar.2006.06.064; Nizamutdinova IT, 2007, INT IMMUNOPHARMACOL, V7, P343, DOI 10.1016/j.intimp.2006.11.004; Nokhodchi A, 2007, MICRON, V38, P834, DOI 10.1016/j.micron.2007.06.012; Orlu M, 2006, INT J PHARMACEUT, V318, P103, DOI 10.1016/j.ijpharm.2006.03.025; Pan LL, 2009, PHYTOMEDICINE, V16, P1027, DOI 10.1016/j.phymed.2009.04.003; Rishabh S, 2012, INT J PHARMACEUT, V427, P153; Rizkalla CMZ, 2011, AAPS PHARMSCITECH, V12, P989, DOI 10.1208/s12249-011-9663-5; Sakai S, 2005, BRIT J DERMATOL, V153, P319, DOI 10.1111/j.1365-2133.2005.06756.x; Schnetz E, 2001, EUR J PHARM SCI, V12, P165, DOI 10.1016/S0928-0987(00)00155-X; Simonsen L, 2004, EUR J PHARM SCI, V21, P379, DOI 10.1016/j.ejps.2003.11.004; Sun GP, 2008, EUR J PHARMACOL, V584, P246, DOI 10.1016/j.ejphar.2008.02.016; Tsai YH, 2010, FOOD CHEM, V120, P837, DOI 10.1016/j.foodchem.2009.11.024; Tsao JY, 2010, INT J PHARMACEUT, V402, P123, DOI 10.1016/j.ijpharm.2010.09.033; Wu JB, 2008, J NEUROL SCI, V264, P50, DOI 10.1016/j.jns.2007.06.057; Wu RG, 2012, INT J PHARMACEUT, V438, P91, DOI 10.1016/j.ijpharm.2012.08.052; Zhong SZ, 2009, J NEUROL SCI, V277, P58, DOI 10.1016/j.jns.2008.10.008	31	26	29	2	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 20	2013	8	11							e79881	10.1371/journal.pone.0079881	http://dx.doi.org/10.1371/journal.pone.0079881			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256LY	24278204	Green Published, Green Submitted, gold			2023-01-03	WOS:000327313100065
J	Kim, SA; Lee, BH; Bae, JH; Kim, KJ; Steffensen, SC; Ryu, YH; Leem, JW; Yang, CH; Kim, HY				Kim, Seol Ah; Lee, Bong Hyo; Bae, Jong Han; Kim, Kwang Joong; Steffensen, Scott C.; Ryu, Yeon-Hee; Leem, Joong Woo; Yang, Chae Ha; Kim, Hee Young			Peripheral Afferent Mechanisms Underlying Acupuncture Inhibition of Cocaine Behavioral Effects in Rats	PLOS ONE			English	Article							MANUAL ACUPUNCTURE; NUCLEUS-ACCUMBENS; DOPAMINE RELEASE; STIMULATION; NERVE; ELECTROACUPUNCTURE; RESINIFERATOXIN; MODULATION; ACTIVATION; ANALGESIA	Administration of cocaine increases locomotor activity by enhancing dopamine transmission. To explore the peripheral mechanisms underlying acupuncture treatment for drug addiction, we developed a novel mechanical acupuncture instrument (MAI) for objective mechanical stimulation. The aim of this study was to evaluate whether acupuncture inhibition of cocaine-induced locomotor activity is mediated through specific peripheral nerves, the afferents from superficial or deep tissues, or specific groups of nerve fibers. Mechanical stimulation of acupuncture point HT7 with MAI suppressed cocaine-induced locomotor activity in a stimulus time-dependent manner, which was blocked by severing the ulnar nerve or by local anesthesia. Suppression of cocaine-induced locomotor activity was elicited after HT7 stimulation at frequencies of either 50 (for Meissner corpuscles) or 200 (for Pacinian corpuscles) Hz and was not affected by block of C/Ad-fibers in the ulnar nerve with resiniferatoxin, nor generated by direct stimulation of C/Ad-fiber afferents with capsaicin. These findings suggest that HT7 inhibition of cocaine-induced locomotor activity is mediated by A-fiber activation of ulnar nerve that originates in superficial and deep tissue.	[Kim, Seol Ah; Lee, Bong Hyo; Kim, Kwang Joong; Yang, Chae Ha; Kim, Hee Young] Daegu Haany Univ, Coll Korean Med, Taegu, South Korea; [Bae, Jong Han] Yeungnam Univ, Dept Phys, Gyongsan, Gyeongbuk, South Korea; [Steffensen, Scott C.] Brigham Young Univ, Dept Psychol & Neurosci, Provo, UT 84602 USA; [Ryu, Yeon-Hee] Korea Inst Oriental Med, Div Stand Res, Acupuncture Moxibust & Meridian Res Ctr, Taejon, South Korea; [Leem, Joong Woo] Yonsei Univ, Coll Med, Dept Physiol, Seoul, South Korea	Daegu Haany University; Yeungnam University; Brigham Young University; Korea Institute of Oriental Medicine (KIOM); Yonsei University; Yonsei University Health System	Yang, CH (corresponding author), Daegu Haany Univ, Coll Korean Med, Taegu, South Korea.	chyang@dhu.ac.kr; hykim@dhu.ac.kr		Leem, Joong/0000-0002-1605-2230	National Research Foundation of Korea (NRF); Korea government (MEST) [2011-0016038]; Basic Science Research Program through the National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [2010-0009492]; Korea Institute of Oriental Medicine [K13290]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA020919] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA035958] Funding Source: NIH RePORTER	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Korea government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government); Basic Science Research Program through the National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Korea Institute of Oriental Medicine; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2011-0016038), Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2010-0009492) and Korea Institute of Oriental Medicine (K13290). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BONNEL F, 1985, J HAND SURG-BRIT EUR, V10B, P165, DOI 10.1016/0266-7681(85)90007-5; Cha SW, 1996, HISTOL HISTOPATHOL, V11, P117; Chae Y, 2010, NEUROL RES, V32, pS27, DOI 10.1179/016164109X12537002793805; Dawidson I, 1997, J ORAL REHABIL, V24, P204; DUNDEE JW, 1991, CLIN PHARMACOL THER, V50, P78, DOI 10.1038/clpt.1991.106; Griffin MJ, 1997, OCCUP ENVIRON MED, V54, P73, DOI 10.1136/oem.54.2.73; GUOWEI L, 1979, SCI SINICA, V22, P680; HARPER AA, 1985, J PHYSIOL-LONDON, V359, P31, DOI 10.1113/jphysiol.1985.sp015573; Harrington GS, 2001, BRAIN RES, V897, P188, DOI 10.1016/S0006-8993(01)02139-4; Kandell E.R., 2000, PRINCIPLES NEURAL SC; Kim HY, 2011, NEUROL RES S1, V32, P10; Kim MR, 2005, NEUROSCI LETT, V387, P17, DOI 10.1016/j.neulet.2005.07.007; Kim PS, 2010, J BRACHIAL PLEX PERI, V5, DOI 10.1186/1749-7221-5-6; Kim SN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027566; Lee B, 2009, NEUROSCI LETT, V449, P128, DOI 10.1016/j.neulet.2008.10.089; LEEM JW, 1993, J NEUROPHYSIOL, V70, P2411, DOI 10.1152/jn.1993.70.6.2411; LEEM JW, 1993, J NEUROPHYSIOL, V69, P1684, DOI 10.1152/jn.1993.69.5.1684; Li P, 1998, CIRCULATION, V97, P1186, DOI 10.1161/01.CIR.97.12.1186; Mitchell K, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-94; Napadow V, 2005, HUM BRAIN MAPP, V24, P193, DOI 10.1002/hbm.20081; NAPPI G, 1982, ACUPUNCTURE ELECTRO, V7, P93, DOI 10.3727/036012982816952125; Noguchi E, 1996, JPN J PHYSIOL, V46, P53, DOI 10.2170/jjphysiol.46.53; Pan HL, 2003, J NEUROSCI, V23, P2911; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; SATO A, 1992, NEUROSCI RES, V15, P189, DOI 10.1016/0168-0102(92)90004-V; Soh KS, 2009, J ACUPUNCT MERIDIAN, V2, P93, DOI 10.1016/S2005-2901(09)60041-8; Stux G, 1997, BASICS ACUPUNCTURE; Suter MR, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-53; Tjen-A-Looi SC, 2005, AUTON NEUROSCI-BASIC, V118, P43, DOI 10.1016/j.autneu.2004.12.006; Uchida S, 2000, JPN J PHYSIOL, V50, P495, DOI 10.2170/jjphysiol.50.495; Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6; Wang SM, 2008, ANESTH ANALG, V106, P602, DOI 10.1213/01.ane.0000277493.42335.7b; Yang CH, 2008, EVID-BASED COMPL ALT, V5, P257, DOI 10.1093/ecam/nem081; Yang CH, 2010, ALCOHOL CLIN EXP RES, V34, P2137, DOI 10.1111/j.1530-0277.2010.01310.x; Yoo SS, 2004, NEUROIMAGE, V22, P932, DOI 10.1016/j.neuroimage.2004.02.017; Yoon SS, 2012, PSYCHOPHARMACOLOGY, V222, P303, DOI 10.1007/s00213-012-2683-3; Yoon SS, 2010, BRAIN RES BULL, V81, P625, DOI 10.1016/j.brainresbull.2009.12.011; Yoon SS, 2004, NEUROSCI LETT, V369, P234, DOI 10.1016/j.neulet.2004.07.095; Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004; Zhou W, 2005, J APPL PHYSIOL, V98, P872, DOI 10.1152/japplphysiol.01079.2004	40	16	17	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2013	8	11							e81018	10.1371/journal.pone.0081018	http://dx.doi.org/10.1371/journal.pone.0081018			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256KH	24260531	Green Submitted, Green Published, gold			2023-01-03	WOS:000327308500192
J	Wright, AA; Zhang, BH; Keating, NL; Weeks, JC; Prigerson, HG				Wright, Alexi A.; Zhang, Baohui; Keating, Nancy L.; Weeks, Jane C.; Prigerson, Holly G.			Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CELL LUNG-CANCER; OF-LIFE; MEDICARE BENEFICIARIES; TREATMENT PREFERENCES; PROPENSITY SCORE; MENTAL-HEALTH; HOSPICE CARE; NEAR-DEATH; DISCUSSIONS; QUALITY	Objectives To determine whether the receipt of chemotherapy among terminally ill cancer patients months before death was associated with patients' subsequent intensive medical care and place of death. Design Secondary analysis of a prospective, multi-institution, longitudinal study of patients with advanced cancer. Setting Eight outpatient oncology clinics in the United States. Participants 386 adult patients with metastatic cancers refractory to at least one chemotherapy regimen, whom physicians identified as terminally ill at study enrollment and who subsequently died. Main outcome measures Primary outcomes: intensive medical care (cardiopulmonary resuscitation, mechanical ventilation, or both) in the last week of life and patients' place of death (for example, intensive care unit). Secondary outcomes: survival, late hospice referrals (<= 1 week before death), and dying in preferred place of death. Results 216 (56%) of 386 terminally ill cancer patients were receiving palliative chemotherapy at study enrollment, a median of 4.0 months before death. After propensity score weighted adjustment, use of chemotherapy at enrollment was associated with higher rates of cardiopulmonary resuscitation, mechanical ventilation, or both in the last week of life (14% v 2%; adjusted risk difference 10.5%, 95% confidence interval 5.0% to 15.5%) and late hospice referrals (54% v 37%; 13.6%, 3.6% to 23.6%) but no difference in survival (hazard ratio 1.11, 95% confidence interval 0.90 to 1.38). Patients receiving palliative chemotherapy were more likely to die in an intensive care unit (11% v 2%; adjusted risk difference 6.1%, 1.1% to 11.1%) and less likely to die at home (47% v 66%; -10.8%, -1.0% to -20.6%), compared with those who were not. Patients receiving palliative chemotherapy were also less likely to die in their preferred place, compared with those who were not (65% v 80%; adjusted risk difference -9.4%, -0.8% to -18.1%). Conclusions The use of chemotherapy in terminally ill cancer patients in the last months of life was associated with an increased risk of undergoing cardiopulmonary resuscitation, mechanical ventilation or both and of dying in an intensive care unit. Future research should determine the mechanisms by which palliative chemotherapy affects end of life outcomes and patients' attainment of their goals.	[Wright, Alexi A.; Weeks, Jane C.] Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02215 USA; [Zhang, Baohui; Prigerson, Holly G.] Weill Cornell Med Coll, Ctr End Of Life Res, New York, NY 10065 USA; [Keating, Nancy L.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Cornell University; Harvard University; Harvard Medical School	Prigerson, HG (corresponding author), Weill Cornell Med Coll, Ctr End Of Life Res, New York, NY 10065 USA.	hgp2001@med.cornell.edu	Wright, Alexi/T-5793-2019; Prigerson, Holly/GWV-3283-2022; Keating, Nancy L/I-9968-2019; Prigerson, Holly/L-3800-2019	Keating, Nancy L/0000-0002-8274-4681; Prigerson, Holly/0000-0002-7075-4268	National Institute of Mental Health [MH63892]; National Cancer Institute [CA 106370, CA 156732, 1K07 CA166210, 1R01 CA164021]; American Cancer Society [MRSG-13-013]; Conquer Cancer Foundation of American Society for Clinical Oncology Career Development Award; NATIONAL CANCER INSTITUTE [R01CA106370, R01CA164021, U54CA156732, K07CA166210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063892] Funding Source: NIH RePORTER	National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Conquer Cancer Foundation of American Society for Clinical Oncology Career Development Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	HGP has received research grants MH63892 from the National Institute of Mental Health and CA 106370 and CA 156732 from the National Cancer Institute; AAW has received research grants 1K07 CA166210 from the National Cancer Institute and MRSG-13-013 from the American Cancer Society and a Conquer Cancer Foundation of American Society for Clinical Oncology Career Development Award; NLK received research grant 1R01 CA164021 from the National Cancer Institute. The funding organizations had no role in the design and conduct of the study; collection, analysis, or preparation of the data; or preparation, review, or approval of the manuscript. Any opinions, findings, and conclusions expressed in this material are those of the authors and do not necessarily reflect those of the American Cancer Society, the American Society of Clinical Oncology, or the Conquer Cancer Foundation.	Alonso-Babarro A, 2011, J CLIN ONCOL, V29, P1159, DOI 10.1200/JCO.2010.31.6752; Anders CK, 2009, CANCER INVEST, V27, P13, DOI 10.1080/07357900802484944; Bach PB, 2004, JAMA-J AM MED ASSOC, V292, P2765, DOI 10.1001/jama.292.22.2765; Braga S, 2011, ANN ONCOL, V22, P2345, DOI 10.1093/annonc/mdr416; Buiting HM, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1933; Carlson MDA, 2010, J CLIN ONCOL, V28, P4371, DOI 10.1200/JCO.2009.26.1818; Carlson MDA, 2012, HEALTH AFFAIR, V31, P2690, DOI 10.1377/hlthaff.2012.0286; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; Cavalli-Bjorkman N, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001248; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; de Haes H, 2003, PATIENT EDUC COUNS, V50, P43, DOI 10.1016/S0738-3991(03)00079-X; Donovan KA, 2002, GYNECOL ONCOL, V86, P200, DOI 10.1006/gyno.2002.6748; Earle CC, 2006, J CLIN ONCOL, V24, P838, DOI 10.1200/JCO.2005.03.9388; Earle CC, 2004, J CLIN ONCOL, V22, P315, DOI 10.1200/JCO.2004.08.136; Earle CC, 2008, J CLIN ONCOL, V26, P3860, DOI 10.1200/JCO.2007.15.8253; Emanuel EJ, 2003, ANN INTERN MED, V138, P639, DOI 10.7326/0003-4819-138-8-200304150-00011; Fried TR, 2002, J GERONTOL B-PSYCHOL, V57, pS348, DOI 10.1093/geronb/57.6.S348; Gomes B, 2006, BMJ-BRIT MED J, V332, P515, DOI 10.1136/bmj.38740.614954.55; Greer JA, 2012, J CLIN ONCOL, V30, P394, DOI 10.1200/JCO.2011.35.7996; Harrington SE, 2008, JAMA-J AM MED ASSOC, V299, P2667, DOI 10.1001/jama.299.22.2667; Helft PR, 2005, J CLIN ONCOL, V23, P3146, DOI 10.1200/JCO.2005.07.003; Huskamp HA, 2009, ARCH INTERN MED, V169, P954, DOI 10.1001/archinternmed.2009.127; Jeurkar N, 2012, J CLIN ONCOL, V30, P2783, DOI 10.1200/JCO.2011.41.5711; KARNOFSKY DA, 1968, CANCER-AM CANCER SOC, V22, P730, DOI 10.1002/1097-0142(196810)22:4<730::AID-CNCR2820220407>3.0.CO;2-H; Keating NL, 2010, CANCER-AM CANCER SOC, V116, P998, DOI 10.1002/cncr.24761; Kelley AS, 2013, HEALTH AFFAIR, V32, P552, DOI 10.1377/hlthaff.2012.0851; LAVORI PW, 1995, STAT MED, V14, P1913, DOI 10.1002/sim.4780141707; Li F, 2013, STAT MED, V32, P3373, DOI 10.1002/sim.5786; Mack JW, 2009, CANCER-AM CANCER SOC, V115, P3302, DOI 10.1002/cncr.24360; Matsuyama R, 2006, J CLIN ONCOL, V24, P3490, DOI 10.1200/JCO.2005.03.6236; Morden NE, 2012, HEALTH AFFAIR, V31, P786, DOI 10.1377/hlthaff.2011.0650; Pargament KI, 2000, J CLIN PSYCHOL, V56, P519, DOI 10.1002/(SICI)1097-4679(200004)56:4<519::AID-JCLP6>3.3.CO;2-T; PRIGERSON HG, 1992, J HEALTH SOC BEHAV, V33, P378, DOI 10.2307/2137315; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Saito AM, 2011, BMC PALLIAT CARE, V10, DOI 10.1186/1472-684X-10-14; Schnipper LE, 2012, J CLIN ONCOL, V30, P1715, DOI 10.1200/JCO.2012.42.8375; Silvestri G, 1998, BRIT MED J, V317, P771, DOI 10.1136/bmj.317.7161.771; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; Sulmasy DP, 2010, CANCER-AM CANCER SOC, V116, P3702, DOI 10.1002/cncr.25201; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; Teno JM, 2012, J PAIN SYMPTOM MANAG, V43, P732, DOI 10.1016/j.jpainsymman.2011.05.012; Weeks JC, 2012, NEW ENGL J MED, V367, P1616, DOI 10.1056/NEJMoa1204410; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Wright AA, 2007, NEW ENGL J MED, V357, P324, DOI 10.1056/NEJMp078074; Wright AA, 2010, J CLIN ONCOL, V28, P4457, DOI 10.1200/JCO.2009.26.3863	48	194	194	2	33	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 4	2014	348								g1219	10.1136/bmj.g1219	http://dx.doi.org/10.1136/bmj.g1219			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AC6HV	24594868	Green Published, hybrid			2023-01-03	WOS:000332623400001
J	Atreya, R; Neumann, H; Neufert, C; Waldner, MJ; Billmeier, U; Zopf, Y; Willma, M; App, C; Munster, T; Kessler, H; Maas, S; Gebhardt, B; Heimke-Brinck, R; Reuter, E; Dorje, F; Rau, TT; Uter, W; Wang, TD; Kiesslich, R; Vieth, M; Hannappel, E; Neurath, MF				Atreya, Raja; Neumann, Helmut; Neufert, Clemens; Waldner, Maximilian J.; Billmeier, Ulrike; Zopf, Yurdaguel; Willma, Marcus; App, Christine; Muenster, Tino; Kessler, Hermann; Maas, Stefanie; Gebhardt, Bernd; Heimke-Brinck, Ralph; Reuter, Eva; Doerje, Frank; Rau, Tilman T.; Uter, Wolfgang; Wang, Thomas D.; Kiesslich, Ralf; Vieth, Michael; Hannappel, Ewald; Neurath, Markus F.			In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease	NATURE MEDICINE			English	Article							INFLAMMATORY BOWEL DISEASES; PROPRIA T-LYMPHOCYTES; INFLIXIMAB; APOPTOSIS; ENDOSCOPY; DYSPLASIA; CANCER; ENDOMICROSCOPY; IDENTIFICATION; CHEMOTHERAPY	As antibodies to tumor necrosis factor (TNF) suppress immune responses in Crohn's disease by binding to membrane-bound TNF (mTNF), we created a fluorescent antibody for molecular mTNF imaging in this disease. Topical antibody administration in 25 patients with Crohn's disease led to detection of intestinal mTNF(+) immune cells during confocal laser endomicroscopy. Patients with high numbers of mTNF(+) cells showed significantly higher short-term response rates (92%) at week 12 upon subsequent anti-TNF therapy as compared to patients with low amounts of mTNF(+) cells (15%). This clinical response in the former patients was sustained over a follow-up period of 1 year and was associated with mucosal healing observed in follow-up endoscopy. These data indicate that molecular imaging with fluorescent antibodies has the potential to predict therapeutic responses to biological treatment and can be used for personalized medicine in Crohn's disease and autoimmune or inflammatory disorders.	[Atreya, Raja; Neumann, Helmut; Neufert, Clemens; Waldner, Maximilian J.; Billmeier, Ulrike; Zopf, Yurdaguel; Willma, Marcus; Neurath, Markus F.] Univ Erlangen Nurnberg, Med Clin 1, D-91054 Erlangen, Germany; [App, Christine; Hannappel, Ewald] Univ Erlangen Nurnberg, Dept Biochem, D-91054 Erlangen, Germany; [Muenster, Tino] Univ Erlangen Nurnberg, Dept Anesthesiol, D-91054 Erlangen, Germany; [Kessler, Hermann] Univ Erlangen Nurnberg, Dept Surg, D-91054 Erlangen, Germany; [Maas, Stefanie; Gebhardt, Bernd] Univ Erlangen Nurnberg, Ctr Clin Studies, D-91054 Erlangen, Germany; [Heimke-Brinck, Ralph; Reuter, Eva; Doerje, Frank] Univ Erlangen Nurnberg, Erlangen Univ Hosp, Dept Pharm, D-91054 Erlangen, Germany; [Rau, Tilman T.] Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany; [Uter, Wolfgang] Univ Erlangen Nurnberg, Dept Med Informat Biometry & Epidemiol, D-91054 Erlangen, Germany; [Wang, Thomas D.] Univ Michigan, Div Gastroenterol, Ann Arbor, MI 48109 USA; [Kiesslich, Ralf] St Marys Hosp, Med Clin, Frankfurt, Germany; [Vieth, Michael] Klinikum Bayreuth, Inst Pathol, Bayreuth, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Michigan System; University of Michigan; St. Marien Hospital; Klinikum Bayreuth	Neurath, MF (corresponding author), Univ Erlangen Nurnberg, Med Clin 1, D-91054 Erlangen, Germany.	markus.neurath@uk-erlangen.de	Ralf Kiesslich, Dr./AAK-9313-2021		German Ministry for Science and Education [BMBF ZooMAP 01KI1003G]; Ludwig Demling Research Prize of the Deutsche Morbus Crohn/Colitis Ulcerosa Vereinigung; United European Gastroenterology Federation Research Prize; NATIONAL CANCER INSTITUTE [R01CA142750, P50CA093990, U54CA163059, U54CA136429] Funding Source: NIH RePORTER	German Ministry for Science and Education; Ludwig Demling Research Prize of the Deutsche Morbus Crohn/Colitis Ulcerosa Vereinigung; United European Gastroenterology Federation Research Prize; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank I. Zoller-Utz, P. Drummer and G. Gohring-Waldeck for excellent technical support, A. May for monitoring our study and S. Brand and F. Kolligs (University Hospital Munich-Grosshadern) for their contribution to the follow-up endoscopies. We thank the whole team of the Endoscopy Unit of the Medical Clinic 1 of the University Erlangen-Nuremberg, which greatly supported this work. We thank all patients who participated in this study. This research was supported by the German Research Foundation (clinical research unit KFO257) and the Emerging Fields Initiative and the Interdisciplinary Center for Clinical Research of the University Erlangen-Nuremberg, which helped to establish the infrastructure needed to conduct this study. Funds from the German Ministry for Science and Education (BMBF ZooMAP 01KI1003G) were used for intestinal sample preparation. The infrastructure of the presented project was supported by the Ludwig Demling Research Prize of the Deutsche Morbus Crohn/Colitis Ulcerosa Vereinigung (R.A.) and the United European Gastroenterology Federation Research Prize (M.F.N.).	Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; Atreya R, 2011, GASTROENTEROLOGY, V141, P2026, DOI 10.1053/j.gastro.2011.08.032; Bird-Lieberman EL, 2012, NAT MED, V18, P315, DOI 10.1038/nm.2616; Broadbridge VT, 2012, EXPERT REV ANTICANC, V12, P555, DOI [10.1586/era.12.25, 10.1586/ERA.12.25]; Colombel JF, 2010, NEW ENGL J MED, V362, P1383, DOI 10.1056/NEJMoa0904492; Colombel JF, 2009, INFLAMM BOWEL DIS, V15, P1308, DOI 10.1002/ibd.20956; Danese S, 2012, GUT, V61, P918, DOI 10.1136/gutjnl-2011-300904; Evans AT, 2012, EXPERT OPIN BIOL TH, V12, P363, DOI 10.1517/14712598.2012.658770; Evans JA, 2007, GASTROINTEST ENDOSC, V65, P50, DOI 10.1016/j.gie.2006.04.027; Foersch S, 2010, GUT, V59, P1046, DOI 10.1136/gut.2009.202986; Hanauer SB, 2006, GASTROENTEROLOGY, V130, P323, DOI 10.1053/j.gastro.2005.11.030; Hlavaty T, 2007, INFLAMM BOWEL DIS, V13, P372, DOI 10.1002/ibd.20024; Hsiung PL, 2008, NAT MED, V14, P454, DOI 10.1038/nm1692; Hueber W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001107; Kamada N, 2008, J CLIN INVEST, V118, P2269, DOI [10.1172/JC134610, 10.1172/JCI34610]; Kaymakcalan Z, 2009, CLIN IMMUNOL, V131, P308, DOI 10.1016/j.clim.2009.01.002; Kendall C, 2003, J PATHOL, V200, P602, DOI 10.1002/path.1376; Kiesslich R, 2007, NAT CLIN PRACT ONCOL, V4, P480, DOI 10.1038/ncponc0881; Kiesslich R, 2007, GASTROENTEROLOGY, V132, P874, DOI 10.1053/j.gastro.2007.01.048; Leonardi C, 2012, NEW ENGL J MED, V366, P1190, DOI 10.1056/NEJMoa1109997; Macedo LT, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-89; Medarova Z, 2009, CANCER RES, V69, P1182, DOI 10.1158/0008-5472.CAN-08-2001; Mitoma H, 2005, GASTROENTEROLOGY, V128, P376, DOI 10.1053/j.gastro.2004.11.060; Monteleone G, 2011, CURR OPIN PHARMACOL, V11, P640, DOI 10.1016/j.coph.2011.09.013; Neurath MF, 2012, GUT, V61, P1619, DOI 10.1136/gutjnl-2012-302830; Papp KA, 2012, NEW ENGL J MED, V366, P1181, DOI 10.1056/NEJMoa1109017; Peyrin-Biroulet L, 2010, AM J GASTROENTEROL, V105, P289, DOI 10.1038/ajg.2009.579; Qiu L, 2010, NAT MED, V16, P603, DOI 10.1038/nm.2138; Reinisch W, 2011, GUT, V60, P780, DOI 10.1136/gut.2010.221127; Strober W, 2007, J CLIN INVEST, V117, P514, DOI 10.1172/JCI30587; Tanaka T, 2011, FEBS LETT, V585, P3699, DOI 10.1016/j.febslet.2011.03.023; ten Hove T, 2002, GUT, V50, P206, DOI 10.1136/gut.50.2.206; Van den Brande JMH, 2007, GUT, V56, P509, DOI 10.1136/gut.2006.105379; Van Den Brande JMH, 2003, GASTROENTEROLOGY, V124, P1774, DOI 10.1016/S0016-5085(03)00382-2; Vermeire S, 2004, INFLAMM BOWEL DIS, V10, P661, DOI 10.1097/00054725-200409000-00026; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Waldner MJ, 2011, NAT PROTOC, V6, P1471, DOI 10.1038/nprot.2011.377	37	251	258	1	59	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2014	20	3					313	318		10.1038/nm.3462	http://dx.doi.org/10.1038/nm.3462			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	AC5XZ	24562382	Green Accepted			2023-01-03	WOS:000332595600028
J	Dan, B; Fonteyne, C; de Clety, SC				Dan, Bernard; Fonteyne, Christine; de Clety, Stephan Clement			Self-requested euthanasia for children in Belgium	LANCET			English	Editorial Material							OF-LIFE PRACTICES; END; NETHERLANDS; LAW		[Dan, Bernard; Fonteyne, Christine] Univ Libre Bruxelles, Hop Univ Enfants Reine Fabiola, B-1020 Brussels, Belgium; [de Clety, Stephan Clement] Catholic Univ Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium	Universite Libre de Bruxelles; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Dan, B (corresponding author), Univ Libre Bruxelles, Hop Univ Enfants Reine Fabiola, B-1020 Brussels, Belgium.	bernard.dan@ulb.ac.be		Dan, Bernard/0000-0002-2051-9876				[Anonymous], 2002, MONITEUR BELGE, V2141, P28515; Bilsen J, 2009, NEW ENGL J MED, V361, P1119, DOI 10.1056/NEJMc0904292; Cohen J, 2014, INT J PUBLIC HEALTH, V59, P143, DOI 10.1007/s00038-013-0461-6; Commission Federale de Controle et d'Evaluation de l'Euthanasie, 2013, RAPP CHAMBR LEG 2004; de Haan Jurriaan, 2002, Med Law Rev, V10, P57, DOI 10.1093/medlaw/10.1.57; Feudtner C., 2011, TXB INTERDISCIPLINAR, P7; Leners JC, 2013, EUR GERIATR MED, V4, pS38; Onwuteaka-Philipsen BD, 2012, LANCET, V380, P908, DOI 10.1016/S0140-6736(12)61034-4; Pousset G, 2010, ARCH PEDIAT ADOL MED, V164, P547, DOI 10.1001/archpediatrics.2010.59; Ronen GM, 2013, HAND CLINIC, V111, P107, DOI 10.1016/B978-0-444-52891-9.00011-7; Schneider CE., 1998, PRACTICE AUTONOMY PA; Smets T, 2010, MED CARE, V48, P187, DOI 10.1097/MLR.0b013e3181bd4dde; Steck N, 2013, MED CARE, V51, P938, DOI 10.1097/MLR.0b013e3182a0f427; van der Heide A, 2007, NEW ENGL J MED, V356, P1957, DOI 10.1056/NEJMsa071143; VANDERBURG W, 1991, ETHICS, V102, P42, DOI 10.1086/293369; Verhagen E, 2005, NEW ENGL J MED, V352, P959, DOI 10.1056/NEJMp058026; Vincent JL, 2014, J CRIT CARE, V29, P174, DOI 10.1016/j.jcrc.2013.08.025	17	23	24	1	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 22	2014	383	9918					671	672		10.1016/S0140-6736(14)60110-0	http://dx.doi.org/10.1016/S0140-6736(14)60110-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AB2WR	24560045				2023-01-03	WOS:000331653300004
J	Toth, G; Gardai, SJ; Zago, W; Bertoncini, CW; Cremades, N; Roy, SL; Tambe, MA; Rochet, JC; Galvagnion, C; Skibinski, G; Finkbeiner, S; Bova, M; Regnstrom, K; Chiou, SS; Johnston, J; Callaway, K; Anderson, JP; Jobling, MF; Buell, AK; Yednock, TA; Knowles, TPJ; Vendruscolo, M; Christodoulou, J; Dobson, CM; Schenk, D; McConlogue, L				Toth, Gergely; Gardai, Shyra J.; Zago, Wagner; Bertoncini, Carlos W.; Cremades, Nunilo; Roy, Susan L.; Tambe, Mitali A.; Rochet, Jean-Christophe; Galvagnion, Celine; Skibinski, Gaia; Finkbeiner, Steven; Bova, Michael; Regnstrom, Karin; Chiou, San-San; Johnston, Jennifer; Callaway, Kari; Anderson, John P.; Jobling, Michael F.; Buell, Alexander K.; Yednock, Ted A.; Knowles, Tuomas P. J.; Vendruscolo, Michele; Christodoulou, John; Dobson, Christopher M.; Schenk, Dale; McConlogue, Lisa			Targeting the Intrinsically Disordered Structural Ensemble of alpha-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson's Disease	PLOS ONE			English	Article							MICE LACKING; MEMBRANE; RELEASE; BINDING; NMR; PATHOGENESIS; AGGREGATION; ASSOCIATION; INHIBITORS; MUTATIONS	The misfolding of intrinsically disordered proteins such as alpha-synuclein, tau and the A beta peptide has been associated with many highly debilitating neurodegenerative syndromes including Parkinson's and Alzheimer's diseases. Therapeutic targeting of the monomeric state of such intrinsically disordered proteins by small molecules has, however, been a major challenge because of their heterogeneous conformational properties. We show here that a combination of computational and experimental techniques has led to the identification of a drug-like phenyl-sulfonamide compound (ELN484228), that targets alpha-synuclein, a key protein in Parkinson's disease. We found that this compound has substantial biological activity in cellular models of alpha-synuclein-mediated dysfunction, including rescue of alpha-synuclein-induced disruption of vesicle trafficking and dopaminergic neuronal loss and neurite retraction most likely by reducing the amount of alpha-synuclein targeted to sites of vesicle mobilization such as the synapse in neurons or the site of bead engulfment in microglial cells. These results indicate that targeting alpha-synuclein by small molecules represents a promising approach to the development of therapeutic treatments of Parkinson's disease and related conditions.	[Toth, Gergely; Bertoncini, Carlos W.; Cremades, Nunilo; Galvagnion, Celine; Buell, Alexander K.; Knowles, Tuomas P. J.; Vendruscolo, Michele; Dobson, Christopher M.] Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; [Bertoncini, Carlos W.] Univ Nacl Rosario, SEDIPFAR Serv Descubrimiento Diseno & Desarrollo, RA-2000 Rosario, Argentina; [Roy, Susan L.; Tambe, Mitali A.; Rochet, Jean-Christophe] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; [Toth, Gergely; Gardai, Shyra J.; Zago, Wagner; Bova, Michael; Regnstrom, Karin; Chiou, San-San; Johnston, Jennifer; Callaway, Kari; Anderson, John P.; Jobling, Michael F.; Yednock, Ted A.; Christodoulou, John; Dobson, Christopher M.] Elan Pharmaceut, San Francisco, CA USA; [Christodoulou, John] UCL, Dept Struct & Mol Biol, London, England; [Skibinski, Gaia; Finkbeiner, Steven] Gladstone Inst Neurol Dis, San Francisco, CA USA; [Skibinski, Gaia; Finkbeiner, Steven] Consortium Frontotemporal Dementia Res, Taube Koret Ctr Neurodegenerat Dis Res, San Francisco, CA USA; [Skibinski, Gaia; Finkbeiner, Steven] Hellman Family Fdn, Program Alzheimers Dis Res, San Francisco, CA USA; [Finkbeiner, Steven] UCSF, Dept Neurol, San Francisco, CA USA; [Finkbeiner, Steven] UCSF, Dept Physiol, San Francisco, CA USA	University of Cambridge; National University of Rosario; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of London; University College London; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Toth, G (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	gt293@cam.ac.uk; mv245@cam.ac.uk; cmd44@cam.ac.uk; dale.schenk@prothena.com; lisam@msg.ucsf.edu	Cremades, Nunilo/F-9634-2015; Tambe, Mitali/AGX-3558-2022; Knowles, Tuomas/C-6663-2009; Vendruscolo, Michele/F-5901-2012; Galvagnion, Celine/K-7940-2018; Buell, Alexander/B-4155-2013	Cremades, Nunilo/0000-0002-9138-6687; Tambe, Mitali/0000-0001-9389-2308; Knowles, Tuomas/0000-0002-7879-0140; Vendruscolo, Michele/0000-0002-3616-1610; Galvagnion, Celine/0000-0001-9753-3310; Buell, Alexander/0000-0003-1161-3622; Johnston, Jennifer/0000-0002-4867-9230; Christodoulou, John/0000-0002-6710-3843; Rochet, Jean-Christophe/0000-0002-6484-1541	Elan Pharmaceuticals; Wellcome Trust; EU-FP7 Marie Curie Fellowship; Ramon y Cajal research contract from MICINN-Spain; Human Frontier Science Program Long-term Fellowship; NIH/NINDS; Biotechnology and Biological Sciences Research Council [BB/H003843/1] Funding Source: researchfish; Medical Research Council [MC_G1000734] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039074, R01NS083390] Funding Source: NIH RePORTER; BBSRC [BB/H003843/1] Funding Source: UKRI; MRC [MC_G1000734] Funding Source: UKRI	Elan Pharmaceuticals; Wellcome Trust(Wellcome TrustEuropean Commission); EU-FP7 Marie Curie Fellowship; Ramon y Cajal research contract from MICINN-Spain; Human Frontier Science Program Long-term Fellowship(Human Frontier Science Program); NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Work at Elan and some of the work at the University of Cambridge was funded by Elan Pharmaceuticals. Additional funding came from the Wellcome Trust, EU-FP7 Marie Curie Fellowship, a Ramon y Cajal research contract from MICINN-Spain, a Human Frontier Science Program Long-term Fellowship and the NIH/NINDS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allison JR, 2009, J AM CHEM SOC, V131, P18314, DOI 10.1021/ja904716h; ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Anderson JP, 2006, J BIOL CHEM, V281, P29739, DOI 10.1074/jbc.M600933200; Anwar S, 2011, J NEUROSCI, V31, P7264, DOI 10.1523/JNEUROSCI.6194-10.2011; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Auluck PK, 2010, ANNU REV CELL DEV BI, V26, P211, DOI 10.1146/annurev.cellbio.042308.113313; Ben Gedalya T, 2009, TRAFFIC, V10, P218, DOI 10.1111/j.1600-0854.2008.00853.x; Bertoncini CW, 2005, P NATL ACAD SCI USA, V102, P1430, DOI 10.1073/pnas.0407146102; Bertoncini CW, 2005, J BIOL CHEM, V280, P30649, DOI 10.1074/jbc.C500288200; Bulawa CE, 2012, P NATL ACAD SCI USA, V109, P9629, DOI 10.1073/pnas.1121005109; Burre J, 2010, SCIENCE, V329, P1663, DOI 10.1126/science.1195227; Cabin DE, 2002, J NEUROSCI, V22, P8797; Chandra S, 2004, P NATL ACAD SCI USA, V101, P14966, DOI 10.1073/pnas.0406283101; Chen J, 2010, J AM CHEM SOC, V132, P17015, DOI 10.1021/ja107552s; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Cooper AA, 2006, SCIENCE, V313, P324, DOI 10.1126/science.1129462; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Dedmon MM, 2005, J AM CHEM SOC, V127, P476, DOI 10.1021/ja044834j; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Farrer M, 2001, HUM MOL GENET, V10, P1847, DOI 10.1093/hmg/10.17.1847; Fuchs J, 2007, NEUROLOGY, V68, P916, DOI 10.1212/01.wnl.0000254458.17630.c5; Gaugler MN, 2012, ACTA NEUROPATHOL, V123, P653, DOI 10.1007/s00401-012-0963-y; Gitler AD, 2009, NAT GENET, V41, P308, DOI 10.1038/ng.300; Hackam DJ, 1998, P NATL ACAD SCI USA, V95, P11691, DOI 10.1073/pnas.95.20.11691; Hoyer W, 2002, J MOL BIOL, V322, P383, DOI 10.1016/S0022-2836(02)00775-1; Jensen MR, 2009, STRUCTURE, V17, P1169, DOI 10.1016/j.str.2009.08.001; Kim KS, 2010, J BIOL CHEM, V285, P21416, DOI 10.1074/jbc.M110.103499; Klabunde T, 2000, NAT STRUCT BIOL, V7, P312; Kortvelyesi T, 2003, PROTEINS, V51, P340, DOI 10.1002/prot.10287; Landon MR, 2007, J MED CHEM, V50, P1231, DOI 10.1021/jm061134b; Lendel C, 2009, BIOCHEMISTRY-US, V48, P8322, DOI 10.1021/bi901285x; Liu F, 2008, J NEUROCHEM, V105, P2435, DOI 10.1111/j.1471-4159.2008.05333.x; Liu J, 2003, GENE, V308, P1, DOI 10.1016/S0378-1119(03)00453-0; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; McGann M, 2011, J CHEM INF MODEL, V51, P578, DOI 10.1021/ci100436p; McInnes C, 2007, CURR OPIN CHEM BIOL, V11, P494, DOI 10.1016/j.cbpa.2007.08.033; Metallo SJ, 2010, CURR OPIN CHEM BIOL, V14, P481, DOI 10.1016/j.cbpa.2010.06.169; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Nakamura K, 2011, J BIOL CHEM, V286, P20710, DOI 10.1074/jbc.M110.213538; Nemani VM, 2010, NEURON, V65, P66, DOI 10.1016/j.neuron.2009.12.023; Orwig SD, 2011, BIOCHEMISTRY-US, V50, P10647, DOI 10.1021/bi201619z; Outeiro TF, 2007, SCIENCE, V317, P516, DOI 10.1126/science.1143780; Palokangas H, 1997, J CELL SCI, V110, P1767; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Saiki S, 2012, J NEUROL NEUROSUR PS, V83, P430, DOI 10.1136/jnnp-2011-301205; Salmon L, 2010, J AM CHEM SOC, V132, P8407, DOI 10.1021/ja101645g; Schiesling C, 2008, NEUROPATH APPL NEURO, V34, P255, DOI 10.1111/j.1365-2990.2008.00952.x; Sharma P, 2012, METHOD ENZYMOL, V506, P331, DOI 10.1016/B978-0-12-391856-7.00041-X; Shyra J., 2013, PLOS ONE; Simon-Sanchez J, 2009, NAT GENET, V41, P1308, DOI 10.1038/ng.487; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Su LHJ, 2010, DIS MODEL MECH, V3, P194, DOI 10.1242/dmm.004267; Sudhof T. C., 2011, CSH PERSPECT BIOL, V3, P3, DOI DOI 10.1101/CSHPERSPECT.A005637; Thayanidhi N, 2010, MOL BIOL CELL, V21, P1850, DOI 10.1091/mbc.E09-09-0801; Tompa P, 2005, FEBS LETT, V579, P3346, DOI 10.1016/j.febslet.2005.03.072; Uversky VN, 2010, BBA-PROTEINS PROTEOM, V1804, P1231, DOI 10.1016/j.bbapap.2010.01.017; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Vendruscolo M, 2007, CURR OPIN STRUC BIOL, V17, P15, DOI 10.1016/j.sbi.2007.01.002; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Westphal CH, 2013, J BIOL CHEM, V288, P1829, DOI 10.1074/jbc.M112.418871; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhu M, 2013, J CHEM PHYS, V139, DOI 10.1063/1.4811831	68	92	99	0	62	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2014	9	2							e87133	10.1371/journal.pone.0087133	http://dx.doi.org/10.1371/journal.pone.0087133			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7IR	24551051	Green Published, Green Submitted, gold			2023-01-03	WOS:000331271500015
J	Zhou, H; Wan, JL; Wu, L; Yi, T; Liu, W; Xu, HB; Yang, XL				Zhou, Hui; Wan, Jiangling; Wu, Lei; Yi, Tao; Liu, Wei; Xu, Huibi; Yang, Xiangliang			A New Strategy for Enhancing the Oral Bioavailability of Drugs with Poor Water-Solubility and Low Liposolubility Based on Phospholipid Complex and Supersaturated SEDDS	PLOS ONE			English	Article							DELIVERY SYSTEMS SNEDDS; IN-VIVO PERFORMANCE; LIQUID-CHROMATOGRAPHY; SELF; VITRO; SCUTELLARIN; OPTIMIZATION; IMPACT; BREVISCAPINE; PERMEABILITY	A novel supersaturated self-emulsifying drug delivery system (Super-SEDDS) loaded with scutellarin-phospholipid complex (SPC) was developed. The system aimed to address the limitations presented by conventional SEDDS as delivery carriers for drugs with poor water-solubility, low liposolubility and high dose. As an intermediate, SPC was first prepared based on the response surface design. The presence of amorphous scutellarin was demonstrated through differential scanning calorimetry (DSC) and X-ray diffraction (XRD), while enhanced liposolubility was confirmed through comparison with scutellarin powder via an octanol/water distribution test. On the basis of the solubility study and ternary phase diagram, Super-SEDDS containing SPC of up to 200% equilibrium solubility (S-eq) was designed, which composed of ethyl oleate, Cremophor RH40 and Transcutol HP with a ratio of 60:25:15 (w/w%). The subsequent in vitro lipolysis study and ex vivo intestinal absorption test indicated that Super-SEDDS enhanced the cumulative dissolution from 70% to 100% and improved the intestinal absorption from 0.04 to 0.12 mu g/cm(2) compared with scutellarin powder. Furthermore, an in vivo study demonstrated that Super-SEDDS achieved the AUC(o-t) of scutellarin up to approximate 1.7-fold as scutellarin powder. It was also proved superior to SPC and the conventional SEDDS. Super-SEDDS showed great potential for expanding the usage of SEDDS and could act as an alternative to conventional SEDDS.	[Zhou, Hui; Wan, Jiangling; Wu, Lei; Liu, Wei; Xu, Huibi; Yang, Xiangliang] Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Natl Engn Res Ctr Nanomed, Wuhan 430074, Peoples R China; [Yi, Tao] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau Inst Appl Res Med & Hlth, Taipa, Macau, Peoples R China	Huazhong University of Science & Technology; Macau University of Science & Technology	Yi, T (corresponding author), Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau Inst Appl Res Med & Hlth, Taipa, Macau, Peoples R China.	yiaaron@outlook.com; nanomedicine@hust.edu.cn			Special Project on the Integration of Industry Education Research of Guangdong Province [2009B090300321]; Science and Technology Development Fund of Macao Special Administrative Region [094/2012/A3]; National High Technology Research and Development Program of China [2012AA022704]	Special Project on the Integration of Industry Education Research of Guangdong Province; Science and Technology Development Fund of Macao Special Administrative Region; National High Technology Research and Development Program of China(National High Technology Research and Development Program of China)	This work was financially supported by the Special Project on the Integration of Industry Education Research of Guangdong Province (No. 2009B090300321), the Science and Technology Development Fund of Macao Special Administrative Region (No. 094/2012/A3) and the National High Technology Research and Development Program of China (No. 2012AA022704). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alam MA, 2012, J PHARM PHARMACOL, V64, P326, DOI 10.1111/j.2042-7158.2011.01391.x; Anby MU, 2012, MOL PHARMACEUT, V9, P2063, DOI 10.1021/mp300164u; Buyukozturk F, 2010, J CONTROL RELEASE, V142, P22, DOI 10.1016/j.jconrel.2009.10.005; Cao F, 2006, EUR J PHARM SCI, V29, P385, DOI 10.1016/j.ejps.2006.07.007; Cao Feng, 2006, Yaoxue Xuebao, V41, P595; [陈鹰 CHEN Ying], 2009, [中草药, Chinese Traditional and Herbal Drugs], V40, P374; Fei X, 2009, J DRUG TARGET, V17, P408, DOI 10.1080/10611860902913380; Fernandez S, 2009, PHARM RES-DORDR, V26, P1901, DOI 10.1007/s11095-009-9906-2; Gao P, 2009, J PHARM SCI-US, V98, P516, DOI 10.1002/jps.21451; Ju W Z, 2006, CHIN J CLIN PHARM TH, V11, P292; Kiss L, 2013, J PHARM SCI-US, V102, P1173, DOI 10.1002/jps.23458; Lu Y, 2013, INT J PHARMACEUT, V453, P198, DOI 10.1016/j.ijpharm.2012.08.042; Miller JM, 2011, MOL PHARMACEUT, V8, P1848, DOI 10.1021/mp200181v; Mukherjee T, 2010, J PHARM PHARMACOL, V62, P1112, DOI 10.1111/j.2042-7158.2010.01149.x; Peng Q, 2010, MOL PHARMACEUT, V7, P565, DOI 10.1021/mp900274u; Porter CJH, 2007, NAT REV DRUG DISCOV, V6, P231, DOI 10.1038/nrd2197; Prachi S., 2012, INT RES J PHARM, V3, P1; Ruan JH, 2010, INT J PHARMACEUT, V386, P282, DOI 10.1016/j.ijpharm.2009.11.026; Sakai K, 2012, DRUG DEV IND PHARM, V38, P1254, DOI 10.3109/03639045.2011.645832; Sarparanta MP, 2012, BIOMATERIALS, V33, P3353, DOI 10.1016/j.biomaterials.2012.01.029; Sassene PJ, 2010, J PHARM SCI-US, V99, P4982, DOI 10.1002/jps.22226; Villar AMS, 2012, INT J PHARMACEUT, V431, P161, DOI 10.1016/j.ijpharm.2012.04.001; Singh B, 2011, DRUG DELIV, V18, P599, DOI 10.3109/10717544.2011.604686; Tang SY, 2012, ULTRASON SONOCHEM, V19, P330, DOI 10.1016/j.ultsonch.2011.07.001; Tang Xiao-Qiao, 2005, Zhongguo Zhongyao Zazhi, V30, P222; Thomas N, 2012, J CONTROL RELEASE, V160, P25, DOI 10.1016/j.jconrel.2012.02.027; Ujhelyi Z, 2012, EUR J PHARM SCI, V47, P564, DOI 10.1016/j.ejps.2012.07.005; Ward, 2000, Pharm Sci Technol Today, V3, P346, DOI 10.1016/S1461-5347(00)00302-3; Williams H, 2013, PHARM RES, P1; Wu ZB, 2011, DRUG DEV IND PHARM, V37, P103, DOI 10.3109/03639045.2010.495752; Yang SC, 2004, PHARM RES-DORDR, V21, P261, DOI 10.1023/B:PHAM.0000016238.44452.f1; YOSHIMURA Y, 1989, J FOOD HYG SOC JPN, V30, P218; Yulan S, 2006, J CHROMATOGR B, V830, P1, DOI 10.1016/j.jchromb.2005.10.016; Zhang Hai-yan, 2005, Yaoxue Xuebao, V40, P563; Zhang JJ, 2011, INT J NANOMED, V6, P3405, DOI 10.2147/IJN.S25824; Zhang L, 2012, INT J NANOMED, V7, P151, DOI 10.2147/IJN.S27639; Zhang QY, 2012, J BIOMED NANOTECHNOL, V8, P90, DOI 10.1166/jbn.2012.1371; Zhang XY, 2009, HERALD MED, V5, P571; Zhang ZW, 2011, NANOSCALE, V3, P1780, DOI 10.1039/c0nr00879f; Zhong DF, 2003, J CHROMATOGR B, V796, P439, DOI 10.1016/j.jchromb.2003.08.002; Zhong HJ, 2005, PHARMAZIE, V60, P475	41	23	24	2	48	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2013	8	12							e84530	10.1371/journal.pone.0084530	http://dx.doi.org/10.1371/journal.pone.0084530			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	284MV	24391965	gold, Green Submitted, Green Published			2023-01-03	WOS:000329323900108
J	Vafai, SB; Mootha, VK				Vafai, Scott B.; Mootha, Vamsi K.			A Common Pathway for a Rare Disease?	SCIENCE			English	Editorial Material							MITOCHONDRIAL DISEASE; MTOR		[Vafai, Scott B.; Mootha, Vamsi K.] Massachusetts Gen Hosp, Dept Mol Biol, Howard Hughes Med Inst, Boston, MA 02114 USA; [Vafai, Scott B.; Mootha, Vamsi K.] Massachusetts Gen Hosp, Dept Med, Howard Hughes Med Inst, Boston, MA 02114 USA; [Vafai, Scott B.; Mootha, Vamsi K.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; [Vafai, Scott B.; Mootha, Vamsi K.] Broad Inst, Boston, MA 02141 USA	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Vafai, SB (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Howard Hughes Med Inst, Boston, MA 02114 USA.	vamsi@hms.harvard.edu			Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Bird MJ, 2014, BBA-GEN SUBJECTS, V1840, P1380, DOI 10.1016/j.bbagen.2013.10.017; Dai Y, 2014, HUM MOL GENET, V23, P637, DOI 10.1093/hmg/ddt450; Gilkerson RW, 2012, HUM MOL GENET, V21, P978, DOI 10.1093/hmg/ddr529; Houtkooper RH, 2013, NATURE, V497, P451, DOI 10.1038/nature12188; Johnson SC, 2013, SCIENCE, V342, P1524, DOI 10.1126/science.1244360; Johnson SC, 2013, NATURE, V493, P338, DOI 10.1038/nature11861; Kruse SE, 2008, CELL METAB, V7, P312, DOI 10.1016/j.cmet.2008.02.004; LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216; Pfeffer G, 2013, NAT REV NEUROL, V9, P474, DOI 10.1038/nrneurol.2013.129; Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311; Vafai SB, 2012, NATURE, V491, P374, DOI 10.1038/nature11707	11	19	19	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 20	2013	342	6165					1453	1454		10.1126/science.1248449	http://dx.doi.org/10.1126/science.1248449			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ZI	24357304				2023-01-03	WOS:000328644300037
J	Li, GB; Petiwala, SM; Pierce, DR; Nonn, L; Johnson, JJ				Li, Gongbo; Petiwala, Sakina M.; Pierce, Dana R.; Nonn, Larisa; Johnson, Jeremy J.			Selective Modulation of Endoplasmic Reticulum Stress Markers in Prostate Cancer Cells by a Standardized Mangosteen Fruit Extract	PLOS ONE			English	Article							UNFOLDED PROTEIN RESPONSE; ALPHA-MANGOSTIN; DIETARY DITERPENE; INDUCED APOPTOSIS; CYCLE ARREST; XANTHONES; CARNOSOL; PATHWAY; DEATH	The increased proliferation of cancer cells is directly dependent on the increased activity of the endoplasmic reticulum (ER) machinery which is responsible for protein folding, assembly, and transport. In fact, it is so critical that perturbations in the endoplasmic reticulum can lead to apoptosis. This carefully regulated organelle represents a unique target of cancer cells while sparing healthy cells. In this study, a standardized mangosteen fruit extract (MFE) was evaluated for modulating ER stress proteins in prostate cancer. Two human prostate cancer cell lines, 22Rv1 and LNCaP, and prostate epithelial cells (PrECs) procured from two patients undergoing radical prostatectomy were treated with MFE. Flow cytometry, MTT, BrdU and Western blot were used to evaluate cell apoptosis, viability, proliferation and ER stress. Next, we evaluated MFE for microsomal stability and anti-cancer activity in nude mice. MFE induced apoptosis, decreased viability and proliferation in prostate cancer cells. MFE increased the expression of ER stress proteins. Interestingly, MFE selectively promotes ER stress in prostate cancer cells while sparing PrECs. MFE suppressed tumor growth in a xenograft tumor model without obvious toxicity. Mangosteen fruit extract selectively promotes endoplasmic reticulum stress in cancer cells while sparing non-tumorigenic prostate epithelial cells. Furthermore, in an in vivo setting mangosteen fruit extract significantly reduces xenograft tumor formation.	[Li, Gongbo; Petiwala, Sakina M.; Pierce, Dana R.; Johnson, Jeremy J.] Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL 60607 USA; [Nonn, Larisa] Univ Illinois, Coll Med, Dept Pathol, Chicago, IL 60612 USA; [Nonn, Larisa; Johnson, Jeremy J.] Univ Illinois, Coll Med, Ctr Canc, Chicago, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Johnson, JJ (corresponding author), Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL 60607 USA.	jjjohn@uic.edu	li, gongbo/C-6778-2008		National Institutes of Health/National Cancer Institute [1R03CA138953]; NATIONAL CANCER INSTITUTE [R03CA138953] Funding Source: NIH RePORTER	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health/National Cancer Institute 1R03CA138953 (J. Johnson). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANNAU Z, 1990, NEUROTOXICOL TERATOL, V12, P547, DOI 10.1016/0892-0362(90)90021-4; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Chen JJ, 2014, LEUKEMIA LYMPHOMA, V55, P628, DOI 10.3109/10428194.2013.802312; Gregersen N, 2010, METHODS MOL BIOL, V648, P3, DOI 10.1007/978-1-60761-756-3_1; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Johnson JJ, 2012, CARCINOGENESIS, V33, P413, DOI 10.1093/carcin/bgr291; Johnson JJ, 2010, CANCER PREV RES, V3, P1112, DOI 10.1158/1940-6207.CAPR-10-0168; Johnson JJ, 2008, PHARM RES-DORDR, V25, P2125, DOI 10.1007/s11095-008-9552-0; Lai ED, 2007, PHYSIOLOGY, V22, P193, DOI 10.1152/physiol.00050.2006; Liu KC, 2014, ENVIRON TOXICOL, V29, P428, DOI 10.1002/tox.21769; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Matsumoto K, 2004, BIOORGAN MED CHEM, V12, P5799, DOI 10.1016/j.bmc.2004.08.034; Nabandith Viengvansay, 2004, Asian Pac J Cancer Prev, V5, P433; Nonn L, 2006, CANCER RES, V66, P4516, DOI 10.1158/0008-5472.CAN-05-3796; Obolskiy D, 2009, PHYTOTHER RES, V23, P1047, DOI 10.1002/ptr.2730; Pae HO, 2007, BIOCHEM BIOPH RES CO, V353, P1040, DOI 10.1016/j.bbrc.2006.12.133; Pedraza-Chaverri J, 2008, FOOD CHEM TOXICOL, V46, P3227, DOI 10.1016/j.fct.2008.07.024; Ramaiya A, 2012, CURR DRUG TARGETS, V13, P1698, DOI 10.2174/138945012804545524; Samali A, 2010, INT J CELL BIOL, V2010, DOI [10.1155/2010/830307, DOI 10.1155/2010/830307]; Sato A, 2004, J PHARMACOL SCI, V95, P33, DOI 10.1254/jphs.95.33; Suksamrarn S, 2006, CHEM PHARM BULL, V54, P301, DOI 10.1248/cpb.54.301; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184; Tsai Yien Che, 2010, Genes Cancer, V1, P764; Verfaillie T, 2010, CANC LETT, V332, P249; Walker EB, 2007, J SEP SCI, V30, P1229, DOI 10.1002/jssc.200700024; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang SY, 2012, J CELL BIOL, V197, P857, DOI 10.1083/jcb.201110131; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373	29	20	21	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2013	8	12							e81572	10.1371/journal.pone.0081572	http://dx.doi.org/10.1371/journal.pone.0081572			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276HL	24367485	Green Published, gold, Green Submitted			2023-01-03	WOS:000328740300006
J	Keating, P; Cambrosio, A				Keating, Peter; Cambrosio, Alberto			The art of medicine 21st-century oncology: a tangled web	LANCET			English	Editorial Material									[Keating, Peter] Univ Quebec, Ctr Interuniv Rech Sci & Technol, Montreal, PQ H3C 3P1, Canada; [Keating, Peter] Univ Quebec, Dept Hist, Montreal, PQ H3C 3P1, Canada; [Cambrosio, Alberto] McGill Univ, Dept Social Studies Med, Montreal, PQ, Canada	University of Quebec; University of Quebec Montreal; University of Quebec; University of Quebec Montreal; McGill University	Keating, P (corresponding author), Univ Quebec, Ctr Interuniv Rech Sci & Technol, Montreal, PQ H3C 3P1, Canada.	keating.peter@uqam.ca		Keating, Peter/0000-0001-7236-9761					0	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 14	2013	382	9909					E45	E46		10.1016/S0140-6736(13)62660-4	http://dx.doi.org/10.1016/S0140-6736(13)62660-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	269EI	24350356	Green Submitted			2023-01-03	WOS:000328223700002
J	Chang, TI; Oh, HJ; Kang, EW; Yoo, TH; Shin, SK; Kang, SW; Choi, KH; Han, DS; Han, SH				Chang, Tae Ik; Oh, Hyung Jung; Kang, Ea Wha; Yoo, Tae-Hyun; Shin, Sug Kyun; Kang, Shin-Wook; Choi, Kyu Hun; Han, Dae Suk; Han, Seung Hyeok			A Low Serum Bicarbonate Concentration as a Risk Factor for Mortality in Peritoneal Dialysis Patients	PLOS ONE			English	Article							CHRONIC METABOLIC-ACIDOSIS; HEMODIALYSIS-PATIENTS; ASSOCIATION; NUTRITION; DEATH	Background and Aim: Metabolic acidosis is common in patients with chronic kidney disease and is associated with increased mortality in hemodialysis patients. However, this relationship has not yet been determined in peritoneal dialysis (PD) patients. Methods: This prospective observational study included a total of 441 incident patients who started PD between January 2000 and December 2005. Using time-averaged serum bicarbonate (TA-Bic) levels, we aimed to investigate whether a low serum bicarbonate concentration can predict mortality in these patients. Results: Among the baseline parameters, serum bicarbonate level was positively associated with hemoglobin level and residual glomerular filtration rate (GFR), while it was negatively associated with albumin, C-reactive protein (CRP) levels, peritoneal Kt/V urea, and normalized protein catabolic rate (nPCR) in a multivariable linear regression analysis. During a median follow-up of 34.8 months, 149 deaths were recorded. After adjustment for age, diabetes, coronary artery disease, serum albumin, ferritin, CRP, residual GFR, peritoneal Kt/V urea, nPCR, and percentage of lean body mass, TA-Bic level was associated with a significantly decreased risk of mortality (HR per 1 mEq/L increase, 0.83; 95% CI, 0.76-0.91; p < 0.001). In addition, compared to patients with a TA-Bic level of 24-26 mEq/L, those with a TA-Bic level < 22 and between 22-24 mEq/L conferred a 13.10- and 2.13-fold increased risk of death, respectively. Conclusions: This study showed that a low serum bicarbonate concentration is an independent risk factor for mortality in PD patients. This relationship between low bicarbonate levels and adverse outcome could be related to enhanced inflammation and a more rapid loss of RRF associated with metabolic acidosis. Large randomized clinical trials to correct acidosis are warranted to confirm our findings.	[Chang, Tae Ik; Kang, Ea Wha; Shin, Sug Kyun] Ilsan Hosp, Dept Internal Med, NHIS Med Ctr, Goyangshi, Gyeonggi Do, South Korea; [Oh, Hyung Jung; Yoo, Tae-Hyun; Kang, Shin-Wook; Choi, Kyu Hun; Han, Dae Suk; Han, Seung Hyeok] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Kang, Shin-Wook] Yonsei Univ, Severance Biomed Sci Inst, Seoul 120749, South Korea	NHIS Ilsan Hospital; Yonsei University; Yonsei University Health System; Yonsei University	Han, SH (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea.	hansh@yuhs.ac	Han, Seung Hyeok/K-4559-2018; Han, Seung Hyeok/W-8825-2019	Han, Seung Hyeok/0000-0001-7923-5635; Han, Seung Hyeok/0000-0001-7923-5635; Yoo, Tae-Hyun/0000-0002-9183-4507; Choi, Kyu Hun/0000-0003-0095-9011; Kang, Shin-Wook/0000-0002-5677-4756	Brain Korea 21 Project for Medical Science, Yonsei University; National Research Foundation of Korea (NRF); Korean government (MEST) [2011-0030711]; Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [A102065]	Brain Korea 21 Project for Medical Science, Yonsei University(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea); National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Korean government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government); Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea	This work was supported by the Brain Korea 21 Project for Medical Science, Yonsei University, by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST) (No. 2011-0030711), and by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A102065). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bailey JL, 2000, SEMIN DIALYSIS, V13, P227, DOI 10.1046/j.1525-139x.2000.00063.x; BALLMER PE, 1995, J CLIN INVEST, V95, P39, DOI 10.1172/JCI117668; Bommer J, 2004, AM J KIDNEY DIS, V44, P661, DOI 10.1053/j.ajkd.2004.06.008; Brener ZZ, 2010, AM J MED SCI, V339, P453, DOI 10.1097/MAJ.0b013e3181cf7d5b; Dumler F, 1996, ADV PERIT D, V12, P307; Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272-6386(03)00111-2; Franch H A, 1998, J Am Soc Nephrol, V9, pS78; Goraya N, 2013, CURR OPIN NEPHROL HY, V22, P193, DOI 10.1097/MNH.0b013e32835dcbbe; Grassmann A, 2005, NEPHROL DIAL TRANSPL, V20, P2587, DOI 10.1093/ndt/gfi159; Han SH, 2012, NAT REV NEPHROL, V8, P163, DOI 10.1038/nrneph.2012.12; K/ DOQI National Kidney Foundation, 2000, AM J KIDNEY DIS, V35, pS1, DOI DOI 10.1053/AJKD.2000.V35.AAJKD03517; Kalantar-Zadeh K, 2004, SEMIN DIALYSIS, V17, P455, DOI 10.1111/j.0894-0959.2004.17606.x; Kirschbaum B, 2000, AM J KIDNEY DIS, V35, P1068, DOI 10.1016/S0272-6386(00)70041-2; Kopple JD, 2005, KIDNEY INT, V67, pS21, DOI 10.1111/j.1523-1755.2005.09503.x; Kovesdy CP, 2009, NEPHROL DIAL TRANSPL, V24, P1232, DOI 10.1093/ndt/gfn633; Kraut JA, 2005, AM J KIDNEY DIS, V45, P978, DOI 10.1053/j.ajkd.2005.03.003; Kung S C, 2001, Adv Perit Dial, V17, P235; Lin SH, 2002, NEPHROL DIAL TRANSPL, V17, P2006, DOI 10.1093/ndt/17.11.2006; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; Mactier R, 2009, CLIN PRACTICE GUIDEL; Mehrotra R, 2003, KIDNEY INT, V64, pS13, DOI 10.1046/j.1523-1755.2003.08802.x; Mitch WE, 2002, J AM SOC NEPHROL, V13, pS22; Mujais S, 2003, KIDNEY INT, V64, pS26, DOI 10.1046/j.1523-1755.2003.08803.x; NOLPH KD, 1993, PERITON DIALYSIS INT, V13, P178; Ori Y, 2013, BLOOD PURIFICAT, V35, P181, DOI 10.1159/000346689; Pickering WP, 2002, KIDNEY INT, V61, P1286, DOI 10.1046/j.1523-1755.2002.00276.x; Stein A, 1997, KIDNEY INT, V52, P1089, DOI 10.1038/ki.1997.433; Szeto CC, 2003, J AM SOC NEPHROL, V14, P2119, DOI 10.1097/01.ASN.0000080316.37254.7A; Uribarri J, 1999, AM J KIDNEY DIS, V34, P493, DOI 10.1016/S0272-6386(99)70077-6; Vashistha T, 2013, CLIN J AM SOC NEPHRO, V8, P254, DOI 10.2215/CJN.05780612; Vilar E, 2011, SEMIN DIALYSIS, V24, P487, DOI 10.1111/j.1525-139X.2011.00968.x; Vonesh EF, 2006, KIDNEY INT, V70, pS3, DOI 10.1038/sj.ki.5001910; Woodrow G, 2010, CLIN PRACTICE GUIDEL; Wu DY, 2006, CLIN J AM SOC NEPHRO, V1, P70, DOI 10.2215/CJN.00010505	34	10	10	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2013	8	12							e82912	10.1371/journal.pone.0082912	http://dx.doi.org/10.1371/journal.pone.0082912			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276EU	24349396	Green Submitted, gold, Green Published			2023-01-03	WOS:000328731800085
J	Preissner, SC; Hoffmann, MF; Preissner, R; Dunkel, M; Gewiess, A; Preissner, S				Preissner, Sarah C.; Hoffmann, Michael F.; Preissner, Robert; Dunkel, Mathias; Gewiess, Andreas; Preissner, Saskia			Polymorphic Cytochrome P450 Enzymes (CYPs) and Their Role in Personalized Therapy	PLOS ONE			English	Article							PERCUTANEOUS CORONARY INTERVENTION; CLOPIDOGREL-TREATED PATIENTS; DRUG-INTERACTIONS; CYP2C19 GENOTYPE; ALLELIC VARIANT; GENE-THERAPY; CANCER RISK; CYP2D6; ACTIVATION; EXPRESSION	The cytochrome P450 (CYP) enzymes are major players in drug metabolism. More than 2,000 mutations have been described, and certain single nucleotide polymorphisms (SNPs) have been shown to have a large impact on CYP activity. Therefore, CYPs play an important role in inter-individual drug response and their genetic variability should be factored into personalized medicine. To identify the most relevant polymorphisms in human CYPs, a text mining approach was used. We investigated their frequencies in different ethnic groups, the number of drugs that are metabolized by each CYP, the impact of CYP SNPs, as well as CYP expression patterns in different tissues. The most important polymorphic CYPs were found to be 1A2, 2D6, 2C9 and 2C19. Thirty-four common allele variants in Caucasians led to altered enzyme activity. To compare the relevant Caucasian SNPs with those of other ethnicities a search in 1,000 individual genomes was undertaken. We found 199 non-synonymous SNPs with frequencies over one percent in the 1,000 genomes, many of them not described so far. With knowledge of frequent mutations and their impact on CYP activities, it may be possible to predict patient response to certain drugs, as well as adverse side effects. With improved availability of genotyping, our data may provide a resource for an understanding of the effects of specific SNPs in CYPs, enabling the selection of a more personalized treatment regimen.	[Preissner, Sarah C.; Hoffmann, Michael F.; Preissner, Robert; Dunkel, Mathias; Preissner, Saskia] Charite, ECRC Struct Bioinformat Grp, DKTK, D-13353 Berlin, Germany; [Gewiess, Andreas] Inst Lab Med, Berlin, Germany; [Preissner, Saskia] Charite, CC3, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Preissner, S (corresponding author), Charite, ECRC Struct Bioinformat Grp, DKTK, D-13353 Berlin, Germany.	saskia.preissner@charite.de		preissner, robert/0000-0002-2407-1087; Dunkel, Mathias/0000-0002-6642-483X	BMBF ImmunoTox; European Union Seventh Framework Programme SYNSYS (Synaptic Systems: dissecting brain function in health and disease); DKTK	BMBF ImmunoTox; European Union Seventh Framework Programme SYNSYS (Synaptic Systems: dissecting brain function in health and disease); DKTK	This work was supported by: BMBF ImmunoTox, European Union Seventh Framework Programme SYNSYS (Synaptic Systems: dissecting brain function in health and disease), DKTK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALBERT A, 1958, NATURE, V182, P421, DOI 10.1038/182421a0; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Angiolillo DJ, 2007, J AM COLL CARDIOL, V49, P1505, DOI 10.1016/j.jacc.2006.11.044; Berka K, 2011, J PHYS CHEM A, V115, P11248, DOI 10.1021/jp204488j; Bradford LD, 2002, PHARMACOGENOMICS, V3, P229, DOI 10.1517/14622416.3.2.229; Culhane AC, 2010, NUCLEIC ACIDS RES, V38, pD716, DOI 10.1093/nar/gkp1015; Dai Ze-long, 2012, Zhong Xi Yi Jie He Xue Bao, V10, P647; De Leon J, 2006, PSYCHOSOMATICS, V47, P75, DOI 10.1176/appi.psy.47.1.75; de Leon J, 2009, CNS SPECTRUMS, V14, P19, DOI 10.1017/S1092852900020022; de Leon J, 2009, PHARMACOL RES, V59, P81, DOI 10.1016/j.phrs.2008.10.002; Deenen MJ, 2011, ONCOLOGIST, V16, P820, DOI 10.1634/theoncologist.2010-0259; Dorman G, 2000, TRENDS BIOTECHNOL, V18, P64, DOI 10.1016/S0167-7799(99)01402-X; Dupont AG, 2009, THROMB RES, V124, P6, DOI 10.1016/j.thromres.2009.01.014; Fernandez-Santander A, 2012, CLIN TRANSL ONCOL, V14, P157, DOI 10.1007/s12094-012-0776-4; Flockhart DA, 2000, CHILD ADOL PSYCH CL, V9, P43; Grover S, 2012, CNS NEUROSCI THER, V18, P705, DOI 10.1111/j.1755-5949.2012.00343.x; Guengerich FP, 2008, CHEM RES TOXICOL, V21, P70, DOI 10.1021/tx700079z; Guengerich FP, 1998, MUTAT RES-FUND MOL M, V400, P201; Hasler J A, 1999, Mol Aspects Med, V20, P12; Hulot JS, 2010, J AM COLL CARDIOL, V56, P134, DOI 10.1016/j.jacc.2009.12.071; Huo R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034809; Huttunen KM, 2008, CURR MED CHEM, V15, P2346, DOI 10.2174/092986708785909120; Ingelman-Sundberg M, 2007, PHARMACOL THERAPEUT, V116, P496, DOI 10.1016/j.pharmthera.2007.09.004; Ingelman-Sundberg Magnus, 2005, Toxicol Appl Pharmacol, V207, P52; Johnson M, 2006, CNS SPECTRUMS, V11, P757, DOI 10.1017/S1092852900014887; Jounaidi Y, 2006, MOL CANCER THER, V5, P541, DOI 10.1158/1535-7163.MCT-05-0321; Kassimis G, 2012, THROMB RES, V129, P441, DOI 10.1016/j.thromres.2011.07.022; Kim S, 2011, BLOOD PRESSURE, V9, P7; Kirchheiner J, 2001, ACTA PSYCHIAT SCAND, V104, P173, DOI 10.1034/j.1600-0447.2001.00299.x; Kirchheiner J, 2004, MOL PSYCHIATR, V9, P442, DOI 10.1038/sj.mp.4001494; Laine K, 2004, THER DRUG MONIT, V26, P685, DOI 10.1097/00007691-200412000-00016; Matetzky S, 2004, CIRCULATION, V109, P3171, DOI 10.1161/01.CIR.0000130846.46168.03; McGraw J, 2012, EXPERT OPIN DRUG MET, V8, P371, DOI 10.1517/17425255.2012.657626; McLean KJ, 2005, BIOCHEM SOC T, V33, P796, DOI 10.1042/BST0330796; Mega JL, 2010, JAMA-J AM MED ASSOC, V304, P1821, DOI 10.1001/jama.2010.1543; Mehta SR, 2001, LANCET, V358, P527, DOI 10.1016/S0140-6736(01)05701-4; Mrozikiewicz P, 2011, GINEKOL POL, V82, P925; Nishimura M, 2003, YAKUGAKU ZASSHI, V123, P369; Papp-Jambor C, 2002, ANAESTHESIST, V51, P2, DOI 10.1007/s101-002-8365-5; Patterson LH, 1999, ANTI-CANCER DRUG DES, V14, P473; Penas-Lledo EM, 2012, PHARMACOGENOMICS, V13, P179, DOI [10.2217/PGS.11.146, 10.2217/pgs.11.146]; Pettersen AAR, 2011, THROMB J, V9, DOI 10.1186/1477-9560-9-4; Preissner S, 2010, NUCLEIC ACIDS RES, V38, pD237, DOI 10.1093/nar/gkp970; RAETHER W, 1978, ANN TROP MED PARASIT, V72, P543, DOI 10.1080/00034983.1978.11719358; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Relling MV, 2011, CLIN PHARMACOL THER, V89, P464, DOI 10.1038/clpt.2010.279; Roots I, 2007, E SCHERING RES FDN W, V59, P81; Roth RB, 2006, NEUROGENETICS, V7, P67, DOI 10.1007/s10048-006-0032-6; Ruwali M, 2010, INDIAN J EXP BIOL, V48, P651; Sata F, 2000, CLIN PHARMACOL THER, V67, P48, DOI 10.1067/mcp.2000.104391; Savi P, 2005, SEMIN THROMB HEMOST, V31, P174, DOI 10.1055/s-2005-869523; Seeringer A, 2008, CLIN LAB MED, V28, P619, DOI 10.1016/j.cll.2008.05.006; Sergentanis TN, 2012, MOL BIOL REP, V39, P9921, DOI 10.1007/s11033-012-1860-0; Shalapour S, 2011, HAEMATOL-HEMATOL J, V96, P1627, DOI 10.3324/haematol.2011.047993; Sibbing D, 2010, CIRCULATION, V121, P512, DOI 10.1161/CIRCULATIONAHA.109.885194; Sim Sarah C., 2010, Human Genomics, V4, P278; Sofi F, 2011, PHARMACOGENOMICS J, V11, P199, DOI 10.1038/tpj.2010.21; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Sulem P, 2011, HUM MOL GENET, V20, P2071, DOI 10.1093/hmg/ddr086; Tanabe K, 2012, BIOORG MED CHEM LETT, V22, P1682, DOI 10.1016/j.bmcl.2011.12.106; Tazaki J, 2012, J ATHEROSCLER THROMB, V19, P186, DOI 10.5551/jat.10009; Topf N, 1998, GENE THER, V5, P507, DOI 10.1038/sj.gt.3300611; Worth CL, 2011, NUCLEIC ACIDS RES, V39, pW215, DOI 10.1093/nar/gkr363; Zhou SF, 2009, DRUG METAB REV, V41, P89, DOI 10.1080/03602530902843483	66	110	115	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2013	8	12							e82562	10.1371/journal.pone.0082562	http://dx.doi.org/10.1371/journal.pone.0082562			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275VW	24340040	gold, Green Published, Green Submitted, Green Accepted			2023-01-03	WOS:000328707400081
J	Chen, CH; Tang, SC; Tsai, LK; Yeh, SJ; Chen, KH; Li, CH; Hsiao, YJ; Chen, YW; Yip, BS; Jeng, JS				Chen, Chih-Hao; Tang, Sung-Chun; Tsai, Li-Kai; Yeh, Shin-Joe; Chen, Kai-Hsiang; Li, Chen-Hua; Hsiao, Yu-Jen; Chen, Yu-Wei; Yip, Bak-Sau; Jeng, Jiann-Shing			Proteinuria Independently Predicts Unfavorable Outcome of Ischemic Stroke Patients Receiving Intravenous Thrombolysis	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; RENAL DYSFUNCTION; HEMORRHAGIC TRANSFORMATION; CARDIOVASCULAR-DISEASE; SAFE IMPLEMENTATION; RISK-FACTOR; SITS-MOST; FOLLOW-UP; MICROALBUMINURIA; THERAPY	Background and Purpose: Patients with low estimated glomerular filtration rate (eGFR) and proteinuria may be at increased risk for stroke. This study investigated whether low eGFR and proteinuria are outcome predictors in stroke patients treated with intravenous thrombolysis. Methods: We studied 432 consecutive stroke patients who received thrombolysis from January 2006 to December 2012, in Taiwan. Unfavorable outcome was defined as modified Rankin scale >= 2 at 3 months after stroke. Proteinuria was classified as negative or trace, mild, and moderate to severe. Using logistic regression analysis, we identified independent factors for unfavorable outcome after thrombolysis. Results: Of all patients, 32.7% had proteinuria. Patients with proteinuria were older, had higher frequencies of diabetes mellitus, hyperlipidemia, atrial fibrillation, lower eGFR, and greater severity of stroke upon admission than those without proteinuria. Proteinuria, not low eGFR, was an independent predictor for unfavorable outcome for stroke (OR = 2.00 for mild proteinuria, p = 0.035; OR = 2.54 for moderate to severe proteinuria, p = 0.035). However, no clear relationship was found between proteinuria and symptomatic hemorrhage after thrombolysis. Conclusions: Proteinuria is an independent predictor of unfavorable outcome for acute ischemic stroke in patients treated with intravenous thrombolysis, indicating the crucial role of chronic kidney disease on the effectiveness of thrombolysis.	[Chen, Chih-Hao; Tang, Sung-Chun; Tsai, Li-Kai; Yeh, Shin-Joe; Chen, Yu-Wei; Jeng, Jiann-Shing] Natl Taiwan Univ Hosp, Stroke Ctr, Taipei, Taiwan; [Chen, Chih-Hao; Tang, Sung-Chun; Tsai, Li-Kai; Yeh, Shin-Joe; Chen, Yu-Wei; Jeng, Jiann-Shing] Natl Taiwan Univ Hosp, Dept Neurol, Taipei, Taiwan; [Chen, Chih-Hao] Far Eastern Mem Hosp, Dept Internal Med, Div Neurol, New Taipei City, Taiwan; [Tsai, Li-Kai; Hsiao, Yu-Jen] Natl Taiwan Univ Hosp, Yun Lin Branch, Dept Neurol, Yunlin, Taiwan; [Chen, Kai-Hsiang; Yip, Bak-Sau] Natl Taiwan Univ Hosp, Hsin Chu Branch, Dept Neurol, Hsinchu, Taiwan; [Li, Chen-Hua; Chen, Yu-Wei] Landseed Hosp, Dept Neurol, Tao Yuan, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Far Eastern Memorial Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Jeng, JS (corresponding author), Natl Taiwan Univ Hosp, Stroke Ctr, Taipei, Taiwan.	jsjeng@ntu.edu.tw	yeh, shin-joe/HGV-0244-2022; Chen, Chih-Hao/AAA-7297-2022; Tsai, Li-Kai/HJA-2534-2022	Chen, Chih-Hao/0000-0002-1258-8775; JENG, JIANN-SHING/0000-0002-1456-3686; Yip, Bak-Sau/0000-0001-7942-8293; Tsai, Li-Kai/0000-0001-8420-6951; Tang, Sung-Chun/0000-0003-3731-5973; Yeh, Shin-Joe/0000-0003-1511-6295; CHEN, KAI-HSIANG/0000-0002-9527-4084	National Taiwan University Hospital [NTUH.102-S2186]; Academia Sinica, Taiwan [BM102021169]	National Taiwan University Hospital(National Taiwan University); Academia Sinica, Taiwan(Academia Sinica - Taiwan)	This study was supported in part by grants from the National Taiwan University Hospital (NTUH.102-S2186) and Academia Sinica, Taiwan (BM102021169). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Agrawal V, 2010, NEPHROL DIAL TRANSPL, V25, P1150, DOI 10.1093/ndt/gfp619; Agrawal V, 2009, NAT REV CARDIOL, V6, P301, DOI 10.1038/nrcardio.2009.11; Brosius FC, 2006, CIRCULATION, V114, P1083, DOI 10.1161/CIRCULATIONAHA.106.177321; Chao AC, 2010, STROKE, V41, P885, DOI 10.1161/STROKEAHA.109.575605; Cho BH, 2013, EUR J NEUROL, V20, P1145, DOI 10.1111/ene.12127; Coresh J, 2007, JAMA-J AM MED ASSOC, V298, P2038, DOI 10.1001/jama.298.17.2038; El Nahas AM, 2005, LANCET, V365, P331, DOI 10.1016/S0140-6736(05)17789-7; Fox KAA, 2007, J AM COLL CARDIOL, V49, P2249, DOI 10.1016/j.jacc.2006.12.049; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; KNOBL P, 1993, DIABETOLOGIA, V36, P1045, DOI 10.1007/BF02374497; Koren-Morag N, 2006, NEUROLOGY, V67, P224, DOI 10.1212/01.wnl.0000229099.62706.a3; Lee M, 2010, STROKE, V41, P2625, DOI 10.1161/STROKEAHA.110.581215; Lyrer PA, 2008, NEUROLOGY, V71, P1548, DOI 10.1212/01.wnl.0000338459.82173.78; MacWalter RS, 2002, STROKE, V33, P1630, DOI 10.1161/01.STR.0000016344.49819.F7; Madison JR, 2006, ARCH INTERN MED, V166, P884, DOI 10.1001/archinte.166.8.884; Naganuma M, 2011, CEREBROVASC DIS, V31, P123, DOI 10.1159/000321516; National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995, NEW ENGL J MED, V333, P1581, DOI [10.1056/NEJM199512143332401, DOI 10.1056/NEJM199512143332401]; Ninomiya T, 2009, AM J KIDNEY DIS, V53, P417, DOI 10.1053/j.ajkd.2008.08.032; Norris JW, 1998, CAN J NEUROL SCI, V25, P257, DOI 10.1017/S0317167100034120; Ochodnicky P, 2006, J CARDIOVASC PHARM, V47, pS151, DOI 10.1097/00005344-200606001-00009; Ovbiagele B, 2008, J NEUROL SCI, V271, P21, DOI 10.1016/j.jns.2008.04.007; Rodriguez-Yanez M, 2006, NEUROLOGY, V67, P1172, DOI 10.1212/01.wnl.0000238353.89194.08; Saposnik G, 2012, STROKE, V43, P1315, DOI 10.1161/STROKEAHA.111.646265; Sharma VK, 2010, J STROKE CEREBROVASC, V19, P424, DOI 10.1016/j.jstrokecerebrovasdis.2009.07.015; Slowik A, 2002, CEREBROVASC DIS, V14, P15, DOI 10.1159/000063718; Toyoda K, 2009, STROKE, V40, P3591, DOI 10.1161/STROKEAHA.109.562991; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4; Wahlgren N, 2008, STROKE, V39, P3316, DOI 10.1161/STROKEAHA.107.510768; Wardlaw J M, 2003, Cochrane Database Syst Rev, pCD000213; Wen CP, 2008, LANCET, V371, P2173, DOI 10.1016/S0140-6736(08)60952-6; Yahalom G, 2009, STROKE, V40, P1296, DOI 10.1161/STROKEAHA.108.520882; Yuyun MF, 2004, J INTERN MED, V255, P247, DOI 10.1046/j.1365-2796.2003.01264.x	35	15	15	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 22	2013	8	11							e80527	10.1371/journal.pone.0080527	http://dx.doi.org/10.1371/journal.pone.0080527			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259QP	24278288	Green Submitted, Green Published, gold			2023-01-03	WOS:000327541700029
J	Amadou, A; Fabre, A; Torres-Mejia, G; Ortega-Olvera, C; Angeles-Lierenas, A; McKenzie, F; Biessy, C; Hainaut, P; Romieu, I				Amadou, Amina; Fabre, Alban; Torres-Mejia, Gabriela; Ortega-Olvera, Carolina; Angeles-Lierenas, Angelica; McKenzie, Fiona; Biessy, Carine; Hainaut, Pierre; Romieu, Isabelle			Hormonal Therapy and Risk of Breast Cancer in Mexican Women	PLOS ONE			English	Article							ESTROGEN PLUS PROGESTIN; ORAL-CONTRACEPTIVE USE; REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; DIFFERENT REGIMENS; HEALTH; MAMMOGRAPHY; COHORT	The use of hormonal therapies, including hormonal contraceptives (HC) and postmenopausal hormone replacement therapy (HRT) have been shown to influence breast cancer (BC) risk. However, the variations of these effects among populations and ethnic groups are not completely documented, especially among Hispanic women. We evaluated the association between HC and premenopausal BC risk, and between HRT and postmenopausal BC risk in Mexican women. Data from a Mexican multi-center population-based case-control study ofwomen aged 35 to 69 years were analysed. A total of 1000 cases and 1074 matched controls were recruited between 2004 and 2007. Information on hormonal therapy was collected through a structured questionnaire. Results were analysed using conditional logistic regression models. Overall, HC were used by 422/891 (47.3%) premenopausal women and HRT was used by 220/1117 (19.7%) postmenopausal women. For HC, odds ratios (ORs) for BC were 1.11 (95% confidence interval (CI): 0.82, 1.49) for current users and 1.68 (95% CI: 0.67, 4.21) for ever-users. No clear effect of duration of use was observed. For HRT, the OR for BC was significantly increased in ever users (OR: 1.45; 95% CI: 1.01, 2.08). A non-significant increased risk was observed for combined estrogen/progestin, (OR = 1.85; 95% CI: 0.84, 4.07) whereas no effect was observed for the use of estrogen alone (OR = 1.14; 95% CI: 0.68, 1.91). Our results indicate that, HC had a non-significant effect on the risk of pre-menopausal BC, but suggested that injected contraceptives may slightly increase the risk, whereas HRT had a significant effect on post-menopausal BC in this population. This study provides new information about the effects of HC and HRT on BC risk in a Mexican population, which may be of relevance for the population of Latin America as a whole.	[Amadou, Amina; McKenzie, Fiona; Biessy, Carine; Romieu, Isabelle] Int Agcy Res Canc, Nutr & Metab Sect, Nutr Epidemiol Grp, F-69372 Lyon, France; [Fabre, Alban; Torres-Mejia, Gabriela; Ortega-Olvera, Carolina; Angeles-Lierenas, Angelica] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico; [Hainaut, Pierre] Int Prevent Res Inst, Lyon, France; [Fabre, Alban] INSERM, U1018, Nutr Hormones & Womens Hlth Inst Gustave Roussy, Paris, France	World Health Organization; International Agency for Research on Cancer (IARC); Instituto Nacional de Salud Publica; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Romieu, I (corresponding author), Int Agcy Res Canc, Nutr & Metab Sect, Nutr Epidemiol Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	romieui@iarc.fr	Ortega-Olvera, Carolina/GSN-9621-2022; Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610	Mexican National Council of Science and Technology (CONACyT in Spanish) [SALUD 2002-C01-7462]	Mexican National Council of Science and Technology (CONACyT in Spanish)(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	This study was financially supported by the Mexican National Council of Science and Technology (CONACyT in Spanish; SALUD 2002-C01-7462). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amadou A, 2013, J ONCOL, V2013, DOI 10.1155/2013/906495; Bakken L, 2004, INT J CANCER, V112, P130, DOI 10.1002/ijc.20389; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Beasley JM, 2010, CANCER CAUSE CONTROL, V21, P863, DOI 10.1007/s10552-010-9513-x; Beral V, 2005, BJOG-INT J OBSTET GY, V112, P692, DOI 10.1111/j.1471-0528.2005.00541.x; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Bernstein Leslie, 2003, Cancer, V97, P222, DOI 10.1002/cncr.11014; Bjelic-Radisic V, 2010, WIEN MED WOCHENSCHR, V160, P483, DOI 10.1007/s10354-010-0807-0; Blamey R, 2004, HUM REPROD UPDATE, V10, P281, DOI 10.1093/humupd/dmh025; Boyd NF, 2005, LANCET ONCOL, V6, P798, DOI 10.1016/S1470-2045(05)70390-9; BRONFMAN M, 1988, ARCH INVEST MED, V19, P351; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; Chavarri-Guerra Y, 2012, LANCET ONCOL, V13, pE335, DOI 10.1016/S1470-2045(12)70246-2; Chen CL, 2002, JAMA-J AM MED ASSOC, V287, P734, DOI 10.1001/jama.287.6.734; Chlebowski RT, 2010, JAMA-J AM MED ASSOC, V304, P1684, DOI 10.1001/jama.2010.1500; Chlebowski RT, 2005, JNCI-J NATL CANCER I, V97, P439, DOI 10.1093/jnci/dji064; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Cogliano V, 2005, LANCET ONCOL, V6, P552, DOI 10.1016/S1470-2045(05)70273-4; Fejerman L, 2010, CANCER EPIDEM BIOMAR, V19, P1074, DOI 10.1158/1055-9965.EPI-09-1193; Fournier A, 2005, INT J CANCER, V114, P448, DOI 10.1002/ijc.20710; Gilliland FD, 1998, AM J EPIDEMIOL, V148, P683, DOI 10.1093/aje/148.7.683; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007, IARC Monogr Eval Carcinog Risks Hum, V91, P1; Iatrakis G, 2011, CLIN EXP OBSTET GYN, V38, P225; Iodice S, 2010, EUR J CANCER, V46, P2275, DOI 10.1016/j.ejca.2010.04.018; Jernstrom H, 2003, CANCER CAUSE CONTROL, V14, P673, DOI 10.1023/A:1025635720208; Kahlenborn C, 2006, MAYO CLIN PROC, V81, P1290, DOI 10.4065/81.10.1290; Lee S, 2006, INT J CANCER, V118, P1285, DOI 10.1002/ijc.21481; Lee SA, 2005, BRIT J CANCER, V92, P2049, DOI 10.1038/sj.bjc.6602617; Li CI, 2003, JAMA-J AM MED ASSOC, V289, P3254, DOI 10.1001/jama.289.24.3254; Li R, 2002, CANCER-AM CANCER SOC, V95, P960, DOI 10.1002/cncr.10791; Nelson HD, 2012, ANN INTERN MED, V156, P635, DOI 10.7326/0003-4819-156-9-201205010-00006; Pike MC, 2002, CANCER EPIDEM BIOMAR, V11, P795; Purmonen S, 2008, ONCOL REP, V19, P1627; Reeves GK, 2006, LANCET ONCOL, V7, P910, DOI 10.1016/S1470-2045(06)70911-1; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Sather Sarah, 2012, Tidsskr Nor Laegeforen, V132, P1330, DOI 10.4045/tidsskr.11.1055; Sexton KR, 2011, CANCER-AM CANCER SOC, V117, P5271, DOI 10.1002/cncr.26217; Stahlberg C, 2004, INT J CANCER, V109, P721, DOI 10.1002/ijc.20016; Stefanick ML, 2006, JAMA-J AM MED ASSOC, V295, P1647, DOI 10.1001/jama.295.14.1647; Sweeney C, 2007, INT J CANCER, V121, P2517, DOI 10.1002/ijc.22970; Tjonneland A, 2004, CANCER-AM CANCER SOC, V100, P2328, DOI 10.1002/cncr.20250; Urban M, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001182	42	13	13	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2013	8	11							e79695	10.1371/journal.pone.0079695	http://dx.doi.org/10.1371/journal.pone.0079695			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255RX	24260282	Green Submitted, gold, Green Published			2023-01-03	WOS:000327258600044
J	Messiaen, AS; Forier, K; Nelis, H; Braeckmans, K; Coenye, T				Messiaen, Anne-Sophie; Forier, Katrien; Nelis, Hans; Braeckmans, Kevin; Coenye, Tom			Transport of Nanoparticles and Tobramycin-loaded Liposomes in Burkholderia cepacia Complex Biofilms	PLOS ONE			English	Article							PSEUDOMONAS-AERUGINOSA; BACTERICIDAL EFFICACY; RESISTANT STRAINS; ENHANCED ACTIVITY; AMINOGLYCOSIDES; MECHANISM; AMIKACIN	Due to the intrinsic resistance of Burkholderia cepacia complex (Bcc) to many antibiotics and the production of a broad range of virulence factors, lung infections by these bacteria, primarily occurring in cystic fibrosis (CF) patients, are very difficult to treat. In addition, the ability of Bcc organisms to form biofilms contributes to their persistence in the CF lung. As Bcc infections are associated with poor clinical outcome, there is an urgent need for new effective therapies to treat these infections. In the present study, we investigated whether liposomal tobramycin displayed an increased anti-biofilm effect against Bcc bacteria compared to free tobramycin. Single particle tracking (SPT) was used to study the transport of positively and negatively charged nanospheres in Bcc biofilms as a model for the transport of liposomes. Negatively charged nanospheres became immobilized in close proximity of biofilm cell clusters, while positively charged nanospheres interacted with fiber-like structures, probably eDNA. Based on these data, encapsulation of tobramycin in negatively charged liposomes appeared promising for targeted drug delivery. However, the anti-biofilm effect of tobramycin encapsulated into neutral or anionic liposomes did not increase compared to that of free tobramycin. Probably, the fusion of the anionic liposomes with the negatively charged bacterial surface of Bcc bacteria was limited by electrostatic repulsive forces. The lack of a substantial anti-biofilm effect of tobramycin encapsulated in neutral liposomes could be further investigated by increasing the liposomal tobramycin concentration. However, this was hampered by the low encapsulation efficiency of tobramycin in these liposomes.	[Messiaen, Anne-Sophie; Nelis, Hans; Coenye, Tom] Univ Ghent, Lab Pharmaceut Microbiol, B-9000 Ghent, Belgium; [Forier, Katrien; Braeckmans, Kevin] Univ Ghent, Lab Gen Biochem & Phys Pharm, B-9000 Ghent, Belgium; [Forier, Katrien; Braeckmans, Kevin] Univ Ghent, Ctr Nano & Biophoton, B-9000 Ghent, Belgium	Ghent University; Ghent University; Ghent University	Coenye, T (corresponding author), Univ Ghent, Lab Pharmaceut Microbiol, B-9000 Ghent, Belgium.	Tom.Coenye@Ugent.be	Coenye, Tom/Z-1928-2019; Coenye, Tom/A-6291-2014; Braeckmans, Kevin/HCH-3119-2022	Coenye, Tom/0000-0002-6407-0601; Coenye, Tom/0000-0002-6407-0601; Braeckmans, Kevin/0000-0002-7993-6295; Forier, Katrien/0000-0002-7003-3612	Interuniversity Attraction Poles Programme; Belgian Science Policy Office; Ghent University	Interuniversity Attraction Poles Programme(Belgian Federal Science Policy Office); Belgian Science Policy Office(Belgian Federal Science Policy Office); Ghent University(Ghent University)	This research has been funded by the Interuniversity Attraction Poles Programme initiated by the Belgian Science Policy Office and by a concerted action grant by Ghent University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beaulac C, 1998, J ANTIMICROB CHEMOTH, V41, P35, DOI 10.1093/jac/41.1.35; Braeckmans K, 2010, NANOSCOPY AND MULTIDIMENSIONAL OPTICAL FLUORESCENCE MICROSCOPY; Braeckmans K, 2010, NANO LETT, V10, P4435, DOI 10.1021/nl103264u; Brennan AL, 2002, CURR OPIN INFECT DIS, V15, P175, DOI 10.1097/00001432-200204000-00013; Chang HI, 2012, INT J NANOMED, V7, P49, DOI 10.2147/IJN.S26766; Council of European, 2021, BRIT PHARMACOPOEIA, V10th; Cunha MV, 2004, J CLIN MICROBIOL, V42, P3052, DOI 10.1128/JCM.42.7.3052-3058.2004; Cystic Fibrosis Foundation, 2011, ANN DAT REP CTR DIR; Forier K, 2013, NANOMEDICINE-UK, V8, P935, DOI [10.2217/NNM.12.129, 10.2217/nnm.12.129]; GIWERCMAN B, 1991, ANTIMICROB AGENTS CH, V35, P1008, DOI 10.1128/AAC.35.5.1008; Halwani M, 2007, J ANTIMICROB CHEMOTH, V60, P760, DOI 10.1093/jac/dkm289; Hancock REW, 1998, CLIN INFECT DIS, V27, pS93, DOI 10.1086/514909; Horsley A, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009529.pub2; Li ZL, 2008, J AEROSOL MED PULM D, V21, P245, DOI 10.1089/jamp.2008.0686; Lyczak JB, 2002, CLIN MICROBIOL REV, V15, P194, DOI 10.1128/CMR.15.2.194-222.2002; Mahenthiralingam E, 2005, NAT REV MICROBIOL, V3, P144, DOI 10.1038/nrmicro1085; Meers P, 2008, J ANTIMICROB CHEMOTH, V61, P859, DOI 10.1093/jac/dkn059; Mugabe C, 2006, INT J PHARMACEUT, V307, P244, DOI 10.1016/j.ijpharm.2005.10.005; Mugabe C, 2005, J ANTIMICROB CHEMOTH, V55, P269, DOI 10.1093/jac/dkh518; Mugabe C, 2006, ANTIMICROB AGENTS CH, V50, P2016, DOI 10.1128/AAC.01547-05; NIKAIDO H, 1989, ANTIMICROB AGENTS CH, V33, P1831, DOI 10.1128/AAC.33.11.1831; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Novotny LA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067629; O'Sullivan BP, 2009, LANCET, V373, P1891, DOI 10.1016/S0140-6736(09)60327-5; Omri A, 2002, BIOCHEM PHARMACOL, V64, P1407, DOI 10.1016/S0006-2952(02)01346-1; Peeters E, 2009, J ANTIMICROB CHEMOTH, V64, P801, DOI 10.1093/jac/dkp253; Seidler M, 2010, FEMS YEAST RES, V10, P492, DOI 10.1111/j.1567-1364.2010.00618.x; Sousa Silvia A, 2011, Int J Microbiol, V2011, DOI 10.1155/2011/607575; Symens N, 2011, MOL PHARMACEUT, V8, P1757, DOI 10.1021/mp200120v; Tseng BS, 2013, ENVIRON MICROBIOL, V15, P2865, DOI 10.1111/1462-2920.12155; Zlosnik JEA, 2011, AM J RESP CRIT CARE, V183, P67, DOI 10.1164/rccm.201002-0203OC	31	66	66	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2013	8	11							e79220	10.1371/journal.pone.0079220	http://dx.doi.org/10.1371/journal.pone.0079220			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254DJ	24244452	Green Submitted, Green Published, gold			2023-01-03	WOS:000327143800043
J	Chen, YJ; Wang, YH; Wang, CZ; Ho, ML; Kuo, PL; Huang, MH; Chen, CH				Chen, Yi-Jen; Wang, Yan-Hsiung; Wang, Chau-Zen; Ho, Mei-Ling; Kuo, Po-Lin; Huang, Mao-Hsiung; Chen, Chia-Hsin			Effect of Low Level Laser Therapy on Chronic Compression of the Dorsal Root Ganglion	PLOS ONE			English	Article							TUMOR-NECROSIS-FACTOR; RAT SCIATIC-NERVE; FACTOR-ALPHA; NUCLEUS PULPOSUS; SENSORY NEURONS; MESSENGER-RNA; 780 NM; HYPERALGESIA; IRRADIATION; ALLODYNIA	Dorsal root ganglia (DRG) are vulnerable to physical injury of the intervertebral foramen, and chronic compression of the DRG (CCD) an result in nerve root damage with persistent morbidity. The purpose of this study was to evaluate the effects of low level laser therapy (LLLT) on the DRG in a CCD model and to determine the mechanisms underlying these effects. CCD rats had L-shaped stainless-steel rods inserted into the fourth and fifth lumbar intervertebral foramen, and the rats were then subjected to 0 or 8 J/cm(2) LLLT for 8 consecutive days following CCD surgery. Pain and heat stimuli were applied to test for hyperalgesia following CCD. The levels of TNF-alpha, IL-1 beta and growth-associated protein-43 (GAP-43) messenger RNA (mRNA) expression were measured via real-time PCR, and protein expression levels were analyzed through immunohistochemical analyses. Our data indicate that LLLT significantly decreased the tolerable sensitivity to pain and heat stimuli in the CCD groups. The expression levels of the pro-inflammatory cytokines TNF-alpha and IL-1 beta were increased following CCD, and we found that these increases could be reduced by the application of LLLT. Furthermore, the expression of GAP-43 was enhanced by LLLT. In conclusion, LLLT was able to enhance neural regeneration in rats following CCD and improve rat ambulatory behavior. The therapeutic effects of LLLT on the DRG during CCD may be exerted through suppression of the inflammatory response and induction of neuronal repair genes. These results suggest potential clinical applications for LLLT in the treatment of compression-induced neuronal disorders.	[Chen, Yi-Jen; Huang, Mao-Hsiung; Chen, Chia-Hsin] Kaohsiung Med Univ Hosp, Dept Phys Med & Rehabil, Kaohsiung, Taiwan; [Chen, Yi-Jen; Kuo, Po-Lin] Kaohsiung Med Univ, Inst Clin Med, Coll Med, Kaohsiung, Taiwan; [Wang, Yan-Hsiung; Wang, Chau-Zen; Ho, Mei-Ling] Kaohsiung Med Univ, Coll Med, Orthopaed Res Ctr, Kaohsiung, Taiwan; [Wang, Yan-Hsiung] Kaohsiung Med Univ, Sch Dent, Coll Dent Med, Kaohsiung, Taiwan; [Wang, Chau-Zen; Ho, Mei-Ling] Kaohsiung Med Univ, Dept Physiol, Coll Med, Kaohsiung, Taiwan; [Ho, Mei-Ling] Kaohsiung Med Univ, Grad Inst Med, Sch Med, Kaohsiung, Taiwan; [Kuo, Po-Lin] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan; [Huang, Mao-Hsiung] Kaohsiung Med Univ, Sch Med, Dept Phys Med & Rehabil, Fac Med, Kaohsiung, Taiwan; [Chen, Chia-Hsin] Kaohsiung Municipal Tatung Hosp, Dept Phys Med & Rehabil, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Municipal Ta-Tung Hospital	Chen, CH (corresponding author), Kaohsiung Med Univ Hosp, Dept Phys Med & Rehabil, Kaohsiung, Taiwan.	chchen@kmu.edu.tw	Wang, Yan-Hsiung/ABD-4004-2020	Wang, Yan-Hsiung/0000-0001-8161-7472; Chen, Yi-Jen/0000-0002-5178-2335; Chen, Chia-Hsin/0000-0002-6557-9848; Ho, Mei-Ling/0000-0001-8064-8488	National Health Research Institutes [NHRI-EX 102-9914EC]; National Science Council [NSC97-2314-B-037-004-MY3]; Kaohsiung Medical University [KMU-Q098007, KMU-Q098025, KMU-Q099018]	National Health Research Institutes(National Health Research Institutes, Japan); National Science Council(Ministry of Science and Technology, Taiwan); Kaohsiung Medical University	This study was supported by a grant from the National Health Research Institutes (NHRI-EX 102-9914EC), a grant from the National Science Council (NSC97-2314-B-037-004-MY3) and grants from the Kaohsiung Medical University (KMU-Q098007, KMU-Q098025 and KMU-Q099018). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barbosa RI, 2010, LASER MED SCI, V25, P423, DOI 10.1007/s10103-009-0750-8; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chow RT, 2007, J PERIPHER NERV SYST, V12, P28, DOI 10.1111/j.1529-8027.2007.00114.x; Camara CND, 2011, ACTA CIR BRAS, V26, P12, DOI 10.1590/S0102-86502011000100004; Grava ALD, 2012, EUR SPINE J, V21, P537, DOI 10.1007/s00586-011-2027-8; Gigo-Benato D, 2005, MUSCLE NERVE, V31, P694, DOI 10.1002/mus.20305; Gigo-Benato D, 2010, LASER SURG MED, V42, P673, DOI 10.1002/lsm.20978; Gilchrist Russel V, 2002, Pain Physician, V5, P372; Gu XP, 2007, BRAIN RES, V1174, P39, DOI 10.1016/j.brainres.2007.08.030; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Ho ML, 2009, EUR J CLIN INVEST, V39, P296, DOI 10.1111/j.1365-2362.2009.02092.x; Hsieh YL, 2012, J COMP NEUROL, V520, P2903, DOI 10.1002/cne.23072; Hu SJ, 1998, PAIN, V77, P15, DOI 10.1016/S0304-3959(98)00067-0; Jimbo K, 1998, NEUROSCI LETT, V240, P93, DOI 10.1016/S0304-3940(97)00935-X; Liu B, 2002, J NEUROPHYSIOL, V88, P1393, DOI 10.1152/jn.2002.88.3.1393; Mohammed IFR, 2007, PHOTOMED LASER SURG, V25, P107, DOI 10.1089/pho.2006.1090; Ozaktay AC, 2002, EUR SPINE J, V11, P467, DOI 10.1007/s00586-002-0430-x; Rochkind S, 2007, PHOTOMED LASER SURG, V25, P436, DOI 10.1089/pho.2007.2093; Rothman SM, 2009, J PAIN, V10, P90, DOI 10.1016/j.jpain.2008.07.008; RYDEVIK BL, 1989, SPINE, V14, P574, DOI 10.1097/00007632-198906000-00004; Schaeffer V, 2010, PROG NEUROBIOL, V92, P33, DOI 10.1016/j.pneurobio.2010.04.009; Schafers M, 2003, J NEUROSCI, V23, P2517; Shin DH, 2003, NEUROSCI LETT, V344, P71, DOI 10.1016/S0304-3940(03)00354-9; Snyder SK, 2002, LASER SURG MED, V31, P216, DOI 10.1002/lsm.10098; Song XJ, 1999, J NEUROPHYSIOL, V82, P3347, DOI 10.1152/jn.1999.82.6.3347; VANDERZEE CEEM, 1989, J NEUROSCI, V9, P3505; Watanabe K, 2007, SPINE, V32, P1265, DOI 10.1097/BRS.0b013e318059aef8; Watanabe K, 2011, EUR SPINE J, V20, P1877, DOI 10.1007/s00586-011-1854-y; Wu JY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054067, 10.1371/journal.pone.0067644]; Yamashita M, 2008, SPINE, V33, P1836, DOI 10.1097/BRS.0b013e31817bab2a; Zhang JM, 2000, J NEUROPHYSIOL, V84, P798, DOI 10.1152/jn.2000.84.2.798	31	10	10	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2014	9	3							e89894	10.1371/journal.pone.0089894	http://dx.doi.org/10.1371/journal.pone.0089894			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC4FD	24594641	Green Published, Green Submitted, gold			2023-01-03	WOS:000332475500027
J	Sorup, S; Benn, CS; Poulsen, A; Krause, TG; Aaby, P; Ravn, H				Sorup, Signe; Benn, Christine S.; Poulsen, Anja; Krause, Tyra G.; Aaby, Peter; Ravn, Henrik			Live Vaccine Against Measles, Mumps, and Rubella and the Risk of Hospital Admissions for Nontargeted Infections	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIPHTHERIA-TETANUS-PERTUSSIS; FEMALE-MALE MORTALITY; RANDOMIZED-TRIAL; CHILDHOOD VACCINATION; DANISH; CHILDREN; DISEASE; BIRTH; IMMUNIZATION; SURVIVAL	IMPORTANCE In low-income countries, live measles vaccine reduces mortality from causes other than measles infection. Such nonspecific effects of vaccines might also be important for the health of children in high-income settings. OBJECTIVE To examine whether the live vaccine against measles, mumps, and rubella (MMR) is associated with lower rates of hospital admissions for infections among children in Denmark. DESIGN, SETTING, AND PARTICIPANTS Population-based cohort study of Danish children born 1997-2006 and followed up from ages 11 months to 2 years (last follow-up, August 31, 2008). Nationwide Danish registers provided data on vaccinations and hospital admissions. The recommended vaccination schedule was inactivated vaccine against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (DTaP-IPV-Hib) administered at ages 3, 5, and 12 months and MMR at age 15 months. MAIN OUTCOMES AND MEASURES Incidence rate ratios (IRRs) of hospital admissions for any infection, comparing receipt of MMR vs DTaP-IPV-Hib as the most recent vaccine. Risks, risk difference, and number needed to vaccinate were calculated for receiving MMR on time. RESULTS The study included 495 987 children contributing with 56 889 hospital admissions for any type of infection during 509 427 person-years (rate, 11.2 per 100 person-years). Receiving the live MMR vaccine after the inactivated DTaP-IPV-Hib-vaccine was associated with a lower rate of hospital admissions for any infection. [GRAPHICS] The risk of admission for an infection between ages 16 months and 24 months was 4.6% (95% CI, 4.5%-4.7%) for receiving MMR on time and 5.1% (95% CI, 5.0%-5.2%) for not receiving MMR on time. The risk difference was 0.5 percentage point (95% CI, 0.4-0.6), and the number needed to vaccinate with MMR before age 16 months to prevent 1 infectious disease admission was 201 (95% CI, 159-272). CONCLUSIONS AND RELEVANCE In a cohort of Danish children, receipt of live MMR vs inactivated DTaP-IPV-Hib as the most recent vaccine was associated with a lower rate of hospital admissions for any infections. These findings require replication in other high-income populations.	[Sorup, Signe; Benn, Christine S.; Aaby, Peter; Ravn, Henrik] Statens Serum Inst, Bandim Hlth Project, Res Ctr Vitamins & Vaccines CVIVA, DK-2300 Copenhagen S, Denmark; [Benn, Christine S.] Univ Southern Denmark, Inst Clin Res, Odense, Denmark; [Benn, Christine S.] Odense Univ Hosp, DK-5000 Odense, Denmark; [Benn, Christine S.; Aaby, Peter; Ravn, Henrik] INDEPTH Network, Bandim Hlth Project, Bissau, Guinea Bissau; [Poulsen, Anja] Rigshosp, Child & Adolescent Clin, DK-2100 Copenhagen, Denmark; [Krause, Tyra G.] Statens Serum Inst, Dept Infect Dis Epidemiol, DK-2300 Copenhagen S, Denmark	Statens Serum Institut; University of Southern Denmark; University of Southern Denmark; Odense University Hospital; Rigshospitalet; University of Copenhagen; Statens Serum Institut	Sorup, S (corresponding author), Statens Serum Inst, Bandim Hlth Project, CVIVA, Artillerivej 5, DK-2300 Copenhagen S, Denmark.	sgs@ssi.dk		Poulsen, Anja/0000-0002-9656-1552; Sorup, Signe/0000-0003-1942-683X; Aaby, Peter/0000-0001-8331-1389	Health Foundation [2009B132]; Rosalie Petersen Foundation; Novo Nordisk Foundation; European Research Council (ERC) [ERC-StG-243149]; Danish National Research Foundation (DNRF) [DNRF108]	Health Foundation; Rosalie Petersen Foundation; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); European Research Council (ERC)(European Research Council (ERC)European Commission); Danish National Research Foundation (DNRF)(Danmarks Grundforskningsfond)	This work was supported by the Health Foundation (2009B132 [Dr Sorup]); the Rosalie Petersen Foundation (Dr Sorup); and the Novo Nordisk Foundation (research professorship grant [Dr Aaby]). Dr Benn holds a European Research Council (ERC) Starting Grant (ERC-StG-243149). The Danish National Research Foundation (DNRF) supports the Research Center for Vitamins and Vaccines (DNRF108).	Aaby P, 2006, VACCINE, V24, P2764, DOI 10.1016/j.vaccine.2006.01.004; AABY P, 1995, BRIT MED J, V311, P481, DOI 10.1136/bmj.311.7003.481; Aaby P, 2003, PEDIATR INFECT DIS J, V22, P798, DOI 10.1097/01.inf.0000083821.33187.b5; Aaby P, 2003, LANCET, V361, P2183, DOI 10.1016/S0140-6736(03)13771-3; Aaby P, 2003, INT J EPIDEMIOL, V32, P106, DOI 10.1093/ije/dyg005; Aaby P, 2007, PEDIATR INFECT DIS J, V26, P247, DOI 10.1097/01.inf.0000256735.05098.01; Aaby P, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000761; Aaby P, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000707; Aaby P, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e3769; Aaby P, 2011, J INFECT DIS, V204, P245, DOI 10.1093/infdis/jir240; Aaby P, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6495; Andersen JS, 2011, SCAND J PUBLIC HEALT, V39, P34, DOI 10.1177/1403494810394718; Andersen PK, 2002, STAT METHODS MED RES, V11, P91, DOI 10.1191/0962280202SM276ra; Austin PC, 2010, J CLIN EPIDEMIOL, V63, P46, DOI 10.1016/j.jclinepi.2009.03.012; Baadsgaard M, 2011, SCAND J PUBLIC HEALT, V39, P103, DOI 10.1177/1403494811405098; Benn CS, 2013, TRENDS IMMUNOL, V34, P431, DOI 10.1016/j.it.2013.04.004; Biering-Sorensen S, 2012, PEDIATR INFECT DIS J, V31, P306, DOI 10.1097/INF.0b013e3182458289; Carrillo-Santisteve P, 2012, CLIN MICROBIOL INFEC, V18, P50, DOI 10.1111/j.1469-0691.2012.03982.x; Cook R, 2007, STAT BIOL HEALTH, P161; Davis K, 2002, HEALTH POLICY, V59, P119, DOI 10.1016/S0168-8510(01)00202-0; Farrington CP, 2009, TROP MED INT HEALTH, V14, P977, DOI 10.1111/j.1365-3156.2009.02302.x; Frolich A, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-252; Garly ML, 2004, PEDIATR INFECT DIS J, V23, P1086, DOI 10.1097/01.inf.0000145700.77286.94; Hviid A, 2005, JAMA-J AM MED ASSOC, V294, P699, DOI 10.1001/jama.294.6.699; Jensen VM, 2011, SCAND J PUBLIC HEALT, V39, P91, DOI 10.1177/1403494810394715; Kamper-Jorgensen M, 2006, ARCH DIS CHILD, V91, P401, DOI 10.1136/adc.2005.085787; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Knudsen LB, 1998, DAN MED BULL, V45, P320; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Martins CL, 2014, J INFECT DIS, V209, P1731, DOI 10.1093/infdis/jit804; Mullooly JP, 2011, VACCINE, V29, P7611, DOI 10.1016/j.vaccine.2011.08.022; Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965; Roth AE, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c671; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Shann F, 2010, ARCH DIS CHILD, V95, P662, DOI 10.1136/adc.2009.157537; Stowe J, 2009, VACCINE, V27, P1422, DOI 10.1016/j.vaccine.2008.12.038; VANBALEN H, 1981, LANCET, V1, P764; Wojcik OP, 2013, VACCINE, V31, P955, DOI 10.1016/j.vaccine.2012.11.100	38	114	114	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	2014	311	8					826	835		10.1001/jama.2014.470	http://dx.doi.org/10.1001/jama.2014.470			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AB4XQ	24570246				2023-01-03	WOS:000331793700022
J	Morisaki, N; Belfort, MB; McCormick, MC; Mori, R; Noma, H; Kusuda, S; Fujimura, M				Morisaki, Naho; Belfort, Mandy B.; McCormick, Marie C.; Mori, Rintaro; Noma, Hisashi; Kusuda, Satoshi; Fujimura, Masanori		Neonatal Res Network Japan	Brief Parenteral Nutrition Accelerates Weight Gain, Head Growth Even in Healthy VLBWs	PLOS ONE			English	Article							LOW-BIRTH-WEIGHT; PRETERM INFANTS; PREMATURE-INFANTS; PROTEIN-INTAKE; OUTCOMES; MORBIDITY; MORTALITY; JAPAN; AGE; SUPPLEMENTATION	Introduction:Whether parenteral nutrition benefits growth of very low birth weight (VLBW) preterm infants in the setting of rapid enteral feeding advancement is unclear. Our aim was to examine this issue using data from Japan, where enteral feeding typically advances at a rapid rate. Methods: We studied 4005 hospitalized VLBW, very preterm (23-32 weeks' gestation) infants who reached full enteral feeding (100 ml/kg/day) by day 14, from 75 institutions in the Neonatal Research Network Japan (2003-2007). Main outcomes were weight gain, head growth, and extra-uterine growth restriction (EUGR, measurement,10 th percentile for postmenstrual age) at discharge. Results: 40% of infants received parenteral nutrition. Adjusting for maternal, infant, and institutional characteristics, infants who received parenteral nutrition had greater weight gain [0.09 standard deviation (SD), 95% CI: 0.02, 0.16] and head growth (0.16 SD, 95% CI: 0.05, 0.28); lower odds of EUGR by head circumference (OR 0.66, 95% CI: 0.49, 0.88). No statistically significant difference was seen in the proportion of infants with EUGR at discharge. SGA infants and infants who took more than a week until full feeding had larger estimates. Discussion: Even in infants who are able to establish enteral nutrition within 2 weeks, deprivation of parenteral nutrition in the first weeks of life could lead to under nutrition, but infants who reached full feeding within one week benefit least. It is important to predict which infants are likely or not likely to advance on enteral feedings within a week and balance enteral and parenteral nutrition for these infants.	[Morisaki, Naho; Mori, Rintaro; Noma, Hisashi] Natl Ctr Child Hlth & Dev, Dept Hlth Policy, Setagaya Ku, Tokyo, Japan; [Morisaki, Naho] Univ Tokyo, Dept Pediat, Bunkyo Ku, Tokyo, Japan; [Belfort, Mandy B.] Boston Childrens Hosp, Div Newborn Med, Boston, MA USA; [Belfort, Mandy B.] Harvard Univ, Sch Med, Boston, MA USA; [McCormick, Marie C.] Beth Israel Deaconess Med Ctr, Dept Neonatol, Boston, MA 02215 USA; [McCormick, Marie C.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Noma, Hisashi] Inst Stat Math, Dept Data Sci, Tachikawa, Tokyo, Japan; [Kusuda, Satoshi] Tokyo Womens Med Univ, Dept Neonatol, Maternal & Perinatal Ctr, Shinjuku Ku, Tokyo, Japan; [Fujimura, Masanori] Osaka Med Ctr & Res Inst Maternal & Child Hlth, Dept Neonatol, Osaka, Japan	National Center for Child Health & Development - Japan; University of Tokyo; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard T.H. Chan School of Public Health; Research Organization of Information & Systems (ROIS); Institute of Statistical Mathematics (ISM) - Japan; Tokyo Women's Medical University	Morisaki, N (corresponding author), Natl Ctr Child Hlth & Dev, Dept Hlth Policy, Setagaya Ku, Tokyo, Japan.	naho0330@gmail.com	Belfort, Mandy/AAN-2024-2021	Morisaki, Naho/0000-0001-6151-4513; Mori, Rintaro/0000-0001-7656-6156; Noma, Hisashi/0000-0002-2520-9949	Ministry of Health, Labor and Welfare [H22-JISEDAI-IPPAN-006]	Ministry of Health, Labor and Welfare(Ministry of Health, Labour and Welfare, Japan)	This study was funded by a Health Labor Sciences Research Grant by the Ministry of Health, Labor and Welfare, in 2004-2008(H22-JISEDAI-IPPAN-006). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aroor Amitha R, 2012, Sultan Qaboos Univ Med J, V12, P33; Belfort MB, 2013, NESTLE NUTR WORKS SE, V71, P171, DOI 10.1159/000342610; Belfort MB, 2011, PEDIATRICS, V128, pE899, DOI 10.1542/peds.2011-0282; Blanco CL, 2012, J PEDIATR GASTR NUTR, V54, P601, DOI 10.1097/MPG.0b013e31824887a0; Blanco CL, 2008, J PEDIATR-US, V153, P535, DOI 10.1016/j.jpeds.2008.04.059; Bombell S, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000504.pub3; Dinerstein A, 2006, J PERINATOL, V26, P436, DOI 10.1038/sj.jp.7211539; Dusick AM, 2003, SEMIN PERINATOL, V27, P302, DOI 10.1016/S0146-0005(03)00044-2; Ehrenkranz RA, 2006, PEDIATRICS, V117, P1253, DOI 10.1542/peds.2005-1368; Ehrenkranz RA, 2007, SEMIN PERINATOL, V31, P48, DOI 10.1053/j.semperi.2007.02.001; Ehrenkranz RA, 2011, PEDIATR RES, V69, P522, DOI 10.1203/PDR.0b013e318217f4f1; Ehrenkranz RA, 2010, EARLY HUM DEV, V86, pS21, DOI 10.1016/j.earlhumdev.2010.01.014; Higgins RD, 2012, J PEDIATR-US, V160, P511, DOI 10.1016/j.jpeds.2011.12.024; Horbar JD, 2002, PEDIATRICS, V110, P143, DOI 10.1542/peds.110.1.143; HUGHES CA, 1983, GUT, V24, P241, DOI 10.1136/gut.24.3.241; Isayama T, 2012, PEDIATRICS, V130, pE957, DOI 10.1542/peds.2012-0336; Janeiro P, 2010, EUR J PEDIATR, V169, P99, DOI 10.1007/s00431-009-0995-z; KENNEDY KA, 2000, COCHRANE DB SYST REV; Kono Y, 2008, PEDIATR INT, V50, P23, DOI 10.1111/j.1442-200X.2007.02516.x; Kono Y, 2011, PEDIATR INT, V53, P1051, DOI 10.1111/j.1442-200X.2011.03480.x; Kusuda S, 2006, PEDIATRICS, V118, pE1130, DOI 10.1542/peds.2005-2724; Kusuda S, 2012, PEDIATR RES, V72, P531, DOI 10.1038/pr.2012.114; Maggio L, 2007, J PEDIATR GASTR NUTR, V44, P124, DOI 10.1097/01.mpg.0000237927.00105.f7; Martin CR, 2009, PEDIATRICS, V124, P649, DOI 10.1542/peds.2008-3258; Moyses HE, 2013, AM J CLIN NUTR, V97, P816, DOI 10.3945/ajcn.112.042028; Poindexter BB, 2006, J PEDIATR-US, V148, P300, DOI 10.1016/j.jpeds.2005.10.038; Stephens BE, 2009, PEDIATRICS, V123, P1337, DOI 10.1542/peds.2008-0211; Trintis J, 2010, J PERINATOL, V30, P403, DOI 10.1038/jp.2009.173; Uehara R, 2011, J EPIDEMIOL, V21, P217, DOI 10.2188/jea.JE20100123; Uhing MR, 2009, CLIN PERINATOL, V36, P165, DOI 10.1016/j.clp.2008.09.010; Garcia LV, 2012, AN PEDIATR, V76, P127, DOI 10.1016/j.anpedi.2011.04.007; Yee WH, 2012, PEDIATRICS, V129, pE298, DOI 10.1542/peds.2011-2022	32	8	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2014	9	2							e88392	10.1371/journal.pone.0088392	http://dx.doi.org/10.1371/journal.pone.0088392			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AB3TA	24586323	Green Published, gold, Green Submitted			2023-01-03	WOS:000331711900027
J	Poonia, B; Pauza, CD				Poonia, Bhawna; Pauza, C. David			Levels of CD56+TIM-3-Effector CD8 T Cells Distinguish HIV Natural Virus Suppressors from Patients Receiving Antiretroviral Therapy	PLOS ONE			English	Article							KILLER NK CELLS; INFECTION; LYMPHOCYTES; EXPRESSION; RECEPTORS; CYTOTOXICITY; CD56; RECONSTITUTION; REPLICATION; CYTOKINES	Prolonged antiretroviral therapy (ART) with effective HIV suppression and reconstitution of CD4 T cells, fails to restore CD8 T cell lytic effector function that is needed to eradicate the viral reservoir. Better understanding of the phenotype and function of circulating CD8 cells in HIV patients will contribute to new targeted therapies directed at increasing CD8 T cell lytic effector function and destruction of the viral reservoir. We show that CD8 T cells from ART treated patients had sharply reduced expression of CD56 (neural cell adhesion molecule-1), a marker associated with cytolytic function whereas elite patients who control HIV in the absence of ART had CD56+ CD8 T cell levels similar to uninfected controls. The CD56+ CD8 T cells had higher perforin upregulation as well as degranulation following stimulation with HIV gag peptides compared with CD56 negative CD8 T cells. Elite patients had the highest frequencies of perforin producing CD56+ CD8 T cells among all HIV+ groups. In patients receiving ART we noted high levels of the exhaustion marker TIM-3 on CD56+ CD8 T cells, implying that defective effector function was related to immune exhaustion. CD56+ CD8 T cells from elite or treated HIV patients responded to PMA plus ionomycin stimulation, and expressed transcription factors T-bet and EOMES at levels similar to uninfected controls. Consequently, the lytic effector defect in chronic HIV disease is due to immune exhaustion and quantitative loss of CD56+ CD8 T cells and this defect is not repaired in patients where viremia is suppressed and CD4 T cells are recovered after ART. Reconstituting the cytotoxic CD56+ subset of CD8+ T cells through new interventions might improve the lytic effector capacity and contribute to reducing the viral reservoir. Our initial studies indicate that IL-15 treatment partly reverses the CD56 defect, implying that myeloid cell defects could be targeted for immune therapy during chronic HIV disease.	[Poonia, Bhawna; Pauza, C. David] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Poonia, B (corresponding author), Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA.	bpoonia@ihv.umaryland.edu		Poonia, Bhawna/0000-0001-9640-0524	Institute of Human Virology Institutional Grant [2010-01]; Public Health Services grant [AI42458]	Institute of Human Virology Institutional Grant; Public Health Services grant(United States Department of Health & Human ServicesUnited States Public Health Service)	This work was supported by Institute of Human Virology Institutional Grant 2010-01 (BP) and Public Health Services grant AI42458 (CDP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexander AAZ, 2008, CLIN CANCER RES, V14, P4232, DOI 10.1158/1078-0432.CCR-07-4912; Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63; BARTSCH U, 1990, J NEUROCYTOL, V19, P550, DOI 10.1007/BF01257243; Boudova S, 2012, J INFECT DIS, V205, P1448, DOI 10.1093/infdis/jis217; Brunetta E, 2009, BLOOD, V114, P3822, DOI 10.1182/blood-2009-06-226332; Chaudhry S, 2013, AIDS; Correia MP, 2011, IMMUNOBIOLOGY, V216, P604, DOI 10.1016/j.imbio.2010.09.012; Crawford TQ, 2011, J VIROL, V85, P12343, DOI 10.1128/JVI.05682-11; Cummings JS, 2008, J LEUKOCYTE BIOL, V84, P371, DOI 10.1189/jlb.1207847; De Maria A, 2003, EUR J IMMUNOL, V33, P2410, DOI 10.1002/eji.200324141; De Smedt M, 2007, BLOOD, V110, P2696, DOI 10.1182/blood-2007-03-082206; Fauci AS, 2005, NAT REV IMMUNOL, V5, P835, DOI 10.1038/nri1711; Finney CA, 2013, J ACQUIR IMMUNE DEFI; Hardy G, 2004, HIV MED, V5, P67, DOI 10.1111/j.1468-1293.2004.00187.x; Hay CM, 1999, J VIROL, V73, P5509, DOI 10.1128/JVI.73.7.5509-5519.1999; Hersperger AR, 2011, BLOOD, V117, P3799, DOI 10.1182/blood-2010-12-322727; Hersperger AR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000917; Hirsch HH, 2004, CLIN INFECT DIS, V38, P1159, DOI 10.1086/383034; Hong JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060186; Hou W, 2012, J LEUKOCYTE BIOL, V92, P343, DOI 10.1189/jlb.0312146; Intlekofer AM, 2008, SCIENCE, V321, P408, DOI 10.1126/science.1159806; Jones RB, 2008, J EXP MED, V205, P2763, DOI 10.1084/jem.20081398; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; Killian MS, 2011, J VIROL, V85, P1696, DOI 10.1128/JVI.01120-10; Lopez M, 2008, AIDS RES; Lopez M, 2008, EUR J IMMUNOL, V38, P1548, DOI 10.1002/eji.200738054; Mavilio D, 2005, P NATL ACAD SCI USA, V102, P2886, DOI 10.1073/pnas.0409872102; Mavilio D, 2003, P NATL ACAD SCI USA, V100, P15011, DOI 10.1073/pnas.2336091100; Migueles SA, 2008, IMMUNITY, V29, P1009, DOI 10.1016/j.immuni.2008.10.010; Mueller YM, 2003, BLOOD, V101, P1024, DOI 10.1182/blood-2002-07-1957; O'Connell KA, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-63; Pittet MJ, 2000, J IMMUNOL, V164, P1148, DOI 10.4049/jimmunol.164.3.1148; Quiros-Roldan E, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-94; Rangachari M, 2012, NAT MED, V18, P1394, DOI 10.1038/nm.2871; Ribeiro-dos-Santos P, 2012, BLOOD, V119, P4928, DOI 10.1182/blood-2011-12-395186; Riedel DJ, 2009, AIDS, V23, P1955, DOI 10.1097/QAD.0b013e32832ff1ff; Rosenberg ES, 1999, IMMUNOL LETT, V66, P89, DOI 10.1016/S0165-2478(98)00165-5; Santin AD, 2001, CLIN CANCER RES, V7, p804S; Scott-Algara D, 2005, J CLIN IMMUNOL, V25, P57, DOI 10.1007/s10875-005-0358-3; Sondergaard SR, 1999, CELL IMMUNOL, V197, P91, DOI 10.1006/cimm.1999.1565; SPITS H, 1995, BLOOD, V85, P2654, DOI 10.1182/blood.V85.10.2654.bloodjournal85102654; Takasaki S, 2000, CELL BIOL INT, V24, P101, DOI 10.1006/cbir.1999.0457; Tarazona R, 2002, J CLIN IMMUNOL, V22, P176, DOI 10.1023/A:1015476114409; Tarazona R, 2002, AIDS, V16, P197, DOI 10.1097/00002030-200201250-00008; Trabattoni D, 2004, AIDS, V18, P859, DOI 10.1097/00002030-200404090-00003; Trabattoni D, 2002, J BIOL REG HOMEOS AG, V16, P25; Trimble LA, 2000, J VIROL, V74, P7320, DOI 10.1128/JVI.74.16.7320-7330.2000; Xu HB, 2012, FASEB J, V26, P2294, DOI 10.1096/fj.11-195180; Yan JY, 2013, J VIROL, V87, P5170, DOI 10.1128/JVI.02379-12	50	16	16	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2014	9	2							e88884	10.1371/journal.pone.0088884	http://dx.doi.org/10.1371/journal.pone.0088884			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7CL	24520422	Green Published, Green Submitted, gold			2023-01-03	WOS:000331254600113
J	de Mello, RA; Geros, S; Alves, MP; Moreira, F; Avezedo, I; Dinis, J				de Mello, Ramon Andrade; Geros, Sandra; Alves, Marcos Pantarotto; Moreira, Filipa; Avezedo, Isabel; Dinis, Jose			Cetuximab Plus Platinum-Based Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Retrospective Study in a Single Comprehensive European Cancer Institution	PLOS ONE			English	Article							GROWTH-FACTOR RECEPTOR; PHASE-II MULTICENTER; 1ST-LINE TREATMENT; ANTIBODY CETUXIMAB; INDUCED NAUSEA; RECURRENT; ASSOCIATION; CISPLATIN; POLYMORPHISM; COMBINATION	Background: The use of cetuximab in combination with platinum (P) plus 5-fluorouracil (F) has previously been demonstrated to be effective in the treatment of metastatic squamous cell cancer of head and neck (SCCHN). We investigated the efficacy and outcome of this protocol as a first-line treatment for patients with recurrent or metastatic disease. We evaluated overall-survival (OS), progression-free-survival (PFS), overall response rate (ORR) and the treatment toxicity profile in a retrospective cohort. Patients and Methods: This study enrolled 121 patients with untreated recurrent or metastatic SCCHN. The patients received PF+ cetuximab every 3 weeks for a maximum of 6 cycles. Patients with stable disease who received PF+ cetuximab continued to receive cetuximab until disease progressed or unacceptable toxic effects were experienced, whichever occurred first. Results: The median patient age was 53 (37-78) years. The patient cohort was 86.8% male. The addition of cetuximab to PF in the recurrent or metastatic setting provided an OS of 11 months (Confidential Interval, CI, 95%, 8.684-13.316) and PFS of 8 months (CI 95%, 6.051-9.949). The disease control rate was 48.9%, and the ORR was 23.91%. The most common grade 3 or 4 adverse events in the PF+ cetuximab regimen were febrile neutropenia (5.7%), skin rash (3.8%) and mucosistis (3.8%). Conclusions: The results of this study suggest that cetuximab plus platinum-fluorouracil chemotherapy is a good option for systemic treatment in advanced SSCHN patients. This regimen has a well-tolerated toxicity profile.	[de Mello, Ramon Andrade; Alves, Marcos Pantarotto; Avezedo, Isabel; Dinis, Jose] Portuguese Oncol Inst, Head & Neck Unit, Dept Med Oncol, Oporto, Portugal; [de Mello, Ramon Andrade] Univ Algarve, Dept Med & Biomed Sci, Sch Med, Faro, Portugal; [de Mello, Ramon Andrade; Moreira, Filipa] Univ Porto, Dept Med, Fac Med, P-4100 Oporto, Portugal; [Geros, Sandra] Portuguese Oncol Inst, Head & Neck Unit, Serv Otorhinolaryngol, Oporto, Portugal; [Geros, Sandra] Ctr Hosp Vila Nova de Gaia Espinho, Dept Otorhinolaryngol & Cerv Facial Surg, Vila Nova De Gaia, Portugal	Portuguese Institute of Oncology; Universidade do Algarve; Universidade do Porto; Portuguese Institute of Oncology	de Mello, RA (corresponding author), Portuguese Oncol Inst, Head & Neck Unit, Dept Med Oncol, Oporto, Portugal.	ramondemello@gmail.com	De+Mello, Ramon Andrade/ABG-4463-2020	De+Mello, Ramon Andrade/0000-0002-9640-4573; Pantarotto, Marcos/0000-0002-7863-8069				Araujo AP, 2011, WORLD J GASTROENTERO, V17, P488, DOI 10.3748/wjg.v17.i4.488; Argiris A, 2013, ANN ONCOL, V24, P220, DOI 10.1093/annonc/mds245; Barroso S, 2008, ACTA MEDICA PORT, V21, P7; Baselga J, 2005, J CLIN ONCOL, V23, P5568, DOI 10.1200/JCO.2005.07.119; Brand TM, 2013, RADIOTHER ONCOL, V13, pS0167; Burtness B, 2005, J CLIN ONCOL, V23, P8646, DOI 10.1200/JCO.2005.02.4646; Burtness B, 2013, LANCET ONCOL, V14, pE302, DOI 10.1016/S1470-2045(13)70085-8; Celio L, 2013, PATIENT PREFER ADHER, V7, P391, DOI 10.2147/PPA.S31288; Clark JI, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0358-x; Cohen EEW, 2006, J CLIN ONCOL, V24, P2659, DOI 10.1200/JCO.2005.05.4577; Cohen EEW, 2009, LANCET ONCOL, V10, P247, DOI 10.1016/S1470-2045(09)70002-6; Cortinovis D, 2013, TUMORI J, V99, P45, DOI 10.1700/1248.13787; Costa BM, 2007, CLIN CANCER RES, V13, P2621, DOI 10.1158/1078-0432.CCR-06-2606; De Mello RA, 2012, CLINICS, V67, P1349, DOI 10.6061/clinics/2012(11)22; de Mello RA, 2012, TUMOR BIOL, V33, P1341, DOI 10.1007/s13277-012-0382-7; de Mello RA, 2011, WORLD J CLIN ONCOL, V2, P367, DOI 10.5306/wjco.v2.i11.367; De Oliveira MG, 2012, MOL MED REP, V6, P163, DOI 10.3892/mmr.2012.876; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Flowers CR, 2013, J CLIN ONCOL, V31, P794, DOI 10.1200/JCO.2012.45.8661; Freifeld AG, 2011, CLIN INFECT DIS, V52, pE56, DOI 10.1093/cid/cir073; Goodwin WJ, 2000, LARYNGOSCOPE, V110, P1, DOI 10.1097/00005537-200003001-00001; Gregoire V, 2010, ANN ONCOL, V21, pv184, DOI 10.1093/annonc/mdq185; Grunberg S, 2011, J CLIN ONCOL, V29, P1495, DOI 10.1200/JCO.2010.31.7859; Haddad R, 2003, ONCOLOGIST, V8, P35, DOI 10.1634/theoncologist.8-1-35; Herbst RS, 2005, J CLIN ONCOL, V23, P5578, DOI 10.1200/JCO.2005.07.120; Hesketh PJ, 2008, NEW ENGL J MED, V358, P2482, DOI 10.1056/NEJMra0706547; Hitt R, 2012, ANN ONCOL, V23, P1016, DOI 10.1093/annonc/mdr367; Ho AS, 2013, HEAD NECK; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Link H, 2013, ONKOLOGIE, V36, P266, DOI 10.1159/000350306; Lynch TJ, 2010, J CLIN ONCOL, V28, P911, DOI 10.1200/JCO.2009.21.9618; Massa E, 2010, ORAL ONCOL, V46, P818, DOI 10.1016/j.oraloncology.2010.08.013; Mesia R, 2010, ANN ONCOL, V21, P1967, DOI 10.1093/annonc/mdq077; PIZZO PA, 1993, NEW ENGL J MED, V328, P1323; Shahbazi M, 2002, LANCET, V359, P397, DOI 10.1016/S0140-6736(02)07600-6; Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656; Vermorken JB, 2007, NEW ENGL J MED, V357, P1695, DOI 10.1056/NEJMoa071028; Yoshino T, 2013, JPN J CLIN ONCOL, V43, P524, DOI 10.1093/jjco/hyt034; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X	39	29	29	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2014	9	2							e86697	10.1371/journal.pone.0086697	http://dx.doi.org/10.1371/journal.pone.0086697			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA1BH	24516537	Green Published, Green Submitted, gold			2023-01-03	WOS:000330830700012
J	Kirschner, N; Ginsburg, J; Sulmasy, LS				Kirschner, Neil; Ginsburg, Jack; Sulmasy, Lois Snyder		Hlth Public Policy Comm Amer Coll	Prescription Drug Abuse: Executive Summary of a Policy Position Paper From the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Review							PAIN		[Kirschner, Neil; Ginsburg, Jack; Sulmasy, Lois Snyder] Amer Coll Physicians, Philadelphia, PA USA	American College of Physicians	Kirschner, N (corresponding author), Amer Coll Physicians, 25 Massachusetts Ave NW,Suite 700, Washington, DC 20001 USA.	nkirschner@acponline.org		Arora, Vineet/0000-0002-4745-7599				Centers for Disease Control and Prevention, 2013, OP DRIV CONT INCR DR; Centers for Disease Control and Prevention, 2010, NSDUH SER H; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Furrow BR, 2001, J LAW MED ETHICS, V29, P28; Girion Lisa, 2012, LOS ANGELES TIMES; Government Accountability Office, 2011, GAO12115; Institute of Medicine, 2011, REL PAIN AM BLUEPR T; Lembke A, 2012, NEW ENGL J MED, V367, P1580, DOI 10.1056/NEJMp1208498; National Institute of Drug Abuse, 2011, COMM AB PRESCR DRUGS; National Institute on Drug Abuse, 2013, TOP BRIEF DRUG AB PR; National Institute on Drug Abuse, 2011, RES REP PRESCR DRUGS; Partnership for a Drug-Free America and MetLife Foundation, 2011, 2010 PARTN ATT TRACK; Snyder L, 2012, ANN INTERN MED, V156, DOI 10.7326/0003-4819-156-1-201201031-00001; Substance Abuse and Mental Health Services Administration, 2011, NSDUH SER H	14	48	48	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 4	2014	160	3					198	+		10.7326/M13-2209	http://dx.doi.org/10.7326/M13-2209			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AA2VE	24323199				2023-01-03	WOS:000330951500007
J	Almeida, ICT; Soares, M; Bozza, FA; Shinotsuka, CR; Bujokas, R; Souza-Dantas, VC; Ely, EW; Salluh, JIF				Almeida, Isabel C. T.; Soares, Marcio; Bozza, Fernando A.; Shinotsuka, Cassia Righy; Bujokas, Renata; Souza-Dantas, Vicente Ces; Ely, E. Wesley; Salluh, Jorge I. F.			The Impact of Acute Brain Dysfunction in the Outcomes of Mechanically Ventilated Cancer Patients	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; CONFUSION ASSESSMENT METHOD; DELIRIUM; ICU; RELIABILITY; ADMISSION; SEDATION; VALIDITY; TRIAL	Introduction: Delirium and coma are a frequent source of morbidity for ICU patients. Several factors are associated with the prognosis of mechanically ventilated (MV) cancer patients, but no studies evaluated delirium and coma (acute brain dysfunction). The present study evaluated the frequency and impact of acute brain dysfunction on mortality. Methods: The study was performed at National Cancer Institute, Rio de Janeiro, Brazil. We prospectively enrolled patients ventilated >48 h with a diagnosis of cancer. Acute brain dysfunction was assessed during the first 14 days of ICU using RASS/CAM-ICU. Patients were followed until hospital discharge. Univariate and multivariable analysis were performed to evaluate factors associated with hospital mortality. Results: 170 patients were included. 73% had solid tumors, age 65 [53-72 (median, IQR 25%-75%)] years. SAPS II score was 54[46-63] points and SOFA score was (7 [6-9]) points. Median duration of MV was 13 (6-21) days and ICU stay was 14 (7.5-22) days. ICU mortality was 54% and hospital mortality was 66%. Acute brain dysfunction was diagnosed in 161 patients (95%). Survivors had more delirium/coma-free days [4(1,5-6) vs 1(0-2), p<0.001]. In multivariable analysis the number of days of delirium/coma-free days were associated with better outcomes as they were independent predictors of lower hospital mortality [0.771 (0.681 to 0.873), p<0.001]. Conclusions: Acute brain dysfunction in MV cancer patients is frequent and independently associated with increased hospital mortality. Future studies should investigate means of preventing or mitigating acute brain dysfunction as they may have a significant impact on clinical outcomes.	[Almeida, Isabel C. T.; Soares, Marcio; Shinotsuka, Cassia Righy; Bujokas, Renata; Souza-Dantas, Vicente Ces; Salluh, Jorge I. F.] Inst Nacl Canc, Intens Care Unit, Rio De Janeiro, Brazil; [Almeida, Isabel C. T.; Soares, Marcio; Shinotsuka, Cassia Righy; Bujokas, Renata; Souza-Dantas, Vicente Ces; Salluh, Jorge I. F.] Inst Nacl Canc, Postgrad Program, Rio De Janeiro, Brazil; [Soares, Marcio; Bozza, Fernando A.; Shinotsuka, Cassia Righy; Salluh, Jorge I. F.] DOr Inst Res & Educ, Rio De Janeiro, Brazil; [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Intens Care Lab, IPEC, Rio De Janeiro, Brazil; [Ely, E. Wesley] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Ely, E. Wesley] Vet Affairs Tennessee Valley Geriatr Res Educ Cli, Nashville, TN USA	National Cancer Institute (Inca); National Cancer Institute (Inca); IDOR - Instituto D'Or de Ensino e Pesquisa; Fundacao Oswaldo Cruz; Vanderbilt University; Geriatric Research Education & Clinical Center	Salluh, JIF (corresponding author), Inst Nacl Canc, Intens Care Unit, Rio De Janeiro, Brazil.	jorgesalluh@gmail.com	Shinotsuka, Cássia Righy/H-9181-2013; Ely, E. Wesley/Z-2018-2019; Salluh, Jorge/AAF-2682-2021; Almeida, Igor C./AAF-9409-2019; dantas, vicente c souza/L-2648-2013; Soares, Marcio/B-3083-2013; Bozza, Fernando A/A-2618-2013	Shinotsuka, Cássia Righy/0000-0002-9206-9552; Ely, E. Wesley/0000-0003-3957-2172; Salluh, Jorge/0000-0002-8164-1453; Almeida, Igor C./0000-0002-2443-8213; Soares, Marcio/0000-0003-2503-6088; Bozza, Fernando A/0000-0003-4878-0256	CNPq; FAPERJ	CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPERJ(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ))	MS and JIFS received individual research grants from CNPq and FAPERJ, Brazilian governmental agencies for research funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Azoulay E, 2004, MEDICINE, V83, P360, DOI 10.1097/01.md.0000145370.63676.fb; Azoulay E, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-5; Caraceni A, 2000, CANCER-AM CANCER SOC, V89, P1145, DOI 10.1002/1097-0142(20000901)89:5<1145::AID-CNCR24>3.0.CO;2-X; Clegg A, 2011, AGE AGEING, V40, P23, DOI 10.1093/ageing/afq140; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; Gusmao-Flores D, 2012, CRIT CARE, V16, DOI 10.1186/cc11407; Gusmao-Flores D, 2011, CLINICS, V66, P1917, DOI 10.1590/S1807-59322011001100011; JJS MD, 2012, BEST PRACT RES CLIN, V26, P327, DOI [10.1016/j.bpa.2012.08.003., DOI 10.1016/J.BPA.2012.08.003]; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Lawlor PG, 2000, ARCH INTERN MED, V160, P786, DOI 10.1001/archinte.160.6.786; Lecuyer L, 2007, CRIT CARE MED, V35, P808, DOI 10.1097/01.CCM.0000256846.27192.7A; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; MD GM, 2012, BEST PRACT RES CLIN, V26, P311, DOI [10.1016/j.bpa.2012.07.001., DOI 10.1016/J.BPA.2012.07.001]; Milbrandt EB, 2004, CRIT CARE MED, V32, P955, DOI 10.1097/01.CCM.0000119429.16055.92; Neufeld KJ, 2011, PSYCHOSOMATICS, V52, P133, DOI 10.1016/j.psym.2010.12.018; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Rosolem M, 2009, CRIT CARE, V13, pP56, DOI [10.1186/cc7858., DOI 10.1186/CC7858]; Saczynski JS, 2012, NEW ENGL J MED, V367, P30, DOI 10.1056/NEJMoa1112923; Salluh JI, 2010, CRIT CARE, V14, DOI 10.1186/cc9333; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Soares M, 2005, CRIT CARE MED, V33, P520, DOI 10.1097/01.ccm.0000155783.46747.04; Soares M, 2010, INTENS CARE MED, V36, P1188, DOI 10.1007/s00134-010-1807-7; Soares M, 2010, CRIT CARE CLIN, V26, P41, DOI 10.1016/j.ccc.2009.09.005; Soares M, 2010, CRIT CARE MED, V38, P9, DOI 10.1097/CCM.0b013e3181c0349e; Taccone FS, 2009, CRIT CARE, V13, DOI 10.1186/cc7713; Takeuchi M, 2012, ANN SURG ONCOL, V19, P3963, DOI 10.1245/s10434-012-2432-1; Thiery G, 2005, J CLIN ONCOL, V23, P4406, DOI 10.1200/JCO.2005.01.487	32	20	24	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2014	9	1							e85332	10.1371/journal.pone.0085332	http://dx.doi.org/10.1371/journal.pone.0085332			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297VL	24465538	gold, Green Published, Green Submitted			2023-01-03	WOS:000330283100037
J	Zhang, HJ; Liu, X; Liu, YB; Wu, Y; Li, HX; Zhao, CB; Li, HZ; Meng, QG; Li, W				Zhang, Hanjun; Liu, Xing; Liu, Youbin; Wu, Yin; Li, Hongxi; Zhao, Chengbin; Li, Huazhe; Meng, Qinggang; Li, Wei			Effect of Hematoporphyrin Monomethyl Ether-Sonodynamic Therapy (HMME-SDT) on Hypertrophic Scarring	PLOS ONE			English	Article							CELLS	Objective: The aim of the present study was to explore the potential for hematoporphyrin monomethyl ether-Sonodynamic Therapy (HMME-SDT) treatment of hypertrophic scars within rabbit ears. Methods: 60 white rabbits were randomly divided into five groups: 1) untreated controls, 2) lesioned, 3) lesioned + HMME, 4) lesioned + US (Ultrasound), and 5) lesioned + HMME-SDT. After induction of a lesion upon the ears of the rabbits, hypertrophic scars were assessed at 14, 28, 42 and 56 days post-lesion +/- treatment. Assessments consisted of visual inspection in the change of the skin, scar formation pathological morphology by hematoxylin and eosin (HE) staining technique with optical microscopy, calculation of a hypertrophic index, fibroblastic density measures, and observation of collagen changes in the scar tissue by Van Gieson's (VG) Stain along with calculation of collagen area density. Results: With continued HMME-SDT treatment there was a gradual improvement in all parameters over the duration of the experiment. The lesion-induced scars of rabbits receiving HMME-SDT treatment were soft, the size was reduced, hyperplasia was flat and the color pale. The fibroblasts and collagens were reduced and the collagens were light red, sparse and orderly. The hypertrophic index was reduced, since the fibroblastic density was lowered and collagen area density was decreased. Conclusion: HMME is an effective sonosensitizer and the combination of HMME-SDT treatment can exert significant benefits in reducing the formation of hypertrophic scars.	[Zhang, Hanjun; Liu, Xing; Liu, Youbin; Wu, Yin; Li, Hongxi; Zhao, Chengbin; Li, Huazhe; Li, Wei] Harbin Med Univ, Dept Orthopaed Surg, Harbin, Peoples R China; [Meng, Qinggang] First Hosp Harbin City, Dept Orthopaed Surg, Harbin, Peoples R China	Harbin Medical University	Zhao, CB (corresponding author), Harbin Med Univ, Dept Orthopaed Surg, Harbin, Peoples R China.	Zhaochengbin9129@126.com; mengqinggang2009@126.com; liwei9129@126.com			Heilongjiang Provincial Health Bureau [2012-690, 2012-726]; Heilongjiang Province traditional Chinese medical science Bureau [zh1112-z177]; Heilongjiang province science and technology plan and technological project [GC10C303-4]; Harbin technological innovative personnel and special fund project [2012RFXXS066]	Heilongjiang Provincial Health Bureau; Heilongjiang Province traditional Chinese medical science Bureau; Heilongjiang province science and technology plan and technological project; Harbin technological innovative personnel and special fund project	This work is supported in part by funding from Heilongjiang Provincial Health Bureau funding: (2012-690, 2012-726), Heilongjiang Province traditional Chinese medical science Bureau (zh1112-z177), Heilongjiang province science and technology plan and technological project (GC10C303-4), Harbin technological innovative personnel and special fund project (2012RFXXS066). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Branski LK, 2012, CHIRURG, V83, P831, DOI 10.1007/s00104-011-2243-0; Furusawa Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029012; Lee JH, 2012, PHYTOMEDICINE, V19, P1223, DOI 10.1016/j.phymed.2012.08.002; Li W, 2014, ZHONGHUA SH IN PRESS; Li YX, 2012, ULTRASONICS, V52, P490, DOI 10.1016/j.ultras.2011.10.013; Liu H, 2012, Biomed Opt Express, V3, P3278, DOI 10.1364/BOE.3.003278; Lv Y, 2012, CELLULAR PHYSL BIOCH, V30, DOI [10.1159/000339067, DOI 10.1159/000339067.PMID:22739213]; Morris DE, 1997, PLAST RECONSTR SURG, V100, P674, DOI 10.1097/00006534-199709000-00021; Nomikou N, 2012, CHEMMEDCHEM, V7, P1465, DOI 10.1002/cmdc.201200233; Stewart TL, 2012, J BURN CARE RES, V33, P764, DOI 10.1097/BCR.0b013e318257db36; Tang W, 2011, ULTRASONICS, V51, P777, DOI 10.1016/j.ultras.2011.02.008; Yang JY, 2012, ANN PLASTIC SURG, V69, DOI [10.1097/SAP.0b013e318274d876, DOI 10.1097/SAP.0B013E318274D876.PMID:23154335]	12	8	10	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2014	9	1							e86003	10.1371/journal.pone.0086003	http://dx.doi.org/10.1371/journal.pone.0086003			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297GT	24465834	Green Published, Green Submitted, gold			2023-01-03	WOS:000330244500163
J	Boufassa, F; Lechenadec, J; Meyer, L; Costagliola, D; Hunt, PW; Pereyra, F; Deeks, S; Pancino, G; Taulera, O; Lichterfeld, M; Delobel, P; Saez-Cirion, A; Lambotte, O				Boufassa, Faroudy; Lechenadec, Jerome; Meyer, Laurence; Costagliola, Dominique; Hunt, Peter W.; Pereyra, Florencia; Deeks, Steve; Pancino, Gianfranco; Taulera, Olivier; Lichterfeld, Mathias; Delobel, Pierre; Saez-Cirion, Asier; Lambotte, Olivier		ANRS CO18 HIV Controllers Cohort; Cascade Collaboration Eurocoord; SCOPE Cohort; Int HIV Controllers Study	Blunted Response to Combination Antiretroviral Therapy in HIV Elite Controllers: An International HIV Controller Collaboration	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LOW-LEVEL VIREMIA; CD4 CELL COUNTS; DISEASE PROGRESSION; VIRAL SUPPRESSION; ABSENCE; INFECTION; INDIVIDUALS; REPLICATION; COINFECTION	Objective: HIV "elite controllers'' (ECs) spontaneously control viral load, but some eventually require combination antiretroviral treatment (cART), due to a loss of viral control or a decline in CD4 T-cell counts. Here we studied the CD4 T-cell count dynamics after cART initiation among 34 ECs followed in U.S. and European cohorts, by comparison with chronically viremic patients (VIRs). Methods: ECs were defined as patients with at least >= 5 viral load (VL) measurements below 400 copies/mL during at least a 5-year period despite never receiving ART and were selected from the French ANRS CO18 cohort, the U.S. SCOPE cohort, the International HIV Controllers study and the European CASCADE collaboration. VIRs were selected from the ANRS COPANA cohort of recently-diagnosed (< 1 year) ART-naive HIV-1-infected adults. CD4 T-cell count dynamics after cART initiation in both groups were modelled with piecewise mixed linear models. Results: After cART initiation, CD4 T-cell counts showed a biphasic rise in VIRs with: an initial rapid increase during the first 3 months (+0.63 root CD4/month), followed by +0.19 root CD4/month. This first rapid phase was not observed in ECs, in whom the CD4Tc count increased steadily, at a rate similar to that of the second phase observed in VIRs. After cART initiation at a CD4 T-cell count of 300/mm(3), the estimated mean CD4 T-cell gain during the first 12 months was 139/mm(3) in VIRs and 80/mm(3) in ECs (p = 0.048). Conclusions: cART increases CD4 T-cell counts in elite controllers, albeit less markedly than in other patients.	[Boufassa, Faroudy; Meyer, Laurence] CESP Ctr Res Epidemiol & Populat Hlth, INSERM, Epidemiol HIV & STI Team, Le Kremlin Bicetre, France; [Boufassa, Faroudy; Lechenadec, Jerome; Meyer, Laurence] Univ Paris 11, Le Kremlin Bicetre, France; [Meyer, Laurence] Hop Bicetre, AP HP, Serv Sante Publ, Le Kremlin Bicetre, France; [Costagliola, Dominique] Univ Paris 06, Paris, France; [Costagliola, Dominique] INSERM, Paris, France; [Hunt, Peter W.; Deeks, Steve] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Hunt, Peter W.; Deeks, Steve] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA; [Hunt, Peter W.; Deeks, Steve] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA; [Pereyra, Florencia] Massachusetts Gen Hosp, Ragon Inst, MIT, Cambridge, MA USA; [Pereyra, Florencia] Harvard Univ, Cambridge, MA 02138 USA; [Taulera, Olivier] Hop St Louis, Paris, France; [Lichterfeld, Mathias] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; [Delobel, Pierre] Hop Purpan, Serv Malad Infect & Trop, Toulouse, France; [Delobel, Pierre] Fac Med Toulouse, INSERM, F-31073 Toulouse, France; [Saez-Cirion, Asier] Inst Pasteur, Unite Regulat Infect Retrovirales, Paris, France; [Lambotte, Olivier] Hop Bicetre, AP HP, Serv Med Interne, Le Kremlin Bicetre, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Harvard University; Massachusetts General Hospital; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Boufassa, F (corresponding author), CESP Ctr Res Epidemiol & Populat Hlth, INSERM, Epidemiol HIV & STI Team, Le Kremlin Bicetre, France.	faroudy.boufassa@inserm.fr	Hunt, Peter W./P-2976-2017; Lambotte, Olivier/GRT-0160-2022; Costagliola, Dominique/H-5849-2011; Lichterfeld, Mathias/B-2042-2008; Delobel, Pierre/Q-6028-2019; Delobel, Pierre/K-3166-2014; Saez-Cirion, Asier/A-8640-2008	Hunt, Peter W./0000-0002-4571-4870; Costagliola, Dominique/0000-0003-0765-0869; Lichterfeld, Mathias/0000-0001-9865-8350; Delobel, Pierre/0000-0002-2874-3581; Delobel, Pierre/0000-0002-2874-3581; Saez-Cirion, Asier/0000-0003-2406-7536; Deeks, Steven/0000-0001-6371-747X; Hladek, Melissa/0000-0002-0625-2474	ANRS (Agence nationale de recherches sur le sida et les hepatites virales); European Union under EuroCoord [260694]; Bill and Melinda Gates Foundation; Harvard University Center for AIDS Research [P-30-AI060354]; National Institutes of Health/National Institute of Allergy and Infectious Diseases [P30 AI027763]; AIDS Healthcare Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI060354, P30AI027763] Funding Source: NIH RePORTER	ANRS (Agence nationale de recherches sur le sida et les hepatites virales)(ANRSFrench National Research Agency (ANR)); European Union under EuroCoord; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Harvard University Center for AIDS Research; National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); AIDS Healthcare Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The ANRS CO18 HIV Controllers Cohort was funded by ANRS (Agence nationale de recherches sur le sida et les hepatites virales). The CASCADE Collaboration has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under EuroCoord grant agreement n<SUP>o</SUP> 260694. The Bill and Melinda Gates Foundation, AIDS Healthcare Foundation and Harvard University Center for AIDS Research (P-30-AI060354) for The International HIV Controllers Study and the SCOPE Cohort is supported by a grant from the National Institutes of Health/National Institute of Allergy and Infectious Diseases: P30 AI027763. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Bailey JR, 2006, J EXP MED, V203, P1357, DOI 10.1084/jem.20052319; Blankson JN, 2007, J VIROL, V81, P2508, DOI 10.1128/JVI.02165-06; Bosch RJ, 2006, JAIDS-J ACQ IMM DEF, V43, P433, DOI 10.1097/01.qai.0000243097.27029.b7; De Luca A, 2002, ARCH INTERN MED, V162, P2125, DOI 10.1001/archinte.162.18.2125; Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010; Grabar S, 2004, AIDS, V18, P2029, DOI 10.1097/00002030-200410210-00007; Greub G, 2000, LANCET, V356, P1800, DOI 10.1016/S0140-6736(00)03232-3; Hatano H, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003691; Hatano H, 2009, J VIROL, V83, P329, DOI 10.1128/JVI.01763-08; Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143; Hunt PW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015924; Hunt PW, 2003, AIDS, V17, P1907, DOI 10.1097/00002030-200309050-00009; Lambotte O, 2005, CLIN INFECT DIS, V41, P1053, DOI 10.1086/433188; Lifson AR, 2011, AIDS RES THER, V8, DOI 10.1186/1742-6405-8-2; Madec Y, 2005, AIDS, V19, P2001, DOI 10.1097/01.aids.0000194134.28135.cd; Madec Y, 2013, AIDS, V27, P2451, DOI 10.1097/01.aids.0000431945.72365.01; Mocroft A, 2013, CLIN INFECT DIS, V57, P1038, DOI 10.1093/cid/cit423; Okulicz JF, 2010, CLIN INFECT DIS, V50, P1187, DOI 10.1086/651421; Okulicz JF, 2009, J INFECT DIS, V200, P1714, DOI 10.1086/646609; Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786; Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271; Pereyra F, 2009, J INFECT DIS, V200, P984, DOI 10.1086/605446; Rockstroh JK, 2005, J INFECT DIS, V192, P992, DOI 10.1086/432762; Saez-Cirion A, 2007, TRENDS IMMUNOL, V28, P532, DOI 10.1016/j.it.2007.09.002; Saez-Cirion A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003211; Sajadi MM, 2012, AIDS, V26, P1879, DOI 10.1097/QAD.0b013e328357f5d1; Sauce D, 2011, BLOOD, V117, P5142, DOI 10.1182/blood-2011-01-331306; Smith CJ, 2004, J INFECT DIS, V190, P1860, DOI 10.1086/425075; Toulowni G, 2008, JAIDS-J ACQ IMM DEF, V49, P492, DOI 10.1097/QAI.0b013e318186ead2; Vingert B, 2012, J VIROL, V86, P10661, DOI 10.1128/JVI.00056-12; Wood E, 2000, AIDS, V14, P1955, DOI 10.1097/00002030-200009080-00011; Yang Y, 2012, AIDS, V26, P701, DOI 10.1097/QAD.0b013e3283519b22	33	21	21	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2014	9	1							e85516	10.1371/journal.pone.0085516	http://dx.doi.org/10.1371/journal.pone.0085516			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297EA	24465584	Green Published, gold, Green Submitted			2023-01-03	WOS:000330237000041
J	Degos, B; Deniau, JM; Chavez, M; Maurice, N				Degos, Bertrand; Deniau, Jean-Michel; Chavez, Mario; Maurice, Nicolas			Subthalamic Nucleus High-Frequency Stimulation Restores Altered Electrophysiological Properties of Cortical Neurons in Parkinsonian Rat	PLOS ONE			English	Article							DEEP-BRAIN-STIMULATION; MOTOR CORTEX EXCITABILITY; NIGRA PARS RETICULATA; GENETICALLY-DETERMINED SPIKE; BASAL GANGLIA; WAVE DISCHARGES; STRIATAL NEURONS; THALAMIC NEURONS; ABSENCE EPILEPSY; IN-VIVO	Electrophysiological recordings performed in parkinsonian patients and animal models have confirmed the occurrence of alterations in firing rate and pattern of basal ganglia neurons, but the outcome of these changes in thalamo-cortical networks remains unclear. Using rats rendered parkinsonian, we investigated, at a cellular level in vivo, the electrophysiological changes induced in the pyramidal cells of the motor cortex by the dopaminergic transmission interruption and further characterized the impact of high-frequency electrical stimulation of the subthalamic nucleus, a procedure alleviating parkinsonian symptoms. We provided evidence that a lesion restricted to the substantia nigra pars compacta resulted in a marked increase in the mean firing rate and bursting pattern of pyramidal neurons of the motor cortex. These alterations were underlain by changes of the electrical membranes properties of pyramidal cells including depolarized resting membrane potential and increased input resistance. The modifications induced by the dopaminergic loss were more pronounced in cortico-striatal than in cortico-subthalamic neurons. Furthermore, subthalamic nucleus high-frequency stimulation applied at parameters alleviating parkinsonian signs regularized the firing pattern of pyramidal cells and restored their electrical membrane properties.	[Degos, Bertrand; Deniau, Jean-Michel; Maurice, Nicolas] CNRS UMR7241, INSERM U1050, Coll France, Team Dynam & Pathophysiol Neuronal Networks,CIRB, Paris, France; [Degos, Bertrand] Hop La Pitie Salpetriere, APHP, Ctr Reference Malad Parkinson, Dept Neurol, Paris, France; [Chavez, Mario] Univ Paris 06, CNRS UMR 7225, Inst Cerveau & Moelle Epiniere, Ctr Rech, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite	Degos, B (corresponding author), CNRS UMR7241, INSERM U1050, Coll France, Team Dynam & Pathophysiol Neuronal Networks,CIRB, Paris, France.	bertrand.degos@psl.aphp.fr	Chavez, Mario/D-8495-2011	Chavez, Mario/0000-0003-0390-4833	Agence Nationale de la Recherche [ANR-05-JCJC-0076, ANR-05-NEUR-013]; Institut National de la Sante et de la Recherche Medicale (INSERM)	Agence Nationale de la Recherche(French National Research Agency (ANR)); Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm))	This work was supported by Agence Nationale de la Recherche (grants number: ANR-05-JCJC-0076 and ANR-05-NEUR-013). B. D. was the recipient of a poste d'accueil from the Institut National de la Sante et de la Recherche Medicale (INSERM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; Ballion B, 2008, EUR J NEUROSCI, V27, P2313, DOI 10.1111/j.1460-9568.2008.06192.x; BARANYI A, 1993, J NEUROPHYSIOL, V69, P1850, DOI 10.1152/jn.1993.69.6.1850; BENAZZOUZ A, 1993, EUR J NEUROSCI, V5, P382, DOI 10.1111/j.1460-9568.1993.tb00505.x; Blandini F, 1996, FUNCT NEUROL, V11, P3; Boraud T, 2002, PROG NEUROBIOL, V66, P265, DOI 10.1016/S0301-0082(01)00033-8; Bosch C, 2011, J PHYSIOL-LONDON, V589, P4189, DOI 10.1113/jphysiol.2011.211367; Bruno RM, 2003, J NEUROSCI, V23, P9565; Calabresi P, 2000, TRENDS NEUROSCI, V23, pS57, DOI 10.1016/S1471-1931(00)00017-3; CARLSSON M, 1990, TRENDS NEUROSCI, V13, P272, DOI 10.1016/0166-2236(90)90108-M; Ceballos-Baumann AO, 1999, ARCH NEUROL-CHICAGO, V56, P997, DOI 10.1001/archneur.56.8.997; Chen R, 2001, CLIN NEUROPHYSIOL, V112, P600, DOI 10.1016/S1388-2457(01)00466-7; Costa RM, 2006, NEURON, V52, P359, DOI 10.1016/j.neuron.2006.07.030; Cruikshank SJ, 2007, NAT NEUROSCI, V10, P462, DOI 10.1038/nn1861; Cunic D, 2002, NEUROLOGY, V58, P1665, DOI 10.1212/WNL.58.11.1665; Dauper J, 2002, NEUROLOGY, V59, P700, DOI 10.1212/WNL.59.5.700; Degenetais E, 2002, CEREB CORTEX, V12, P1, DOI 10.1093/cercor/12.1.1; Degos B, 2005, J NEUROSCI, V25, P7687, DOI 10.1523/JNEUROSCI.1056-05.2005; Degos B, 2008, EUR J NEUROSCI, V27, P2599, DOI 10.1111/j.1460-9568.2008.06229.x; Degos B, 2009, CEREB CORTEX, V19, P1616, DOI 10.1093/cercor/bhn199; Dejean C, 2009, CEREB CORTEX, V19, P1055, DOI 10.1093/cercor/bhn149; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; DOUDET DJ, 1990, EXP BRAIN RES, V80, P177; Fogelson N, 2006, CEREB CORTEX, V16, P64, DOI 10.1093/cercor/bhi084; Fraix V, 2008, CLIN NEUROPHYSIOL, V119, P2513, DOI 10.1016/j.clinph.2008.07.217; Galati S, 2006, EUR J NEUROSCI, V23, P2923, DOI 10.1111/j.1460-9568.2006.04816.x; Garcia L, 2003, J NEUROSCI, V23, P8743; Goldberg JA, 2002, J NEUROSCI, V22, P4639, DOI 10.1523/JNEUROSCI.22-11-04639.2002; Gradinaru V, 2009, SCIENCE, V324, P354, DOI 10.1126/science.1167093; Grill WM, 2008, J COMPUT NEUROSCI, V24, P81, DOI 10.1007/s10827-007-0043-9; Gubellini P, 2006, EUR J NEUROSCI, V24, P1802, DOI 10.1111/j.1460-9568.2006.05047.x; HALL RD, 1974, BRAIN RES, V66, P23, DOI 10.1016/0006-8993(74)90076-6; Hashimoto T, 2003, J NEUROSCI, V23, P1916; Haslinger B, 2005, NEUROIMAGE, V28, P598, DOI 10.1016/j.neuroimage.2005.06.034; HERKENHAM M, 1979, J COMP NEUROL, V183, P487, DOI 10.1002/cne.901830304; Hershey T, 2003, NEUROLOGY, V61, P816, DOI 10.1212/01.WNL.0000083991.81859.73; Hilker R, 2003, MOVEMENT DISORD, V18, P41, DOI 10.1002/mds.10297; Kita T, 2012, J NEUROSCI, V32, P5990, DOI 10.1523/JNEUROSCI.5717-11.2012; Kuriakose R, 2010, CEREB CORTEX, V20, P1926, DOI 10.1093/cercor/bhp269; LEGENDY CR, 1985, J NEUROPHYSIOL, V53, P926, DOI 10.1152/jn.1985.53.4.926; Li Q, 2012, NEURON, V76, P1030, DOI 10.1016/j.neuron.2012.09.032; Li S, 2007, J NEUROPHYSIOL, V98, P3525, DOI 10.1152/jn.00808.2007; Limousin P, 1997, ANN NEUROL, V42, P283, DOI 10.1002/ana.410420303; Lopes da Silva F, 1989, Brain Topogr, V2, P9; Mahon S, 2003, J PHYSIOL-LONDON, V550, P947, DOI 10.1113/jphysiol.2003.043125; Mahon S, 2006, J NEUROSCI, V26, P12587, DOI 10.1523/JNEUROSCI.3987-06.2006; Mallet N, 2008, J NEUROSCI, V28, P4795, DOI 10.1523/JNEUROSCI.0123-08.2008; Meeren HKM, 2002, J NEUROSCI, V22, P1480, DOI 10.1523/JNEUROSCI.22-04-01480.2002; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; Parr-Brownlie LC, 2005, J NEUROSCI, V25, P5700, DOI 10.1523/JNEUROSCI.0523-05.2005; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Payoux P, 2004, ARCH NEUROL-CHICAGO, V61, P1307, DOI 10.1001/archneur.61.8.1307; Paz JT, 2007, J NEUROSCI, V27, P929, DOI 10.1523/JNEUROSCI.4677-06.2007; Paz JT, 2005, J NEUROSCI, V25, P2092, DOI 10.1523/JNEUROSCI.4689-04.2005; Pessiglione M, 2005, J NEUROSCI, V25, P1523, DOI 10.1523/JNEUROSCI.4056-04.2005; Pierantozzi M, 2002, CLIN NEUROPHYSIOL, V113, P108, DOI 10.1016/S1388-2457(01)00694-0; Pinault D, 1998, J PHYSIOL-LONDON, V509, P449, DOI 10.1111/j.1469-7793.1998.449bn.x; Polack PO, 2009, CEREB CORTEX, V19, P2078, DOI 10.1093/cercor/bhn237; RALL W, 1969, BIOPHYS J, V9, P1483, DOI 10.1016/S0006-3495(69)86467-2; Robin K, 2009, J NEUROSCI METH, V179, P142, DOI 10.1016/j.jneumeth.2009.01.020; Sabatini U, 2000, BRAIN, V123, P394, DOI 10.1093/brain/123.2.394; Scholz B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001589; SIMONS DJ, 1989, J NEUROPHYSIOL, V61, P311, DOI 10.1152/jn.1989.61.2.311; Slaght S, 2004, J NEUROSCI, V24, P6816, DOI 10.1523/JNEUROSCI.1449-04.2004; Slaght SNJ, 2002, J NEUROSCI, V22, P2323, DOI 10.1523/JNEUROSCI.22-06-02323.2002; Strafella AP, 2000, CLIN NEUROPHYSIOL, V111, P1198, DOI 10.1016/S1388-2457(00)00316-3; Tai CH, 2003, FASEB J, V17, P1820, DOI 10.1096/fj.03-0163com; Thomson AM, 2003, CEREB CORTEX, V13, P5, DOI 10.1093/cercor/13.1.5; Tseng KY, 2001, J NEUROSCI, V21, P6430, DOI 10.1523/JNEUROSCI.21-16-06430.2001; Welter ML, 2004, ARCH NEUROL-CHICAGO, V61, P89, DOI 10.1001/archneur.61.1.89; Wichmann T, 1999, EXP BRAIN RES, V125, P397, DOI 10.1007/s002210050696; ZHENG F, 2011, J PHYSL, V11, P2781; ZOLD CL, 2008, NEUR M PLANN	73	22	23	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2013	8	12							e83608	10.1371/journal.pone.0083608	http://dx.doi.org/10.1371/journal.pone.0083608			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	284NF	24391793	Green Published, gold, Green Submitted			2023-01-03	WOS:000329325200090
J	Oudeman, EA; Frijns, CJM; Klijn, CJM				Oudeman, Eline A.; Frijns, Catharina J. M.; Klijn, Catharina J. M.			Multiple Cerebral Infarctions and Intracranial Vessel Abnormalities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							B-CELL LYMPHOMA; INTRAVASCULAR LYMPHOMA; MANAGEMENT		[Oudeman, Eline A.; Frijns, Catharina J. M.; Klijn, Catharina J. M.] Univ Med Ctr Utrecht, Dept Neurol & Neurosurg, Brain Ctr Rudolf Magnus, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Oudeman, EA (corresponding author), Univ Med Ctr Utrecht, Dept Neurol & Neurosurg, POB 85500, NL-3508 GA Utrecht, Netherlands.	e.a.oudeman@gmail.com	Klijn, C.J.M./E-1700-2016	Klijn, C.J.M./0000-0002-8495-4578				Ferreri AJM, 2004, BRIT J HAEMATOL, V127, P173, DOI 10.1111/j.1365-2141.2004.05177.x; Kadkhodayan Y, 2004, RADIOLOGY, V233, P878, DOI 10.1148/radiol.2333031621; Matsue K, 2011, ANN HEMATOL, V90, P417, DOI 10.1007/s00277-010-1101-3; Ponzoni M, 2007, J CLIN ONCOL, V25, P3168, DOI 10.1200/JCO.2006.08.2313; Shimada K, 2009, LANCET ONCOL, V10, P895, DOI 10.1016/S1470-2045(09)70140-8; Zuckerman D, 2006, ONCOLOGIST, V11, P496, DOI 10.1634/theoncologist.11-5-496	6	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	2013	310	24					2668	2669		10.1001/jama.2013.284467	http://dx.doi.org/10.1001/jama.2013.284467			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277KN	24368467				2023-01-03	WOS:000328818000019
J	van Abeelen, AFM; Elias, SG; de Jong, PA; Grobbee, DE; Bossuyt, PMM; van der Schouw, YT; Roseboom, TJ; Uiterwaal, CSPM				van Abeelen, Annet F. M.; Elias, Sjoerd G.; de Jong, Pim A.; Grobbee, Diederick E.; Bossuyt, Patrick M. M.; van der Schouw, Yvonne T.; Roseboom, Tessa J.; Uiterwaal, Cuno S. P. M.			Famine in the Young and Risk of Later Hospitalization for COPD and Asthma	PLOS ONE			English	Article							LUNG-FUNCTION; MECHANICS; DISEASE	Background: Undernutrition during critical periods of growth and development may permanently affect lung physiology and function. Objectives: To investigate whether acute undernutrition in childhood or young adulthood increases the risk of later hospitalization for obstructive airways disease, chronic obstructive pulmonary disease (COPD), or asthma. Methods: We studied 7,841 women from Prospect-EPIC who experienced the 1944-45 Dutch famine between ages 0 and 21. Pulmonary outcomes were measured by registered hospital admissions and exposure-blinded computed tomography (CT) in a subgroup of 295 women. With Cox proportional hazard regression we explored effects of famine exposure on risk of hospitalization for obstructive airways disease, COPD, and asthma. With logistic regression we explored effects of famine on risk of CT evidence of pulmonary disease. Results: Risks of hospitalization for obstructive airways disease, COPD, and asthma were increased after moderate famine exposure, and significantly increased after severe famine exposure: hazard ratios for obstructive airways disease were 1.31 (95% CI: 0.97 to 1.77) and 1.57 (95% CI: 1.10 to 2.23) respectively. Associations between famine exposure and hospitalization for COPD were stronger in ever-smokers than in never-smokers. Conclusions: Acute undernutrition in childhood or young adulthood is associated with an increased risk of later COPD and asthma hospitalization, possibly through increased sensitivity for tobacco smoke.	[van Abeelen, Annet F. M.; Elias, Sjoerd G.; Grobbee, Diederick E.; van der Schouw, Yvonne T.; Uiterwaal, Cuno S. P. M.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [van Abeelen, Annet F. M.; Bossuyt, Patrick M. M.; Roseboom, Tessa J.] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, NL-1105 AZ Amsterdam, Netherlands; [de Jong, Pim A.] Univ Med Ctr Utrecht, Dept Radiol, Utrecht, Netherlands; [Roseboom, Tessa J.] Univ Amsterdam, Acad Med Ctr, Dept Obstet & Gynecol, NL-1105 AZ Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Utrecht University Medical Center; University of Amsterdam; Academic Medical Center Amsterdam	van Abeelen, AFM (corresponding author), Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.	annetvanabeelen@gmail.com	de Jong, Pim A/G-7220-2014; Grobbee, Diederick/C-7651-2014; Elias, Sjoerd G/E-6057-2011; van der Schouw, Yvonne T./F-8327-2014; Bossuyt, Patrick M/AAR-1183-2021; Bossuyt, Patrick M./B-4557-2016	de Jong, Pim A/0000-0003-4840-6854; Grobbee, Diederick/0000-0003-4472-4468; Elias, Sjoerd G/0000-0003-3903-4024; van der Schouw, Yvonne T./0000-0002-4605-435X; Bossuyt, Patrick M/0000-0003-4427-0128; Bossuyt, Patrick M./0000-0003-4427-0128; Roseboom, Tessa/0000-0003-0564-5994	"Europe Against Cancer'' Program of the European Commission (SANCO); Dutch Ministry of Health; Dutch Cancer Society; ZonMw; Netherlands Organization for Health Research and Development; World Cancer Research Fund (WCRF)	"Europe Against Cancer'' Program of the European Commission (SANCO)(European CommissionEuropean Commission Joint Research Centre); Dutch Ministry of Health; Dutch Cancer Society(KWF Kankerbestrijding); ZonMw(Netherlands Organization for Health Research and Development); Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development); World Cancer Research Fund (WCRF)(World Cancer Research Fund International (WCRF))	The Prospect-EPIC study was supported by "Europe Against Cancer'' Program of the European Commission (SANCO); the Dutch Ministry of Health; the Dutch Cancer Society; ZonMw, the Netherlands Organization for Health Research and Development; World Cancer Research Fund (WCRF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barker DJP, 1998, MOTHERS BABIES DIS L; Bogin Barry, 1999, PATTERNS HUMAN GROWT; Boker LK, 2001, EUR J EPIDEMIOL, V17, P1047, DOI 10.1023/A:1020009325797; Burger G, 1948, TUSSEN ONS VOLK HONG; Cameron N, 2002, YEARB PHYS ANTHROPOL, V45, P159, DOI 10.1002/ajpa.10183; Coxson HO, 2004, AM J RESP CRIT CARE, V170, P748, DOI 10.1164/rccm.200405-651OC; Dias CM, 2004, J APPL PHYSIOL, V97, P1888, DOI 10.1152/japplphysiol.00091.2004; Eisner MD, 2010, AM J RESP CRIT CARE, V182, P693, DOI 10.1164/rccm.200811-1757ST; Elias SG, 2004, J NATL CANCER I, V96, P539, DOI 10.1093/jnci/djh087; Jones A, 2008, EUR HEART J, V29, P2164, DOI 10.1093/eurheartj/ehn292; Jong Loe de, 1981, KONINKRIJK NEDERLAND; Lawlor DA, 2005, THORAX, V60, P851, DOI 10.1136/thx.2005.042408; Lopuhaa CE, 2000, THORAX, V55, P555, DOI 10.1136/thorax.55.7.555; Mataloun MMGB, 2009, BRAZ J MED BIOL RES, V42, P606, DOI 10.1590/S0100-879X2009000700004; Narayanan M, 2012, AM J RESP CRIT CARE, V185, P186, DOI 10.1164/rccm.201107-1348OC; Riboli E, 1997, INT J EPIDEMIOL S1, V26, pS6; Ryter Stefan W, 2010, Proc Am Thorac Soc, V7, P13, DOI 10.1513/pats.200909-101JS; SAHEBJAMI H, 1979, AM REV RESPIR DIS, V119, P443; Statistics Netherlands, DOODS UITG LIJST LEE; Statistics Netherlands, BEV GESL LEEFT BURG; Statistics Netherlands, 2020, BEV HUISH BEV VAN 18; Trienekens GM., 1985, TUSSEN ONS VOLK HONG; United Nations Food and Agriculture Organization FAO, 2010, FOOD COMES 1 FAO 8 M; World Health Organization, 2011, NCD MORT MORB	24	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2013	8	12							e82636	10.1371/journal.pone.0082636	http://dx.doi.org/10.1371/journal.pone.0082636			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278IG	24376558	Green Published, gold, Green Submitted			2023-01-03	WOS:000328882000019
J	Onitilo, AA; Onesti, JK; Single, RM; Engel, JM; James, TA; Bowles, EJA; Feigelson, HS; Barney, T; McCahill, LE				Onitilo, Adedayo A.; Onesti, Jill K.; Single, Richard M.; Engel, Jessica M.; James, Ted A.; Bowles, Erin J. Aiello; Feigelson, Heather Spencer; Barney, Tom; McCahill, Laurence E.			Utilization of Neoadjuvant Chemotherapy Varies in the Treatment of Women with Invasive Breast Cancer	PLOS ONE			English	Article							SURGICAL ADJUVANT BREAST; PREOPERATIVE CHEMOTHERAPY; CONSERVING SURGERY; MASTECTOMY RATES; THERAPY; QUALITY; RECOMMENDATIONS; CHOICE	Background: Treatment with neoadjuvant chemotherapy (NAG) has made it possible for some women to be successfully treated with breast conservation therapy (BCT) who were initially considered ineligible. Factors related to current practice patterns of NAC use are important to understand particularly as the surgical treatment of invasive breast cancer has changed. The goal of this study was to determine variations in neoadjuvant chemotherapy use in a large multi-center national database of patients with breast cancer. Methods: We evaluated NAC use in patients with initially operable invasive breast cancer and potential impact on breast conservation rates. Records of 2871 women ages 18-years and older diagnosed with 2907 invasive breast cancers from January 2003 to December 2008 at four institutions across the United States were examined using the Breast Cancer Surgical Outcomes (BRCASO) database. Main outcome measures included NAC use and association with pre-operatively identified clinical factors, surgical approach (partial mastectomy [PM] or total mastectomy [TM]), and BCT failure (initial PM followed by subsequent TM). Results: Overall, NAC utilization was 3.8%l. Factors associated with NAC use included younger age, pre-operatively known positive nodal status, and increasing clinical tumor size. NAC use and BCT failure rates increased with clinical tumor size, and there was significant variation in NAC use across institutions. Initial TM frequency approached initial PM frequency for tumors >30-40mm; BCT failure rate was 22.7% for tumors >40mm. Only 2.7% of patients undergoing initial PM and 7.2% undergoing initial TM received NAC. Conclusions: NAC use in this study was infrequent and varied among institutions. Infrequent NAC use in patients suggests that NAC may be underutilized in eligible patients desiring breast conservation.	[Onitilo, Adedayo A.] Marshfield Clin Fdn Med Res & Educ, Dept Hematol & Oncol, Weston, WI USA; [Onitilo, Adedayo A.] Univ Queensland, Sch Populat Hlth, Clin Epidemiol Unit, Brisbane, Qld, Australia; [Onesti, Jill K.] Grand Rapids Med Educ Partners, Grand Rapids, MI USA; [Single, Richard M.] Univ Vermont, Burlington, VT USA; [Engel, Jessica M.] St Michaels Hosp, Marshfield Clin Canc Care, Stevens Point, WI USA; [James, Ted A.] Univ Vermont, Coll Med, Burlington, VT USA; [Bowles, Erin J. Aiello] Grp Hlth Cooperat Puget Sound, Res Inst, Seattle, WA 98121 USA; [Feigelson, Heather Spencer] Kaiser Permanente Colorado, Denver, CO USA; [Barney, Tom; McCahill, Laurence E.] Van Andel Res Inst, Grand Rapids, MI USA	University of Queensland; University of Vermont; University of Vermont; Group Health Cooperative; Kaiser Permanente; Van Andel Institute	Onitilo, AA (corresponding author), Marshfield Clin Fdn Med Res & Educ, Dept Hematol & Oncol, Weston, WI USA.	onitilo.adedayo@marshfieldclinic.org			National Institute of Health	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was funded under the American recovery and Reinvestment Act of 2009 by National Institute of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bonadonna G, 1998, J CLIN ONCOL, V16, P93, DOI 10.1200/JCO.1998.16.1.93; Bowles EJA, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-136; Caldon LJM, 2007, EUR J CANCER, V43, P1662, DOI 10.1016/j.ejca.2007.04.021; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Damle S, 2011, ANN SURG ONCOL, V18, P1356, DOI 10.1245/s10434-010-1434-0; Fisher B, 1997, J CLIN ONCOL, V15, P2483, DOI 10.1200/JCO.1997.15.7.2483; Fisher B, 1998, J CLIN ONCOL, V16, P2672, DOI 10.1200/JCO.1998.16.8.2672; Foster JA, 2009, J NATL COMPR CANC NE, V7, P697, DOI 10.6004/jnccn.2009.0049; Gilligan MA, 2002, MED CARE, V40, P181; Gomez SL, 2004, ETHNIC DIS, V14, P134; Gralow JR, 2008, J CLIN ONCOL, V26, P814, DOI 10.1200/JCO.2007.15.3510; Habermann EB, 2010, J CLIN ONCOL, V28, P3437, DOI 10.1200/JCO.2009.27.6774; HALL WH, 1991, JAMA-J AM MED ASSOC, V265, P391; James TA, 2010, J CLIN ONCOL, V28; James T, 2009, BREAST J, V15, P524, DOI 10.1111/j.1524-4741.2009.00771.x; James TA, 2010, J CLIN ONCOL, V28, pE364, DOI 10.1200/JCO.2009.27.9703; Jatoi I, 2005, AM J CLIN ONCOL-CANC, V28, P289, DOI 10.1097/01.coc.0000156922.58631.d7; Kaufmann M, 2007, ANN ONCOL, V18, P1927, DOI 10.1093/annonc/mdm201; Kaufmann M, 2010, CANCER-AM CANCER SOC, V116, P1184, DOI 10.1002/cncr.24874; McCahill LE, 2009, ARCH SURG-CHICAGO, V144, P455, DOI 10.1001/archsurg.2009.56; McCahill LE, 2009, AM J SURG, V197, P216, DOI 10.1016/j.amjsurg.2007.12.056; McGuire KP, 2009, ANN SURG ONCOL, V16, P2682, DOI 10.1245/s10434-009-0635-x; Mieog JSD, 2007, BRIT J SURG, V94, P1189, DOI 10.1002/bjs.5894; Moreno-Aspitia A, 2012, CRIT REV ONCOL HEMAT, V82, P187, DOI 10.1016/j.critrevonc.2011.04.013; Nattinger AB, 2001, J NATL CANCER I, V93, P1344, DOI 10.1093/jnci/93.17.1344; Peintinger F, 2006, CANCER-AM CANCER SOC, V107, P1248, DOI 10.1002/cncr.22111; Poggi MM, 2003, CANCER, V98, P697, DOI 10.1002/cncr.11580; Rastogi P, 2008, J CLIN ONCOL, V26, P778, DOI 10.1200/JCO.2007.15.0235; Roth SL, 2010, STRAHLENTHER ONKOL, V186, P299, DOI 10.1007/s00066-010-2143-0; Temple WJ, 2006, J CLIN ONCOL, V24, P3367, DOI 10.1200/JCO.2005.02.7771; Thomas A, 2006, ANTICANCER RES, V26, P1677	31	10	10	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2013	8	12							e84535	10.1371/journal.pone.0084535	http://dx.doi.org/10.1371/journal.pone.0084535			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276IX	24376822	Green Published, Green Submitted, gold			2023-01-03	WOS:000328745100174
J	Choi, JS; Baek, HM; Kim, S; Kim, MJ; Youk, JH; Moon, HJ; Kim, EK; Nam, YK				Choi, Ji Soo; Baek, Hyeon-Man; Kim, Suhkmann; Kim, Min Jung; Youk, Ji Hyun; Moon, Hee Jung; Kim, Eun-Kyung; Nam, Youn Ki			Magnetic Resonance Metabolic Profiling of Breast Cancer Tissue Obtained with Core Needle Biopsy for Predicting Pathologic Response to Neoadjuvant Chemotherapy	PLOS ONE			English	Article							SURGICAL ADJUVANT BREAST; PREOPERATIVE CHEMOTHERAPY; GENE-EXPRESSION; CHOLINE METABOLISM; DIAGNOSIS; SIGNATURES; SURVIVAL; MARKERS; WOMEN; PROGNOSIS	The purpose of this study was to determine whether metabolic profiling of core needle biopsy (CNB) samples using high-resolution magic angle spinning (HR-MAS) magnetic resonance spectroscopy (MRS) could be used for predicting pathologic response to neoadjuvant chemotherapy (NAC) in patients with locally advanced breast cancer. After institutional review board approval and informed consent were obtained, CNB tissue samples were collected from 37 malignant lesions in 37 patients before NAC treatment. The metabolic profiling of CNB samples were performed by HR-MAS MRS. Metabolic profiles were compared according to pathologic response to NAC using the Mann-Whitney test. Multivariate analysis was performed with orthogonal projections to latent structure-discriminant analysis (OPLS-DA). Various metabolites including choline-containing compounds were identified and quantified by HR-MAS MRS in all 37 breast cancer tissue samples obtained by CNB. In univariate analysis, the metabolite concentrations and metabolic ratios of CNB samples obtained with HR-MAS MRS were not significantly different between different pathologic response groups. However, there was a trend of lower levels of phosphocholine/creatine ratio and choline-containing metabolite concentrations in the pathologic complete response group compared to the non-pathologic complete response group. In multivariate analysis, the OPLS-DA models built with HR-MAS MR metabolic profiles showed visible discrimination between the pathologic response groups. This study showed OPLS-DA multivariate analysis using metabolic profiles of pretreatment CNB samples assessed by HR-MAS MRS may be used to predict pathologic response before NAC, although we did not identify the metabolite showing statistical significance in univariate analysis. Therefore, our preliminary results raise the necessity of further study on HR-MAS MR metabolic profiling of CNB samples for a large number of cancers.	[Choi, Ji Soo; Kim, Min Jung; Youk, Ji Hyun; Moon, Hee Jung; Kim, Eun-Kyung] Yonsei Univ, Coll Med, Res Inst Radiol Sci, Dept Radiol, Seoul, South Korea; [Choi, Ji Soo] Samsung Med Ctr, Dept Radiol, Seoul, South Korea; [Baek, Hyeon-Man] Korea Basic Sci Inst, Div Magnet Resonance, Chungbuk, South Korea; [Baek, Hyeon-Man] Univ Sci & Technol, Dept Bioanalyt Sci, Taejon, South Korea; [Kim, Suhkmann] Pusan Natl Univ, Dept Chem, Busan, South Korea; [Kim, Suhkmann] Pusan Natl Univ, Chem Inst Funct Mat, Busan, South Korea; [Nam, Youn Ki] Agilent Technol Korea, Seoul, South Korea	Yonsei University; Yonsei University Health System; Sungkyunkwan University (SKKU); Samsung Medical Center; Korea Basic Science Institute (KBSI); Pusan National University; Pusan National University	Kim, MJ (corresponding author), Yonsei Univ, Coll Med, Res Inst Radiol Sci, Dept Radiol, Seoul, South Korea.	mines@yuhs.ac	Kim, Eun-Kyung/E-5211-2017	Kim, Eun-Kyung/0000-0002-3368-5013; Moon, Hee Jung/0000-0002-5643-5885	Basic Science Research Program of the National Research Foundation of Korea; Ministry of Science, ICT&Future Planning, Republic of Korea [2013R1A1A3013165]	Basic Science Research Program of the National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Science, ICT&Future Planning, Republic of Korea(Ministry of Science, ICT & Future Planning, Republic of Korea)	This study was supported by the Basic Science Research Program of the National Research Foundation of Korea funded by the Ministry of Science, ICT&Future Planning, Republic of Korea (preparation of the manuscript. grant 2013R1A1A3013165). The funders had no role in study design, data collection and analysis, decision to publish, or or preparation of the manuscript.	Ackerstaff E, 2003, J CELL BIOCHEM, V90, P525, DOI 10.1002/jcb.10659; Alvarado-Cabrero I, 2009, ANN DIAGN PATHOL, V13, P151, DOI 10.1016/j.anndiagpath.2009.02.003; Amat S, 2005, BREAST CANCER RES TR, V94, P255, DOI 10.1007/s10549-005-9008-8; Baek HM, 2008, MAGN RESON IMAGING, V26, P523, DOI 10.1016/j.mri.2007.10.002; Baek HM, 2009, RADIOLOGY, V251, P653, DOI 10.1148/radiol.2512080553; Bassett LW, 2007, RADIOL CLIN N AM, V45, P881, DOI 10.1016/j.rcl.2007.06.010; Bathen TF, 2007, BREAST CANCER RES TR, V104, P181, DOI 10.1007/s10549-006-9400-z; Begley JKP, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3132; Brindle JT, 2002, NAT MED, V8, P1439, DOI 10.1038/nm802; Bruening W, 2010, ANN INTERN MED, V152, P238, DOI 10.7326/0003-4819-152-1-201001050-00190; Cao MD, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-39; Cao MD, 2012, NMR BIOMED, V25, P369, DOI 10.1002/nbm.1762; Cecil KM, 2001, BREAST CANCER RES TR, V68, P45, DOI 10.1023/A:1017911211090; Chang J, 1999, J CLIN ONCOL, V17, P3058, DOI 10.1200/JCO.1999.17.10.3058; Chen JH, 2011, NMR BIOMED, V24, P316, DOI 10.1002/nbm.1595; Chen YZ, 2011, CANCER LETT, V302, P63, DOI 10.1016/j.canlet.2010.12.014; Choi JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051712; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Ellis P, 1998, J CLIN ONCOL, V16, P107, DOI 10.1200/JCO.1998.16.1.107; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Fisher B, 1997, J CLIN ONCOL, V15, P2483, DOI 10.1200/JCO.1997.15.7.2483; Fisher B, 1998, J CLIN ONCOL, V16, P2672, DOI 10.1200/JCO.1998.16.8.2672; Gianni L, 2005, J CLIN ONCOL, V23, P7265, DOI 10.1200/JCO.2005.02.0818; Glunde K, 2008, CANCER RES, V68, P172, DOI 10.1158/0008-5472.CAN-07-2678; Glunde K, 2006, EXPERT REV MOL DIAGN, V6, P821, DOI 10.1586/14737159.6.6.821; Goldhirsch A, 2001, J CLIN ONCOL, V19, P3817, DOI 10.1200/JCO.2001.19.18.3817; Hylton NM, 2012, RADIOLOGY, V263, P663, DOI 10.1148/radiol.12110748; Jones RL, 2006, BRIT J CANCER, V94, P358, DOI 10.1038/sj.bjc.6602950; Jones RL, 2006, LANCET ONCOL, V7, P869, DOI 10.1016/S1470-2045(06)70906-8; Katz-Brull R, 2002, CANCER RES, V62, P1966; Li M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025563; MacKinnon N, 2012, METABOLOMICS, V8, P1026, DOI 10.1007/s11306-012-0398-4; Makris A, 1998, ANN ONCOL, V9, P1179, DOI 10.1023/A:1008400706949; Moestue SA, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-433; Mountford CE, 2001, BRIT J SURG, V88, P1234, DOI 10.1046/j.0007-1323.2001.01864.x; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Prevos R, 2012, EUR RADIOL, V22, P2607, DOI 10.1007/s00330-012-2653-5; Rastogi P, 2008, J CLIN ONCOL, V26, P778, DOI 10.1200/JCO.2007.15.0235; Roebuck JR, 1998, RADIOLOGY, V209, P269, DOI 10.1148/radiology.209.1.9769842; Rouzier R, 2005, J CLIN ONCOL, V23, P8331, DOI 10.1200/JCO.2005.01.2898; Shah T, 2010, NMR BIOMED, V23, P633, DOI 10.1002/nbm.1510; Shin HJ, 2012, NMR BIOMED, V25, P1349, DOI 10.1002/nbm.2807; SINGER S, 1995, CANCER RES, V55, P5140; Sinha S, 2009, NMR BIOMED, V22, P3, DOI 10.1002/nbm.1270; Sitter B, 2006, NMR BIOMED, V19, P30, DOI 10.1002/nbm.992; Sitter B, 2010, NMR BIOMED, V23, P424, DOI 10.1002/nbm.1478; Somashekar BS, 2012, J PROTEOME RES, V11, P4873, DOI 10.1021/pr300345x; Somashekar BS, 2011, J PROTEOME RES, V10, P5232, DOI 10.1021/pr200800w; Symmans WF, 2007, J CLIN ONCOL, V25, P4414, DOI 10.1200/JCO.2007.10.6823; Thuerigen O, 2006, J CLIN ONCOL, V24, P1839, DOI 10.1200/JCO.2005.04.7019; Tripathi P, 2013, J PROTEOME RES, V12, P3519, DOI 10.1021/pr4004135; Tripathi P, 2012, INT J BIOCHEM CELL B, V44, P1852, DOI 10.1016/j.biocel.2012.06.025; Wen H, 2010, J HEPATOL, V52, P228, DOI 10.1016/j.jhep.2009.11.002; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Wolmark N, 2001, J Natl Cancer Inst Monogr, P96	56	37	38	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2013	8	12							e83866	10.1371/journal.pone.0083866	http://dx.doi.org/10.1371/journal.pone.0083866			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276HY	24367616	gold, Green Published, Green Submitted			2023-01-03	WOS:000328741900024
J	Zhao, G; Dai, CL; Zhao, MW; You, Q; Chen, A				Zhao, Guang; Dai, Caili; Zhao, Mingwei; You, Qing; Chen, Ang			Investigation of Preparation and Mechanisms of a Dispersed Particle Gel Formed from a Polymer Gel at Room Temperature	PLOS ONE			English	Article							PROFILE MODIFICATION; WATER SHUTOFF; TIME; ION	A dispersed particle gel (DPG) was successfully prepared from a polymer gel at room temperature. The polymer gel system, morphology, viscosity changes, size distribution, and zeta potential of DPG particles were investigated. The results showed that zirconium gel systems with different strengths can be cross-linked within 2.5 h at low temperature. Scanning electron microscopy (SEM), transmission electron microscopy (TEM), and atomic force microscopy (AFM) results showed that the particles were polygonal particles with nano-size distribution. According to the viscosity changes, the whole preparation process can be divided into two major stages: the bulk gel cross-linking reaction period and the DPG particle preparation period. A polymer gel with a 3-dimensional network was formed in the bulk gel cross-linking reaction period whereas shearing force and frictional force were the main driving forces for the preparation of DPG particles, and thus affected the morphology of DPG particles. High shearing force and frictional force reduced the particle size distribution, and then decreased the zeta potential (absolute value). The whole preparation process could be completed within 3 h at room temperature. It could be an efficient and energy-saving technology for preparation of DPG particles.	[Zhao, Guang; Dai, Caili; Zhao, Mingwei; Chen, Ang] China Univ Petr, State Key Lab Heavy Oil Proc, Qingdao, Shandong, Peoples R China; [You, Qing] China Univ Geosci, Sch Energy Resources, Beijing, Peoples R China	China University of Petroleum; China University of Geosciences	Zhao, G (corresponding author), China Univ Petr, State Key Lab Heavy Oil Proc, Qingdao, Shandong, Peoples R China.	zhaoguang.sdau@163.com; daicl306@163.com	Chen, Ang/HII-3354-2022	Dai, Cai li/0000-0002-7477-8865; Zhao, Guang/0000-0002-2254-3511	National Natural Science Foundation of China [51174221]; Science Funds for Distinguished Young Scholar of Shandong Province [JQ201013]; Program for New Century Excellent Talents in University [20110226]; Program for Changjiang Scholars and Innovative Reserch Team in University [IRT1294]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science Funds for Distinguished Young Scholar of Shandong Province; Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); Program for Changjiang Scholars and Innovative Reserch Team in University(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT))	This work was sponsored by Supported by National Natural Science Foundation of China (number 51174221), Science Funds for Distinguished Young Scholar of Shandong Province (number JQ201013), Program for New Century Excellent Talents in University (number 20110226), Program for Changjiang Scholars and Innovative Reserch Team in University (IRT1294). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Muntasheri GA, 2007, J PETROL SCI ENG, V59, P73, DOI 10.1016/j.petrol.2007.02.010; ALBONICO P, 1992, J POLYM SCI POL CHEM, V30, P1071, DOI 10.1002/pola.1992.080300612; Bai BJ, 2007, SPE RESERV EVAL ENG, V10, P415, DOI 10.2118/89389-PA; Bai BJ, 2004, 2004 SPE DOE 14 S IM; Beverte L, 2013, J APPL POLYM SCI, DOI [10.1002/app.39477, DOI 10.1002/APP.39477]; Chauveteau G, 2001, 2001 SPE INT S OILF; Chauveteau G, 1999, INT S OILF CHEM C HE; Chung T, 2012, ENERG SOURCE PART A, V34, P122, DOI 10.1080/15567030903567683; Dai CL, 2014, J APPL POLYM SCI, V131, DOI 10.1002/app.39462; Dai CL, 2012, MOLECULES, V17, P14484, DOI 10.3390/molecules171214484; Fernandes Heloise Pöckel, 2011, Rev. Bras. Hematol. Hemoter., V33, P297, DOI 10.5581/1516-8484.20110080; Fu CL, 2011, J PHYS CHEM B, V115, P11345, DOI 10.1021/jp207957a; Goudarzi A., 2013, SPE REG AAPG PAC SEC; LOCKHART TP, 1991, J APPL POLYM SCI, V43, P1527, DOI 10.1002/app.1991.070430815; Lu J, 2011, ADV MATER RES-SWITZ, V152-153, P1471, DOI 10.4028/www.scientific.net/AMR.152-153.1471; Matsuo M, 2002, POLYMER, V43, P5299, DOI 10.1016/S0032-3861(02)00290-2; Mohanraj V. J., 2006, Tropical Journal of Pharmaceutical Research, V5, P561; Moradi-Araghi A, 2000, J PETROL SCI ENG, V26, P1, DOI 10.1016/S0920-4105(00)00015-2; Ni HF, 2003, J COLLOID INTERF SCI, V260, P344, DOI 10.1016/S0021-9797(02)00229-1; Perez D, 2001, SPE DRILL COMPLETION, V16, P182, DOI 10.2118/73196-PA; Shu P, 1987, US Patent, Patent No. [4,676,930 A, 4676930]; Simjoo M, 2007, IRAN J CHEM CHEM ENG, V26, P99; Stokes DJ, 2003, PHILOS T R SOC A, V361, P2771, DOI 10.1098/rsta.2003.1279; Sze A, 2003, J COLLOID INTERF SCI, V261, P402, DOI 10.1016/S0021-9797(03)00142-5; Vossoughi S, 2000, J PETROL SCI ENG, V26, P199, DOI 10.1016/S0920-4105(00)00034-6; Wassmuth FR, 2009, J CAN PETROL TECHNOL, V48, P55, DOI 10.2118/09-02-55; You Q., 2013, J ENERGY RESOUR TECH, V135, P1; You Q., 2011, ENH OIL REC C HELD K; Young G., 1996, PERM BAS OIL GAS REC; Zhang B, 2010, PETROL GEOL REV EFF, V17, P42; Zhao F.L., 2001, OILFIELD CHEM, P308; Zhao FL, 1999, J CHINA U PETROL, V23, P49; [赵福麟 Zhao Fulin], 2006, [石油学报, Acta Petrolei Sinica], V27, P71; Zhao G, 2013, J SOL-GEL SCI TECHN, V65, P392, DOI 10.1007/s10971-012-2951-z; Zhou W., 2013, INT PETR TECHN C HEL	35	14	17	4	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 6	2013	8	12							e82651	10.1371/journal.pone.0082651	http://dx.doi.org/10.1371/journal.pone.0082651			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273WJ	24324817	Green Published, gold, Green Submitted			2023-01-03	WOS:000328566700096
J	Perez-Shibayama, C; Gil-Cruz, C; Nussbacher, M; Allgauer, E; Cervantes-Barragan, L; Zust, R; Ludewig, B				Perez-Shibayama, Christian; Gil-Cruz, Cristina; Nussbacher, Monika; Allgaeuer, Eva; Cervantes-Barragan, Luisa; Zuest, Roland; Ludewig, Burkhard			Dendritic Cell-Specific Delivery of Flt3L by Coronavirus Vectors Secures Induction of Therapeutic Antitumor Immunity	PLOS ONE			English	Article							COLONY-STIMULATING FACTOR; ANTIGEN-PRESENTING CELLS; REGULATORY T-CELLS; IMMUNOTHERAPY; INTERLEUKIN-2; ACTIVATION; VIRUS; LYMPHOCYTES; RESPONSES; SEQUENCE	Efficacy of antitumor vaccination depends to a large extent on antigen targeting to dendritic cells (DCs). Here, we assessed antitumor immunity induced by attenuated coronavirus vectors which exclusively target DCs in vivo and express either lymphocyte-or DC-activating cytokines in combination with a GFP-tagged model antigen. Tracking of in vivo transduced DCs revealed that vectors encoding for Fms-like tyrosine kinase 3 ligand (Flt3L) exhibited a higher capacity to induce DC maturation compared to vectors delivering IL-2 or IL-15. Moreover, Flt3L vectors more efficiently induced tumor-specific CD8+ T cells, expanded the epitope repertoire, and provided both prophylactic and therapeutic tumor immunity. In contrast, IL-2-or IL-15-encoding vectors showed a substantially lower efficacy in CD8+ T cell priming and failed to protect the host once tumors had been established. Thus, specific in vivo targeting of DCs with coronavirus vectors in conjunction with appropriate conditioning of the microenvironment through Flt3L represents an efficient strategy for the generation of therapeutic antitumor immunity.	[Perez-Shibayama, Christian; Gil-Cruz, Cristina; Nussbacher, Monika; Allgaeuer, Eva; Cervantes-Barragan, Luisa; Zuest, Roland; Ludewig, Burkhard] Kantonsspital, Inst Immunobiol, St Gallen, Switzerland; [Cervantes-Barragan, Luisa] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; [Zuest, Roland] Agcy Sci Technol & Res, Singapore Immunol Network, Singapore, Singapore	Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen; Washington University (WUSTL); Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN)	Ludewig, B (corresponding author), Kantonsspital, Inst Immunobiol, St Gallen, Switzerland.	burkhard.ludewig@kssg.ch		Gil Cruz, Cristina/0000-0001-5285-6503	Wilhelm Sander Foundation; European Commission; TOLERAGE project	Wilhelm Sander Foundation; European Commission(European CommissionEuropean Commission Joint Research Centre); TOLERAGE project	This study received financial support from the Wilhelm Sander Foundation (to B.L.) and through the TOLERAGE project funded by the European Commission. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmadzadeh M, 2006, BLOOD, V107, P2409, DOI 10.1182/blood-2005-06-2399; Albertini MR, 2012, CANCER IMMUNOL IMMUN, V61, P2261, DOI 10.1007/s00262-012-1286-5; Caballero OL, 2009, CANCER SCI, V100, P2014, DOI 10.1111/j.1349-7006.2009.01303.x; CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019; Cavallo F, 2011, CANCER IMMUNOL IMMUN, V60, P319, DOI 10.1007/s00262-010-0968-0; Cawood R, 2012, TRENDS MOL MED, V18, P564, DOI 10.1016/j.molmed.2012.07.007; Cervantes-Barragan L, 2010, MBIO, V1, DOI 10.1128/mBio.00171-10; Cervantes-Barragan L, 2009, J IMMUNOL, V182, P1099, DOI 10.4049/jimmunol.182.2.1099; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Curran MA, 2009, CANCER RES, V69, P7747, DOI 10.1158/0008-5472.CAN-08-3289; Decker WK, 2011, CYTOKINE GROWTH F R, V22, P177, DOI 10.1016/j.cytogfr.2011.07.001; Dolcetti L, 2010, EUR J IMMUNOL, V40, P22, DOI 10.1002/eji.200939903; Draper SJ, 2008, NAT MED, V14, P819, DOI 10.1038/nm.1850; Dubois S, 2002, IMMUNITY, V17, P537, DOI 10.1016/S1074-7613(02)00429-6; Eriksson KK, 2006, CLIN DEV IMMUNOL, V13, P353, DOI 10.1080/17402520600579168; Eriksson Klara Kristin, 2008, V454, P237, DOI 10.1007/978-1-59745-181-9_18; Guermonprez P, 2013, NAT MED, V19, P730, DOI 10.1038/nm.3197; Hermans IF, 1998, CANCER RES, V58, P3909; Jacobs JFM, 2009, NEURO-ONCOLOGY, V11, P394, DOI 10.1215/15228517-2008-104; Jakobisiak M, 2011, CYTOKINE GROWTH F R, V22, P99, DOI 10.1016/j.cytogfr.2011.04.001; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kantoff PW, 2010, J CLIN ONCOL, V28, P1099, DOI 10.1200/JCO.2009.25.0597; Klebanoff CA, 2006, IMMUNOL REV, V211, P214, DOI 10.1111/j.0105-2896.2006.00391.x; Kratky W, 2011, P NATL ACAD SCI USA, V108, P17414, DOI 10.1073/pnas.1108945108; Krebs P, 2005, J IMMUNOL, V174, P4559, DOI 10.4049/jimmunol.174.8.4559; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; Kuo LL, 2007, J VIROL, V81, P2249, DOI 10.1128/JVI.01577-06; Larocca C, 2011, CANCER J, V17, P359, DOI 10.1097/PPO.0b013e3182325e63; Liao W, 2013, IMMUNITY, V38, P13, DOI 10.1016/j.immuni.2013.01.004; Marabelle A, 2013, J CLIN INVEST, P64859; Marks-Konczalik J, 2000, P NATL ACAD SCI USA, V97, P11445, DOI 10.1073/pnas.200363097; McDermott DF, 2007, CLIN CANCER RES, V13, p716S, DOI 10.1158/1078-0432.CCR-06-1872; Morse MA, 2000, J CLIN ONCOL, V18, P3883, DOI 10.1200/JCO.2000.18.23.3883; Ochsenbein AF, 2001, NATURE, V411, P1058, DOI 10.1038/35082583; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; Prevost-Blondel A, 1998, J IMMUNOL, V161, P2187; Restifo NP, 2012, NAT REV IMMUNOL, V12, P269, DOI 10.1038/nri3191; Schiller JT, 2012, VACCINE, V30, pF123, DOI 10.1016/j.vaccine.2012.04.108; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Serafini P, 2004, CANCER RES, V64, P6337, DOI 10.1158/0008-5472.CAN-04-0757; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Small EJ, 2011, J CLIN ONCOL, V29, P3595, DOI 10.1200/JCO.2011.37.8653; Sporri R, 2005, NAT IMMUNOL, V6, P163, DOI 10.1038/ni1162; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Turley SJ, 2010, NAT REV IMMUNOL, V10, P813, DOI 10.1038/nri2886; van der Burg SH, 2011, TRENDS IMMUNOL, V32, P97, DOI 10.1016/j.it.2010.12.006; Waldmann TA, 2006, NAT REV IMMUNOL, V6, P595, DOI 10.1038/nri1901; Watkins SK, 2011, J CLIN INVEST, V121, P1361, DOI 10.1172/JCI44325; Willimsky G, 2007, IMMUNOL REV, V220, P102, DOI 10.1111/j.1600-065X.2007.00578.x; WITMERPACK MD, 1987, J EXP MED, V166, P1484, DOI 10.1084/jem.166.5.1484; Zust R, 2007, PLOS PATHOG, V3, P1062, DOI 10.1371/journal.ppat.0030109	52	7	7	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2013	8	11							e81442	10.1371/journal.pone.0081442	http://dx.doi.org/10.1371/journal.pone.0081442			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261IJ	24312302	Green Published, gold, Green Submitted			2023-01-03	WOS:000327657900032
J	Mercer, DK; Robertson, J; Wright, K; Miller, L; Smith, S; Stewart, CS; O'Neil, DA				Mercer, Derry K.; Robertson, Jennifer; Wright, Kristine; Miller, Lorna; Smith, Shane; Stewart, Colin S.; O'Neil, Deborah A.			A Prodrug Approach to the Use of Coumarins as Potential Therapeutics for Superficial Mycoses	PLOS ONE			English	Article							ANTIMICROBIAL ACTIVITY; BETA-GLUCOSIDASE; DERIVATIVES; ESCULETIN; ESCULIN; DESIGN	Superficial mycoses are fungal infections of the outer layers of the skin, hair and nails that affect 20-25% of the world's population, with increasing incidence. Treatment of superficial mycoses, predominantly caused by dermatophytes, is by topical and/or oral regimens. New therapeutic options with improved efficacy and/or safety profiles are desirable. There is renewed interest in natural product-based antimicrobials as alternatives to conventional treatments, including the treatment of superficial mycoses. We investigated the potential of coumarins as dermatophyte-specific antifungal agents and describe for the first time their potential utility as topical antifungals for superficial mycoses using a prodrug approach. Here we demonstrate that an inactive coumarin glycone, esculin, is hydrolysed to the antifungal coumarin aglycone, esculetin by dermatophytes. Esculin is hydrolysed to esculetin beta-glucosidases. We demonstrate that beta-glucosidases are produced by dermatophytes as well as members of the dermal microbiota, and that this activity is sufficient to hydrolyse esculin to esculetin with concomitant antifungal activity. A beta-glucosidase inhibitor (conduritol B epoxide), inhibited antifungal activity by preventing esculin hydrolysis. Esculin demonstrates good aqueous solubility (<6 g/l) and could be readily formulated and delivered topically as an inactive prodrug in a water-based gel or cream. This work demonstrates proof-of-principle for a therapeutic application of glycosylated coumarins as inactive prodrugs that could be converted to an active antifungal in situ. It is anticipated that this approach will be applicable to other coumarin glycones.	[Mercer, Derry K.; Robertson, Jennifer; Wright, Kristine; Miller, Lorna; Smith, Shane; Stewart, Colin S.; O'Neil, Deborah A.] NovaBiotics Ltd, Bucksburn, Aberdeen, Scotland		Mercer, DK (corresponding author), NovaBiotics Ltd, Bucksburn, Aberdeen, Scotland.	derry@novabiotics.co.uk	ONeil, Deborah/GWN-2741-2022; Mercer, Derry Keith/AAI-3341-2020	Mercer, Derry Keith/0000-0001-8950-0076				Aoyama Takahiko, 2005, Drug Metab Pharmacokinet, V20, P485, DOI 10.2133/dmpk.20.485; Aureli M, 2012, J INHERIT METAB DIS, V35, P1081, DOI 10.1007/s10545-012-9478-x; Breiden B, 2007, EUR J CELL BIOL, V86, P657, DOI 10.1016/j.ejcb.2007.02.006; CHANG F, 1993, COMP BIOCHEM PHYS A, V105, P251; Clinical and Laboratory Standards Institute-CLSI, 2008, M38A2 CLSI, Vsecond; Crawford F, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001434.pub2; de Hoog GS, 2000, ATLAS CLIN FUNGI; Dekic BR, 2010, MOLECULES, V15, P2246, DOI 10.3390/molecules15042246; Duncan SH, 2004, BRIT J NUTR, V91, P749, DOI 10.1079/BJN20041101; FACKLAM RR, 1970, APPL MICROBIOL, V20, P245, DOI 10.1128/AEM.20.2.245-250.1970; Fidalgo Ana, 2004, Dermatitis, V15, P54, DOI 10.2310/6620.2004.20376; Foti C, 2001, Australas J Dermatol, V42, P145, DOI 10.1046/j.1440-0960.2001.00501.x; Ghannoum M, 2011, J CLIN MICROBIOL; Ghannoum MA, 2006, J CLIN MICROBIOL, V44, P4353, DOI 10.1128/JCM.00688-06; Gomez BL, 2003, CURR OPIN INFECT DIS, V16, P91, DOI 10.1097/00001432-200304000-00005; Gonzalez A, 2009, J CLIN MICROBIOL, V47, P48, DOI 10.1128/JCM.01422-08; Grice EA, 2011, NAT REV MICROBIOL, V9, P244, DOI 10.1038/nrmicro2537; Havlickova B, 2008, MYCOSES, V51, P2, DOI 10.1111/j.1439-0507.2008.01606.x; Huttunen KM, 2011, PHARMACOL REV, V63, P750, DOI 10.1124/pr.110.003459; Jana S, 2010, CURR MED CHEM, V17, P3874, DOI 10.2174/092986710793205426; Johann S, 2007, MEM I OSWALDO CRUZ, V102, P681, DOI [10.1590/S0074-02762007005000087, 10.1590/S0074-02762007000600004]; Kumar R, 2012, FITOTERAPIA, V83, P230, DOI 10.1016/j.fitote.2011.11.003; Lee BC, 2007, ARCH PHARM RES, V30, P1293, DOI 10.1007/BF02980270; Lim EK, 2004, BIOTECHNOL BIOENG, V87, P623, DOI 10.1002/bit.20154; Maranhao FCA, 2011, CAN J MICROBIOL, V57, P333, DOI [10.1139/w11-011, 10.1139/W11-011]; Marren K, 2011, PHYSICIAN SPORTSMED, V39, P75, DOI 10.3810/psm.2011.09.1923; Millikan LE, 2010, CLIN DERMATOL, V28, P212, DOI 10.1016/j.clindermatol.2009.12.016; Munoz-Munoz JL, 2007, BIOSCI BIOTECH BIOCH, V71, P390, DOI 10.1271/bbb.60431; Murray P.R., 2003, MANUAL CLIN MICROBIO, V8th; Redoules D, 2005, J INVEST DERMATOL, V125, P270, DOI 10.1111/j.0022-202X.2005.23785.x; Riveiro ME, 2010, CURR MED CHEM, V17, P1325, DOI 10.2174/092986710790936284; Simon C, 2010, J EXP BOT, V61, P3355, DOI 10.1093/jxb/erq157; Sissi C, 2010, CELL MOL LIFE SCI, V67, P2001, DOI 10.1007/s00018-010-0299-5; Smolinske S. C., 1992, CRC HDB FOOD DRUG CO; Wallace SJ, 2010, J PHYS CHEM B, V114, P4836, DOI 10.1021/jp100458x; WORKMAN WE, 1982, APPL ENVIRON MICROB, V44, P1289, DOI 10.1128/AEM.44.6.1289-1295.1982; Wu L, 2009, CURR MED CHEM, V16, P4236, DOI 10.2174/092986709789578187; Yamada K, 2011, PLANT CELL PHYSIOL, V52, P2039, DOI 10.1093/pcp/pcr156; YANG SJ, 1985, BIOCHIM BIOPHYS ACTA, V828, P236; Youngchim S, 2011, MICROBIOL-SGM, V157, P2348, DOI 10.1099/mic.0.047928-0	40	17	18	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2013	8	11							e80760	10.1371/journal.pone.0080760	http://dx.doi.org/10.1371/journal.pone.0080760			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256KH	24260474	Green Published, gold, Green Submitted			2023-01-03	WOS:000327308500172
J	Labrunee, M; Despas, F; Marque, P; Guiraud, T; Galinier, M; Senard, JM; Pathak, A				Labrunee, Marc; Despas, Fabien; Marque, Philippe; Guiraud, Thibaut; Galinier, Michel; Senard, Jean Michel; Pathak, Atul			Acute electromyostimulation Decreases Muscle Sympathetic Nerve Activity in Patients with Advanced Chronic Heart Failure (EMSICA Study)	PLOS ONE			English	Article							RESYNCHRONIZATION THERAPY; BAROREFLEX SENSITIVITY; STIMULATION TENS; RATE-VARIABILITY; SUBSTANCE-P; EXERCISE; RESPONSES; REFLEX; ACTIVATION; REPRODUCIBILITY	Background: Muscle passive contraction of lower limb by neuromuscular electrostimulation (NMES) is frequently used in chronic heart failure (CHF) patients but no data are available concerning its action on sympathetic activity. However, Transcutaneous Electrical Nerve Stimulation (TENS) is able to improve baroreflex in CHF. The primary aim of the present study was to investigate the acute effect of TENS and NMES compared to Sham stimulation on sympathetic overactivity as assessed by Muscle Sympathetic Nerve Activity (MSNA). Methods: We performed a serie of two parallel, randomized, double blinded and sham controlled protocols in twenty-two CHF patients in New York Heart Association (NYHA) Class III. Half of them performed stimulation by TENS, and the others tested NMES. Results: Compare to Sham stimulation, both TENS and NMES are able to reduce MSNA (63.5 +/- 3.5 vs 69.7 +/- 3.1 bursts / min, p < 0.01 after TENS and 51.6 +/- 3.3 vs 56.7 +/- 3.3 bursts /min, p < 0, 01 after NMES). No variation of blood pressure, heart rate or respiratory parameters was observed after stimulation. Conclusion: The results suggest that sensory stimulation of lower limbs by electrical device, either TENS or NMES, could inhibit sympathetic outflow directed to legs in CHF patients. These properties could benefits CHF patients and pave the way for a new non-pharmacological approach of CHF.	[Labrunee, Marc; Despas, Fabien; Guiraud, Thibaut; Senard, Jean Michel; Pathak, Atul] NIH, Toulouse, France; [Labrunee, Marc; Despas, Fabien; Guiraud, Thibaut; Senard, Jean Michel; Pathak, Atul] Med ResearchTeam, Inst Malad Metab & Cardiovasc, Toulouse, France; [Labrunee, Marc; Despas, Fabien; Marque, Philippe; Galinier, Michel; Senard, Jean Michel; Pathak, Atul] Univ Toulouse 3, Fac Med, F 31432, F-31062 Toulouse, France; [Labrunee, Marc; Galinier, Michel; Pathak, Atul] Univ Hosp, F 31073, Toulouse, France; [Labrunee, Marc; Marque, Philippe] Univ Hosp, Phys Med & Rehabil unit, F 31073, Toulouse, France; [Despas, Fabien; Senard, Jean Michel; Pathak, Atul] Univ Hosp, Clin Pharmacol Unit, F 31073, Toulouse, France; [Guiraud, Thibaut] Cardiopulm Rehabil Ctr, St Orens De Gameville, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; CHU de Toulouse; CHU de Toulouse	Labrunee, M (corresponding author), NIH, Toulouse, France.	marclabrunee@gmail.com	MARQUE, Philippe/AAC-4798-2019; Pathak, Atul/ABC-5223-2020	Pathak, Atul/0000-0001-6151-0096; LABRUNEE, MARC/0000-0001-7782-5703; GALINIER, Michel/0000-0003-1735-3390; Guiraud, Thibaut/0000-0002-9525-5422; Senard, Jean-Michel/0000-0001-7679-1281	Toulouse Hospital; "Fondation pour l'avenir" organism	Toulouse Hospital; "Fondation pour l'avenir" organism	This work was supported by Toulouse Hospital (http://www.chu-toulouse.fr/-delegation-a-la-recherche-clinique) and the "Fondation pour l'avenir" organism for financial support (http://www.fondationdelavenir.org/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banerjee Prithwish, 2010, Curr Heart Fail Rep, V7, P52, DOI 10.1007/s11897-010-0013-9; Barretto ACP, 2009, INT J CARDIOL, V135, P302, DOI 10.1016/j.ijcard.2008.03.056; Casillas J. -M., 2008, Annales de Readaptation et de Medecine Physique, V51, P461, DOI 10.1016/j.annrmp.2008.04.006; Clark AL, 1996, J AM COLL CARDIOL, V28, P1092, DOI 10.1016/S0735-1097(96)00323-3; De Matos LDNJ, 2004, J CARD FAIL, V10, P496, DOI 10.1016/j.cardfail.2004.03.006; Deley G, 2005, EUR J CARDIOV PREV R, V12, P226, DOI 10.1097/00149831-200506000-00007; Despas F, 2009, J HYPERTENS, V27, P1849, DOI 10.1097/HJH.0b013e32832e8d0f; Dobsak P, 2006, CIRC J, V70, P75, DOI 10.1253/circj.70.75; Donadio V, 2002, J PHYSIOL-LONDON, V544, P285, DOI 10.1113/jphysiol.2002.019596; Esler M, 2000, Heart Fail Rev, V5, P17; FERGUSON DW, 1984, CIRCULATION, V69, P451, DOI 10.1161/01.CIR.69.3.451; Fisher WJ, 1999, J PHYSIOL-LONDON, V520, P621, DOI 10.1111/j.1469-7793.1999.00621.x; Fraga R, 2007, EUR J HEART FAIL, V9, P630, DOI 10.1016/j.ejheart.2007.03.003; Franchitto N, 2013, INT J CARDIOL, V168, P2352, DOI 10.1016/j.ijcard.2013.01.023; Franchitto N, 2010, HYPERTENSION, V55, P1012, DOI 10.1161/HYPERTENSIONAHA.109.146779; Gademan MGJ, 2011, INT J CARDIOL, V152, P237, DOI 10.1016/j.ijcard.2010.07.022; Galinier M, 2000, EUR HEART J, V21, P475, DOI 10.1053/euhj.1999.1875; GARRISON DW, 1994, PAIN, V58, P309, DOI 10.1016/0304-3959(94)90124-4; Garrison DW, 1996, NEUROSCI LETT, V216, P125; Grassi G, 1997, CLIN SCI, V92, P285, DOI 10.1042/cs0920285; Grassi G, 2008, EUR J HEART FAIL, V10, P1186, DOI 10.1016/j.ejheart.2008.09.013; Hamdan MH, 2002, AM J CARDIOL, V89, P1047, DOI 10.1016/S0002-9149(02)02273-7; HENRIKSEN O, 1991, ACTA PHYSIOL SCAND, V143, P33; Houssiere A, 2005, AM J PHYSIOL-HEART C, V288, pH1724, DOI 10.1152/ajpheart.01043.2004; Karavidas AI, 2006, EUR J CARDIOV PREV R, V13, P592, DOI 10.1097/01.hjr.0000219111.02544.ff; La Rovere MT, 2009, J AM COLL CARDIOL, V53, P193, DOI 10.1016/j.jacc.2008.09.034; MARTINI F, 1995, J AUTONOM NERV SYST, V51, P143, DOI 10.1016/0165-1838(94)00126-5; Middlekauff HR, 2007, J APPL PHYSIOL, V102, P492, DOI 10.1152/japplphysiol.00994.2006; Najem B, 2005, J CARD FAIL, V11, P529, DOI 10.1016/j.cardfail.2005.04.001; Nuhr MJ, 2004, EUR HEART J, V25, P136, DOI 10.1016/j.ehj.2003.09.027; Piepoli Massimo F, 2007, J Appl Physiol (1985), V102, P494; Potts JT, 1999, J PHYSIOL-LONDON, V514, P829, DOI 10.1111/j.1469-7793.1999.829ad.x; Robinson AJ, 1996, J ORTHOP SPORT PHYS, V24, P208, DOI 10.2519/jospt.1996.24.4.208; Roveda F, 2003, J AM COLL CARDIOL, V42, P854, DOI 10.1016/S0735-1097(03)00831-3; Sandercock GRH, 2005, INT J CARDIOL, V103, P238, DOI 10.1016/j.ijcard.2004.09.013; Sbruzzi G, 2010, EUR J CARDIOV PREV R, V17, P254, DOI 10.1097/HJR.0b013e328339b5a2; SJOLUND BH, 1988, J NEUROSURG, V68, P279, DOI 10.3171/jns.1988.68.2.0279; Smart NA, 2013, INT J CARDIOL, V167, P80, DOI 10.1016/j.ijcard.2011.12.019; STERNS DA, 1991, CIRCULATION, V84, P2034, DOI 10.1161/01.CIR.84.5.2034; Wu MY, 2008, AUTON NEUROSCI-BASIC, V138, P9, DOI 10.1016/j.autneu.2007.11.001; Zhou W, 2006, J APPL PHYSIOL, V100, P926, DOI 10.1152/japplphysiol.01130.2005; Zhou W, 2009, AM J PHYSIOL-HEART C, V297, pH859, DOI 10.1152/ajpheart.00149.2009	42	9	10	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2013	8	11							e79438	10.1371/journal.pone.0079438	http://dx.doi.org/10.1371/journal.pone.0079438			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255PK	24265770	gold, Green Published, Green Submitted			2023-01-03	WOS:000327252100103
J	Shih, CC; Hsu, YT; Wang, HH; Chen, TL; Tsai, CC; Lane, HL; Yeh, CC; Sung, FC; Chiu, WT; Cherng, YG; Liao, CC				Shih, Chun-Chuan; Hsu, Yi-Ting; Wang, Hwang-Huei; Chen, Ta-Liang; Tsai, Chin-Chuan; Lane, Hsin-Long; Yeh, Chun-Chieh; Sung, Fung-Chang; Chiu, Wen-Ta; Cherng, Yih-Giun; Liao, Chien-Chang			Decreased Risk of Stroke in Patients with Traumatic Brain Injury Receiving Acupuncture Treatment: A Population-Based Retrospective Cohort Study	PLOS ONE			English	Article							TRADITIONAL CHINESE MEDICINE; ADVERSE OUTCOMES; WEIGHT-LOSS; TAIWAN; COUNTRIES; EPILEPSY; STRATEGY; CHILDREN; RECOVERY	Background: Patients with traumatic brain injury (TBI) face increased risk of stroke. Whether acupuncture can help to protect TBI patients from stroke has not previously been studied. Methods: Taiwan's National Health Insurance Research Database was used to conduct a retrospective cohort study of 7409 TBI patients receiving acupuncture treatment and 29,636 propensity-score-matched TBI patients without acupuncture treatment in 2000-2008 as controls. Both TBI cohorts were followed until the end of 2010 and adjusted for immortal time to measure the incidence and adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) of new-onset stroke in the multivariable Cox proportional hazard models. Results: TBI patients with acupuncture treatment (4.9 per 1000 person-years) had a lower incidence of stroke compared with those without acupuncture treatment (7.5 per 1000 person-years), with a HR of 0.59 (95% CI = 0.50-0.69) after adjustment for sociodemographics, coexisting medical conditions and medications. The association between acupuncture treatment and stroke risk was investigated by sex and age group (20-44, 45-64, and >= 65 years). The probability curve with log-rank test showed that TBI patients receiving acupuncture treatment had a lower probability of stroke than those without acupuncture treatment during the follow-up period (p < 0.0001). Conclusion: Patients with TBI receiving acupuncture treatment show decreased risk of stroke compared with those without acupuncture treatment. However, this study was limited by lack of information regarding lifestyles, biochemical profiles, TBI severity, and acupuncture points used in treatments.	[Shih, Chun-Chuan; Tsai, Chin-Chuan; Lane, Hsin-Long] I Shou Univ, Sch Chinese Med Postbaccalaureate, Kaohsiung, Taiwan; [Hsu, Yi-Ting] China Med Univ Hosp, Neurosci Lab, Dept Neurol, Taichung, Taiwan; [Wang, Hwang-Huei] China Med Univ, Grad Inst Integrated Med, Coll Chinese Med, Taichung, Taiwan; [Chen, Ta-Liang; Liao, Chien-Chang] Taipei Med Univ Hosp, Dept Anesthesiol, Taipei, Taiwan; [Chen, Ta-Liang; Liao, Chien-Chang] Taipei Med Univ Hosp, Ctr Hlth Policy Res, Taipei, Taiwan; [Chen, Ta-Liang; Liao, Chien-Chang] Taipei Med Univ, Sch Med, Coll Med, Taipei, Taiwan; [Yeh, Chun-Chieh] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan; [Sung, Fung-Chang] China Med Univ, Dept Publ Hlth, Taichung, Taiwan; [Chiu, Wen-Ta] Taipei Med Univ, Grad Inst Injury Prevent & Control, Taipei, Taiwan; [Cherng, Yih-Giun] Taipei Med Univ, Dept Anesthesiol, Shuang Ho Hosp, New Taipei City, Taiwan; [Liao, Chien-Chang] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan	I Shou University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; China Medical University Taiwan; China Medical University Taiwan; Taipei Medical University; Taipei Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan	Liao, CC (corresponding author), Taipei Med Univ Hosp, Dept Anesthesiol, Taipei, Taiwan.	jacky48863027@yahoo.com.tw	Yeh, Chun Chieh/I-4893-2019; Yeh, Chun Chieh/Y-3304-2019	Yeh, Chun Chieh/0000-0001-6753-7564; Hsu, Yi-ting/0000-0002-8552-131X; Cherng, Yih-Giun/0000-0002-0201-4380	Committee on Chinese Medicine and Pharmacy, Department of Health, Taiwan [CCMP98-RD-038, CCMP99-RD-035]; National Science Council, Taiwan [102-2314-B-038-021-MY3]; Taiwan Department of Health Clinical Trial and Research Center of Excellence [DOH102-TD-B-111-004]	Committee on Chinese Medicine and Pharmacy, Department of Health, Taiwan; National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Taiwan Department of Health Clinical Trial and Research Center of Excellence	This study is supported in part by a Grant from the Committee on Chinese Medicine and Pharmacy, Department of Health, Taiwan (CCMP98-RD-038 and CCMP99-RD-035), the National Science Council, Taiwan (102-2314-B-038-021-MY3), and Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the paper.	Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Burke JF, 2013, NEUROLOGY, V81, P33, DOI 10.1212/WNL.0b013e318297eecf; Cabioglu MT, 2005, AM J CHINESE MED, V33, P525, DOI 10.1142/S0192415X05003132; Chang CC, 2013, BRIT J SURG, V100, P684, DOI 10.1002/bjs.9065; Chen YH, 2011, STROKE, V42, P2733, DOI 10.1161/STROKEAHA.111.620112; Choi DC, 2010, NEUROBIOL DIS, V39, P272, DOI 10.1016/j.nbd.2010.04.003; Dhond RP, 2008, PAIN, V136, P407, DOI 10.1016/j.pain.2008.01.011; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Engberg AW, 2007, J HEAD TRAUMA REHAB, V22, P221, DOI 10.1097/01.HTR.0000281837.62226.54; Fang JL, 2009, HUM BRAIN MAPP, V30, P1196, DOI 10.1002/hbm.20583; Feigin VL, 2007, LANCET NEUROL, V6, P94, DOI 10.1016/S1474-4422(07)70007-8; Flachskampf FA, 2007, CIRCULATION, V115, P3121, DOI 10.1161/CIRCULATIONAHA.106.661140; He Jing, 2005, J Tradit Chin Med, V25, P171; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hsieh CH, 2010, AM J CHINESE MED, V38, P675, DOI 10.1142/S0192415X10008147; Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F; Ishibe N, 2009, J HEAD TRAUMA REHAB, V24, P424, DOI 10.1097/HTR.0b013e3181c13426; Kim DD, 2006, MICROCIRCULATION, V13, P577, DOI 10.1080/10739680600885210; Levesque LE, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5087; Liao CC, 2013, ANN SURG, V257, P433, DOI 10.1097/SLA.0b013e31827b9b25; Liao CC, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/387164; Liao CC, 2012, J TRAUMA ACUTE CARE, V73, P1327, DOI 10.1097/TA.0b013e31826fc87f; Liao CC, 2012, J NEUROL NEUROSUR PS, V83, P1186, DOI 10.1136/jnnp-2012-302337; Liao CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031527; Lin JA, 2013, ANN RHEUMATOL DIS; O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3; Quah-Smith I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012619; Shih CC, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/262039; Shih CC, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-191; Shih CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032540; Shih CC, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-27; Shih CC, 2009, CHINESE MED J-PEKING, V122, P1544, DOI 10.3760/cma.j.issn.0366-6999.2009.13.013; Sze FKH, 2002, STROKE, V33, P2604, DOI 10.1161/01.STR.0000035908.74261.C9; Tseng YJ, 2013, J ALTERN COMPLEM MED, V19, P474, DOI 10.1089/acm.2012.0163; Wong V, 2013, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD007700.PUB3; Wu P, 2010, STROKE, V41, pE171, DOI 10.1161/STROKEAHA.109.573576; Yeh CC, 2013, MAYO CLIN PROC, V88, P1091, DOI 10.1016/j.mayocp.2013.06.024; Yeh CC, 2013, DIABETES CARE, V36, P3216, DOI 10.2337/dc13-0770; Yeh CC, 2013, J NEUROL NEUROSUR PS, V84, P441, DOI 10.1136/jnnp-2012-302547; Zollman FS, 2012, J HEAD TRAUMA REHAB, V27, P135, DOI 10.1097/HTR.0b013e3182051397	40	16	16	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2014	9	2							e89208	10.1371/journal.pone.0089208	http://dx.doi.org/10.1371/journal.pone.0089208			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AB3TA	24586597	Green Published, gold, Green Submitted			2023-01-03	WOS:000331711900105
J	Wise, J				Wise, Jacqui			Patent wars: affordable medicines versus intellectual property rights	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							INDIA; DRUG					jacquiyoung1@gmail.com						[Anonymous], 2013, BRAZILS PATENT REFOR; Arie S, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2949; Arie S, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2099; Arie S, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e6015; Bagcchi S, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1094; Bollyky T, 2013, WHY CHEMOTHERAPY COS; Global Intellectual Property Center, MEAS MOM; Light DW, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4348; Limb M, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5197; Medecins Sans Frontieres, 2013, TRANSP PARTN AGR; Office of the United States Trade Representative, 2013, 2013 SPEC 301 REP; UCL School of Pharmacy, PAT NEEDS MED INN GL; UCL School of Pharmacy, 2013, HLTH HLTH CAR IND NA	13	2	2	1	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 17	2014	348								g1533	10.1136/bmj.g1533	http://dx.doi.org/10.1136/bmj.g1533			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AB9ZG	24535664				2023-01-03	WOS:000332153700004
J	Ding, XH; Hu, JB; Wen, CP; Ding, ZS; Yao, L; Fan, YS				Ding, Xinghong; Hu, Jinbo; Wen, Chengping; Ding, Zhishan; Yao, Li; Fan, Yongsheng			Rapid Resolution Liquid Chromatography Coupled with Quadrupole Time-of-Flight Mass Spectrometry-Based Metabolomics Approach to Study the Effects of Jieduquyuziyin Prescription on Systemic Lupus Erythematosus	PLOS ONE			English	Article							PLATELET-ACTIVATING-FACTOR; INTESTINAL MICROBIOTA; SAMPLE PREPARATION; EXPRESSION; CELLS; MS; 12-LIPOXYGENASE; METABONOMICS; METHODOLOGY; TRYPTOPHAN	Jieduquyuziyin prescription (JP), a traditional Chinese medicine (TCM) prescription, has been widely used for the clinical treatment of systemic lupus erythematosus (SLE). However, the complex chemical constituents of JP and the multifactorial pathogenesis of SLE make research on the therapeutic mechanism of JP in SLE challenging. In this paper, a serum metabolomics approach based on rapid resolution liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (RRLC-Q-TOF/MS) was employed to acquire the metabolic characteristics of serum samples obtained from mice in the SLE model group, JP-treated group, prednisone acetate (PA)-treated group and control group. The orthogonal partial least squares (OPLS) was applied to recognize metabolic patterns, and an obvious separation of groups was obtained. Thirteen metabolites, namely, phosphatidylethanolamine (PE 20:3), hepoxilin B3, lyso-phosphatidylethanolamine (lyso-PE 22:6), 12S-hydroxypentaenoic acid (12S-HEPE), traumatic acid, serotonin, platelet-activating factor (PAF), phosphatidylcholine (PC 20:5), eicosapentaenoic acid (EPA), 12(S)-hydroxyei-cosatetraenoic acid (12S-HETE), 14-hydroxy docosahexaenoic acid (14-HDOHE), lyso-phosphatidylcholine (lyso-PC 20:4), and indole acetaldehyde, were identified and characterized as differential metabolites involved in the pathogenesis of SLE. After treatment with JP, the relative content of 12(S)-HETE, PAF, 12(S)-HEPE, EPA, PE (20:3), Lyso-PE(22:6), and 14-HDOHE were effectively regulated, which suggested that the therapeutic effects of JP on SLE may involve regulating disturbances to the metabolism of unsaturated fatty acid, tryptophan and phospholipid. This research also demonstrated that metabolomics is a powerful tool for researching complex disease mechanisms and evaluating the mechanism of action of TCM.	[Ding, Xinghong] Zhejiang Chinese Med Univ, Anal & Testing Ctr, Hangzhou, Zhejiang, Peoples R China; [Hu, Jinbo; Yao, Li] Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Hangzhou, Zhejiang, Peoples R China; [Wen, Chengping; Fan, Yongsheng] Zhejiang Chinese Med Univ, Coll Basic Med, Hangzhou, Zhejiang, Peoples R China; [Ding, Zhishan] Zhejiang Chinese Med Univ, Coll Life Sci, Hangzhou, Zhejiang, Peoples R China	Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University	Fan, YS (corresponding author), Zhejiang Chinese Med Univ, Coll Basic Med, Hangzhou, Zhejiang, Peoples R China.	applezjtcm@126.com		chengping, Wen/0000-0001-9254-6235; Yao, Li/0000-0001-8720-3027	National Natural Science Foundation of China [81001515]; Research Fund for the Doctoral Program of Higher Education of China [20093322120001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Fund for the Doctoral Program of Higher Education of China(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP))	This study was supported by grants from the National Natural Science Foundation of China (No. 81001515), the Research Fund for the Doctoral Program of Higher Education of China (No. 20093322120001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alegre E, 2008, CLIN CHIM ACTA, V393, P132, DOI 10.1016/j.cca.2008.03.011; An ZL, 2010, J PROTEOME RES, V9, P4071, DOI 10.1021/pr100265g; Duffau P, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001001; [范永升 Fan Yongsheng], 2005, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V20, P667; Gabrielsson J, 2006, CHEMOMETR INTELL LAB, V84, P153, DOI 10.1016/j.chemolab.2006.03.013; Gika H, 2011, BIOANALYSIS, V3, P1647, DOI [10.4155/BIO.11.122, 10.4155/bio.11.122]; Gika HG, 2008, J CHROMATOGR B, V871, P299, DOI 10.1016/j.jchromb.2008.05.048; Goodpaster AM, 2011, CHEMOMETR INTELL LAB, V109, P162, DOI 10.1016/j.chemolab.2011.08.009; Gurevitz Samuel L, 2013, Consult Pharm, V28, P110, DOI 10.4140/TCP.n.2013.110; Hu JB, 2013, CHROMATOGRAPHIA, V76, P791, DOI 10.1007/s10337-013-2476-9; HWANG D, 1989, FASEB J, V3, P2052, DOI 10.1096/fasebj.3.9.2501132; Kang SW, 2001, KIDNEY INT, V59, P1354, DOI 10.1046/j.1523-1755.2001.0590041354.x; Lahti L, 2013, PEERJ, V1, DOI 10.7717/peerj.32; Laparra JM, 2010, PHARMACOL RES, V61, P219, DOI 10.1016/j.phrs.2009.11.001; Le Rond S, 2005, IMMUNOLOGY, V116, P297, DOI 10.1111/j.1365-2567.2005.02224.x; Manson JJ, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-6; Manzi S, 2000, ANN RHEUM DIS, V59, P321, DOI 10.1136/ard.59.5.321; Maynard CL, 2012, NATURE, V489, P231, DOI 10.1038/nature11551; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Minhas Ujla, 2012, Inflammopharmacology, V20, P195, DOI 10.1007/s10787-011-0102-8; Mori Trevor A, 2004, Curr Atheroscler Rep, V6, P461, DOI 10.1007/s11883-004-0087-5; Nicholson JK, 1999, XENOBIOTICA, V29, P1181, DOI 10.1080/004982599238047; Papavasiliou EC, 2005, KIDNEY INT, V68, P246, DOI 10.1111/j.1523-1755.2005.00399.x; PERICO N, 1988, LAB INVEST, V58, P163; Price Sarah, 2010, Nat Rev Rheumatol, V6, P613, DOI 10.1038/nrrheum.2010.164; Psychogios N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016957; Reddy MA, 2002, AM J PHYSIOL-RENAL, V283, pF985, DOI 10.1152/ajprenal.00181.2002; Reeves WH, 2009, TRENDS IMMUNOL, V30, P455, DOI 10.1016/j.it.2009.06.003; Ruiz-Irastorza G, 2012, RHEUMATOLOGY, V51, P1145, DOI 10.1093/rheumatology/ker410; Sana Theodore R, 2008, J Biomol Tech, V19, P258; SATOH M, 1994, J EXP MED, V180, P2341, DOI 10.1084/jem.180.6.2341; Theodoridis G, 2008, TRAC-TREND ANAL CHEM, V27, P251, DOI 10.1016/j.trac.2008.01.008; Thibault DL, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2771; Vance JE, 2008, J LIPID RES, V49, P1377, DOI 10.1194/jlr.R700020-JLR200; Velagapudi VR, 2010, J LIPID RES, V51, P1101, DOI 10.1194/jlr.M002774; Vuckovic D, 2012, ANAL BIOANAL CHEM, V403, P1523, DOI 10.1007/s00216-012-6039-y; Weckwerth W, 2003, ANNU REV PLANT BIOL, V54, P669, DOI 10.1146/annurev.arplant.54.031902.135014; Wen C., 2007, CHIN ARCH TRADITI CH, V25, P1599; Xu G.W., 2009, WORLD SCI TECHNOL, V11, P107; Yost CC, 2010, BIOCHIMIE, V92, P692, DOI 10.1016/j.biochi.2010.02.011	40	23	23	1	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2014	9	2							e88223	10.1371/journal.pone.0088223	http://dx.doi.org/10.1371/journal.pone.0088223			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA1AT	24505438	Green Published, gold, Green Submitted			2023-01-03	WOS:000330829200143
J	Yuan, SY				Yuan, Sanying			China should reduce the overuse of intravenous infusion	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HEALTH		Sichuan Univ, Dept Liver Surg, West China Hosp, Chengdu 610064, Sichuan, Peoples R China	Sichuan University	Yuan, SY (corresponding author), Sichuan Univ, Dept Liver Surg, West China Hosp, Chengdu 610064, Sichuan, Peoples R China.	ysy404@126.com						An JG, 2013, LANCET, V382, P936, DOI 10.1016/S0140-6736(13)61928-5; [Anonymous], 2010, LANCET, V376, P657, DOI 10.1016/S0140-6736(10)61315-3; [Anonymous], MOST 8 6 MILLION DOC; [Anonymous], 2013, CHINA NEWS      0910; Blumenthal D, 2005, NEW ENGL J MED, V353, P1165, DOI 10.1056/NEJMhpr051133; Harris DM, 2005, J LAW MED ETHICS, V33, P456, DOI 10.1111/j.1748-720X.2005.tb00512.x; Hesketh T, 2004, BRIT MED J, V329, P1427, DOI 10.1136/bmj.329.7480.1427; Hesketh T, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5730; Hui L, 1997, PEDIATR INFECT DIS J, V16, P560, DOI 10.1097/00006454-199706000-00005; Li Z, 2011, BEIJING TODAY   0114; Liu T, 2006, BRIT MED J, V333, P365, DOI 10.1136/bmj.38943.408021.80; Ming Zhang, 2011, TIANJIN J NURSING, V19, P102; Shan J., 2012, CHINA DAILY; Sue DT, 2010, CHINESE RURAL HLTH S, V30, P296; Yan ZG, 1998, CHINA PHARM, V9, P246; Yip WCM, 2012, LANCET, V379, P833, DOI 10.1016/S0140-6736(11)61880-1	16	14	15	1	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 4	2014	348								g1262	10.1136/bmj.g1262	http://dx.doi.org/10.1136/bmj.g1262			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AA4IV	24495923				2023-01-03	WOS:000331060200005
J	Deletre, E; Martin, T; Campagne, P; Bourguet, D; Cadin, A; Menut, C; Bonafos, R; Chandre, F				Deletre, Emilie; Martin, Thibaud; Campagne, Pascal; Bourguet, Denis; Cadin, Andy; Menut, Chantal; Bonafos, Romain; Chandre, Fabrice			Repellent, Irritant and Toxic Effects of 20 Plant Extracts on Adults of the Malaria Vector Anopheles gambiae Mosquito	PLOS ONE			English	Article							THROUGHPUT SCREENING SYSTEM; ESSENTIAL OILS; AEDES-AEGYPTI; SPATIAL REPELLENT; CONTACT IRRITANT; BURKINA-FASO; INSECT; PEST; DIPTERA; IDENTIFICATION	Pyrethroid insecticides induce an excito-repellent effect that reduces contact between humans and mosquitoes. Insecticide use is expected to lower the risk of pathogen transmission, particularly when impregnated on long-lasting treated bednets. When applied at low doses, pyrethroids have a toxic effect, however the development of pyrethroid resistance in several mosquito species may jeopardize these beneficial effects. The need to find additional compounds, either to kill disease-carrying mosquitoes or to prevent mosquito contact with humans, therefore arises. In laboratory conditions, the effects (i. e., repellent, irritant and toxic) of 20 plant extracts, mainly essential oils, were assessed on adults of Anopheles gambiae, a primary vector of malaria. Their effects were compared to those of DEET and permethrin, used as positive controls. Most plant extracts had irritant, repellent and/or toxic effects on An. gambiae adults. The most promising extracts, i. e. those combining the three types of effects, were from Cymbopogon winterianus, Cinnamomum zeylanicum and Thymus vulgaris. The irritant, repellent and toxic effects occurred apparently independently of each other, and the behavioural response of adult An. gambiae was significantly influenced by the concentration of the plant extracts. Mechanisms underlying repellency might, therefore, differ from those underlying irritancy and toxicity. The utility of the efficient plant extracts for vector control as an alternative to pyrethroids may thus be envisaged.	[Deletre, Emilie; Martin, Thibaud; Cadin, Andy] Cirad, UR Hortsys, Montpellier, France; [Martin, Thibaud; Campagne, Pascal] ICIPE, Plant Hlth Dept, Nairobi, Kenya; [Bourguet, Denis] INRA CIRAD IRD Montpellier SupAgro, UMR CBGP, Montpellier, France; [Menut, Chantal] Fac Pharm Montpellier, Inst Biomol Max Mousseron, Montpellier, France; [Bonafos, Romain] USAE, Montpellier SupAgro, Montpellier, France; [Chandre, Fabrice] IRD CNRS UM1 UM2, UMR MiVEGEC, Montpellier, France	CIRAD; International Centre of Insect Physiology & Ecology (ICIPE); CIRAD; INRAE; Institut Agro; Montpellier SupAgro; Institut de Recherche pour le Developpement (IRD); Ecole nationale superieure de chimie de Montpellier; Universite de Montpellier; Institut Agro; Montpellier SupAgro; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier	Deletre, E (corresponding author), Cirad, UR Hortsys, Montpellier, France.	emilie.deletre@cirad.fr	Chandre, Fabrice/Q-3429-2019	Chandre, Fabrice/0000-0002-1994-9705; Bourguet, Denis/0000-0002-2109-5323	Mutavie fundation; IRD; CIRAD	Mutavie fundation; IRD; CIRAD	This study was financed by Mutavie fundation (grant Agreement). The authors also thank IRD, CIRAD for financial support. The funding sources had no involvement at any stage in the preparation of this paper and the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott WS, 1925, J ECON ENTOMOL, V18, P265, DOI 10.1093/jee/18.2.265a; Achee NL, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-164; Achee NL, 2009, J AM MOSQUITO CONTR, V25, P156, DOI 10.2987/08-5831.1; Amer A, 2006, PARASITOL RES, V99, P466, DOI 10.1007/s00436-006-0182-3; [Anonymous], [No title captured]; Awolola T., 2012, MALAR CONTROL ELIMIN, V1; Barnard DR, 1999, J MED ENTOMOL, V36, P625, DOI 10.1093/jmedent/36.5.625; Bourguet D, 2013, TRENDS ECOL EVOL, V28, P110, DOI 10.1016/j.tree.2012.09.001; Cook SM, 2007, ANNU REV ENTOMOL, V52, P375, DOI 10.1146/annurev.ento.52.110405.091407; Corbel V, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-47; Dabire KR, 2009, TROP MED INT HEALTH, V14, P396, DOI 10.1111/j.1365-3156.2009.02243.x; DAVIS EE, 1976, J COMP PHYSIOL, V105, P43, DOI 10.1007/BF01380052; de Boer H, 2010, J MED ENTOMOL, V47, P400, DOI 10.1603/ME09273; Dekker T, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-183; Ditzen M, 2008, SCIENCE, V319, P1838, DOI 10.1126/science.1153121; Djogbenou L, 2008, AM J TROP MED HYG, V78, P298, DOI 10.4269/ajtmh.2008.78.298; Djogbenou L, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-70; Dusfour I, 2009, J VECTOR ECOL, V34, P232, DOI [10.3376/038.034.0209, 10.1111/j.1948-7134.2009.00031.x]; Foster SP, 1997, ANNU REV ENTOMOL, V42, P123, DOI 10.1146/annurev.ento.42.1.123; Grieco JP, 2005, J AM MOSQUITO CONTR, V21, P404, DOI 10.2987/8756-971X(2006)21[404:ANHSST]2.0.CO;2; Harrewijn Paul, 1995, Chemoecology, V5-6, P55, DOI 10.1007/BF01259434; Hilje L, 2006, ADV PHYTOMED, V3, P379; HOLM S, 1979, SCAND J STAT, V6, P65; Hothorn T, 2008, BIOMETRICAL J, V50, P346, DOI 10.1002/bimj.200810425; Isman MB, 2000, CROP PROT, V19, P603, DOI 10.1016/S0261-2194(00)00079-X; Isman MB, 2006, ANNU REV ENTOMOL, V51, P45, DOI 10.1146/annurev.ento.51.110104.151146; Ramirez GIJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048698; Licciardi S, 2006, MED VET ENTOMOL, V20, P288, DOI 10.1111/j.1365-2915.2006.00630.x; Maia MF, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-S1-S11; Matthews, 1978, INSECT BEHAV; Specos MMM, 2010, T ROY SOC TROP MED H, V104, P653, DOI 10.1016/j.trstmh.2010.06.004; Moretti AN, 2013, J MED ENTOMOL, V50, P1046, DOI 10.1603/ME12248; Namountougou M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048412; NARAHASHI T, 1971, B WORLD HEALTH ORGAN, V44, P337; Pickett JA, 2008, P NATL ACAD SCI USA, V105, P13195, DOI 10.1073/pnas.0807167105; Pridgeon JW, 2009, J AM MOSQUITO CONTR, V25, P168, DOI 10.2987/08-5837.1; R Development Core Team, 2012, R LANG ENV STAT COMP; Raghavendra K, 2011, PARASITOL RES, V108, P757, DOI 10.1007/s00436-010-2232-0; Ranson H, 2011, TRENDS PARASITOL, V27, P91, DOI 10.1016/j.pt.2010.08.004; Rattan RS, 2010, CROP PROT, V29, P913, DOI 10.1016/j.cropro.2010.05.008; Regnault-Roger C., 1997, INTEGR PEST MANAG RE, V2, P25, DOI [10.1023/A:1018472227889, DOI 10.1023/A:1018472227889]; Regnault-Roger C, 2002, BIOPESTICIDE ORIGINE; Regnault-Roger C, 2012, ANNU REV ENTOMOL, V57, P405, DOI 10.1146/annurev-ento-120710-100554; Said SH, 2009, J AM MOSQUITO CONTR, V25, P436, DOI 10.2987/09-5895.1; Syed Z, 2008, P NATL ACAD SCI USA, V105, P13598, DOI 10.1073/pnas.0805312105; Tawatsin A, 2001, J VECTOR ECOL, V26, P76; Temu EA, 2013, PLOS ONE, V7, P9, DOI DOI 10.1371/J0URNAL.-P0NE.0044986; Thanispong K, 2010, J MED ENTOMOL, V47, P833, DOI 10.1603/ME09246; White GB, 2007, INSECT REPELLENTS PR, P31; WHO, 2011, WORLD MALARIA REPORT 2011, P1; *WHO, 1993, WHO TECHN REP SER, V839; WHO, 2008, WORLD MAL REP 2008, P10; WHO UNICEF, 2005, WORLD MALARIA REPORT; World Health Organisation, 1998, TEST PROC INS RES MO; World Health Organisation, 2013, GUID EFF TEST SPAT R; Yadouleton A, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-60; Zaim M, 2000, MED VET ENTOMOL, V14, P1, DOI 10.1046/j.1365-2915.2000.00211.x; Zoubiri S, J SAUDI CHE IN PRESS	58	46	48	0	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2013	8	12							e82103	10.1371/journal.pone.0082103	http://dx.doi.org/10.1371/journal.pone.0082103			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278IG	24376515	Green Published, gold, Green Submitted			2023-01-03	WOS:000328882000006
J	Millier, A; Cohen, J; Toumi, M				Millier, Aurelie; Cohen, Joshua; Toumi, Mondher			Economic Impact of a triptan Rx-To-OTC Switch in Six EU Countries	PLOS ONE			English	Article							QUALITY-OF-LIFE; HEALTH-CARE UTILIZATION; MEDICATION OVERUSE; COST-EFFECTIVENESS; CHRONIC MIGRAINE; PREVALENCE; MANAGEMENT; DISABILITY; GUIDELINES; DIAGNOSIS	Introduction: Triptans have been safely and effectively used in the management of migraine for more than fifteen years, and it seems reasonable to wonder what would be the economic impact of moving a specific triptan to OTC availability. The objective of this study was then to examine the economic impact of payer policies of a triptan Rx-toOTC switch in six EU countries (France, UK, Spain, Italy, Germany and Poland). Methods: A decision model was used to model the budgetary impact of a triptan Rx-to-OTC switch from the thirdparty payer (TPP) and the societal perspectives, using a one-year timeframe. Results: From the TPP perspective, it is estimated that the current overall direct spending on the management of migraine attacks across the 6 EU Member States is (sic)582 million annually, and that the savings would reach (sic)75 million (13% of the overall direct economic burden of migraine). From the societal perspective, 86 million annually would be added. Conclusions: Given evidence of effectiveness and safety, and given the potential savings, a triptan Rx-to-OTC switch is a reasonable public policy decision.	[Millier, Aurelie] Creativ Ceut, Hlth Econ & Outcomes Res Dept, Paris, France; [Cohen, Joshua] Tufts Univ, Tufts Ctr, Study Drug Dev, Boston, MA 02111 USA; [Toumi, Mondher] Univ Lyon 1, Unite Format & Rech Odontol, F-69365 Lyon, France	Tufts University; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Millier, A (corresponding author), Creativ Ceut, Hlth Econ & Outcomes Res Dept, Paris, France.	ami@creativ-ceutical.com						Abel H, 2009, OPTOMETRY, V80, P138, DOI 10.1016/j.optm.2008.06.008; [Anonymous], 2011, BMC NEUROLOGY; [Anonymous], 2005, SOIK HEALTHC COSTS D; [Anonymous], EC PUBL HLTH VAL SEL; [Anonymous], 2010, ANN SURVEY HOURS EAR; [Anonymous], 2010, WART STAW KAP POR RY; Baggott M, 2000, JAMA-J AM MED ASSOC, V284, P2190, DOI 10.1001/jama.284.17.2190; Banque mondiale, 2011, BANQUE MONDIALE INDI; Bewertungsmalistab Einheitlicher, 2011, EBM; British. Association for the Study of Headache, 2007, GUID HEALTHC PROF DI; Brown JS, 2006, CEPHALALGIA, V26, P1473, DOI 10.1111/j.1468-2982.2006.01240.x; Christian Lucas, 2011, CEPH CHRON QUOT AB M; Cohen J, 2013, J Med Econ, V16, P835, DOI 10.3111/13696998.2013.793693; Creac'h C, 2009, HEADACHE, V49, P519, DOI 10.1111/j.1526-4610.2009.01365.x; D'Amico D, 2005, HEADACHE, V45, P553, DOI 10.1111/j.1526-4610.2005.05109.x; D'Amico D, 2003, NEUROL SCI, V24, pS97; Demarin V, 2005, ACTA MED CROATICA, V62, P99; Falagas ME, 2007, INT J CLIN PRACT, V61, P1569, DOI 10.1111/j.1742-1241.2007.01423.x; Food and Drug Administration, 2005, T0523 FAO; Gallai V, 2001, J HEADACHE PAIN, V2, P125; Geraud G, 2004, CLIN THER, V26, P1305; Gerth WC, 2001, PHARMACOECONOMICS, V19, P197, DOI 10.2165/00019053-200119020-00006; Gomez-Gerique Juan Antonio, 2004, Eur J Health Econ, V5, P278, DOI 10.1007/s10198-003-0222-1; Guidotti M, 2009, CLIN DRUG INVEST, V29, P693, DOI 10.2165/11315330-000000000-00000; Haag G, 2011, J HEADACHE PAIN, V12, P201, DOI 10.1007/s10194-010-0266-4; Ilioudi Stamatia, 2010, Int J Electron Healthc, V5, P327, DOI 10.1504/IJEH.2010.036205; Jamieson DG, 2002, AM J MED, V112, P135, DOI 10.1016/S0002-9343(01)01064-6; Jensen K, 1998, CEPHALALGIA, V18, P9, DOI 10.1046/j.1468-2982.1998.1801009.x; Johnston MM, 2010, DRUGS, V70, P1505, DOI 10.2165/11537990-000000000-00000; Kalra Arun A, 2007, Ther Clin Risk Manag, V3, P449; KOFOED LL, 1985, GERIATRICS, V40, P55; Lainez JM, 2007, REV CLIN ESP, V207, P190, DOI [10.1157/13101849, DOI 10.1157/13101849.PUBMED:17475183]; Lainez MJA, 2005, HEADACHE, V45, P883, DOI 10.1111/j.1526-4610.2005.05156.x; Landy SH, 2012, HEADACHE, V52, P363, DOI 10.1111/j.1526-4610.2011.02029.x; Lanteri-Minet M, 2011, CEPHALALGIA, V31, P837, DOI 10.1177/0333102411398400; Lipton RB, 2003, NEUROLOGY, V60, P441, DOI 10.1212/WNL.60.3.441; Lordick F, 2007, EUR J CANCER, V43, P299, DOI 10.1016/j.ejca.2006.09.019; MacGregor EA, 2004, CURR MED RES OPIN, V20, P1777, DOI 10.1185/030079904X10142; MacGregor EA, 1998, DRUG TODAY, V34, P1027, DOI 10.1358/dot.1998.34.12.487488; Matias-Guiu J, 2011, CEPHALALGIA, V31, P463, DOI 10.1177/0333102410382794; National Institute on Drug Abuse, 2001, NIH PUBLICATION; Navarro A, 2011, BMC NEUROLOGY BMC NE, V20, P11; Perearnau P, 2006, REV NEUROL-FRANCE, V162, P347, DOI 10.1016/S0035-3787(06)75021-4; Radtke A, 2009, HEADACHE, V49, P79, DOI 10.1111/j.1526-4610.2008.01263.x; Raybaud H, 2011, MIGRAINES CEPHALEES; Roncolato M, 2000, EUR NEUROL, V43, P102, DOI 10.1159/000008143; Scottish Intercollegiate Guidelines Network, 2008, DIAGN MAN HEAD AD GU; Societe Suisse pour l'etude des cephalees, 2008, CEPH ALG FAC REC THE; Stefanache F, 2006, HEADACHE CRANIAL NEU, P140; Steiner T, 2008, EC COST MIGRANINE HA; Steiner TJ, 2003, CEPHALALGIA, V23, P519, DOI 10.1046/j.1468-2982.2003.00568.x; Stepien A, 2003, BOL, P3; Stovner LJ, 2009, J HEADACHE PAIN, V10, P395, DOI 10.1007/s10194-009-0156-9; Tfelt-Hansen P, 2007, CNS DRUGS, V21, P877, DOI 10.2165/00023210-200721110-00001; Villalon Carlos M., 2003, Current Vascular Pharmacology, V1, P71, DOI 10.2174/1570161033386826; Williams AE, 2006, EUR RESPIR REV, V15, P4, DOI 10.1183/09059180.06.00009801; Winner P, 2005, CLIN THER, V27, P1785, DOI 10.1016/j.clinthera.2005.11.009; Yu J, 2009, J PAIN PALLIATIVE CA, V23, P693	58	11	11	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2013	8	12							e84088	10.1371/journal.pone.0084088	http://dx.doi.org/10.1371/journal.pone.0084088			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276HY	24367628	Green Published, gold, Green Submitted			2023-01-03	WOS:000328741900029
J	Tan, CQ; Peng, LB; Zeng, XH; Li, JH; Wan, XM; Chen, GN; Yi, LD; Luo, X; Zhao, ZY				Tan, Chongqing; Peng, Liubao; Zeng, Xiaohui; Li, Jianhe; Wan, Xiaomin; Chen, Gannong; Yi, Lidan; Luo, Xia; Zhao, Ziying			Economic Evaluation of First-Line Adjuvant Chemotherapies for Resectable Gastric Cancer Patients in China	PLOS ONE			English	Article							MULTICENTER PHASE-II; S-1 PLUS CISPLATIN; ORAL FLUOROPYRIMIDINE; CAPECITABINE; OXALIPLATIN; TRIAL; ADENOCARCINOMA; GASTRECTOMY; THERAPY	Background: First-line postoperative adjuvant chemotherapies with S-1 and capecitabine and oxaliplatin (XELOX) were first recommended for resectable gastric cancer patients in the 2010 and 2011 Chinese NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer; however, their economic impact in China is unknown. Objective: The aim of this study was to compare the cost-effectiveness of adjuvant chemotherapy with XELOX, with S-1 and no treatment after a gastrectomy with extended (D2) lymph-node dissection among patients with stage II-IIIB gastric cancer. Methods: A Markov model, based on data from two clinical phase III trials, was developed to analyse the cost-effectiveness of patients in the XELOX group, S-1 group and surgery only (SO) group. The costs were estimated from the perspective of Chinese healthcare system. The utilities were assumed on the basis of previously published reports. Costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICER) were calculated with a lifetime horizon. One-way and probabilistic sensitivity analyses were performed. Results: For the base case, XELOX had the lowest total cost ($44,568) and cost-effectiveness ratio ($7,360/QALY). The relative scenario analyses showed that SO was dominated by XELOX and the ICERs of S-1 was $58,843/QALY compared with XELOX. The one-way sensitivity analysis showed that the most influential parameter was the utility of disease-free survival. The probabilistic sensitivity analysis predicted a 75.8% likelihood that the ICER for XELOX would be less than $13,527 compared with S-1. When ICER was more than $38,000, the likelihood of cost-effectiveness achieved by S-1 group was greater than 50%. Conclusions: Our results suggest that for patients in China with resectable disease, first-line adjuvant chemotherapy with XELOX after a D2 gastrectomy is a best option comparing with S-1 and SO in view of our current study. In addition, S-1 might be a better choice, especially with a higher value of willingness-to-pay threshold.	[Tan, Chongqing; Peng, Liubao; Li, Jianhe; Wan, Xiaomin; Yi, Lidan] Cent S Univ, Xiangya Hosp 2, Dept Pharm, Changsha, Hunan, Peoples R China; [Tan, Chongqing; Peng, Liubao; Li, Jianhe; Wan, Xiaomin; Yi, Lidan; Luo, Xia; Zhao, Ziying] Cent S Univ, Sch Pharmaceut Sci, Changsha, Hunan, Peoples R China; [Zeng, Xiaohui] Cent S Univ, Xiangya Hosp 2, PET CT Ctr, Changsha, Hunan, Peoples R China; [Chen, Gannong] Cent S Univ, Xiangya Hosp 2, Dept Surg, Changsha, Hunan, Peoples R China	Central South University; Central South University; Central South University; Central South University	Peng, LB (corresponding author), Cent S Univ, Xiangya Hosp 2, Dept Pharm, Changsha, Hunan, Peoples R China.	pengliubao@126.com	Wan, Xiaomin/GPX-4388-2022	/0000-0001-5315-8141	National Natural Science Foundation of China [81173028]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The manuscript was supported by a grant from the National Natural Science Foundation of China (No. 81173028). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ajani JA, 2006, J CLIN ONCOL, V24, P663, DOI 10.1200/JCO.2005.04.2994; [Anonymous], 2007, RITUXMIAB TREATMENT; [Anonymous], 2010, GROSS DOMESTIC PRODU; Bang YJ, 2012, LANCET, V379, P315, DOI 10.1016/S0140-6736(11)61873-4; Boku N, 2009, LANCET ONCOL, V10, P1063, DOI 10.1016/S1470-2045(09)70259-1; China Center for Health Economic Research, CHIN GUID PHARM EV V; [寸晓乐 Cun Xiaole], 2010, [中国公共卫生, China Public Health], V26, P703; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; Dong NN, 2009, AM J CLIN ONCOL-CANC, V32, P559, DOI 10.1097/COC.0b013e3181967db3; Gockel I, 2005, CHIRURG, V76, P250, DOI 10.1007/s00104-004-0950-5; Guangzhou, 2010, REPORT ANTITUMOR ANT; Hoyle M, 2010, VALUE HEALTH, V13, P61, DOI 10.1111/j.1524-4733.2009.00617.x; Hu Bing, 2012, CHINESE MED, V30, P280; International Agency for Research on Cancer, 2008, STOM CANC IND MORT P; Koizumi W, 2008, LANCET ONCOL, V9, P215, DOI 10.1016/S1470-2045(08)70035-4; Kubota T, 2008, BRIT J CANCER, V98, P1301, DOI 10.1038/sj.bjc.6604332; Liu CY, 2008, ANTI-CANCER DRUG, V19, P825, DOI 10.1097/CAD.0b013e32830c457e; Miwa M, 1998, EUR J CANCER, V34, P1274, DOI 10.1016/S0959-8049(98)00058-6; National Comprehensive Cancer Network (NCCN), 2010, NCCN CLIN PRACT GUID, V2; NCCN, 2019, NCCN CLIN PRACTICE G; Paoletti X, 2010, JAMA-J AM MED ASSOC, V303, P1729, DOI 10.1001/jama.2010.534; Park YH, 2008, CANCER CHEMOTH PHARM, V61, P623, DOI 10.1007/s00280-007-0515-7; Peng LB, 2009, PHARMACOECONOMICS, V27, P873, DOI 10.2165/11314750-000000000-00000; Sakamaki H., 2009, OPEN HLTH SERV POLIC, V2, P26, DOI [10.2174/1874924000902010026, DOI 10.2174/1874924000902010026]; Sakuramoto S, 2007, NEW ENGL J MED, V357, P1810, DOI 10.1056/NEJMoa072252; Sasako M, 2011, J CLIN ONCOL, V29, P4387, DOI 10.1200/JCO.2011.36.5908; Shen Jinfang, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0032530, DOI 10.1371/JOURNAL.PONE.0032530]; ShuPeng, 2011, GANSU J TCM, V24, P76; Tong Zong-pei, 2011, J ANHUI TCM COLL, V30, P30; Wilson D, 2005, CLIN ONCOL-UK, V17, P81, DOI 10.1016/j.clon.2004.10.006; Wu B, 2012, CLIN THER, V34, P468, DOI 10.1016/j.clinthera.2012.01.012	31	8	11	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2013	8	12							e83396	10.1371/journal.pone.0083396	http://dx.doi.org/10.1371/journal.pone.0083396			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275VW	24340099	Green Published, gold, Green Submitted			2023-01-03	WOS:000328707400132
J	Tang, RB; Huang, W; Yan, FH; Lu, Y; Chai, WM; Yang, GY; Chen, KM				Tang, Rongbiao; Huang, Wei; Yan, Fuhua; Lu, Yong; Chai, Wei-Min; Yang, Guo-Yuan; Chen, Ke-Min			In-Line Phase Contrast Imaging of Hepatic Portal Vein Embolization with Radiolucent Embolic Agents in Mice: A Preliminary Study	PLOS ONE			English	Article							TRIS-ACRYL GELATIN; ARTERY EMBOLIZATION; LIVER; VISUALIZATION; MICROSPHERES; ANGIOGRAPHY; HYPERTROPHY; RESECTION; ANATOMY	It is crucial to understand the distribution of embolic agents inside target liver during and after the hepatic portal vein embolization (PVE) procedure. For a long time, the problem has not been well solved due to the radiolucency of embolic agents and the resolution limitation of conventional radiography. In this study, we first reported use of fluorescent carboxyl microspheres (FCM) as radiolucent embolic agents for embolizing hepatic portal veins. The fluorescent characteristic of FCM could help to determine their approximate location easily. Additionally, the microspheres were found to be fairly good embolizing agents for PVE. After the livers were excised and fixed, they were imaged by in-line phase contrast imaging (PCI), which greatly improved the detection of the radiolucent embolic agents as compared to absorption contrast imaging (ACI). The preliminary study has for the first time shown that PCI has great potential in the pre-clinical investigation of PVE with radiolucent embolic agents.	[Tang, Rongbiao; Huang, Wei; Yan, Fuhua; Lu, Yong; Chai, Wei-Min; Chen, Ke-Min] Shanghai Jiao Tong Univ, Dept Radiol, Rui Jin Hosp, Sch Med, Shanghai 200030, Peoples R China; [Yang, Guo-Yuan] Shanghai Jiao Tong Univ, Neurosci & Neuroengn Ctr, Med X Res Inst, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Tang, RB (corresponding author), Shanghai Jiao Tong Univ, Dept Radiol, Rui Jin Hosp, Sch Med, Shanghai 200030, Peoples R China.	tangme8688258@sina.com; keminchenrj@163.com			Natural Science Foundation of China [81301347, 81271740]; Nation Basic Research Program of China (973 Program) [2010CB834305]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Nation Basic Research Program of China (973 Program)(National Basic Research Program of China)	This research was supported by the Natural Science Foundation of China (Grant no. 81301347 and 81271740) and Nation Basic Research Program of China (973 Program 2010CB834305). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdalla EK, 2001, BRIT J SURG, V88, P165, DOI 10.1046/j.1365-2168.2001.01658.x; Arfelli F, 2010, PHYS MED BIOL, V55, P1643, DOI 10.1088/0031-9155/55/6/008; Azoulay D, 2000, ANN SURG, V231, P480, DOI 10.1097/00000658-200004000-00005; Bravin A, 2013, PHYS MED BIOL, V58, pR1, DOI 10.1088/0031-9155/58/1/R1; Broering DC, 2002, J GASTROINTEST SURG, V6, P905, DOI 10.1016/S1091-255X(02)00122-1; Chen R-C, 2012, J SYNCHROTRON RAD, V19; Fink C, 2003, J MAGN RESON IMAGING, V18, P59, DOI 10.1002/jmri.10318; Furrer K, 2008, HEPATOLOGY, V47, P1615, DOI 10.1002/hep.22164; Gao X, 2006, COMPUT MED IMAG GRAP, V30, P339, DOI 10.1016/j.compmedimag.2006.09.003; Hartog A, 2009, BJA EDUC, V9, P1, DOI 10.1093/bjaceaccp/mkn050; Hwang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063552; Huang JY, 2006, WORLD J GASTROENTERO, V12, P408, DOI 10.3748/wjg.v12.i3.408; Kitchen MJ, 2005, BRIT J RADIOL, V78, P1018, DOI 10.1259/bjr/13024611; Kobayashi S, 2004, J HEPATOL, V40, P405, DOI 10.1016/j.jhep.2003.11.029; Laperle CM, 2008, PHYS MED BIOL, V53, P6911, DOI 10.1088/0031-9155/53/23/017; Laurent A, 2006, INVEST RADIOL, V41, P8, DOI 10.1097/01.rli.0000188027.34400.f3; Lewis RA, 2004, PHYS MED BIOL, V49, P3573, DOI 10.1088/0031-9155/49/16/005; Madoff DC, 2005, RADIOGRAPHICS, V25, pS191, DOI 10.1148/rg.25si055504; Madoff DC, 2002, RADIOGRAPHICS, V22, P1063, DOI 10.1148/radiographics.22.5.g02se161063; Osuga K, 2012, INT J CLIN ONCOL, V17, P306, DOI 10.1007/s10147-012-0445-1; Parsons DW, 2008, J ANAT, V213, P217, DOI 10.1111/j.1469-7580.2008.00950.x; Pelage JP, 2003, J VASC INTERV RADIOL, V14, P15, DOI 10.1097/01.RVI.0000052287.26939.b0; Shen DW, 2013, SCI REP-UK, V3, DOI 10.1038/srep01697; Simpson SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053805; Snigirev A, 1995, REV SCI INSTRUM, V66, P5486, DOI 10.1063/1.1146073; Tang RB, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0049256, 10.1371/journal.pone.0045597]; Tang RBA, 2012, PHYS MED BIOL, V57, P3051, DOI 10.1088/0031-9155/57/10/3051; Tang RB, 2011, PHYS MED BIOL, V56, P3503, DOI 10.1088/0031-9155/56/12/004; Tao Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039936; Wilkins SW, 1996, NATURE, V384, P335, DOI 10.1038/384335a0; Xi Y, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3607292; Yoon W, 2004, EXPERT OPIN PHARMACO, V5, P361, DOI 10.1517/eoph.5.2.361.26480; Zhang L, 2011, EUR J RADIOL, V80, P158, DOI 10.1016/j.ejrad.2010.08.019; Zhang X, 2008, PHYS MED BIOL, V53, P5735, DOI 10.1088/0031-9155/53/20/011; Zhang X, 2013, EUR RADIOL, V23, P417, DOI 10.1007/s00330-012-2630-z	35	5	5	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2013	8	12							e80919	10.1371/journal.pone.0080919	http://dx.doi.org/10.1371/journal.pone.0080919			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	265KD	24324646	Green Published, gold, Green Submitted			2023-01-03	WOS:000327949300057
J	Gu, M; Zhang, Y; Fan, SJ; Ding, XB; Ji, G; Huang, C				Gu, Ming; Zhang, Yu; Fan, Shengjie; Ding, Xiaobo; Ji, Guang; Huang, Cheng			Extracts of Rhizoma Polygonati Odorati Prevent High-Fat Diet-Induced Metabolic Disorders in C57BL/6 Mice	PLOS ONE			English	Article							ACTIVATED RECEPTOR-GAMMA; PEROXISOME PROLIFERATOR; PPAR-ALPHA; INSULIN SENSITIVITY; UNCOUPLING PROTEIN-2; MESSENGER-RNA; TARGET GENES; GLUCOSE; LIVER; POLYSACCHARIDES	Polygonatum odoratum (Mill.) Druce belongs to the genus Polygonatum family of plants. In traditional Chinese medicine, the root of Polygonatum odoratum, Rhizoma Polygonati Odorati, is used both for food and medicine to prevent and treat metabolic disorders such as hyperlipidemia, hyperglycemia, obesity and cardiovascular disease. However, there is no solid experimental evidence to support these applications, and the underlying mechanism is also needed to be elucidated. Here, we examined the effect of the extract of Rhizoma Polygonati Odorati (ER) on metabolic disorders in diet-induced C57BL/6 obese mice. In the preventive experiment, the ER blocked body weight gain, and lowered serum total cholesterol (TC), triglyceride (TG) and fasting blood glucose, improved glucose tolerance test (GTT) and insulin tolerance test (ITT), reduced the levels of serum insulin and leptin, and increased serum adiponectin levels in mice fed with a high-fat diet significantly. In the therapeutic study, we induced obesity in the mice and treated the obese mice with ER for two weeks. We found that ER treatments reduced serum TG and fasting blood glucose, and improved glucose tolerance in the mice. Gene expression analysis showed that ER increased the mRNA levels of peroxisome proliferator-activated receptors (PPAR) c and a and their downstream target genes in mice livers, adipose tissues and HepG2 cells. Our data suggest that ER ameliorates metabolic disorders and enhances the mRNA expression of PPARs in obese C57BL/6 mice induced by high-fat diet.	[Gu, Ming; Zhang, Yu; Fan, Shengjie; Ding, Xiaobo; Huang, Cheng] Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai, Peoples R China; [Ding, Xiaobo] Southwest Univ, Coll Hort & Landscape Architecture, Chongqing, Peoples R China; [Ding, Xiaobo] Minist Educ, Key Lab Hort Sci Southern Mountainous Reg, Chongqing, Peoples R China; [Ji, Guang] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Inst Digest Dis, Shanghai, Peoples R China	Shanghai University of Traditional Chinese Medicine; Southwest University - China; Shanghai University of Traditional Chinese Medicine	Ji, G (corresponding author), Shanghai Univ Tradit Chinese Med, Longhua Hosp, Inst Digest Dis, Shanghai, Peoples R China.	jiliver@vip.sina.com; chuang.shutcm@gmail.com						Aerni-Flessner L, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-63; Ahmed W, 2007, J INTERN MED, V262, P184, DOI 10.1111/j.1365-2796.2007.01825.x; Ahren B, 1997, AM J PHYSIOL-REG I, V273, pR113, DOI 10.1152/ajpregu.1997.273.1.R113; Baffy G, 2005, FRONT BIOSCI-LANDMRK, V10, P2082, DOI 10.2741/1683; Berger JP, 2005, TRENDS PHARMACOL SCI, V26, P244, DOI 10.1016/j.tips.2005.03.003; Chakravarthy MV, 2009, CELL, V138, P476, DOI 10.1016/j.cell.2009.05.036; Chen HB, 2001, J ETHNOPHARMACOL, V74, P225, DOI 10.1016/S0378-8741(00)00359-7; Chen W, 2008, EXP CLIN ENDOCR DIAB, V116, P468, DOI 10.1055/s-2008-1058081; Choi SB, 2002, BIOSCI BIOTECH BIOCH, V66, P2036, DOI 10.1271/bbb.66.2036; Choudhary M, 2012, FUNCT FOODS HEALTH D, V2, P188, DOI 10.31989/ffhd.v2i6.90; Deng YF, 2012, J ETHNOPHARMACOL, V141, P228, DOI 10.1016/j.jep.2012.02.023; Diano S, 2012, TRENDS MOL MED, V18, P52, DOI 10.1016/j.molmed.2011.08.003; Dutchak PA, 2012, CELL, V148, P556, DOI 10.1016/j.cell.2011.11.062; Duval C, 2007, BBA-MOL CELL BIOL L, V1771, P961, DOI 10.1016/j.bbalip.2007.05.003; Furuhashi M, 2008, NAT REV DRUG DISCOV, V7, P489, DOI 10.1038/nrd2589; Geloen A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037633; Gong ZW, 2009, ENDOCRINOLOGY, V150, P104, DOI 10.1210/en.2008-0322; Goto T, 2013, MOL NUTR FOOD RES, V57, P20, DOI 10.1002/mnfr.201200522; Guarner V, 2012, AGING DIS, V3, P269; Guo L, 2006, PHARMACOL THERAPEUT, V111, P145, DOI 10.1016/j.pharmthera.2005.10.009; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Huang HY, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/856381; Huang THW, 2005, BASIC CLIN PHARMACOL, V96, P3, DOI 10.1111/j.1742-7843.2005.pto960102.x; Jia W, 2003, PHYTOTHER RES, V17, P1127, DOI 10.1002/ptr.1398; Jin ML, 2013, INT J BIOL MACROMOL, V54, P16, DOI 10.1016/j.ijbiomac.2012.11.023; Kanagasabapathy G, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-261; Kim H, 2004, DIABETES, V53, pS60, DOI 10.2337/diabetes.53.2007.S60; Kotani K, 2004, J CLIN INVEST, V114, P1666, DOI 10.1172/JCI200421341; Kruger N J, 1994, Methods Mol Biol, V32, P9; Kumar V, 2012, CRIT REV FOOD SCI, V52, P899, DOI 10.1080/10408398.2010.512671; LEMBERGER T, 1994, J BIOL CHEM, V269, P24527; Li HaiMing, 2010, Food and Drug, V12, P102; Li X., 2012, ISRN ENDOCRINOL, V2012; Lin E, 2007, DIABETES, V56, P735, DOI 10.2337/db06-1161; Lin H. W., 1994, Yaoxue Xuebao, V29, P215; Liu B, 2009, BBA-GEN SUBJECTS, V1790, P840, DOI 10.1016/j.bbagen.2009.04.020; Mezei O, 2003, J NUTR, V133, P1238; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; Muhlhausler BS, 2009, ENDOCRINOLOGY, V150, P4287, DOI 10.1210/en.2009-0462; Nakamura YK, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-60; Oh KS, 2006, BIOCHEM BIOPH RES CO, V345, P1232, DOI 10.1016/j.bbrc.2006.04.182; Sahagun DO, 2012, PPAR RES, V2012, DOI 10.1155/2012/318613; Park MY, 2005, LIFE SCI, V77, P3344, DOI 10.1016/j.lfs.2005.05.043; Prieto P, 1999, ANAL BIOCHEM, V269, P337, DOI 10.1006/abio.1999.4019; Ramberg JE, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-54; Schadinger SE, 2005, AM J PHYSIOL-ENDOC M, V288, pE1195, DOI 10.1152/ajpendo.00513.2004; Serisier S, 2008, BRIT J NUTR, V99, P1208, DOI 10.1017/S0007114507862386; Shi YG, 2004, NAT REV DRUG DISCOV, V3, P695, DOI 10.1038/nrd1469; Shu XS, 2009, J ETHNOPHARMACOL, V124, P539, DOI 10.1016/j.jep.2009.05.006; Sterchele PF, 1996, ARCH BIOCHEM BIOPHYS, V326, P281, DOI 10.1006/abbi.1996.0077; Stumvoll M, 2005, LANCET, V365, P1333, DOI 10.1016/S0140-6736(05)61032-X; Tordjman K, 2002, J LIPID RES, V43, P936; Toth PP, 2009, CURR ATHEROSCLER REP, V11, P71, DOI 10.1007/s11883-009-0012-z; Tsao R, 2003, J AGR FOOD CHEM, V51, P6347, DOI 10.1021/jf0346298; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; Vick MM, 2007, J ANIM SCI, V85, P1144, DOI 10.2527/jas.2006-673; Waki H, 2007, CELL METAB, V5, P357, DOI 10.1016/j.cmet.2007.03.010; Wang JL, 2001, DIABETES, V50, P2786, DOI 10.2337/diabetes.50.12.2786; Wang WJ, 2013, J INTEGR MED-JIM, V11, P153, DOI 10.3736/jintegrmed2013033; Wong CC, 2006, FOOD CHEM, V97, P705, DOI 10.1016/j.foodchem.2005.05.049; Xiao C, 2012, ARCH PHARM RES, V35, P1793, DOI 10.1007/s12272-012-1012-z; [徐光域 Xu Guangyu], 2005, [食品科学, Food Science], V26, P342; Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292; Yonezawa T, 2009, IUBMB LIFE, V61, P1123, DOI 10.1002/iub.264; Zang MW, 2006, DIABETES, V55, P2180, DOI 10.2337/db05-1188; Zhou J, 2008, GASTROENTEROLOGY, V134, P556, DOI 10.1053/j.gastro.2007.11.037	66	21	24	2	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2013	8	11							e81724	10.1371/journal.pone.0081724	http://dx.doi.org/10.1371/journal.pone.0081724			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MX	24312343	Green Published, Green Submitted, gold			2023-01-03	WOS:000327670300046
J	Wise, J				Wise, Jacqui			Polypharmacy: a necessary evil The rise of patients taking four or more drugs is an aspect of modern medicine that requires some urgent attention, finds a new report. Jacqui Wise examines its recommendations	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												jacquiyoung1@gmail.com						Guthrie B, 2012, PRIM HEALTH CARE RES, V13, P45; Health and Social Care Information Centre, 2012, PRESCR DISP COMM STA; The King's Fund, 2013, POL MED OPT MAK IT S	3	40	43	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 28	2013	347								f7033	10.1136/bmj.f7033	http://dx.doi.org/10.1136/bmj.f7033			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263GN	24286985				2023-01-03	WOS:000327795500001
J	Rossi, F; Bernardo, ME; Bellini, G; Luongo, L; Conforti, A; Manzo, I; Guida, F; Cristino, L; Imperatore, R; Petrosino, S; Nobili, B; Di Marzo, V; Locatelli, F; Maione, S				Rossi, Francesca; Bernardo, Maria Ester; Bellini, Giulia; Luongo, Livio; Conforti, Antonella; Manzo, Iolanda; Guida, Francesca; Cristino, Luigia; Imperatore, Roberta; Petrosino, Stefania; Nobili, Bruno; Di Marzo, Vincenzo; Locatelli, Franco; Maione, Sabatino			The Cannabinoid Receptor Type 2 as Mediator of Mesenchymal Stromal Cell Immunosuppressive Properties	PLOS ONE			English	Article							THERAPY POSITION STATEMENT; HUMAN BONE-MARROW; STEM-CELLS; INTERNATIONAL-SOCIETY; CB2 RECEPTORS; EXPRESSION; CYTOKINE; SYSTEM; ACTIVATION; DISEASES	Mesenchymal stromal cells are non-hematopoietic, multipotent progenitor cells producing cytokines, chemokines, and extracellular matrix proteins that support hematopoietic stem cell survival and engraftment, influence immune effector cell development, maturation, and function, and inhibit alloreactive T-cell responses. The immunosuppressive properties of human mesenchymal stromal cells have attracted much attention from immunologists, stem cell biologists and clinicians. Recently, the presence of the endocannabinoid system in hematopoietic and neural stem cells has been demonstrated. Endocannabinoids, mainly acting through the cannabinoid receptor subtype 2, are able to modulate cytokine release and to act as immunosuppressant when added to activated T lymphocytes. In the present study, we have investigated, through a multidisciplinary approach, the involvement of the endocannabinoids in migration, viability and cytokine release of human mesenchymal stromal cells. We show, for the first time, that cultures of human mesenchymal stromal cells express all of the components of the endocannabinoid system, suggesting a potential role for the cannabinoid CB2 receptor as a mediator of anti-inflammatory properties of human mesenchymal stromal cells, as well as of their survival pathways and their capability to home and migrate towards endocannabinoid sources.	[Rossi, Francesca; Manzo, Iolanda; Nobili, Bruno] Univ Naples 2, Dept Women Child & Gen & Specialist Surg, Naples, Italy; [Rossi, Francesca; Bernardo, Maria Ester; Conforti, Antonella; Nobili, Bruno; Locatelli, Franco] IRCCS Bambino Gesu Children Hosp, Dept Oncohaematol, Rome, Italy; [Bellini, Giulia; Luongo, Livio; Manzo, Iolanda; Guida, Francesca; Maione, Sabatino] Univ Naples 2, Dept Expt Med, Naples, Italy; [Luongo, Livio; Cristino, Luigia; Imperatore, Roberta; Petrosino, Stefania; Di Marzo, Vincenzo; Maione, Sabatino] Endocannabinoid Res Grp, Naples, Italy; [Cristino, Luigia] CNR, Inst Cybernet, I-80125 Naples, Italy; [Imperatore, Roberta; Petrosino, Stefania; Di Marzo, Vincenzo] CNR, Inst Biomol Chem, I-80125 Naples, Italy; [Locatelli, Franco] Univ Pavia, I-27100 Pavia, Italy	Universita della Campania Vanvitelli; IRCCS Bambino Gesu; Universita della Campania Vanvitelli; Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR); Consiglio Nazionale delle Ricerche (CNR); University of Pavia	Rossi, F (corresponding author), Univ Naples 2, Dept Women Child & Gen & Specialist Surg, Naples, Italy.	fra.rossi76@libero.it	Luongo, Livio/GXV-1993-2022; Conforti, Antonella/H-2209-2012; Cristino, Luigia/AAE-3934-2020; Di Marzo, Vincenzo/AAD-7742-2019	Conforti, Antonella/0000-0001-8524-5936; Cristino, Luigia/0000-0002-0182-4699; Di Marzo, Vincenzo/0000-0002-1490-3070; Luongo, Livio/0000-0002-1949-2039; IMPERATORE, Roberta/0000-0003-3609-2771; Maione, Sabatino/0000-0003-3850-6704; Rossi, Francesca/0000-0003-2879-6277				Bari M, 2011, STEM CELLS DEV, V20, P139, DOI 10.1089/scd.2009.0515; Bernardo ME, 2009, ANN NY ACAD SCI, V1176, P101, DOI 10.1111/j.1749-6632.2009.04607.x; Bernardo ME, 2011, BEST PRACT RES CL HA, V24, P73, DOI 10.1016/j.beha.2010.11.002; Casiraghi F, 2013, CURR OPIN ORGAN TRAN, V18, P51, DOI 10.1097/MOT.0b013e32835c5016; Cencioni MT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008688; Compagnucci C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054271; Contartese A, 2012, PHARMACOL RES, V66, P555, DOI 10.1016/j.phrs.2012.08.003; Correa F, 2005, BRIT J PHARMACOL, V145, P441, DOI 10.1038/sj.bjp.0706215; De Miguel MP, 2012, CURR MOL MED, V12, P574; Do Y, 2004, J IMMUNOL, V173, P2373, DOI 10.4049/jimmunol.173.4.2373; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Figueroa FE, 2012, BIOL RES, V45, P269, DOI 10.4067/S0716-97602012000300008; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; Grimaldi P, 2009, P NATL ACAD SCI USA, V106, P11131, DOI 10.1073/pnas.0812789106; Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234; Jiang SX, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000641; Jiang SX, 2011, BLOOD, V117, P827, DOI 10.1182/blood-2010-01-265082; Keating A, 2012, CELL STEM CELL, V10, P709, DOI 10.1016/j.stem.2012.05.015; Kim DH, 2005, CYTOKINE, V31, P119, DOI 10.1016/j.cyto.2005.04.004; Klein TW, 2000, P SOC EXP BIOL MED, V225, P1, DOI 10.1046/j.1525-1373.2000.22501.x; Liotta F, 2008, STEM CELLS, V26, P279, DOI 10.1634/stemcells.2007-0454; Luongo L, 2010, NEUROBIOL DIS, V37, P177, DOI 10.1016/j.nbd.2009.09.021; Majumdar MK, 2000, J HEMATOTH STEM CELL, V9, P841, DOI 10.1089/152581600750062264; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Pistoia V, 2010, EXPERT REV CLIN IMMU, V6, P211, DOI 10.1586/ECI.09.86; Prasanna SJ, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0014189, 10.1371/journal.pone.0009016]; Rossi F, 2009, BONE, V44, P476, DOI 10.1016/j.bone.2008.10.056; Rossi F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042259; Rossi F, 2012, PHARMACOL RES, V66, P88, DOI 10.1016/j.phrs.2012.03.011; Rossi F, 2011, HAEMATOL-HEMATOL J, V96, P1883, DOI 10.3324/haematol.2011.045732; Rossi F, 2011, HEPATOLOGY, V54, P1102, DOI 10.1002/hep.24440; Rossi F, 2011, BONE, V48, P997, DOI 10.1016/j.bone.2011.01.001; Scutt A, 2007, CALCIFIED TISSUE INT, V80, P50, DOI 10.1007/s00223-006-0171-7; Stella N, 2009, NEUROPHARMACOLOGY, V56, P244, DOI 10.1016/j.neuropharm.2008.07.037; Yuan M, 2002, J NEUROIMMUNOL, V133, P124, DOI 10.1016/S0165-5728(02)00370-3	36	28	29	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 27	2013	8	11							e80022	10.1371/journal.pone.0080022	http://dx.doi.org/10.1371/journal.pone.0080022			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261GG	24312195	Green Published, gold			2023-01-03	WOS:000327652100021
J	Sun, J; Jin, CL; Wu, HA; Zhao, JM; Cui, YH; Liu, HR; Wu, LX; Shi, Y; Zhu, B				Sun, Jie; Jin, Chunlan; Wu, Huangan; Zhao, Jimeng; Cui, Yunhua; Liu, Huirong; Wu, Lingxiang; Shi, Yin; Zhu, Bing			Effects of Electro-Acupuncture on Ovarian P450arom, P450c17 alpha and mRNA Expression Induced by Letrozole in PCOS Rats	PLOS ONE			English	Article							INDUCED POLYCYSTIC OVARIES; LOW-FREQUENCY ELECTROACUPUNCTURE; BLOOD-FLOW RESPONSES; NERVE GROWTH-FACTOR; ANESTHETIZED RATS; GENE-EXPRESSION; GRANULOSA-CELLS; ESTROUS-CYCLE; DIHYDROTESTOSTERONE; STIMULATION	Hyperandrogenism is a core factor in the series of reproductive and endocrine metabolic disorders involved in polycystic ovary syndrome (PCOS). Abnormalities in enzymatic activity and the expression of ovarian granular cell layer P450arom and theca cell P450c17 alpha can lead to an atypical environment of local ovarian hormones, including excessive androgen levels. Rat models prepared with letrozole exhibit similar endocrine and histological changes to those that occur in human PCOS. We used such a model to study the role of electro-acupuncture (EA) in regulating ovarian P450arom and P450C17 alpha enzymatic activity and mRNA expression in PCOS rats. Female Sprague Dawley (SD) rats aged 42 days were randomly divided into 3 groups (control, PCOS, and PCOS EA) consisting of 10 rats each. The PCOS and PCOS EA groups were administered a gavage of 1.0 mg/kg(-1) of letrozole solution once daily for 21 consecutive days. Beginning in the ninth week, the PCOS EA group was administered low-frequency EA treatment daily for 14 consecutive days. After the treatment, we obtained the following results. The estrous cycles were restored in 8 of the 10 rats in the PCOS EA group, and their ovarian morphologies and ultrastructures normalized. The peripheral blood measurements (with ELISA) showed significantly decreased androgens (i.e., androstenedione and testosterone) with significantly increased estrogens (i.e., estrone, estradiol) and increased P450arom with decreased P450C17 alpha. Immunohistochemistry and Western blotting methods showed enhanced expression of ovarian granular cell layer P450arom as well as decreased expression of theca cell layer P450C17 alpha. Fluorescence quantitative PCR methods showed enhanced expression of ovarian granular cell layer P450arom mRNA as well as decreased expression of theca cell layer P450C17 alpha mRNA. These results may help explain the effects of electro-acupuncture in changing the local ovarian hyperandrogenic environment and improving reproductive and endocrine metabolic disorders in PCOS.	[Sun, Jie; Zhao, Jimeng; Shi, Yin] Shanghai Univ TCM, Shanghai, Peoples R China; [Wu, Huangan; Cui, Yunhua; Liu, Huirong; Wu, Lingxiang; Shi, Yin] Shanghai Inst Acupuncture Moxibust & Meridians, Shanghai, Peoples R China; [Jin, Chunlan; Zhu, Bing] China Acad Chinese Med Sci, Inst Acumoxibust, Beijing, Peoples R China	Shanghai University of Traditional Chinese Medicine; China Academy of Chinese Medical Sciences	Shi, Y (corresponding author), Shanghai Univ TCM, Shanghai, Peoples R China.	flysy0636@163.com; zhubing@mail.cintcm.ac.cn			Shanghai Municipal Health Bureau [20124049]; Research Project of Autonomous Selection of China Academy of Traditional Chinese Medicine [ZZKF06004]	Shanghai Municipal Health Bureau; Research Project of Autonomous Selection of China Academy of Traditional Chinese Medicine	This work was supported by grants from Shanghai Municipal Health Bureau (Project No. 20124049, URL: http://www.smhb.gov.cn/); Research Project of Autonomous Selection of China Academy of Traditional Chinese Medicine in 2012 (Project No. ZZKF06004, URL: http://www.catcm.ac.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Araki H, 1996, J VET MED SCI, V58, P787, DOI 10.1292/jvms.58.787; Bai YH, 2004, GYNECOL OBSTET INVES, V57, P80, DOI 10.1159/000075382; Burger LL, 2007, AM J PHYSIOL-ENDOC M, V293, pE277, DOI 10.1152/ajpendo.00447.2006; Cameron VA, 2002, AM J PHYSIOL-ENDOC M, V282, pE139, DOI 10.1152/ajpendo.2002.282.1.E139; CUMMING DC, 1984, CLIN ENDOCRINOL, V20, P643, DOI 10.1111/j.1365-2265.1984.tb00114.x; Dunaif A, 2001, ANNU REV MED, V52, P401, DOI 10.1146/annurev.med.52.1.401; DUNLAP KD, 1988, PHYSIOL BEHAV, V42, P199, DOI 10.1016/0031-9384(88)90298-3; FAN YS, 1992, GENOMICS, V14, P1110, DOI 10.1016/S0888-7543(05)80140-5; Feng Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006638; Foecking EM, 2008, HORM BEHAV, V53, P673, DOI 10.1016/j.yhbeh.2007.12.013; FRANKS S, 1985, CLIN OBSTET GYNAECOL, V12, P605; Guttmann-Bauman I, 2005, J PEDIATR ENDOCR MET, V18, P499; Harlow CR, 2007, J ENDOCRINOL, V192, P41, DOI 10.1677/joe.1.06689; Iwabuchi J, 2007, J STEROID BIOCHEM, V107, P149, DOI 10.1016/j.jsbmb.2007.01.007; Jedel E, 2011, AM J PHYSIOL-ENDOC M, V300, pE37, DOI 10.1152/ajpendo.00495.2010; Kafali H, 2004, ARCH MED RES, V35, P103, DOI 10.1016/j.arcmed.2003.10.005; Magoffin DA, 2005, INT J BIOCHEM CELL B, V37, P1344, DOI 10.1016/j.biocel.2005.01.016; Manneras L, 2009, AM J PHYSIOL-REG I, V296, pR1124, DOI 10.1152/ajpregu.90947.2008; Manni L, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-21; MCNATTY KP, 1979, J CLIN ENDOCR METAB, V49, P687, DOI 10.1210/jcem-49-5-687; Mettus RV, 2003, ONCOGENE, V22, P8413, DOI 10.1038/sj.onc.1206888; MOON YS, 1978, J CLIN ENDOCR METAB, V47, P263, DOI 10.1210/jcem-47-2-263; Norman RJ, 2007, LANCET, V370, P685, DOI 10.1016/S0140-6736(07)61345-2; Okubo T, 2000, J CLIN ENDOCR METAB, V85, P4889, DOI 10.1210/jc.85.12.4889; Qin KN, 1998, MOL CELL ENDOCRINOL, V145, P111, DOI 10.1016/S0303-7207(98)00177-4; Qu J.Y., 2009, J INT REPROD HLTH FA, V28, P121; RUSH ME, 1982, P SOC EXP BIOL MED, V169, P216, DOI 10.3181/00379727-169-41334; Sakurada Y, 2006, HISTOCHEM CELL BIOL, V126, P735, DOI 10.1007/s00418-006-0205-2; Shi Y, 2010, CHINESE ARCH TRADITI, V28, P805; Shiina H, 2006, P NATL ACAD SCI USA, V103, P224, DOI 10.1073/pnas.0506736102; Stener-Victorin E, 2008, J NEUROENDOCRINOL, V20, P290, DOI 10.1111/j.1365-2826.2007.01634.x; Stener-Victorin E, 2000, BIOL REPROD, V63, P1497, DOI 10.1095/biolreprod63.5.1497; Stener-Victorin E, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-44; Stener-Victorin E, 2004, BIOL REPROD, V70, P329, DOI 10.1095/biolreprod.103.022368; Stener-Victorin E, 2003, AUTON NEUROSCI-BASIC, V108, P50, DOI 10.1016/j.autneu.2003.08.006; Stener-Victorin E, 2000, ACTA OBSTET GYN SCAN, V79, P180, DOI 10.1034/j.1600-0412.2000.079003180.x; Stener-Victorin E, 2001, NEUROPEPTIDES, V35, P227, DOI 10.1054/npep.2002.0878; Stener-Victorin E, 2006, J APPL PHYSIOL, V101, P84, DOI 10.1152/japplphysiol.01593.2005; Stener-Victorin Elisabet, 2003, Reprod Biol Endocrinol, V1, P33, DOI 10.1186/1477-7827-1-33	39	37	44	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2013	8	11							e79382	10.1371/journal.pone.0079382	http://dx.doi.org/10.1371/journal.pone.0079382			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256KH	24260211	Green Submitted, Green Published, gold			2023-01-03	WOS:000327308500056
J	Sagoo, MS; Harbour, JW; Stebbing, J; Bowcock, AM				Sagoo, M. S.; Harbour, J. W.; Stebbing, J.; Bowcock, A. M.			Combined PKC and MEK inhibition for treating metastatic uveal melanoma	ONCOGENE			English	Editorial Material							SOMATIC MUTATIONS; GNAQ; SF3B1	Uveal melanoma (UM) is the most common primary intraocular malignancy and the second most common form of melanoma. UM has a strong tendency for metastatic disease, and no effective treatments have yet been identified. Activating oncogenic mutations are commonly found in GNAQ and GNA11 in UM, and inhibiting key downstream effectors of the GNAQ/11 signaling pathway represents a rational therapeutic approach for treating metastatic UM. Chen et al., doi:10.1038/onc.2013.418, now confirm activation of the MAPK and PKC pathways as a result of GNAQ and GNA11 activating mutations in melanocytes, and they demonstrate that MAPK activation occurs downstream of PKC activation. PKC inhibitors disrupt MAPK signaling and block proliferation of GNAQ/11 mutant UM cell lines and slow the in vivo growth of xenografted UM tumors without inducing their shrinkage. However, a combination of PKC and MEK inhibition led to sustained MAPK pathway inhibition and tumor regression in vivo. Hence, the authors concluded that MEK and PKC inhibition is synergistic, with superior efficacy to treatment of GNAQ/GNA11 mutant UMs with either drug alone.	[Sagoo, M. S.] Moorfields Eye Hosp, Ocular Oncol Serv, London, England; [Sagoo, M. S.] St Bartholomews Hosp, London, England; [Sagoo, M. S.] UCL Inst Ophthalmol, London, England; [Harbour, J. W.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst & Sylvester Comprehens Can, Ocular Oncol Serv, Miami, FL 33136 USA; [Stebbing, J.] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London SW3 6LY, England; [Bowcock, A. M.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England	University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of London; Queen Mary University London; University of London; University College London; Bascom Palmer Eye Institute; University of Miami; Imperial College London; Imperial College London	Bowcock, AM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Guy Scadding Bldg,Royal Brompton Campus, London SW3 6LY, England.	a.bowcock@imperial.ac.uk	Harbour, J. William/B-1448-2015	Harbour, J. William/0000-0002-1104-9809; Sagoo, Mandeep/0000-0003-1530-3824; Stebbing, Justin/0000-0002-1117-6947; Bowcock, Anne/0000-0001-8691-9090	NCI NIH HHS [1R01 CA16187001, R01 CA125970, 5R01 CA12597007] Funding Source: Medline; Department of Health [NIHR-RP-011-053] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA125970] Funding Source: NIH RePORTER; Cancer Research UK [14549] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))		Chen X, 2014, ONCOGENE, V33, P4724, DOI 10.1038/onc.2013.418; Harbour J William, 2013, Am Soc Clin Oncol Educ Book, P388, DOI 10.1200/EdBook_AM.2013.33.388; Harbour JW, 2013, NAT GENET, V45, P133, DOI 10.1038/ng.2523; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Ho AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040439; Khalili JS, 2012, CLIN CANCER RES, V18, P4345, DOI 10.1158/1078-0432.CCR-11-3227; Landreville S, 2012, CLIN CANCER RES, V18, P408, DOI 10.1158/1078-0432.CCR-11-0946; Martin M, 2013, NAT GENET, V45, P933, DOI 10.1038/ng.2674; Onken MD, 2008, INVEST OPHTH VIS SCI, V49, P5230, DOI 10.1167/iovs.08-2145; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Wu XQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029622; Zuidervaart W, 2005, BRIT J CANCER, V92, P2032, DOI 10.1038/sj.bjc.6602598	13	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4722	4723		10.1038/onc.2013.555	http://dx.doi.org/10.1038/onc.2013.555			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24413085	Green Accepted			2023-01-03	WOS:000343239500002
J	Park, EY; Kim, BH; Lee, EJ; Chang, E; Kim, DW; Choi, SY; Park, JH				Park, Eun Young; Kim, Bo Hye; Lee, Eun Ji; Chang, EunSun; Kim, Dae Won; Choi, Soo Young; Park, Jong Hoon			Targeting of Receptor for Advanced Glycation End Products Suppresses Cyst Growth in Polycystic Kidney Disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						Adenovirus; Inflammation; Kidney; Proliferation; Receptor for Advanced Glycation End Products (RAGE); Transgenic Mice; Cystic Disease; Cystogenesis	AUTOSOMAL-DOMINANT; DIABETIC-NEPHROPATHY; RAGE; INHIBITION; SIROLIMUS; BLOCKADE; PKD1; MICE; INACTIVATION; PROGRESSION	Background: Receptor of advanced glycation end product (RAGE) mediates not only proinflammatory signaling, but also stimulates cell proliferation and survival-related signaling. Results: Inhibiting RAGE resulted in slowed cyst growth in an autosomal dominant polycystic kidney disease (ADPKD) mouse model and improved renal function. Conclusion: RAGE inhibition is highly effective against cyst enlargement in vivo. Significance: RAGE signaling may play a role in cystogenesis and could be a new therapeutic target for PKD. Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder. Although a myriad of research groups have attempted to identify a new therapeutic target for ADPKD, no drug has worked well in clinical trials. Our research group has focused on the receptor for advanced glycation end products (RAGE) gene as a novel target for ADPKD. This gene is involved in inflammation and cell proliferation. We have already confirmed that blocking RAGE function attenuates cyst growth in vitro. Based on this previous investigation, our group examined the effect of RAGE on cyst enlargement in vivo. PC2R mice, a severe ADPKD mouse model that we generated, were utilized. An adenovirus containing anti-RAGE shRNA was injected intravenously into this model. We observed that RAGE gene knockdown resulted in loss of kidney weight and volume. Additionally, the cystic area that originated from different nephron segments decreased in size because of down-regulation of the RAGE gene. Blood urea nitrogen and creatinine values tended to be lower after inhibiting RAGE. Based on these results, we confirmed that the RAGE gene could be an effective target for ADPKD treatment.	[Park, Eun Young; Kim, Bo Hye; Lee, Eun Ji; Chang, EunSun; Park, Jong Hoon] Sookmyung Womens Univ, Dept Biol Sci, Seoul 140742, South Korea; [Kim, Dae Won; Choi, Soo Young] Hallym Univ, Dept Biomed Sci, Chunchon 200702, South Korea; [Kim, Dae Won; Choi, Soo Young] Hallym Univ, Res Inst Biosci & Biotechnol, Chunchon 200702, South Korea	Sookmyung Women's University; Hallym University; Hallym University	Park, JH (corresponding author), Sookmyung Womens Univ, Dept Biol Sci, Seoul 140742, South Korea.	parkjh@sookmyung.ac.kr			Cr analyses agency; Cr official agency	Cr analyses agency; Cr official agency	We thank Dr. Chulho Lee for the BUN and Cr analyses and official agencies for financial support.	Arumugam T, 2004, J BIOL CHEM, V279, P5059, DOI 10.1074/jbc.M310124200; Bello-Reuss E, 2001, KIDNEY INT, V60, P37, DOI 10.1046/j.1523-1755.2001.00768.x; Bierhaus A, 2005, J MOL MED, V83, P876, DOI 10.1007/s00109-005-0688-7; Bohlender JM, 2005, AM J PHYSIOL-RENAL, V289, pF645, DOI 10.1152/ajprenal.00398.2004; Bukanov NO, 2006, NATURE, V444, P949, DOI 10.1038/nature05348; Busch M, 2010, EUR J CLIN INVEST, V40, P742, DOI 10.1111/j.1365-2362.2010.02317.x; Chapin HC, 2010, J CELL BIOL, V191, P701, DOI 10.1083/jcb.201006173; Chung ACK, 2010, J AM SOC NEPHROL, V21, P249, DOI 10.1681/ASN.2009010018; COHEN MP, 1995, J CLIN INVEST, V95, P2338, DOI 10.1172/JCI117926; Cowley BD, 2001, KIDNEY INT, V60, P2087, DOI 10.1046/j.1523-1755.2001.00065.x; DAgati V, 2010, TRENDS ENDOCRIN MET, V21, P50, DOI 10.1016/j.tem.2009.07.003; Forbes JM, 2005, J AM SOC NEPHROL, V16, P2363, DOI 10.1681/ASN.2005010062; Giannini C, 2012, PEDIATR NEPHROL, V27, P269, DOI 10.1007/s00467-011-1988-5; Guo JC, 2008, J AM SOC NEPHROL, V19, P961, DOI 10.1681/ASN.2007101109; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Ishihara K, 2003, FEBS LETT, V550, P107, DOI 10.1016/S0014-5793(03)00846-9; Kelly DJ, 2001, J AM SOC NEPHROL, V12, P2098, DOI 10.1681/ASN.V12102098; Li XG, 2008, NAT MED, V14, P863, DOI 10.1038/nm1783; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Natoli TA, 2010, NAT MED, V16, P788, DOI 10.1038/nm.2171; Novalic Z, 2012, J AM SOC NEPHROL, V23, P842, DOI 10.1681/ASN.2011040340; Omori S, 2006, J AM SOC NEPHROL, V17, P1604, DOI 10.1681/ASN.2004090800; Park EY, 2010, AM J NEPHROL, V32, P169, DOI 10.1159/000315859; Park EY, 2009, J BIOL CHEM, V284, P7214, DOI 10.1074/jbc.M805890200; Riehl A, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-12; Serra AL, 2010, NEW ENGL J MED, V363, P820, DOI 10.1056/NEJMoa0907419; Shibazaki S, 2008, HUM MOL GENET, V17, P1505, DOI 10.1093/hmg/ddn039; Sourris KC, 2010, DIABETOLOGIA, V53, P2442, DOI 10.1007/s00125-010-1837-2; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Takiar V, 2011, P NATL ACAD SCI USA, V108, P2462, DOI 10.1073/pnas.1011498108; Torres VE, 2007, J INTERN MED, V261, P17, DOI 10.1111/j.1365-2796.2006.01743.x; Torres VE, 2006, NAT CLIN PRACT NEPHR, V2, P40, DOI 10.1038/ncpneph0070; Walz G, 2010, NEW ENGL J MED, V363, P830, DOI 10.1056/NEJMoa1003491; Wei F, 2008, KIDNEY INT, V74, P1310, DOI 10.1038/ki.2008.395; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6; Xia S, 2010, DEVELOPMENT, V137, P1075, DOI 10.1242/dev.049437; Xu N, 2006, J NEPHROL, V19, P529; Zafar I, 2010, KIDNEY INT, V78, P754, DOI 10.1038/ki.2010.250; Zhu P, 2012, EXP DERMATOL, V21, P123, DOI 10.1111/j.1600-0625.2011.01408.x	40	13	14	4	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2014	289	13					9254	9262		10.1074/jbc.M113.514166	http://dx.doi.org/10.1074/jbc.M113.514166			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	AD7UJ	24515114	Green Published, hybrid			2023-01-03	WOS:000333472100043
J	Olfson, M; Marcus, SC; Bridge, JA				Olfson, Mark; Marcus, Steven C.; Bridge, Jeffrey A.			Focusing Suicide Prevention on Periods of High Risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DELIBERATE SELF-HARM; CARE		[Olfson, Mark] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; [Olfson, Mark] New York State Psychiat Inst & Hosp, New York, NY 10032 USA; [Marcus, Steven C.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA; [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA; [Bridge, Jeffrey A.] Nationwide Childrens Hosp, Res Inst, Ctr Innovat Pediat Practice, Columbus, OH USA; [Bridge, Jeffrey A.] Ohio State Univ, Columbus, OH 43210 USA	Columbia University; New York State Psychiatry Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Pennsylvania Medicine; Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University	Olfson, M (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York State Psychiat Inst, 1051 Riverside Dr, New York, NY 10032 USA.	mo49@columbia.edu	Olfson, Mark/AAA-8547-2021; Bridge, Jeff/GQR-0436-2022		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U19HS021112] Funding Source: NIH RePORTER; AHRQ HHS [U19 HS021112] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], IMPROVING QUALITY AN; Appleby L, 1999, BRIT MED J, V318, P1235; Baker SP, 2013, AM J PREV MED, V44, P146, DOI 10.1016/j.amepre.2012.10.010; Betz ME, 2013, DEPRESS ANXIETY, V30, P1005, DOI 10.1002/da.22071; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; Kuo CJ, 2012, BRIT J PSYCHIAT, V200, P405, DOI 10.1192/bjp.bp.111.099366; Marcus SC, 2012, AM J PUBLIC HEALTH, V102, P1145, DOI 10.2105/AJPH.2011.300598; Olfson M, 2013, AM J PSYCHIAT, V170, P1442, DOI 10.1176/appi.ajp.2013.12121506; Qin P, 2005, ARCH GEN PSYCHIAT, V62, P427, DOI 10.1001/archpsyc.62.4.427; While D, 2012, LANCET, V379, P1005, DOI 10.1016/S0140-6736(11)61712-1	10	67	68	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	2014	311	11					1107	1108		10.1001/jama.2014.501	http://dx.doi.org/10.1001/jama.2014.501			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AD1RC	24515285				2023-01-03	WOS:000333010100011
J	Lai, ECC; Hsieh, CY; Yang, YHK; Lin, SJ				Lai, Edward Chia-Cheng; Hsieh, Cheng-Yang; Yang, Yea-Huei Kao; Lin, Swu-Jane			Detecting Potential Adverse Reactions of Sulpiride in Schizophrenic Patients by Prescription Sequence Symmetry Analysis	PLOS ONE			English	Article							ORAL-HEALTH STATUS; DOUBLE-BLIND; ANTIEPILEPTIC DRUGS; HIP FRACTURE; RISK; PNEUMONIA; HALOPERIDOL; PREVALENCE; MEDICATION; PROLACTIN	Purpose: Previous studies have demonstrated sulpiride to be significantly more effective than haloperidol, risperidone and olanzapine in schizophrenic treatment; however, only limited information is available on the potential risks associated with sulpiride treatment. This study attempts to provide information on the potential risks of sulpiride treatment of schizophrenia, especially with regard to unexpected adverse effects. Materials and Methods: Patients with schizophrenia aged 18 and older, newly prescribed with a single antipsychotic medication from the National Health Insurance Research Database of Taiwan in the period from 2003 to 2010 were included. A within-subject comparison method, prescription sequence symmetry analysis (PSSA) was employed to efficiently identify potential causal relationships while controlling for potential selection bias. Results: A total of 5,750 patients, with a mean age of 39, approximately half of whom were male, constituted the study cohort. The PSSA found that sulpiride was associated with EPS (adjusted SR, 1.73; 95% CI, 1.46-2.06) and hyperprolactinemia (12.04; 1.59-91.2). In comparison, EPS caused by haloperidol has a magnitude of 1.99 when analyzed with PSSA, and hyperprolactinemia caused by amisulpride has a magnitude of 8.05, respectively. Another finding was the unexpected increase in the use of stomatological corticosteroids, emollient laxatives, dermatological preparations of corticosteroids, quinolone antibacterials, and topical products for joint and muscular pain, after initiation of sulpiride treatment. Conclusions: We found sulpiride to be associated with an increased risk of EPS and hyperprolactinemia, and the potential risk could be as high as that induced by haloperidol and amisulpride, respectively. Additionally, our study provides grounds for future investigations into the associations between sulpiride and the increased use of additional drugs for managing adverse effects, including stomatological, dermatological, and musculoskeletal or joint side effects, constipation, and pneumonia.	[Lai, Edward Chia-Cheng; Hsieh, Cheng-Yang; Yang, Yea-Huei Kao] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Tainan 70101, Taiwan; [Hsieh, Cheng-Yang] Tainan Sin Lau Hosp, Dept Neurol, Tainan, Taiwan; [Yang, Yea-Huei Kao] Natl Cheng Kung Univ, Hlth Outcome Res Ctr, Tainan 70101, Taiwan; [Lin, Swu-Jane] Univ Illinois, Coll Pharm, Dept Pharm Adm, Chicago, IL USA	National Cheng Kung University; National Cheng Kung University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Yang, YHK (corresponding author), Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Tainan 70101, Taiwan.	yhkao@mail.ncku.edu.tw	Hsieh, Cheng-Yang/W-4841-2019	Hsieh, Cheng-Yang/0000-0002-8772-4073	Food and Drug Administration, Department of Health, Executive Yuan, Taiwan	Food and Drug Administration, Department of Health, Executive Yuan, Taiwan	This study was supported in part by grants from the Food and Drug Administration, Department of Health, Executive Yuan, Taiwan. No additional funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Zakwani IS, 2003, CURR MED RES OPIN, V19, P619, DOI 10.1185/030079903125002270; BRATFOS O, 1979, ACTA PSYCHIAT SCAND, V60, P1, DOI 10.1111/j.1600-0447.1979.tb00259.x; Buchanan RW, 2010, SCHIZOPHRENIA BULL, V36, P71, DOI 10.1093/schbul/sbp116; Caughey GE, 2010, PHARMACOEPIDEM DR S, V19, P977, DOI 10.1002/pds.2009; Chen CC, 2012, EPILEPSIA, V53, P283, DOI 10.1111/j.1528-1167.2011.03332.x; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Cookson J, 2012, J PSYCHOPHARMACOL, V26, P42, DOI 10.1177/0269881112442016; Farley JF, 2012, PRIM CARE COMPANION, V14; Garrison SR, 2012, ARCH INTERN MED, V172, P120, DOI 10.1001/archinternmed.2011.1029; GERLACH J, 1985, BRIT J PSYCHIAT, V147, P283, DOI 10.1192/bjp.147.3.283; Hallas J, 1996, EPIDEMIOLOGY, V7, P478, DOI 10.1097/00001648-199609000-00004; Inder WJ, 2011, AUST NZ J PSYCHIAT, V45, P830, DOI 10.3109/00048674.2011.589044; Kim EY, 2012, PHARMACOPSYCHIATRY, V45, P57, DOI 10.1055/s-0031-1291175; KIVELA SL, 1987, INT J GERIATR PSYCH, V2, P255, DOI 10.1002/gps.930020409; Kossioni AE, 2012, GERODONTOLOGY, V29, P272, DOI 10.1111/j.1741-2358.2012.00633.x; Kreyenbuhl J, 2010, SCHIZOPHRENIA BULL, V36, P94, DOI 10.1093/schbul/sbp130; Kuo CJ, 2012, SCHIZOPHR B, V39, P648; Lacro JP, 2002, J CLIN PSYCHIAT, V63, P892, DOI 10.4088/JCP.v63n1007; Lai ECC, 2013, PHARMACOEPIDEM DR S, V22, P1071, DOI 10.1002/pds.3498; Lai ECC, 2013, SCHIZOPHRENIA BULL, V39, P673, DOI 10.1093/schbul/sbs002; Leucht S, 2009, LANCET, V373, P31, DOI 10.1016/S0140-6736(08)61764-X; Maclure M, 2012, PHARMACOEPIDEM DR S, V21, P50, DOI 10.1002/pds.2330; MORRIS JA, 1988, BRIT MED J, V296, P1313, DOI 10.1136/bmj.296.6632.1313; O'Brien JM, 1999, ANN PHARMACOTHER, V33, P1046, DOI 10.1345/aph.19017; Omori IM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007811; Ozbilen M, 2012, CURR MED CHEM, V19, P5214, DOI 10.2174/092986712803530476; Pratt N, 2011, DRUG SAFETY, V34, P567, DOI 10.2165/11588470-000000000-00000; PUGH CR, 1983, BRIT J PSYCHIAT, V143, P151, DOI 10.1192/bjp.143.2.151; Rummel-Kluge C, 2012, SCHIZOPHRENIA BULL, V38, P167, DOI 10.1093/schbul/sbq042; Rummel-Kluge C, 2010, SCHIZOPHR RES, V123, P225, DOI 10.1016/j.schres.2010.07.012; SCHWARTZ M, 1990, J NEUROL NEUROSUR PS, V53, P800, DOI 10.1136/jnnp.53.9.800; Sjogren R, 2000, J CLIN NURS, V9, P632, DOI 10.1046/j.1365-2702.2000.00380.x; Soares BG, 2000, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001162, 10.1002/14651858.CD001162, DOI 10.1002/14651858.CD001162.PUBMED:10796605]; Star K, 2010, BRIT J GEN PRACT, V60, DOI 10.3399/bjgp10X532396; Trifiro Gianluca, 2011, Curr Infect Dis Rep, V13, P262, DOI 10.1007/s11908-011-0175-y; Trifiro G, 2010, ANN INTERN MED, V152, P418, DOI 10.7326/0003-4819-152-7-201004060-00006; Tsiropoulos I, 2009, PHARMACOEPIDEM DR S, V18, P483, DOI 10.1002/pds.1736; Wahab IA, 2013, PHARMACOEPIDEM DR S, V22, P496, DOI 10.1002/pds.3417; World Health Organization Collaborating Centre for Drug Statistics Methodology, AN THER CHEM COD CLA; Wu CY, 2010, GASTROENTEROLOGY, V139, P1165, DOI 10.1053/j.gastro.2010.06.067; Yang SY, 2007, CLIN PHARMACOL THER, V81, P586, DOI 10.1038/sj.clpt.6100069	41	16	19	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2014	9	2							e89795	10.1371/journal.pone.0089795	http://dx.doi.org/10.1371/journal.pone.0089795			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC3BU	24587038	gold, Green Published, Green Submitted			2023-01-03	WOS:000332390800040
J	Fan, SH; Wang, YY; Lu, J; Zheng, YL; Wu, DM; Li, MQ; Hu, B; Zhang, ZF; Cheng, W; Shan, Q				Fan, Shao-hua; Wang, Yan-yan; Lu, Jun; Zheng, Yuan-lin; Wu, Dong-mei; Li, Meng-qiu; Hu, Bin; Zhang, Zi-feng; Cheng, Wei; Shan, Qun			Luteoloside Suppresses Proliferation and Metastasis of Hepatocellular Carcinoma Cells by Inhibition of NLRP3 Inflammasome	PLOS ONE			English	Article							LONICERA-JAPONICA; INDUCE APOPTOSIS; CANCER; ACTIVATION; AUTOPHAGY; LUTEOLIN-7-O-GLUCOSIDE; ACCUMULATION; INVASION; NECROSIS; RECEPTOR	The inflammasome is a multi-protein complex which when activated regulates caspase-1 activation and IL-1 beta secretion. Inflammasome activation is mediated by NLR proteins that respond to stimuli. Among NLRs, NLRP3 senses the widest array of stimuli. NLRP3 inflammasome plays an important role in the development of many cancer types. However, Whether NLRP3 inflammasome plays an important role in the process of hepatocellular carcinoma (HCC) is still unknown. Here, the anticancer effect of luteoloside, a naturally occurring flavonoid isolated from the medicinal plant Gentiana macrophylla, against HCC cells and the underlying mechanisms were investigated. Luteoloside significantly inhibited the proliferation of HCC cells in vitro and in vivo. Live-cell imaging and transwell assays showed that the migration and invasive capacities of HCC cells, which were treated with luteoloside, were significantly inhibited compared with the control cells. The inhibitory effect of luteoloside on metastasis was also observed in vivo in male BALB/c-nu/nu mouse lung metastasis model. Further studies showed that luteoloside could significantly reduce the intracellular reactive oxygen species (ROS) accumulation. The decreased levels of ROS induced by luteoloside was accompanied by decrease in expression of NLRP3 inflammasome resulting in decrease in proteolytic cleavage of caspase-1. Inactivation of caspase-1 by luteoloside resulted in inhibition of IL-1 beta. Thus, luteoloside exerts its inhibitory effect on proliferation, invasion and metastasis of HCC cells through inhibition of NLRP3 inflammasome. Our results indicate that luteoloside can be a potential therapeutic agent not only as an adjuvant therapy for HCC, but also, in the control and prevention of metastatic HCC.	[Fan, Shao-hua; Lu, Jun; Zheng, Yuan-lin; Wu, Dong-mei; Li, Meng-qiu; Hu, Bin; Zhang, Zi-feng; Shan, Qun] Jiangsu Normal Univ, Sch Life Sci, Key Lab Biotechnol Med Plants Jiangsu Prov, Xuzhou, Jiangsu, Peoples R China; [Wang, Yan-yan] First Peoples Hosp Xuzhou, Dept Funct Examinat, Xuzhou, Jiangsu, Peoples R China; [Cheng, Wei] China Univ Min & Technol, Sch Environm & Spatial Informat, Xuzhou, Jiangsu, Peoples R China	Jiangsu Normal University; China University of Mining & Technology	Zheng, YL (corresponding author), Jiangsu Normal Univ, Sch Life Sci, Key Lab Biotechnol Med Plants Jiangsu Prov, Xuzhou, Jiangsu, Peoples R China.	ylzheng@jsnu.edu.cn	cheng, wei/AAW-2548-2020; Lu, Jun/N-6109-2019	cheng, wei/0000-0003-4795-8104; Lu, Jun/0000-0002-2801-5330	Priority Academic Program Development of Jiangsu Higher Education Institutions; Natural Science Foundation for Colleges and Universities in Jiangsu Province [12KJB320001]; National Natural Science Foundation of China [81171012, 81271225, 30950031]	Priority Academic Program Development of Jiangsu Higher Education Institutions; Natural Science Foundation for Colleges and Universities in Jiangsu Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the Priority Academic Program Development of Jiangsu Higher Education Institutions, the Natural Science Foundation for Colleges and Universities in Jiangsu Province (12KJB320001), the National Natural Science Foundation of China (81171012, 81271225, and 30950031). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad I, 2013, TOXICOL APPL PHARM, V270, P70, DOI 10.1016/j.taap.2013.03.027; Ai J, 2011, JNCI-J NATL CANCER I, V103, P1696, DOI 10.1093/jnci/djr360; Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263; Baskar AA, 2011, NUTR CANCER, V63, P130, DOI 10.1080/01635581.2010.516869; Bruchard M, 2013, NAT MED, V19, P57, DOI 10.1038/nm.2999; Chen GY, 2011, GASTROENTEROLOGY, V141, P1986, DOI 10.1053/j.gastro.2011.10.002; Chen KL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072927; Chen LC, 2012, EMBO MOL MED, V4, P1276, DOI 10.1002/emmm.201201569; Chow MT, 2012, IMMUNOL CELL BIOL, V90, P983, DOI 10.1038/icb.2012.46; Chow MT, 2012, CANCER RES, V72, P5721, DOI 10.1158/0008-5472.CAN-12-0509; Chuang SY, 2013, P NATL ACAD SCI USA, V110, P16079, DOI 10.1073/pnas.1306556110; Dai ZJ, 2013, MOLECULES, V18, P934, DOI 10.3390/molecules18010934; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Fan S, 2013, ONCOGENE, V32, P1682, DOI 10.1038/onc.2012.183; Fan SH, 2009, INT IMMUNOPHARMACOL, V9, P91, DOI 10.1016/j.intimp.2008.10.008; Fan ShaoHua, 2012, Journal of Medicinal Plants Research, V6, P3694, DOI 10.5897/JMPR11.170; Feng RT, 2010, J AGR FOOD CHEM, V58, P3957, DOI 10.1021/jf9025458; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Ghasemi R, 2013, NUTR CANCER, V65, P590, DOI 10.1080/01635581.2013.770043; Hu C, 2004, MOL CELL BIOCHEM, V265, P107, DOI 10.1023/B:MCBI.0000044364.73144.fe; Hu HZ, 2011, GUT, V60, P710, DOI 10.1136/gut.2010.220020; Hu QH, 2012, BIOCHEM PHARMACOL, V84, P113, DOI 10.1016/j.bcp.2012.03.005; Hua KF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076754; Iorio F, 2010, P NATL ACAD SCI USA, V107, P14621, DOI 10.1073/pnas.1000138107; Jorgensen HG, 2007, BLOOD, V109, P4016, DOI 10.1182/blood-2006-11-057521; Lee YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081540; Li SG, 2010, CANCER LETT, V298, P222, DOI 10.1016/j.canlet.2010.07.009; Longo L, 2008, MOL CANCER THER, V7, P2476, DOI 10.1158/1535-7163.MCT-08-0361; Menon SG, 2007, CANCER RES, V67, P6392, DOI 10.1158/0008-5472.CAN-07-0225; Miracco C, 2010, HUM PATHOL, V41, P503, DOI 10.1016/j.humpath.2009.09.004; Papeleu P, 2003, J HEPATOL, V39, P374, DOI 10.1016/S0168-8278(03)00288-5; Qiu F, 2013, BIOMED CHROMATOGR, V27, P311, DOI 10.1002/bmc.2793; Qu Y, 2011, J CLIN INVEST, V121, P212, DOI 10.1172/JCI43144; Sahasrabuddhe VV, 2012, JNCI-J NATL CANCER I, V104, P1808, DOI 10.1093/jnci/djs452; Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015; Sethman CR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070994; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sorbara MT, 2011, CELL RES, V21, P558, DOI 10.1038/cr.2011.20; Sun X, 2011, J CELL BIOCHEM, V112, P2019, DOI 10.1002/jcb.23121; Tang H, 2010, NAT IMMUNOL, V11, P608, DOI 10.1038/ni.1883; Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725; Ungerback J, 2012, CARCINOGENESIS, V33, P2126, DOI 10.1093/carcin/bgs256; van Deventer HW, 2010, CANCER RES, V70, P10161, DOI 10.1158/0008-5472.CAN-10-1921; Walter A, 2010, FASEB J, V24, P3360, DOI 10.1096/fj.09-149419; Wang C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038285; Wen HT, 2011, NAT IMMUNOL, V12, P408, DOI 10.1038/ni.2022; Wen SM, 2014, CANCER TREAT REV, V40, P31, DOI 10.1016/j.ctrv.2013.07.008; Xiong JH, 2013, FOOD CHEM, V138, P327, DOI 10.1016/j.foodchem.2012.10.127; Yao J, 2010, HEPATOLOGY, V51, P846, DOI 10.1002/hep.23443; Zamora-Ros R, 2013, INT J CANCER, V133, P2429, DOI 10.1002/ijc.28257; Zhang Y, 2014, ARCH TOXICOL, V88, P97, DOI 10.1007/s00204-013-1085-6; Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831	53	83	90	4	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2014	9	2							e89961	10.1371/journal.pone.0089961	http://dx.doi.org/10.1371/journal.pone.0089961			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC3BC	24587153	gold, Green Published, Green Submitted			2023-01-03	WOS:000332389000118
J	Tseng, CK; Lin, CK; Chang, HW; Wu, YH; Yen, FL; Chang, FR; Chen, WC; Yeh, CC; Lee, JC				Tseng, Chin-Kai; Lin, Chun-Kuang; Chang, Hsueh-Wei; Wu, Yu-Hsuan; Yen, Feng-Lin; Chang, Fang-Rong; Chen, Wei-Chun; Yeh, Chi-Chen; Lee, Jin-Ching			Aqueous Extract of Gracilaria tenuistipitata Suppresses LPS-Induced NF-kappa B and MAPK Activation in RAW 264.7 and Rat Peritoneal Macrophages and Exerts Hepatoprotective Effects on Carbon Tetrachloride-Treated Rat	PLOS ONE			English	Article							LIVER-INJURY; MOLECULAR-MECHANISMS; SIGNALING PATHWAYS; CELL-SURVIVAL; NITRIC-OXIDE; INFLAMMATION; LIPOPOLYSACCHARIDE; DAMAGE; HOMEOSTASIS; INHIBITION	In addition to the previous investigations of bioactivity of aqueous extract of the edible Gracilaria tenuistipitata (AEGT) against H2O2-induced DNA damage and hepatitis C virus replication, the purpose of this study is to evaluate the potential therapeutic properties of AEGT against inflammation and hepatotoxicity using lipopolysaccharide (LPS)-stimulated mouse RAW 264.7 cells, primary rat peritoneal macrophages and carbon tetrachloride (CCl4)-induced acute hepatitis model in rats. AEGT concentration-dependently inhibited the elevated RNA and protein levels of inducible nitric oxide synthase and cyclooxygenase-2, thereby reducing nitric oxide and prostaglandin E2 levels, respectively. Moreover, AEGT significantly suppressed the production of LPS-induced proinflammatory cytokines, including interleukin (IL)-1 beta, IL-6 and tumor necrosis factor-alpha. These inhibitory effects were associated with the suppression of nuclear factor-kappa B activation and mitogen-activated protein kinase phosphorylation by AEGT in LPS-stimulated cells. In addition, we highlighted the hepatoprotective and curative effects of AEGT in a rat model of CCl4-intoxicated acute liver injury, which was evident from reduction in the elevated serum aspartate aminotransferase and alanine aminotransferase levels as well as amelioration of histological damage by pre-treatment or post-treatment of AEGT. In conclusion, the results demonstrate that AEGT may serve as a potential supplement in the prevention or amelioration of inflammatory diseases.	[Tseng, Chin-Kai] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan; [Tseng, Chin-Kai] Natl Cheng Kung Univ, Coll Med, Ctr Infect Dis & Signaling Res, Tainan 70101, Taiwan; [Lin, Chun-Kuang] Natl Sun Yat Sen Univ, Doctoral Degree Program Marine Biotechnol, Kaohsiung 80424, Taiwan; [Chang, Hsueh-Wei] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Biomed Sci & Environm Biol, Ctr Canc, Kaohsiung, Taiwan; [Wu, Yu-Hsuan; Lee, Jin-Ching] Kaohsiung Med Univ, Dept Biotechnol, Coll Life Sci, Kaohsiung, Taiwan; [Yen, Feng-Lin] Kaohsiung Med Univ, Dept Fragrance & Cosmet Sci, Coll Pharm, Kaohsiung, Taiwan; [Chen, Wei-Chun] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan; [Chang, Fang-Rong; Yeh, Chi-Chen; Lee, Jin-Ching] Kaohsiung Med Univ, Grad Inst Nat Prod, Coll Pharm, Kaohsiung, Taiwan	National Cheng Kung University; National Cheng Kung University; National Sun Yat Sen University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University	Lee, JC (corresponding author), Kaohsiung Med Univ, Dept Biotechnol, Coll Life Sci, Kaohsiung, Taiwan.	jclee@kmu.edu.tw	Chang, Hsueh-Wei/C-9654-2009	Chang, Hsueh-Wei/0000-0003-0068-2366; Chang, Fang-Rong/0000-0003-2549-4193; Lee, Jin-Ching/0000-0003-0729-9589; Wu, Yu-Hsuan/0000-0002-2175-3867	National Science Council of Taiwan [NSC 101-2311-B-037-002-MY3, NSC 101-2622-B-037-001-CC3]; Kaohsiung Medical University Research Foundation, Taiwan [KMUER014]; Department of Health, Executive Yuan, Taiwan [DOH102-TD-C-111-002]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Kaohsiung Medical University Research Foundation, Taiwan; Department of Health, Executive Yuan, Taiwan	This work was funded by grants from the National Science Council of Taiwan (NSC 101-2311-B-037-002-MY3 and NSC 101-2622-B-037-001-CC3), Kaohsiung Medical University Research Foundation, Taiwan (KMUER014) and The Department of Health, Executive Yuan, Taiwan (DOH102-TD-C-111-002). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AJISAKA T, 1993, HYDROBIOLOGIA, V261, P335; APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; Chan ED, 2001, AM J PHYSIOL-CELL PH, V280, pC441, DOI 10.1152/ajpcell.2001.280.3.C441; CHANG KP, 1976, SCIENCE, V193, P678, DOI 10.1126/science.948742; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Chen KJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057704; Crispe IN, 2009, ANNU REV IMMUNOL, V27, P147, DOI 10.1146/annurev.immunol.021908.132629; Feldmann M, 2008, J CLIN INVEST, V118, P3533, DOI 10.1172/JCI37346; Fujihara M, 2003, PHARMACOL THERAPEUT, V100, P171, DOI 10.1016/j.pharmthera.2003.08.003; Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423; Gonciarz M, 2010, J PHYSIOL PHARMACOL, V61, P705; Jaeschke H, 2011, J GASTROEN HEPATOL, V26, P173, DOI 10.1111/j.1440-1746.2010.06592.x; Javed S, 2011, ALTERN MED REV, V16, P239; Jeong JB, 2011, ARCH PHARM RES, V34, P2109, DOI 10.1007/s12272-011-1214-9; JOHNSON SJ, 1992, J PATHOL, V166, P351, DOI 10.1002/path.1711660406; Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017; Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006; Kim JK, 2012, INFLAMM RES, V61, P319, DOI 10.1007/s00011-011-0413-7; Kim MM, 2009, PHYTOTHER RES, V23, P628, DOI 10.1002/ptr.2674; KOOP DR, 1992, FASEB J, V6, P724, DOI 10.1096/fasebj.6.2.1537462; Krakauer Teresa, 2004, Current Drug Targets - Inflammation and Allergy, V3, P317; Lee CW, 2012, J AGR FOOD CHEM, V60, P4662, DOI 10.1021/jf2050137; Lee JC, 2011, ANTIVIR RES, V89, P35, DOI 10.1016/j.antiviral.2010.11.003; Lin AW, 1996, J BIOL CHEM, V271, P11911, DOI 10.1074/jbc.271.20.11911; LIU RH, 1995, MUTAT RES-REV GENET, V339, P73, DOI 10.1016/0165-1110(95)90004-7; Medzhitov R, 2009, NAT REV IMMUNOL, V9, P692, DOI 10.1038/nri2634; Muriel P, 2009, J APPL TOXICOL, V29, P91, DOI 10.1002/jat.1393; Pasparakis M, 2009, NAT REV IMMUNOL, V9, P778, DOI 10.1038/nri2655; Patrick L, 2006, ALTERN MED REV, V11, P114; Piva R, 2006, ANTIOXID REDOX SIGN, V8, P478, DOI 10.1089/ars.2006.8.478; Pradhan SC, 2006, INDIAN J MED RES, V124, P491; Ren K, 2009, BRAIN RES REV, V60, P57, DOI 10.1016/j.brainresrev.2008.12.020; Ryan S, 2011, PHYTOTHER RES, V25, P765, DOI 10.1002/ptr.3309; Sasaki S, 2002, EUR J IMMUNOL, V32, P3197, DOI 10.1002/1521-4141(200211)32:11<3197::AID-IMMU3197>3.0.CO;2-1; SLATER TF, 1985, PHILOS T R SOC B, V311, P633, DOI 10.1098/rstb.1985.0169; SLATER TF, 1984, BIOCHEM J, V222, P1; Tacke F, 2009, CLIN REV ALLERG IMMU, V36, P4, DOI 10.1007/s12016-008-8091-0; Veres B, 2004, J PHARMACOL EXP THER, V310, P247, DOI 10.1124/jpet.104.065151; Yang JI, 2012, MOLECULES, V17, P7241, DOI 10.3390/molecules17067241	40	31	32	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2014	9	1							e86557	10.1371/journal.pone.0086557	http://dx.doi.org/10.1371/journal.pone.0086557			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301BI	24475143	gold, Green Submitted, Green Published			2023-01-03	WOS:000330507300080
J	Weiss, RA				Weiss, Robin A.			Immunotherapy for HIV Infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Two recent studies show that a hybrid virus, the simian immunodeficiency virus bearing the envelope antigens of HIV-1, can be cleared from the blood of rhesus macaques by the infusion of monoclonal antibodies. The provision of immunotherapy through antibody infusion has a venerable and valuable record in the treatment of infectious disease. In 1901, the first Nobel Prize in Physiology or Medicine was awarded to Emil von Behring for serum therapy, especially its application against diphtheria, and more recently, postexposure prophylaxis against rabies has combined antibody treatment with active immunization. Although immunotherapy for chronic, persistent infections is more problematic, new studies by Barouch et al.(1) and Shingai et al.(2) on the treatment of rhesus macaques indicate that monoclonal antibodies show much promise in clearing infection with a hybrid form of the simian immunodeficiency ...	UCL, Div Infect & Immun, London WC1E 6BT, England	University of London; University College London	Weiss, RA (corresponding author), UCL, Div Infect & Immun, London WC1E 6BT, England.							Balazs AB, 2012, NATURE, V481, P81, DOI 10.1038/nature10660; Barouch DH, 2013, NATURE, V503, P224, DOI 10.1038/nature12744; Hansen SG, 2013, NATURE, V502, P100, DOI 10.1038/nature12519; Shingai M, 2013, NATURE, V503, P277, DOI 10.1038/nature12746; Watkins JD, 2013, AIDS, V27, pF13, DOI 10.1097/QAD.0b013e328360eac6	5	5	5	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 23	2014	370	4					379	380		10.1056/NEJMcibr1314577	http://dx.doi.org/10.1056/NEJMcibr1314577			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294HP	24450898				2023-01-03	WOS:000330036200015
J	Huang, GY; Xu, JJ; Xu, L; Wang, SF; Li, RP; Liu, K; Zheng, J; Cai, ZY; Zhang, K; Luo, YD; Xu, WG				Huang, Guoyang; Xu, Jiajun; Xu, Li; Wang, Shifeng; Li, Runping; Liu, Kan; Zheng, Juan; Cai, Zhiyu; Zhang, Kun; Luo, Yuandeng; Xu, Weigang			Hyperbaric Oxygen Preconditioning Induces Tolerance against Oxidative Injury and Oxygen-Glucose Deprivation by Up-Regulating Heat Shock Protein 32 in Rat Spinal Neurons	PLOS ONE			English	Article							ISCHEMIA-REPERFUSION INJURY; CORD-INJURY; INCREASED EXPRESSION; HEME OXYGENASE-1; HEAT-SHOCK-PROTEIN-70; ANTIOXIDANT; REPAIR	Objective: Hyperbaric oxygen (HBO) preconditioning (HBO-PC) has been testified to have protective effects on spinal cord injury (SCI). However, the mechanisms remain enigmatic. The present study aimed to explore the effects of HBO-PC on primary rat spinal neurons against oxidative injury and oxygen-glucose deprivation (OGD) and the relationship with heat shock proteins (HSPs). Methods: Primary rat spinal neurons after 7 days of culture were used in this study. HSPs were detected in rat spinal neurons following a single exposure to HBO at different time points by Western blot. Using lactate dehydrogenase release assay and cell counting kit-8 assay, the injuries induced by hydrogen peroxide (H2O2) insult or OGD were determined and compared among neurons treated with HBO-PC with or without HSP inhibitors. Results: The results of Western blot showed that HSP27, HSP70 and HSP90 have a slight but not significant increase in primary neurons following HBO exposure. However, HSP32 expression significantly increased and reached highest at 12 h following HBO exposure. HBO-PC significantly increased the cell viability and decreased the medium lactate dehydrogenase content in cultures treated with H2O2 or OGD. Pretreatment with zinc protoporphyrin IX, a specific inhibitor of HSP32, significantly blocked the protective effects of HBO-PC. Conclusions: These results suggest that HBO-PC could protect rat spinal neurons in vitro against oxidative injury and OGD mostly by up-regulating of HSP32 expression.	[Huang, Guoyang; Xu, Jiajun; Xu, Li; Li, Runping; Liu, Kan; Zheng, Juan; Cai, Zhiyu; Zhang, Kun; Luo, Yuandeng; Xu, Weigang] Second Mil Med Univ, Fac Naval Med, Dept Diving & Hyperbar Med, Shanghai, Peoples R China; [Wang, Shifeng] Inst Naval Med, Shanghai, Peoples R China	Naval Medical University	Xu, WG (corresponding author), Second Mil Med Univ, Fac Naval Med, Dept Diving & Hyperbar Med, Shanghai, Peoples R China.	wgxu@hotmail.com	xu, wei/HHD-2891-2022		National Natural Science Foundation of China [81171873]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China, No. 81171873. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Waili NS, 2005, ADV THER, V22, P659, DOI 10.1007/BF02849960; Baranano DE, 2000, J BIOL CHEM, V275, P15166, DOI 10.1074/jbc.275.20.15166; Blatteau JE, 2011, NEUROCRIT CARE, V15, P120, DOI 10.1007/s12028-010-9370-1; Chow AM, 2013, CELL STRESS CHAPERON, V18, P155, DOI 10.1007/s12192-012-0364-0; Coselli JS, 2007, ANN THORAC SURG, V83, pS862, DOI 10.1016/j.athoracsur.2006.10.088; Dong HL, 2002, ANESTHESIOLOGY, V96, P907, DOI 10.1097/00000542-200204000-00018; GRIM PS, 1990, JAMA-J AM MED ASSOC, V263, P2216; He XZ, 2011, J SURG RES, V170, pE271, DOI 10.1016/j.jss.2011.06.008; Jiang XY, 2006, J NEUROSCI METH, V158, P13, DOI 10.1016/j.jneumeth.2006.05.014; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Latchman DS, 2001, CARDIOVASC RES, V51, P637, DOI 10.1016/S0008-6363(01)00354-6; Li QB, 2007, LIFE SCI, V80, P1087, DOI 10.1016/j.lfs.2006.11.043; Liu Y, 2011, CLIN EXP PHARMACOL P, V38, P675, DOI 10.1111/j.1440-1681.2011.05560.x; Lu PG, 2012, NEUROL RES, V34, P944, DOI 10.1179/1743132812Y.0000000096; Macario AJL, 2007, FRONT BIOSCI-LANDMRK, V12, P2588, DOI 10.2741/2257; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1981, BIOCHIM BIOPHYS ACTA, V673, P339, DOI 10.1016/0304-4165(81)90465-7; Ni XX, 2013, EXP BIOL MED, V238, P12, DOI 10.1258/ebm.2012.012101; Nie H, 2006, J CEREBR BLOOD F MET, V26, P666, DOI 10.1038/sj.jcbfm.9600221; Norenberg MD, 2004, J NEUROTRAUM, V21, P429, DOI 10.1089/089771504323004575; Redaelli CA, 2001, TRANSPL INT, V14, P351, DOI 10.1007/s001470100000; Reddy SJ, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E4; Robinson MB, 2005, J NEUROSCI, V25, P9735, DOI 10.1523/JNEUROSCI.1912-05.2005; Shyu WC, 2004, CELL MOL NEUROBIOL, V24, P257, DOI 10.1023/B:CEMN.0000018620.41913.d2; Soejima Y, 2012, MED GAS RES, V2, DOI 10.1186/2045-9912-2-9; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Tai PA, 2010, J NEUROTRAUM, V27, P1121, DOI 10.1089/neu.2009.1162; Thom SR, 2009, J APPL PHYSIOL, V106, P988, DOI 10.1152/japplphysiol.91004.2008; Topuz K, 2010, ARCH MED RES, V41, P506, DOI 10.1016/j.arcmed.2010.10.004; Tsuchihashi Sei-ichiro, 2004, Ann Transplant, V9, P84; Verhoeven EL, 2009, EUR J VASC ENDOVASC, V38, P155, DOI 10.1016/j.ejvs.2009.05.002; Wang LP, 2009, J NEUROTRAUM, V26, P55, DOI 10.1089/neu.2008.0538; Zhang Q, 2010, NEUROL RES, V32, P852, DOI 10.1179/016164110X12556180206112	33	27	32	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2014	9	1							e85967	10.1371/journal.pone.0085967	http://dx.doi.org/10.1371/journal.pone.0085967			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297EA	24465817	Green Submitted, Green Published, gold			2023-01-03	WOS:000330237000080
J	Messing, J; Thole, C; Niehues, M; Shevtsova, A; Glocker, E; Boren, T; Hensel, A				Messing, Jutta; Thoele, Christian; Niehues, Michael; Shevtsova, Anna; Glocker, Erik; Boren, Thomas; Hensel, Andreas			Antiadhesive Properties of Abelmoschus esculentus (Okra) Immature Fruit Extract against Helicobacter pylori Adhesion	PLOS ONE			English	Article							INHIBIT ADHESION; BINDING; INFECTION; LIPOPOLYSACCHARIDE; POLYSACCHARIDES; RECURRENCE; LAMININ; PROTEIN; MILK	Background: Traditional Asian and African medicine use immature okra fruits (Abelmoschus esculentus) as mucilaginous food to combat gastritis. Its effectiveness is due to polysaccharides that inhibit the adhesion of Helicobacter pylori to stomach tissue. The present study investigates the antiadhesive effect in mechanistic detail. Methodology: A standardized aqueous fresh extract (Okra FE) from immature okra fruits was used for a quantitative in vitro adhesion assay with FITC-labled H. pylori J99, 2 clinical isolates, AGS cells, and fluorescence-activated cell sorting. Bacterial adhesins affected by FE were pinpointed using a dot-blot overlay assay with immobilized Lewis(b), sialyl-Lewis(a), H-1, laminin, and fibronectin. I-125-radiolabeled Okra FE polymer served for binding studies to different H. pylori strains and interaction experiments with BabA and SabA. Iron nanoparticles with different coatings were used to investigate the influence of the charge-dependence of an interaction on the H. pylori surface. Principal findings: Okra FE dose-dependently (0.2 to 2 mg/mL) inhibited H. pylori binding to AGS cells. FE inhibited the adhesive binding of membrane proteins BabA, SabA, and HpA to its specific ligands. Radiolabeled compounds from FE bound non-specifically to different strains of H. pylori, as well as to BabA/SabA deficient mutants, indicating an interaction with a still-unknown membrane structure in the vicinity of the adhesins. The binding depended on the charge of the inhibitors. Okra FE did not lead to subsequent feedback regulation or increased expression of adhesins or virulence factors. Conclusion: Non-specific interactions between high molecular compounds from okra fruits and the H. pylori surface lead to strong antiadhesive effects.	[Messing, Jutta; Thoele, Christian; Niehues, Michael; Hensel, Andreas] Univ Munster, Inst Pharmaceut Biol & Phytochem, D-48149 Munster, Germany; [Shevtsova, Anna; Boren, Thomas] Umea Univ, Umea, Sweden; [Glocker, Erik] Univ Hosp Freiburg, Dept Med Microbiol & Hyg, Reference Ctr Helicobacter Pylori, Freiburg, Germany	University of Munster; Umea University; University of Freiburg	Hensel, A (corresponding author), Univ Munster, Inst Pharmaceut Biol & Phytochem, D-48149 Munster, Germany.	ahensel@uni-muenster.de			German Research Foundation, DFG (International Research Training Group 1549 Molecular and Cellular Glyco-Sciences MCGS, Munster Hyderabad); Vetenskapsradet/VR(M), Cancerfonden	German Research Foundation, DFG (International Research Training Group 1549 Molecular and Cellular Glyco-Sciences MCGS, Munster Hyderabad)(German Research Foundation (DFG)); Vetenskapsradet/VR(M), Cancerfonden	Financial support by the German Research Foundation, DFG (International Research Training Group 1549 Molecular and Cellular Glyco-Sciences MCGS, Munster Hyderabad), to AH, JM, and CT and from Vetenskapsradet/VR(M), Cancerfonden to TB is acknowledged, and was in part performed within the Umea Centre for Microbial Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Aspholm M, 2006, PLOS PATHOG, V2, P989, DOI 10.1371/journal.ppat.0020110; Aspholm-Hurtig M, 2004, SCIENCE, V305, P519, DOI 10.1126/science.1098801; Dubois A, 1999, GASTROENTEROLOGY, V116, P90, DOI 10.1016/S0016-5085(99)70232-5; Gisbert JP, 2005, AM J GASTROENTEROL, V100, P2083, DOI 10.1111/j.1572-0241.2005.50043.x; Gloaguen V, 2007, PLANTA MED, V73, P1402, DOI 10.1055/s-2007-990237; Hirmo S, 1998, FEMS IMMUNOL MED MIC, V20, P275, DOI 10.1111/j.1574-695X.1998.tb01137.x; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Khamri W, 2005, INFECT IMMUN, V73, P7677, DOI 10.1128/IAI.73.11.7677-7686.2005; Kunz C, 2000, ANNU REV NUTR, V20, P699, DOI 10.1146/annurev.nutr.20.1.699; Lengsfeld C, 2004, PLANTA MED, V70, P620, DOI 10.1055/s-2004-827184; Lengsfeld C, 2004, J AGR FOOD CHEM, V52, P1495, DOI 10.1021/jf030666n; Lengsfeld C, 2007, ANIM FEED SCI TECH, V135, P113, DOI 10.1016/j.anifeedsci.2006.11.017; Linden S, 2002, GASTROENTEROLOGY, V123, P1923, DOI 10.1053/gast.2002.37076; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; Motulsky H., 2004, FITTING MODELS BIOL, P352, DOI 10.1002/pst.167; Mysore JV, 1999, GASTROENTEROLOGY, V117, P1316, DOI 10.1016/S0016-5085(99)70282-9; Niehues A., 2010, MOL NUTR FOOD RES, V54, P1; Niehues M, 2010, International Patent application, Patent No. [PCT/NL2010/050158, 2010050158]; Niv Y, 2008, WORLD J GASTROENTERO, V14, P1477, DOI 10.3748/wjg.14.1477; Odenbreit S, 2002, INT J MED MICROBIOL, V292, P247, DOI 10.1078/1438-4221-00204; Odenbreit S, 1999, MOL MICROBIOL, V31, P1537, DOI 10.1046/j.1365-2958.1999.01300.x; Parente F, 2003, HELICOBACTER, V8, P252, DOI 10.1046/j.1523-5378.2003.00152.x; Selgrad M, 2011, CURR OPIN GASTROEN, V27, P565, DOI 10.1097/MOG.0b013e32834bb818; Sengkhamparn N, 2009, CARBOHYD RES, V344, P1824, DOI 10.1016/j.carres.2008.10.012; Sengkhamparn N, 2009, CARBOHYD RES, V344, P1842, DOI 10.1016/j.carres.2008.11.022; Shmuely H, 2004, DIAGN MICR INFEC DIS, V50, P231, DOI 10.1016/j.diagmicrobio.2004.08.011; Simon PM, 1997, INFECT IMMUN, V65, P750, DOI 10.1128/IAI.65.2.750-757.1997; Stingl K, 2005, INT J MED MICROBIOL, V295, P307, DOI 10.1016/j.ijmm.2005.06.006; Sun HY, 2007, J BIOL CHEM, V282, P9973, DOI 10.1074/jbc.M610285200; VALKONEN KH, 1993, FEMS IMMUNOL MED MIC, V7, P29, DOI 10.1111/j.1574-695X.1993.tb00378.x; Valkonen KH, 1997, INFECT IMMUN, V65, P916, DOI 10.1128/IAI.65.3.916-923.1997; Van de Bovenkamp JHB, 2003, HELICOBACTER, V8, P521, DOI 10.1046/j.1523-5378.2003.00173.x; Wittschier N, 2007, PHYTOMEDICINE, V14, P285, DOI 10.1016/j.phymed.2006.12.008; Wittschier N, 2009, J ETHNOPHARMACOL, V125, P218, DOI 10.1016/j.jep.2009.07.009; Yamaoka Yoshio, 2008, P37	37	44	50	1	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2014	9	1							e84836	10.1371/journal.pone.0084836	http://dx.doi.org/10.1371/journal.pone.0084836			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	291XP	24416297	Green Submitted, Green Published, gold			2023-01-03	WOS:000329866300039
J	Gravitz, L				Gravitz, Lauren			Cancer Immunotherapy	NATURE			English	Editorial Material																			0	36	36	6	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 19	2013	504	7480					S1	S1		10.1038/504S1a	http://dx.doi.org/10.1038/504S1a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	273ZR	24352357	Bronze			2023-01-03	WOS:000328575300001
J	Ryland, LK; Doshi, UA; Shanmugavelandy, SS; Fox, TE; Aliaga, C; Broeg, K; Baab, KT; Young, M; Khan, O; Haakenson, JK; Jarbadan, NR; Liao, J; Wang, HG; Feith, DJ; Loughran, TP; Liu, X; Kester, M				Ryland, Lindsay K.; Doshi, Ushma A.; Shanmugavelandy, Sriram S.; Fox, Todd E.; Aliaga, Cesar; Broeg, Kathleen; Baab, Kendall Thomas; Young, Megan; Khan, Osman; Haakenson, Jeremy K.; Jarbadan, Nancy Ruth; Liao, Jason; Wang, Hong-Gang; Feith, David J.; Loughran, Thomas P., Jr.; Liu, Xin; Kester, Mark			C6-Ceramide Nanoliposomes Target the Warburg Effect in Chronic Lymphocytic Leukemia	PLOS ONE			English	Article							SHORT-CHAIN CERAMIDE; GENE-EXPRESSION; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; CELL-DEATH; CANCER; PROTEIN; SURVIVAL; FLUDARABINE; GENERATION; INHIBITION	Ceramide is a sphingolipid metabolite that induces cancer cell death. When C6-ceramide is encapsulated in a nanoliposome bilayer formulation, cell death is selectively induced in tumor models. However, the mechanism underlying this selectivity is unknown. As most tumors exhibit a preferential switch to glycolysis, as described in the "Warburg effect", we hypothesize that ceramide nanoliposomes selectively target this glycolytic pathway in cancer. We utilize chronic lymphocytic leukemia (CLL) as a cancer model, which has an increased dependency on glycolysis. In CLL cells, we demonstrate that C6-ceramide nanoliposomes, but not control nanoliposomes, induce caspase 3/7-independent necrotic cell death. Nanoliposomal ceramide inhibits both the RNA and protein expression of GAPDH, an enzyme in the glycolytic pathway, which is overexpressed in CLL. To confirm that ceramide targets GAPDH, we demonstrate that downregulation of GAPDH potentiates the decrease in ATP after ceramide treatment and exogenous pyruvate treatment as well as GAPDH overexpression partially rescues ceramide-induced necrosis. Finally, an in vivo murine model of CLL shows that nanoliposomal C6-ceramide treatment elicits tumor regression, concomitant with GAPDH downregulation. We conclude that selective inhibition of the glycolytic pathway in CLL cells with nanoliposomal C6-ceramide could potentially be an effective therapy for leukemia by targeting the Warburg effect.	[Ryland, Lindsay K.; Doshi, Ushma A.; Shanmugavelandy, Sriram S.; Fox, Todd E.; Young, Megan; Haakenson, Jeremy K.; Wang, Hong-Gang; Kester, Mark] Penn State Coll Med, Dept Pharmacol, Hershey, PA USA; [Ryland, Lindsay K.; Aliaga, Cesar; Broeg, Kathleen; Baab, Kendall Thomas; Young, Megan; Khan, Osman; Jarbadan, Nancy Ruth; Liao, Jason; Wang, Hong-Gang; Feith, David J.; Loughran, Thomas P., Jr.; Liu, Xin; Kester, Mark] Penn State Coll Med, Penn State Hershey Canc Inst, Hershey, PA USA; [Loughran, Thomas P., Jr.; Liu, Xin] Penn State Coll Med, Dept Med, Hershey, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Kester, M (corresponding author), Penn State Coll Med, Dept Pharmacol, Hershey, PA USA.	mkester@psu.edu	Kester, Mark/ABG-4615-2020; Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571; Young, Megan/0000-0003-1751-9979	National Institutes of Health [CA133525, CA098472]; Pennsylvania Tobacco Settlement Fund [R01HL76789]; NATIONAL CANCER INSTITUTE [R01CA133525, P01CA171983, R01CA098472] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076789] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pennsylvania Tobacco Settlement Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by National Institutes of Health grant nos. CA133525 and CA098472 (to T. P. L.) and Pennsylvania Tobacco Settlement Fund, R01HL76789 (to M. K.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; Bagnara D, 2011, BLOOD, V117, P5463, DOI 10.1182/blood-2010-12-324210; Biswal SS, 2000, TOXICOLOGY, V154, P45, DOI 10.1016/S0300-483X(00)00296-1; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Chalfant CE, 2001, J BIOL CHEM, V276, P44848, DOI 10.1074/jbc.M106291200; Chapman JV, 2010, BIOCHEM PHARMACOL, V80, P308, DOI 10.1016/j.bcp.2010.04.001; Clarke CJ, 2006, BIOCHEMISTRY-US, V45, P11247, DOI 10.1021/bi061307z; Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; FOON KA, 1990, ANN INTERN MED, V113, P525, DOI 10.7326/0003-4819-113-7-525; Fox TE, 2007, J BIOL CHEM, V282, P12450, DOI 10.1074/jbc.M700082200; Geschwind JFH, 2002, CANCER RES, V62, P3909; Guenther GG, 2008, P NATL ACAD SCI USA, V105, P17402, DOI 10.1073/pnas.0802781105; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hetz CA, 2002, J CELL SCI, V115, P4671, DOI 10.1242/jcs.00153; Hofheinz RD, 2005, ANTI-CANCER DRUG, V16, P691, DOI 10.1097/01.cad.0000167902.53039.5a; Huttmann A, 2006, LEUKEMIA, V20, P1774, DOI 10.1038/sj.leu.2404363; Jiang YX, 2011, CANCER BIOL THER, V12, P574, DOI 10.4161/cbt.12.7.15971; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kueck A, 2007, GYNECOL ONCOL, V107, P450, DOI 10.1016/j.ygyno.2007.07.065; Kumagai S, 2008, BIOCHEM BIOPH RES CO, V365, P362, DOI 10.1016/j.bbrc.2007.10.199; Lavallard VJ, 2009, CANCER RES, V69, P3013, DOI 10.1158/0008-5472.CAN-08-2731; Liu X, 2010, BLOOD, V116, P4192, DOI 10.1182/blood-2010-02-271080; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loisel S, 2005, LEUKEMIA RES, V29, P1347, DOI 10.1016/j.leukres.2005.04.017; MELO JV, 1986, INT J CANCER, V38, P531, DOI 10.1002/ijc.2910380413; Mengubas K, 1999, ONCOGENE, V18, P2499, DOI 10.1038/sj.onc.1202622; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Ramos B, 2003, MOL PHARMACOL, V64, P502, DOI 10.1124/mol.64.2.502; Rathmell JC, 2007, CELL, V129, P861, DOI 10.1016/j.cell.2007.05.030; Revillion F, 2000, EUR J CANCER, V36, P1038, DOI 10.1016/S0959-8049(00)00051-4; Rivenzon-Segal D, 2000, AM J PHYSIOL-ENDOC M, V279, pE508, DOI 10.1152/ajpendo.2000.279.3.E508; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200; Shanmugam M, 2009, CURR OPIN ONCOL, V21, P531, DOI 10.1097/CCO.0b013e32832f57ec; Sirover MA, 2005, J CELL BIOCHEM, V95, P45, DOI 10.1002/jcb.20399; Song SW, 2007, NAT CELL BIOL, V9, P869, DOI 10.1038/ncb0807-869; Stover TC, 2005, CLIN CANCER RES, V11, P3465, DOI 10.1158/1078-0432.CCR-04-1770; Sundararaj KP, 2004, J BIOL CHEM, V279, P6152, DOI 10.1074/jbc.M310549200; Tagaram HRS, 2011, GUT, V60, P695, DOI 10.1136/gut.2010.216671; Tran MA, 2008, CLIN CANCER RES, V14, P3571, DOI 10.1158/1078-0432.CCR-07-4881; Veldurthy A, 2008, BLOOD, V112, P1443, DOI 10.1182/blood-2007-11-123984; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Watson DG, 2013, CELL SIGNAL, V25, P1011, DOI 10.1016/j.cellsig.2013.01.002; Yang J, 2010, BLOOD, V115, P51, DOI 10.1182/blood-2009-06-223719; Yeluri S, 2009, J CANCER RES CLIN, V135, P867, DOI 10.1007/s00432-009-0590-8; Zhao XB, 2008, J PHARM SCI-US, V97, P1508, DOI 10.1002/jps.21046	48	28	28	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2013	8	12							e84648	10.1371/journal.pone.0084648	http://dx.doi.org/10.1371/journal.pone.0084648			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276HY	24367685	Green Published, Green Submitted, gold			2023-01-03	WOS:000328741900060
J	Lekawanvijit, S; Kumfu, S; Wang, BH; Manabe, M; Nishijima, F; Kelly, DJ; Krum, H; Kompa, AR				Lekawanvijit, Suree; Kumfu, Sirinart; Wang, Bing H.; Manabe, Minako; Nishijima, Fuyuhiko; Kelly, Darren J.; Krum, Henry; Kompa, Andrew R.			The Uremic Toxin Adsorbent AST-120 Abrogates Cardiorenal Injury Following Myocardial Infarction	PLOS ONE			English	Article							ACUTE KIDNEY INJURY; INDOXYL SULFATE; RENAL-FUNCTION; MOLECULE-1 KIM-1; GENE-EXPRESSION; RAT; OVERLOAD; HYPERTROPHY; DYSFUNCTION; FIBROSIS	An accelerated progressive decline in renal function is a frequent accompaniment of myocardial infarction (MI). Indoxyl sulfate (IS), a uremic toxin that accumulates from the early stages of chronic kidney disease (CKD), is contributory to both renal and cardiac fibrosis. IS levels can be reduced by administration of the oral adsorbent AST-120, which has been shown to ameliorate pathological renal and cardiac fibrosis in moderate to severe CKD. However, the cardiorenal effect of AST-120 on less severe renal dysfunction in the post-MI setting has not previously been well studied. MI-induced Sprague-Dawley rats were randomized to receive either AST-120 (MI+ AST-120) or were untreated (MI+Vehicle) for 16 weeks. Serum IS levels were measured at baseline, 8 and 16 weeks. Echocardiography and glomerular filtration rate (GFR) were assessed prior to sacrifice. Renal and cardiac tissues were assessed for pathological changes using histological and immunohistochemical methods, Western blot analysis and real-time PCR. Compared with sham, MI+ Vehicle animals had a significant reduction in left ventricular ejection fraction (by 42%, p<0.001) and fractional shortening (by 52%, p<0.001) as well as lower GFR (p<0.05) and increased serum IS levels (p<0.05). A significant increase in interstitial fibrosis in the renal cortex was demonstrated in MI+Vehicle animals (p<0.001). Compared with MI+ Vehicle, MI+ AST-120 animals had increased GFR (by 13.35%, p<0.05) and reduced serum IS (p<0.001), renal interstitial fibrosis (p<0.05), and renal KIM-1, collagen-IV and TIMP-1 expression (p<0.05). Cardiac function did not change with AST-120 treatment, however gene expression of TGF-beta 1 and TNF-alpha as well as collagen-I and TIMP-1 protein expression was decreased in the non-infarcted myocardium (p<0.05). In conclusion, reduction of IS attenuates cardio-renal fibrotic processes in the post-MI kidney. KIM-1 appears to be a sensitive renal injury biomarker in this setting and is correlated with serum IS levels.	[Lekawanvijit, Suree; Wang, Bing H.; Krum, Henry; Kompa, Andrew R.] Monash Univ, Dept Epidemiol & Prevent Med, Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic 3004, Australia; [Kelly, Darren J.; Kompa, Andrew R.] Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic, Australia; [Lekawanvijit, Suree] Chiang Mai Univ, Fac Med, Dept Pathol, Chiang Mai 50000, Thailand; [Lekawanvijit, Suree; Kumfu, Sirinart] Chiang Mai Univ, Fac Med, Cardiac Electrophysiol Res & Training Ctr, Chiang Mai 50000, Thailand; [Manabe, Minako; Nishijima, Fuyuhiko] Kureha Corp, Dept Pharmaceut, Tokyo, Japan	Monash University; St Vincent's Hospital Melbourne; University of Melbourne; Chiang Mai University; Chiang Mai University	Krum, H (corresponding author), Monash Univ, Dept Epidemiol & Prevent Med, Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic 3004, Australia.	henry.krum@monash.edu		Kelly, Darren/0000-0003-4850-3929; Kompa, Andrew/0000-0003-1002-2302	National Health and Medical Research Council of Australia [334008, 546272]; Ananda Mahidol Foundation; Thailand Research Fund, Thailand; Prince Doctor Fund under the Royal Patronage of Her Royal Highness Princess Galyanivadhana, Chiang Mai University, Thailand; Thailand Research Fund Royal Golden Jubilee PhD project, Thailand	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Ananda Mahidol Foundation; Thailand Research Fund, Thailand(Thailand Research Fund (TRF)); Prince Doctor Fund under the Royal Patronage of Her Royal Highness Princess Galyanivadhana, Chiang Mai University, Thailand; Thailand Research Fund Royal Golden Jubilee PhD project, Thailand	This work was supported by National Health and Medical Research Council of Australia [Program Grants #334008 and 546272]. S. L. is supported by Ananda Mahidol Foundation and Thailand Research Fund, Thailand; and a recipient of a scholarship from Prince Doctor Fund under the Royal Patronage of Her Royal Highness Princess Galyanivadhana, Chiang Mai University, Thailand. S. K. is a recipient of a scholarship from Thailand Research Fund Royal Golden Jubilee PhD project, Thailand. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anavekar NS, 2004, NEW ENGL J MED, V351, P1285, DOI 10.1056/NEJMoa041365; Atoh K, 2009, DIABETES RES CLIN PR, V83, P220, DOI 10.1016/j.diabres.2008.09.053; Frantz S, 2009, CARDIOVASC RES, V81, P474, DOI 10.1093/cvr/cvn292; Goldberg A, 2005, AM HEART J, V150, P330, DOI 10.1016/j.ahj.2004.09.055; Goldberg A, 2009, KIDNEY INT, V76, P900, DOI 10.1038/ki.2009.295; Goldman S, 1995, J Card Fail, V1, P169, DOI 10.1016/1071-9164(95)90019-5; Ichimura T, 1998, J BIOL CHEM, V273, P4135, DOI 10.1074/jbc.273.7.4135; JERUMS G, 1989, DIABETIC MED, V6, P772, DOI 10.1111/j.1464-5491.1989.tb01277.x; Jose P, 2006, J AM SOC NEPHROL, V17, P2886, DOI 10.1681/ASN.2006010063; Kelly DJ, 1998, KIDNEY INT, V54, P343, DOI 10.1046/j.1523-1755.1998.00019.x; KLOPPER JF, 1972, J NUCL MED, V13, P107; Kobayashi N, 2002, NEPHRON, V91, P480, DOI 10.1159/000064291; Kompa AR, 2010, PEPTIDES, V31, P1523, DOI 10.1016/j.peptides.2010.04.026; Lan RP, 2012, AM J PHYSIOL-RENAL, V302, pF1210, DOI 10.1152/ajprenal.00660.2011; Lekawanvijit S, 2012, CIRC RES, V111, P1470, DOI 10.1161/CIRCRESAHA.112.278457; Lekawanvijit S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041281; Lekawanvijit S, 2012, AM J PHYSIOL-HEART C, V302, pH1884, DOI 10.1152/ajpheart.00967.2011; Lekawanvijit S, 2010, EUR HEART J, V31, P1771, DOI 10.1093/eurheartj/ehp574; Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013; Liao RL, 2005, CIRCULATION, V111, P2416, DOI 10.1161/01.CIR.0000167557.59069.D9; Mann DL, 2003, ANNU REV PHYSIOL, V65, P81, DOI 10.1146/annurev.physiol.65.092101.142249; Martin J, 2005, CARDIOVASC RES, V65, P694, DOI 10.1016/j.cardiores.2004.10.041; Miyazaki T, 1997, KIDNEY INT, V52, pS15; Miyazaki T, 2000, NEPHROL DIAL TRANSPL, V15, P1773, DOI 10.1093/ndt/15.11.1773; NIWA T, 1994, J LAB CLIN MED, V124, P96; Parikh CR, 2008, ARCH INTERN MED, V168, P987, DOI 10.1001/archinte.168.9.987; Phrommintikul A, 2008, AM J PHYSIOL-HEART C, V294, pH1804, DOI 10.1152/ajpheart.01078.2007; Rached E, 2008, TOXICOL SCI, V103, P371, DOI 10.1093/toxsci/kfn040; Shibahara H, 2010, J NEPHROL, V23, P535; Shimizu H, 2011, AM J PHYSIOL-CELL PH, V301, pC1201, DOI 10.1152/ajpcell.00471.2010; Tamada S, 2006, J PHARMACOL SCI, V100, P17, DOI 10.1254/jphs.FMJ05003X4; Tzanidis A, 2001, J MOL CELL CARDIOL, V33, P969, DOI 10.1006/jmcc.2001.1361; van Timmeren MM, 2007, J PATHOL, V212, P209, DOI 10.1002/path.2175	33	29	30	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2013	8	12							e83687	10.1371/journal.pone.0083687	http://dx.doi.org/10.1371/journal.pone.0083687			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276FP	24349545	Green Published, gold			2023-01-03	WOS:000328734200099
J	Shen, YC; Wang, JF; Han, XH; Yang, HY; Wang, S; Lin, DM; Shi, YK				Shen, Yinchen; Wang, Jianfei; Han, Xiaohong; Yang, Hongying; Wang, Shuai; Lin, Dongmei; Shi, Yuankai			Effectors of Epidermal Growth Factor Receptor Pathway: The Genetic Profiling of KRAS, BRAF, PIK3CA, NRAS Mutations in Colorectal Cancer Characteristics and Personalized Medicine	PLOS ONE			English	Article							WILD-TYPE; MONOCLONAL-ANTIBODIES; TARGETED THERAPIES; 1ST-LINE TREATMENT; METASTATIC SITES; PHASE-III; K-RAS; PANITUMUMAB; CETUXIMAB; FLUOROURACIL	Mutations in KRAS oncogene are recognized biomarkers that predict lack of response to anti- epidermal growth factor receptor (EGFR) antibody therapies. However, some patients with KRAS wild-type tumors still do not respond, so other downstream mutations in BRAF, PIK3CA and NRAS should be investigated. Herein we used direct sequencing to analyze mutation status for 676 patients in KRAS (codons 12, 13 and 61), BRAF (exon 11 and exon 15), PIK3CA (exon 9 and exon 20) and NRAS (codons12, 13 and 61). Clinicopathological characteristics associations were analyzed together with overall survival (OS) of metastatic colorectal cancer patients (mCRC). We found 35.9% (242/674) tumors harbored a KRAS mutation, 6.96% (47/675) harbored a BRAF mutation, 9.9% (62/625) harbored a PIK3CA mutation and 4.19% (26/621) harbored a NRAS mutation. KRAS mutation coexisted with BRAF, PIK3CA and NRAS mutation, PIK3CA exon9 mutation appeared more frequently in KRAS mutant tumors (P = 0.027) while NRAS mutation almost existed in KRAS wild-types (P<0.001). Female patients and older group harbored a higher KRAS mutation (P = 0.018 and P = 0.031, respectively); BRAF (V600E) mutation showed a higher frequency in colon cancer and poor differentiation tumors (P = 0.020 and P = 0.030, respectively); proximal tumors appeared a higher PIK3CA mutation (P<0.001) and distant metastatic tumors shared a higher NRAS mutation (P = 0.010). However, in this study no significant result was found between OS and gene mutation in mCRC group. To our knowledge, the first large-scale retrospective study on comprehensive genetic profile which associated with anti- EGFR MoAbs treatment selection in East Asian CRC population, appeared a specific genotype distribution picture, and the results provided a better understanding between clinicopathological characteristics and gene mutations in CRC patients.	[Shen, Yinchen; Wang, Jianfei; Han, Xiaohong; Wang, Shuai; Shi, Yuankai] Peking Union Med Coll, Canc Inst Hosp, Dept Med Oncol, Beijing 100021, Peoples R China; [Shen, Yinchen; Wang, Jianfei; Han, Xiaohong; Yang, Hongying; Wang, Shuai; Lin, Dongmei; Shi, Yuankai] Chinese Acad Med Sci, Beijing 100730, Peoples R China; [Shen, Yinchen; Wang, Jianfei; Han, Xiaohong; Wang, Shuai; Shi, Yuankai] Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China; [Yang, Hongying; Lin, Dongmei] Peking Union Med Coll, Canc Inst Hosp, Dept Pathol, Beijing 100021, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College	Shi, YK (corresponding author), Peking Union Med Coll, Canc Inst Hosp, Dept Med Oncol, Beijing 100021, Peoples R China.	syuankaipumc@126.com	han, xiao/HDN-9782-2022	, Yinchen Shen/0000-0003-0179-2911	Research Special Fund for Public Welfare Industry of Health [200902002-1]; National Science and Technology Major Project [2008ZX09312, 2012ZX09303012]; National High Technology Research and Development Program of China [2011AA02A110]; Beijing Municipal Science and Technology Commission [Z121107005112005, Z121102009212055]; Special Funds for Central Health Authority [B2009B124]; Major Research Program of Cancer Institute and Hospital of Chinese Academy of Medical Sciences [LC2012A18]	Research Special Fund for Public Welfare Industry of Health; National Science and Technology Major Project; National High Technology Research and Development Program of China(National High Technology Research and Development Program of China); Beijing Municipal Science and Technology Commission(Beijing Municipal Science & Technology Commission); Special Funds for Central Health Authority; Major Research Program of Cancer Institute and Hospital of Chinese Academy of Medical Sciences	This study was supported in part by grants from the Research Special Fund for Public Welfare Industry of Health (200902002-1), National Science and Technology Major Project (2008ZX09312, 2012ZX09303012), National High Technology Research and Development Program of China (2011AA02A110) (http://www.863.gov.cn/); Beijing Municipal Science and Technology Commission (Z121107005112005, Z121102009212055), Special Funds for Central Health Authority (B2009B124) and Major Research Program of Cancer Institute and Hospital of Chinese Academy of Medical Sciences (LC2012A18). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170; Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Artale S, 2008, J CLIN ONCOL, V26, P4217, DOI 10.1200/JCO.2008.18.7286; Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116; Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158; Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397; Cappuzzo F, 2008, BRIT J CANCER, V99, P83, DOI 10.1038/sj.bjc.6604439; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Day FL, 2013, CLIN CANCER RES, V19, P3285, DOI 10.1158/1078-0432.CCR-12-3614; De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6; De Roock W, 2010, JAMA-J AM MED ASSOC, V304, P1812, DOI 10.1001/jama.2010.1535; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; De Roock W, 2009, NEW ENGL J MED, V360, P834; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X; Hsieh LL, 2012, CLIN CHIM ACTA, V413, P1605, DOI 10.1016/j.cca.2012.04.029; Irahara N, 2010, DIAGN MOL PATHOL, V19, P157, DOI 10.1097/PDM.0b013e3181c93fd1; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kim A, 2013, INT J CANCER, V133, P984, DOI 10.1002/ijc.28073; Kumar K, 2009, CLIN CANCER RES, V15, P1155, DOI 10.1158/1078-0432.CCR-08-1029; Laurent-Puig P, 2009, J CLIN ONCOL, V27, P5924, DOI 10.1200/JCO.2008.21.6796; Li HT, 2011, ONCOL REP, V25, P1691, DOI 10.3892/or.2011.1217; Liao WJ, 2010, ANAT REC, V293, P1506, DOI 10.1002/ar.21202; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Mao C, 2012, ANN ONCOL, V23, P1518, DOI 10.1093/annonc/mdr464; Mao C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036653; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Neumann J, 2009, PATHOL RES PRACT, V205, P858, DOI 10.1016/j.prp.2009.07.010; Normanno N, 2009, NAT REV CLIN ONCOL, V6, P519, DOI 10.1038/nrclinonc.2009.111; Ogino S, 2009, J CLIN ONCOL, V27, P1477, DOI 10.1200/JCO.2008.18.6544; Peeters M, 2013, CLIN CANCER RES, V19, P1902, DOI 10.1158/1078-0432.CCR-12-1913; Rako I, 2012, NEOPLASMA, V59, P376, DOI 10.4149/neo_2012_049; Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452; Santini D, 2008, ONCOLOGIST, V13, P1270, DOI 10.1634/theoncologist.2008-0181; Saridaki Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015980; Sartore-Bianchi A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007287; Sartore-Bianchi A, 2009, CANCER RES, V69, P1851, DOI 10.1158/0008-5472.CAN-08-2466; Seymour MT, 2013, LANCET ONCOL, V14, P749, DOI 10.1016/S1470-2045(13)70163-3; Shen H, 2011, WORLD J GASTROENTERO, V17, P809, DOI 10.3748/wjg.v17.i6.809; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Siena S, 2009, JNCI-J NATL CANCER I, V101, P1308, DOI 10.1093/jnci/djp280; Souglakos J, 2009, BRIT J CANCER, V101, P465, DOI 10.1038/sj.bjc.6605164; Tejpar S, 2012, J CLIN ONCOL, V30, P3570, DOI 10.1200/JCO.2012.42.2592; Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022; Wang JF, 2013, CANCER BIOMARK, V13, P89, DOI 10.3233/CBM-130334; Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105	50	73	76	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2013	8	12							e81628	10.1371/journal.pone.0081628	http://dx.doi.org/10.1371/journal.pone.0081628			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275VW	24339949	Green Published, gold, Green Submitted			2023-01-03	WOS:000328707400026
J	Attia, E				Attia, Evelyn			Anorexia nervosa in adolescents: challenges remain	LANCET			English	Editorial Material									[Attia, Evelyn] Columbia Univ, Med Ctr, New York, NY 10032 USA; [Attia, Evelyn] Weill Cornell Med Coll, New York, NY USA	Columbia University; Cornell University	Attia, E (corresponding author), Columbia Univ, Med Ctr, New York, NY 10032 USA.	ea12@columbia.edu						American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; Attia E, 2007, AM J PSYCHIAT, V164, P1805, DOI 10.1176/appi.ajp.2007.07071151; Attia E, 2009, NEW ENGL J MED, V360, P500, DOI 10.1056/NEJMct0805569; Bulik CM, 2007, INT J EAT DISORDER, V40, P310, DOI 10.1002/eat.20367; Herpertz-Dahlmann B, 2013, LANCET; Kaplan AS, 2009, PSYCHOL MED, V39, P1037, DOI 10.1017/S003329170800442X; Lock J, 2010, ARCH GEN PSYCHIAT, V67, P1025, DOI 10.1001/archgenpsychiatry.2010.128; Olmsted MP, 2013, PSYCHOTHER RES, V23, P277, DOI 10.1080/10503307.2012.721937; Striegel-Moore RH, 2000, INT J EAT DISORDER, V27, P381; Walsh BT, 2013, AM J PSYCHIAT, V170, P477, DOI 10.1176/appi.ajp.2012.12081074	10	9	9	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	2014	383	9924					1191	1192		10.1016/S0140-6736(13)62550-7	http://dx.doi.org/10.1016/S0140-6736(13)62550-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AE6LO	24439239				2023-01-03	WOS:000334104600006
J	Furman, RR; Sharman, JP; Coutre, SE; Cheson, BD; Pagel, JM; Hillmen, P; Barrientos, JC; Zelenetz, AD; Kipps, TJ; Flinn, I; Ghia, P; Eradat, H; Ervin, T; Lamanna, N; Coiffier, B; Pettitt, AR; Ma, S; Stilgenbauer, S; Cramer, P; Aiello, M; Johnson, DM; Miller, LL; Li, D; Jahn, TM; Dansey, RD; Hallek, M; O'Brien, SM				Furman, Richard R.; Sharman, Jeff P.; Coutre, Steven E.; Cheson, Bruce D.; Pagel, John M.; Hillmen, Peter; Barrientos, Jacqueline C.; Zelenetz, Andrew D.; Kipps, Thomas J.; Flinn, Ian; Ghia, Paolo; Eradat, Herbert; Ervin, Thomas; Lamanna, Nicole; Coiffier, Bertrand; Pettitt, Andrew R.; Ma, Shuo; Stilgenbauer, Stephan; Cramer, Paula; Aiello, Maria; Johnson, Dave M.; Miller, Langdon L.; Li, Daniel; Jahn, Thomas M.; Dansey, Roger D.; Hallek, Michael; O'Brien, Susan M.			Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENOMIC ABERRATIONS; SURVIVAL; INHIBITOR; EXPRESSION; CAL-101; MUTATION; DISEASE; PI3K	BackgroundPatients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies with acceptable side-effect profiles are needed for this patient population. MethodsIn this multicenter, randomized, double-blind, placebo-controlled, phase 3 study, we assessed the efficacy and safety of idelalisib, an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase, in combination with rituximab versus rituximab plus placebo. We randomly assigned 220 patients with decreased renal function, previous therapy-induced myelosuppression, or major coexisting illnesses to receive rituximab and either idelalisib (at a dose of 150 mg) or placebo twice daily. The primary end point was progression-free survival. At the first prespecified interim analysis, the study was stopped early on the recommendation of the data and safety monitoring board owing to overwhelming efficacy. ResultsThe median progression-free survival was 5.5 months in the placebo group and was not reached in the idelalisib group (hazard ratio for progression or death in the idelalisib group, 0.15; P<0.001). Patients receiving idelalisib versus those receiving placebo had improved rates of overall response (81% vs. 13%; odds ratio, 29.92; P<0.001) and overall survival at 12 months (92% vs. 80%; hazard ratio for death, 0.28; P=0.02). Serious adverse events occurred in 40% of the patients receiving idelalisib and rituximab and in 35% of those receiving placebo and rituximab. ConclusionsThe combination of idelalisib and rituximab, as compared with placebo and rituximab, significantly improved progression-free survival, response rate, and overall survival among patients with relapsed CLL who were less able to undergo chemotherapy. (Funded by Gilead; ClinicalTrials.gov number, NCT01539512.) A placebo-controlled study of idelalisib in patients with relapsed chronic lymphocytic leukemia who were receiving rituximab was stopped early because of significant improvement in rates of response, progression-free survival, and overall survival with idelalisib. Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia among adults. Standard treatments include combinations of purine analogues, alkylating agents, and monoclonal antibodies. In younger patients without major coexisting illnesses, these regimens can provide high response rates of durable length but have substantial toxic effects. As a result, these treatments often have unacceptable side effects in older patients and those with coexisting illnesses.(1) Patients with relapsed CLL often have limited options because of the development of resistance to, or persisting toxic effects of, previous therapies. This is particularly true for elderly patients and those with coexisting illnesses.(2) For these patients, ...	[Furman, Richard R.] Weill Cornell Med Coll, New York, NY USA; [Zelenetz, Andrew D.] Columbia Univ, Mem Sloan Kettering Canc Ctr, Med Ctr, New York, NY USA; [Lamanna, Nicole] Columbia Univ, Dept Med, Med Ctr, New York, NY USA; [Sharman, Jeff P.] US Oncol Res, Springfield, OR USA; [Coutre, Steven E.] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Aiello, Maria; Johnson, Dave M.; Miller, Langdon L.; Li, Daniel; Jahn, Thomas M.; Dansey, Roger D.] Gilead Sci Inc, Foster City, CA 94404 USA; [Cheson, Bruce D.] Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA; [Pagel, John M.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA; [Hillmen, Peter] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England; [Pettitt, Andrew R.] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England; [Barrientos, Jacqueline C.] Hofstra North Shore LIJ, Sch Med, New Hyde Pk, NY USA; [Kipps, Thomas J.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Flinn, Ian] Sarah Cannon Res Inst, Nashville, TN USA; [Ghia, Paolo] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Milan, Italy; [Eradat, Herbert] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Ervin, Thomas] Florida Canc Specialists, Englewood, CO USA; [Coiffier, Bertrand] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France; [Ma, Shuo] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Stilgenbauer, Stephan] Univ Ulm, D-89069 Ulm, Germany; [Cramer, Paula; Hallek, Michael] Univ Cologne, D-50931 Cologne, Germany; [O'Brien, Susan M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	Cornell University; Columbia University; Memorial Sloan Kettering Cancer Center; Columbia University; US Oncology Network; Stanford University; Gilead Sciences; Georgetown University; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Saint James's University Hospital; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; Hofstra University; University of California System; University of California San Diego; Sarah Cannon Research Institute; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; CHU Lyon; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Ulm University; University of Cologne; University of Texas System; UTMD Anderson Cancer Center	Furman, RR (corresponding author), Weill Cornell Med Coll, Div Hematol Oncol, 525 E 68th St, New York, NY 10065 USA.	rrfurman@med.cornell.edu	Barrientos, Jacqueline/AAE-6683-2022; Hallek, Michael/Y-3191-2019; Stilgenbauer, Stephan/ABE-6609-2020; Lamanna, Nicole/ABB-7835-2020; Ghia, Paolo/K-7138-2016	Hallek, Michael/0000-0002-7425-4455; Lamanna, Nicole/0000-0003-3331-9491; Ghia, Paolo/0000-0003-3750-7342; Flinn, Ian/0000-0001-6724-290X; Coutre, Steven/0000-0001-8420-5748; Barrientos, Jacqueline Claudia/0000-0001-6018-5535	Gilead; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA081534, P30CA060553] Funding Source: NIH RePORTER	Gilead(Gilead Sciences); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by Gilead	Barrientos JC, 2013, J CLIN ONCOL, V31; Bernal A, 2001, BLOOD, V98, P3050, DOI 10.1182/blood.V98.10.3050; Brown JR, 2013, J CLIN ONCOL, V31; Burger JA, 1999, BLOOD, V94, P3658, DOI 10.1182/blood.V94.11.3658.423k11_3658_3667; Byrd JC, 2001, J CLIN ONCOL, V19, P2153, DOI 10.1200/JCO.2001.19.8.2153; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Chen LG, 2002, BLOOD, V100, P4609, DOI 10.1182/blood-2002-06-1683; Cheson BD, 2012, J CLIN ONCOL, V30, P2820, DOI 10.1200/JCO.2012.43.3748; Chiorazzi N, 2005, NEW ENGL J MED, V352, P804, DOI 10.1056/NEJMra041720; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Eichhorst B, 2009, LEUKEMIA LYMPHOMA, V50, P171, DOI 10.1080/10428190802688517; Extermann M, 1998, J CLIN ONCOL, V16, P1582, DOI 10.1200/JCO.1998.16.4.1582; Furman RR, 2000, J IMMUNOL, V164, P2200, DOI 10.4049/jimmunol.164.4.2200; Gattei V, 2008, BLOOD, V111, P865, DOI 10.1182/blood-2007-05-092486; Gribben JG, 2011, J CLIN ONCOL, V29, P544, DOI 10.1200/JCO.2010.32.3865; Hallek M, 2012, BLOOD; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Herishanu Y, 2011, BLOOD, V117, P563, DOI 10.1182/blood-2010-05-284984; Herman SEM, 2010, BLOOD, V116, P2078, DOI 10.1182/blood-2010-02-271171; Hoellenriegel J, 2011, BLOOD, V118, P3603, DOI 10.1182/blood-2011-05-352492; Huhn D, 2001, BLOOD, V98, P1326, DOI 10.1182/blood.V98.5.1326; Itala M, 2002, EUR J HAEMATOL, V69, P129, DOI 10.1034/j.1600-0609.2002.02786.x; Krober A, 2002, BLOOD, V100, P1410, DOI 10.1182/blood.V100.4.1410.h81602001410_1410_1416; Lannutti BJ, 2011, BLOOD, V117, P591, DOI 10.1182/blood-2010-03-275305; National Comprehensive Cancer Network, 2013, NCCN CLIN PRACT GUID; O'Brien SM, 2001, J CLIN ONCOL, V19, P2165, DOI 10.1200/JCO.2001.19.8.2165; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Wierda, 2010, J CLIN ONCOL, V28, P3670, DOI 10.1200/JCO.2010.31.3544; Wierda WG, 2010, J CLIN ONCOL, V28, P1749, DOI 10.1200/JCO.2009.25.3187; Zenz T, 2010, J CLIN ONCOL, V28, P4473, DOI 10.1200/JCO.2009.27.8762	31	1262	1306	1	110	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 13	2014	370	11					997	1007		10.1056/NEJMoa1315226	http://dx.doi.org/10.1056/NEJMoa1315226			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AC7ED	24450857	Green Accepted			2023-01-03	WOS:000332689100007
J	Chetchotisakd, P; Chierakul, W; Chaowagul, W; Anunnatsiri, S; Phimda, K; Mootsikapun, P; Chaisuksant, S; Pilaikul, J; Thinkhamrop, B; Phiphitaporn, S; Susaengrat, W; Toondee, C; Wongrattanacheewin, S; Wuthiekanun, V; Chantratita, N; Thaipadungpanit, J; Day, NP; Limmathurotsakul, D; Peacock, SJ				Chetchotisakd, Ploenchan; Chierakul, Wirongrong; Chaowagul, Wipada; Anunnatsiri, Siriluck; Phimda, Kriangsak; Mootsikapun, Piroon; Chaisuksant, Seksan; Pilaikul, Jiraporn; Thinkhamrop, Bandit; Phiphitaporn, Sunchai; Susaengrat, Wattanachai; Toondee, Chalongchai; Wongrattanacheewin, Surasakdi; Wuthiekanun, Vanaporn; Chantratita, Narisara; Thaipadungpanit, Janjira; Day, Nicholas P.; Limmathurotsakul, Direk; Peacock, Sharon J.			Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial	LANCET			English	Article							BURKHOLDERIA-PSEUDOMALLEI; NORTHEAST THAILAND; RECURRENT MELIOIDOSIS; MAINTENANCE THERAPY; CHLORAMPHENICOL; COTRIMOXAZOLE; SUSCEPTIBILITY; EPIDEMIOLOGY; RESISTANCE; RELAPSE	Background Melioidosis, an infectious disease caused by the Gram-negative bacillus Burkholderia pseudomallei, is difficult to cure. Antimicrobial treatment comprises intravenous drugs for at least 10 days, followed by oral drugs for at least 12 weeks. The standard oral regimen based on trial evidence is trimethoprim-sulfamethoxaxole (TMP-SMX) plus doxycycline. This regimen is used in Thailand but is associated with side-effects and poor adherence by patients, and TMP-SMX alone is recommended in Australia. We compared the efficacy and side-effects of TMP-SMX with TMP-SMX plus doxycycline for the oral phase of melioidosis treatment. Methods For this multi-centre, double-blind, non-inferiority, randomised placebo-controlled trial, we enrolled patients (aged >= 15 years) from five centres in northeast Thailand with culture-confirmed melioidosis who had received a course of parenteral antimicrobial drugs. Using a computer-generated sequence, we randomly assigned patients to receive TMP-SMX plus placebo or TMP-SMX plus doxycycline for 20 weeks (1:1; block size of ten, stratified by study site). We followed patients up every 4 months for 1 year and annually thereafter to the end of the study. The primary endpoint was culture-confirmed recurrent melioidosis, and the non-inferiority margin was a hazard ratio (HR) of 1.7. This study is registered with www.controlled-trials.com, number ISRCTN86140460. Findings We enrolled and randomly assigned 626 patients: 311 to TMP-SMX plus placebo and 315 to TMP-SMX plus doxycycline. 16 patients (5%) in the TMP-SMX plus placebo group and 21 patients (7%) in the TMP-SMX plus doxycycline group developed culture-confirmed recurrent melioidosis (HR 0.81; 95% CI 0.42-1.55). The criterion for non-inferiority was met (p=0.01). Adverse drug reactions were less common in the TMP-SMX plus placebo group than in the TMP-SMX plus doxycycline group (122 [39%] vs 167 [53%]). Interpretation Our findings suggest that TMP-SMX is not inferior to TMP-SMX plus doxycycline for the oral phase of melioidosis treatment, and is preferable on the basis of safety and tolerance by patients.	[Chetchotisakd, Ploenchan; Anunnatsiri, Siriluck; Mootsikapun, Piroon; Wongrattanacheewin, Surasakdi] Khon Kaen Univ, Fac Med, Khon Kaen, Thailand; [Chetchotisakd, Ploenchan; Anunnatsiri, Siriluck; Wongrattanacheewin, Surasakdi] Khon Kaen Univ, Melioidosis Res Ctr, Khon Kaen, Thailand; [Chierakul, Wirongrong; Wuthiekanun, Vanaporn; Chantratita, Narisara; Thaipadungpanit, Janjira; Day, Nicholas P.; Limmathurotsakul, Direk; Peacock, Sharon J.] Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand; [Chaowagul, Wipada] Sappasithiprasong Hosp, Ubon Ratchathani, Thailand; [Phimda, Kriangsak; Phiphitaporn, Sunchai] Udon Thani Hosp, Udon Thani, Thailand; [Chaisuksant, Seksan; Susaengrat, Wattanachai] Khon Kaen Hosp, Khon Kaen, Thailand; [Pilaikul, Jiraporn; Toondee, Chalongchai] Mahasarakam Hosp, Mahasarakam, Thailand; [Thinkhamrop, Bandit] Khon Kaen Univ, Fac Publ Hlth, Khon Kaen, Thailand; [Day, Nicholas P.] Univ Oxford, Churchill Hosp, Oxford, England; [Peacock, Sharon J.] Univ Cambridge, Addenbrookes Hosp, Cambridge CB2 2QQ, England	Khon Kaen University; Khon Kaen University; Mahidol University; Khon Kaen University; University of Oxford; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Limmathurotsakul, D (corresponding author), Mahidol Univ, Fac Trop Med, 420-6 Rajvithi Rd, Bangkok 10400, Thailand.	direk@tropmedres.ac	Peacock, Sharon J/ABE-6331-2020; Thaipadungpanit, Janjira/ABF-9857-2021; Chierakul, Wirongrong/AAC-3226-2020; Chantratita, Narisara/P-2169-2019	Thaipadungpanit, Janjira/0000-0002-6184-3381; Chierakul, Wirongrong/0000-0003-2103-9425; Limmathurotsakul, Direk/0000-0001-7240-5320; Peacock, Sharon/0000-0002-1718-2782	Thailand Research Fund; Melioidosis Research Center; Center of Excellence in Specific Health Problems in Greater Mekong Sub-region cluster; Wellcome Trust; Higher Education Research Promotion and National Research University Project of Thailand; Office of the Higher Education Commission, through the Center of Excellence in Specific Health Problems in Greater Mekong Sub-region cluster (SHeP-GMS), Khon Kaen University; Wellcome Trust [077166/Z/05/A, 089275/Z/09/Z]	Thailand Research Fund(Thailand Research Fund (TRF)); Melioidosis Research Center; Center of Excellence in Specific Health Problems in Greater Mekong Sub-region cluster; Wellcome Trust(Wellcome TrustEuropean Commission); Higher Education Research Promotion and National Research University Project of Thailand; Office of the Higher Education Commission, through the Center of Excellence in Specific Health Problems in Greater Mekong Sub-region cluster (SHeP-GMS), Khon Kaen University; Wellcome Trust(Wellcome TrustEuropean Commission)	Thailand Research Fund, the Melioidosis Research Center, the Center of Excellence in Specific Health Problems in Greater Mekong Sub-region cluster, and the Wellcome Trust.; Partial results of this study were discussed at a workshop on the treatment of and post-exposure prophylaxis for Burkholderia pseudomallei and Burkholderia mallei infection (Nov 30, 2010; Townsville, QLD, Australia), 5 and at the World Melioidosis Congress (Dec 1-3, 2010, Townsville, QLD, Australia). We thank all patients, their relatives, staff of the hospitals who participated in the study, and the data and safety monitoring board, including Bart Currie, Boonmee Sathapatayavongs, and Visanu Thamlikitkul. The drugs used in this study were made and donated by the Siam Pharmaceutical Company. The study was funded by the Thailand Research Fund; the Melioidosis Research Center; the Higher Education Research Promotion and National Research University Project of Thailand; the Office of the Higher Education Commission, through the Center of Excellence in Specific Health Problems in Greater Mekong Sub-region cluster (SHeP-GMS), Khon Kaen University; and the Wellcome Trust (077166/Z/05/A and 089275/Z/09/Z).	Chantratita N, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000182; Chaowagul W, 1999, CLIN INFECT DIS, V29, P375, DOI 10.1086/520218; Chaowagul W, 2005, ANTIMICROB AGENTS CH, V49, P4020, DOI 10.1128/AAC.49.10.4020-4025.2005; Cheng AC, 2005, CLIN MICROBIOL REV, V18, P383, DOI 10.1128/CMR.18.2.383-416.2005; Cheng AC, 2008, AM J TROP MED HYG, V78, P208, DOI 10.4269/ajtmh.2008.78.208; Cheng AC, 2009, ANTIMICROB AGENTS CH, V53, P4193, DOI 10.1128/AAC.01301-08; Chetchotisakd Ploenchan, 2001, American Journal of Tropical Medicine and Hygiene, V64, P24; Chusri S, 2012, AM J TROP MED HYG, V87, P927, DOI 10.4269/ajtmh.2012.12-0136; Clinical and Laboratory Standards Institute, 2006, M100S16 CLIN LAB STA; Currie BJ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000900; Currie BJ, 2000, T ROY SOC TROP MED H, V94, P301, DOI 10.1016/S0035-9203(00)90333-X; D'Agostino RB, 2003, STAT MED, V22, P169, DOI 10.1002/sim.1425; DANCE DAB, 1989, J ANTIMICROB CHEMOTH, V24, P295, DOI 10.1093/jac/24.3.295; Godoy D, 2003, J CLIN MICROBIOL, V41, P2068, DOI 10.1128/JCM.41.5.2068-2079.2003; Leder K, 2013, ANN INTERN MED, V158, P456, DOI 10.7326/0003-4819-158-6-201303190-00005; Limmathurotsakul D, 2007, J CLIN MICROBIOL, V45, P3830, DOI 10.1128/JCM.01297-07; Limmathurotsakul D, 2006, CLIN INFECT DIS, V43, P979, DOI 10.1086/507632; Limmathurotsakul D, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002072; Limmathurotsakul D, 2010, AM J TROP MED HYG, V82, P1113, DOI 10.4269/ajtmh.2010.10-0038; Lipsitz Rebecca, 2012, Emerg Infect Dis, V18, pe2, DOI 10.3201/eid1812.120638; Maharjan B, 2005, J CLIN MICROBIOL, V43, P6032, DOI 10.1128/JCM.43.12.6032-6034.2005; National Cancer Institute National Institutes of Health, COMM TERM CRIT ADV E; Piliouras P, 2002, INT J ANTIMICROB AG, V19, P427, DOI 10.1016/S0924-8579(02)00016-X; Pocock SJ, 2003, FUND CLIN PHARMACOL, V17, P483, DOI 10.1046/j.1472-8206.2003.00162.x; RAJCHANUVONG A, 1995, T ROY SOC TROP MED H, V89, P546, DOI 10.1016/0035-9203(95)90104-3; Wiersinga WJ, 2012, NEW ENGL J MED, V367, P1035, DOI 10.1056/NEJMra1204699; Wuthiekanun V, 2005, J ANTIMICROB CHEMOTH, V55, P1029, DOI 10.1093/jac/dki151; Wuthiekanun V, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000496	28	71	71	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 1	2014	383	9919					807	814		10.1016/S0140-6736(13)61951-0	http://dx.doi.org/10.1016/S0140-6736(13)61951-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AC3EV	24284287	hybrid, Green Published			2023-01-03	WOS:000332398700027
J	Fisher, DA; Harris, PNA				Fisher, Dale A.; Harris, Patrick N. A.			Melioidosis: refining management of a tropical time bomb	LANCET			English	Editorial Material							BURKHOLDERIA-PSEUDOMALLEI; NORTHEAST THAILAND; RECURRENT MELIOIDOSIS; RELAPSE		[Fisher, Dale A.] Natl Univ Singapore Hosp, Dept Med, Singapore 119228, Singapore; Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 119228, Singapore	National University of Singapore; National University of Singapore	Fisher, DA (corresponding author), Natl Univ Singapore Hosp, Dept Med, Singapore 119228, Singapore.	mdcfda@nus.edu.sg	Harris, Patrick/P-3813-2014	Harris, Patrick/0000-0002-2895-0345				[Anonymous], 1967, TIME; Chaowagul W, 1999, CLIN INFECT DIS, V29, P375, DOI 10.1086/520218; Chetchotisakd P, 2014, LANCET, V383, P807, DOI 10.1016/S0140-6736(13)61951-0; Currie BJ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000900; Currie BJ, 2000, T ROY SOC TROP MED H, V94, P301, DOI 10.1016/S0035-9203(00)90333-X; DANCE DAB, 1989, J ANTIMICROB CHEMOTH, V24, P311, DOI 10.1093/jac/24.3.311; Jones AL, 1996, INFECT IMMUN, V64, P782, DOI 10.1128/IAI.64.3.782-790.1996; Limmathurotsakul D, 2007, J CLIN MICROBIOL, V45, P3830, DOI 10.1128/JCM.01297-07; Limmathurotsakul D, 2006, CLIN INFECT DIS, V43, P979, DOI 10.1086/507632; Maharjan B, 2005, J CLIN MICROBIOL, V43, P6032, DOI 10.1128/JCM.43.12.6032-6034.2005; Ngauy V, 2005, J CLIN MICROBIOL, V43, P970, DOI 10.1128/JCM.43.2.970-972.2005; Wiersinga WJ, 2012, NEW ENGL J MED, V367, P1035, DOI 10.1056/NEJMra1204699; Wuthiekanun V, 2006, AM J TROP MED HYG, V74, P1074, DOI 10.4269/ajtmh.2006.74.1074	13	13	18	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 1	2014	383	9919					762	764		10.1016/S0140-6736(13)62143-1	http://dx.doi.org/10.1016/S0140-6736(13)62143-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AC3EV	24284288	hybrid			2023-01-03	WOS:000332398700007
J	Torres-Rosas, R; Yehia, G; Pena, G; Mishra, P; Thompson-Bonilla, MD; Moreno-Eutimio, MA; Arriaga-Pizano, LA; Isibasi, A; Ulloa, L				Torres-Rosas, Rafael; Yehia, Ghassan; Pena, Geber; Mishra, Priya; del Rocio Thompson-Bonilla, Maria; Adan Moreno-Eutimio, Mario; Andrea Arriaga-Pizano, Lourdes; Isibasi, Armando; Ulloa, Luis			Dopamine mediates vagal modulation of the immune system by electroacupuncture	NATURE MEDICINE			English	Article							CHOLINERGIC ANTIINFLAMMATORY PATHWAY; TUMOR-NECROSIS-FACTOR; VAGUS NERVE; REGULATORY LYMPHOCYTES; SEVERE SEPSIS; SEPTIC SHOCK; DOUBLE-BLIND; ACUPUNCTURE; STIMULATION; FENOLDOPAM	Previous anti-inflammatory strategies against sepsis, a leading cause of death in hospitals, had limited efficacy in clinical trials, in part because they targeted single cytokines and the experimental models failed to mimic clinical settings(1-3). Neuronal networks represent physiological mechanisms, selected by evolution to control inflammation, that can be exploited for the treatment of inflammatory and infectious disorders(3). Here, we report that sciatic nerve activation with electroacupuncture controls systemic inflammation and rescues mice from polymicrobial peritonitis. Electroacupuncture at the sciatic nerve controls systemic inflammation by inducing vagal activation of aromatic L-amino acid decarboxylase, leading to the production of dopamine in the adrenal medulla. Experimental models with adrenolectomized mice mimic clinical adrenal insufficiency(4), increase the susceptibility to sepsis and prevent the anti-inflammatory effects of electroacupuncture. Dopamine inhibits cytokine production via dopamine type 1 (D1) receptors. D1 receptor agonists suppress systemic inflammation and rescue mice with adrenal insufficiency from polymicrobial peritonitis. Our results suggest a new anti-inflammatory mechanism mediated by the sciatic and vagus nerves that modulates the production of catecholamines in the adrenal glands. From a pharmacological perspective, the effects of selective dopamine agonists mimic the anti-inflammatory effects of electroacupuncture and can provide therapeutic advantages to control inflammation in infectious and inflammatory disorders.	[Torres-Rosas, Rafael; Yehia, Ghassan; Pena, Geber; Mishra, Priya; del Rocio Thompson-Bonilla, Maria; Ulloa, Luis] Rutgers State Univ, New Jersey Med Sch, Dept Surg, Lab Antiinflammatory Signaling, Newark, NJ 07102 USA; [Torres-Rosas, Rafael; Andrea Arriaga-Pizano, Lourdes; Isibasi, Armando] Natl Med Ctr Siglo XXI, Med Res Unit Immunochem, Mexico City, DF, Mexico; [del Rocio Thompson-Bonilla, Maria] Inst Social Secur & Serv States Employees Res Ins, Mexico City, DF, Mexico; [Adan Moreno-Eutimio, Mario] Hosp Juarez Mexico, Lab Immunobiol, Mexico City, DF, Mexico; [Ulloa, Luis] Rutgers State Univ, New Jersey Med Sch, Ctr Immunol & Inflammat, Newark, NJ 07102 USA	Rutgers State University Newark; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University Newark; Rutgers State University New Brunswick; Rutgers State University Medical Center	Ulloa, L (corresponding author), Rutgers State Univ, New Jersey Med Sch, Dept Surg, Lab Antiinflammatory Signaling, Newark, NJ 07102 USA.	mail@luisulloa.com	Ulloa, Luis/AAE-8751-2019; Moreno-Eutimio, Mario Adán/E-6899-2019; Torres-Rosas, Rafael/G-6936-2019; Arriaga-Pizano, Lourdes/AAI-9628-2021; pena, Geber/AAD-5890-2019	Ulloa, Luis/0000-0002-7702-7549; Moreno-Eutimio, Mario Adán/0000-0002-9955-8498; Torres-Rosas, Rafael/0000-0002-5934-003X; Arriaga-Pizano, Lourdes/0000-0003-4433-2106; 	Mexican National Council for Science and Technology; Department of Surgery of the New Jersey Medical School; Foundation of University of Medicine and Dentistry of New Jersey; US National Institutes of Health [RO1-GM084125]; University Autonoma Benito Juarez de Oaxaca; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084125] Funding Source: NIH RePORTER	Mexican National Council for Science and Technology(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Department of Surgery of the New Jersey Medical School; Foundation of University of Medicine and Dentistry of New Jersey; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University Autonoma Benito Juarez de Oaxaca; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank P. Morcillo, J.M. Inclan-Rico and J.R. Berlin for their comments and suggestions and M. Marks (University of Colorado) and B. Kobilka (Stanford University) for the alpha<INF>7</INF>nAChR and beta<INF>2</INF>AR knockout mice. R.T.-R. was supported by the University Autonoma Benito Juarez de Oaxaca. M.d.R.T.-B. was supported by the Mexican National Council for Science and Technology. L.U. is supported by the faculty program of the Department of Surgery of the New Jersey Medical School, the Foundation of University of Medicine and Dentistry of New Jersey and US National Institutes of Health grant RO1-GM084125.	Abraham E, 2001, CRIT CARE MED, V29, P503, DOI 10.1097/00003246-200103000-00006; Altavilla D, 2006, SHOCK, V25, P500, DOI 10.1097/01.shk.0000209539.91553.82; Angus DC, 2013, NEW ENGL J MED, V369, P840, DOI [10.1056/NEJMra1208623, 10.1056/NEJMc1312359]; Annane D, 2008, CURR PHARM DESIGN, V14, P1882, DOI 10.2174/138161208784980626; Bernik TR, 2002, J VASC SURG, V36, P1231, DOI 10.1067/mva.2002.129643; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Cal B., 2009, J CELL MOL MED, V13, P3774; COUPLAND RE, 1989, J ANAT, V163, P173; DENEF C, 1980, NATURE, V285, P243, DOI 10.1038/285243a0; Ernst E, 2011, PAIN, V152, P755, DOI 10.1016/j.pain.2010.11.004; Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562; GORISSEN H, 1979, NATURE, V279, P72, DOI 10.1038/279072a0; GRENADER A, 1991, J PHARMACOL EXP THER, V258, P193; Huston JM, 2006, J EXP MED, V203, P1623, DOI 10.1084/jem.20052362; LEE A, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003281.PUB2; Morelli A, 2005, CRIT CARE MED, V33, P2451, DOI 10.1097/01.CCM.0000186413.04875.EF; Napadow V, 2004, J ALTERN COMPLEM MED, V10, P565, DOI 10.1089/1075553041323849; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Pena G, 2011, J IMMUNOL, V187, P718, DOI 10.4049/jimmunol.1100013; PULLAN RD, 1994, NEW ENGL J MED, V330, P811, DOI 10.1056/NEJM199403243301202; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; Ulloa L, 2005, NAT REV DRUG DISCOV, V4, P673, DOI 10.1038/nrd1797; Ulloa L, 2005, TRENDS MOL MED, V11, P56, DOI 10.1016/j.molmed.2004.12.007; Ulloa L, 2009, CURR PHARM DESIGN, V15, P1918, DOI 10.2174/138161209788453248; Van Westerloo DJ, 2006, GASTROENTEROLOGY, V130, P1822, DOI 10.1053/j.gastro.2006.02.022; van Westerloo DJ, 2005, J INFECT DIS, V191, P2138, DOI 10.1086/430323; Vida G, 2011, FASEB J, V25, P4476, DOI 10.1096/fj.11-191007; Vida G, 2011, J IMMUNOL, V186, P4340, DOI 10.4049/jimmunol.1003722; Wang H, 2004, NAT MED, V10, P1216, DOI 10.1038/nm1124; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; WEBER RR, 1988, BRIT J CLIN PHARMACO, V25, P17, DOI 10.1111/j.1365-2125.1988.tb03276.x; Wu HM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004131.pub2	33	330	369	12	126	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2014	20	3					291	295		10.1038/nm.3479	http://dx.doi.org/10.1038/nm.3479			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	AC5XZ	24562381	Green Accepted			2023-01-03	WOS:000332595600024
J	Jiang, JH; Chuang, DY; Zong, YJ; Patel, J; Brownstein, K; Lei, W; Lu, CH; Simonyi, A; Gu, ZZ; Cui, JK; Rottinghaus, GE; Fritsche, KL; Lubahn, DB; Folk, WR; Sun, GY				Jiang, Jinghua; Chuang, Dennis Y.; Zong, Yijia; Patel, Jayleenkumar; Brownstein, Korey; Lei, Wei; Lu, Chi-Hua; Simonyi, Agnes; Gu, Zezong; Cui, Jiankun; Rottinghaus, George E.; Fritsche, Kevin L.; Lubahn, Dennis B.; Folk, William R.; Sun, Grace Y.			Sutherlandia frutescens Ethanol Extracts Inhibit Oxidative Stress and Inflammatory Responses in Neurons and Microglial Cells	PLOS ONE			English	Article							INDUCED COX-2 EXPRESSION; SHOOT AQUEOUS EXTRACT; IFN-GAMMA; NADPH OXIDASE; SIGNALING PATHWAYS; FABACEAE; MECHANISMS; NEURODEGENERATION; INDUCTION; INOS	Sutherlandia frutescens (L.) R. Br. (SF) is a medicinal plant indigenous to southern Africa and used in folk and contemporary remedies for stress, chronic diseases, cancer, and HIV/AIDS. While previous studies have focused on physiological effects of SF on cellular and systemic abnormalities associated with these diseases, little is known about its effects in the brain and immune cells in the central nervous system. Results of this study indicate that ethanol extracts of SF (SF-E) suppress NMDA-induced reactive oxygen species (ROS) production in neurons, and LPS- and IFN gamma-induced ROS and nitric oxide (NO) production in microglial cells. SF-E's action on microglial cells appears to be mediated through inhibition of the IFN gamma-induced p-ERK1/2 signaling pathway which is central to regulating a number of intracellular metabolic processes including enhancing STAT1 alpha phosphorylation and filopodia formation. The involvement of SF in these pathways suggests the potential for novel therapeutics for stress and prevention, and/or treatment of HIV/AIDS as well as other inflammatory diseases in the brain.	[Jiang, Jinghua; Patel, Jayleenkumar; Brownstein, Korey; Simonyi, Agnes; Lubahn, Dennis B.; Folk, William R.; Sun, Grace Y.] Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; [Chuang, Dennis Y.; Zong, Yijia] Univ Missouri, Interdisciplinary Neurosci Program, Columbia, MO USA; [Lei, Wei; Lu, Chi-Hua; Fritsche, Kevin L.; Lubahn, Dennis B.] Univ Missouri, Div Anim Sci, Columbia, MO USA; [Simonyi, Agnes; Gu, Zezong; Cui, Jiankun; Sun, Grace Y.] Univ Missouri, Ctr Translat Neurosci, Columbia, MO USA; [Gu, Zezong; Cui, Jiankun; Sun, Grace Y.] Univ Missouri, Dept Pathol & Anat Sci, Columbia, MO USA; [Rottinghaus, George E.; Fritsche, Kevin L.; Lubahn, Dennis B.; Folk, William R.; Sun, Grace Y.] Univ Missouri, Ctr Bot Interact Studies, Columbia, MO USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Sun, GY (corresponding author), Univ Missouri, Dept Biochem, Columbia, MO 65211 USA.	sung@missouri.edu		Folk, William/0000-0003-2216-3233; Lei, Wei/0000-0002-0374-8642	NIH [2P01 AG08357]; NIA; National Center for Complementary and Alternative Medicines (NCCAM) [P50AT006273]; Office of Dietary Supplements (ODS); National Cancer Institute (NCI); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [P50AT006273] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Center for Complementary and Alternative Medicines (NCCAM)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Office of Dietary Supplements (ODS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	This publication was made possible by NIH Grants 2P01 AG08357 from NIA and P50AT006273 from the National Center for Complementary and Alternative Medicines (NCCAM), the Office of Dietary Supplements (ODS), and the National Cancer Institute (NCI). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIA, NCCAM, ODS, NCI, or the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; BERNATOWICZ A, 1995, J NEUROIMMUNOL, V60, P53, DOI 10.1016/0165-5728(95)00053-5; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Boisse L, 2008, NEUROL CLIN, V26, P799, DOI 10.1016/j.ncl.2008.04.002; Brennan AM, 2009, NAT NEUROSCI, V12, P857, DOI 10.1038/nn.2334; Brown GC, 2007, BIOCHEM SOC T, V35, P1119, DOI 10.1042/BST0351119; Brown GC, 2010, NITRIC OXIDE-BIOL CH, V23, P153, DOI 10.1016/j.niox.2010.06.001; Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9; Chen KQ, 2007, J IMMUNOL, V178, P1759, DOI 10.4049/jimmunol.178.3.1759; Chuang DY, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-15; De Stefano D, 2006, J MOL MED, V84, P65, DOI 10.1007/s00109-005-0713-x; Faleschini MT, 2013, S AFR J BOT, V85, P48, DOI 10.1016/j.sajb.2012.11.007; Fernandes AC, 2004, J ETHNOPHARMACOL, V95, P1, DOI 10.1016/j.jep.2004.05.024; Fu X, 2010, PLANTA MED, V76, P178, DOI 10.1055/s-0029-1186030; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527; Guo LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070565; He Y, 2011, ASN NEURO, V3, P13, DOI 10.1042/AN20100025; Jensen MD, 2009, NEUROCHEM INT, V55, P362, DOI 10.1016/j.neuint.2009.04.002; Joska JA, 2010, AIDS BEHAV, V14, P371, DOI 10.1007/s10461-009-9538-x; Jung JS, 2010, BIOCHEM BIOPH RES CO, V397, P323, DOI 10.1016/j.bbrc.2010.05.117; Katerere DR, 2005, PHYTOTHER RES, V19, P779, DOI 10.1002/ptr.1719; Kundu JK, 2005, CANCER LETT, V218, P21, DOI 10.1016/j.canlet.2004.07.029; Mills E, 2005, NUTR J, V4, DOI 10.1186/1475-2891-4-19; Na HK, 2004, BIOFACTORS, V21, P149, DOI 10.1002/biof.552210130; Neher JJ, 2011, J IMMUNOL, V186, P4973, DOI 10.4049/jimmunol.1003600; Ojewole JAO, 2004, METHOD FIND EXP CLIN, V26, P409; Ojewole JAO, 2008, BRAIN RES BULL, V75, P126, DOI 10.1016/j.brainresbull.2007.08.002; Prevoo D, 2004, ENDOCR RES, V30, P745, DOI 10.1081/ERC-200044020; Shelat PB, 2008, J NEUROCHEM, V106, P45, DOI 10.1111/j.1471-4159.2008.05347.x; Shen SM, 2005, NEUROCHEM INT, V47, P298, DOI 10.1016/j.neuint.2005.03.007; Sheng WW, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-121; Spencer JPE, 2012, MOL ASPECTS MED, V33, P83, DOI 10.1016/j.mam.2011.10.016; Sun GY, 2010, MOL NEUROBIOL, V41, P53, DOI 10.1007/s12035-010-8119-3; Takeuchi H, 2006, J BIOL CHEM, V281, P21362, DOI 10.1074/jbc.M600504200; van Wyk BE, 2008, J ETHNOPHARMACOL, V119, P620, DOI 10.1016/j.jep.2008.08.003; Wang JY, 2006, CURR PHARM DESIGN, V12, P3521, DOI 10.2174/138161206778343109	37	23	24	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2014	9	2							e89748	10.1371/journal.pone.0089748	http://dx.doi.org/10.1371/journal.pone.0089748			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC2ZX	24587007	Green Published, gold, Green Submitted			2023-01-03	WOS:000332385900076
J	Chiu, THT; Huang, HY; Chiu, YF; Pan, WH; Kao, HY; Chiu, JPC; Lin, MN; Lin, CL				Chiu, Tina H. T.; Huang, Hui-Ya; Chiu, Yen-Feng; Pan, Wen-Harn; Kao, Hui-Yi; Chiu, Jason P. C.; Lin, Ming-Nan; Lin, Chin-Lon			Taiwanese Vegetarians and Omnivores: Dietary Composition, Prevalence of Diabetes and IFG	PLOS ONE			English	Article							INSULIN SENSITIVITY; VEGETABLE INTAKE; TYPE-2; RISK; ASSOCIATION; HEALTH; FRUIT	Introduction: Vegetarian diets have been shown to improve glucose metabolism and reduce risk for diabetes in Westerners but whether Chinese vegetarian diets have the same benefits is unknown. Methods: We evaluated the association between diet and diabetes/impaired fasting glucose (IFG) among 4384 Taiwanese Buddhist volunteers and identified diabetes/IFG cases from a comprehensive review of medical history and fasting plasma glucose. Results: Vegetarians had higher intakes of carbohydrates, fiber, calcium, magnesium, total and non-heme iron, folate, vitamin A, and lower intakes of saturated fat, cholesterol, and vitamin B12. Besides avoiding meat and fish, vegetarians had higher intakes of soy products, vegetables, whole grains, but similar intakes of dairy and fruits, compared with omnivores. The crude prevalence of diabetes in vegetarians versus omnivores is 0.6% versus 2.3% in pre-menopausal women, 2.8% versus 10% in menopausal women, and 4.3% versus 8.1% in men. Polytomous logistic regression adjusting for age, body mass index, family history of diabetes, education, leisure time physical activity, smoking and alcohol, showed that this vegetarian diet was negatively associated with diabetes and IFG in men (OR for diabetes: 0.49, 95% CI: 0.28-0.89; OR for IFG: 0.66, 95% CI: 0.46-0.95); in pre-menopausal women (OR for diabetes: 0.26, 95% CI: 0.06-1.21; OR for IFG: 0.60, 95% CI: 0.35-1.04); and in menopausal women (OR for diabetes: 0.25, 95% CI: 0.15-0.42; OR for IFG: 0.73, 95% CI: 0.56-0.95). Conclusion: We found a strong protective association between Taiwanese vegetarian diet and diabetes/IFG, after controlling for various potential confounders and risk factors.	[Chiu, Tina H. T.; Lin, Chin-Lon] Tzu Chi Fdn, Hualien, Taiwan; [Chiu, Tina H. T.; Pan, Wen-Harn] Natl Taiwan Univ, Grad Inst Epidemiol & Prevent Med, Taipei 10764, Taiwan; [Huang, Hui-Ya; Lin, Ming-Nan] Buddhist Dalin Tzu Chi Hosp, Dept Family Med, Dalin, Chiayi County, Taiwan; [Chiu, Yen-Feng; Kao, Hui-Yi] Natl Hlth Res Inst, Dept Biostat & Bioinformat, Inst Populat Hlth Sci, Zhunan, Miaoli County, Taiwan; [Pan, Wen-Harn] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Chiu, Jason P. C.] Univ British Columbia, Dept Comp Sci, Vancouver, BC V6T 1W5, Canada; [Lin, Ming-Nan] Tzu Chi Univ, Dept Family Med, Coll Med, Hualien, Taiwan; [Lin, Chin-Lon] Buddhist Hualien Tzu Chi Hosp, Dept Internal Med, Hualien, Taiwan; [Lin, Chin-Lon] Tzu Chi Univ, Dept Internal Med, Coll Med, Hualien, Taiwan	National Taiwan University; Buddhist Tzu Chi General Hospital; National Health Research Institutes - Taiwan; Academia Sinica - Taiwan; University of British Columbia; Tzu Chi University; Tzu Chi University	Lin, MN (corresponding author), Buddhist Dalin Tzu Chi Hosp, Dept Family Med, Dalin, Chiayi County, Taiwan.	mingnan.lin@gmail.com	Chiu, Yen-Feng/E-3847-2010; Pan, Wen-Harn/F-9972-2010	Pan, Wen-Harn/0000-0001-9136-0658; Chiu, Tina H. T./0000-0002-1773-1104	Buddhist Tzu Chi General Hospital in Taiwan [TCRD-I9605-02]	Buddhist Tzu Chi General Hospital in Taiwan	The study was supported by a grant (TCRD-I9605-02) from the Buddhist Tzu Chi General Hospital in Taiwan. Tzu Chi Hospital's website: or preparation of the manuscript. http://www.tzuchi.com.tw/tzuchi/mainpage/Default.aspx. The funders had no role in study design, data collection and analysis, decision to publish,	Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI 10.2337/dc10-s062; Grundy Scott M, 2005, Crit Pathw Cardiol, V4, P198; [Anonymous], 1988, NUTR COMP DAT BANK F; Assari S, 2013, INT J PREVENTIVE MED, V4, P208; Aune D, 2009, DIABETOLOGIA, V52, P2277, DOI 10.1007/s00125-009-1481-x; Balder HF, 2006, CANCER EPIDEM BIOMAR, V15, P717, DOI 10.1158/1055-9965.EPI-05-0772; Barnard ND, 2009, AM J CLIN NUTR, V89, pS1588, DOI 10.3945/ajcn.2009.26736H; Carmody RN, 2011, P NATL ACAD SCI USA, V108, P19199, DOI 10.1073/pnas.1112128108; Chan JCN, 2009, JAMA-J AM MED ASSOC, V301, P2129, DOI 10.1001/jama.2009.726; Chiang JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071799; Chiu TH, 2013, PUBLIC HLTH IN PRESS; Cooper AJ, 2012, EUR J CLIN NUTR, V66, P1082, DOI 10.1038/ejcn.2012.85; Cooper AJ, 2012, DIABETES CARE, V35, P1293, DOI 10.2337/dc11-2388; Craig WJ, 2009, J AM DIET ASSOC, V109, P1266, DOI 10.1016/j.jada.2009.05.027; Davey GK, 2003, PUBLIC HEALTH NUTR, V6, P259, DOI 10.1079/PHN2002430; Dong JY, 2011, DIABETES CARE, V34, P2116, DOI 10.2337/dc11-0518; Gregg EW, 2004, DIABETES CARE, V27, P2806, DOI 10.2337/diacare.27.12.2806; Gu D, 2003, DIABETOLOGIA, V46, P1190, DOI 10.1007/s00125-003-1167-8; Hua NW, 2001, BRIT J NUTR, V86, P515, DOI 10.1079/BJN2001421; Hung CJ, 2006, BRIT J NUTR, V95, P129, DOI 10.1079/BJN20051588; Kahleova H, 2011, DIABETIC MED, V28, P549, DOI 10.1111/j.1464-5491.2010.03209.x; Kuo CS, 2004, EUR J CLIN NUTR, V58, P312, DOI 10.1038/sj.ejcn.1601783; Novotny JA, 2012, AM J CLIN NUTR, V96, P296, DOI 10.3945/ajcn.112.035782; Odegaard AO, 2011, DIABETES CARE, V34, P880, DOI 10.2337/dc10-2350; Palli D, 2013, DIABETOLOGIA, V56, P47, DOI 10.1007/s00125-012-2718-7; Rajpathak SN, 2009, BBA-GEN SUBJECTS, V1790, P671, DOI 10.1016/j.bbagen.2008.04.005; Rizzo NS, 2013, J ACAD NUTR IN PRESS; Seawell AH, 2013, PSYCHOL HLT IN PRESS; Tonstad S, 2013, NUTR METAB CARDIOVAS, V23, P292, DOI 10.1016/j.numecd.2011.07.004; Tonstad S, 2009, DIABETES CARE, V32, P791, DOI 10.2337/dc08-1886; Villegas Raquel, 2006, Int J Med Sci, V3, P152; Wells JCK, 2006, ARCH DIS CHILD, V91, P612, DOI 10.1136/adc.2005.085522; Wollstonecroft MM, 2012, P NATL ACAD SCI USA, V109, pE991, DOI 10.1073/pnas.1201050109; Zhai FY, 2009, NUTR REV, V67, pS56, DOI 10.1111/j.1753-4887.2009.00160.x	34	49	52	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2014	9	2							e88547	10.1371/journal.pone.0088547	http://dx.doi.org/10.1371/journal.pone.0088547			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7DT	24523914	Green Submitted, Green Published, gold			2023-01-03	WOS:000331258100063
J	Zhang, MY; Zhang, HF; Shi, CX; McGoogan, JM; Zhang, BH; Zhao, LL; Zhang, MZ; Rou, KM; Wu, ZY				Zhang, Minying; Zhang, Huifang; Shi, Cynthia X.; McGoogan, Jennifer M.; Zhang, Baohua; Zhao, Linglong; Zhang, Mianzhi; Rou, Keming; Wu, Zunyou			Sexual Dysfunction Improved in Heroin-Dependent Men after Methadone Maintenance Treatment in Tianjin, China	PLOS ONE			English	Article							BUPRENORPHINE MAINTENANCE; RECEIVING METHADONE; ERECTILE DYSFUNCTION; INTERNATIONAL INDEX; PLASMA TESTOSTERONE; USERS; BEHAVIOR; ADDICTION; SCALE; CARE	Objective: To investigate whether methadone maintenance treatment (MMT) is correlated with sexual dysfunction in heroin-dependent men and to determine the prevalence and risk factors of sexual dysfunction among men on MMT. Methods: The study included a retrospective survey and a cross-sectional survey which contained interviews of 293 men who are currently engaged in MMT. The results of the two surveys were compared. For a subset of 43 participants, radioimmunoassay was additionally conducted using retrospective and prospective blood samples to test the levels of plasma testosterone and luteinizing hormone. Other study evaluations were the International Index of Erectile Function (IIEF-15), and Self-rating Depression Scale. Results: Sexual dysfunction in all five IIEF-15 domains (erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction) was strongly associated with long-term use of heroin. A decrease in the severity of sexual dysfunction was associated with MMT initiation. Erectile dysfunction, lack of sexual desire, inability to orgasm, and lack of intercourse satisfaction were significantly correlated with increasing age of the participants. Methadone dose and duration of methadone treatment were not found to be associated with sexual dysfunction. The level of plasma testosterone significantly declined during methadone treatment, but results from multivariate analysis indicated low levels of testosterone were not the main cause of sexual dysfunction. No correlation between reported depression status and sexual function was found. Conclusions: While high levels of sexual dysfunction were reported by heroin-dependent men in our study before and after MMT initiation, MMT appears to be correlated with improved sexual function in the population of the study.	[Zhang, Minying; Zhang, Huifang] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China; [Shi, Cynthia X.; McGoogan, Jennifer M.; Rou, Keming; Wu, Zunyou] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China; [Zhang, Baohua] Ankang Hosp, Tianjin, Peoples R China; [Zhao, Linglong; Zhang, Mianzhi] Publ Secur Hosp, Tianjin, Peoples R China	Nankai University; Chinese Center for Disease Control & Prevention; National Center for AIDS/STD Control & Prevention, Chinese Center for Disease Control & Prevention	Zhang, MY (corresponding author), Nankai Univ, Sch Med, Tianjin 300071, Peoples R China.	zhangminying@nankai.edu.cn; wuzy@263.net	zhang, hui/GXH-6098-2022; Zhang, Hui/HHN-8494-2022		China-Bill Melinda Gates Foundation program on HIV/AIDS	China-Bill Melinda Gates Foundation program on HIV/AIDS	This work was supported by China-Bill Melinda Gates Foundation program on HIV/AIDS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABEL EL, 1984, J PSYCHOACTIVE DRUGS, V16, P205, DOI 10.1080/02791072.1984.10524313; AZIZI F, 1973, STEROIDS, V22, P467, DOI 10.1016/0039-128X(73)90002-0; BELL J, 1992, BRIT J ADDICT, V87, P251; Bliesener N, 2005, J CLIN ENDOCR METAB, V90, P203, DOI 10.1210/jc.2004-0929; Brown R, 2005, J ADDICT DIS, V24, P91, DOI 10.1300/J069v24n02_08; Brown R, 2004, POSTGRAD MED J, V80, P654, DOI 10.1136/pgmj.2004.022988; Chekuri V, 2012, ADDICT BEHAV, V37, P124, DOI 10.1016/j.addbeh.2011.08.005; CICERO TJ, 1975, NEW ENGL J MED, V292, P882, DOI 10.1056/NEJM197504242921703; CROWLEY TJ, 1978, INT J ADDICT, V13, P285, DOI 10.3109/10826087809039281; CUSHMAN P, 1972, NEW YORK STATE J MED, V72, P1261; Hallinan R, 2009, INT J ANDROL, V32, P131, DOI 10.1111/j.1365-2605.2007.00824.x; Hallinan R, 2008, J SEX MED, V5, P684, DOI 10.1111/j.1743-6109.2007.00702.x; HANBURY R, 1977, AM J DRUG ALCOHOL AB, V4, P13, DOI 10.3109/00952997709002743; Isidori AM, 2005, CLIN ENDOCRINOL, V63, P381, DOI 10.1111/j.1365-2265.2005.02350.x; Jamieson BLA Inc, 2002, LIT REV METH MAINT T; Langendam MW, 2001, AM J PUBLIC HEALTH, V91, P774, DOI 10.2105/AJPH.91.5.774; Li T, 2010, GUIDE CHINA MED, V8, P29; MENDELSON JH, 1975, J PHARMACOL EXP THER, V192, P211; MENDELSON JH, 1975, J PHARMACOL EXP THER, V195, P296; Ng M L, 2004, Sex Health, V1, P35, DOI 10.1071/SH03020; OCONNOR PG, 1994, NEW ENGL J MED, V331, P450, DOI 10.1056/NEJM199408183310707; Palha A, 2002, J SEX MARITAL THER, V28, P427; PFAUS JG, 1987, NEUROSCI BIOBEHAV R, V11, P1, DOI 10.1016/S0149-7634(87)80002-7; Quaglio G, 2008, DRUG ALCOHOL DEPEN, V94, P12, DOI 10.1016/j.drugalcdep.2007.09.025; Gomes ALQ, 2012, J SEX MED, V9, P180, DOI 10.1111/j.1743-6109.2011.02467.x; RAGNI G, 1988, INT J ANDROL, V11, P93, DOI 10.1111/j.1365-2605.1988.tb00984.x; Rosen RC, 1997, UROLOGY, V49, P822, DOI 10.1016/S0090-4295(97)00238-0; Shen LL, 2012, INT J PSYCHIAT MED, V44, P257, DOI 10.2190/PM.44.3.f; SMITH DE, 1982, J PSYCHOACTIVE DRUGS, V14, P91, DOI 10.1080/02791072.1982.10471916; SPRING WD, 1992, INT J ADDICT, V27, P1325, DOI 10.3109/10826089209047354; Vemter A, 2003, INFORM POLICYMAKERS; Ward J, 1994, Drug Alcohol Rev, V13, P327, DOI 10.1080/09595239400185431; YANCOVITZ SR, 1991, AM J PUBLIC HEALTH, V81, P1185, DOI 10.2105/AJPH.81.9.1185; [尹潞 YIN Lu], 2006, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V15, P385; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	35	25	26	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2014	9	2							e88289	10.1371/journal.pone.0088289	http://dx.doi.org/10.1371/journal.pone.0088289			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7CL	24520361	Green Submitted, Green Published, gold			2023-01-03	WOS:000331254600052
J	Zender, L				Zender, Lars			CANCER Interference identifies immune modulators	NATURE			English	Editorial Material							SCREEN		[Zender, Lars] Univ Tubingen, D-72076 Tubingen, Germany; [Zender, Lars] German Canc Res Ctr, German Ctr Translat Canc Res, Heidelberg, Germany	Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ)	Zender, L (corresponding author), Univ Tubingen, D-72076 Tubingen, Germany.	lars.zender@med.uni-tuebingen.de						Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bric A, 2009, CANCER CELL, V16, P324, DOI 10.1016/j.ccr.2009.08.015; Guo LY, 2013, P NATL ACAD SCI USA, V110, pE1849, DOI 10.1073/pnas.1305070110; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Meacham CE, 2009, NAT GENET, V41, P1133, DOI 10.1038/ng.451; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Wuestefeld T, 2013, CELL, V153, P389, DOI 10.1016/j.cell.2013.03.026; Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061; Zhou PH, 2014, NATURE, V506, P52, DOI 10.1038/nature12988	10	0	0	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 6	2014	506	7486					39	40		10.1038/nature13050	http://dx.doi.org/10.1038/nature13050			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BA	24476819				2023-01-03	WOS:000330648100023
J	Zhou, YT; Liao, QF; Lin, MN; Deng, XJ; Zhang, PT; Yao, MC; Zhang, L; Xie, ZY				Zhou, Yuting; Liao, Qiongfeng; Lin, Manna; Deng, Xuejiao; Zhang, Peiting; Yao, Meicun; Zhang, Lei; Xie, Zhiyong			Combination of H-1 NMR- and GC-MS-Based Metabonomics to Study on the Toxicity of Coptidis Rhizome in Rats	PLOS ONE			English	Article							CHAIN FATTY-ACIDS; METABOLOMICS; METABOLITES; DIARRHEA; EXTRACT	Background: Coptidis Rhizome (CR), widely applied to treat with heat and toxicity, is one of the most commonly used traditional Chinese medicine (TCM), however, an extensive dosage can induce toxicity. Diarrhea is one of the most frequent side effects of CR treatment. Methodology/Principal Findings: In this study, metabonomics was combined with the multivariate statistical analysis to discover the endogenous metabolites which related to the diarrheal induced by CR. The male Sprague-Dawley rats were dosed with 4.95 g CR/kg weight. Urine samples were collected at day 21 (before treatment), and days 14 and 21 for NMR analysis. Serum and tissues were collected at day 14 for GC-MS analysis and histopathological examination, respectively. The urine and serum metabolic profiles provided clearer distinction between CR-treated group and control group, which was confirmed by body weight change and diarrhea. Through multivariate statistical analysis, 12 marker metabolites from 1 H NMR and 8 ones from GC-MS have been found. Among those metabolites, hippurate, acetate, alanine, glycine and glutamate are likely to break the balance of gut microbiota, whereas, lactate and 2-ketoisovalerate showed association with energy metabolism. Meanwhile, we observed that the CR-induced toxicity will recover when the treatment was stopped. Conclusions/significance: These results suggest that the main reason for the CR-associated diarrhea might be disturbance in the normal gut microbiota. This metabonomics approach may provide an effective way to study the alteration of gut microbiota, which is expected to find broader application in other drug-induced gastrointestinal reaction assessment.	[Zhou, Yuting; Lin, Manna; Deng, Xuejiao; Zhang, Peiting; Yao, Meicun; Xie, Zhiyong] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510275, Guangdong, Peoples R China; [Liao, Qiongfeng; Lin, Manna; Zhang, Lei] Guangzhou Univ Chinese Med, Sch Chinese Mat Med, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Guangzhou University of Chinese Medicine	Xie, ZY (corresponding author), Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510275, Guangdong, Peoples R China.	xiezy2074@yahoo.com		Xie, Zhi/0000-0002-5589-4836	Natural Science Foundation of China [81274028]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by Natural Science Foundation of China, number 81274028. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bando K, 2011, J APPL TOXICOL, V31, P524, DOI 10.1002/jat.1591; Bao Yuqin, 1983, CHINESE J INTEGRATED, V3, P31; Boyd DR, 2005, CHEM COMMUN, P3989, DOI 10.1039/b506944k; BUGAUT M, 1987, COMP BIOCHEM PHYS B, V86, P439, DOI 10.1016/0305-0491(87)90433-0; Calvani R, 2010, INT J OBESITY, V34, P1095, DOI 10.1038/ijo.2010.44; Choi UK, 2007, J MICROBIOL BIOTECHN, V17, P1880; Ciborowski M, 2012, J PROTEOME RES, V11, P6231, DOI 10.1021/pr3008946; CLAUSEN MR, 1991, GASTROENTEROLOGY, V101, P1497, DOI 10.1016/0016-5085(91)90384-W; Collino S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056564; Fan G, 2012, ANAL CHIM ACTA, V747, P76, DOI 10.1016/j.aca.2012.08.038; Garaulet M, 2001, AM J CLIN NUTR, V74, P585; Guirl MJ, 2003, AM J GASTROENTEROL, V98, P2219, DOI 10.1016/S0002-9270(03)00701-9; Hochrein J, 2012, J PROTEOME RES, V11, P6242, DOI 10.1021/pr3009034; HOLMES E, 1992, MOL PHARMACOL, V42, P922; Jung HA, 2009, BIOL PHARM BULL, V32, P1433, DOI 10.1248/bpb.32.1433; Kokushi E, 2012, ENVIRON TOXICOL, V27, P404, DOI 10.1002/tox.20653; Li M, 2008, P NATL ACAD SCI USA, V105, P2117, DOI 10.1073/pnas.0712038105; LILY P, 2009, J TRADITIONAL CHINES, V2, P019; Lu JY, 2012, J PROTEOME RES, V11, P4705, DOI 10.1021/pr300523x; Lu J, 2011, J ETHNOPHARMACOL, V134, P911, DOI 10.1016/j.jep.2011.01.049; MacKinnon N, 2013, J MAGN RESON, V226, P93, DOI 10.1016/j.jmr.2012.11.008; March J., 1992, ADV ORGANIC CHEM REA, V4th; Ni Y, 2007, FEBS LETT, V581, P707, DOI 10.1016/j.febslet.2007.01.036; Nicholls AW, 2003, CHEM RES TOXICOL, V16, P1395, DOI 10.1021/tx0340293; Normile D, 2003, SCIENCE, V299, P188, DOI 10.1126/science.299.5604.188; O'Sullivan A, 2013, J PROTEOME RES, V12, P481, DOI 10.1021/pr3009176; Park JC, 2009, J TOXICOL ENV HEAL A, V72, P374, DOI 10.1080/15287390802647195; Pechlivanis A, 2013, J PROTEOME RES, V12, P470, DOI 10.1021/pr300846x; Phipps AN, 1998, XENOBIOTICA, V28, P527, DOI 10.1080/004982598239443; READ NW, 1986, CLIN GASTROENTEROL, V15, P657; Robertson DG, 2011, TOXICOL SCI, V120, pS146, DOI 10.1093/toxsci/kfq358; Smith EA, 1997, MICROBIAL ECOL, V33, P180, DOI 10.1007/s002489900020; Stone R, 2008, SCIENCE, V319, P709, DOI 10.1126/science.319.5864.709; Sun J, 2008, J CHROMATOGR B, V871, P328, DOI 10.1016/j.jchromb.2008.04.008; Tan GG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034157; Tang BW, 2012, J ETHNOPHARMACOL, V141, P134, DOI 10.1016/j.jep.2012.02.011; Tang J, 2009, J ETHNOPHARMACOL, V126, P5, DOI 10.1016/j.jep.2009.08.009; Tjong YW, 2011, J ETHNOPHARMACOL, V135, P754, DOI 10.1016/j.jep.2011.04.007; Um SY, 2012, ANAL CHIM ACTA, V722, P87, DOI 10.1016/j.aca.2012.01.062; Walker AW, 2013, PHARMACOL RES, V69, P75, DOI 10.1016/j.phrs.2012.09.008; Wang N, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-239; Wang XJ, 2012, J PROTEOME RES, V11, P1284, DOI 10.1021/pr200963e; Wang XJ, 2011, J PHARMACEUT BIOMED, V55, P859, DOI 10.1016/j.jpba.2011.01.042; Wuolikainen A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017947; Xigyan Z, 2013, CHINA J CHINESE MAT, V38, P546; Xiyan Z, 2013, CHINA J CHINESE MAT, V38, P292; Yang HJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016641; Young VB, 2004, J CLIN MICROBIOL, V42, P1203, DOI 10.1128/JCM.42.3.1203-1206.2004	48	12	17	1	86	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2014	9	2							e88281	10.1371/journal.pone.0088281	http://dx.doi.org/10.1371/journal.pone.0088281			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA1AT	24505462	Green Submitted, gold, Green Published			2023-01-03	WOS:000330829200164
J	Szic, KSV; de Beeck, KO; Ratman, D; Wouters, A; Beck, IM; Declerck, K; Heyninck, K; Fransen, E; Bracke, M; De Bosscher, K; Lardon, F; Van Camp, G; Berghe, WV				Szic, Katarzyna Szarc vel; de Beeck, Ken Op; Ratman, Dariusz; Wouters, An; Beck, Ilse M.; Declerck, Ken; Heyninck, Karen; Fransen, Erik; Bracke, Marc; De Bosscher, Karolien; Lardon, Filip; Van Camp, Guy; Berghe, Wim Vanden			Pharmacological Levels of Withaferin A (Withania somnifera) Trigger Clinically Relevant Anticancer Effects Specific to Triple Negative Breast Cancer Cells	PLOS ONE			English	Article							HISTONE DEMETHYLASES; KAPPA-B; GROWTH; INVASION; EXPRESSION; METHYLATION; LAMININ-511; ACTIVATION; PREVENTION; REGULATORS	Withaferin A (WA) isolated from Withania somnifera (Ashwagandha) has recently become an attractive phytochemical under investigation in various preclinical studies for treatment of different cancer types. In the present study, a comparative pathway-based transcriptome analysis was applied in epithelial-like MCF-7 and triple negative mesenchymal MDA-MB-231 breast cancer cells exposed to different concentrations of WA which can be detected systemically in in vivo experiments. Whereas WA treatment demonstrated attenuation of multiple cancer hallmarks, the withanolide analogue Withanone (WN) did not exert any of the described effects at comparable concentrations. Pathway enrichment analysis revealed that WA targets specific cancer processes related to cell death, cell cycle and proliferation, which could be functionally validated by flow cytometry and real-time cell proliferation assays. WA also strongly decreased MDA-MB-231 invasion as determined by single-cell collagen invasion assay. This was further supported by decreased gene expression of extracellular matrix-degrading proteases (uPA, PLAT, ADAM8), cell adhesion molecules (integrins, laminins), pro-inflammatory mediators of the metastasis-promoting tumor microenvironment (TNFSF12, IL6, ANGPTL2, CSF1R) and concomitant increased expression of the validated breast cancer metastasis suppressor gene (BRMS1). In line with the transcriptional changes, nanomolar concentrations of WA significantly decreased protein levels and corresponding activity of uPA in MDA-MB-231 cell supernatant, further supporting its anti-metastatic properties. Finally, hierarchical clustering analysis of 84 chromatin writer-reader-eraser enzymes revealed that WA treatment of invasive mesenchymal MDA-MB-231 cells reprogrammed their transcription levels more similarly towards the pattern observed in non-invasive MCF-7 cells. In conclusion, taking into account that sub-cytotoxic concentrations of WA target multiple metastatic effectors in therapy-resistant triple negative breast cancer, WA-based therapeutic strategies targeting the uPA pathway hold promise for further (pre)clinical development to defeat aggressive metastatic breast cancer.	[Szic, Katarzyna Szarc vel; Declerck, Ken; Berghe, Wim Vanden] Univ Antwerp, Dept Biomed Sci, Lab Prot Chem Prote & Epigenet Signaling PPES, B-2020 Antwerp, Belgium; [de Beeck, Ken Op; Fransen, Erik; Van Camp, Guy] Univ Antwerp, Dept Biomed Sci, Ctr Med Genet, B-2020 Antwerp, Belgium; [de Beeck, Ken Op; Wouters, An; Lardon, Filip] Univ Antwerp, Dept Oncol, Lab Canc Res & Clin Oncol, Ctr Oncol Res CORE, B-2020 Antwerp, Belgium; [Ratman, Dariusz; De Bosscher, Karolien] Univ Ghent, VIB Dept Med Prot Res, Cytokine Receptor Lab, Nucl Receptor Signaling Unit, B-9000 Ghent, Belgium; [Beck, Ilse M.; Bracke, Marc] Univ Ghent, Dept Radiat Therapy & Expt Canc Res, Lab Expt Canc Res LECR, B-9000 Ghent, Belgium; [Heyninck, Karen] Univ Ghent, Lab Eukaryot Gene Express & Signal Transduct LEGE, B-9000 Ghent, Belgium; [Fransen, Erik] Univ Antwerp, StatUa Ctr Stat, B-2020 Antwerp, Belgium	University of Antwerp; University of Antwerp; University of Antwerp; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Ghent University; University of Antwerp	Berghe, WV (corresponding author), Univ Antwerp, Dept Biomed Sci, Lab Prot Chem Prote & Epigenet Signaling PPES, B-2020 Antwerp, Belgium.	wim.vandenberghe@ua.ac.be	Van Camp, Guy/F-3386-2013; Fransen, Erik/C-4102-2015; Beck, Ilse/B-2410-2014; de Beeck, Ken Op/J-5248-2016; Wouters, An/B-5384-2017; Berghe, Wim Vanden/S-6425-2018; Vanden Berghe, Wim/HGE-4696-2022; Lardon, Filip/A-3559-2010	Van Camp, Guy/0000-0001-5105-9000; Fransen, Erik/0000-0001-7785-4790; de Beeck, Ken Op/0000-0001-5527-6838; Wouters, An/0000-0001-7771-1239; Berghe, Wim Vanden/0000-0003-0161-7355; Lardon, Filip/0000-0001-7174-4144; Beck, Ilse/0000-0002-1927-5480; De Bosscher, Karolien/0000-0001-5059-9718; Declerck, Ken/0000-0001-8104-8054	Strategic Basic Research (SBO) grant of the Agency for Innovation by Science and Technology (IWT); Special Research Fund (BOF) of The University of Antwerp, Belgium	Strategic Basic Research (SBO) grant of the Agency for Innovation by Science and Technology (IWT); Special Research Fund (BOF) of The University of Antwerp, Belgium	Research has been supported by the Strategic Basic Research (SBO) grant of the Agency for Innovation by Science and Technology (IWT) and the Special Research Fund (BOF) of The University of Antwerp, Belgium. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ACS, 2013, WHAT AR KEY STAT BRE; Albini A, 2012, NAT REV CLIN ONCOL, V9, P498, DOI 10.1038/nrclinonc.2012.120; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300; Bhat WW, 2012, GENE, V499, P25, DOI 10.1016/j.gene.2012.03.004; Blair Lauren P, 2011, Cancers (Basel), V3, P1383, DOI 10.3390/cancers3011383; Boimel PJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3108; Brown KD, 2013, BREAST CANCER RES TR, V137, P329, DOI 10.1007/s10549-012-2351-7; BRUNNER N, 1983, BRIT J CANCER, V47, P641, DOI 10.1038/bjc.1983.102; Castellana B, 2012, J CANCER, V3, P175, DOI 10.7150/jca.4120; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Chia J, 2007, AM J PATHOL, V170, P2135, DOI 10.2353/ajpath.2007.060709; Chiappetta G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-17; Cock-Rada A, 2013, BIOL CELL, V105, P73, DOI 10.1111/boc.201200029; De Wever O, 2010, INT J DEV BIOL, V54, P887, DOI 10.1387/ijdb.092948ow; Duffy Michael J, 2011, Clin Proteomics, V8, P9, DOI 10.1186/1559-0275-8-9; Dumartin L, 2011, CANCER RES, V71, P7091, DOI 10.1158/0008-5472.CAN-11-1367; Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311; Edmonds MD, 2009, INT J CANCER, V125, P1778, DOI 10.1002/ijc.24616; Endo M, 2012, CANCER RES, V72, P1784, DOI 10.1158/0008-5472.CAN-11-3878; Floor SL, 2012, TRENDS MOL MED, V18, P509, DOI 10.1016/j.molmed.2012.06.005; GENTLEMAN RCV, 2005, BIOINFORMATICS COMPU, V19; Grigoriadis A, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-619; Grin B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039065; Hahm ER, 2012, CANC LETT; Hahm ER, 2013, JNCI-J NATL CANCER I, V105, P1111, DOI 10.1093/jnci/djt153; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He YL, 2012, ACTA BIOCH BIOPH SIN, V44, P70, DOI 10.1093/abbs/gmr109; Hurst DR, 2011, INT REV CEL MOL BIO, V286, P107, DOI 10.1016/B978-0-12-385859-7.00003-3; Jayaprakasam B, 2003, LIFE SCI, V74, P125, DOI 10.1016/j.lfs.2003.07.007; Johnson DG, 2013, CELL, V152, P685, DOI 10.1016/j.cell.2013.01.017; Kaileh M, 2007, J BIOL CHEM, V282, P4253, DOI 10.1074/jbc.M606728200; Lee J, 2012, BREAST CANCER RES TR, V136, P45, DOI 10.1007/s10549-012-2239-6; Lee J, 2010, CARCINOGENESIS, V31, P1991, DOI 10.1093/carcin/bgq175; Ma LQ, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-79; Mazar AP, 2011, CURR PHARM DESIGN, V17, P1970; Mirza S, 2013, J BREAST CANCER, V16, P23, DOI 10.4048/jbc.2013.16.1.23; Mishra L C, 2000, Altern Med Rev, V5, P334; Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731; Miyazaki K, 2006, CANCER SCI, V97, P91, DOI 10.1111/j.1349-7006.2006.00150.x; Nanda R, 2011, SEMIN ONCOL, V38, P254, DOI 10.1053/j.seminoncol.2011.01.007; Natoli G, 2009, CURR OPIN DRUG DISC, V12, P607; Ndlovu MN, 2009, MOL CELL BIOL, V29, P5488, DOI 10.1128/MCB.01657-08; Nijwening JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025235; O'Donnell PH, 2012, INVEST NEW DRUG, V30, P604, DOI 10.1007/s10637-010-9537-9; Pereira F, 2011, HUM MOL GENET, V20, P4655, DOI 10.1093/hmg/ddr399; Pouliot N, 2013, CELL ADHES MIGR, V7, P142, DOI 10.4161/cam.22125; Ramadoss S, 2012, J BIOL CHEM, V287, P44508, DOI 10.1074/jbc.M112.424903; Rockway TW, 2003, CURR PHARM DESIGN, V9, P1483, DOI 10.2174/1381612033454649; Santana-Davila R, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-42; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Smith SC, 2009, NAT REV CANCER, V9, P253, DOI 10.1038/nrc2594; Smyth GK., 2004, STAT APPL GENET MOL, V3, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Stan SD, 2008, CANCER RES, V68, P7661, DOI 10.1158/0008-5472.CAN-08-1510; Stan SD, 2008, NUTR CANCER, V60, P51, DOI 10.1080/01635580802381477; Steffan JJ, 2011, CANCER LETT, V310, P109, DOI 10.1016/j.canlet.2011.06.011; Subbaram S, 2011, EXPERT OPIN THER TAR, V15, P1197, DOI 10.1517/14728222.2011.609557; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Thaiparambil JT, 2011, INT J CANCER, V129, P2744, DOI 10.1002/ijc.25938; Tian MZ, 2011, CELL SIGNAL, V23, P951, DOI 10.1016/j.cellsig.2010.10.015; Vanden Berghe W, 2012, BIOCHEM PHARMACOL, V84, P1282, DOI 10.1016/j.bcp.2012.08.027; Vyas A. R., 2013, AAPS J, DOI 10.1208/s12248-013-9531-1; Widodo N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013536; Yu HX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051239; Zambelli F, 2012, NUCLEIC ACIDS RES, V40, pW510, DOI 10.1093/nar/gks483	65	52	53	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2014	9	2							e87850	10.1371/journal.pone.0087850	http://dx.doi.org/10.1371/journal.pone.0087850			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302TD	24498382	gold, Green Published, Green Submitted			2023-01-03	WOS:000330626900128
J	Sasaoka, N; Sakamoto, M; Kanemori, S; Kan, M; Tsukano, C; Takemoto, Y; Kakizuka, A				Sasaoka, Norio; Sakamoto, Megumi; Kanemori, Shoko; Kan, Michiru; Tsukano, Chihiro; Takemoto, Yoshiji; Kakizuka, Akira			Long-Term Oral Administration of Hop Flower Extracts Mitigates Alzheimer Phenotypes in Mice	PLOS ONE			English	Article							AMYLOID PRECURSOR PROTEIN; ALLEVIATE MENOPAUSAL DISCOMFORTS; HUMULUS-LUPULUS L.; GAMMA-SECRETASE; BETA-PROTEIN; COGNITIVE DECLINE; ACID RECEPTOR; DOUBLE-BLIND; DISEASE; MUTATION	Coincident with the expanding population of aged people, the incidence of Alzheimer disease (AD) is rapidly increasing in most advanced countries. At present, no effective prophylactics are available. Among several pathological mechanisms proposed for AD, the "amyloid hypothesis" has been most widely accepted, in which accumulation or deposition of A beta is considered to be the initial event. Thus, prevention of A beta production would be an ideal strategy for the treatment or prevention of AD. A beta is produced via the proteolytic cleavage of its precursor protein, APP (amyloid precursor protein), by two different enzymes, beta and gamma-secretases. Indeed, inhibitors against either or both enzymes have been developed and tested for clinical efficacy. Based on the "amyloid hypothesis", we developed a luciferase-based screening method to monitor gamma-secretase activity, screened more than 1,600 plant extracts, most of which have long been used in Chinese medicine, and observed that Hop extracts significantly inhibit A beta production in cultured cells. A major component of the inhibitory activity was purified, and its chemical identity was determined by NMR to be Garcinielliptone HC. In vivo, oral administration of Hop extracts to AD model mice decreased A beta depositions in the cerebral cortex of the parietal lobe, hippocampus, and artery walls (amyloid angiopathy) in the brains. In a Morris water maze test, AD model mice that had daily consumed Hop extracts in their drinking water showed significant mitigation of memory impairment at ages of 9 and 12 months. Moreover, in the open field test oral administration of Hop extracts also prevented an emotional disturbance that appeared in the AD mice at 18 months. Despite lifelong consumption of Hop extracts, no deleterious side effects were observed at any age. These results support the "amyloid hypothesis", and indicate that Hop extract is a promising candidate for an effective prophylactic for AD.	[Sasaoka, Norio; Sakamoto, Megumi; Kanemori, Shoko; Kan, Michiru; Kakizuka, Akira] Kyoto Univ, Grad Sch Biostudies, Lab Funct Biol, Sakyo Ku, Kyoto, Japan; [Tsukano, Chihiro; Takemoto, Yoshiji] Kyoto Univ, Dept Organ Chem, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto, Japan	Kyoto University; Kyoto University	Kakizuka, A (corresponding author), Kyoto Univ, Grad Sch Biostudies, Lab Funct Biol, Sakyo Ku, Kyoto, Japan.	kakizuka@lif.kyoto-u.ac.jp	Takemoto, Yoshiji/C-7099-2009; Tsukano, Chihiro/B-7697-2014	Tsukano, Chihiro/0000-0002-9361-0857	Solution-Oriented Research for Science and Technology of the Japan Science and Technology Agency; Ministry of Health, Labour, and Welfare of Japan	Solution-Oriented Research for Science and Technology of the Japan Science and Technology Agency; Ministry of Health, Labour, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	This work was supported by research grants from Solution-Oriented Research for Science and Technology of the Japan Science and Technology Agency and the Ministry of Health, Labour, and Welfare of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akazawa H, 2012, CHEM BIODIVERS, V9, P1045, DOI 10.1002/cbdv.201100233; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Blennow K, 2012, ARCH NEUROL-CHICAGO, V69, P1002, DOI 10.1001/archneurol.2012.90; Braak H, 1997, NEUROBIOL AGING, V18, P351, DOI 10.1016/S0197-4580(97)00056-0; Chadwick LR, 2006, PHYTOMEDICINE, V13, P119, DOI 10.1016/j.phymed.2004.07.006; Choi Y, 2008, COMB CHEM HIGH T SCR, V11, P1; CLARK RF, 1995, NAT GENET, V11, P219, DOI 10.1038/ng1095-219; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; Crusio WE, 2001, BEHAV BRAIN RES, V125, P127, DOI 10.1016/S0166-4328(01)00280-7; Delrieu J, 2012, J NEUROCHEM, V120, P186, DOI 10.1111/j.1471-4159.2011.07458.x; Desai A, 2012, ATHEROSCLEROSIS, V223, P130, DOI 10.1016/j.atherosclerosis.2012.05.004; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Erkkola R, 2010, PHYTOMEDICINE, V17, P389, DOI 10.1016/j.phymed.2010.01.007; Extance A, 2010, NAT REV DRUG DISCOV, V9, P749, DOI 10.1038/nrd3288; Martinez-Aguilar JF, 2009, J AGR FOOD CHEM, V57, P1933, DOI 10.1021/jf802141d; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Funato H, 1998, AM J PATHOL, V152, P1633; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Godbolt AK, 2004, ARCH NEUROL-CHICAGO, V61, P1743, DOI 10.1001/archneur.61.11.1743; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Heyerick A, 2006, MATURITAS, V54, P164, DOI 10.1016/j.maturitas.2005.10.005; Howard R, 2012, NEW ENGL J MED, V366, P893, DOI 10.1056/NEJMoa1106668; Janus C, 2004, LEARN MEMORY, V11, P337, DOI 10.1101/lm.70104; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jonsson T, 2012, NATURE, V488, P96, DOI 10.1038/nature11283; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kelleher RJ, 2010, SCIENCE, V330, P1055, DOI 10.1126/science.1198668; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Koike M, 2010, J BIOL CHEM, V285, P21736, DOI 10.1074/jbc.M109.099283; Kumari P, 2011, ANAL BIOCHEM, V415, P134, DOI 10.1016/j.ab.2011.04.010; Levine AJ, 2004, ARCH CLIN NEUROPSYCH, V19, P769, DOI 10.1016/j.acn.2003.09.004; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; Li T, 2007, J NEUROSCI, V27, P10849, DOI 10.1523/JNEUROSCI.2152-07.2007; Lu YH, 2008, PHYTOCHEMISTRY, V69, P225, DOI 10.1016/j.phytochem.2007.06.026; Morelli L, 2012, INT J ALZHEIMERS DIS, V2012; Mori-Konya C, 2009, GENES CELLS, V14, P483, DOI 10.1111/j.1365-2443.2009.01286.x; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; Nelson PT, 2011, ACTA NEUROPATHOL, V121, P571, DOI 10.1007/s00401-011-0826-y; Neugroschl J, 2010, MT SINAI J MED, V77, P3, DOI 10.1002/msj.20165; Nilsson LNG, 2004, NEUROBIOL AGING, V25, P1153, DOI 10.1016/j.neurobiolaging.2003.12.011; Okochi M, 2013, CELL REP, V3, P42, DOI 10.1016/j.celrep.2012.11.028; Prasad S, 2012, PREV MED, V54, pS29, DOI 10.1016/j.ypmed.2011.11.011; Raschetti R, 2005, EUR J CLIN PHARMACOL, V61, P361, DOI 10.1007/s00228-005-0946-1; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SAITOU M, 1994, J BIOL CHEM, V269, P19101; Sarnyai Z, 2000, P NATL ACAD SCI USA, V97, P14731, DOI 10.1073/pnas.97.26.14731; Sato K, 2004, EUR J MED CHEM, V39, P573, DOI 10.1016/j.ejmech.2004.02.013; Selkoe DJ, 2012, SCIENCE, V337, P1488, DOI 10.1126/science.1228541; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Thomas P, 2007, MUTAGENESIS, V22, P15, DOI 10.1093/mutage/gel055; Van Cleemput M, 2009, J NAT PROD, V72, P1220, DOI 10.1021/np800740m; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Viswanathan A, 2011, ANN NEUROL, V70, P871, DOI 10.1002/ana.22516; vom Berg J, 2012, NAT MED, V18, P1812, DOI 10.1038/nm.2965; von Bernhardi R, 2010, J ALZHEIMERS DIS, V19, P405, DOI 10.3233/JAD-2010-1248; Wang BX, 2010, SCIENCE, V330, P1065, DOI 10.1126/science.1196284; Wang Xiao-Ping, 2008, Neurosci Bull, V24, P105, DOI 10.1007/s12264-008-0105-7; Wharton W, 2011, J ALZHEIMERS DIS, V26, P495, DOI 10.3233/JAD-2011-110341; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Yamamoto Y, 2001, CELL DEATH DIFFER, V8, P871, DOI 10.1038/sj.cdd.4400901	64	20	20	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2014	9	1							e87185	10.1371/journal.pone.0087185	http://dx.doi.org/10.1371/journal.pone.0087185			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301ZC	24489866	Green Submitted, Green Published, gold			2023-01-03	WOS:000330570000116
J	Hong, IS; Lee, HY; Kim, HP				Hong, In-Sun; Lee, Hwa-Yong; Kim, Hyun-Pyo			Anti-Oxidative Effects of Rooibos Tea (Aspalathus linearis) on Immobilization-Induced Oxidative Stress in Rat Brain	PLOS ONE			English	Article							HONEYBUSH CYCLOPIA-INTERMEDIA; CAMELLIA-SINENSIS TEAS; PULMONATE LAND SNAIL; AFRICAN HERBAL TEAS; NEURODEGENERATIVE DISEASES; LIPID-PEROXIDATION; PSYCHIATRIC-DISORDERS; GLUTATHIONE-REDUCTASE; SUPEROXIDE-DISMUTASE; CARBON-TETRACHLORIDE	Exposure to chronic psychological stress may be related to increased reactive oxygen species (ROS) or free radicals, and thus, long-term exposure to high levels of oxidative stress may cause the accumulation of oxidative damage and eventually lead to many neurodegenerative diseases. Compared with other organs, the brain appears especially susceptible to excessive oxidative stress due to its high demand for oxygen. In the case of excessive ROS production, endogenous defense mechanisms against ROS may not be sufficient to suppress ROS-associated oxidative damage. Dietary antioxidants have been shown to protect neurons against a variety of experimental neurodegenerative conditions. In particular, Rooibos tea might be a good source of antioxidants due to its larger proportion of polyphenolic compounds. An optimal animal model for stress should show the features of a stress response and should be able to mimic natural stress progression. However, most animal models of stress, such as cold-restraint, electric foot shock, and burn shock, usually involve physical abuse in addition to the psychological aspects of stress. Animals subjected to chronic restraint or immobilization are widely believed to be a convenient and reliable model to mimic psychological stress. Therefore, in the present study, we propose that immobilization-induced oxidative stress was significantly attenuated by treatment with Rooibos tea. This conclusion is demonstrated by Rooibos tea's ability to (i) reverse the increase in stress-related metabolites (5-HIAA and FFA), (ii) prevent lipid peroxidation (LPO), (iii) restore stress-induced protein degradation (PD), (iv) regulate glutathione metabolism (GSH and GSH/GSSG ratio), and (v) modulate changes in the activities of antioxidant enzymes (SOD and CAT).	[Hong, In-Sun; Lee, Hwa-Yong] Seoul Natl Univ, Adult Stem Cell Res Ctr, Seoul, South Korea; [Hong, In-Sun; Lee, Hwa-Yong] Seoul Natl Univ, Dept Vet Publ Hlth, Lab Stem Cell & Tumor Biol, Seoul, South Korea; [Kim, Hyun-Pyo] Jungwon Univ, Dept Biomed Sci, Chungbuk, South Korea	Seoul National University (SNU); Seoul National University (SNU); Jungwon University	Kim, HP (corresponding author), Jungwon Univ, Dept Biomed Sci, Chungbuk, South Korea.	khpsss@jwu.ac.kr			Animal and Plant Quarantine Agency, Ministry of Agriculture, Food and Rural Affairs [Z-1541745-2012-13-09]	Animal and Plant Quarantine Agency, Ministry of Agriculture, Food and Rural Affairs	This study was supported by a grant (Project Code No., Z-1541745-2012-13-09) from Animal and Plant Quarantine Agency, Ministry of Agriculture, Food and Rural Affairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADEOLA O, 1993, J ANIM SCI, V71, P968, DOI 10.2527/1993.714968x; Al-Abrash ASA, 2000, SAUDI MED J, V21, P826; Baba H, 2009, PEDIATR INT, V51, P700, DOI 10.1111/j.1442-200X.2009.02835.x; Behl C, 2002, BIOL CHEM, V383, P521, DOI 10.1515/BC.2002.053; Behl C, 2002, FREE RADICAL BIO MED, V33, P182, DOI 10.1016/S0891-5849(02)00883-3; BENEDETTI A, 1980, BIOCHIM BIOPHYS ACTA, V620, P281, DOI 10.1016/0005-2760(80)90209-X; Benzie IFF, 1999, NUTR CANCER, V34, P83, DOI 10.1207/S15327914NC340112; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Bramati L, 2002, J AGR FOOD CHEM, V50, P5513, DOI 10.1021/jf025697h; Buege J A, 1978, Methods Enzymol, V52, P302; Byers JP, 2006, TOXICOLOGY, V228, P291, DOI 10.1016/j.tox.2006.09.009; Chen W, 2013, PHYTOMEDICINE, V20, P380, DOI 10.1016/j.phymed.2012.10.006; Claeyssen R, 2008, BIOL TRACE ELEM RES, V126, pS80, DOI 10.1007/s12011-008-8210-z; CORTAMIRA NO, 1991, BRIT J NUTR, V66, P423, DOI 10.1079/BJN19910045; Couto N, 2013, J PROTEOME RES, V12, P2885, DOI 10.1021/pr4001948; Das A, 2000, PHARMACOL RES, V42, P213, DOI 10.1006/phrs.2000.0678; Dringen R, 2000, EUR J BIOCHEM, V267, P4912, DOI 10.1046/j.1432-1327.2000.01597.x; Dringen R, 2000, PROG NEUROBIOL, V62, P649, DOI 10.1016/S0301-0082(99)00060-X; Esch T, 2002, NEUROENDOCRINOL LETT, V23, P199; Esch Tobias, 2003, Med Sci Monit, V9, pRA23; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FORDYCE MK, 1975, J NUTR, V105, P1150, DOI 10.1093/jn/105.9.1150; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; Fukasawa R, 2009, J OLEO SCI, V58, P275, DOI 10.5650/jos.58.275; GALASKO GTF, 1989, FOOD CHEM TOXICOL, V27, P49, DOI 10.1016/0278-6915(89)90092-6; Gawryluk JW, 2011, INT J NEUROPSYCHOPH, V14, P123, DOI 10.1017/S1461145710000805; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; Gilgun-Sherki Y, 2001, NEUROPHARMACOLOGY, V40, P959, DOI 10.1016/S0028-3908(01)00019-3; GUTTERIDGE JMC, 1995, CLIN CHEM, V41, P1819; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; HERMESLIMA M, 1995, AM J PHYSIOL-REG I, V268, pR1386, DOI 10.1152/ajpregu.1995.268.6.R1386; Jorgensen H, 2002, EUR J ENDOCRINOL, V147, P815, DOI 10.1530/eje.0.1470815; Joshi D, 2005, J MED FOOD, V8, P392, DOI 10.1089/jmf.2005.8.392; Joubert E, 2009, J AGR FOOD CHEM, V57, P4204, DOI 10.1021/jf9005033; Kawano A, 2009, PHYTOMEDICINE, V16, P437, DOI 10.1016/j.phymed.2008.11.009; Kelly G S, 1999, Altern Med Rev, V4, P249; KOEPPEN BH, 1966, BIOCHEM J, V99, P604, DOI 10.1042/bj0990604; Koopmans SJ, 2005, PHYSIOL BEHAV, V85, P469, DOI 10.1016/j.physbeh.2005.05.010; Kovacs P, 1996, PHARMAZIE, V51, P51; Kucharska J, 2004, PHYSIOL RES, V53, P515; Kullisaar T, 2003, BRIT J NUTR, V90, P449, DOI 10.1079/BJN2003896; Kumar P, 2006, BEHAV PHARMACOL, V17, P485, DOI 10.1097/00008877-200609000-00014; Lamosova D, 1997, COMP BIOCHEM PHYS C, V116, P39, DOI 10.1016/S0742-8413(96)00138-7; Lampe JW, 1999, AM J CLIN NUTR, V70, p475S, DOI 10.1093/ajcn/70.3.475s; Landis GN, 2005, MECH AGEING DEV, V126, P365, DOI 10.1016/j.mad.2004.08.012; Lepage O, 2003, J EXP BIOL, V206, P3589, DOI 10.1242/jeb.00614; Liu JK, 1999, NEUROCHEM RES, V24, P1479, DOI 10.1023/A:1022597010078; Liu JK, 1996, FASEB J, V10, P1532, DOI 10.1096/fasebj.10.13.8940299; Lu J, 2006, BEHAV BRAIN RES, V171, P251, DOI 10.1016/j.bbr.2006.03.043; Lyle N, 2012, NEUROCHEM RES, V37, P2748, DOI 10.1007/s11064-012-0867-1; Madrigal JLM, 2001, J NEUROCHEM, V76, P532, DOI 10.1046/j.1471-4159.2001.00108.x; Maestre I, 2003, ENDOCRINOLOGY, V144, P335, DOI 10.1210/en.2001-211282; Mariani E, 2005, J CHROMATOGR B, V827, P65, DOI 10.1016/j.jchromb.2005.04.023; Marnewick J, 2005, CANCER LETT, V224, P193, DOI 10.1016/j.canlet.2004.11.014; Marnewick JL, 2011, J ETHNOPHARMACOL, V133, P46, DOI 10.1016/j.jep.2010.08.061; Marnewick JL, 2009, FOOD CHEM TOXICOL, V47, P220, DOI 10.1016/j.fct.2008.11.004; Marnewick JL, 2000, MUTAT RES-GEN TOX EN, V471, P157, DOI 10.1016/S1383-5718(00)00128-5; Marnewick JL, 2004, MUTAT RES-GEN TOX EN, V558, P145, DOI 10.1016/j.mrgentox.2003.12.003; Marnewick JL, 2003, J AGR FOOD CHEM, V51, P8113, DOI 10.1021/jf0344643; McEwen BS, 2004, ANN NY ACAD SCI, V1032, P1, DOI 10.1196/annals.1314.001; Metz GA, 2005, EUR J NEUROSCI, V22, P1190, DOI 10.1111/j.1460-9568.2005.04285.x; MISRA HP, 1972, J BIOL CHEM, V247, P3170; Miyamoto Y, 2003, BIOL CHEM, V384, P567, DOI 10.1515/BC.2003.064; MOHANDAS J, 1984, BIOCHEM PHARMACOL, V33, P1801, DOI 10.1016/0006-2952(84)90353-8; Mozaffarian D, 2007, EUR HEART J, V28, P2699, DOI 10.1093/eurheartj/ehm451; Nadaoka I, 2012, BIOMED RES-TOKYO, V33, P133, DOI 10.2220/biomedres.33.133; Naidu PS, 2004, PHARMACOLOGY, V70, P59, DOI 10.1159/000074669; Pastore A, 2001, CLIN CHEM, V47, P1467; Posmyk MM, 2005, J PLANT PHYSIOL, V162, P403, DOI 10.1016/j.jplph.2004.08.004; Poulsen HE, 1998, EUR J CANCER PREV, V7, P9; Ramos-Vasconcelos GR, 2003, J EXP BIOL, V206, P675, DOI 10.1242/jeb.00124; Sahin E, 2004, BEHAV BRAIN RES, V155, P241, DOI 10.1016/j.bbr.2004.04.022; Schuliga M, 2002, TOXICOL SCI, V70, P183, DOI 10.1093/toxsci/70.2.183; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; Suresh S, 2010, INT J ANDROL, V33, P22, DOI 10.1111/j.1365-2605.2008.00949.x; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Torres ILS, 2001, BRAZ J MED BIOL RES, V34, P241, DOI 10.1590/S0100-879X2001000200012; Trevisanato SI, 2000, NUTR REV, V58, P1, DOI 10.1111/j.1753-4887.2000.tb01818.x; Ulicna O, 2008, GEN PHYSIOL BIOPHYS, V27, P179; Ulicna O, 2006, PHYSIOL RES, V55, P157, DOI 10.33549/physiolres.930778; Uysal N, 2005, PHYSIOL RES, V54, P437, DOI 10.33549/physiolres.930632; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Wang XL, 2004, DIABETES, V53, P129, DOI 10.2337/diabetes.53.1.129; Wilson JX, 1997, CAN J PHYSIOL PHARM, V75, P1149, DOI 10.1139/cjpp-75-10-11-1149; WINBERG S, 1993, NEUROREPORT, V4, P399, DOI 10.1097/00001756-199304000-00014; Wolf R, 1998, J EUR ACAD DERMATOL, V10, P103, DOI 10.1111/j.1468-3083.1998.tb00709.x; YOSHIKAWA T, 1990, ADV EXP MED BIOL, V264, P171; Zaidi SMKR, 2004, CLIN CHIM ACTA, V340, P229, DOI 10.1016/j.cccn.2003.11.003	91	44	47	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2014	9	1							e87061	10.1371/journal.pone.0087061	http://dx.doi.org/10.1371/journal.pone.0087061			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297GT	24466326	Green Published, Green Submitted, gold			2023-01-03	WOS:000330244500290
J	Kleiman, LB; Krebs, AM; Kim, SY; Hong, TS; Haigis, KM				Kleiman, Laura B.; Krebs, Angela M.; Kim, Stephen Y.; Hong, Theodore S.; Haigis, Kevin M.			Comparative Analysis of Radiosensitizers for K-RAS Mutant Rectal Cancers	PLOS ONE			English	Article							CHECKPOINT KINASE 1; GROWTH-FACTOR RECEPTOR; MEDIATES RADIORESISTANCE; RADIATION-RESISTANCE; SELECTIVE INHIBITOR; LOCAL RECURRENCE; HUMAN CHK1; IN-VITRO; PHOSPHORYLATION; ABROGATION	Approximately 40% of rectal cancers harbor activating K-RAS mutations, and these mutations are associated with poor clinical response to chemoradiotherapy. We aimed to identify small molecule inhibitors (SMIs) that synergize with ionizing radiation (IR) ("radiosensitizers") that could be incorporated into current treatment strategies for locally advanced rectal cancers (LARCs) expressing mutant K-RAS. We first optimized a high-throughput assay for measuring individual and combined effects of SMIs and IR that produces similar results to the gold standard colony formation assay. Using this screening platform and K-RAS mutant rectal cancer cell lines, we tested SMIs targeting diverse signaling pathways for radiosensitizing activity and then evaluated our top hits in follow-up experiments. The two most potent radiosensitizers were the Chk1/2 inhibitor AZD7762 and the PI3K/mTOR inhibitor BEZ235. The chemotherapeutic agent 5-fluorouracil (5-FU), which is used to treat LARC, synergized with AZD7762 and enhanced radiosensitization by AZD7762. This study is the first to compare different SMIs in combination with IR for the treatment of K-RAS mutant rectal cancer, and our findings suggest that Chk1/2 inhibitors should be evaluated in new clinical trials for LARC.	[Kleiman, Laura B.; Krebs, Angela M.; Kim, Stephen Y.; Haigis, Kevin M.] Massachusetts Gen Hosp, Mol Pathol Unit, Ctr Canc Res, Charlestown, MA 02129 USA; [Kleiman, Laura B.; Krebs, Angela M.; Kim, Stephen Y.; Haigis, Kevin M.] Massachusetts Gen Hosp, Ctr Syst Biol, Charlestown, MA USA; [Krebs, Angela M.] Univ Freiburg, Inst Mol Med & Cell Res, Freiburg, Germany; [Hong, Theodore S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Freiburg; Harvard University; Massachusetts General Hospital	Haigis, KM (corresponding author), Massachusetts Gen Hosp, Mol Pathol Unit, Ctr Canc Res, Charlestown, MA 02129 USA.	KHAIGIS@PARTNERS.ORG			American Cancer Society [MGO-114877, PF-11-260-01]; pilot project grant from the Proton Beam Federal Share program	American Cancer Society(American Cancer Society); pilot project grant from the Proton Beam Federal Share program	This work was funded by the American Cancer Society (MGO-114877 to K.M.H. and PF-11-260-01 to L.B.K.) and by a pilot project grant from the Proton Beam Federal Share program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAM IJ, 1994, LANCET, V344, P707, DOI 10.1016/S0140-6736(94)92206-3; Aklilu M, 2011, NAT REV CLIN ONCOL, V8, P649, DOI 10.1038/nrclinonc.2011.118; Anderson VE, 2011, CANCER RES, V71, P463, DOI 10.1158/0008-5472.CAN-10-1252; Azad A, 2011, MOL CANCER RES, V9, P1696, DOI 10.1158/1541-7786.MCR-11-0312; Begg AC, 2011, NAT REV CANCER, V11, P239, DOI 10.1038/nrc3007; Bernhard EJ, 2000, CANCER RES, V60, P6597; Bosset JF, 2006, NEW ENGL J MED, V355, P1114, DOI 10.1056/NEJMoa060829; Brunner TB, 2005, CANCER RES, V65, P8433, DOI 10.1158/0008-5472.CAN-05-0158; Carlessi L, 2007, MOL CANCER THER, V6, P935, DOI 10.1158/1535-7163.MCT-06-0567; Carlessi L, 2010, BBA-MOL CELL RES, V1803, P1213, DOI 10.1016/j.bbamcr.2010.06.002; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; Cengel KA, 2007, NEOPLASIA, V9, P341, DOI 10.1593/neo.06823; Chen T, 2012, DRUG DISCOV TODAY, V17, P194, DOI 10.1016/j.drudis.2011.12.009; Dai Y, 2010, CLIN CANCER RES, V16, P376, DOI 10.1158/1078-0432.CCR-09-1029; Debucquoy A, 2010, CLIN CANCER RES, V16, P2709, DOI 10.1158/1078-0432.CCR-09-1622; Elshaikh M, 2006, ANNU REV MED, V57, P19, DOI 10.1146/annurev.med.57.121304.131431; Eng C, 2010, ONCOLOGIST, V15, P73, DOI 10.1634/theoncologist.2009-0167; Eriksson D, 2010, TUMOR BIOL, V31, P363, DOI 10.1007/s13277-010-0042-8; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fokas E, 2012, CANCER RES, V72, P239, DOI 10.1158/0008-5472.CAN-11-2263; Folkesson J, 2005, J CLIN ONCOL, V23, P5644, DOI 10.1200/JCO.2005.08.144; Garcia-Aguilar J, 2011, ANN SURG, V254, P486, DOI 10.1097/SLA.0b013e31822b8cfa; Grana TM, 2002, CANCER RES, V62, P4142; Gupta AK, 2001, CANCER RES, V61, P4278; Hong TS, 2012, CANCER DISCOV, V2, P117, DOI 10.1158/2159-8290.CD-11-0315; Jobson AG, 2009, J PHARMACOL EXP THER, V331, P816, DOI 10.1124/jpet.109.154997; Konstantinidou G, 2009, CANCER RES, V69, P7644, DOI 10.1158/0008-5472.CAN-09-0823; Leung-Pineda V, 2006, MOL CELL BIOL, V26, P7529, DOI 10.1128/MCB.00447-06; Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009; Ma ZK, 2012, MOL MED REP, V6, P897, DOI 10.3892/mmr.2012.999; Manfredi S, 2006, BRIT J SURG, V93, P1115, DOI 10.1002/bjs.5349; Maugeri-Sacca M, 2013, CANCER TREAT REV, V39, P525, DOI 10.1016/j.ctrv.2012.10.007; McKenna WG, 2003, ONCOGENE, V22, P5866, DOI 10.1038/sj.onc.1206699; McNeely S, 2010, CELL CYCLE, V9, P995, DOI 10.4161/cc.9.5.10935; Minjgee M, 2011, INT J RADIAT ONCOL, V81, P1506, DOI 10.1016/j.ijrobp.2011.05.057; Mitchell JB, 2010, CLIN CANCER RES, V16, P2076, DOI 10.1158/1078-0432.CCR-09-3277; Morgan MA, 2006, CELL CYCLE, V5, P1983, DOI 10.4161/cc.5.17.3184; Morgan MA, 2010, CANCER RES, V70, P4972, DOI 10.1158/0008-5472.CAN-09-3573; Mukherjee B, 2012, NEOPLASIA, V14, P34, DOI 10.1593/neo.111512; Niida H, 2005, J BIOL CHEM, V280, P39246, DOI 10.1074/jbc.M505009200; Oliver AW, 2006, EMBO J, V25, P3179, DOI 10.1038/sj.emboj.7601209; Parsels LA, 2011, CLIN CANCER RES, V17, P3706, DOI 10.1158/1078-0432.CCR-10-3082; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Redon CE, 2010, CLIN CANCER RES, V16, P4532, DOI 10.1158/1078-0432.CCR-10-0523; Rodel C, 2005, J CLIN ONCOL, V23, P8688, DOI 10.1200/JCO.2005.02.1329; Santiskulvong C, 2011, CLIN CANCER RES, V17, P2373, DOI 10.1158/1078-0432.CCR-10-2289; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Vance SM, 2011, CELL CYCLE, V10, P4321, DOI 10.4161/cc.10.24.18661; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Xiao Z, 2005, ONCOGENE, V24, P1403, DOI 10.1038/sj.onc.1208309; Xiao Z, 2006, MOL CANCER THER, V5, P1935, DOI 10.1158/1535-7163.MCT-06-0077; Yang H, 2011, BIOCHEM BIOPH RES CO, V406, P53, DOI 10.1016/j.bbrc.2011.01.106; Zabludoff SD, 2008, MOL CANCER THER, V7, P2955, DOI 10.1158/1535-7163.MCT-08-0492; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019	55	20	20	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2013	8	12							e82982	10.1371/journal.pone.0082982	http://dx.doi.org/10.1371/journal.pone.0082982			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276EU	24349411	Green Submitted, Green Published, gold			2023-01-03	WOS:000328731800086
J	Sperber, J; Lipcsey, M; Larsson, A; Larsson, A; Sjolin, J; Castegren, M				Sperber, Jesper; Lipcsey, Miklos; Larsson, Anders; Larsson, Anders; Sjolin, Jan; Castegren, Markus			Lung Protective Ventilation Induces Immunotolerance and Nitric Oxide Metabolites in Porcine Experimental Postoperative Sepsis	PLOS ONE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; MECHANICAL VENTILATION; TIDAL VOLUMES; ENDOTOXIN TOLERANCE; EXPERIMENTAL-MODEL; ORGAN DYSFUNCTION; INJURY; RESPONSES	Low tidal volume ventilation is beneficial in patients with severe pulmonary dysfunction and would, in theory, reduce postoperative complications if implemented during routine surgery. The study aimed to investigate whether low tidal volume ventilation and high positive end-expiratory pressure (PEEP) in a large animal model of postoperative sepsis would attenuate the systemic inflammatory response and organ dysfunction. Thirty healthy pigs were randomized to three groups: Group Prot-7h, i.e. protective ventilation for 7 h, was ventilated with a tidal volume of 6 mL x kg(-1) for 7 h; group Prot-5h, i.e. protective ventilation for 5 h, was ventilated with a tidal volume of 10 mL x kg(-1) for 2 h, after which the group was ventilated with a tidal volume of 6 mL x kg(-1); and a control group that was ventilated with a tidal volume of 10 mL x kg(-1) for 7 h. In groups Prot-7h and Prot-5h PEEP was 5 cmH(2)O for 2 h and 10 cmH(2)O for 5 h. In the control group PEEP was 5 cmH(2)O for the entire experiment. After surgery for 2 h, postoperative sepsis was simulated with an endotoxin infusion for 5 h. Low tidal volume ventilation combined with higher PEEP led to lower levels of interleukin 6 and 10 in plasma, higher PaO2/FiO(2), better preserved functional residual capacity and lower plasma troponin I as compared with animals ventilated with a medium high tidal volume and lower PEEP. The beneficial effects of protective ventilation were seen despite greater reductions in cardiac index and oxygen delivery index. In the immediate postoperative phase low V-T ventilation with higher PEEP was associated with reduced ex vivo plasma capacity to produce TNF-alpha upon endotoxin stimulation and higher nitrite levels in urine. These findings might represent mechanistic explanations for the attenuation of systemic inflammation and inflammatory-induced organ dysfunction.	[Sperber, Jesper; Castegren, Markus] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden; [Sperber, Jesper; Sjolin, Jan; Castegren, Markus] Uppsala Univ, Dept Med Sci, Uppsala, Sweden; [Lipcsey, Miklos; Larsson, Anders] Uppsala Univ, Dept Surg Sci Anaesthesiol & Intens Care, Uppsala, Sweden; [Larsson, Anders] Uppsala Univ, Dept Med Sci Biochem Struct & Funct, Uppsala, Sweden	Uppsala University; Uppsala University; Uppsala University; Uppsala University	Sperber, J (corresponding author), Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden.	jesper.sperber@dll.se	Castegren, Markus/AAF-2620-2019; Lipcsey, Miklos/K-4308-2012	Lipcsey, Miklos/0000-0002-1976-4129; Castegren, Markus/0000-0002-9292-0298; Sperber, Jesper/0000-0001-8731-6953	Sormland County Council; Swedish Heart and Lung foundation; Family Olinder-Nielsen's Foundation; Uppsala University Hospital	Sormland County Council; Swedish Heart and Lung foundation(Swedish Heart-Lung Foundation); Family Olinder-Nielsen's Foundation; Uppsala University Hospital	"The R&D funds of the Sormland County Council and Uppsala University Hospital, the Swedish Heart and Lung foundation as well as the Family Olinder-Nielsen's Foundation contributed with financial support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BERSTEN AD, 2003, OHS INTENSIVE CARE M, P1113; Blum JM, 2013, ANESTHESIOLOGY, V118, P19, DOI 10.1097/ALN.0b013e3182794975; Bregeon F, 2005, ANESTHESIOLOGY, V102, P331; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; BUNNELL JB, 1981, ANN BIOMED ENG, V9, P645, DOI 10.1007/BF02364777; Buttenschoen K, 2008, LANGENBECK ARCH SURG, V393, P473, DOI 10.1007/s00423-008-0317-3; Carlsson M, 2009, CRIT CARE MED, V37, P1031, DOI 10.1097/CCM.0b013e31819b5683; Castegren M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053221; Castegren M, 2012, SHOCK, V37, P501, DOI 10.1097/SHK.0b013e318249bb0d; Cavaillon JM, 2003, J ENDOTOXIN RES, V9, P101, DOI 10.1179/096805103125001487; Cormio M, 1999, J NEUROSURG, V90, P9, DOI 10.3171/jns.1999.90.1.0009; Costa ELV, 2013, CRIT CARE, V17, DOI 10.1186/cc12556; Determann RM, 2010, CRIT CARE, V14, DOI 10.1186/cc8230; Dias MB, 2005, J APPL PHYSIOL, V98, P1322, DOI 10.1152/japplphysiol.01243.2004; Feihl F, 2009, INTENS CARE MED, V35, P198, DOI 10.1007/s00134-008-1298-y; Fu Y, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002526; Gajic O, 2004, CRIT CARE MED, V32, P1817, DOI 10.1097/01.CCM.0000133019.52531.30; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; Jaecklin T, 2010, INTENS CARE MED, V36, P750, DOI 10.1007/s00134-010-1850-4; LARSSON A, 1987, ANESTHESIOLOGY, V67, P543, DOI 10.1097/00000542-198710000-00016; Lipcsey M, 2006, J ENDOTOXIN RES, V12, P99, DOI 10.1179/096805106X89053; Lipcsey M, 2008, SHOCK, V29, P173, DOI 10.1097/SHK.0b013e318067dfbc; Lipcsey M, 2009, CRIT CARE MED, V37, P2782, DOI 10.1097/CCM.0b013e3181a988f8; Moriondo A, 2011, ACTA PHYSIOL, V203, P331, DOI 10.1111/j.1748-1716.2011.02317.x; O'Mahony DS, 2006, CRIT CARE, V10, DOI 10.1186/cc5050; Poli-De-Figueiredo LF, 2008, SHOCK, V30, P53, DOI 10.1097/SHK.0b013e318181a343; Putensen C, 2007, ANESTHESIOLOGY, V106, P1085, DOI 10.1097/01.anes.0000265424.07486.8c; Quilez ME, 2012, CURR OPIN CRIT CARE, V18, P23, DOI 10.1097/MCC.0b013e32834ef3ea; Schmidhammer R, 2006, SHOCK, V25, P389, DOI 10.1097/01.shk.0000209529.43367.00; Schultz MJ, 2007, ANESTHESIOLOGY, V106, P1226, DOI 10.1097/01.anes.0000267607.25011.e8; Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092; Tremblay LN, 1998, P ASSOC AM PHYSICIAN, V110, P482; Treschan TA, 2012, BRIT J ANAESTH, V109, P263, DOI 10.1093/bja/aes140; Vobruba V, 2013, EXP LUNG RES, V39, P1, DOI 10.3109/01902148.2012.737404; Wang HH, 2011, J CELL PHYSIOL, V226, P2244, DOI 10.1002/jcp.22560; West MA, 2002, CRIT CARE MED, V30, pS64, DOI 10.1097/00003246-200201001-00009	36	7	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2013	8	12							e83182	10.1371/journal.pone.0083182	http://dx.doi.org/10.1371/journal.pone.0083182			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276EU	24349457	gold, Green Submitted, Green Published			2023-01-03	WOS:000328731800101
J	Stokholm, J; Schjorring, S; Pedersen, L; Bischoff, AL; Folsgaard, N; Carson, CG; Chawes, BLK; Bonnelykke, K; Molgaard, A; Krogfelt, KA; Bisgaard, H				Stokholm, Jakob; Schjorring, Susanne; Pedersen, Louise; Bischoff, Anne Louise; Folsgaard, Nilofar; Carson, Charlotte G.; Chawes, Bo L. K.; Bonnelykke, Klaus; Molgaard, Anne; Krogfelt, Karen A.; Bisgaard, Hans			Prevalence and Predictors of Antibiotic Administration during Pregnancy and Birth	PLOS ONE			English	Article							URINARY-TRACT-INFECTIONS; B-STREPTOCOCCAL DISEASE; PRESCRIPTION DRUG-USE; RISK-FACTORS; SMOKING; ASTHMA; PREVENTION; BLOOD	Background: Antibiotic treatment during pregnancy and birth is very common. In this study, we describe the estimated prevalence of antibiotic administration during pregnancy and birth in the COPSAC(2010) pregnancy cohort, and analyze dependence on social and lifestyle-related factors. Methods: 706 pregnant women from the novel unselected Copenhagen Prospective Study on Asthma in Childhood (COPSAC(2010)) pregnancy cohort participated in this analysis. Detailed information on oral antibiotic prescriptions during pregnancy filled at the pharmacy was obtained and verified longitudinally. Information on intrapartum antibiotics, social, and lifestyle-factors was obtained by personal interviews. Results: The prevalence of antibiotic use was 37% during pregnancy and 33% intrapartum. Lower maternal age at birth; adjusted odds ratio (aOR) 0.94, 95% CI, [0.90-0.98], p = 0.003 and maternal smoking; aOR 1.97, 95% CI, [1.07-3.63], p = 0.030 were associated with use of antibiotics for urinary tract infection during pregnancy. Maternal educational level (low vs. high), aOR 2.32, 95% CI, [1.24-4.35], p = 0.011, maternal asthma; aOR 1.99, 95% CI, [1.33-2.98], p < 0.001 and previous childbirth; aOR 1.80, 95% CI, [1.21-2.66], p = 0.004 were associated with use of antibiotics for respiratory tract infection during pregnancy. Lower gestational age; aOR 0.72, 95% CI, [0.61-0.85], p < 0.001, maternal smoking; aOR 2.84, 95% CI, [1.33-6.06], p = 0.007, and nulliparity; aOR 1.79, 95% CI, [1.06-3.02], p = 0.030 were associated with administration of intrapartum antibiotics in women giving birth vaginally. Conclusion: Antibiotic administration during pregnancy and birth may be influenced by social and lifestyle-factors. Understanding such risk factors may guide preventive strategies in order to avoid unnecessary use of antibiotics.	[Stokholm, Jakob; Pedersen, Louise] Univ Copenhagen, Naestved Hosp, Copenhagen Prospect Studies Asthma Childhood, Naestved, Denmark; [Stokholm, Jakob; Pedersen, Louise; Bischoff, Anne Louise; Folsgaard, Nilofar; Carson, Charlotte G.; Chawes, Bo L. K.; Bonnelykke, Klaus; Molgaard, Anne; Bisgaard, Hans] Univ Copenhagen, Copenhagen Univ Hosp, Copenhagen Prospect Studies Asthma Childhood, Copenhagen, Denmark; [Schjorring, Susanne; Krogfelt, Karen A.] Statens Serum Inst, Dept Microbiol Surveillance & Res, DK-2300 Copenhagen, Denmark	Naestved Hospital; University of Copenhagen; University of Copenhagen; Statens Serum Institut	Bisgaard, H (corresponding author), Univ Copenhagen, Copenhagen Univ Hosp, Copenhagen Prospect Studies Asthma Childhood, Copenhagen, Denmark.	bisgaard@copsac.com	Bisgaard, Hans/N-4761-2016; Krogfelt, Karen Angeliki/P-2430-2018; Krogfelt, Karen Angeliki A/O-8145-2016	Bisgaard, Hans/0000-0003-4131-7592; Krogfelt, Karen Angeliki A/0000-0001-7536-3453; Chawes, Bo/0000-0001-6846-6243; Stokholm, Jakob/0000-0003-4989-9769; Bonnelykke, Klaus/0000-0003-2003-1018; Schjorring, Susanne/0000-0001-5575-7252	Lundbeck Foundation; Strategic Research Foundation; Pharmacy Foundation of 1991; Augustinus Foundation; Danish Medical Research Council	Lundbeck Foundation(Lundbeckfonden); Strategic Research Foundation; Pharmacy Foundation of 1991; Augustinus Foundation; Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC))	COPSAC is funded by private and public research funds all listed on www.copsac.com. The Lundbeck Foundation; The Strategic Research Foundation; the Pharmacy Foundation of 1991; Augustinus Foundation; the Danish Medical Research Council and The Danish Pediatric Asthma Centre provided core support for COPSAC. No pharmaceutical companies were involved in the study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amann U, 2006, PHARMACOEPIDEM DR S, V15, P327, DOI 10.1002/pds.1225; Ananth CV, 1996, AM J EPIDEMIOL, V144, P881, DOI 10.1093/oxfordjournals.aje.a009022; Andrade SE, 2004, AM J OBSTET GYNECOL, V191, P398, DOI 10.1016/j.ajog.2004.04.025; [Anonymous], 2004, INT J GYNECOL OBSTET, V85, P315; [Anonymous], 1996, MMWR Recomm Rep, V45, P1; Beyens MN, 2003, THERAPIE, V58, P505, DOI 10.2515/therapie:2003082; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bisgaard H, 2013, CLIN EXP ALLERGY, V43, P1384, DOI 10.1111/cea.12213; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; BONATI M, 1992, INT J GYNECOL OBSTET, V39, P185; CEDERQVIST LL, 1984, AM J OBSTET GYNECOL, V148, P1123, DOI 10.1016/0002-9378(84)90639-2; CUNNINGHAM FG, 1994, BAILLIERE CLIN OB GY, V8, P353, DOI 10.1016/S0950-3552(05)80325-6; Daw JR, 2012, CLIN THER, V34, P239, DOI 10.1016/j.clinthera.2011.11.025; Forbes RL, 2011, THORAX; Haider G, 2010, J PAK MED ASSOC, V60, P213; Hanif Shamayela, 2006, J Coll Physicians Surg Pak, V16, P514; Jamieson DJ, 2006, EMERG INFECT DIS, V12, P1638, DOI 10.3201/eid1211.060152; Little P, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13190; Marchant S, 2006, PAEDIATR PERINAT EP, V20, P392, DOI 10.1111/j.1365-3016.2006.00743.x; Mignini L, 2009, OBSTET GYNECOL, V113, P346, DOI 10.1097/AOG.0b013e318194f109; Mitchell AA, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.02.029; Moore MR, 2003, LANCET INFECT DIS, V3, P201, DOI 10.1016/S1473-3099(03)00577-2; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Norgaard M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030850; Olesen C, 1999, EUR J CLIN PHARMACOL, V55, P139, DOI 10.1007/s002280050608; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; Salihu HM, 2007, EARLY HUM DEV, V83, P713, DOI 10.1016/j.earlhumdev.2007.08.002; Santos F, 2010, PHARMACOEPIDEM DR S, V19, P418, DOI 10.1002/pds.1915; Smaill FM, 2011, COCHRANE LIB; STAMM WE, 1991, REV INFECT DIS, V13, P77; Turan A, 2011, ANESTHESIOLOGY, V114, P837, DOI 10.1097/ALN.0b013e318210f560; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]	33	73	74	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2013	8	12							e82932	10.1371/journal.pone.0082932	http://dx.doi.org/10.1371/journal.pone.0082932			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275VW	24340068	Green Published, Green Submitted, gold			2023-01-03	WOS:000328707400104
J	Issa-Nummer, Y; Darb-Esfahani, S; Loibl, S; Kunz, G; Nekljudova, V; Schrader, I; Sinn, BV; Ulmer, HU; Kronenwett, R; Just, M; Kuhn, T; Diebold, K; Untch, M; Holms, F; Blohmer, JU; Habeck, JO; Dietel, M; Overkamp, F; Krabisch, P; von Minckwitz, G; Denkert, C				Issa-Nummer, Yasmin; Darb-Esfahani, Silvia; Loibl, Sibylle; Kunz, Georg; Nekljudova, Valentina; Schrader, Iris; Sinn, Bruno Valentin; Ulmer, Hans-Ullrich; Kronenwett, Ralf; Just, Marianne; Kuehn, Thorsten; Diebold, Kurt; Untch, Michael; Holms, Frank; Blohmer, Jens-Uwe; Habeck, Joerg-Olaf; Dietel, Manfred; Overkamp, Friedrich; Krabisch, Petra; von Minckwitz, Gunter; Denkert, Carsten			Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer - A Substudy of the Neoadjuvant GeparQuinto Trial	PLOS ONE			English	Article							REGULATORY T-CELLS; PREOPERATIVE CHEMOTHERAPY; PROGNOSTIC-FACTOR; PERIPHERAL-BLOOD; IMMUNE-RESPONSE; B-CELLS; CYCLOPHOSPHAMIDE; LYMPHOCYTES; IMMUNOSURVEILLANCE; SURVIVAL	Introduction: We have recently described an increased lymphocytic infiltration rate in breast carcinoma tissue is a significant response predictor for anthracycline/taxane-based neoadjuvant chemotherapy (NACT). The aim of this study was to prospectively validate the tumor-associated lymphocyte infiltrate as predictive marker for response to anthracycline/taxane-based NACT. Patients and Methods: The immunological infiltrate was prospectively evaluated in a total of 313 core biopsies from HER2 negative patients of the multicenter PREDICT study, a substudy of the neoadjuvant GeparQuinto study. Intratumoral lymphocytes (iTuLy), stromal lymphocytes (strLy) as well as lymphocyte-predominant breast cancer (LPBC) were evaluated by histopathological assessment. Pathological complete response (pCR) rates were analyzed and compared between the defined subgroups using the exact test of Fisher. Results: Patients with lymphocyte-predominant breast cancer (LPBC) had a significantly increased pCR rate of 36.6%, compared to non-LPBC patients (14.3%, p<0.001). LPBC and stromal lymphocytes were significantly independent predictors for pCR in multivariate analysis (LPBC: OR 2.7, p = 0.003, strLy: OR 1.2, p = 0.01). The amount of intratumoral lymphocytes was significantly predictive for pCR in univariate (OR 1.2, p = 0.01) but not in multivariate logistic regression analysis (OR 1.2, p = 0.11). Conclusion: Confirming previous investigations of our group, we have prospectively validated in an independent cohort that an increased immunological infiltrate in breast tumor tissue is predictive for response to anthracycline/taxane-based NACT. Patients with LPBC and increased stromal lymphocyte infiltration have significantly increased pCR rates. The lymphocytic infiltrate is a promising additional parameter for histopathological evaluation of breast cancer core biopsies.	[Issa-Nummer, Yasmin; Loibl, Sibylle; Nekljudova, Valentina; von Minckwitz, Gunter] German Breast Grp, Neu Isenburg, Germany; [Darb-Esfahani, Silvia; Sinn, Bruno Valentin; Dietel, Manfred; Denkert, Carsten] Charite, Inst Pathol, D-13353 Berlin, Germany; [Kunz, Georg] St Johannes Hosp, Dept Gynecol & Obstet, Dortmund, Germany; [Schrader, Iris] Frauenklin Henriettenstiftung, Hannover, Germany; [Ulmer, Hans-Ullrich] Stadt Klinikum Karlsruhe, Frauenklin, Karlsruhe, Germany; [Kronenwett, Ralf] Sividon Diagnost GmbH, Cologne, Germany; [Just, Marianne] Schwerpunktpraxis Bielefeld, Bielefeld, Germany; [Kuehn, Thorsten] Klinikum Esslingen, Klin Frauenheilkunde & Geburtshilfe, Esslingen, Germany; [Diebold, Kurt] Gemeinschaftspraxis Pathol Hamm, Hamm, Germany; [Untch, Michael] Helios Klinikum Berlin Buch, Breast Ctr, Berlin, Germany; [Holms, Frank] St Barbara Klin Hamm Heessen, Gynakol & Geburtshilfe, Hamm, Germany; [Blohmer, Jens-Uwe] St Gertrauden Krankenhaus Berlin, Breast Ctr, Berlin, Germany; [Habeck, Joerg-Olaf] Zentrum Histopathol Chemnitz, Chemnitz, Germany; [Overkamp, Friedrich] Oncol Nova GmbH Recklinghausen, Recklinghausen, Germany; [Krabisch, Petra] Klinikum Chemnitz, Breast Ctr, Chemnitz, Germany; [von Minckwitz, Gunter] Univ Womens Hosp, Frankfurt, Germany	German Breast Group; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; St. Johannes Hospital; Municipal Hospital Karlsruhe; Helios Kliniken; Chemnitz Clinic	Loibl, S (corresponding author), German Breast Grp, Neu Isenburg, Germany.	Sibylle.Loibl@germanbreastgroup.de	Denkert, Carsten/AHE-2675-2022	Blohmer, Jens-Uwe/0000-0002-7969-250X; Denkert, Carsten/0000-0002-2249-0982	German Ministry of Research (BMBF) [01ES0725]	German Ministry of Research (BMBF)(Federal Ministry of Education & Research (BMBF))	This project has been supported by a grant from the German Ministry of Research (BMBF, Neo-Predict project, number 01ES0725). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AALTOMAA S, 1992, EUR J CANCER, V28A, P859, DOI 10.1016/0959-8049(92)90134-N; Bates GJ, 2006, J CLIN ONCOL, V24, P5373, DOI 10.1200/JCO.2006.05.9584; Carson WE, 2004, CLIN CANCER RES, V10, P3401, DOI 10.1158/1078-0432.CCR-1016-03; Coronella JA, 2001, CANCER RES, V61, P7889; Coronella-Wood JA, 2003, CANCER IMMUNOL IMMUN, V52, P715, DOI 10.1007/s00262-003-0409-4; DeNardo DG, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1746; DeNardo D, 2010, CANCER METAST REV, V29, P309, DOI 10.1007/s10555-010-9223-6; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Disis ML, 2010, J CLIN ONCOL, V28, P4531, DOI 10.1200/JCO.2009.27.2146; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Estevez LG, 2004, CLIN CANCER RES, V10, P3249, DOI 10.1158/1078-0432.CCR-03-0133; Fisher B, 1998, J CLIN ONCOL, V16, P2672, DOI 10.1200/JCO.1998.16.8.2672; Ghiringhelli F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI 10.1007/s00262-006-0225-8; Gianni L, 2005, J CLIN ONCOL, V23, P7265, DOI 10.1200/JCO.2005.02.0818; Gobert M, 2009, CANCER RES, V69, P2000, DOI 10.1158/0008-5472.CAN-08-2360; Hansen MH, 2002, J IMMUNOL, V169, P2701, DOI 10.4049/jimmunol.169.5.2701; Hansen MH, 2001, P NATL ACAD SCI USA, V98, P12659, DOI 10.1073/pnas.171460798; Hiraoka K, 2006, BRIT J CANCER, V94, P275, DOI 10.1038/sj.bjc.6602934; Hornychova H, 2008, CANCER INVEST, V26, P1024, DOI 10.1080/07357900802098165; Houghton AN, 2004, J CLIN INVEST, V114, P468, DOI 10.1172/JCI200422685; Ichim CV, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-8; Kaufmann M, 2006, J CLIN ONCOL, V24, P1940, DOI 10.1200/JCO.2005.02.6187; Ladoire S, 2008, CLIN CANCER RES, V14, P2413, DOI 10.1158/1078-0432.CCR-07-4491; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; Mahmoud SMA, 2012, BREAST CANCER RES TR, V132, P545, DOI 10.1007/s10549-011-1620-1; Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037; Mahmoud SMA, 2011, BREAST CANCER RES TR, V127, P99, DOI 10.1007/s10549-010-0987-8; Marsigliante S, 1999, CANCER LETT, V139, P33, DOI 10.1016/S0304-3835(98)00379-6; Menard C, 2008, CANCER IMMUNOL IMMUN, V57, P1579, DOI 10.1007/s00262-008-0505-6; Menard S, 1997, CLIN CANCER RES, V3, P817; Merlo A, 2009, J CLIN ONCOL, V27, P1746, DOI 10.1200/JCO.2008.17.9036; Nelson BH, 2010, J IMMUNOL, V185, P4977, DOI 10.4049/jimmunol.1001323; Ono M, 2012, BREAST CANCER RES TR, V132, P793, DOI 10.1007/s10549-011-1554-7; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Pages F, 2010, ONCOGENE, V29, P1093, DOI 10.1038/onc.2009.416; PUNT CJA, 1994, CANCER IMMUNOL IMMUN, V38, P225, DOI 10.1007/s002620050058; Rastogi P, 2008, J CLIN ONCOL, V26, P778, DOI 10.1200/JCO.2007.15.0235; Rodriguez-Pinto D, 2005, CELL IMMUNOL, V238, P67, DOI 10.1016/j.cellimm.2006.02.005; Rody A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2234; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; Smith IC, 2002, J CLIN ONCOL, V20, P1456, DOI 10.1200/JCO.20.6.1456; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Smyth MJ, 2001, NAT IMMUNOL, V2, P293, DOI 10.1038/86297; van der Most RG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006982; von Minckwitz G, 2005, J CLIN ONCOL, V23, P2676, DOI 10.1200/JCO.2005.05.078; von Minckwitz G, 2008, JNCI-J NATL CANCER I, V100, P542, DOI 10.1093/jnci/djn085; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zitvogel L, 2004, ADV IMMUNOL, V84, P131, DOI 10.1016/S0065-2776(04)84004-5; Zitvogel L, 2011, NAT REV CLIN ONCOL, V8, P151, DOI 10.1038/nrclinonc.2010.223	50	150	153	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2013	8	12							e79775	10.1371/journal.pone.0079775	http://dx.doi.org/10.1371/journal.pone.0079775			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	265IN	24312450	gold, Green Submitted, Green Published			2023-01-03	WOS:000327944500008
J	Dharmarajan, K; Hsieh, AF; Lin, Z; Bueno, H; Ross, JS; Horwitz, LI; Barreto, JA; Kim, N; Suter, LG; Bernheim, SM; Drye, EE; Krumholz, HM				Dharmarajan, Kumar; Hsieh, Angela F.; Lin, Zhenqiu; Bueno, Hector; Ross, Joseph S.; Horwitz, Leora I.; Barreto-Filho, Jose Augusto; Kim, Nancy; Suter, Lisa G.; Bernheim, Susannah M.; Drye, Elizabeth E.; Krumholz, Harlan M.			Hospital readmission performance and patterns of readmission: retrospective cohort study of Medicare admissions	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; QUALITY-OF-CARE; RISK-STANDARDIZED MORTALITY; URBAN-RURAL DIFFERENCES; SAFETY-NET HOSPITALS; HEART-FAILURE; PATIENT OUTCOMES; HEALTH-CARE; RATES; REHOSPITALIZATION	Objectives To determine whether high performing hospitals with low 30 day risk standardized readmission rates have a lower proportion of readmissions from specific diagnoses and time periods after admission or instead have a similar distribution of readmission diagnoses and timing to lower performing institutions. Design Retrospective cohort study. Setting Medicare beneficiaries in the United States. Participants Patients aged 65 and older who were readmitted within 30 days after hospital admission for heart failure, acute myocardial infarction, or pneumonia in 2007-09. Main outcome measures Readmission diagnoses were classified with a modified version of the Centers for Medicare and Medicaid Services' condition categories, and readmission timing was classified by day (0-30) after hospital discharge. Hospital 30 day risk standardized readmission rates over the three years of study were calculated with public reporting methods of the US federal government, and hospitals were categorized with bootstrap analysis as having high, average, or low readmission performance for each index condition. High and low performing hospitals had >= 95% probability of having an interval estimate respectively less than or greater than the national 30 day readmission rate over the three year period of study. All remaining hospitals were considered average performers. Results For readmissions in the 30 days after the index admission, there were 320 003 after 1 291 211 admissions for heart failure (4041 hospitals), 102 536 after 517 827 admissions for acute myocardial infarction (2378 hospitals), and 208 438 after 1 135 932 admissions for pneumonia (4283 hospitals). The distribution of readmissions by diagnosis was similar across categories of hospital performance for all three conditions. High performing hospitals had fewer readmissions for all common diagnoses. Median time to readmission was similar by hospital performance for heart failure and acute myocardial infarction, though was 1.4 days longer among high versus low performing hospitals for pneumonia (P<0.001). Findings were unchanged after adjustment for other hospital characteristics potentially associated with readmission patterns. Conclusions High performing hospitals have proportionately fewer 30 day readmissions without differences in readmission diagnoses and timing, suggesting the possible benefit of strategies that lower risk of readmission globally rather than for specific diagnoses or time periods after hospital stay.	[Dharmarajan, Kumar] Columbia Univ, Med Ctr, Dept Internal Med, Div Cardiol, New York, NY 10032 USA; [Hsieh, Angela F.; Lin, Zhenqiu; Bernheim, Susannah M.; Drye, Elizabeth E.; Krumholz, Harlan M.] Yale Univ, New Haven Hosp, Ctr Outcomes Res & Evaluat, New Haven, CT 06510 USA; [Bueno, Hector] Univ Gregorio Maranon, Gen Hosp, Dept Cardiol, Madrid 28007, Spain; [Ross, Joseph S.; Horwitz, Leora I.; Kim, Nancy] Yale Univ, Sch Med, Gen Internal Med Sect, New Haven, CT 06520 USA; [Barreto-Filho, Jose Augusto] Univ Fed Sergipe, Div Cardiol, BR-49060100 Aracaju, Sergipe, Brazil; [Drye, Elizabeth E.] Yale Univ, Sch Med, Rheumatol Sect, New Haven, CT 06520 USA	Columbia University; Yale University; General University Gregorio Maranon Hospital; Yale University; Universidade Federal de Sergipe; Yale University	Dharmarajan, K (corresponding author), Columbia Univ, Med Ctr, Dept Internal Med, Div Cardiol, 630 West 168th St,Box 93,PH 10-203, New York, NY 10032 USA.	kumar.dharmarajan@columbia.edu	, Harlan/AAI-2875-2020; Bueno, Hector/I-3910-2015; Horwitz, Leora/ABD-1292-2020; Horwitz, Leora/A-6959-2009	Bueno, Hector/0000-0003-0277-7596; Ross, Joseph/0000-0002-9218-3320; Horwitz, Leora/0000-0003-1800-6040	National Heart, Lung, and Blood Institute; National Heart, Lung, and Blood Institute [T32HL007854]; Centers of Excellence Scholar in Geriatric Medicine at Yale by the John A Hartford Foundation; American Federation for Aging Research; National Institute on Aging [K08AG032886, K08AG038336]; American Federation for Aging Research through the Paul B Beeson Career Development Award Program; CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Ministry of Education, Brazil) [3436-10-1]; (Center for Cardiovascular Outcomes Research at Yale University) from the National Heart, Lung, and Blood Institute [1U01HL105270-03]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL105270, T32HL007854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG032886, K08AG038336] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Centers of Excellence Scholar in Geriatric Medicine at Yale by the John A Hartford Foundation; American Federation for Aging Research; National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); American Federation for Aging Research through the Paul B Beeson Career Development Award Program; CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Ministry of Education, Brazil)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); (Center for Cardiovascular Outcomes Research at Yale University) from the National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was funded by the National Heart, Lung, and Blood Institute, which had no role in the design, conduct, or analysis of the study or in the decision to submit the manuscript for publication. KD was supported by grant T32HL007854 from the National Heart, Lung, and Blood Institute and as a Centers of Excellence Scholar in Geriatric Medicine at Yale by the John A Hartford Foundation and the American Federation for Aging Research during the time that the work was conducted. JSR and LIH are supported by grants K08AG032886 and K08AG038336 from the National Institute on Aging and by the American Federation for Aging Research through the Paul B Beeson Career Development Award Program, respectively. JAB-F was supported by grant 3436-10-1 from CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Ministry of Education, Brazil) during the time that the work was conducted. HMK is supported by grant 1U01HL105270-03 (Center for Cardiovascular Outcomes Research at Yale University) from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the American Federation for Aging Research.	Ash AS, 2012, STAT ISSUES ASSESSIN; Baldrige Performance Excellence Program, 2013, 2013 2014 HLTH CAR C; Baldwin LM, 2010, J RURAL HEALTH, V26, P51, DOI 10.1111/j.1748-0361.2009.00265.x; Bernheim SM, 2007, AM HEART J, V153, P313, DOI 10.1016/j.ahj.2006.10.037; Bernheim SM, 2010, CIRC-CARDIOVASC QUAL, V3, P459, DOI 10.1161/CIRCOUTCOMES.110.957613; Birman-Deych E, 2005, MED CARE, V43, P480, DOI 10.1097/01.mlr.0000160417.39497.a9; Bradley EH, 2012, ANN INTERN MED, V156, P618, DOI 10.7326/0003-4819-156-9-201205010-00003; Bucholz EM, 2011, AM J CARDIOL, V108, P943, DOI 10.1016/j.amjcard.2011.05.023; Calvillo-King L, 2013, J GEN INTERN MED, V28, P269, DOI 10.1007/s11606-012-2235-x; Centers for Medicare and Medicaid Services, 2011, MED HOSP QUAL CHARTB; Centers for Medicare and Medicaid Services, MED HOSP COMP QUAL C; Chan L, 2006, J RURAL HEALTH, V22, P140, DOI 10.1111/j.1748-0361.2006.00022.x; Chaudhry SI, 2010, NEW ENGL J MED, V363, P2301, DOI 10.1056/NEJMoa1010029; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Curry LA, 2011, ANN INTERN MED, V154, P384, DOI 10.7326/0003-4819-154-6-201103150-00003; Department of Health and Human Services, 2013, PROGR REP CMS US SEN; Dharmarajan K, 2013, JAMA-J AM MED ASSOC, V309, P355, DOI 10.1001/jama.2012.216476; Dudas V, 2001, AM J MED, V111, P26, DOI 10.1016/S0002-9343(01)00966-4; Dunlay SM, 2012, ANN INTERN MED, V157, P11, DOI 10.7326/0003-4819-157-1-201207030-00004; Epstein AM, 2011, NEW ENGL J MED, V365, P2287, DOI 10.1056/NEJMsa1101942; Evangelista LS, 2000, AM J CARDIOL, V86, P1339, DOI 10.1016/S0002-9149(00)01238-8; Gaskin DJ, 2001, HEALTH SERV RES, V36, P25; Hammill BG, 2011, CIRC-CARDIOVASC QUAL, V4, P60, DOI 10.1161/CIRCOUTCOMES.110.954693; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Hartman L, 2007, J RURAL HEALTH, V23, P254, DOI 10.1111/j.1748-0361.2007.00098.x; Howie-Esquivel J, 2012, AM J CRIT CARE, V21, pE65, DOI 10.4037/ajcc2012382; Jasti H, 2008, CLIN INFECT DIS, V46, P550, DOI 10.1086/526526; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Joynt KE, 2011, JAMA-J AM MED ASSOC, V306, P45, DOI 10.1001/jama.2011.902; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Joynt KE, 2011, ANN INTERN MED, V154, P94, DOI 10.7326/0003-4819-154-2-201101180-00008; Joynt KE, 2011, CIRC-CARDIOVASC QUAL, V4, P53, DOI 10.1161/CIRCOUTCOMES.110.950964; Kaboli PJ, 2012, ANN INTERN MED, V157, P837, DOI 10.7326/0003-4819-157-12-201212180-00003; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; Kiyota Y, 2004, AM HEART J, V148, P99, DOI 10.1016/j.ahj.2004.02.013; Kocher RP, 2011, JAMA-J AM MED ASSOC, V306, P1794, DOI 10.1001/jama.2011.1561; Koehler F, 2011, CIRCULATION, V123, P1873, DOI 10.1161/CIRCULATIONAHA.111.018473; Krumholz HM, 2011, CIRC-CARDIOVASC QUAL, V4, P243, DOI 10.1161/CIRCOUTCOMES.110.957498; Krumholz HM, 2009, CIRC-CARDIOVASC QUAL, V2, P407, DOI 10.1161/CIRCOUTCOMES.109.883256; Lindenauer PK, 2011, J HOSP MED, V6, P142, DOI 10.1002/jhm.890; Lindenauer Peter K, 2010, J Hosp Med, V5, pE12, DOI 10.1002/jhm.822; Lutfiyya MN, 2007, INT J QUAL HEALTH C, V19, P141, DOI 10.1093/intqhc/mzm010; National Quality Forum, 2008, NAT VOL CONS STAND H; Neupane B, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-22; O'Connor CM, 2010, AM HEART J, V159, P841, DOI 10.1016/j.ahj.2010.02.023; Pope GC, 2004, HEALTH CARE FINANC R, V25, P119; Probst JC, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-40; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Ross JS, 2012, HEALTH AFFAIR, V31, P1739, DOI 10.1377/hlthaff.2011.1028; Shah SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047420; Sheikh K, 2001, ARCH INTERN MED, V161, P737, DOI 10.1001/archinte.161.5.737; Skull SA, 2008, EPIDEMIOL INFECT, V136, P232, DOI 10.1017/S0950268807008564	52	65	68	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	2013	347								f6571	10.1136/bmj.f6571	http://dx.doi.org/10.1136/bmj.f6571			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	258KF	24259033	Green Published, hybrid			2023-01-03	WOS:000327457400001
J	Wang, QZ; Gao, CL; Wang, HC; Lang, LL; Yue, T; Lin, HL				Wang, Qinzhou; Gao, Cuilian; Wang, Hongchun; Lang, Lingling; Yue, Tao; Lin, Hualiang			Ischemic Stroke Hospital Admission Associated with Ambient Temperature in Jinan, China	PLOS ONE			English	Article							CORONARY-HEART-DISEASE; RED-CELL COUNTS; AIR-POLLUTION; BLOOD-VISCOSITY; COLD WEATHER; MORTALITY; RISK; PRESSURE; CLIMATE; INFARCTION	Background: This study estimated the effects of ambient temperature and relative humidity on hospital admissions for ischemic stroke during 1990-2009 in Jinan, China. Methods: To account for possible delayed effects and harvesting effect, we examined the impact of meteorological factors up to 30 days before each admission using a distributed lag non-linear model; we controlled for season, long-term trend, day of week and public holidays in the analysis. Stratified analyses were also done for summer and winter. Results: A total of 1,908 ischemic stroke hospital admissions were observed between 1990 and 2009. We found a strong non-linear acute effect of daily temperatures on ischemic stroke hospital admission. With the mean temperature 15 degrees C as the reference, the relative risk (RR) was 1.43 (95% confidence interval (CI): 1.10-1.85) for 0 degrees C daily temperature on the same day, and 0.43 (95% CI: 0.31-0.59) for 30 degrees C daily temperature on the same day, respectively. The effect of ambient temperature was similar in summer and winter. No significant association was observed between relative humidity and ischemic stroke hospitalization. Conclusions: Low temperature might be a risk factor for ischemic stroke, and high temperature might be protective factor of ischemic stroke occurrence in Jinan, China.	[Wang, Qinzhou] Shandong Univ, Qilu Hosp, Dept Neurol, Jinan 250100, Peoples R China; [Gao, Cuilian; Wang, Hongchun] Shandong Univ, Qilu Hosp, Jinan 250100, Peoples R China; [Lang, Lingling; Lin, Hualiang] Guangdong Prov Ctr Dis Control & Prevent, Guangdong Prov Inst Publ Hlth, Guangzhou, Guangdong, Peoples R China; [Yue, Tao] Zibo Ctr Hosp, Cadre Hlth Care Dept, Zibo, Peoples R China	Shandong University; Shandong University; Chinese Center for Disease Control & Prevention; Guangdong Provincial Center for Disease Control & Prevention	Lin, HL (corresponding author), Guangdong Prov Ctr Dis Control & Prevent, Guangdong Prov Inst Publ Hlth, Guangzhou, Guangdong, Peoples R China.	linhualiang2002@163.com	Lin, Hualiang/E-6622-2010	Lin, Hualiang/0000-0002-2462-5158	National Major Research Program of China [2012CB955500]	National Major Research Program of China	The study was supported by National Major Research Program of China (Ref. No. 2012CB955500). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Analitis A, 2008, AM J EPIDEMIOL, V168, P1397, DOI 10.1093/aje/kwn266; BERGINER VM, 1989, STROKE, V20, P65, DOI 10.1161/01.STR.20.1.65; Chang CL, 2004, J CLIN EPIDEMIOL, V57, P749, DOI 10.1016/j.jclinepi.2003.10.016; CHEN ZY, 1995, STROKE, V26, P569, DOI 10.1161/01.STR.26.4.569; Dawson J, 2008, ACTA NEUROL SCAND, V117, P85, DOI 10.1111/j.1600-0404.2007.00916.x; Donaldson GC, 1997, BRIT MED J, V315, P1055, DOI 10.1136/bmj.315.7115.1055; Ebi KL, 2004, INT J BIOMETEOROL, V49, P48, DOI 10.1007/s00484-004-0207-5; Feigin VL, 2000, EUR J NEUROL, V7, P171, DOI 10.1046/j.1468-1331.2000.00016.x; Field TS, 2002, STROKE, V33, P1751, DOI 10.1161/01.STR.0000020384.92499.59; Gasparrini A, 2010, STAT MED, V29, P2224, DOI 10.1002/sim.3940; Gasparrini A, 2012, OCCUP ENVIRON MED, V69, P56, DOI 10.1136/oem.2010.059782; Gasparrini A, 2011, J STAT SOFTW, V43, P1, DOI 10.18637/jss.v043.i08; Gasparrini A, 2010, ENVIRON RES, V110, P633, DOI 10.1016/j.envres.2010.06.005; Geng L, 2012, CHINESE MED RECORD, V13, P31; Goggins W, 2011, INT J BIOMETEOROL, P1; Goldberg MS, 2011, ENVIRON RES, V111, P853, DOI 10.1016/j.envres.2011.05.022; Guo YM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016511; Ha J, 2012, INT J BIOMETEOROL, P1; Hong YC, 2003, EPIDEMIOLOGY, V14, P473, DOI 10.1097/01.ede.0000078420.82023.e3; Hong YC, 2002, STROKE, V33, P2165, DOI 10.1161/01.STR.0000026865.52610.5B; Hori A, 2012, INT J ENVIRON HEAL R, V22, P416, DOI 10.1080/09603123.2011.650155; Ishigami A, 2008, ENV HLTH, V7, P1; Jia Q, 2010, CLIN EXP PHARMACOL P, V37, P259, DOI 10.1111/j.1440-1681.2009.05290.x; Kalkstein LS, 1997, ENVIRON HEALTH PERSP, V105, P84, DOI 10.2307/3433067; KEATINGE WR, 1984, BMJ-BRIT MED J, V289, P1405, DOI 10.1136/bmj.289.6456.1405; KEATINGE WR, 1986, AM J MED, V81, P795, DOI 10.1016/0002-9343(86)90348-7; Kyobutungi C, 2005, EUR J EPIDEMIOL, V20, P693, DOI 10.1007/s10654-005-0703-x; Kysely J, 2009, CLIM RES, V38, P105, DOI 10.3354/cr00775; Lavallee P, 2002, STROKE, V33, P513, DOI 10.1161/hs0202.102328; Lessler J, 2009, LANCET INFECT DIS, V9, P291, DOI 10.1016/S1473-3099(09)70069-6; Lim Y-K, 2012, INT J BIOMETEOROL, P1; Lin HL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068417; Lin HL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065585; Lin HJ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0066403, 10.1371/journal.pone.0066661]; Lisabeth LD, 2008, ANN NEUROL, V64, P53, DOI 10.1002/ana.21403; Liu Fang, 2004, Zhonghua Liu Xing Bing Xue Za Zhi, V25, P962; Ma WJ, 2011, EPIDEMIOLOGY, V22, pS17, DOI 10.1097/01.ede.0000391707.80682.21; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; McArthur K, 2010, EXPERT REV NEUROTHER, V10, P243, DOI 10.1586/ERN.09.154; Mechtouff L, 2012, INT J STROKE; Medina-Ramon M, 2006, ENVIRON HEALTH PERSP, V114, P1331, DOI 10.1289/ehp.9074; Nyquist PA, 2001, NEUROLOGY, V56, P190, DOI 10.1212/WNL.56.2.190; PAN WH, 1995, LANCET, V345, P353, DOI 10.1016/S0140-6736(95)90341-0; Peng RD, 2006, J R STAT SOC A STAT, V169, P179, DOI 10.1111/j.1467-985X.2006.00410.x; Tian L, 2013, AM J RESP CRIT CARE; Wang XY, 2009, INT J BIOMETEOROL, V53, P535, DOI 10.1007/s00484-009-0241-4; Widlansky ME, 2007, AM J CARDIOL, V100, P518, DOI 10.1016/j.amjcard.2007.03.055; WOODHOUSE PR, 1993, J HYPERTENS, V11, P1267; World Health Organization, 2004, WORLD HLTH REP 2004; Yang L, 2008, APPL ENERG, V85, P800, DOI 10.1016/j.apenergy.2007.11.002	50	31	31	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2013	8	11							e80381	10.1371/journal.pone.0080381	http://dx.doi.org/10.1371/journal.pone.0080381			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256LO	24260379	Green Submitted, gold, Green Published			2023-01-03	WOS:000327311900065
J	Zhao, LX; Li, DD; Hu, DD; Hu, GH; Yan, L; Wang, Y; Jiang, YY				Zhao, Lan-Xue; Li, De-Dong; Hu, Dan-Dan; Hu, Gan-Hai; Yan, Lan; Wang, Yan; Jiang, Yuan-Ying			Effect of Tetrandrine against Candida albicans Biofilms	PLOS ONE			English	Article							CELL-SURFACE HYDROPHOBICITY; STAPHYLOCOCCUS-AUREUS BIOFILMS; IN-VITRO ACTIVITY; ANTIFUNGAL RESISTANCE; FUNGAL PATHOGEN; VIRULENCE; ADHERENCE; MORPHOGENESIS; FANGCHINOLINE; ACTIVATION	Candida albicans is the most common human fungal pathogen and has a high propensity to develop biofilms that are resistant to traditional antifungal agents. In this study, we investigated the effect of tetrandrine (TET) on growth, biofilm formation and yeast-to-hypha transition of C. albicans. We characterized the inhibitory effect of TET on hyphal growth and addressed its possible mechanism of action. Treatment of TET at a low concentration without affecting fungal growth inhibited hyphal growth in both liquid and solid Spider media. Real-time RT-PCR revealed that TET down-regulated the expression of hypha-specific genes ECE1, ALS3 and HWP1, and abrogated the induction of EFG1 and RAS1, regulators of hyphal growth. Addition of cAMP restored the normal phenotype of the SC5314 strain. These results indicate that TET may inhibit hyphal growth through the Ras1p-cAMP-PKA pathway. In vivo, at a range of concentrations from 4 mg/L to 32 mg/L, TET prolonged the survival of C. albicans-infected Caenorhabditis elegans significantly. This study provides useful information for the development of new strategies to reduce the incidence of C. albicans biofilm-associated infections.	[Zhao, Lan-Xue; Li, De-Dong; Hu, Dan-Dan; Hu, Gan-Hai; Yan, Lan; Wang, Yan; Jiang, Yuan-Ying] Second Mil Med Univ, Sch Pharm, New Drug Res & Dev Ctr, Shanghai, Peoples R China; [Zhao, Lan-Xue] Shanghai Jiao Tong Univ, Sch Med, Dept Pharm, Inst Med Sci, Shanghai 200030, Peoples R China; [Hu, Gan-Hai] Fujian Univ Tradit Chinese Med, Dept Pharm, Fuzhou, Peoples R China	Naval Medical University; Shanghai Jiao Tong University; Fujian University of Traditional Chinese Medicine	Wang, Y (corresponding author), Second Mil Med Univ, Sch Pharm, New Drug Res & Dev Ctr, Shanghai, Peoples R China.	wangyansmmu@126.com; jiangyuanying@126.com	Li, Dedong/R-7044-2019; jiang, anyi/GPT-0379-2022	Wang, Yan/0000-0003-1084-1957	National Key Basic Research Program of China [2013CB531602]; National Natural Science Foundation of China [81273558, 81072678, 90913008]; National Science and Technology Major Project of the Ministry of Science and Technology of China [2011ZX09102-002-01]; Shanghai Science and Technology Major Project [10431902200]	National Key Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Project of the Ministry of Science and Technology of China; Shanghai Science and Technology Major Project	This work was supported by the National Key Basic Research Program of China (2013CB531602), the National Natural Science Foundation of China (81273558, 81072678 and 90913008), the National Science and Technology Major Project of the Ministry of Science and Technology of China (2011ZX09102-002-01), and Shanghai Science and Technology Major Project (10431902200). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexander BD, 1997, DRUGS, V54, P657, DOI 10.2165/00003495-199754050-00002; Arikan S, 1997, MYCOSES, V40, P291, DOI 10.1111/j.1439-0507.1997.tb00234.x; Azie N, 2012, DIAGN MICR INFEC DIS, V73, P293, DOI 10.1016/j.diagmicrobio.2012.06.012; BECKSAGUE CM, 1993, J INFECT DIS, V167, P1247, DOI 10.1093/infdis/167.5.1247; BIRSE CE, 1993, INFECT IMMUN, V61, P3648, DOI 10.1128/IAI.61.9.3648-3655.1993; Braga PC, 2008, INT J ANTIMICROB AG, V31, P472, DOI 10.1016/j.ijantimicag.2007.12.013; Braun BR, 2000, GENETICS, V155, P57; Breger J, 2007, PLOS PATHOG, V3, P168, DOI 10.1371/journal.ppat.0030018; Cao YY, 2008, INT J ANTIMICROB AG, V32, P73, DOI 10.1016/j.ijantimicag.2008.01.026; Chaffin WL, 2008, MICROBIOL MOL BIOL R, V72, P495, DOI 10.1128/MMBR.00032-07; Chandra J, 2001, J DENT RES, V80, P903, DOI 10.1177/00220345010800031101; Chandra J, 2001, J BACTERIOL, V183, P5385, DOI 10.1128/JB.183.18.5385-5394.2001; Chen F, 1997, BIOCHEM BIOPH RES CO, V231, P99, DOI 10.1006/bbrc.1997.6057; Chen LL, 2013, NEUROL RES, V35, P614, DOI 10.1179/1743132813Y.0000000175; Chen YJ, 1999, BIOL PHARM BULL, V22, P703, DOI 10.1248/bpb.22.703; Chen Y, 2009, ANTICANCER RES, V29, P3163; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; Crnich CJ, 2002, CLIN INFECT DIS, V34, P1232, DOI 10.1086/339863; Davey ME, 2000, MICROBIOL MOL BIOL R, V64, P847, DOI 10.1128/MMBR.64.4.847-867.2000; Dong Y, 1997, LIFE SCI, V60, pPL135, DOI 10.1016/S0024-3205(96)00695-9; Dongari-Bagtzoglou A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007967; Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167-193.2002; Donlan RM, 2001, CLIN INFECT DIS, V33, P1387, DOI 10.1086/322972; Fallarero A, 2013, INT J MOL SCI, V14, P12054, DOI 10.3390/ijms140612054; Fang JH, 1996, CHIN PHARM J, V31, P454; Feng QH, 1999, J BACTERIOL, V181, P6339, DOI 10.1128/JB.181.20.6339-6346.1999; Ferreira AV, 2013, MYCOPATHOLOGIA, V175, P265, DOI 10.1007/s11046-013-9638-z; Fu LW, 2002, EUR J CANCER, V38, P418, DOI 10.1016/S0959-8049(01)00356-2; Gao Y, 1965, CHINESE J INTERN MED, V13, P504; GRALLA EJ, 1974, CANCER CHEMOTH REP 3, V5, P79; Hasan F, 2009, MICROBES INFECT, V11, P753, DOI 10.1016/j.micinf.2009.04.018; HAWSER SP, 1995, ANTIMICROB AGENTS CH, V39, P2128, DOI 10.1128/AAC.39.9.2128; Hogan DA, 2009, FUTURE MICROBIOL, V4, P1263, DOI [10.2217/fmb.09.106, 10.2217/FMB.09.106]; Kim HS, 1997, J ETHNOPHARMACOL, V58, P117, DOI 10.1016/S0378-8741(97)00092-5; KLOTZ SA, 1985, INFECT IMMUN, V50, P97, DOI 10.1128/IAI.50.1.97-101.1985; Lane S, 2001, J BIOL CHEM, V276, P48988, DOI 10.1074/jbc.M104484200; Lane S, 2001, MOL CELL BIOL, V21, P6418, DOI 10.1128/MCB.21.19.6418-6428.2001; Leberer E, 2001, MOL MICROBIOL, V42, P673, DOI 10.1046/j.1365-2958.2001.02672.x; Lee JH, 2002, INT J ONCOL, V21, P1239; Li DD, 2013, FUNGAL GENET BIOL, V51, P50, DOI 10.1016/j.fgb.2012.11.010; LI Q, 1981, Chinese Journal of Tuberculosis and Respiratory Diseases, V4, P321; LI TL, 1982, ECOTOX ENVIRON SAFE, V6, P528, DOI 10.1016/0147-6513(82)90034-3; Liang RM, 2009, ACTA PHARMACOL SIN, V30, P1709, DOI 10.1038/aps.2009.157; Luo G, 2002, APMIS, V110, P601, DOI 10.1034/j.1600-0463.2002.1100902.x; Maki DG, 2001, EMERG INFECT DIS, V7, P342, DOI 10.3201/eid0702.010240; MartinezMartinez L, 1996, J ANTIMICROB CHEMOTH, V38, P1107, DOI 10.1093/jac/38.6.1107; Miwa T, 2004, EUKARYOT CELL, V3, P919, DOI 10.1128/EC.3.4.919-931.2004; Nett JE, 2011, EUKARYOT CELL, V10, P1660, DOI 10.1128/EC.05126-11; NGUYEN MH, 1995, ARCH INTERN MED, V155, P2429, DOI 10.1001/archinte.155.22.2429; Nobile CJ, 2006, CELL MICROBIOL, V8, P1382, DOI 10.1111/j.1462-5822.2006.00761.x; Nobile CJ, 2006, PLOS PATHOG, V2, P636, DOI 10.1371/journal.ppat.0020063; Okoli I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007025; Pappas PG, 2004, CLIN INFECT DIS, V38, P161, DOI 10.1086/380796; Pierce CG, 2008, NAT PROTOC, V3, P1494, DOI [10.1038/nport.2008.141, 10.1038/nprot.2008.141]; Pompilio A, 2008, FEMS MICROBIOL LETT, V287, P41, DOI 10.1111/j.1574-6968.2008.01292.x; Pukkila-Worley R, 2009, EUKARYOT CELL, V8, P1750, DOI 10.1128/EC.00163-09; Quan H, 2006, ANTIMICROB AGENTS CH, V50, P1096, DOI 10.1128/AAC.50.3.1096-1099.2006; Ramage G, 2005, EUKARYOT CELL, V4, P633, DOI 10.1128/EC.4.4.633-638.2005; Ramage G, 2002, APPL ENVIRON MICROB, V68, P5459, DOI 10.1128/AEM.68.11.5459-5463.2002; Ramage Gordon, 2001, Revista Iberoamericana de Micologia, V18, P163; Ramage G, 2009, CRIT REV MICROBIOL, V35, P340, DOI 10.3109/10408410903241436; Rocha CRC, 2001, MOL BIOL CELL, V12, P3631, DOI 10.1091/mbc.12.11.3631; Samaranayake YH, 1995, APMIS, V103, P707, DOI 10.1111/j.1699-0463.1995.tb01427.x; Sandberg M, 2008, INT J ANTIMICROB AG, V32, P233, DOI 10.1016/j.ijantimicag.2008.04.022; Seneviratne CJ, 2008, ORAL DIS, V14, P582, DOI 10.1111/j.1601-0825.2007.01424.x; Shen YC, 2001, MOL PHARMACOL, V60, P1083, DOI 10.1124/mol.60.5.1083; Stoldt VR, 1997, EMBO J, V16, P1982, DOI 10.1093/emboj/16.8.1982; Sudbery PE, 2011, NAT REV MICROBIOL, V9, P737, DOI 10.1038/nrmicro2636; Sundstrom P, 2002, CELL MICROBIOL, V4, P461, DOI 10.1046/j.1462-5822.2002.00206.x; Tobudic S, 2010, MYCOSES, V53, P208, DOI 10.1111/j.1439-0507.2009.01690.x; Tronchin G, 2008, MED MYCOL, V46, P749, DOI 10.1080/13693780802206435; Vila TVM, 2013, J ANTIMICROB CHEMOTH, V68, P113, DOI 10.1093/jac/dks353; Wang G, 2004, TRENDS PHARMACOL SCI, V25, P120, DOI 10.1016/j.tips.2004.01.009; WEY SB, 1988, ARCH INTERN MED, V148, P2642, DOI 10.1001/archinte.148.12.2642; Xu WL, 2006, LEUKEMIA RES, V30, P407, DOI 10.1016/j.leukres.2005.08.005; Yao WX, 2002, ACTA PHARMACOL SIN, V23, P1069; YU XF, 1983, ECOTOX ENVIRON SAFE, V7, P306, DOI 10.1016/0147-6513(83)90075-1; Zhang D, 2010, CHINESE J ZOONOSES, V3, P010; Zhang H, 2010, PLANTA MED, V76, P53, DOI 10.1055/s-0029-1185973; Zheng XD, 2004, EMBO J, V23, P1845, DOI 10.1038/sj.emboj.7600195	80	48	54	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2013	8	11							e79671	10.1371/journal.pone.0079671	http://dx.doi.org/10.1371/journal.pone.0079671			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256KH	24260276	Green Published, Green Submitted, gold			2023-01-03	WOS:000327308500086
J	Corwin, D; Holdsworth, C; Rockne, RC; Trister, AD; Mrugala, MM; Rockhill, JK; Stewart, RD; Phillips, M; Swanson, KR				Corwin, David; Holdsworth, Clay; Rockne, Russell C.; Trister, Andrew D.; Mrugala, Maciej M.; Rockhill, Jason K.; Stewart, Robert D.; Phillips, Mark; Swanson, Kristin R.			Toward Patient-Specific, Biologically Optimized Radiation Therapy Plans for the Treatment of Glioblastoma	PLOS ONE			English	Article							NEWLY-DIAGNOSED GLIOBLASTOMAS; HIGH-GRADE GLIOMAS; CONFORMAL RADIOTHERAPY; MODEL; CLASSIFICATION; SURVIVAL; PATTERNS; GROWTH; BRAIN	Purpose: To demonstrate a method of generating patient-specific, biologically-guided radiotherapy dose plans and compare them to the standard-of-care protocol. Methods and Materials: We integrated a patient-specific biomathematical model of glioma proliferation, invasion and radiotherapy with a multiobjective evolutionary algorithm for intensity-modulated radiation therapy optimization to construct individualized, biologically-guided plans for 11 glioblastoma patients. Patient-individualized, spherically-symmetric simulations of the standard-of-care and optimized plans were compared in terms of several biological metrics. Results: The integrated model generated spatially non-uniform doses that, when compared to the standard-of-care protocol, resulted in a 67% to 93% decrease in equivalent uniform dose to normal tissue, while the therapeutic ratio, the ratio of tumor equivalent uniform dose to that of normal tissue, increased between 50% to 265%. Applying a novel metric of treatment response (Days Gained) to the patient-individualized simulation results predicted that the optimized plans would have a significant impact on delaying tumor progression, with increases from 21% to 105% for 9 of 11 patients. Conclusions: Patient-individualized simulations using the combination of a biomathematical model with an optimization algorithm for radiation therapy generated biologically-guided doses that decreased normal tissue EUD and increased therapeutic ratio with the potential to improve survival outcomes for treatment of glioblastoma.	[Corwin, David; Rockne, Russell C.; Swanson, Kristin R.] Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA; [Holdsworth, Clay; Trister, Andrew D.; Rockhill, Jason K.; Stewart, Robert D.; Phillips, Mark] Univ Washington, Med Ctr, Dept Radiat Oncol, Seattle, WA 98195 USA; [Holdsworth, Clay] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA; [Trister, Andrew D.] Sage Bionetworks, Seattle, WA USA; [Mrugala, Maciej M.] Univ Washington, Med Ctr, Dept Neurol, Seattle, WA 98195 USA; [Swanson, Kristin R.] Northwestern Univ, Dept Engn Sci & Appl Math, McCormick Sch Engn, Evanston, IL 60208 USA	Northwestern University; Feinberg School of Medicine; University of Washington; University of Washington Seattle; Harvard University; Brigham & Women's Hospital; University of Washington; University of Washington Seattle; Northwestern University	Swanson, KR (corresponding author), Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA.	Kristin.Swanson@northwestern.edu	Stewart, Robert/A-3609-2013; Rockne, Russell/T-1549-2017	Stewart, Robert/0000-0001-5946-0595; Rockne, Russell/0000-0002-1557-159X; Trister, Andrew/0000-0002-7070-0139	National Institutes of Health (NIH) [R01 NS060752, R01 CA16437]; James D. McDonnell Foundation; NATIONAL CANCER INSTITUTE [R01CA216437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS060752] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James D. McDonnell Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was funded under National Institutes of Health (NIH) R01 NS060752, NIH R01 CA16437 and the James D. McDonnell Foundation with PI: K. R. Swanson (http://grants.nih.gov/grants/oer.htm). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Blinkov SM., 1968, HUMAN BRAIN FIGURES; Chan JL, 2002, J CLIN ONCOL, V20, P1635, DOI 10.1200/JCO.20.6.1635; Emami B, 1991, J NUCL MED, V15, P109, DOI DOI 10.1016/0360-3016(91)90171-Y; Hall EJ, RADIOBIOLOGY RADIOLO, V7th; Holdsworth CH, 2012, PHYS MED BIOL, V57, DOI 10.1088/0031-9155/57/24/8271; Jena R, 2005, CLIN ONCOL-UK, V17, P581, DOI 10.1016/j.clon.2005.04.012; Kim Y, 2010, ACTA ONCOL, V49, P1374, DOI 10.3109/02841861003767539; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Lawrence YR, 2010, INT J RADIAT ONCOL, V76, pS20, DOI 10.1016/j.ijrobp.2009.02.091; Lee SW, 1999, INT J RADIAT ONCOL, V43, P79, DOI 10.1016/S0360-3016(98)00266-1; Maucort-Boulch D, 2010, CANCER RADIOTHER, V14, P34, DOI 10.1016/j.canrad.2009.08.141; Narayana A, 2007, BRIT J RADIOL, V80, P347, DOI 10.1259/bjr/65349468; Neal ML, 2013, CANCER RES, V73, P2976, DOI 10.1158/0008-5472.CAN-12-3588; Neal ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051951; Rockne R, 2010, PHYS MED BIOL, V55, P3271, DOI 10.1088/0031-9155/55/12/001; Rockne R, 2009, J MATH BIOL, V58, P561, DOI 10.1007/s00285-008-0219-6; Stall B, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-5; Stewart RD, 2007, MED PHYS, V34, P3739, DOI 10.1118/1.2779861; Stewart RD, 2011, IMAG MED DIAGN THER, P105; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Szeto MD, 2009, CANCER RES, V69, P4502, DOI 10.1158/0008-5472.CAN-08-3884; THIBAULT J, 1987, NUMER HEAT TRANSFER, V12, P457, DOI 10.1080/10407788708913597; Tome WA, 2000, INT J RADIAT ONCOL, V48, P593, DOI 10.1016/S0360-3016(00)00666-0; Wang CH, 2009, CANCER RES, V69, P9133, DOI 10.1158/0008-5472.CAN-08-3863; Zaider M, 2011, MED PHYS, V38, P574, DOI 10.1118/1.3521406	25	76	78	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2013	8	11							e79115	10.1371/journal.pone.0079115	http://dx.doi.org/10.1371/journal.pone.0079115			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255PK	24265748	Green Published, gold			2023-01-03	WOS:000327252100081
J	Marcus, DM				Marcus, Donald M.			PERSONAL VIEW Turning a blind eye to alternative medicine education	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SCIENCE		[Marcus, Donald M.] Baylor Coll Med, Texas Med Ctr, Dept Med, Houston, TX 77030 USA; [Marcus, Donald M.] Baylor Coll Med, Texas Med Ctr, Dept Immunol, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston	Marcus, DM (corresponding author), Baylor Coll Med, Texas Med Ctr, Dept Med, Houston, TX 77030 USA.	dmarcus@bcm.edu						Bevanger L, 2012, UK U DROP ALTERNATIV; Colquhoun D, 2007, NATURE, V446, P373, DOI 10.1038/446373a; Ernst E, 2008, J PAIN SYMPTOM MANAG, V35, P544, DOI 10.1016/j.jpainsymman.2007.07.004; Flexner A., 1910, MED ED US CANADA, P43; Hamburg MA, COMMUNICATION; Harel Z, 2013, JAMA INTERN MED, V173, P926, DOI 10.1001/jamainternmed.2013.379; Long J., FDA GMP INSPECTORS C; Ludmerer KM, 2010, ACAD MED, V85, P193, DOI 10.1097/ACM.0b013e3181c8f1e7; MacLennan AH, 2012, MED J AUSTRALIA, V196, P225, DOI 10.5694/mja12.10128; Marcus DM, 2012, ARCH INTERN MED, V172, P1035, DOI 10.1001/archinternmed.2012.2687; Marcus DM, 2009, ACAD MED, V84, P1229, DOI 10.1097/ACM.0b013e3181b185f4; Nahin Richard L, 2009, Natl Health Stat Report, P1; Offit PA, 2013, DO YOU BELIEVE MAGIC, P94; Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012; United States Government Accountability Office, 2010, HERB DIET SUPPL EX D; US Government Accountability Office, 2009, DIET SUPPL FDA SHOUL	16	2	2	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	2013	347								f5827	10.1136/bmj.f5827	http://dx.doi.org/10.1136/bmj.f5827			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231OK	24473448				2023-01-03	WOS:000325426300005
J	Naci, H; Ioannidis, JPA				Naci, Huseyin; Ioannidis, John P. A.			Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; CARDIAC REHABILITATION; MYOCARDIAL-INFARCTION; NETWORK METAANALYSIS; PRESCRIBING EXERCISE; COMPETING INTERVENTIONS; SECONDARY PREVENTION; HEART-FAILURE; DISEASE	Objective To determine the comparative effectiveness of exercise versus drug interventions on mortality outcomes. Design Metaepidemiological study. Eligibility criteria Meta-analyses of randomised controlled trials with mortality outcomes comparing the effectiveness of exercise and drug interventions with each other or with control (placebo or usual care). Data sources Medline and Cochrane Database of Systematic Reviews, May 2013. Main outcome measure Mortality. Data synthesis We combined study level death outcomes from exercise and drug trials using random effects network meta-analysis. Results We included 16 (four exercise and 12 drug) meta-analyses. Incorporating an additional three recent exercise trials, our review collectively included 305 randomised controlled trials with 339 274 participants. Across all four conditions with evidence on the effectiveness of exercise on mortality outcomes (secondary prevention of coronary heart disease, rehabilitation of stroke, treatment of heart failure, prevention of diabetes), 14 716 participants were randomised to physical activity interventions in 57 trials. No statistically detectable differences were evident between exercise and drug interventions in the secondary prevention of coronary heart disease and prediabetes. Physical activity interventions were more effective than drug treatment among patients with stroke (odds ratios, exercise v anticoagulants 0.09, 95% credible intervals 0.01 to 0.70 and exercise v antiplatelets 0.10, 0.01 to 0.62). Diuretics were more effective than exercise in heart failure (exercise v diuretics 4.11, 1.17 to 24.76). Inconsistency between direct and indirect comparisons was not significant. Conclusions Although limited in quantity, existing randomised trial evidence on exercise interventions suggests that exercise and many drug interventions are often potentially similar in terms of their mortality benefits in the secondary prevention of coronary heart disease, rehabilitation after stroke, treatment of heart failure, and prevention of diabetes.	[Naci, Huseyin] Univ London London Sch Econ & Polit Sci, LSE Hlth, London WC2A 2AE, England; [Naci, Huseyin] Harvard Univ, Sch Med, Dept Populat Med, Drug Policy Res Grp, Boston, MA USA; [Naci, Huseyin] Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Ioannidis, John P. A.] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA	University of London; London School Economics & Political Science; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Stanford University	Naci, H (corresponding author), Univ London London Sch Econ & Polit Sci, LSE Hlth, Houghton St, London WC2A 2AE, England.	HNacih.naci@lse.ac.uk	Ioannidis, John P. A./G-9836-2011					Ades PA, 2001, NEW ENGL J MED, V345, P892, DOI 10.1056/NEJMra001529; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Barnes PM., 2012, NCHS DATA BRIE, V86, P8; Belardinelli R, 2012, J AM COLL CARDIOL, V60, P1521, DOI 10.1016/j.jacc.2012.06.036; Berge E, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003242; Blair SN, 2009, BRIT J SPORT MED, V43, P1; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Brazzelli M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003316.pub4; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Byberg L, 2009, BRIT J SPORT MED, V43, P482, DOI 10.1136/bmj.b688; Cartwright N., 2012, EVIDENCE BASED POLIC, DOI DOI 10.1093/ACPROF:OSOBL/9780199841608.001.0001; Chatterjee S, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f55; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cooper NJ, 2009, STAT MED, V28, P1861, DOI 10.1002/sim.3594; Davidson PM, 2010, EUR J CARDIOV PREV R, V17, P393, DOI 10.1097/HJR.0b013e328334ea56; Davies EJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003331.pub3; Department of Health, 2011, UK PHYS ACT GUID; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dias S., 2011, NICE DSU TECHNICAL S; Dias S, 2013, MED DECIS MAKING, V33, P607, DOI 10.1177/0272989X12458724; Domanski MJ, 1999, J AM COLL CARDIOL, V33, P598, DOI 10.1016/S0735-1097(98)00609-3; Faris RF, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003838.pub3; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Fletcher GF, 1996, CIRCULATION, V94, P857, DOI 10.1161/01.CIR.94.4.857; Fong DYT, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e70; Freemantle N, 1999, BMJ-BRIT MED J, V318, P1730, DOI 10.1136/bmj.318.7200.1730; Garcia-Aymerich J, 2006, THORAX, V61, P772, DOI 10.1136/thx.2006.060145; Getz L, 2004, SCAND J PRIM HEALTH, V22, P202, DOI 10.1080/02813430410006693; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Heran BS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003040.pub2; Heran BS, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001800.pub3, 10.1002/14651858.CD001800.pub2]; Hopper I, 2011, EUR J CARDIOV PREV R, V18, P813, DOI 10.1177/1741826711421687; Jansen JP, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-159; Khan KM, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4141; Knols R, 2005, J CLIN ONCOL, V23, P3830, DOI 10.1200/JCO.2005.02.148; Kujala UM, 2009, BRIT J SPORT MED, V43, P550, DOI 10.1136/bjsm.2009.059808; Kujala UM, 2004, SCAND J MED SCI SPOR, V14, P339, DOI 10.1111/j.1600-0838.2004.413.x; Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8; Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Mills EJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2914; Moynihan R, 2002, BMJ-BRIT MED J, V324, P859, DOI 10.1136/bmj.324.7342.859; Naci H, 2013, EUR J PREV CARDIOL, V20, P641, DOI 10.1177/2047487313480435; Naci H, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4261; NHS Information System, 2012, PRESCR DISP COMM ENG; Orrow G, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1389; Pavey TG, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6462; Pedersen BK, 2006, SCAND J MED SCI SPOR, V16, P3, DOI 10.1111/j.1600-0838.2006.00520.x; Pereira TV, 2011, J CLIN EPIDEMIOL, V64, P1060, DOI 10.1016/j.jclinepi.2010.12.012; Roddy E, 2005, ANN RHEUM DIS, V64, P544, DOI 10.1136/ard.2004.028746; Salanti G, 2008, STAT METHODS MED RES, V17, P279, DOI 10.1177/0962280207080643; Salanti G, 2008, ANN INTERN MED, V148, P544, DOI 10.7326/0003-4819-148-7-200804010-00011; Samitz G, 2011, INT J EPIDEMIOL, V40, P1382, DOI 10.1093/ije/dyr112; Sandercock PAG, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000029.pub2; Sigal RJ, 2006, DIABETES CARE, V29, P1433, DOI 10.2337/dc06-9910; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; Song FJ, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4909; Sorenson C, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4849; Taylor RS, 2004, AM J MED, V116, P682, DOI 10.1016/j.amjmed.2004.01.009; Thompson PD, 2013, J AM COLL CARDIOL, V62, P715, DOI 10.1016/j.jacc.2013.03.030; Townsend N., 2012, PHYS ACTIVITY STAT 2; Warburton DER, 2006, CAN MED ASSOC J, V174, P961, DOI 10.1503/cmaj.1040750; Wardlaw JM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000213.pub2; Wen CP, 2011, LANCET, V378, P1244, DOI 10.1016/S0140-6736(11)60749-6; West RR, 2012, HEART, V98, P637, DOI 10.1136/heartjnl-2011-300302; Westin S, 2005, BRIT MED J, V330, P1461, DOI 10.1136/bmj.330.7506.1461; Williams Nefyn H, 2011, BMJ, V343, pd6615, DOI 10.1136/bmj.d6615	67	334	342	3	85	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	2013	347								f5577	10.1136/bmj.f5577	http://dx.doi.org/10.1136/bmj.f5577			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231OK	24473061	Green Published, hybrid, Green Accepted			2023-01-03	WOS:000325426300002
J	Paz-Ares, L; Corral, J				Paz-Ares, Luis; Corral, Jesus			Treatment for early-stage lung cancer: what next?	LANCET			English	Editorial Material							ADJUVANT CHEMOTHERAPY; PREOPERATIVE CHEMOTHERAPY; TRIAL; SURGERY; PLACEBO		[Paz-Ares, Luis; Corral, Jesus] Hosp Univ Virgen del Rocio, Inst Biomed Sevilla IBIS, Med Oncol Serv, Seville 41013, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital	Paz-Ares, L (corresponding author), Hosp Univ Virgen del Rocio, Inst Biomed Sevilla IBIS, Med Oncol Serv, Seville 41013, Spain.	lpazares@hotmail.com	Paz-Ares, Luis/AAH-2750-2019					Auperin A, 2010, LANCET, V375, P1267, DOI 10.1016/S0140-6736(10)60059-1; Burdett S, 2006, J THORAC ONCOL, V1, P611; DeMatteo RP, 2009, LANCET, V373, P1097, DOI 10.1016/S0140-6736(09)60500-6; Felip E, 2010, J CLIN ONCOL, V28, P3138, DOI 10.1200/JCO.2009.27.6204; Goss GD, 2013, J CLIN ONCOL, V31, P3320, DOI 10.1200/JCO.2013.51.1816; Hamada C, 2009, J THORAC ONCOL, V4, P1511, DOI 10.1097/JTO.0b013e3181bbf1f2; IARC, LUNG CANC EST INC MO; NSCLC Meta-analyses Collaborative Group, 2014, LANCET; Pignon JP, 2008, J CLIN ONCOL, V26, P3552, DOI 10.1200/JCO.2007.13.9030; Rastogi P, 2008, J CLIN ONCOL, V26, P778, DOI 10.1200/JCO.2007.15.0235; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Westeel V, 2013, EUR J CANCER, V49, P2654, DOI 10.1016/j.ejca.2013.04.013; Yang X-N, 2013, ASCO ANN M CHIC IL U	14	6	8	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 3	2014	383	9928					1528	1530		10.1016/S0140-6736(14)60002-7	http://dx.doi.org/10.1016/S0140-6736(14)60002-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AG5YO	24576775	hybrid			2023-01-03	WOS:000335495400007
J	Prieto, MJ; Zabala, NED; Marotta, CH; Gutierrez, HC; Arevalo, RA; Chiaramoni, NS; Alonso, SD				Jimena Prieto, Maria; del Rio Zabala, Nahuel Eduardo; Hernan Marotta, Cristian; Carreno Gutierrez, Hector; Arevalo Arevalo, Rosario; Silvia Chiaramoni, Nadia; del Valle Alonso, Silvia			Optimization and In Vivo Toxicity Evaluation of G4.5 Pamam Dendrimer-Risperidone Complexes	PLOS ONE			English	Article							ORAL-DRUG DELIVERY; POLY(AMIDOAMINE) DENDRIMERS; ANTIPSYCHOTIC-DRUGS; VISUAL PATHWAY; CELL VIABILITY; ZEBRAFISH; CARRIERS; BRAIN; MODEL; AUTISM	Risperidone is an approved antipsychotic drug belonging to the chemical class of benzisoxazole. This drug has low solubility in aqueous medium and poor bioavailability due to extensive first-pass metabolism and high protein binding (>90%). Since new strategies to improve efficient treatments are needed, we studied the efficiency of anionic G4.5 PAMAM dendrimers as nanocarriers for this therapeutic drug. To this end, we explored dendrimer-risperidone complexation dependence on solvent concentration, pH and molar relationship. The best dendrimer-risperidone incorporation (46 risperidone molecules per dendrimer) was achieved with a mixture of chloroform: methanol 50:50 v/v solution pH 3. In addition, to explore the possible effects of this complex, in vivo studies were carried out in the zebrafish model. Changes in the development of dopaminergic neurons and motoneurons were studied using tyrosine hydroxylase and calretinin, respectively. Physiological changes were studied through histological sections stained with hematoxylin-eosin to observe possible morphological brain changes. The most significant changes were observed when larvae were treated with free risperidone, and no changes were observed when larvae were treated with the complex.	[Jimena Prieto, Maria; del Rio Zabala, Nahuel Eduardo; Hernan Marotta, Cristian; Silvia Chiaramoni, Nadia; del Valle Alonso, Silvia] Natl Univ Quilmes, Dept Sci & Technol, Biomembrane Lab, Buenos Aires, DF, Argentina; [Jimena Prieto, Maria; del Rio Zabala, Nahuel Eduardo; Hernan Marotta, Cristian; Silvia Chiaramoni, Nadia; del Valle Alonso, Silvia] CCT La Plata, CONICET, IMBICE, La Plata, Buenos Aires, Argentina; [Carreno Gutierrez, Hector; Arevalo Arevalo, Rosario] Univ Salamanca, Sch Med, Dept Cell Biol & Pathol, Inst Neurosci Castilla & Leon, E-37008 Salamanca, Spain	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of La Plata; University of Salamanca	Prieto, MJ (corresponding author), Natl Univ Quilmes, Dept Sci & Technol, Biomembrane Lab, Buenos Aires, DF, Argentina.	jprieto@unq.edu.ar	del V. Alonso, Silvia/A-2064-2017; Arévalo, Rosario/L-5649-2014	del V. Alonso, Silvia/0000-0003-4243-2146; Arévalo, Rosario/0000-0001-5849-1736; Prieto, Maria Jimena/0000-0003-1111-1200	Universidad Nacional de Quilmes (Buenos Aires, Argentina); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET, Argentina); Ministerio Nacional de Ciencia, Tecnologia e Innovacion Productiva (MINCYT), Buenos Aires (Argentina)	Universidad Nacional de Quilmes (Buenos Aires, Argentina); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET, Argentina)(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Ministerio Nacional de Ciencia, Tecnologia e Innovacion Productiva (MINCYT), Buenos Aires (Argentina)	This research was supported by a grant from Universidad Nacional de Quilmes (Buenos Aires, Argentina), Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET, Argentina) and Ministerio Nacional de Ciencia, Tecnologia e Innovacion Productiva (MINCYT), Buenos Aires (Argentina). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Airhart MJ, 2007, NEUROTOXICOL TERATOL, V29, P652, DOI 10.1016/j.ntt.2007.07.005; Alonso-Romanowski S, 2003, CHEM PHYS LIPIDS, V122, P191, DOI 10.1016/S0009-3084(02)00190-1; Arenzana FJ, 2006, ANAT EMBRYOL, V211, P323, DOI 10.1007/s00429-006-0084-2; Arenzana FJ, 2006, NEUROTOXICOL TERATOL, V28, P342, DOI 10.1016/j.ntt.2006.02.001; BOSCH P, 2003, REV PLASTICOS MODERN, V86, P242; Braun CS, 2005, J PHARM SCI-US, V94, P423, DOI 10.1002/jps.20251; Canetta E, 2004, NUCL INSTRUM METH B, V213, P71, DOI 10.1016/S0168-583X(03)01536-2; Chakraborty C, 2009, CURR DRUG METAB, V10, P116, DOI 10.2174/138920009787522197; Chen CZS, 2000, BIOMACROMOLECULES, V1, P473, DOI 10.1021/bm0055495; Cheng YY, 2008, EUR J MED CHEM, V43, P1791, DOI 10.1016/j.ejmech.2007.09.030; Cheng YY, 2007, EUR J MED CHEM, V42, P1032, DOI 10.1016/j.ejmech.2006.12.035; Chiaramoni NS, 2007, BIOTECHNOL LETT, V29, P1637, DOI 10.1007/s10529-007-9454-y; Choi JS, 2004, J CONTROL RELEASE, V99, P445, DOI 10.1016/j.jconrel.2004.07.027; Clemente D, 2002, BRAIN RES, V925, P183, DOI 10.1016/S0006-8993(01)03279-6; Connors K, 1996, J INORG BIOCHEM, V62, P155; Courchesne E, 2007, NEURON, V56, P399, DOI 10.1016/j.neuron.2007.10.016; D'Emanuele A, 2005, ADV DRUG DELIVER REV, V57, P2147, DOI 10.1016/j.addr.2005.09.012; Fischer D, 2003, BIOMATERIALS, V24, P1121, DOI 10.1016/S0142-9612(02)00445-3; Froehlich E, 2011, BIOMACROMOLECULES, V12, P511, DOI 10.1021/bm1013102; Giansante C, 2009, J ORG CHEM, V74, P7335, DOI 10.1021/jo9014134; Gutierrez-Nava M, 2004, CHEM-EUR J, V10, P5076, DOI 10.1002/chem.200400157; Han M, 2005, POLYMER, V46, P3481, DOI 10.1016/j.polymer.2005.02.107; Hu YL, 2011, INT J NANOMED, V6, P3351, DOI 10.2147/IJN.S25853; JANSEN JFGA, 1994, SCIENCE, V266, P1226, DOI 10.1126/science.266.5188.1226; Prieto MJ, 2011, EUR J MED CHEM, V46, P845, DOI 10.1016/j.ejmech.2010.12.021; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kumar M, 2008, INT J PHARM, V358, P285, DOI 10.1016/j.ijpharm.2008.03.029; Ma ML, 2007, EUR J MED CHEM, V42, P93, DOI 10.1016/j.ejmech.2006.07.015; Mallamace F, 2002, PHYSICA A, V304, P235, DOI 10.1016/S0378-4371(01)00548-9; Malone RP, 2009, DRUGS, V69, P535, DOI 10.2165/00003495-200969050-00003; MANNENS G, 1994, PSYCHOPHARMACOLOGY, V114, P566, DOI 10.1007/BF02244986; Marshall CR, 2008, AM J HUM GENET, V82, P477, DOI 10.1016/j.ajhg.2007.12.009; McGrath P, 2008, DRUG DISCOV TODAY, V13, P394, DOI 10.1016/j.drudis.2008.03.002; Mecke A, 2004, CHEM PHYS LIPIDS, V132, P3, DOI 10.1016/j.chemphyslip.2004.09.001; Peterson RT, 2012, ANNU REV PHARMACOL, V52, P433, DOI 10.1146/annurev-pharmtox-010611-134751; Prieto M, 2013, J NANOMEDINE BIOTHER, V4; Prieto MJ, 2006, INT J PHARMACEUT, V326, P160, DOI 10.1016/j.ijpharm.2006.05.068; Prieto M, 2008, INT J PHARMACEUT, V360, P204, DOI 10.1016/j.ijpharm.2008.04.045; Prieto MJ, 2012, OPEN J MED CHEM, V02, P129, DOI DOI 10.4236/ojmc.2012.24016; Seibt KJ, 2009, TOXICOL IN VITRO, V23, P78, DOI 10.1016/j.tiv.2008.10.003; Sravan Kumar M, 2010, INT J PHARM SCI RES, P122; Svenson S, 2009, EUR J PHARM BIOPHARM, V71, P445, DOI 10.1016/j.ejpb.2008.09.023; Sweet DM, 2009, J CONTROL RELEASE, V138, P78, DOI 10.1016/j.jconrel.2009.04.022; Taira MC, 2004, DRUG DELIV, V11, P123, DOI 10.1080/10717540490280769; Tajarobi F, 2001, INT J PHARM, V215, P263, DOI 10.1016/S0378-5173(00)00679-7; Tessier C, 2008, J COLLOID INTERF SCI, V320, P469, DOI 10.1016/j.jcis.2008.01.034; Uppuluri S, 2000, MACROMOLECULES, V33, P2551, DOI 10.1021/ma990634u; Uppuluri S, 1998, MACROMOLECULES, V31, P4498, DOI 10.1021/ma971199b; Welch P, 1998, MACROMOLECULES, V31, P5892, DOI 10.1021/ma980198w; Weruaga E, 2000, J CHEM NEUROANAT, V19, P1, DOI 10.1016/S0891-0618(00)00046-6; Wong J, 2008, ADV DRUG DELIVER REV, V60, P939, DOI 10.1016/j.addr.2007.11.008; Xiangyang S, 2008, ADV MATER, V20, P1671	52	25	27	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2014	9	2							e90393	10.1371/journal.pone.0090393	http://dx.doi.org/10.1371/journal.pone.0090393			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC3DW	24587349	Green Submitted, Green Published, gold			2023-01-03	WOS:000332396200188
J	Ilott, NE; Schneider, T; Mill, J; Schalkwyk, L; Brolese, G; Bizarro, L; Stolerman, IP; Dempster, E; Asherson, P				Ilott, Nicholas E.; Schneider, Tomasz; Mill, Jonathan; Schalkwyk, Leonard; Brolese, Giovana; Bizarro, Lisiane; Stolerman, Ian P.; Dempster, Emma; Asherson, Philip			Long-Term Effects of Gestational Nicotine Exposure and Food-Restriction on Gene Expression in the Striatum of Adolescent Rats	PLOS ONE			English	Article							LOW-BIRTH-WEIGHT; DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; MESSENGER-RNA EXPRESSION; IMMEDIATE-EARLY GENES; PRENATAL NICOTINE; MATERNAL SMOKING; DIFFERENTIAL REGULATION; BRAIN-REGIONS; C-FOS	Gestational exposure to environmental toxins such as nicotine may result in detectable gene expression changes in later life. To investigate the direct toxic effects of prenatal nicotine exposure on later brain development, we have used transcriptomic analysis of striatal samples to identify gene expression differences between adolescent Lister Hooded rats exposed to nicotine in utero and controls. Using an additional group of animals matched for the reduced food intake experienced in the nicotine group, we were also able to assess the impact of imposed food-restriction on gene expression profiles. We found little evidence for a role of gestational nicotine exposure on altered gene expression in the striatum of adolescent offspring at a significance level of p<0.01 and | log2 fold change >0.5|, although we cannot exclude the possibility of nicotine-induced changes in other brain regions, or at other time points. We did, however, find marked gene expression differences in response to imposed food-restriction. Food-restriction resulted in significant group differences for a number of immediate early genes (IEGs) including Fos, Fosb, Fosl2, Arc, Junb, Nr4a1 and Nr4a3. These genes are associated with stress response pathways and therefore may reflect long-term effects of nutritional deprivation on the development of the stress system.	[Ilott, Nicholas E.; Mill, Jonathan; Schalkwyk, Leonard; Dempster, Emma; Asherson, Philip] Kings Coll London, Inst Psychiat, MRC, Social Genet & Dev Psychiat SGDP Ctr, London WC2R 2LS, England; [Ilott, Nicholas E.] Univ Oxford, MRC, Funct Genom Unit, Dept Physiol Anat & Genet, Oxford, England; [Schneider, Tomasz; Stolerman, Ian P.] Kings Coll London, Inst Psychiat, Dept addict, London WC2R 2LS, England; [Schneider, Tomasz] Univ Oxford, Oxford, England; [Mill, Jonathan; Dempster, Emma] Univ Exeter, Sch Med, Exeter, Devon, England; [Brolese, Giovana; Bizarro, Lisiane] Univ Fed Rio Grande do Sul, Inst Psicol, Dept Psicol Desenvolvimento & Personalidade, Porto Alegre, RS, Brazil	University of London; King's College London; University of Oxford; University of London; King's College London; University of Oxford; University of Exeter; Universidade Federal do Rio Grande do Sul	Ilott, NE (corresponding author), Kings Coll London, Inst Psychiat, MRC, Social Genet & Dev Psychiat SGDP Ctr, London WC2R 2LS, England.	Nicholas.ilott@dpag.ox.ac.uk	BIZARRO, LISIANE/AAS-6424-2021; Mill, Jonathan/B-5678-2014; Schalkwyk, Leonard C/A-2150-2010; BIZARRO, LISIANE/F-7872-2012; Dempster, Emma L/C-8592-2014	BIZARRO, LISIANE/0000-0003-3070-5944; Mill, Jonathan/0000-0003-1115-3224; Schalkwyk, Leonard C/0000-0001-7030-5756; BIZARRO, LISIANE/0000-0003-3070-5944; Dempster, Emma L/0000-0003-1257-5314; Asherson, Philip/0000-0003-2667-2254; Ilott, Nicholas/0000-0002-8432-8622; Stolerman, Ian/0000-0002-2703-5137	Wellcome Trust; Medical Research Council [G9817803B] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Wellcome Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abreu-Villaca Y, 2011, BEHAV BRAIN RES, V221, P367, DOI 10.1016/j.bbr.2009.12.049; Allen JK, 2010, NEUROSCIENCE, V169, P1901, DOI 10.1016/j.neuroscience.2010.06.029; Altmann S, 2012, BRIT J NUTR, V107, P791, DOI 10.1017/S0007114511003667; Badlissi D, 2001, CAN J PUBLIC HEALTH, V92, P272, DOI 10.1007/BF03404959; Banerjee PS, 2009, EUR J NEUROSCI, V29, P465, DOI 10.1111/j.1460-9568.2008.06601.x; Beauvais G, 2010, BRAIN RES, V1318, P1, DOI 10.1016/j.brainres.2009.12.083; Blake KV, 2000, EARLY HUM DEV, V57, P137, DOI 10.1016/S0378-3782(99)00064-X; Cao JR, 2011, INT J NEUROPSYCHOPH, V14, P157, DOI 10.1017/S1461145710000179; Carmona S, 2009, BIOL PSYCHIAT, V66, P972, DOI 10.1016/j.biopsych.2009.05.013; Chen H, 2005, EUR J NEUROSCI, V22, P380, DOI 10.1111/j.1460-9568.2005.04229.x; Cubillo A, 2011, PSYCHIAT RES-NEUROIM, V193, P17, DOI 10.1016/j.pscychresns.2010.12.014; Cubillo A, 2010, J PSYCHIATR RES, V44, P629, DOI 10.1016/j.jpsychires.2009.11.016; Daberkow DP, 2008, NEUROTOX RES, V14, P307, DOI 10.1007/BF03033855; Das Banerjee T, 2007, ACTA PAEDIATR, V96, P1269, DOI 10.1111/j.1651-2227.2007.00430.x; Fernandes C, 2004, EUR J NEUROSCI, V19, P2576, DOI 10.1111/j.0953-816X.2004.03358.x; GRUNBERG NE, 1987, PSYCHOPHARMACOLOGY, V91, P221; Guzowski JF, 2000, J NEUROSCI, V20, P3993; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; KAMME F, 1995, EUR J NEUROSCI, V7, P2007, DOI 10.1111/j.1460-9568.1995.tb00623.x; Kane VB, 2004, J PHARMACOL EXP THER, V308, P521, DOI 10.1124/jpet.103.059899; Karimi M, 2006, EPIGENETICS-US, V1, P45; Kirbach BB, 2011, J NEUROSCI RES, V89, P162, DOI 10.1002/jnr.22536; Laborie C, 2011, J NEUROENDOCRINOL, V23, P711, DOI 10.1111/j.1365-2826.2011.02159.x; LAM SK, 1992, AUST NZ J OBSTET GYN, V32, P125, DOI 10.1111/j.1479-828X.1992.tb01923.x; Langley K, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-26; Linnet KM, 2003, AM J PSYCHIAT, V160, P1028, DOI 10.1176/appi.ajp.160.6.1028; Lv JX, 2008, NEUROTOXICOLOGY, V29, P722, DOI 10.1016/j.neuro.2008.04.015; Manuel-Apolinar L, 2010, ARCH MED RES, V41, P240, DOI 10.1016/j.arcmed.2010.06.002; Mao CP, 2008, BRAIN RES, V1189, P43, DOI 10.1016/j.brainres.2007.10.089; Mineur YS, 2011, SCIENCE, V332, P1330, DOI 10.1126/science.1201889; Morrow BA, 1999, J NEUROSCI, V19, P5666; MURRIN LC, 1987, LIFE SCI, V40, P1699, DOI 10.1016/0024-3205(87)90020-8; Ons S, 2010, EUR J NEUROSCI, V31, P2043, DOI 10.1111/j.1460-9568.2010.07242.x; Palou M, 2012, BR J NUTR, V28, P1; Paloyelis Yannis, 2007, Expert Rev Neurother, V7, P1337, DOI 10.1586/14737175.7.10.1337; Park MK, 2006, BRAIN RES, V1094, P119, DOI 10.1016/j.brainres.2006.04.001; Parker CC, 2012, BEHAV GENET, V42, P437, DOI 10.1007/s10519-011-9524-8; Pauly JR, 2004, INT J DEV NEUROSCI, V22, P329, DOI 10.1016/j.ijdevneu.2004.05.009; Pavlovsky AA, 2013, NEUROSCIENCE, V246, P160, DOI 10.1016/j.neuroscience.2013.04.057; Perlov E, 2009, WORLD J BIOL PSYCHIA, V10, P355, DOI 10.1080/15622970802176032; PETERS MA, 1982, ARCH INT PHARMACOD T, V257, P155; Pinaud R, 2001, MOL BRAIN RES, V91, P50, DOI 10.1016/S0169-328X(01)00121-8; Salas R, 2008, NEUROSCI LETT, V440, P32, DOI 10.1016/j.neulet.2008.05.038; Salvador JM, 2013, ADV EXP MED BIOL, V793, P1, DOI 10.1007/978-1-4614-8289-5_1; Sanghavi D M, 1995, J Ky Med Assoc, V93, P286; Sarkisian MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044207; Schneider T, 2012, PSYCHOPHARMACOLOGY B; Schneider T, 2011, NEUROPSYCHOPHARMACOL, V36, P1114, DOI 10.1038/npp.2010.249; Schneider T, 2010, BEHAV PHARMACOL, V21, P206, DOI 10.1097/FBP.0b013e32833a5bb5; Sebert SP, 2010, REPRODUCTION, V139, P265, DOI 10.1530/REP-09-0173; Shi LM, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-S9-S10; Smith MA, 1997, ENDOCRINOLOGY, V138, P4622, DOI 10.1210/en.138.11.4622; Sora I, 2009, INT REV NEUROBIOL, V85, P29, DOI 10.1016/S0074-7742(09)85003-4; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Thapar A, 2003, AM J PSYCHIAT, V160, P1985, DOI 10.1176/appi.ajp.160.11.1985; Thiriet N, 2001, BRAIN RES, V919, P31, DOI 10.1016/S0006-8993(01)02991-2; Tirosh I, 2011, P NATL ACAD SCI USA, V108, P16693, DOI 10.1073/pnas.1113718108; Tizabi Y, 1997, PHARMACOL BIOCHEM BE, V58, P141, DOI 10.1016/S0091-3057(96)00461-3; UMEMOTO S, 1994, NEUROREPORT, V6, P201, DOI 10.1097/00001756-199412300-00051; Vaglenova J, 2004, BEHAV BRAIN RES, V150, P159, DOI 10.1016/j.bbr.2003.07.005; Ventura SJ, 2003, PEDIATRICS, V111, P1176; Wang JQ, 1996, BRAIN RES BULL, V39, P349, DOI 10.1016/0361-9230(96)00002-0; Wei JX, 2011, INT J NEUROPSYCHOPH, V14, P91, DOI 10.1017/S1461145710000416; Winzer-Serhan UH, 2008, FRONT BIOSCI-LANDMRK, V13, P636, DOI 10.2741/2708; Zeng XS, 2013, FREE RADIC BIOL MED	67	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2014	9	2							e88896	10.1371/journal.pone.0088896	http://dx.doi.org/10.1371/journal.pone.0088896			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AB3TA	24586432	Green Submitted, Green Published, Green Accepted, gold			2023-01-03	WOS:000331711900059
J	Helvik, AS; Skancke, RH; Selbaek, G; Engedal, K				Helvik, Anne-Sofie; Skancke, Randi Helene; Selbaek, Geir; Engedal, Knut			Nursing Home Admission during the First Year after Hospitalization - The Contribution of Cognitive Impairment	PLOS ONE			English	Article							MINI-MENTAL-STATE; OLDER-PEOPLE; PREDICTORS; DEMENTIA; CARE; PREVALENCE; CRITERIA; POPULATION; PLACEMENT; SYMPTOMS	Objective: The importance of cognitive and physical functioning for nursing home admission among medically hospitalized older patients is rarely studied in a one-year follow-up perspective. This study aims to explore the association between patient characteristics and nursing home admission within one year after hospitalization in persons 65 years or more. Design: A one-year longitudinal study. Methods: We included 463 (234 women) persons aged 65 years or more from internal medical wards in a rural area of Norway. Cognitive function was assessed using the Mini Mental State Examination; physical and instrumental functional status was assessed using the physical self-maintenance scale and instrumental activities of daily living scale of Lawton and Brody. Comorbidity was measured with the Charlson index. Admission to nursing home within one year (yes versus no) was analyzed using logistic regression analysis and Cox proportional hazard regression analysis. Results: The mean age of the sample was 80.5 (SD 7.4) years, mean Mini Mental State Examination score was 24.1 (SD 3.8) (maximum score is 30). In adjusted analysis participants with cognitive impairment (a Mini Mental State Examination score,25) or impaired physical functioning at baseline had higher risk of admission to nursing home within one year (OR 3.0, 95% CI 1.5-6.2 and OR 3.5, 95% CI 1.8-9.6, respectively). The time before admission was also associated with cognitive impairment and impaired physical functioning in the adjusted analysis (HR 2.6 95% CI 1.4-4.8 and HR 3.7, 95% CI 1.5-8.9, respectively). Conclusion: Impaired cognitive and physical functioning increased the risk for nursing home admission within one year after hospitalization. However, putative regressors, such as education and social network were not included in the analysis.	[Helvik, Anne-Sofie; Skancke, Randi Helene] Norwegian Univ Sci & Technol NTNU, Fac Med, Dept Publ Hlth & Gen Practice, Trondheim, Norway; [Helvik, Anne-Sofie] St Olavs Univ Hosp, Trondheim, Norway; [Helvik, Anne-Sofie; Skancke, Randi Helene] Innlandet Hosp Trust, Div Tynset, Tynset, Norway; [Selbaek, Geir] Innlandet Hosp Trust, Ctr Old Age Psychiat Res, Ottestad, Norway; [Selbaek, Geir] Akershus Univ Hosp, Lorenskog, Norway; [Selbaek, Geir; Engedal, Knut] Oslo Univ Hosp, Norwegian Ctr Dementia Res, Ullevaal, Norway; [Engedal, Knut] Univ Oslo, Fac Med, Oslo, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Innlandet Hospital Trust; Innlandet Hospital Trust; University of Oslo; University of Oslo; University of Oslo	Helvik, AS (corresponding author), Norwegian Univ Sci & Technol NTNU, Fac Med, Dept Publ Hlth & Gen Practice, Trondheim, Norway.	Anne-Sofie.Helvik@ntnu.no		Selbaek, Geir/0000-0001-6511-8219	Norwegian Ministry of Health and Care Services; Innlandet Hospital Trust	Norwegian Ministry of Health and Care Services; Innlandet Hospital Trust	The research was funded by collaboration between the Norwegian Ministry of Health and Care Services, and Innlandet Hospital Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achterberg W, 1999, Tijdschr Gerontol Geriatr, V30, P264; Alladi S, 2006, PSYCHOL MED, V36, P507, DOI 10.1017/S0033291705006744; Bilotta C, 2009, HEALTH SOC CARE COMM, V17, P543, DOI 10.1111/j.1365-2524.2009.00853.x; Brevik I, 2010, NEW HOME CARE SERVIC; Campbell SE, 2004, AGE AGEING, V33, P110, DOI 10.1093/ageing/afh036; De Saint-Hubert M, 2010, J NUTR HEALTH AGING, V14, P394, DOI 10.1007/s12603-010-0086-x; Drame M, 2011, J NUTR HEALTH AGING, V15, P399, DOI 10.1007/s12603-011-0004-x; Eaker ED, 2002, J CLIN EPIDEMIOL, V55, P462, DOI 10.1016/S0895-4356(01)00498-X; Ehlenbach WJ, 2010, JAMA-J AM MED ASSOC, V303, P763, DOI 10.1001/jama.2010.167; Engedal K, 1988, Compr Gerontol A, V2, P87; Fjaertoft H, 2005, CEREBROVASC DIS, V19, P376, DOI 10.1159/000085543; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fullerton CA, 2009, PSYCHIAT SERV, V60, P965, DOI 10.1176/appi.ps.60.7.965; Gaugler Joseph E, 2007, BMC Geriatr, V7, P13, DOI 10.1186/1471-2318-7-13; Harris Y, 2006, J AM GERIATR SOC, V54, P593, DOI 10.1111/j.1532-5415.2006.00687.x; Helvik AS, 2011, NORD J PSYCHIAT, V65, P338, DOI 10.3109/08039488.2011.560684; Helvik AS, 2010, AGING MENT HEALTH, V14, P861, DOI 10.1080/13607861003801003; Helvik AS, 2010, INT J GERIATR PSYCH, V25, P150, DOI 10.1002/gps.2312; Heun R, 1998, INT J GERIATR PSYCH, V13, P368, DOI 10.1002/(SICI)1099-1166(199806)13:6<368::AID-GPS775>3.3.CO;2-0; Hirdes JP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-9; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; HUNT, 2009, HLTH STUD NORD TROND; Inouye SK, 2006, J GEN INTERN MED, V21, P1276, DOI 10.1111/j.1525-1497.2006.00613.x; Kirkevold O, 2004, SCAND J CARING SCI, V18, P281, DOI 10.1111/j.1471-6712.2004.00278.x; Kivela S L, 1985, Scand J Prim Health Care, V3, P39, DOI 10.3109/02813438509017736; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; Luppa M, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-186; McCusker J, 2002, J GERONTOL A-BIOL, V57, pM569, DOI 10.1093/gerona/57.9.M569; McDowell I, 1997, J CLIN EPIDEMIOL, V50, P377, DOI 10.1016/S0895-4356(97)00060-7; Mora Fernandez Jesus, 2009, Rev Esp Geriatr Gerontol, V44, P186, DOI 10.1016/j.regg.2009.03.008; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Nygaard H A, 2000, Tidsskr Nor Laegeforen, V120, P3113; NYGAARD H A, 1992, Scandinavian Journal of Primary Health Care, V10, P128, DOI 10.3109/02813439209014049; Portegijs E, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2012.04.003; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Romoren T, 1999, PATIENTS RESIDENTS N; RUBENSTEIN LZ, 1986, HEALTH SERV RES, V20, P881; RUBENSTEIN LZ, 1984, J AM GERIATR SOC, V32, P503, DOI 10.1111/j.1532-5415.1984.tb02235.x; Satish S, 1996, J AM GERIATR SOC, V44, P914, DOI 10.1111/j.1532-5415.1996.tb01860.x; Schneeweiss S, 2003, HEALTH SERV RES, V38, P1103, DOI 10.1111/1475-6773.00165; Selbaek G, 2007, INT J GERIATR PSYCH, V22, P843, DOI 10.1002/gps.1749; Smith GE, 2001, NEUROLOGY, V57, P1467, DOI 10.1212/WNL.57.8.1467; Snaith RP., 1994, HOSP ANXIETY DEPRESS; Sorbye LW, 2010, J MULTIDISCIP HEALTH, V3, P11; Thygesen E, 2009, INT J OLDER PEOPLE N, V4, P12, DOI 10.1111/j.1748-3743.2008.00132.x; Tropea J, 2008, AUSTRALAS J AGEING, V27, P150, DOI 10.1111/j.1741-6612.2008.00301.x; Tsai ACH, 2011, ARCH GERONTOL GERIAT, V53, P298, DOI 10.1016/j.archger.2010.12.003; Tuokko H, 2000, CLIN NEUROPSYCHOL, V14, P504, DOI 10.1076/clin.14.4.504.7200; Vogels RLC, 2007, EUR J HEART FAIL, V9, P440, DOI 10.1016/j.ejheart.2006.11.001; Wilson RS, 2012, NEUROLOGY, V78, P950, DOI 10.1212/WNL.0b013e31824d5894; WINOGRAD CH, 1991, J AM GERIATR SOC, V39, P778, DOI 10.1111/j.1532-5415.1991.tb02700.x; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	52	11	11	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2014	9	1							e86116	10.1371/journal.pone.0086116	http://dx.doi.org/10.1371/journal.pone.0086116			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	302RF	24497936	Green Published, Green Submitted, gold			2023-01-03	WOS:000330621900016
J	Walther, J; Schastak, S; Dukic-Stefanovic, S; Wiedemann, P; Neuhaus, J; Claudepierre, T				Walther, Jan; Schastak, Stanislas; Dukic-Stefanovic, Sladjana; Wiedemann, Peter; Neuhaus, Jochen; Claudepierre, Thomas			Efficient Photodynamic Therapy on Human Retinoblastoma Cell Lines	PLOS ONE			English	Article							ANTITUMOR IMMUNITY; HEREDITARY RETINOBLASTOMA; TARGETING MITOCHONDRIA; MEMBRANE-POTENTIALS; TRANSGENIC MICE; MOUSE MODEL; IN-VITRO; CANCER; APOPTOSIS; EXPRESSION	Photodynamic therapy (PDT) has shown to be a promising technique to treat various forms of malignant neoplasia. The photodynamic eradication of the tumor cells is achieved by applying a photosensitizer either locally or systemically and following local activation through irradiation of the tumor mass with light of a specific wavelength after a certain time of incubation. Due to preferential accumulation of the photosensitizer in tumor cells, this procedure allows a selective inactivation of the malignant tumor while sparing the surrounding tissue to the greatest extent. These features and requirements make the PDT an attractive therapeutic option for the treatment of retinoblastoma, especially when surgical enucleation is a curative option. This extreme solution is still in use in case of tumours that are resistant to conventional chemotherapy or handled too late due to poor access to medical care in less advanced country. In this study we initially conducted in-vitro investigations of the new cationic water-soluble photo sensitizer tetrahydroporphyrin-tetratosylat (THPTS) regarding its photodynamic effect on human Rb-1 and Y79 retinoblastoma cells. We were able to show, that neither the incubation with THPTS without following illumination, nor the sole illumination showed a considerable effect on the proliferation of the retinoblastoma cells, whereas the incubation with THPTS combined with following illumination led to a maximal cytotoxic effect on the tumor cells. Moreover the phototoxicity was lower in normal primary cells from retinal pigmented epithelium demonstrating a higher phototoxic effect of THPTS in cancer cells than in this normal retinal cell type. The results at hand form an encouraging foundation for further in-vivo studies on the therapeutic potential of this promising photosensitizer for the eyeball and vision preserving as well as potentially curative therapy of retinoblastoma.	[Walther, Jan; Schastak, Stanislas; Dukic-Stefanovic, Sladjana; Wiedemann, Peter; Claudepierre, Thomas] Univ Leipzig, Fac Med, Dept Ophthalmol, D-04109 Leipzig, Germany; [Neuhaus, Jochen] Univ Leipzig, Dept Urol, D-04109 Leipzig, Germany	Leipzig University; Leipzig University	Claudepierre, T (corresponding author), Univ Leipzig, Fac Med, Dept Ophthalmol, D-04109 Leipzig, Germany.	thomas.claudepierre@medizin.uni-leipzig.de		Claudepierre, Thomas/0000-0001-6968-8518	Ophthalmology Department at the Faculty of Medicine of the University of Leipzig; Stifterverbrand fur die Deutsche Wissenchaft; German Research Foundation (DFG); Leipzig University	Ophthalmology Department at the Faculty of Medicine of the University of Leipzig; Stifterverbrand fur die Deutsche Wissenchaft; German Research Foundation (DFG)(German Research Foundation (DFG)); Leipzig University	This work was funded by the Ophthalmology Department at the Faculty of Medicine of the University of Leipzig. TC is supported by a grant from the "Stifterverbrand fur die Deutsche Wissenchaft". In addition, authors acknowledge support from the German Research Foundation (DFG) and Leipzig University within the program of Open Access Publishing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aerts I, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-31; Aerts I, 2010, PHOTODIAGN PHOTODYN, V7, P275, DOI 10.1016/j.pdpdt.2010.09.003; Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114; Backlund LM, 2003, CLIN CANCER RES, V9, P4151; Basile KJ, 2012, ADV PHARMACOL, V65, P315, DOI 10.1016/B978-0-12-397927-8.00010-5; Belicha-Villanueva A, 2012, LASER SURG MED, V44, P60, DOI 10.1002/lsm.21160; BINGGELI R, 1986, J THEOR BIOL, V123, P377, DOI 10.1016/S0022-5193(86)80209-0; Botul JB, 2002, ZYCIC SCKSUALNC IMMA; CANTI G, 1994, ANTI-CANCER DRUG, V5, P443, DOI 10.1097/00001813-199408000-00009; Canturk S, 2010, BRIT J OPHTHALMOL, V94, P1432, DOI 10.1136/bjo.2009.168062; Castano AP, 2008, P NATL ACAD SCI USA, V105, P5495, DOI 10.1073/pnas.0709256105; Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894; Chakravarti A, 2003, J CLIN ONCOL, V21, P3328, DOI 10.1200/JCO.2003.12.151; Chan Helen S L, 2005, Ophthalmol Clin North Am, V18, P55, DOI 10.1016/j.ohc.2004.11.002; Chintagumpala M, 2007, ONCOLOGIST, V12, P1237, DOI 10.1634/theoncologist.12-10-1237; DAVIS S, 1985, J BIOL CHEM, V260, P3844; De Potter Patrick, 2002, Curr Opin Ophthalmol, V13, P331; Dukic-Stefanovic S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052567; Dyer MA, 2005, NAT REV CANCER, V5, P91, DOI 10.1038/nrc1545; Engelmann FM, 2007, J BIOENERG BIOMEMBR, V39, P175, DOI 10.1007/s10863-007-9075-0; Firczuk M, 2011, FRONT BIOSCI-LANDMRK, V16, P208, DOI 10.2741/3684; Gerner C, 2000, J BIOL CHEM, V275, P39018, DOI 10.1074/jbc.M006495200; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Gogvadze V, 2011, CURR PHARM DESIGN, V17, P4034, DOI 10.2174/138161211798764933; Goldhoff P, 2012, J NEUROPATH EXP NEUR, V71, P83, DOI 10.1097/NEN.0b013e31823fe8f1; Gollnick SO, 2010, IMMUNOL RES, V46, P216, DOI 10.1007/s12026-009-8119-4; Goodrich DW, 2006, ONCOGENE, V25, P5233, DOI 10.1038/sj.onc.1209616; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; Hendrzak-Henion JA, 1999, PHOTOCHEM PHOTOBIOL, V69, P575, DOI 10.1562/0031-8655(1999)069<0575:ROTISI>2.3.CO;2; Henry CM, 2013, MEASURING APOPTOSIS; Ho HK, 2006, BIOCHEM PHARMACOL, V72, P80, DOI 10.1016/j.bcp.2006.03.019; Hockenbery DM, 2010, ENVIRON MOL MUTAGEN, V51, P476, DOI 10.1002/em.20552; Hollborn M, 2010, INVEST OPHTH VIS SCI, V51, P2721, DOI 10.1167/iovs.09-4661; Kaneko T, 2004, ORAL ONCOL, V40, P787, DOI 10.1016/j.oraloncology.2004.01.007; Klein G, 2003, EUR J CANCER, V39, P808, DOI 10.1016/S0959-8049(02)00875-4; Korbelik M, 2007, BRIT J CANCER, V97, P1381, DOI 10.1038/sj.bjc.6604059; Kousis PC, 2007, CANCER RES, V67, P10501, DOI 10.1158/0008-5472.CAN-07-1778; Kwon O, 2012, CELL SIGNAL, V24, P943, DOI 10.1016/j.cellsig.2011.12.017; Laurie NA, 2005, CLIN CANCER RES, V11, P7569, DOI 10.1158/1078-0432.CCR-05-0849; Lenaz G, 2012, ADV EXP MED BIOL, V942, P93, DOI 10.1007/978-94-007-2869-1_5; Maillard P., 2010, Annales Pharmaceutiques Francaises, V68, P195, DOI 10.1016/j.pharma.2010.03.001; Melamud A, 2006, AM FAM PHYSICIAN, V73, P1039; Mills MD, 1999, SURV OPHTHALMOL, V43, P508, DOI 10.1016/S0039-6257(99)00047-8; Mroz P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015194; Mroz P, 2011, EXPERT REV CLIN IMMU, V7, P75, DOI [10.1586/eci.10.81, 10.1586/ECI.10.81]; Munoz-Pinedo C, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.123; N'cho M, 2001, HUM IMMUNOL, V62, P310, DOI 10.1016/S0198-8859(01)00214-2; Nemeth KM, 2011, CANCER-AM CANCER SOC, V117, P421, DOI 10.1002/cncr.25574; Nishimura S, 2001, J CLIN ONCOL, V19, P4182, DOI 10.1200/JCO.2001.19.21.4182; NORK TM, 1995, ARCH OPHTHALMOL-CHIC, V113, P791, DOI 10.1001/archopht.1995.01100060117046; O'Connor AE, 2009, PHOTOCHEM PHOTOBIOL, V85, P1053, DOI 10.1111/j.1751-1097.2009.00585.x; Peng D, 1996, CANCER RES, V56, P3666; Poulaki V, 2007, INVEST OPHTH VIS SCI, V48, P4706, DOI 10.1167/iovs.06-1147; Rivellese M J, 2000, J Ophthalmic Nurs Technol, V19, P134; Schastak S, 2008, METHOD FIND EXP CLIN, V30, P17, DOI 10.1358/mf.2008.30.1.1134340; Schastak S, 2005, J PHOTOCH PHOTOBIO B, V78, P203, DOI 10.1016/j.jphotobiol.2004.11.006; Schastak S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011674; Shelton LM, 2010, J NEURO-ONCOL, V99, P165, DOI 10.1007/s11060-010-0115-y; St Denis TG, 2011, PHOTOCH PHOTOBIO SCI, V10, P792, DOI 10.1039/c0pp00326c; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; van Duijnhoven FH, 2005, CLIN EXP METASTAS, V22, P247, DOI 10.1007/s10585-005-8479-7; VIRTANEN I, 1988, LAB INVEST, V59, P649; von Tappeiner H., 1900, MUENCH MED WCHSCHR, V47, P5; Westermark B, 2012, UPSALA J MED SCI, V117, P251, DOI 10.3109/03009734.2012.676574; WINDLE JJ, 1990, NATURE, V343, P665, DOI 10.1038/343665a0	66	21	21	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2014	9	1							e87453	10.1371/journal.pone.0087453	http://dx.doi.org/10.1371/journal.pone.0087453			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302RF	24498108	Green Published, gold, Green Submitted			2023-01-03	WOS:000330621900114
J	Kunkel, J; Asuri, P				Kunkel, Jeffrey; Asuri, Prashanth			Function, Structure, and Stability of Enzymes Confined in Agarose Gels	PLOS ONE			English	Article							MOLECULAR CONFINEMENT; PROTEIN AGGREGATION; CROWDED ENVIRONMENTS; SERUM-ALBUMIN; ELECTROPHORESIS; INTERMEDIATE; TEMPERATURE; GALLERIES; SPHERES; SHAPE	Research over the past few decades has attempted to answer how proteins behave in molecularly confined or crowded environments when compared to dilute buffer solutions. This information is vital to understanding in vivo protein behavior, as the average spacing between macromolecules in the cell cytosol is much smaller than the size of the macromolecules themselves. In our study, we attempt to address this question using three structurally and functionally different model enzymes encapsulated in agarose gels of different porosities. Our studies reveal that under standard buffer conditions, the initial reaction rates of the agarose-encapsulated enzymes are lower than that of the solution phase enzymes. However, the encapsulated enzymes retain a higher percentage of their activity in the presence of denaturants. Moreover, the concentration of agarose used for encapsulation had a significant effect on the enzyme functional stability; enzymes encapsulated in higher percentages of agarose were more stable than the enzymes encapsulated in lower percentages of agarose. Similar results were observed through structural measurements of enzyme denaturation using an 8-anilinonaphthalene-1-sulfonic acid fluorescence assay. Our work demonstrates the utility of hydrogels to study protein behavior in highly confined environments similar to those present in vivo; furthermore, the enhanced stability of gel-encapsulated enzymes may find use in the delivery of therapeutic proteins, as well as the design of novel strategies for biohybrid medical devices.	[Kunkel, Jeffrey; Asuri, Prashanth] Santa Clara Univ, Dept Bioengn, Santa Clara, CA 95053 USA	Santa Clara University	Asuri, P (corresponding author), Santa Clara Univ, Dept Bioengn, Santa Clara, CA 95053 USA.	asurip@scu.edu			School of Engineering, Santa Clara University	School of Engineering, Santa Clara University	This project funded by the School of Engineering, Santa Clara University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bismuto E, 2002, BIOPOLYMERS, V67, P85, DOI 10.1002/bip.10058; Bolis D, 2004, J MOL BIOL, V336, P203, DOI 10.1016/j.jmb.2003.11.056; Calamai M, 2005, BIOPHYS J, V89, P4201, DOI 10.1529/biophysj.105.068726; Du F, 2006, J MOL BIOL, V364, P469, DOI 10.1016/j.jmb.2006.09.018; Eggers DK, 2001, PROTEIN SCI, V10, P250, DOI 10.1110/ps.36201; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Finn TE, 2012, J BIOL CHEM, V287, P21530, DOI 10.1074/jbc.M112.372961; Gabellieri E, 2003, BIOPHYS J, V85, P3214, DOI 10.1016/S0006-3495(03)74739-0; GRIESS GA, 1993, BIOPHYS J, V65, P138, DOI 10.1016/S0006-3495(93)81072-5; GRIESS GA, 1989, BIOPOLYMERS, V28, P1475, DOI 10.1002/bip.360280811; GUHA S, 1995, BIOCHEMISTRY-US, V34, P6925, DOI 10.1021/bi00021a003; Homouz D, 2008, P NATL ACAD SCI USA, V105, P11754, DOI 10.1073/pnas.0803672105; Jones F, 2002, APPL BIOCHEM BIOTECH, V98, P627, DOI 10.1385/ABAB:98-100:1-9:627; Juarez J, 2009, BIOPHYS J, V96, P2353, DOI 10.1016/j.bpj.2008.12.3901; Kayser V, 2011, MABS-AUSTIN, V3, P408, DOI 10.4161/mabs.3.4.15677; Kim J, 2006, BIOTECHNOL ADV, V24, P296, DOI 10.1016/j.biotechadv.2005.11.006; Kumar CV, 2002, CHEM COMMUN, P2382, DOI 10.1039/b206988a; Kumar CV, 2000, J AM CHEM SOC, V122, P830, DOI 10.1021/ja993310u; Liang JF, 2000, J PHARM SCI, V89, P979, DOI 10.1002/1520-6017(200008)89:8<979::AID-JPS2>3.0.CO;2-H; Liu HH, 2004, BIOSENS BIOELECTRON, V20, P294, DOI 10.1016/j.bios.2004.01.015; Mahajan R, 2010, INDIAN J PHARM SCI, V72, P223, DOI 10.4103/0250-474X.65010; Morelli MJ, 2011, BIOPHYS J, V101, P2882, DOI 10.1016/j.bpj.2011.10.053; Munishkina LA, 2008, BIOCHEMISTRY-US, V47, P8993, DOI 10.1021/bi8008399; Nwamba C. O., 2012, ENZYME RES, V2012; Pastor I, 2011, J PHYS CHEM B, V115, P1115, DOI 10.1021/jp105296c; RAO SVR, 1993, BIOCHEM MOL BIOL INT, V29, P63; Rivas G, 2001, P NATL ACAD SCI USA, V98, P3150, DOI 10.1073/pnas.051634398; Samiotakis A, 2009, INT J MOL SCI, V10, P572, DOI 10.3390/ijms10020572; Sasahara K, 2003, J MOL BIOL, V326, P1227, DOI 10.1016/S0022-2836(02)01443-2; SCOPES RK, 1995, CLIN CHIM ACTA, V237, P17, DOI 10.1016/0009-8981(95)06060-Q; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Singh SM, 2010, PROTEINS, V78, P2625, DOI 10.1002/prot.22778; Yadav SC, 2011, PEPTIDES, V32, P173, DOI 10.1016/j.peptides.2010.10.003; Yuan JM, 2008, PROTEIN SCI, V17, P2156, DOI 10.1110/ps.037325.108; Zhou HX, 2008, ANNU REV BIOPHYS, V37, P375, DOI 10.1146/annurev.biophys.37.032807.125817; Zhou HX, 2013, FEBS LETT, V587, P394, DOI 10.1016/j.febslet.2013.01.030; Zhou HX, 2008, ARCH BIOCHEM BIOPHYS, V469, P76, DOI 10.1016/j.abb.2007.07.013	37	21	21	1	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2014	9	1							e86785	10.1371/journal.pone.0086785	http://dx.doi.org/10.1371/journal.pone.0086785			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297GT	24466239	Green Published, gold, Green Submitted			2023-01-03	WOS:000330244500286
J	Lopez-De-Andres, A; Jimenez-Garcia, R; Hernandez-Barrera, V; Jimenez-Trujillo, I; Gallardo-Pino, C; de Miguel, AG; Carrasco-Garrido, P				Lopez-de-Andres, Ana; Jimenez-Garcia, Rodrigo; Hernandez-Barrera, Valentin; Jimenez-Trujillo, Isabel; Gallardo-Pino, Carmen; Gil de Miguel, Angel; Carrasco-Garrido, Pilar			National Trends over One Decade in Hospitalization for Acute Myocardial Infarction among Spanish Adults with Type 2 Diabetes: Cumulative Incidence, Outcomes and Use of Percutaneous Coronary Intervention	PLOS ONE			English	Article							SEX DISPARITIES; RISK-FACTORS; FOLLOW-UP; MORTALITY; MELLITUS; DISEASE; PEOPLE; WOMEN; HEART; SURVIVAL	Background: This study aims to describe trends in the rate of acute myocardial infarction (AMI) and use of percutaneous coronary interventions (PCI) in patients with and without type 2 diabetes in Spain, 2001-2010. Methods: We selected all patients with a discharge of AMI using national hospital discharge data. Discharges were grouped by diabetes status: type 2 diabetes and no diabetes. In both groups PCIs were identified. The cumulative incidence of discharges attributed to AMI were calculated overall and stratified by diabetes status and year. We calculated length of stay and in-hospital mortality (IHM). Use of PCI was calculated stratified by diabetes status. Multivariate analysis was adjusted by age, sex, year and comorbidity. Results: From 2001 to 2010, 513,517 discharges with AMI were identified (30.3% with type 2 diabetes). The cumulative incidence of discharges due to AMI in diabetics patients increased (56.3 in 2001 to 71 cases per 100,000 in 2004), then decreased to 61.9 in 2010. Diabetic patients had significantly higher IHM (OR, 1.14; 95% CI, 1.05-1.17). The proportion of diabetic patients that underwent PCI increased from 11.9% in 2001 to 41.6% in 2010. Adjusted incidence of discharge in patients with diabetes who underwent PCI increased significantly (IRR, 3.49; 95% CI, 3.30-3.69). The IHM among diabetics patients who underwent a PCI did not change significantly over time. Conclusions: AMI hospitalization rates increased initially but declining slowly. From 2001 to 2010 the proportion of diabetic patients who undergo a PCI increased almost four-fold. Older age and more comorbidity may explain why IHM did not improve after a PCI.	[Lopez-de-Andres, Ana; Jimenez-Garcia, Rodrigo; Hernandez-Barrera, Valentin; Jimenez-Trujillo, Isabel; Gallardo-Pino, Carmen; Gil de Miguel, Angel; Carrasco-Garrido, Pilar] Rey Juan Carlos Univ, Prevent Med & Publ Hlth Dept, Madrid, Spain	Universidad Rey Juan Carlos	Lopez-De-Andres, A (corresponding author), Rey Juan Carlos Univ, Prevent Med & Publ Hlth Dept, Madrid, Spain.	ana.lopez@urjc.es	Jimenez-Garcia, Rodrigo/D-4953-2019; Jimenez-Trujillo, Isabel/AAP-7746-2021; Lopez-de-Andres, Ana/D-4498-2019; Lopez-de-Andres, Ana/AAD-8703-2019	Jimenez-Garcia, Rodrigo/0000-0001-5906-9393; Jimenez-Trujillo, Isabel/0000-0002-9394-6799; Lopez-de-Andres, Ana/0000-0001-5551-5181; Lopez-de-Andres, Ana/0000-0001-5551-5181; Hernandez-Barrera, Valentin/0000-0001-5790-1959; GIL DE MIGUEL, ANGEL/0000-0003-1295-7101	FIS (Fondo de Investigaciones Sanitarias-Health Research Fund, Instituto de Salud Carlos III) [PI10/00360]	FIS (Fondo de Investigaciones Sanitarias-Health Research Fund, Instituto de Salud Carlos III)	This study forms part of research funded by the FIS (Fondo de Investigaciones Sanitarias-Health Research Fund, grant no. PI10/00360, Instituto de Salud Carlos III). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aronson D, 2010, REV ENDOCR METAB DIS, V11, P75, DOI 10.1007/s11154-010-9135-3; Blondal M, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-96; Booth GL, 2006, DIABETES CARE, V29, P32, DOI 10.2337/diacare.29.1.32; Bottle A, 2009, DIABETOLOGIA, V52, P74, DOI 10.1007/s00125-008-1170-1; Champney KP, 2007, AM HEART J, V153, P970, DOI 10.1016/j.ahj.2007.03.036; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Degano IR, 2013, REV ESP CARDIOL, V66, P472, DOI [10.1016/j.rec.2013.01.018, 10.1016/j.recesp.2013.01.019]; Ferrara A, 2008, DIABETES CARE, V31, P69, DOI 10.2337/dc07-1244; Flaherty JD, 2005, JAMA-J AM MED ASSOC, V293, P1501, DOI 10.1001/jama.293.12.1501; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Gore MO, 2012, CIRC-CARDIOVASC QUAL, V5, P791, DOI 10.1161/CIRCOUTCOMES.112.965491; Gouni-Berthold I, 2008, DIABETES CARE, V31, P1389, DOI 10.2337/dc08-0194; Hirakawa Y, 2007, DIABETES RES CLIN PR, V75, P59, DOI 10.1016/j.diabres.2006.04.011; Instituto Nacional de Estadistica (INE), 2010, POP EST; Instituto Nacional de Gestion Sanitaria Ministerio de Sanidad y Consumo, 2001, CONJ MIN BAS DAT; Trujillo IJ, 2010, DIABETES METAB, V36, P29, DOI 10.1016/j.diabet.2009.06.007; Jimenez-Garcia R, 2009, J DIABETES COMPLICAT, V23, P394, DOI 10.1016/j.jdiacomp.2008.06.002; Leong A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075256; Lopez-de-Andres A, 2013, DIABETES RES CLIN PR, V99, P300, DOI 10.1016/j.diabres.2012.12.011; Lopez-de-Andres A, 2011, DIABETES CARE, V34, P1570, DOI 10.2337/dc11-0077; Luscher TF, 2003, CIRCULATION, V108, P1655, DOI 10.1161/01.CIR.0000089189.70578.E2; Maier B, 2006, J INVEST MED, V54, P143, DOI 10.2310/6650.2006.05056; Ministry of Health Social Services and Equality, CONJ MIN BAS DAT; Norhammar A, 2008, HEART, V94, P1565, DOI 10.1136/hrt.2007.135038; Ouhoummane N, 2010, CAN J CARDIOL, V26, P523, DOI 10.1016/S0828-282X(10)70465-7; Petersen M, 2008, DIABETES CARE, V31, P1271, DOI 10.2337/dc08-9017; Rana JS, 2010, DIABETES CARE, V33, P1976, DOI 10.2337/dc10-0247; Ribera A, 2008, REV ESP CARDIOL, V61, P843, DOI 10.1016/S1885-5857(08)60232-7; Roche Madonna M, 2013, Diabetes Care, V36, P2582, DOI 10.2337/dc12-1272; Ruiz-Ramos Miguel, 2006, Gac Sanit, V20 Suppl 1, P15, DOI 10.1157/13086022; Ryden L, 2007, EUR HEART J, V28, P88, DOI [10.1093/eurheartj/ehl260, 10.1093/eurheartj/ehm124]; Singh M, 2013, MAYO CLIN PROC, V88, P22, DOI 10.1016/j.mayocp.2012.09.014; Svensson AM, 2007, INT J CARDIOL, V119, P319, DOI 10.1016/j.ijcard.2006.07.156; Thomsen Reimar Wernich, 2012, Clin Epidemiol, V4, P43, DOI 10.2147/CLEP.S30083; Vaccaro O, 2004, ARCH INTERN MED, V164, P1438, DOI 10.1001/archinte.164.13.1438; Vamos EP, 2012, DIABETES CARE, V35, P265, DOI 10.2337/dc11-1682; Whiteley L, 2005, DIABETES CARE, V28, P1588, DOI 10.2337/diacare.28.7.1588	37	11	12	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2014	9	1							e85697	10.1371/journal.pone.0085697	http://dx.doi.org/10.1371/journal.pone.0085697			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297DH	24454920	gold, Green Published, Green Submitted			2023-01-03	WOS:000330235100122
J	Navarro-Gonzalez, I; Perez-Sanchez, H; Martin-Pozuelo, G; Garcia-Alonso, J; Periago, MJ				Navarro-Gonzalez, Inmaculada; Perez-Sanchez, Horacio; Martin-Pozuelo, Gala; Garcia-Alonso, Javier; Jesus Periago, Maria			The Inhibitory Effects of Bioactive Compounds of Tomato Juice Binding to Hepatic HMGCR: In Vivo Study and Molecular Modelling	PLOS ONE			English	Article							COENZYME-A REDUCTASE; CHLOROGENIC ACID; COA REDUCTASE; VITAMIN-C; LYCOPENE; METABOLISM; PRODUCTS; BIOAVAILABILITY; CAROTENOIDS; NARINGENIN	The hypocholesterolemic effect of tomato juice has been investigated in an intervention study with rats, along with the possible inhibition effect of bioactive tomato compounds binding to the HMGCR enzyme. Two experimental groups (n = 8 Sprague-Dawley rats) were fed ad libitum for five weeks, with water or tomato juice provided to the control and intervention groups, respectively. Total, LDL and HDL cholesterol, and total triglycerides were analysed in plasma, and the lycopene content and the expression and activity of the enzyme HMGCR were determined in liver samples. A computational molecular modelling was carried out to determine the interactions between HMGCR and lycopene, chlorogenic acid and naringenin. Total, LDL and HDL cholesterol were significantly lower in the intervention group after the intake of tomato juice. In addition, a significant reduction in HMGCR activity was observed, although this was not accompanied by changes in gene expression. The molecular modelling showed that components of tomato can bind to the active site of the enzyme and compete with the ligand HMGCoA. Lycopene, from tomato juice, accumulates in the liver and can inhibit the activity of the rate-limiting enzyme of cholesterol biosynthesis, HMGCR.	[Navarro-Gonzalez, Inmaculada; Martin-Pozuelo, Gala; Garcia-Alonso, Javier; Jesus Periago, Maria] Univ Murcia, Fac Vet Sci, Dept Food Sci & Nutr, Murcia, Spain; [Perez-Sanchez, Horacio] Catholic Univ Murcia UCAM, Dept Comp Sci, Murcia, Spain	University of Murcia; Universidad Catolica de Murcia	Navarro-Gonzalez, I (corresponding author), Univ Murcia, Fac Vet Sci, Dept Food Sci & Nutr, Campus Espinardo Reg Campus Int Excellence Campus, Murcia, Spain.	inmaculada.navarro@um.es; horacio@ucam.edu	Pérez-Sánchez, Horacio/O-5017-2016; Periago, María Jesús/K-5251-2017	Pérez-Sánchez, Horacio/0000-0003-4468-7898; 	projects MINECO (Spanish)/FEDER-EU [BIO2012-38103]; CONSOLIDER Fun-C-Food CSD; Research Regional Agency Fundacion Seneca (Murcia, Spain) [12031/PI/09]; Murcia University	projects MINECO (Spanish)/FEDER-EU; CONSOLIDER Fun-C-Food CSD; Research Regional Agency Fundacion Seneca (Murcia, Spain); Murcia University	This research was supported by the projects MINECO (Spanish)/FEDER-EU BIO2012-38103 and CONSOLIDER Fun-C-Food CSD2007, and by the Research Regional Agency Fundacion Seneca (Murcia, Spain) project 12031/PI/09. GMP acknowledges a PhD fellowship from Murcia University. The authors also thank Zumos Hesperia Filab and Juver Alimentacion (Cabezo de Torres, Murcia, Spain) for providing the tomato juice samples. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arab L, 2000, AM J CLIN NUTR, V71, p1691S, DOI 10.1093/ajcn/71.6.1691S; BEG ZH, 1973, BIOCHEM BIOPH RES CO, V54, P1362, DOI 10.1016/0006-291X(73)91137-6; BILHEIMER DW, 1989, P NATL ACAD SCI USA, V80, P4142; Bohm V, 2001, J SEP SCI, V24, P955, DOI 10.1002/1615-9314(20011201)24:12&lt;955::AID-JSSC955&gt;3.0.CO;2-; BROWN MS, 1980, J LIPID RES, V21, P505; Chen ZY, 2008, J AGR FOOD CHEM, V56, P8761, DOI 10.1021/jf801566r; DI MASCIO P, 1989, ARCH BIOCHEM BIOPHYS, V274, P532, DOI 10.1016/0003-9861(89)90467-0; Felgines C, 2000, AM J PHYSIOL-GASTR L, V279, pG1148, DOI 10.1152/ajpgi.2000.279.6.G1148; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; Frohlich K, 2007, INT J VITAM NUTR RES, V77, P369, DOI 10.1024/0300-9831.77.6.369; Fuhrman B, 1997, BIOCHEM BIOPH RES CO, V233, P658, DOI 10.1006/bbrc.1997.6520; Garcia-Alonso FJ, 2012, EUR J NUTR, V51, P415, DOI 10.1007/s00394-011-0225-0; Garcia-Valverde V, 2013, FOOD BIOPROCESS TECH, V6, P391, DOI 10.1007/s11947-011-0687-3; Gark VK, 1983, 3 HYDROXY 3 METHYLGL, P29; Gonthier MP, 2003, J NUTR, V133, P1853, DOI 10.1093/jn/133.6.1853; Hazai E, 2006, BIOORGAN MED CHEM, V14, P6859, DOI 10.1016/j.bmc.2006.06.045; Hsu YM, 2008, BIOSCI BIOTECH BIOCH, V72, P677, DOI 10.1271/bbb.70402; Hu MY, 2008, NUTRITION, V24, P1030, DOI 10.1016/j.nut.2008.05.006; Istvan ES, 2000, EMBO J, V19, P819, DOI 10.1093/emboj/19.5.819; Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344; Jacob K, 2008, BRIT J NUTR, V99, P137, DOI 10.1017/S0007114507791894; Periago MJ, 2009, INT J FOOD SCI NUTR, V60, P694, DOI 10.3109/09637480701833457; Karthikesan K, 2010, CHEM-BIOL INTERACT, V188, P643, DOI 10.1016/j.cbi.2010.07.026; Lafay S, 2006, J NUTR, V136, P1192, DOI 10.1093/jn/136.5.1192; Lafay S, 2006, BRIT J NUTR, V96, P39, DOI 10.1079/BJN20061714; Lee SH, 1999, ANN NUTR METAB, V43, P173, DOI 10.1159/000012783; Leopoldini M, 2010, J AGR FOOD CHEM, V58, P10768, DOI 10.1021/jf102576j; Li AC, 2004, J LIPID RES, V45, P2161, DOI 10.1194/jlr.R400010-JLR200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mordente A, 2011, CURR MED CHEM, V18, P1146, DOI 10.2174/092986711795029717; Navarro-Fernandez J, 2012, J MED CHEM, V55, P6403, DOI 10.1021/jm300621j; Omar MH, 2012, J AGR FOOD CHEM, V60, P5205, DOI 10.1021/jf3001185; Palozza P, 2010, CURR MED CHEM, V17, P2547, DOI 10.2174/092986710791556041; Palozza P, 2011, J NUTR BIOCHEM, V22, P971, DOI 10.1016/j.jnutbio.2010.08.010; Rai SK, 2009, LIFE SCI, V85, P211, DOI 10.1016/j.lfs.2009.05.020; Rao AV, 2007, PHARMACOL RES, V55, P207, DOI 10.1016/j.phrs.2007.01.012; RAO AV, 1975, CLIN CHEM, V21, P1523; Rao AV, 1998, FOOD RES INT, V31, P737, DOI 10.1016/S0963-9969(99)00053-8; Richelle M, 2010, BRIT J NUTR, V103, P1800, DOI 10.1017/S0007114510000103; Ried K, 2011, MATURITAS, V68, P299, DOI 10.1016/j.maturitas.2010.11.018; Sanchez-Moreno C, 2006, J NUTR BIOCHEM, V17, P183, DOI 10.1016/j.jnutbio.2005.07.001; Sesso HD, 2012, J NUTR, V142, P326, DOI 10.3945/jn.111.150631; Silaste ML, 2007, BRIT J NUTR, V98, P1251, DOI 10.1017/S0007114507787445; Stroganov OV, 2008, J CHEM INF MODEL, V48, P2371, DOI 10.1021/ci800166p; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; Willcox JK, 2003, CRIT REV FOOD SCI, V43, P1, DOI 10.1080/10408690390826437	46	35	35	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 2	2014	9	1							e83968	10.1371/journal.pone.0083968	http://dx.doi.org/10.1371/journal.pone.0083968			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286ID	24392102	Green Published, gold, Green Submitted			2023-01-03	WOS:000329460100026
J	Lin, RJ				Lin, Richard J.			The Role of Palliative Care in Medical Education	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Lin, Richard J.] Weill Cornell Med Coll, New York, NY 10065 USA	Cornell University	Lin, RJ (corresponding author), Weill Cornell Med Coll, Dept Med, 525 East 68th St,Box 130, New York, NY 10065 USA.	ril9016@med.cornell.edu		Lin, Richard/0000-0002-0834-7880	NCATS NIH HHS [UL1 TR000457] Funding Source: Medline; NIA NIH HHS [P30 AG022845] Funding Source: Medline	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Case AA, 2013, J PALLIAT MED, V16, P230, DOI 10.1089/jpm.2012.0436; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; Cook DA, 2010, MED EDUC, V44, P765, DOI 10.1111/j.1365-2923.2010.03723.x; Quill TE, 2013, NEW ENGL J MED, V368, P1173, DOI 10.1056/NEJMp1215620; Sanchez-Reilly Sandra, 2013, J Support Oncol, V11, P75; Swetz KM, 2012, ANN INTERN MED, V156; Thistlethwaite J, 2012, MED EDUC, V46, P58, DOI 10.1111/j.1365-2923.2011.04143.x; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64	8	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 17	2013	159	12					848	+		10.7326/0003-4819-159-12-201312170-00010	http://dx.doi.org/10.7326/0003-4819-159-12-201312170-00010			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290ED	24490267	Green Accepted			2023-01-03	WOS:000329735300017
J	He, MM; Zhang, DS; Wang, F; Wang, ZQ; Luo, HY; Jin, Y; Wei, XL; Xu, RH				He, Ming-ming; Zhang, Dong-sheng; Wang, Feng; Wang, Zhi-qiang; Luo, Hui-yan; Jin, Ying; Wei, Xiao-li; Xu, Rui-hua			The Role of Non-Curative Surgery in Incurable, Asymptomatic Advanced Gastric Cancer	PLOS ONE			English	Article							TRIAL COMPARING GASTRECTOMY; QUALITY-OF-LIFE; PALLIATIVE GASTRECTOMY; STAGE-IV; INTRAPERITONEAL CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; SURGICAL-TREATMENT; CENTER EXPERIENCE; SURVIVAL BENEFIT; RESECTION	Background: Although general agreement exists on palliative surgery with intent of symptom palliation in advanced gastric cancer (AGC), the role of non-curative surgery for incurable, asymptomatic AGC is hotly debated. We aim to clarify the role of non-curative surgery in patients with incurable, asymptomatic AGC under the first-line chemotherapy. Methods: A total of 737 patients with incurable, asymptomatic advanced gastric adenocarcinoma between January 2008 and May 2012 at the Sun Yat-sen University Cancer Center were retrospectively analyzed, comprising 414 patients with non-curative surgery plus first-line chemotherapy, and 323 patients with first-line chemotherapy only. The clinicopathologic data, survival, and prognosis were evaluated, with propensity score adjustment for selection bias. Results: The median overall survival (OS) outcomes significantly favored non-curative surgery group over first-line chemotherapy only group in entire population (28.00 versus 10.37 months, P = 0.000), stage 4 patients (23.87 versus 10.37 months, P = 0.000), young patients (28.70 versus 10.37 months, P = 0.000) and elderly patients (23.07 versus 10.27 months, P = 0.031). The median OS advantages of non-curative surgery over first-line chemotherapy only were also maintained when the analyses were restricted to single organ metastasis (P = 0.001), distant lymph node metastasis (P = 0.002), peritoneal metastasis (P = 0.000), and multi-organ metastasis (P = 0.010). Significant OS advantages of non-curative surgery over chemotherapy only were confirmed solid by multivariate analyses before and after adjustment on propensity score (P = 0.000). Small subsets of patients with surgery of single metastatic lesion after previous curative gastrectomy, and with surgery of both primary and single metastatic sites showed sound median OS. Conclusions: There is a role for non-curative surgery plus first-line chemotherapy for incurable, asymptomatic AGC, in terms of survival. Randomized controlled trials are warranted to fill a gap in knowledge about the value of metastectomy and patient selection strategies.	[He, Ming-ming; Zhang, Dong-sheng; Wang, Feng; Wang, Zhi-qiang; Luo, Hui-yan; Jin, Ying; Wei, Xiao-li; Xu, Rui-hua] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [He, Ming-ming; Zhang, Dong-sheng; Wang, Feng; Wang, Zhi-qiang; Luo, Hui-yan; Jin, Ying; Wei, Xiao-li; Xu, Rui-hua] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University	Xu, RH (corresponding author), State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China.	xurh@sysucc.org.cn	xu, rui/GRX-5734-2022; 骆, 卉妍/GWR-3383-2022; Xu, Rui-Hua/AAW-4766-2021	骆, 卉妍/0000-0001-6312-9299; Xu, Rui-Hua/0000-0001-9771-8534	National High Technology Research and Development Program of China (863 Program), China [2012AA02A506]; Science and Technology Department of Guangdong Province, China [2012B031800088]; Medical Scientific Research Foundation of Guangdong Province, China [C2011019]	National High Technology Research and Development Program of China (863 Program), China(National High Technology Research and Development Program of China); Science and Technology Department of Guangdong Province, China; Medical Scientific Research Foundation of Guangdong Province, China	This study was supported by National High Technology Research and Development Program of China (863 Program), China (No. 2012AA02A506), the Science and Technology Department of Guangdong Province, China (No. 2012B031800088), and Medical Scientific Research Foundation of Guangdong Province, China (No. C2011019). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Amawi Tariq, 2011, Pol Przegl Chir, V83, P449, DOI 10.2478/v10035-011-0070-0; Amaral L, 2012, HEPATO-GASTROENTEROL, V59, P1651, DOI 10.5754/hge10201; An JY, 2009, ARCH SURG-CHICAGO, V144, P38, DOI 10.1001/archsurg.2008.502; Budisin NI, 2009, J BUON, V14, P593; Chen S, 2012, J SURG ONCOL, V106, P862, DOI 10.1002/jso.23158; Chen WW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068974; Cheong JH, 2007, ANN SURG ONCOL, V14, P61, DOI 10.1245/s10434-006-9205-7; Coniglio A, 2004, J SURG ONCOL, V88, P201, DOI 10.1002/jso.20153; CROOKES PF, 1995, AM J SURG, V170, P602, DOI 10.1016/S0002-9610(99)80024-5; Dittmar Y, 2009, ZBL CHIR, V134, P77, DOI 10.1055/s-0028-1098793; Dittmar Y, 2012, LANGENBECK ARCH SURG, V397, P745, DOI 10.1007/s00423-012-0902-3; Fujitani K, 2008, JPN J CLIN ONCOL, V38, P504, DOI 10.1093/jjco/hyn058; Gastinger I, 2012, CHIRURG, V83, P472, DOI 10.1007/s00104-011-2143-3; Glockzin G, 2009, WORLD J SURG ONCOL, V7, DOI 10.1186/1477-7819-7-5; Hanazaki K, 2001, HEPATO-GASTROENTEROL, V48, P285; Hansson LE, 2000, EUR J SURG, V166, P787, DOI 10.1080/110241500447425; Hartgrink HH, 2002, BRIT J SURG, V89, P1438, DOI 10.1046/j.1365-2168.2002.02220.x; Heemskerk Vincent H, 2007, World J Surg Oncol, V5, P81, DOI 10.1186/1477-7819-5-81; Huang KH, 2010, WORLD J SURG, V34, P1015, DOI 10.1007/s00268-010-0467-7; Jacquet P, 1996, Cancer Treat Res, V82, P359; Japanese Gastric Cancer Association, 1998, GASTRIC CANCER, V1, P10, DOI DOI 10.1007/S101209800016; Joffe MM, 1999, AM J EPIDEMIOL, V150, P327; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Karoui M, 2011, DIS COLON RECTUM, V54, P930, DOI 10.1097/DCR.0b013e31821cced0; Kerkar SP, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-121; Kikuchi S, 1999, HEPATO-GASTROENTEROL, V46, P584; Kikuchi S, 2000, HEPATO-GASTROENTEROL, V47, P563; Kim DY, 2008, LANGENBECK ARCH SURG, V393, P31, DOI 10.1007/s00423-007-0206-1; Ko KJ, 2012, WORLD J SURG, V36, P1800, DOI 10.1007/s00268-012-1566-4; Kunisaki C, 2005, HEPATO-GASTROENTEROL, V52, P314; Kunisaki C, 2003, ANTICANCER RES, V23, P1853; Kunisaki C, 2008, ANTICANCER RES, V28, P1309; Li C, 2010, J GASTROINTEST SURG, V14, P282, DOI 10.1007/s11605-009-1095-0; Lin SZ, 2008, J CANCER RES CLIN, V134, P187, DOI 10.1007/s00432-007-0268-z; Liu XW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037284; Maetani I, 2005, J GASTROENTEROL, V40, P932, DOI 10.1007/s00535-005-1651-7; Mahar AL, 2012, GASTRIC CANCER, V15, pS125, DOI 10.1007/s10120-011-0088-3; Medina-Franco H, 2004, AM J SURG, V187, P543, DOI 10.1016/j.amjsurg.2003.12.045; Miner TJ, 2004, J AM COLL SURGEONS, V198, P1013, DOI 10.1016/j.jamcollsurg.2004.02.007; MONSON JRT, 1991, CANCER, V68, P1863, DOI 10.1002/1097-0142(19911101)68:9<1863::AID-CNCR2820680902>3.0.CO;2-1; Nazli O, 2007, HEPATO-GASTROENTEROL, V54, P298; Onate-Ocana LF, 2007, GASTRIC CANCER, V10, P215, DOI 10.1007/s10120-007-0437-4; Ouchi K, 1998, J SURG ONCOL, V69, P41, DOI 10.1002/(SICI)1096-9098(199809)69:1<41::AID-JSO8>3.0.CO;2-K; Saidi RF, 2006, WORLD J SURG, V30, P21, DOI 10.1007/s00268-005-0129-3; Saito H, 2009, LANGENBECK ARCH SURG, V394, P99, DOI 10.1007/s00423-008-0398-z; Samarasam I, 2006, ANZ J SURG, V76, P60, DOI 10.1111/j.1445-2197.2006.03649.x; Shen JG, 2006, WORLD J GASTROENTERO, V12, P3883, DOI 10.3748/wjg.v12.i24.3883; Shim JH, 2012, J SURG ONCOL, V106, P753, DOI 10.1002/jso.23121; Shiraishi Norio, 2000, Gastric Cancer, V3, P211, DOI 10.1007/PL00011719; Sougioultzis S, 2011, EJSO-EUR J SURG ONC, V37, P312, DOI 10.1016/j.ejso.2011.01.019; Stupart D, 2009, S AFR J SURG, V44, P52; Sugarbaker Paul H, 2003, Semin Surg Oncol, V21, P233, DOI 10.1002/ssu.10042; Tamura Shigeyuki, 2010, Gan To Kagaku Ryoho, V37, P2279; Wagner AD, 2006, J CLIN ONCOL, V24, P2903, DOI 10.1200/JCO.2005.05.0245; Zhang XF, 2004, WORLD J GASTROENTERO, V10, P3405	55	25	31	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2013	8	12							e83921	10.1371/journal.pone.0083921	http://dx.doi.org/10.1371/journal.pone.0083921			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276GD	24358318	gold, Green Published, Green Submitted			2023-01-03	WOS:000328735700143
J	Liang, J; Zhang, B; Shen, RW; Liu, JB; Gao, MH; Li, Y; Li, YY; Zhang, W				Liang, Jie; Zhang, Bei; Shen, Ruo-wu; Liu, Jia-Bao; Gao, Mei-hua; Li, Ying; Li, Yuan-Yuan; Zhang, Wen			Preventive Effect of Halofuginone on Concanavalin A-Induced Liver Fibrosis	PLOS ONE			English	Article							NF-KAPPA-B; HEPATIC STELLATE CELLS; MATRIX METALLOPROTEINASES; HEPATOCELLULAR-CARCINOMA; CARDIAC FIBROBLASTS; COLLAGEN-SYNTHESIS; TISSUE INHIBITORS; REL PROTEINS; INJURY; GROWTH	Halofuginone (HF) is an active component of extracts derived from the plant alkaloid febrifugine and has shown therapeutic promise in animal models of fibrotic disease. Our main objectives were to clarify the suppressive effect of HF on concanavalin A (ConA)-induced liver fibrosis. ConA injection into the tail vein caused a great increase in the serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, while orally administration of HF significantly decreased the levels of the transaminases. In addition, the levels of hyaluronic acid (HA), procollagen III (PCIII) and TGF-beta 1 in the serum and collagen I, alpha-SMA, tissue inhibitors of metalloproteinase 2 (TIMP2) and Smad3 in the liver tissue were significantly lowered with the treatment of HF. Histological examination also demonstrated that HF significantly reduced the severity of liver fibrosis. Since ConA-induced liver fibrosis is caused by the repeated activation of T cells, immunomodulatory substances might be responsible for the suppressive effect of HF. We found that the production of nuclear factor (NF)-kB in the serum was increased in ConA-treated group, while decreased significantly with the treatment of HF. The changes of inflammatory cytokines tumor necrosis factor (TNF-alpha), IL-6 and IL-1 beta in the serum followed the same rhythm. All together, our findings indicate that orally administration HF (10ppm) would attenuate the liver fibrosis by suppressing the synthesis of collagen I and inflammation-mediated liver injury.	[Liang, Jie; Zhang, Bei; Gao, Mei-hua; Li, Ying; Li, Yuan-Yuan; Zhang, Wen] Qingdao Univ, Dept Immunol, Coll Med, Qingdao 266071, Peoples R China; [Shen, Ruo-wu] Qingdao Univ, Dept Anat, Coll Med, Qingdao 266071, Peoples R China; [Liu, Jia-Bao] Qingdao Univ, Dept Radiol, Affiliated Hosp, Qingdao 266071, Peoples R China	Qingdao University; Qingdao University; Qingdao University	Zhang, B (corresponding author), Qingdao Univ, Dept Immunol, Coll Med, Qingdao 266071, Peoples R China.	zhangbei124@aliyun.com; shenruowu@aliyun.com	li, jia/GVT-7587-2022; Liu, Jia-Bao/C-7850-2015	Liu, Jia-Bao/0000-0002-9620-7692	 [81072398]		This study was supported by grant-in-aids for The National Natural Science Foundation of China (81072398). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atamas SP, 2002, LIFE SCI, V72, P631, DOI 10.1016/S0024-3205(02)02299-3; Bansal R, 2011, HEPATOLOGY, V54, P586, DOI 10.1002/hep.24395; Benchetrit S, 2007, ISR MED ASSOC J, V9, P30; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Bruck R, 2001, HEPATOLOGY, V33, P379, DOI 10.1053/jhep.2001.21408; Claria J, 2012, GUT, V61, P792, DOI 10.1136/gutjnl-2011-301968; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Elsharkawy AM, 2007, HEPATOLOGY, V46, P590, DOI 10.1002/hep.21802; Friedman SL, 2008, GASTROENTEROLOGY, V134, P1655, DOI 10.1053/j.gastro.2008.03.003; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gu Y-Y, 2011, ZHONGGUO HAIYANG DAX, V9; Gurantz D, 2005, J MOL CELL CARDIOL, V38, P505, DOI 10.1016/j.yjmcc.2004.12.015; Hayden MS, 2011, CELL RES, V21, P223, DOI 10.1038/cr.2011.13; Iredale JP, 1997, INT J BIOCHEM CELL B, V29, P43, DOI 10.1016/S1357-2725(96)00118-5; Itoh A, 2009, BIOL PHARM BULL, V32, P1215, DOI 10.1248/bpb.32.1215; Jagavelu K, 2010, HEPATOLOGY, V52, P590, DOI 10.1002/hep.23739; Jaruga B, 2004, AM J PHYSIOL-GASTR L, V287, pG471, DOI 10.1152/ajpgi.00018.2004; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; Leiba M, 2006, J LEUKOCYTE BIOL, V80, P399, DOI 10.1189/jlb.0705409; Liu C, 2010, LAB INVEST, V90, P1805, DOI 10.1038/labinvest.2010.123; Luedde T, 2011, NAT REV GASTRO HEPAT, V8, P108, DOI 10.1038/nrgastro.2010.213; McGaha TL, 2002, J INVEST DERMATOL, V118, P461, DOI 10.1046/j.0022-202x.2001.01690.x; Meindl-Beinker NM, 2012, DIGEST DIS, V30, P514, DOI 10.1159/000341704; Moon SK, 2008, ACTA OTO-LARYNGOL, V128, P144, DOI 10.1080/00016480701477610; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; Nakamura T, 2000, HEPATOLOGY, V32, P247, DOI 10.1053/jhep.2000.9109; Nelson EF, 2012, MOL VIS, V18, P479; Nguyen-Pouplin J, 2007, J ETHNOPHARMACOL, V109, P417, DOI 10.1016/j.jep.2006.08.011; Park SY, 2010, J KOREAN MED SCI, V25, P570, DOI 10.3346/jkms.2010.25.4.570; Perepelyuk M, 2013, AM J PHYSIOL-GASTR L, V304, pG605, DOI 10.1152/ajpgi.00222.2012; Pines A, 2003, BIOL BLOOD MARROW TR, V9, P417, DOI 10.1016/S1083-8791(03)00151-4; Pines M, 1997, J HEPATOL, V27, P391, DOI 10.1016/S0168-8278(97)80186-9; Pines M, 1998, GEN PHARMACOL, V30, P445, DOI 10.1016/S0306-3623(97)00307-8; Ren ZH, 2012, INT IMMUNOPHARMACOL, V14, P698, DOI 10.1016/j.intimp.2012.10.008; Richard S, 2000, RHEUMATOLOGY, V39, P50, DOI 10.1093/rheumatology/39.1.50; Ruiz-Ortega M, 2007, CARDIOVASC RES, V74, P196, DOI 10.1016/j.cardiores.2007.02.008; Schultz GS, 2009, WOUND REPAIR REGEN, V17, P153, DOI 10.1111/j.1524-475X.2009.00466.x; Schwabe RF, 2006, AM J PHYSIOL-GASTR L, V290, pG583, DOI 10.1152/ajpgi.00422.2005; Shahar I, 1996, CLIN IMMUNOL IMMUNOP, V79, P244, DOI 10.1006/clin.1996.0075; Siwik DA, 2000, CIRC RES, V86, P1259, DOI 10.1161/01.RES.86.12.1259; Sun B, 2008, ONCOGENE, V27, P6228, DOI 10.1038/onc.2008.300; Thabut D, 2011, HEPATOLOGY, V54, P573, DOI 10.1002/hep.24427; Tiegs G, 2010, J AUTOIMMUN, V34, P1, DOI 10.1016/j.jaut.2009.08.008; Venugopal SK, 2010, AM J PHYSIOL-GASTR L, V298, pG101, DOI 10.1152/ajpgi.00220.2009; Wang C, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0070725, 10.1371/journal.pone.0060462, 10.1371/journal.pone.0077273, 10.1371/journal.pone.0081882]; Watanabe A, 2006, BIOL PHARM BULL, V29, P1651, DOI 10.1248/bpb.29.1651; Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277; Xavier S, 2004, J BIOL CHEM, V279, P15167, DOI 10.1074/jbc.M309798200; Xia YZ, 2013, EUR J PHARMACOL, V714, P105, DOI 10.1016/j.ejphar.2013.06.012; Yin MingShi, 2012, African Journal of Pharmacy and Pharmacology, V6, P2870	51	24	28	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2013	8	12							e82232	10.1371/journal.pone.0082232	http://dx.doi.org/10.1371/journal.pone.0082232			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276GD	24358159	Green Submitted, gold, Green Published			2023-01-03	WOS:000328735700048
J	Cheong, KB; Zhang, JP; Huang, Y; Zhang, ZJ				Cheong, Kah Bik; Zhang, Ji-ping; Huang, Yong; Zhang, Zhang-jin			The Effectiveness of Acupuncture in Prevention and Treatment of Postoperative Nausea and Vomiting - A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							TRADITIONAL CHINESE ACUPUNCTURE; P6 ACUPUNCTURE; ELECTROACUPOINT STIMULATION; ANTIEMETIC PROPHYLAXIS; ACUPOINT STIMULATION; ACUPRESSURE; ACUSTIMULATION; CHILDREN; PATIENT; ONDANSETRON	Background: Acupuncture therapy for preventive and treatment of postoperative nausea and vomiting(PONV), a condition which commonly present after anaesthesia and surgery is a subject of growing interest. Objective: This paper included a systematic review and meta-analysis on the effect of different type of acupuncture and acupoint selection in PONV prevention and treatment. Methods: Randomised controlled trials(RCTs) comparing acupuncture with non-acupuncture treatment were identified from databases PubMed, Cochrane, EBSCO, Ovid, CNKI and Wanfangdata. Meta-analysis on eligible studies was performed using fixed-effects model with RevMan 5.2. Results were expressed as RR for dichotomous data, with 95%CI. Results: Thirty RCTs, 1276 patients (intervention) and 1258 patients (control) were identified. Meta-analysis showed that PC6 acupuncture significantly reduced the number of cases of early vomiting (postoperative 0-6h) (RR=0.36, 95% CI 0.19,0.71; P=0.003) and nausea (postoperative 0-24h) (RR=0.25, 95% CI 0.10,0.61; P=0.002), but not early nausea (postoperative 0-6h) (RR=0.64, 95% CI 0.34,1.19; P=0.150) and vomiting (postoperative 0-24h) (RR=0.82, 95% CI 0.48,1.38; P=0.450). PC6 acupressure significantly reduced the number of cases of nausea (RR=0.71, 95% CI 0.57,0.87; P=0.001) and vomiting (RR=0.62, 95% CI 0.49,0.80; P=0.000) at postoperative 0-24h. PC6 electroacupoint stimulation significantly reduced the number of cases of nausea (RR=0.49, 95% CI 0.38,0.63; P<0.000) and vomiting (RR=0.50, 95% CI 0.36,0.70; P<0.000) at postoperative 0-24h. Stimulation of PC6 with other acupoint(s) significantly reduced the number of cases of nausea and vomiting (RR=0.29, 95% CI 0.17,0.49; P<0.000) at postoperative 0-24h. Stimulation of other acupoint(s)(non PC6) also significantly reduced the number of cases of nausea and vomiting (RR=0.63, 95% CI 0.49,0.81; P=0.000) at postoperative 0-24h. However, the quality of study was generally low in studies of PC6 combined with other acupoint(s) and other acupoint(s). Details of blinding were not reported in most reports. Conclusions: Besides PC6, PC6 combined with other acupoint(s) and other alternative acupoint(s) might be beneficial in prevention and treatment of PONV, the evidence justifies future high-quality studies.	[Cheong, Kah Bik; Zhang, Ji-ping; Huang, Yong] Southern Med Univ, Sch Tradit Chinese Med, Guangzhou, Guangdong, Peoples R China; [Zhang, Zhang-jin] Univ Hong Kong, Sch Chinese Med, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China	Southern Medical University - China; University of Hong Kong	Huang, Y (corresponding author), Southern Med Univ, Sch Tradit Chinese Med, Guangzhou, Guangdong, Peoples R China.	nanfanglihuang@163.com	zhang, zhang/GQZ-6804-2022; zhang, zheng/HCH-9684-2022; Cheong, Kah Bik/B-3545-2008	Cheong, Kah Bik/0000-0003-2062-6599	Committee of development and reform, Guangdong Province [431]	Committee of development and reform, Guangdong Province	This work was supported by Committee of development and reform, Guangdong Province [2009] 431. It was the 3rd-stage "211 project" key subject construction project of Guangdong Province. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALLEN DL, 1994, ANAESTH INTENS CARE, V22, P691, DOI 10.1177/0310057X9402200608; AlSadi M, 1997, ANAESTHESIA, V52, P658, DOI 10.1111/j.1365-2044.1997.143-az0147.x; AMIR SH, 2007, J ANAESTH CLIN PHARM, V23, P383; ANDRZEJOWSKI J, 1996, ACUPUNCT MED, V14, P68, DOI DOI 10.1136/AIM.14.2.68; Arnberger M, 2007, ANESTHESIOLOGY, V107, P903, DOI 10.1097/01.anes.0000290617.98058.d9; [白红梅 Bai Hongmei], 2012, [临床麻醉学杂志, The Journal of Clinical Anesthestology], V28, P1158; Boehler M, 2002, ANESTH ANALG, V94, P872, DOI 10.1097/00000539-200204000-00018; Chattopadhyay S, 2011, AOB PLANTS, DOI 10.1093/aobpla/plr002; Chen M, 2006, CHIN J CLIN REHABIL, V10, P112; CHEN XH, 1992, BEHAV BRAIN RES, V47, P143, DOI 10.1016/S0166-4328(05)80120-2; Chu Y C, 1998, Acta Anaesthesiol Sin, V36, P11; Doran K, 2010, AM J CRIT CARE, V19, P553, DOI 10.4037/ajcc2010900; DUNDEE JW, 1986, BRIT MED J, V293, P583, DOI 10.1136/bmj.293.6547.583; DUNDEE JW, 1989, BRIT J ANAESTH, V63, pP630; El-Bandrawy A. M., 2013, British Journal of Medicine and Medical Research, V3, P2247; Gan TJ, 2004, ANESTH ANALG, V99, P1070, DOI [10.1213/01.ANE.0000130355.91214.9E, 10.1213/01.ane.0000130355.91214.9e]; Gan TJ, 2006, ANESTH ANALG, V102, P1884, DOI 10.1213/01.ANE.0000219597.16143.4D; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Habib AS, 2006, ANESTH ANALG, V102, P581, DOI 10.1213/01.ane.0000189217.19600.5c; Harmon D, 2000, BRIT J ANAESTH, V84, P463; Kim KS, 2002, ANESTH ANALG, V95, P1103, DOI 10.1097/00000539-200210000-00059; Klein AA, 2004, J CARDIOTHOR VASC AN, V18, P68, DOI 10.1053/j.jvca.2003.10.014; Lee A, 1999, ANESTH ANALG, V88, P1362, DOI 10.1097/00000539-199906000-00031; LEE A, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003281.PUB2; Lee A, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003281.pub3; Li BG, 2011, J LIAONING U TCM, V13, P135; LI GP, 2013, CHINESE J ETHNOMEDIC, V22, P31; LI J, 2011, J QILU NURSING, V17, P122; Lin JG, 2002, PAIN, V99, P509, DOI 10.1016/S0304-3959(02)00261-0; Liodden I, 2011, ACUPUNCT MED, V29, P9, DOI 10.1136/aim.2010.002915; LIU SF, 2010, 2010 INT S OV PROSP, P335; Liu YY, 2008, CHIN J INTEGR MED, V14, P94, DOI 10.1007/s11655-008-0094-4; Lu ZX, 2009, J ZHEJIANG COLL TRAD, V33, P862; LV H, 2012, J TRADITIONAL CHINES, V31, P23; Lv JQ, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-153; Ma Ting-Ting, 2010, Zhongguo Zhen Jiu, V30, P407; MacPherson Hugh, 2010, J Evid Based Med, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x; Majholm B, 2011, EUR J ANAESTH, V28, P412, DOI 10.1097/EJA.0b013e32833f6f42; MAYER DJ, 1977, BRAIN RES, V121, P368, DOI 10.1016/0006-8993(77)90161-5; Norheim AJ, 2010, ACUPUNCT MED, V28, P71, DOI 10.1136/aim.2009.002220; Ouyang Ming-wen, 2009, Zhongguo Zhen Jiu, V29, P915; PEI Y, 2010, J TRADITIONAL CHINES, V28, P36; Pettersson PH, 2012, J CLIN NURS, V21, P1799, DOI 10.1111/j.1365-2702.2012.04114.x; Schlager A, 1998, BRIT J ANAESTH, V81, P529, DOI 10.1093/bja/81.4.529; Schulz KF, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-32; Shenkman Z, 1999, ANESTHESIOLOGY, V90, P1311, DOI 10.1097/00000542-199905000-00015; Shiao SYPK, 2006, EXPLORE-NY, V2, P200, DOI 10.1016/j.explore.2006.02.004; Streitberger K, 2004, ANAESTHESIA, V59, P142, DOI 10.1111/j.1365-2044.2004.03577.x; Tang Wei, 2013, Zhongguo Zhen Jiu, V33, P159; Turgut S, 2007, EUR J ANAESTH, V24, P87, DOI 10.1017/S0265021506001190; Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602; WANG H, 2004, CHONGQING MED J, V33, P1647; WANG SQ, 2012, NURSING SCI, V27, P49; Wang XQ, 2010, J NEUROSURG ANESTH, V22, P128, DOI 10.1097/ANA.0b013e3181c9fbde; WANG ZY, 2009, CHINESE J MISDIAGNOS, V9, P5350; WEIGHTMAN WM, 1987, BRIT MED J, V295, P1379, DOI 10.1136/bmj.295.6610.1379; Wetzel B, 2011, CLIN J PAIN, V27, P262, DOI 10.1097/AJP.0b013e3181fd516c; White PF, 2005, ANESTH ANALG, V100, P367, DOI 10.1213/01.ANE.0000144425.16116.0A; Windle P E, 2001, J Perianesth Nurs, V16, P158, DOI 10.1053/jpan.2001.24040; Xu M, 2012, J NEUROSURG ANESTH, V24, P312, DOI 10.1097/ANA.0b013e31825eb5ef; YANG LC, 1993, ACTA ANAESTH SCAND, V37, P192, DOI 10.1111/j.1399-6576.1993.tb03699.x; Yang Wei, 2011, Zhen Ci Yan Jiu, V36, P292; YAO AJ, 2012, ASIA PACIFIC TRADITI, V8, P82; YENTIS SM, 1991, BRIT J ANAESTH, V67, P779, DOI 10.1093/bja/67.6.779; Yentis SM, 1998, ACUPUNCT MED, V16, P10, DOI DOI 10.1136/AIM.16.1.10; Yu Jian-ming, 2010, Zhen Ci Yan Jiu, V35, P43; YUAN J, 2000, MODERN J INTEGRATED, V9, P1358; ZENG QL, 1999, SHANGHAI J ACUPUNCTU, V18, P8; ZENG ZD, 2011, CHIN J MOD DRUG APPL, V5, P59; ZHANG ZY, 2010, GUIDE CHINA MED, V8, P209, DOI DOI 10.3969/J.ISSN.1671-8194.2010.33.149	70	68	77	3	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2013	8	12							e82474	10.1371/journal.pone.0082474	http://dx.doi.org/10.1371/journal.pone.0082474			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276FP	24349293	Green Published, Green Submitted, gold			2023-01-03	WOS:000328734200046
J	Nesbitt, RC; Lohela, TJ; Manu, A; Vesel, L; Okyere, E; Edmond, K; Owusu-Agyei, S; Kirkwood, BR; Gabrysch, S				Nesbitt, Robin C.; Lohela, Terhi J.; Manu, Alexander; Vesel, Linda; Okyere, Eunice; Edmond, Karen; Owusu-Agyei, Seth; Kirkwood, Betty R.; Gabrysch, Sabine			Quality along the Continuum: A Health Facility Assessment of Intrapartum and Postnatal Care in Ghana	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; VITAMIN-A SUPPLEMENTATION; EMERGENCY OBSTETRIC CARE; MATERNAL SURVIVAL; SYSTEMATIC ANALYSIS; NEONATAL-MORTALITY; CHILD-MORTALITY; HOME-VISITS; OF-CARE; PROTOCOL	Objective: To evaluate quality of routine and emergency intrapartum and postnatal care using a health facility assessment, and to estimate "effective coverage" of skilled attendance in Brong Ahafo, Ghana. Methods: We conducted an assessment of all 86 health facilities in seven districts in Brong Ahafo. Using performance of key signal functions and the availability of relevant drugs, equipment and trained health professionals, we created composite quality categories in four dimensions: routine delivery care, emergency obstetric care (EmOC), emergency newborn care (EmNC) and non-medical quality. Linking the health facility assessment to surveillance data we estimated "effective coverage" of skilled attendance as the proportion of births in facilities of high quality. Findings: Delivery care was offered in 64/86 facilities; only 3-13% fulfilled our requirements for the highest quality category in any dimension. Quality was lowest in the emergency care dimensions, with 63% and 58% of facilities categorized as "low" or "substandard" for EmOC and EmNC, respectively. This implies performing less than four EmOC or three EmNC signal functions, and/or employing less than two skilled health professionals, and/or that no health professionals were present during our visit. Routine delivery care was "low" or "substandard" in 39% of facilities, meaning 25/64 facilities performed less than six routine signal functions and/or had less than two skilled health professionals and/or less than one midwife. While 68% of births were in health facilities, only 18% were in facilities with "high" or "highest" quality in all dimensions. Conclusion: Our comprehensive facility assessment showed that quality of routine and emergency intrapartum and postnatal care was generally low in the study region. While coverage with facility delivery was 68%, we estimated "effective coverage" of skilled attendance at 18%, thus revealing a large "quality gap." Effective coverage could be a meaningful indicator of progress towards reducing maternal and newborn mortality.	[Nesbitt, Robin C.; Gabrysch, Sabine] Heidelberg Univ, Inst Publ Hlth, Epidemiol & Biostat Unit, Heidelberg, Germany; [Lohela, Terhi J.] Helsinki Univ Hosp, Dept Anaesthesiol & Intens Care Med, Jorvi Hosp, Espoo, Finland; [Manu, Alexander; Okyere, Eunice; Owusu-Agyei, Seth] Ghana Hlth Serv, Kintampo Hlth Res Ctr, Kintampo, Ghana; [Manu, Alexander; Vesel, Linda; Kirkwood, Betty R.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Maternal & Child Hlth Intervent Res Grp, London WC1, England; [Edmond, Karen] Univ Western Australia, Sch Paediat & Child Hlth, Subiaco, WA, Australia	Ruprecht Karls University Heidelberg; University of Helsinki; Helsinki University Central Hospital; Ghana Health Service; Kintampo Health Research Centre; University of London; London School of Hygiene & Tropical Medicine; University of Western Australia	Nesbitt, RC (corresponding author), Heidelberg Univ, Inst Publ Hlth, Epidemiol & Biostat Unit, Heidelberg, Germany.	robin.nesbitt@uni-heidelberg.de	Gabrysch, Sabine/A-3503-2013	Gabrysch, Sabine/0000-0002-7081-0506; Lohela, Terhi/0000-0002-6596-1780; Kirkwood, Betty/0000-0001-5274-6072; Owusu-Agyei, Seth/0000-0002-0807-1781; Okyere, Eunice/0000-0003-3566-7561	University of Heidelberg; European Social Fund; Ministry of Science, Research and the Arts Baden-Wurttemberg; Daimer and Benz Foundation; Baden-Wurttemberg Foundation; WHO; Bill and Melinda Gates Foundation; UK Department of International Development (DFID)	University of Heidelberg; European Social Fund(European Social Fund (ESF)); Ministry of Science, Research and the Arts Baden-Wurttemberg; Daimer and Benz Foundation; Baden-Wurttemberg Foundation; WHO(World Health Organization); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); UK Department of International Development (DFID)	Sabine Gabrysch is paid by the University of Heidelberg through a Margarete von Wrangell Fellowship supported by the European Social Fund and by the Ministry of Science, Research and the Arts Baden-Wurttemberg. She is also supported by postdoctoral fellowships of the Daimer and Benz Foundation and the Baden-Wurttemberg Foundation. The latter funded part of the fieldwork and funds Robin Nesbitt who is employed as a doctoral student at the University of Heidelberg. The HFA was partly funded by WHO, Save the Children's Saving Newborn Lives (SNL) programme from the Bill and Melinda Gates Foundation, and the UK Department of International Development (DFID) for the benefit of developing countries; the views expressed are not necessarily those of DFID. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Averting Maternal Death and Disability Program (AMDD), 2003, US UN PROC IND EM OB; Bahl R, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-22; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Chan M, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000223; Dzakpasu S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049430; Edmond K, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000658; Filippi V, 2006, LANCET, V368, P1535, DOI 10.1016/S0140-6736(06)69384-7; Gabrysch S, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001340; Gabrysch S, 2011, INT J GYNECOL OBSTET, V114, P174, DOI 10.1016/j.ijgo.2011.05.007; Ghana Statistical Service Research, 2008, GHAN DEM HLTH SURV 2; Graham WJ, 2012, LANCET, V379, pE5, DOI 10.1016/S0140-6736(10)62267-2; Hozumi D, 2006, PROFILES HLTH FACILI; Keyes EB, 2011, INT J GYNECOL OBSTET, V115, P94, DOI 10.1016/j.ijgo.2011.07.009; Kinney MV, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000294; Kirkwood BR, 2013, LANCET, V381, P2184, DOI 10.1016/S0140-6736(13)60095-1; Kirkwood BR, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-58; Kirkwood BR, 2010, LANCET, V375, P1640, DOI 10.1016/S0140-6736(10)60311-X; Kyei NNA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046475; Lawn JE, 2009, INT J GYNECOL OBSTET, V107, pS5, DOI 10.1016/j.ijgo.2009.07.016; Levine AC, 2008, INT J EMERG MED, V1, P113, DOI 10.1007/s12245-008-0032-4; Lozano R, 2011, LANCET, V378, P1139, DOI 10.1016/S0140-6736(11)61337-8; Ministry of Health (MOH), 2011, NAT ASS EM OBST NEWB; Oestergaard MZ, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001080; Paxton A, 2006, INT J GYNECOL OBSTET, V95, P192, DOI 10.1016/j.ijgo.2006.08.009; Pitchforth E, 2010, SOC SCI MED, V71, P1739, DOI 10.1016/j.socscimed.2010.08.001; Pittrof R, 2002, ACTA OBSTET GYN SCAN, V81, P277, DOI 10.1034/j.1600-0412.2002.810401.x; Raven JH, 2012, MIDWIFERY, V28, pE676, DOI 10.1016/j.midw.2011.09.003; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; Shankar A, 2008, LANCET, V371, P1223, DOI 10.1016/S0140-6736(08)60536-X; Shengelia B, 2005, SOC SCI MED, V61, P97, DOI 10.1016/j.socscimed.2004.11.055; Stanton CK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060694; van den Broek NR, 2009, BJOG-INT J OBSTET GY, V116, P18, DOI 10.1111/j.1471-0528.2009.02333.x; Vesel L, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002326; World Health Organization (WHO); UNFPA; UNICEF; Columbia University. Mailman School of Public Health, 2009, MON EM OBST CAR HDB	35	82	82	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 27	2013	8	11							e81089	10.1371/journal.pone.0081089	http://dx.doi.org/10.1371/journal.pone.0081089			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261GG	24312265	gold, Green Published, Green Submitted, Green Accepted			2023-01-03	WOS:000327652100060
J	Leal, ECP; de Almeida, P; Tomazoni, SS; de Carvalho, PDC; Lopes-Martins, RAB; Frigo, L; Joensen, J; Johnson, MI; Bjordal, JM				Pinto Leal-Junior, Ernesto Cesar; de Almeida, Patricia; Tomazoni, Shaiane Silva; Camillo de Carvalho, Paulo de Tarso; Brandao Lopes-Martins, Rodrigo Alvaro; Frigo, Lucio; Joensen, Jon; Johnson, Mark I.; Bjordal, Jan Magnus			Superpulsed Low-Level Laser Therapy Protects Skeletal Muscle of mdx Mice against Damage, Inflammation and Morphological Changes Delaying Dystrophy Progression	PLOS ONE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; SIGNALING PATHWAY; ORAL MUCOSITIS; LIGHT THERAPY; IN-VIVO; 660 NM; IRRADIATION; PAIN	Aim: To evaluate the effects of preventive treatment with low-level laser therapy (LLLT) on progression of dystrophy in mdx mice. Methods: Ten animals were rando mu ly divided into 2 experimental groups treated with superpulsed LLLT (904 nm, 15 mW, 700 Hz, 1 J) or placebo-LLLT at one point overlying the tibialis anterior muscle (bilaterally) 5 times per week for 14 weeks (from 6th to 20th week of age). Morphological changes, creatine kinase (CK) activity and mRNA gene expression were assessed in animals at 20th week of age. Results: Animals treated with LLLT showed very few morphological changes in skeletal muscle, with less atrophy and fibrosis than animals treated with placebo-LLLT. CK was significantly lower (p = 0.0203) in animals treated with LLLT (864.70 U.l(-1), SEM 226.10) than placebo (1708.00 U.l(-1), SEM 184.60). mRNA gene expression of inflammatory markers was significantly decreased by treatment with LLLT (p<0.05): TNF-alpha (placebo-control = 0.51 mu g/mu l [SEM 0.12], - LLLT = 0.048 mu g/mu l [SEM 0.01]), IL-1 beta (placebo-control = 2.292 mu g/mu l [SEM 0.74], - LLLT = 0.12 mu g/mu l [SEM 0.03]), IL-6 (placebo-control = 3.946 mu g/mu l [SEM 0.98], - LLLT = 0.854 mu g/mu l [SEM 0.33]), IL-10 (placebo-control = 1.116 mu g/mu l [SEM 0.22], - LLLT = 0.352 mu g/mu l [SEM 0.15]), and COX-2 (placebo-control = 4.984 mu g/mu l [SEM 1.18], LLLT = 1.470 mu g/mu l [SEM 0.73]). Conclusion: Irradiation of superpulsed LLLT on successive days five times per week for 14 weeks decreased morphological changes, skeletal muscle damage and inflammation in mdx mice. This indicates that LLLT has potential to decrease progression of Duchenne muscular dystrophy.	[Pinto Leal-Junior, Ernesto Cesar; de Almeida, Patricia; Camillo de Carvalho, Paulo de Tarso] Univ Nove de Julho UNINOVE, Postgrad Program Rehabil Sci, Sao Paulo, Brazil; [Pinto Leal-Junior, Ernesto Cesar; Camillo de Carvalho, Paulo de Tarso] Univ Nove de Julho UNINOVE, Postgrad Program Biophoton Appl Hlth Sci, Sao Paulo, Brazil; [Tomazoni, Shaiane Silva; Brandao Lopes-Martins, Rodrigo Alvaro] Univ Sao Paulo, Dept Pharmacol, Sao Paulo, Brazil; [Frigo, Lucio] Univ Cruzeiro Sul, Biol Sci & Hlth Ctr, Sao Paulo, Brazil; [Joensen, Jon] Bergen Univ Coll, Dept Physiotherapy Occupat Therapy & Radiog, Bergen, Norway; [Johnson, Mark I.] Leeds Metropolitan Univ, Fac Hlth & Social Sci, Leeds LS1 3HE, W Yorkshire, England; [Bjordal, Jan Magnus] Univ Bergen, Physiotherapy Res Grp, Bergen, Norway	Universidade Nove de Julho; Universidade Nove de Julho; Universidade de Sao Paulo; Universidade Cruzeiro do Sul; Western Norway University of Applied Sciences; Leeds Beckett University; University of Bergen	Leal, ECP (corresponding author), Univ Nove de Julho UNINOVE, Postgrad Program Rehabil Sci, Sao Paulo, Brazil.	ernesto.leal.junior@gmail.com	Tomazoni, Shaiane Silva/H-9000-2016; Lopes-Martins, Rodrigo A B/E-2013-2013; Bjordal, Jan Magnus/T-7122-2019; Frigo, Lucio/K-1564-2015; Frigo, Lucio/D-1708-2017; Leal-Junior, Ernesto Cesar/H-8920-2016; de Tarso C de Carvalho, Paulo/G-5333-2011	Tomazoni, Shaiane Silva/0000-0002-0822-4864; Lopes-Martins, Rodrigo A B/0000-0002-4533-1335; Frigo, Lucio/0000-0001-9131-1071; Leal-Junior, Ernesto Cesar/0000-0001-6393-7616; de Tarso C de Carvalho, Paulo/0000-0001-9624-4103; de Almeida Mattos, Patricia/0000-0001-6738-094X	FAPESP [2010/52404-0, 2012/06832-5]	FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	Professor Ernesto Cesar Pinto Leal-Junior would like to thank FAPESP research grant number 2010/52404-0. Professor Lucio Frigo would like to thank FAPESP research grant number 2012/06832-5. FAPESP had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aimbire F, 2007, PHOTOMED LASER SURG, V25, P112, DOI 10.1089/pho.2006.1041; Aimbire F, 2006, PHOTOMED LASER SURG, V24, P33, DOI 10.1089/pho.2006.24.33; Albertini R, 2007, J PHOTOCH PHOTOBIO B, V89, P50, DOI 10.1016/j.jphotobiol.2007.08.005; Albertini R, 2004, J PHOTOCH PHOTOBIO B, V74, P101, DOI 10.1016/j.jphotobiol.2004.03.002; Avni D, 2005, PHOTOMED LASER SURG, V23, P273, DOI 10.1089/pho.2005.23.273; Barber BJ, 2013, J PEDIATR-US, V163, P1080, DOI 10.1016/j.jpeds.2013.05.060; Basford JR, 1999, ARCH PHYS MED REHAB, V80, P647, DOI 10.1016/S0003-9993(99)90167-3; Bjordal JM, 2006, BRIT J SPORT MED, V40, P76, DOI 10.1136/bjsm.2005.020842; Chamberlain JS, 2007, FASEB J, V21, P2195, DOI 10.1096/fj.06-7353com; Chow RT, 2006, PAIN, V124, P201, DOI 10.1016/j.pain.2006.05.018; Chow RT, 2009, LANCET, V374, P1897, DOI 10.1016/S0140-6736(09)61522-1; Cox GF, 1997, CURR OPIN CARDIOL, V12, P329; de Almeida P, 2012, LASER MED SCI, V27, P453, DOI 10.1007/s10103-011-0957-3; de Almeida P, 2011, PHOTOCHEM PHOTOBIOL, V87, P1159, DOI 10.1111/j.1751-1097.2011.00968.x; De Marchi T, 2012, LASER MED SCI, V27, P231, DOI 10.1007/s10103-011-0955-5; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; Emery AEH, 2003, DUCHENNE MUSCULAR DY; Fairclough RJ, 2011, EXP PHYSIOL, V96, P1101, DOI 10.1113/expphysiol.2010.053025; Gautam AP, 2012, RADIOTHER ONCOL, V104, P349, DOI 10.1016/j.radonc.2012.06.011; Goldman J A, 1980, Lasers Surg Med, V1, P93, DOI 10.1002/lsm.1900010110; Gur A, 2004, LASER SURG MED, V35, P229, DOI 10.1002/lsm.20082; Hayworth CR, 2010, PHOTOCHEM PHOTOBIOL, V86, P673, DOI 10.1111/j.1751-1097.2010.00732.x; Hegedus B, 2009, PHOTOMED LASER SURG, V27, P577, DOI 10.1089/pho.2008.2297; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lebel DE, 2013, J BONE JOINT SURG AM, V95A, P1057, DOI 10.2106/JBJS.L.01577; Li M, 2013, NEUROREPORT, V24, P924, DOI 10.1097/WNR.0000000000000028; Lim W, 2013, PHOTOCHEM PHOTOBIOL, V89, P199, DOI 10.1111/j.1751-1097.2012.01225.x; MCGEACHIE JK, 1993, J NEUROL SCI, V119, P169, DOI 10.1016/0022-510X(93)90130-Q; Moriyama Y, 2005, PHOTOCHEM PHOTOBIOL, V81, P1351, DOI 10.1562/2005-02-28-RA-450; Ozcelik O, 2008, J CLIN PERIODONTOL, V35, P250, DOI 10.1111/j.1600-051X.2007.01194.x; Partridge TA, 2013, FEBS J, V280, P4177, DOI 10.1111/febs.12267; Leal ECP, 2008, PHOTOMED LASER SURG, V26, P419, DOI 10.1089/pho.2007.2160; Leal ECP, 2010, J ORTHOP SPORT PHYS, V40, P524, DOI 10.2519/jospt.2010.3294; Leal ECP, 2010, EUR J APPL PHYSIOL, V108, P1083, DOI 10.1007/s00421-009-1321-1; Leal ECP, 2009, LASER MED SCI, V24, P857, DOI 10.1007/s10103-008-0633-4; Leal ECP, 2009, LASER SURG MED, V41, P572, DOI 10.1002/lsm.20810; Leal ECP, 2009, PHOTOMED LASER SURG, V27, P617, DOI 10.1089/pho.2008.2350; Leal ECP, 2009, LASER MED SCI, V24, P425, DOI 10.1007/s10103-008-0592-9; Ramaswamy KS, 2011, J PHYSIOL-LONDON, V589, P1195, DOI 10.1113/jphysiol.2010.201921; Rao S, 2012, ARCH DIS CHILD, V97, P1000, DOI 10.1136/archdischild-2012-302457; Ricotti V, 2013, J NEUROL NEUROSUR PS, V84, P698, DOI 10.1136/jnnp-2012-303902; Rizzi CF, 2006, LASER SURG MED, V38, P704, DOI 10.1002/lsm.20371; Rochkind S, 2007, PHOTOMED LASER SURG, V25, P137, DOI 10.1089/pho.2007.2076; Schubert MM, 2007, SUPPORT CARE CANCER, V15, P1145, DOI 10.1007/s00520-007-0238-7; Serra F, 2012, MUSCLE NERVE, V46, P773, DOI 10.1002/mus.23432; Silveira PCL, 2009, J PHOTOCH PHOTOBIO B, V95, P89, DOI 10.1016/j.jphotobiol.2009.01.004; Stergioulas A, 2008, AM J SPORT MED, V36, P881, DOI 10.1177/0363546507312165; Takema T, 2000, LASER MED SCI, V15, P35, DOI 10.1007/s101030050045; Thomas GD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049350; Tullberg M, 2003, PAIN, V105, P89, DOI 10.1016/S0304-3959(03)00166-0; Xu XY, 2008, PHOTOMED LASER SURG, V26, P197, DOI 10.1089/pho.2007.2125	53	28	31	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2014	9	3							e89453	10.1371/journal.pone.0089453	http://dx.doi.org/10.1371/journal.pone.0089453			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC4GP	24599021	Green Submitted, Green Published, gold, Green Accepted			2023-01-03	WOS:000332479400013
J	Bruells, CS; Bergs, I; Rossaint, R; Du, J; Bleilevens, C; Goetzenich, A; Weis, J; Wiggs, MP; Powers, SK; Hein, M				Bruells, Christian S.; Bergs, Ingmar; Rossaint, Rolf; Du, Jun; Bleilevens, Christian; Goetzenich, Andreas; Weis, Joachim; Wiggs, Michael P.; Powers, Scott K.; Hein, Marc			Recovery of Diaphragm Function following Mechanical Ventilation in a Rodent Model	PLOS ONE			English	Article							OXIDATIVE STRESS; DYSFUNCTION; EXPRESSION; CALPAIN; FAILURE; RAT	Background: Mechanical ventilation (MV) induces diaphragmatic muscle fiber atrophy and contractile dysfunction (ventilator induced diaphragmatic dysfunction, VIDD). It is unknown how rapidly diaphragm muscle recovers from VIDD once spontaneous breathing is restored. We hypothesized that following extubation, the return to voluntary breathing would restore diaphragm muscle fiber size and contractile function using an established rodent model. Methods: Following 12 hours of MV, animals were either euthanized or, after full wake up, extubated and returned to voluntary breathing for 12 hours or 24 hours. Acutely euthanized animals served as controls (each n = 8/group). Diaphragmatic contractility, fiber size, protease activation, and biomarkers of oxidative damage in the diaphragm were assessed. Results: 12 hours of MV induced VIDD. Compared to controls diaphragm contractility remained significantly depressed at 12 h after extubation but rebounded at 24 h to near control levels. Diaphragmatic levels of oxidized proteins were significantly elevated after MV (p = 0.002) and normalized at 24 hours after extubation. Conclusions: These findings indicate that diaphragm recovery from VIDD, as indexed by fiber size and contractile properties, returns to near control levels within 24 hours after returning to spontaneous breathing. Besides the down-regulation of proteolytic pathways and oxidative stress at 24 hours after extubation further repairing mechanisms have to be determined.	[Bruells, Christian S.; Bergs, Ingmar; Rossaint, Rolf; Du, Jun; Bleilevens, Christian; Hein, Marc] Univ Excellence, Rhein Westfal TH Aachen, Univ Hosp, Dept Surg Intens & Intermediate Care, Aachen, Germany; [Bruells, Christian S.; Bergs, Ingmar; Rossaint, Rolf; Du, Jun; Bleilevens, Christian; Hein, Marc] Univ Excellence, Rhein Westfal TH Aachen, Univ Hosp, Dept Anesthesiol, Aachen, Germany; [Goetzenich, Andreas] Univ Excellence, Rhein Westfal TH Aachen, Univ Hosp, Dept Cardiothorac & Vasc Surg, Aachen, Germany; [Weis, Joachim] Univ Excellence, Rhein Westfal TH Aachen, Univ Hosp, Inst Neuropathol, Aachen, Germany; [Weis, Joachim] Univ Excellence, Rhein Westfal TH Aachen, Univ Hosp, JARA Translat Brain Med, Aachen, Germany; [Wiggs, Michael P.; Powers, Scott K.] Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL USA	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; State University System of Florida; University of Florida	Bruells, CS (corresponding author), Univ Excellence, Rhein Westfal TH Aachen, Univ Hosp, Dept Surg Intens & Intermediate Care, Aachen, Germany.	cbruells@ukaachen.de	Bleilevens, Christian/AAG-8034-2020; Weis, Joachim/G-1984-2014	Bleilevens, Christian/0000-0002-2104-1843; Weis, Joachim/0000-0003-3280-6773	Deutsche Forschungsgemeinschaft [RO 2000/14]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The work has been funded by the Deutsche Forschungsgemeinschaft (RO 2000/14). CSB was research fellow of the medical faculty of the RWTH Aachen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANZUETO A, 1992, J APPL PHYSIOL, V72, P529, DOI 10.1152/jappl.1992.72.2.529; Bercault N, 2004, CRIT CARE MED, V32, P998, DOI 10.1097/01.CCM.0000119422.93413.08; Callahan LA, 2005, AM J RESP CRIT CARE, V172, P861, DOI 10.1164/rccm.200410-1344OC; Cholette J, 2009, CRIT CARE MED, V37, pA434, DOI 10.1097/CCM.0b013e3181b6e760; Criswell DS, 2003, CHEST, V124, P2302, DOI 10.1378/chest.124.6.2302; Esteban A, 1999, AM J RESP CRIT CARE, V159, P512, DOI 10.1164/ajrccm.159.2.9803106; Frutos-Vivar F, 2011, J CRIT CARE, V26, P502, DOI 10.1016/j.jcrc.2010.12.015; Gayan-Ramirez G, 2003, INTENS CARE MED, V29, P825, DOI 10.1007/s00134-003-1688-0; Huang TT, 2011, J THORAC CARDIOV SUR, V142, P1214, DOI 10.1016/j.jtcvs.2011.02.025; Hussain SNA, 2010, AM J RESP CRIT CARE, V182, P1377, DOI 10.1164/rccm.201002-0234OC; Jaber S, 2008, ANESTHESIOLOGY, V108, P651, DOI 10.1097/ALN.0b013e31816725a6; Jaber S, 2011, CRIT CARE, V15, DOI 10.1186/cc10023; Jiang TX, 1998, AM J RESP CRIT CARE, V157, P736, DOI 10.1164/ajrccm.157.3.9707056; KILARSKI W, 1990, J ANAT, V168, P13; Levine S, 1997, NEW ENGL J MED, V337, P1799, DOI 10.1056/NEJM199712183372503; McClung JM, 2009, AM J PHYSIOL-CELL PH, V296, pC363, DOI 10.1152/ajpcell.00497.2008; McClung JM, 2007, FASEB J, V21, pA1306; McClung JM, 2007, AM J RESP CRIT CARE, V175, P150, DOI 10.1164/rccm.200601-142OC; Nelson WB, 2012, CRIT CARE MED, V40, P1857, DOI 10.1097/CCM.0b013e318246bb5d; Powers SK, 2011, CRIT CARE MED, V39, P1749, DOI 10.1097/CCM.0b013e3182190b62; Powers SK, 2002, J APPL PHYSIOL, V92, P1851, DOI 10.1152/japplphysiol.00881.2001; Quinnell TG, 2006, CHEST, V129, P133, DOI 10.1378/chest.129.1.133; Richard C, 2005, INTENS CARE MED, V31, P1605, DOI 10.1007/s00134-005-2698-x; Smuder AJ, 2010, FREE RADICAL BIO MED, V49, P1152, DOI 10.1016/j.freeradbiomed.2010.06.025; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Thomas D, 2013, J APPL PHYSIOL, V115, P775, DOI 10.1152/japplphysiol.00302.2012; Van Gammeren D, 2005, CHEST, V127, P2204, DOI 10.1378/chest.127.6.2204; Whidden MA, 2010, J APPL PHYSIOL, V108, P1376, DOI 10.1152/japplphysiol.00098.2010; Whidden MA, 2009, J APPL PHYSIOL, V106, P385, DOI 10.1152/japplphysiol.91106.2008	29	15	15	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2014	9	1							e87460	10.1371/journal.pone.0087460	http://dx.doi.org/10.1371/journal.pone.0087460			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301BI	24475293	gold, Green Submitted, Green Published			2023-01-03	WOS:000330507300188
J	Yang, AX; Chong, NJ; Jiang, YF; Catalano, J; Puri, RK; Khleif, SN				Yang, Amy X.; Chong, Numju; Jiang, Yufei; Catalano, Jennifer; Puri, Raj K.; Khleif, Samir N.			Molecular Characterization of Antigen-Peptide Pulsed Dendritic Cells: Immature Dendritic Cells Develop a Distinct Molecular Profile when Pulsed with Antigen Peptide	PLOS ONE			English	Article							NECROSIS-FACTOR-ALPHA; OLIGONUCLEOTIDE MICROARRAYS; INTERFERON-GAMMA; GENE-EXPRESSION; CERVICAL-CANCER; TUMOR-ANTIGEN; IN-VITRO; MATURATION; INDUCTION; IMMUNITY	As dendritic cells (DCs) are the most potent professional antigen-presenting cells, they are being tested as cancer vaccines for immunotherapy of established cancers. Although numerous studies have characterized DCs by their phenotype and function, few have identified potential molecular markers of antigen presentation prior to vaccination of host. In this study we generated pre-immature DC (piDC), immature DC (iDC), and mature DC (mDC) from human peripheral blood monocytes (PBMC) obtained from HLA-A2 healthy donors, and pulsed them with human papillomavirus E7 peptide (p11-20), a class I HLA-A2 binding antigen. We then characterized DCs for cell surface phenotype and gene expression profile by microarray technology. We identified a set of 59 genes that distinguished three differentiation stages of DCs (piDC, iDC and mDC). When piDC, iDC and mDC were pulsed with E7 peptide for 2 hrs, the surface phenotype did not change, however, iDCs rather than mDCs showed transcriptional response by up-regulation of a set of genes. A total of 52 genes were modulated in iDC upon antigen pulsing. Elongation of pulse time for iDCs to 10 and 24 hrs did not significantly bring further changes in gene expression. The E7 peptide up-modulated immune response (KPNA7, IGSF6, NCR3, TREM2, TUBAL3, IL8, NFKBIA), pro-apoptosis (BTG1, SEMA6A, IGFBP3 and SRGN), anti-apoptosis (NFKBIA), DNA repair (MRPS11, RAD21, TXNRD1), and cell adhesion and cell migration genes (EPHA1, PGF, IL8 and CYR61) in iDCs. We confirmed our results by Q-PCR analysis. The E7 peptide but not control peptide (PADRE) induced up-regulation of NFKB1A gene only in HLA-A2 positive iDCs and not in HLA-A2 negative iDCs. These results suggest that E7 up-regulation of genes is specific and HLA restricted and that these genes may represent markers of antigen presentation and help rapidly assess the quality of dendritic cells prior to administration to the host.	[Yang, Amy X.; Catalano, Jennifer; Puri, Raj K.] US FDA, Tumor Vaccines & Biotechnol Branch, Div Cellular & Gene Therapies, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA; [Chong, Numju; Jiang, Yufei; Khleif, Samir N.] NCI, Vaccine Branch, Bethesda, MD 20892 USA; [Khleif, Samir N.] Georgia Regent Univ, Ctr Canc, Augusta, GA USA	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Georgia; Augusta University	Puri, RK (corresponding author), US FDA, Tumor Vaccines & Biotechnol Branch, Div Cellular & Gene Therapies, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA.	raj.puri@fda.hhs.gov	jiang, yu/HGU-0029-2022					Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592; Beatty P, 2012, ONCOIMMUNOLOGY, V1, P263, DOI 10.4161/onci.18950; Carlos CA, 2005, J IMMUNOL, V175, P1628, DOI 10.4049/jimmunol.175.3.1628; Cascio S, 2011, J BIOL CHEM, V286, P42248, DOI 10.1074/jbc.M111.297630; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; Cools N, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-49; Dietz AB, 2000, BIOCHEM BIOPH RES CO, V275, P731, DOI 10.1006/bbrc.2000.3372; Han J, 2005, GENOMICS, V86, P252, DOI 10.1016/j.ygeno.2005.04.009; Han TH, 2009, J IMMUNOTHER, V32, P399, DOI 10.1097/CJI.0b013e31819e1773; Jin P, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-4; Jonuleit H, 1997, EUR J IMMUNOL, V27, P3135, DOI 10.1002/eji.1830271209; Le Naour F, 2001, J BIOL CHEM, V276, P17920, DOI 10.1074/jbc.M100156200; Lindstedt M, 2002, INT IMMUNOL, V14, P1203, DOI 10.1093/intimm/dxf082; McIlroy D, 2005, J LEUKOCYTE BIOL, V78, P794, DOI 10.1189/jlb.0105029; Messmer D, 2003, INT IMMUNOL, V15, P491, DOI 10.1093/intimm/dxg052; Moschella F, 2001, BRIT J HAEMATOL, V114, P444, DOI 10.1046/j.1365-2141.2001.02953.x; Murakami M, 1999, CANCER RES, V59, P1184; Sallusto F, 2018, J IMMUNOL, V200, P887, DOI 10.1084/jem.179.4.1109; Santin AD, 1999, J VIROL, V73, P5402, DOI 10.1128/JVI.73.7.5402-5410.1999; Schlom J, 2012, JNCI-J NATL CANCER I, V104, P599, DOI 10.1093/jnci/djs033; Soumelis V, 2006, EUR J IMMUNOL, V36, P2286, DOI 10.1002/eji.200636026; Tsukui T, 1996, CANCER RES, V56, P3967; Tureci O, 2003, FASEB J, V17, P836, DOI 10.1096/fj.02-0724com; Welters MJP, 2008, CLIN CANCER RES, V14, P178, DOI 10.1158/1078-0432.CCR-07-1880; Yang AX, 2006, MOL BIOTECHNOL, V34, P303, DOI 10.1385/MB:34:3:303	26	11	12	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2014	9	1							e86306	10.1371/journal.pone.0086306	http://dx.doi.org/10.1371/journal.pone.0086306			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301BI	24475103	Green Published, gold, Green Submitted			2023-01-03	WOS:000330507300052
J	Cuypers, K; Thijs, H; Meesen, RLJ				Cuypers, Koen; Thijs, Herbert; Meesen, Raf L. J.			Optimization of the Transcranial Magnetic Stimulation Protocol by Defining a Reliable Estimate for Corticospinal Excitability	PLOS ONE			English	Article							MOTOR-EVOKED-POTENTIALS; LONGITUDINAL DATA-ANALYSIS; BRAIN-STIMULATION; MUSCLE; CORTEX; VARIABILITY; RESPONSES; OUTPUT; AGE	The goal of this study was to optimize the transcranial magnetic stimulation (TMS) protocol for acquiring a reliable estimate of corticospinal excitability (CSE) using single-pulse TMS. Moreover, the minimal number of stimuli required to obtain a reliable estimate of CSE was investigated. In addition, the effect of two frequently used stimulation intensities [110% relative to the resting motor threshold (rMT) and 120% rMT] and gender was evaluated. Thirty-six healthy young subjects (18 males and 18 females) participated in a double-blind crossover procedure. They received 2 blocks of 40 consecutive TMS stimuli at either 110% rMT or 120% rMT in a randomized order. Based upon our data, we advise that at least 30 consecutive stimuli are required to obtain the most reliable estimate for CSE. Stimulation intensity and gender had no significant influence on CSE estimation. In addition, our results revealed that for subjects with a higher rMT, fewer consecutive stimuli were required to reach a stable estimate of CSE. The current findings can be used to optimize the design of similar TMS experiments.	[Cuypers, Koen; Meesen, Raf L. J.] Hasselt Univ, Fac Med & Life Sci, REVAL Rehabil Res Ctr, Biomed Res Inst, Diepenbeek, Belgium; [Cuypers, Koen; Meesen, Raf L. J.] Katholieke Univ Leuven, Motor Control Lab, Res Ctr Movement Control & Neuroplast, Dept Biomed Kinesiol,Grp Biomed Sci, Heverlee, Belgium; [Thijs, Herbert] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat, BioStat 1, Diepenbeek, Belgium; [Thijs, Herbert] Univ Louvain, Interuniv Inst Biostat & Stat Bioinformat, BioStat 1, Louvain, Belgium	Hasselt University; KU Leuven; Hasselt University; Hasselt University	Meesen, RLJ (corresponding author), Hasselt Univ, Fac Med & Life Sci, REVAL Rehabil Res Ctr, Biomed Res Inst, Diepenbeek, Belgium.	raf.meesen@uhasselt.be	Meesen, Raf L/F-2582-2019; Cuypers, Koen/N-9918-2018	Meesen, Raf L/0000-0002-7938-3758; 	Flanders Fund for Scientific Research [G075810]; Special Research Fund UHasselt	Flanders Fund for Scientific Research(FWO); Special Research Fund UHasselt	This work is supported by the Flanders Fund for Scientific Research (G075810). Koen Cuypers is supported by the Special Research Fund UHasselt. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BRASILNETO JP, 1992, J CLIN NEUROPHYSIOL, V9, P132, DOI 10.1097/00004691-199201000-00014; Buccolieri A, 2004, J PHYSIOL-LONDON, V558, P685, DOI 10.1113/jphysiol.2004.064774; Choudhury KR, 2011, IRISH J MED SCI, V180, P873, DOI 10.1007/s11845-011-0722-4; Christie A, 2007, J NEUROSCI METH, V164, P320, DOI 10.1016/j.jneumeth.2007.05.011; Cuypers K, 2013, NEUROSCI LETT; Darling WG, 2006, EXP BRAIN RES, V174, P376, DOI 10.1007/s00221-006-0468-9; Ellaway PH, 1998, ELECTROMYOGR MOTOR C, V109, P104, DOI 10.1016/S0924-980X(98)00007-1; Ferreri F, 2003, ANN NEUROL, V53, P102, DOI 10.1002/ana.10416; Fujiyama H, 2012, J COGNITIVE NEUROSCI, V24, P1253, DOI 10.1162/jocn_a_00201; Funase K, 1999, NEUROSCI LETT, V271, P25, DOI 10.1016/S0304-3940(99)00467-X; Grupe DW, 2013, NAT REV NEUROSCI, V14, P488, DOI 10.1038/nrn3524; HESS CW, 1987, J PHYSIOL-LONDON, V388, P397, DOI 10.1113/jphysiol.1987.sp016621; Julkunen P, 2009, NEUROIMAGE, V44, P790, DOI 10.1016/j.neuroimage.2008.09.040; Jung NH, 2010, BRAIN STIMUL, V3, P87, DOI 10.1016/j.brs.2009.10.003; KIERS L, 1993, ELECTROEN CLIN NEURO, V89, P415, DOI 10.1016/0168-5597(93)90115-6; KOKATE TG, 1994, J PHARMACOL EXP THER, V270, P1223; LAN NC, 1994, HORM BEHAV, V28, P537, DOI 10.1006/hbeh.1994.1052; Levin O, 2011, NEUROSCI LETT, V487, P53, DOI 10.1016/j.neulet.2010.09.072; Lewis GN, 2013, CLIN NEUROPHYSIOL; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Magistris MR, 1999, BRAIN, V122, P265, DOI 10.1093/brain/122.2.265; Magistris MR, 1998, BRAIN, V121, P437, DOI 10.1093/brain/121.3.437; Mantovani A, 2013, PSYCHIAT RES; Mars RB, 2007, EXP BRAIN RES, V182, P125, DOI 10.1007/s00221-007-1055-4; Meesen RLJ, 2011, HUM BRAIN MAPP, V32, P872, DOI 10.1002/hbm.21075; MEYER BU, 1991, ELECTROEN CLIN NEURO, V81, P38, DOI 10.1016/0168-5597(91)90102-4; Nielsen JF, 1996, J CLIN NEUROPHYSIOL, V13, P423, DOI 10.1097/00004691-199609000-00005; Nitsche MA, 2005, J PHYSIOL-LONDON, V568, P291, DOI 10.1113/jphysiol.2005.092429; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pennisi G, 2002, CLIN NEUROPHYSIOL, V113, P1536, DOI 10.1016/S1388-2457(02)00255-9; Pitcher JB, 2003, J PHYSIOL-LONDON, V546, P605, DOI 10.1113/jphysiol.2002.029454; Rosler KM, 2002, CLIN NEUROPHYSIOL, V113, P1680, DOI 10.1016/S1388-2457(02)00263-8; Sahota Preeti, 2005, Neurol India, V53, P197; Smith AE, 2011, J APPL PHYSIOL, V110, P206, DOI 10.1152/japplphysiol.00403.2010; Smith MJ, 1999, NEUROLOGY, V53, P2069, DOI 10.1212/WNL.53.9.2069; Smith MJ, 2002, ANN NEUROL, V51, P599, DOI 10.1002/ana.10180; Taylor JL, 2001, MUSCLE NERVE, V24, P18, DOI 10.1002/1097-4598(200101)24:1<18::AID-MUS2>3.3.CO;2-4; Vaalto S, 2011, HUM BRAIN MAPP, V32, P1692, DOI 10.1002/hbm.21137; Veniero D, 2013, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00352; Wassermann EM, 2002, CLIN NEUROPHYSIOL, V113, P1165, DOI 10.1016/S1388-2457(02)00144-X; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	42	49	49	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2014	9	1							e86380	10.1371/journal.pone.0086380	http://dx.doi.org/10.1371/journal.pone.0086380			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298QQ	24475111	Green Published, Green Submitted, gold			2023-01-03	WOS:000330339800041
J	Cheah, KY; Howarth, GS; Bastian, SEP				Cheah, Ker Yeaw; Howarth, Gordon Stanley; Bastian, Susan Elaine Putnam			Grape Seed Extract Dose-Responsively Decreases Disease Severity in a Rat Model of Mucositis; Concomitantly Enhancing Chemotherapeutic Effectiveness in Colon Cancer Cells	PLOS ONE			English	Article							SMALL-INTESTINAL MUCOSITIS; PROANTHOCYANIDIN EXTRACT; LINE CACO-2; BREATH TEST; 5-FLUOROURACIL; APOPTOSIS; EXPRESSION; GROWTH; METHOTREXATE; INFLAMMATION	Objective: Mucositis is a serious disorder of the gastrointestinal tract that results from cancer chemotherapy. We investigated the effects of increasing grape seed extract doses on the severity of chemotherapy in a rat model and its coincident impact on chemotherapeutic effectiveness in colon cancer cells. Design: Female Dark Agouti rats were gavaged with grape seed extract (400-1000 mg/kg) or water (day 3-11) and were injected intraperitoneally with 5-Fluorouracil (150 mg/kg) or saline (control) on day 9 to induce mucositis. Daily metabolic data were collected and rats were sacrificed on day 12. Intestinal tissues were collected for histological and myeloperoxidase analyses. Caco-2 cell viability was examined in response to grape seed extract in combination with 5-Fluorouracil by 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyl-tetrazolium bromide) assay. Results: Compared with 5-Fluorouracil controls, grape seed extract (400-1000 mg/kg) significantly decreased the histological damage score (P<0.05) in the jejunum. Grape seed extract (1000 mg/kg) increased jejunal crypt depth by 25% (P<0.05) in 5-Fluorouracil treated rats compared to 5-Fluorouracil controls, and attenuated the 5-Fluorouracil -induced reduction of mucosal thickness (25%, P<0.05). Grape seed extract (600 mg/kg) decreased myeloperoxidase activity by 55% (P<0.01) compared to 5-Fluorouracil controls. Grape seed extract was more effective at ameliorating 5-Fluorouracil induced intestinal injury, with effects most pronounced in the proximal jejunum. Grape seed extract (10-25 ug/mL) significantly enhanced the growth-inhibitory effects of 5-Fluorouracil by 26% (P<0.05) in Caco-2 cells and was more potent than 5-Fluorouracil at 50-100 mu g/mL. Conclusion: Grape seed extract may represent a new therapeutic option to decrease the symptoms of intestinal mucositis while concurrently impacting on the viability of colon cancer cells.	[Cheah, Ker Yeaw; Bastian, Susan Elaine Putnam] Univ Adelaide, Sch Agr Food & Wine, Adelaide, SA 5005, Australia; [Cheah, Ker Yeaw; Howarth, Gordon Stanley] Children Youth & Womens Hlth Serv, Ctr Paediat & Adolescent Gastroenterol, Adelaide, SA, Australia; [Howarth, Gordon Stanley] Univ Adelaide, Sch Anim & Vet Sci, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide	Bastian, SEP (corresponding author), Univ Adelaide, Sch Agr Food & Wine, Waite Campus, Adelaide, SA 5005, Australia.	sue.bastian@adelaide.edu.au	Howarth, Gordon/AAM-8699-2020	Howarth, Gordon/0000-0001-6979-6084; Bastian, Susan/0000-0002-8790-2044	South Australian Health and Medical Research Institute Cancer Council Senior Research Fellowship; University of Adelaide	South Australian Health and Medical Research Institute Cancer Council Senior Research Fellowship; University of Adelaide	Professor Gordon Howarth is supported by a South Australian Health and Medical Research Institute Cancer Council Senior Research Fellowship. No financial agreements are in place. This research was supported by The University of Adelaide, being a member of the Wine Innovation Cluster, Waite Campus, Adelaide, South Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal C, 2002, CARCINOGENESIS, V23, P1869, DOI 10.1093/carcin/23.11.1869; Appeldoorn MM, 2009, J AGR FOOD CHEM, V57, P1084, DOI 10.1021/jf803059z; Bagchi D, 1997, RES COMMUN MOL PATH, V95, P179; Bagchi DB, 2003, MUTAT RES-FUND MOL M, V523, P87, DOI 10.1016/S0027-5107(02)00324-X; Bindon KA, 2010, J AGR FOOD CHEM, V58, P2520, DOI 10.1021/jf9037453; Bowen JM, 2007, CANCER CHEMOTH PHARM, V59, P337, DOI 10.1007/s00280-006-0275-9; Cheah KY, 2013, DIGEST DIS SCI, V58, P970, DOI 10.1007/s10620-012-2464-1; Cheah KY, 2009, CANCER BIOL THER, V8, P382, DOI 10.4161/cbt.8.4.7453; Cho ML, 2009, IMMUNOL LETT, V124, P102, DOI 10.1016/j.imlet.2009.05.001; D'Archivio Massimo, 2007, Ann Ist Super Sanita, V43, P348; Dinicola S, 2010, BRIT J NUTR, V104, P824, DOI 10.1017/S0007114510001522; Duncan M, 2003, ALIMENT PHARM THER, V18, P853, DOI 10.1046/j.1365-2036.2003.01784.x; Engelbrecht AM, 2007, CANCER LETT, V258, P144, DOI 10.1016/j.canlet.2007.08.020; Fine A M, 2000, Altern Med Rev, V5, P144; Fishbein AB, 2009, ARCH PHARM RES, V32, P505, DOI 10.1007/s12272-009-1405-9; GLICK Z, 1970, J NUTR, V100, P509, DOI 10.1093/jn/100.5.509; Gu LW, 2004, J NUTR, V134, P613, DOI 10.1093/jn/134.3.613; Howarth GS, 1996, J NUTR, V126, P2519, DOI 10.1093/jn/126.10.2519; Hsu CP, 2009, ANTICANCER RES, V29, P283; Huynh-Delerme C, 2005, TOXICOL IN VITRO, V19, P439, DOI 10.1016/j.tiv.2004.08.003; Jordan A, 2003, EUR J NUTR, V42, P324, DOI 10.1007/s00394-003-0427-1; Keefe DM, 2008, EXPERT OPIN EMERG DR, V13, P511, DOI [10.1517/14728214.13.3.511, 10.1517/14728214.13.3.511 ]; Kodach LL, 2006, CARCINOGENESIS, V27, P508, DOI 10.1093/carcin/bgi307; KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344; Li WG, 2001, ACTA PHARMACOL SIN, V22, P1117; Logan RM, 2007, CANCER TREAT REV, V33, P448, DOI 10.1016/j.ctrv.2007.03.001; Manach C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/ajcn/79.5.727; Mauger CA, 2007, DIGEST DIS SCI, V52, P612, DOI 10.1007/s10620-006-9464-y; Pelton NS, 2004, SCAND J GASTROENTERO, V39, P1015, DOI 10.1080/00365520410003416; Santos-Buelga C, 2000, J SCI FOOD AGR, V80, P1094, DOI [10.1002/(SICI)1097-0010(20000515)80:7<1094::AID-JSFA569>3.3.CO;2-T, 10.1002/(SICI)1097-0010(20000515)80:7&lt;1094::AID-JSFA569&gt;3.0.CO;2-1]; Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370; Scalbert A, 2002, BIOMED PHARMACOTHER, V56, P276, DOI 10.1016/S0753-3322(02)00205-6; Soares PMG, 2008, CANCER CHEMOTH PHARM, V63, P91, DOI 10.1007/s00280-008-0715-9; Sonis ST, 1999, CANCER-AM CANCER SOC, V85, P2103, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2103::AID-CNCR2>3.0.CO;2-0; Stringer Andrea M, 2007, J Support Oncol, V5, P259; Terra X, 2011, J NUTR BIOCHEM, V22, P380, DOI 10.1016/j.jnutbio.2010.03.006; Terra X, 2009, J NUTR BIOCHEM, V20, P210, DOI 10.1016/j.jnutbio.2008.02.005; TOMAS FM, 1991, BIOCHEM J, V276, P547, DOI 10.1042/bj2760547; Tooley KL, 2006, CANCER BIOL THER, V5, P1275, DOI 10.4161/cbt.5.10.3303; Tsang C, 2005, BRIT J NUTR, V94, P170, DOI 10.1079/BJN20051480; Urpi-Sarda M, 2009, ANAL BIOANAL CHEM, V394, P1545, DOI 10.1007/s00216-009-2676-1; Watanabe H, 2013, MED MOL MORPHOL, V46, P97, DOI 10.1007/s00795-013-0012-5; Wren AF, 2002, J AGR FOOD CHEM, V50, P2180, DOI 10.1021/jf011066w; Yamakoshi J, 2002, FOOD CHEM TOXICOL, V40, P599, DOI 10.1016/S0278-6915(02)00006-6	44	39	40	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2014	9	1							e85184	10.1371/journal.pone.0085184	http://dx.doi.org/10.1371/journal.pone.0085184			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297GT	24465501	Green Published, Green Submitted, gold			2023-01-03	WOS:000330244500041
J	Scholefield, BR; Perkins, GD; Duncan, HP; Gao, F; Morris, KP				Scholefield, Barnaby R.; Perkins, Gavin D.; Duncan, Heather P.; Gao, Fang; Morris, Kevin P.			Should children who have a cardiac arrest be treated with therapeutic hypothermia?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							2010 INTERNATIONAL CONSENSUS; CARDIOVASCULAR CARE SCIENCE; CARDIOPULMONARY-RESUSCITATION; TREATMENT RECOMMENDATIONS; EPIDEMIOLOGY		[Scholefield, Barnaby R.; Duncan, Heather P.; Morris, Kevin P.] Birmingham Childrens Hosp, Intens Care Unit, Birmingham B4 6NH, W Midlands, England; [Scholefield, Barnaby R.; Gao, Fang] Univ Birmingham, Perioperat Anaesthesia & Crit Care Trials Grp, Birmingham B15 2TT, W Midlands, England; [Perkins, Gavin D.] Univ Warwick & Heart England NHS Fdn Trust, Coventry, W Midlands, England	University of Birmingham; University of Birmingham; Heart of England NHS Foundation Trust	Scholefield, BR (corresponding author), Birmingham Childrens Hosp, Intens Care Unit, Birmingham B4 6NH, W Midlands, England.	Barney.scholefield@bch.nhs.uk	Scholefield, Barney/ABG-7312-2021; Duncan, Heather/AAX-4143-2020; Perkins, Gavin/E-7613-2010; Smith, Fang G/H-8451-2018	Duncan, Heather/0000-0003-1771-8644; Smith, Fang G/0000-0002-8095-0609; Perkins, Gavin/0000-0003-3027-7548; Scholefield, Barney/0000-0002-6198-4985				Abend NS, 2009, NEUROLOGY, V72, P1931, DOI 10.1212/WNL.0b013e3181a82687; Atkins DL, 2009, CIRCULATION, V119, P1484, DOI 10.1161/CIRCULATIONAHA.108.802678; Bembea MM, 2010, PEDIATR CRIT CARE ME, V11, P723, DOI 10.1097/PCC.0b013e3181dde659; Buttram S, 2009, CRITICAL CARE MED S, V37, P480; de Caen AR, 2010, RESUSCITATION, V81, pE213, DOI 10.1016/j.resuscitation.2010.08.028; Deakin CD, 2010, RESUSCITATION, V81, pE93, DOI 10.1016/j.resuscitation.2010.08.027; Deasy C, 2010, RESUSCITATION, V81, P1095, DOI 10.1016/j.resuscitation.2010.04.029; Doherty DR, 2009, CIRCULATION, V119, P1492, DOI 10.1161/CIRCULATIONAHA.108.791384; Fink EL, 2010, PEDIATR CRIT CARE ME, V11, P66, DOI 10.1097/PCC.0b013e3181c58237; Haque IU, 2006, PEDIATR CRIT CARE ME, V7, P7, DOI 10.1097/01.PCC.0000192322.45123.80; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Meert KL, 2009, PEDIATR CRIT CARE ME, V10, P544, DOI 10.1097/PCC.0b013e3181a7045c; Moler FW, 2011, CRIT CARE MED, V39, P141, DOI 10.1097/CCM.0b013e3181fa3c17; Nielsen N, 2011, INT J CARDIOL, V151, P333, DOI 10.1016/j.ijcard.2010.06.008; Scholefield B, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009442.pub2; Scholefield BR, 2010, ARCH DIS CHILD, V95, P796, DOI 10.1136/adc.2009.176735; Topjian A, 2011, PEDIATR CRIT CARE ME, V12, pE127, DOI 10.1097/PCC.0b013e3181e28717; Zhao H, 2007, J CEREBR BLOOD F MET, V27, P1879, DOI 10.1038/sj.jcbfm.9600540	20	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 16	2014	348								f7672	10.1136/bmj.f7672	http://dx.doi.org/10.1136/bmj.f7672			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293MP	24435412				2023-01-03	WOS:000329976100001
J	Kiguli, S; Akech, SO; Mtove, G; Opoka, RO; Engoru, C; Olupot-Olupot, P; Nyeko, R; Evans, J; Crawley, J; Prevatt, N; Reyburn, H; Levin, M; George, EC; South, A; Babiker, AG; Gibb, DM; Maitland, K				Kiguli, Sarah; Akech, Samuel O.; Mtove, George; Opoka, Robert O.; Engoru, Charles; Olupot-Olupot, Peter; Nyeko, Richard; Evans, Jennifer; Crawley, Jane; Prevatt, Natalie; Reyburn, Hugh; Levin, Michael; George, Elizabeth C.; South, Annabelle; Babiker, Abdel G.; Gibb, Diana M.; Maitland, Kathryn			WHO guidelines on fluid resuscitation in children: missing the FEAST data	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							AFRICAN CHILDREN; SEPTIC SHOCK; BOLUS; MORTALITY; SUPPORT; SEPSIS		[Kiguli, Sarah; Opoka, Robert O.] Makerere Univ, Mulago Hosp, Dept Paediat, Kampala, Uganda; [Akech, Samuel O.] Kilifi Clin Trials Facil, KEMRI Wellcome Trust Res Programme, Kilifi, Kenya; [Mtove, George] Hosp Teule, Joint Malaria Programme, Dept Paediat, Muheza, Tanzania; [Engoru, Charles] Soroti Reg Referral Hosp, Dept Paediat, Soroti, Uganda; [Olupot-Olupot, Peter] Mbale Reg Referral Hosp, Dept Paediat, Mbale, Uganda; [Nyeko, Richard] St Marys Hosp, Dept Paediat, Lacor, Uganda; [Evans, Jennifer] Univ Wales Hosp, Dept Paediat, Cardiff CF4 4XW, S Glam, Wales; [Crawley, Jane] Univ Oxford, Nuffield Dept Med, Oxford, England; [Prevatt, Natalie; Levin, Michael; Maitland, Kathryn] Fac Med, Dept Paediat, Wellcome Trust Ctr Clin Trop Med, London W2 1PG, England; [Reyburn, Hugh] Joint Malaria Programme, Moshi, Tanzania; [George, Elizabeth C.; South, Annabelle; Babiker, Abdel G.; Gibb, Diana M.] UCL, Med Res Council, Clin Trials Unit, London, England	Makerere University; Mulago National Referral Hospital; Cardiff University; University of Oxford; University of London; London School of Hygiene & Tropical Medicine; Medical Research Council Clinical Trials Unit; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of London; University College London	Maitland, K (corresponding author), Fac Med, Dept Paediat, Wellcome Trust Ctr Clin Trop Med, St Marys Campus, London W2 1PG, England.	k.maitland@imperial.ac.uk	George, Elizabeth/V-3381-2017	George, Elizabeth/0000-0002-2928-3580; Maitland, Kathryn/0000-0002-0007-0645; Levin, Michael/0000-0003-2767-6919; Mtove, George/0000-0001-5173-0829; South, Annabelle/0000-0001-8912-2001	Medical Research Council [G0601027, G0801439] Funding Source: researchfish; MRC [G0601027, G0801439] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akech S, 2010, BMJ-BRIT MED J, V341, pc4416; [Anonymous], 2012, WHO TECH REP SER, V972, P1; Brierley J, 2009, CRIT CARE MED, V37, P666, DOI 10.1097/CCM.0b013e31819323c6; Dellinger RP, 2008, INTENS CARE MED, V34, P17, DOI 10.1007/s00134-007-0934-2; Dondorp AM, 2010, LANCET, V376, P1647, DOI 10.1016/S0140-6736(10)61924-1; Dunser MW, 2012, INTENS CARE MED, V38, P557, DOI [10.1007/s00134-012-2468-5, 10.1007/s00134-012-2521-4]; Duke T, 2011, LANCET, V378, P1685, DOI 10.1016/S0140-6736(11)60881-7; Ford N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043953; Hilton AK, 2012, CRIT CARE, V16, DOI 10.1186/cc11154; Kleinman ME, 2010, CIRCULATION, V122, pS876, DOI 10.1161/CIRCULATIONAHA.110.971101; Maitland K, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-68; Maitland K, 2011, NEW ENGL J MED, V365, P1351; Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549; Otieno H, 2004, ARCH DIS CHILD, V89, P977, DOI 10.1136/adc.2003.043901; Pamba A, 2004, ARCH DIS CHILD, V89, P950, DOI 10.1136/adc.2003.032516; Ralston ME, 2013, LANCET, V381, P256, DOI 10.1016/S0140-6736(12)61191-X; Sleight P., 2000, CURR CONTR TRIALS C, V1, P25; Southall DP, 2011, ARCH DIS CHILD, V96, P905, DOI 10.1136/archdischild-2011-300436; World Health Organization, 2005, EM TRIAG ASS TREATM; World Health Organization, 2013, GUIDELINES MANAGEMEN; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	21	13	13	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 14	2014	348								f7003	10.1136/bmj.f7003	http://dx.doi.org/10.1136/bmj.f7003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293MN	24423891	Green Published, Green Accepted, Green Submitted, hybrid			2023-01-03	WOS:000329975900002
J	Menzies, AM; Haydu, LE; Carlino, MS; Azer, MWF; Carr, PJA; Kefford, RF; Long, GV				Menzies, Alexander M.; Haydu, Lauren E.; Carlino, Matteo S.; Azer, Mary W. F.; Carr, Peter J. A.; Kefford, Richard F.; Long, Georgina V.			Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma	PLOS ONE			English	Article							BRAF-MUTANT; TUMOR MICROENVIRONMENT; MEK INHIBITION; VEMURAFENIB; DABRAFENIB	Background: MAPK inhibitors (MAPKi) are active in BRAF-mutant metastatic melanoma patients, but the extent of response and progression-free survival (PFS) is variable, and complete responses are rare. We sought to examine the patterns of response and progression in patients treated with targeted therapy. Methods: MAPKi-naive patients treated with combined dabrafenib and trametinib had all metastases >= 5 mm (lymph nodes >= 15 mm in short axis) visible on computed tomography measured at baseline and throughout treatment. Results: 24 patients had 135 measured metastases (median 4.5/patient, median diameter 16 mm). Time to best response (median 5.5 mo, range 1.7-20.1 mo), and the degree of best response (median -70%, range +9 to -100%) varied amongst patients. 17% of patients achieved complete response (CR), whereas 53% of metastases underwent CR, including 42% >= 10 mm. Metastases that underwent CR were smaller than non-CR metastases (median 11 vs 20 mm, P<0.001). PFS was variable among patients (median 8.2 mo, range 2.6-18.3 mo), and 50% of patients had disease progression in new metastases only. Only 1% (1/71) of CR-metastases subsequently progressed. Twelve-month overall survival was poorer in those with a more heterogeneous initial response to therapy than less heterogeneous (67% vs 93%, P=0.009). Conclusion: Melanoma response and progression with MAPKi displays marked inter-and intra-patient heterogeneity. Most metastases undergo complete response, yet only a small proportion of patients achieve an overall complete response. Similarly, disease progression often occurs only in a subset of the tumor burden, and often in new metastases alone. Clinical heterogeneity, likely reflecting molecular heterogeneity, remains a barrier to the effective treatment of melanoma patients.	[Menzies, Alexander M.; Haydu, Lauren E.; Carlino, Matteo S.; Kefford, Richard F.; Long, Georgina V.] Melanoma Inst Australia, Sydney, NSW, Australia; [Menzies, Alexander M.; Haydu, Lauren E.; Carlino, Matteo S.; Carr, Peter J. A.; Kefford, Richard F.; Long, Georgina V.] Univ Sydney, Sydney, NSW 2006, Australia; [Carlino, Matteo S.; Azer, Mary W. F.; Kefford, Richard F.] Westmead Hosp, Crown Princess Mary Canc Ctr, Sydney, NSW, Australia; [Carr, Peter J. A.] Westmead Hosp, Dept Radiol, Sydney, NSW, Australia; [Carlino, Matteo S.; Kefford, Richard F.] Westmead Inst Canc Res, Westmead, NSW, Australia	Melanoma Institute Australia; University of Sydney; University of Sydney; University of Sydney; University of Sydney	Menzies, AM (corresponding author), Melanoma Inst Australia, Sydney, NSW, Australia.	alexander.menzies@sydney.edu.au	Long, Georgina V/C-1771-2013; Carlino, Matteo/GRS-7198-2022	Long, Georgina V/0000-0001-8894-3545; Menzies, Alexander Maxwell/0000-0001-5183-7562; Kefford, Richard/0000-0001-9251-9229; Carlino, Matteo/0000-0002-7861-4104	National Health and Medical Research Council of Australia (NHMRC); Cancer Institute NSW; Australian Cancer Research Foundation; Melanoma Foundation of the University of Sydney; Melanoma Institute Australia; GlaxoSmithKline	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW; Australian Cancer Research Foundation; Melanoma Foundation of the University of Sydney(University of Sydney); Melanoma Institute Australia; GlaxoSmithKline(GlaxoSmithKline)	This work was supported by Program Grants from the National Health and Medical Research Council of Australia (NHMRC), Cancer Institute NSW, Australian Cancer Research Foundation, the Melanoma Foundation of the University of Sydney and Melanoma Institute Australia. GlaxoSmithKline funded the clinical trial from which these data were obtained. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ackerman A, 2013, CANCER IN PRESS; Ascierto PA, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-107; Azer MF, 2013, CANCER IN PRESS; Carlino MS, 2013, MOL CANCER THER, V12, P1332, DOI 10.1158/1535-7163.MCT-13-0011; Carlino MS, 2013, EUR J CANCER, V49, P395, DOI 10.1016/j.ejca.2012.08.018; Chan M, 2013, J CLIN ONCOLOGY, V31; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Frederick DT, 2013, CLIN CANCER RES, V19, P1225, DOI 10.1158/1078-0432.CCR-12-1630; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Katona TM, 2007, AM J SURG PATHOL, V31, P1029, DOI 10.1097/PAS.0b013e31802b3488; Kim KB, 2011, J CLIN ONCOLOGY, V29; Lin J, 2011, BRIT J CANCER, V104, P464, DOI 10.1038/sj.bjc.6606072; McArthur GA, 2012, J CLIN ONCOL, V30, P1628, DOI 10.1200/JCO.2011.39.1938; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Takata M, 2000, INT J CANCER, V85, P492, DOI 10.1002/(SICI)1097-0215(20000215)85:4<492::AID-IJC8>3.3.CO;2-R; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wilmott JS, 2012, MOL CANCER THER, V11, P2704, DOI 10.1158/1535-7163.MCT-12-0530; Wilmott JS, 2012, CLIN CANCER RES, V18, P1386, DOI 10.1158/1078-0432.CCR-11-2479; Yancovitz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029336	22	58	58	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2014	9	1							e85004	10.1371/journal.pone.0085004	http://dx.doi.org/10.1371/journal.pone.0085004			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286IW	24400126	Green Published, Green Submitted, gold			2023-01-03	WOS:000329462700060
J	Donati, S; Satolli, R; Colombo, C; Senatore, S; Cotichini, R; Da Cas, R; Alegiani, SS; Mosconi, P				Donati, Serena; Satolli, Roberto; Colombo, Cinzia; Senatore, Sabrina; Cotichini, Rodolfo; Da Cas, Roberto; Alegiani, Stefania Spila; Mosconi, Paola			Informing Women on Menopause and Hormone Therapy: Know the Menopause a Multidisciplinary Project Involving Local Healthcare System	PLOS ONE			English	Article								Background: Hormone therapy (HT) in the menopause is still a tricky question among healthcare providers, women and mass media. Informing women about hormone replacement therapy was a Consensus Conference (CC) organized in 2008: the project Know the Menopause has been launched to shift out the results to women and healthcare providers and to assess the impact of the cc's statement. Methods: And Findings: The project, aimed at women aged 45-60 years, was developed in four Italian Regions: Lombardy, Tuscany, Lazio, Sicily, each with one Local Health Unit (LHU) as "intervention" and one as "control". Activities performed were: survey on the press; training courses for health professionals; educational materials for target populations; survey aimed at women, general practitioners (GPs), and gynaecologists; data analysis on HT drugs' prescription. Local activities were: training courses; public meetings; dissemination on mass media. About 3,700 health professionals were contacted and 1,800 participated in the project. About 146,500 printed leaflets on menopause were distributed to facilitate the dialogue among women and health care professionals. Training courses and educational cascade-process activities: participation ranged 25-72% of GPs, 17-71% of gynaecologists, 14-78% of pharmacists, 34-85% of midwives. Survey: 1,281 women interviewed. More than 90% believed menopause was a normal phase in life. More than half did not receive information about menopause and therapies. HT prescription analysis: prevalence fell from 6% to 4% in five years. No differences in time trends before-after the intervention. Major limitations are: organizational difficulties met by LHU, too short time for some local activities. Conclusions: A huge amount of information was spread through health professionals and women. The issue of menopause was also used to discuss women's wellbeing. This project offered an opportunity to launch a multidisciplinary, multimodal approach to menopause looking not only at pharmacological aspects, but also at quality of life and information.	[Donati, Serena; Senatore, Sabrina; Cotichini, Rodolfo; Da Cas, Roberto; Alegiani, Stefania Spila] Ist Super Sanita, Ctr Nazl Epidemiol Sorveglianza & Promoz Salute, I-00161 Rome, Italy; [Satolli, Roberto] Agenzia Editoria Sci Zadig, Milan, Italy; [Colombo, Cinzia; Mosconi, Paola] IRCCS, Ist Ric Farmacol Mario Negri, Lab Med Res & Consumers Involvement, Milan, Italy	Istituto Superiore di Sanita (ISS); Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Mosconi, P (corresponding author), IRCCS, Ist Ric Farmacol Mario Negri, Lab Med Res & Consumers Involvement, Milan, Italy.	paola.mosconi@marionegri.it	Colombo, Cinzia/K-8981-2016; Paola, Mosconi/K-5596-2016; COLOMBO, CINZIA/ABG-6433-2020	Colombo, Cinzia/0000-0001-6639-694X; Paola, Mosconi/0000-0003-0415-3744; COLOMBO, CINZIA/0000-0001-6639-694X; Donati, Serena/0000-0002-4607-2072	Italian Agency for Drugs (AIFA)	Italian Agency for Drugs (AIFA)	This work was supported by the Italian Agency for Drugs (AIFA) in the context of a multi-regional project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, MENOPAUSE, V19, P257, DOI 10.1097/gme.0b013e31824b970a; Colombo C, 2010, EUR J OBSTET GYN R B, V153, P56, DOI 10.1016/j.ejogrb.2010.07.026; de Villiers TJ, 2013, CLIMACTERIC, V16, P203, DOI 10.3109/13697137.2013.771520; Donati S, 2009, MATURITAS, V63, P246, DOI 10.1016/j.maturitas.2009.04.001; Guallar E, 2013, ANN INTERN MED, V158, P69, DOI 10.7326/0003-4819-158-1-201301010-00015; Mosconi P, 2010, OBSTET GYNECOL, V116, P442, DOI 10.1097/AOG.0b013e3181eb539c; Mosconi Paola, 2009, BMC Womens Health, V9, P14, DOI 10.1186/1472-6874-9-14; Mosconi P, 2009, CANCER J, V15, P344, DOI 10.1097/PPO.0b013e3181b282c2; Moyer VA, 2013, ANN INTERN MED, V158, P47, DOI 10.7326/0003-4819-158-1-201301010-00553; NELSON HD, 2012, ANN INTERN MED, V157, pW1; Nelson HD, 2012, ANN INTERN MED, V157, P104, DOI 10.7326/0003-4819-157-2-201207170-00466; Pal L, 2012, MENOPAUSE, V19, P597, DOI 10.1097/gme.0b013e31825397f0; Schierbeck LL, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6409	13	13	13	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2013	8	12							e85121	10.1371/journal.pone.0085121	http://dx.doi.org/10.1371/journal.pone.0085121			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	284MV	24391988	Green Submitted, gold, Green Published			2023-01-03	WOS:000329323900131
J	Chang, DK; Li, PC; Lu, RM; Jane, WN; Wu, HC				Chang, De-Kuan; Li, Pi-Chun; Lu, Ruei-Min; Jane, Wann-Neng; Wu, Han-Chung			Peptide-Mediated Liposomal Doxorubicin Enhances Drug Delivery Efficiency and Therapeutic Efficacy in Animal Models	PLOS ONE			English	Article							TUMOR VASCULATURE; ANTI-HER2 IMMUNOLIPOSOMES; CANCER-CELLS; ENDOCYTOSIS; MECHANISM; NANOPARTICLES; CHEMOTHERAPY; EXOCYTOSIS; CARCINOMA; MEMBRANE	Lung cancer ranks among the most common malignancies, and is the leading cause of cancer-related mortality worldwide. Chemotherapy for lung cancer can be made more specific to tumor cells, and less toxic to normal tissues, through the use of ligand-mediated drug delivery systems. In this study, we investigated the targeting mechanism of the ligand-mediated drug delivery system using a peptide, SP5-2, which specifically binds to non-small cell lung cancer (NSCLC) cells. Conjugation of SP5-2 to liposomes enhanced the amount of drug delivered directly into NSCLC cells, through receptor-mediated endocytosis. Functional SP5-2 improved the therapeutic index of Lipo-Dox by enhancing therapeutic efficacy, reducing side effects, and increasing the survival rate of tumor-bearing mice in syngenic, metastatic and orthotopic animal models. Accumulation of SP5-2-conjugated liposomal doxorubicin (SP5-2-LD) in tumor tissues was 11.2-fold higher than that of free doxorubicin, and the area under the concentration-time curve (AUC(0-72) (hours)) was increased 159.2-fold. Furthermore, the experiment of bioavailability was assessed to confirm that SP5-2 elevates the uptake of the liposomal drugs by the tumor cells in vivo. In conclusion, the use of SP5-2-conjugated liposomes enhances pharmacokinetic properties, improves efficacy and safety profiles, and allows for controlled biodistribution and drug release.	[Chang, De-Kuan; Li, Pi-Chun; Lu, Ruei-Min; Wu, Han-Chung] Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan; [Jane, Wann-Neng] Acad Sinica, Inst Plant & Microbial Biol, Taipei 115, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan	Wu, HC (corresponding author), Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan.	hcw0928@gate.sinica.edu.tw	Wu, Han-Chung/B-1209-2011; Lu, Ruei-Min/ABF-4388-2021	Wu, Han-Chung/0000-0002-5185-1169; Lu, Ruei-Min/0000-0003-3792-5499	Academia Sinica; National Science Council, Taiwan [NSC-100-2325-B-001-011, NSC-100-2321-B-001-038]	Academia Sinica(Academia Sinica - Taiwan); National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by Academia Sinica and the National Science Council (NSC-100-2325-B-001-011 and NSC-100-2321-B-001-038), Taiwan (to HC Wu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833; Allen TM, 2002, NAT REV CANCER, V2, P750, DOI 10.1038/nrc903; Andreopoulou E, 2007, ANN ONCOL, V18, P716, DOI 10.1093/annonc/mdl484; ARTALEJO CR, 1995, P NATL ACAD SCI USA, V92, P8328, DOI 10.1073/pnas.92.18.8328; Baish JW, 1996, MICROVASC RES, V51, P327, DOI 10.1006/mvre.1996.0031; Bosslet K, 1998, CANCER RES, V58, P1195; Cai WB, 2008, NAT PROTOC, V3, P89, DOI 10.1038/nprot.2007.478; Camus P, 2004, BRIT J CANCER, V91, pS18, DOI 10.1038/sj.bjc.6602063; Chang DK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004171; Chinn P, 2003, CANCER IMMUNOL IMMUN, V52, P257, DOI 10.1007/s00262-002-0347-6; Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078-0432.CCR-07-1441; Dharap SS, 2005, P NATL ACAD SCI USA, V102, P12962, DOI 10.1073/pnas.0504274102; Falciani C, 2011, CHEMMEDCHEM, V6, P678, DOI 10.1002/cmdc.201000463; Farge E, 1999, AM J PHYSIOL-CELL PH, V276, pC725, DOI 10.1152/ajpcell.1999.276.3.C725; FREI E, 1980, AM J MED, V69, P585, DOI 10.1016/0002-9343(80)90472-6; Frei E, 1998, CLIN CANCER RES, V4, P2027; Frenkel V, 2006, ACAD RADIOL, V13, P469, DOI 10.1016/j.acra.2005.08.024; Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004; GAZIT Y, 1995, PHYS REV LETT, V75, P2428, DOI 10.1103/PhysRevLett.75.2428; HARAN G, 1993, BIOCHIM BIOPHYS ACTA, V1151, P201, DOI 10.1016/0005-2736(93)90105-9; HARDING C, 1983, J CELL BIOL, V97, P329, DOI 10.1083/jcb.97.2.329; Harrington KJ, 2001, CLIN CANCER RES, V7, P243; Heldin CH, 2004, NAT REV CANCER, V4, P806, DOI 10.1038/nrc1456; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; Kim ES, 2001, LUNG CANCER-J IASLC, V34, P427, DOI 10.1016/S0169-5002(01)00278-1; Kirpotin D, 1997, BIOCHEMISTRY-US, V36, P66, DOI 10.1021/bi962148u; Kok MB, 2009, MAGN RESON MED, V61, P1022, DOI 10.1002/mrm.21910; Laginha KM, 2005, CLIN CANCER RES, V11, P6944, DOI 10.1158/1078-0432.CCR-05-0343; Lee RJ, 1998, BIOSCIENCE REP, V18, P69, DOI 10.1023/A:1020132226113; Lee TY, 2007, CANCER RES, V67, P10958, DOI 10.1158/0008-5472.CAN-07-2233; Lee TY, 2004, CANCER RES, V64, P8002, DOI 10.1158/0008-5472.CAN-04-1948; Li TH, 2010, LUNG CANCER, V68, P89, DOI 10.1016/j.lungcan.2009.05.009; Lo A, 2008, MOL CANCER THER, V7, P579, DOI 10.1158/1535-7163.MCT-07-2359; Lu RM, 2011, BIOMATERIALS, V32, P3265, DOI 10.1016/j.biomaterials.2010.12.061; Maule M, 2007, JNCI-J NATL CANCER I, V99, P790, DOI 10.1093/jnci/djk180; Mayer LD, 1997, J PHARMACOL EXP THER, V280, P1406; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Miller AD, 2003, CURR MED CHEM, V10, P1195, DOI 10.2174/0929867033457485; Miller Andrew D, 2004, Methods Mol Med, V90, P107; Muggia F, 2001, EUR J CANCER, V37, pS15; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Novello Silvia, 2003, Oncology (Williston Park), V17, P357; Park JW, 2002, CLIN CANCER RES, V8, P1172; Pastorino F, 2006, CANCER RES, V66, P10073, DOI 10.1158/0008-5472.CAN-06-2117; Peto R, 1999, NAT MED, V5, P15, DOI 10.1038/4691; Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Ross JS, 2004, AM J CLIN PATHOL, V122, P598, DOI 10.1309/5CWPU41AFR1VYM3F; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307; THOMAS P, 1994, J CELL BIOL, V124, P667, DOI 10.1083/jcb.124.5.667; Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864; Voigt W, 2005, METH MOLEC MED, V110, P39; Wu HC, 2010, J ONCOL, V2010, DOI 10.1155/2010/723798; Zuhorn IS, 2002, J MEMBRANE BIOL, V189, P167, DOI 10.1007/s00232-002-1015-7	55	35	36	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2013	8	12							e83239	10.1371/journal.pone.0083239	http://dx.doi.org/10.1371/journal.pone.0083239			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281RE	24386166	gold, Green Published, Green Submitted			2023-01-03	WOS:000329117900027
J	Ghate, NB; Chaudhuri, D; Sarkar, R; Sajem, AL; Panja, S; Rout, J; Mandal, N				Ghate, Nikhil Baban; Chaudhuri, Dipankar; Sarkar, Rhitajit; Sajem, Albert L.; Panja, Sourav; Rout, Jayashree; Mandal, Nripendranath			An Antioxidant Extract of Tropical Lichen, Parmotrema reticulatum, Induces Cell Cycle Arrest and Apoptosis in Breast Carcinoma Cell Line MCF-7	PLOS ONE			English	Article							ANTICANCER; ANTIMYCOBACTERIAL; METABOLITES; INDUCTION; COMPLEX; DEATH	This report highlights the phytochemical analysis, antioxidant potential and anticancer activity against breast carcinoma of 70% methanolic extract of lichen, Parmotrema reticulatum (PRME). Phytochemical analysis of PRME confirms the presence of various phytoconstituents like alkaloids, carbohydrates, flavonoids, glycosides, phenols, saponins, tannins, anthraquinones, and ascorbic acid; among which alkaloids, phenols and flavonoids are found in abundant amount. High performance liquid chromatography (HPLC) analysis of PRME revealed the presence of catechin, purpurin, tannic acid and reserpine. Antioxidant activity was evaluated by nine separate methods. PRME showed excellent hydroxyl and hypochlorous radical scavenging as well as moderate DPPH, superoxide, singlet oxygen, nitric oxide and peroxynitrite scavenging activity. Cytotoxicity of PRME was tested against breast carcinoma (MCF-7), lung carcinoma (A549) and normal lung fibroblast (WI-38) using WST-1 method. PRME was found cytotoxic against MCF-7 cells with an IC50 value 130.03 +/- 3.11 mu g/ml while negligible cytotoxicity was observed on A549 and WI-38 cells. Further flow cytometric study showed that PRME halted the MCF-7 cells in S and G2/M phases and induces apoptosis in dose as well as time dependent manner. Cell cycle arrest was associated with downregulation of cyclin B1, Cdk-2 and Cdc25C as well as slight decrease in the expression of Cdk-1 and cyclin A1 with subsequent upregulation of p53 and p21. Moreover PRME induced Bax and inhibited Bcl-2 expression, which results in increasing Bax/Bcl-2 ratio and activation of caspase cascade. This ultimately leads to PARP degradation and induces apoptosis in MCF-7 cells. It can be hypothesised from the current study that the antioxidant and anticancer potential of the PRME may reside in the phytoconstitutents present in it and therefore, PRME may be used as a possible source of natural antioxidant that may be developed to an anticancer agent.	[Ghate, Nikhil Baban; Chaudhuri, Dipankar; Sarkar, Rhitajit; Panja, Sourav; Mandal, Nripendranath] Bose Inst, Div Mol Med, Kolkata, India; [Sajem, Albert L.; Rout, Jayashree] Assam Univ, Dept Ecol & Environm Sci, Silchar, Assam, India	Department of Science & Technology (India); Bose Institute; Assam University	Mandal, N (corresponding author), Bose Inst, Div Mol Med, Kolkata, India.	mandaln@rediffmail.com	Ghate, Nikhil/T-4153-2017; Panja, Sourav/AFO-5798-2022; Mandal, Nripendranath/ABC-3918-2020; Sarkar, Rhitajit/B-9567-2008; PANJA, SOURAV/AAA-7163-2022; Chudhuri, Dipankar/AAU-6215-2021	Ghate, Nikhil/0000-0002-4447-3737; Panja, Sourav/0000-0001-8540-5266; Mandal, Nripendranath/0000-0002-8733-3566; Sarkar, Rhitajit/0000-0001-7287-0388; Chaudhuri, Dipankar/0000-0001-7991-0469	Department of Biotechnology (DBT), Govt. of India [BT/183/NE/TBP/2011]	Department of Biotechnology (DBT), Govt. of India(Department of Biotechnology (DBT) India)	The authors would like to acknowledge Department of Biotechnology (DBT), Govt. of India (Sanction order No.: BT/183/NE/TBP/2011 dated 23.04.2012 and URL: http://dbtindia.nic.in/index.asp) for funding to conduct this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, GLOBOCAN 2008; Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Awasthi D. D., 1988, J HATTORI BOT LAB, V65, P207; Balaji P., 2007, Research Journal of Botany, V2, P54; Baral B, 2011, J MICROB BIOTEC FOOD, V1, P98; Begum S, 2012, NAT PROD RES, V26, P2084, DOI 10.1080/14786419.2011.625502; Behera BC, 2005, BIOTECHNOL LETT, V27, P991, DOI 10.1007/s10529-005-7847-3; Boustie Joel, 2005, Plant Genetic Resources Characterization and Utilization, V3, P273, DOI 10.1079/PGR200572; Brisdelli F, 2013, PHYTOTHER RES, V27, P431, DOI 10.1002/ptr.4739; Chaudhuri D, 2012, ASIAN J PHARM CLIN R, V5, P193, DOI DOI 10.1186/0717-6287-47-24; Divakar PK, 2005, LICHENOLOGIST, V37, P55, DOI 10.1017/S0024282904014586; Ghate NB, 2014, CYTOTECHNOLOGY, V66, P209, DOI 10.1007/s10616-013-9553-7; GOLDIN A, 1957, SCIENCE, V125, P156, DOI 10.1126/science.125.3239.156-a; HALLIWELL B, 1991, AM J MED, V91, pS14, DOI 10.1016/0002-9343(91)90279-7; Harborne JB, 1995, PHYTOCHEMICAL DICT H, V4; Hazra B, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-63; Honda NK, 2010, PHYTOMEDICINE, V17, P328, DOI 10.1016/j.phymed.2009.07.018; Hu WC, 2011, FOOD CHEM TOXICOL, V49, P799, DOI 10.1016/j.fct.2010.12.001; Isemura M, 2000, BIOFACTORS, V13, P81, DOI 10.1002/biof.5520130114; Kessler M, 2003, J PHARM PHARMACOL, V55, P131, DOI 10.1211/002235702559; Khan M, 2011, ASIAN PAC J CANCER P, V12, P3235; KINSELLA JE, 1993, FOOD TECHNOL-CHICAGO, V47, P85; Kochevar IE, 2000, METHOD ENZYMOL, V319, P20; Kokate CK, 2003, TEST BOOK PHARMACOGN, P105; Kumar M., 2012, ASIAN PAC J TROP DIS, V2S, pS692, DOI [DOI 10.1016/S2222-1808(12)60245-X, 10.1016/S2222-1808(12)60245-X]; Kurokawa S, 2001, MYCOTAXON, V77, P225; Lai LS, 2001, J AGR FOOD CHEM, V49, P963, DOI 10.1021/jf001146k; Li BH, 2010, CANCER LETT, V289, P62, DOI 10.1016/j.canlet.2009.08.002; Liu YQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038000; Manojlovic NT, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/452431; MARTINEZ V, 1987, PHYTOCHEMISTRY, V26, P2619, DOI 10.1016/S0031-9422(00)83891-1; Muller K, 2001, APPL MICROBIOL BIOT, V56, P9, DOI 10.1007/s002530100684; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nawar W. W., 1996, LIPIDS FOOD CHEM, P225; Nyska A, 2002, TOXICOL PATHOL, V30, P620, DOI 10.1080/01926230290166724; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Rankovic B., 2010, KRAGUJEVAC J SCI, V32, P65; Rankovic BR, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-97; Reddy VG, 2001, BIOCHEM BIOPH RES CO, V282, P409, DOI 10.1006/bbrc.2001.4593; RICEEVANS CA, 1995, FREE RADICAL RES, V22, P375, DOI 10.3109/10715769509145649; Sati S. C., 2011, British Microbiology Research Journal, V1, P26; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Sharma B. C., 2012, IOSR J PHARM, V2, P54; Shebaby WN, 2013, PHYTOTHER RES, V27, P737, DOI 10.1002/ptr.4776; Shrestha G, 2013, PHYTOCHEM REV, V12, P229, DOI 10.1007/s11101-013-9283-7; Sinha S.N., 2011, INT J PHARM BIO SCI, V2, P23; Stanly C., 2011, Journal of Pharmacy Research, V4, P2824; Su D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054505; Sun WM, 2008, ADV EXP MED BIOL, V614, P179, DOI 10.1007/978-0-387-74911-2_21; Tadhani MB, 2007, J FOOD COMPOS ANAL, V20, P323, DOI 10.1016/j.jfca.2006.08.004; de Jesus NZT, 2012, INT J MOL SCI, V13, P3203, DOI 10.3390/ijms13033203; Taylor BS, 1997, ARCH SURG-CHICAGO, V132, P1177; Tiwari P., 2011, NATURE SCI, V9, P167; Torres K, 1998, CANCER RES, V58, P3620; Triggiani D, 2009, BIOLOGIA, V64, P59, DOI 10.2478/s11756-009-0005-y; Verma N, 2008, APPL BIOCHEM BIOTECH, V151, P167, DOI 10.1007/s12010-008-8164-9; Wang XD, 2001, GENE DEV, V15, P2922; Yadav V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047796; Yao LH, 2004, PLANT FOOD HUM NUTR, V59, P113, DOI 10.1007/s11130-004-0049-7; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	61	46	46	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2013	8	12							e82293	10.1371/journal.pone.0082293	http://dx.doi.org/10.1371/journal.pone.0082293			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276GD	24358166	gold, Green Published, Green Submitted			2023-01-03	WOS:000328735700055
J	Anderson, RA; Qin, BL; Canini, F; Poulet, L; Roussel, AM				Anderson, Richard A.; Qin, Bolin; Canini, Frederic; Poulet, Laurent; Roussel, Anne Marie			Cinnamon Counteracts the Negative Effects of a High Fat/High Fructose Diet on Behavior, Brain Insulin Signaling and Alzheimer-Associated Changes	PLOS ONE			English	Article							GROWTH-FACTOR EXPRESSION; AMYLOID-BETA; MEMORY; DISEASE; EXTRACT; RESISTANCE; DEFICITS; GLYCOGEN; GLUCOSE; HEMOGLOBIN	Insulin resistance leads to memory impairment. Cinnamon (CN) improves peripheral insulin resistance but its effects in the brain are not known. Changes in behavior, insulin signaling and Alzheimer-associated mRNA expression in the brain were measured in male Wistar rats fed a high fat/high fructose (HF/HFr) diet to induce insulin resistance, with or without CN, for 12 weeks. There was a decrease in insulin sensitivity associated with the HF/HFr diet that was reversed by CN. The CN fed rats were more active in a Y maze test than rats fed the control and HF/HFr diets. The HF/HFr diet fed rats showed greater anxiety in an elevated plus maze test that was lessened by feeding CN. The HF/HFr diet also led to a down regulation of the mRNA coding for GLUT1 and GLUT3 that was reversed by CN in the hippocampus and cortex. There were increases in Insr, Irs1 and Irs2 mRNA in the hippocampus and cortex due to the HF/HFr diet that were not reversed by CN. Increased peripheral insulin sensitivity was also associated with increased glycogen synthase in both hippocampus and cortex in the control and HF/HFr diet animals fed CN. The HF/HFr diet induced increases in mRNA associated with Alzheimers including PTEN, Tau and amyloid precursor protein (App) were also alleviated by CN. In conclusion, these data suggest that the negative effects of a HF/HFr diet on behavior, brain insulin signaling and Alzheimer-associated changes were alleviated by CN suggesting that neuroprotective effects of CN are associated with improved whole body insulin sensitivity and related changes in the brain.	[Anderson, Richard A.; Qin, Bolin] ARS, Diet Genom & Immunol Lab, Beltsville Human Nutr Res Ctr, USDA, Beltsville, MD USA; [Qin, Bolin] Integr Nutraceut Int, Springhill, TN USA; [Canini, Frederic; Poulet, Laurent] Army Inst Res Biol, Grenoble, France; [Poulet, Laurent; Roussel, Anne Marie] Univ Grenoble 1, Natl Inst Hlth, Grenoble, France; [Canini, Frederic] Ecole Val de Grace, Paris, France	United States Department of Agriculture (USDA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Anderson, RA (corresponding author), ARS, Diet Genom & Immunol Lab, Beltsville Human Nutr Res Ctr, USDA, Beltsville, MD USA.	Richard.anderson@ars.usda.gov		Poulet, Laurent/0000-0003-2795-4122	USDA/ARS/USA [CRADA:58-3K95-7-1184]; French National Agency for Research [PNRA 007]	USDA/ARS/USA(United States Department of Agriculture (USDA)USDA Agricultural Research Service); French National Agency for Research(French National Research Agency (ANR))	The work was funded by USDA/ARS/USA CRADA:58-3K95-7-1184 and French National Agency for Research (PNRA 007). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akilen R, 2010, DIABETIC MED, V27, P1159, DOI 10.1111/j.1464-5491.2010.03079.x; Anderson RA, 2004, J AGR FOOD CHEM, V52, P65, DOI 10.1021/jf034916b; Benedict C, 2012, DIABETES CARE, V35, P488, DOI 10.2337/dc11-2075; Brown AM, 2007, GLIA, V55, P1263, DOI 10.1002/glia.20557; Bruehl H, 2010, J CLIN EXP NEUROPSYC, V32, P487, DOI 10.1080/13803390903224928; Buwalda B, 2001, PHYSIOL BEHAV, V73, P371, DOI 10.1016/S0031-9384(01)00493-0; Cao Heping, 2007, J Inflamm (Lond), V4, P1, DOI 10.1186/1476-9255-4-1; Cao HP, 2007, ARCH BIOCHEM BIOPHYS, V459, P214, DOI 10.1016/j.abb.2006.12.034; Cao HP, 2010, PHYTOMEDICINE, V17, P1027, DOI 10.1016/j.phymed.2010.03.023; Convit A, 2005, NEUROBIOL AGING, V26, pS31, DOI 10.1016/j.neurobiolaging.2005.09.018; Couturier K, 2010, ARCH BIOCHEM BIOPHYS, V501, P158, DOI 10.1016/j.abb.2010.05.032; Couturier K, 2011, METABOLISM, V60, P1590, DOI 10.1016/j.metabol.2011.03.016; Craft S, 2003, PSYCHONEUROENDOCRINO, V28, P809, DOI 10.1016/S0306-4530(02)00087-2; Crawford P, 2009, J AM BOARD FAM MED, V22, P507, DOI 10.3122/jabfm.2009.05.080093; CRUZ APM, 1994, PHARMACOL BIOCHEM BE, V49, P171, DOI 10.1016/0091-3057(94)90472-3; Cruz NF, 2002, J CEREBR BLOOD F MET, V22, P1476, DOI 10.1097/01.WCB.0000034362.37277.C0; de la Monte SM, 2005, J ALZHEIMERS DIS, V7, P45; de la Monte Suzanne M, 2008, J Diabetes Sci Technol, V2, P1101; Dellu F, 1997, NEUROBIOL LEARN MEM, V67, P112, DOI 10.1006/nlme.1997.3746; Frisardi V, 2010, J ALZHEIMERS DIS, V21, P57, DOI 10.3233/JAD-2010-100015; Frydman-Marom A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016564; Gibbs ME, 2012, NEUROCHEM RES, V37, P2456, DOI 10.1007/s11064-012-0805-2; Gonzales MM, 2010, OBESITY, V18, P2131, DOI 10.1038/oby.2010.183; Grundy SM, 2008, ARTERIOSCL THROM VAS, V28, P629, DOI 10.1161/ATVBAHA.107.151092; Gupta A, 2011, NEUROPHARMACOLOGY, V60, P910, DOI 10.1016/j.neuropharm.2011.01.033; Holmes C, 2008, LANCET, V372, P216, DOI 10.1016/S0140-6736(08)61075-2; Irvine EE, 2011, LEARN MEMORY, V18, P375, DOI 10.1101/lm.2111311; Jarvill-Taylor KJ, 2001, J AM COLL NUTR, V20, P327, DOI 10.1080/07315724.2001.10719053; Jiao LH, 2013, FOOD CHEM TOXICOL, V56, P398, DOI 10.1016/j.fct.2013.02.049; Khan A, 2003, DIABETES CARE, V26, P3215, DOI 10.2337/diacare.26.12.3215; Killday KB, 2011, J NAT PROD, V74, P1833, DOI 10.1021/np1007944; Killick R, 2009, BIOCHEM BIOPH RES CO, V386, P257, DOI 10.1016/j.bbrc.2009.06.032; Kim B, 2012, TRENDS ENDOCRIN MET, V23, P133, DOI 10.1016/j.tem.2011.12.004; Kosari S, 2012, BEHAV BRAIN RES, V235, P98, DOI 10.1016/j.bbr.2012.07.017; Legendre A, 2006, AM J PHYSIOL-REG I, V291, pR1288, DOI 10.1152/ajpregu.00234.2006; Lester-Coll N, 2006, J ALZHEIMERS DIS, V9, P13; Lu JM, 2010, CARCINOGENESIS, V31, P481, DOI 10.1093/carcin/bgp292; Lu T, 2012, NUTR RES, V32, P408, DOI 10.1016/j.nutres.2012.05.003; Lu ZL, 2011, PHYTOMEDICINE, V18, P298, DOI 10.1016/j.phymed.2010.08.008; Park CR, 2000, PHYSIOL BEHAV, V68, P509, DOI 10.1016/S0031-9384(99)00220-6; Park CR, 2001, NEUROSCI BIOBEHAV R, V25, P311, DOI 10.1016/S0149-7634(01)00016-1; Parra MA, 2009, BRAIN, V132, P1057, DOI 10.1093/brain/awp036; Peterson DW, 2009, J ALZHEIMERS DIS, V17, P585, DOI 10.3233/JAD-2009-1083; Prasad A, 1996, PHYSIOL BEHAV, V60, P1039, DOI 10.1016/0031-9384(96)00135-7; Preuss HG, 2006, J AM COLL NUTR, V25, P144, DOI 10.1080/07315724.2006.10719525; Qin B, 2010, HORM METAB RES, V42, P187, DOI 10.1055/s-0029-1242746; Qin Bolin, 2010, J Diabetes Sci Technol, V4, P685; Qutub AA, 2005, BRAIN RES REV, V49, P595, DOI 10.1016/j.brainresrev.2005.03.002; Reger MA, 2008, J ALZHEIMERS DIS, V13, P323, DOI 10.3233/jad-2008-13309; Rivera EJ, 2005, J ALZHEIMERS DIS, V8, P247; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; Ryu BR, 1999, J NEUROBIOL, V39, P536, DOI 10.1002/(SICI)1097-4695(19990615)39:4<536::AID-NEU7>3.0.CO;2-J; Schioth HB, 2012, MOL NEUROBIOL, V46, P4, DOI 10.1007/s12035-011-8229-6; Soulis G, 2007, BEHAV NEUROSCI, V121, P483, DOI 10.1037/0735-7044.121.3.483; Souza CG, 2007, LIFE SCI, V81, P198, DOI 10.1016/j.lfs.2007.05.001; Stranahan AM, 2008, HIPPOCAMPUS, V18, P1085, DOI 10.1002/hipo.20470; Stuart CA, 2011, BRAIN RES, V1384, P15, DOI 10.1016/j.brainres.2011.02.014; Takashima Akihiko, 2012, Front Mol Neurosci, V5, P47, DOI 10.3389/fnmol.2012.00047; Talbot K, 2012, J CLIN INVEST, V122, P1316, DOI 10.1172/JCI59903; Wang JG, 2007, FERTIL STERIL, V88, P240, DOI 10.1016/j.fertnstert.2006.11.082; White CL, 2009, NEUROBIOL DIS, V35, P3, DOI 10.1016/j.nbd.2009.04.002; Woods SC, 2003, CURR PHARM DESIGN, V9, P795, DOI 10.2174/1381612033455323; Ziegenfuss TN, 2006, J INT SOC SPORT NUTR, V3, DOI 10.1186/1550-2783-3-2-45	63	44	45	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2013	8	12							e83243	10.1371/journal.pone.0083243	http://dx.doi.org/10.1371/journal.pone.0083243			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276FP	24349472	Green Published, gold, Green Submitted			2023-01-03	WOS:000328734200070
J	Kendall, EA; Theron, D; Franke, MF; van Helden, P; Victor, TC; Murray, MB; Warren, RM; Jacobson, KR				Kendall, Emily A.; Theron, Danie; Franke, Molly F.; van Helden, Paul; Victor, Thomas C.; Murray, Megan B.; Warren, Robin M.; Jacobson, Karen R.			Alcohol, Hospital Discharge, and Socioeconomic Risk Factors for Default from Multidrug Resistant Tuberculosis Treatment in Rural South Africa: A Retrospective Cohort Study	PLOS ONE			English	Article							TREATMENT OUTCOMES; TREATMENT FAILURE; RETREATMENT	Background: Default from multidrug-resistant tuberculosis (MDR-TB) treatment remains a major barrier to cure and epidemic control. We sought to identify patient risk factors for default from MDR-TB treatment and high-risk time periods for default in relation to hospitalization and transition to outpatient care. Methods: We retrospectively analyzed a cohort of 225 patients who initiated MDR-TB treatment between 2007 through 2010 at a rural TB hospital in the Western Cape Province, South Africa. Results: Fifty percent of patients were cured or completed treatment, 27% defaulted, 14% died, 4% failed treatment, and 5% transferred out. Recent alcohol use was common (63% of patients). In multivariable proportional hazards regression, older age (hazard ratio [HR]= 0.97 [95% confidence interval 0.94-0.99] per year of greater age), formal housing (HR=0.38 [0.19-0.78]), and steady employment (HR= 0.41 [0.19-0.90]) were associated with decreased risk of default, while recent alcohol use (HR= 2.1 [1.1-4.0]), recent drug use (HR= 2.0 [1.0-3.6]), and Coloured (mixed ancestry) ethnicity (HR= 2.3 [1.1-5.0]) were associated with increased risk of default (P< 0.05). Defaults occurred throughout the first 18 months of the two-year treatment course but were especially frequent among alcohol users after discharge from the initial four-to-five-month in-hospital phase of treatment, with the highest default rates occurring among alcohol users within two months of discharge. Default rates during the first two months after discharge were also elevated for patients who received care from mobile clinics. Conclusions: Among patients who were not cured or did not complete MDR-TB treatment, the majority defaulted from treatment. Younger, economically-unstable patients and alcohol and drug users were particularly at risk. For alcohol users as well as mobile-clinic patients, the early outpatient treatment phase is a high-risk period for default that could be targeted in efforts to increase treatment completion rates.	[Kendall, Emily A.] Johns Hopkins Univ Hosp, Sch Med, Div Infect Dis, Baltimore, MD 21287 USA; [Theron, Danie] Brewelskloof Hosp, Worcester, South Africa; [Franke, Molly F.; Murray, Megan B.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA; [van Helden, Paul; Victor, Thomas C.; Warren, Robin M.; Jacobson, Karen R.] Univ Stellenbosch, Div Mol Biol & Human Genet, Fac Med & Hlth Sci, ZA-7505 Tygerberg, South Africa; [Murray, Megan B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Jacobson, Karen R.] Boston Univ, Sch Med, Infect Dis Sect, Boston, MA 02118 USA	Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Harvard Medical School; Stellenbosch University; Harvard University; Harvard T.H. Chan School of Public Health; Boston University	Kendall, EA (corresponding author), Johns Hopkins Univ Hosp, Sch Med, Div Infect Dis, Baltimore, MD 21287 USA.	ekendal2@jhmi.edu	Franke, Molly/AAK-7559-2020; Jacobson, Karen/AAX-9461-2021	Franke, Molly/0000-0002-4890-5728; Jacobson, Karen/0000-0003-4239-3685; Kendall, Emily/0000-0002-0083-422X; Warren, Robin/0000-0001-5741-7358	Partners Center of Expertise Travel Grant; Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene Postdoctoral Fellowship in Tropical Infectious Diseases; National Institutes of Health/Fogarty International Center [1K01 TW009213]; FOGARTY INTERNATIONAL CENTER [K01TW009213] Funding Source: NIH RePORTER	Partners Center of Expertise Travel Grant; Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene Postdoctoral Fellowship in Tropical Infectious Diseases; National Institutes of Health/Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	This work was supported by a Partners Center of Expertise Travel Grant (E. A. K., http://www.partners.org/Graduate-Medical-Education/CentersOf-Expertise/Global-And-Humanitarian-Health/Funding-And-Resources/Global-Travel-Grants. aspx); the Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene Postdoctoral Fellowship in Tropical Infectious Diseases (K. R. J., http://www.astmh.org/ASTMH_Sponsored_Fellowships/3506.htm); and the National Institutes of Health/Fogarty International Center (1K01 TW009213 to K. R. J., www.nih.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams S, 2009, CAPE WINELANDS OVERB; Andrews JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015735; [Anonymous], 2012, GLOB TUB REP 2012; [Anonymous], 2010, MAN DRUG RES TUB POL; Brasil Pedro Emmanuel Alvarenga Americano do, 2008, Cad. Saúde Pública, V24, ps485, DOI 10.1590/S0102-311X2008001600003; Brust JCM, 2010, INT J TUBERC LUNG D, V14, P413; Dooley KE, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-140; Farley JE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020436; Franke MF, 2008, CLIN INFECT DIS, V46, P1844, DOI 10.1086/588292; Geneva: World Health Organization, 2013, MULT RES TUB 2013 UP; Holtz TH, 2006, INT J TUBERC LUNG D, V10, P649; Jenkins HE, 2013, INT J TUBERC LUNG D, V17, P373, DOI 10.5588/ijtld.12.0464; Jha UM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008873; Johnston JC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006914; Kliiman K, 2010, INT J TUBERC LUNG D, V14, P454; Korenromp EL, 2009, INT J TUBERC LUNG D, V13, P283; Laserson KF, 2005, INT J TUBERC LUNG D, V9, P640; Lemanski C, 2009, HABITAT INT, V33, P472, DOI 10.1016/j.habitatint.2009.03.002; London L, 2000, DRUG ALCOHOL DEPEN, V59, P199, DOI 10.1016/S0376-8716(99)00120-9; Muture BN, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-696; Nathanson E, 2006, EMERG INFECT DIS, V12, P1389, DOI 10.3201/eid1209.051618; Ojo OA, 2010, SAMJ S AFR MED J, V100, P180, DOI 10.7196/SAMJ.3767; Orenstein EW, 2009, LANCET INFECT DIS, V9, P153, DOI 10.1016/S1473-3099(09)70041-6; Rehm J, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-450; Schafer JL, 2010, ANAL INCOMPLETE MULT; Shean KP, 2008, INT J TUBERC LUNG D, V12, P1182; Shin S, 2013, ADDICTION, V108, P1387, DOI 10.1111/add.12148; Shin SS, 2010, AM J RESP CRIT CARE, V182, P426, DOI 10.1164/rccm.200911-1768OC; Toczek A, 2013, INT J TUBERC LUNG D, V17, P299, DOI 10.5588/ijtld.12.0537; Van der Walt M, 2009, NATL STUDY IDENTIFY; World Health Organization, 2011, WHO PROGRESS REPORT	31	41	42	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2013	8	12							e83480	10.1371/journal.pone.0083480	http://dx.doi.org/10.1371/journal.pone.0083480			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276FP	24349518	gold, Green Published			2023-01-03	WOS:000328734200092
J	Napolitano, F; Izzo, MT; Di Giuseppe, G; Angelillo, IF				Napolitano, Francesco; Izzo, Maria Teresa; Di Giuseppe, Gabriella; Angelillo, Italo F.		Collaborative Working Grp	Frequency of Inappropriate Medication Prescription in Hospitalized Elderly Patients in Italy	PLOS ONE			English	Article							ADVERSE DRUG EVENTS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACUTELY ILL POPULATION; OLDER-ADULTS; BEERS CRITERIA; PRIMARY-CARE; AVIAN INFLUENZA; RISK-FACTORS; PREVALENCE; AMIODARONE	Background: Older people often need comprehensive treatment, including many medications, and polypharmacy is common. The aims of this cross-sectional investigation were to examine the potentially inappropriate medication during the hospitalization and to identify the factors that may influence such inappropriateness among elderly in Italy. Methods: A sample of 605 individuals aged 65 years and older admitted in non-academic public acute care hospitals was randomly selected. Prescription of inappropriate medications were evaluated during the period from the day of admission to a randomly preselected day (index day). Beers Criteria were used to evaluate appropriateness. Results: At least one potentially inappropriate medication prescription from the day of hospital admission to the index day has been observed in 188 patients (31.1%), and respectively 84.1% and 15.9% of them had received one or two inappropriate medications. A total of 15 medications was prescribed inappropriately to these 188 patients, for 215 times with a total of 1143 doses. The multivariate logistic regression analysis revealed that the significant predictors for having at least one potentially inappropriate medication prescription during the hospitalization were: patients having an elementary education level, a lower pre-admission performance-based measure of basic activities of daily living, having received an inappropriate drug before the hospitalization, a hospital stay in the general and in the specialties surgical wards, a longer length of hospital stay from the admission to the index day, and having received a higher number of drugs from the day of the hospital admission to the index day. The most prevalent inappropriate medications administered were ketorolac (27.4%), amiodarone (19.1%), and clonidine (11.2%). Conclusions: This study supports the need for clinical guidelines implementation to assist physicians in choosing the most appropriate drugs for the elderly and for effective education of all physicians.	[Napolitano, Francesco; Izzo, Maria Teresa; Di Giuseppe, Gabriella; Angelillo, Italo F.; Collaborative Working Grp] Univ Naples 2, Dept Expt Med, Naples, Italy	Universita della Campania Vanvitelli	Napolitano, F (corresponding author), Univ Naples 2, Dept Expt Med, Naples, Italy.	italof.angelillo@unina2.it	Angelillo, Italo Francesco/AAK-1301-2021	Angelillo, Italo Francesco/0000-0003-1213-6602; DI GIUSEPPE, Gabriella/0000-0003-4466-6683; Napolitano, Francesco/0000-0003-4694-2418	Italian Ministry of University and Research [MIUR/PRIN2008-H8YFRE]	Italian Ministry of University and Research(Ministry of Education, Universities and Research (MIUR))	This work was supported by the following Research Grant: Programs of Scientific Research of Relevant National Interest by the Italian Ministry of University and Research (MIUR/PRIN2008-H8YFRE). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbate R, 2008, AM J INFECT CONTROL, V36, P39, DOI 10.1016/j.ajic.2007.01.006; Abbate R, 2006, EMERG INFECT DIS, V12, P1762, DOI 10.3201/eid1211.060671; Abd Wahab MS, 2012, INT J CLIN PHARM-NET, V34, P855, DOI 10.1007/s11096-012-9681-8; Akazawa M, 2010, AM J GERIATR PHARMAC, V8, P146, DOI 10.1016/j.amjopharm.2010.03.005; Berdot Sarah, 2009, BMC Geriatr, V9, P30, DOI 10.1186/1471-2318-9-30; Bregnhoj L, 2007, PHARM WORLD SCI, V29, P109, DOI 10.1007/s11096-007-9108-0; Brekke M, 2008, SCAND J PRIM HEALTH, V26, P80, DOI 10.1080/02813430802002875; Buck MD, 2009, AM J GERIATR PHARMAC, V7, P84, DOI 10.1016/j.amjopharm.2009.03.001; Chang CH, 2011, PHARMACOEPIDEM DR S, V20, P763, DOI 10.1002/pds.2140; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen LL, 2012, INT J CLIN PHARM-NET, V34, P596, DOI 10.1007/s11096-012-9651-1; Chen YC, 2009, PHARMACOEPIDEM DR S, V18, P53, DOI 10.1002/pds.1684; Colloca G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046669; Dedhiya SD, 2010, AM J GERIATR PHARMAC, V8, P562, DOI 10.1016/S1543-5946(10)80005-4; Di Giuseppe G, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-36; Ernawati DK, 2008, BRIT J CLIN PHARMACO, V66, P82, DOI 10.1111/j.1365-2125.2008.03177.x; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; Finlayson E, 2011, J AM GERIATR SOC, V59, P2139, DOI 10.1111/j.1532-5415.2011.03567.x; Fu AZ, 2007, MED CARE, V45, P472, DOI 10.1097/01.mlr.0000254571.05722.34; Gallagher P, 2011, EUR J CLIN PHARMACOL, V67, P1175, DOI 10.1007/s00228-011-1061-0; Gallagher PF, 2008, AGE AGEING, V37, P96, DOI 10.1093/ageing/afm116; Gnjidic D, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-115; Hamilton H, 2011, ARCH INTERN MED, V171, P1013, DOI 10.1001/archinternmed.2011.215; Harugeri A, 2010, J POSTGRAD MED, V56, P186, DOI 10.4103/0022-3859.68642; KATZ S, 1983, J AM GERIATR SOC, V31, P721, DOI 10.1111/j.1532-5415.1983.tb03391.x; Kim MH, 2011, CLIN THER, V33, P1668, DOI 10.1016/j.clinthera.2011.10.005; Lai HY, 2009, CLIN THER, V31, P1859, DOI 10.1016/j.clinthera.2009.08.023; Lanas A, 2006, GUT, V55, P1731, DOI 10.1136/gut.2005.080754; Lehnert T, 2011, MED CARE RES REV, V68, P387, DOI 10.1177/1077558711399580; Lin HY, 2008, DRUG AGING, V25, P49, DOI 10.2165/00002512-200825010-00006; Lund BC, 2010, ANN PHARMACOTHER, V44, P957, DOI 10.1345/aph.1M657; Maio V, 2010, J CLIN PHARM THER, V35, P219, DOI 10.1111/j.1365-2710.2009.01094.x; Marcum ZA, 2012, AM J GERIATR PHARMAC, V10, P151, DOI 10.1016/j.amjopharm.2012.03.002; Meurer WJ, 2010, ACAD EMERG MED, V17, P231, DOI [10.1111/j.1553-2712.2010.00667.x, 10.1111/j.1553-2712.2010.00717.x]; Vishwas H, 2012, GERIATR GERONTOL INT, V12, P506, DOI 10.1111/j.1447-0594.2011.00806.x; O'Mahony D, 2008, AGE AGEING, V37, P138, DOI 10.1093/ageing/Afm189; Oliveira MG, 2012, INT J CLIN PHARM-NET, V34, P626, DOI 10.1007/s11096-012-9656-9; Onder G, 2005, EUR J CLIN PHARMACOL, V61, P453, DOI 10.1007/s00228-005-0928-3; Opondo D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043617; Passman RS, 2012, AM J MED, V125, P447, DOI 10.1016/j.amjmed.2011.09.020; Pelullo CP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042856; Radosevic N, 2008, PHARMACOEPIDEM DR S, V17, P733, DOI 10.1002/pds.1531; Rothberg MB, 2008, J HOSP MED, V3, P91, DOI 10.1002/jhm.290; Ruggiero C, 2009, DRUG AGING, V26, P15, DOI 10.2165/11534630-000000000-00000; Ryan C, 2009, BRIT J CLIN PHARMACO, V68, P936, DOI 10.1111/j.1365-2125.2009.03531.x; Sacerdote C, 2012, INT J EPIDEMIOL, V41, P1162, DOI 10.1093/ije/dys091; Sakuma M, 2011, PHARMACOEPIDEM DR S, V20, P386, DOI 10.1002/pds.2110; Munoz-Torrero JFS, 2010, EUR J CLIN PHARMACOL, V66, P1257, DOI 10.1007/s00228-010-0866-6; Schafer A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014060; Serebruany VL, 2005, AM J CARDIOL, V95, P1218, DOI 10.1016/j.amjcard.2005.01.049; Sessa A, 2010, EUR J PUBLIC HEALTH, V20, P631, DOI 10.1093/eurpub/ckp204; Shiyanbola OO, 2010, AM J GERIATR PHARMAC, V8, P245, DOI 10.1016/j.amjopharm.2010.06.002; Song YP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068599; Stata Corporation, 2007, STAT REF MAN REL 10	55	31	32	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2013	8	12							e82359	10.1371/journal.pone.0082359	http://dx.doi.org/10.1371/journal.pone.0082359			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	276EU	24349262	Green Published, Green Submitted, gold			2023-01-03	WOS:000328731800058
J	Padhi, S; Bullock, I; Li, L; Stroud, M				Padhi, Smita; Bullock, Ian; Li, Lilian; Stroud, Mike		Guideline Dev Grp	Intravenous fluid therapy for adults in hospital: summary of NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Padhi, Smita; Bullock, Ian; Li, Lilian] Royal Coll Physicians, Natl Clin Guideline Ctr, London NW1 4LE, England; [Stroud, Mike] Southampton Univ Hosp NHS Trust, Southampton SO16 6YD, Hants, England	Royal College of Physicians; University of Southampton; University Hospital Southampton NHS Foundation Trust	Padhi, S (corresponding author), Royal Coll Physicians, Natl Clin Guideline Ctr, London NW1 4LE, England.	smita.padhi@rcplondon.ac.uk	Lobo, Dileep/AAC-6207-2020	Lobo, Dileep/0000-0003-1187-5796; Wonderling, David/0000-0003-0315-6273; Nolan, Jerry/0000-0003-3141-3812				[Anonymous], AC ILL PAT HOSP REC; *NAT CONF ENQ PER, 1999, EXTR AG 1999 REP NAT; National Confidential Enquiry into Perioperative Deaths, 2011, KNOW RISK REV PER CA; National Institute for Health and Care Excellence, 2013, INTR FLUID THER AD H; Resuscitation Council UK, 2011, ADV LIF SUPP; Royal College of Physicians, 2017, NATL EARLY WARNING S	6	38	43	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 10	2013	347								f7073	10.1136/bmj.f7073	http://dx.doi.org/10.1136/bmj.f7073			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	273ZL	24326887				2023-01-03	WOS:000328574700002
J	Rajasekaran, D; Palombo, EA; Yeo, TC; Ley, DLS; Tu, CL; Malherbe, F; Grollo, L				Rajasekaran, Dhivya; Palombo, Enzo A.; Yeo, Tiong Chia; Ley, Diana Lim Siok; Tu, Chu Lee; Malherbe, Francois; Grollo, Lara			Identification of Traditional Medicinal Plant Extracts with Novel Anti-Influenza Activity	PLOS ONE			English	Article							INFLUENZA-VIRUS INFECTION; ANTIVIRAL ACTIVITY; HERBAL MEDICINE; NEURAMINIDASE; AGENTS; HEMAGGLUTINATION; INACTIVATION; INHIBITORS; CAPSULE; FUSION	The emergence of drug resistant variants of the influenza virus has led to a need to identify novel and effective antiviral agents. As an alternative to synthetic drugs, the consolidation of empirical knowledge with ethnopharmacological evidence of medicinal plants offers a novel platform for the development of antiviral drugs. The aim of this study was to identify plant extracts with proven activity against the influenza virus. Extracts of fifty medicinal plants, originating from the tropical rainforests of Borneo used as herbal medicines by traditional healers to treat flu-like symptoms, were tested against the H1N1 and H3N1 subtypes of the virus. In the initial phase, in vitro micro-inhibition assays along with cytotoxicity screening were performed on MDCK cells. Most plant extracts were found to be minimally cytotoxic, indicating that the compounds linked to an ethnomedical framework were relatively innocuous, and eleven crude extracts exhibited viral inhibition against both the strains. All extracts inhibited the enzymatic activity of viral neuraminidase and four extracts were also shown to act through the hemagglutination inhibition (HI) pathway. Moreover, the samples that acted through both HI and neuraminidase inhibition (NI) evidenced more than 90% reduction in virus adsorption and penetration, thereby indicating potent action in the early stages of viral replication. Concurrent studies involving Receptor Destroying Enzyme treatments of HI extracts indicated the presence of sialic acid-like component(s) that could be responsible for hemagglutination inhibition. The manifestation of both modes of viral inhibition in a single extract suggests that there may be a synergistic effect implicating more than one active component. Overall, our results provide substantive support for the use of Borneo traditional plants as promising sources of novel anti-influenza drug candidates. Furthermore, the pathways involving inhibition of hemagglutination could be a solution to the global occurrence of viral strains resistant to neuraminidase drugs.	[Rajasekaran, Dhivya; Palombo, Enzo A.; Malherbe, Francois; Grollo, Lara] Swinburne Univ Technol, Fac Life & Social Sci, Environm & Biotechnol Ctr, Hawthorn, Vic 3122, Australia; [Yeo, Tiong Chia; Ley, Diana Lim Siok; Tu, Chu Lee] Sarawak Biodivers Ctr, Kuching, Sarawak, Malaysia	Swinburne University of Technology	Grollo, L (corresponding author), Swinburne Univ Technol, Fac Life & Social Sci, Environm & Biotechnol Ctr, Hawthorn, Vic 3122, Australia.	lgrollo@swin.edu.au	Malherbe, François Clément/ABG-8109-2020; Palombo, Enzo/AAV-8632-2021	Malherbe, François Clément/0000-0001-6127-4169; Palombo, Enzo/0000-0001-5889-1393; Rajasekaran, Dhivya/0000-0003-4369-9985	Grollo Ruzzene Foundation	Grollo Ruzzene Foundation	This project was supported by funds from the Grollo Ruzzene Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albin R, 1997, ANTIVIR RES, V35, P139, DOI 10.1016/S0166-3542(97)00023-5; Ali NAA, 2001, J ETHNOPHARMACOL, V74, P173, DOI 10.1016/S0378-8741(00)00364-0; Basavaraja B. M., 2011, Journal of Global Pharma Technology, V3, P14; Bouvier NM, 2008, VACCINE, V26, pD49, DOI 10.1016/j.vaccine.2008.07.039; Chai PPK, 2006, MED PLANTS SARAWAK; Chang TT, 2011, J TAIWAN INST CHEM E, V42, P563, DOI 10.1016/j.jtice.2010.11.001; Chang TT, 2011, MOL SIMULAT, V37, P361, DOI 10.1080/08927022.2010.543973; Chattopadhyay D, 2007, MINI-REV MED CHEM, V7, P275, DOI 10.2174/138955707780059844; Chen DY, 2010, FOOD CHEM, V119, P1346, DOI 10.1016/j.foodchem.2009.09.011; Chiang LC, 2002, ANTIVIR RES, V55, P53, DOI 10.1016/S0166-3542(02)00007-4; Dan K, 2013, PHARMACOLOGY, V91, P314, DOI 10.1159/000350188; De Logu A, 2000, ANTIVIR RES, V48, P177, DOI 10.1016/S0166-3542(00)00127-3; Duan ZP, 2011, CHINESE MED J-PEKING, V124, P2925, DOI 10.3760/cma.j.issn.0366-6999.2011.18.024; Focho DA, 2010, J MED PLANTS RES, V4, P2148; Grienke U, 2012, NAT PROD REP, V29, P11, DOI 10.1039/c1np00053e; Grienke U, 2010, J MED CHEM, V53, P778, DOI 10.1021/jm901440f; Hokari R, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/794970; Hsieh CF, 2012, J ETHNOPHARMACOL, V143, P57, DOI 10.1016/j.jep.2012.05.061; Ison MG, 2011, CURR OPIN VIROL, V1, P563, DOI 10.1016/j.coviro.2011.09.002; Jassim SAA, 2003, J APPL MICROBIOL, V95, P412, DOI 10.1046/j.1365-2672.2003.02026.x; Kaur R, 2011, INT J PHARM BIOSCIEN, V2, P387; Kinoshita E, 2012, BIOSCI BIOTECH BIOCH, V76, P1633, DOI 10.1271/bbb.120112; Kiyohara H, 2012, PHYTOMEDICINE, V19, P111, DOI 10.1016/j.phymed.2011.07.004; Kiyohara H, 2012, J NAT MED-TOKYO, V66, P55, DOI 10.1007/s11418-011-0550-x; Krauss S, 2007, PLOS PATHOG, V3, P1684, DOI 10.1371/journal.ppat.0030167; Lee JB, 2012, FOOD CHEM, V134, P2164, DOI 10.1016/j.foodchem.2012.04.016; Luo C, 1999, J GEN VIROL, V80, P2969, DOI 10.1099/0022-1317-80-11-2969; Maji S., 2010, Journal of Phytology, V2, P57; Matrosovich MN, 2004, J VIROL, V78, P12665, DOI 10.1128/JVI.78.22.12665-12667.2004; McCaughey Conall, 2010, Ulster Med J, V79, P46; Nabeshima S, 2012, J INFECT CHEMOTHER, V18, P534, DOI 10.1007/s10156-012-0378-7; Nguyen TNA, 2011, FOOD CHEM, V124, P437, DOI 10.1016/j.foodchem.2010.06.049; Oh DY, 2008, J CLIN MICROBIOLOGY; Pleschka S, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-197; Pourianfar HR, 2012, INDIAN J VIROL, V23, P303, DOI 10.1007/s13337-012-0105-0; Pourianfar HR, 2012, VIRUS RES, V169, P22, DOI 10.1016/j.virusres.2012.06.025; REED L. J., 1938, AMER JOUR HYG, V27, P493; Roberts NA, 2001, PROG DRUG RES, V56, P195; Salleh KM, 2002, KEMENTERIAN SAINS TD; Shin WJ, 2010, MICROBIOL IMMUNOL, V54, P11, DOI 10.1111/j.1348-0421.2009.00173.x; Song JM, 2005, ANTIVIR RES, V68, P66, DOI 10.1016/j.antiviral.2005.06.010; Sriwilaijaroen N, 2012, ANTIVIR RES, V94, P139, DOI 10.1016/j.antiviral.2012.02.013; STEGMANN T, 1987, J BIOL CHEM, V262, P17744; Su B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008495; Tayal S, 2012, INT BRAZ J UROL, V38, P204, DOI 10.1590/S1677-55382012000200008; Tong SX, 2012, P NATL ACAD SCI USA, V109, P4269, DOI 10.1073/pnas.1116200109; Uchide N, 2008, MINI-REV MED CHEM, V8, P491, DOI 10.2174/138955708784223530; Wagner H, 2009, PHYTOMEDICINE, V16, P97, DOI 10.1016/j.phymed.2008.12.018; Wang XY, 2006, PHYTOTHER RES, V20, P335, DOI 10.1002/ptr.1892; Wirotesangthong M, 2009, MICROBIOL IMMUNOL, V53, P66, DOI 10.1111/j.1348-0421.2008.00095.x; Won JN, 2013, J MICROBIOL BIOTECHN, V23, P125, DOI 10.4014/jmb.1210.10074; World Health Organization [WHO], 2002, WHO AN INFL MAN; Yaacob M., 2009, TUMBUHAN UBATAN POPU; Zhong JY, 2013, J TRADIT CHIN MED, V33, P200, DOI 10.1016/S0254-6272(13)60125-9	54	56	58	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 27	2013	8	11							e79293	10.1371/journal.pone.0079293	http://dx.doi.org/10.1371/journal.pone.0079293			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261GG	24312177	Green Published, gold			2023-01-03	WOS:000327652100008
J	Kang, SC; Lim, SY; Song, YJ				Kang, Se Chan; Lim, Sue Yeon; Song, Yoon-Jae			Lupeol Is One of Active Components in the Extract of Chrysanthemum indicum Linne That Inhibits LMP1-Induced NF-kappa B Activation	PLOS ONE			English	Article							EPSTEIN-BARR-VIRUS; LATENT MEMBRANE-PROTEIN; DIETARY TRITERPENE LUPEOL; PROSTATE-CANCER CELLS; SIGNALING PATHWAYS; LYMPHOCYTE TRANSFORMATION; ANTICANCER DRUGS; APOPTOTIC DEATH; TRANSCRIPTION; EXPRESSION	We have previously reported that seventy percent ethanol extract of Chrysanthemum indicum Linne (CIE) strongly reduces Epstein-Barr virus (EBV)-transformed lymphoblastoid cell line (LCL) survival by inhibiting virus-encoded latent infection membrane protein 1 (LMP1)-induced NF-kappa B activation. To identify an active compound(s) in CIE that inhibits LMP1-induced NF-kappa B activation, activity-guided fractionation was employed. The CH2Cl2 fraction of CIE strongly reduced LMP1-induced NF-kappa B activation and LCL viability with relatively low cytotoxic effects on primary human foreskin fibroblast (HFF), HeLa or Burkitt's lymphoma (BL41) cells. Furthermore, lupeol, a pentacyclic triterpene, was identified in the CH2Cl2 fraction of CIE to attenuate LMP1-induced NF-kappa B activation and LCL viability. This study demonstrates that lupeol is one of active compounds in the CH2Cl2 fraction of CIE that inhibits LMP1-induced NF-kappa B activation and reduces NF-kappa B-dependent LCL viability.	[Kang, Se Chan; Lim, Sue Yeon; Song, Yoon-Jae] Gachon Univ, Dept Life Sci, Songnam, Kyeonggi Do, South Korea	Gachon University	Song, YJ (corresponding author), Gachon Univ, Dept Life Sci, Songnam, Kyeonggi Do, South Korea.	songyj@gachon.ac.kr			Bio-industry Technology Development Program, Ministry of Agriculture, Food and Rural Affairs [311063-5]; National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology (MEST) [2010-0003301]	Bio-industry Technology Development Program, Ministry of Agriculture, Food and Rural Affairs; National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology (MEST)(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This research was supported by Bio-industry Technology Development Program, Ministry of Agriculture, Food and Rural Affairs (No. 311063-5) and by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Education, Science and Technology (MEST) (No. 2010-0003301). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Bari W, 2011, INFECT IMMUN, V79, P3149, DOI 10.1128/IAI.01237-10; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Cahir-McFarland ED, 2004, J VIROL, V78, P4108, DOI 10.1128/JVI.78.8.4108-4119.2004; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Chen LC, 2011, INT J ONCOL, V39, P883, DOI 10.3892/ijo.2011.1104; Cheng WM, 2005, J ETHNOPHARMACOL, V101, P334, DOI 10.1016/j.jep.2005.04.035; Cheon MS, 2009, J ETHNOPHARMACOL, V122, P473, DOI 10.1016/j.jep.2009.01.034; Chun HS, 2008, J MED FOOD, V11, P246, DOI 10.1089/jmf.2007.542; Coant N, 2010, MOL CELL BIOL, V30, P2636, DOI 10.1128/MCB.01194-09; de Oliveira DE, 2010, TRENDS MICROBIOL, V18, P248, DOI 10.1016/j.tim.2010.04.001; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Freyberg Z, 2010, AM J PSYCHIAT, V167, P388, DOI 10.1176/appi.ajp.2009.08121873; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Guo C, 2009, ONCOGENE, V28, P1151, DOI 10.1038/onc.2008.460; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HUEN DS, 1995, ONCOGENE, V10, P549; HURLEY EA, 1991, J VIROL, V65, P3958, DOI 10.1128/JVI.65.7.3958-3963.1991; Izumi KM, 1999, J VIROL, V73, P9908, DOI 10.1128/JVI.73.12.9908-9916.1999; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000141; KATO T, 1987, ARCH INT PHARMACOD T, V285, P288; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Kieff E., 2007, FIELDS VIROLOGY, Vfifth, P2603; Kim IS, 2011, FOOD CHEM TOXICOL, V49, P963, DOI 10.1016/j.fct.2011.01.002; Kim JE, 2012, FOOD CHEM TOXICOL, V50, P1524, DOI 10.1016/j.fct.2012.02.034; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; Lee DY, 2009, J ETHNOPHARMACOL, V123, P149, DOI 10.1016/j.jep.2009.02.009; Lee TK, 2007, CANCER RES, V67, P8800, DOI 10.1158/0008-5472.CAN-07-0801; Li W, 2013, ARCH PHARM RES; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; Misra UK, 2006, J BIOL CHEM, V281, P13694, DOI 10.1074/jbc.M511694200; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; Pongjit K, 2011, HUM EXP TOXICOL, V30, P1931, DOI 10.1177/0960327111402242; Prasad S, 2009, CANCER BIOL THER, V8, P1639, DOI 10.4161/cbt.8.17.9204; Rickinson AB, 2007, FIELDS VIROLOGY, V2, P2655; Saito N, 2003, J BIOL CHEM, V278, P46565, DOI 10.1074/jbc.M302549200; Saleem M, 2005, CANCER RES, V65, P11203, DOI 10.1158/0008-5472.CAN-05-1965; Saleem M, 2005, CARCINOGENESIS, V26, P1956, DOI 10.1093/carcin/bgi157; Saleem M, 2004, ONCOGENE, V23, P5203, DOI 10.1038/sj.onc.1207641; Sen R, 2006, IMMUNITY, V25, P871, DOI 10.1016/j.immuni.2006.12.003; Shih VFS, 2011, CELL RES, V21, P86, DOI 10.1038/cr.2010.161; Song YJ, 2005, J VIROL, V79, P2597, DOI 10.1128/JVI.79.4.2597-2603.2005; Song YJ, 2008, P NATL ACAD SCI USA, V105, P18448, DOI 10.1073/pnas.0809933105; Su JY, 2011, J ETHNOPHARMACOL; Tarapore RS, 2010, CARCINOGENESIS, V31, P1844, DOI 10.1093/carcin/bgq169; Tarapore RS, 2013, MOL NUTR FOOD RES; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; Wang ZD, 2010, ONCOL REP, V23, P413, DOI 10.3892/or_00000650	58	23	23	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 26	2013	8	11							e82688	10.1371/journal.pone.0082688	http://dx.doi.org/10.1371/journal.pone.0082688			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259SK	24303085	gold, Green Published, Green Submitted			2023-01-03	WOS:000327546400103
J	Holderried, F; Heine, D; Wagner, R; Mahling, M; Fenik, Y; Herrmann-Werner, A; Riessen, R; Weyrich, P; Zipfel, S; Celebi, N				Holderried, Friederike; Heine, Daniel; Wagner, Robert; Mahling, Moritz; Fenik, Yelena; Herrmann-Werner, Anne; Riessen, Reimer; Weyrich, Peter; Zipfel, Stephan; Celebi, Nora			Problem-Based Training Improves Recognition of Patient Hazards by Advanced Medical Students during Chart Review: A Randomized Controlled Crossover Study	PLOS ONE			English	Article							COMMON PRESCRIPTION ERRORS; ADVERSE EVENTS; SAFETY; CLERKSHIPS; COMMUNICATION; UNDERGRADUATE; SUPERVISION; INFORMATION	Background: Patient chart review is the gold standard for detection of potential patient hazards (i.e. medication errors or failure to follow up actionable results) in both routine clinical care and patient safety research. However, advanced medical students' ability to read patient charts and to identify patient hazards is rather poor. We therefore investigated whether it is possible to teach advanced medical students how to identify patient hazards independent of context (i.e. cancer versus cardiac failure) in patient charts. Methods: All fifth-year medical students in one semester (n = 123) were randomized into two groups. One group (IC) received a patient chart review-training first and then a control-intervention and the other group (CI) received the control-intervention first and then the patient chart review-training. Before and after the teaching sessions, students reviewed different scenarios with standardized fictional patient charts containing 12 common patient hazards. Two blinded raters rated the students' notes for any patient hazard addressed in the notes using a checklist. The students were blinded to the study question and design. There was no external funding and no harm for the participating students. Results: A total of 35 data sets had to be excluded because of missing data. Overall, the students identified 17% (IQR 8-29%) of the patient hazards before the training and 56% (IQR 41-66%) of the patient hazards after the training. At the second assessment students identified more patient hazards than at the first. They identified even more in the third. The effect was most pronounced after the patient chart review training (all p < .01). Conclusion: Patient chart review exercises and problem-based patient chart review training improve students' abilities to recognize patient hazards independent of context during patient chart review.	[Holderried, Friederike] Univ Tubingen, Sch Med, Off Dean Student Affairs, Tubingen, Germany; [Heine, Daniel] Univ Hosp Tuebingen, Dept Anaesthesiol, Tubingen, Germany; [Mahling, Moritz; Fenik, Yelena] Univ Tubingen, Sch Med, Tubingen, Germany; [Herrmann-Werner, Anne; Zipfel, Stephan] Univ Hosp Tuebingen, Dept Internal Med 6, Tubingen, Germany; [Riessen, Reimer] Univ Hosp Tuebingen, Med Intens Care Unit, Tubingen, Germany; [Wagner, Robert; Weyrich, Peter] Univ Hosp Tuebingen, Dept Internal Med 4, Tubingen, Germany; [Celebi, Nora] Nephrol Ctr Marienpk, Stuttgart, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Herrmann-Werner, A (corresponding author), Univ Hosp Tuebingen, Dept Internal Med 6, Tubingen, Germany.	anne.herrmann-werner@med.uni-tuebingen.de	Riessen, Reimer/AFR-0686-2022; Wagner, Robert/B-3689-2012	Wagner, Robert/0000-0002-6120-0191; /0000-0001-7960-4015; Herrmann-Werner, Anne/0000-0003-2413-7047; Holderried, Friederike/0000-0003-1828-0920; Zipfel, Stephan/0000-0003-1659-4440				Callen J, 2011, BMJ QUAL SAF, V20, P194, DOI 10.1136/bmjqs.2010.044339; Celebi N, 2010, N-S ARCH PHARMACOL, V382, P171, DOI 10.1007/s00210-010-0530-9; Celebi N, 2012, MED TEACH, V34, P1087, DOI 10.3109/0142159X.2012.716570; Celebi N, 2012, BMC MED EDUC, V12, DOI 10.1186/1472-6920-12-24; Celebi N, 2009, MED EDUC, V43, P1010, DOI 10.1111/j.1365-2923.2009.03452.x; Chapman N E, 2001, Healthc Inform, V18, P37; Chapman NE, 2001, HEALTHC INFORM, V18, P42; de Feijter JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031125; de Feijter JM, 2011, ADV HEALTH SCI EDUC, V16, P347, DOI 10.1007/s10459-010-9266-z; de Vries EN, 2008, QUAL SAF HEALTH CARE, V17, P216, DOI 10.1136/qshc.2007.023622; Grant J, 2003, MED EDUC, V37, P140, DOI 10.1046/j.1365-2923.2003.01415.x; Heaton A, 2008, BRIT J CLIN PHARMACO, V66, P128, DOI 10.1111/j.1365-2125.2008.03197.x; Howley LD, 2004, ACAD MED, V79, P276, DOI 10.1097/00001888-200403000-00017; Kolb DA FR, 1975, TOWARD AN APPLIED TH; Krahenbuhl-Melcher A, 2007, DRUG SAFETY, V30, P379; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Lesar TS, 1997, JAMA-J AM MED ASSOC, V277, P312, DOI 10.1001/jama.277.4.312; Lesar TS, 1997, ARCH INTERN MED, V157, P1569, DOI 10.1001/archinte.157.14.1569; MARQUIS Y, 1984, MED EDUC, V18, P117, DOI 10.1111/j.1365-2923.1984.tb00984.x; Murff HJ, 2003, J BIOMED INFORM, V36, P131, DOI 10.1016/j.jbi.2003.08.003; Nikendei C, 2008, MED TEACH, V30, P88, DOI 10.1080/01421590701753468; Rancourt Carol, 2004, BMC Geriatr, V4, P9, DOI 10.1186/1471-2318-4-9; Remmen R, 1999, MED EDUC, V33, P600, DOI 10.1046/j.1365-2923.1999.00467.x; Vincent C., 2010, PATIENT SAFETY, V2nd Ed.; Vogt EM, 2002, DRUG SAFETY, V25, P313, DOI 10.2165/00002018-200225050-00002; Zwaan L, 2010, ARCH INTERN MED, V170, P1015, DOI 10.1001/archinternmed.2010.146	26	2	2	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2014	9	2							e89198	10.1371/journal.pone.0089198	http://dx.doi.org/10.1371/journal.pone.0089198			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AB3UC	24586591	Green Published, gold, Green Submitted			2023-01-03	WOS:000331714700071
J	Martines, MS; Mendes, MM; Shimizu, MHM; Rodrigues, VM; de Castro, I; Ferreira, SR; Malheiros, DMAC; Yu, L; Burdmann, EA				Martines, Monique Silva; Mendes, Mirian M.; Shimizu, Maria H. M.; Rodrigues, Veridiana Melo; de Castro, Isac; Ferreira Filho, Sebastiao R.; Malheiros, Denise M. A. C.; Yu, Luis; Burdmann, Emmanuel A.			Effects of Schizolobium parahyba Extract on Experimental Bothrops Venom-Induced Acute Kidney Injury	PLOS ONE			English	Article							ALTERNATUS SNAKE-VENOM; ACUTE-RENAL-FAILURE; AQUEOUS EXTRACT; NEPHROTOXICITY; BITE; ANTIVENOMS; BIOMARKERS; BURDEN; INDIA	Background: Venom-induced acute kidney injury (AKI) is a frequent complication of Bothrops snakebite with relevant morbidity and mortality. The aim of this study was to assess the effects of Schizolobium parahyba (SP) extract, a natural medicine with presumed anti-Bothrops venom effects, in an experimental model of Bothrops jararaca venom (BV)-induced AKI. Methodology: Groups of 8 to 10 rats received infusions of 0.9% saline (control, C), SP 2 mg/kg, BV 0.25 mg/kg and BV immediately followed by SP (treatment, T) in the doses already described. After the respective infusions, animals were assessed for their glomerular filtration rate (GFR, inulin clearance), renal blood flow (RBF, Doppler), blood pressure (BP, intra-arterial transducer), renal vascular resistance (RVR), urinary osmolality (UO, freezing point), urinary neutrophil gelatinase-associated lipocalin (NGAL, enzyme-linked immunosorbent assay [ ELISA]), lactate dehydrogenase (LDH, kinetic method), hematocrit (Hct, microhematocrit), fibrinogen (Fi, Klauss modified) and blinded renal histology (acute tubular necrosis score). Principal Findings: BV caused significant decreases in GFR, RBF, UO, HcT and Fi; significant increases in RVR, NGAL and LDH; and acute tubular necrosis. SP did not prevent these changes; instead, it caused a significant decrease in GFR when used alone. Conclusion: SP administered simultaneously with BV, in an approximate 10: 1 concentration, did not prevent BV-induced AKI, hemolysis and fibrinogen consumption. SP used alone caused a decrease in GFR.	[Martines, Monique Silva; Shimizu, Maria H. M.; Malheiros, Denise M. A. C.; Yu, Luis; Burdmann, Emmanuel A.] Univ Sao Paulo, Sch Med, Div Nephrol, LIM 12, BR-05508 Sao Paulo, Brazil; [Mendes, Mirian M.] Goias Fed Univ, Inst Biol Sci, Jatai, Goias, Brazil; [Rodrigues, Veridiana Melo] Univ Fed Uberlandia, Inst Genet & Biochem, BR-38400 Uberlandia, MG, Brazil; [de Castro, Isac] Univ Sao Paulo, Sch Med, Div Nephrol, Sao Paulo, Brazil; [Ferreira Filho, Sebastiao R.] Univ Fed Uberlandia, Div Nephrol, BR-38400 Uberlandia, MG, Brazil	Universidade de Sao Paulo; Universidade Federal de Goias; Universidade Federal de Uberlandia; Universidade de Sao Paulo; Universidade Federal de Uberlandia	Burdmann, EA (corresponding author), Univ Sao Paulo, Sch Med, Div Nephrol, LIM 12, BR-05508 Sao Paulo, Brazil.	burdmann@usp.br	Castro, Isac de/J-1984-2015; de Castro, Isac/AAA-8990-2021; Mendes, Mirian Machado/G-9781-2012; MALHEIROS, DENISE MAC/L-7382-2017; Mendes, Mirian Machado/AAI-6249-2021; Burdmann, Emmanuel/B-7023-2009; Yu, Luis/E-8735-2012; Shimizu, Maria/B-7887-2013; rodrigues, veridiana/A-3662-2013; Ferreira-Filho, S R/G-2354-2012; Burdmann, Emmanuel/AAY-1966-2020	Castro, Isac de/0000-0002-1160-3064; MALHEIROS, DENISE MAC/0000-0002-0409-816X; Mendes, Mirian Machado/0000-0003-2878-1999; Burdmann, Emmanuel/0000-0002-7644-8579; rodrigues, veridiana/0000-0002-3386-9197; Ferreira-Filho, S R/0000-0003-4176-9572; Yu, Luis/0000-0001-9102-0063	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil [134872/2010-0]	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	EAB is partially supported by a grant from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil. MSM was supported by a grant from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) (process number 134872/2010-0), Brazil. No additional funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antunes TC, 2010, TOXICON, V56, P1443, DOI 10.1016/j.toxicon.2010.08.011; Athappan Ganesh, 2008, Saudi J Kidney Dis Transpl, V19, P404; Boer-Lima PA, 1999, AM J TROP MED HYG, V61, P698, DOI 10.4269/ajtmh.1999.61.698; Bonventre JV, 2009, NEPHROL DIAL TRANSPL, V24, P3265, DOI 10.1093/ndt/gfp010; Brown NI, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001670; BURDMANN EA, 1993, AM J TROP MED HYG, V48, P82, DOI 10.4269/ajtmh.1993.48.82; Chippaux JP, 2011, TOXICON, V57, P586, DOI 10.1016/j.toxicon.2010.12.022; Cruz LS, 2009, ETHN DIS S1, V19; de Castroa I, 2004, TOXICON, V43, P833, DOI 10.1016/j.toxicon.2004.03.015; Downey P, 2001, AM J PHYSIOL-RENAL, V280, pF607, DOI 10.1152/ajprenal.2001.280.4.F607; Gutierrez JM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002162; Gutierrez Jose Maria, 2011, Inflammation & Allergy Drug Targets, V10, P369; Harrison RA, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000569; Harshavardhan L, 2013, J CLIN DIAGN RES, V7, P853, DOI 10.7860/JCDR/2013/5495.2957; Hasan SMK, 2012, TROP DOCT, V42, P41, DOI 10.1258/td.2011.110137; Kanjanabuch T, 2008, SEMIN NEPHROL, V28, P363, DOI 10.1016/j.semnephrol.2008.04.005; Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218; Krawczeski CD, 2011, J AM COLL CARDIOL, V58, P2301, DOI 10.1016/j.jacc.2011.08.017; Linardi A, 2011, BBA-GEN SUBJECTS, V1810, P895, DOI 10.1016/j.bbagen.2011.06.006; Mello SM, 2010, TOXICON, V55, P470, DOI 10.1016/j.toxicon.2009.09.018; Mendes MM, 2008, PHYTOTHER RES, V22, P859, DOI 10.1002/ptr.2371; Mendes MM, 2010, PHYTOTHER RES, V24, P459, DOI 10.1002/ptr.2956; Mohapatra B, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001018; Molander M, 2012, J ETHNOPHARMACOL, V139, P863, DOI 10.1016/j.jep.2011.12.032; Naicker S, 2008, SEMIN NEPHROL, V28, P348, DOI 10.1016/j.semnephrol.2008.04.003; Nascimento JM, 2007, BIOCHEM CELL BIOL, V85, P591, DOI 10.1139/O07-067; de Morais ICO, 2013, TOXICON, V61, P38, DOI 10.1016/j.toxicon.2012.10.005; Pinho FMO, 2008, SEMIN NEPHROL, V28, P354, DOI 10.1016/j.semnephrol.2008.04.004; Otero-Patino R, 2009, TOXICON, V54, P998, DOI 10.1016/j.toxicon.2009.07.001; Pinho FMO, 2005, KIDNEY INT, V67, P659, DOI 10.1111/j.1523-1755.2005.67122.x; Rahman R, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000860; Ribeiro L A, 1998, Rev Assoc Med Bras (1992), V44, P312, DOI 10.1590/S0104-42301998000400010; Sapirstein A, 2000, BBA-MOL CELL BIOL L, V1488, P139, DOI 10.1016/S1388-1981(00)00116-5; Sgrignolli LR, 2011, NEPHRON CLIN PRACT, V119, pC131, DOI 10.1159/000324228; Sgrignolli LR, 1995, JASN, V16, p540A; Suchithra N, 2008, EMERG MED J, V25, P200, DOI 10.1136/emj.2007.051136; Vale LHF, 2008, BASIC CLIN PHARMACOL, V103, P104, DOI 10.1111/j.1742-7843.2008.00248.x; Vale LHF, 2011, CURR TOP MED CHEM, V11, P2566; Waring WS, 2011, CLIN TOXICOL, V49, P720, DOI 10.3109/15563650.2011.615319; Warrell DA, 2010, LANCET, V375, P77, DOI 10.1016/S0140-6736(09)61754-2; Williams DJ, 2011, J PROTEOMICS, V74, P1735, DOI 10.1016/j.jprot.2011.05.027; Williamson GB, 2012, AM J BOT, V99, P1010, DOI 10.3732/ajb.1100516; World Health Organization, 2016, WHO GUID PROD CONTR; Zornetta I, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001526	44	8	8	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2014	9	2							e86828	10.1371/journal.pone.0086828	http://dx.doi.org/10.1371/journal.pone.0086828			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7IR	24551041	Green Published, gold, Green Submitted			2023-01-03	WOS:000331271500009
J	Sgarra, L; Leo, V; Addabbo, F; Iacobazzi, D; Carratu, MR; Montagnani, M; Potenza, MA				Sgarra, Luca; Leo, Valentina; Addabbo, Francesco; Iacobazzi, Dominga; Carratu, Maria Rosaria; Montagnani, Monica; Potenza, Maria Assunta			Intermittent Losartan Administration Triggers Cardiac Post-Conditioning in Isolated Rat Hearts: Role of BK2 Receptors	PLOS ONE			English	Article							KALLIDIN-LIKE PEPTIDE; MITOCHONDRIAL PERMEABILITY TRANSITION; ISCHEMIC REPERFUSION INJURY; MYOCARDIAL INFARCT SIZE; ANGIOTENSIN-II; MEDIATED VASODILATION; SIGNALING PATHWAYS; SALVAGE KINASE; RABBIT HEARTS; CARDIOPROTECTION	Introduction: The angiotensin (Ang) and bradykinin (BK) tissue-system plays a pivotal role in post-conditioning, but the efficacy of angiotensin type 1 receptor (AT1R) blockers (ARBs) in post-ischemic strategies is still under investigation. We evaluated functional and morphological outcomes, together with activation of cytosolic RISK pathway kinases, in rat hearts subjected to losartan (LOS) or irbesartan (IRB) post-ischemic administration. Methods: Isolated rat hearts underwent 30 min ischemia and 120 min reperfusion. Post-conditioning was obtained by intermittent (10 s/each) or continuous drug infusion during the first 3 min of reperfusion. Left ventricular end-diastolic pressure (LVEDP), left ventricular developed pressure (dLVP), coronary flow (CF), and left ventricular infarct mass (IM) were measured together with the activation status of RISK kinases Akt, p42/44 MAPK and GSK3b. Results: When compared to hearts subjected to ischemia/reperfusion (iI/R) alone, continuous IRB or LOS administration did not significantly reduce total infarct mass (cIRB or cLOS vs. iI/R, p = 0.2). Similarly, intermittent IRB (iIRB) was not able to enhance cardioprotection. Conversely, intermittent LOS administration (iLOS) significantly ameliorated cardiac recovery (iLOS vs iI/R, p<0.01). Differences between iLOS and iIRB persisted under continuous blockade of AT2R (iLOS+ cPD vs. iIRB+ cPD, p<0.05). Interestingly, iLOS cardioprotection was lost when BK2R was simultaneously blocked (iLOS+ cHOE vs. iI/R, p = 0.6), whereas concurrent administration of iBK and iIRB replicated iLOS effects (iIRB+ iBK vs. iLOS, p = 0.7). At the molecular level, iIRB treatment did not significantly activate RISK kinases, whereas both iLOS and iBK treatments were associated with activation of the Akt/GSK3b branch of the RISK pathways (p, 0.05 vs. iI/R, for both). Conclusions: Our results suggest that intermittent losartan is effective in mediating post-conditioning cardioprotection, whereas irbesartan is not. The infarct mass reduction by intermittent losartan seem mainly related on its specific ability to modulate BK2R, and only modestly associated on AT1R blocking properties.	[Sgarra, Luca; Leo, Valentina; Addabbo, Francesco; Iacobazzi, Dominga; Carratu, Maria Rosaria; Montagnani, Monica; Potenza, Maria Assunta] Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol, Bari, Italy	Universita degli Studi di Bari Aldo Moro	Montagnani, M (corresponding author), Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol, Bari, Italy.	monica.montagnani@uniba.it	Sgarra, Luca/AAC-4773-2022; Montagnani, Monica/AAV-2057-2020	Montagnani, Monica/0000-0002-5697-8185; Potenza, Maria Assunta/0000-0002-9995-1468; Carratu, Maria/0000-0002-9709-6533; IACOBAZZI, DOMINGA/0000-0001-5977-0518; Leo, Valentina/0000-0003-3368-5133; Sgarra, Luca/0000-0001-8475-8270	Italian Ministry for Instruction, University and Research (MIUR) [PRIN 2010YK7Z5K_008]; University of Bari [ORBA10DLZD]	Italian Ministry for Instruction, University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR)); University of Bari	This work was supported by a research grant award from the Italian Ministry for Instruction, University and Research (MIUR) PRIN 2010YK7Z5K_008 (to MM), and by a research grant from the University of Bari (ORBA10DLZD to MM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Batenburg WW, 2004, CIRCULATION, V109, P2296, DOI 10.1161/01.CIR.0000128696.12245.57; Bhuiyan MA, 2009, LIFE SCI, V85, P136, DOI 10.1016/j.lfs.2009.05.001; Bonde MM, 2011, REGUL PEPTIDES, V167, P21, DOI 10.1016/j.regpep.2010.11.003; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunner HR, 1997, AM J HYPERTENS, V10, p311S, DOI 10.1016/S0895-7061(97)00391-9; Burns RJ, 2002, J AM COLL CARDIOL, V39, P30, DOI 10.1016/S0735-1097(01)01711-9; Campbell DJ, 2005, CIRCULATION, V111, P315, DOI 10.1161/01.CIR.0000153269.07762.3B; Chachisvilis M, 2006, P NATL ACAD SCI USA, V103, P15463, DOI 10.1073/pnas.0607224103; Darling CE, 2005, AM J PHYSIOL-HEART C, V289, pH1618, DOI 10.1152/ajpheart.00055.2005; Das DK, 1995, J MOL CELL CARDIOL, V27, P181; Das S, 2006, CELL BIOCHEM BIOPHYS, V44, P103, DOI 10.1385/CBB:44:1:103; Driamov S, 2004, BASIC RES CARDIOL, V99, P299, DOI 10.1007/s00395-004-0468-5; FEOLDE E, 1993, J MOL CELL CARDIOL, V25, P1359, DOI 10.1006/jmcc.1993.1148; Flynn JD, 2003, PHARMACOTHERAPY, V23, P1401, DOI 10.1592/phco.23.14.1401.31947; Garlid KD, 2003, BBA-BIOENERGETICS, V1606, P1, DOI 10.1016/S0005-2728(03)00109-9; Gelpi RJ, 2002, BASIC RES CARDIOL, V97, P40, DOI 10.1007/s395-002-8386-0; Gomez L, 2008, CIRCULATION, V117, P2761, DOI 10.1161/CIRCULATIONAHA.107.755066; Gross ER, 2004, CIRC RES, V94, P960, DOI 10.1161/01.RES.0000122392.33172.09; Halkos ME, 2004, ANN THORAC SURG, V78, P961, DOI 10.1016/j.athoracsur.2004.03.033; Hausenloy DJ, 2007, HEART FAIL REV, V12, P217, DOI 10.1007/s10741-007-9026-1; Hausenloy DJ, 2011, ANTIOXID REDOX SIGN, V14, P893, DOI 10.1089/ars.2010.3360; Heusch G, 2013, LANCET, V381, P166, DOI 10.1016/S0140-6736(12)60916-7; Hilgenfeldt U, 2005, BRIT J PHARMACOL, V146, P958, DOI 10.1038/sj.bjp.0706409; Hostrup A, 2012, CELL PHYSIOL BIOCHEM, V30, P642, DOI 10.1159/000341445; Kimura S, 2005, HYPERTENSION, V45, P860, DOI 10.1161/01.HYP.0000163462.98381.7f; Liu X, 2006, BRIT J PHARMACOL, V148, P825, DOI 10.1038/sj.bjp.0706799; Liu XX, 2005, BRIT J PHARMACOL, V146, P952, DOI 10.1038/sj.bjp.0706402; Lo MW, 1995, CLIN PHARMACOL THER, V58, P641, DOI 10.1016/0009-9236(95)90020-9; Marktanner R, 2006, CLIN EXP PHARMACOL P, V33, P787, DOI 10.1111/j.1440-1681.2006.04439.x; Messadi-Laribi E, 2008, CLIN EXP PHARMACOL P, V35, P489, DOI 10.1111/j.1440-1681.2008.04902.x; Michel MC, 2013, PHARMACOL REV, V65, P809, DOI 10.1124/pr.112.007278; Miki T, 1996, J AM COLL CARDIOL, V28, P1616, DOI 10.1016/S0735-1097(96)00371-3; Nishino Y, 2008, CIRC RES, V103, P307, DOI 10.1161/CIRCRESAHA.107.169953; Ovize M, 2010, CARDIOVASC RES, V87, P406, DOI 10.1093/cvr/cvq129; Penna C, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-013-0371-z; Penna C, 2007, CARDIOVASC RES, V75, P168, DOI 10.1016/j.cardiores.2007.03.001; Penna C, 2009, BASIC RES CARDIOL, V104, P390, DOI 10.1007/s00395-008-0762-8; Perrelli MG, 2011, WORLD J CARDIOL, V3, P186, DOI 10.4330/wjc.v3.i6.186; Potenza MA, 2009, AM J PHYSIOL-ENDOC M, V297, pE685, DOI 10.1152/ajpendo.00291.2009; Przyklenk K, 2008, J AM COLL CARDIOL, V51, P1393, DOI 10.1016/j.jacc.2007.11.070; Quinlan CL, 2008, AM J PHYSIOL-HEART C, V295, pH953, DOI 10.1152/ajpheart.00520.2008; Sanada S, 2011, AM J PHYSIOL-HEART C, V301, pH1723, DOI 10.1152/ajpheart.00553.2011; Sato M, 2000, CIRCULATION, V102; Schmidt B, 2003, J MED CHEM, V46, P2261, DOI 10.1021/jm0204237; Schwarz ER, 1997, CARDIOVASC DRUG THER, V11, P687, DOI 10.1023/A:1007743125918; Tong HY, 2002, CIRC RES, V90, P377, DOI 10.1161/01.RES.0000012567.95445.55; Tsang A, 2004, CIRC RES, V95, P230, DOI 10.1161/01.RES.0000138303.76488.fe; van Esch JHM, 2006, BRIT J PHARMACOL, V148, P452, DOI 10.1038/sj.bjp.0706762; Weiss JN, 2003, CIRC RES, V93, P292, DOI 10.1161/01.RES.0000087542.26971.D4; Yang XM, 2004, J AM COLL CARDIOL, V44, P1103, DOI 10.1016/j.jacc.2004.05.060; Zhao ZQ, 2006, CARDIOVASC RES, V70, P200, DOI 10.1016/j.cardiores.2006.01.024; Zhao ZQ, 2003, AM J PHYSIOL-HEART C, V285, pH579, DOI 10.1152/ajpheart.01064.2002	52	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2014	9	2							e88542	10.1371/journal.pone.0088542	http://dx.doi.org/10.1371/journal.pone.0088542			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7CL	24520397	Green Submitted, gold, Green Published			2023-01-03	WOS:000331254600088
J	Bobrowski, L; Lukaszuk, T; Lindholm, B; Stenvinkel, P; Heimburger, O; Axelsson, J; Barany, P; Carrero, JJ; Qureshi, AR; Luttropp, K; Debowska, M; Nordfors, L; Schalling, M; Waniewski, J				Bobrowski, Leon; Lukaszuk, Tomasz; Lindholm, Bengt; Stenvinkel, Peter; Heimburger, Olof; Axelsson, Jonas; Barany, Peter; Carrero, Juan Jesus; Qureshi, Abdul Rashid; Luttropp, Karin; Debowska, Malgorzata; Nordfors, Louise; Schalling, Martin; Waniewski, Jacek			Selection of Genetic and Phenotypic Features Associated with Inflammatory Status of Patients on Dialysis Using Relaxed Linear Separability Method	PLOS ONE			English	Article							CANCER CLASSIFICATION; CLASSIFIERS; BIOMARKERS	Identification of risk factors in patients with a particular disease can be analyzed in clinical data sets by using feature selection procedures of pattern recognition and data mining methods. The applicability of the relaxed linear separability (RLS) method of feature subset selection was checked for high-dimensional and mixed type (genetic and phenotypic) clinical data of patients with end-stage renal disease. The RLS method allowed for substantial reduction of the dimensionality through omitting redundant features while maintaining the linear separability of data sets of patients with high and low levels of an inflammatory biomarker. The synergy between genetic and phenotypic features in differentiation between these two subgroups was demonstrated.	[Bobrowski, Leon; Debowska, Malgorzata; Waniewski, Jacek] Inst Biocybernet & Biomed Engn, Warsaw, Poland; [Bobrowski, Leon; Lukaszuk, Tomasz] Bialystok Tech Univ, Bialystok, Poland; [Lindholm, Bengt; Stenvinkel, Peter; Heimburger, Olof; Axelsson, Jonas; Barany, Peter; Carrero, Juan Jesus; Qureshi, Abdul Rashid; Luttropp, Karin; Debowska, Malgorzata; Nordfors, Louise; Schalling, Martin] Karolinska Inst, Baxter Novum & Renal Med, Stockholm, Sweden; [Carrero, Juan Jesus; Luttropp, Karin; Nordfors, Louise; Schalling, Martin] Karolinska Inst, Ctr Mol Med, Stockholm, Sweden	Polish Academy of Sciences; Nalecz Institute of Biocybernetics & Biomedical Engineering of the Polish Academy of Sciences; Bialystok University of Technology; Karolinska Institutet; Karolinska Institutet	Bobrowski, L (corresponding author), Inst Biocybernet & Biomed Engn, Warsaw, Poland.	l.bobrowski@pb.edu.pl	Łukaszuk, Tomasz/T-5454-2018; Bobrowski, Leon/T-9230-2018; Barany, Peter/I-6116-2019; Qureshi, Abdul Rashid Tony/G-1358-2010; Schalling, Martin/F-1518-2015; Debowska, Malgorzata/F-3035-2015; Lindholm, Bengt/P-1334-2017	Łukaszuk, Tomasz/0000-0003-0489-7567; Bobrowski, Leon/0000-0003-4735-2460; Barany, Peter/0000-0001-6501-8293; Qureshi, Abdul Rashid Tony/0000-0003-0536-5327; Schalling, Martin/0000-0001-5011-2922; Debowska, Malgorzata/0000-0001-8741-7930; Stenvinkel, Peter/0000-0002-8785-4820; Carrero, Juan Jesus/0000-0003-4763-2024; Lindholm, Bengt/0000-0003-4269-4293; Heimburger, Olof/0000-0003-0901-4145	Polish National Center for Research and Development [N R13 0014 04]; Institute of Biocybernetics and Biomedical Engineering PAS [4.2/St/2012]; Bialystok University of Technology [S/WI/2/2013]; GENECURE [LSHM-CT-2006-037697]; Swedish Research Council [Dnr 521-2012-2721]; Baxter Healthcare Corporation	Polish National Center for Research and Development; Institute of Biocybernetics and Biomedical Engineering PAS; Bialystok University of Technology; GENECURE(European Commission); Swedish Research Council(Swedish Research CouncilEuropean Commission); Baxter Healthcare Corporation	This work was supported by Polish National Center for Research and Development [N R13 0014 04]; Institute of Biocybernetics and Biomedical Engineering PAS [4.2/St/2012]; Bialystok University of Technology [S/WI/2/2013]; GENECURE [grant LSHM-CT-2006-037697]; Swedish Research Council (Dnr 521-2012-2721). Baxter Novum is the result of a grant from Baxter Healthcare Corporation to Karolinska Institutet. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad T, 2012, NAT REV CARDIOL, V9, P347, DOI 10.1038/nrcardio.2012.37; Bobrowski L, 2001, ST HEAL T, V84, P1309; BOBROWSKI L, 1991, PATTERN RECOGN, V24, P863, DOI 10.1016/0031-3203(91)90005-P; Bobrowski L., 2005, DATA MINING BASED CO; Bobrowski L, 2011, SELECTED WORKS BIOIN; Bobrowski L, 2009, BIOCYBERN BIOMED ENG, V29, P43; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Demsar J, 2006, J MACH LEARN RES, V7, P1; Ding C, 2003, PROCEEDINGS OF THE 2003 IEEE BIOINFORMATICS CONFERENCE, P523, DOI 10.1109/CSB.2003.1227396; Ding SF, 2012, ARTIF INTELL REV, V37, P169, DOI 10.1007/s10462-011-9225-y; Duan KB, 2005, IEEE T NANOBIOSCI, V4, P228, DOI 10.1109/TNB.2005.853657; Duda R, 2001, PATTERN CLASSIFICATI, Vsecond; Fouque D, 2008, KIDNEY INT, V73, P391, DOI 10.1038/sj.ki.5002585; Guyon I, 2002, MACH LEARN, V46, P389, DOI 10.1023/A:1012487302797; Hall M. A., 2000, P 17 INT C MACH LEAR, P359, DOI DOI 10.1016/J.ESWA.2015.02.049; Hand D, 2001, ADAP COMP MACH LEARN; Johnson R.A., 1991, APPL MULTIVARIATE ST; KIRA K, 1992, MACHINE LEARNING /, P249; Kononenko I, 1994, MACH LEARN, V94; Liu H, 2008, CH CRC DATA MIN KNOW, P3; Luttropp K, 2009, SEMIN DIALYSIS, V22, P417, DOI 10.1111/j.1525-139X.2009.00592.x; Minsky ML, 1987, PERCEPTRONS EXPANDED; Pecoits R, 2003, KIDNEY INT, V63, pS162, DOI 10.1046/j.1523-1755.63.s84.39.x; Stenvinkel P, 1999, KIDNEY INT, V55, P1899, DOI 10.1046/j.1523-1755.1999.00422.x; Stenvinkel P, 2008, CLIN J AM SOC NEPHRO, V3, P505, DOI 10.2215/CJN.03670807; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vapnik V, 1988, STAT LEARNING THEORY; Witten I, 2000, DATA MINING PRACITCA; Wu TT, 2009, BIOINFORMATICS, V25, P714, DOI 10.1093/bioinformatics/btp041	29	4	4	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2014	9	1							e86630	10.1371/journal.pone.0086630	http://dx.doi.org/10.1371/journal.pone.0086630			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301CJ	24489753	Green Published, Green Submitted, gold			2023-01-03	WOS:000330510000064
J	Prior, A; Laursen, TM; Larsen, KK; Johnsen, SP; Christensen, J; Andersen, G; Vestergaard, M				Prior, Anders; Laursen, Thomas Munk; Larsen, Karen Kjaer; Johnsen, Soren Paaske; Christensen, Jakob; Andersen, Grethe; Vestergaard, Mogens			Post-Stroke Mortality, Stroke Severity, and Preadmission Antipsychotic Medicine Use - A Population-Based Cohort Study	PLOS ONE			English	Article							CEREBRAL-ARTERY OCCLUSION; ATTENUATES BRAIN-DAMAGE; ISCHEMIA IN-VIVO; TREATMENT STRATEGIES; RELATIVE RISK; SCHIZOPHRENIA; SURVIVAL; POLYPHARMACY; MEDICATIONS; OLANZAPINE	Background and Purpose: It has been suggested that antipsychotic medication may be neuroprotective and may reduce post-stroke mortality, but studies are few and ambiguous. We aimed to investigate the post-stroke effects of preadmission antipsychotic use. Methods: We conducted a nationwide, population-based cohort study of 81,143 persons admitted with stroke in Denmark from 2003-2010. Using Danish health care databases, we extracted data on preadmission use of antipsychotics and confounding factors. We examined the association between current, former, and never use of antipsychotics and stroke severity, length of hospital stay, and 30-day post-stroke mortality using logistic regression analysis, survival analysis, and propensity score matching. Results: Current users of antipsychotics had a higher risk of severe or very severe stroke on The Scandinavian Stroke Scale than never users of antipsychotics (adjusted odds ratios, 1.43; 95% CI, 1.29-1.58). Current users were less likely to be discharged from hospital within 30 days of admission than never users (probability of non-discharge, 27.0% vs. 21.9%). Antipsychotics was associated with an increased 30-day post-stroke mortality among current users (adjusted mortality rate ratios, 1.42; 95% CI, 1.29-1.55), but not among former users (adjusted mortality rate ratios, 1.05; 95% CI, 0.98-1.14). Conclusions: Preadmission use of antipsychotics was associated with a higher risk of severe stroke, a longer duration of hospital stay, and a higher post-stroke mortality, even after adjustment for known confounders. Antipsychotics play an important role in the treatment of many psychiatric conditions, but our findings do not support the hypothesis that they reduce stroke severity or post-stroke mortality.	[Prior, Anders; Larsen, Karen Kjaer; Vestergaard, Mogens] Aarhus Univ, Dept Publ Hlth, Res Unit Gen Practice, Aarhus, Denmark; [Prior, Anders; Larsen, Karen Kjaer; Vestergaard, Mogens] Aarhus Univ, Dept Publ Hlth, Sect Gen Practice, Aarhus, Denmark; [Laursen, Thomas Munk] Aarhus Univ, Natl Ctr Register Based Res, iPSYCH, Aarhus, Denmark; [Johnsen, Soren Paaske] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus, Denmark; [Christensen, Jakob; Andersen, Grethe] Aarhus Univ Hosp, Dept Neurol, DK-8000 Aarhus, Denmark	Aarhus University; Aarhus University; Aarhus University; Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH); Aarhus University; Aarhus University	Prior, A (corresponding author), Aarhus Univ, Dept Publ Hlth, Res Unit Gen Practice, Aarhus, Denmark.	anders.prior@alm.au.dk	Laursen, Thomas Munk/AFQ-8066-2022; Prior, Anders/P-8628-2014; Vestergaard, Mogens/M-9333-2014	Prior, Anders/0000-0003-4053-3701; Vestergaard, Mogens/0000-0001-8830-2174; Christensen, Jakob/0000-0002-9385-6435; Andersen, Grethe/0000-0001-6807-2500; Laursen, Thomas Munk/0000-0001-6934-1784	Danish Heart Association; Lundbeck Foundation; Lundbeck Foundation [R155-2014-1724, R155-2012-11280] Funding Source: researchfish	Danish Heart Association; Lundbeck Foundation(Lundbeckfonden); Lundbeck Foundation(Lundbeckfonden)	This study was funded by unrestricted grants from the Danish Heart Association (http://www.hjerteforeningen.dk/om_os/in_english/) and The Lundbeck Foundation (http://www.lundbeckfoundation.com/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen KK, 2011, STROKE, V42, P2806, DOI 10.1161/STROKEAHA.111.619049; Andersen P. K., 2012, STAT MODELS BASED CO; Andersen TF, 1999, DAN MED BULL, V46, P263; ASPLUND K, 1985, STROKE, V16, P885; Baandrup L, 2010, J CLIN PSYCHIAT, V71, P103, DOI 10.4088/JCP.08m04818yel; Bushe CJ, 2010, J PSYCHOPHARMACOL, V24, P17, DOI 10.1177/1359786810382468; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Doehner W, 2013, EUR HEART J, V34, P268, DOI 10.1093/eurheartj/ehs340; GLOBUS MYT, 1987, NEUROLOGY, V37, P1712, DOI 10.1212/WNL.37.11.1712; Goldstein LB, 1997, CURR OPIN NEUROL, V10, P52, DOI 10.1097/00019052-199702000-00011; Goldstein LB, 1990, NEUROREHABILITATION, V4, P137; Haberg A, 2006, NEUROCHEM INT, V48, P531, DOI 10.1016/j.neuint.2005.12.025; Hazell AS, 2007, NEUROCHEM INT, V50, P941, DOI 10.1016/j.neuint.2007.04.026; John M Eisenberg Center for Clinical Decisions and Communications Science, 2012, COMP EFFECTIVENESS R; Kam KY, 2012, PROG NEURO-PSYCHOPH, V39, P69, DOI 10.1016/j.pnpbp.2012.05.010; Kang JH, 2011, PSYCHOSOM MED, V73, P106, DOI 10.1097/PSY.0b013e3181fdc2c9; Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717; Kisely S, 2009, BRIT J PSYCHIAT, V195, P545, DOI 10.1192/bjp.bp.109.067082; Leucht S, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008016.pub2; LINDENSTROM E, 1991, CEREBROVASC DIS, V1, P103, DOI 10.1159/000108825; Maher AR, 2011, JAMA-J AM MED ASSOC, V306, P1359, DOI 10.1001/jama.2011.1360; Mainz J, 2004, INT J QUAL HEALTH C, V16, pI45, DOI 10.1093/intqhc/mzh031; Mittal V, 2011, AM J ALZHEIMERS DIS, V26, P10, DOI 10.1177/1533317510390351; Montout C, 2002, SCHIZOPHR RES, V57, P147, DOI 10.1016/S0920-9964(01)00325-5; Osborn DPJ, 2007, ARCH GEN PSYCHIAT, V64, P242, DOI 10.1001/archpsyc.64.2.242; Pedersen CB, 2006, DAN MED BULL, V53, P441; Rosthoj S, 2004, COMPUT METH PROG BIO, V74, P69, DOI 10.1016/S0169-2607(03)00069-5; Tiihonen J, 2012, ARCH GEN PSYCHIAT, V69, P476, DOI 10.1001/archgenpsychiatry.2011.1532; Tiihonen J, 2009, LANCET, V374, P620, DOI 10.1016/S0140-6736(09)60742-X; Tsai KY, 2012, SCHIZOPHR RES, V138, P41, DOI 10.1016/j.schres.2012.02.013; VANHASSELT P, 1973, NEUROPHARMACOLOGY, V12, P245, DOI 10.1016/0028-3908(73)90109-3; Vargo JM, 1996, BEHAV BRAIN RES, V72, P39; VARGO JM, 1989, BEHAV NEUROSCI, V103, P1017, DOI 10.1037/0735-7044.103.5.1017; Vemmos K, 2011, STROKE, V42, P30, DOI 10.1161/STROKEAHA.110.593434; World Health Organization and Alzheimers Disease International, 2012, DEM PUBL HLTH PRIOR; Yulug B, 2008, J NEUROPSYCH CLIN N, V20, P107, DOI 10.1176/jnp.2008.20.1.107a; Yulug B, 2006, BRAIN RES BULL, V69, P656, DOI 10.1016/j.brainresbull.2006.03.017; Yulug B, 2006, BRAIN RES BULL, V71, P296, DOI 10.1016/j.brainresbull.2006.09.018; Yulug B, 2009, BRAIN RES BULL, V80, P95, DOI 10.1016/j.brainresbull.2009.06.013	40	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2014	9	1							e84103	10.1371/journal.pone.0084103	http://dx.doi.org/10.1371/journal.pone.0084103			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	291WL	24416196	Green Published, gold			2023-01-03	WOS:000329862500097
J	Ryan, C; Ross, S; Davey, P; Duncan, EM; Francis, JJ; Fielding, S; Johnston, M; Ker, J; Lee, AJ; MacLeod, MJ; Maxwell, S; McKay, GA; McLay, JS; Webb, DJ; Bond, C				Ryan, Cristin; Ross, Sarah; Davey, Peter; Duncan, Eilidh M.; Francis, Jill J.; Fielding, Shona; Johnston, Marie; Ker, Jean; Lee, Amanda Jane; MacLeod, Mary Joan; Maxwell, Simon; McKay, Gerard A.; McLay, James S.; Webb, David J.; Bond, Christine			Prevalence and Causes of Prescribing Errors: The PRescribing Outcomes for Trainee Doctors Engaged in Clinical Training (PROTECT) Study	PLOS ONE			English	Article							IN-HOSPITAL INPATIENTS; MEDICAL-STUDENTS; JUNIOR DOCTORS; INTERVENTIONS	Objectives: Study objectives were to investigate the prevalence and causes of prescribing errors amongst foundation doctors (i.e. junior doctors in their first (F1) or second (F2) year of post-graduate training), describe their knowledge and experience of prescribing errors, and explore their self-efficacy (i.e. confidence) in prescribing. Method: A three-part mixed-methods design was used, comprising: prospective observational study; semi-structured interviews and cross-sectional survey. All doctors prescribing in eight purposively selected hospitals in Scotland participated. All foundation doctors throughout Scotland participated in the survey. The number of prescribing errors per patient, doctor, ward and hospital, perceived causes of errors and a measure of doctors' self-efficacy were established. Results: 4710 patient charts and 44,726 prescribed medicines were reviewed. There were 3364 errors, affecting 1700 (36.1%) charts (overall error rate: 7.5%; F1: 7.4%; F2: 8.6%; consultants: 6.3%). Higher error rates were associated with : teaching hospitals (p<0.001), surgical (p =<0.001) or mixed wards (0.008) rather than medical ward, higher patient turnover wards (p<0.001), a greater number of prescribed medicines (p<0.001) and the months December and June (p<0.001). One hundred errors were discussed in 40 interviews. Error causation was multi-factorial; work environment and team factors were particularly noted. Of 548 completed questionnaires (national response rate of 35.4%), 508 (92.7% of respondents) reported errors, most of which (328 (64.6%) did not reach the patient. Pressure from other staff, workload and interruptions were cited as the main causes of errors. Foundation year 2 doctors reported greater confidence than year 1 doctors in deciding the most appropriate medication regimen. Conclusions: Prescribing errors are frequent and of complex causation. Foundation doctors made more errors than other doctors, but undertook the majority of prescribing, making them a key target for intervention. Contributing causes included work environment, team, task, individual and patient factors. Further work is needed to develop and assess interventions that address these.	[Ryan, Cristin] Queens Univ Belfast, Sch Pharm, Belfast, Antrim, North Ireland; [Ross, Sarah; MacLeod, Mary Joan; McLay, James S.] Univ Aberdeen, Sch Med & Dent, Aberdeen, Scotland; [Davey, Peter; Ker, Jean] Univ Dundee, Sch Med, Dundee, Scotland; [Duncan, Eilidh M.] Univ Aberdeen, Hlth Serv Res Unit, Aberdeen, Scotland; [Francis, Jill J.] City Univ London, Hlth Serv Res & Management Div, London EC1V 0HB, England; [Fielding, Shona; Lee, Amanda Jane] Univ Aberdeen, Med Stat Team, Aberdeen, Scotland; [Johnston, Marie] Univ Aberdeen, Aberdeen, Scotland; [Maxwell, Simon] Univ Edinburgh, Clin Pharmacol Unit, Edinburgh, Midlothian, Scotland; [McKay, Gerard A.] Glasgow Royal Infirm, Dept Clin Pharmacol, Glasgow G4 0SF, Lanark, Scotland; [Webb, David J.] Univ Edinburgh, Royal Infirm Edinburgh, Clin Pharmacol Unit, Edinburgh, Midlothian, Scotland; [Bond, Christine] Univ Aberdeen, Ctr Acad Primary Care, Aberdeen, Scotland	Queens University Belfast; University of Aberdeen; University of Dundee; University of Aberdeen; City University London; University of Aberdeen; University of Aberdeen; University of Edinburgh; University of Glasgow; Royal Infirmary of Edinburgh; University of Edinburgh; University of Aberdeen	Bond, C (corresponding author), Univ Aberdeen, Ctr Acad Primary Care, Aberdeen, Scotland.	c.m.bond@abdn.ac.uk	Francis, Jill/AHE-6998-2022	Ryan, Cristin/0000-0002-6037-4413; Macleod, Mary Joan/0000-0003-2115-8184; Duncan, Eilidh/0000-0002-1009-9732; Francis, Jill/0000-0001-5784-8895; Maxwell, Simon/0000-0002-3032-7237	Scottish Chief Scientists Office; Chief Scientist Office [CZH/4/505, HSRU2] Funding Source: researchfish	Scottish Chief Scientists Office; Chief Scientist Office	This project was funded by the Scottish Chief Scientists Office. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2008, DEV EVALUATING COMPL; Bandura A., 1994, ENCY HUMAN BEHAV, V4, P71; Bandura A., 1986, SOCIAL FDNS THOUGHTS; Coombes ID, 2008, MED J AUSTRALIA, V188, P89, DOI 10.5694/j.1326-5377.2008.tb01529.x; De Amici D, 2000, CONTROL CLIN TRIALS, V21, P103, DOI 10.1016/S0197-2456(99)00054-9; Dean B, 2000, QUAL HEALTH CARE, V9, P232, DOI 10.1136/qhc.9.4.232; Dean B, 2002, LANCET, V359, P1373, DOI 10.1016/S0140-6736(02)08350-2; Franklin BD, 2011, POSTGRAD MED J, V87, P739, DOI 10.1136/pgmj.2011.117879; Heaton A, 2008, BRIT J CLIN PHARMACO, V66, P128, DOI 10.1111/j.1365-2125.2008.03197.x; Lewis PJ, 2009, DRUG SAFETY, V32, P379, DOI 10.2165/00002018-200932050-00002; Marteau TM, 1989, PSYCHOL HEALTH, V3, P173; Mayo E, 1993, HUMAN PROBLEMS IND C, V3, P53; Michie S, 2008, APPL PSYCHOL-INT REV, V57, P660, DOI 10.1111/j.1464-0597.2008.00341.x; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-10; Reason J., 1990, HUMAN ERROR; Ross S, 2012, POSTGRAD MED J, DOI [10.1136/postgradmedj-2011-130602, DOI 10.1136/P0STGRADMEDJ-2011-130602]; Ross S, 2013, BMJ QUAL SAF, V22, P97, DOI 10.1136/bmjqs-2012-001175; Ross S, 2009, BRIT J CLIN PHARMACO, V67, P662, DOI 10.1111/j.1365-2125.2009.03395.x; Ross S, 2009, BRIT J CLIN PHARMACO, V67, P629, DOI 10.1111/j.1365-2125.2008.03330.x; Ryan C, 2013, BR J CLIN P IN PRESS; T Dornan, 2009, DEPTH INVESTIGATION; Tobaiqy M, 2007, BRIT J CLIN PHARMACO, V64, P363, DOI 10.1111/j.1365-2125.2007.02925.x; WYNNE G, 1987, BRIT MED J, V294, P1198, DOI 10.1136/bmj.294.6581.1198	23	104	107	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2014	9	1							e79802	10.1371/journal.pone.0079802	http://dx.doi.org/10.1371/journal.pone.0079802			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286IH	24404122	Green Accepted, Green Published, gold, Green Submitted			2023-01-03	WOS:000329460800001
J	Bwakura-Dangarembizi, M; Kendall, L; Bakeera-Kitaka, S; Nahirya-Ntege, P; Keishanyu, R; Nathoo, K; Spyer, MJ; Kekitiinwa, A; Lutaakome, J; Mhute, T; Kasirye, P; Munderi, P; Musiime, V; Gibb, DM; Walker, AS; Prendergast, AJ				Bwakura-Dangarembizi, Mutsawashe; Kendall, Lindsay; Bakeera-Kitaka, Sabrina; Nahirya-Ntege, Patricia; Keishanyu, Rosette; Nathoo, Kusum; Spyer, Moira J.; Kekitiinwa, Adeodata; Lutaakome, Joseph; Mhute, Tawanda; Kasirye, Philip; Munderi, Paula; Musiime, Victor; Gibb, Diana M.; Walker, A. Sarah; Prendergast, Andrew J.		Arrow Trial Team	A Randomized Trial of Prolonged Co-trimoxazole in HIV-Infected Children in Africa	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS; HUMAN-IMMUNODEFICIENCY-VIRUS; INSECTICIDE-TREATED BEDNETS; ANTIRETROVIRAL THERAPY; COTE-DIVOIRE; OPPORTUNISTIC INFECTIONS; HIV-1-INFECTED ADULTS; UGANDAN CHILDREN; MORTALITY; MALARIA	BackgroundCo-trimoxazole (fixed-dose trimethoprim-sulfamethoxazole) prophylaxis administered before antiretroviral therapy (ART) reduces morbidity in children infected with the human immunodeficiency virus (HIV). We investigated whether children and adolescents receiving long-term ART in sub-Saharan Africa could discontinue co-trimoxazole. MethodsWe conducted a randomized, noninferiority trial of stopping versus continuing daily open-label co-trimoxazole in children and adolescents in Uganda and Zimbabwe. Eligible participants were older than 3 years of age, had been receiving ART for more than 96 weeks, were using insecticide-treated bed nets (in malaria-endemic areas), and had not had Pneumocystis jirovecii pneumonia. Coprimary end points were hospitalization or death and adverse events of grade 3 or 4. ResultsA total of 758 participants were randomly assigned to stop or continue co-trimoxazole (382 and 376 participants, respectively), after receiving ART for a median of 2.1 years (interquartile range, 1.8 to 2.3). The median age was 7.9 years (interquartile range, 4.6 to 11.1), and the median CD4 T-cell percentage was 33% (interquartile range, 26 to 39). Participants who stopped co-trimoxazole had higher rates of hospitalization or death than those who continued (72 participants [19%] vs. 48 [13%]; hazard ratio, 1.64; 95% confidence interval [CI], 1.14 to 2.37; P=0.007; noninferiority not shown). There was no evidence of variation across ages (P=0.93 for interaction). A total of 2 participants in the prophylaxis-stopped group (1%) died, as did 3 in the prophylaxis-continued group (1%). Most hospitalizations in the prophylaxis-stopped group were for malaria (49 events, vs. 21 in the prophylaxis-continued group) or infections other than malaria (53 vs. 25), particularly pneumonia, sepsis, and meningitis. Rates of adverse events of grade 3 or 4 were similar in the two groups (hazard ratio, 1.20; 95% CI, 0.83 to 1.72; P=0.33), but more grade 4 adverse events occurred in the prophylaxis-stopped group (hazard ratio, 2.04; 95% CI, 0.99 to 4.22; P=0.05), with anemia accounting for the largest number of events (12, vs. 2 with continued prophylaxis). ConclusionsContinuing co-trimoxazole prophylaxis after 96 weeks of ART was beneficial, as compared with stopping prophylaxis, with fewer hospitalizations for both malaria and infection not related to malaria. (Funded by the United Kingdom Medical Research Council and others; ARROW Current Controlled Trials number, ISRCTN24791884.)	[Bwakura-Dangarembizi, Mutsawashe; Nathoo, Kusum; Mhute, Tawanda] Univ Zimbabwe, Coll Hlth Sci, Harare, Zimbabwe; [Kendall, Lindsay; Spyer, Moira J.; Gibb, Diana M.; Walker, A. Sarah; Prendergast, Andrew J.] UCL, MRC, Clin Trials Unit, London WC2B 6NH, England; [Prendergast, Andrew J.] Univ London Queen Mary, Ctr Paediat, Blizard Inst, London, England; [Bakeera-Kitaka, Sabrina; Kekitiinwa, Adeodata; Musiime, Victor] Mulago Hosp, Paediat Infect Dis Clin Baylor Uganda, Kampala, Uganda; [Keishanyu, Rosette; Musiime, Victor] Joint Clin Res Ctr, Kampala, Uganda; [Nahirya-Ntege, Patricia; Lutaakome, Joseph; Munderi, Paula] Uganda Res Unit AIDS, Uganda Virus Res Inst, Entebbe, Uganda; [Nahirya-Ntege, Patricia; Lutaakome, Joseph; Munderi, Paula] Uganda Res Unit AIDS, MRC, Entebbe, Uganda	University of Zimbabwe; Medical Research Council Clinical Trials Unit; University of London; University College London; University of London; Queen Mary University London; Mulago National Referral Hospital; Joint Clinic Research Center - United Arab Emirates; Uganda Virus Research Institute	Prendergast, AJ (corresponding author), UCL, MRC, Clin Trials Unit, Aviat House,125 Kingsway, London WC2B 6NH, England.	a.prendergast@qmul.ac.uk	Walker, Sarah/HDM-8717-2022; Bwakura-Dangarembizi, Mutsa/D-5686-2018	Kendall, Lindsay/0000-0003-2812-0154; Kasirye, Phillip/0000-0001-6620-483X; Bwakura-Dangarembizi, Mutsa/0000-0001-7751-6177; Prendergast, Andrew/0000-0001-7904-7992; Musiime, Victor/0000-0001-7472-9054	U.K. Medical Research Council; U.K. Department for International Development; ViiV Healthcare; GlaxoSmithKline; MRC [MC_EX_G0300400, MC_U122886353] Funding Source: UKRI; Medical Research Council [MC_U122886353, MC_EX_G0300400] Funding Source: researchfish	U.K. Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); U.K. Department for International Development; ViiV Healthcare; GlaxoSmithKline(GlaxoSmithKline); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by the U.K. Medical Research Council and the U.K. Department for International Development. ViiV Healthcare and GlaxoSmithKline donated first-line drugs for the Antiretroviral Research for Watoto (ARROW) trial and provided funding for virologic assays.	Anglaret X, 2000, AIDS, V14, P2628, DOI 10.1097/00002030-200011100-00036; Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; Anglaret X, 2012, CLIN INFECT DIS, V54, P714, DOI 10.1093/cid/cir898; [Anonymous], 1994, INT C HARM TECHN REQ; Badri M, 2001, AIDS, V15, P1143, DOI 10.1097/00002030-200106150-00009; Campbell JD, 2012, CLIN INFECT DIS, V54, P1204, DOI 10.1093/cid/cis013; Chintu C, 2004, LANCET, V364, P1865, DOI 10.1016/S0140-6736(04)17442-4; Chintu C, 2002, LANCET, V360, P985, DOI 10.1016/S0140-6736(02)11082-8; Corbett EL, 2002, CLIN INFECT DIS, V34, P1251, DOI 10.1086/339540; Date AA, 2010, B WORLD HEALTH ORGAN, V88, P253, DOI 10.2471/BLT.09.066522; Forgacs P, 2009, ANTIMICROB AGENTS CH, V53, P4789, DOI 10.1128/AAC.01658-08; Gasasira AF, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-177; Gibb DM, 2013, LANCET, V381, P1391, DOI 10.1016/S0140-6736(12)62198-9; Gibb DM, 2000, LANCET, V355, P1331, DOI 10.1016/S0140-6736(00)02117-6; Gilks CF, 1996, LANCET, V347, P718, DOI 10.1016/S0140-6736(96)90076-8; Grimwade K, 2005, AIDS, V19, P163, DOI 10.1097/00002030-200501280-00008; Gsponer T, 2012, PEDIATRICS, V130, pE966, DOI 10.1542/peds.2011-3020; Hamel MJ, 2008, AM J TROP MED HYG, V79, P320, DOI 10.4269/ajtmh.2008.79.320; Hamer DH, 2008, AM J TROP MED HYG, V79, P299, DOI 10.4269/ajtmh.2008.79.299; Kamya MR, 2007, AIDS, V21, P2059, DOI 10.1097/QAD.0b013e3282ef6da1; Kreuzer KA, 1997, BRIT J HAEMATOL, V96, P235, DOI 10.1046/j.1365-2141.1997.d01-2031.x; Malamba SS, 2006, AM J TROP MED HYG, V75, P375, DOI 10.4269/ajtmh.2006.75.375; Mermin J, 2006, LANCET, V367, P1256, DOI 10.1016/S0140-6736(06)68541-3; Mermin J, 2004, LANCET, V364, P1428, DOI 10.1016/S0140-6736(04)17225-5; Mulenga V, 2007, AIDS, V21, P77, DOI 10.1097/QAD.0b013e3280114ed7; Nachman S, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1847; Nunn AJ, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a257; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Prendergast A, 2011, CLIN INFECT DIS, V52, P953, DOI 10.1093/cid/cir029; Royston P, 2002, STAT MED, V21, P2175, DOI 10.1002/sim.1203; Sutcliffe CG, 2009, LANCET INFECT DIS, V9, P736; Suthar AB, 2012, B WORLD HEALTH ORGAN, V90, P128, DOI 10.2471/BLT.11.093260; Thera MA, 2005, J INFECT DIS, V192, P1823, DOI 10.1086/498249; Urschel S, 2005, AIDS, V19, P2103, DOI 10.1097/01.aids.0000194795.20928.2b; Walker AS, 2010, LANCET, V375, P1278, DOI 10.1016/S0140-6736(10)60057-8; WHO, 2010, GUID TREATM MAL, V2nd; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; World Health Organization, 2006, WHO CAS DEF HIV SURV; World Health Organization, 2010, ANT THER HIV INF INF; World Health Organization (WHO), 2006, GUID COTR PROPH HIV	40	79	79	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 2	2014	370	1					41	53		10.1056/NEJMoa1214901	http://dx.doi.org/10.1056/NEJMoa1214901			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284XA	24382064	Green Accepted, Green Published			2023-01-03	WOS:000329354100009
J	Weenen, TC; Ramezanpour, B; Pronker, ES; Commandeur, H; Claassen, E				Weenen, Tamar C.; Ramezanpour, Bahar; Pronker, Esther S.; Commandeur, Harry; Claassen, Eric			Food-Pharma Convergence in Medical Nutrition - Best of Both Worlds?	PLOS ONE			English	Article							CROSS IMPACT ANALYSIS; FUNCTIONAL FOODS; PATENT CITATIONS; TECHNOLOGY; INNOVATION; INDUSTRY; NUTRACEUTICALS; ACCEPTANCE; DIFFUSION; PRODUCTS	At present, industries within the health and life science sector are moving towards one another resulting in new industries such as the medical nutrition industry. Medical nutrition products are specific nutritional compositions for intervention in disease progression and symptom alleviation. Industry convergence, described as the blurring of boundaries between industries, plays a crucial role in the shaping of new markets and industries. Assuming that the medical nutrition industry has emerged from the convergence between the food and pharma industries, it is crucial to research how and which distinct industry domains have contributed to establish this relatively new industry. The first two stages of industry convergence (knowledge diffusion and consolidation) are measured by means of patent analysis. First, the extent of knowledge diffusion within the medical nutrition industry is graphed in a patent citation interrelations network. Subsequently the consolidation based on technological convergence is determined by means of patent co-classification. Furthermore, the medical nutrition core domain and technology interrelations are measured by means of a cross impact analysis. This study proves that the medical nutrition industry is a result of food and pharma convergence. It is therefore crucial for medical nutrition companies to effectively monitor technological developments within as well as across industry boundaries. This study further reveals that although the medical nutrition industry's core technology domain is food, technological development is mainly driven by pharmaceutical/pharmacological technologies Additionally, the results indicate that the industry has surpassed the knowledge diffusion stage of convergence, and is currently in the consolidation phase of industry convergence. Nevertheless, while the medical nutrition can be classified as an industry in an advanced phase of convergence, one cannot predict that the pharma and food industry segments will completely converge or whether the medical industry will become an individual successful industry.	[Weenen, Tamar C.; Commandeur, Harry] Erasmus Univ, Fac Econ, Rotterdam, Netherlands; [Weenen, Tamar C.; Claassen, Eric] Erasmus MC, Dept Virol, Rotterdam, Netherlands; [Ramezanpour, Bahar; Claassen, Eric] Vrije Univ Amsterdam, Athena Inst, Amsterdam, Netherlands; [Pronker, Esther S.] Viroclin, Rotterdam, Netherlands; [Commandeur, Harry] Nyenrode Business Univ, Breukelen, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Vrije Universiteit Amsterdam; Nyenrode Business University	Weenen, TC (corresponding author), Erasmus Univ, Fac Econ, Rotterdam, Netherlands.	tamarchekaweenen@gmail.com	Han, KyungJu/J-5563-2014	Han, KyungJu/0000-0002-5006-1886				[Anonymous], 2001, 8498 NBER; Bagchi D, 2008, FOOD SCI TECHNOL-INT, P1; Blackman M, 1995, WORLD PATENT INFORM, V17, P115, DOI DOI 10.1016/0172-2190(95)00012-O; Borgatti S.P., 2002, UCINET 6 WINDOWS SOF; Bossink BAG, 2004, J CONSTR ENG M, V130, P337, DOI 10.1061/(ASCE)0733-9364(2004)130:3(337); Breschi S, 2003, RES POLICY, V32, P69, DOI 10.1016/S0048-7333(02)00004-5; Broring S, 2006, R&D MANAGE, V36, P487, DOI 10.1111/j.1467-9310.2006.00449.x; Broring S., 2007, CREAT INNOV MANAG, V16, P165, DOI DOI 10.1111/J.1467-8691.2007.00425.X; Chang SB, 2009, TECHNOL FORECAST SOC, V76, P107, DOI 10.1016/j.techfore.2008.03.014; Choi C, 2007, TECHNOL FORECAST SOC, V74, P1296, DOI 10.1016/j.techfore.2006.10.008; Csardi G, 2007, PHYSICA A, V374, P783, DOI 10.1016/j.physa.2006.08.022; Curran CS, 2011, TECHNOL FORECAST SOC, V78, P256, DOI 10.1016/j.techfore.2010.06.021; Curran CS, 2010, TECHNOL FORECAST SOC, V77, P385, DOI 10.1016/j.techfore.2009.10.002; Dahlin KB, 2005, RES POLICY, V34, P717, DOI 10.1016/j.respol.205.03.009; Dernis H, 2002, NEW SCI TECHNOLOGY I, V27, P129; Duysters G., 1998, INT J ECON BUS, V5, P355, DOI DOI 10.1080/13571519884431; El-Sohaimy S. A., 2012, World Applied Sciences Journal, V20, P691; ENZER S, 1972, FUTURES, V4, P30, DOI 10.1016/0016-3287(72)90023-7; Ernst H, 1997, SMALL BUS ECON, V9, P361, DOI 10.1023/A:1007921808138; Eussen SRBM, 2011, EUR J PHARMACOL, V668, pS2, DOI 10.1016/j.ejphar.2011.07.008; Furst P, 2000, NUTRITION, V16, P603, DOI 10.1016/S0899-9007(00)00321-X; Georgiou NA, 2011, EUR J PHARMACOL, V651, P1, DOI 10.1016/j.ejphar.2010.11.007; Geum Y, 2012, ETRI J, V34, P439, DOI 10.4218/etrij.12.1711.0010; Gilbert L., 1997, Journal of Nutraceuticals, Functional and Medical Foods, V1, P5; Greenstein S, 1997, COMPETING IN THE AGE OF DIGITAL CONVERGENCE, P201; Grunert KG, 2000, INT DAIRY J, V10, P575, DOI 10.1016/S0958-6946(00)00085-6; Hacklin F, 2008, CONTRIB MANAG SCI, P1, DOI 10.1007/978-3-7908-1990-8; Henry CJ, 2010, EUR J CLIN NUTR, V64, P657, DOI 10.1038/ejcn.2010.101; Howlett J, 2008, ILSI EUR CONCISE MON, P1; Hu AGZ, 2003, INT J IND ORGAN, V21, P849, DOI 10.1016/S0167-7187(03)00035-3; Jaffe A., 1999, ECON INNOV NEW TECH, V8, P105, DOI DOI 10.1080/10438599900000006; Jeong GH, 1997, TECHNOL FORECAST SOC, V55, P203, DOI 10.1016/S0040-1625(96)00209-0; Johnstone N, 2010, ENVIRON RESOUR ECON, V45, P133, DOI 10.1007/s10640-009-9309-1; Karvonen M, 2012, TECHNOLOGICAL FORECA; KATZ L., 1996, IND CORP CHANG, V5, P1079, DOI DOI 10.1093/ICC/5.4.1079; Kim C, 2011, EXPERT SYST APPL, V38, P12559, DOI 10.1016/j.eswa.2011.04.042; Lee H, 2009, EXPERT SYST APPL, V36, P894, DOI 10.1016/j.eswa.2007.10.026; Lukach R., 2002, 754 CESIFO; Medical Nutrition International Industry (MNI), 2012, OR NUTR SUPPL TACKL; Nemet GF, 2012, RES POLICY, V41, P190, DOI 10.1016/j.respol.2011.08.009; OECD, 1994, US PAT DAT SCI TECHN; Pennings J. M., 2000, MARKET CONVERGENCE F; Phyllis Balch A, 2010, PRESCRIPTION NUTR HE; Prahalad CK, 1998, RES TECHNOL MANAGE, V41, P14, DOI 10.1080/08956308.1998.11671205; Pronker ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057755; SCHULER A, 1991, IEEE T ENG MANAGE, V38, P224, DOI 10.1109/17.83755; Shi XL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006547; Siro I, 2008, APPETITE, V51, P456, DOI 10.1016/j.appet.2008.05.060; Suzuki J, 2004, RES POLICY, V33, P531, DOI 10.1016/j.respol.2003.10.005; Teratanavat R, 2006, J FOOD SCI, V71, pS533, DOI 10.1111/j.1750-3841.2006.00120.x; Thorleuchter D, 2010, TECHNOL FORECAST SOC, V77, P1037, DOI 10.1016/j.techfore.2010.03.002; TRAJTENBERG M, 1990, RAND J ECON, V21, P172, DOI 10.2307/2555502; Tseng FM, 2011, TECHNOL FORECAST SOC, V78, P332, DOI 10.1016/j.techfore.2010.10.010; van Kreijl CF, 2006, OUR FOOD OUR HLTH HL, P189; Verhagen H, 2010, ARCH BIOCHEM BIOPHYS, V501, P6, DOI 10.1016/j.abb.2010.04.012; von Delft S, 2013, LETT EDITOR, V10, P67; Weaver B, 2007, RES PROPOSAL IND CON; Weenen T, 2013, PHARMANUTRITION; Weenen TC, 2013, BRIDGING PH IN PRESS; Weststrate JA, 2002, BRIT J NUTR, V88, pS233, DOI 10.1079/BJN2002688; Williams J, 2009, HLTH LIFESCIENCES IR; Yoon B., 2004, J HIGH TECHNOLOGY MA, V15, P37, DOI [10.1016/j.hitech.2003.09.003, DOI 10.1016/J.HITECH.2003.09.003]	62	15	16	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2013	8	12							e82609	10.1371/journal.pone.0082609	http://dx.doi.org/10.1371/journal.pone.0082609			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	276GD	24358214	gold, Green Published, Green Submitted			2023-01-03	WOS:000328735700087
J	Barker, D; Barker, M; Fleming, T; Lampl, M				Barker, David; Barker, Mary; Fleming, Tom; Lampl, Michelle			Support mothers to secure future public health	NATURE			English	Editorial Material							CARDIOVASCULAR-DISEASE; WOMEN		[Barker, David; Barker, Mary] Univ Southampton, MRC, Lifecourse Epidemiol Unit, Southampton SO9 5NH, Hants, England; [Barker, David] Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR 97201 USA; [Fleming, Tom] Univ Southampton, Ctr Biol Sci, Southampton SO9 5NH, Hants, England; [Lampl, Michelle] Ctr Study Human Hlth, Atlanta, GA USA; [Lampl, Michelle] Emory Univ, Atlanta, GA 30322 USA	University of Southampton; Oregon Health & Science University; University of Southampton; Emory University	Barker, D (corresponding author), Emory Univ, Ctr Study Human Hlth, Atlanta, GA 30322 USA.	meb@mrc.soton.ac.uk	Lampl, Michelle L/B-1619-2013	Barker, Mary/0000-0003-2976-0217	BBSRC [BB/F007450/1, BB/I001840/1] Funding Source: UKRI; MRC [MC_UP_A620_1017, G0100558, MC_UU_12011/4] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/I001840/1] Funding Source: researchfish; Biotechnology and Biological Sciences Research Council [BB/F007450/1] Funding Source: Medline; Medical Research Council [G0100558, MC_UP_A620_1017, MC_UU_12011/4] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Barker DJP, 2013, PLACENTA, V34, P841, DOI 10.1016/j.placenta.2013.07.063; Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235; Barker DJP, 1997, BRIT MED BULL, V53, P96; BARKER DJP, 1989, NATURE, V338, P371, DOI 10.1038/338371a0; Barker M, 2008, PUBLIC HEALTH NUTR, V11, P1229, DOI 10.1017/S136898000800178X; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Chen L, 2012, NAT REV ENDOCRINOL, V8, P228, DOI 10.1038/nrendo.2011.183; Laslett LJ, 2012, J AM COLL CARDIOL, V60, pS1, DOI 10.1016/j.jacc.2012.11.002; Manandhar DS, 2004, LANCET, V364, P970, DOI 10.1016/S0140-6736(04)17021-9; Robker RL, 2009, J CLIN ENDOCR METAB, V94, P1533, DOI 10.1210/jc.2008-2648	10	60	62	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 12	2013	504	7479					209	211		10.1038/504209a	http://dx.doi.org/10.1038/504209a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	267TQ	24350368	Bronze			2023-01-03	WOS:000328121500014
J	Binder, BYK; Sondergaard, CS; Nolta, JA; Leach, JK				Binder, Bernard Y. K.; Sondergaard, Claus S.; Nolta, Jan A.; Leach, J. Kent			Lysophosphatidic Acid Enhances Stromal Cell-Directed Angiogenesis	PLOS ONE			English	Article							MESENCHYMAL STEM-CELLS; SELF-ASSEMBLING PEPTIDES; GROWTH-FACTOR DELIVERY; SPHINGOSINE 1-PHOSPHATE; THERAPEUTIC TARGET; PROGENITOR CELLS; CARDIAC-FUNCTION; VEGF; DIFFERENTIATION; ACTIVATION	Ischemic diseases such as peripheral vascular disease (PVD) affect more than 15% of the general population and in severe cases result in ulcers, necrosis, and limb loss. While the therapeutic delivery of growth factors to promote angiogenesis has been widely investigated, large-scale implementation is limited by strategies to effectively deliver costly recombinant proteins. Multipotent adipose-derived stromal cells (ASC) and progenitor cells from other tissue compartments secrete bioactive concentrations of angiogenic molecules, making cell-based strategies for in situ delivery of angiogenic cytokines an exciting alternative to the use of recombinant proteins. Here, we show that the phospholipid lysophosphatidic acid (LPA) synergistically improves the proangiogenic effects of ASC in ischemia. We found that LPA upregulates angiogenic growth factor production by ASC under two-and three-dimensional in vitro models of serum deprivation and hypoxia (SD/H), and that these factors significantly enhance endothelial cell migration. The concurrent delivery of LPA and ASC in fibrin gels significantly improves vascularization in a murine critical hindlimb ischemia model compared to LPA or ASC alone, thus exhibiting the translational potential of this method. Furthermore, these results are achieved using an inexpensive lipid molecule, which is orders-of-magnitude less costly than recombinant growth factors that are under investigation for similar use. Our results demonstrate a novel strategy for enhancing cell-based strategies for therapeutic angiogenesis, with significant applications for treating ischemic diseases.	[Binder, Bernard Y. K.; Leach, J. Kent] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA; [Leach, J. Kent] Univ Calif Davis, Sch Med, Dept Orthopaed Surg, Davis, CA 95616 USA; [Sondergaard, Claus S.] Univ Calif Davis, Sch Med, Dept Surg, Div Cardiothorac Surg, Sacramento, CA 95817 USA; [Nolta, Jan A.] Univ Calif Davis, Sch Med, Dept Hematol Oncol, Sacramento, CA 95817 USA; [Nolta, Jan A.] Univ Calif Davis, Sch Med, Dept Cell Biol, Sacramento, CA 95817 USA; [Nolta, Jan A.] Univ Calif Davis, Sch Med, Dept Human Anat, Sacramento, CA 95817 USA; [Nolta, Jan A.] Univ Calif Davis, Sch Med, Stem Cell Program, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Leach, JK (corresponding author), Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA.	jkleach@ucdavis.edu		Nolta, Jan/0000-0003-4576-8542	National Institutes of Health [1R21AG036963]; AO Craniomaxillofacial Foundation [C10-39L]; California Institute for Regenerative Medicine UC Davis Stem Cell Training Program [CIRM T1-00006, CIRM TG2-01163]; NATIONAL INSTITUTE ON AGING [R21AG036963] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AO Craniomaxillofacial Foundation; California Institute for Regenerative Medicine UC Davis Stem Cell Training Program; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This project was supported by grants from the National Institutes of Health 1R21AG036963 and AO Craniomaxillofacial Foundation (C10-39L) to JKL. This project was also supported by the California Institute for Regenerative Medicine UC Davis Stem Cell Training Program (BYB, CIRM T1-00006, CIRM TG2-01163). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7; Awojoodu AO, 2013, P NATL ACAD SCI USA, V110, P13785, DOI 10.1073/pnas.1221309110; Binder BY, 2013, TISSUE EN A IN PRESS; Bunnell BA, 2008, METHODS, V45, P115, DOI 10.1016/j.ymeth.2008.03.006; Cao YH, 2010, NAT REV DRUG DISCOV, V9, P107, DOI 10.1038/nrd3055; Chamberlain G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002934; Chen JH, 2008, STEM CELLS, V26, P135, DOI 10.1634/stemcells.2007-0098; Cheung WK, 2010, CYTOTHERAPY, V12, P554, DOI 10.3109/14653241003709694; Davis HE, 2011, ACTA BIOMATER, V7, P691, DOI 10.1016/j.actbio.2010.09.007; Davis HE, 2011, ANN BIOMED ENG, V39, P1, DOI 10.1007/s10439-010-0135-y; de Villiers JA, 2009, STEM CELL REV REP, V5, P256, DOI 10.1007/s12015-009-9084-y; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Fierro FA, 2011, STEM CELLS, V29, P1727, DOI 10.1002/stem.720; Guo HD, 2012, BIOCHEM BIOPH RES CO, V424, P105, DOI 10.1016/j.bbrc.2012.06.080; He JW, 2010, TISSUE ENG PT A, V16, P127, DOI [10.1089/ten.tea.2009.0255, 10.1089/ten.TEA.2009.0255]; He JW, 2010, J CELL BIOCHEM, V110, P87, DOI 10.1002/jcb.22514; Hoch AI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035579; Jeon ES, 2010, EXP MOL MED, V42, P280, DOI 10.3858/emm.2010.42.4.027; Katare R, 2013, ARTERIOSCL THROM VAS, V33, P1872, DOI 10.1161/ATVBAHA.113.301217; Kim JH, 2011, BIOMATERIALS, V32, P6080, DOI 10.1016/j.biomaterials.2011.05.003; Lee J, 2006, CLIN CANCER RES, V12, P6351, DOI 10.1158/1078-0432.CCR-06-1252; Lee MJ, 2008, J CELL BIOCHEM, V104, P499, DOI 10.1002/jcb.21641; Lin K, 2008, CYTOTHERAPY, V10, P417, DOI 10.1080/14653240801982979; Liu XB, 2009, STEM CELLS DEV, V18, P947, DOI 10.1089/scd.2008.0352; Mansell JP, 2013, BBA-MOL CELL BIOL L, V1831, P105, DOI 10.1016/j.bbalip.2012.04.005; Masiello LM, 2006, BONE, V39, P72, DOI 10.1016/j.bone.2005.12.013; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Murphy Kaitlin C, 2012, BMC Res Notes, V5, P423, DOI 10.1186/1756-0500-5-423; Nakagami H, 2006, J ATHEROSCLER THROMB, V13, P77, DOI 10.5551/jat.13.77; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Ozaki Harunobu, 2003, J Atheroscler Thromb, V10, P125; Park SY, 2007, CANCER LETT, V258, P63, DOI 10.1016/j.canlet.2007.08.011; Peach G, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5208; Pyne NJ, 2008, BBA-MOL CELL BIOL L, V1781, P467, DOI 10.1016/j.bbalip.2008.05.004; Riordan NH, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-29; Rivera-Lopez CM, 2008, ANGIOGENESIS, V11, P301, DOI 10.1007/s10456-008-9113-5; Saranadasa M, 2011, CYTOKINE, V53, P115, DOI 10.1016/j.cyto.2010.06.012; Shammas NW, 2007, VASC HEALTH RISK MAN, V3, P229, DOI 10.2147/vhrm.2007.3.2.229; Silva EA, 2007, J THROMB HAEMOST, V5, P590, DOI 10.1111/j.1538-7836.2007.02386.x; Silva EA, 2008, P NATL ACAD SCI USA, V105, P14347, DOI 10.1073/pnas.0803873105; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Sun QH, 2010, PHARM RES-DORDR, V27, P264, DOI 10.1007/s11095-009-0014-0; Systems RD, 2012, R D SYST ANN CAT; Tigyi G, 2010, BRIT J PHARMACOL, V161, P241, DOI 10.1111/j.1476-5381.2010.00815.x; van Hinsbergh VWM, 2001, ANN NY ACAD SCI, V936, P426; Walter DH, 2007, ARTERIOSCL THROM VAS, V27, P275, DOI 10.1161/01.ATV.0000254669.12675.70; Zisch AH, 2003, FASEB J, V17, P2260, DOI 10.1096/fj.02-1041fje	48	9	10	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2013	8	12							e82134	10.1371/journal.pone.0082134	http://dx.doi.org/10.1371/journal.pone.0082134			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	265IN	24312635	Green Submitted, Green Published, gold			2023-01-03	WOS:000327944500119
J	Rogers, KD; Kemp, A; McLachlan, AJ; Blyth, F				Rogers, Kris D.; Kemp, Anna; McLachlan, Andrew J.; Blyth, Fiona			Adverse Selection? A Multi-Dimensional Profile of People Dispensed Opioid Analgesics for Persistent Non-Cancer Pain	PLOS ONE			English	Article							PRESCRIPTION; HEALTH; TRENDS	Objectives: This study investigates utilisation patterns for prescription opioid analgesics in the Australian community and how these are associated with a framework of individual-level factors related to healthcare use. Methods: Self-reported demographic and health information from participants in the 45 and Up Study cohort were linked to pharmaceutical claims from 2006-2009. Participants comprised 19,816 people with >= 1 opioid analgesic dispensing in the 12-months after recruitment to the cohort and 79,882 people not dispensed opioid analgesics. All participants were aged >= 45 years, were social security pharmaceutical beneficiaries, with no history of cancer. People dispensed opioid analgesics were classified as having acute (dispensing period,90 days), episodic (>= 90 days and,3 'authority' prescriptions for increased quantity supply) or long-term treatment (>= 90 days and >= 3 authority prescriptions). Results: Of participants dispensed opioid analgesic 52% received acute treatment, 25% episodic treatment and 23% long-term treatment. People dispensed opioid analgesics long-term had an average of 14.9 opioid analgesic prescriptions/year from 2.0 doctors compared with 1.5 prescriptions from 1.1 doctors for people receiving acute treatment. People dispensed opioid analgesics reported more need-related factors such as poorer physical functioning and higher psychological distress. Long-term users were more likely to have access-related factors such as low-income and living outside major cities. After simultaneous adjustment, association with predisposing health factors and access diminished, but indicators of need such as osteoarthritis treatment, paracetamol use, and poor physical function were the strongest predictors for all opioid analgesic users. Conclusions: People dispensed opioid analgesics were in poorer health, reported higher levels of distress and poorer functioning than people not receiving opioid analgesics. Varying dispensing profiles were evident among people dispensed opioid analgesics for persistent pain, with those receiving episodic and long-term treatment dispensed the strongest opioid analgesics. The findings highlight the broad range of factors associated with longer term opioid analgesics use.	[Rogers, Kris D.; Blyth, Fiona] Sax Inst, Sydney, NSW, Australia; [Rogers, Kris D.; Blyth, Fiona] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia; [Kemp, Anna] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia; [McLachlan, Andrew J.] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia; [McLachlan, Andrew J.; Blyth, Fiona] Concord Hosp, Ctr Educ & Res Ageing, Sydney, NSW, Australia	University of Sydney; University of Sydney; University of Western Australia; University of Sydney; Concord Repatriation General Hospital	Rogers, KD (corresponding author), Sax Inst, Sydney, NSW, Australia.	kris.rogers@sydney.edu.au	Kemp-Casey, Anna/AAU-7292-2021; Kemp-Casey, Anna/F-1283-2013	Kemp-Casey, Anna/0000-0002-0018-962X; Kemp-Casey, Anna/0000-0002-0018-962X; McLachlan, Andrew/0000-0003-4674-0242	NHMRC [402810]; Bupa Health Foundation	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Bupa Health Foundation	This study was part of the 45 and Up Study Bupa Health Foundation Policy in Action Roundtable work program and was also supported by NHMRC grant 402810; the Bupa Health Foundation is the sole funder of the Policy in Action Roundtable. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alam A, 2012, ARCH INTERN MED, V172, P425, DOI 10.1001/archinternmed.2011.1827; Andersen R, 2005, MILBANK Q, V83; Andrews G, 2001, AUST NZ J PUBL HEAL, V25, P494, DOI 10.1111/j.1467-842X.2001.tb00310.x; Australia Medicare, 2008, AUTH PRESCR; Australian Government Department of Health and Aged Care, 2001, MEAS REM ACC REM IND; Australian Government Department of Health and Aged Care, 2008, EXP PRESCR 12 MONTHS; Australian Government Department of Health and Ageing, 2011, EXP PRESCR 12 MONTHS; Banks E, 2008, INT J EPIDEMIOL, V37, P941, DOI 10.1093/ije/dym184; Blyth FM, 2003, MED J AUSTRALIA, V179, P84, DOI 10.5694/j.1326-5377.2003.tb05441.x; Boudreau D, 2009, PHARMACOEPIDEM DR S, V18, P1166, DOI 10.1002/pds.1833; Braden JB, 2008, J PAIN, V9, P1026, DOI 10.1016/j.jpain.2008.06.002; Cerda M, 2013, DRUG ALCOHOL DEPENDE; Chapman CR, 2010, J PAIN, V11, P807, DOI 10.1016/j.jpain.2010.02.019; Dhalla IA, 2009, CAN MED ASSOC J, V181, P891, DOI 10.1503/cmaj.090784; Edlund MJ, 2010, CLIN J PAIN, V26, P1, DOI 10.1097/AJP.0b013e3181b99f35; Harrison CM, 2012, MED J AUSTRALIA, V196, P380, DOI 10.5694/mja12.10168; Hynd A, 2008, PHARMACOEPIDEM DR S, V17, P1091, DOI 10.1002/pds.1670; Khademi H, 2012, BMJ, V344; Leong M, 2009, INTERN MED J, V39, P676, DOI 10.1111/j.1445-5994.2009.01982.x; Longman C, 2011, DRUG ALCOHOL REV, V30, P355, DOI 10.1111/j.1465-3362.2010.00212.x; McManus P, 1998, MED J AUSTRALIA, V169, P285, DOI 10.5694/j.1326-5377.1998.tb140268.x; Mealing NM, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-26; Roxburgh A, 2011, MED J AUSTRALIA, V195, P280, DOI 10.5694/mja10.11450; SIMPSON EH, 1949, NATURE, V163, P688, DOI 10.1038/163688a0; Stewart AL, 1992, MEASURING FUNCTIONIN, P86; Sullivan MD, 2010, PAIN, V151, P567, DOI 10.1016/j.pain.2010.08.036; Von Korff M, 2008, CLIN J PAIN, V24, P521, DOI 10.1097/AJP.0b013e318169d03b; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	28	38	38	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2013	8	12							e80095	10.1371/journal.pone.0080095	http://dx.doi.org/10.1371/journal.pone.0080095			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	265IN	24312456	Green Published, Green Submitted, gold			2023-01-03	WOS:000327944500011
J	Suberu, JO; Gorka, AP; Jacobs, L; Roepe, PD; Sullivan, N; Barker, GC; Lapkin, AA				Suberu, John O.; Gorka, Alexander P.; Jacobs, Lauren; Roepe, Paul D.; Sullivan, Neil; Barker, Guy C.; Lapkin, Alexei A.			Anti-Plasmodial Polyvalent Interactions in Artemisia annua L. Aqueous Extract - Possible Synergistic and Resistance Mechanisms	PLOS ONE			English	Article							IN-VITRO; ANTIMALARIAL ACTIVITY; CHLOROGENIC ACID; HERBAL TEA; ROSMARINIC ACID; QING-HAO; ANTIOXIDANT; FALCIPARUM; CHEMISTRY; DIHYDROARTEMISININ	Artemisia annua hot water infusion (tea) has been used in in vitro experiments against P. falciparum malaria parasites to test potency relative to equivalent pure artemisinin. High performance liquid chromatography (HPLC) and mass spectrometric analyses were employed to determine the metabolite profile of tea including the concentrations of artemisinin (47.5 +/- 0.8 mg L-1), dihydroartemisinic acid (70.0 +/- 0.3 mg L-1), arteannuin B (1.3 +/- 0.0 mg L-1), isovitexin (105.0 +/- 7.2 mg L-1) and a range of polyphenolic acids. The tea extract, purified compounds from the extract, and the combination of artemisinin with the purified compounds were tested against chloroquine sensitive and chloroquine resistant strains of P. falciparum using the DNA-intercalative SYBR Green I assay. The results of these in vitro tests and of isobologram analyses of combination effects showed mild to strong antagonistic interactions between artemisinin and the compounds (9-epi-artemisinin and artemisitene) extracted from A. annua with significant (IC50 < 1 mu M) anti-plasmodial activities for the combination range evaluated. Mono-caffeoylquinic acids, tri-caffeoylquinic acid, artemisinic acid and arteannuin B showed additive interaction while rosmarinic acid showed synergistic interaction with artemisinin in the chloroquine sensitive strain at a combination ratio of 1: 3 (artemisinin to purified compound). In the chloroquine resistant parasite, using the same ratio, these compounds strongly antagonised artemisinin anti-plasmodial activity with the exception of arteannuin B, which was synergistic. This result would suggest a mechanism targeting parasite resistance defenses for arteannuin B's potentiation of artemisinin.	[Suberu, John O.; Barker, Guy C.] Univ Warwick, Sch Life Sci, Coventry CV4 7AL, W Midlands, England; [Gorka, Alexander P.; Jacobs, Lauren; Roepe, Paul D.] Georgetown Univ, Dept Chem, Ctr Infect Dis, Washington, DC 20057 USA; [Sullivan, Neil] Sensapharm Ltd, Business & Innovat Ctr, Sunderland, England; [Lapkin, Alexei A.] Univ Cambridge, Dept Chem Engn & Biotechnol, Cambridge, England	University of Warwick; Georgetown University; University of Cambridge	Barker, GC (corresponding author), Univ Warwick, Sch Life Sci, Coventry CV4 7AL, W Midlands, England.	guy.barker@warwick.ac.uk	Lapkin, Alexei/CAG-1632-2022	Barker, Guy Cameron/0000-0002-3250-0355	Engineering and Physical Sciences Research Council (EPSRC, UK); SensaPharm Ltd; Chemistry Innovation Knowledge Transfer Network (CIKTN, UK)	Engineering and Physical Sciences Research Council (EPSRC, UK)(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); SensaPharm Ltd; Chemistry Innovation Knowledge Transfer Network (CIKTN, UK)	This study was funded by Engineering and Physical Sciences Research Council (EPSRC, UK) and SensaPharm Ltd via an Industrial CASE PhD studentship. The award was allocated competitively by Chemistry Innovation Knowledge Transfer Network (CIKTN, UK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ACTON N, 1987, PLANTA MED, P266, DOI 10.1055/s-2006-962700; AGRAWAL PK, 1991, PHYTOCHEMISTRY, V30, P3469, DOI 10.1016/0031-9422(91)83234-C; [Anonymous], 2012, WO POS STAT EFF NONP; Belkaid A, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-7; Bennett TN, 2004, ANTIMICROB AGENTS CH, V48, P1807, DOI 10.1128/AAC.48.5.1807-1810.2004; BERENBAUM MC, 1978, J INFECT DIS, V137, P122, DOI 10.1093/infdis/137.2.122; Bilia AR, 2002, LIFE SCI, V70, P769, DOI 10.1016/S0024-3205(01)01447-3; Bozdech Z, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-23; Bray PG, 2005, BIOCHEM PHARMACOL, V70, P1158, DOI 10.1016/j.bcp.2005.07.021; Cao DD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021071; Carbonara T, 2012, J PHARMACEUT BIOMED, V62, P79, DOI 10.1016/j.jpba.2012.01.015; Cui L, 2012, MOL MICROBIOL, V86, P111, DOI 10.1111/j.1365-2958.2012.08180.x; De Donno A, 2012, T ROY SOC TROP MED H, V106, P696, DOI 10.1016/j.trstmh.2012.07.008; de Magalhaes PM, 2012, FOOD CHEM, V134, P864, DOI 10.1016/j.foodchem.2012.02.195; de Ridder S, 2008, J ETHNOPHARMACOL, V120, P302, DOI 10.1016/j.jep.2008.09.017; Ding XC, 2011, TRENDS PARASITOL, V27, P73, DOI 10.1016/j.pt.2010.11.006; Eastman RT, 2009, NAT REV MICROBIOL, V7, P864, DOI 10.1038/nrmicro2239; Eckstein-Ludwig U, 2003, NATURE, V424, P957, DOI 10.1038/nature01813; ELFORD BC, 1987, T ROY SOC TROP MED H, V81, P434, DOI 10.1016/0035-9203(87)90161-1; Erkan N, 2008, FOOD CHEM, V110, P76, DOI 10.1016/j.foodchem.2008.01.058; Feng RT, 2005, J BIOL CHEM, V280, P27888, DOI 10.1074/jbc.M503347200; Fivelman QL, 2004, ANTIMICROB AGENTS CH, V48, P4097, DOI 10.1128/AAC.48.11.4097-4102.2004; Friedman M, 1997, J AGR FOOD CHEM, V45, P1523, DOI 10.1021/jf960900s; Golenser J, 2006, INT J PARASITOL, V36, P1427, DOI 10.1016/j.ijpara.2006.07.011; Gulcin I, 2006, TOXICOLOGY, V217, P213, DOI 10.1016/j.tox.2005.09.011; Haynes RK, 2006, CURR TOP MED CHEM, V6, P509, DOI 10.2174/156802606776743129; Haynes RK, 2003, ANTIMICROB AGENTS CH, V47, P1175, DOI 10.1128/AAC.47.3.1175.2003; Hsu E, 2006, T ROY SOC TROP MED H, V100, P505, DOI 10.1016/j.trstmh.2005.09.020; Hsu E, 2006, BRIT J CLIN PHARMACO, V61, P666, DOI 10.1111/j.1365-2125.2006.02673.x; Jansen FH, 2006, T ROY SOC TROP MED H, V100, P285, DOI 10.1016/j.trstmh.2005.08.004; Jefford CW, 2001, CURR MED CHEM, V8, P1803, DOI 10.2174/0929867013371608; Klonis N, 2011, P NATL ACAD SCI USA, V108, P11405, DOI 10.1073/pnas.1104063108; LANSBURY PT, 1986, TETRAHEDRON LETT, V27, P3967, DOI 10.1016/S0040-4039(00)84886-8; Li W, 2005, PLOS GENET, V1, P329, DOI 10.1371/journal.pgen.0010036; LIU KCSC, 1992, PLANT CELL REP, V11, P637, DOI 10.1007/BF00236389; Miketova P, 1999, J MASS SPECTROM, V34, P1240, DOI 10.1002/(SICI)1096-9888(199912)34:12<1240::AID-JMS896>3.0.CO;2-B; Mouton J, 2013, PLANTA MED, V79, P468, DOI 10.1055/s-0032-1328324; Nemekaite-Ceniene A, 2005, ARCH BIOCHEM BIOPHYS, V441, P182, DOI 10.1016/j.abb.2005.07.002; Noratto G, 2009, J AGR FOOD CHEM, V57, P5219, DOI 10.1021/jf900259m; O'Neill PM, 2010, MOLECULES, V15, P1705, DOI 10.3390/molecules15031705; Pandey AV, 1999, J BIOL CHEM, V274, P19383, DOI 10.1074/jbc.274.27.19383; Petersen M, 2003, PHYTOCHEMISTRY, V62, P121, DOI 10.1016/S0031-9422(02)00513-7; Rath K, 2004, AM J TROP MED HYG, V70, P128, DOI 10.4269/ajtmh.2004.70.128; Sidhu ABS, 2006, J INFECT DIS, V194, P528, DOI 10.1086/507115; Suberu J, 2013, J PHARMACEUT BIOMED, V84, P269, DOI 10.1016/j.jpba.2013.06.025; Tepe B, 2007, FOOD CHEM, V100, P985, DOI 10.1016/j.foodchem.2005.10.062; VANDERKOOY F, 2011, J PLANT RES, V77, P1754, DOI DOI 10.1055/S-0030-1271065; Vivas L, 2007, J ANTIMICROB CHEMOTH, V59, P658, DOI 10.1093/jac/dkl563; Wagner H, 2005, PURE APPL CHEM, V77, P1, DOI 10.1351/pac200577010001; Wagner H, 2009, PHYTOMEDICINE, V16, P97, DOI 10.1016/j.phymed.2008.12.018; Wagner H, 2011, FITOTERAPIA, V82, P34, DOI 10.1016/j.fitote.2010.11.016; Wang J, 2010, PLOS ONE, V5, pA158, DOI 10.1371/journal.pone.0009582; Wang LH, 2007, J CHEM ENG DATA, V52, P757, DOI 10.1021/je0603426; Weathers PJ, 2012, PLANTA MED, V78, P1024, DOI 10.1055/s-0032-1314949; Weina P. J., 2008, Parassitologia (Rome), V50, P25; Willcox M, 2004, TRA HERB, V4, P43; Willcox M, 2009, J ALTERN COMPLEM MED, V15, P101, DOI 10.1089/acm.2008.0327; WOERDENBAG HJ, 1993, J NAT PROD, V56, P849, DOI 10.1021/np50096a007; Wright CW, 2010, MOLECULES, V15, P804, DOI 10.3390/molecules15020804; Xu JG, 2012, J AGR FOOD CHEM, V60, P11625, DOI 10.1021/jf303771s; Yordi E. G., 2012, ANTIOXIDANT PROOXIDA; Zhang B, 2008, SEP PURIF TECHNOL, V62, P480, DOI 10.1016/j.seppur.2008.02.013	62	49	51	2	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2013	8	11							e80790	10.1371/journal.pone.0080790	http://dx.doi.org/10.1371/journal.pone.0080790			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254DJ	24244716	Green Published, gold			2023-01-03	WOS:000327143800163
J	Gandhi, AK; Shi, T; Li, MY; Jungnelius, U; Romano, A; Tabernero, J; Siena, S; Schafer, PH; Chopra, R				Gandhi, Anita K.; Shi, Tao; Li, Mingyu; Jungnelius, Ulf; Romano, Alfredo; Tabernero, Josep; Siena, Salvatore; Schafer, Peter H.; Chopra, Rajesh			Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients	PLOS ONE			English	Article							MULTIPLE-MYELOMA; CELL; CEREBLON; INHIBIT; CC-5013; CC-4047; TARGET	This study assessed the immunomodulatory effects in previously treated KRAS-mutant metastatic colorectal cancer patients participating in a phase II multicenter, open-label clinical trial receiving lenalidomide alone or lenalidomide plus cetuximab. The main findings show the T cell immunostimulatory properties of lenalidomide as the drug induced a decrease in the percentage CD45RA(+) naive T cells 3-fold while increasing the percentage HLA-DR+ activated T helper cells and percentage total CD45RO(+) CD8(+) memory T cytotoxic cells, 2.6- and 2.1-fold respectively (p<0.0001). In addition, lenalidomide decreased the percentage of circulating CD19(+) B cells 2.6-fold (p<0.0001). Lenalidomide increased a modest, yet significant, 1.4-fold change in the percentage of circulating natural killer cells. Our findings indicate that lenalidomide significantly activates T cells, suggestive of an immunotherapeutic role for this drug in settings of maintenance therapy and tumor immunity. Furthermore, reported for the first time is the effect of lenalidomide in combination with cetuximab on T cell function, including increases in circulating naive and central memory T cells. In summary, lenalidomide and cetuximab have significant effects on circulating immune cells in patients with colorectal carcinoma.	[Gandhi, Anita K.; Schafer, Peter H.; Chopra, Rajesh] Celgene Corp, Dept Translat Dev, Summit, NJ 07901 USA; [Shi, Tao] Celgene Corp, Dept Sci Informat Syst, San Diego, CA USA; [Li, Mingyu] Celgene Corp, Dept Biostat & Programming, Summit, NJ USA; [Jungnelius, Ulf; Romano, Alfredo] Celgene, Clin Res & Dev, Summit, NJ USA; [Tabernero, Josep] Vall dHebron Univ Hosp, Barcelona, Spain; [Tabernero, Josep] Univ Autonoma Barcelona, Vall dHebron Inst Oncol, E-08193 Barcelona, Spain; [Siena, Salvatore] Osped Niguarda Ca Granda, Milan, Italy	Bristol-Myers Squibb; Celgene Corporation; Bristol-Myers Squibb; Celgene Corporation; Bristol-Myers Squibb; Celgene Corporation; Bristol-Myers Squibb; Celgene Corporation; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Vall d'Hebron Institut d'Oncologia (VHIO); IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda	Gandhi, AK (corresponding author), Celgene Corp, Dept Translat Dev, Summit, NJ 07901 USA.	agandhi@celgene.com	SIENA, SALVATORE/AAC-5806-2019; Tabernero, Josep/AAG-5026-2019	SIENA, SALVATORE/0000-0002-2681-2846; Tabernero, Josep/0000-0002-2495-8139; , Tao/0000-0001-5489-2655	Celgene Corporation; Oncologia Ca' Granda Onlus (OCGO) Fondazione; Cancer Research UK [11566] Funding Source: researchfish	Celgene Corporation(Bristol-Myers SquibbCelgene Corporation); Oncologia Ca' Granda Onlus (OCGO) Fondazione; Cancer Research UK(Cancer Research UK)	The authors would like to thank Robert Beck for coordinating data transfers and analysis. Medical editorial services were provided by Kim Grootscholten, MSc, of Excerpta Medica BV, funded by Celgene Corporation. Salvatore Siena is supported by Oncologia Ca' Granda Onlus (OCGO) Fondazione. The authors are fully responsible for content and editorial decisions for this manuscript. Celgene Corporation funded this study and was entirely responsible for study design, data collection and analysis and decision to publish.	[Anonymous], 2012, R LANG ENV STAT COMP; Barbera-Guillem E, 2000, CANCER IMMUNOL IMMUN, V48, P541, DOI 10.1007/PL00006672; Bartlett JB, 2004, BRIT J CANCER, V90, P955, DOI 10.1038/sj.bjc.6601579; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Botta C, 2012, J IMMUNOTHER, V35, P440, DOI 10.1097/CJI.0b013e31825943aa; Corral LG, 1999, J IMMUNOL, V163, P380; Ferrajoli A, 2008, BLOOD, V111, P5291, DOI 10.1182/blood-2007-12-130120; Galustian C, 2009, CANCER IMMUNOL IMMUN, V58, P1033, DOI 10.1007/s00262-008-0620-4; Gandhi AK, 2010, CURR CANCER DRUG TAR, V10, P155; Hernandez-Ilizaliturri FJ, 2005, CLIN CANCER RES, V11, P5984, DOI 10.1158/1078-0432.CCR-05-0577; Hsu AK, 2011, BLOOD, V117, P1605, DOI 10.1182/blood-2010-04-278432; Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319; Kneppers E, 2011, BLOOD, V118, P2413, DOI 10.1182/blood-2011-04-348292; Lopez-Girona A, 2012, LEUKEMIA, V26, P2326, DOI 10.1038/leu.2012.119; Schafer PH, 2003, J PHARMACOL EXP THER, V305, P1222, DOI 10.1124/jpet.102.048496; Siena S, 2013, PLOS ONE IN PRESS, V8; Smyth GK., 2004, STAT APPL GENET MOL, V3, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Streetly MJ, 2008, BRIT J HAEMATOL, V141, P41, DOI 10.1111/j.1365-2141.2008.07013.x; Wu L, 2008, J CLIN ONCOL S15, V26; Wu L, 2008, CLIN CANCER RES, V14, P4650, DOI 10.1158/1078-0432.CCR-07-4405; Zhu D, 2008, CANCER IMMUNOL IMMUN, V57, P1849, DOI 10.1007/s00262-008-0512-7; Zhu YX, 2011, BLOOD, V118, P4771, DOI 10.1182/blood-2011-05-356063	22	23	25	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2013	8	11							e80437	10.1371/journal.pone.0080437	http://dx.doi.org/10.1371/journal.pone.0080437			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255EG	24244687	Green Published, Green Submitted, gold			2023-01-03	WOS:000327221600209
J	Carr, SK; Chen, JH; Cooper, WN; Constancia, M; Yeo, GSH; Ozanne, SE				Carr, Sarah K.; Chen, Jian-Hua; Cooper, Wendy N.; Constancia, Miguel; Yeo, Giles S. H.; Ozanne, Susan E.			Maternal diet amplifies the hepatic aging trajectory of Cidea in male mice and leads to the development of fatty liver	FASEB JOURNAL			English	Article						developmental programming; maternal low protein; catch-up growth; lipid accumulation; epigenetic	POSTNATAL-GROWTH LEADS; LIFE-SPAN; PRENATAL EXPOSURE; DEFENSE CAPACITY; GENE-EXPRESSION; ADIPOSE-TISSUE; DNA-DAMAGE; EFFECTOR-A; RESTRICTION; PROTEIN	The importance of the early environment on long-term heath and life span is well documented. However, the molecular mechanisms mediating these effects remain poorly understood. Male offspring from a maternal protein restriction model, in which animals are exposed to a low-protein diet while in utero and then are cross-fostered to normally fed dams, demonstrate low birth weight, catch-up growth, and reduced life span (recuperated offspring). In the current study, we used microarray analysis to identify hepatic genes that changed with age. Cell death-inducing DNA fragmentation factor, subunit-like effector A (Cidea), a transcriptional coactivator that has been implicated in lipid accumulation demonstrated one of the largest age-associated increases in expression (200-fold, P<0.001). This increase was exaggerated approximate to 3-fold in recuperated offspring. These demonstrated increased hepatic lipid accumulation, higher levels of transcription factors important in lipid regulation, and greater oxidative stress. In vitro analysis revealed that Cidea expression was regulated by oxidative stress and DNA methylation. These findings suggest that maternal diet modulates the age-associated changes in Cidea expression through several mechanisms. This expression affects hepatic lipid metabolism in these animals and thus provides a mechanism by which maternal diet can contribute to the metabolic health and ultimately the life span of the offspring.Carr, S. K., Chen, J.-H., Cooper, W. N., Constancia, M., Yeo, G. S. H., Ozanne, S. E. Maternal diet amplifies the hepatic ageing trajectory of Cidea in male mice and leads to the development of fatty liver.	[Carr, Sarah K.; Chen, Jian-Hua; Cooper, Wendy N.; Constancia, Miguel; Yeo, Giles S. H.; Ozanne, Susan E.] Univ Cambridge, Wellcome Trust MRC Inst Metab Sci, MRC Metab Dis Unit, Metab Res Labs,Addenbrookes Hosp, Cambridge CB2 OQQ, England; [Constancia, Miguel] Univ Cambridge, Ctr Trophoblast Res, Cambridge CB2 OQQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge	Carr, SK (corresponding author), Univ Cambridge, Wellcome Trust MRC Inst Metab Sci, MRC Metab Dis Unit, Metab Res Labs,Addenbrookes Hosp, Level 4,Box 289, Cambridge CB2 OQQ, England.	sb716@cam.ac.uk	Constancia, Miguel/F-6654-2013	Yeo, Giles See How/0000-0001-8823-3615; Ozanne, Susan/0000-0001-8753-5144; Constancia, Miguel/0000-0002-8976-1679	UK Biotechnology and Biological Science Research Council; BBSRC [BB/D01235X/1, BB/E002161/1, BB/D01235X/2] Funding Source: UKRI; MRC [MC_UU_12012/5, MC_UU_12012/1, MC_UU_12012/4, G0600717] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E002161/1, BB/D01235X/1, BB/D01235X/2] Funding Source: researchfish; British Heart Foundation [FS/09/029/27902] Funding Source: researchfish; Medical Research Council [MC_UU_12012/5/B, MC_UU_12012/1, MC_UU_12012/5, G0600717B, G0600717, MC_UU_12012/4] Funding Source: researchfish	UK Biotechnology and Biological Science Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the UK Biotechnology and Biological Science Research Council. S.E.O. is a British Heart Foundation Senior Fellow.	ANDERSON JM, 1972, J CLIN PATHOL, V25, P867, DOI 10.1136/jcp.25.10.867; Barrientos A, 1997, MOL BRAIN RES, V52, P284, DOI 10.1016/S0169-328X(97)00278-7; Berends LM, 2013, INT J OBESITY, V37, P1051, DOI 10.1038/ijo.2012.196; Bruce KD, 2009, HEPATOLOGY, V50, P1796, DOI 10.1002/hep.23205; Burns SP, 1997, J CLIN INVEST, V100, P1768, DOI 10.1172/JCI119703; Chen JH, 2004, J BIOL CHEM, V279, P49439, DOI 10.1074/jbc.M409153200; Chen JH, 2010, CLIN SCI, V119, P373, DOI 10.1042/CS20100230; Chen JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004950; Cooper WN, 2012, FASEB J, V26, P1782, DOI 10.1096/fj.11-192708; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Glatz JFC, 2010, PHYSIOL REV, V90, P367, DOI 10.1152/physrev.00003.2009; Gong JY, 2009, CURR OPIN LIPIDOL, V20, P121, DOI 10.1097/MOL.0b013e328328d0bb; Haffner SM, 2006, OBESITY, V14, p121S, DOI 10.1038/oby.2006.291; HARRISON DE, 1984, P NATL ACAD SCI-BIOL, V81, P1835, DOI 10.1073/pnas.81.6.1835; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Jennings BJ, 1999, FEBS LETT, V448, P4, DOI 10.1016/S0014-5793(99)00336-1; Kelder Bruce, 2007, Comp Hepatol, V6, P4, DOI 10.1186/1476-5926-6-4; Knebel B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031812; Li D, 2008, NUCLEIC ACIDS RES, V36, P330, DOI 10.1093/nar/gkm1028; Li YP, 2010, DIABETES, V59, P2400, DOI 10.2337/db10-0385; Medina-Gomez G, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030064; Nathanielsz PW, 2003, J PHYSIOL-LONDON, V548, P333, DOI 10.1113/jphysiol.2003.040527; Nicklas JA, 2004, ENVIRON MOL MUTAGEN, V44, P313, DOI 10.1002/em.20050; Okamoto Y, 2002, HEPATOL RES, V23, P138, DOI 10.1016/S1386-6346(01)00172-3; Ozanne SE, 2004, NATURE, V427, P411, DOI 10.1038/427411b; Peeters A, 2003, ANN INTERN MED, V138, P24, DOI 10.7326/0003-4819-138-1-200301070-00008; Ravelli ACJ, 1998, LANCET, V351, P173, DOI 10.1016/S0140-6736(97)07244-9; Roseboom TJ, 2000, BRIT J HAEMATOL, V111, P112, DOI 10.1046/j.1365-2141.2000.02268.x; Strable MS, 2010, CRIT REV BIOCHEM MOL, V45, P199, DOI 10.3109/10409231003667500; Tarry-Adkins JL, 2008, FASEB J, V22, P2037, DOI 10.1096/fj.07-099523; Tarry-Adkins JL, 2009, FASEB J, V23, P1521, DOI 10.1096/fj.08-122796; Tarry-Adkins JL, 2013, FASEB J, V27, P379, DOI 10.1096/fj.12-218685; Toh SY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002890; Viswakarma N, 2007, J BIOL CHEM, V282, P18613, DOI 10.1074/jbc.M701983200; Yajnik CS, 2008, DIABETOLOGIA, V51, P29, DOI 10.1007/s00125-007-0793-y; Zhou LK, 2012, HEPATOLOGY, V56, P95, DOI 10.1002/hep.25611; Zhou ZH, 2003, NAT GENET, V35, P49, DOI 10.1038/ng1225	37	12	12	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2191	2201		10.1096/fj.13-242727	http://dx.doi.org/10.1096/fj.13-242727			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24481968				2023-01-03	WOS:000335336000022
J	Wang, X; Fang, Y; Yang, SM; Jiang, MH; Yan, KK; Wu, LN; Lv, B; Shen, Q				Wang, Xiao; Fang, Yu; Yang, Shimin; Jiang, Minghuan; Yan, Kangkang; Wu, Lina; Lv, Bing; Shen, Qian			Access to Paediatric Essential Medicines: A Survey of Prices, Availability, Affordability and Price Components in Shaanxi Province, China	PLOS ONE			English	Article							CHILDREN; LIST	Objective: To evaluate the prices and availability of paediatric essential medicines in Shaanxi Province, China. Methods: Price and availability data for 28 paediatric essential medicines were collected from 60 public hospitals and 60 retail pharmacies in six areas of Shaanxi Province using a standardised methodology developed by the World Health Organization and Health Action International, during November to December 2012. Affordability was measured as the number of days' wages required for the lowest-paid unskilled government worker to purchase standard treatments for common conditions. Data on medicine price components were collected from hospitals, wholesalers and distributors to obtain price mark-ups. Findings: The mean availabilities of originator brands (OBs) and lowest-priced generics (LPGs) were 10.8% and 27.3% in the public hospitals and 11.9% and 20.6% in the private pharmacies. The public procurement and retail prices were 2.25 and 2.59 times the international reference prices (IRPs) for three OBs, and 0.52 and 0.93 times for 20 LPGs. In the private sector, the final prices for OBs and LPGs were 3.89 and 1.25 times their IRPs. The final price in the private sector was 2.7% lower than in the public sector for OBs, and 14.1% higher for LPGs. Generally, standard treatments cost less than 1 day's wages in both sectors. Distribution mark-ups applied to brand salbutamol in Xi'an was 65.5%, and up to 185.3% for generic. Cumulative mark-ups for LPGs in Ankang were also high, from 33% to 50%. The manufacturer's selling price is the largest contributor to the final price in both areas. Conclusions: The government should approve a list of national paediatric essential medicines. The availability, price and affordability of these should be improved in both public hospitals and private pharmacies to enable children to obtain effective treatment. Measures should be taken to improve the efficiency of the centralised medicine purchasing system.	[Wang, Xiao; Fang, Yu; Yang, Shimin; Jiang, Minghuan; Yan, Kangkang; Wu, Lina; Lv, Bing; Shen, Qian] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharm Adm, Xian 710049, Peoples R China; [Fang, Yu] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA; [Fang, Yu] Harvard Pilgrim Hlth Care Inst, Boston, MA USA	Xi'an Jiaotong University; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care	Fang, Y (corresponding author), Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharm Adm, Xian 710049, Peoples R China.	yufang@mail.xjtu.edu.cn; lvb1990@163.com			National Natural Science Fund [71103141/G0308]; Fundamental Research Funds for the Central Universities [2011jdhz62]; Shaanxi Provincial Social Science Fund [10E066]	National Natural Science Fund(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Shaanxi Provincial Social Science Fund	This medicine price survey was conducted with financial support from the National Natural Science Fund (No: 71103141/G0308), the Fundamental Research Funds for the Central Universities (No: 2011jdhz62) and the Shaanxi Provincial Social Science Fund (No: 10E066). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1977, WHO TECHN REP SER; [Anonymous], 2013, PEOPLES DAILY ONLINE; [Anonymous], 2004, INCR ACC ESS MED DEV; [Anonymous], 2011, RD WHO MOD LIST ESS; Anson A, 2012, GLOBALIZATION HEALTH, V8, DOI 10.1186/1744-8603-8-22; Babar ZUD, 2007, PLOS MED, V4, P466, DOI 10.1371/journal.pmed.0040082; Balasubramaniam R., 2011, CEYLON MEDICAL JOURNAL, V56, P101, DOI 10.4038/cmj.v56i3.3597; Braine T, 2007, B WORLD HEALTH ORGAN, V85, P249; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Chen W, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-211; Department of Human Resources and Social Security of Shaanxi Province, 2012, LOW WAG REG SHAANX P; Fang Y, 2013, LANCET GLOB HEALTH, V1, pE227, DOI 10.1016/S2214-109X(13)70072-X; Finney E, 2011, CHILDRENS MED SITUAT; Gitanjali B, 2011, J PHARMACOL PHARMACO, V2, P95, DOI 10.4103/0976-500X.81900; Health Action International, 2012, MED PRIC AV AFF PRIC; Hu S., 2010, FINANCING PRICING UT; IMS Consulting Group, 2013, EXPL IMP REV EDL ASS; Jiang MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070836; Laing R, 2003, LANCET, V361, P1723, DOI 10.1016/S0140-6736(03)13375-2; Management Sciences for Health, 2011, INT DRUG PRIC IND GU; Niens LM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000333; Ravindran L, 2012, INDIAN J PHARMACOL, V44, P536, DOI 10.4103/0253-7613.99347; Robertson J, 2009, B WORLD HEALTH ORGAN, V87, P231, DOI 10.2471/BLT.08.053645; Seiter A, 2010, GENERIC DRUG POLICY; State Food and Drug Administration, 2011, NOT STOPP SAIL US AM; Sun Q., 2004, SURVEY MED PRICES AV; The Ministry of Health, 2012, CHIN NAT EML; The Shaanxi Provincial Government, 2012, IMPL OP SHAANX PROV; Tian X, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-401; WHO Health Action International, 2008, MEAS MED PRIC AV AFF, V2nd; World Health Organization, 2012, WORLD HLTH STAT 2012; World Health Organization, 2011, SEL ESS MED; World Health Organization, 2013, CHILDR RED MORT; World Health Organization, 2009, BETT MED CHILDR PROJ; World Health Organization and Health Action International, 2003, MED PRIC NEW APPR ME; Yang H, 2010, HEALTH POLICY PLANN, V25, P219, DOI 10.1093/heapol/czp056; Ye L., 2006, SURVEY MED PRICES AV	37	23	27	1	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2014	9	3							e90365	10.1371/journal.pone.0090365	http://dx.doi.org/10.1371/journal.pone.0090365			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC4CT	24595099	gold, Green Published, Green Submitted			2023-01-03	WOS:000332468900098
J	Mohammed, M; Ch, S; Ch, RV				Mohammed, Mujahid; Ch, Sasikala; Ch, Ramana V.			Aniline Is an Inducer, and Not a Precursor, for Indole Derivatives in Rubrivivax benzoatilyticus JA2	PLOS ONE			English	Article							AMINO-ACID BIOSYNTHESIS; ESCHERICHIA-COLI; MICROBIAL TRANSFORMATION; OXIDATIVE STRESS; TRYPTOPHAN; PATHWAY; IDENTIFICATION; GENES; BIODEGRADATION; METABOLITES	Rubrivivax benzoatilyticus JA2 and other anoxygenic photosynthetic bacteria produce indole derivatives when exposed to aniline, a xenobiotic compound. Though this phenomenon has been reported previously, the role of aniline in the production of indoles is still a biochemical riddle. The present study aims at understanding the specific role of aniline (as precursor or stimulator) in the production of indoles and elucidating the biochemical pathway of indoles in aniline-exposed cells by using stable isotope approaches. Metabolic profiling revealed tryptophan accumulation only in aniline exposed cells along with indole 3-acetic acid (IAA) and indole 3-aldehyde (IAld), the two major catabolites of tryptophan. Deuterium labelled aniline feeding studies revealed that aniline is not a precursor of indoles in strain JA2. Further, production of indoles only in aniline-exposed cells suggests that aniline is an indoles stimulator. In addition, production of indoles depended on the presence of a carbon source, and production enhanced when carbon sources were added to the culture. Isotope labelled fumarate feeding identified, fumarate as the precursor of indole, indicating de novo synthesis of indoles. Glyphosate (shikimate pathway inhibitor) inhibited the indoles production, accumulation of tryptophan, IAA and IAld indicating that indoles synthesis in strain JA2 occurs via the de novo shikimate pathway. The up-regulation of anthranilate synthase gene and induction of anthranilate synthase activity correlated well with tryptophan production in strain JA2. Induction of tryptophan aminotransferase and tryptophan 2-monooxygenase activities corroborated well with IAA levels, suggesting that tryptophan catabolism occurs simultaneously in aniline exposed cells. Our study demonstrates that aniline (stress) stimulates tryptophan/indoles synthesis via the shikimate pathway by possibly modulating the metabolic pathway.	[Mohammed, Mujahid; Ch, Ramana V.] Univ Hyderabad, Sch Life Sci, Dept Plant Sci, Hyderabad 500134, Andhra Pradesh, India; [Ch, Sasikala] Univ Hyderabad, J NT, IST, Bacterial Discovery Lab,Ctr Environm, Hyderabad 500134, Andhra Pradesh, India	University of Hyderabad; University of Hyderabad	Ch, RV (corresponding author), Univ Hyderabad, Sch Life Sci, Dept Plant Sci, Hyderabad 500134, Andhra Pradesh, India.	r449@sify.com	sasikala, Ch/AAP-8460-2020; sasikala, Ch/AAS-4530-2021	sasikala, Ch/0000-0003-1952-5045; 				Balderas-Hernandez VE, 2009, MICROB CELL FACT, V8, DOI 10.1186/1475-2859-8-19; Boon N, 2001, APPL ENVIRON MICROB, V67, P1107, DOI 10.1128/AEM.67.3.1107-1115.2001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carmona M, 2009, MICROBIOL MOL BIOL R, V73, P71, DOI 10.1128/MMBR.00021-08; CERNIGLIA CE, 1981, ARCH MICROBIOL, V130, P272, DOI 10.1007/BF00425939; Chakravarthy SK, 2007, INT J SYST EVOL MICR, V57, P2453, DOI 10.1099/ijs.0.65105-0; Consonni C, 2010, PLANT PHYSIOL, V152, P1544, DOI 10.1104/pp.109.147660; Dominguez-Cuevas P, 2006, J BIOL CHEM, V281, P11981, DOI 10.1074/jbc.M509848200; Drzyzga O, 1996, APPL ENVIRON MICROB, V62, P1710, DOI 10.1128/AEM.62.5.1710-1716.1996; Gazarian IG, 1998, BIOCHEM J, V333, P223, DOI 10.1042/bj3330223; Gordon SAPL, 1975, PLANT PHYSIOL, V10, P37; GORONTZY T, 1993, J GEN MICROBIOL, V139, P1331, DOI 10.1099/00221287-139-6-1331; Gosset G, 2009, CURR OPIN BIOTECH, V20, P651, DOI 10.1016/j.copbio.2009.09.012; Hamilton S, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-599; Hirasawa T, 2007, J BIOTECHNOL, V131, P34, DOI 10.1016/j.jbiotec.2007.05.010; Ikeda M, 2006, APPL MICROBIOL BIOT, V69, P615, DOI 10.1007/s00253-005-0252-y; Imaoka A, 2008, J GEN PLANT PATHOL, V74, P109, DOI 10.1007/s10327-007-0066-0; Johnson CH, 2012, ANNU REV PHARMACOL, V52, P37, DOI 10.1146/annurev-pharmtox-010611-134748; Kang K, 2011, PLANT J, V66, P247, DOI 10.1111/j.1365-313X.2011.04486.x; Kang K, 2009, PLANT PHYSIOL, V150, P1380, DOI 10.1104/pp.109.138552; KONOPKA A, 1989, APPL ENVIRON MICROB, V55, P385, DOI 10.1128/AEM.55.2.385-389.1989; Kuczynska-Wisnik D, 2010, RES MICROBIOL, V161, P847, DOI 10.1016/j.resmic.2010.09.012; Lee JH, 2010, FEMS MICROBIOL REV, V34, P426, DOI 10.1111/j.1574-6976.2009.00204.x; Liang O, 2005, MICROBIOL-SGM, V151, P3435, DOI 10.1099/mic.0.28137-0; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maeda H, 2012, ANNU REV PLANT BIOL, V63, P73, DOI 10.1146/annurev-arplant-042811-105439; Malhotra M, 2009, EUR J SOIL BIOL, V45, P73, DOI 10.1016/j.ejsobi.2008.05.006; Maurice CF, 2013, CELL, V152, P39, DOI 10.1016/j.cell.2012.10.052; Merino E, 2008, CURR OPIN MICROBIOL, V11, P78, DOI 10.1016/j.mib.2008.02.005; Mittal M, 2008, J ENVIRON SCI HEAL A, V43, P1027, DOI 10.1080/10934520802059896; Mujahid M, 2011, APPL MICROBIOL BIOT, V89, P1001, DOI 10.1007/s00253-010-2951-2; Mujahid M, 2010, CURR MICROBIOL, V61, P285, DOI 10.1007/s00284-010-9609-2; Panina EM, 2001, J MOL MICROB BIOTECH, V3, P529; Park S, 2009, PLANTA, V230, P1197, DOI 10.1007/s00425-009-1015-2; Pedras MSC, 2009, PHYTOCHEMISTRY, V70, P1129, DOI 10.1016/j.phytochem.2009.05.015; Pluvinage B, 2007, BIOCHEMISTRY-US, V46, P7069, DOI 10.1021/bi700351w; POWELL LE, 1964, PLANT PHYSIOL, V39, P836, DOI 10.1104/pp.39.5.836; Ramos JL, 2002, ANNU REV MICROBIOL, V56, P743, DOI 10.1146/annurev.micro.56.012302.161038; Schonbrunn E, 2001, P NATL ACAD SCI USA, V98, P1376, DOI 10.1073/pnas.98.4.1376; SCRIBNER JD, 1979, CHEM-BIOL INTERACT, V26, P11, DOI 10.1016/0009-2797(79)90090-5; SHANKAR S, 1995, MOL MICROBIOL, V17, P935, DOI 10.1111/j.1365-2958.1995.mmi_17050935.x; Shanker V, 2006, CURR MICROBIOL, V52, P413, DOI 10.1007/s00284-005-0057-3; Shen T, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/605219; Spaepen S, 2007, FEMS MICROBIOL REV, V31, P425, DOI 10.1111/j.1574-6976.2007.00072.x; Suzuki H, 2007, J BACTERIOL, V189, P2155, DOI 10.1128/JB.01708-06; Teufel R, 2010, P NATL ACAD SCI USA, V107, P14390, DOI 10.1073/pnas.1005399107; Han TH, 2011, RES MICROBIOL, V162, P108, DOI 10.1016/j.resmic.2010.11.005; Vangnai AS, 2007, FEMS MICROBIOL LETT, V268, P209, DOI 10.1111/j.1574-6968.2006.00579.x; Villa F, 2012, ENVIRON MICROBIOL, V14, P1753, DOI 10.1111/j.1462-2920.2011.02678.x; Xie G, 2003, MICROBIOL MOL BIOL R, V67, P303, DOI 10.1128/MMBR.67.3.303-342.2003; Xu P, 2007, TRENDS BIOTECHNOL, V25, P571, DOI 10.1016/j.tibtech.2007.08.011; Zhao JM, 1998, PLANT CELL, V10, P359, DOI 10.1105/tpc.10.3.359	52	10	10	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2014	9	2							e87503	10.1371/journal.pone.0087503	http://dx.doi.org/10.1371/journal.pone.0087503			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7FJ	24533057	gold, Green Published			2023-01-03	WOS:000331262600015
J	Montaner, JSG; Lima, VD; Harrigan, PR; Lourenco, L; Yip, B; Nosyk, B; Wood, E; Kerr, T; Shannon, K; Moore, D; Hogg, RS; Barrios, R; Gilbert, M; Krajden, M; Gustafson, R; Daly, P; Kendall, P				Montaner, Julio S. G.; Lima, Viviane D.; Harrigan, P. Richard; Lourenco, Lillian; Yip, Benita; Nosyk, Bohdan; Wood, Evan; Kerr, Thomas; Shannon, Kate; Moore, David; Hogg, Robert S.; Barrios, Rolando; Gilbert, Mark; Krajden, Mel; Gustafson, Reka; Daly, Patricia; Kendall, Perry			Expansion of HAART Coverage Is Associated with Sustained Decreases in HIV/AIDS Morbidity, Mortality and HIV Transmission: The "HIV Treatment as Prevention'' Experience in a Canadian Setting	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; INJECTING DRUG-USERS; HOMOSEXUAL-MEN; EXPANDING ACCESS; INFECTION; RISK; SEX; RNA; RECOMMENDATIONS; STRATEGIES	Background: There has been renewed call for the global expansion of highly active antiretroviral therapy (HAART) under the framework of HIV treatment as prevention (TasP). However, population-level sustainability of this strategy has not been characterized. Methods: We used population-level longitudinal data from province-wide registries including plasma viral load, CD4 count, drug resistance, HAART use, HIV diagnoses, AIDS incidence, and HIV-related mortality. We fitted two Poisson regression models over the study period, to relate estimated HIV incidence and the number of individuals on HAART and the percentage of virologically suppressed individuals. Results: HAART coverage, median pre-HAART CD4 count, and HAART adherence increased over time and were associated with increasing virological suppression and decreasing drug resistance. AIDS incidence decreased from 6.9 to 1.4 per 100,000 population (80% decrease, p = 0.0330) and HIV-related mortality decreased from 6.5 to 1.3 per 100,000 population (80% decrease, p = 0.0115). New HIV diagnoses declined from 702 to 238 cases (66% decrease; p = 0.0004) with a consequent estimated decline in HIV incident cases from 632 to 368 cases per year (42% decrease; p = 0.0003). Finally, our models suggested that for each increase of 100 individuals on HAART, the estimated HIV incidence decreased 1.2% and for every 1% increase in the number of individuals suppressed on HAART, the estimated HIV incidence also decreased by 1%. Conclusions: Our results show that HAART expansion between 1996 and 2012 in BC was associated with a sustained and profound population-level decrease in morbidity, mortality and HIV transmission. Our findings support the long-term effectiveness and sustainability of HIV treatment as prevention within an adequately resourced environment with no financial barriers to diagnosis, medical care or antiretroviral drugs. The 2013 Consolidated World Health Organization Antiretroviral Therapy Guidelines offer a unique opportunity to further evaluate TasP in other settings, particularly within generalized epidemics, and resource-limited setting, as advocated by UNAIDS.	[Montaner, Julio S. G.; Lima, Viviane D.; Harrigan, P. Richard; Lourenco, Lillian; Yip, Benita; Nosyk, Bohdan; Wood, Evan; Kerr, Thomas; Shannon, Kate; Moore, David; Hogg, Robert S.; Barrios, Rolando] Providence Hlth Care, BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada; [Montaner, Julio S. G.; Lima, Viviane D.; Harrigan, P. Richard; Wood, Evan; Kerr, Thomas; Shannon, Kate; Moore, David] Univ British Columbia, Dept Med, Div Aids, Vancouver, BC, Canada; [Nosyk, Bohdan; Hogg, Robert S.] Simon Fraser Univ, Fac Hlth Sci, Vancouver, BC, Canada; [Gilbert, Mark; Krajden, Mel] BC Ctr Dis Control, Vancouver, BC, Canada; [Barrios, Rolando; Gustafson, Reka; Daly, Patricia] Vancouver Coastal Hlth Author, Vancouver, BC, Canada; [Kendall, Perry] Minist Hlth British Columbia, Victoria, BC, Canada	B.C. Centre for Excellence in HIV/AIDS; University of British Columbia; Simon Fraser University; Vancouver Coastal Health Research Institute	Montaner, JSG (corresponding author), Providence Hlth Care, BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada.	jmontaner@cfenet.ubc.ca	Hogg, Robert S/B-2783-2012	Hogg, Robert S/0000-0003-3463-5488	British Columbia Ministry of Health; Avant-Garde Award [1DP1DA026182]; National Institute of Drug Abuse (NIDA), at the US National Institutes of Health (NIH) [1R01DA036307-01]; Knowledge Translation Award from the Canadian Institutes of Health Research (CIHR); Scholar Award from the Michael Smith Foundation for Health Research; New Investigator Award from CIHR; NIDA award [R03DA033851, R01DA028532]; CIHR award [MOP-125948, MOP-102742]; Tier 1 Canada Research Chair in Inner City Medicine; Abbvie, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and ViiV Healthcare; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA028532, DP1DA026182, R01DA036307, R03DA033851] Funding Source: NIH RePORTER	British Columbia Ministry of Health; Avant-Garde Award; National Institute of Drug Abuse (NIDA), at the US National Institutes of Health (NIH); Knowledge Translation Award from the Canadian Institutes of Health Research (CIHR); Scholar Award from the Michael Smith Foundation for Health Research; New Investigator Award from CIHR(Canadian Institutes of Health Research (CIHR)); NIDA award; CIHR award(Canadian Institutes of Health Research (CIHR)); Tier 1 Canada Research Chair in Inner City Medicine; Abbvie, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and ViiV Healthcare; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The work here described [Treatment as Prevention in BC initiative (PI: JM)] has been financially supported by the British Columbia Ministry of Health, as well as an Avant-Garde Award (No. 1DP1DA026182) and grant 1R01DA036307-01 from the National Institute of Drug Abuse (NIDA), at the US National Institutes of Health (NIH). In addition, JM was funded through a Knowledge Translation Award from the Canadian Institutes of Health Research (CIHR). VDL is supported by a Scholar Award from the Michael Smith Foundation for Health Research and a New Investigator Award from CIHR, and by a NIDA award (R03DA033851) and CIHR award (MOP-125948). TK was supported in part by a NIDA award (R01DA028532) and a CIHR award (MOP-102742). EW is supported by a Tier 1 Canada Research Chair in Inner City Medicine. Additional limited unrestricted funding was provided by Abbvie, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and ViiV Healthcare. None of the funders played any role in study design, data collection and analysis, decision to publish, preparation or review of the manuscript.	[Anonymous], 2013, 7 IAS C HIV PATH TRE; [Anonymous], HIV AIDS ANN REP; [Anonymous], 2012, SUBPR POP PROJ PEOPL; [Anonymous], BRIT COL CTR EXC HIV; Archibald C, 2013, COMMUNICATION; Avettand-Fenoel V, 2008, AIDS, V22, P1880, DOI 10.1097/QAD.0b013e32830fbdbc; Baggaley RF, 2010, AIDS, V24, P2418, DOI 10.1097/QAD.0b013e32833dbdfd; British Columbia Vital Statistics Agency, ANN REP; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Celum C, 2012, ANTIVIR THER, V17, P1483, DOI 10.3851/IMP2492; Coates TJ, 2008, LANCET, V372, P669, DOI 10.1016/S0140-6736(08)60886-7; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Cremin I, 2013, AIDS, V27, P447, DOI 10.1097/QAD.0b013e32835ca2dd; Das M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011068; Doherty M, 2013, 2013 INT TREATM PREV; Donnell D, 2010, LANCET, V375, P2092, DOI 10.1016/S0140-6736(10)60705-2; Fang CT, 2004, J INFECT DIS, V190, P879, DOI 10.1086/422601; Ford N, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001535; Garnett GP, 2012, CURR OPIN HIV AIDS, V7, P157, DOI 10.1097/COH.0b013e3283504ab7; Granich R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030216; Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Hastie T., 1990, GEN ADDITIVE MODELS, DOI DOI 10.1201/9780203753781; Hogg RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047260; Hontelez JAC, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001534; Hull MW, 2012, CURR OPIN HIV AIDS, V7, P579, DOI 10.1097/COH.0b013e3283590617; Jin FY, 2010, AIDS, V24, P907, DOI 10.1097/QAD.0b013e3283372d90; Johnson Victoria A, 2013, Top Antivir Med, V21, P6; Johnston KM, 2010, AIDS, V24, P1929, DOI 10.1097/QAD.0b013e32833af85d; Kato M, 2013, J ACQUIR IMMUNE DEFI; Kerr T, 2012, JOINT UN PROGRAMME H; Kirk GD, 2011, 8 C RETR OPP INF BOS; Lafeuillade A, 2009, HIV CLIN TRIALS, V10, P324, DOI 10.1310/hct1005-324; Lagakos SW, 2008, NEW ENGL J MED, V358, P1543, DOI 10.1056/NEJMp0802028; Lester RT, 2013, BCMJ, V55, P204; Lima VD, 2008, AIDS, V22, P2371, DOI 10.1097/QAD.0b013e328315cdd3; McCormick AW, 2007, CLIN INFECT DIS, V44, P1115, DOI 10.1086/512816; Montaner JSG, 2006, LANCET, V368, P531, DOI 10.1016/S0140-6736(06)69162-9; Montaner JSG, 2011, LANCET, V378, P208, DOI 10.1016/S0140-6736(11)60821-0; Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1; Muessig KE, 2012, AIDS, V26, P2267, DOI 10.1097/QAD.0b013e328355713d; Peter M. C., 1989, GEN LINEAR MODELS; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706; Rotheram-Borus MJ, 2009, ANNU REV CLIN PSYCHO, V5, P143, DOI 10.1146/annurev.clinpsy.032408.153530; Stolte IG, 2001, SEX TRANSM INFECT, V77, P184, DOI 10.1136/sti.77.3.184; Tanser F, 2013, SCIENCE, V339, P966, DOI 10.1126/science.1228160; Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961; Vermund SH, 2013, JAIDS-J ACQ IMM DEF, V63, pS12, DOI 10.1097/QAI.0b013e31829202a2; Vermund SH, 2009, CURR OPIN HIV AIDS, V4, P266, DOI 10.1097/COH.0b013e32832c91dd; Vittinghoff E, 1999, AM J EPIDEMIOL, V150, P306, DOI 10.1093/oxfordjournals.aje.a010003; Wagner BG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041212; Walensky RP, 2013, NEW ENGL J MED, V369, P1715, DOI 10.1056/NEJMsa1214720; Wand H, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-19; Werb D, 2010, LANCET INFECT DIS, V10, P464, DOI 10.1016/S1473-3099(10)70097-9; Wood E, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1649; Wood S.N, 2017, GEN ADDITIVE MODELS; World Health Organization, INT STAT CLASS DIS R; Wu Z, 2013, 2013 INT TREATM PREV; Yan P, 2011, STAT COMMUNICATIONS, DOI [10.2202/1948-4690.1011, DOI 10.2202/1948-4690.1011]; Yang QY, 2010, CAN J PUBLIC HEALTH, V101, P486, DOI 10.1007/BF03403969; Zuckerman RA, 2004, J INFECT DIS, V190, P156, DOI 10.1086/421246	61	225	235	1	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2014	9	2							e87872	10.1371/journal.pone.0087872	http://dx.doi.org/10.1371/journal.pone.0087872			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7FJ	24533061	gold, Green Published, Green Submitted			2023-01-03	WOS:000331262600019
J	Yang, J; Farioli, A; Korre, M; Kales, SN				Yang, Justin; Farioli, Andrea; Korre, Maria; Kales, Stefanos N.			Modified Mediterranean Diet Score and Cardiovascular Risk in a North American Working Population	PLOS ONE			English	Article							CORONARY-HEART-DISEASE; SUGAR-SWEETENED BEVERAGES; METABOLIC SYNDROME; WEIGHT-GAIN; CARDIORESPIRATORY FITNESS; LIFE-STYLE; FOOD; PREDICTION; MORTALITY; HEALTH	Introduction: Greater adherence to a Mediterranean diet is linked to lower risk for cardiovascular morbidity/mortality in studies of Mediterranean cohorts, older subjects, and/or those with existing health conditions. No studies have examined the effects of this dietary pattern in younger working populations in the United States. We investigated the effects of Mediterranean diet adherence on cardiovascular disease (CVD) biomarkers, metabolic syndrome and body composition in an occupationally active, non-Mediterranean cohort. Methods: A cross-sectional study in a cohort of 780 career male firefighters, ages 18 years or older, from the United States Midwest. No dietary intervention was performed. A modified Mediterranean diet score (mMDS) was developed for assessment of adherence to a Mediterranean dietary pattern from a previously administered life-style questionnaire that examined pre-existing dietary habits. Clinical data from fire department medical examinations were extracted and analyzed. Results: Obese subjects had significantly lower mMDS, and they reported greater fast/take-out food consumption (p < 0.001) and intake of sweetened drinks during meals (p = 0.002). After multivariate adjustment, higher mMDS was inversely related to risk of weight gain over the past 5 years (odds ratio [OR]: 0.57, 95% confidence interval [CI]: 0.39-0.84, p for trend across score quartiles: 0.01); as well as the presence of metabolic syndrome components (OR: 0.65, 95% CI: 0.44-0.94, p for trend across score quartiles: 0.04). Higher HDL-cholesterol (p = 0.008) and lower LDL-cholesterol (p = 0.04) were observed in those with higher mMDS in linear regression after multivariate adjustment for age, BMI and physical activity. Conclusions: In a cohort of young and active US adults, greater adherence to a Mediterranean-style dietary pattern had significant inverse associations with metabolic syndrome, LDL-cholesterol and reported weight gain, and was significantly and independently associated with higher HDL-cholesterol. Our results support the potential effectiveness of this diet in young, non-Mediterranean working cohorts, and justify future intervention studies.	[Yang, Justin; Farioli, Andrea; Korre, Maria; Kales, Stefanos N.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth Environm & Occupat Med & Epide, Boston, MA 02115 USA; [Yang, Justin; Korre, Maria; Kales, Stefanos N.] Harvard Univ, Sch Med, Cambridge Hlth Alliance, Cambridge, MA 02138 USA; [Farioli, Andrea] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Cambridge Health Alliance; University of Bologna	Kales, SN (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth Environm & Occupat Med & Epide, 665 Huntington Ave, Boston, MA 02115 USA.	skales@hsph.harvard.edu	Farioli, Andrea/K-9256-2016	Farioli, Andrea/0000-0003-2001-2140; Yang, Justin/0000-0002-9743-2074	U.S. Department of Homeland Security [EMW-2006-FP-01493, EMW-2009-FP-00835]	U.S. Department of Homeland Security(United States Department of Homeland Security (DHS))	Supported in part by grants from the U.S. Department of Homeland Security (EMW-2006-FP-01493 and EMW-2009-FP-00835 to Dr. Kales). No additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644; Alcacera MA, 2008, EUR J CLIN NUTR, V62, P1178, DOI 10.1038/sj.ejcn.1602833; Martinez-Gonzalez MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043134; Babio N, 2009, PUBLIC HEALTH NUTR, V12, P1607, DOI 10.1017/S1368980009990449; Barrington WE, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.120001; Baur DM, 2012, J OBES, V2012, DOI 10.1155/2012/710903; Baur DM, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-480; Baur DM, 2012, J STRENGTH COND RES, V26, P2331, DOI 10.1519/JSC.0b013e31823e9b19; Baur DM, 2011, J OCCUP ENVIRON MED, V53, P1155, DOI 10.1097/JOM.0b013e31822c9e47; Biener L, 1999, HEALTH EDUC BEHAV, V26, P478, DOI 10.1177/109019819902600407; Binkley JK, 2000, INT J OBESITY, V24, P1032, DOI 10.1038/sj.ijo.0801356; Blanck HM, 2009, HEALTH EDUC BEHAV, V36, P289, DOI 10.1177/1090198107303308; Bonaccio M, 2013, APPETITE, V68, P139, DOI 10.1016/j.appet.2013.04.026; Di Daniele N, 2013, ACTA DIABETOL, V50, P409, DOI 10.1007/s00592-012-0445-7; Duffey KJ, 2012, AM J CLIN NUTR, V95, P909, DOI 10.3945/ajcn.111.026682; Durand G, 2011, MED SCI SPORT EXER, V43, P1752, DOI 10.1249/MSS.0b013e318215cf25; Esposito K, 2004, JAMA-J AM MED ASSOC, V292, P1440, DOI 10.1001/jama.292.12.1440; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Fung TT, 2009, CIRCULATION, V119, P1093, DOI 10.1161/CIRCULATIONAHA.108.816736; Guthrie JF, 2000, J AM DIET ASSOC, V100, P43, DOI 10.1016/S0002-8223(00)00018-3; Kafatos A, 1997, AM J CLIN NUTR, V65, P1882, DOI 10.1093/ajcn/65.6.1882; Knoops KTB, 2004, JAMA-J AM MED ASSOC, V292, P1433, DOI 10.1001/jama.292.12.1433; Leiba A, 2013, J AM SOC HYPERTENS, V7, P40, DOI 10.1016/j.jash.2012.11.002; Leighton F, 2009, PUBLIC HEALTH NUTR, V12, P1635, DOI 10.1017/S1368980009990486; Malik VS, 2006, AM J CLIN NUTR, V84, P274; Malik VS, 2010, CIRCULATION, V121, P1356, DOI 10.1161/CIRCULATIONAHA.109.876185; Martinez-Gonzalez MA, 2011, NUTR METAB CARDIOVAS, V21, P237, DOI 10.1016/j.numecd.2009.10.005; Mitrou PN, 2007, ARCH INTERN MED, V167, P2461, DOI 10.1001/archinte.167.22.2461; Mozaffarian D, 2011, NEW ENGL J MED, V364, P2392, DOI 10.1056/NEJMoa1014296; Nadtochiy SM, 2011, NUTRITION, V27, P733, DOI 10.1016/j.nut.2010.12.006; Nagler EM, 2013, CANCER CAUSE CONTROL, V24, P637, DOI 10.1007/s10552-012-9998-6; Nettleton JA, 2009, AM J CLIN NUTR, V90, P647, DOI 10.3945/ajcn.2009.27597; Nielsen SJ, 2004, AM J PREV MED, V27, P205, DOI 10.1016/j.amepre.2004.05.005; Odegaard AO, 2012, CIRCULATION, V126, P182, DOI 10.1161/CIRCULATIONAHA.111.084004; Panagiotakos DB, 2003, J HYPERTENS, V21, P1483, DOI 10.1097/00004872-200308000-00011; Pereira MA, 2005, LANCET, V365, P36, DOI 10.1016/S0140-6736(04)17663-0; Ronksley Paul E, 2011, BMJ, V342, pd671, DOI 10.1136/bmj.d671; ROYSTON P, 1991, STATA TECHNICAL B RE, P110; Schwarzfuchs D, 2012, NEW ENGL J MED, V367, P1373, DOI 10.1056/NEJMc1204792; Shai I, 2008, NEW ENGL J MED, V359, P229, DOI 10.1056/NEJMoa0708681; Sofi F, 2010, AM J CLIN NUTR, V92, P1189, DOI 10.3945/ajcn.2010.29673; TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457; Trichopoulou A, 2005, BMJ-BRIT MED J, V330, P991, DOI 10.1136/bmj.38415.644155.8F; Trichopoulou A, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2337; Urquiaga I, 2010, ATHEROSCLEROSIS, V211, P694, DOI 10.1016/j.atherosclerosis.2010.04.020; Vincent-Baudry S, 2005, AM J CLIN NUTR, V82, P964, DOI 10.1093/ajcn/82.5.964; Wannamethee SG, 2005, ARCH INTERN MED, V165, P2644, DOI 10.1001/archinte.165.22.2644; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Woodward-Lopez G, 2011, PUBLIC HEALTH NUTR, V14, P499, DOI 10.1017/S1368980010002375	49	59	60	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2014	9	2							e87539	10.1371/journal.pone.0087539	http://dx.doi.org/10.1371/journal.pone.0087539			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VA	24503596	Green Published, gold			2023-01-03	WOS:000330631800044
J	Wang, XT; Dai, Y; Zhao, S; Tang, JX; Li, HJ; Xing, YT; Qu, GL; Li, XS; Dai, JR; Zhu, YC; Zhang, XG				Wang, Xiaoting; Dai, Yang; Zhao, Song; Tang, Jianxia; Li, Hongjun; Xing, Yuntian; Qu, Guoli; Li, Xinsong; Dai, Jianrong; Zhu, Yinchang; Zhang, Xueguang			PAMAM-Lys, a Novel Vaccine Delivery Vector, Enhances the Protective Effects of the SjC23 DNA Vaccine against Schistosoma japonicum Infection	PLOS ONE			English	Article							PLASMID DNA; GENE DELIVERY; MOUSE MUSCLE; CHINA; EXPRESSION; PIGS; EXPERIENCES; PARAMYOSIN; CHALLENGE; DENDRIMER	Background: Schistosomiasis japonica remains a major public-health concern in China. Praziquantel-based chemotherapy effectively reduces both infections and intensity; however, it can not prevent re-infection. Furthermore, there is an increasing concern about praziquantel resistance following long-term repeated use of the drug in endemic areas. Therefore, development of a schistosomiasis vaccine, as a strategy to prevent and control schistosomiasis japonica, has been given high priority. The present study was conducted to develop PAMAM dendrimers as a novel vaccine delivery vector for a schistosomiasis japonica DNA vaccine and evaluate its ability to enhance protective effects against Schistosoma japonicum infection. Methodology/Principal Findings: Lysine was used to modify 4.0G PAMAM, and the modified product PAMAM-Lys was synthesized. PAMAM-Lys showed both high transfection and low cytotocity for gene delivery in vitro. DNA vaccines combined with PAMAM-Lys produced higher level of protection compare with naked DNA vaccines against S. japonicum infection in a mouse model. Futhermore, antibodies from mice immunized with PAMAM-Lys combined DNA vaccines were significantly higher than those of mice immunized with the naked DNA vaccines. The PAMAM-Lys vector elicited a predominantly IgG2a antibody response and a tremendously increase in the production of IL-2 and IFN-gamma. Conclusion/Significance: Lysine-modified PAMAM-Lys is an excellent vector. PAMAM-Lys may enhance the immunoreactivity of DNA vaccine and increase the protective effect of the SjC23 DNA vaccine against S. japonicum infection.	[Wang, Xiaoting; Zhang, Xueguang] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Clin Immunol,Med Coll, Jiangsu Stem Cell Key Lab,Inst Med Biotechnol, Suzhou, Peoples R China; [Wang, Xiaoting; Dai, Yang; Zhao, Song; Tang, Jianxia; Li, Hongjun; Xing, Yuntian; Qu, Guoli; Dai, Jianrong; Zhu, Yinchang] Jiangsu Prov Key Lab Mol Biol Parasites, Minist Hlth, Jiangsu Inst Parasit Dis, Key Lab Technol Parasit Dis Prevent & Control, Wuxi, Jiangsu, Peoples R China; [Li, Xinsong] Southeast Univ, Sch Chem & Chem Engn, Biomat & Drug Delivery Labs, Nanjing, Jiangsu, Peoples R China	Soochow University - China; Southeast University - China	Zhu, YC (corresponding author), Jiangsu Prov Key Lab Mol Biol Parasites, Minist Hlth, Jiangsu Inst Parasit Dis, Key Lab Technol Parasit Dis Prevent & Control, Wuxi, Jiangsu, Peoples R China.	yczhu2006@aliyun.com; xueguangzh@126.com.cn	Wang, Xiaoting/AAI-3159-2020		National Program on Key Basic Research Project(973 Program) [2013CB530501]; Chinese National Natural Science Foundation of China [81000749, 81000748]; Jiangsu Provincial Nature Science Foundation [BK2010152]; Chinese Ministry of Health [LW201005]; Jiangsu Province's Outstanding Medical Academic Leader program [LJ201132]	National Program on Key Basic Research Project(973 Program)(National Basic Research Program of China); Chinese National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Provincial Nature Science Foundation; Chinese Ministry of Health; Jiangsu Province's Outstanding Medical Academic Leader program	The study has been financially supported by the following grants: National Program on Key Basic Research Project(973 Program, Grant No. 2013CB530501); Chinese National Natural Science Foundation of China (No: 81000749 and 81000748); Jiangsu Provincial Nature Science Foundation (BK2010152); Scientific Research Project from Chinese Ministry of Health (LW201005); and Jiangsu Province's Outstanding Medical Academic Leader program (LJ201132). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bickle QD, 2001, VET PARASITOL, V100, P51, DOI 10.1016/S0304-4017(01)00483-6; Choi JS, 2004, J CONTROL RELEASE, V99, P445, DOI 10.1016/j.jconrel.2004.07.027; Da'Dara AA, 2008, VACCINE, V26, P3617, DOI 10.1016/j.vaccine.2008.04.080; Dai Y, 2009, CLIN VACCINE IMMUNOL, V16, P1796, DOI 10.1128/CVI.00231-09; Dennig Jorg, 2002, J Biotechnol, V90, P339; Doenhoff Michael J, 2006, Expert Rev Anti Infect Ther, V4, P199, DOI 10.1586/14787210.4.2.199; Eberl M, 2001, INFECT IMMUN, V69, P5352, DOI 10.1128/IAI.69.9.5352-5362.2001; Fenwick A, 2006, CURR OPIN INFECT DIS, V19, P577, DOI 10.1097/01.qco.0000247591.13671.6a; Gao Q, 2007, CHEM RES, V18, P41; Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3; Hao Yang, 2008, Chinese Journal of Schistosomiasis Control, V20, P401; Hogg KG, 2003, INFECT IMMUN, V71, P3563, DOI 10.1128/IAI.71.6.3563-3571.2003; Hu Y, 2007, EXP PARASITOL, V115, P379, DOI 10.1016/j.exppara.2006.09.022; Jain K, 2010, INT J PHARMACEUT, V394, P122, DOI 10.1016/j.ijpharm.2010.04.027; Kamimura Kenya, 2011, Pharmaceut Med, V25, P293; Li CY, 2006, CELL MOL BIOL LETT, V11, P449, DOI 10.2478/s11658-006-0036-0; LIU SX, 1995, VACCINE, V13, P603, DOI 10.1016/0264-410X(94)00045-O; McManus DP, 2008, CLIN MICROBIOL REV, V21, P225, DOI 10.1128/CMR.00046-07; McManus DP, 2000, INT J PARASITOL, V30, P265, DOI 10.1016/S0020-7519(99)00200-3; McManus DP, 1998, INT J PARASITOL, V28, P1739, DOI 10.1016/S0020-7519(98)00151-9; Ren JianGong, 2002, Chinese Journal of Schistosomiasis Control, V14, P98; Ross AGP, 2002, NEW ENGL J MED, V346, P1212, DOI 10.1056/NEJMra012396; SHI YE, 1990, EXP PARASITOL, V71, P100, DOI 10.1016/0014-4894(90)90012-2; Steinmann P, 2006, LANCET INFECT DIS, V6, P411, DOI 10.1016/S1473-3099(06)70521-7; Sun WY, 1999, PROTEIN EXPRES PURIF, V17, P410, DOI 10.1006/prep.1999.1140; Sun XL, 2010, MINI-REV MED CHEM, V10, P108, DOI 10.2174/138955710791185109; Taylor MG, 1998, VACCINE, V16, P1290, DOI 10.1016/S0264-410X(98)00055-3; Wang LD, 2009, TROP MED INT HEALTH, V14, P1475, DOI 10.1111/j.1365-3156.2009.02403.x; Wang LD, 2008, LANCET, V372, P1793, DOI 10.1016/S0140-6736(08)61358-6; Wang LD, 2008, LANCET, V372, P1598, DOI 10.1016/S0140-6736(08)61365-3; Wang Shi-Ping, 2009, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V27, P402; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wolff JA, 2005, ADV GENET, V54, P3, DOI 10.1016/S0065-2660(05)54001-X; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; Zheng Hao, 2012, Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi, V24, P621; Zhou SH, 2000, VACCINE, V18, P3196, DOI 10.1016/S0264-410X(99)00555-1; Zhu Y, 2006, PARASITOLOGY, V132, P67, DOI 10.1017/S0031182005008644; Zhu YC, 2004, VACCINE, V23, P78, DOI 10.1016/j.vaccine.2004.04.031; Zhu Yinchang, 2004, Southeast Asian Journal of Tropical Medicine and Public Health, V35, P518; Zhu Yinchang, 2002, Southeast Asian J Trop Med Public Health, V33, P207; Zhu Yingchang, 2003, Southeast Asian Journal of Tropical Medicine and Public Health, V34, P697	41	11	12	2	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2014	9	1							e86578	10.1371/journal.pone.0086578	http://dx.doi.org/10.1371/journal.pone.0086578			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302PJ	24497955	Green Submitted, Green Published, gold			2023-01-03	WOS:000330617100020
J	Lee, S; Ryu, JH; Kim, H; Kim, KH; Ahn, HS; Hann, HJ; Cho, Y; Park, YM; Kim, SJ; Kang, DH; Choi, KB; Ryu, DR				Lee, Shina; Ryu, Jung-Hwa; Kim, Hyunwook; Kim, Kyoung Hoon; Ahn, Hyeong Sik; Hann, Hoo Jae; Cho, Yongjae; Park, Young Mi; Kim, Seung-Jung; Kang, Duk-Hee; Choi, Kyu Bok; Ryu, Dong-Ryeol			An Assessment of Survival among Korean Elderly Patients Initiating Dialysis: A National Population-Based Study	PLOS ONE			English	Article							STAGE RENAL-DISEASE; REPLACEMENT THERAPY; PERITONEAL-DIALYSIS; HEALTH INSURANCE; UNITED-STATES; HEMODIALYSIS; MORTALITY; OUTCOMES; CHOICE; MODALITY	Background: Although the proportion of the elderly patients with incident end-stage renal disease (ESRD) patients has been increasing in Korea, there has been a lack of information on outcomes of dialysis treatment. This study aimed to assess the survival rate and to elucidate predictors for all-cause mortality among elderly Korean patients initiating dialysis. Methods: We analyzed 11,301 patients (6,138 men) aged 65 years or older who had initiated dialysis from 2005 to 2008 and had followed up (median, 37.8 months; range, 3-84 months). Baseline demographics, comorbidities and mortality data were obtained using the database from the Health Insurance Review & Assessment Service. Results: The unadjusted 5-year survival rate was 37.6% for all elderly dialysis patients, and the rate decreased with increasing age categories; 45.9% (65 similar to 69), 37.5% (70 similar to 74), 28.4% (75 similar to 79), 24.1% (80 similar to 84), and 13.7% (>= 85 years). The multivariate Cox proportional hazard model revealed that age, sex, dialysis modality, the type of insurance, and comorbidities such as diabetes mellitus, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, hemiparesis, liver disease, and any malignancy were independent predictors for mortality. In addition, survival rate was significantly higher in patients on hemodialysis compared to patients on peritoneal dialysis during the whole follow-up period in the intention-to-treat analysis. Conclusions: Survival rate was significantly associated with age, sex, and various comorbidities in Korean elderly patients initiating dialysis. The results of our study can help to provide relevant guidance on the individualization strategy in elderly ESRD patients requiring dialysis.	[Lee, Shina; Ryu, Jung-Hwa; Kim, Seung-Jung; Kang, Duk-Hee; Choi, Kyu Bok; Ryu, Dong-Ryeol] Ewha Womans Univ, Dept Internal Med, Sch Med, Seoul, South Korea; [Kim, Hyunwook] Wonkwang Univ, Coll Med, Sanbon Hosp, Dept Internal Med, Gunpo, South Korea; [Kim, Kyoung Hoon] Korea Univ, Dept Publ Hlth, Grad Sch, Seoul, South Korea; [Ahn, Hyeong Sik] Korea Univ, Coll Med, Dept Prevent Med, Seoul 136705, South Korea; [Hann, Hoo Jae; Cho, Yongjae; Park, Young Mi] Ewha Womans Univ, Ewha Med Res Inst, Sch Med, Seoul, South Korea	Ewha Womans University; Wonkwang University; Korea University; Korea University; Korea University Medicine (KU Medicine); Ewha Womans University	Ryu, DR (corresponding author), Ewha Womans Univ, Dept Internal Med, Sch Med, Seoul, South Korea.	drryu@ewha.ac.kr		Ryu, Dong-Ryeol/0000-0002-5309-7606	Korean Academy of Medical Sciences; Ewha Global Top5 Grant of Ewha Womans University	Korean Academy of Medical Sciences; Ewha Global Top5 Grant of Ewha Womans University	This study was supported by a 2011 grant from the Korean Academy of Medical Sciences; and by the Ewha Global Top5 Grant of Ewha Womans University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Canaud B, 2011, CLIN J AM SOC NEPHRO, V6, P1651, DOI 10.2215/CJN.03530410; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Glaudet F, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-131; HELD PJ, 1990, AM J KIDNEY DIS, V15, P451, DOI 10.1016/S0272-6386(12)70363-3; Hemmelgarn BR, 2003, AM J KIDNEY DIS, V42, P125, DOI 10.1016/S0272-6386(03)00415-3; Jager KJ, 2003, CLIN NEPHROL, V60, P352; Jassal SV, 2007, CAN MED ASSOC J, V177, P1033, DOI 10.1503/cmaj.061765; Jeong HS, 2011, HEALTH AFFAIR, V30, P136, DOI 10.1377/hlthaff.2008.0816; Jin DC, 2012, KIDNEY RES CLIN PRAC, V31, P62, DOI 10.1016/j.krcp.2012.01.005; Jin Dong Chan, 2011, Korean Journal of Internal Medicine, V26, P123, DOI 10.3904/kjim.2011.26.2.123; Kurella M, 2007, ANN INTERN MED, V146, P177, DOI 10.7326/0003-4819-146-3-200702060-00006; Kwon S, 2009, HEALTH POLICY PLANN, V24, P63, DOI 10.1093/heapol/czn037; Lamping DL, 2000, LANCET, V356, P1543, DOI 10.1016/S0140-6736(00)03123-8; Letourneau I, 2003, AM J NEPHROL, V23, P71, DOI 10.1159/000068040; Liem YS, 2007, KIDNEY INT, V71, P153, DOI 10.1038/sj.ki.5002014; Lok CE, 2012, SEMIN NEPHROL, V32, P530, DOI 10.1016/j.semnephrol.2012.10.003; McDonald SP, 2009, J AM SOC NEPHROL, V20, P155, DOI 10.1681/ASN.2007111188; Merighi JR, 2012, HEMODIAL INT, V16, P242, DOI 10.1111/j.1542-4758.2011.00649.x; Munshi SK, 2001, NEPHROL DIAL TRANSPL, V16, P128, DOI 10.1093/ndt/16.1.128; Murtagh FEM, 2007, NEPHROL DIAL TRANSPL, V22, P1955, DOI 10.1093/ndt/gfm153; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rosner MH, 2012, CONTRIB NEPHROL, V178, P83, DOI 10.1159/000337817; Song YJ, 2009, JPN MED ASS J, V52, P206; U S Renal Data System. USRDS, 2012, ANN DAT REP ATL CHRO; Villar E, 2007, J AM SOC NEPHROL, V18, P2125, DOI 10.1681/ASN.2006091048; Winkelmayer WC, 2002, J AM SOC NEPHROL, V13, P2353, DOI 10.1097/01.ASN.0000025785.41314.76; Yoshino M, 2006, J AM SOC NEPHROL, V17, P3510, DOI 10.1681/ASN.2006020156	27	7	14	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2014	9	1							e86776	10.1371/journal.pone.0086776	http://dx.doi.org/10.1371/journal.pone.0086776			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297VL	24466236	Green Published, gold, Green Submitted			2023-01-03	WOS:000330283100212
J	Seiger, N; van Veen, M; Almeida, H; Steyerberg, EW; van Meurs, AHJ; Carneiro, R; Alves, CF; Maconochie, I; van der Lei, J; Moll, HA				Seiger, Nienke; van Veen, Mirjam; Almeida, Helena; Steyerberg, Ewout W.; van Meurs, Alfred H. J.; Carneiro, Rita; Alves, Claudio F.; Maconochie, Ian; van der Lei, Johan; Moll, Henriette A.			Improving the Manchester Triage System for Pediatric Emergency Care: An International Multicenter Study	PLOS ONE			English	Article							VITAL SIGNS; ACUITY SCALE; SEVERITY; IMPUTATION	Objectives: This multicenter study examines the performance of the Manchester Triage System (MTS) after changing discriminators, and with the addition use of abnormal vital sign in patients presenting to pediatric emergency departments (EDs). Design: International multicenter study Settings: EDs of two hospitals in The Netherlands (2006-2009), one in Portugal (November-December 2010), and one in UK (June-November 2010). Patients: Children (< 16years) triaged with the MTS who presented at the ED. Methods: Changes to discriminators (MTS 1) and the value of including abnormal vital signs (MTS 2) were studied to test if this would decrease the number of incorrect assignment. Admission to hospital using the new MTS was compared with those in the original MTS. Likelihood ratios, diagnostic odds ratios (DORs), and c-statistics were calculated as measures for performance and compared with the original MTS. To calculate likelihood ratios and DORs, the MTS had to be dichotomized in low urgent and high urgent. Results: 60,375 patients were included, of whom 13% were admitted. When MTS 1 was used, admission to hospital increased from 25% to 29% for MTS ` very urgent' patients and remained similar in lower MTS urgency levels. The diagnostic odds ratio improved from 4.8 (95% CI 4.5-5.1) to 6.2 (95% CI 5.9-6.6) and the c-statistic remained 0.74. MTS 2 did not improve the performance of the MTS. Conclusions: MTS 1 performed slightly better than the original MTS. The use of vital signs (MTS 2) did not improve the MTS performance.	[Seiger, Nienke; van Veen, Mirjam; Moll, Henriette A.] Erasmus MC Sophia Childrens Hosp, Dept Pediat, Rotterdam, Netherlands; [Almeida, Helena; Carneiro, Rita; Alves, Claudio F.] Hosp Fernando Fonseca, Dept Pediat, Amadora, Portugal; [Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [van Meurs, Alfred H. J.] Juliana Childrens Hosp, Haga Hosp, Dept Pediat, The Hague, Netherlands; [Maconochie, Ian] Imperial Coll Healthcare NHS Trust, St Marys Hosp, Dept Pediat Accid & Emergency, London, England; [van der Lei, Johan] Erasmus MC, Dept Med Informat, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Hospital Professor Doutor Fernando Fonseca, EPE; Erasmus University Rotterdam; Erasmus MC; Haga Hospital; Imperial College London; Erasmus University Rotterdam; Erasmus MC	Moll, HA (corresponding author), Erasmus MC Sophia Childrens Hosp, Dept Pediat, Rotterdam, Netherlands.	h.a.moll@erasmusmc.nl		Maconochie, Ian/0000-0001-6319-8550	Europe Container Terminals B.V.	Europe Container Terminals B.V.	The study was funded by an unrestricted grant from Europe Container Terminals B.V. This funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2003, ANN EMERG MED, V42, P530, DOI 10.1067/mem.2003.377; Armstrong B, 2008, EMERG MED J, V25, P799, DOI 10.1136/emj.2007.052951; Baumann MR, 2005, ACAD EMERG MED, V12, P219, DOI 10.1197/j.aem.2004.09.023; Cooper RJ, 2002, ANN EMERG MED, V39, P223, DOI 10.1067/mem.2002.121524; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Donders ART, 2006, J CLIN EPIDEMIOL, V59, P1087, DOI 10.1016/j.jclinepi.2006.01.014; FitzGerald G, 2010, EMERG MED J, V27, P86, DOI 10.1136/emj.2009.077081; Fleming S, 2011, LANCET, V377, P1011, DOI 10.1016/S0140-6736(10)62226-X; Gilboy N, 2005, J EMERG NURS, V31, P357, DOI 10.1016/j.jen.2005.05.011; Gilboy N, 2005, EMERGENCY SEVERITY I; Glas AS, 2003, J CLIN EPIDEMIOL, V56, P1129, DOI 10.1016/S0895-4356(03)00177-X; Gravel J, 2012, ANN EMERG MED; Gravel Jocelyn, 2006, Paediatr Child Health, V11, P211; Ma W, 2008, AM J EMERG MED, V26, P893, DOI 10.1016/j.ajem.2008.02.024; Mackway-Jones K, 2006, EMERGENCY TRIAGE, Vxiii; Mackway-Jones K, 1997, EMERGENCY TRIAGE, Vix; Maldonado T, 2004, PEDIATRICS, V114, P356, DOI 10.1542/peds.114.2.356; McGillivray David, 2006, Paediatr Child Health, V11, P209; Moll HA, 2010, J CLIN EPIDEMIOL, V63, P384, DOI 10.1016/j.jclinepi.2009.07.009; Roukema J, 2006, EMERG MED J, V23, P906, DOI 10.1136/emj.2006.038877; Salk ED, 1998, ANN EMERG MED, V32, P655, DOI 10.1016/S0196-0644(98)70063-0; Seiger N, 2011, ARCH DIS CHILD, V96, P653, DOI 10.1136/adc.2010.206797; Steyerberg EW, 2007, J CLIN EPIDEMIOL, V60, P979, DOI 10.1016/j.jclinepi.2007.03.003; van Veen M, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1501; Veen van M, 2012, EMERG MED J; Warren DW, 2008, CAN J EMERG MED, V10, P224	26	28	28	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2014	9	1							e83267	10.1371/journal.pone.0083267	http://dx.doi.org/10.1371/journal.pone.0083267			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297DH	24454699	Green Published, gold, Green Submitted			2023-01-03	WOS:000330235100007
J	Al-Salahi, OSA; Ji, D; Majid, AMSA; Kit-Lam, C; Abdullah, WZ; Zaki, A; Din, SKKJ; Yusoff, NM; Majid, ASA				Al-Salahi, Omar Saeed Ali; Ji, Dan; Majid, Amin Malik Shah Abdul; Kit-Lam, Chan; Abdullah, Wan Zaidah; Zaki, Abdelhamid; Din, Shah Kamal Khan Jamal; Yusoff, Narazah Mohd; Majid, Aman Shah Abdul			Anti-Tumor Activity of Eurycoma longifolia Root Extracts against K-562 Cell Line: In Vitro and In Vivo Study	PLOS ONE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CYCLE ARREST; DNA-DAMAGE; GROWTH ARREST; CYTOCHROME-C; CANCER-CELLS; ANTIPROLIFERATIVE ACTIVITY; PLASMODIUM-FALCIPARUM; SIGNALING PATHWAYS; INDUCED APOPTOSIS	Eurycoma longifolia Jack has been widely used in traditional medicine for its antimalarial, aphrodisiac, anti-diabetic, antimicrobial and anti-pyretic activities. Its anticancer activity has also been recently reported on different solid tumors, however no anti-leukemic activity of this plant has been reported. Thus the present study assesses the in vitro and in vivo anti-proliferative and apoptotic potentials of E. longifolia on K-562 leukemic cell line. The K-562 cells (purchased from ATCC) were isolated from patients with chronic myelocytic leukemia (CML) were treated with the various fractions (TAF273, F3 and F4) of E. longifolia root methanolic extract at various concentrations and time intervals and the anti-proliferative activity assessed by MTS assay. Flow cytometry was used to assess the apoptosis and cell cycle arrest. Nude mice injected subcutaneously with 10(7) K-562 cells were used to study the anti-leukemic activity of TAF273 in vivo. TAF273, F3 and F4 showed various degrees of growth inhibition with IC50 values of 19, 55 and 62 mu g/ml, respectively. TAF273 induced apoptosis in a dose and time dependent manner. TAF273 arrested cell cycle at G1and S phases. Intraperitoneal administration of TAF273 (50 mg/kg) resulted in a significant growth inhibition of subcutaneous tumor in TAF273-treated mice compared with the control mice (P = 0.024). TAF273 shows potent anti-proliferative activity in vitro and in vivo models of CML and therefore, justifies further efforts to define more clearly the potential benefits of using TAF273 as a novel therapeutic strategy for CML management.	[Al-Salahi, Omar Saeed Ali; Zaki, Abdelhamid; Yusoff, Narazah Mohd; Majid, Aman Shah Abdul] Univ Sains Malaysia, AMDI, Kepala Batas, Pulau Pinang, Malaysia; [Ji, Dan] Third Mil Med Univ, Southwest Hosp, Southwest Eye Hosp, Key Lab Visual Damage & Regenerat & Restorat Chon, Chongqing, Peoples R China; [Majid, Amin Malik Shah Abdul; Kit-Lam, Chan] Univ Sains Malaysia, Sch Pharmaceut Sci, George Town, Malaysia; [Abdullah, Wan Zaidah] USM, Sch Med Sci, Dept Haematol, Kubang Kerian, Kelantan, Malaysia; [Zaki, Abdelhamid] Cairo Univ, Natl Res Ctr, Therapeut Chem Dept, Cairo, Egypt; [Din, Shah Kamal Khan Jamal] Hosp Sultanah Bhiyah, OMF Surg, Alor Setar, Kedah, Malaysia	Universiti Sains Malaysia; Army Medical University; Universiti Sains Malaysia; Universiti Sains Malaysia; Egyptian Knowledge Bank (EKB); Cairo University; National Research Centre (NRC)	Yusoff, NM (corresponding author), Univ Sains Malaysia, AMDI, Kepala Batas, Pulau Pinang, Malaysia.	narazah@amdi.usm.edu.my; amanshah75@gmail.com	Abdullah, Wan Zaidah/K-9935-2017; Majid, Aman Shah Abdul/I-3809-2012; Abdullah, Wan Zaidah/E-3526-2012; Mohd Yusoff, Narazah/I-3203-2017	Abdullah, Wan Zaidah/0000-0002-4008-6772; Majid, Aman Shah Abdul/0000-0001-9679-122X; Abdullah, Wan Zaidah/0000-0002-4008-6772; Abdul Majid, Amin Malik Shah/0000-0001-7499-2258; Mohd Yusoff, Narazah/0000-0001-6801-2508				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Baran Y, 2007, J BIOL CHEM, V282, P10922, DOI 10.1074/jbc.M610157200; Bunch RT, 1997, CELL GROWTH DIFFER, V8, P779; Chan KL, 2004, J ETHNOPHARMACOL, V92, P223, DOI 10.1016/j.jep.2004.02.025; De Feudis P, 2000, NEOPLASIA, V2, P202, DOI 10.1038/sj.neo.7900086; Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5; Eshkoor SA, 2008, ARCH MED RES, V39, P668, DOI 10.1016/j.arcmed.2008.06.003; Gao L, 2006, CHINESE MED J-PEKING, V119, P911, DOI 10.1097/00029330-200606010-00006; Gupta M, 2006, J BIOL CHEM, V281, P17552, DOI 10.1074/jbc.M600950200; Gupta MK, 2003, WORLD J GASTROENTERO, V9, P1144, DOI 10.3748/wjg.v9.i6.1144; Han ZY, 1999, MOL CELL BIOL, V19, P1381; Jabbour E, 2009, BLOOD, V114, P2037, DOI 10.1182/blood-2009-01-197715; Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533; Jin SQ, 2003, ONCOGENE, V22, P8536, DOI 10.1038/sj.onc.1206907; Jiwajinda S, 2002, J ETHNOPHARMACOL, V82, P55, DOI 10.1016/S0378-8741(02)00160-5; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Katz AJ, 2005, STEM CELLS, V23, P412, DOI 10.1634/stemcells.2004-0021; Kaur M, 2009, J NUTR, V139, p1806S, DOI 10.3945/jn.109.106864; KELLOFF GJ, 1993, J CELL BIOCHEM, P2; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kim DW, 2009, INT J HEMATOL, V89, P664, DOI 10.1007/s12185-009-0326-1; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Liang YY, 2005, CELL SIGNAL, V17, P243, DOI 10.1016/j.cellsig.2004.07.006; Lim TH, 2005, ANN ACAD MED SINGAP, V34, P533; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Low BS, 2013, J ETHNOPHARMACOL, V149, P201, DOI 10.1016/j.jep.2013.06.023; Low B, 2011, NAT PROD COMMUN, V6, P337; Low BS, 2005, PLANTA MED, V71, P803, DOI 10.1055/s-2005-871259; Mahfudh N., 2008, CANC MOL, V4, P109; Moroy T, 2004, INT J BIOCHEM CELL B, V36, P1424, DOI 10.1016/S1357-2725(03)00432-1; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; O'Brien S, 2009, J NATL COMPR CANC NE, V7, P984, DOI 10.6004/jnccn.2009.0065; Payne SR, 2008, MOL CELL BIOL, V28, P258, DOI 10.1128/MCB.01536-07; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Purwantinings Hussin AH, 2009, INT J PHARM PHARM SC, V3, P343; Quentmeier H, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-6; Shi L, 2010, BIOCHEM BIOPH RES CO, V396, P224, DOI 10.1016/j.bbrc.2010.04.068; Siafakas AR, 2009, INT J BIOCHEM CELL B, V41, P986, DOI 10.1016/j.biocel.2008.06.018; Suh Y, 2009, CARCINOGENESIS, V30, P300, DOI 10.1093/carcin/bgn269; Tee TT, 2007, ANTICANCER RES, V27, P3425; Teh CH, 2009, ACTA CRYSTALLOGR E, V65, pO898, DOI 10.1107/S1600536809010502; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Ueda JY, 2002, BIOL PHARM BULL, V25, P753, DOI 10.1248/bpb.25.753; von Bueren AO, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-19; Wang F, 2009, BMB REP, V42, P725, DOI 10.5483/BMBRep.2009.42.11.725; Weiss RS, 2003, MOL CELL BIOL, V23, P791, DOI 10.1128/MCB.23.3.791-803.2003; Wernsdorfer WH, 2009, WIEN KLIN WOCHENSCHR, V121, P23, DOI 10.1007/s00508-009-1230-7; Wong PF, 2012, PHYTOMEDICINE, V19, P138, DOI 10.1016/j.phymed.2011.07.001; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zakaria Y, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-16; Zhuang HQ, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-12	53	16	19	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2014	9	1							e83818	10.1371/journal.pone.0083818	http://dx.doi.org/10.1371/journal.pone.0083818			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286JC	24409284	gold, Green Published, Green Submitted			2023-01-03	WOS:000329463500008
J	Moon, TD; Silva, WP; Buene, M; Morais, L; Valverde, E; Vermund, SH; Brentlinger, PE				Moon, Troy D.; Silva, Wilson P.; Buene, Manuel; Morais, Luis; Valverde, Emilio; Vermund, Sten H.; Brentlinger, Paula E.			Bacteremia as a Cause of Fever in Ambulatory, HIV-Infected Mozambican Adults: Results and Policy Implications from a Prospective Observational Study	PLOS ONE			English	Article							BLOOD-STREAM INFECTIONS; ANTIRETROVIRAL THERAPY HAART; SEVERE FEBRILE ILLNESS; SALMONELLA; RESISTANCE; CHILDREN; MALARIA; TRENDS; PREDICTORS; TANZANIA	Fever is typically treated empirically in rural Mozambique. We examined the distribution and antimicrobial susceptibility patterns of bacterial pathogens isolated from blood-culture specimens, and clinical characteristics of ambulatory HIV-infected febrile patients with and without bacteremia. This analysis was nested within a larger prospective observational study to evaluate the performance of new Mozambican guidelines for fever and anemia in HIV-infected adults (clinical trial registration NCT01681914, www.clinicaltrials.gov); the guidelines were designed to be used by non-physician clinicians who attended ambulatory HIV-infected patients in very resource-constrained peripheral health units. In 2012 (April-September), we recruited 258 HIV-infected adults with documented fever or history of recent fever in three sites within Zambezia Province, Mozambique. Although febrile patients were routinely tested for malaria, blood culture capacity was unavailable in Zambezia prior to study initiation. We confirmed bacteremia in 39 (15.1%) of 258 patients. The predominant organisms were non-typhoid Salmonella, nearly all resistant to multiple first-line antibiotics (ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole). Features most associated with bacteremia included higher temperature, lower CD4+ T-lymphocyte count, lower hemoglobin, and headache. Introduction of blood cultures allowed us to: 1) confirm bacteremia in a substantial proportion of patients; 2) tailor specific antimicrobial therapy for confirmed bacteremia based on known susceptibilities; 3) make informed choices of presumptive antibiotics for patients with suspected bacteremia; and 4) construct a preliminary clinical profile to help clinicians determine who would most likely benefit from presumptive bacteremia treatment. Our findings demonstrate that in resource-limited settings, there is urgent need to expand local microbiologic capacity to better identify and treat cases of bacteremia in HIV-infected and other patients, and to support surveillance. Data on the prevalence and susceptibility patterns of important pathogens can guide national formulary and prescribing practices.	[Moon, Troy D.; Vermund, Sten H.] Vanderbilt Inst Global Hlth, Nashville, TN USA; [Moon, Troy D.; Silva, Wilson P.; Buene, Manuel; Morais, Luis; Valverde, Emilio; Vermund, Sten H.; Brentlinger, Paula E.] Friends Global Hlth, Maputo, Mozambique	Vanderbilt University	Moon, TD (corresponding author), Vanderbilt Inst Global Hlth, Nashville, TN USA.	troy.moon@vanderbilt.edu	Vermund, Sten/AAD-3592-2020; Valverde, Emilio/ABD-2715-2021	Vermund, Sten/0000-0001-7289-8698; Valverde, Emilio/0000-0002-0437-1816; Brentlinger, Paula/0000-0002-4865-8915; Moon, Troy/0000-0002-1637-829X	President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) [U2GPS000631]; NCATS/NIH [UL1 TR000445]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER	President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC)(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NCATS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR), through the Centers for Disease Control and Prevention (CDC) under the terms of Cooperative Agreement U2GPS000631 to Vanderbilt University. The REDCap (Research Electronic Data Capture) on-line database that were used for initial data entry and management was supported by grant number UL1 TR000445 from NCATS/NIH. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adeyemi AI, 2010, J HEALTH POPUL NUTR, V28, P318; Ali Jemal, 2008, Ethiop Med J, V46, P155; [Anonymous], 2011, WORLD HLTH STAT; [Anonymous], COUNTR HLTH PROF; [Anonymous], 2009, KIRBY BAUER DISK DIF; Arthur G, 2001, CLIN INFECT DIS, V33, P248, DOI 10.1086/321820; Bassat Q, 2009, TROP MED INT HEALTH, V14, P1011, DOI 10.1111/j.1365-3156.2009.02326.x; Bedell RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039347; Bell M, 2001, Int J Infect Dis, V5, P63, DOI 10.1016/S1201-9712(01)90027-X; Brentlinger PE, 2013, 20 C RETR OPP INF CR; CELUM CL, 1987, J INFECT DIS, V156, P998, DOI 10.1093/infdis/156.6.998; Chen HM, 2013, PEDIATR NEONATOL, V54, P147, DOI 10.1016/j.pedneo.2013.01.010; CLSI Publishes, 2012, ANT SUSC TEST STAND; Cunnington AJ, 2012, NAT MED, V18, P120, DOI 10.1038/nm.2601; Daxboeck F, 2004, DIAGN MICR INFEC DIS, V48, P1, DOI 10.1016/j.diagmicrobio.2003.08.001; Donati KD, 2003, J CHEMOTHERAPY, V15, P60, DOI 10.1179/joc.2003.15.1.60; Dougle ML, 1997, E AFR MED J, V74, P353; Elzi L, 2012, CLIN MICROBIOL INFEC, V18, pE355, DOI 10.1111/j.1469-0691.2012.03964.x; Feasey NA, 2012, LANCET, V379, P2489, DOI 10.1016/S0140-6736(11)61752-2; GLASER JB, 1985, ANN INTERN MED, V102, P189, DOI 10.7326/0003-4819-102-2-189; Gordon MA, 2008, CLIN INFECT DIS, V46, P963, DOI 10.1086/529146; Guerrini V, 2013, TUBERCULOSIS, V93, P405, DOI 10.1016/j.tube.2013.02.017; Hall KK, 2006, CLIN MICROBIOL REV, V19, P788, DOI 10.1128/CMR.00062-05; Hill PC, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-2; INSIDA, 2009, INQ NAC PREV RISC CO; Lahuerta M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037125; Mackenzie G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010568; Malik M, 2012, ANTIMICROB AGENTS CH, V56, P3879, DOI 10.1128/AAC.00474-12; Mandomando I, 2010, AM J TROP MED HYG, V83, P152, DOI 10.4269/ajtmh.2010.09-0578; Meynard J-L, 2003, HIV Med, V4, P127, DOI 10.1046/j.1468-1293.2003.00146.x; Ministerio da Saude Republica de Mocambique, 2008, PLAN DES REC HUM 200; Moon TD, 2011, INT J STD AIDS, V22, P621, DOI 10.1258/ijsa.2011.010442; Moon Troy D, 2010, Retrovirology (Auckl), V3, P1; Mootsikapun P, 2007, INT J INFECT DIS, V11, P226, DOI 10.1016/j.ijid.2006.02.010; Murray P.R, 1995, MANUAL CLIN MICROBIO, V6th; Muyanja SZ, 2011, TROP MED INT HEALTH, V16, P756, DOI 10.1111/j.1365-3156.2011.02754.x; Mzileni Mogiyana Olga, 2008, Pol Arch Med Wewn, V118, P548; Nadjm B, 2012, T ROY SOC TROP MED H, V106, P688, DOI 10.1016/j.trstmh.2012.08.006; Ogunsola F T, 2009, Niger Postgrad Med J, V16, P186; Peters RPH, 2004, TROP MED INT HEALTH, V9, P928, DOI 10.1111/j.1365-3156.2004.01288.x; Reddy EA, 2010, LANCET INFECT DIS, V10, P417, DOI 10.1016/S1473-3099(10)70072-4; Republica de Mocambique Ministerio da Saude Direccao Nacional de Assistencia Medica Seccao dos Laboratorios Clinicos, 2013, PLAN OP REV LAB MIC; Reyburn H, 2004, BMJ-BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55; Ruiz J, 2008, AM J TROP MED HYG, V79, P918, DOI 10.4269/ajtmh.2008.79.918; Sajadi MM, 2012, CLIN INFECT DIS, V55, P976, DOI 10.1093/cid/cis596; Sigauque B, 2009, PEDIATR INFECT DIS J, V28, P108, DOI 10.1097/INF.0b013e318187a87d; Tacconelli E, 1998, CLIN INFECT DIS, V27, P901, DOI 10.1086/517165; Tayler-Smith K, 2011, TROP MED INT HEALTH, V16, P579, DOI 10.1111/j.1365-3156.2011.02740.x; Thriemer K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030350; Tran VTN, 2012, T ROY SOC TROP MED H, V106, P26, DOI 10.1016/j.trstmh.2011.10.004; Tumbarello M, 2000, J ACQ IMMUN DEF SYND, V23, P145; van der Meeren BT, 2013, SAMJ S AFR MED J, V103, P382, DOI [10.7196/SAMJ.5941, 10.7196/samj.5941, 10.7196/sam]; van Lettow M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048856; Varma JK, 2010, EMERG INFECT DIS, V16, P1569, DOI 10.3201/eid1610.091686; Vigilancia Epidemiologica do HIV e seu Impacto Demografico em Mocambique Atualizacao Ronda, 2009, VIG EP HIV E SEU IMP; Vlieghe ER, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001933; World Health Organization, 2003, GEN PRINC GOOD CHRON; World Health Organization, 2008, TASK SHIFT RAT RED; World Health Organization, WHO CAS DEF HIV SURV	59	17	19	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2013	8	12							e83591	10.1371/journal.pone.0083591	http://dx.doi.org/10.1371/journal.pone.0083591			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282SX	24386229	gold, Green Published, Green Submitted			2023-01-03	WOS:000329194700050
J	Sensi, L; Tedesco, D; Mimmi, S; Rucci, P; Pisano, E; Pedrini, L; McDonald, KM; Fantini, MP				Sensi, Luigi; Tedesco, Dario; Mimmi, Stefano; Rucci, Paola; Pisano, Emilio; Pedrini, Luciano; McDonald, Kathryn M.; Fantini, Maria Pia		AAA-Working Grp	Hospitalization Rates and Post-Operative Mortality for Abdominal Aortic Aneurysm in Italy over the Period 2000-2011	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; OPEN REPAIR; INCREASING INCIDENCE; ENDOVASCULAR REPAIR; ADMINISTRATIVE DATA; SMOKING BAN; EPIDEMIOLOGY; ENGLAND; WALES; RISK	Background: Recent studies have reported declines in incidence, prevalence and mortality for abdominal aortic aneurysms (AAAs) in various countries, but evidence from Mediterranean countries is lacking. The aim of this study is to examine the trend of hospitalization and post-operative mortality rates for AAAs in Italy during the period 2000-2011, taking into account the introduction of endovascular aneurysm repair (EVAR) in 1990s. Methods: This retrospective cohort study was carried out in Emilia-Romagna, an Italian region with 4.5 million inhabitants. A total of 19,673 patients hospitalized for AAAs between 2000 and 2011, were identified from the hospital discharge records (HDR) database. Hospitalization rates, percentage of OSR and EVAR and 30-day mortality rates were calculated for unruptured (uAAAs) and ruptured AAAs (rAAAs). Results: Adjusted hospitalization rates decreased on average by 2.9% per year for uAAAs and 3.2% for rAAAs (p<0.001). The temporal trend of 30-day mortality rates remained stable for both groups. The percentage of EVAR for uAAAs increased significantly from 2006 to 2011 (42.7 versus 60.9% respectively, mean change of 3.9% per year, p<0.001). No significant difference in mortality was found between OSR and EVAR for uAAAs and rAAAs. Conclusions: The incidence and trend of hospitalization rates for rAAAs and uAAAs decreased significantly in the last decade, while 30-day mortality rates in operated patients remained stable. OSR continued to be the most common surgery in rAAAs, although the gap between OSR and EVAR recently declined. The EVAR technique became the preferred surgery for uAAAs since 2008.	[Sensi, Luigi; Pisano, Emilio; Pedrini, Luciano] Maggiore Hosp, Dept Surg, Vasc Surg Unit, Bologna, Italy; [Tedesco, Dario; Mimmi, Stefano; Rucci, Paola; Fantini, Maria Pia] Alma Mater Studiorum Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy; [McDonald, Kathryn M.] Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford Ctr Hlth Policy, Stanford, CA 94305 USA; Maggiore Hosp, Vasc Surg Unit, Bologna, Italy	AUSL di Bologna; University of Bologna; Stanford University; AUSL di Bologna	Fantini, MP (corresponding author), Alma Mater Studiorum Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy.	mariapia.fantini@unibo.it	Tedesco, Dario/AAD-8342-2022; Tedesco, Dario/AAC-1848-2019	Tedesco, Dario/0000-0002-5027-5446; Rucci, Paola/0000-0002-7704-0831				Anjum A, 2012, EUR J VASC ENDOVASC, V43, P161, DOI 10.1016/j.ejvs.2011.11.014; [Anonymous], 2013, NHS ABD AORT AN SCRE; Aylin P, 2007, BMJ-BRIT MED J, V334, P1044, DOI 10.1136/bmj.39168.496366.55; Barone-Adesi F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017419; Blanchard JF, 1999, EPIDEMIOL REV, V21, P207, DOI 10.1093/oxfordjournals.epirev.a017997; Bown MJ, 2011, AM J HUM GENET, V89, P619, DOI 10.1016/j.ajhg.2011.10.002; Buonanno P, 2013, HEALTH POLICY, V109, P192, DOI 10.1016/j.healthpol.2012.10.009; Burns H., 2010, SCOTTISH ABDOMINAL A; Casey K, 2013, J VASC SURG, V57, P89, DOI 10.1016/j.jvs.2012.07.005; Cesaroni G, 2008, CIRCULATION, V117, P1183, DOI 10.1161/CIRCULATIONAHA.107.729889; Cheng SWK, 2003, WORLD J SURG, V27, P241, DOI 10.1007/s00268-002-6470-x; Choke E, 2012, EUR J VASC ENDOVASC, V44, P549, DOI 10.1016/j.ejvs.2012.08.011; Choke E, 2012, CIRCULATION, V125, P1617, DOI 10.1161/CIRCULATIONAHA.111.077503; FOWKES FGR, 1989, BRIT MED J, V298, P33, DOI 10.1136/bmj.298.6665.33; Giardina S, 2011, J VASC SURG, V54, P938, DOI 10.1016/j.jvs.2011.03.264; Greenblatt DY, 2012, ANN SURG, V256, P595, DOI 10.1097/SLA.0b013e31826b4bfe; Greenhalgh RM, 2005, LANCET, V365, P2179, DOI 10.1016/S0140-6736(05)66627-5; Greenhalgh RM, 2004, LANCET, V364, P843, DOI 10.1016/S0140-6736(04)16979-1; Gretarsdottir S, 2010, NAT GENET, V42, P692, DOI 10.1038/ng.622; Gupta PK, 2012, EUR J VASC ENDOVASC, V43, P506, DOI 10.1016/j.ejvs.2012.02.006; Hernandez-Boussard T, 2012, J AM COLL SURGEONS, V214, P788, DOI 10.1016/j.jamcollsurg.2012.01.045; Hultgren R, 2012, BRIT J SURG, V99, P647, DOI 10.1002/bjs.8685; Istituto Superiore di Sanita, 2010, RAPP ANN FUM IT ANN; Kuivaniemi H, 2012, ANN VASC SURG, V26, P862, DOI 10.1016/j.avsg.2012.02.005; Lederle FA, 2009, JAMA-J AM MED ASSOC, V302, P1535, DOI 10.1001/jama.2009.1426; Min SI, 2012, J KOREAN MED SCI, V27, P416, DOI 10.3346/jkms.2012.27.4.416; Ministero della Salute, 2011, DOC TECN IND RID CAR; Mofidi R, 2008, BRIT J SURG, V95, P1475, DOI 10.1002/bjs.6432; Norman PE, 2007, CONNECT TISSUE RES, V48, P125, DOI 10.1080/03008200701331524; Norman PE, 2011, J VASC SURG, V53, P274, DOI 10.1016/j.jvs.2010.08.087; Palombo D, 2010, J CARDIOVASC SURG, V51, P777; Parodi J C, 1991, Ann Vasc Surg, V5, P491, DOI 10.1007/BF02015271; Pieroni L, 2013, HEALTH POLICY, V111, P116, DOI 10.1016/j.healthpol.2013.04.001; Reitsma JB, 1996, EUR J VASC ENDOVASC, V12, P446, DOI 10.1016/S1078-5884(96)80012-8; Sandiford P, 2011, BRIT J SURG, V98, P645, DOI 10.1002/bjs.7461; Schermerhorn ML, 2011, J AM COLL SURGEONS, V212, P349, DOI 10.1016/j.jamcollsurg.2010.12.003; Schwarze ML, 2009, J VASC SURG, V50, P722, DOI 10.1016/j.jvs.2009.05.010; Shteinberg D, 2000, EUR J VASC ENDOVASC, V20, P462, DOI 10.1053/ejvs.2000.1210; Sternbergh WC, 2000, J VASC SURG, V31, P237, DOI 10.1016/S0741-5214(00)90154-X; Svensjo S, 2011, CIRCULATION, V124, P1118, DOI 10.1161/CIRCULATIONAHA.111.030379; Yuen E, 2011, TUMORI, V97, P428, DOI 10.1700/950.10393; 1998, LANCET, V352, P1649	42	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2013	8	12							e83855	10.1371/journal.pone.0083855	http://dx.doi.org/10.1371/journal.pone.0083855			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282SX	24386294	Green Published, Green Submitted, gold			2023-01-03	WOS:000329194700075
J	Mooney, PD; Hadjivassiliou, M; Sanders, DS				Mooney, Peter D.; Hadjivassiliou, Marios; Sanders, David S.			Coeliac disease	BMJ-BRITISH MEDICAL JOURNAL			English	Review							GLUTEN-FREE DIET; T-CELL LYMPHOMA; QUALITY-OF-LIFE; PRIMARY-CARE; SENSITIVE ENTEROPATHY; CLINICAL-FEATURES; CHANGING FACE; BONE MASS; RISK; MALIGNANCY		[Mooney, Peter D.; Sanders, David S.] Royal Hallamshire Hosp, Reg Gastrointestinal & Liver Unit, Sheffield S10 2JF, S Yorkshire, England; [Hadjivassiliou, Marios] Royal Hallamshire Hosp, Dept Neurol, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield; University of Sheffield	Mooney, PD (corresponding author), Royal Hallamshire Hosp, Reg Gastrointestinal & Liver Unit, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.	peter.mooney@sth.nhs.uk						Aziz I, 2010, ALIMENT PHARM THER, V32, P1392, DOI 10.1111/j.1365-2036.2010.04477.x; Barratt SM, 2011, J GASTROINTEST LIVER, V20, P241; Barratt SM, 2011, EUR J GASTROEN HEPAT, V23, P159, DOI 10.1097/MEG.0b013e328342a547; Berti I, 2006, DIGEST LIVER DIS, V38, P461, DOI 10.1016/j.dld.2005.12.007; Biagi F, 2009, BRIT J NUTR, V102, P882, DOI 10.1017/S0007114509301579; Bianchi ML, 2008, OSTEOPOROSIS INT, V19, P1705, DOI 10.1007/s00198-008-0624-0; Biesiekierski JR, 2011, AM J GASTROENTEROL, V106, P508, DOI 10.1038/ajg.2010.487; Biesiekierski JR, 2011, AM J GASTROENTEROL, V106, P15; Card TR, 2004, ALIMENT PHARM THER, V20, P769, DOI 10.1111/j.1365-2036.2004.02177.x; Carroccio A, 2012, AM J GASTROENTEROL, V107, P1898, DOI 10.1038/ajg.2012.236; Catassi C, 2010, ANN MED, V42, P530, DOI 10.3109/07853890.2010.514285; Ciclitira P, 2010, MANAGEMENT ADULTS CO; COOPER BT, 1982, DIGESTION, V23, P89, DOI 10.1159/000198692; Corazza GR, 1996, BONE, V18, P525, DOI 10.1016/8756-3282(96)00071-3; DAVIDSON LSP, 1950, BMJ-BRIT MED J, V1, P1157, DOI 10.1136/bmj.1.4663.1157; Esteve M, 2006, GUT, V55, P1739, DOI 10.1136/gut.2006.095299; Evans KE, 2011, AM J GASTROENTEROL, V106, P1837, DOI 10.1038/ajg.2011.171; Fasano A, 2003, ARCH INTERN MED, V163, P286, DOI 10.1001/archinte.163.3.286; Fasano A, 2001, GASTROENTEROLOGY, V120, P636, DOI 10.1053/gast.2001.22123; Ford AC, 2009, ARCH INTERN MED, V169, P651, DOI 10.1001/archinternmed.2009.22; Gale J, 2000, J CLIN ONCOL, V18, P795, DOI 10.1200/JCO.2000.18.4.795; GOUGH KR, 1962, GUT, V3, P232, DOI 10.1136/gut.3.3.232; Green PHR, 2003, AM J MED, V115, P191, DOI 10.1016/S0002-9343(03)00302-4; Hadithi M, 2007, ANN INTERN MED, V147, P294, DOI 10.7326/0003-4819-147-5-200709040-00003; Hadjivassiliou M, 2010, LANCET NEUROL, V9, P318, DOI 10.1016/S1474-4422(09)70290-X; Hall NJ, 2009, ALIMENT PHARM THER, V30, P315, DOI 10.1111/j.1365-2036.2009.04053.x; Hallert C, 1999, NUTRITION, V15, P795; HARRIS OD, 1967, AM J MED, V42, P899, DOI 10.1016/0002-9343(67)90071-X; Hin H, 1999, BMJ-BRIT MED J, V318, P164, DOI 10.1136/bmj.318.7177.164; HOLMES GKT, 1976, GUT, V17, P612, DOI 10.1136/gut.17.8.612; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; Hopper AD, 2008, CLIN GASTROENTEROL H, V6, P314, DOI 10.1016/j.cgh.2007.12.008; Hopper AD, 2007, BMJ-BRIT MED J, V334, P729, DOI 10.1136/bmj.39133.668681.BE; Husby S, 2012, J PEDIATR GASTR NUTR, V54, P136, DOI 10.1097/MPG.0b013e31821a23d0; Kane EV, 2011, CANCER CAUSE CONTROL, V22, P1435, DOI 10.1007/s10552-011-9818-4; Kaukinen K, 2002, EUR J GASTROEN HEPAT, V14, P311, DOI 10.1097/00042737-200203000-00017; Kochhar R, 2012, DIGEST LIVER DIS, V44, P530, DOI 10.1016/j.dld.2012.01.004; Korponay-Szabo IR, 2007, BMJ-BRIT MED J, V335, P1244, DOI 10.1136/bmj.39405.472975.80; Lebwohl B, 2013, ANN INTERN MED, V159, P169, DOI 10.7326/0003-4819-159-3-201308060-00006; Leffler D, 2013, GUT, V62, P996, DOI 10.1136/gutjnl-2012-302196; Leffler DA, 2010, AM J GASTROENTEROL, V105, P2520, DOI 10.1038/ajg.2010.276; Lewis NR, 2006, ALIMENT PHARM THER, V24, P47, DOI 10.1111/j.1365-2036.2006.02967.x; Lewis NR, 2009, ALIMENT PHARM THER, V31, P73, DOI 10.1111/j.1365-2036.2009.04110.x; Logan RFA, 2009, GUT, V58, P618, DOI 10.1136/gut.2008.161182; Lohi S, 2007, ALIMENT PHARM THERAP, V26, P1217, DOI 10.1111/j.1365-2036.2007.03502.x; Ludvigsson JF, 2008, GUT, V57, P1074, DOI 10.1136/gut.2007.133868; Ludvigsson JF, 2013, AM J GASTROENTEROL, V108, P818, DOI 10.1038/ajg.2013.60; Ludvigsson JF, 2013, GUT, V62, P43, DOI 10.1136/gutjnl-2011-301346; McGowan KE, 2009, PEDIATRICS, V124, P1572, DOI 10.1542/peds.2008-2373; Meyer D, 2001, AM J GASTROENTEROL, V96, P112; Mooney PD, 2014, DIGEST LIVER DIS, V46, P32, DOI 10.1016/j.dld.2013.08.127; Mooney Peter D, 2013, Expert Opin Med Diagn, V7, P645, DOI 10.1517/17530059.2013.836179; Mustalahti K, 2010, ANN MED, V42, P587, DOI 10.3109/07853890.2010.505931; Naiyer AJ, 2009, J CLIN GASTROENTEROL, V43, P225, DOI 10.1097/MCG.0b013e31816200e5; National Institute for Health and Clinical Excellence, 2009, COEL DIS REC ASS COE; Novakovic BJ, 2006, ONCOL REP, V16, P191; Oberhuber G, 1999, EUR J GASTROEN HEPAT, V11, P1185, DOI 10.1097/00042737-199910000-00019; Olen O, 2011, DIGEST LIVER DIS, V43, P862, DOI 10.1016/j.dld.2011.07.012; Passananti V, 2012, DIGEST LIVER DIS, V44, P379, DOI 10.1016/j.dld.2011.12.012; Rosinach M, 2012, DIGEST LIVER DIS, V44, P643, DOI 10.1016/j.dld.2012.03.006; Rubio-Tapia A, 2008, CLIN GASTROENTEROL H, V6, P983, DOI 10.1016/j.cgh.2008.04.008; Rubio-Tapia A, 2013, AM J GASTROENTEROL, V108, P656, DOI 10.1038/ajg.2013.79; Rubio-Tapia A, 2010, GUT, V59, P547, DOI 10.1136/gut.2009.195131; Rubio-Tapia A, 2009, GASTROENTEROLOGY, V137, P88, DOI 10.1053/j.gastro.2009.03.059; Sainsbury A, 2011, ALIMENT PHARM THER, V34, P33, DOI 10.1111/j.1365-2036.2011.04685.x; Sainsbury A, 2013, CLIN GASTROENTEROL H, V11, P359, DOI 10.1016/j.cgh.2012.11.033; Sanders DS, 2002, POSTGRAD MED J, V78, P31, DOI 10.1136/pmj.78.915.31; Sharkey LM, 2013, ALIMENT PHARM THER, V38, P1278, DOI 10.1111/apt.12510; Silano M, 2008, DIGEST DIS SCI, V53, P972, DOI 10.1007/s10620-007-9952-8; van der Windt DAWM, 2010, JAMA-J AM MED ASSOC, V303, P1738, DOI 10.1001/jama.2010.549; van Heel DA, 2006, GUT, V55, P1037, DOI 10.1136/gut.2005.075119; Wang XQ, 2011, J PEDIATR GASTR NUTR, V53, P368, DOI 10.1097/MPG.0b013e31822a0128; West J, 2004, BRIT MED J, V329, P716, DOI 10.1136/bmj.38169.486701.7C	73	39	40	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 3	2014	348								g1561	10.1136/bmj.g1561	http://dx.doi.org/10.1136/bmj.g1561			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AC6HK	24589518				2023-01-03	WOS:000332622000001
J	Perera, PND; Hu, Q; Tang, JJ; Li, L; Barnhart, M; Doycheva, DM; Zhang, JH; Tang, JP				Perera, Pradilka N. Drunalini; Hu, Qin; Tang, Junjia; Li, Li; Barnhart, Margaret; Doycheva, Desislava M.; Zhang, John H.; Tang, Jiping			Delayed Remote Ischemic Postconditioning Improves Long Term Sensory Motor Deficits in a Neonatal Hypoxic Ischemic Rat Model	PLOS ONE			English	Article							BRAIN-INJURY; STIMULATING FACTOR; DAMAGE; BEHAVIOR	Objective: Remote Ischemic Postconditioning (RIPC) is a promising therapeutic intervention wherein a sub-lethal ischemic insult induced in one organ (limb) improves ischemia in an organ distant to it (brain). The main objective of this study was to investigate the long-term functional effects of delayed RIPC in a neonatal hypoxia-ischemia (HI) rat model. Method: 10 day old rat pups were subjected to delayed RIPC treatment and randomized into four groups: 1) Sham, 2) HI induced, 3) HI +24 hr delayed RIPC, and 4) HI +24 hr delayed RIPC with three consecutive daily treatments. Neurobehavioral tests, brain weights, gross and microscopic brain tissue morphologies, and systemic organ weights were evaluated at five weeks post surgery. Results: HI induced rats performed significantly worse than sham but both groups of delayed RIPC treatment showed improvement of sensory motor functions. Furthermore, compared to the HI induced group, the delayed RIPC treatment groups showed no further detrimental changes on brain tissue, both grossly and morphologically, and no changes on the systemic organ weights. Conclusion: Delayed RIPC significantly improves long term sensory motor deficits in a neonatal HI rat model. A 24 hr delayed treatment does not significantly attenuate morphological brain injury but does attenuate sensory motor deficits. Sensory motor deficits improve with both a single treatment and with three consecutive daily treatments, and the consecutive treatments are possibly being more beneficial.	[Perera, Pradilka N. Drunalini; Hu, Qin; Tang, Junjia; Li, Li; Doycheva, Desislava M.; Zhang, John H.; Tang, Jiping] Loma Linda Univ, Sch Med, Dept Physiol & Pharmacol, Loma Linda, CA 92350 USA; [Barnhart, Margaret; Zhang, John H.] Loma Linda Univ, Sch Med, Dept Neurosurg, Loma Linda, CA USA; [Zhang, John H.] Loma Linda Univ, Sch Med, Dept Anesthesiol, Loma Linda, CA USA	Loma Linda University; Loma Linda University; Loma Linda University	Tang, JP (corresponding author), Loma Linda Univ, Sch Med, Dept Physiol & Pharmacol, Loma Linda, CA 92350 USA.	jtang@llu.edu	Hu, Qin/N-8930-2017	Hu, Qin/0000-0002-2270-8822; Doycheva, Desislava/0000-0001-7795-5989	NIH [NS060936, NS078755]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS078755, R01NS060936] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was supported by NIH grant NS060936 to Jiping Tang and NS078755 to John H. Zhang. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Calvert JW, 2002, BRAIN RES, V951, P1, DOI 10.1016/S0006-8993(02)03094-9; Dezfulian C, 2013, TRANSL STROKE RES, V4, P19, DOI 10.1007/s12975-012-0224-3; Dobrivojevic M, 2013, CROAT MED J, V54, P3, DOI 10.3325/cmj.2013.54.3; Doycheva D, 2013, TRANSL STROKE RES, V4, P171, DOI 10.1007/s12975-012-0225-2; Fathali N, 2010, INTENS CARE MED, V36, P1602, DOI 10.1007/s00134-010-1913-6; Hasegawa Y, 2013, TRANSL STROKE RES, V4, P524, DOI 10.1007/s12975-013-0260-7; Hasseldam H, 2013, NEUROL RES, V35, P336, DOI 10.1179/1743132812Y.0000000130; Hu Q, 2009, EXP NEUROL, V216, P35, DOI 10.1016/j.expneurol.2008.11.007; Hughes RN, 2004, NEUROSCI BIOBEHAV R, V28, P497, DOI 10.1016/j.neubiorev.2004.06.006; Kim BR, 2008, YONSEI MED J, V49, P836, DOI 10.3349/ymj.2008.49.5.836; Lai MC, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/609813; Lekic T, 2011, EXP NEUROL, V227, P96, DOI 10.1016/j.expneurol.2010.09.017; Lekic T, 2010, J NEUROTRAUM, V27, P627, DOI 10.1089/neu.2009.1163; Loukogeorgakis SP, 2007, CIRCULATION, V116, P1386, DOI 10.1161/CIRCULATIONAHA.106.653782; Lubics A, 2005, BEHAV BRAIN RES, V157, P157, DOI 10.1016/j.bbr.2004.06.019; PALMER C, 1990, PEDIATR RES, V27, P332, DOI 10.1203/00006450-199004000-00003; Pazaiti A, 2009, NEONATOLOGY, V95, P33, DOI 10.1159/000151753; Peng B, 2012, BRAIN RES, V1445, P92, DOI 10.1016/j.brainres.2012.01.033; Ren CC, 2009, BRAIN RES, V1288, P88, DOI 10.1016/j.brainres.2009.07.029; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Sidhu RS, 1997, NEUROSCI LETT, V223, P129, DOI 10.1016/S0304-3940(97)13426-7; Soejima Y, 2012, MED GAS RES, V2, DOI 10.1186/2045-9912-2-9; Sun J, 2012, J CEREBR BLOOD F MET, V32, P851, DOI 10.1038/jcbfm.2011.199; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Vannucci R.C, 1997, NEONATAL PERINATAL M, P856; Vannucci RC, 1997, PEDIATRICS, V100, P1004, DOI 10.1542/peds.100.6.1004; VANNUCCI RC, 1997, NEONATAL PERINATAL M, V4, P877; Vinten-Johansen J, 2013, J CARDIOVASC MED, V14, P206, DOI 10.2459/JCM.0b013e32835cecc6; Wang Q, 2011, ANESTH ANALG, V113, P1180, DOI 10.1213/ANE.0b013e31822b885f; Wei M, 2011, CIRC RES, V108, P1220, DOI 10.1161/CIRCRESAHA.110.236190; Yata K, 2007, BRAIN RES, V1145, P227, DOI 10.1016/j.brainres.2007.01.144; Zhao H, 2012, CURR DRUG TARGETS, V13, P173, DOI 10.2174/138945012799201621; Zhao YD, 2013, J NEUROSCI RES, V91, P1165, DOI 10.1002/jnr.23247; Zhou YL, 2011, STROKE, V42, P439, DOI 10.1161/STROKEAHA.110.592162; Zhou YL, 2010, STROKE, V41, P1521, DOI 10.1161/STROKEAHA.110.583757	35	28	28	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2014	9	2							e90258	10.1371/journal.pone.0090258	http://dx.doi.org/10.1371/journal.pone.0090258			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC3DW	24587303	Green Submitted, gold, Green Published			2023-01-03	WOS:000332396200155
J	Mpondo, BCT; Kalluvya, SE; Peck, RN; Kabangila, R; Kidenya, BR; Ephraim, L; Fitzgerald, DW; Downs, JA				Mpondo, Bonaventura C. T.; Kalluvya, Samuel E.; Peck, Robert N.; Kabangila, Rodrick; Kidenya, Benson R.; Ephraim, Lucheri; Fitzgerald, Daniel W.; Downs, Jennifer A.			Impact of Antiretroviral Therapy on Renal Function among HIV-Infected Tanzanian Adults: A Retrospective Cohort Study	PLOS ONE			English	Article							SEROPOSITIVE PATIENTS; KIDNEY-FUNCTION; DISEASE; RISK; DYSFUNCTION; DEATH; PROTEINURIA; NEPHROPATHY; PREVALENCE; PREDICTORS	Background: Data regarding the outcomes of HIV-infected adults with baseline renal dysfunction who start antiretroviral therapy are conflicting. Methods: We followed up a previously-published cohort of HIV-infected adult outpatients in northwest Tanzania who had high prevalence of renal dysfunction at the time of starting antiretroviral therapy (between November 2009 and February 2010). Patients had serum creatinine, proteinuria, microalbuminuria, and CD4(+) T-cell count measured at the time of antiretroviral therapy initiation and at follow-up. We used the adjusted Cockroft-Gault equation to calculate estimated glomerular filtration rates (eGFRs). Results: In this cohort of 171 adults who had taken antiretroviral therapy for a median of two years, the prevalence of renal dysfunction (eGFR <90 mL/min/1.73 m(2)) decreased from 131/171 (76.6%) at the time of ART initiation to 50/171 (29.2%) at the time of follow-up (p<0.001). Moderate dysfunction (eGFR<60 mL/min/1.73 m(2)) decreased from 21.1% at antiretroviral therapy initiation to 1.1% at follow-up (p<0.001), as did the prevalence of microalbuminuria (72% to 44%, p<0.001). Use of tenofovir was not associated with renal dysfunction at follow-up. Conclusion: Mild and moderate renal dysfunction were common in this cohort of HIV-infected adults initiating antiretroviral therapy, and both significantly improved after a median follow-up time of 2 years. Our work supports the renal safety of antiretroviral therapy in African adults with mild-moderate renal dysfunction, suggesting that these regimens do not lead to renal damage in the majority of patients and that they may even improve renal function in patients with mild to moderate renal dysfunction.	[Mpondo, Bonaventura C. T.; Kalluvya, Samuel E.; Peck, Robert N.; Kabangila, Rodrick; Ephraim, Lucheri; Downs, Jennifer A.] Catholic Univ Hlth & Allied Sci, Dept Med, Mwanza, Tanzania; [Mpondo, Bonaventura C. T.; Kalluvya, Samuel E.; Peck, Robert N.; Kabangila, Rodrick; Ephraim, Lucheri; Downs, Jennifer A.] Bugando Med Ctr, Dept Med, Mwanza, Tanzania; [Peck, Robert N.; Fitzgerald, Daniel W.; Downs, Jennifer A.] Weill Cornell Med Coll, Dept Med, New York, NY USA; [Kidenya, Benson R.] Catholic Univ Hlth & Allied Sci, Dept Biochem & Mol Biol, Mwanza, Tanzania	Cornell University	Downs, JA (corresponding author), Catholic Univ Hlth & Allied Sci, Dept Med, Mwanza, Tanzania.	jna2002@med.cornell.edu		Downs, Jennifer/0000-0001-9537-204X; Peck, Robert/0000-0002-4526-2480	United States National Institutes of Health Fogarty International Center [TW 00018]; National Institute of Allergy and Infectious Diseases [K24 AI098627]; Weill Cornell Medical College; Pfizer Inc.; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI098627] Funding Source: NIH RePORTER	United States National Institutes of Health Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Weill Cornell Medical College; Pfizer Inc.(Pfizer); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project was supported in part by a grant from the United States National Institutes of Health Fogarty International Center (TW 00018), the National Institute of Allergy and Infectious Diseases (K24 AI098627), and a scholarship program at Weill Cornell Medical College supported by Pfizer Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atta MG, 2006, NEPHROL DIAL TRANSPL, V21, P2809, DOI 10.1093/ndt/gfl337; Bygrave H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017609; Chi BH, 2011, JAIDS-J ACQ IMM DEF, V58, P475, DOI 10.1097/QAI.0b013e31823058a3; Choi AI, 2009, AIDS, V23, P2143, DOI 10.1097/QAD.0b013e3283313c91; Cooper RD, 2010, CLIN INFECT DIS, V51, P496, DOI 10.1086/655681; Cosgrove CJ, 2002, AM J MED SCI, V323, P102, DOI 10.1097/00000441-200202000-00009; De Beaudrap P, 2010, AIDS RES HUM RETROV, V26, P1221, DOI 10.1089/aid.2009.0261; Emem CP, 2008, NEPHROL DIAL TRANSPL, V23, P741, DOI 10.1093/ndt/gfm836; Estrella M, 2006, CLIN INFECT DIS, V43, P377, DOI 10.1086/505497; Han TM, 2006, KIDNEY INT, V69, P2243, DOI 10.1038/sj.ki.5000339; Ibrahim F, 2012, AM J KIDNEY DIS, V60, P539, DOI 10.1053/j.ajkd.2012.03.006; International Diabetes Federation, 2013, IDF DIABETES ATLAS, V6th ed.; Kirchner Jeffrey T, 2002, AIDS Read, V12, P103; Laradi A, 1998, J AM SOC NEPHROL, V9, P2327; Lucas GM, 2004, AIDS, V18, P541, DOI 10.1097/00002030-200402200-00022; MOSTELLER RD, 1987, NEW ENGL J MED, V317, P1098, DOI 10.1056/nejm198710223171717; Msango L, 2011, AIDS, V25, P1421, DOI 10.1097/QAD.0b013e328348a4b1; Mulenga LB, 2008, AIDS, V22, P1821, DOI 10.1097/QAD.0b013e328307a051; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Peters PJ, 2008, KIDNEY INT, V74, P925, DOI 10.1038/ki.2008.305; Post FA, 2008, CLIN INFECT DIS, V46, P1282, DOI 10.1086/529385; Reid A, 2008, CLIN INFECT DIS, V46, P1271, DOI 10.1086/533468; Sarfo FS, 2013, J INFECTION, V67, P43, DOI 10.1016/j.jinf.2013.03.008; Scheurer Danielle, 2004, AIDS Read, V14, P443; Selik RM, 2002, J ACQ IMMUN DEF SYND, V29, P378, DOI 10.1097/00126334-200204010-00009; Szczech A, 2002, CLIN NEPHROL, V57, P336; Szczech LA, 2002, KIDNEY INT, V61, P195, DOI 10.1046/j.1523-1755.2002.00094.x; TACAIDS/Tanzania ZAC/Tanzania NBS/Tanzania OCGS/Tanzania and Macro International, 2008, TANZ HIV AIDS MAL IN; Wools-Kaloustian K, 2007, NEPHROL DIAL TRANSPL, V22, P2208, DOI 10.1093/ndt/gfm223	29	34	34	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2014	9	2							e89573	10.1371/journal.pone.0089573	http://dx.doi.org/10.1371/journal.pone.0089573			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC3BC	24586882	gold, Green Published, Green Submitted			2023-01-03	WOS:000332389000063
J	Campbell, JTP; Bray, BD; Hoffman, AM; Kavanagh, SJ; Rudd, AG; Tyrrell, PJ				Campbell, James T. P.; Bray, Benjamin D.; Hoffman, Alex M.; Kavanagh, Sara J.; Rudd, Anthony G.; Tyrrell, Pippa J.		Intercollegiate Stroke Working	The Effect of Out of Hours Presentation with Acute Stroke on Processes of Care and Outcomes: Analysis of Data from the Stroke Improvement National Audit Programme (SINAP)	PLOS ONE			English	Article							WEEKDAY ADMISSION; CASE-FATALITY; WEEKEND; MORTALITY; ASSOCIATION; CENTERS; COHORT; TIME	Background: There is inconsistent evidence that patients with stroke admitted to hospital out of regular working hours (such as weekends) experience worse outcomes. We aimed to identify if inequalities in the quality of care and mortality exist in contemporary stroke care in England. Methods: SINAP is a prospective database of acute stroke patients, documenting details of processes of care over the first 72 hours. We compared quality of care indicators and mortality at 72 hours, 7 days and 30 days, for patients who arrived within normal hours (Monday-Friday 8am to 6pm) and for those who arrived out of hours, using multivariable logistic and Cox proportional hazard models. Quality of care was defined according to time from arrival at hospital to interventions (e.g., brain scan), and whether the patient received therapeutic interventions (such as thrombolysis). Results: 45,726 stroke patients were admitted to 130 hospitals in England between 1 April 2010 and 31 January 2012. Patients admitted out of hours (n = 23779) had more features indicative of worse prognosis (haemorrhagic stroke, reduced consciousness, pre stroke dependency). Out of hours admission was significantly associated with longer delays in receiving a CT scan or being admitted to a stroke unit, and reduced odds of receiving thrombolysis. After adjusting for casemix, there was no consistent evidence of higher mortality for patients admitted out of hours, but patients admitted at the weekends had a higher risk of 30 day mortality (OR 1.14, 95% CI 1.06-1.21) Conclusion: Inequalities in the provision of stroke care for people admitted out of regular hours persist in contemporary stroke in England. The association with mortality is small and largely attributable to higher illness severity in patients admitted out of hours.	[Campbell, James T. P.; Hoffman, Alex M.; Kavanagh, Sara J.] Royal Coll Physicians, London NW1 4LE, England; [Bray, Benjamin D.; Rudd, Anthony G.] Kings Coll London, Div Hlth & Social Care Res, London WC2R 2LS, England; [Rudd, Anthony G.] Guys & St Thomas NHS Fdn Trust, Comprehens Biomed Res Ctr, Natl Inst Hlth Res, London, England; [Tyrrell, Pippa J.] Univ Manchester MAHSC, Salford Royal NHS Fdn Trust, Salford, Lancs, England	Royal College of Physicians; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; Salford Royal NHS Foundation Trust	Campbell, JTP (corresponding author), Royal Coll Physicians, London NW1 4LE, England.	james.campbell@rcplondon.ac.uk			Intercollegiate Stroke Working Party	Intercollegiate Stroke Working Party	The authors would like to thank the many hundreds of individuals who have contributed to SINAP. The audits would not be possible without their hard work and dedication. We would also like to thank the Intercollegiate Stroke Working Party for their guidance and work to support SINAP.	Adamson Joy, 2004, J Stroke Cerebrovasc Dis, V13, P171, DOI 10.1016/j.jstrokecerebrovasdis.2004.06.003; Albright KC, 2012, CEREBROVASC DIS, V34, P424, DOI 10.1159/000345077; Albright KC, 2009, CEREBROVASC DIS, V27, P107, DOI 10.1159/000177916; Aujesky D, 2009, CIRCULATION, V119, P962, DOI 10.1161/CIRCULATIONAHA.108.824292; Aylin P, 2010, QUAL SAF HEALTH CARE, V19, P213, DOI 10.1136/qshc.2008.028639; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Crowley RW, 2009, J NEUROSURG, V111, P60, DOI 10.3171/2008.11.JNS081038; Fang JM, 2010, NEUROLOGY, V75, P1589, DOI 10.1212/WNL.0b013e3181fb84bc; Kostis WJ, 2007, NEW ENGL J MED, V356, P1099, DOI 10.1056/NEJMoa063355; Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6; Marco J, 2010, AM J MED QUAL, V25, P312, DOI 10.1177/1062860610366031; Office for National Statistics, 2016, 2011 CENS REL FEM MA; Ogbu UC, 2011, J NEUROL NEUROSUR PS, V82, P8, DOI 10.1136/jnnp.2009.202176; Palmer WL, 2012, ARCH NEUROL-CHICAGO, V69, P1296, DOI 10.1001/archneurol.2012.1030; Reeves MJ, 2009, STROKE, V40, P569, DOI 10.1161/STROKEAHA.108.519355; Rudd AG, 2007, AGE AGEING, V36, P247, DOI 10.1093/ageing/afm007; Sharp AL, 2013, AM J EMERG MED, V31, P835, DOI 10.1016/j.ajem.2013.01.006; Stroke Unit Trailists' Collaboration, 2007, COCHRANE DB SYST REV; Wardlaw JM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000213.pub2; Wong HJ, 2011, J GEN INTERN MED, V26, P1050, DOI 10.1007/s11606-011-1715-8	20	31	31	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2014	9	2							e87946	10.1371/journal.pone.0087946	http://dx.doi.org/10.1371/journal.pone.0087946			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7FJ	24533063	gold, Green Published, Green Submitted			2023-01-03	WOS:000331262600021
J	Jan, C; Lee, M; Roa, R; Herrera, V; Politis, M; Motta, J				Jan, Carmen; Lee, Marcos; Roa, Reina; Herrera, Victor; Politis, Michael; Motta, Jorge			The Association of Tobacco Control Policies and the Risk of Acute Myocardial Infarction Using Hospital Admissions Data	PLOS ONE			English	Article							SMOKE-FREE LEGISLATION; CIGARETTE TAXES; IMPACT; CONSUMPTION; HEALTH; BANS; LAWS; US	Objective: To evaluate the association of a nationwide comprehensive smoking ban (CSB) and tobacco tax increase (TTI) on the risk of acute myocardial infarctions (AMI) in Panama for the period of 2006 - 2010 using hospital admissions data. Methods: Data of AMI cases was gathered from public and private hospitals in the country for the period of January 1, 2006 to December 31, 2010. The number of AMI cases was calculated on a monthly basis. The risk of AMI was estimated for the pre-CSB period (January 2006 to April 2008) and was used as a reference point. Three post-intervention periods were examined: (1) post-CSB from May 2008 to April 2009 (12 months); (2) post-CSB from May 2009 to November 2009 (7 months); and (3) post-TTI from December 2009 to December 2010 (13 months). Relative risks (RR) of AMI were estimated for each post intervention periods by using a Poisson regression model. Mortality registries for the country attributed to myocardial infarction (MI) were obtained from January 2001 to December 2012. The annual percentage change (APC) of the number of deaths from MI was calculated using Joinpoint regression analysis. Results: A total sample size of 2191 AMI cases was selected (monthly mean number of cases 36.52 +/- 8.24 SD). Using the pre-CSB as a reference point (RR = 1.00), the relative risk of AMI during the first CSB period, the second CSB period and post-TTI were 0.982, 1.049, and 0.985, respectively. The APC of deaths from MI from January 2001 to April 2008 was 0.5%. From January 2001 to June 2010 the APC trend was 0.47% and from July 2010 to December 2012 the APC was -0.3%. Conclusions: The implementation of a CSB and TTI in Panama were associated with a decrease in tobacco consumption and a reduction of the RR of AMI.	[Jan, Carmen; Lee, Marcos; Herrera, Victor; Politis, Michael; Motta, Jorge] Gorgas Mem Inst Hlth Studies, Panama City, Panama; [Roa, Reina] Minist Hlth, Panama City, Panama	Instituto Conmemorativo Gorgas de Estudios de la Salud; Ministerio de Salud de la Republica de Panama	Motta, J (corresponding author), Gorgas Mem Inst Hlth Studies, Panama City, Panama.	drjmotta@gmail.com	Motta, Jorge Alejandro/ABI-6006-2020	Roa, Reina/0000-0002-6332-0584	Roswell Park Cancer Institute; Gorgas Memorial Institute of Health Studies	Roswell Park Cancer Institute; Gorgas Memorial Institute of Health Studies	This study was funded in part by Roswell Park Cancer Institute and the Gorgas Memorial Institute of Health Studies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad S, 2008, PUBLIC HEALTH, V122, P3, DOI 10.1016/j.puhe.2007.02.020; Alemu Rahel, 2011, ISRN Cardiol, V2011, P174358, DOI 10.5402/2011/174358; Barnett R, 2009, AUST NZ J PUBL HEAL, V33, P515, DOI 10.1111/j.1753-6405.2009.00446.x; Barone-Adesi F, 2006, EUR HEART J, V27, P2468, DOI 10.1093/eurheartj/ehl201; Barr CD, 2012, AM J EPIDEMIOL, V176, P642, DOI 10.1093/aje/kws267; Bhaskaran K, 2009, HEART, V95, P1760, DOI 10.1136/hrt.2009.175000; Cesaroni G, 2008, CIRCULATION, V117, P1183, DOI 10.1161/CIRCULATIONAHA.107.729889; Chaloupka FJ, 2012, TOB CONTROL, V21, P172, DOI 10.1136/tobaccocontrol-2011-050417; de Korte-de Boer D, 2012, HEART, V98, P995, DOI 10.1136/heartjnl-2012-301702; DeCicca P, 2008, J HEALTH ECON, V27, P918, DOI 10.1016/j.jhealeco.2007.11.005; Desalu OO, 2011, ANN AFR MED, V10, P103, DOI 10.4103/1596-3519.82069; Gasparrini A, 2009, EUR J EPIDEMIOL, V24, P597, DOI 10.1007/s10654-009-9377-0; Glantz SA, 2008, PREV MED, V47, P452, DOI 10.1016/j.ypmed.2008.06.007; Goerre S, 2007, INT J CARDIOL, V118, P36, DOI 10.1016/j.ijcard.2006.06.015; Hahn EJ, 2011, PUBLIC HEALTH REP, V126, P826, DOI 10.1177/003335491112600608; Instituto Conmemorativo Gorgas de Estudios en Salud website, 2000, AN DEM TAB PAN CONTR; Instituto Conmemorativo Gorgas de Estudios en Salud website, PREV FACT RIESG AS E; Instituto Conmemorativo Gorgas de Estudios en Salud website, ENC NAC SAL CAL VID; Jimenez-Ruiz JA, 2008, TOB CONTROL, V17, DOI 10.1136/tc.2007.021030; Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.3.CO;2-Q; Kuo MC, 2003, ALCOHOL CLIN EXP RES, V27, P720, DOI [10.1097/01.ALC.0000065064.61199.79, 10.1111/j.1530-0277.2003.tb04410.x]; Lazuras L, 2009, TOB CONTROL, V18, P127, DOI 10.1136/tc.2008.025841; Lemstra M, 2008, CAN J PUBLIC HEALTH, V99, P62, DOI 10.1007/BF03403743; Lightwood JM, 1997, CIRCULATION, V96, P1089, DOI 10.1161/01.CIR.96.4.1089; Liu Echu, 2008, J Health Care Finance, V34, P91; Pan American Health Organization (PAHO) website, GLOB AD TOB SURV GAT; Pechacek TF, 2004, BRIT MED J, V328, P980, DOI 10.1136/bmj.328.7446.980; Pell JP, 2008, NEW ENGL J MED, V359, P482, DOI 10.1056/NEJMsa0706740; Pope CA, 2009, CIRCULATION, V120, P941, DOI 10.1161/CIRCULATIONAHA.109.857888; Ravara SB, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-134; Rodu B, 2012, J COMMUN HEALTH, V37, P468, DOI 10.1007/s10900-011-9464-5; Ruidavets JB, 2005, CIRCULATION, V111, P563, DOI 10.1161/01.CIR.0000154546.32135.6E; Salloum RG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-534; Sargent RP, 2004, BMJ-BRIT MED J, V328, P977, DOI 10.1136/bmj.38055.715683.55; Schroeder SA, 2009, J AM COLL CARDIOL, V54, P1256, DOI 10.1016/j.jacc.2009.08.006; Seguret F., 2013, EUR J PREV CARDIOL; Showalter MH, 1998, AM J PUBLIC HEALTH, V88, P1118, DOI 10.2105/AJPH.88.7.1118; Sims M, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2161; Stallings-Smith S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062063; Villalbi JR, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000067; Warren CW, 2012, EUR J PUBLIC HEALTH, V22, P712, DOI 10.1093/eurpub/ckr157; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	42	15	16	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2014	9	2							e88784	10.1371/journal.pone.0088784	http://dx.doi.org/10.1371/journal.pone.0088784			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AA7CL	24520421	Green Published, Green Submitted, gold			2023-01-03	WOS:000331254600112
J	Veerbeek, JM; van Wegen, E; van Peppen, R; van der Wees, PJ; Hendriks, E; Rietberg, M; Kwakkel, G				Veerbeek, Janne Marieke; van Wegen, Erwin; van Peppen, Roland; van der Wees, Philip Jan; Hendriks, Erik; Rietberg, Marc; Kwakkel, Gert			What Is the Evidence for Physical Therapy Poststroke? A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							CONSTRAINT-INDUCED MOVEMENT; RANDOMIZED CONTROLLED-TRIAL; FUNCTIONAL ELECTRICAL-STIMULATION; BODY-WEIGHT SUPPORT; SUBACUTE STROKE PATIENTS; ROBOT-ASSISTED THERAPY; TRIGGERED NEUROMUSCULAR STIMULATION; ELECTROMECHANICAL GAIT TRAINER; EXTREMITY MOTOR RECOVERY; UPPER-LIMB FUNCTION	Background: Physical therapy (PT) is one of the key disciplines in interdisciplinary stroke rehabilitation. The aim of this systematic review was to provide an update of the evidence for stroke rehabilitation interventions in the domain of PT. Methods and Findings: Randomized controlled trials (RCTs) regarding PT in stroke rehabilitation were retrieved through a systematic search. Outcomes were classified according to the ICF. RCTs with a low risk of bias were quantitatively analyzed. Differences between phases poststroke were explored in subgroup analyses. A best evidence synthesis was performed for neurological treatment approaches. The search yielded 467 RCTs (N = 25373; median PEDro score 6 [IQR 5-7]), identifying 53 interventions. No adverse events were reported. Strong evidence was found for significant positive effects of 13 interventions related to gait, 11 interventions related to arm-hand activities, 1 intervention for ADL, and 3 interventions for physical fitness. Summary Effect Sizes (SESs) ranged from 0.17 (95%CI 0.03-0.70; I-2 = 0%) for therapeutic positioning of the paretic arm to 2.47 (95%CI 0.84-4.11; I-2 = 77%) for training of sitting balance. There is strong evidence that a higher dose of practice is better, with SESs ranging from 0.21 (95%CI 0.02-0.39; I-2 = 6%) for motor function of the paretic arm to 0.61 (95%CI 0.41-0.82; I-2 = 41%) for muscle strength of the paretic leg. Subgroup analyses yielded significant differences with respect to timing poststroke for 10 interventions. Neurological treatment approaches to training of body functions and activities showed equal or unfavorable effects when compared to other training interventions. Main limitations of the present review are not using individual patient data for meta-analyses and absence of correction for multiple testing. Conclusions: There is strong evidence for PT interventions favoring intensive high repetitive task-oriented and task-specific training in all phases poststroke. Effects are mostly restricted to the actually trained functions and activities. Suggestions for prioritizing PT stroke research are given.	[Veerbeek, Janne Marieke; van Wegen, Erwin; Rietberg, Marc; Kwakkel, Gert] Vrije Univ Amsterdam Med Ctr, MOVE Res Inst Amsterdam, Dept Rehabil Med, Amsterdam, Netherlands; [van Peppen, Roland] Univ Appl Sci Utrecht, Dept Physiotherapy, Utrecht, Netherlands; [van der Wees, Philip Jan] Radboud Univ Nijmegen, Sci Inst Qual Healthcare IQ Healthcare, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Hendriks, Erik] Maastricht Univ, Dept Epidemiol, Maastricht, Netherlands; [Kwakkel, Gert] Reade Ctr Rehabil & Rheumatol, Dept Neurorehabil, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Radboud University Nijmegen; Maastricht University	Kwakkel, G (corresponding author), Vrije Univ Amsterdam Med Ctr, MOVE Res Inst Amsterdam, Dept Rehabil Med, Amsterdam, Netherlands.	g.kwakkel@vumc.nl	Veerbeek, Janne/W-7424-2019; van der Wees, Philip Jan/L-4748-2015	Veerbeek, Janne/0000-0002-6337-6780; Kwakkel, Gert/0000-0002-4041-4043; van Wegen, Erwin/0000-0002-7920-9995	Royal Dutch Society for Physical Therapy (KNGF) [8091.1]	Royal Dutch Society for Physical Therapy (KNGF)	This research project was supported by the Royal Dutch Society for Physical Therapy (KNGF grant no. 8091.1; http://www.fysionet.nl/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abu Tariah H, 2010, INT J THER REHABIL, V17, P638; Ada L, 2005, ARCH PHYS MED REHAB, V86, P230, DOI 10.1016/j.apmr.2004.02.031; Ada L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003863.pub2; Ada L, 2003, ARCH PHYS MED REHAB, V84, P1486, DOI 10.1016/S0003-9993(03)00349-6; Ada L, 2010, STROKE, V41, P1237, DOI 10.1161/STROKEAHA.109.569483; Aidar FJ, 2007, REV NEUROLOGIA, V45, P518, DOI 10.33588/rn.4509.2006366; Aisen ML, 1997, ARCH NEUROL-CHICAGO, V54, P443, DOI 10.1001/archneur.1997.00550160075019; Akbari A., 2006, J MED SCI, V6, P382, DOI [10.3923/jms.2006.382.388, DOI 10.3923/JMS.2006.382.388]; Alberts JL, 2004, NEUROREHAB NEURAL RE, V18, P250, DOI 10.1177/1545968304271370; Ali M, 2013, INT J STROKE, V8, P18, DOI 10.1111/j.1747-4949.2012.00973.x; Allison R, 2007, CLIN REHABIL, V21, P614, DOI 10.1177/0269215507077364; Alon G, 2008, AM J PHYS MED REHAB, V87, P627, DOI 10.1097/PHM.0b013e31817fabc1; Alon G, 2007, NEUROREHAB NEURAL RE, V21, P207, DOI 10.1177/1545968306297871; Altman DG, 2006, TRIALS, V7, DOI 10.1186/1745-6215-7-6; Altschuler EL, 1999, LANCET, V353, P2035, DOI 10.1016/S0140-6736(99)00920-4; Ambrosini E, 2011, STROKE, V42, P1068, DOI 10.1161/STROKEAHA.110.599068; American Physical Therapy Association, 2011, TOD PHYS THER COMPR; Andersen HE, 2002, CLIN REHABIL, V16, P593, DOI 10.1191/0269215502cr528oa; [Anonymous], 2004, J GERIATR PHYS THER, DOI [10.1519/00139143-200408000-00004, DOI 10.1519/00139143-200408000-00004]; Ansari N N, 2007, Electromyogr Clin Neurophysiol, V47, P137; Appel C, 2011, CLIN REHABIL, V25, P833, DOI 10.1177/0269215510397392; Argstatter H, 2007, NEUROLOGIE REHABILIT, V13, P159; Armagan O, 2003, AM J PHYS MED REHAB, V82, P856, DOI [10.1097/01.PHM.0000091984.72486.E0, 10.1097/01.PHM.0000091984.72486.EO]; Askim T, 2010, STROKE, V41, P1697, DOI 10.1161/STROKEAHA.110.584284; Atteya Abdul-Alim A, 2004, Neurosciences (Riyadh), V9, P24; Azab M, 2009, TOP STROKE REHABIL, V16, P207, DOI 10.1310/tsr1603-207; Bagley P, 2005, CLIN REHABIL, V19, P354, DOI 10.1191/0269215505cr874oa; BAKER LL, 1986, PHYS THER, V66, P1930, DOI 10.1093/ptj/66.12.1930; Bakhtiary AH, 2008, CLIN REHABIL, V22, P418, DOI 10.1177/0269215507084008; Bale M, 2008, CLIN REHABIL, V22, P911, DOI 10.1177/0269215508090092; Barbeau H, 2003, ARCH PHYS MED REHAB, V84, P1458, DOI 10.1016/S0003-9993(03)00361-7; Barclay-Goddard RE, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005950.pub4; Barker RN, 2008, STROKE, V39, P1800, DOI 10.1161/STROKEAHA.107.498485; Barker RN, 2009, EXP BRAIN RES, V196, P483, DOI 10.1007/s00221-009-1872-8; Barrett JA, 2001, CLIN REHABIL, V15, P32, DOI 10.1191/026921501672264719; Baskett JJ, 1999, CLIN REHABIL, V13, P23, DOI 10.1191/026921599701532090; BASMAJIAN JV, 1987, ARCH PHYS MED REHAB, V68, P267; BASMAJIAN JV, 1975, ARCH PHYS MED REHAB, V56, P231; BASMAJIAN JV, 1982, ARCH PHYS MED REHAB, V63, P613; BATE PJ, 1992, ARCH PHYS MED REHAB, V73, P1050; Bayouk JF, 2006, INT J REHABIL RES, V29, P51, DOI 10.1097/01.mrr.0000192100.67425.84; Beckerman H, 1996, CLIN REHABIL, V10, P112, DOI DOI 10.1177/026921559601000205; Bernhardt J, 2004, STROKE, V35, P1005, DOI 10.1161/01.STR.0000120727.40792.40; Bernhardt J, 2008, STROKE, V39, P390, DOI 10.1161/STROKEAHA.107.492363; Bernhardt J, 2007, CEREBROVASC DIS, V24, P157, DOI 10.1159/000103626; Bhatt E, 2007, EXP BRAIN RES, V182, P435, DOI 10.1007/s00221-007-1001-5; BINDER SA, 1981, PHYS THER, V61, P886, DOI 10.1093/ptj/61.6.886; Blennerhassett J, 2004, AUST J PHYSIOTHER, V50, P219, DOI 10.1016/S0004-9514(14)60111-2; Boake C, 2007, NEUROREHAB NEURAL RE, V21, P14, DOI 10.1177/1545968306291858; BOGATAJ U, 1995, PHYS THER, V75, P490, DOI 10.1093/ptj/75.6.490; Bonan IV, 2004, ARCH PHYS MED REHAB, V85, P274, DOI 10.1016/j.apmr.2003.06.016; Borenstein M, 2009, SUBGROUP ANAL INTRO, P149; Borenstein M, 2013, PREV SCI, V14, P134, DOI 10.1007/s11121-013-0377-7; Bourbonnais D, 2002, AM J PHYS MED REHAB, V81, P890, DOI 10.1097/00002060-200212000-00002; BOWMAN BR, 1979, ARCH PHYS MED REHAB, V60, P497; Bradley L, 1998, CLIN REHABIL, V12, P11, DOI 10.1191/026921598677671932; Braun SM, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2010.07.009; Brazzelli M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003316.pub4; Britto RR, 2011, ARCH PHYS MED REHAB, V92, P184, DOI 10.1016/j.apmr.2010.09.029; Britton E, 2008, CLIN REHABIL, V22, P458, DOI 10.1177/0269215507084644; Brock K, 2011, CLIN REHABIL, V25, P903, DOI 10.1177/0269215511406557; Broeren J, 2008, CEREBROVASC DIS, V26, P289, DOI 10.1159/000149576; Brogardh C, 2006, CLIN REHABIL, V20, P218, DOI 10.1191/0269215506cr937oa; Brogardh C, 2010, ARCH PHYS MED REHAB, V91, P460, DOI 10.1016/j.apmr.2009.11.009; Brogardh C, 2009, J REHABIL MED, V41, P231, DOI 10.2340/16501977-0312; Buma F, 2013, RESTOR NEUROL NEUROS, V31, P707, DOI 10.3233/RNN-130332; Burgar CG, 2011, J REHABIL RES DEV, V48, P445, DOI 10.1682/JRRD.2010.04.0062; Burge E, 2008, ARCH PHYS MED REHAB, V89, P1857, DOI 10.1016/j.apmr.2008.03.023; Burridge JH, 1997, CLIN REHABIL, V11, P201, DOI 10.1177/026921559701100303; BUTEFISCH C, 1995, J NEUROL SCI, V130, P59, DOI 10.1016/0022-510X(95)00003-K; Byl N, 2003, NEUROREHAB NEURAL RE, V17, P176, DOI 10.1177/0888439003257137; Byl NN, 2008, NEUROREHAB NEURAL RE, V22, P494, DOI 10.1177/1545968308317431; Cacchio A, 2009, NEUROREHAB NEURAL RE, V23, P792, DOI 10.1177/1545968309335977; Cacchio A, 2009, NEW ENGL J MED, V361, P634, DOI 10.1056/NEJMc0902799; Cambier DC, 2003, CLIN REHABIL, V17, P14, DOI 10.1191/0269215503cr580oa; Carey JR, 2007, NEUROREHAB NEURAL RE, V21, P216, DOI 10.1177/1545968306292381; CAREY JR, 1990, ARCH PHYS MED REHAB, V71, P888; Carey JR, 2002, BRAIN, V125, P773, DOI 10.1093/brain/awf091; Carey L, 2011, NEUROREHAB NEURAL RE, V25, P304, DOI 10.1177/1545968310397705; Carmeli E, 2011, PHYSIOTHER RES INT, V16, P191, DOI 10.1002/pri.485; Carr Mitchell, 2003, Top Stroke Rehabil, V9, P57; Cauraugh J, 2000, STROKE, V31, P1360, DOI 10.1161/01.STR.31.6.1360; Cauraugh JH, 2008, CEREBROVASC DIS, V25, P115, DOI 10.1159/000112321; Cauraugh JH, 2009, RESTOR NEUROL NEUROS, V27, P17, DOI 10.3233/RNN-2009-0455; Cauraugh JH, 2005, NEUROSCI LETT, V382, P39, DOI 10.1016/j.neulet.2005.02.060; Cauraugh JH, 2003, J NEUROL SCI, V215, P13, DOI 10.1016/S0022-510X(03)00169-2; Cauraugh JH, 2003, J NEUROL NEUROSUR PS, V74, P1562, DOI 10.1136/jnnp.74.11.1562; Cauraugh JH, 2003, J NEUROL SCI, V207, P25, DOI 10.1016/S0022-510X(02)00355-6; Cauraugh JH, 2002, STROKE, V33, P1589, DOI 10.1161/01.STR.0000016926.77114.A6; Chae J, 1998, STROKE, V29, P975, DOI 10.1161/01.STR.29.5.975; Chan MKL, 2009, NEUROREHAB NEURAL RE, V23, P357, DOI 10.1177/1545968308326428; Chang WH, 2012, NEUROREHAB NEURAL RE, V26, P318, DOI 10.1177/1545968311408916; Chen I-Chun, 2002, Chang Gung Med J, V25, P583; Chen JC, 2005, STROKE, V36, P2665, DOI 10.1161/01.STR.0000189992.06654.ab; Chen JC, 2011, CLIN REHABIL, V25, P823, DOI 10.1177/0269215511399591; Chen SC, 2005, DISABIL REHABIL, V27, P105, DOI 10.1080/09638280400009022; Cheng JS, 2010, ARCH PHYS MED REHAB, V91, P505, DOI 10.1016/j.apmr.2009.11.022; Cheng PT, 2001, ARCH PHYS MED REHAB, V82, P1650, DOI 10.1053/apmr.2001.26256; Chollet F, 2011, LANCET NEUROL, V10, P123, DOI 10.1016/S1474-4422(10)70314-8; Chow Daniel S, 2012, Surg Neurol Int, V3, P27, DOI 10.4103/2152-7806.92941; Chu KS, 2004, ARCH PHYS MED REHAB, V85, P870, DOI 10.1016/j.apmr.2003.11.001; Church C, 2006, STROKE, V37, P2995, DOI 10.1161/01.STR.0000248969.78880.82; Cohen J., 1988, STAT POWER ANAL BEHA, P18, DOI [10.4324/9780203771587, DOI 10.1016/B978-0-12-179060-8.50006-2]; COLBORNE GR, 1993, ARCH PHYS MED REHAB, V74, P1100, DOI 10.1016/0003-9993(93)90069-M; Conroy SS, 2011, ARCH PHYS MED REHAB, V92, P1754, DOI 10.1016/j.apmr.2011.06.016; Cooke EV, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-60; Cooke EV, 2010, NEUROREHAB NEURAL RE, V24, P88, DOI 10.1177/1545968309343216; COZEAN CD, 1988, ARCH PHYS MED REHAB, V69, P401; Craig LE, 2008, NURS EDUC TODAY, V28, P77, DOI 10.1016/j.nedt.2007.02.011; Crosbie J, 2007, UK STROK FOR C, P9; Crow J L, 1989, Int Disabil Stud, V11, P155; da Cunha IT, 2002, ARCH PHYS MED REHAB, V83, P1258, DOI 10.1053/apmr.2002.34267; da Cunha IT, 2001, J REHABIL RES DEV, V38, P245; Cameirao MDS, 2011, RESTOR NEUROL NEUROS, V29, P287, DOI 10.3233/RNN-2011-0599; Dahl AE, 2008, CLIN REHABIL, V22, P436, DOI 10.1177/0269215507084581; Daly JJ, 2005, J REHABIL RES DEV, V42, P723, DOI 10.1682/JRRD.2005.02.0048; Davidson I, 2005, CLIN REHABIL, V19, P126, DOI 10.1191/0269215505cr841oa; De Boissezon X, 2005, ISOKINET EXERC SCI, P91; de Jong LD, 2006, CLIN REHABIL, V20, P656, DOI 10.1191/0269215506cre1007oa; de Kroon JR, 2008, CLIN REHABIL, V22, P690, DOI 10.1177/0269215508088984; de Kroon JR, 2004, AM J PHYS MED REHAB, V83, P592, DOI 10.1097/01.phm.0000133435.61610.55; de Seze M, 2001, ARCH PHYS MED REHAB, V82, P793, DOI 10.1053/apmr.2001.0820793; Dean CM, 2007, AUST J PHYSIOTHER, V53, P97, DOI 10.1016/S0004-9514(07)70042-9; Dean CM, 2010, J PHYSIOTHER, V56, P97, DOI 10.1016/S1836-9553(10)70039-4; Dean CM, 2000, ARCH PHYS MED REHAB, V81, P409, DOI 10.1053/mr.2000.3839; Dean CM, 2000, AUST J PHYSIOTHER, V46, P35, DOI 10.1016/S0004-9514(14)60312-3; Dean CM, 1997, STROKE, V28, P722, DOI 10.1161/01.STR.28.4.722; Dechaumont-Palacin S, 2008, NEUROREHAB NEURAL RE, V22, P154, DOI 10.1177/1545968307307118; Desrosiers J, 2005, CLIN REHABIL, V19, P581, DOI 10.1191/0269215505cr896oa; Desrosiers J, 2007, ARCH PHYS MED REHAB, V88, P1095, DOI 10.1016/j.apmr.2007.06.017; Di Lauro A, 2003, J NEUROL, V250, P1206, DOI 10.1007/s00415-003-0185-2; Dias D, 2007, Eura Medicophys, V43, P499; Dobke B, 2010, NEUROL REHABIL, V16, P173; Dobkin BH, 2012, NEUROREHAB NEURAL RE, V26, P308, DOI 10.1177/1545968312439687; Dobkin BH, 2010, NEUROREHAB NEURAL RE, V24, P235, DOI 10.1177/1545968309357558; Dobkin BH, 2007, NEUROREHAB NEURAL RE, V21, P3, DOI 10.1177/1545968306297329; Dogan-Aslan M, 2012, J STROKE CEREBROVASC, V21, P187, DOI 10.1016/j.jstrokecerebrovasdis.2010.06.006; Dohle C, 2009, NEUROREHAB NEURAL RE, V23, P209, DOI 10.1177/1545968308324786; Donaldson C, 2009, NEUROREHAB NEURAL RE, V23, P389, DOI 10.1177/1545968308326635; Donkervoort M, 2001, NEUROPSYCHOL REHABIL, V11, P549, DOI 10.1080/09602010143000093; Doyle S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006331.pub2; Dromerick AW, 2009, NEUROLOGY, V73, P195, DOI 10.1212/WNL.0b013e3181ab2b27; Dromerick AW, 2000, STROKE, V31, P2984, DOI 10.1161/01.STR.31.12.2984; Drummond A, 1995, CLIN REHABIL, V9, P283, DOI DOI 10.1177/026921559500900402; Drummond A, 1996, BRIT J OCCUPATIONAL, V59, P330, DOI DOI 10.1177/030802269605900712; Duncan P, 1998, STROKE, V29, P2055, DOI 10.1161/01.STR.29.10.2055; Duncan P, 2003, STROKE, V34, P2173, DOI 10.1161/01.STR.0000083699.95351.F2; Duncan PW, 2011, NEW ENGL J MED, V364, P2026, DOI 10.1056/NEJMoa1010790; Dwan K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003081; Eich HJ, 2004, CLIN REHABIL, V18, P640, DOI 10.1191/0269215504cr779oa; Ellis MD, 2009, NEUROREHAB NEURAL RE, V23, P862, DOI 10.1177/1545968309332927; Elsner B, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.00009645, DOI 10.1002/14651858]; ENGARDT M, 1993, SCAND J REHABIL MED, V25, P41; English C, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007513.pub2; Sucar LE, 2010, IEEE ENG MED BIO, P3690, DOI 10.1109/IEMBS.2010.5627458; Erel S, 2011, CLIN REHABIL, V25, P515, DOI 10.1177/0269215510390719; Eser F, 2008, EUR J PHYS REHAB MED, V44, P19; Faghri P D, 1997, J Hand Ther, V10, P29; FAGHRI PD, 1994, ARCH PHYS MED REHAB, V75, P73; Fang YN, 2003, CLIN REHABIL, V17, P608, DOI 10.1191/0269215503cr655oa; Ferrante S, 2008, EUR J PHYS REHAB MED, V44, P159; Ferreira HP, 2011, TOP STROKE REHABIL, V18, P155, DOI 10.1310/tsr1802-155; Feys H, 2004, STROKE, V35, P924, DOI 10.1161/01.STR.0000121645.44752.f7; Feys HM, 1998, STROKE, V29, P785, DOI 10.1161/01.STR.29.4.785; Fil A, 2011, CLIN REHABIL, V25, P51, DOI 10.1177/0269215510375919; Fischer HC, 2007, TOP STROKE REHABIL, V14, P1, DOI 10.1310/tsr1401-1; Fisher S, 2011, TOP STROKE REHABIL, V18, P269, DOI 10.1310/tsr1803-269; Flansbjer UB, 2008, J REHABIL MED, V40, P42, DOI 10.2340/16501977-0129; Franceschini M, 2009, STROKE, V40, P3079, DOI 10.1161/STROKEAHA.109.555540; Francisco G, 1998, ARCH PHYS MED REHAB, V79, P570, DOI 10.1016/S0003-9993(98)90074-0; French B, 2008, HEALTH TECHNOL ASSES, V12, P1; French B, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006073.pub2; French B, 2008, Health Technol Assess, V12, pix; French B, 2008, HEALTH TECHNOL ASSES, V12, pix; Gabler NB, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-43; Gabr U, 2005, CLIN REHABIL, V19, P737, DOI 10.1191/0269215505cr909oa; Galvin R, 2011, STROKE, V42, P681, DOI 10.1161/STROKEAHA.110.594689; Gauthier LV, 2008, STROKE, V39, P1520, DOI 10.1161/STROKEAHA.107.502229; Geiger RA, 2001, PHYS THER, V81, P995, DOI 10.1093/ptj/81.4.995; Gelber DA, 1995, J NEUROL REHABIL, V9, P191; Geyh S, 2004, J REHABIL MED, V36, P135, DOI 10.1080/16501960410016776; Gilbertson L, 2000, BRIT MED J, V320, P603, DOI 10.1136/bmj.320.7235.603; GLASSER L, 1986, PHYS THER, V66, P673, DOI 10.1093/ptj/66.5.673; Gok H, 2008, CLIN REHABIL, V22, P922, DOI 10.1177/0269215508090673; Goljar N, 2010, INT J REHABIL RES, V33, P205, DOI 10.1097/MRR.0b013e328333de61; Gordon NF, 2004, STROKE, V35, P1230, DOI 10.1161/01.STR.0000127303.19261.19; Grant T, 1997, CAN J REHABIL, V11, P69; Green J, 2002, LANCET, V359, P199, DOI 10.1016/S0140-6736(02)07443-3; GREENBERG S, 1980, AM J OCCUP THER, V34, P738, DOI 10.5014/ajot.34.11.738; Griffin A, 2006, CLIN REHABIL, V20, P287, DOI 10.1191/0269215505cr941oa; Grimshaw J, 1995, J Eval Clin Pract, V1, P37, DOI 10.1111/j.1365-2753.1995.tb00006.x; Grimshaw J, 1995, Qual Health Care, V4, P55, DOI 10.1136/qshc.4.1.55; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Gustafsson L, 2006, CLIN REHABIL, V20, P277, DOI 10.1191/0269215506cr944oa; Hammer A, 2009, CLIN REHABIL, V23, P424, DOI 10.1177/0269215508101734; Hanger HC, 2000, CLIN REHABIL, V14, P370, DOI 10.1191/0269215500cr339oa; Hara Y, 2008, DISABIL REHABIL, V30, P296, DOI 10.1080/09638280701265539; Hara Y, 2006, AM J PHYS MED REHAB, V85, P977, DOI 10.1097/01.phm.0000247853.61055.f8; Harrington R, 2010, CLIN REHABIL, V24, P3, DOI 10.1177/0269215509347437; Harris JE, 2009, STROKE, V40, P2123, DOI 10.1161/STROKEAHA.108.544585; HATANO S, 1976, B WORLD HEALTH ORGAN, V54, P541; Hayner K, 2010, AM J OCCUP THER, V64, P528, DOI 10.5014/ajot.2010.08027; HEBB D. O., 1949; Heckmann J, 1997, EUR J PHYS MED REHAB, V7, P138; Hedges LV, 2004, PSYCHOL METHODS, V9, P426, DOI 10.1037/1082-989X.9.4.426; Hedges LV, 2001, PSYCHOL METHODS, V6, P203, DOI 10.1037/1082-989X.6.3.203; Heidari M, 2011, QOM U MED SCI J, V4, P48; Heldmann B, 2000, NEUROREPORT, V11, P3193, DOI 10.1097/00001756-200009280-00029; Heller F., 2005, Annales de Readaptation et de Medecine Physique, V48, P187, DOI 10.1016/j.annrmp.2005.02.002; Hemmen B, 2007, CLIN REHABIL, V21, P587, DOI 10.1177/0269215507075502; Henderson A, 2007, TOP STROKE REHABIL, V14, P52, DOI 10.1310/tsr1402-52; Hesse S, 2008, AM J PHYS MED REHAB, V87, P779, DOI 10.1097/PHM.0b013e318186b4bc; Hesse S, 2005, STROKE, V36, P1960, DOI 10.1161/01.STR.0000177865.37334.ce; Hesse S, 2011, CLIN REHABIL, V25, P146, DOI 10.1177/0269215510382148; Hidler J, 2009, NEUROREHAB NEURAL RE, V23, P5, DOI 10.1177/1545968308326632; Hirst A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035621; Holmgren E, 2010, EUR J PHYSIOTHER, V12, P115, DOI 10.3109/14038196.2010.491555; Hornby TG, 2008, STROKE, V39, P1786, DOI 10.1161/STROKEAHA.107.504779; Housman SJ, 2009, NEUROREHAB NEURAL RE, V23, P505, DOI 10.1177/1545968308331148; Howe TE, 2005, CLIN REHABIL, V19, P45, DOI 10.1191/0269215505cr786oa; Hsieh YW, 2011, NEUROREHAB NEURAL RE, V25, P503, DOI 10.1177/1545968310394871; Hsu SS, 2010, STROKE, V41, P821, DOI 10.1161/STROKEAHA.109.574160; Hsu WY, 2012, STROKE, V43, P1849, DOI 10.1161/STROKEAHA.111.649756; Hu XL, 2009, NEUROREHAB NEURAL RE, V23, P837, DOI 10.1177/1545968309338191; Hui-Chan Christina W Y, 2009, Hong Kong Med J, V15, P42; Huijgen BCH, 2008, J TELEMED TELECARE, V14, P249, DOI 10.1258/jtt.2008.080104; Hunter SM, 2011, NEUROREHAB NEURAL RE, V25, P314, DOI 10.1177/1545968310390223; HURD WW, 1980, AM J PHYS MED REHAB, V59, P73; Husemann B, 2007, STROKE, V38, P349, DOI 10.1161/01.STR.0000254607.48765.cb; Ietswaart M, 2011, BRAIN, V134, P1373, DOI 10.1093/brain/awr077; Inaba M, 1973, Phys Ther, V53, P28; INGLIS J, 1984, ARCH PHYS MED REHAB, V65, P755; Intercollegiate Stroke Working Party, 2012, NAT CLIN GUID STROK; INTISO D, 1994, STROKE, V25, P1189, DOI 10.1161/01.STR.25.6.1189; Ivey FM, 2007, STROKE, V38, P2752, DOI 10.1161/STROKEAHA.107.490391; Ivey FM, 2011, STROKE, V42, P1994, DOI 10.1161/STROKEAHA.110.607879; Ivey FM, 2010, STROKE, V41, P2913, DOI 10.1161/STROKEAHA.110.599977; Jaffe DL, 2004, J REHABIL RES DEV, V41, P283, DOI 10.1682/JRRD.2004.03.0283; Janssen TW, 2008, ARCH PHYS MED REHAB, V89, P463, DOI 10.1016/j.apmr.2007.09.028; Janssen WGM, 2002, PHYS THER, V82, P866, DOI 10.1093/ptj/82.9.866; Jeong SH, 2007, APPL NURS RES, V20, P125, DOI 10.1016/j.apnr.2007.04.005; Johannsen L, 2010, NEUROREHAB NEURAL RE, V24, P243, DOI 10.1177/1545968309347679; Johansson T, 2011, J TELEMED TELECARE, V17, P1, DOI 10.1258/jtt.2010.100105; JOHN J, 1986, INT J REHABIL RES, V9, P35, DOI 10.1097/00004356-198603000-00004; Johnstone M., 1989, PHYSIOTHERAPY, V75, P381; JONGBLOED L, 1991, AM J OCCUP THER, V45, P420, DOI 10.5014/ajot.45.5.420; Jonsdottir J, 2010, NEUROREHAB NEURAL RE, V24, P478, DOI 10.1177/1545968309355986; Jung SH, 2005, ARCH PHYS MED REHAB, V86, P2218, DOI 10.1016/j.apmr.2005.04.015; Kahn LE, 2006, J NEUROENG REHABIL, V3, DOI 10.1186/1743-0003-3-12; Kalra L, 2004, BMJ-BRIT MED J, V328, P1099, DOI 10.1136/bmj.328.7448.1099; Kamps A., 2005, NEUROL REHABIL, V11, P1; Karthikbabu S, 2011, CLIN REHABIL, V25, P709, DOI 10.1177/0269215510397393; Katz-Leurer M, 2006, CLIN REHABIL, V20, P398, DOI 10.1191/0269215505cr960oa; Katz-Leurer M, 2003, CLIN REHABIL, V17, P735, DOI 10.1191/0269215503cr671oa; Katz-Leurer M, 2007, NEUROREHABILITATION, V22, P267; Keith RA, 1996, J ROY SOC MED, V89, P631, DOI 10.1177/014107689608901109; Kennisnetwerk CVA Nederland, 2012, ZORGST CVA TIA; Kent DM, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-85; Kerdoncuff V., 2004, Annales de Readaptation et de Medecine Physique, V47, P169, DOI 10.1016/j.annrmp.2003.11.005; Kim C M, 2001, J Stroke Cerebrovasc Dis, V10, P265, DOI 10.1053/jscd.2001.123775; Kim DG, 2008, NEUROREHABILITATION, V23, P239; Kim JH, 2009, AM J PHYS MED REHAB, V88, P693, DOI 10.1097/PHM.0b013e3181b33350; Kimberley TJ, 2004, EXP BRAIN RES, V154, P450, DOI 10.1007/s00221-003-1695-y; King TI, 1996, AM J OCCUP THER, V50, P62, DOI 10.5014/ajot.50.1.62; Kirkham JJ, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c365; Kjellstrom T, 2007, CEREBROVASC DIS, V23, P231; Klaiput A, 2009, NEUROREHAB NEURAL RE, V23, P351, DOI 10.1177/1545968308324227; Kluding PM, 2008, ARCH PHYS MED REHAB, V89, P449, DOI 10.1016/j.apmr.2007.12.005; Kojovic J, 2009, J NEUROSCI METH, V181, P100, DOI 10.1016/j.jneumeth.2009.04.005; Kollen BJ, 2009, STROKE, V40, pE89, DOI 10.1161/STROKEAHA.108.533828; Kosak MC, 2000, NEUROREHAB NEURAL RE, V14, P13, DOI 10.1177/154596830001400102; Kowalczewski J, 2007, ARCH PHYS MED REHAB, V88, P833, DOI 10.1016/j.apmr.2007.03.036; Koyuncu E, 2010, DISABIL REHABIL, V32, P560, DOI 10.3109/09638280903183811; Kutner NG, 2010, PHYS THER, V90, P493, DOI 10.2522/ptj.20090160; Kuys SS, 2011, CLIN REHABIL, V25, P316, DOI 10.1177/0269215510382928; Kwakkel G, 2013, INT J STROKE, V8, P25, DOI 10.1111/j.1747-4949.2012.00967.x; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; Kwakkel G, 1999, LANCET, V354, P191, DOI 10.1016/S0140-6736(98)09477-X; Lai SM, 2006, J AM GERIATR SOC, V54, P240, DOI 10.1111/j.1532-5415.2006.00573.x; Lam YS, 2006, NEUROREHABILITATION, V21, P245; Langhammer B, 2003, CLIN REHABIL, V17, P731, DOI 10.1191/0269215503cr670oa; Langhammer B, 2000, CLIN REHABIL, V14, P361, DOI 10.1191/0269215500cr338oa; Langhammer B, 2007, CLIN REHABIL, V21, P495, DOI 10.1177/0269215507075207; Langhammer B, 2010, CLIN REHABIL, V24, P46, DOI 10.1177/0269215509343328; Langhorne P, 2003, J NEUROL NEUROSUR PS, V74, P18; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Langhorne P, 2010, CEREBROVASC DIS, V29, P352, DOI 10.1159/000278931; Lannin NA, 2007, STROKE, V38, P111, DOI 10.1161/01.STR.0000251722.77088.12; Lau KWK, 2011, J REHABIL MED, V43, P709, DOI 10.2340/16501977-0838; Laufer Y, 2001, J REHABIL RES DEV, V38, P69; LEANDRI M, 1990, SCAND J REHABIL MED, V22, P69; Lee MJ, 2008, J AM GERIATR SOC, V56, P976, DOI 10.1111/j.1532-5415.2008.01707.x; Lee MJ, 2010, MED SCI SPORT EXER, V42, P23, DOI 10.1249/MSS.0b013e3181b07a31; LEE TD, 1991, PHYS THER, V71, P150, DOI 10.1093/ptj/71.2.150; Lennon O, 2008, CLIN REHABIL, V22, P125, DOI 10.1177/0269215507081580; Letombe A., 2010, Annals of Physical and Rehabilitation Medicine, V53, P632, DOI 10.1016/j.rehab.2010.09.004; Levin MF, 2009, NEUROREHAB NEURAL RE, V23, P313, DOI 10.1177/1545968308328727; Lewek MD, 2009, PHYS THER, V89, P829, DOI 10.2522/ptj.20080180; Lin Jau-Hong, 2004, Kaohsiung Journal of Medical Sciences, V20, P18; Lin KC, 2007, CLIN REHABIL, V21, P1075, DOI 10.1177/0269215507079843; Lin KC, 2010, AM J PHYS MED REHAB, V89, P177, DOI 10.1097/PHM.0b013e3181cf1c78; Lin KC, 2010, NEUROREHAB NEURAL RE, V24, P42, DOI 10.1177/1545968309345268; Lin KC, 2009, NEUROREHAB NEURAL RE, V23, P441, DOI 10.1177/1545968308328719; Lin KC, 2009, NEUROREHAB NEURAL RE, V23, P160, DOI 10.1177/1545968308320642; Lin ZL, 2011, J REHABIL MED, V43, P506, DOI 10.2340/16501977-0807; Lincoln NB, 1999, STROKE, V30, P573, DOI 10.1161/01.STR.30.3.573; Linn SL, 1999, STROKE, V30, P963, DOI 10.1161/01.STR.30.5.963; Lippert-Gruner M, 1999, NEUROLOGICAL REHABIL, V5, P275; Liston R, 2000, AGE AGEING, V29, P311, DOI 10.1093/ageing/29.4.311; Liu Karen P Y, 2009, Hong Kong Med J, V15, P37; Liu KP, 2004, ARCH PHYS MED REHAB, V85, P1403, DOI 10.1016/j.apmr.2003.12.035; Lo AC, 2010, NEW ENGL J MED, V362, P1772, DOI 10.1056/NEJMoa0911341; Logan PA, 1997, CLIN REHABIL, V11, P107, DOI 10.1177/026921559701100203; Lord S, 2008, CLIN REHABIL, V22, P215, DOI 10.1177/0269215507081922; Luft AR, 2008, STROKE, V39, P3341, DOI 10.1161/STROKEAHA.108.527531; Luft AR, 2004, JAMA-J AM MED ASSOC, V292, P1853, DOI 10.1001/jama.292.15.1853; Lum PS, 2006, J REHABIL RES DEV, V43, P631, DOI 10.1682/JRRD.2005.02.0044; Lynch D, 2005, CLIN REHABIL, V19, P594, DOI 10.1191/0269215505cr901oa; Lynch EA, 2007, ARCH PHYS MED REHAB, V88, P1101, DOI 10.1016/j.apmr.2007.06.010; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Macdonell R A, 1994, J Stroke Cerebrovasc Dis, V4, P155, DOI 10.1016/S1052-3057(10)80178-8; MacKinnon JR, 1991, CANADIAN J OCCUPATIO, V58, P17, DOI DOI 10.1161/01.STR.0000251722.77088.12; Macko RF, 2005, STROKE, V36, P2206, DOI 10.1161/01.STR.0000181076.91805.89; Malouin F, 2009, J NEUROL PHYS THER, V33, P195, DOI 10.1097/NPT.0b013e3181c2112b; MANDEL AR, 1990, ARCH PHYS MED REHAB, V71, P649; Mangold S, 2009, NEUROREHAB NEURAL RE, V23, P184, DOI 10.1177/1545968308324548; Mann GE, 2005, NEUROMODULATION, V8, P193, DOI 10.1111/j.1525-1403.2005.05238.x; Marigold DS, 2005, J AM GERIATR SOC, V53, P416, DOI 10.1111/j.1532-5415.2005.53158.x; Masiero S, 2007, ARCH PHYS MED REHAB, V88, P142, DOI 10.1016/j.apmr.2006.10.032; Masiero S, 2011, J REHABIL RES DEV, V48, P355, DOI 10.1682/JRRD.2010.04.0063; Mayr A, 2008, HANDCHIR MIKROCHIR P, V40, P66, DOI 10.1055/s-2007-989425; Mayr A, 2007, NEUROREHAB NEURAL RE, V21, P307, DOI 10.1177/1545968307300697; McClellan R, 2004, AUST J PHYSIOTHER, V50, P163, DOI 10.1016/S0004-9514(14)60154-9; McDonnell MN, 2007, NEUROREHAB NEURAL RE, V21, P435, DOI 10.1177/1545968307300437; Mead GE, 2007, J AM GERIATR SOC, V55, P892, DOI 10.1111/j.1532-5415.2007.01185.x; *MED RES COUNC, 2000, FRAM DEV EV RCTS COM; Mehrholz J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006185.pub2; Mehrholz J, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006676.pub2; Mehrholz J, 2008, DISABIL REHABIL, V30, P830, DOI 10.1080/09638280701419326; Mehrholz J, 2012, J REHABIL MED, V44, P193, DOI 10.2340/16501977-0943; Mehrholz J, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008186.pub2; Merkert J, 2011, Z GERONTOL GERIATR, V44, P256, DOI 10.1007/s00391-011-0170-9; MERLETTI R, 1978, SCAND J REHABIL MED, V10, P147; Mesci N, 2009, DISABIL REHABIL, V31, P2047, DOI 10.3109/09638280902893626; Michaelsen SM, 2006, STROKE, V37, P186, DOI 10.1161/01.STR.0000196940.20446.c9; Michaelsen SM, 2004, STROKE, V35, P1914, DOI 10.1161/01.STR.0000132569.33572.75; Michielsen ME, 2011, NEUROREHAB NEURAL RE, V25, P223, DOI 10.1177/1545968310385127; Miller EL, 2010, STROKE, V41, P2402, DOI 10.1161/STR.0b013e3181e7512b; Mirelman A, 2010, GAIT POSTURE, V31, P433, DOI 10.1016/j.gaitpost.2010.01.016; Mirelman A, 2009, STROKE, V40, P169, DOI 10.1161/STROKEAHA.108.516328; Moore JL, 2010, STROKE, V41, P129, DOI 10.1161/STROKEAHA.109.563247; Moreland JD, 2003, ARCH PHYS MED REHAB, V84, P1433, DOI 10.1016/S0003-9993(03)00360-5; Moreland JD, 1998, ARCH PHYS MED REHAB, V79, P134, DOI 10.1016/S0003-9993(98)90289-1; Morioka S, 2003, CLIN REHABIL, V17, P600, DOI 10.1191/0269215503cr654oa; Morone G, 2011, NEUROREHAB NEURAL RE, V25, P636, DOI 10.1177/1545968311401034; Morris JH, 2008, ARCH PHYS MED REHAB, V89, P1237, DOI 10.1016/j.apmr.2007.11.039; Moseley AM, 2002, AUST J PHYSIOTHER, V48, P43, DOI 10.1016/S0004-9514(14)60281-6; Mudge S, 2009, ARCH PHYS MED REHAB, V90, P1989, DOI 10.1016/j.apmr.2009.07.015; Mudie MH, 2001, NEUROREHAB NEURAL RE, V15, P129, DOI 10.1177/154596830101500206; Mudie MH, 2002, CLIN REHABIL, V16, P582, DOI 10.1191/0269215502cr527oa; Mudie MH, 2000, DISABIL REHABIL, V22, P23, DOI 10.1080/096382800297097; Mueller K, 2007, RESTOR NEUROL NEUROS, V25, P501; Muir KW, 2002, STROKE, V33, P1545, DOI 10.1161/01.STR.0000018684.86293.AB; MULDER T, 1986, AM J PHYS MED REHAB, V65, P173; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Myint JMWW, 2008, CLIN REHABIL, V22, P112, DOI 10.1177/0269215507080141; Myint M W W, 2008, Hong Kong Med J, V14, P40; Newsam CJ, 2004, ARCH PHYS MED REHAB, V85, P2040, DOI 10.1016/j.apmr.2004.02.029; Ng MFW, 2008, STROKE, V39, P154, DOI 10.1161/STROKEAHA.107.495705; Ng SSM, 2007, STROKE, V38, P2953, DOI 10.1161/STROKEAHA.107.490318; Ng SSM, 2009, CLIN REHABIL, V23, P1093, DOI 10.1177/0269215509342327; Nilsson L, 2001, CLIN REHABIL, V15, P515, DOI 10.1191/026921501680425234; Noh DK, 2008, CLIN REHABIL, V22, P966, DOI 10.1177/0269215508091434; Norrving Bo, 2007, Int J Stroke, V2, P139, DOI 10.1111/j.1747-4949.2007.00109.x; Nour K., 2002, Therapeutic Recreation Journal, V36, P48; O'Connor RJ, 2004, NEUROLOGY, V62, P1842, DOI 10.1212/01.WNL.0000116136.22922.D6; Olawale OA, 2011, CLIN REHABIL, V25, P442, DOI 10.1177/0269215510389199; Olney SJ, 2006, STROKE, V37, P476, DOI 10.1161/01.STR.0000199061.85897.b7; Otterman NM, 2012, STROKE, V43, P2395, DOI 10.1161/STROKEAHA.112.660092; Ouellette MM, 2004, STROKE, V35, P1404, DOI 10.1161/01.STR.0000127785.73065.34; Outermans JC, 2010, CLIN REHABIL, V24, P979, DOI 10.1177/0269215509360647; Page SJ, 2005, ARCH PHYS MED REHAB, V86, P399, DOI 10.1016/j.apmr.2004.10.002; Page SJ, 2002, NEUROREHAB NEURAL RE, V16, P290, DOI 10.1177/154596802401105225; Page SJ, 2001, J REHABIL RES DEV, V38, P583; Page SJ, 2005, NEUROREHAB NEURAL RE, V19, P27, DOI 10.1177/1545968304272701; Page SJ, 2000, OCCUP THER J RES, V20, P200, DOI 10.1177/153944920002000304; Page SJ, 2001, PHYS THER, V81, P1455, DOI 10.1093/ptj/81.8.1455; Page SJ, 2004, ARCH PHYS MED REHAB, V85, P14, DOI 10.1016/S0003-9993(03)00481-7; Page SJ, 2008, CLIN REHABIL, V22, P610, DOI 10.1177/0269215508088987; Page SJ, 2008, PHYS THER, V88, P333, DOI 10.2522/ptj.20060029; Page SJ, 2007, STROKE, V38, P1293, DOI 10.1161/01.STR.0000260205.67348.2b; Page SJ, 2011, CLIN REHABIL, V25, P627, DOI 10.1177/0269215510395793; Page SJ, 2009, NEUROREHAB NEURAL RE, V23, P382, DOI 10.1177/1545968308326427; Pang MY, 2006, ARCH PHYS MED REHAB, V87, P1, DOI 10.1016/j.apmr.2005.08.113; Pang MYC, 2005, J AM GERIATR SOC, V53, P1667, DOI 10.1111/j.1532-5415.2005.53521.x; Paoloni M, 2010, NEUROREHAB NEURAL RE, V24, P254, DOI 10.1177/1545968309349940; Park HJ, 2011, CLIN REHABIL, V25, P451, DOI 10.1177/0269215510389200; Parker CJ, 2001, CLIN REHABIL, V15, P42, DOI 10.1191/026921501666968247; Partridge C, 2000, Physiother Res Int, V5, P230, DOI 10.1002/pri.203; Patil P, 2011, EUR J PHYS REHAB MED, V47, P427; Peurala SH, 2005, ARCH PHYS MED REHAB, V86, P1557, DOI 10.1016/j.apmr.2005.02.005; Peurala SH, 2009, J REHABIL MED, V41, P166, DOI 10.2340/16501977-0304; Piron L, 2003, ST HEAL T, V94, P265; Piron L, 2008, J TELEMED TELECARE, V14, P257, DOI 10.1258/jtt.2008.080304; Piron L, 2007, 2007 VIRTUAL REHABILITATION, P119; Piron L, 2010, NEUROREHAB NEURAL RE, V24, P501, DOI 10.1177/1545968310362672; Piron L, 2009, J REHABIL MED, V41, P1016, DOI 10.2340/16501977-0459; Platz T, 2005, CLIN REHABIL, V19, P714, DOI 10.1191/0269215505cr904oa; Platz T, 2001, NEUROPSYCHOLOGIA, V39, P687, DOI 10.1016/S0028-3932(01)00005-7; Platz T, 2009, NEUROREHAB NEURAL RE, V23, P706, DOI 10.1177/1545968309335974; Ploughman M, 2004, ARCH PHYS MED REHAB, V85, P1417, DOI 10.1016/j.apmr.2004.01.018; Pohl M, 2007, CLIN REHABIL, V21, P17, DOI 10.1177/0269215506071281; Pohl M, 2002, STROKE, V33, P553, DOI 10.1161/hs0202.102365; Pollock A, 2012, LANCET NEUROL, V11, P209, DOI 10.1016/S1474-4422(12)70029-7; Pollock AS, 2000, CLIN REHABIL, V14, P402, DOI 10.1191/0269215500cr342oa; Pollock AS, 2002, CLIN REHABIL, V16, P473, DOI 10.1191/0269215502cr520oa; Pomeroy VM, 2006, STROKE, V37, P2441, DOI 10.1161/01.STR.0000236634.26819.cc; Pomeroy VM, 2001, CLIN REHABIL, V15, P390, DOI 10.1191/026921501678310199; POOLE JL, 1990, OCCUP THER J RES, V10, P360, DOI 10.1177/153944929001000605; Popovic MB, 2003, J REHABIL RES DEV, V40, P443, DOI 10.1682/JRRD.2003.09.0443; Popovic MR, 2005, NEUROMODULATION, V8, P58, DOI 10.1111/j.1094-7159.2005.05221.x; POTEMPA K, 1995, STROKE, V26, P101, DOI 10.1161/01.STR.26.1.101; Powell J, 1999, STROKE, V30, P1384, DOI 10.1161/01.STR.30.7.1384; Quaney BM, 2009, NEUROREHAB NEURAL RE, V23, P879, DOI 10.1177/1545968309338193; Rabadi MH, 2008, CLIN REHABIL, V22, P1071, DOI 10.1177/0269215508095358; Riccio I, 2010, EUR J PHYS REHAB MED, V46, P19; Richards CL, 2004, NEUROREHAB NEURAL RE, V18, P199, DOI 10.1177/1545968304269397; RICHARDS CL, 1993, ARCH PHYS MED REHAB, V74, P612, DOI 10.1016/0003-9993(93)90159-8; Riley RD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c221; Rimmer JH, 2000, MED SCI SPORT EXER, V32, P1990, DOI 10.1097/00005768-200012000-00004; Ring H, 2005, J REHABIL MED, V37, P32, DOI 10.1080/16501970410035387; Ro T, 2006, NEUROCASE, V12, P50, DOI 10.1080/13554790500493415; ROBICHAUD JA, 1992, PHYS THER, V72, P176, DOI 10.1093/ptj/72.3.176; Robinson W, 2008, AUST J PHYSIOTHER, V54, P33, DOI 10.1016/S0004-9514(08)70063-1; Rodgers H, 2003, CLIN REHABIL, V17, P579, DOI 10.1191/0269215503cr652oa; Roger Veronique L, 2011, Circulation, V123, pe18, DOI 10.1161/CIR.0b013e3182009701; Roper TA, 1999, AGE AGEING, V28, P9, DOI 10.1093/ageing/28.1.9; Rose V, 1980, AUST OCCUP THER J, V34, P59; Rothgangel AS, 2004, NEDERLANDS TIJD SCHR, V114, P36; Royal College of Physicians Clinical Effectiveness and Evaluation Unit on behalf of the Intercollegiate Stroke Working Party, 2013, SENT STROK NAT AUD P; Rydwik E, 2006, CLIN REHABIL, V20, P645, DOI 10.1191/0269215506cre986oa; Sackley CM, 1997, DISABIL REHABIL, V19, P536, DOI 10.3109/09638289709166047; Salbach NM, 2005, J AM GERIATR SOC, V53, P576, DOI 10.1111/j.1532-5415.2005.53203.x; Salbach NM, 2004, CLIN REHABIL, V18, P509, DOI 10.1191/0269215504cr763oa; Sangvatanakul P, 2010, J VASC NURS, V28, P121, DOI 10.1016/j.jvn.2010.09.001; Saposnik G, 2011, STROKE, V42, P1380, DOI 10.1161/STROKEAHA.110.605451; Saposnik G, 2010, STROKE, V41, P1477, DOI 10.1161/STROKEAHA.110.584979; Sawaki L, 2008, NEUROREHAB NEURAL RE, V22, P505, DOI 10.1177/1545968308317531; Schauer M, 2003, CLIN REHABIL, V17, P713, DOI 10.1191/0269215503cr668oa; Schulz KF, 2011, INT J SURG, V9, P672, DOI 10.1016/j.ijsu.2011.09.004; Schwartz I, 2009, PM&R, V1, P516, DOI 10.1016/j.pmrj.2009.03.009; Mano TS, 2011, MED CLIN-BARCELONA, V137, P297, DOI 10.1016/j.medcli.2010.10.024; Sheehan JL, 2006, CLIN REHABIL, V20, P1032, DOI 10.1177/0269215506071267; Sherrington C, 2000, MANUAL THER, V5, P223, DOI 10.1054/math.2000.0372; Shin HK, 2008, NEUROSCI LETT, V442, P174, DOI 10.1016/j.neulet.2008.07.026; Shindo K, 2011, NEUROREHAB NEURAL RE, V25, P830, DOI 10.1177/1545968311408917; SHUMWAYCOOK A, 1988, ARCH PHYS MED REHAB, V69, P395; Sims J, 2009, INT J GERIATR PSYCH, V24, P76, DOI 10.1002/gps.2082; Singh S, 2008, PHYSIOTHER OCCUP THE, V1, P73; SIVENIUS J, 1985, STROKE, V16, P928, DOI 10.1161/01.STR.16.6.928; Slade A, 2002, J REHABIL MED, V34, P260, DOI 10.1080/165019702760390347; Smania N, 2000, ARCH PHYS MED REHAB, V81, P379, DOI 10.1053/mr.2000.6921; Smania N, 2006, NEUROLOGY, V67, P2050, DOI 10.1212/01.wnl.0000247279.63483.1f; SMITH DS, 1981, BMJ-BRIT MED J, V282, P517, DOI 10.1136/bmj.282.6263.517; Smith K N, 1979, Aust J Physiother, V25, P155, DOI 10.1016/S0004-9514(14)61038-2; Smith LN, 2008, NURS EDUC TODAY, V28, P337, DOI 10.1016/j.nedt.2007.06.008; Sonde L, 1998, SCAND J REHABIL MED, V30, P95; Sonde L, 2000, CLIN REHABIL, V14, P14, DOI 10.1191/026921500673534278; States RA, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006075.pub2; Stein J, 2004, AM J PHYS MED REHAB, V83, P720, DOI 10.1097/01.PHM.0000137313.14480.CE; Stein J, 2010, AM J PHYS MED REHAB, V89, P697, DOI 10.1097/PHM.0b013e3181ec9aa8; Stern P H, 1970, Arch Phys Med Rehabil, V51, P526; Stinear CM, 2008, BRAIN, V131, P1381, DOI 10.1093/brain/awn051; Stoykov ME, 2009, NEUROREHAB NEURAL RE, V23, P945, DOI 10.1177/1545968309338190; Stroke Unit Trialists' Collaboration, 2007, COCHRANE DATABASE SY; Studenski S, 2005, STROKE, V36, P1764, DOI 10.1161/01.STR.0000174192.87887.70; Suat E, 2011, TOP STROKE REHABIL, V18, P231, DOI 10.1310/tsr1803-231; Sullivan KJ, 2007, PHYS THER, V87, P1580, DOI 10.2522/ptj.20060310; Sullivan KJ, 2002, ARCH PHYS MED REHAB, V83, P683, DOI 10.1053/apmr.2002.32488; Summers JJ, 2007, J NEUROL SCI, V252, P76, DOI 10.1016/j.jns.2006.10.011; Sun SF, 2010, NEUROREHAB NEURAL RE, V24, P34, DOI 10.1177/1545968309341060; SUNDERLAND A, 1992, J NEUROL NEUROSUR PS, V55, P530, DOI 10.1136/jnnp.55.7.530; Sungkarat S, 2011, CLIN REHABIL, V25, P360, DOI 10.1177/0269215510386125; Suputtitada Areerat, 2004, Journal of the Medical Association of Thailand, V87, P1482; Suputtitada Areerat, 2004, Journal of the Medical Association of Thailand, V87, pS107; Sutbeyaz S, 2007, ARCH PHYS MED REHAB, V88, P555, DOI 10.1016/j.apmr.2007.02.034; Sutbeyaz ST, 2010, CLIN REHABIL, V24, P240, DOI 10.1177/0269215509358932; Takahashi CD, 2008, BRAIN, V131, P425, DOI 10.1093/brain/awm311; Takami A, 2010, J PHYS THER SCI, V22, P177, DOI 10.1589/jpts.22.177; Tang QP, 2005, PHYS THER, V85, P1020, DOI 10.1093/ptj/85.10.1020; Tarkka IM, 2011, TOHOKU J EXP MED, V225, P71, DOI 10.1620/tjem.225.71; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; Teixeira-Salmela LF, 1999, ARCH PHYS MED REHAB, V80, P1211, DOI 10.1016/S0003-9993(99)90018-7; Tekeoolu Y, 1998, CLIN REHABIL, V12, P277, DOI 10.1191/026921598672873816; Thaut AH, 2007, NEUROREHAB NEURAL RE, V21, P455, DOI 10.1177/1545968307300523; Tufel S, 2010, IND J PHYSIOTHER OCC, V4, P40; Wellwood I, 2004, CLIN REHABIL, V18, P529, DOI 10.1191/0269215504cr768oa; World Confederation for Physical Therapy, 2013, WORLD CONF PHYS THER; World Health Organization, 2001, ICF INT CLASFUNCT; Thaut MH, 1997, J NEUROL SCI, V151, P207, DOI 10.1016/S0022-510X(97)00146-9; Thielman G, 2008, NEUROREHAB NEURAL RE, V22, P697, DOI 10.1177/1545968308315998; Thielman G, 2010, J NEUROL PHYS THER, V34, P138, DOI 10.1097/NPT.0b013e3181efa1e8; Thielman GT, 2004, ARCH PHYS MED REHAB, V85, P1613, DOI 10.1016/j.apmr.2004.01.028; Thrasher TA, 2008, NEUROREHAB NEURAL RE, V22, P706, DOI 10.1177/1545968308317436; Tihanyi J, 2010, ACTA PHYSIOL HUNG, V97, P172, DOI 10.1556/APhysiol.97.2010.2.3; Tihanyi TK, 2007, CLIN REHABIL, V21, P782, DOI 10.1177/0269215507077814; Toledano-Zarhi A, 2011, NEUROREHABILITATION, V28, P85, DOI 10.3233/NRE-2011-0636; Tong RK, 2006, ARCH PHYS MED REHAB, V87, P1298, DOI 10.1016/j.apmr.2006.06.016; Torriani C, 2008, REV NEUROCIENC, V16, P25; Tung FL, 2010, CLIN REHABIL, V24, P533, DOI 10.1177/0269215509360751; Turner L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000030.pub2; Turton AJ, 2005, CLIN REHABIL, V19, P600, DOI 10.1191/0269215505cr891oa; van Delden AEQ, 2013, DISABIL REHABIL, V35, P1961, DOI 10.3109/09638288.2013.768303; van der Lee JH, 1999, STROKE, V30, P2369, DOI 10.1161/01.STR.30.11.2369; van Nes IJW, 2006, STROKE, V37, P2331, DOI 10.1161/01.STR.0000236494.62957.f3; Van Peppen RPS, 2004, CLIN REHABIL, V18, P833, DOI 10.1191/0269215504cr843oa; van Tulder MW, 1999, SPINE, V24, P1113, DOI 10.1097/00007632-199906010-00011; van Vliet PM, 2005, J NEUROL NEUROSUR PS, V76, P503, DOI 10.1136/jnnp.2004.040436; Varoqui D, 2011, MOTOR CONTROL, V15, P187, DOI 10.1123/mcj.15.2.187; Veerbeek JM, 2011, STROKE, V42, P3311, DOI 10.1161/STROKEAHA.111.623819; Veerbeek JM, 2011, STROKE, V42, P1482, DOI 10.1161/STROKEAHA.110.604090; Verheyden G, 2009, NEUROREHAB NEURAL RE, V23, P281, DOI 10.1177/1545968308321776; Vickrey BG, 2013, STROKE, V44, P2338, DOI 10.1161/STROKEAHA.113.001196; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; Volpe BT, 2008, NEUROREHAB NEURAL RE, V22, P305, DOI 10.1177/1545968307311102; Volpe BT, 1999, NEUROLOGY, V53, P1874, DOI 10.1212/WNL.53.8.1874; Volpe BT, 2000, NEUROLOGY, V54, P1938, DOI 10.1212/WNL.54.10.1938; WADE DT, 1992, BRIT MED J, V304, P609, DOI 10.1136/bmj.304.6827.609; WADE DT, 1987, J NEUROL NEUROSUR PS, V50, P177, DOI 10.1136/jnnp.50.2.177; Walker C, 2000, PHYS THER, V80, P886, DOI 10.1093/ptj/80.9.886; Walker MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5; Wall J, 1987, NEUROREHAB NEURAL RE, V1, P115; Waller SM, 2008, HUM MOVEMENT SCI, V27, P749, DOI 10.1016/j.humov.2008.03.006; Wang Q, 2011, J REHABIL MED, V43, P619, DOI 10.2340/16501977-0819; Wang RY, 2000, AM J PHYS MED REHAB, V79, P385, DOI 10.1097/00002060-200007000-00011; Wang RY, 2005, CLIN REHABIL, V19, P155, DOI 10.1191/0269215505cr850oa; Wang RY, 2002, AM J PHYS MED REHAB, V81, P283, DOI 10.1097/00002060-200204000-00007; Wang T, 2007, BRAIN INJURY, V21, P1203, DOI 10.1080/02699050701633064; Wardlaw JM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000213.pub2; Weaver CS, 2004, STROKE, V35, P1216, DOI 10.1161/01.STR.0000125010.70652.93; Werner C, 2002, STROKE, V33, P2895, DOI 10.1161/01.STR.0000035734.61539.f6; Werner RA, 1996, AM J PHYS MED REHAB, V75, P114, DOI 10.1097/00002060-199603000-00006; Westlake KP, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-18; Wevers L, 2009, STROKE, V40, P2450, DOI 10.1161/STROKEAHA.108.541946; Whitall J, 2011, NEUROREHAB NEURAL RE, V25, P118, DOI 10.1177/1545968310380685; Williams JM, 1982, PHYSIOTHER CAN, V34, P327; Williams JA, 2010, PHYS THER, V90, P398, DOI 10.2522/ptj.20090075; WINCHESTER P, 1983, PHYS THER, V63, P1096, DOI 10.1093/ptj/63.7.1096; Winstein CJ, 2004, ARCH PHYS MED REHAB, V85, P620, DOI 10.1016/j.apmr.2003.06.027; Wittenberg GF, 2003, NEUROREHAB NEURAL RE, V17, P48, DOI 10.1177/0888439002250456; Wolf SL, 2010, STROKE, V41, P2309, DOI 10.1161/STROKEAHA.110.588723; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; Wolny T, 2010, CLIN REHABIL, V24, P810, DOI 10.1177/0269215510367561; Woodbury ML, 2009, NEUROREHAB NEURAL RE, V23, P78, DOI 10.1177/1545968308318836; Woodford H, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004585.pub2; Wright P, 2004, COMP ELECT STIMULATI; Wu CY, 2007, NEUROREHAB NEURAL RE, V21, P460, DOI 10.1177/1545968307303411; Wu CY, 2007, ARCH PHYS MED REHAB, V88, P964, DOI 10.1016/j.apmr.2007.05.012; Wu CY, 2007, ARCH PHYS MED REHAB, V88, P273, DOI 10.1016/j.apmr.2006.11.021; Wu CY, 2011, NEUROREHAB NEURAL RE, V25, P130, DOI 10.1177/1545968310380686; Wu Ching-Yi, 2010, Chang Gung Med J, V33, P628; Wu HC, 2010, STROKE, V41, P2378, DOI 10.1161/STROKEAHA.110.593673; Yagura H, 2006, ARCH PHYS MED REHAB, V87, P529, DOI 10.1016/j.apmr.2005.11.035; Yan TB, 2005, STROKE, V36, P80, DOI 10.1161/01.STR.0000149623.24906.63; Yan TB, 2009, J REHABIL MED, V41, P312, DOI 10.2340/16501977-0325; Yang YR, 2008, GAIT POSTURE, V28, P201, DOI 10.1016/j.gaitpost.2007.11.007; Yang YR, 2007, ARCH PHYS MED REHAB, V88, P1236, DOI 10.1016/j.apmr.2007.06.762; Yang YR, 2006, CLIN REHABIL, V20, P860, DOI 10.1177/0269215506070701; Yang YR, 2010, ARCH PHYS MED REHAB, V91, P513, DOI 10.1016/j.apmr.2009.11.021; Yang YR, 2005, CLIN REHABIL, V19, P264, DOI 10.1191/0269215505cr860oa; Yavuzer G, 2008, EUR J PHYS REHAB MED, V44, P237; Yavuzer G, 2006, ARCH PHYS MED REHAB, V87, P536, DOI 10.1016/j.apmr.2005.12.041; Yavuzer G, 2008, ARCH PHYS MED REHAB, V89, P393, DOI 10.1016/j.apmr.2007.08.162; Yavuzer G, 2007, ARCH PHYS MED REHAB, V88, P710, DOI 10.1016/j.apmr.2007.02.030; Yavuzer G, 2006, CLIN REHABIL, V20, P960, DOI 10.1177/0269215506070315; Yelnik AP, 2008, NEUROREHAB NEURAL RE, V22, P468, DOI 10.1177/1545968308315996; Yen CL, 2008, NEUROREHAB NEURAL RE, V22, P22, DOI 10.1177/1545968307301875; Yen Jyh-Geng, 2005, Acta Neurol Taiwan, V14, P16; You SH, 2005, STROKE, V36, P1166, DOI 10.1161/01.STR.0000162715.43417.91; Young J, 1991, CLIN REHABIL, V5, P283; YOUNG JB, 1992, BRIT MED J, V304, P1085, DOI 10.1136/bmj.304.6834.1085	582	594	619	13	224	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2014	9	2							e87987	10.1371/journal.pone.0087987	http://dx.doi.org/10.1371/journal.pone.0087987			33	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI6GY	24505342	Green Submitted, Green Published, gold			2023-01-03	WOS:000336971300027
J	Yu, CH; Yu, CC				Yu, Chuan-Hang; Yu, Cheng-Chia			Photodynamic Therapy with 5-Aminolevulinic acid (ALA) Impairs Tumor Initiating and Chemo-Resistance Property in Head and Neck Cancer-Derived Cancer Stem Cells	PLOS ONE			English	Article							ORAL VERRUCOUS HYPERPLASIA; METASTASIS; APOPTOSIS; NANOG	Background: Head and neck cancer (HNC) ranks the fourth leading malignancy and cancer death in male population in Taiwan. Despite recent therapeutic advances, the prognosis for HNC patients is still dismal. New strategies are urgently needed to improve the chemosensitization to conventional chemotherapeutic drugs and clinical responses of HNC patients. Studies have demonstrated that topical 5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) is being used in the treatment of various human premalignant and malignant lesions with some encouraging clinical outcomes. However, the molecular mechanisms of ALA-PDT in the therapeutic effect in HNC tumorigenesis and whether ALA-PDT as chemosensitizer for HNC treatment remain unclear. Accumulating data support cancer stem cells (CSCs) contributes chemoresistance in HNC. Based on the previous studies, the purpose of the study is to investigate the effect of ALA-PDT on CSCs and chemosensitization property in HNC. Methodology/Principal Finding: CSCs marker ALDH1 activity of HNC cells with ALA-PDT treatment as assessed by the Aldefluor assay flow cytometry analysis. Secondary Sphere-forming self-renewal, stemness markers expression, and invasiveness of HNC-CSCs with ALA-PDT treatment were presented. We observed that the treatment of ALA-PDT significantly down-regulated the ALDH1 activity and CD44 positivity of HNC-CSCs. Moreover, ALA-PDT reduced self-renewal property and stemness signatures expression (Oct4 and Nanog) in sphere-forming HNC-CSCs. ALA-PDT sensitized highly tumorigenic HNC-CSCs to conventional chemotherapies. Lastly, synergistic effect of ALA-PDT and Cisplatin treatment attenuated invasiveness/colongenicity property in HNC-CSCs. Conclusion/Significance: Our results provide insights into the clinical prospect of ALA-PDT as a potential chemo-adjuvant therapy against head and neck cancer through eliminating CSCs property.	[Yu, Chuan-Hang; Yu, Cheng-Chia] Chung Shan Med Univ, Sch Dent, Taichung, Taiwan; [Yu, Chuan-Hang; Yu, Cheng-Chia] Chung Shan Med Univ Hosp, Dept Dent, Taichung, Taiwan; [Yu, Cheng-Chia] Chung Shan Med Univ, Inst Oral Sci, Taichung, Taiwan	Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University	Yu, CH (corresponding author), Chung Shan Med Univ, Sch Dent, Taichung, Taiwan.	d94422004@ntu.edu.tw; ccyu@csmu.edu.tw			National Science Council [100-2632-B-040-001-MY3, 101-2314-B-040-016, 102-2628-B-040 -001 - MY3]	National Science Council(Ministry of Science and Technology, Taiwan)	This study is supported by research grant from National Science Council (100-2632-B-040-001-MY3, 101-2314-B-040-016, 102-2628-B-040 -001 - MY3).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chen HM, 2005, LASER SURG MED, V37, P114, DOI 10.1002/lsm.20214; Chen HM, 2004, ORAL ONCOL, V40, P630, DOI 10.1016/j.oraloncology.2003.12.010; Chen HM, 2011, J ORAL PATHOL MED, V40, P483, DOI 10.1111/j.1600-0714.2010.00973.x; Chen YW, 2010, MOL CANCER THER, V9, P2879, DOI 10.1158/1535-7163.MCT-10-0504; Chen YC, 2010, ORAL ONCOL, V46, P158, DOI 10.1016/j.oraloncology.2009.11.007; Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404; Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Green B, 2013, BRIT J ORAL MAX SURG, V51, P283, DOI 10.1016/j.bjoms.2012.11.011; Haddad RI, 2008, NEW ENGL J MED, V359, P1143, DOI 10.1056/NEJMra0707975; Hu FW, 2012, MOL NUTR FOOD RES, V56, P1247, DOI 10.1002/mnfr.201200150; Korkaya H, 2010, NAT CELL BIOL, V12, P419, DOI 10.1038/ncb0510-419; Lisnjak IO, 2005, EXP ONCOL, V27, P333; Lo JF, 2011, CANCER RES, V71, P1912, DOI 10.1158/0008-5472.CAN-10-2350; Lo WL, 2011, J PATHOL, V223, P482, DOI 10.1002/path.2826; Lou PJ, 2004, BRIT J CANCER, V91, P441, DOI 10.1038/sj.bjc.6601993; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wu MJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-283; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yang TH, 2007, ORAL ONCOL, V43, P358, DOI 10.1016/j.oraloncology.2006.04.007; Yu CC, 2013, CANCER RES, V73, P3425, DOI 10.1158/0008-5472.CAN-12-3840; Yu CC, 2011, J ONCOL, V2011, DOI 10.1155/2011/609259; Yu CC, 2011, ORAL ONCOL, V47, P202, DOI 10.1016/j.oraloncology.2010.12.001; Yu CH, 2008, ORAL ONCOL, V44, P595, DOI 10.1016/j.oraloncology.2007.08.016; Yu CH, 2013, J ORAL PATHOL MED, V42, P257, DOI 10.1111/jop.12007	30	31	33	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2014	9	1							e87129	10.1371/journal.pone.0087129	http://dx.doi.org/10.1371/journal.pone.0087129			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298QQ	24475244	Green Published, gold, Green Submitted			2023-01-03	WOS:000330339800087
J	Zhang, CS; Zhu, CT; Ling, Y; Zhou, XF; Dong, CL; Luo, JD; Liu, YP				Zhang, Changsong; Zhu, Changtai; Ling, Yang; Zhou, Xifa; Dong, Chunlei; Luo, Judong; Liu, Yongping			The Clinical Value of Huangqi Injection in the Treatment of Leucopenia: A Meta-Analysis of Clinical Controlled Trials	PLOS ONE			English	Article							CHEMOTHERAPY-INDUCED LEUKOPENIA; CELL LUNG-CANCER	Background: Huangqi injection is derived from Astragalus membranaceus root. In China, recent reports of Huangqi injection for the treatment of leucopenia have emerged. However, a systematic review of these reports has not been performed. Thus, we conducted a meta-analysis of clinical controlled trials to assess the clinical value of Huangqi injection in the treatment of leucopenia. Methods: We searched the Chinese Biomedical Literature Database (CBM), Wanfang Database, China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Full-text Database (VIP), as well as PubMed and EMBASE to collect the data about trials of Huangqi injection for treating leucopenia. A meta-analysis was performed using RevMan 5.2 software. Results: A total of 13 studies involving 841 patients were included in this study. The overall study quality was lower according to the Jadad scale. The meta-analysis showed that experimentally treated patients experienced greater therapeutic efficacy and lower white blood cell counts than control groups treated with Western medicine (P < 0.05). No publication bias was evident, according to Egger's test. Conclusions: The validity of this meta-analysis was limited by the overall poor quality of the included studies. Huangqi injection may have potential clinical value in the treatment of leucopenia, but confirmation with rigorously well-designed multi-center trials is needed.	[Zhang, Changsong; Zhu, Changtai; Ling, Yang; Liu, Yongping] Soochow Univ, Dept Oncol, Changzhou Tumor Hosp, Changzhou, Peoples R China; [Zhu, Changtai; Dong, Chunlei] Soochow Univ, Dept Lab Med, Changzhou Tumor Hosp, Changzhou, Peoples R China; [Zhou, Xifa; Luo, Judong] Soochow Univ, Dept Radiat Oncol, Changzhou Tumor Hosp, Changzhou, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China	Zhang, CS (corresponding author), Soochow Univ, Dept Oncol, Changzhou Tumor Hosp, Changzhou, Peoples R China.	hbzcs@126.com; zct101@163.com; lingyang11566@163.com	zhu, changtai/W-6581-2019; Zhu, Changtai/V-1583-2017	zhu, changtai/0000-0002-5250-1937; Zhu, Changtai/0000-0002-5250-1937	Natural Science Foundation of China [81071799, 81372212]; Science and Technology Bureau of Changzhou Municipality [CJ2012202]; Natural Science Foundation of Jiangsu [BK2011251]; Jiangsu Provincial Special Program of Medical Science [BL2013012]; Health Talents Project for Jiangsu [LJ201157, RC2011038, BRA2011038]; "831" Health Talents Project of Changzho Municipality	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Bureau of Changzhou Municipality; Natural Science Foundation of Jiangsu(Natural Science Foundation of Jiangsu Province); Jiangsu Provincial Special Program of Medical Science; Health Talents Project for Jiangsu; "831" Health Talents Project of Changzho Municipality	This project was supported by the Natural Science Foundation of China (81071799, 81372212), the Science and Technology Bureau of Changzhou Municipality (CJ2012202), the Natural Science Foundation of Jiangsu (BK2011251), Jiangsu Provincial Special Program of Medical Science (BL2013012), the Health Talents Project for Jiangsu (LJ201157; RC2011038; BRA2011038), and the "831" Health Talents Project of Changzho Municipality. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguilar-Ponce JL, 2013, ORAL ONCOL, V49, P249, DOI 10.1016/j.oraloncology.2012.09.008; Bao XN., 1999, ZHONG YI YAO LI YU L, V15, P39; Bruserud O, 1998, CANCER IMMUNOL IMMUN, V46, P221, DOI 10.1007/s002620050481; Cai Xiao-yan, 2006, Zhongguo Zhong Xi Yi Jie He Za Zhi, V26, P443; Dai Y, 1999, ZHEJIANG ZHONG YI ZA, V34, P42; Dong J, 2010, ZHONG YI YAO DAO BAO, V16, P87; Fan JH, 2007, HAINAN YI XUE YUAN X, V13, P233; Feng CL, 2000, SHI YONG ZHONG YI NE, V2, P23; Fu SF, 2009, YAO WU PING JIA YAN, V32, P54; Fu SF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019604; Gao P, 2000, CHANGCHUN ZHONG YI X, V4, P24; Hayashi K, 2011, YAKUGAKU ZASSHI, V131, P139, DOI 10.1248/yakushi.131.139; Hooper C, 2012, AUST VET J, V90, P24, DOI 10.1111/j.1751-0813.2011.00877.x; Huang CS, 2012, ASIAN PAC J CANCER P, V13, P4481, DOI 10.7314/APJCP.2012.13.9.4481; Jadad AR, 1996, J CLIN EPIDEMIOL, V49, P235, DOI 10.1016/0895-4356(95)00062-3; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Li MX, 2011, J ETHNOPHARMACOL, V133, P412, DOI 10.1016/j.jep.2010.10.012; Li QZ, 1997, SHANGHAI YI YAO, V18, P21; Liu BJ, 2000, LIAONING YAO WU YU L, V3, P13; Liu Z Q, 2001, Zhongguo Zhong Xi Yi Jie He Za Zhi, V21, P274; Luo WW, 2000, ZHONGHUA SHEN ZANG B, V16, P189; McCulloch M, 2006, J CLIN ONCOL, V24, P419, DOI 10.1200/JCO.2005.03.6392; Mo GW, 2005, GUANGZHOU ZHONG YI Y, V22, P13; Mo WX, 2009, NE KE, V4, P64; Moher D, 1996, INT J TECHNOL ASSESS, V12, P195, DOI 10.1017/S0266462300009570; Qin HZ, 2011, YI XUE XIN XI, V24, P151; Qu W, 2000, TIANJIN YAO XUE, V4, P71; Shafi MS, 2009, JCPSP-J COLL PHYSICI, V19, P346, DOI 06.2009/JCPSP.346349; [是俊凤 Shi Junfeng], 2002, [上海第二医科大学学报, Acta Universitatis Medicinalis Secondae Shanghai], V22, P245; Su Li, 2007, Zhong Xi Yi Jie He Xue Bao, V5, P272; Tang JC, 2007, SHI YONG YI XUE ZA Z, V23, P280; Wang HJ, 2007, LANZHOU DA XUE XUE B, V33, P76; Wang HJ, 2007, SICHUAN ZHONG YI, V25, P20; Wroblova K, 2012, DIGEST DIS SCI, V57, P2394, DOI 10.1007/s10620-012-2163-y; Wu T, 2005, COCHRANE DB SYST REV, V25; Xiao AQ, 2007, TAISHAN YI XUE YUAN, V28, P706; Xiao L, 2012, ZHONGGUO ZHI YE YAO, V9, P25; Xu L, 2008, CONTEMP CLIN TRIALS, V29, P727, DOI 10.1016/j.cct.2008.05.003; Yang DS, 2001, XIAN DAI ZHONG XI YI, V10, P812; Zhang MJ, 1999, LIN CHUANG XUE YE XU, V12, P28; Zhang YS, 2000, SHI ZHEN GUO YI GUO, V11, P935; Zhou WB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037249; Zhu XL, 2001, ZHONGGUO ZHONG XI YI, V8, P284; Zou Yu-he, 2003, Zhongguo Zhong Xi Yi Jie He Za Zhi, V23, P733	44	7	8	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2013	8	12							e83123	10.1371/journal.pone.0083123	http://dx.doi.org/10.1371/journal.pone.0083123			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276EU	24349444	Green Published, Green Submitted, gold			2023-01-03	WOS:000328731800096
J	Liepelt-Scarfone, I; Berger, MF; Prakash, D; Csoti, I; Graber, S; Maetzler, W; Berg, D				Liepelt-Scarfone, Inga; Berger, Monika Fruhmann; Prakash, Deborah; Csoti, Ilona; Graeber, Susanne; Maetzler, Walter; Berg, Daniela			Clinical Characteristics with an Impact on ADL Functions of PD Patients with Cognitive Impairment Indicative of Dementia	PLOS ONE			English	Article							PARKINSONS-DISEASE DEMENTIA; QUALITY-OF-LIFE; INSTRUMENTAL ACTIVITIES; DIAGNOSTIC-CRITERIA; DISABILITY; DEFICITS; DECLINE; BURDEN; INDIVIDUALS; PROGRESSION	Background: Dementia in Parkinson's disease (PD) is defined as cognitive decline severe enough to affect activities of daily living function (ADL). The aim of our exploratory study was to compare two groups of PD patients. Both groups had cognitive deficits severe enough to justify diagnosis of dementia, but they differed according to caregivers' rating on ADL dysfunction. Parameters which differed between the two groups were interpreted to affect the caregivers' perception of ADL dysfunction in PD patients with cognitive impairment indicative of Parkinson's disease dementia. Methodology/Principal Findings: Thirty of 131 Parkinson's disease patients fulfilled the Movement Disorders Society Task Force - recommended, cognitive Level-I-criteria for dementia. According to standardized caregiver ratings, volunteers were grouped into 18 patients with (ADL-) and 12 without instrumental activities of daily living dysfunction (ADL+). Caregiver activities of daily living function ratings closely correlated with self-estimates of patients and those of physician (p<0.001). ADL-patients performed worse on tests assessing visual-construction (p<0.05) and attention (p=0.03) than ADL+ patients. Moreover, the postural instability and gait disorder subtype was more frequent in ADL-patients (p=0.009). ADL-patients tended to have more communication problems (p=0.05), more anxiety (p=0.05) and showed a tendency to be treated more often with neuroleptics (p=0.049) than ADL+. Conclusions/Significance: Results indicate that worse attention, visual-construction abilities, the postural instability and gait disorder subtype, communication problems, medication and presence of anxiety are related to activities of daily living dysfunctions in Parkinson's disease patients with cognitive decline indicative of dementia. Our data suggests that not only cognitive factors but also non-cognitive factors seem to be linked to the diagnosis of Parkinson's disease dementia associated with significant impact on instrumental activities of daily living function. Further studies with larger sample sizes are needed to verify our results.	[Liepelt-Scarfone, Inga; Berger, Monika Fruhmann; Prakash, Deborah; Graeber, Susanne; Maetzler, Walter; Berg, Daniela] German Ctr Neurodegenerat Dis DZNE, Tubingen, Germany; [Liepelt-Scarfone, Inga; Berger, Monika Fruhmann; Prakash, Deborah; Graeber, Susanne; Maetzler, Walter; Berg, Daniela] Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurodegenerat, Tubingen, Germany; [Csoti, Ilona] Gertrudis Hosp, Dept Neurol, Leun Biskirchen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Liepelt-Scarfone, I (corresponding author), German Ctr Neurodegenerat Dis DZNE, Tubingen, Germany.	Inga.Liepelt@dzne.de	Berg, Daniela/A-8728-2019; Maetzler, Walter/AAE-5831-2020; Maetzler, Walter/A-6796-2011	Berg, Daniela/0000-0001-5796-5442; Maetzler, Walter/0000-0002-5945-4694; Maetzler, Walter/0000-0002-5945-4694				Aarsland D, 2004, ARCH NEUROL-CHICAGO, V61, P1906, DOI 10.1001/archneur.61.12.1906; Aarsland D, 2012, NAT REV NEUROL, V8, P35, DOI 10.1038/nrneurol.2011.189; Alves G, 2005, NEUROLOGY, V65, P1436, DOI 10.1212/01.wnl.0000183359.50822.f2; Alves G, 2006, MOVEMENT DISORD, V21, P1123, DOI 10.1002/mds.20897; Azuma T, 2003, INT J GERIATR PSYCH, V18, P1043, DOI 10.1002/gps.1015; Barton B, 2012, MOVEMENT DISORD, V27, P248, DOI 10.1002/mds.24059; Bronnick K, 2006, J NEUROL NEUROSUR PS, V77, P1136, DOI 10.1136/jnnp.2006.093146; Cahn DA, 1998, ARCH CLIN NEUROPSYCH, V13, P575, DOI 10.1016/S0887-6177(98)00024-9; Christ JBM, 2013, PARKINSONISM RELAT D, V19, P371, DOI 10.1016/j.parkreldis.2012.11.004; Colman KSF, 2009, CORTEX, V45, P930, DOI 10.1016/j.cortex.2008.12.010; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Di Battista ME, 2011, J NEURAL TRANSM, V118, P1609, DOI 10.1007/s00702-011-0638-1; Dubois B, 2007, MOVEMENT DISORD, V22, P2314, DOI 10.1002/mds.21844; Dujardin K, 2010, MOVEMENT DISORD, V25, P2769, DOI 10.1002/mds.23391; Dymek MP, 2001, NEUROLOGY, V56, P17, DOI 10.1212/WNL.56.1.17; Emre M, 2007, MOVEMENT DISORD, V22, P1689, DOI 10.1002/mds.21507; Esselink RAJ, 2004, NEUROLOGY, V62, P201, DOI 10.1212/01.WNL.0000103235.12621.C3; Fahn S.R.L.E., 1987, RECENT DEV PARKINSON; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Forsaa EB, 2010, NEUROLOGY, V75, P1270, DOI 10.1212/WNL.0b013e3181f61311; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; Goldman JG, 2012, MOVEMENT DISORD, V27, P1129, DOI 10.1002/mds.25062; Grosset K, 2004, MOVEMENT DISORD, V19, P1370, DOI 10.1002/mds.20210; Haerting C, 2000, WECHSLER GEDACHTNIST; Hariz GM, 2011, ACTA NEUROL SCAND, V123, P20, DOI 10.1111/j.1600-0404.2010.01344.x; Hautzinger M., 1995, BECKS DEPRESSIONS IN; Hely MA, 2008, MOVEMENT DISORD, V23, P837, DOI 10.1002/mds.21956; Ho AK, 1998, BEHAV NEUROL, V11, P131, DOI 10.1155/1999/327643; Hobson JP, 2001, CLIN REHABIL, V15, P241, DOI 10.1191/026921501666767060; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Holroyd S, 2005, NEUROLOGY, V64, P2134, DOI 10.1212/01.WNL.0000165958.12724.0D; JANKOVIC J, 1990, NEUROLOGY, V40, P1529, DOI 10.1212/WNL.40.10.1529; Jankovic J, 2001, ARCH NEUROL-CHICAGO, V58, P1611, DOI 10.1001/archneur.58.10.1611; Jenkinson C, 1997, AGE AGEING, V26, P353, DOI 10.1093/ageing/26.5.353; Kalbe E, 2008, PARKINSONISM RELAT D, V14, P93, DOI 10.1016/j.parkreldis.2007.06.008; Liepelt I., 2007, Z NEUROPSYCHOL, V18, P193, DOI DOI 10.1024/1016-264X.18.3.193; Liepelt-Scarfone I, 2011, PARKINSONS DIS-US, V2011, DOI 10.4061/2011/540843; Marson D, 2001, NEUROLOGIST, V7, P317, DOI 10.1097/00127893-200111000-00001; Martinez-Martin P, 2008, MOVEMENT DISORD, V23, P1673, DOI 10.1002/mds.22106; Martinez-Martin R, 2011, PARKINSONISM RELAT D, V17, P621, DOI 10.1016/j.parkreldis.2011.05.017; Memory Clinic. NPZ, 2005, CONS EST REG ALZH DI; Miller N, 2008, CLIN REHABIL, V22, P14, DOI 10.1177/0269215507079096; Oswald W.D., 1999, NURNBERGER ALTERS IN, V4th; Poletti M, 2012, J NEUROL SCI, V317, P97, DOI 10.1016/j.jns.2012.02.022; Rasovska H, 2011, J NEUROL SCI, V310, P279, DOI 10.1016/j.jns.2011.07.048; Razani J, 2007, J AM GERIATR SOC, V55, P1415, DOI 10.1111/j.1532-5415.2007.01307.x; Riedel O, 2010, J NEUROL, V257, P1073, DOI 10.1007/s00415-010-5465-z; Roland KP, 2010, MOVEMENT DISORD, V25, P189, DOI 10.1002/mds.22939; Rosenthal E, 2010, MOVEMENT DISORD, V25, P1170, DOI 10.1002/mds.23073; Schwab J., 1969, PROJECTION TECHNIQUE; STARKSTEIN SE, 1992, J NEUROL NEUROSUR PS, V55, P377, DOI 10.1136/jnnp.55.5.377; Stepkina D A, 2010, Neurosci Behav Physiol, V40, P61, DOI 10.1007/s11055-009-9223-6; Stoffers D, 2007, BRAIN, V130, P1847, DOI 10.1093/brain/awm034; Tucha O, 2004, TOWER LONDON; Warrington EK, 1992, THESIS THAMES VALLEY; Williams-Gray CH, 2009, BRAIN, V132, P2958, DOI 10.1093/brain/awp245; Zhao YJ, 2008, EUR J NEUROL, V15, P737, DOI 10.1111/j.1468-1331.2008.02178.x; Zimmermann P., 2002, TESTBATTERIE AUFMERK	58	10	10	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2013	8	12							e82902	10.1371/journal.pone.0082902	http://dx.doi.org/10.1371/journal.pone.0082902			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	275VD	24349393	gold, Green Published, Green Submitted			2023-01-03	WOS:000328705200113
J	Starmer, AJ; Sectish, TC; Simon, DW; Keohane, C; McSweeney, ME; Chung, EY; Yoon, CS; Lipsitz, SR; Wassner, AJ; Harper, MB; Landrigan, CP				Starmer, Amy J.; Sectish, Theodore C.; Simon, Dennis W.; Keohane, Carol; McSweeney, Maireade E.; Chung, Erica Y.; Yoon, Catherine S.; Lipsitz, Stuart R.; Wassner, Ari J.; Harper, Marvin B.; Landrigan, Christopher P.			Rates of Medical Errors and Preventable Adverse Events Among Hospitalized Children Following Implementation of a Resident Handoff Bundle	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRUG EVENTS; SIGN-OUT; PATIENT-CARE; HOUSE STAFF; HEALTH-CARE; CONTINUITY; SAFETY; INTERVENTION; EDUCATION; IMPACT	IMPORTANCE Handoff miscommunications are a leading cause of medical errors. Studies comprehensively assessing handoff improvement programs are lacking. OBJECTIVE To determine whether introduction of a multifaceted handoff program was associated with reduced rates of medical errors and preventable adverse events, fewer omissions of key data in written handoffs, improved verbal handoffs, and changes in resident-physician workflow. DESIGN, SETTING, AND PARTICIPANTS Prospective intervention study of 1255 patient admissions (642 before and 613 after the intervention) involving 84 resident physicians (42 before and 42 after the intervention) from July-September 2009 and November 2009-January 2010 on 2 inpatient units at Boston Children's Hospital. INTERVENTIONS Resident handoff bundle, consisting of standardized communication and handoff training, a verbal mnemonic, and a new team handoff structure. On one unit, a computerized handoff tool linked to the electronic medical record was introduced. MAIN OUTCOMES AND MEASURES The primary outcomes were the rates of medical errors and preventable adverse events measured by daily systematic surveillance. The secondary outcomes were omissions in the printed handoff document and resident time-motion activity. RESULTS Medical errors decreased from 33.8 per 100 admissions (95% CI, 27.3-40.3) to 18.3 per 100 admissions (95% CI, 14.7-21.9; P < .001), and preventable adverse events decreased from 3.3 per 100 admissions (95% CI, 1.7-4.8) to 1.5 (95% CI, 0.51-2.4) per 100 admissions (P = .04) following the intervention. There were fewer omissions of key handoff elements on printed handoff documents, especially on the unit that received the computerized handoff tool (significant reductions of omissions in 11 of 14 categories with computerized tool; significant reductions in 2 of 14 categories without computerized tool). Physicians spent a greater percentage of time in a 24-hour period at the patient bedside after the intervention (8.3%; 95% CI 7.1%-9.8%) vs 10.6%(95% CI, 9.2%-12.2%; P = .03). The average duration of verbal handoffs per patient did not change. Verbal handoffs were more likely to occur in a quiet location (33.3%; 95% CI, 14.5%-52.2% vs 67.9%; 95% CI, 50.6%-85.2%; P = .03) and private location (50.0%; 95% CI, 30%-70% vs 85.7%; 95% CI, 72.8%-98.7%; P = .007) after the intervention. CONCLUSIONS AND RELEVANCE Implementation of a handoff bundle was associated with a significant reduction in medical errors and preventable adverse events among hospitalized children. Improvements in verbal and written handoff processes occurred, and resident workflow did not change adversely.	[Starmer, Amy J.; Sectish, Theodore C.; Simon, Dennis W.; McSweeney, Maireade E.; Chung, Erica Y.; Wassner, Ari J.; Harper, Marvin B.; Landrigan, Christopher P.] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Gen Pediat,Dept Med, Boston, MA 02115 USA; [Starmer, Amy J.] Oregon Hlth & Sci Univ, Doernbecher Childrens Hosp, Portland, OR 97201 USA; [Simon, Dennis W.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA; [Keohane, Carol; Yoon, Catherine S.; Lipsitz, Stuart R.; Landrigan, Christopher P.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA; [Keohane, Carol; Yoon, Catherine S.; Lipsitz, Stuart R.; Landrigan, Christopher P.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Sleep Med, Boston, MA 02115 USA; [Chung, Erica Y.] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Providence, RI 02903 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Oregon Health & Science University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Starmer, AJ (corresponding author), Harvard Univ, Sch Med, Boston Childrens Hosp, Div Gen Pediat,Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.	amy.starmer@childrens.harvard.edu	Harper, Marvin B/O-9780-2017; Ramotar, Matt W/K-2193-2019	Harper, Marvin B/0000-0003-1385-0218; Landrigan, Christopher/0000-0001-8386-4100; Wassner, Ari/0000-0003-0894-9301	Controlled Risk Insurance Company Risk Management Foundation Grant Program; Boston Children's Hospital Program for Patient Safety and Quality Research Grant Program; Agency for Healthcare Research and Quality [T32 HP10018, 1K12HS019456-01]; Child Health Corporation of America; National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) [UL1TR000128]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K12HS019456] Funding Source: NIH RePORTER	Controlled Risk Insurance Company Risk Management Foundation Grant Program; Boston Children's Hospital Program for Patient Safety and Quality Research Grant Program; Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Child Health Corporation of America; National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This study was supported by the Controlled Risk Insurance Company Risk Management Foundation Grant Program as well as a grant from the Boston Children's Hospital Program for Patient Safety and Quality Research Grant Program. Dr Starmer was supported by grants T32 HP10018, a National Research Service Award in Pediatrics and 1K12HS019456-01 from the Oregon Comparative Effectiveness Research K12 Program through the Agency for Healthcare Research and Quality. Dr Landrigan is partially supported by the Child Health Corporation of America for his work as a member of the PRIS Network Executive Council. Some support for statistical analyses provided in part by the Oregon Clinical and Translational Research Institute (OCTRI) and grant UL1TR000128 from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH).	Arora V, 2005, QUAL SAF HEALTH CARE, V14, P401, DOI 10.1136/qshc.2005.015107; Arora V, 2006, JT COMM J QUAL PATIE, V32, P646, DOI 10.1016/S1553-7250(06)32084-3; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Cohen MD, 2010, QUAL SAF HEALTH CARE, V19, P493, DOI 10.1136/qshc.2009.033480; Desai SV, 2013, JAMA INTERN MED, V173, P649, DOI 10.1001/jamainternmed.2013.2973; Gordon M, 2011, MED EDUC, V45, P1081, DOI 10.1111/j.1365-2923.2011.04049.x; Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119; Horwitz LI, 2007, J GEN INTERN MED, V22, P1470, DOI 10.1007/s11606-007-0331-0; Horwitz LI, 2006, ARCH INTERN MED, V166, P1173, DOI 10.1001/archinte.166.11.1173; Horwitz LI, 2009, ANN EMERG MED, V53, P701, DOI 10.1016/j.annemergmed.2008.05.007; Kaushal R, 2001, JAMA-J AM MED ASSOC, V285, P2114, DOI 10.1001/jama.285.16.2114; Kitch BT, 2008, JT COMM J QUAL PATIE, V34, P563, DOI 10.1016/S1553-7250(08)34071-9; Kripalani S, 2012, ANN INTERN MED, V157, P1, DOI 10.7326/0003-4819-157-1-201207030-00003; Landrigan CP, 2010, NEW ENGL J MED, V363, P2124, DOI 10.1056/NEJMsa1004404; Landrigan CP, 2004, NEW ENGL J MED, V351, P1838, DOI 10.1056/NEJMoa041406; Leonard M, 2004, QUAL SAF HEALTH CARE, V13, pI85, DOI 10.1136/qshc.2004.010033; Li P, 2013, J HOSP MED, V8, P456, DOI 10.1002/jhm.1988; Lipsitz SR, 2000, BIOMETRICS, V56, P528, DOI 10.1111/j.0006-341X.2000.00528.x; McDonald KM, 2007, CLOSING THE QUALITY, V7; Morimoto T, 2004, QUAL SAF HEALTH CARE, V13, P306, DOI 10.1136/qshc.2004.010611; Nasca TJ, 2010, NEW ENGL J MED, V363, DOI 10.1056/NEJMsb1005800; Patterson ES, 2004, INT J QUAL HEALTH C, V16, P125, DOI 10.1093/intqhc/mzh026; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Pizziferri L, 2005, J BIOMED INFORM, V38, P176, DOI 10.1016/j.jbi.2004.11.009; Poon EG, 2010, NEW ENGL J MED, V362, P1698, DOI 10.1056/NEJMsa0907115; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Resar R, 2005, JT COMM J QUAL PATIE, V31, P243, DOI 10.1016/S1553-7250(05)31031-2; Riesenberg LA, 2009, ACAD MED, V84, P1775, DOI 10.1097/ACM.0b013e3181bf51a6; Riesenberg LA, 2009, AM J MED QUAL, V24, P196, DOI 10.1177/1062860609332512; Rothschild JM, 2005, CRIT CARE MED, V33, P1694, DOI 10.1097/01.CCM.0000171609.91035.BD; The Joint Commission, SENTINEL EVENT STATI; Van Eaton EG, 2005, J AM COLL SURGEONS, V200, P538, DOI 10.1016/j.jamcollsurg.2004.11.009; Wohlauer MV, 2012, ACAD MED, V87, P411, DOI 10.1097/ACM.0b013e318248e766; Young JQ, 2011, ANN INTERN MED, V155, P309, DOI 10.7326/0003-4819-155-5-201109060-00354; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	36	185	186	1	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	2013	310	21					2262	2270		10.1001/jama.2013.281961	http://dx.doi.org/10.1001/jama.2013.281961			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262OV	24302089				2023-01-03	WOS:000327746300011
J	Huber, M; Treutler, T; Martus, P; Kurzidim, A; Kreutz, R; Beige, J				Huber, Matthias; Treutler, Till; Martus, Peter; Kurzidim, Antje; Kreutz, Reinhold; Beige, Joachim			Dialysis-Associated Hypertension Treated with Telmisartan - DiaTel: A Pilot, Placebo-Controlled, Cross-Over, Randomized Trial	PLOS ONE			English	Article							BLOOD-PRESSURE; RENAL REPLACEMENT; OXIDATIVE STRESS; HEMODIALYSIS; PHARMACOKINETICS; OLMESARTAN; INHIBITORS; MORTALITY; DISEASE; RISK	Treatment of hypertension in hemodialysis (HD) patients is characterised by lack of evidence for both the blood pressure (BP) target goal and the recommended drug class to use. Telmisartan, an Angiotensin receptor blocker (ARB) that is metabolised in the liver and not excreted via HD extracorporeal circuit might be particularly suitable for HD patients. We designed and conducted a randomised, placebo-controlled, double-blind and cross-over trial for treatment of dialysis-associated hypertension with telmisartan 80 mg once daily or placebo on top of standard antihypertensive treatment excluding other Renin-Angiotensin-System (RAS) blockers. In 29 patients after randomization we analysed BP after a treatment period of 8 weeks, while 13 started with telmisartan and 16 with placebo; after 8 weeks 11 continued with telmisartan and 12 with placebo after cross-over, respectively. Patients exhibited a significant reduction of systolic pre-HD BP from 141.9 +/- 21.8 before to 131.3 +/- 17.3 mmHg after the first treatment period with telmisartan or placebo. However, no average significant influence of telmisartan was observed compared to placebo. The latter may be due to a large inter-individual variability of BP responses reaching from a 40 mmHg decrease under placebo to 40 mmHg increase under telmisartan. Antihypertensive co-medication was changed for clinical reasons in 7 out of 21 patients with no significant difference between telmisartan and placebo groups. Our starting hypothesis, that telmisartan on top of standard therapy lowers systolic office BP in HD patients could not be confirmed. In conclusion, this small trial indicates that testing antihypertensive drug efficacy in HD patients is challenging due to complicated standardization of concomitant medication and other confounding factors, e. g. volume status, salt load and neurohormonal activation, that influence BP control in HD patients.	[Treutler, Till; Kurzidim, Antje; Beige, Joachim] Kuratorium Dialysis & Transplantat KfH Renal Unit, Dept Infect Dis & Nephrol, Leipzig, Germany; [Huber, Matthias; Kreutz, Reinhold] Charite Med Ctr Berlin, Dept Clin Pharmacol & Toxicol, Berlin, Germany; [Martus, Peter] Charite Med Ctr Berlin, Dept Clin Stat & Biometry, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Beige, J (corresponding author), Kuratorium Dialysis & Transplantat KfH Renal Unit, Dept Infect Dis & Nephrol, Leipzig, Germany.	Joachim.Beige@sanktgeorg.de	Beige, Joachim/A-3446-2017; Kreutz, Reinhold/AEV-0507-2022	Beige, Joachim/0000-0002-1907-825X; Kreutz, Reinhold/0000-0002-4818-211X	Bayer Healthcare (Germany)	Bayer Healthcare (Germany)(Bayer AGBayer Healthcare Pharmaceuticals)	This study was in parts powered by a scientific grant from Bayer Healthcare (Germany) for patient's organization and coordination (AK) and biometrics (PM). No additional external funding was received for the study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abderrahim E, 2004, TRANSPL P, V36, P1820, DOI 10.1016/j.transproceed.2004.07.014; Agarwal R, 2011, AM J NEPHROL, V34, P381, DOI 10.1159/000331067; Aslam S, 2006, KIDNEY INT, V70, P2109, DOI 10.1038/sj.ki.5001983; Casas JP, 2005, LANCET, V366, P2026, DOI 10.1016/S0140-6736(05)67814-2; CHOBANIAN AV, 2003, HYPERTENSION, V42, P1206, DOI [DOI 10.1161/01.HYP.0000107251.49515.c2, DOI 10.1161/01.HYP.0000107251.49515.C2]; Foley RN, 2005, J AM SOC NEPHROL, V16, P489, DOI 10.1681/ASN.2004030203; Kadowaki D, 2007, HYPERTENS RES, V30, P395, DOI 10.1291/hypres.30.395; Kjeldsen SE, 2004, AM HEART J, V148, P747, DOI 10.1016/j.ahj.2004.04.037; Mancia G, 2007, EUR HEART J, V28, P1462, DOI [10.1093/eurheartj/ehm236, 10.1093/eurheartj/eht151]; Matsumae T, 2001, NEPHRON, V88, P113, DOI 10.1159/000045970; Shimada H, 2005, HYPERTENS RES, V28, P987, DOI 10.1291/hypres.28.987; Stangier J, 2000, J CLIN PHARMACOL, V40, P1365; Tanaka H, 2009, CLIN EXP NEPHROL, V13, P61, DOI 10.1007/s10157-008-0067-0; Tobin MD, 2005, STAT MED, V24, P2911, DOI 10.1002/sim.2165; Tozawa M, 2002, KIDNEY INT, V61, P717, DOI 10.1046/j.1523-1755.2002.00173.x	15	3	3	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2013	8	11							e79322	10.1371/journal.pone.0079322	http://dx.doi.org/10.1371/journal.pone.0079322			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256KH	24260194	gold, Green Published, Green Submitted			2023-01-03	WOS:000327308500042
J	Mao, XD; Zheng, HC; Liu, ZW; Wu, Y; Na, RS; Wang, CP; Zheng, XL; Gao, J; Wu, LM; Shi, XH; Liu, C; Sheng, HG				Mao, Xudong; Zheng, Hongchao; Liu, Zhiwen; Wu, Yan; Na, Risu; Wang, Chunping; Zheng, Xulei; Gao, Jing; Wu, Liming; Shi, Xiaohong; Liu, Cong; Sheng, Hongguang			Analysis of 25(OH) D Serum Concentrations of Hospitalized Elderly Patients in the Shanghai Area	PLOS ONE			English	Article							VITAMIN-D DEFICIENCY; 25-HYDROXYVITAMIN D; GENE-EXPRESSION; D INSUFFICIENCY; US POPULATION; D-3	Objective: To find an association between basic characteristics, seasons as well as disease types and 25-Hydroxyvitamin D serum concentrations in Chinese patients. Methods: We randomly selected 5470 Chinese patients with various diseases, who were hospitalized between May 2012 and August 2013 in Shanghai and analyzed their serum 25-Hydroxyvitamin D2 (25 (OH) D2) and 25-Hydroxyvitamin D3 (25(OH) D3) concentrations with liquid chromatography-tandem mass spectrometry (LC-MS/MS) as well as their parathyroid hormone (PTH) and serum creatinine blood levels. The resulting data were analyzed by linear regression and variance analyses or multivariate analysis with covariance. Results: The 25(OH) D serum concentrations were lowest in December. Among the subjects with a median age of 83.0 +/- 16.0, the median 25(OH) D2, 25(OH) D3 and total 25(OH) D serum concentrations were 1.00 +/- 1.80 ng/ml, 12.20 +/- 8.50 ng/ml and 14.80 +/- 9.80 respectively, indicating a prevalent 25(OH) D deficiency. According to our multivariate analysis of covariance, the factors affecting 25(OH) D2 and 25(OH) D3 serum concentrations included age, creatinine, PTH, season and type of disease, whereas gender correlated only with 25(OH) D2 and 25(OH) D2 and D3 values correlated negatively with each other. Our results further revealed that 25(OH) D3 levels were low while 25(OH) D2 levels were high among patients with lung diseases, dyskinesia and coronary heart diseases. In addition, participants with diabetes and cerebral infarction had higher 25(OH) D3 serum concentrations compared with lung disease patients. Conclusion: Vitamin D intake particularly during winter and summer seasons is important especially for elderly lung disease, dyskinesia and coronary heart disease patients to improve their quality of life.	[Mao, Xudong; Liu, Zhiwen; Na, Risu; Wang, Chunping; Zheng, Xulei; Wu, Liming; Shi, Xiaohong; Liu, Cong; Sheng, Hongguang] Xuhui Dist Cent Hosp, Dept Endocrinol, Shanghai, Peoples R China; [Zheng, Hongchao] Xuhui Dist Cent Hosp, Dept Cardiol, Shanghai, Peoples R China; [Wu, Yan] Shanghai Mental Hlth Ctr, Dept Psychiat, Shanghai, Peoples R China; [Gao, Jing] Xuhui Dist Cent Hosp, Dept Informat, Shanghai, Peoples R China		Mao, XD (corresponding author), Xuhui Dist Cent Hosp, Dept Endocrinol, Shanghai, Peoples R China.	maoxud@sina.com; zhcmxd@163.com	Wu, liming/AAH-5415-2019		 [81170734]		This work was supported by Research Grants (81170734). Funder's website: http://www.nutrition.ac.cn/PI/PI_lihx.asp. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Davies P, 2010, AM J RESP CRIT CARE, V181, P94, DOI 10.1164/ajrccm.181.1.94a; Dawson-Hughes B, 2010, OSTEOPOROSIS INT, V21, P1151, DOI 10.1007/s00198-010-1285-3; Demetriou ETW, 2012, ENDOCR PRACT, V18, P399, DOI 10.4158/EP11268.OR; Dorjgochoo T, 2012, BRIT J NUTR, V108, P449, DOI 10.1017/S0007114511005745; Douglas AS, 1995, J EPIDEMIOL COMMUN H, V49, P575, DOI 10.1136/jech.49.6.575; Du XQ, 2001, AM J CLIN NUTR, V74, P494; Gibney KB, 2008, CLIN INFECT DIS, V46, P443, DOI 10.1086/525268; Ginde AA, 2009, ARCH INTERN MED, V169, P626, DOI 10.1001/archinternmed.2008.604; Holick MF, 2004, AM J CLIN NUTR, V80, p1678S, DOI 10.1093/ajcn/80.6.1678S; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385; Hong W, 2011, CHIN J OSTEOPOROSIS, V4, P224; Jacques PF, 1997, AM J CLIN NUTR, V66, P929, DOI 10.1093/ajcn/66.4.929; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; MACLAUGHLIN J, 1985, J CLIN INVEST, V76, P1536, DOI 10.1172/JCI112134; Mansoor S, 2010, CLIN BIOCHEM, V43, P1431, DOI 10.1016/j.clinbiochem.2010.09.022; MERKE J, 1989, J CLIN INVEST, V83, P1903, DOI 10.1172/JCI114097; Mithal A, 2009, OSTEOPOROSIS INT, V20, P1807, DOI 10.1007/s00198-009-0954-6; Nibbelink KA, 2007, J STEROID BIOCHEM, V103, P533, DOI 10.1016/j.jsbmb.2006.12.099; Pike JW, 2007, J BONE MINER RES, V22, pV16, DOI [10.1359/jbmr.07s207, 10.1359/JBMR.07S207]; Ralph AP, 2008, TRENDS MICROBIOL, V16, P336, DOI 10.1016/j.tim.2008.04.003; Ralph AR, 2013, LANCET INFECT DIS, V13, P77, DOI 10.1016/S1473-3099(12)70275-X; Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704; Rucker D, 2002, CAN MED ASSOC J, V166, P1517; Sai AJ, 2011, J CLIN ENDOCR METAB, V96, pE436, DOI 10.1210/jc.2010-1886; Scragg R, 2008, AM J EPIDEMIOL, V168, P577, DOI 10.1093/aje/kwn163; Shin SY, 2013, J CLIN LAB ANAL, V27, P284, DOI 10.1002/jcla.21598; VANDERWIELEN RPJ, 1995, LANCET, V346, P207, DOI 10.1016/S0140-6736(95)91266-5; [汪纯 WANG Chun], 2011, [上海医学, Shanghai Medical Journal], V34, P166; Wu-Wong JR, 2006, ATHEROSCLEROSIS, V186, P20, DOI 10.1016/j.atherosclerosis.2005.06.046; Zhu H, 2010, CHIN J OSTEOPROSIS B, V3, P157	31	6	6	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2014	9	3							e90729	10.1371/journal.pone.0090729	http://dx.doi.org/10.1371/journal.pone.0090729			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC4GP	24599155	gold, Green Submitted, Green Published			2023-01-03	WOS:000332479400127
J	Zeng, XH; Li, JH; Peng, LB; Wang, YH; Tan, CQ; Chen, GN; Wan, XM; Lu, Q; Yi, LD				Zeng, Xiaohui; Li, Jianhe; Peng, Liubao; Wang, Yunhua; Tan, Chongqing; Chen, Gannong; Wan, Xiaomin; Lu, Qiong; Yi, Lidan			Economic Outcomes of Maintenance Gefitinib for Locally Advanced/Metastatic Non-Small-Cell Lung Cancer with Unknown EGFR Mutations: A Semi-Markov Model Analysis	PLOS ONE			English	Article							COST-EFFECTIVENESS; 1ST-LINE CHEMOTHERAPY; SUPPORTIVE CARE; DOUBLE-BLIND; PHASE-III; THERAPY; ERLOTINIB; CISPLATIN; PLACEBO; MULTICENTER	Background: Maintenance gefitinib significantly prolonged progression-free survival (PFS) compared with placebo in patients from eastern Asian with locally advanced/metastatic non-small-cell lung cancer (NSCLC) after four chemotherapeutic cycles (21 days per cycle) of first-line platinum-based combination chemotherapy without disease progression. The objective of the current study was to evaluate the cost-effectiveness of maintenance gefitinib therapy after four chemotherapeutic cycle's stand first-line platinum-based chemotherapy for patients with locally advanced or metastatic NSCLC with unknown EGFR mutations, from a Chinese health care system perspective. Methods and Findings: A semi-Markov model was designed to evaluate cost-effectiveness of the maintenance gefitinib treatment. Two-parametric Weibull and Log-logistic distribution were fitted to PFS and overall survival curves independently. One-way and probabilistic sensitivity analyses were conducted to assess the stability of the model designed. The model base-case analysis suggested that maintenance gefitinib would increase benefits in a 1, 3, 6 or 10-year time horizon, with incremental $184,829, $19,214, $19,328, and $ 21,308 per quality-adjusted life-year (QALY) gained, respectively. The most sensitive influential variable in the cost-effectiveness analysis was utility of PFS plus rash, followed by utility of PFS plus diarrhoea, utility of progressed disease, price of gefitinib, cost of follow-up treatment in progressed survival state, and utility of PFS on oral therapy. The price of gefitinib is the most significant parameter that could reduce the incremental cost per QALY. Probabilistic sensitivity analysis indicated that the cost-effective probability of maintenance gefitinib was zero under the willingness-to-pay (WTP) threshold of $16,349 (3xper-capita gross domestic product of China). The sensitivity analyses all suggested that the model was robust. Conclusions: Maintenance gefitinib following first-line platinum-based chemotherapy for patients with locally advanced/metastatic NSCLC with unknown EGFR mutations is not cost-effective. Decreasing the price of gefitinib may be a preferential choice for meeting widely treatment demands in China.	[Zeng, Xiaohui; Wang, Yunhua] Cent South Univ, Xiangya Hosp 2, PET CT Ctr, Changsha, Hunan, Peoples R China; [Li, Jianhe; Peng, Liubao; Tan, Chongqing; Wan, Xiaomin; Lu, Qiong; Yi, Lidan] Cent South Univ, Xiangya Hosp 2, Dept Pharm, Changsha, Hunan, Peoples R China; [Li, Jianhe; Tan, Chongqing; Wan, Xiaomin] Cent South Univ, Sch Pharmaceut Sci, Changsha, Hunan, Peoples R China; [Chen, Gannong] Cent South Univ, Xiangya Hosp 2, Dept Surg, Changsha, Hunan, Peoples R China	Central South University; Central South University; Central South University; Central South University	Peng, LB (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Pharm, Changsha, Hunan, Peoples R China.	pengliubao@126.com	Wan, Xiaomin/GPX-4388-2022	/0000-0001-5315-8141	National Natural Science Foundation of China [81173028]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was funded by National Natural Science Foundation of China (No. 81173028) (URL: http://www.nsfc.gov.cn/Portal0/default152.htm). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Azzoli CG, 2009, J CLIN ONCOL, V27, P6251, DOI 10.1200/JCO.2009.23.5622; Bareschino Maria Anna, 2011, J Thorac Dis, V3, P122, DOI 10.3978/j.issn.2072-1439.2010.12.08; Brodowicz T, 2006, LUNG CANCER, V52, P155, DOI 10.1016/j.lungcan.2006.01.006; Cappuzzo F, 2010, LANCET ONCOL, V11, P521, DOI 10.1016/S1470-2045(10)70112-1; China Center for Health Economic Research, 2010, CHIN GUID PHARM EC E; Ciuleanu T, 2009, LANCET, V374, P1432, DOI 10.1016/S0140-6736(09)61497-5; Cohen MH, 2010, ONCOLOGIST, V15, P1344, DOI 10.1634/theoncologist.2010-0257; Cohen MH, 2010, ONCOLOGIST, V15, P1352, DOI 10.1634/theoncologist.2010-0224; D'Addario G, 2009, ANN ONCOL, V20, P68, DOI 10.1093/annonc/mdp132; Fathi AT, 2008, SEMIN THORAC CARDIOV, V20, P210, DOI 10.1053/j.semtcvs.2008.09.002; Fidias PM, 2009, J CLIN ONCOL, V27, P591, DOI 10.1200/JCO.2008.17.1405; Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859; Greenhalgh J, 2010, HEALTH TECHNOL ASSES, V14, P33, DOI 10.3310/hta14suppl2/05; Jackson CH, 2010, INT J BIOSTAT, V6, DOI 10.2202/1557-4679.1269; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Klein R, 2010, J THORAC ONCOL, V5, P1263, DOI 10.1097/JTO.0b013e3181e15d16; Latimer NR, 2013, MED DECIS MAKING, V33, P743, DOI 10.1177/0272989X12472398; Latimer NR, 2011, NICE DSU TECHNICAL S; Liu Q, 2011, LANCET, V377, P2064, DOI 10.1016/S0140-6736(11)60167-0; Matter-Walstra K, 2012, VALUE HEALTH, V15, P65, DOI 10.1016/j.jval.2011.08.1737; Nafees B, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-84; Nation Comprehensive Cancer Network, 2013, NONSM CELL LUNG CANC; National Bureau of Statistics of China, 2012, CHIN STAT YB 2012; National Cancer Institute, 2013, SEER STAT FACT SHEET; Paz-Ares L, 2012, LANCET ONCOL, V13, P247, DOI 10.1016/S1470-2045(12)70063-3; Tsuchiya T, 2011, LUNG CANCER, V74, P521, DOI 10.1016/j.lungcan.2011.04.002; Vergnenegre A, 2012, CLINICOECONOMIC OUTC, V4, P31, DOI 10.2147/CEOR.S25923; Walleser S, 2012, CLINICOECONOMIC OUTC, V4, P269, DOI 10.2147/CEOR.S31794; WHO, COST EFF THRESH; Wu B, 2011, CLIN THER, V33, P1446, DOI 10.1016/j.clinthera.2011.09.016; Zeng X, 2013, CLIN THER, V35, P54, DOI 10.1016/j.clinthera.2012.12.013; Zeng XH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048323; Zhang L, 2012, LANCET ONCOL, V13, P466, DOI 10.1016/S1470-2045(12)70117-1; Zhu J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-39	34	17	19	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2014	9	2							e88881	10.1371/journal.pone.0088881	http://dx.doi.org/10.1371/journal.pone.0088881			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AB3UC	24586426	Green Published, gold, Green Submitted			2023-01-03	WOS:000331714700038
J	Hainfeld, JF; O'Connor, MJ; Lin, P; Qian, LP; Slatkin, DN; Smilowitz, HM				Hainfeld, James F.; O'Connor, Michael J.; Lin, Ping; Qian, Luping; Slatkin, Daniel N.; Smilowitz, Henry M.			Infrared-Transparent Gold Nanoparticles Converted by Tumors to Infrared Absorbers Cure Tumors in Mice by Photothermal Therapy	PLOS ONE			English	Article							CANCER-CELLS; OPTICAL-PROPERTIES; HYPERTHERMIA; DELIVERY; IMMUNOCYTOCHEMISTRY; NANOSHELLS; PARTICLES; EFFICACY; SURGERY; AGENTS	Gold nanoparticles (AuNPs) absorb light and can be used to heat and ablate tumors. The "tissue window'' at,800 nm (near infrared, NIR) is optimal for best tissue penetration of light. Previously, large, 50-150 nm, gold nanoshells and nanorods that absorb well in the NIR have been used. Small AuNPs that may penetrate tumors better unfortunately barely absorb at 800 nm. We show that small AuNPs conjugated to anti-tumor antibodies are taken up by tumor cells that catalytically aggregate them (by enzyme degradation of antibodies and pH effects), shifting their absorption into the NIR region, thus amplifying their photonic absorption. The AuNPs are NIR transparent until they accumulate in tumor cells, thus reducing background heating in blood and non-targeted cells, increasing specificity, in contrast to constructs that are always NIR-absorptive. Treatment of human squamous cell carcinoma A431 which overexpresses epidermal growth factor receptor (EGFr) in subcutaneous murine xenografts with anti-EGFr antibodies conjugated to 15 nm AuNPs and NIR resulted in complete tumor ablation in most cases with virtually no normal tissue damage. The use of targeted small AuNPs therefore provides a potent new method of selective NIR tumor therapy.	[Hainfeld, James F.; O'Connor, Michael J.; Lin, Ping; Qian, Luping; Slatkin, Daniel N.] Nanoprobes Inc, Yaphank, NY USA; [Smilowitz, Henry M.] Univ Connecticut, Ctr Hlth, Dept Cell Biol, Farmington, CT USA	University of Connecticut	Hainfeld, JF (corresponding author), Nanoprobes Inc, Yaphank, NY USA.	hainfeld@nanoprobes.com			NIH [R44CA130225]; NATIONAL CANCER INSTITUTE [R44CA130225] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Studies were funded by grants from NIH (R44CA130225) and the Dr. med. h.c. Erwin Braun Stiftung Basel. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chauhan VP, 2011, ANGEW CHEM INT EDIT, V50, P11417, DOI 10.1002/anie.201104449; Connor EE, 2005, SMALL, V1, P325, DOI 10.1002/smll.200400093; CONNOR WG, 1977, RADIOLOGY, V123, P497, DOI 10.1148/123.2.497; El-Sayed IH, 2006, CANCER LETT, V239, P129, DOI 10.1016/j.canlet.2005.07.035; Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078; FUCHS S, 2004, GER MED SCI, V2; Hainfeld JF, 2008, US Patent Application, Patent No. 20080279946; Hartel M, 2006, BRIT J SURG, V93, P952, DOI 10.1002/bjs.5429; Hirsch LR, 2003, P NATL ACAD SCI USA, V100, P13549, DOI 10.1073/pnas.2232479100; HOFFMANN G, 1994, ADV EXP MED BIOL, V345, P181; Hong R, 2006, J AM CHEM SOC, V128, P1078, DOI 10.1021/ja056726i; Huang XH, 2006, PHOTOCHEM PHOTOBIOL, V82, P412, DOI 10.1562/2005-12-14-RA-754; Jain PK, 2006, J PHYS CHEM B, V110, P7238, DOI 10.1021/jp057170o; Kampinga HH, 2006, INT J HYPERTHER, V22, P191, DOI 10.1080/02656730500532028; Kawai N, 2005, PROSTATE, V64, P373, DOI 10.1002/pros.20253; Khlebtsov B, 2006, NANOTECHNOLOGY, V17, P5167, DOI 10.1088/0957-4484/17/20/022; Kong G, 2000, CANCER RES, V60, P4440; Ku G, 2005, OPT LETT, V30, P507, DOI 10.1364/OL.30.000507; Lee H, 2011, INT J HYPERTHER, V27, P698, DOI 10.3109/02656736.2011.608217; Liu YL, 2007, ANAL CHEM, V79, P2221, DOI 10.1021/ac061578f; Loo C, 2004, TECHNOL CANCER RES T, V3, P33, DOI 10.1177/153303460400300104; Melling AC, 2001, LANCET, V358, P876, DOI 10.1016/S0140-6736(01)06071-8; Mercer JB, 2008, GER MED SCI, V6; Mukherjee Priyabrata, 2007, Journal of Nanobiotechnology, V5, P4, DOI 10.1186/1477-3155-5-4; Nam J, 2009, J AM CHEM SOC, V131, P13639, DOI 10.1021/ja902062j; O'Neal DP, 2004, CANCER LETT, V209, P171, DOI 10.1016/j.canlet.2004.02.004; Oldenburg SJ, 1999, APPL PHYS LETT, V75, P2897, DOI 10.1063/1.125183; Portet D, 2001, J COLLOID INTERF SCI, V238, P37, DOI 10.1006/jcis.2001.7500; Qian XM, 2008, NAT BIOTECHNOL, V26, P83, DOI 10.1038/nbt1377; Rechberger W, 2003, OPT COMMUN, V220, P137, DOI 10.1016/S0030-4018(03)01357-9; Robinson JM, 2000, J HISTOCHEM CYTOCHEM, V48, P487, DOI 10.1177/002215540004800406; Shen YQ, 2009, NANOMED-NANOTECHNOL, V5, P192, DOI 10.1016/j.nano.2008.09.003; Shukla R, 2005, LANGMUIR, V21, P10644, DOI 10.1021/la0513712; Souza GR, 2006, P NATL ACAD SCI USA, V103, P1215, DOI 10.1073/pnas.0509739103; Stern JM, 2007, J ENDOUROL, V21, P939, DOI 10.1089/end.2007.0437; Su KH, 2003, NANO LETT, V3, P1087, DOI 10.1021/nl034197f; TAKIZAWA T, 1994, J HISTOCHEM CYTOCHEM, V42, P1615, DOI 10.1177/42.12.7983362; von Maltzahn G, 2009, CANCER RES, V69, P3892, DOI 10.1158/0008-5472.CAN-08-4242; Wolff JA, 2008, MOL THER, V16, P8, DOI 10.1038/sj.mt.6300326; Yanase S, 2009, PHOTOMED LASER SURG, V27, P791, DOI 10.1089/pho.2008.2329	40	48	48	1	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2014	9	2							e88414	10.1371/journal.pone.0088414	http://dx.doi.org/10.1371/journal.pone.0088414			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7CL	24520385	Green Published, gold, Green Submitted			2023-01-03	WOS:000331254600076
J	Farsani, SF; Souverein, PC; van der Vorst, MMJ; Mantel-Teeuwisse, AK; Knibbe, CAJ; de Boer, A				Farsani, Soulmaz Fazeli; Souverein, Patrick C.; van der Vorst, Marja M. J.; Mantel-Teeuwisse, Aukje K.; Knibbe, Catherijne A. J.; de Boer, Anthonius			Disease History and Medication Use as Risk Factors for the Clinical Manifestation of Type 1 Diabetes in Children and Young Adults: An Explorative Case Control Study	PLOS ONE			English	Article							ENVIRONMENTAL-FACTORS; CHILDHOOD; EPIDEMIOLOGY; PATHOGENESIS; POPULATION; PREVALENCE; MELLITUS	Background: There is a highly variable asymptomatic period of beta cell destruction prior to the clinical presentation of type1 diabetes. It is not well known what triggers type 1 diabetes to become a clinically overt disease. This explorative study aimed to identify the association between disease history/medication use and the clinical manifestation of type 1 diabetes. Methodology/Principal Findings: An explorative case control study was conducted in the Dutch PHARMO Record Linkage System. Cases (n = 1,107) were younger than 25 years and had at least 2 insulin prescriptions between 1999 and 2009. For each case, up to 4 controls (without any prescription for the glucose lowering medications (n = 4,424)) were matched by age and sex. Conditional logistic regression analysis was used to evaluate the association between disease history/medication use in the year prior to the diagnosis of type1 diabetes and clinical manifestation of this disease. Type1 diabetes was significantly associated with a history of mental disorder (odds ratio (OR) 8.0, 95% confidence interval (CI) 1.5-43.7), anemia (OR 5.1, 95% CI 1.1-22.9), and disease of digestive system (OR 2.6, 95% CI 1.2-5.5). The following drug exposures were significantly associated with the clinical manifestation of type 1 diabetes: "systemic hormonal preparations'' (OR 1.7, 95% CI 1.1-2.6), medications for "blood and blood forming organs'' (OR 1.6, 95% CI 1.1-2.6), "alimentary tract and metabolism'' (OR 1.3, 95% CI 1.1-1.6), and "anti-infectives for systemic use'' (OR 1.2, 95% CI 1.01-1.4). Conclusions: Our explorative study demonstrated that in the year prior to the presentation of type1 diabetes in children and young adults, hospitalization for a diverse group of diseases and drug exposures were significantly more prevalent compared with age-and sex-matched diabetes-free controls.	[Farsani, Soulmaz Fazeli; Souverein, Patrick C.; Mantel-Teeuwisse, Aukje K.; de Boer, Anthonius] Univ Utrecht, UIPS, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands; [van der Vorst, Marja M. J.] St Antonius Hosp, Dept Pediat, Nieuwegein, Netherlands; [Knibbe, Catherijne A. J.] St Antonius Hosp, Dept Clin Pharm, Nieuwegein, Netherlands; [Knibbe, Catherijne A. J.] Leiden Univ, Leiden Acad Ctr Drug Res, Div Pharmacol, Leiden, Netherlands	Utrecht University; St. Antonius Hospital Utrecht; St. Antonius Hospital Utrecht; Leiden University; Leiden University - Excl LUMC	de Boer, A (corresponding author), Univ Utrecht, UIPS, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands.	a.deboer@uu.nl	Mantel-Teeuwisse, Aukje/I-8902-2016; Farsani, Soulmaz Fazeli/AAG-9598-2020	Souverein, Patrick/0000-0002-7452-0477	department of Pharmaceutical Sciences, Utrecht University	department of Pharmaceutical Sciences, Utrecht University	This project was funded by the department of Pharmaceutical Sciences, Utrecht University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akerblom HK, 2002, AM J MED GENET, V115, P18, DOI 10.1002/ajmg.10340; Akerblom HK, 1998, DIABETES METAB REV, V14, P31, DOI 10.1002/(SICI)1099-0895(199803)14:1&lt;31::AID-; Aronsson CA, 2013, PUBLIC HEALTH NUTR, V16, P1390, DOI 10.1017/S1368980013000293; Atkinson MA, 2001, LANCET, V358, P221, DOI 10.1016/S0140-6736(01)05415-0; Blackburn DF, 2006, CAN J CARDIOL, V22, P229, DOI 10.1016/S0828-282X(06)70902-3; Daneman D, 2006, LANCET, V367, P847, DOI 10.1016/S0140-6736(06)68341-4; De Block CEM, 2008, J CLIN ENDOCR METAB, V93, P363, DOI 10.1210/jc.2007-2134; De Bruin ML, 2005, J CLIN EPIDEMIOL, V58, P1325, DOI 10.1016/j.jclinepi.2005.04.009; Gale EAM, 2002, DIABETES, V51, P3353, DOI 10.2337/diabetes.51.12.3353; Green A, 2000, LANCET, V355, P873; Guglielmi C, 2012, DIABETES-METAB RES, V28, P40, DOI 10.1002/dmrr.2345; HAGGLOF B, 1991, DIABETOLOGIA, V34, P579, DOI 10.1007/BF00400277; Haynes A, 2007, DIABETIC MED, V24, P564, DOI 10.1111/j.1464-5491.2007.02149.x; Herings RMC, 1996, J CLIN EPIDEMIOL, V49, P115, DOI 10.1016/0895-4356(95)00552-8; HERINGS RMC, 1995, PHARM WORLD SCI, V17, P17, DOI 10.1007/BF01875553; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; Houweling LMA, 2013, J PEDIATR-US, V163, P61, DOI 10.1016/j.jpeds.2012.12.014; Hsia YF, 2009, BRIT J CLIN PHARMACO, V67, P242, DOI 10.1111/j.1365-2125.2008.03347.x; Izzedine Hassane, 2005, Expert Opin Drug Saf, V4, P1097, DOI 10.1517/14740338.4.6.1097; Knip M, 2005, DIABETES, V54, pS125, DOI 10.2337/diabetes.54.suppl_2.S125; Knip M, 2002, HORM RES, V57, P6, DOI 10.1159/000053305; Krischer J, 2007, PEDIATR DIABETES, V8, P286; Lau HS, 1997, J CLIN EPIDEMIOL, V50, P619, DOI 10.1016/S0895-4356(97)00040-1; Luna B, 2001, JAMA-J AM MED ASSOC, V286, P1945, DOI 10.1001/jama.286.16.1945; Ma RCW, 2009, NAT REV ENDOCRINOL, V5, P529, DOI 10.1038/nrendo.2009.180; Malcova H, 2006, EUR J PEDIATR, V165, P114, DOI 10.1007/s00431-005-0008-9; Martikainen MH, 2013, ACTA DIABETOL, V50, P737, DOI 10.1007/s00592-012-0393-2; Overbeek Jetty A, 2011, BMC Res Notes, V4, P402, DOI 10.1186/1756-0500-4-402; PANDIT MK, 1993, ANN INTERN MED, V118, P529, DOI 10.7326/0003-4819-118-7-199304010-00008; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Svensson J, 2005, EUR J EPIDEMIOL, V20, P429, DOI 10.1007/s10654-005-0878-1; Vaarala O, 2008, DIABETES, V57, P2555, DOI 10.2337/db08-0331; Vehik K, 2011, DIABETES-METAB RES, V27, P3, DOI 10.1002/dmrr.1141; Visalli N, 2003, ARCH DIS CHILD, V88, P695, DOI 10.1136/adc.88.8.695; Ziegler AG, 2003, JAMA-J AM MED ASSOC, V290, P1721, DOI 10.1001/jama.290.13.1721	35	4	4	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2014	9	2							e87408	10.1371/journal.pone.0087408	http://dx.doi.org/10.1371/journal.pone.0087408			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302TD	24498320	Green Published, gold, Green Submitted			2023-01-03	WOS:000330626900066
J	Tarpgaard, LS; Guren, TK; Glimelius, B; Christensen, IJ; Pfeiffer, P; Kure, EH; Sorbye, H; Ikdahl, T; Yilmaz, M; Johansen, JS; Tveit, KM				Tarpgaard, Line S.; Guren, Tormod K.; Glimelius, Bengt; Christensen, Ib J.; Pfeiffer, Per; Kure, Elin H.; Sorbye, Halfdan; Ikdahl, Tone; Yilmaz, Mette; Johansen, Julia S.; Tveit, Kjell Magne			Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study	PLOS ONE			English	Article							GROWTH-FACTOR RECEPTOR; PHASE-III TRIAL; SERUM YKL-40; 1ST-LINE TREATMENT; PROTEIN EXPRESSION; FLUOROURACIL; CHEMOTHERAPY; INFLAMMATION; LEUCOVORIN; CARCINOMA	Background: We aim to test the hypothesis that high plasma YKL-40 is associated with short progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC) treated with first-line oxaliplatin and 5-flourouracil with or without cetuximab. Patients and Methods: A total of 566 patients in the NORDIC VII Study were randomized 1:1:1 to arm A (Nordic FLOX), arm B (Nordic FLOX + cetuximab), or arm C (Nordic FLOX + cetuximab for 16 weeks followed by cetuximab alone as maintenance therapy). Pretreatment plasma samples were available from 510 patients. Plasma YKL-40 was determined by ELISA and dichotomized according to the age-corrected 95% YKL-40 level in 3130 healthy subjects. Results: Pretreatment plasma YKL-40 was elevated in 204 patients (40%), and median YKL-40 was higher in patients with mCRC than in healthy subjects (age adjusted, P < 0.001). Patients with elevated YKL-40 had shorter PFS than patients with normal YKL-40 (7.5 vs. 8.2 months; hazard ratio (HR) = 1.27 95% confidence interval (CI) 1.05-1.53 P = 0.013) and shorter OS (16.8 vs. 23.9 months; HR = 1.33, 1.04-1.69, P = 0.024). Multivariate Cox analysis demonstrated that elevated pretreatment YKL-40 was an independent biomarker of short OS (HR = 1.12, 1.01-1.25, P = 0.033). The ratio of the updated plasma YKL-40 (i.e. level after 1, 2, 8 weeks of treatment, and at end of treatment compared to the baseline level) was associated with OS (HR = 1.27, 1.06-1.52, P = 0.011). Conclusions: Plasma YKL-40 is an independent prognostic biomarker in patients with mCRC treated with first-line oxaliplatin-based therapy alone or combined with cetuximab.	[Tarpgaard, Line S.; Pfeiffer, Per] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark; [Tarpgaard, Line S.; Pfeiffer, Per] Univ Southern Denmark, Odense, Denmark; [Guren, Tormod K.; Ikdahl, Tone; Tveit, Kjell Magne] Oslo Univ Hosp, Dept Oncol, Oslo, Norway; [Glimelius, Bengt] Uppsala Univ, Dept Radiol, Uppsala, Sweden; [Glimelius, Bengt] Uppsala Univ, Dept Oncol, Uppsala, Sweden; [Glimelius, Bengt] Uppsala Univ, Dept Radiat Sci, Uppsala, Sweden; [Glimelius, Bengt] Karolinska Inst, Dept Pathol & Oncol, Stockholm, Sweden; [Christensen, Ib J.] Copenhagen Univ Hosp, Finsen Lab, Copenhagen, Denmark; [Christensen, Ib J.] Univ Copenhagen, Biotech Res & Innovat Ctr BRIC, Copenhagen, Denmark; [Kure, Elin H.] Oslo Univ Hosp, Dept Genet, Inst Canc Res, Oslo, Norway; [Sorbye, Halfdan] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway; [Yilmaz, Mette] Aalborg Hosp, Dept Oncol, Aalborg, Denmark; [Johansen, Julia S.] Copenhagen Univ Hosp, Herlev Hosp, Dept Oncol, Copenhagen, Denmark; [Johansen, Julia S.] Copenhagen Univ Hosp, Herlev Hosp, Dept Med, Copenhagen, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; University of Oslo; Uppsala University; Uppsala University; Uppsala University; Karolinska Institutet; University of Copenhagen; University of Copenhagen; University of Oslo; University of Bergen; Haukeland University Hospital; Aalborg University; Aalborg University Hospital; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Herlev & Gentofte Hospital	Tarpgaard, LS (corresponding author), Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark.	line.tarpgaard@rsyd.dk		Pfeiffer, Per/0000-0002-2925-0586; Tarpgaard, Line/0000-0001-8505-2544	Odense University Hospital; University of Southern Denmark; Ministry of Science, Technology and Innovation, Denmark; Merck KGaA; Sanofi-Aventis	Odense University Hospital; University of Southern Denmark; Ministry of Science, Technology and Innovation, Denmark(Ministry of Energy, Science, Technology, Environment and Climate Change (MESTECC), Malaysia); Merck KGaA(Merck & Company); Sanofi-Aventis(Sanofi-Aventis)	This work was supported by Odense University Hospital and University of Southern Denmark by paid salary to Line Schmidt Tarpgaard. Expenses regarding the YKL-40 analysis were supported from "Joint Proof-of-Concept-Fund, the Ministry of Science, Technology and Innovation, Denmark". Quidel provided the study with some of the YKL-40 ELISA kits. The NORDIC VII Study received funding by Merck KGaA and Sanofi-Aventis. The study sponsors had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. The authors had full access to all the data in the study and had the final responsibility for the decision to submit the manuscript for publication. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allin KH, 2012, BRIT J CANCER, V106, P199, DOI 10.1038/bjc.2011.501; Altman DG, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001216; Bojesen SE, 2011, CLIN CHIM ACTA, V412, P709, DOI 10.1016/j.cca.2011.01.022; Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632; Brochner CB, 2012, J HISTOCHEM CYTOCHEM, V60, P188, DOI 10.1369/0022155411433331; Bussink AP, 2007, GENETICS, V177, P959, DOI 10.1534/genetics.107.075846; Chen CC, 2011, CLIN IMMUNOL, V140, P268, DOI 10.1016/j.clim.2011.04.007; Cintin C, 1999, BRIT J CANCER, V79, P1494, DOI 10.1038/sj.bjc.6690238; Cintin C, 2002, CANCER-AM CANCER SOC, V95, P267, DOI 10.1002/cncr.10644; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860; Faibish M, 2011, MOL CANCER THER, V10, P742, DOI 10.1158/1535-7163.MCT-10-0868; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Francescone R, 2013, ONCOGENE; Francescone RA, 2011, J BIOL CHEM, V286, P15332, DOI 10.1074/jbc.M110.212514; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; He CH, 2013, CELL REP, V4, P830, DOI 10.1016/j.celrep.2013.07.032; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Iwamoto FM, 2011, NEURO-ONCOLOGY, V13, P1244, DOI 10.1093/neuonc/nor117; Johansen JS, 2007, J HISTOCHEM CYTOCHEM, V55, P1213, DOI 10.1369/jhc.7A7245.2007; Johansen JS, 2007, CLIN CANCER RES, V13, P3244, DOI 10.1158/1078-0432.CCR-06-2616; Johansen JS, 2010, CLIN CHEM, V56, P1580, DOI 10.1373/clinchem.2010.146530; Johansen JS, 2009, FUTURE ONCOL, V5, P1065, DOI 10.2217/FON.09.66; Johansen JS, 2009, J CLIN ONCOL, V27, P572, DOI 10.1200/JCO.2008.18.8367; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Junker N, 2005, CANCER SCI, V96, P183, DOI 10.1111/j.1349-7006.2005.00026.x; Klein S, 2009, CURR OPIN CELL BIOL, V21, P185, DOI 10.1016/j.ceb.2008.12.006; Krasinskas A. M., 2011, PATHOLOG RES INT, V2011, P6, DOI DOI 10.4061/2011/932932; Lee CG, 2011, ANNU REV PHYSIOL, V73, P479, DOI 10.1146/annurev-physiol-012110-142250; Libreros S, 2012, INT J CANCER, V131, P377, DOI 10.1002/ijc.26379; Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2; Nicolaisen NJ, 2007, J CLIN ONCOLOGY 1 S, V25, P14517; Nielsen AR, 2011, CYTOKINE, V55, P152, DOI 10.1016/j.cyto.2011.03.014; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Rehli M, 1997, GENOMICS, V43, P221, DOI 10.1006/geno.1997.4778; Ringsholt M, 2007, J MOL HISTOL, V38, P33, DOI 10.1007/s10735-006-9075-0; Roslind A, 2008, INT J CANCER, V122, P857, DOI 10.1002/ijc.23152; Schmidt H, 2006, J CLIN ONCOL, V24, P798, DOI 10.1200/JCO.2005.03.7960; Schultz Nicolai A, 2010, Cancers (Basel), V2, P1453, DOI 10.3390/cancers2031453; Shao R, 2009, ONCOGENE, V28, P4456, DOI 10.1038/onc.2009.292; Tol J, 2010, CLIN THER, V32, P437, DOI 10.1016/j.clinthera.2010.03.012; Tveit KM, 2012, J CLIN ONCOL, V30, P1755, DOI 10.1200/JCO.2011.38.0915; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019	43	17	19	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2014	9	2							e87746	10.1371/journal.pone.0087746	http://dx.doi.org/10.1371/journal.pone.0087746			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302TD	24498368	Green Published, Green Submitted, gold			2023-01-03	WOS:000330626900114
J	Zhang, W; Chen, S; Li, N; Zhang, JZ; Chen, W				Zhang, Wei; Chen, Song; Li, Na; Zhang, Jia Zheng; Chen, Wei			Correlated Diffusion of Colloidal Particles near a Liquid-Liquid Interface	PLOS ONE			English	Article							TIME SELF-DIFFUSION; HYDRODYNAMIC INTERACTION; QUASI-2-DIMENSIONAL SUSPENSIONS; SPHERICAL-PARTICLE; PLANAR BOUNDARY; WATER-INTERFACE; BROWNIAN-MOTION; SPHERES; MICRORHEOLOGY; MEMBRANE	Optical microscopy and multi-particle tracking are used to investigate the cross-correlated diffusion of quasi two-dimensional colloidal particles near an oil-water interface. The behaviors of the correlated diffusion along longitudinal and transverse direction are asymmetric. It is shown that the characteristic length for longitudinal and transverse correlated diffusion are particle diameter d and the distance z from particle center to the interface, respectively, for large particle separation r. The longitudinal and transverse correlated diffusion coefficient D-parallel to(r) and D-perpendicular to(r) are independent of the colloidal area fraction n when n<0.3, which indicates that the hydrodynamic interactions(HIs) among the particles are dominated by HIs through the surrounding fluid for small n. For high area fraction n>0.4, the power law exponent for the spatial decay of D-perpendicular to(r) begins to decrease, which suggests the HIs are more contributed from the 2D particle monolayer self for large n.	[Zhang, Wei; Chen, Song; Li, Na; Zhang, Jia Zheng; Chen, Wei] Fudan Univ, Dept Phys, State Key Lab Surface Phys, Shanghai 200433, Peoples R China; [Zhang, Wei] Northwestern Polytech Univ, Dept Appl Phys, Xian 710072, Peoples R China; [Zhang, Wei] Jinan Univ, Dept Phys, Guangzhou, Guangdong, Peoples R China; [Chen, Wei] Chinese Acad Sci, Kavli Inst Theoret Phys China, Beijing, Peoples R China	Fudan University; Northwestern Polytechnical University; Jinan University; Chinese Academy of Sciences	Zhang, W (corresponding author), Fudan Univ, Dept Phys, State Key Lab Surface Phys, Shanghai 200433, Peoples R China.	wzhangph@gmail.com; phchenwei@fudan.edu.cn	Chen, Song/AAB-1137-2021	Chen, Song/0000-0003-0813-2545	National Science Fund for Talent Trainning in Basic Science [J1103204]	National Science Fund for Talent Trainning in Basic Science	National Science Fund for Talent Trainning in Basic Science (Grant No. J1103204). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bickel T, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.041403; Binks B. P., 2006, COLLOIDAL PARTICLES; Blawzdziewicz J, 2010, J CHEM PHYS, V133, DOI 10.1063/1.3475217; Chen W, 2008, EPL-EUROPHYS LETT, V84, DOI 10.1209/0295-5075/84/28003; Cichocki B, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2724815; Crocker JC, 2000, PHYS REV LETT, V85, P888, DOI 10.1103/PhysRevLett.85.888; Cui BX, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.258301; Diamant H, 2005, J PHYS-CONDENS MAT, V17, pS4047, DOI 10.1088/0953-8984/17/49/003; Diamant H, 2005, J PHYS-CONDENS MAT, V17, pS2787, DOI 10.1088/0953-8984/17/31/003; Dufresne ER, 2000, PHYS REV LETT, V85, P3317, DOI 10.1103/PhysRevLett.85.3317; LEE SH, 1979, J FLUID MECH, V93, P705, DOI 10.1017/S0022112079001981; Levine AJ, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.061606; Lin BH, 2000, PHYS REV E, V62, P3909, DOI 10.1103/PhysRevE.62.3909; Mbamala EC, 2002, J PHYS-CONDENS MAT, V14, P4881, DOI 10.1088/0953-8984/14/19/313; Oppenheimer N, 2010, PHYS REV E, V82, DOI 10.1103/PhysRevE.82.041912; Oppenheimer N, 2009, BIOPHYS J, V96, P3041, DOI 10.1016/j.bpj.2009.01.020; Ortega F, 2010, CURR OPIN COLLOID IN, V15, P237, DOI 10.1016/j.cocis.2010.03.001; Peng Y, 2009, J FLUID MECH, V618, P243, DOI 10.1017/S0022112008004114; PERKINS GS, 1992, PHYSICA A, V189, P447, DOI 10.1016/0378-4371(92)90056-V; PERKINS GS, 1991, PHYSICA A, V171, P575, DOI 10.1016/0378-4371(91)90302-S; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Prasad V, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.176001; Pushkar P L, 2011, SOFT MATTER, V7, P6844; SAFFMAN PG, 1976, J FLUID MECH, V73, P593, DOI 10.1017/S0022112076001511; Savin T, 2005, BIOPHYS J, V88, P623, DOI [10.1529/biophysj.104.042457, 10.1529/biophysj.104.04245]; Shlomovitz R, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.137802; Sickert M, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.126104; Wang GM, 2011, J OPTICS-UK, V13, DOI 10.1088/2040-8978/13/4/044009; Wang GM, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.248303; Whitesides GM, 2001, PHYS TODAY, V54, P42, DOI 10.1063/1.1387591; Wu CY, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3243334; Wu J, 2006, APPL PHYS LETT, V89; Zhang W, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.168304	33	9	9	2	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2014	9	1							e85173	10.1371/journal.pone.0085173	http://dx.doi.org/10.1371/journal.pone.0085173			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297FH	24465498	Green Submitted, Green Published, gold			2023-01-03	WOS:000330240500036
J	Chen, C; Naidoo, N; Er, B; Cheong, A; Fong, NP; Tay, CY; Chan, KM; Tan, BY; Menon, E; Ee, CH; Lee, KK; Ng, YS; Teo, YY; Koh, GCH				Chen, Cynthia; Naidoo, Nasheen; Er, Benjamin; Cheong, Angela; Fong, Ngan Phoon; Tay, Choo Yian; Chan, Kin Ming; Tan, Boon Yeow; Menon, Edward; Ee, Chye Hua; Lee, Kok Keng; Ng, Yee Sien; Teo, Yik Ying; Koh, Gerald C. H.			Factors Associated with Nursing Home Placement of All Patients Admitted for Inpatient Rehabilitation in Singapore Community Hospitals from 1996 to 2005: A Disease Stratified Analysis	PLOS ONE			English	Article							STROKE REHABILITATION; CARE UTILIZATION; HIP FRACTURE; RISK; OUTCOMES; INSTITUTIONALIZATION; POPULATION; ADMISSIONS; MORTALITY; SERVICES	Objectives: To (1) identify social and rehabilitation predictors of nursing home placement, (2) investigate the association between effectiveness and efficiency in rehabilitation and nursing home placement of patients admitted for inpatient rehabilitation from 1996 to 2005 by disease in Singapore. Design: National data were retrospectively extracted from medical records of community hospital. Data Sources: There were 12,506 first admissions for rehabilitation in four community hospitals. Of which, 8,594 (90.3%) patients were discharged home and 924 (9.7%) patients were discharged to a nursing home. Other discharge destinations such as sheltered home (n = 37), other community hospital (n = 31), death in community hospital (n = 12), acute hospital (n = 1,182) and discharge against doctor's advice (n = 24) were excluded. Outcome Measure: Nursing home placement. Results: Those who were discharged to nursing home had 33% lower median rehabilitation effectiveness and 29% lower median rehabilitation efficiency compared to those who were discharged to nursing homes. Patients discharged to nursing homes were significantly older (mean age: 77 vs. 73 years), had lower mean Bathel Index scores (40 vs. 48), a longer median length of stay (40 vs. 33 days) and a longer time to rehabilitation (19 vs. 15 days), had a higher proportion without a caregiver (28 vs. 7%), being single (21 vs. 7%) and had dementia (23 vs. 10%). Patients admitted for lower limb amputation or falls had an increased odds of being discharged to a nursing home by 175% (p < 0.001) and 65% (p = 0.043) respectively compared to stroke patients. Conclusions: In our study, the odds of nursing home placement was found to be increased in Chinese, males, single or widowed or separated/divorced, patients in high subsidy wards for hospital care, patients with dementia, without caregivers, lower functional scores at admission, lower rehabilitation effectiveness or efficiency at discharge and primary diagnosis groups such as fractures, lower limb amputation and falls in comparison to strokes.	[Chen, Cynthia; Naidoo, Nasheen; Er, Benjamin; Cheong, Angela; Fong, Ngan Phoon; Teo, Yik Ying; Koh, Gerald C. H.] Natl Univ Singapore, Natl Univ Hlth Syst, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore; [Tay, Choo Yian] Agcy Integrated Care, Planning Div, Singapore, Singapore; [Chan, Kin Ming] Ang Mo Kio Thye Hua Kwan Hosp, Med Serv, Singapore, Singapore; [Tan, Boon Yeow] St Lukes Hosp, Med Serv, Singapore, Singapore; [Menon, Edward] St Andrews Community Hosp, Med Serv, Singapore, Singapore; [Ee, Chye Hua; Lee, Kok Keng] Bright Vis Hosp, Singapore, Singapore; [Ng, Yee Sien] Singapore Gen Hosp, Dept Rehabil Med, Singapore, Singapore; [Teo, Yik Ying] Agcy Sci Technol & Res, Genome Inst Singapore, Singapore, Singapore; [Teo, Yik Ying] Natl Univ Singapore, Grad Sch Integrat Sci & Engn, Singapore 117548, Singapore; [Teo, Yik Ying] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore 117548, Singapore	National University of Singapore; Singapore General Hospital; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; National University of Singapore	Koh, GCH (corresponding author), Natl Univ Singapore, Natl Univ Hlth Syst, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore.	Gerald_Koh@nuhs.edu.sg	CHEN, CYNTHIA/O-6203-2016; /AAR-5357-2020	Koh, Choon Huat Gerald/0000-0002-6453-6897; Naidoo, Nasheen/0000-0001-8613-4808; Ng, Yee-Sien/0000-0003-1377-5852	National University of Singapore (NUS) Start-Up Grant; NUS Provost Matching Grant; NUS Academic Research Fund; Ministry of Health (Singapore) Health Services Research Competitive Research [HSRG/0006/2013]	National University of Singapore (NUS) Start-Up Grant(National University of Singapore); NUS Provost Matching Grant; NUS Academic Research Fund; Ministry of Health (Singapore) Health Services Research Competitive Research(Ministry of Health-Singapore)	This study was supported by a National University of Singapore (NUS) Start-Up Grant, the NUS Provost Matching Grant, the NUS Academic Research Fund, and Ministry of Health (Singapore) Health Services Research Competitive Research Grant Number HSRG/0006/2013. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bhandari VK, 2005, ARCH PHYS MED REHAB, V86, P2081, DOI 10.1016/j.apmr.2005.05.008; Carter GM HO, 2003, CASE MIX CERTIFICATI; Coward RT, 1996, J GERONTOL B-PSYCHOL, V51, pS258, DOI 10.1093/geronb/51B.5.S258; CRYSTAL S, 1989, SOC WORK, V34, P277, DOI 10.1093/sw/34.3.277-a; Department of Statistics (DOS), 2012, KEY ANN IND; Department of Statistics Singapore, 2011, SING CENS POP 2010; Elderly and Continuing Care Division; Ministry of Health (Singapore), 2004, HEALTHC SERV ELD INF; Foley D J, 1992, J Aging Health, V4, P155, DOI 10.1177/089826439200400201; Gan KY, 2012, COMMUNICATION; Gaugler Joseph E, 2007, BMC Geriatr, V7, P13, DOI 10.1186/1471-2318-7-13; Goh SN, 2011, ASIA PAC J SOC WORK, V21, P31, DOI 10.1080/21650993.2011.9756095; Graham JE, 2008, J GERONTOL A-BIOL, V63, P860, DOI 10.1093/gerona/63.8.860; HEINEMANN AW, 1987, ARCH NEUROL-CHICAGO, V44, P1167, DOI 10.1001/archneur.1987.00520230051013; JETTE AM, 1992, GERONTOLOGIST, V32, P634, DOI 10.1093/geront/32.5.634; Kane RA, 1987, LONG TERM CARE PRINC; Koh GCH, 2012, ANN ACAD MED SINGAP, V41, P494; Koh GCH, 2012, INT J STROKE, V7, P606, DOI 10.1111/j.1747-4949.2011.00612.x; Lee T, 2001, PUBLIC HEALTH NURS, V18, P443, DOI 10.1046/j.1525-1446.2001.00443.x; Levy PS, 2000, STAT METHODS MED RES, V9, P41, DOI 10.1191/096228000666554731; Lim ES, 2009, AUST SOC WORK, V62, P90, DOI 10.1080/03124070802626901; Lum TY, 2005, J GERONTOL SOC WORK, V45, P3, DOI 10.1300/J083v45n04_02; MILLER B, 1994, J GERONTOL, V49, pS14, DOI 10.1093/geronj/49.1.S14; Miller EA, 2000, MED CARE RES REV, V57, P259, DOI 10.1177/107755870005700301; Ministry of Health (MOH), 2013, HOSP SERV; Ministry of Health (MOH), 2012, SING HEALTHC SYST SE; Ministry of Health (MOH), 2012, NURSING HOMES; Ministry of Health (MOH), 2004, HEALTHC SERV ELD INF; National Population And Talent Division (NPTD), 2012, PROJ FOR MANP DEM HE; Ng TP, 2006, J AM GERIATR SOC, V54, P21, DOI 10.1111/j.1532-5415.2005.00533.x; OECD, 2011, HELP WANTED PROVIDIN; Ottenbacher KJ, 2003, MED CARE, V41, P232, DOI 10.1097/00005650-200302000-00005; PEARLMAN DN, 1992, GERONTOLOGIST, V32, P527, DOI 10.1093/geront/32.4.527; Scharlach AE, 2006, J GERONTOL SOC WORK, V47, P133, DOI 10.1300/J083v47n01_09; SHAH S, 1990, STROKE, V21, P241, DOI 10.1161/01.STR.21.2.241; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; SHAPIRO E, 1988, GERONTOLOGIST, V28, P237, DOI 10.1093/geront/28.2.237; Smith GE, 2000, J AM GERIATR SOC, V48, P519, DOI 10.1111/j.1532-5415.2000.tb04998.x; STEINBACH U, 1992, J GERONTOL, V47, pS183, DOI 10.1093/geronj/47.4.S183; Van Baalen B, 2008, BRAIN INJURY, V22, P25, DOI 10.1080/02699050701810662; WINGARD DL, 1987, GERONTOLOGIST, V27, P156, DOI 10.1093/geront/27.2.156; Yap L. K. P., 2003, SMJ Singapore Medical Journal, V44, P065	41	10	10	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2013	8	12							e82697	10.1371/journal.pone.0082697	http://dx.doi.org/10.1371/journal.pone.0082697			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	278IG	24376567	Green Submitted, Green Published, gold			2023-01-03	WOS:000328882000022
J	Colombo, GL; Agabiti-Rosei, E; Margonato, A; Mencacci, C; Montecucco, CM; Trevisan, R				Colombo, Giorgio L.; Agabiti-Rosei, Enrico; Margonato, Alberto; Mencacci, Claudio; Montecucco, Carlo Maurizio; Trevisan, Roberto			Off-Patent Generic Medicines vs. Off-Patent Brand Medicines for Six Reference Drugs: A Retrospective Claims Data Study from Five Local Healthcare Units in the Lombardy Region of Italy	PLOS ONE			English	Article							ADHERENCE; THERAPY; STATIN; PRICE; DISCONTINUATION; SUBSTITUTION; COMPETITION; IMPACT; RATES; COST	The scientific documentation supporting the potential clinical and economic benefits of a growing use of off-patent generic drugs in clinical practice seems to be limited in Italy as yet. Methods: We compared differences in outcomes between off-patent generic drugs and off-patent brand drugs in real clinical practice. The outcomes were: persistence and compliance with therapy, mortality, and other health resources consumption (hospitalizations, specialist examinations, other drugs) and total costs. Retrospective analysis was carried out by using the administrative databases of five Local Healthcare Units (ASLs - Aziende Sanitarie Locali) in the Lombardy Region of Italy. Data from the five ASLs were aggregated through a meta-analysis, which produced an estimate indicator of the mean or percentage difference between the two groups (branded vs. generic) and their respective significance tests. The therapeutic areas and studied drugs were: diabetes: metformin - A10BA02; hypertension: amlodipine - C08CA01; dyslipidemia: simvastatin - C10AA01; psychiatry: sertraline - N06AB06; cardiology: propafenone - C01BC03; osteoporosis: alendronate - M05BA04. Results: The 5 Local Healthcare Units (ASL) represent a population of 3,847,004 inhabitants. The selected sample included 347,073 patients, or 9.02% of the total ASL population; 67% of the patients were treated with off-patent brand drugs. The average age was 68 years, with no difference between the two groups. After 34 months of observation, compliance and persistence were in favor to generic drugs in all therapeutic areas and statistically significant in the metformin, amlodipine, simvastatin, and sertraline groups. The clinical outcomes (hospitalizations, mortality, and other health costs) show no statistically significant differences between off-patent generic vs. off-patent brand medicines. Conclusions: Off-patent generic drugs appear to be a therapy option of choice in Italy as well, based on clinical outcomes and economic consequences, both for the National Health Service and patients, considering that the price difference between brand and generic drugs is completely charged on patients.	[Colombo, Giorgio L.] Univ Pavia, Dept Drug Sci, I-27100 Pavia, Italy; [Colombo, Giorgio L.] SAVE Anal Valutaz Econ, Milan, Italy; [Agabiti-Rosei, Enrico] Spedali Civil Brescia, Div Med & Surg, I-25125 Brescia, Italy; [Margonato, Alberto] San Raffaele Univ Hosp, Div Cardiol, Milan, Italy; [Mencacci, Claudio] AO Fatebenefratelli & Oftalm, Dept Neurosci, Milan, Italy; [Montecucco, Carlo Maurizio] Univ Pavia, Div Rheumatol, IRCCS Policlin S Matteo, I-27100 Pavia, Italy; [Trevisan, Roberto] Osped Riuniti Bergamo, Unit Diabetol, I-24100 Bergamo, Italy	University of Pavia; Hospital Spedali Civili Brescia; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS Fondazione San Matteo; University of Pavia; Ospedali Riuniti di Bergamo	Colombo, GL (corresponding author), Univ Pavia, Dept Drug Sci, Via Palestro 3, I-27100 Pavia, Italy.	giorgio.colombo@unipv.it	MARGONATO, ALBERTO/B-4185-2015; TREVISAN, ROBERTO/Q-8706-2016; MONTECUCCO, CARLOMAURIZIO/K-5236-2018	TREVISAN, ROBERTO/0000-0003-0420-4468; MONTECUCCO, CARLOMAURIZIO/0000-0001-8263-3925	DOC Generici, Milan (Italy)	DOC Generici, Milan (Italy)	This work was supported by a DOC Generici, Milan (Italy), non-discretionary educational grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahrens W, 2007, PHARMACOEPIDEM DR S, V16, P1298, DOI 10.1002/pds.1494; AIFA Italian Medicines Agency - Gruppo di lavoro OSMED L'uso dei farmaci in Italia, 2012, RAPP OSMED GENN SETT; Aronica A, 2011, CLINICOECONOMICS ITA, V6, P15; Atar D, 2009, ANN MED, V41, P242, DOI 10.1080/07853890902729786; Borenstein M., 2009, INTRO META ANAL; Caetano PA, 2006, CLIN THER, V28, P1411, DOI 10.1016/j.clinthera.2006.09.021; Catapano AL, 2010, CARE, V6, P33; Cerra C, 2004, PHARMACOECONOMICS IT, V6, P141, DOI DOI 10.1007/BF03320632; Colombo GL, 2012, PATIENT PREFER ADHER, V6, P653, DOI 10.2147/PPA.S33968; CRAMER JA, 1995, AM J HEALTH-SYST PH, V52, pS27, DOI 10.1093/ajhp/52.14_Suppl_3.S27; Davit BM, 2009, ANN PHARMACOTHER, V43, P1583, DOI 10.1345/aph.1M141; DiMatteo MR, 2002, MED CARE, V40, P794, DOI 10.1097/01.MLR.0000024612.61915.2D; Dylst P, 2011, PHARMACOECONOMICS, V29, P875, DOI 10.2165/11585970-000000000-00000; Ellis JJ, 2004, J GEN INTERN MED, V19, P638, DOI 10.1111/j.1525-1497.2004.30516.x; Hess LM, 2006, ANN PHARMACOTHER, V40, P1280, DOI 10.1345/aph.1H018; Kesselheim AS, 2008, JAMA-J AM MED ASSOC, V300, P2514, DOI 10.1001/jama.2008.758; Lexchin J, 2004, HEALTH POLICY, V68, P47, DOI 10.1016/j.healthpol.2003.07.007; Mazzaglia G, 2009, CIRCULATION, V120, P1598, DOI 10.1161/CIRCULATIONAHA.108.830299; Normand SLT, 1999, STAT MED, V18, P321, DOI 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.3.CO;2-G; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Peters JR, 2009, DERMATOL THER, V22, P229, DOI 10.1111/j.1529-8019.2009.01236.x; Puig-Junoy J, 2010, PHARMACOECONOMICS, V28, P649, DOI 10.2165/11535360-000000000-00000; Roblin DW, 2005, MED CARE, V43, P951, DOI 10.1097/01.mlr.0000178216.23514.b7; Ruggeri I, 2012, CLINICOECONOMIC OUTC, V4, P375, DOI 10.2147/CEOR.S36499; Sabat E, 2003, ADHERENCE LONG TERM; Shrank WH, 2006, ARCH INTERN MED, V166, P332, DOI 10.1001/archinte.166.3.332; Simoens S, 2007, CURR MED RES OPIN, V23, P2647, DOI 10.1185/030079907X233395; Simoens Steven, 2008, J Med Econ, V11, P171, DOI 10.3111/13696990801939716; Van Wijk BLG, 2006, ANN PHARMACOTHER, V40, P15, DOI 10.1345/aph.1G163; Vlahiotis A, 2011, J MANAGE CARE PHARM, V17, P123; WHO, WORLD HLTH REP HLTH	31	17	17	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2013	8	12							e82990	10.1371/journal.pone.0082990	http://dx.doi.org/10.1371/journal.pone.0082990			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276HL	24367576	Green Published, Green Submitted, gold			2023-01-03	WOS:000328740300087
J	Liao, XM; Zhou, XL; Mak, NK; Leung, KN				Liao, Xuemei; Zhou, Xuelin; Mak, Nai-ki; Leung, Kwok-nam			Tryptanthrin Inhibits Angiogenesis by Targeting the VEGFR2-Mediated ERK1/2 Signalling Pathway	PLOS ONE			English	Article							METASTATIC COLORECTAL-CANCER; GROWTH-FACTOR RECEPTORS; IN-VIVO; ENDOTHELIAL-CELLS; TUMOR ANGIOGENESIS; KINASE INHIBITORS; LEUKEMIA-CELLS; MECHANISMS; VEGFR2; VITRO	Angiogenesis is a key step for tumour growth and metastasis, and anti-angiogenesis has been proposed as an important strategy for cancer therapy. Tryptanthrin is a weakly basic alkaloid isolated from the dried roots of medicinal indigo plants and has been shown to possess anti-tumour activities on various cancer cell types. This study aims to investigate the in vitro and in vivo anti-angiogenic activities of tryptanthrin and to unravel its underlying molecular action mechanisms. Our results show that tryptanthrin inhibited the in vitro proliferation, migration, and tube formation of the human microvascular endothelial cells (HMEC-1) in a concentration-dependent manner and significantly suppressed angiogenesis in Matrigel plugs in mice. Mechanistic studies indicated that tryptanthrin reduced the expression of several pro-angiogenic factors (Ang-1, PDGFB and MMP2). Tryptanthrin was also found to suppress the VEGFR2-mediated ERK1/2 signalling pathway in HMEC-1 cells and molecular docking simulation indicated that tryptanthrin could bound to the ATP-binding site of VEGFR2. Collectively, the present study demonstrated that tryptanthrin exhibited both in vitro and in vivo anti-angiogenic activities by targeting the VEGFR2-mediated ERK1/2 signalling pathway and might have therapeutic potential for the treatment of angiogenesis-related diseases.	[Liao, Xuemei; Leung, Kwok-nam] Chinese Univ Hong Kong, Sch Life Sci, Biochem Programme, Shatin, Hong Kong, Peoples R China; [Zhou, Xuelin] Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China; [Mak, Nai-ki] Hong Kong Baptist Univ, Dept Biol, Kowloon Tong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Hong Kong Baptist University	Leung, KN (corresponding author), Chinese Univ Hong Kong, Sch Life Sci, Biochem Programme, Shatin, Hong Kong, Peoples R China.	knleung@cuhk.edu.hk	ZHOU, Xuelin/L-4359-2013	ZHOU, Xuelin/0000-0002-4051-7851	School of Life Sciences, The Chinese University of Hong Kong	School of Life Sciences, The Chinese University of Hong Kong	This work was supported by the general research funding of the School of Life Sciences, The Chinese University of Hong Kong. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; BAR RS, 1989, ENDOCRINOLOGY, V124, P1841, DOI 10.1210/endo-124-4-1841; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Cattaneo MG, 2003, BRIT J PHARMACOL, V138, P377, DOI 10.1038/sj.bjp.0705051; Chan HL, 2009, CELL MOL IMMUNOL, V6, P335, DOI 10.1038/cmi.2009.44; Chan JYW, 2011, J ETHNOPHARMACOL, V137, P64, DOI 10.1016/j.jep.2011.04.021; Chan YK, 2012, BIOCHEM PHARMACOL, V83, P598, DOI 10.1016/j.bcp.2011.12.003; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; He MF, 2010, INT J CANCER, V126, P266, DOI 10.1002/ijc.24694; HONDA G, 1979, PLANTA MED, V37, P172, DOI 10.1055/s-0028-1097320; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Hurwitz HI, 2005, J CLIN ONCOL, V23, P3502, DOI 10.1200/JCO.2005.10.017; KANEKO T, 1992, STROKE, V23, P1637, DOI 10.1161/01.STR.23.11.1637; Kankanala J, 2012, BRIT J PHARMACOL, V166, P737, DOI 10.1111/j.1476-5381.2011.01801.x; Karkkainen MJ, 2000, ONCOGENE, V19, P5598, DOI 10.1038/sj.onc.1203855; Kimoto T, 2001, PATHOL INT, V51, P315, DOI 10.1046/j.1440-1827.2001.01204.x; Koch S, 2011, BIOCHEM J, V437, P169, DOI 10.1042/BJ20110301; Lai L, 2012, BRIT J PHARMACOL, V165, P1084, DOI 10.1111/j.1476-5381.2011.01532.x; Lee K, 2010, EUR J MED CHEM, V45, P5420, DOI 10.1016/j.ejmech.2010.09.002; Liao XM, 2013, CHEM-BIOL INTERACT, V203, P512, DOI 10.1016/j.cbi.2013.03.001; Lin YK, 2009, J ETHNOPHARMACOL, V125, P51, DOI 10.1016/j.jep.2009.06.014; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; McTigue MA, 1999, STRUCT FOLD DES, V7, P319, DOI 10.1016/S0969-2126(99)80042-2; Mu XM, 2012, MOLECULES, V17, P6854, DOI 10.3390/molecules17066854; Nanobashvili J., 2003, EUR SURG, V35, P214, DOI 10.1007/s10353-003-0012-0; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Paz K, 2005, FRONT BIOSCI-LANDMRK, V10, P1415, DOI 10.2741/1629; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Recio MC, 2006, PLANTA MED, V72, P539, DOI 10.1055/s-2006-931562; Risau W, 1992, GROWTH FACTORS, V7, P261, DOI 10.3109/08977199209046408; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Schrenk D, 1997, BIOCHEM PHARMACOL, V54, P165, DOI 10.1016/S0006-2952(97)00150-0; Shojaei F, 2012, CANCER LETT, V320, P130, DOI 10.1016/j.canlet.2012.03.008; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takahashi S, 2011, BIOL PHARM BULL, V34, P1785, DOI 10.1248/bpb.34.1785; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Tong YG, 2005, INT J CANCER, V114, P843, DOI 10.1002/ijc.20804; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Yu ST, 2007, BIOCHEM BIOPH RES CO, V358, P79, DOI 10.1016/j.bbrc.2007.04.107; Yue GGL, 2011, BRIT J PHARMACOL, V164, P1883, DOI 10.1111/j.1476-5381.2011.01458.x; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; Zhou XL, 2013, PHYTOMEDICINE, V20, P367, DOI 10.1016/j.phymed.2012.09.021; Zhu XG, 2011, J PHARM PHARM SCI, V14, P325, DOI 10.18433/J3501W	48	44	46	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2013	8	12							e82294	10.1371/journal.pone.0082294	http://dx.doi.org/10.1371/journal.pone.0082294			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276GD	24358167	Green Published, gold, Green Submitted			2023-01-03	WOS:000328735700056
J	Zhang, S; An, QZ; Li, QY; Huang, J; Chen, X; Chen, XY; Zhang, J; Wang, YT; Yang, GY; Zhu, W				Zhang, Song; An, Qingzhu; Li, Qianyun; Huang, Jun; Chen, Xi; Chen, Xiaoyan; Zhang, Jun; Wang, Yongting; Yang, Guo-Yuan; Zhu, Wei			Therapeutic Benefit of Bone Marrow-Derived Endothelial Progenitor Cell Transplantation after Experimental Aneurysm Embolization with Coil in Rats	PLOS ONE			English	Article							GUGLIELMI DETACHABLE COIL; INTRACRANIAL ANEURYSMS; ENDOVASCULAR TREATMENT; CEREBRAL ANEURYSMS; SACCULAR ANEURYSMS; MOBILIZATION; NEOVASCULARIZATION; RETREATMENT; PLATINUM; REPAIR	Aneurysm embolization with coil is now widely used clinically. However, the recurrence of aneurysms after embolization has always plagued neurosurgeons because the endothelial layer of the aneurysm neck loses its integrity after being embolized by coil. Bone marrow-derived endothelial progenitor cells (BM-EPCs) could be incorporated into injured endothelium and differentiate into mature endothelial cells during vascular repairing processes. The aim of our study is to explore the effects of BM-EPCs on aneurysm repairing and remodeling in a rat embolization model of abdominal aortic aneurysm. BM-EPC proliferation, migration and tube formation were not affected by super-paramagnetic iron oxide nanoparticle (SPIO) labeling compared to the controls (p>0.05). The number of SPIO-labeled cells greatly increased in EPC transplanted rats compared to that of phosphate buffered saline treated rats. SPIO-labeled EPC (SPIO-EPC) are mainly located in the aneurysm neck and surrounded by fibrous tissue. A histology study showed that the aneurysm orifice was closed with neointima and the aneurysm was filled with newly formed fibrous tissue. The SPIO-EPC accumulated in the aneurysm neck, which accelerated focal fibrous tissue remodeling, suggesting that BM-EPCs play a crucial role in repairing and remodeling the aneurysm neck orifice.	[Zhang, Song; An, Qingzhu; Chen, Xi; Zhu, Wei] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai 200433, Peoples R China; [Zhang, Jun] Fudan Univ, Huashan Hosp, Dept Radiol, Shanghai 200433, Peoples R China; [Li, Qianyun; Huang, Jun; Chen, Xiaoyan; Wang, Yongting; Yang, Guo-Yuan] Shanghai Jiao Tong Univ, Neurosci & Neuroengn Res Ctr, Med X Res Inst, Shanghai 200030, Peoples R China; [Li, Qianyun; Huang, Jun; Chen, Xiaoyan; Wang, Yongting; Yang, Guo-Yuan] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200030, Peoples R China	Fudan University; Fudan University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Yang, GY (corresponding author), Shanghai Jiao Tong Univ, Neurosci & Neuroengn Res Ctr, Med X Res Inst, Shanghai 200030, Peoples R China.	gyyang0626@gmail.com; weszhu398@yahoo.com	Wang, Yongting/C-2916-2014	zhang, jun/0000-0003-1849-9199; Qianyun, li/0000-0001-5089-2084	National Natural Science Foundation of China [30973105, 81070939, 81100868]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The study was supported by the National Natural Science Foundation of China 30973105 (WZ), 81070939 (GYY), and 81100868 (YTW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aronson JP, 2012, J NEUROSURG, V117, P546, DOI 10.3171/2012.5.JNS091308; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Cekirge HS, 2000, ACTA RADIOL, V41, P111; Dai D, 2005, AM J NEURORADIOL, V26, P1932; Fang XG, 2012, J CLIN NEUROSCI, V19, P1283, DOI 10.1016/j.jocn.2011.09.038; Friedman JA, 2003, AM J NEURORADIOL, V24, P526; Fujinaka Toshiyuki, 2012, Masui, V61, P962; Grasso G, 2009, MED SCI MONITOR, V15, pCS63; GUGLIELMI G, 1991, J NEUROSURG, V75, P1, DOI 10.3171/jns.1991.75.1.0001; Horowitz M, 1999, NEUROSURGERY, V44, P712, DOI 10.1097/00006123-199904000-00013; Ii M, 2005, CIRCULATION, V111, P1114, DOI 10.1161/01.CIR.0000157144.24888.7E; JUVELA S, 1992, NEUROSURGERY, V30, P7, DOI 10.1227/00006123-199201000-00002; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kallmes DF, 1999, RADIOLOGY, V213, P217, DOI 10.1148/radiology.213.1.r99oc16217; Kamei N, 2012, J NEUROSCI RES, V90, P2281, DOI 10.1002/jnr.23113; Kawamoto A, 2003, CIRCULATION, V107, P461, DOI 10.1161/01.CIR.0000046450.89986.50; Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57; Lehtinen T, 2012, J INVASIVE CARDIOL, V24, P631; Li H, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-46; Matsumaru Y, 2004, INTERV NEURORADIOL, V10, P167, DOI 10.1177/15910199040100S129; Miller-Kasprzak E, 2007, ARCH IMMUNOL THER EX, V55, P247, DOI 10.1007/s00005-007-0027-5; Morris LM, 2010, WOUND REPAIR REGEN, V18, P383, DOI 10.1111/j.1524-475X.2010.00596.x; Reul J, 1997, AM J NEURORADIOL, V18, P35; Scacciatella P, 2013, MINERVA CARDIOANGIOL, V61, P211; Shintani S, 2001, CIRCULATION, V103, P2776, DOI 10.1161/hc2301.092122; Solander S, 1999, J NEUROSURG, V90, P857, DOI 10.3171/jns.1999.90.5.0857; Spetzger U, 1998, SURG NEUROL, V49, P491, DOI 10.1016/S0090-3019(96)00437-5; Suh W, 2005, STEM CELLS, V23, P1571, DOI 10.1634/stemcells.2004-0340; Sung SH, 2013, INT J CARDIOL, V168, P1070, DOI 10.1016/j.ijcard.2012.11.002; Tong FC, 2000, J CLIN NEUROSCI, V7, P244, DOI 10.1054/jocn.1999.0211; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; Wei HJ, 2011, NEUROSCI LETT, V498, P114, DOI 10.1016/j.neulet.2011.04.061; Wei HJ, 2011, J NEUROSCI RES, V89, P1822, DOI 10.1002/jnr.22696; Zampetaki A, 2008, CARDIOVASC RES, V78, P413, DOI 10.1093/cvr/cvn081	34	14	17	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2014	9	2							e90069	10.1371/journal.pone.0090069	http://dx.doi.org/10.1371/journal.pone.0090069			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC3DW	24587209	Green Published, Green Submitted, gold			2023-01-03	WOS:000332396200118
J	Teismann, H; Wollbrink, A; Okamoto, H; Schlaug, G; Rudack, C; Pantev, C				Teismann, Henning; Wollbrink, Andreas; Okamoto, Hidehiko; Schlaug, Gottfried; Rudack, Claudia; Pantev, Christo			Combining Transcranial Direct Current Stimulation and Tailor-Made Notched Music Training to Decrease Tinnitus-Related Distress - A Pilot Study	PLOS ONE			English	Article							NONINVASIVE BRAIN-STIMULATION; LEFT AUDITORY-CORTEX; NEUROSCIENCE; PLASTICITY; RESPONSES; SESSIONS; STROKE; TDCS	The central auditory system has a crucial role in tinnitus generation and maintenance. Curative treatments for tinnitus do not yet exist. However, recent attempts in the therapeutic application of both acoustic stimulation/training procedures and electric/magnetic brain stimulation techniques have yielded promising results. Here, for the first time we combined tailor-made notched music training (TMNMT) with transcranial direct current stimulation (tDCS) in an effort to modulate TMNMT efficacy in the treatment of 32 patients with tonal tinnitus and without severe hearing loss. TMNMT is characterized by regular listening to so-called notched music, which is generated by digitally removing the frequency band of one octave width centered at the individual tinnitus frequency. TMNMT was applied for 10 subsequent days (2.5 hours of daily treatment). During the initial 5 days of treatment and the initial 30 minutes of TMNMT sessions, tDCS (current strength: 2 mA; anodal (N = 10) vs. cathodal (N = 11) vs. sham (N = 11) groups) was applied simultaneously. The active electrode was placed on the head surface over left auditory cortex; the reference electrode was put over right supra-orbital cortex. To evaluate treatment outcome, tinnitus-related distress and perceived tinnitus loudness were assessed using standardized tinnitus questionnaires and a visual analogue scale. The results showed a significant treatment effect reflected in the Tinnitus Handicap Questionnaire that was largest after 5 days of treatment. This effect remained significant at the end of follow-up 31 days after treatment cessation. Crucially, tDCS did not significantly modulate treatment efficacy - it did not make a difference whether anodal, cathodal, or sham tDCS was applied. Possible explanations for the findings and functional modifications of the experimental design for future studies (e.g. the selection of control conditions) are discussed.	[Teismann, Henning; Wollbrink, Andreas; Pantev, Christo] Univ Hosp, Inst Biomagnetism & Biosignalanal, Munster, Germany; [Teismann, Henning] Univ Hosp, Inst Epidemiol & Social Med, Munster, Germany; [Okamoto, Hidehiko] Natl Inst Physiol Sci, Dept Integrat Physiol, Okazaki, Aichi 444, Japan; [Schlaug, Gottfried] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; [Schlaug, Gottfried] Harvard Univ, Sch Med, Boston, MA USA; [Rudack, Claudia] Univ Hosp, Dept Otorhinolaryngol, Munster, Germany	University of Munster; University of Munster; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Munster	Teismann, H (corresponding author), Univ Hosp, Inst Biomagnetism & Biosignalanal, Munster, Germany.	h.teismann@uni-muenster.de	Okamoto, Hidehiko/A-7934-2008	Okamoto, Hidehiko/0000-0003-2799-3340	Interdisziplinare Zentrum fur Klinische Forschung Munster [CRA05]; Japan Society for the Promotion of Science for Young Scientists [23689070]; Deutsche Forschungsgemeinschaft; Open Access Publication Fund of the University of Munster	Interdisziplinare Zentrum fur Klinische Forschung Munster; Japan Society for the Promotion of Science for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Open Access Publication Fund of the University of Munster	This work was supported by the "Interdisziplinare Zentrum fur Klinische Forschung Munster'' (CRA05) and the ''Japan Society for the Promotion of Science for Young Scientists'' (23689070). We acknowledge support by the "Deutsche Forschungsgemeinschaft'' and the "Open Access Publication Fund of the University of Munster''. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arnold W, 1996, ORL J OTO-RHINO-LARY, V58, P195, DOI 10.1159/000276835; Blood AJ, 2001, P NATL ACAD SCI USA, V98, P11818, DOI 10.1073/pnas.191355898; Davis PB, 2007, EAR HEARING, V28, P242, DOI 10.1097/AUD.0b013e3180312619; De Ridder D, 2011, P NATL ACAD SCI USA, V108, P8075, DOI 10.1073/pnas.1018466108; Del Bo L, 2011, TEXTBOOK OF TINNITUS, P597, DOI 10.1007/978-1-60761-145-5_74; DYMOND AM, 1975, BIOL PSYCHIAT, V10, P101; Eggermont JJ, 2006, ACTA OTO-LARYNGOL, V126, P9, DOI 10.1080/03655230600895259; Eggermont JJ, 2004, TRENDS NEUROSCI, V27, P676, DOI 10.1016/j.tins.2004.08.010; Eggermont JJ, 2012, FRONT SYST NEUROSCI, V6, DOI 10.3389/fnsys.2012.00053; Faber M, 2012, BRAIN STIMUL, V5, P492, DOI 10.1016/j.brs.2011.09.003; Frank E, 2012, J NEUROL, V259, P327, DOI 10.1007/s00415-011-6189-4; Fregni F, 2006, EUR J NEUROL, V13, P996, DOI 10.1111/j.1468-1331.2006.01414.x; Fregni F, 2007, NAT CLIN PRACT NEURO, V3, P383, DOI 10.1038/ncpneuro0530; Fritsch B, 2010, NEURON, V66, P198, DOI 10.1016/j.neuron.2010.03.035; Garin P, 2011, J NEUROL, V258, P1940, DOI 10.1007/s00415-011-6037-6; Giraud AL, 1999, NEUROREPORT, V10, P1, DOI 10.1097/00001756-199901180-00001; HALLAM RS, 1988, BRIT J CLIN PSYCHOL, V27, P213, DOI 10.1111/j.2044-8260.1988.tb00778.x; Hautzinger M, 1977, PSYCHIAT PRAX, V39, P302, DOI DOI 10.1055/S-0032-1326702; Kaltenbach JA, 2011, TEXTBOOK OF TINNITUS, P259, DOI 10.1007/978-1-60761-145-5_31; Kaltenbach JA, 2011, HEARING RES, V276, P52, DOI 10.1016/j.heares.2010.12.003; KUK FK, 1990, EAR HEARING, V11, P434, DOI 10.1097/00003446-199012000-00005; Langguth B, 2006, ACTA OTO-LARYNGOL, V126, P84, DOI 10.1080/03655230600895317; Langguth B, 2012, LANCET, V379, P1926, DOI 10.1016/S0140-6736(12)60561-3; Langguth B, 2012, FRONT SYST NEUROSCI, V6, DOI 10.3389/fnsys.2012.00015; Langguth B, 2009, EXPERT OPIN EMERG DR, V14, P687, DOI 10.1517/14728210903206975; Lindenberg R, 2012, NEUROREHAB NEURAL RE, V26, P479, DOI 10.1177/1545968311427568; Lockwood AH, 2001, NEUROLOGY, V56, P472, DOI 10.1212/WNL.56.4.472; Lockwood AH, 1998, NEUROLOGY, V50, P114, DOI 10.1212/WNL.50.1.114; Mathys C, 2010, FRONT PSYCHOL, V1, DOI 10.3389/fpsyg.2010.00193; Mirz F, 1999, HEARING RES, V134, P133, DOI 10.1016/S0378-5955(99)00075-1; Mirz F, 2000, NEUROREPORT, V11, P633, DOI 10.1097/00001756-200002280-00039; Neuling Toralf, 2012, Front Psychiatry, V3, P83; Newman CW, 1996, ARCH OTOLARYNGOL, V122, P143; NITSCHE MA, 2007, TMS BUCH HDB TRANSKR, P533; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Okamoto H, 2005, EUR J NEUROSCI, V21, P1957, DOI 10.1111/j.1460-9568.2005.04022.x; Okamoto H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017022; Okamoto H, 2010, P NATL ACAD SCI USA, V107, P1207, DOI 10.1073/pnas.0911268107; Pantev C, 1999, BRAIN RES, V842, P192, DOI 10.1016/S0006-8993(99)01835-1; Pantev C, 2012, FRONT SYST NEUROSCI, V6, DOI 10.3389/fnsys.2012.00050; Plewnia C, 2007, HUM BRAIN MAPP, V28, P238, DOI 10.1002/hbm.20270; PREECE J, 2003, GERIATR AGEING, V6, DOI DOI 10.1288/00005537-195005000-00002/ABSTRACT.ACCESSED; Reyes SA, 2002, HEARING RES, V171, P43, DOI 10.1016/S0378-5955(02)00346-5; Roberts LE, 2011, TEXTBOOK OF TINNITUS, P563, DOI 10.1007/978-1-60761-145-5_72; Schlaug G, 2011, NEUROPSYCHOL REV, V21, P288, DOI 10.1007/s11065-011-9181-y; Schlaug G, 2008, ARCH NEUROL-CHICAGO, V65, P1571, DOI 10.1001/archneur.65.12.1571; Schlee W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003720; Schmitz N, 2000, QUAL LIFE RES, V9, P185, DOI 10.1023/A:1008931926181; Spielberger C.D., 1970, MANUAL STATE TRAIT A, DOI 10.2307/1831273; Stracke Henning, 2010, Commun Integr Biol, V3, P274; Tass PA, 2012, RESTOR NEUROL NEUROS, V30, P137, DOI 10.3233/RNN-2012-110218; Teismann H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024685; Tyler RS, 2012, J AM ACAD AUDIOL, V23, P115, DOI 10.3766/jaaa.23.2.6; Vanneste S, 2011, BRAIN STIMUL, V4, P242, DOI 10.1016/j.brs.2010.12.001; Vanneste S, 2011, EUR J NEUROSCI, V34, P605, DOI 10.1111/j.1460-9568.2011.07778.x; Vanneste S, 2011, EXP BRAIN RES, V210, P217, DOI 10.1007/s00221-011-2617-z; Vanneste S, 2010, EXP BRAIN RES, V202, P779, DOI 10.1007/s00221-010-2183-9; Vines BW, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00230; Wang HT, 2001, CHINESE MED J-PEKING, V114, P848; Zaehle T, 2011, EXP BRAIN RES, V215, P135, DOI 10.1007/s00221-011-2879-5; Zheng Y, 2011, NEUROSCIENCE, V193, P143, DOI 10.1016/j.neuroscience.2011.07.026	61	36	36	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2014	9	2							e89904	10.1371/journal.pone.0089904	http://dx.doi.org/10.1371/journal.pone.0089904			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC2ZX	24587113	Green Published, gold			2023-01-03	WOS:000332385900093
J	Shi, XD; Chen, GJ; Guo, LW; Si, Y; Zhu, M; Pilla, S; Liu, B; Gong, SQ; Kent, KC				Shi, Xudong; Chen, Guojun; Guo, Lian-Wang; Si, Yi; Zhu, Men; Pilla, Srikanth; Liu, Bo; Gong, Shaoqin; Kent, K. Craig			Periadventitial Application of Rapamycin-Loaded Nanoparticles Produces Sustained Inhibition of Vascular Restenosis	PLOS ONE			English	Article							MUSCLE-CELL PROLIFERATION; DRUG-ELUTING STENTS; IN-VIVO; NEOINTIMAL HYPERPLASIA; RE-ENDOTHELIALIZATION; PERIVASCULAR DELIVERY; PLGA NANOPARTICLES; DENDRITIC CELLS; GENE-TRANSFER; TGF-BETA	Open vascular reconstructions frequently fail due to the development of recurrent disease or intimal hyperplasia (IH). This paper reports a novel drug delivery method using a rapamycin-loaded poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs)/pluronic gel system that can be applied periadventitially around the carotid artery immediately following the open surgery. In vitro studies revealed that rapamycin dispersed in pluronic gel was rapidly released over 3 days whereas release of rapamycin from rapamycin-loaded PLGA NPs embedded in pluronic gel was more gradual over 4 weeks. In cultured rat vascular smooth muscle cells (SMCs), rapamycin-loaded NPs produced durable (14 days versus 3 days for free rapamycin) inhibition of phosphorylation of S6 kinase (S6K1), a downstream target in the mTOR pathway. In a rat balloon injury model, periadventitial delivery of rapamycin-loaded NPs produced inhibition of phospho-S6K1 14 days after balloon injury. Immunostaining revealed that rapamycin-loaded NPs reduced SMC proliferation at both 14 and 28 days whereas rapamycin alone suppressed proliferation at day 14 only. Moreover, rapamycin-loaded NPs sustainably suppressed IH for at least 28 days following treatment, whereas rapamycin alone produced suppression on day 14 with rebound of IH by day 28. Since rapamycin, PLGA, and pluronic gel have all been approved by the FDA for other human therapies, this drug delivery method could potentially be translated into human use quickly to prevent failure of open vascular reconstructions.	[Shi, Xudong; Guo, Lian-Wang; Si, Yi; Liu, Bo; Kent, K. Craig] Univ Wisconsin Hosp & Clin, Dept Surg, Madison, WI 53792 USA; [Chen, Guojun; Zhu, Men; Pilla, Srikanth; Gong, Shaoqin] Univ Wisconsin, Wisconsin Inst Discovery, Madison, WI 53715 USA; [Chen, Guojun; Zhu, Men; Gong, Shaoqin] Univ Wisconsin, Mat Sci Program, Madison, WI 53706 USA; [Gong, Shaoqin] Univ Wisconsin, Dept Biomed Engn, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Gong, SQ (corresponding author), Univ Wisconsin, Wisconsin Inst Discovery, Madison, WI 53715 USA.	sgong@engr.wisc.edu; kent@surgery.wisc.edu	Pilla, Srikanth/F-4622-2011	Pilla, Srikanth/0000-0003-3728-6578; Zhu, Men/0000-0001-9399-8444	National Heart, Lung, Blood Institute [R01-HL-068673]; National Science Foundation [DMR 1032187]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068673] Funding Source: NIH RePORTER	National Heart, Lung, Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Science Foundation(National Science Foundation (NSF)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by National Heart, Lung, Blood Institute Grant R01-HL-068673 (to KCK) and a grant from National Science Foundation (DMR 1032187 to SG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abizaid A, 2010, CIRC-CARDIOVASC INTE, V3, P384, DOI 10.1161/CIRCINTERVENTIONS.109.891192; Acharya S, 2011, ADV DRUG DELIVER REV, V63, P170, DOI 10.1016/j.addr.2010.10.008; Avgoustakis K, 2002, J CONTROL RELEASE, V79, P123, DOI 10.1016/S0168-3659(01)00530-2; Brown MA, 2010, ARTERIOSCL THROM VAS, V30, P2150, DOI 10.1161/ATVBAHA.110.207076; Cartiera MS, 2009, BIOMATERIALS, V30, P2790, DOI 10.1016/j.biomaterials.2009.01.057; Chorny M, 2000, CRIT REV THER DRUG, V17, P249; CLOWES MM, 1994, J CLIN INVEST, V93, P644, DOI 10.1172/JCI117016; Curcio A, 2011, CIRC J, V75, P1287, DOI 10.1253/circj.CJ-11-0366; Daemen J, 2008, AM J CARDIOL, V101, P1105, DOI 10.1016/j.amjcard.2007.11.074; Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043; Ding M, 2011, ARTERIOSCL THROM VAS, V31, P1403, DOI 10.1161/ATVBAHA.110.216804; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Guzman LA, 1996, CIRCULATION, V94, P1441, DOI 10.1161/01.CIR.94.6.1441; Inoue T, 2011, JACC-CARDIOVASC INTE, V4, P1057, DOI 10.1016/j.jcin.2011.05.025; Jhunjhunwala S, 2009, J CONTROL RELEASE, V133, P191, DOI 10.1016/j.jconrel.2008.10.011; Jim J, 2012, J VASC SURG, V55, P1394, DOI 10.1016/j.jvs.2011.11.061; Kawatsu S, 2007, ANN THORAC SURG, V84, P560, DOI 10.1016/j.athoracsur.2007.02.034; Kundi R, 2009, CARDIOVASC RES, V84, P326, DOI 10.1093/cvr/cvp220; Liuzzo John P, 2005, J Invasive Cardiol, V17, P497; Lu JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI 10.1586/ERM.09.15; Luscher TF, 2007, CIRCULATION, V115, P1051, DOI 10.1161/CIRCULATIONAHA.106.675934; Lutsiak MEC, 2002, PHARM RES-DORDR, V19, P1480, DOI 10.1023/A:1020452531828; Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377; Martin-Banderas L, 2013, MINI-REV MED CHEM, V13, P58, DOI 10.2174/138955713804484721; Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4; Pires NMM, 2005, BIOMATERIALS, V26, P5386, DOI 10.1016/j.biomaterials.2005.01.063; Rajathurai T, 2010, CIRC-CARDIOVASC INTE, V3, P157, DOI 10.1161/CIRCINTERVENTIONS.109.864660; Reddy MK, 2008, CIRC-CARDIOVASC INTE, V1, P209, DOI 10.1161/CIRCINTERVENTIONS.108.830018; Rosner D, 2005, CARDIOVASC RES, V66, P601, DOI 10.1016/j.cardiores.2005.01.006; Seedial SM, 2013, J VASC SURG, V57, P1403, DOI 10.1016/j.jvs.2012.12.069; Semete B, 2010, NANOMED-NANOTECHNOL, V6, P662, DOI 10.1016/j.nano.2010.02.002; Si Y, 2012, ARTERIOSCL THROM VAS, V32, P943, DOI 10.1161/ATVBAHA.111.244921; Siow RCM, 2003, CARDIOVASC RES, V59, P212, DOI 10.1016/S0008-6363(03)00292-X; Siqueira DA, 2007, EUR HEART J, V28, P1304, DOI 10.1093/eurheartj/ehm114; Tian W, 2006, J ENDOVASC THER, V13, P616, DOI 10.1583/05-1802MR.1; Tsai S, 2009, AM J PHYSIOL-HEART C, V297, pH540, DOI 10.1152/ajpheart.91478.2007; Virmani R, 2004, CORONARY ARTERY DIS, V15, P313, DOI 10.1097/00019501-200409000-00003; Yang J, 2013, BIOMATERIALS, V34, P1635, DOI 10.1016/j.biomaterials.2012.11.006; Zhu WW, 2006, J BIOMED MATER RES B, V77B, P135, DOI 10.1002/jbm.b.30412; Zohlnhofer D, 2004, MOL PHARMACOL, V65, P880, DOI 10.1124/mol.65.4.880	40	30	34	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2014	9	2							e89227	10.1371/journal.pone.0089227	http://dx.doi.org/10.1371/journal.pone.0089227			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AB3VI	24586612	gold, Green Submitted, Green Published			2023-01-03	WOS:000331717900065
J	Tewari, KS; Sill, MW; Long, HJ; Penson, RT; Huang, H; Ramondetta, LM; Landrum, LM; Oaknin, A; Reid, TJ; Leitao, MM; Michael, HE; Monk, BJ				Tewari, Krishnansu S.; Sill, Michael W.; Long, Harry J., III; Penson, Richard T.; Huang, Helen; Ramondetta, Lois M.; Landrum, Lisa M.; Oaknin, Ana; Reid, Thomas J.; Leitao, Mario M.; Michael, Helen E.; Monk, Bradley J.			Improved Survival with Bevacizumab in Advanced Cervical Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GYNECOLOGIC-ONCOLOGY-GROUP; SQUAMOUS-CELL CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; RANDOMIZED-TRIAL; UTERINE CERVIX; PHASE-II; CISPLATIN; RECURRENT; PERSISTENT; TOPOTECAN	BackgroundVascular endothelial growth factor (VEGF) promotes angiogenesis, a mediator of disease progression in cervical cancer. Bevacizumab, a humanized anti-VEGF monoclonal antibody, has single-agent activity in previously treated, recurrent disease. Most patients in whom recurrent cervical cancer develops have previously received cisplatin with radiation therapy, which reduces the effectiveness of cisplatin at the time of recurrence. We evaluated the effectiveness of bevacizumab and nonplatinum combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer. MethodsUsing a 2-by-2 factorial design, we randomly assigned 452 patients to chemotherapy with or without bevacizumab at a dose of 15 mg per kilogram of body weight. Chemotherapy consisted of cisplatin at a dose of 50 mg per square meter of body-surface area, plus paclitaxel at a dose of 135 or 175 mg per square meter or topotecan at a dose of 0.75 mg per square meter on days 1 to 3, plus paclitaxel at a dose of 175 mg per square meter on day 1. Cycles were repeated every 21 days until disease progression, the development of unacceptable toxic effects, or a complete response was documented. The primary end point was overall survival; a reduction of 30% in the hazard ratio for death was considered clinically important. ResultsGroups were well balanced with respect to age, histologic findings, performance status, previous use or nonuse of a radiosensitizing platinum agent, and disease status. Topotecan-paclitaxel was not superior to cisplatin-paclitaxel (hazard ratio for death, 1.20). With the data for the two chemotherapy regimens combined, the addition of bevacizumab to chemotherapy was associated with increased overall survival (17.0 months vs. 13.3 months; hazard ratio for death, 0.71; 98% confidence interval, 0.54 to 0.95; P=0.004 in a one-sided test) and higher response rates (48% vs. 36%, P=0.008). Bevacizumab, as compared with chemotherapy alone, was associated with an increased incidence of hypertension of grade 2 or higher (25% vs. 2%), thromboembolic events of grade 3 or higher (8% vs. 1%), and gastrointestinal fistulas of grade 3 or higher (3% vs. 0%). ConclusionsThe addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer was associated with an improvement of 3.7 months in median overall survival. (Funded by the National Cancer Institute; GOG 240 ClinicalTrials.gov number, NCT00803062.)	[Tewari, Krishnansu S.] Univ Calif Irvine, Med Ctr, Orange, CA 92868 USA; [Sill, Michael W.; Huang, Helen] SUNY Buffalo, Roswell Pk Canc Inst, Buffalo, NY 14260 USA; [Long, Harry J., III] Mayo Clin, Rochester, MN USA; [Penson, Richard T.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Ramondetta, Lois M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Landrum, Lisa M.] Univ Oklahoma, Oklahoma City, OK USA; [Oaknin, Ana] Vall dHebron Univ Hosp, Barcelona, Spain; [Reid, Thomas J.] Univ Cincinnati, Coll Med, Womens Canc Ctr Kettering, Kettering, OH USA; [Leitao, Mario M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Michael, Helen E.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Monk, Bradley J.] Univ Arizona, Ctr Canc, Phoenix, AZ USA; [Monk, Bradley J.] Creighton Univ, St Josephs Hosp & Med Ctr, Phoenix, AZ USA	University of California System; University of California Irvine; Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Mayo Clinic; Harvard University; Massachusetts General Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Hospital Universitari Vall d'Hebron; University System of Ohio; University of Cincinnati; Memorial Sloan Kettering Cancer Center; Indiana University System; Indiana University Bloomington; University of Arizona; Creighton University; St. Joseph's Hospital and Medical Center	Tewari, KS (corresponding author), Univ Calif Irvine, Med Ctr, Div Gynecol Oncol, 101 City Dr S,Bldg 56, Orange, CA 92868 USA.	ktewari@uci.edu			NCI NIH HHS [P30 CA016672, U10 CA037517, U10 CA180858, UG1 CA233329] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA037517, P30CA016672, U10CA180858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 2011, COMM TERM CRIT ADV E; Bahadori HR, 2001, CANCER CHEMOTH PHARM, V48, P188, DOI 10.1007/s002800100327; Bloss JD, 2002, J CLIN ONCOL, V20, P1832, DOI 10.1200/JCO.2002.07.045; Bodily JM, 2011, CANCER RES, V71, P1187, DOI 10.1158/0008-5472.CAN-10-2626; BONOMI P, 1985, J CLIN ONCOL, V3, P1079, DOI 10.1200/JCO.1985.3.8.1079; Cancer Therapy Evaluation Program, 2006, COMM TERM CRIT ADV E; Cella D.F, 1997, MANUAL FUNCTIONAL AS; Clere N, 2007, EXP CELL RES, V313, P3239, DOI 10.1016/j.yexcr.2007.06.029; COX DR, 1972, J R STAT SOC B, V34, P187; Diggle P., 1993, ANAL LONGITUDINAL DA; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Long HJ, 2005, J CLIN ONCOL, V23, P4626, DOI 10.1200/JCO.2005.10.021; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCGUIRE WP, 1989, J CLIN ONCOL, V7, P1462, DOI 10.1200/JCO.1989.7.10.1462; Monk BJ, 2007, J CLIN ONCOL, V25, P2952, DOI 10.1200/JCO.2007.10.8324; Monk BJ, 2010, J CLIN ONCOL, V28, P3562, DOI 10.1200/JCO.2009.26.9571; Monk BJ, 2009, J CLIN ONCOL, V27, P4649, DOI 10.1200/JCO.2009.21.8909; Monk BJ, 2009, J CLIN ONCOL, V27, P1069, DOI 10.1200/JCO.2008.18.9043; Moore DH, 2010, GYNECOL ONCOL, V116, P44, DOI 10.1016/j.ygyno.2009.09.006; Moore DH, 2004, J CLIN ONCOL, V22, P3113, DOI 10.1200/JCO.2004.04.170; No JH, 2009, ANN NY ACAD SCI, V1171, P105, DOI 10.1111/j.1749-6632.2009.04891.x; Omura GA, 1997, J CLIN ONCOL, V15, P165, DOI 10.1200/JCO.1997.15.1.165; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Tang XD, 2007, CLIN CANCER RES, V13, P2568, DOI 10.1158/1078-0432.CCR-06-2704; Tewari Krishnansu S, 2005, Curr Oncol Rep, V7, P419, DOI 10.1007/s11912-005-0007-z; Tewari KS, 2009, ONKOLOGIE, V32, P552, DOI 10.1159/000232385; Tewari KS, 2009, SEMIN ONCOL, V36, P170, DOI 10.1053/j.seminoncol.2008.12.008; Tewari Krishnansu Sujata, 2010, Clin Adv Hematol Oncol, V8, P108; Tewari KS, 2000, GYNECOL ONCOL, V77, P137, DOI 10.1006/gyno.2000.5729; Tewari KS, 2012, CLIN GYNECOLOGIC ONC; Tewari KS., 2011, CLIN OVARIAN CANC, V4, P90; Tewari KS., 2010, AM J HEMATOL ONCOL, V9, P31; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; THIGPEN JT, 1989, GYNECOL ONCOL, V32, P198, DOI 10.1016/S0090-8258(89)80033-2; Tiersten AD, 2004, GYNECOL ONCOL, V92, P635, DOI 10.1016/j.ygyno.2003.11.019; WIEAND S, 1994, STAT MED, V13, P1453, DOI 10.1002/sim.4780131321	38	859	916	4	95	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 20	2014	370	8					734	743		10.1056/NEJMoa1309748	http://dx.doi.org/10.1056/NEJMoa1309748			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AB1DO	24552320	Green Accepted, Green Published			2023-01-03	WOS:000331531900008
J	Kauffman, RC; Villalobos, A; Bowen, JH; Adamson, L; Schinazi, RF				Kauffman, Robert C.; Villalobos, Andradi; Bowen, Joanne H.; Adamson, Lourdes; Schinazi, Raymond F.			Residual Viremia in an RT-SHIV Rhesus Macaque HAART Model Marked by the Presence of a Predominant Plasma Clone and a Lack of Viral Evolution	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; CD4(+) T-CELLS; HIV-1 DRUG-RESISTANCE; REVERSE-TRANSCRIPTASE; RALTEGRAVIR INTENSIFICATION; INFECTION; REPLICATION; RESERVOIR; PCR	Highly active antiretroviral therapy (HAART) significantly reduces HIV-1 replication and prevents progression to AIDS. However, residual low-level viremia (LLV) persists and long-lived viral reservoirs are maintained in anatomical sites. These reservoirs permit a recrudescence of viremia upon cessation of therapy and thus HAART must be maintained indefinitely. HIV-1 reservoirs include latently infected resting memory CD4(+) T-cells and macrophages which may contribute to residual viremia. It has not been conclusively determined if a component of LLV may also be due to residual replication in cells with sub-therapeutic drug levels and/or long-lived chronically infected cells. In this study, RT-SHIVmac239 diversity was characterized in five rhesus macaques that received a five-drug HAART regimen [tenofovir, emtricitabine, zidovudine, amdoxovir, (A, C, T, G nucleoside analogs) and the non-nucleoside reverse transcriptase (RT) inhibitor efavirenz]. Before maximal viral load suppression, longitudinal plasma viral RNA RT diversity was analyzed using a 454 sequencer. After suppression, LLV RT diversity (amino acids 65-210) was also assessed. LLV samples had viral levels less than our standard detection limit (50 viral RNA copies/mL) and few transient blips <200 RNA copies/mL. HAART was discontinued in three macaques after 42 weeks of therapy resulting in viral rebound. The level of viral divergence and the prevalence of specific alleles in LLV was similar to pre-suppression viremia. While some LLV sequences contained mutations not observed in the pre-suppression profile, LLV was not characterized by temporal viral evolution or apparent selection of drug resistance mutations. Similarly, resistance mutations were not detected in the viral rebound population. Interestingly, one macaque maintained a putative LLV predominant plasma clone sequence. Together, these results suggest that residual replication did not markedly contribute to LLV and that this model mimics the prevalence and phylogenetic characteristics of LLV during human HAART. Therefore, this model may be ideal for testing HIV-1 eradication strategies.	[Kauffman, Robert C.; Villalobos, Andradi; Bowen, Joanne H.; Adamson, Lourdes] Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; [Kauffman, Robert C.; Villalobos, Andradi; Schinazi, Raymond F.] Emory Univ, Sch Med, Biochem Pharmacol Lab, Dept Pediat,Ctr AIDS Res, Atlanta, GA 30322 USA; [Schinazi, Raymond F.] Vet Affairs Med Ctr, Decatur, GA 30033 USA	University of California System; University of California Davis; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Schinazi, RF (corresponding author), Emory Univ, Sch Med, Biochem Pharmacol Lab, Dept Pediat,Ctr AIDS Res, Atlanta, GA 30322 USA.	rschina@emory.edu	Schinazi, Raymond F/B-6777-2017		California HIV/AIDS Research Program - Predoctoral Fellowship [D09-B-311]; NIH [R01-0D011094]; Emory University Center for AIDS NIG grant [2P30AI050409]; Department of Veterans Affairs; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI050409] Funding Source: NIH RePORTER	California HIV/AIDS Research Program - Predoctoral Fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Emory University Center for AIDS NIG grant; Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Study was supported by: California HIV/AIDS Research Program - Predoctoral Fellowship # D09-B-311 to Robert C. Kauffman; NIH grants # R01-0D011094 to Drs. Thomas W. North and Raymond F. Schinazi, and the Emory University Center for AIDS NIG grant 2P30AI050409. Dr. Schinazi is also funded by the Department of Veterans Affairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambrose Z, 2004, J VIROL, V78, P13553, DOI 10.1128/JVI.78.24.13553-13561.2004; Anderson JA, 2011, J VIROL, V85, P5220, DOI 10.1128/JVI.00284-11; Apetrei C, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002892; Bailey JR, 2006, J VIROL, V80, P6441, DOI 10.1128/JVI.00591-06; Brennan TP, 2009, J VIROL, V83, P8470, DOI 10.1128/JVI.02568-08; Buzon MJ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002314; Buzon MJ, 2010, NAT MED, V16, P460, DOI 10.1038/nm.2111; Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972; Chun TW, 2000, NAT MED, V6, P757, DOI 10.1038/77481; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; Daigle D SB, 2011, CURR PROTOC MOL BIOL; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756; Deere JD, 2010, UNPUB; Deere JD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011640; Di Mascio M, 2003, J VIROL, V77, P12165, DOI 10.1128/JVI.77.22.12165-12172.2003; Dinoso JB, 2009, P NATL ACAD SCI USA, V106, P9403, DOI 10.1073/pnas.0903107106; Dinoso JB, 2009, J VIROL, V83, P9247, DOI 10.1128/JVI.00840-09; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Evering TH, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002506; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gandhi RT, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000321; Garcia-Lerma JG, 2008, PLOS MED, V5, P291, DOI 10.1371/journal.pmed.0050028; GRANT CK, 1977, J IMMUNOL, V119, P401; Gunthard HF, 1999, J VIROL, V73, P9404; Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555; Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001; Hatano H, 2013, J INFECT DIS, V208, P1436, DOI 10.1093/infdis/jit453; Havlir DV, 2001, JAMA-J AM MED ASSOC, V286, P171, DOI 10.1001/jama.286.2.171; Havlir DV, 2003, J VIROL, V77, P11212, DOI 10.1128/JVI.77.20.11212-11219.2003; Hermankova M, 2001, JAMA-J AM MED ASSOC, V286, P196, DOI 10.1001/jama.286.2.196; Hofman MJ, 2004, ANTIMICROB AGENTS CH, V48, P3483, DOI 10.1128/AAC.48.9.3483-3490.2004; Johnson Jennifer A, 2009, Curr Infect Dis Rep, V11, P311, DOI 10.1007/s11908-009-0046-y; Johnson Victoria A, 2011, Top Antivir Med, V19, P156; Johnston R, 2012, J INT AIDS SOC, V15, DOI 10.1186/1758-2652-15-16; Joos B, 2008, P NATL ACAD SCI USA, V105, P16725, DOI 10.1073/pnas.0804192105; Josefsson L, 2013, P NATL ACAD SCI USA, V110, pE4987, DOI 10.1073/pnas.1308313110; Judo MSB, 1998, NUCLEIC ACIDS RES, V26, P1819, DOI 10.1093/nar/26.7.1819; Kearney M, 2011, J VIROL, V85, P1067, DOI 10.1128/JVI.01701-10; Kieffer TL, 2004, J INFECT DIS, V189, P1452, DOI 10.1086/382488; Koppensteiner H, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-82; Lee GQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046181; Leutenegger CM, 2001, AIDS RES HUM RETROV, V17, P243, DOI 10.1089/088922201750063160; LJUNGDAHLSTAHLE E, 1992, ANTIMICROB AGENTS CH, V36, P2418, DOI 10.1128/AAC.36.11.2418; Maldarelli F, 2007, PLOS PATHOG, V3, P484, DOI 10.1371/journal.ppat.0030046; Martinez-Picado J, 2002, J VIROL, V76, P12344, DOI 10.1128/JVI.76.23.12344-12348.2002; Mavigner M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007658; North TW, 2010, J VIROL, V84, P2913, DOI 10.1128/JVI.02356-09; North TW, 2005, J VIROL, V79, P7349, DOI 10.1128/JVI.79.12.7349-7354.2005; Nottet HSLM, 2009, JAIDS-J ACQ IMM DEF, V50, P345, DOI 10.1097/QAI.0b013e318197eb04; ODELBERG SJ, 1995, NUCLEIC ACIDS RES, V23, P2049, DOI 10.1093/nar/23.11.2049; Palmer S, 2003, J CLIN MICROBIOL, V41, P4531, DOI 10.1128/JCM.41.10.4531-4536.2003; Palmer S, 2008, P NATL ACAD SCI USA, V105, P3879, DOI 10.1073/pnas.0800050105; Persaud D, 2004, J VIROL, V78, P968, DOI 10.1128/JVI.78.2.968-979.2004; Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577; Rhee SY, 2003, NUCLEIC ACIDS RES, V31, P298, DOI 10.1093/nar/gkg100; Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706; Rose PP, 2000, BIOINFORMATICS, V16, P400, DOI 10.1093/bioinformatics/16.4.400; Sahu GK, 2009, J MED VIROL, V81, P9, DOI 10.1002/jmv.21366; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Shafer RW, 2006, J INFECT DIS, V194, pS51, DOI 10.1086/505356; Shao W, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-18; Shao W, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-101; Shiu C, 2009, J VIROL, V83, P9731, DOI 10.1128/JVI.00570-09; Shytaj IL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002774; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961; Tobin NH, 2005, J VIROL, V79, P9625, DOI 10.1128/JVI.79.15.9625-9634.2005; UBERLA K, 1995, P NATL ACAD SCI USA, V92, P8210, DOI 10.1073/pnas.92.18.8210; Van Rompay KKA, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-25; Van Rompay KKA, 2012, ANTIMICROB AGENTS CH, V56, P4980, DOI 10.1128/AAC.01095-12; Vandenbroucke I, 2011, BIOTECHNIQUES, V51, P167, DOI 10.2144/000113733; Wu JY, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-255; Zhang LQ, 2000, J CLIN INVEST, V106, P839, DOI 10.1172/JCI10565	78	8	10	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2014	9	2							e88258	10.1371/journal.pone.0088258	http://dx.doi.org/10.1371/journal.pone.0088258			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA1AT	24505452	Green Published, Green Submitted, gold			2023-01-03	WOS:000330829200155
J	Tatham, KC; Patel, KP				Tatham, Kate C.; Patel, Kinesh P.			Suitability of common drugs for patients who avoid animal products	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							MEDICATION		[Tatham, Kate C.] Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Sect Anaesthet Pain Med & Intens Care, London, England; [Patel, Kinesh P.] St Marks Hosp, Wolfson Unit Endoscopy, Harrow HA1 3UJ, Middx, England	Imperial College London; Imperial College London	Patel, KP (corresponding author), St Marks Hosp, Wolfson Unit Endoscopy, Harrow HA1 3UJ, Middx, England.	kinesh.patel@gmail.com	Tatham, Kate/AAB-5839-2020	Tatham, Kate/0000-0003-3080-8011				Al-Tabakha MM, 2010, J PHARM PHARM SCI, V13, P428, DOI 10.18433/J3K881; BBC News, 2013, BBC NEWS; Bendelstein Y, 2005, GELATIN REVISITED; Clery E, 2010, FOOD TECHNOLOGIES FI; National Institute for Health and Care Excellence, 2009, MED ADH CG76 NICE; RICHARDSON NJ, 1994, ECOL FOOD NUTR, V33, P1, DOI 10.1080/03670244.1994.9991412; Sattar SP, 2004, ANN PHARMACOTHER, V38, P621, DOI 10.1345/aph.1D324; Vegetarian Society, WHAT IS VEG; Vissamsetti B, 2012, POSTGRAD MED J, V88, P499, DOI 10.1136/postgradmedj-2011-130306; World Health Organization (WHO), 2001, US UNL JUR UNCL SUBS	10	18	18	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 4	2014	348								g401	10.1136/bmj.g401	http://dx.doi.org/10.1136/bmj.g401			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AA4IV	24496281				2023-01-03	WOS:000331060200015
J	Theisen, LL; Erdelmeier, CAJ; Spoden, GA; Boukhallouk, F; Sausy, A; Florin, L; Muller, CP				Theisen, Linda L.; Erdelmeier, Clemens A. J.; Spoden, Gilles A.; Boukhallouk, Fatima; Sausy, Aurelie; Florin, Luise; Muller, Claude P.			Tannins from Hamamelis virginiana Bark Extract: Characterization and Improvement of the Antiviral Efficacy against Influenza A Virus and Human Papillomavirus	PLOS ONE			English	Article							GREEN TEA; CONDOM USE; EPIGALLOCATECHIN GALLATE; VEGETABLE TANNINS; GENITAL WARTS; GALLIC ACID; IN-VITRO; CATECHINS; PROANTHOCYANIDINS; POLYPHENOL	Antiviral activity has been demonstrated for different tannin-rich plant extracts. Since tannins of different classes and molecular weights are often found together in plant extracts and may differ in their antiviral activity, we have compared the effect against influenza A virus (IAV) of Hamamelis virginiana L. bark extract, fractions enriched in tannins of different molecular weights and individual tannins of defined structures, including pseudotannins. We demonstrate antiviral activity of the bark extract against different IAV strains, including the recently emerged H7N9, and show for the first time that a tannin-rich extract inhibits human papillomavirus (HPV) type 16 infection. As the best performing antiviral candidate, we identified a highly potent fraction against both IAV and HPV, enriched in high molecular weight condensed tannins by ultrafiltration, a simple, reproducible and easily upscalable method. This ultrafiltration concentrate and the bark extract inhibited early and, to a minor extent, later steps in the IAV life cycle and tannin-dependently inhibited HPV attachment. We observed interesting mechanistic differences between tannin structures: High molecular weight tannin containing extracts and tannic acid (1702 g/mol) inhibited both IAV receptor binding and neuraminidase activity. In contrast, low molecular weight compounds (<500 g/mol) such as gallic acid, epigallocatechin gallate or hamamelitannin inhibited neuraminidase but not hemagglutination. Average molecular weight of the compounds seemed to positively correlate with receptor binding (but not neuraminidase) inhibition. In general, neuraminidase inhibition seemed to contribute little to the antiviral activity. Importantly, antiviral use of the ultrafiltration fraction enriched in high molecular weight condensed tannins and, to a lesser extent, the unfractionated bark extract was preferable over individual isolated compounds. These results are of interest for developing and improving plant-based antivirals.	[Theisen, Linda L.; Sausy, Aurelie; Muller, Claude P.] Ctr Rech Publ Sante, Inst Immunol, Lab Natl Sante, Luxembourg, Luxembourg; [Erdelmeier, Clemens A. J.] Dr Willmar Schwabe GmbH & Co KG, Dept Preclin Res, Karlsruhe, Germany; [Spoden, Gilles A.; Boukhallouk, Fatima; Florin, Luise] Johannes Gutenberg Univ Mainz, Dept Med Microbiol & Hyg, Univ Med Ctr, D-55122 Mainz, Germany	Luxembourg Institute of Health; Dr. Willmar Schwabe GmbH & Co. KG; Johannes Gutenberg University of Mainz	Muller, CP (corresponding author), Ctr Rech Publ Sante, Inst Immunol, Lab Natl Sante, Luxembourg, Luxembourg.	Claude.Muller@crp-sante.lu		Sausy, Aurelie/0000-0003-2090-7198	Dr. Willmar Schwabe GmbH Co. KG; AFR PhD grant of the Fonds National de la Recherche, Luxembourg [2903120]	Dr. Willmar Schwabe GmbH Co. KG; AFR PhD grant of the Fonds National de la Recherche, Luxembourg(Luxembourg National Research Fund)	The study was in part financially supported by Dr. Willmar Schwabe GmbH & Co. KG (http://www.schwabepharma.com/international). Linda L. Theisen was supported by an AFR PhD grant (Nr 2903120) of the Fonds National de la Recherche, Luxembourg (http://www.fnr.lu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ainsworth EA, 2007, NAT PROTOC, V2, P875, DOI 10.1038/nprot.2007.102; [Anonymous], FACT SHEET INFL SEAS; BATESMITH EC, 1975, PHYTOCHEMISTRY, V14, P1107, DOI 10.1016/0031-9422(75)85197-1; Baz M, 2009, NEW ENGL J MED, V361, P2296, DOI 10.1056/NEJMc0910060; Betts JW, 2011, INT J ANTIMICROB AG, V38, P421, DOI 10.1016/j.ijantimicag.2011.07.006; Buck CB, 2006, P NATL ACAD SCI USA, V103, P1516, DOI 10.1073/pnas.0508033103; Buck CB, 2004, J VIROL, V78, P751, DOI 10.1128/JVI.78.2.751-757.2004; Buck CB, 2006, PLOS PATHOG, V2, P671, DOI 10.1371/journal.ppat.0020069; CARSON RS, 1953, J BACTERIOL, V66, P572, DOI 10.1002/path.1700660233; Cerqueira C, 2013, CELL MICROBIOL, V15, P1818, DOI 10.1111/cmi.12150; Chelimo C, 2013, J INFECTION, V66, P207, DOI 10.1016/j.jinf.2012.10.024; Ciesek S, 2011, HEPATOLOGY, V54, P1947, DOI 10.1002/hep.24610; Cowan MM, 1999, CLIN MICROBIOL REV, V12, P564, DOI 10.1128/CMR.12.4.564; da Silva AP, 2000, PHYTOTHER RES, V14, P612, DOI 10.1002/1099-1573(200012)14:8&lt;612::AID-PTR677&gt;3.0.CO;2-T; Dauer A, 1998, PLANTA MED, V64, P324, DOI 10.1055/s-2006-957443; Dauer A, 2003, PLANTA MED, V69, P89, DOI 10.1055/s-2003-37022; Deters A, 2001, PHYTOCHEMISTRY, V58, P949, DOI 10.1016/S0031-9422(01)00361-2; Ehrhardt C, 2007, ANTIVIR RES, V76, P38, DOI 10.1016/j.antiviral.2007.05.002; Erdelmeier CAJ, 1996, PLANTA MED, V62, P241, DOI 10.1055/s-2006-957868; European Directorate for the Quality of Medicines & Healthcare, 2008, EUROPEAN PHARMACOPOE, P328; European Food Safety Authority, 2009, EFSA J, V954, P1; Florin L, 2012, MED MICROBIOL IMMUN, V201, P437, DOI 10.1007/s00430-012-0270-1; Frazier RA, 2010, J PHARMACEUT BIOMED, V51, P490, DOI 10.1016/j.jpba.2009.05.035; Ganatra Rahul, 2012, Morbidity and Mortality Weekly Report, V61, P414; Gaur AH, 2010, NEW ENGL J MED, V362, P88, DOI 10.1056/NEJMc0910893; Gescher K, 2011, ANTIVIR RES, V89, P9, DOI 10.1016/j.antiviral.2010.10.007; HAGERMAN AE, 1992, ACS SYM SER, V506, P236; Haidari M, 2009, PHYTOMEDICINE, V16, P1127, DOI 10.1016/j.phymed.2009.06.002; Hamilton BS, 2012, VIRUSES-BASEL, V4, P1144, DOI 10.3390/v4071144; Hashimoto T, 1999, BIOSCI BIOTECH BIOCH, V63, P2252, DOI 10.1271/bbb.63.2252; Haslam E, 1996, J NAT PROD, V59, P205, DOI 10.1021/np960040+; Haslam E, 2007, PHYTOCHEMISTRY, V68, P2713, DOI 10.1016/j.phytochem.2007.09.009; Hull Vance Stacy, 2011, Biomed Sci Instrum, V47, P177; Hurt AC, 2011, NEW ENGL J MED, V365, P2541, DOI 10.1056/NEJMc1111078; IKIGAI H, 1993, BIOCHIM BIOPHYS ACTA, V1147, P132, DOI 10.1016/0005-2736(93)90323-R; Imanishi N, 2002, MICROBIOL IMMUNOL, V46, P491, DOI 10.1111/j.1348-0421.2002.tb02724.x; Ishii T, 2011, BIOSCI BIOTECH BIOCH, V75, P100, DOI 10.1271/bbb.100600; Janecki A, 2011, J ETHNOPHARMACOL, V133, P147, DOI 10.1016/j.jep.2010.09.018; Gonzalez MJ, 2010, J AGR FOOD CHEM, V58, P4274, DOI 10.1021/jf904032y; Jobstl E, 2006, J AGR FOOD CHEM, V54, P4077, DOI 10.1021/jf053259f; Kimmel EM, 2011, ANTIVIR RES, V90, P80, DOI 10.1016/j.antiviral.2011.02.011; Kittel C, 2004, VIROLOGY, V324, P67, DOI 10.1016/j.virol.2004.03.035; Knappe M, 2007, J BIOL CHEM, V282, P27913, DOI 10.1074/jbc.M705127200; Kratz JM, 2008, MEM I OSWALDO CRUZ, V103, P437, DOI 10.1590/S0074-02762008000500005; Lackenby A, 2011, EUROSURVEILLANCE, V16, P10; Laux P, 1993, Z PHYTOTHER, V14, P155; Li M, 2013, CURR DRUG METAB, V14, P432, DOI 10.2174/1389200211314040006; Lin LT, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-187; Lin LT, 2011, J VIROL, V85, P4386, DOI 10.1128/JVI.01492-10; Liu G, 2011, ARCH VIROL, V156, P1359, DOI 10.1007/s00705-011-0989-9; MacKay D, 2001, Altern Med Rev, V6, P126; Manhart LE, 2002, SEX TRANSM DIS, V29, P725, DOI 10.1097/00007435-200211000-00018; Mantani N, 1999, ANTIVIR RES, V44, P193, DOI 10.1016/S0166-3542(99)00067-4; Mi X, 2011, PHOTODERMATOL PHOTO, V27, P176, DOI 10.1111/j.1600-0781.2011.00592.x; Minoda K, 2010, J NUTR SCI VITAMINOL, V56, P331, DOI 10.3177/jnsv.56.331; Mistrangelo M, 2010, COLORECTAL DIS, V12, P799, DOI 10.1111/j.1463-1318.2009.01960.x; NAKAYAMA M, 1993, ANTIVIR RES, V21, P289, DOI 10.1016/0166-3542(93)90008-7; Nance CL, 2003, J ALLERGY CLIN IMMUN, V112, P851, DOI 10.1016/j.jaci.2003.08.048; Nielson CM, 2010, J INFECT DIS, V202, P445, DOI 10.1086/653708; Ono N, 2001, J VIROL, V75, P4399, DOI 10.1128/JVI.75.9.4399-4401.2001; Raff AB, 2013, J VIROL, V87, P6062, DOI 10.1128/JVI.00330-13; Repp KK, 2012, J INFECT DIS, V205, P1287, DOI 10.1093/infdis/jis181; Roberts JN, 2007, NAT MED, V13, P857, DOI 10.1038/nm1598; Sanchez-Tena S, 2012, J NAT PROD, V75, P26, DOI 10.1021/np200426k; SAPP M, 1994, J GEN VIROL, V75, P3375, DOI 10.1099/0022-1317-75-12-3375; Sarni-Manchado P, 1999, J AGR FOOD CHEM, V47, P42, DOI 10.1021/jf9805146; Sasaki H, 2004, CARIES RES, V38, P2, DOI 10.1159/000073913; Schneider MA, 2011, CELL MICROBIOL, V13, P32, DOI 10.1111/j.1462-5822.2010.01515.x; Selinka HC, 2007, J VIROL, V81, P10970, DOI 10.1128/JVI.00998-07; SETO JT, 1966, VIROLOGY, V30, P731, DOI 10.1016/0042-6822(66)90178-4; Song JM, 2005, ANTIVIR RES, V68, P66, DOI 10.1016/j.antiviral.2005.06.010; Spoden G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003313; Spoden GA, 2012, ANTIMICROB AGENTS CH, V56, P75, DOI 10.1128/AAC.05147-11; Steinmann J, 2013, BRIT J PHARMACOL, V168, P1059, DOI 10.1111/bph.12009; TAKECHI M, 1985, PHYTOCHEMISTRY, V24, P2245, DOI 10.1016/S0031-9422(00)83018-6; Takeda M, 2005, J VIROL, V79, P14346, DOI 10.1128/JVI.79.22.14346-14354.2005; Theisen LL, 2012, ANTIVIR RES, V94, P147, DOI 10.1016/j.antiviral.2012.03.006; Tourino S, 2008, CHEM RES TOXICOL, V21, P696, DOI 10.1021/tx700425n; Ueda K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055343; van der Vries E, 2010, NEW ENGL J MED, V363, P1381, DOI 10.1056/NEJMc1003749; VENNAT B, 1988, PLANTA MED, P454, DOI 10.1055/s-2006-962499; Wagner H, 1999, PHARMAZEUTISCHE BIOL, V2; Wang HF, 2003, J PHARMACEUT BIOMED, V33, P539, DOI 10.1016/S0731-7085(03)00303-0; Williamson MP, 2006, J ALLERGY CLIN IMMUN, V118, P1369, DOI 10.1016/j.jaci.2006.08.016; Winer RL, 2006, NEW ENGL J MED, V354, P2645, DOI 10.1056/NEJMoa053284; Wolff HH, 2007, EUR J PEDIATR, V166, P943, DOI 10.1007/s00431-006-0363-1	87	50	59	0	52	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2014	9	1							e88062	10.1371/journal.pone.0088062	http://dx.doi.org/10.1371/journal.pone.0088062			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302RF	24498245	gold, Green Published, Green Submitted			2023-01-03	WOS:000330621900211
J	Selfe, J; Alexander, J; Costello, JT; May, K; Garratt, N; Atkins, S; Dillon, S; Hurst, H; Davison, M; Przybyla, D; Coley, A; Bitcon, M; Littler, G; Richards, J				Selfe, James; Alexander, Jill; Costello, Joseph T.; May, Karen; Garratt, Nigel; Atkins, Stephen; Dillon, Stephanie; Hurst, Howard; Davison, Matthew; Przybyla, Daria; Coley, Andrew; Bitcon, Mark; Littler, Greg; Richards, Jim			The Effect of Three Different (-135 degrees C) Whole Body Cryotherapy Exposure Durations on Elite Rugby League Players	PLOS ONE			English	Article							ANTERIOR KNEE; TEMPERATURE; MUSCLE; CRYOSTIMULATION	Background: Whole body cryotherapy (WBC) is the therapeutic application of extreme cold air for a short duration. Minimal evidence is available for determining optimal exposure time. Purpose: To explore whether the length of WBC exposure induces differential changes in inflammatory markers, tissue oxygenation, skin and core temperature, thermal sensation and comfort. Method: This study was a randomised cross over design with participants acting as their own control. Fourteen male professional first team super league rugby players were exposed to 1, 2, and 3 minutes of WBC at -135 degrees C. Testing took place the day after a competitive league fixture, each exposure separated by seven days. Results: No significant changes were found in the inflammatory cytokine interleukin six. Significant reductions (p<0.05) in deoxyhaemoglobin for gastrocnemius and vastus lateralis were found. In vastus lateralis significant reductions (p<0.05) in oxyhaemoglobin and tissue oxygenation index (p<0.05) were demonstrated. Significant reductions (p<0.05) in skin temperature were recorded. No significant changes were recorded in core temperature. Significant reductions (p<0.05) in thermal sensation and comfort were recorded. Conclusion: Three brief exposures to WBC separated by 1 week are not sufficient to induce physiological changes in IL-6 or core temperature. There are however significant changes in tissue oxyhaemoglobin, deoxyhaemoglobin, tissue oxygenation index, skin temperature and thermal sensation. We conclude that a 2 minute WBC exposure was the optimum exposure length at temperatures of -135 degrees C and could be applied as the basis for future studies.	[Selfe, James] Univ Cent Lancashire, Allied Hlth Res Unit, Preston PR1 2HE, Lancs, England; [Alexander, Jill; May, Karen; Littler, Greg; Richards, Jim] Univ Cent Lancashire, AHRu, Preston PR1 2HE, Lancs, England; [Costello, Joseph T.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Kelvin Grove, Qld, Australia; [Garratt, Nigel] Univ Cent Lancashire, SSTO, Preston PR1 2HE, Lancs, England; [Atkins, Stephen; Dillon, Stephanie; Hurst, Howard; Davison, Matthew; Przybyla, Daria] Univ Cent Lancashire, SENS, Preston PR1 2HE, Lancs, England; [Coley, Andrew; Bitcon, Mark] Wigan Warriors Rugby League, Wigan, England	University of Central Lancashire; University of Central Lancashire; Queensland University of Technology (QUT); University of Central Lancashire; University of Central Lancashire	Alexander, J (corresponding author), Univ Cent Lancashire, AHRu, Preston PR1 2HE, Lancs, England.	jalexander3@uclan.ac.uk	Costello, Joseph/G-6294-2011; Costello, Joseph/AAW-8764-2020; Costello, Joseph/J-1374-2012; Richards, Jim/AAI-7331-2020	Costello, Joseph/0000-0001-9510-7932; Costello, Joseph/0000-0001-9510-7932; Costello, Joseph/0000-0001-9510-7932; Richards, Jim/0000-0002-4004-3115; Alexander, Jill/0000-0002-6492-1621; Selfe, James/0000-0001-9931-4998; Littler, Greg/0000-0002-2575-0874	University of Central Lancashire	University of Central Lancashire	Jill Alexander was funded to work on the project by a University of Central Lancashire innovation voucher. The use of the mobile Cryochamber, liquid nitrogen and specialist operator were provided free of charge by BOC Linde throughout the testing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1995, ERG THERM ENV ASS IN; Austin DJ, 2013, J STRENGTH COND RES, V27, P14, DOI 10.1519/JSC.0b013e31824e108c; Austin DJ, 2011, J STRENGTH COND RES, V25, P1898, DOI 10.1519/JSC.0b013e3181e83a5b; Banfi G, 2010, SPORTS MED, V7, P1; Banfi G, 2009, J THERM BIOL, V34, P55, DOI 10.1016/j.jtherbio.2008.10.003; Cholewka A, 2012, SKIN RES TECHNOL, V18, P180, DOI 10.1111/j.1600-0846.2011.00550.x; Costello J, 2012, PLOS ONE, V7, P1; Costello JT, 2012, SCAND J MED SCI SPOR, V22, P190, DOI 10.1111/j.1600-0838.2011.01292.x; Costello JT, 2012, J THERM BIOL, V37, P103, DOI 10.1016/j.jtherbio.2011.11.008; Costello JT, 2013, ACSM; Delpy DT, 1997, PHILOS T R SOC B, V352, P649, DOI 10.1098/rstb.1997.0046; Flouris AD, 2008, EUR J APPL PHYSIOL, V104, P491, DOI 10.1007/s00421-008-0798-3; Flouris AD, 2009, J APPL PHYSIOL, V106, P1264, DOI 10.1152/japplphysiol.91426.2008; Fonda B, 2013, SCAND J MED SCI SPOR, V23, pE270, DOI 10.1111/sms.12074; Gabbett TJ, 2012, J SCI MED SPORT, V15, P80, DOI 10.1016/j.jsams.2011.07.004; Gregson W, 2011, AM J SPORT MED, V39, P1316, DOI 10.1177/0363546510395497; Hausswirth C, 2011, PLOS ONE, V12, P1; Karki A, 2004, THERMOL INT, V14, P137; Lombardi G, 2013, PLOS ONE, V8, P1; Lubkowska A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046352; Lubkowska A, 2010, CRYOBIOLOGY, V61, P22, DOI 10.1016/j.cryobiol.2010.03.010; Lubkowska A, 2010, EUR J APPL PHYSIOL, V109, P67, DOI 10.1007/s00421-009-1207-2; Murkin J M, 2009, Br J Anaesth, V103 Suppl 1, pi3, DOI 10.1093/bja/aep299; Pedersen BK, 2008, PHYSIOL REV, V88, P1379, DOI 10.1152/physrev.90100.2007; Pedersen Bente Klarlund, 2011, J Exp Biol, V214, P337, DOI 10.1242/jeb.048074; Pournot H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022748; Reynolds JD, 2007, P NATL ACAD SCI USA, V104, P17058, DOI 10.1073/pnas.0707958104; Ring EFJ, 2015, INFRARED IMAGING: A CASEBOOK IN CLINICAL MEDICINE, DOI 10.1088/978-0-7503-1143-4ch1; Savic M, 2013, J THERM BIOL, V38, P186, DOI 10.1016/j.jtherbio.2013.02.004; Selfe J, 2006, ARCH PHYS MED REHAB, V87, P1630, DOI 10.1016/j.apmr.2006.08.346; Selfe J, 2010, KNEE, V17, P319, DOI 10.1016/j.knee.2009.10.005; Stocks JM, 2004, AVIAT SPACE ENVIR MD, V75, P444; Twist C, 2012, J SPORT SCI, V30, P359, DOI 10.1080/02640414.2011.640707; Wozniak A, 2007, EUR J APPL PHYSIOL, V100, P137, DOI 10.1007/s00421-007-0404-0; Ziemann E, 2012, J ATHL TRAINING, V47, P664, DOI 10.4085/1062-6050-47.6.13	35	51	55	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2014	9	1							e86420	10.1371/journal.pone.0086420	http://dx.doi.org/10.1371/journal.pone.0086420			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301ZC	24489726	gold, Green Published, Green Accepted			2023-01-03	WOS:000330570000039
J	Smith, TJS; Rubenstein, LS; Nachman, KE				Smith, Tyler J. S.; Rubenstein, Leonard S.; Nachman, Keeve E.			Availability of Information about Airborne Hazardous Releases from Animal Feeding Operations	PLOS ONE			English	Article							EASTERN NORTH-CAROLINA; QUALITY-OF-LIFE; NEIGHBORING RESIDENTS; HEALTH; AMMONIA; EXPOSURE; ODORS; HOMES	Introduction: Air from animal feeding operations (AFOs) has been shown to transport numerous contaminants of public health concern. While federal statutes like the Emergency Planning and Community Right-to-Know Act (EPCRA) generally require that facilities report hazardous releases, AFOs have been exempted from most of these requirements by the U. S. Environmental Protection Agency (EPA). We assessed the availability of information about AFO airborne hazardous releases following these exemptions. Methods: We submitted public records requests to 7 states overlapping with or adjacent to the Chesapeake Bay watershed for reports of hazardous releases made by AFOs under EPCRA. From the records received, we calculated the proportion of AFOs in each state for which >= 1 reports were available. We also determined the availability of specific types of information required under EPCRA. The numbers of AFOs permitted under the Clean Water Act (CWA) or analogous state laws, as determined from permitting databases obtained from states, were used as denominators. Results: We received both EPCRA reports and permitting databases from 4 of 7 states. Across these 4 states, the mean proportion of AFOs for which >= 1 EPCRA reports were available was 15% (range: 2-33%). The mean proportions of AFOs for which the name or identity of the substance released, >= 1 estimates of quantity released, and information about nearby population density and sensitive populations were available were 15% (range: 2-33%), 8% (range: 0-22%), and 14% (range: 2-8%), respectively. Discussion: These results suggest that information about the airborne hazardous releases of a large majority of AFOs is not available under federal law in the states that we investigated. While the results cannot be attributed to specific factors by this method, attention to multiple factors, including revision of the EPA's exemptions, may increase the availability of information relevant to the health of populations living or working near AFOs.	[Smith, Tyler J. S.; Rubenstein, Leonard S.; Nachman, Keeve E.] Johns Hopkins Univ, Johns Hopkins Ctr Livable Future, Baltimore, MD 21218 USA; [Smith, Tyler J. S.; Nachman, Keeve E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA; [Rubenstein, Leonard S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Nachman, Keeve E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Nachman, KE (corresponding author), Johns Hopkins Univ, Johns Hopkins Ctr Livable Future, Baltimore, MD 21218 USA.	knachman@jhsph.edu		Smith, Tyler/0000-0003-4692-2206; Nachman, Keeve/0000-0003-4925-4151	Johns Hopkins Center for a Livable Future	Johns Hopkins Center for a Livable Future	The study was funded by a Directed Research grant from the Johns Hopkins Center for a Livable Future. The Center (aside from TJSS and KEN, who are both authors and CLF staff members) had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aneja VP, 2009, ENVIRON SCI TECHNOL, V43, P4234, DOI 10.1021/es8024403; Assardourian E, 2004, STAT WORLD 2004 WORL; Blunden J, 2008, ATMOS ENVIRON, V42, P3315, DOI 10.1016/j.atmosenv.2007.06.040; Bullers S, 2005, HUM ECOL, V33, P1, DOI 10.1007/s10745-005-1653-3; Centner TJ, 2010, ENVIRON INT, V36, P237, DOI 10.1016/j.envint.2009.11.007; Chapin A, 2005, ENVIRON HEALTH PERSP, V113, P137, DOI 10.1289/ehp.7473; Cole D, 2000, ENVIRON HEALTH PERSP, V108, P685, DOI 10.2307/3434721; Copeland C, 2011, ANIMAL WASTE HAZARDO; DEMARCHI S, 2006, ASSESSING ACCURACY, V32, P57; Donham Kelley J, 2006, J Agromedicine, V11, P15, DOI 10.1300/J096v11n03_03; Gilchrist MJ, 2007, ENVIRON HEALTH PERSP, V115, P313, DOI 10.1289/ehp.8837; Graham JP, 2010, J WATER HEALTH, V8, P646, DOI 10.2166/wh.2010.075; Heinzen T, 2008, NY U ENV LAW J, V17, P1482; Ko G, 2010, ENVIRON SCI TECHNOL, V44, P3442, DOI 10.1021/es9026024; Merchant JA, 2005, ENVIRON HEALTH PERSP, V113, P350, DOI 10.1289/ehp.7240; National Chicken Council U.S. Poultry & Egg Association National Turkey Federation, PET EX EPCRA CERCLA; Radon K, 2004, ANN AGR ENV MED, V11, P59; Radon K, 2007, EPIDEMIOLOGY, V18, P300, DOI 10.1097/01.ede.0000259966.62137.84; SCHIFFMAN SS, 1995, BRAIN RES BULL, V37, P369, DOI 10.1016/0361-9230(95)00015-1; Schinasi L, 2011, EPIDEMIOLOGY, V22, P208, DOI 10.1097/EDE.0b013e3182093c8b; Thu K., 1997, Journal of Agricultural Safety and Health, V3, P13; US Department of Agriculture, 2007, CENS AGR STAT PROF N; US Environmental Protection Agency, CERCLA EPCRA ADM REP; US Environmental Protection Agency, SAB REV EMISSIONS LA; US Environmental Protection Agency, 1985, FED REGISTER, V50, P13456; US Environmental Protection Agency, 2007, FED REG, V72, P73700; US Environmental Protection Agency, 2012, FED REGISTER, V77, P42679; US Environmental Protection Agency, 2011, FED REGISTER, V76, P65431; US Environmental Protection Agency Agriculture, AIR MON; US Government Accountability Office, CONC AN FEED OP EPA; US National Research Council, 2002, AIR EM AN FEED OP CU; USEPA, 2008, FED REGISTER, V73, P76948; Williams DL, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-72; Wilson SM, 2007, ATMOS ENVIRON, V41, P4977, DOI 10.1016/j.atmosenv.2006.12.055; Wing S, 2000, ENVIRON HEALTH PERSP, V108, P225, DOI 10.2307/3454438; Wing S, 2000, ENVIRON HEALTH PERSP, V108, P233, DOI 10.2307/3454439; 2005, FED REG, V70, P4958	37	2	2	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2013	8	12							e85342	10.1371/journal.pone.0085342	http://dx.doi.org/10.1371/journal.pone.0085342			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	284MV	24400039	gold, Green Published, Green Submitted			2023-01-03	WOS:000329323900147
J	Fecteau, S; Levasseur-Moreau, J; Garcia-Molina, A; Kumru, H; Vergara, RP; Bernabeu, M; Roig, T; Pascual-Leone, A; Tormos, JM				Fecteau, Shirley; Levasseur-Moreau, Jean; Garcia-Molina, Alberto; Kumru, Hatiche; Pelayo Vergara, Raul; Bernabeu, Monste; Roig, Teresa; Pascual-Leone, Alvaro; Maria Tormos, Jose			Risk Taking in Hospitalized Patients with Acute and Severe Traumatic Brain Injury	PLOS ONE			English	Article							DECISION-MAKING PROCESSES; COGNITIVE REHABILITATION; EXECUTIVE FUNCTION; HEAD-INJURY; TASK BART; ATTENTION; DYSFUNCTION; PROPENSITY; MORTALITY; BEHAVIOR	Rehabilitation can improve cognitive deficits observed in patients with traumatic brain injury (TBI). However, despite rehabilitation, the ability of making a choice often remains impaired. Risk taking is a daily activity involving numerous cognitive processes subserved by a complex neural network. In this work we investigated risk taking using the Balloon Analogue Risk Task (BART) in patients with acute TBI and healthy controls. We hypothesized that individuals with TBI will take less risk at the BART as compared to healthy individuals. We also predicted that within the TBI group factors such as the number of days since the injury, severity of the injury, and sites of the lesion will play a role in risk taking as assessed with the BART. Main findings revealed that participants with TBI displayed abnormally cautious risk taking at the BART as compared to healthy subjects. Moreover, healthy individuals showed increased risk taking throughout the task which is in line with previous work. However, individuals with TBI did not show this increased risk taking during the task. We also investigated the influence of three patients' characteristics on their performance at the BART: Number of days post injury, Severity of the head injury, and Status of the frontal lobe. Results indicate that performance at the BART was influenced by the number of days post injury and the status of the frontal lobe, but not by the severity of the head injury. Reported findings are encouraging for risk taking seems to naturally improve with time postinjury. They support the need of conducting longitudinal prospective studies to ultimately identify impaired and intact cognitive skills that should be trained postinjury.	[Fecteau, Shirley; Levasseur-Moreau, Jean] Univ Laval, Ctr Rech Univ Sante Mentale Quebec, Ctr Interdisciplinaire Rech Readaptat & Integrat, Sch Med, Quebec City, PQ, Canada; [Fecteau, Shirley; Pascual-Leone, Alvaro] Harvard Univ, Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, Sch Med, Boston, MA 02215 USA; [Garcia-Molina, Alberto; Kumru, Hatiche; Pelayo Vergara, Raul; Bernabeu, Monste; Roig, Teresa; Pascual-Leone, Alvaro; Maria Tormos, Jose] Inst Univ Neurorehabil Adscrit UAB, Inst Guttmann, Barcelona, Spain; [Garcia-Molina, Alberto; Kumru, Hatiche; Pelayo Vergara, Raul; Bernabeu, Monste; Roig, Teresa; Pascual-Leone, Alvaro; Maria Tormos, Jose] Univ Autonoma Barcelona, Bellaterra, Cerdanyola Del, Spain; [Garcia-Molina, Alberto; Kumru, Hatiche; Pelayo Vergara, Raul; Bernabeu, Monste; Roig, Teresa; Pascual-Leone, Alvaro; Maria Tormos, Jose] Fundacio Inst Invest Ciencies Salut Germans Trias, Barcelona, Spain	Laval University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Autonomous University of Barcelona; Fundacio Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol (IGTP)	Fecteau, S (corresponding author), Univ Laval, Ctr Rech Univ Sante Mentale Quebec, Ctr Interdisciplinaire Rech Readaptat & Integrat, Sch Med, Quebec City, PQ, Canada.	shirley.fecteau@fmed.ulaval.ca	Kumru, Hatice/ABB-1109-2021; Pascual-Leone, Alvaro/AAC-5101-2019; Fecteau, Shirley/N-3017-2016	Pascual-Leone, Alvaro/0000-0001-8975-0382; Fecteau, Shirley/0000-0002-9781-4451; Garcia-Molina, Alberto/0000-0002-5014-7591; Kumru, Hatice/0000-0002-0501-1660; Tormos Munoz, Jose Maria/0000-0002-8764-2289	Canada Research Chair in Cognitive Neuroplasticity; National Center for Research Resources: Harvard-Thorndike General Clinical Research Center at BIDMC [NCRR MO1 RR01032]; Harvard Clinical and Translational Science Center [UL1 RR025758]; NIH [K24 RR018875]; Foundation La Marato TV3 [071931]; Instituto de Salud Carlos III [PI082004]; NATIONAL CENTER FOR RESEARCH RESOURCES [K24RR018875, UL1RR025758, M01RR001032] Funding Source: NIH RePORTER	Canada Research Chair in Cognitive Neuroplasticity; National Center for Research Resources: Harvard-Thorndike General Clinical Research Center at BIDMC(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Harvard Clinical and Translational Science Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Foundation La Marato TV3; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by grants from the Canada Research Chair in Cognitive Neuroplasticity to SF, from the National Center for Research Resources: Harvard-Thorndike General Clinical Research Center at BIDMC (NCRR MO1 RR01032) and Harvard Clinical and Translational Science Center (UL1 RR025758), NIH grant K24 RR018875 to APL, and by the Foundation La Marato TV3 (071931) and grant PI082004 from the Instituto de Salud Carlos III to JMT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aklin WM, 2005, BEHAV RES THER, V43, P215, DOI 10.1016/j.brat.2003.12.007; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Baguley I, 2000, BRAIN INJURY, V14, P505; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Bechara A, 2004, BRAIN COGNITION, V55, P30, DOI 10.1016/j.bandc.2003.04.001; Bechara A, 2001, NEUROPSYCHOLOGIA, V39, P376, DOI 10.1016/S0028-3932(00)00136-6; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; Bonatti E, 2008, COGN BEHAV NEUROL, V21, P164, DOI 10.1097/WNN.0b013e318184e688; Boyle PA, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-53; Cernich AN, 2010, CURR TREAT OPTION NE, V12, P412, DOI 10.1007/s11940-010-0085-6; Chiu CYP, 2012, DEV NEUROPSYCHOL, V37, P176, DOI 10.1080/87565641.2011.632796; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Clark L, 2003, NEUROPSYCHOLOGIA, V41, P1474, DOI 10.1016/S0028-3932(03)00081-2; Dams-O'Connor K, 2010, PSYCHIAT CLIN N AM, V33, P893, DOI 10.1016/j.psc.2010.08.002; Donovan NJ, 2011, BRAIN INJURY, V25, P348, DOI 10.3109/02699052.2011.556105; Drechsler R, 2008, J NEURAL TRANSM, V115, P201, DOI 10.1007/s00702-007-0814-5; Floden D, 2008, NEUROPSYCHOLOGIA, V46, P213, DOI 10.1016/j.neuropsychologia.2007.07.020; Garcia-Molina A, 2007, NEUROLOGIA, V22, P206; Gentleman D, 2001, TRAUMA, V3, P193, DOI DOI 10.1177/146040860100300401; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Gordon W.A., 2005, TXB TRAUMATIC BRAIN, P655; Kennedy MRT, 2006, NEUROPSYCHOL REV, V16, P151, DOI 10.1007/s11065-006-9012-8; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Krishnan M, 2012, CLIN NEUROPSYCHOL, V26, P951, DOI 10.1080/13854046.2012.708166; Leblanc N, 2005, DEV NEUROPSYCHOL, V28, P829, DOI 10.1207/s15326942dn2803_5; Leigh BC, 1999, ADDICTION, V94, P371, DOI 10.1046/j.1360-0443.1999.9433717.x; Lejuez C, 2003, J ADOLESCENCE, V26, P475, DOI 10.1016/S0140-1971(03)00036-8; Lejuez CW, 2005, NICOTINE TOB RES, V7, P71, DOI 10.1080/14622200412331328484; Lejuez CW, 2004, ADDICT BEHAV, V29, P1643, DOI 10.1016/j.addbeh.2004.02.035; Lejuez CW, 2003, EXP CLIN PSYCHOPHARM, V11, P26, DOI 10.1037/1064-1297.11.1.26; Lejuez CW, 2002, J EXP PSYCHOL-APPL, V8, P75, DOI 10.1037//1076-898X.8.2.75; Lu J, 2005, ACT NEUR S, V95, P281; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; Matheson L, 2010, WORK, V36, P413, DOI 10.3233/WOR-2010-1043; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Novack TA, 2000, BRAIN INJURY, V14, P987; Nybo T, 1999, BRAIN INJURY, V13, P759; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Rahman S, 2001, TRENDS COGN SCI, V5, P271, DOI 10.1016/S1364-6613(00)01650-8; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Schlund MW, 2002, BRAIN INJURY, V16, P527, DOI 10.1080/02699050110113679; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Shore AD, 2005, BRAIN INJURY, V19, P613, DOI 10.1080/02699050400013568; Sigurdardottir S, 2010, NEUROPSYCHOLOGY, V24, P504, DOI 10.1037/a0018934; Silver JM, 2005, TXB TRAUMATIC BRAIN, P259; Smith K, 2002, MANAGE SCI, V48, P711, DOI 10.1287/mnsc.48.6.711.194; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TEASDALE G, 1974, LANCET, V2, P81; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8; Tsaousides T, 2009, MT SINAI J MED, V76, P173, DOI 10.1002/msj.20099; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Zak PJ, 2004, PHILOS T R SOC B, V359, P1737, DOI 10.1098/rstb.2004.1544	62	5	5	2	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 26	2013	8	12							e83598	10.1371/journal.pone.0083598	http://dx.doi.org/10.1371/journal.pone.0083598			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	281QS	24386232	gold, Green Published, Green Submitted			2023-01-03	WOS:000329116700061
J	Lee, YS; Ju, HK; Kim, YJ; Lim, TG; Uddin, MR; Kim, YB; Baek, JH; Kwon, SW; Lee, KW; Seo, HS; Park, SU; Yang, TJ				Lee, Yun Sun; Ju, Hyun Kyoung; Kim, Yeon Jeong; Lim, Tae-Gyu; Uddin, Md Romij; Kim, Yeon Bok; Baek, Jin Hong; Kwon, Sung Won; Lee, Ki Won; Seo, Hak Soo; Park, Sang Un; Yang, Tae-Jin			Enhancement of Anti-Inflammatory Activity of Aloe vera Adventitious Root Extracts through the Alteration of Primary and Secondary Metabolites via Salicylic Acid Elicitation	PLOS ONE			English	Article							ANTIOXIDANT ACTIVITY; SUSPENSION-CULTURES; BARBADENSIS MILLER; PHENOLIC-COMPOUNDS; MASS-SPECTROMETRY; METHYL JASMONATE; ANTHRAQUINONES; GROWTH; ACCUMULATION; TISSUE	Aloe vera (Asphodeloideae) is a medicinal plant in which useful secondary metabolites are plentiful. Among the representative secondary metabolites of Aloe vera are the anthraquinones including aloe emodin and chrysophanol, which are tricyclic aromatic quinones synthesized via a plant-specific type III polyketide biosynthesis pathway. However, it is not yet clear which cellular responses can induce the pathway, leading to production of tricyclic aromatic quinones. In this study, we examined the effect of endogenous elicitors on the type III polyketide biosynthesis pathway and identified the metabolic changes induced in elicitor-treated Aloe vera adventitious roots. Salicylic acid, methyl jasmonate, and ethephon were used to treat Aloe vera adventitious roots cultured on MS liquid media with 0.3 mg/L IBA for 35 days. Aloe emodin and chrysophanol were remarkably increased by the SA treatment, more than 10-11 and 5-13 fold as compared with untreated control, respectively. Ultra-performance liquid chromatography-electrospray ionization mass spectrometry analysis identified a total of 37 SA-induced compounds, including aloe emodin and chrysophanol, and 3 of the compounds were tentatively identified as tricyclic aromatic quinones. Transcript accumulation analysis of polyketide synthase genes and gas chromatography mass spectrometry showed that these secondary metabolic changes resulted from increased expression of octaketide synthase genes and decreases in malonyl-CoA, which is the precursor for the tricyclic aromatic quinone biosynthesis pathway. In addition, anti-inflammatory activity was enhanced in extracts of SA-treated adventitious roots. Our results suggest that SA has an important role in activation of the plant specific-type III polyketide biosynthetic pathway, and therefore that the efficacy of Aloe vera as medicinal agent can be improved through SA treatment.	[Lee, Yun Sun; Kim, Yeon Jeong; Seo, Hak Soo; Yang, Tae-Jin] Seoul Natl Univ, Coll Agr & Life Sci, Plant Genom & Breeding Inst, Dept Plant Sci, Seoul, South Korea; [Lee, Yun Sun; Kim, Yeon Jeong; Seo, Hak Soo; Yang, Tae-Jin] Seoul Natl Univ, Coll Agr & Life Sci, Res Inst Agr & Life Sci, Seoul, South Korea; [Ju, Hyun Kyoung; Kwon, Sung Won] Seoul Natl Univ, Coll Pharm, Seoul, South Korea; [Ju, Hyun Kyoung; Kwon, Sung Won] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul, South Korea; [Lim, Tae-Gyu] Seoul Natl Univ, Inst Green Bio Sci & Technol, Pyeongchang, South Korea; [Uddin, Md Romij; Kim, Yeon Bok; Park, Sang Un] Chungnam Natl Univ, Dept Crop Sci, Taejon, South Korea; [Baek, Jin Hong] Kim Jeong Moon Aloe Co LTD, Seoul, South Korea; [Lee, Ki Won] Seoul Natl Univ, Ctr Agr Biomat, Dept Agr Biotechnol, Seoul, South Korea; [Seo, Hak Soo] Seoul Natl Univ, BioMAX Inst, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Chungnam National University; Seoul National University (SNU); Seoul National University (SNU)	Yang, TJ (corresponding author), Seoul Natl Univ, Coll Agr & Life Sci, Plant Genom & Breeding Inst, Dept Plant Sci, Seoul, South Korea.	tjyang@snu.ac.kr	Yang, Tae-Jin/AAT-5274-2020; Lim, Tae-Gyu/AAO-8475-2020; Lee, Yun Sun/AAF-2932-2021; Lee, Ki Won/M-4114-2018	Lim, Tae-Gyu/0000-0001-6930-9565; Uddin, Md. Romij/0000-0003-2188-7619	Kim Jeong Moon Aloe Co; Rural Development Administration, Republic of Korea [PJ008202]	Kim Jeong Moon Aloe Co; Rural Development Administration, Republic of Korea(Rural Development Administration (RDA), Republic of Korea)	This work was supported by the Kim Jeong Moon Aloe Co and Next-Generation BioGreen21 Program (No. PJ008202), Rural Development Administration, Republic of Korea (http://atis.rda.go.kr/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe I, 2005, J AM CHEM SOC, V127, P12709, DOI 10.1021/ja053945v; Ali MB, 2006, PLANT CELL REP, V25, P613, DOI 10.1007/s00299-005-0065-6; ALTENBACH SB, 1981, VIROLOGY, V112, P25, DOI 10.1016/0042-6822(81)90608-5; Benhamou N, 1996, TRENDS PLANT SCI, V1, P233; BENNETT RN, 1994, NEW PHYTOL, V127, P617, DOI 10.1111/j.1469-8137.1994.tb02968.x; Boudreau MD, 2006, J ENVIRON SCI HEAL C, V24, P103, DOI 10.1080/10590500600614303; Bulgakov VP, 2002, J BIOTECHNOL, V97, P213, DOI 10.1016/S0168-1656(02)00067-6; Chiang L, 2007, PROCESS BIOCHEM, V42, P757, DOI 10.1016/j.procbio.2007.01.005; Coste A, 2011, PLANT CELL TISS ORG, V106, P279, DOI 10.1007/s11240-011-9919-5; De Vos RCH, 2007, NAT PROTOC, V2, P778, DOI 10.1038/nprot.2007.95; DICOSMO F, 1985, TRENDS BIOTECHNOL, V3, P318, DOI 10.1016/0167-7799(85)90036-8; Dong JA, 2010, J BIOTECHNOL, V148, P99, DOI 10.1016/j.jbiotec.2010.05.009; Farag MA, 2008, PLANT PHYSIOL, V146, P387, DOI 10.1104/pp.107.108431; Farag MA, 2009, PLANT PHYSIOL, V151, P1096, DOI 10.1104/pp.109.141481; GAMBORG OL, 1968, EXP CELL RES, V50, P151, DOI 10.1016/0014-4827(68)90403-5; He ZH, 2009, J ETHNOPHARMACOL, V121, P313, DOI 10.1016/j.jep.2008.11.008; Jung H, 2002, KOREAN J BIOTECHNOL, V7, P525; Jung SK, 2008, CANCER RES, V68, P6021, DOI 10.1158/0008-5472.CAN-08-0899; Jung SK, 2013, FOOD SCI BIOTECHNOL, V22, P507, DOI 10.1007/s10068-013-0108-7; KAWAI K, 1993, PHYTOTHER RES, V7, pS5, DOI 10.1002/ptr.2650070705; Kiehne A, 1996, Z LEBENSM UNTERS FOR, V202, P48, DOI 10.1007/BF01229684; Kovacik J, 2009, PLANT CELL REP, V28, P135, DOI 10.1007/s00299-008-0627-5; Kwon JY, 2009, CARCINOGENESIS, V30, P1932, DOI 10.1093/carcin/bgp216; Lee KM, 2009, CANCER RES, V69, P8043, DOI 10.1158/0008-5472.CAN-09-2316; Lee S, 2012, J AGR FOOD CHEM, V60, P11222, DOI 10.1021/jf3026309; Lee YS, 2011, PLANT OMICS, V4, P190; Matsuda F, 2009, PLANT J, V57, P555, DOI 10.1111/j.1365-313X.2008.03705.x; Mizuuchi Y, 2009, FEBS J, V276, P2391, DOI 10.1111/j.1742-4658.2009.06971.x; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Ong ES, 2009, MOL BIOSYST, V5, P288, DOI 10.1039/b811850g; Park MY, 2009, BIOSCI BIOTECH BIOCH, V73, P828, DOI 10.1271/bbb.80714; Pu GB, 2009, PLANT CELL REP, V28, P1127, DOI 10.1007/s00299-009-0713-3; Pussa T, 2009, PHYTOCHEM ANALYSIS, V20, P98, DOI 10.1002/pca.1102; Rao SR, 2002, BIOTECHNOL ADV, V20, P101, DOI 10.1016/S0734-9750(02)00007-1; Reynolds T, 1999, J ETHNOPHARMACOL, V68, P3, DOI 10.1016/S0378-8741(99)00085-9; ROY SC, 1991, SCI HORTIC-AMSTERDAM, V47, P107, DOI 10.1016/0304-4238(91)90032-T; Rozen S, 2000, Methods Mol Biol, V132, P365; Sawada Y, 2009, PLANT CELL PHYSIOL, V50, P37, DOI 10.1093/pcp/pcn183; SCHENK RU, 1972, CAN J BOTANY, V50, P199, DOI 10.1139/b72-026; Song R, 2011, BIOMED CHROMATOGR, V25, P417, DOI 10.1002/bmc.1467; Song R, 2009, RAPID COMMUN MASS SP, V23, P537, DOI 10.1002/rcm.3907; Sumner LW, 2007, METABOLOMICS, V3, P211, DOI 10.1007/s11306-007-0082-2; Tamarat R, 2002, LAB INVEST, V82, P747, DOI 10.1097/01.LAB.0000017372.76297.EB; Tan ZJ, 2011, SEP SCI TECHNOL, V46, P1503, DOI 10.1080/01496395.2011.563766; Xie Y, 2007, J LIQ CHROMATOGR R T, V30, P1475, DOI 10.1080/10826070701277117; Yagi A, 1998, PHYTOCHEMISTRY, V47, P1267, DOI 10.1016/S0031-9422(97)00745-0; Ye M, 2007, J AM SOC MASS SPECTR, V18, P82, DOI 10.1016/j.jasms.2006.08.009; Yen GC, 2000, FOOD CHEM, V70, P437, DOI 10.1016/S0308-8146(00)00108-4; Yonekura-Sakakibara K, 2008, PLANT CELL, V20, P2160, DOI 10.1105/tpc.108.058040; Yousefzadi M, 2010, BIOTECHNOL LETT, V32, P1739, DOI 10.1007/s10529-010-0343-4; Yu DH, 2011, J SEP SCI, V34, P1133, DOI 10.1002/jssc.201100012; Zhao J, 2005, BIOTECHNOL ADV, V23, P283, DOI 10.1016/j.biotechadv.2005.01.003	52	24	28	1	54	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2013	8	12							e82479	10.1371/journal.pone.0082479	http://dx.doi.org/10.1371/journal.pone.0082479			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276GD	24358188	Green Submitted, gold, Green Published			2023-01-03	WOS:000328735700069
J	Parikh, RB; Kirch, RA; Smith, TJ; Temel, JS				Parikh, Ravi B.; Kirch, Rebecca A.; Smith, Thomas J.; Temel, Jennifer S.			Early Specialty Palliative Care-Translating Data in Oncology into Practice	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CELL LUNG-CANCER; RANDOMIZED CONTROLLED-TRIAL; IMPROVE; OPPORTUNITIES; CHEMOTHERAPY; PERCEPTIONS; ACCESS; IMPACT; MODEL; LIFE		[Parikh, Ravi B.] Harvard Univ, Sch Med, Boston, MA USA; [Temel, Jennifer S.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Kirch, Rebecca A.] Amer Canc Soc, Washington, DC USA; [Smith, Thomas J.] Johns Hopkins Univ, Baltimore, MD USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; American Cancer Society; Johns Hopkins University	Temel, JS (corresponding author), Massachusetts Gen Hosp, Div Hematol Oncol, 55 Fruit St,Yawkey 7B, Boston, MA 02114 USA.	jtemel@partners.org		Smith, Thomas/0000-0003-3040-6434	NCI NIH HHS [P30 CA006973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 2013, OV APPR; [Anonymous], 2012, PALL CAR SERV SOL BE; Bakitas M, 2009, JAMA-J AM MED ASSOC, V302, P741, DOI 10.1001/jama.2009.1198; Brumley R, 2007, J AM GERIATR SOC, V55, P993, DOI 10.1111/j.1532-5415.2007.01234.x; Brumley Richard D, 2003, J Palliat Med, V6, P715, DOI 10.1089/109662103322515220; Center to Advance Palliative Care, 2011, 2011 PUBL OP RES PAL; Center to Advance Palliative Care, 2011, STAT BY STAT REP CAR; Centers for Medicare and Medicaid Services, 2013, MED HOSP BEN; Chen AB, 2013, J CLIN ONCOL, V31, P2730, DOI 10.1200/JCO.2012.48.5748; Ciemins EL, 2007, J PALLIAT MED, V10, P1347, DOI 10.1089/jpm.2007.0065; Gade G, 2008, J PALLIAT MED, V11, P180, DOI 10.1089/jpm.2007.0055; Goldsmith B, 2008, J PALLIAT MED, V11, P1094, DOI 10.1089/jpm.2008.0053; Greer JA, 2013, CA CANC J CLIN; Greer JA, 2012, J CLIN ONCOL, V30, P394, DOI 10.1200/JCO.2011.35.7996; Hauptman PJ, 2005, ARCH INTERN MED, V165, P374, DOI 10.1001/archinte.165.4.374; Higginson IJ, 2011, POSTGRAD MED J, V87, P769, DOI 10.1136/postgradmedj-2011-130290; Hui D, 2010, JAMA-J AM MED ASSOC, V303, P1054, DOI 10.1001/jama.2010.258; *I MED, 2003, IMPR PALL CAR CANC S; Institute for Healthcare Improvement, 2013, IHI TRIPL AIM IN; Kaiser Family Foundation, 2012, MED SPEND FIN FACT S; Krakauer R, 2009, HEALTH AFFAIR, V28, P1357, DOI 10.1377/hlthaff.28.5.1357; Meier~ DE, 2010, PALLIATIVE CARE TRAN, V1st; Meier DE, 2011, MILBANK Q, V89, P343, DOI 10.1111/j.1468-0009.2011.00632.x; Morrison LJ, 2012, J PALLIAT MED, V15, P784, DOI 10.1089/jpm.2011.0482; Morrison RS, 2008, ARCH INTERN MED, V168, P1783, DOI 10.1001/archinte.168.16.1783; Pirl WF, 2012, J CLIN ONCOL, V30, P1310, DOI 10.1200/JCO.2011.38.3166; Quill TE, 2013, NEW ENGL J MED, V368, P1173, DOI 10.1056/NEJMp1215620; Spettell CM, 2009, J PALLIAT MED, V12, P827, DOI 10.1089/jpm.2009.0089; Sulmasy DP, 2008, J PALLIAT MED, V11, P707, DOI 10.1089/jpm.2007.0210; Temel JS, 2011, J CLIN ONCOL, V29, P2319, DOI 10.1200/JCO.2010.32.4459; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Weeks JC, 2012, NEW ENGL J MED, V367, P1616, DOI 10.1056/NEJMoa1204410; Zimmermann C, 2012, 2012 AM SOC CLIN ONC	33	178	183	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 12	2013	369	24					2347	2351		10.1056/NEJMsb1305469	http://dx.doi.org/10.1056/NEJMsb1305469			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	268FV	24328469	Green Accepted, Bronze			2023-01-03	WOS:000328156300014
J	Warsow, G; Struckmann, S; Kerkhoff, C; Reimer, T; Engel, N; Fuellen, G				Warsow, Gregor; Struckmann, Stephan; Kerkhoff, Claus; Reimer, Toralf; Engel, Nadja; Fuellen, Georg			Differential Network Analysis Applied to Preoperative Breast Cancer Chemotherapy Response	PLOS ONE			English	Article							LEUCINE-ZIPPER KINASE; B-MYB; IN-VIVO; EXPRESSION; PROTEIN; CELLS; SUBTYPES; REGULATOR; MELK; CLASSIFICATION	In silico approaches are increasingly considered to improve breast cancer treatment. One of these treatments, neoadjuvant TFAC chemotherapy, is used in cases where application of preoperative systemic therapy is indicated. Estimating response to treatment allows or improves clinical decision-making and this, in turn, may be based on a good understanding of the underlying molecular mechanisms. Ever increasing amounts of high throughput data become available for integration into functional networks. In this study, we applied our software tool ExprEssence to identify specific mechanisms relevant for TFAC therapy response, from a gene/protein interaction network. We contrasted the resulting active subnetwork to the subnetworks of two other such methods, OptDis and KeyPathwayMiner. We could show that the ExprEssence subnetwork is more related to the mechanistic functional principles of TFAC therapy than the subnetworks of the other two methods despite the simplicity of ExprEssence. We were able to validate our method by recovering known mechanisms and as an application example of our method, we identified a mechanism that may further explain the synergism between paclitaxel and doxorubicin in TFAC treatment: Paclitaxel may attenuate MELK gene expression, resulting in lower levels of its target MYBL2, already associated with doxorubicin synergism in hepatocellular carcinoma cell lines. We tested our hypothesis in three breast cancer cell lines, confirming it in part. In particular, the predicted effect on MYBL2 could be validated, and a synergistic effect of paclitaxel and doxorubicin could be demonstrated in the breast cancer cell lines SKBR3 and MCF-7.	[Warsow, Gregor; Struckmann, Stephan; Fuellen, Georg] Univ Rostock, Sch Med, Inst Biostat & Informat Med & Ageing Res, D-18055 Rostock, Germany; [Warsow, Gregor] Ernst Moritz Arndt Univ Greifswald, Dept Math & Informat, Greifswald, Germany; [Warsow, Gregor] Univ Med Greifswald, Dept Anat & Cell Biol, Greifswald, Germany; [Kerkhoff, Claus] Univ Osnabruck, Dept Biomed Sci, Sch Human Sci, D-49069 Osnabruck, Germany; [Reimer, Toralf] Univ Rostock, Sch Med, Dept Obstet & Gynecol, D-18055 Rostock, Germany; [Engel, Nadja] Univ Rostock, Sch Med, Dept Cell Biol, D-18055 Rostock, Germany	University of Rostock; Ernst Moritz Arndt Universitat Greifswald; Greifswald Medical School; University Osnabruck; University of Rostock; University of Rostock	Engel, N (corresponding author), Univ Rostock, Sch Med, Dept Cell Biol, D-18055 Rostock, Germany.	nadja.engel-lutz@uni-rostock.de; fuellen@uni-rostock.de	Reimer, Toralf/R-8199-2019	Struckmann, Stephan/0000-0002-8565-7962; Engel, Nadja/0000-0002-6362-9282	BMBF [01GN0901]; DFG [FU583/2-1, FU583/2-2]	BMBF(Federal Ministry of Education & Research (BMBF)); DFG(German Research Foundation (DFG))	ExprEssence development is funded by the BMBF (01GN0901) and the DFG (FU583/2-1, FU583/2-2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abba MC, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1617; Alcaraz N, 2012, INTEGR BIOL-UK, V4, P756, DOI 10.1039/c2ib00133k; Baumbach J, 2012, PROCEEDINGS OF THE FOURTEENTH INTERNATIONAL CONFERENCE ON GENETIC AND EVOLUTIONARY COMPUTATION CONFERENCE, P169, DOI 10.1145/2330163.2330188; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breitling R, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-100; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Cabusora L, 2005, BIOINFORMATICS, V21, P2898, DOI 10.1093/bioinformatics/bti440; Calvisi DF, 2011, HEPATOLOGY, V53, P1226, DOI 10.1002/hep.24174; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Chou J, 2010, J CELL PHYSIOL, V222, P42, DOI 10.1002/jcp.21943; Chuang HY, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100180; Dao P, 2011, BIOINFORMATICS, V27, pI205, DOI 10.1093/bioinformatics/btr245; Davis AP, 2013, NUCLEIC ACIDS RES, V41, pD1104, DOI 10.1093/nar/gks994; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Engel N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047833; Gevaert O, 2006, BIOINFORMATICS, V22, pE184, DOI 10.1093/bioinformatics/btl230; Hannemann J, 2006, BRIT J CANCER, V95, P1334, DOI 10.1038/sj.bjc.6603449; Hebbard LW, 2010, CANCER RES, V70, P8863, DOI 10.1158/0008-5472.CAN-10-1295; Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861; Ideker T, 2008, GENOME RES, V18, P644, DOI 10.1101/gr.071852.107; Ideker T, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2011.99; Ideker Trey, 2002, Bioinformatics, V18 Suppl 1, pS233; Joaquin M, 2003, J BIOL CHEM, V278, P44255, DOI 10.1074/jbc.M308953200; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Liekens AML, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r57; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LONG BH, 1994, CANCER RES, V54, P4355; Lund MJ, 2010, CANCER-AM CANCER SOC, V116, P2549, DOI 10.1002/cncr.25016; Mannefeld M, 2009, CANCER RES, V69, P4073, DOI 10.1158/0008-5472.CAN-08-4156; Nacu S, 2007, BIOINFORMATICS, V23, P850, DOI 10.1093/bioinformatics/btm019; Nakano I, 2005, J CELL BIOL, V170, P413, DOI 10.1083/jcb.200412115; Pickard MR, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2350; Popovici V, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2468; Raschella G, 1999, CANCER RES, V59, P3365; Saito R, 2012, NAT METHODS, V9, P1069, DOI [10.1038/NMETH.2212, 10.1038/nmeth.2212]; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Seong HA, 2002, BIOCHEM J, V361, P597, DOI 10.1042/0264-6021:3610597; Seong HA, 2003, J BIOL CHEM, V278, P9655, DOI 10.1074/jbc.M207478200; Staiger C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034796; Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973; Tegze B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030804; Thorner AR, 2009, ONCOGENE, V28, P742, DOI 10.1038/onc.2008.430; Ulitsky I, 2008, LECT N BIOINFORMAT, V4955, P347; Vantieghem K, 2006, ACTA BIOMEDICA LOVAN, V371; Verlinden L, 2005, J BIOL CHEM, V280, P37319, DOI 10.1074/jbc.M503587200; Warsow G, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-164; Yang XR, 2011, JNCI-J NATL CANCER I, V103, P250, DOI 10.1093/jnci/djq526	48	12	12	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2013	8	12							e81784	10.1371/journal.pone.0081784	http://dx.doi.org/10.1371/journal.pone.0081784			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275VD	24349128	gold, Green Submitted, Green Published			2023-01-03	WOS:000328705200050
J	Larsen, MD; Hallas, J				Larsen, Michael Due; Hallas, Jesper			Hospital Physicians' Influence on Gastrointestinal Protection during Treatment with Non-Steroidal Anti-Inflammatory Drugs and Acetylsalicylic Acid and the Impact on Prescribing in Primary Care	PLOS ONE			English	Article							EXPERT CONSENSUS DOCUMENT; PEPTIC-ULCER DISEASE; LOW-DOSE ASPIRIN; ANTIPLATELET THERAPY; NSAID USE; RISK; COMPLICATIONS; COMMUNICATION; PREVENTION; CONTINUITY	Background: The aim of this study was to describe the use of gastrointestinal (GI) protection before, during and after hospitalisation for elderly patients using NSAID or low-dose ASA. Methods: This study included all elderly patients (75+) admitted to hospital in the period of 1st April 2010 to 31st March 2011 at Odense University Hospital, Denmark, who were regular users of NSAID or low-dose ASA before hospital admission, or had one of these drugs initiated during hospital stay. By using pharmacy dispensing data and a hospital-based pharmacoepidemiological database, the treatment strategy for the individual patients was followed across hospital stay. Results: In total, 3,587 patients were included. Before hospital admission, 93 of 245 NSAID users (38.0%) and 597 of 1994 user of low-dose ASA (29.9%) had used GI protection. During hospital stay, use of GI protection increased to 75% and 33.9%, respectively. When hospital physicians initiated new treatment with NSAID or with low-dose ASA, 305 of 555 (55.0%) and 647 of 961 (67.3%) were initiated without concomitant use of GI protection. When hospital physicians initiated GI protection, 26.8-51.0% were continued in primary care after discharge. Conclusions: During hospital stay, the use of GI protection increases, but when new treatment with NSAIDs or low-dose ASA is initiated in hospital, the use of gastrointestinal protection is low. The low use of GI protection is carried on in primary care after discharge.	[Larsen, Michael Due; Hallas, Jesper] Univ So Denmark, Odense M, Denmark	University of Southern Denmark	Larsen, MD (corresponding author), Univ So Denmark, Odense M, Denmark.	mdlarsen@health.sdu.dk		Larsen, Michael Due/0000-0002-0623-2481; Hallas, Jesper/0000-0002-8097-8708				Abraham NS, 2010, AM J GASTROENTEROL, V105, P2533, DOI 10.1038/ajg.2010.445; Andrade SE, 2006, PHARMACOEPIDEM DR S, V15, P565, DOI 10.1002/pds.1230; Bhatt DL, 2008, AM J GASTROENTEROL, V103, P2890, DOI 10.1111/j.1572-0241.2008.02216.x; CHAN KWA, 1993, J CLIN EPIDEMIOL, V46, P113, DOI 10.1016/0895-4356(93)90016-T; Danish State Serum Institute, 2013, DISTR OV THE COUNT A; Federman Alex D, 2006, Am J Geriatr Pharmacother, V4, P306; Fosbol EL, 2008, PHARMACOEPIDEM DR S, V17, P822, DOI 10.1002/pds.1592; Gaist D, 1997, DAN MED BULL, V44, P445; Glintborg B, 2007, QUAL SAF HEALTH CARE, V16, P34, DOI 10.1136/qshc.2006.019828; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; Hernandez-Diaz S, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-22; Himmel W, 2004, INT J CLIN PHARM TH, V42, P103; Johannesdottir Sigrun Alba, 2012, Clin Epidemiol, V4, P13, DOI 10.2147/CLEP.S26958; Kirkwood BR., 2005, ESSENTIAL MED STAT, V2nd; Krag A, 2006, ALIMENT PHARM THER, V23, P1713, DOI 10.1111/j.1365-2036.2006.02950.x; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Laine L, 2006, ALIMENT PHARM THER, V24, P897, DOI 10.1111/j.1365-2036.2006.03077.x; Mahe I, 2003, DRUG AGING, V20, P999; Mansur N, 2008, DRUG AGING, V25, P861, DOI 10.2165/00002512-200825100-00005; Ng FH, 2010, GASTROENTEROLOGY, V138, P82, DOI 10.1053/j.gastro.2009.09.063; Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965; Rostom A, 2002, COCHRANE DATABASE SY; Schneeweiss S, 2005, J CLIN EPIDEMIOL, V58, P323, DOI 10.1016/j.jclinepi.2004.10.012; Serrano P, 2002, ALIMENT PHARM THER, V16, P1945, DOI 10.1046/j.1365-2036.2002.01355.x; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; The Danish College of General Practitioners, 2013, DYSP; The Danish College of General Practitioners, AELDR PAT; The Danish Society of Cardiology, FARM KARD KOMPL; Visser LE, 2002, BRIT J CLIN PHARMACO, V53, P183, DOI 10.1046/j.0306-5251.2001.01190.x; Wettermark B, 2013, PHARMACOEPIDEMIOLOGY; WHO Collaborating Centre for Drug Statistics Methodology, 2010, GUID ATC CLASS DDD A; Yeomans ND, 2005, ALIMENT PHARM THER, V22, P795, DOI 10.1111/j.1365-2036.2005.02649.x	32	0	0	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 6	2013	8	12							e81845	10.1371/journal.pone.0081845	http://dx.doi.org/10.1371/journal.pone.0081845			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273WJ	24349137	gold, Green Submitted, Green Published			2023-01-03	WOS:000328566700052
J	Mikol, BA; Cohenz, B; Haxa, K; Conway', L; Kelly, N; Stare, D; Tropiano, C; Gilmans, A; Seward, SL; Larson, E				Mikol, Benjamin A.; Cohenz, Bevin; Haxa, Katharine; Conway', Laurie; Kelly, Nicole; Stare, Dianne; Tropiano, Christina; Gilmans, Allan; Seward, Samuel L., Jr.; Larson, Elaine			Personal and Household Hygiene, Environmental Contamination, and Health in Undergraduate Residence Halls in New York City, 2011	PLOS ONE			English	Article							HAND HYGIENE; COLLEGE; DISINFECTION; STUDENTS; DISEASE; HOME; SALMONELLA; SYMPTOMS; SURFACES; ILLNESS	Background: While several studies have documented the importance of hand washing in the university setting, the added role of environmental hygiene remains poorly understood. The purpose of this study was to characterize the personal and environmental hygiene habits of college students, define the determinants of hygiene in this population, and assess the relationship between reported hygiene behaviors, environmental contamination, and health status. Methods: 501 undergraduate students completed a previously validated survey assessing baseline demographics, hygiene habits, determinants of hygiene, and health status. Sixty survey respondents had microbiological samples taken from eight standardized surfaces in their dormitory environment. Bacterial contamination was assessed using standard quantitative bacterial culture techniques. Additional culturing for coagulase-positive Staphylococcus and coliforms was performed using selective agar. Results: While the vast majority of study participants (n = 461, 92%) believed that hand washing was important for infection prevention, there was a large amount of variation in reported personal hygiene practices. More women than men reported consistent hand washing before preparing food (p = .002) and after using the toilet (p = .001). Environmental hygiene showed similar variability although 73.3% (n = 367) of subjects reported dormitory cleaning at least once per month. Contamination of certain surfaces was common, with at least one third of all bookshelves, desks, refrigerator handles, toilet handles, and bathroom door handles positive for >10 CFU of bacteria per 4 cm(2) area. Coagulase-positive Staphylococcus was detected in three participants' rooms (5%) and coliforms were present in six students' rooms (10%). Surface contamination with any bacteria did not vary by frequency of cleaning or frequency of illness (p>.05). Conclusions: Our results suggest that surface contamination, while prevalent, is unrelated to reported hygiene or health in the university setting. Further research into environmental reservoirs of infectious diseases may delineate whether surface decontamination is an effective target of hygiene interventions in this population.	[Mikol, Benjamin A.] Columbia Univ, Coll Phys & Surg, Div Infect Dis, New York, NY 10027 USA; [Mikol, Benjamin A.; Cohenz, Bevin; Conway', Laurie; Larson, Elaine] Columbia Univ, Ctr Interdisciplinary Res Reduce Antimicrobial Re, New York, NY USA; [Cohenz, Bevin; Larson, Elaine] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA; [Haxa, Katharine; Conway', Laurie; Kelly, Nicole; Stare, Dianne; Tropiano, Christina; Larson, Elaine] Columbia Univ, Sch Nursing, New York, NY USA; [Gilmans, Allan] CUNY Bronx Community Coll, Dept Biol & Med Lab Technol, Bronx, NY USA; [Seward, Samuel L., Jr.] Columbia Univ, Hlth Serv, New York, NY USA	Columbia University; Columbia University; Columbia University; Columbia University; City University of New York (CUNY) System; Columbia University	Mikol, BA (corresponding author), Columbia Univ, Coll Phys & Surg, Div Infect Dis, New York, NY 10027 USA.	bm2266@columbia.edu		Kelly, Nicole/0000-0003-4476-5462; Conway, Laurie/0000-0001-8657-7633	"Training in Interdisciplinary Research to Reduce Antimicrobial Resistance," NIH at Columbia University [T90 NR010824]; The Clorox Company; NATIONAL INSTITUTE OF NURSING RESEARCH [T90NR010824] Funding Source: NIH RePORTER	"Training in Interdisciplinary Research to Reduce Antimicrobial Resistance," NIH at Columbia University; The Clorox Company; NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	This research was supported by "Training in Interdisciplinary Research to Reduce Antimicrobial Resistance," NIH T90 NR010824 at Columbia University and by the The Clorox Company. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aiello AE, 2008, AM J PUBLIC HEALTH, V98, P1372, DOI 10.2105/AJPH.2007.124610; Barker J, 2000, J APPL MICROBIOL, V89, P137, DOI 10.1046/j.1365-2672.2000.01091.x; Barker J, 2004, J HOSP INFECT, V58, P42, DOI 10.1016/j.jhin.2004.04.021; Barker J, 2003, J APPL MICROBIOL, V95, P1351, DOI 10.1046/j.1365-2672.2003.02127.x; Brooke JS, 2009, J ENVIRON HEALTH, V71, P17; Bruce MG, 2001, JAMA-J AM MED ASSOC, V286, P688, DOI 10.1001/jama.286.6.688; Cogan TA, 2002, J APPL MICROBIOL, V92, P885, DOI 10.1046/j.1365-2672.2002.01598.x; Cozad A, 2003, AM J INFECT CONTROL, V31, P243, DOI 10.1067/mic.2003.49; CURTIS V, 1993, B WORLD HEALTH ORGAN, V71, P23; Curtis V, 2003, SOC SCI MED, V57, P657, DOI 10.1016/S0277-9536(02)00409-4; Curtis V, 2011, LANCET INFECT DIS, V11, P312, DOI 10.1016/S1473-3099(10)70224-3; HERSH BS, 1991, AM J PUBLIC HEALTH, V81, P360, DOI 10.2105/AJPH.81.3.360; Judah G, 2010, EPIDEMIOL INFECT, V138, P409, DOI 10.1017/S0950268809990641; Judah G, 2009, AM J PUBLIC HEALTH, V99, pS405, DOI 10.2105/AJPH.2009.164160; Kak V, 2007, INFECT DIS CLIN N AM, V21, P773, DOI 10.1016/j.idc.2007.06.004; Kniehl E, 2005, J HOSP INFECT, V59, P180, DOI 10.1016/j.jhin.2004.06.016; Larson EL, 2004, ANN INTERN MED, V140, P321, DOI 10.7326/0003-4819-140-5-200403020-00007; MASTERTON RG, 1995, J HOSP INFECT, V29, P318, DOI 10.1016/0195-6701(95)90284-8; Miko BA, 2012, AM J INFECT CONTROL, V40, P940, DOI [10.1016/j.ajic.2011.12.015, 10.1016/j.ajic]; Roberts MC, 2011, J APPL MICROBIOL, V110, P1531, DOI 10.1111/j.1365-2672.2011.05017.x; Roberts MC, 2011, AM J INFECT CONTROL, V39, P382, DOI 10.1016/j.ajic.2010.09.008; Sandora TJ, 2008, PEDIATRICS, V121, pE1555, DOI 10.1542/peds.2007-2597; SOSIN DM, 1989, PEDIATRICS, V84, P779; Tsuang WM, 2004, J ENVIRON HEALTH, V66, P39; White C, 2003, AM J INFECT CONTROL, V31, P364, DOI 10.1016/S0196-6553(03)00041-5	25	3	3	0	60	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 27	2013	8	11							e81460	10.1371/journal.pone.0081460	http://dx.doi.org/10.1371/journal.pone.0081460			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261GG	24312303	Green Published, gold			2023-01-03	WOS:000327652100081
J	Weidner, C; Wowro, SJ; Rousseau, M; Freiwald, A; Kodelja, V; Abdel-Aziz, H; Kelber, O; Sauer, S				Weidner, Christopher; Wowro, Sylvia J.; Rousseau, Morten; Freiwald, Anja; Kodelja, Vitam; Abdel-Aziz, Heba; Kelber, Olaf; Sauer, Sascha			Antidiabetic Effects of Chamomile Flowers Extract in Obese Mice through Transcriptional Stimulation of Nutrient Sensors of the Peroxisome Proliferator-Activated Receptor (PPAR) Family	PLOS ONE			English	Article							NATURAL-PRODUCTS; GAMMA; INFLAMMATION; MECHANISMS; DISCOVERY; POTENT; L.; IBEROGAST(R); MODULATORS; COMPONENTS	Given the significant increases in the incidence of metabolic diseases, efficient strategies for preventing and treating of these common disorders are urgently needed. This includes the development of phytopharmaceutical products or functional foods to prevent or cure metabolic diseases. Plant extracts from edible biomaterial provide a potential resource of structurally diverse molecules that can synergistically interfere with complex disorders. In this study we describe the safe application of ethanolic chamomile (Matricaria recutita) flowers extract (CFE) for the treatment and prevention of type 2 diabetes and associated disorders. We show in vitro that this extract activates in particular nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR gamma) and its isotypes. In a cellular context, in human primary adipocytes CFE administration (300 mu g/ml) led to specific expression of target genes of PPAR gamma, whereas in human hepatocytes CFE-induced we detected expression changes of genes that were regulated by PPAR alpha. In vivo treatment of insulin-resistant high-fat diet (HFD)-fed C57BL/6 mice with CFE (200 mg/kg/d) for 6 weeks considerably reduced insulin resistance, glucose intolerance, plasma triacylglycerol, non-esterified fatty acids (NEFA) and LDL/VLDL cholesterol. Co-feeding of lean C57BL/6 mice a HFD with 200 mg/kg/d CFE for 20 weeks showed effective prevention of fatty liver formation and hepatic inflammation, indicating additionally hepatoprotective effects of the extract. Moreover, CFE treatment did not reveal side effects, which have otherwise been associated with strong synthetic PPAR-targeting molecules, such as weight gain, liver disorders, hemodilution or bone cell turnover. Taken together, modulation of PPARs and other factors by chamomile flowers extract has the potential to prevent or treat type 2 diabetes and related disorders.	[Weidner, Christopher; Wowro, Sylvia J.; Rousseau, Morten; Freiwald, Anja; Kodelja, Vitam; Sauer, Sascha] Max Planck Inst Mol Genet, Otto Warburg Lab, D-14195 Berlin, Germany; [Weidner, Christopher] Free Univ Berlin, Dept Biol Chem & Pharm, Berlin, Germany; [Abdel-Aziz, Heba; Kelber, Olaf] Steigerwald Arzneimittelwerk GmbH, Dept Sci, Darmstadt, Germany	Max Planck Society; Free University of Berlin; Bayer AG; Steigerwald Pharmaceutical Factory GmbH	Sauer, S (corresponding author), Max Planck Inst Mol Genet, Otto Warburg Lab, Ihnestr 73, D-14195 Berlin, Germany.	sauer@molgen.mpg.de	Kelber, Olaf/AAH-4819-2021	Kelber, Olaf/0000-0003-3334-5833; Wowro, Sylvia/0000-0003-1728-9210; Abdel-Aziz, Heba/0000-0002-4808-5926	German Ministry for Education and Research (BMBF) [0315082]; European Union [262055]; Max Planck Society	German Ministry for Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); European Union(European Commission); Max Planck Society(Max Planck SocietyFoundation CELLEX)	The authors' work is supported by the German Ministry for Education and Research (BMBF, grant number 0315082), the European Union (FP7/2007-2013, under grant agreement number no 262055 (ESGI)), and the Max Planck Society. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2010, NAT REV DRUG DISCOV, V9, P828; Argmann CA, 2005, EUR J CLIN INVEST, V35, P82, DOI 10.1111/j.1365-2362.2005.01456.x; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Cemek M, 2008, J NAT MED-TOKYO, V62, P284, DOI 10.1007/s11418-008-0228-1; Cho N, 2008, CURR TOP MED CHEM, V8, P1483, DOI 10.2174/156802608786413474; Christensen KB, 2010, PHYTOTHER RES, V24, pS129, DOI 10.1002/ptr.3005; Chuang CC, 2011, ANNU REV NUTR, V31, P155, DOI 10.1146/annurev-nutr-072610-145149; Cock TA, 2004, EMBO REP, V5, P142, DOI 10.1038/sj.embor.7400082; Doshi LS, 2010, EXPERT OPIN INV DRUG, V19, P489, DOI 10.1517/13543781003640169; Eddouks M, 2005, DIABETES RES CLIN PR, V67, P189, DOI 10.1016/j.diabres.2004.07.015; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Ganesan A, 2004, CURR OPIN BIOTECH, V15, P584, DOI 10.1016/j.copbio.2004.09.002; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Gupta AK, 2006, AM J PHARM TOXICOL, V1, P17, DOI [DOI 10.3844/AJPTSP.2006.17.20, 10.3844/ajptsp.2006.17.20]; Harbourne N, 2009, FOOD CHEM, V115, P15, DOI 10.1016/j.foodchem.2008.11.044; Heikkinen S, 2007, CURR PROTOC MOL BIOL, DOI DOI 10.1002/0471142727.MB29B03S77; Heinle H, 2006, PHYTOMEDICINE, V13, P75, DOI 10.1016/j.phymed.2006.03.013; Hohenester B, 2004, NEUROGASTROENT MOTIL, V16, P765, DOI 10.1111/j.1365-2982.2004.00548.x; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Kahn SE, 2006, NATURE, V444, P840, DOI 10.1038/nature05482; Kato A, 2008, J AGR FOOD CHEM, V56, P8206, DOI 10.1021/jf8014365; Kliewer SA, 2001, RECENT PROG HORM RES, V56, P239, DOI 10.1210/rp.56.1.239; Kroll U, 2006, PHYTOMEDICINE, V13, P12, DOI 10.1016/j.phymed.2006.03.016; Lalloyer F, 2010, ARTERIOSCL THROM VAS, V30, P894, DOI 10.1161/ATVBAHA.108.179689; Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026; Li JWH, 2009, SCIENCE, V325, P161, DOI 10.1126/science.1168243; Liang YC, 2001, FEBS LETT, V496, P12, DOI 10.1016/S0014-5793(01)02393-6; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McCarty MF, 2005, MED HYPOTHESES, V64, P151, DOI 10.1016/j.mehy.2004.03.036; Medjakovic S, 2010, NUTRIENTS, V2, P241, DOI 10.3390/nu2030241; Meierhofer D, 2013, MOL CELL PROTEOMICS, V12, P1965, DOI 10.1074/mcp.M112.025031; Michalik L, 2006, PHARMACOL REV, V58, P726, DOI 10.1124/pr.58.4.5; Moreno M, 2010, PPAR RES, V2010, DOI 10.1155/2010/435689; Mueller M, 2008, J AGR FOOD CHEM, V56, P11621, DOI 10.1021/jf802298w; Muller M, 2003, NAT REV GENET, V4, P315, DOI 10.1038/nrg1047; Portincasa P, 2006, CURR MED CHEM, V13, P2889, DOI 10.2174/092986706778521878; Pourcet Benoit, 2006, Expert Opin Emerg Drugs, V11, P379, DOI 10.1517/14728214.11.3.379; Puhl AC, 2012, MOL PHARMACOL, V81, P788, DOI 10.1124/mol.111.076216; Rosen CJ, 2010, NEW ENGL J MED, V363, P803, DOI 10.1056/NEJMp1008233; Singh Ompal, 2011, Pharmacogn Rev, V5, P82, DOI 10.4103/0973-7847.79103; Smyth S, 2006, NAT MED, V12, P75, DOI 10.1038/nm0106-75; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Wegener T, 2006, PHYTOMEDICINE, V13, P20, DOI 10.1016/j.phymed.2006.07.001; Weidner C, 2013, DIABETOLOGIA; Weidner C, 2012, P NATL ACAD SCI USA, V109, P7257, DOI 10.1073/pnas.1116971109; *WHO, 2003, OB OV FACT SHEET; Wilkinson AS, 2008, J AGR FOOD CHEM, V56, P3037, DOI 10.1021/jf800046n; Yang XY, 2006, CELL, V126, P801, DOI 10.1016/j.cell.2006.06.050	50	32	34	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2013	8	11							e80335	10.1371/journal.pone.0080335	http://dx.doi.org/10.1371/journal.pone.0080335			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255PK	24265809	Green Accepted, Green Published, gold, Green Submitted			2023-01-03	WOS:000327252100145
J	Magnus, DC; Wilfond, BS; Caplan, AL				Magnus, David C.; Wilfond, Benjamin S.; Caplan, Arthur L.			Accepting Brain Death	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DONOR RULE	The cases of Jahi McMath and Marlise Munoz have reopened public debate about brain death. But the law and ethics have long recognized that deferring to medical expertise regarding the diagnosis of brain death is the most reasonable way to manage the process of dying. Two cases in which patients have been determined to be dead according to neurologic criteria (brain death) have recently garnered national headlines. In Oakland, California, Jahi McMath's death was determined by means of multiple independent neurologic examinations, including one ordered by a court. Her family refused to accept that she had died and went to court to prevent physicians at Children's Hospital and Research Center in Oakland from discontinuing ventilator support. Per a court-supervised agreement, the body was given to the family 3 weeks after the initial determination. The family's attorney stated that ventilatory support was continued and nutritional support ...	[Magnus, David C.] Stanford Univ, Ctr Biomed Eth, Palo Alto, CA 94304 USA; [Wilfond, Benjamin S.] Seattle Childrens Hosp, Treuman Katz Ctr Pediat Eth, Seattle, WA USA; [Caplan, Arthur L.] NYU, Div Med Eth, New York, NY USA	Stanford University; Seattle Children's Hospital	Magnus, DC (corresponding author), Stanford Univ, Ctr Biomed Eth, Palo Alto, CA 94304 USA.							[Anonymous], 1968, JAMA, V205, P337; Bernat JL, 2013, NEW ENGL J MED, V369, P1289, DOI 10.1056/NEJMp1308078; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1981, DEFINING DEATH A REP; Truog RD, 2013, NEW ENGL J MED, V369, P1287, DOI 10.1056/NEJMp1307220	4	51	52	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 6	2014	370	10					891	894		10.1056/NEJMp1400930	http://dx.doi.org/10.1056/NEJMp1400930			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AC2EB	24499177				2023-01-03	WOS:000332309800004
J	Young, MJ; Lehmann, LS				Young, Michael J.; Lehmann, Lisa Soleymani			Undocumented Injustice? Medical Repatriation and the Ends of Health Care	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MENTAL-HEALTH; SAFETY-NET; TRANSFERS; IMMIGRATION; REFUGEES		[Young, Michael J.; Lehmann, Lisa Soleymani] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Lehmann, Lisa Soleymani] Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Young, MJ (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							[Anonymous], 1936, CHICAGO TRIBUNE; [Anonymous], 2013, 900863 ICN CTR MED M; [Anonymous], 2013, 1699 UCLA CTR HLTH P; Appel JM, 2012, AM J BIOETHICS, V12, P9, DOI 10.1080/15265161.2012.692436; Banatvala N, 1998, PREHOSP DISASTER MED, V13, P17; Breen JO, 2012, NEW ENGL J MED, V366, P2045, DOI 10.1056/NEJMp1202039; Coast J, 2001, Health Expect, V4, P243, DOI 10.1046/j.1369-6513.2001.00147.x; Daniels N, ROUTLEDGE C IN PRESS; HIMMELSTEIN DU, 1984, AM J PUBLIC HEALTH, V74, P494, DOI 10.2105/AJPH.74.5.494; Kane C., 2003, IMPACT EMTALA PHYS P; KELLERMANN AL, 1988, AM J PUBLIC HEALTH, V78, P1287, DOI 10.2105/AJPH.78.10.1287; Kuczewski M, 2012, AM J BIOETHICS, V12, P1, DOI 10.1080/15265161.2012.692433; McNamara RM, 2013, J EMERG MED, V45, P111, DOI 10.1016/j.jemermed.2012.12.019; Monger R., 2009, FOREIGN BORN COMPONE; New York Lawyers for the Public Interest Center for Social Justice at Seton Hall Law School, 2012, DISCH DEP DANG JOURN; Parmet WE, 2013, NEW ENGL J MED, V369, P596, DOI 10.1056/NEJMp1306637; Passel J.S., 2013, POPULATION DECLINE U; Pfeffer N, 1991, IS QUALITY GOOD YOU, P45; Pitt D., 2013, ASS PRESS       0424; Portes A., 2006, IMMIGRANT AM PORTRAI, V3rd; Ramji-Nogales J, 2007, STANFORD LAW REV, V60, P295; Sabin M, 2006, REV PANAM SALUD PUBL, V19, P163, DOI 10.1590/S1020-49892006000300004; SCHIFF RL, 1986, NEW ENGL J MED, V314, P552, DOI 10.1056/NEJM198602273140905; Shah JP, 2012, J GEN INTERN MED, V27, P1142, DOI 10.1007/s11606-012-2040-6; Sommers BD, 2013, NEW ENGL J MED, V369, P593, DOI 10.1056/NEJMp1306636; Tienda M, 2013, DAEDALUS-US, V142, P48, DOI 10.1162/DAED_a_00218; von Lersner U, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-88; Young MJ, 2012, CRIT CARE MED, V40, P261, DOI 10.1097/CCM.0b013e31822d750d; Zallman L, 2013, HEALTH AFFAIR, V32, P1153, DOI 10.1377/hlthaff.2012.1223	29	9	10	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 13	2014	370	7					669	673		10.1056/NEJMhle1311198	http://dx.doi.org/10.1056/NEJMhle1311198			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AA6CX	24521116				2023-01-03	WOS:000331187500017
J	Trapecar, M; Goropevsek, A; Gorenjak, M; Gradisnik, L; Rupnik, MS				Trapecar, Martin; Goropevsek, Ales; Gorenjak, Mario; Gradisnik, Lidija; Rupnik, Marjan Slak			A Co-Culture Model of the Developing Small Intestine Offers New Insight in the Early Immunomodulation of Enterocytes and Macrophages by Lactobacillus spp. through STAT1 and NF-kB p65 Translocation	PLOS ONE			English	Article							KAPPA-B ACTIVATION; IMMUNE CELLS; GUT; MODULATION; PATHWAYS; RECEPTOR; STRAINS; ELICIT	The early establishment of a complete microbiome has been shown to play an integral part in the development and maintenance of an intact intestine and its immune system, although much remains unknown about the specific mechanisms of immune modulation in newborns. In our study we show in a co-culture model of the undeveloped small intestine that members of Lactobacillus spp. influence STAT1 and NF-kB p65 nuclear translocation in both intestinal epithelial cells as well as underlying macrophages. Moreover, by using imaging flow cytometry we were able to monitor each individual cell and create a framework of the percentage of cells in which translocation occurred in challenged versus control cell populations. We also observed a significant difference in baseline translocation in intestinal cells when cultured alone versus those in a co-culture model, underpinning the importance of 3D models over monolayer set-ups in epithelial in vitro research. In conclusion, our work offers new insights into the potential routes by which the commensal microbiome primes the early immune system to fight pathogens, and shows how strain-specific these mechanisms really are.	[Trapecar, Martin; Gradisnik, Lidija; Rupnik, Marjan Slak] Univ Maribor, Fac Med, Inst Physiol, SLO-2000 Maribor, Slovenia; [Goropevsek, Ales] Univ Clin Ctr Maribor, Dept Lab Diagnost, Maribor, Slovenia; [Gorenjak, Mario] Univ Maribor, Fac Med, SLO-2000 Maribor, Slovenia	University of Maribor; University of Maribor; University of Maribor	Trapecar, M (corresponding author), Univ Maribor, Fac Med, Inst Physiol, SLO-2000 Maribor, Slovenia.	martin.trapecar@gmail.com	Rupnik, Marjan Slak/R-4738-2019; Trapecar, Martin/AAL-5800-2020; Slak Rupnik, Marjan/E-6246-2015	Rupnik, Marjan Slak/0000-0002-3744-4882; Trapecar, Martin/0000-0002-0860-8948; Slak Rupnik, Marjan/0000-0002-3744-4882; Goropevsek, Ales/0000-0002-2188-578X; Gorenjak, Mario/0000-0003-4208-9683				Boirivant M, 2008, MUCOSAL IMMUNOL, V1, pS47, DOI 10.1038/mi.2008.52; Botic T, 2007, INT J FOOD MICROBIOL, V115, P227, DOI 10.1016/j.ijfoodmicro.2006.10.044; Bruno MEC, 2011, MUCOSAL IMMUNOL, V4, P468, DOI 10.1038/mi.2011.8; Cencic A, 2010, INT J FOOD MICROBIOL, V141, pS4, DOI 10.1016/j.ijfoodmicro.2010.03.026; Clavel Thomas, 2007, Curr Issues Intest Microbiol, V8, P25; Cross ML, 2001, INT IMMUNOPHARMACOL, V1, P891, DOI 10.1016/S1567-5769(01)00025-X; Curtis MM, 2011, MUCOSAL IMMUNOL, V4, P133, DOI 10.1038/mi.2010.89; de Kivit S, 2011, IMMUNOBIOLOGY, V216, P518, DOI 10.1016/j.imbio.2010.08.005; Gonzalez-Navajas JM, 2012, NAT REV IMMUNOL, V12, P125, DOI 10.1038/nri3133; Haller D, 2004, IMMUNOLOGY, V112, P310, DOI 10.1111/j.1365-2567.2004.01874.x; Haller D, 2000, GUT, V47, P79, DOI 10.1136/gut.47.1.79; Hu XY, 2008, IMMUNOL REV, V226, P41, DOI 10.1111/j.1600-065X.2008.00707.x; Ivec M, 2007, ANTIVIR RES, V75, P266, DOI 10.1016/j.antiviral.2007.03.013; Kim YG, 2006, MICROBES INFECT, V8, P994, DOI 10.1016/j.micinf.2005.10.019; Maguire O, 2011, CYTOM PART A, V79A, P461, DOI 10.1002/cyto.a.21068; Maragkoudakis PA, 2010, INT J FOOD MICROBIOL, V141, pS91, DOI 10.1016/j.ijfoodmicro.2009.12.024; Matsuguchi T, 2003, CLIN DIAGN LAB IMMUN, V10, P259, DOI 10.1128/CDLI.10.2.259-266.2003; Matsumoto S, 2005, CLIN EXP IMMUNOL, V140, P417, DOI 10.1111/j.1365-2249.2005.02790.x; Miettinen M, 2000, J IMMUNOL, V164, P3733, DOI 10.4049/jimmunol.164.7.3733; Mileti E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007056; MohanKumar K, 2012, AM J PHYSIOL-GASTR L, V303, pG93, DOI 10.1152/ajpgi.00016.2012; Nanthakumar NN, 2000, P NATL ACAD SCI USA, V97, P6043, DOI 10.1073/pnas.97.11.6043; Nissen L, 2009, INT J FOOD MICROBIOL, V135, P288, DOI 10.1016/j.ijfoodmicro.2009.08.027; Parlesak A, 2004, SCAND J IMMUNOL, V60, P477, DOI 10.1111/j.0300-9475.2004.01495.x; Patel RM, 2010, GUT MICROBES, V1, P186, DOI 10.4161/gmic.1.3.12484; Reich NC, 2007, CYTOKINE GROWTH F R, V18, P511, DOI 10.1016/j.cytogfr.2007.06.021; Sanz Y, 2009, INT REV IMMUNOL, V28, P397, DOI 10.3109/08830180903215613; Thomas CM, 2010, GUT MICROBES, V1, P148, DOI 10.4161/gmic.1.3.11712; Trapecar M, 2011, APMIS, V119, P877, DOI 10.1111/j.1600-0463.2011.02797.x; Yang JB, 2008, CELL RES, V18, P443, DOI 10.1038/cr.2008.41	30	34	35	1	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2014	9	1							e86297	10.1371/journal.pone.0086297	http://dx.doi.org/10.1371/journal.pone.0086297			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297DQ	24454965	Green Submitted, gold, Green Published			2023-01-03	WOS:000330236000025
J	Young, C; Wong, KY; Cheung, LK				Young, Cecilia; Wong, Kin Yau; Cheung, Lim K.			A Survey on Hong Kong Secondary School Students' Knowledge of Emergency Management of Dental Trauma	PLOS ONE			English	Article							PERMANENT TEETH; INJURIES; SCHOOLCHILDREN; AVULSION; GUIDELINES; CHILDREN; PREVALENCE; TEACHERS; ETIOLOGY	Objectives: To investigate Hong Kong secondary school students' knowledge of emergency management of dental trauma. Method: A questionnaire survey on randomly selected secondary school students using cluster sampling. Results: Only 36.6% (209/571) of the respondents were able to correctly identify the appropriate place for treatment of dental injury. 55.2% of the respondents knew the suitable time for treatment. Only 24.7% of the respondents possessed the knowledge of how to correctly manage fractured teeth. Only 23.6% of them knew how to manage displaced teeth. 62.5% of them correctly answered that knocked-out deciduous teeth should not be replanted to the original position, but few of them (23.6%) knew that permanent teeth should be replanted. Moreover, 37.1% of the respondents correctly identified at least one of the appropriate media for storing a knocked-out tooth. First-aid training and acquisition of dental injury information from other sources were significant factors that positive responses from these questions would lead to higher scores. Conclusion: Hong Kong secondary school students' knowledge of emergency management of dental trauma is considered insufficient. An educational campaign in secondary schools dedicated to students is recommended. Prior first-aid training and acquisition of dental injury information from other sources positively relate to the level of knowledge. Dental trauma emergency management is recommended to be added to first-aid publications and be taught to students and health professionals.	[Wong, Kin Yau] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA; [Cheung, Lim K.] Univ Hong Kong, Fac Dent, Hong Kong, Hong Kong, Peoples R China	University of North Carolina; University of North Carolina Chapel Hill; University of Hong Kong		ceciliatyp@yahoo.com.hk	; Young, Cecilia/K-1699-2018	, Kin Yau/0000-0001-9066-1619; Young, Cecilia/0000-0003-1698-7738				Andersson L, 2006, DENT TRAUMATOL, V22, P57, DOI 10.1111/j.1600-9657.2006.00338.x; Andersson L, 2012, DENT TRAUMATOL, V28, P88, DOI 10.1111/j.1600-9657.2012.01125.x; Andreasen FM, 2007, TXB COLOUR ATLAS TRA; Andreasen FM, 2007, TXB COLOR ATLAS TRAU, P290; Andreasen JO, 2002, DENT TRAUMATOL, V18, P116, DOI 10.1034/j.1600-9657.2002.00079.x; Andreasen JO, 2007, TXB COLOUR ATLAS TRA, P444; Bendo CB, 2010, J PUBLIC HEALTH DENT, V70, P313, DOI 10.1111/j.1752-7325.2010.00190.x; Biagi R, 2010, EUR J PAEDIATR DENT, V11, P66; Castilho LR, 2009, DENT TRAUMATOL, V25, P429, DOI 10.1111/j.1600-9657.2008.00756.x; Fakhruddin KS, 2008, DENT TRAUMATOL, V24, P305, DOI 10.1111/j.1600-9657.2007.00548.x; Fariniuk LF, 2010, J APPL ORAL SCI, V18, P343, DOI 10.1590/S1678-77572010000400004; Faus-Damia M, 2011, MED ORAL PATOL ORAL, V16, pE292, DOI 10.4317/medoral.16.e292; Flores MT, 2007, DENT TRAUMATOL, V23, P196, DOI 10.1111/j.1600-9657.2007.00627.x; Flores MT, 2007, DENT TRAUMATOL, V23, P130, DOI 10.1111/j.1600-9657.2007.00605.x; Flores MT, 2007, TXB COLOUR ATLAS TRA, P869; Glendor U, 2009, DENT TRAUMATOL, V25, P19, DOI 10.1111/j.1600-9657.2008.00694.x; Huang BY, 2009, DENT TRAUMATOL, V25, P64, DOI 10.1111/j.1600-9657.2008.00685.x; Lam R, 2008, DENT TRAUMATOL, V24, P663, DOI 10.1111/j.1600-9657.2008.00689.x; Levin L, 2007, DENT TRAUMATOL, V23, P356, DOI 10.1111/j.1600-9657.2006.00473.x; Lieger O, 2009, DENT TRAUMATOL, V25, P406, DOI 10.1111/j.1600-9657.2009.00798.x; Naidoo S, 2009, DENT TRAUMATOL, V25, P224, DOI 10.1111/j.1600-9657.2008.00749.x; Navabazam A, 2010, DENT TRAUMATOL, V26, P154, DOI 10.1111/j.1600-9657.2009.00861.x; Noori AJ, 2009, DENT TRAUMATOL, V25, P442, DOI 10.1111/j.1600-9657.2009.00791.x; Thelen DS, 2010, DENT TRAUMATOL, V26, P284, DOI 10.1111/j.1600-9657.2010.00918.x; Underwood M, 1998, BRIT J GEN PRACT, V48, P1089; Wilson S, 1997, PEDIATR EMERG CARE, V13, P12, DOI 10.1097/00006565-199702000-00004; Young C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074833; Young C, 2012, HONG KONG MED J, V18, P362	28	7	7	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2014	9	1							e84406	10.1371/journal.pone.0084406	http://dx.doi.org/10.1371/journal.pone.0084406			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286IW	24400088	Green Published, gold, Green Submitted			2023-01-03	WOS:000329462700022
J	Simoens, S				Simoens, Steven			Assessment of Methodological Quality of Economic Evaluations in Belgian Drug Reimbursement Applications	PLOS ONE			English	Article								Objectives: This paper aims to assess the methodological quality of economic evaluations included in Belgian reimbursement applications for Class 1 drugs. Materials and Methods: For 19 reimbursement applications submitted during 2011 and Spring 2012, a descriptive analysis assessed the methodological quality of the economic evaluation, evaluated the assessment of that economic evaluation by the Drug Reimbursement Committee and the response to that assessment by the company. Compliance with methodological guidelines issued by the Belgian Healthcare Knowledge Centre was assessed using a detailed checklist of 23 methodological items. The rate of compliance was calculated based on the number of economic evaluations for which the item was applicable. Results: Economic evaluations tended to comply with guidelines regarding perspective, target population, subgroup analyses, comparator, use of comparative clinical data and final outcome measures, calculation of costs, incremental analysis, discounting and time horizon. However, more attention needs to be paid to the description of limitations of indirect comparisons, the choice of an appropriate analytic technique, the expression of unit costs in values for the current year, the estimation and valuation of outcomes, the presentation of results of sensitivity analyses, and testing the face validity of model inputs and outputs. Also, a large variation was observed in the scope and depth of the quality assessment by the Drug Reimbursement Committee. Conclusions: Although general guidelines exist, pharmaceutical companies and the Drug Reimbursement Committee would benefit from the existence of a more detailed checklist of methodological items that need to be reported in an economic evaluation.	Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Louvain, Belgium	KU Leuven	Simoens, S (corresponding author), Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Louvain, Belgium.	steven.simoens@pharm.kuleuven.be		Simoens, Steven/0000-0002-9512-2005	Pharma.be, the Belgian association of the innovative pharmaceutical industry	Pharma.be, the Belgian association of the innovative pharmaceutical industry	Financial support for this research was received from Pharma.be, the Belgian association of the innovative pharmaceutical industry. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cleemput I, 2008, GUIDELINES PHARMACOE; De Rijdt T, 2010, PHARMACOECONOMICS EU, P60; Denis A, 2011, PHARMACOECONOMICS, V29, P883, DOI 10.2165/11585980-000000000-00000; Hoomans T, 2012, PHARMACOECONOMICS, V30, P219, DOI 10.2165/11539850-000000000-00000; Simoens S, 2012, J CLIN PHARM THER, V37, P182, DOI 10.1111/j.1365-2710.2011.01277.x; Simoens S, 2010, INT J ENV RES PUB HE, V7, P1835, DOI 10.3390/ijerph7041835; Yong JHE, 2013, PHARMACOECONOMICS, V31, P229, DOI 10.1007/s40273-012-0022-5	7	4	4	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2013	8	12							e85411	10.1371/journal.pone.0085411	http://dx.doi.org/10.1371/journal.pone.0085411			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282SX	24386474	gold, Green Published, Green Submitted			2023-01-03	WOS:000329194700136
J	Wei, HF; Zhao, LK; Li, W; Fan, KX; Qian, WZ; Hou, S; Wang, H; Dai, M; Hellstrom, I; Hellstrom, KE; Guo, YJ				Wei, Huafeng; Zhao, Likun; Li, Wei; Fan, Kexing; Qian, Weizhu; Hou, Sheng; Wang, Hao; Dai, Min; Hellstrom, Ingegerd; Hellstrom, Karl Erik; Guo, Yajun			Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin	PLOS ONE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; PERIPHERAL-BLOOD LYMPHOCYTES; EPITHELIAL OVARIAN-CANCER; ANTITUMOR IMMUNITY; T-CELLS; MONOCLONAL-ANTIBODY; ANTI-PD-1 ANTIBODY; DENDRITIC CELLS; IMMUNOTHERAPY; INFLAMMATION	There is an urgent need for improved therapy for advanced ovarian carcinoma, which may be met by administering immune-modulatory monoclonal antibodies (mAbs) to generate a tumor-destructive immune response. Using the ID8 mouse ovarian cancer model, we investigated the therapeutic efficacy of various mAb combinations in mice with intraperitoneal (i.p.) tumor established by transplanting 3 x 10(6) ID8 cells 10 days previously. While most of the tested mAbs were ineffective when given individually or together, the data confirm our previous finding that 2 i.p. injections of a combination of anti-CD137 with anti-PD-1 mAbs doubles overall survival. Mice treated with this mAb combination have a significantly increased frequency and total number of CD8(+) T cells both in the peritoneal lavage and spleens, and these cells are functional as demonstrated by antigen-specific cytolytic activity and IFN-gamma production. While administration of anti-CD137 mAb as a single agent similarly increases CD8(+) T cells, these have no functional activity, which may be attributed to up-regulation of co-inhibitory PD-1 and TIM-3 molecules induced by CD137. Addition of the anti-cancer drug cisplatin to the 2 mAb combination increased overall survival >90 days (and was probably curative) by a mechanism which included a systemic CD8(+) T cell response with tumor specificity and immunological memory. Strikingly, combined treatment of cisplatin and CD137/PD-1 mAb also gave rise to the long-term survival of mice with established TC1 lung tumors. A similar combination of the 2 mAbs and cisplatin should be considered for clinical 'translation'.	[Wei, Huafeng; Li, Wei; Fan, Kexing; Qian, Weizhu; Hou, Sheng; Wang, Hao; Guo, Yajun] Second Mil Med Univ, Int Joint Canc Inst, Shanghai, Peoples R China; [Zhao, Likun; Guo, Yajun] S China Univ Technol, Sch Biosci & Bioengn, Guangzhou, Guangdong, Peoples R China; [Wei, Huafeng; Li, Wei; Fan, Kexing; Qian, Weizhu; Hou, Sheng; Wang, Hao; Guo, Yajun] Liaocheng Univ, Sch Pharm, Liaocheng, Peoples R China; [Dai, Min; Hellstrom, Ingegerd; Hellstrom, Karl Erik] Univ Washington, Harborview Med Ctr, Dept Pathol, Seattle, WA 98104 USA	Naval Medical University; South China University of Technology; Liaocheng University; Harborview Medical Center; University of Washington; University of Washington Seattle	Guo, YJ (corresponding author), Second Mil Med Univ, Int Joint Canc Inst, Shanghai, Peoples R China.	yguo_smmu@163.com	DAI, M/GPS-8291-2022		National Natural Science Foundation of China [81372528]; Ministry of Science & Technology of China "973" [2012CB917104]; Ministry of Education of China; Shanghai Commission of Education for excellent research team in Oncology; U.S. National Institutes of Health [RO1CA134487]; NATIONAL CANCER INSTITUTE [R01CA134487] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science & Technology of China "973"; Ministry of Education of China(Ministry of Education, China); Shanghai Commission of Education for excellent research team in Oncology; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Natural Science Foundation of China (No. 81372528), Ministry of Science & Technology of China "973" (No. 2012CB917104), special grants from Ministry of Education of China and Shanghai Commission of Education for excellent research team in Oncology and Shanghai Key Project in Oncology as well as by RO1CA134487 from U.S. National Institutes of Health. The funding agencies had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali AY, 2012, ANN NY ACAD SCI, V1271, P58, DOI 10.1111/j.1749-6632.2012.06734.x; Ascierto PA, 2010, SEMIN ONCOL, V37, P508, DOI 10.1053/j.seminoncol.2010.09.008; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cubillos-Ruiz JR, 2009, J CLIN INVEST, V119, P2231, DOI 10.1172/JCI37716; Curran MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019499; Dai M, 2013, J IMMUNOTHER, V36, P248, DOI 10.1097/CJI.0b013e3182943549; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Feng QH, 2012, GYNECOL ONCOL, V127, P412, DOI 10.1016/j.ygyno.2012.07.098; Fourcade J, 2010, J EXP MED, V207, P2175, DOI 10.1084/jem.20100637; Graziani G, 2012, PHARMACOL RES, V65, P9, DOI 10.1016/j.phrs.2011.09.002; Hall M, 2013, BRIT J CANCER, V108, P250, DOI 10.1038/bjc.2012.541; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Kandalaft LE, 2011, J CLIN ONCOL, V29, P925, DOI 10.1200/JCO.2009.27.2369; Kim YH, 2008, CANCER RES, V68, P7264, DOI 10.1158/0008-5472.CAN-08-1365; Krempski J, 2011, J IMMUNOL, V186, P6905, DOI 10.4049/jimmunol.1100274; Leary A, 2012, B CANCER, V99, P1161, DOI 10.1684/bdc.2012.1667; Li QS, 2004, CANCER RES, V64, P1130, DOI 10.1158/0008-5472.CAN-03-1715; Lipson EJ, 2013, CLIN CANCER RES, V19, P462, DOI 10.1158/1078-0432.CCR-12-2625; Mantia-Smaldone GM, 2012, HUM VACC IMMUNOTHER, V8, P1179, DOI 10.4161/hv.20738; McNamara JO, 2008, J CLIN INVEST, V118, P376, DOI 10.1172/JCI33365; Ozols RF, 2003, J CLIN ONCOL, V21, P3194, DOI 10.1200/JCO.2003.02.153; Pardoll D, 2012, J EXP MED, V209, P201, DOI 10.1084/jem.20112275; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Ramakrishna V, 2003, INT IMMUNOL, V15, P751, DOI 10.1093/intimm/dxg074; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Santin AD, 2001, GYNECOL OBSTET INVES, V51, P254, DOI 10.1159/000058060; Schondorf T, 1998, J SOC GYNECOL INVEST, V5, P102, DOI 10.1016/S1071-5576(97)00112-3; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sznol M, 2013, CLIN CANCER RES, V19, P1021, DOI 10.1158/1078-0432.CCR-12-2063; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Verbrugge I, 2012, CANCER RES, V72, P3163, DOI 10.1158/0008-5472.CAN-12-0210; Vermeij R, 2012, CURR PHARM DESIGN, V18, P3804, DOI 10.2174/138161212802002805; Wei HF, 2008, CANCER RES, V68, P3854, DOI 10.1158/0008-5472.CAN-07-6051; Wei HF, 2012, GYNECOL ONCOL, V125, P727, DOI 10.1016/j.ygyno.2012.03.018; Wei HF, 2012, J IMMUNOTHER, V35, P267, DOI 10.1097/CJI.0b013e31824d72ee; Wilcox RA, 2002, J CLIN INVEST, V109, P651, DOI 10.1172/JCI200214184; Xiao H, 2007, CLIN CANCER RES, V13, P1823, DOI 10.1158/1078-0432.CCR-06-2154; Yang Y, 2007, CANCER RES, V67, P2339, DOI 10.1158/0008-5472.CAN-06-3593; Yao S, 2013, NAT REV DRUG DISCOV, V12, P130, DOI 10.1038/nrd3877; Zhang HT, 2006, MOL CANCER THER, V5, P149, DOI 10.1158/1535-7163.MCT-05-0206; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	44	66	91	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2013	8	12							e84927	10.1371/journal.pone.0084927	http://dx.doi.org/10.1371/journal.pone.0084927			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276HY	24367702	Green Published, gold			2023-01-03	WOS:000328741900071
J	Block, SD; Billings, JA				Block, Susan D.; Billings, J. Andrew			A need for scalable outpatient palliative care interventions	LANCET			English	Editorial Material							CELL LUNG-CANCER; WORKFORCE SHORTAGE		[Block, Susan D.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02215 USA; [Block, Susan D.] Brigham & Womens Hosp, Boston, MA 02215 USA; [Block, Susan D.; Billings, J. Andrew] Harvard Univ, Sch Med, Ctr Palliat Care, Boston, MA USA; [Billings, J. Andrew] Massachusetts Gen Hosp, Cambridge Hlth Alliance, Boston, MA 02114 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Cambridge Health Alliance; Massachusetts General Hospital	Block, SD (corresponding author), Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02215 USA.	sblock@partners.org						Higginson IJ, 2010, CANCER J, V16, P423, DOI 10.1097/PPO.0b013e3181f684e5; Jacobsen J, 2011, J PALLIAT MED, V14, P459, DOI 10.1089/jpm.2010.0382; Lupu D, 2010, J PAIN SYMPTOM MANAG, V40, P899, DOI 10.1016/j.jpainsymman.2010.07.004; Maison D, 2010, J PAIN SYMPTOM MANAG, V40, P912, DOI 10.1016/j.jpainsymman.2010.09.011; Rabow M, 2013, J PALLIAT MED, V16, P1540, DOI 10.1089/jpm.2013.0153; Smith TJ, 2012, J CLIN ONCOL, V30, P880, DOI 10.1200/JCO.2011.38.5161; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Zimmermann C, 2014, LANCET	8	37	37	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	2014	383	9930					1699	1700		10.1016/S0140-6736(13)62676-8	http://dx.doi.org/10.1016/S0140-6736(13)62676-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AH6UO	24559580				2023-01-03	WOS:000336267300006
J	Burgio, KL				Burgio, Kathryn L.			Pelvic floor muscle training for pelvic organ prolapse	LANCET			English	Editorial Material							OVERACTIVE BLADDER		[Burgio, Kathryn L.] Univ Alabama Birmingham, Birmingham, AL 35244 USA; [Burgio, Kathryn L.] Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL 35244 USA	University of Alabama System; University of Alabama Birmingham; Geriatric Research Education & Clinical Center	Burgio, KL (corresponding author), Univ Alabama Birmingham, Birmingham, AL 35244 USA.	kburgio@uabmc.edu						Bo K, 2004, INT UROGYNECOL J, V15, P76, DOI 10.1007/s00192-004-1125-0; Braekken IH, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.02.037; Burgio KL, 2011, J AM GERIATR SOC, V59, P2209, DOI 10.1111/j.1532-5415.2011.03724.x; Ellerkmann RM, 2001, AM J OBSTET GYNECOL, V185, P1332, DOI 10.1067/mob.2001.119078; Gormley EA, 2012, J UROLOGY, V188, P2455, DOI 10.1016/j.juro.2012.09.079; Hagen S, 2010, NEUROUROL URODYNAM, V29, P1055; Hagen S, 2014, LANCET, V383, P796, DOI 10.1016/S0140-6736(13)61977-7; Hendrix SL, 2002, AM J OBSTET GYNECOL, V186, P1160, DOI 10.1067/mob.2002.123819; Johnson TM, 2013, BR J UROL INT, V110, P100; Kashyap R, 2013, INT J GYNECOL OBSTET, V121, P69, DOI 10.1016/j.ijgo.2012.11.012; Moore K., 2013, INCONTINENCE, P1101, DOI DOI 10.1183/13993003.00541-2019; Mouritsen L, 2003, INT UROGYNECOL J PEL, V14, P122, DOI 10.1007/s00192-002-1024-1; Olsen AL, 1997, OBSTET GYNECOL, V89, P501, DOI 10.1016/S0029-7844(97)00058-6	13	3	3	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 1	2014	383	9919					760	762		10.1016/S0140-6736(13)62372-7	http://dx.doi.org/10.1016/S0140-6736(13)62372-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AC3EV	24290405				2023-01-03	WOS:000332398700006
J	Kumar, R; Kaur, R; Singh, AP; Arora, S				Kumar, Rakesh; Kaur, Rajbir; Singh, Amrit Pal; Arora, Saroj			Diminution of Hepatic Response to 7, 12-dimethylbenz(alpha) anthracene by Ethyl Acetate Fraction of Acacia catechu Willd. through Modulation of Xenobiotic and Anti-Oxidative Enzymes in Rats	PLOS ONE			English	Article							GLUTATHIONE S-TRANSFERASES; LIPID-PEROXIDATION; LIVER-MICROSOMES; EXTRACT; PHYTOCHEMICALS; PURIFICATION; HEPATOTOXIN; REDUCTASE; ASSAY	Background: Liver is the primary metabolizing site of body and is prone to damage by exogenous as well as endogenous intoxicants. Polycyclic aromatic hydrocarbons such as 7, 12-dimethylbenz(a) anthracene (DMBA) is an exogenous hepatotoxin, which is well known for modulating phase I, II and anti-oxidative enzymes of liver. Plants contain plethora of polyphenolic compounds which can reverse the damaging effect of various xenobiotics. The present study investigated protective role of the ethyl acetate fraction of Acacia catechu Willd. (EAF) against DMBA induced alteration in hepatic metabolizing and anti-oxidative enzymes in rats. Methodology and Principal Findings: The rats were subjected to hepatic damage by treating with DMBA for 7 weeks on alternative days and treatment schedule was terminated at the end of 14 weeks. The rats were euthanized at the end of protocol and livers were homogenized. The liver homogenates were used to analyse phase I (NADPH-cytochrome P450 reducatse, NADH-cytochrome b5 reductase, cytochrome P420, cytochrome b5), phase II (glutathione-S-transferase, DT diaphorase and gamma-Glutamyl transpeptidase) and antioxidative enzymes (catalase, superoxide dismutase, ascorbate peroxidase, glutathione reductase, guiacol peroxidase and lactate dehydrogenase). Furthermore, other oxidative stress parameters (thiobarbituric acid reactive substances, lipid hydroperoxides and conjugated dienes and reduced glutathione) and liver marker enzymes (serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase and alkaline phosphatase) were also studied. The DMBA induced significant changes in activity of hepatic enzymes that was reversed by treatment with three dose levels of EAF. Conclusion: It is concluded that EAF affords hepato-protection against DMBA in rats through modulation of phase I, II and anti-oxidative enzymes.	[Kumar, Rakesh; Kaur, Rajbir; Arora, Saroj] Guru Nanak Dev Univ, Dept Bot & Environm Sci, Amritsar, Punjab, India; [Singh, Amrit Pal] Guru Nanak Dev Univ, Dept Pharmaceut Sci, Amritsar, Punjab, India	Guru Nanak Dev University; Guru Nanak Dev University	Arora, S (corresponding author), Guru Nanak Dev Univ, Dept Bot & Environm Sci, Amritsar, Punjab, India.	jrosh1@rediffmail.com	Kumar, Rakesh/ABD-1065-2020; Singh, Amrit Pal/ABI-8109-2020; Arora, Saroj/AAV-3682-2021	Kumar, Rakesh/0000-0001-7664-0803; Singh, Amrit Pal/0000-0002-7658-241X; Arora, Saroj/0000-0002-4086-5653	Guru Nanak Dev University, Amritsar; University Grants Commission, New Delhi	Guru Nanak Dev University, Amritsar; University Grants Commission, New Delhi(University Grants Commission, India)	The authors thank financial support of Guru Nanak Dev University, Amritsar and University Grants Commission, New Delhi, under the university with potential for excellence (UPE), BSR and CPEPA programme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aebi H, 1984, Methods Enzymol, V105, P121; Al-Attar A. M., 2004, Pakistan Journal of Nutrition, V3, P304; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; ASADA K, 1992, PHYSIOL PLANTARUM, V85, P235, DOI 10.1111/j.1399-3054.1992.tb04728.x; Barros L, 2011, FOOD CHEM, V127, P1600, DOI 10.1016/j.foodchem.2011.02.024; Bharali Rupjyoti, 2003, Asian Pac J Cancer Prev, V4, P131; Bursal E, 2011, FOOD RES INT, V44, P1482, DOI 10.1016/j.foodres.2011.03.031; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; Chauhan G, 2011, IND J RES, V5, P1; Chiu CS, 2013, FOOD CHEM, V141, P1087, DOI 10.1016/j.foodchem.2013.04.031; Choi SJ, 2003, J BIOCHEM MOL BIOL, V36, P332; Deckers GH, 2002, EUR J CANCER, V38, P443, DOI 10.1016/S0959-8049(01)00391-4; Devasagayam TPA, 2003, INDIAN J BIOCHEM BIO, V40, P300; El-Demerdash FM, 2011, J ENVIRON SCI HEAL C, V29, P145, DOI 10.1080/10590501.2011.577679; Ernster, 1967, METHOD ENZYMOL, V10, P309, DOI [DOI 10.1016/0076-6879(67)10059-1, 10.1016/0076-6879(67)10059-1]; Gayathari V., 2011, INT J PHARM SCI, V3, P108; Gnaiger E., 2010, MITO PHYSL NET, V08, P1; Guengerich FP, 2009, NAT PROTOC, V4, P1245, DOI 10.1038/nprot.2009.121; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Harmeet Singh, 2011, European Journal of Medicinal Plants, V1, P162; HOOSER SB, 1989, VET PATHOL, V26, P246, DOI 10.1177/030098588902600309; Jancova P, 2010, BIOMED PAP, V154, P103, DOI 10.5507/bp.2010.017; JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N; Jones V, 2013, CANCER LETT, V335, P251, DOI 10.1016/j.canlet.2013.02.056; Kamel R, 2013, ARCH PHARM RES, DOI [10.1007/s12272-013-0110-x, DOI 10.1007/S]; KONO Y, 1978, ARCH BIOCHEM BIOPHYS, V186, P189, DOI 10.1016/0003-9861(78)90479-4; Kwon HJ, 2014, HEPATOLOGY, V59, P1094, DOI 10.1002/hep.26748; Landi L, 1997, FREE RADICAL BIO MED, V22, P329, DOI 10.1016/S0891-5849(96)00294-8; Liu JY, 2013, TOXICOL SCI, V135, P144, DOI 10.1093/toxsci/kft135; MIHARA K, 1972, J BIOCHEM-TOKYO, V71, P725; OMURA T, 1964, J BIOL CHEM, V239, P2370; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; Partridge A H, 2001, J Natl Cancer Inst Monogr, P135; Pistol GC, 2013, BR J NUTR, V20, P1; Putter J., 1974, METHODS ENZYMATIC AN, VSecond, P685, DOI [10.1016/B978-0-12- 091302-2.50033-5, 10.1016/B978-0-12-091302-2.50033-5, DOI 10.1016/B978-0-12-091302-2.50033-5]; Ray D., 2006, Indian Journal of Pharmacology, V38, P408; Raza H, 1997, COMP BIOCHEM PHYS B, V118, P829, DOI 10.1016/S0305-0491(97)00234-4; Robinson K, 2003, DIGEST DIS SCI, V48, P1804, DOI 10.1023/A:1025415616592; Salama SM, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-56; Seigler DS, 2003, BIOCHEM SYST ECOL, V31, P845, DOI 10.1016/S0305-1978(03)00082-6; SOFFER EE, 1983, SOUTHERN MED J, V76, P681, DOI 10.1097/00007611-198305000-00043; SZASZ G, 1976, CLIN CHEM, V22, P2051; YANG SK, 1975, P NATL ACAD SCI USA, V72, P2601, DOI 10.1073/pnas.72.7.2601; zen T, 2003, PHYTOMEDICINE, V10, P405; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; Zhou QM, 2011, EUR J CANCER, V47, P2240, DOI 10.1016/j.ejca.2011.04.032	46	20	20	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2014	9	2							e90083	10.1371/journal.pone.0090083	http://dx.doi.org/10.1371/journal.pone.0090083			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC3BU	24587216	Green Published, Green Submitted, gold			2023-01-03	WOS:000332390800074
J	Yager, PH; Luginbuhl, LM; Dekker, JP				Yager, Phoebe H.; Luginbuhl, Lynn M.; Dekker, John P.			Case 6-2014: A 35-Day-Old Boy with Fever, Vomiting, Mottled Skin, and Severe Anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEW-YORK-STATE; EXCHANGE-TRANSFUSION; HUMAN BABESIOSIS; CONGENITAL BABESIOSIS; NEW-JERSEY; INFECTIONS; MALARIA; SEPSIS; INFANT; TICKS		[Yager, Phoebe H.; Luginbuhl, Lynn M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [Dekker, John P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Yager, Phoebe H.; Luginbuhl, Lynn M.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Dekker, John P.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Yager, PH (corresponding author), Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.							Adelson ME, 2004, J CLIN MICROBIOL, V42, P2799, DOI 10.1128/JCM.42.6.2799-2801.2004; Aderinboye O, 2010, PEDIATR INFECT DIS J, V29, P188, DOI 10.1097/INF.0b013e3181c3c971; [Anonymous], 2010, BAB SURV MASS 2010; Bizzarro MJ, 2005, PEDIATRICS, V116, P595, DOI 10.1542/peds.2005-0552; Dorman SE, 2000, TRANSFUSION, V40, P375, DOI 10.1046/j.1537-2995.2000.40030375.x; ESERNIOJENSSEN D, 1987, J PEDIATR-US, V110, P570, DOI 10.1016/S0022-3476(87)80552-8; Feigin RD., 2009, FEIGIN CHERRYS TXB P, V6th ed.; Fortunov RM, 2006, PEDIATRICS, V118, P874, DOI 10.1542/peds.2006-0884; Fox LAM, 2006, PEDIATR INFECT DIS J, V25, P169, DOI 10.1097/01.inf.0000195438.09628.b0; Greenhow TL, 2012, PEDIATRICS, V129, pE590, DOI 10.1542/peds.2011-1546; Hatcher JC, 2001, CLIN INFECT DIS, V32, P1117, DOI 10.1086/319742; Joseph JT, 2011, EMERG INFECT DIS, V17, P843, DOI 10.3201/eid1705.101334; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; MELDRUM SC, 1992, CLIN INFECT DIS, V15, P1019, DOI 10.1093/clind/15.6.1019; MILLER KD, 1989, NEW ENGL J MED, V321, P65, DOI 10.1056/NEJM198907133210201; New DL, 1997, J PEDIATR-US, V131, P163, DOI 10.1016/S0022-3476(97)70143-4; Pickering L. K, 2009, RED BOOK 2009 REPORT; Powell VI, 2002, TRANSFUS MED REV, V16, P239, DOI 10.1053/tmrv.2002.33437; Sethi S, 2009, EMERG INFECT DIS, V15, P788, DOI 10.3201/eid1505.070808; Tokarz R, 2010, VECTOR-BORNE ZOONOT, V10, P217, DOI 10.1089/vbz.2009.0036; Vannier E, 2009, INTERDISCIP PERSPECT; Vannier E, 2008, INFECT DIS CLIN N AM, V22, P469, DOI 10.1016/j.idc.2008.03.010; White DJ, 1998, ARCH INTERN MED, V158, P2149, DOI 10.1001/archinte.158.19.2149	23	15	16	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 20	2014	370	8					753	762		10.1056/NEJMcpc1208155	http://dx.doi.org/10.1056/NEJMcpc1208155			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AB1DO	24552323				2023-01-03	WOS:000331531900011
J	Usami, M; Iwadare, Y; Watanabe, K; Kodaira, M; Ushijima, H; Tanaka, T; Harada, M; Tanaka, H; Sasaki, Y; Saito, K				Usami, Masahide; Iwadare, Yoshitaka; Watanabe, Kyota; Kodaira, Masaki; Ushijima, Hirokage; Tanaka, Tetsuya; Harada, Maiko; Tanaka, Hiromi; Sasaki, Yoshinori; Saito, Kazuhiko			Analysis of Changes in Traumatic Symptoms and Daily Life Activity of Children Affected by the 2011 Japan Earthquake and Tsunami over Time	PLOS ONE			English	Article							NORWEGIAN CHILDREN; STRESS-DISORDER; DISASTER; IMPACT	Background: On March 11, 2011, Japan was struck by a massive earthquake and tsunami. The tsunami caused tremendous damage and traumatized a number of people, including children. This study aimed to compare traumatic symptoms and daily life activity among children 20 months after the 2011 Great East Japan Earthquake and Tsunami with those observed after 8 months. Methods: The study comprised two groups. The first comprised 12,524 kindergarten, elementary school, and junior high school children in Ishinomaki City, Miyagi Prefecture, Japan, who were evaluated 8 months after the disaster. The second comprised 10,597 children from the same place who were evaluated 20 months after the disaster. The Post Traumatic Stress Symptoms for Children 15 items (PTSSC-15), a self-completion questionnaire on traumatic symptoms, and a questionnaire on children's daily life were distributed to the children. An effective response was obtained from 11,639 (92.9%, 8 months after) and 10,597 (86.9%, 20 months after) children. Results: The PTSSC-15 score was significantly higher in junior high school girls than in boys. The PTSSC-15 score was significantly higher in 4th-6th grade girls than in boys after 8 months. Elementary and junior high school children evaluated after 20 months had a significantly lower PTSSC-15 score than those evaluated after 8 months. The number of children having breakfast was significantly higher after 8 months than that after 20 months. In both the groups, children of all grades who had breakfast had a significantly lower PTSSC-15 score than those who did not have breakfast. Conclusions: We conclude that traumatic symptoms and daily life activity of children who survived the earthquake and tsunami improved over time.	[Usami, Masahide; Iwadare, Yoshitaka; Watanabe, Kyota; Ushijima, Hirokage; Tanaka, Tetsuya; Harada, Maiko; Tanaka, Hiromi; Sasaki, Yoshinori] Kohnodai Hosp, Natl Ctr Global Hlth & Med, Dept Child & Adolescent Psychiat, Chiba, Japan; [Kodaira, Masaki; Saito, Kazuhiko] Aiiku Hosp, Imperial Gift Fdn, Dept Child Mental Hlth, Tokyo, Japan	National Center for Global Health & Medicine - Japan; Saiseikai Imperial Gift Foundation, Inc.	Usami, M (corresponding author), Kohnodai Hosp, Natl Ctr Global Hlth & Med, Dept Child & Adolescent Psychiat, Chiba, Japan.	usami.masahide@hospk.ncgm.go.jp	Usami, Masahide/G-1404-2015	Usami, Masahide/0000-0002-1145-9971	National Center for Global Health and Medicine [24-108]; Soroptimist International of the Americas Japan Shimomatsu Region; Ishinomaki Rotary Club; Yaohigashi Rotary Club; Tokuyama Rotary Club	National Center for Global Health and Medicine(National Center for Global Health & Medicine - Japan); Soroptimist International of the Americas Japan Shimomatsu Region; Ishinomaki Rotary Club; Yaohigashi Rotary Club; Tokuyama Rotary Club	This work was supported by the grant of National Center for Global Health and Medicine (24-108), Soroptimist International of the Americas Japan Shimomatsu Region, Ishinomaki Rotary Club, Yaohigashi Rotary Club, and Tokuyama Rotary Club. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Balsari S, 2010, NEW ENGL J MED, V362, DOI 10.1056/NEJMp1001820; Becker SM, 2007, J CHILD ADOL PS NURS, V20, P148, DOI 10.1111/j.1744-6171.2007.00105.x; Butler D, 2011, NATURE, V472, P13, DOI 10.1038/472400a; Carballo M, 2005, J ROY SOC MED, V98, P396, DOI 10.1258/jrsm.98.9.396; Chance for Children, 2011, CHANC CHILDR ANN REP; Chemtob CM, 2008, ARCH PEDIAT ADOL MED, V162, P126, DOI 10.1001/archpediatrics.2007.36; Dyb Grete, 2011, Clin Child Psychol Psychiatry, V16, P621, DOI 10.1177/1359104510391048; Fukuchi N, 2012, J CHILD ABUSE NEGLEC, V14, P14; Hafstad GS, 2011, PSYCHOL TRAUMA-US, V3, P130, DOI 10.1037/a0023236; Hayashi K, 2012, ASIA-PAC J PUBLIC HE, V24, P681, DOI 10.1177/1010539512453255; Jensen TK, 2009, ARCH PEDIAT ADOL MED, V163, P856, DOI 10.1001/archpediatrics.2009.151; Jia ZB, 2010, QUAL LIFE RES, V19, P1381, DOI 10.1007/s11136-010-9703-8; Kato H, 1996, ACTA PSYCHIAT SCAND, V93, P477, DOI 10.1111/j.1600-0447.1996.tb10680.x; Kim BN, 2009, J CLIN PSYCHIAT, V70, P1148, DOI 10.4088/JCP.08m04896; Ma XH, 2011, PSYCHIAT RES, V189, P385, DOI [10.1016/j.psychres.2010.12.016, 10.1016/j.psychres.2011.02.016]; Mike T, 2011, No To Hattatsu, V43, P342; Mullett-Hume E, 2008, AM J ORTHOPSYCHIAT, V78, P103, DOI 10.1037/0002-9432.78.1.103; Nakahara S, 2013, J EPIDEMIOL, V23, P70, DOI 10.2188/jea.JE20120114; Oncu EC, 2010, CHILD DEV, V81, P1161, DOI 10.1111/j.1467-8624.2010.01460.x; Piyasil V, 2008, ASEAN J PSYCHIATR, V9, P99; Piyasil Vinadda, 2011, J Med Assoc Thai, V94 Suppl 3, pS138; Piyasil Vinadda, 2007, Journal of the Medical Association of Thailand, V90, P2370; Procter NG, 2011, HOLIST NURS PRACT, V25, P162, DOI 10.1097/HNP.0b013e31821a6955; Tominaga Y, 2002, HATTATSU SHINRI RINS, V8, p29.36; Ularntinon Sirirat, 2008, J Med Assoc Thai, V91 Suppl 3, pS69; Usami M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065398; Usami M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050721; WEISAETH L, 1989, ACTA PSYCHIAT SCAND, V80, P13, DOI 10.1111/j.1600-0447.1989.tb05250.x; Weisz J.R., 2001, EUROPEAN CHILD ADOLE, V10, P12, DOI DOI 10.1007/S007870170003; WHO, 2005, TSUN WREAKS MENT HLT; WHO, MENT HLTH ASS POP AF; Wiguna T, 2010, ASIA-PAC PSYCHIAT, V2, P151, DOI 10.1111/j.1758-5872.2010.00079.x; Yamamoto A, 2011, INT NURS REV, V58, P332, DOI 10.1111/j.1466-7657.2011.00924.x	33	20	20	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2014	9	2							e88885	10.1371/journal.pone.0088885	http://dx.doi.org/10.1371/journal.pone.0088885			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AB3TA	24586427	Green Published, Green Submitted, gold			2023-01-03	WOS:000331711900057
J	Li, Y				Li, Yan			China's misuse of antibiotics should be curbed	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Nottingham Trent Univ, Sch Arts & Humanities, Nottingham, England	Nottingham Trent University	Li, Y (corresponding author), Nottingham Trent Univ, Sch Arts & Humanities, Nottingham, England.	yan.li@ntu.ac.uk						[Anonymous], 2011, ANT HEAV OV CHIN; Chen Z., 2012, REPORT MANAGEMENT CL; Currie J, 2011, J HEALTH ECON, V30, P933, DOI 10.1016/j.jhealeco.2011.05.009; Heddini A, 2009, LANCET, V373, P30, DOI 10.1016/S0140-6736(08)61956-X; Hueston WJ, 1997, J FAM PRACTICE, V44, P261; Jiang C, 2012, TIME; Little P, 1997, BRIT MED J, V315, P350; Sun XY, 2009, SOC SCI MED, V68, P1775, DOI 10.1016/j.socscimed.2009.02.043; Xiao Y., 2010, CHINESE HLTH EC, V29, P94, DOI [10.3969/j.issn.1003-0743.2010.05.034, DOI 10.3969/J.ISSN.1003-0743.2010.05.034]	9	51	58	6	37	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 12	2014	348								g1083	10.1136/bmj.g1083	http://dx.doi.org/10.1136/bmj.g1083			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AA9WT	24523392				2023-01-03	WOS:000331444400002
J	Desai, R; Kilburn, D; Lee, HT; Woodson, SA				Desai, Ravi; Kilburn, Duncan; Lee, Hui-Ting; Woodson, Sarah A.			Increased Ribozyme Activity in Crowded Solutions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						Macromolecular Crowding; Ribozyme; RNA Catalysis; RNA Folding; X-ray Scattering; PEG	GROUP-I INTRON; POLYETHYLENE-GLYCOL; AQUEOUS-SOLUTIONS; CRYSTAL-STRUCTURE; EXCLUDED-VOLUME; CORE HELICES; TRANSFER-RNA; AZOARCUS; CATALYSIS; BINDING	Background: RNAs have evolved to function in the crowded environment of the cell. Results: Large crowder molecules increase the catalytic activity of a group I ribozyme at physiological Mg2+, whereas small neutral molecules do not. Conclusion: Excluded volume due to crowding stabilizes the native active state of RNAs. Significance: Crowding significantly improves RNA folding and function. Noncoding RNAs must function in the crowded environment of the cell. Previous small-angle x-ray scattering experiments showed that molecular crowders stabilize the structure of the Azoarcus group I ribozyme, allowing the ribozyme to fold at low physiological Mg2+ concentrations. Here, we used an RNA cleavage assay to show that the PEG and Ficoll crowder molecules increased the biochemical activity of the ribozyme, whereas sucrose did not. Crowding lowered the Mg2+ threshold at which activity was detected and increased total RNA cleavage at high Mg2+ concentrations sufficient to fold the RNA in crowded or dilute solution. After correcting for solution viscosity, the observed reaction rate was proportional to the fraction of active ribozyme. We conclude that molecular crowders stabilize the native ribozyme and favor the active structure relative to compact inactive folding intermediates.	[Desai, Ravi; Kilburn, Duncan; Lee, Hui-Ting; Woodson, Sarah A.] Johns Hopkins Univ, TC Jenkins Dept Biophys, Baltimore, MD 21218 USA	Johns Hopkins University	Woodson, SA (corresponding author), Johns Hopkins Univ, TC Jenkins Dept Biophys, Baltimore, MD 21218 USA.	swoodson@jhu.edu		Woodson, Sarah/0000-0003-0170-1987	National Institute of Standards and Technology; National Institutes of Health [GM60819]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060819] Funding Source: NIH RePORTER	National Institute of Standards and Technology(National Institute of Standards & Technology (NIST) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by the National Institute of Standards and Technology and by National Institutes of Health Grant GM60819.	Adams PL, 2004, RNA, V10, P1867, DOI 10.1261/rna.7140504; Adams PL, 2004, NATURE, V430, P45, DOI 10.1038/nature02642; Behrouzi R., 2012, THESIS J HOPKINS U; Behrouzi R, 2012, CELL, V149, P348, DOI 10.1016/j.cell.2012.01.057; Buscaglia R, 2013, NUCLEIC ACIDS RES, V41, P7934, DOI 10.1093/nar/gkt440; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.biochem.59.1.543; Chauhan S, 2005, J MOL BIOL, V353, P1199, DOI 10.1016/j.jmb.2005.09.015; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; GONZALEZTELLO P, 1994, J CHEM ENG DATA, V39, P611, DOI 10.1021/je00015a050; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; Kilburn D, 2013, J AM CHEM SOC, V135, P10055, DOI 10.1021/ja4030098; Kilburn D, 2010, J AM CHEM SOC, V132, P8690, DOI 10.1021/ja101500g; Kirincic S, 1999, FLUID PHASE EQUILIBR, V155, P311, DOI 10.1016/S0378-3812(99)00005-9; Kuo LY, 1999, BBA-GENE STRUCT EXPR, V1489, P281, DOI 10.1016/S0167-4781(99)00200-6; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; MINTON AP, 1981, BIOPOLYMERS, V20, P2093, DOI 10.1002/bip.1981.360201006; Moghaddam S, 2009, J MOL BIOL, V393, P753, DOI 10.1016/j.jmb.2009.08.044; Nakano S, 2009, J AM CHEM SOC, V131, P16881, DOI 10.1021/ja9066628; Perez-Salas UA, 2004, BIOCHEMISTRY-US, V43, P1746, DOI 10.1021/bi035642o; Rangan P, 2004, J MOL BIOL, V339, P41, DOI 10.1016/j.jmb.2004.03.059; Rangan P, 2003, J MOL BIOL, V329, P229, DOI 10.1016/S0022-2836(03)00430-3; Rangan P, 2003, P NATL ACAD SCI USA, V100, P1574, DOI 10.1073/pnas.0337743100; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; Sinan S, 2011, J BIOL CHEM, V286, P37304, DOI 10.1074/jbc.M111.287706; Solomatin SV, 2010, NATURE, V463, P681, DOI 10.1038/nature08717; Stahley MR, 2006, CURR OPIN STRUC BIOL, V16, P319, DOI 10.1016/j.sbi.2006.04.005; Strulson CA, 2012, NAT CHEM, V4, P941, DOI [10.1038/NCHEM.1466, 10.1038/nchem.1466]; Tanner MA, 1996, RNA, V2, P74; Zhou HX, 2008, ANNU REV BIOPHYS, V37, P375, DOI 10.1146/annurev.biophys.37.032807.125817	29	40	40	3	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	2014	289	5					2972	2977		10.1074/jbc.M113.527861	http://dx.doi.org/10.1074/jbc.M113.527861			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	AD6WW	24337582	Green Published, hybrid			2023-01-03	WOS:000333403000044
J	Gou, HF; Huang, J; Shi, HS; Chen, XC; Wang, YS				Gou, Hong-Feng; Huang, Juan; Shi, Hua-Shan; Chen, Xin-chuan; Wang, Yong-Sheng			Chemo-Immunotherapy with Oxaliplatin and Interleukin-7 Inhibits Colon Cancer Metastasis in Mice	PLOS ONE			English	Article							T-CELLS COOPERATE; IN-VIVO; ADOPTIVE IMMUNOTHERAPY; GENE-TRANSFER; IL-7; EXPRESSION; EXPANSION; MELANOMA; CD8(+); HOMEOSTASIS	Combination of immunotherapy and chemotherapy has shown promise for cancer. Interleukin-7 (IL-7) can potentially enhance immune responses against tumor, while oxaliplatin (OXP), a platinum-based drug, can promote a favorable immune microenvironment and stimulate anticancer immune responses. We evaluated the anti-tumor activity of IL-7 combining OXP against a murine colon carcinoma in vitro and in vivo and studied the tumor immune microenvironment to investigate whether the combined treatment affects on the local immune cell populations. Utilizing lung and abdomen metastasis models by inoculation of CT26 mice colon cancer cells, we evaluated the anti-tumor efficacy of combining IL-7 and OXP in mice models. Tumor immune microenvironment was evaluated by flow cytometric analysis and immunohistochemical staining. Our study showed that the in vivo administration of IL-7 combined with OXP markedly inhibited the growth of tumors in lung and abdomen metastasis models of colon cancer. IL-7 alone had no effect on tumor growth in mice and IL-7 did not alter cell sensitivity to OXP in culture. The antitumor effect of combining IL-7 and OXP correlated with a marked increase in the number of tumor-infiltrating activated CD8+ T cells and a marked decrease in the number of regulatory T (Treg) cells in spleen. Our data suggest that OXP plus IL-7 treatment inhibits tumor cell growth by immunoregulation rather than direct cytotoxicity. Our findings justify further evaluation of combining IL-7 and chemotherapy as a novel experimental cancer therapy.	[Gou, Hong-Feng; Huang, Juan] Sichuan Univ, West China Med Sch, West China Hosp, Dept Abdominal Canc,Canc Ctr,State Key Lab Biothe, Chengdu 610064, Peoples R China; [Shi, Hua-Shan] Sichuan Univ, West China Med Sch, West China Hosp, Dept Head & Neck Canc,Canc Ctr,State Key Lab Biot, Chengdu 610064, Peoples R China; [Chen, Xin-chuan] Sichuan Univ, West China Med Sch, West China Hosp, Dept Hematol, Chengdu 610064, Peoples R China; [Wang, Yong-Sheng] Sichuan Univ, West China Med Sch, West China Hosp, Dept Thorac Canc,Canc Ctr,State Key Lab Biotherap, Chengdu 610064, Peoples R China	Sichuan University; Sichuan University; Sichuan University; Sichuan University	Wang, YS (corresponding author), Sichuan Univ, West China Med Sch, West China Hosp, Dept Thorac Canc,Canc Ctr,State Key Lab Biotherap, Chengdu 610064, Peoples R China.	wangys75@gmail.com		Shi, Hua-shan/0000-0002-9958-9892				Andersson A, 2009, J IMMUNOL, V182, P6951, DOI 10.4049/jimmunol.0803340; AOKI T, 1992, P NATL ACAD SCI USA, V89, P3850, DOI 10.1073/pnas.89.9.3850; Aspinall R, 2004, ANN NY ACAD SCI, V1019, P116, DOI 10.1196/annals.1297.021; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Chen G, 2013, CANCER IMMUNOL IMMUN, V62, P203, DOI 10.1007/s00262-012-1388-0; Cho Y, 2003, CANCER RES, V63, P1555; DUBINETT SM, 1993, J IMMUNOL, V151, P6670; FREITAS AA, 1993, IMMUNOL TODAY, V14, P25, DOI 10.1016/0167-5699(93)90320-K; Fry TJ, 2002, BLOOD, V99, P3892, DOI 10.1182/blood.V99.11.3892; Fry TJ, 2001, BLOOD, V97, P2983, DOI 10.1182/blood.V97.10.2983; Gabrilovich D, 2004, NAT REV IMMUNOL, V4, P941, DOI 10.1038/nri1498; Gabrilovich DI, 2007, CANCER RES, V67, P425, DOI 10.1158/0008-5472.CAN-06-3037; Gonzalez-Aparicio M, 2011, GUT, V60, P341, DOI 10.1136/gut.2010.211722; Hernandez-Alcoceba R, 2012, ONCOIMMUNOLOGY, V1, P97, DOI 10.4161/onci.1.1.17930; HOCK H, 1991, J EXP MED, V174, P1291, DOI 10.1084/jem.174.6.1291; Huang M, 2002, J CLIN INVEST, V109, P931, DOI 10.1172/JCI200214685; Ives NJ, 2007, J CLIN ONCOL, V25, P5426, DOI 10.1200/JCO.2007.12.0253; Jiang Q, 2005, CYTOKINE GROWTH F R, V16, P513, DOI 10.1016/j.cytogfr.2005.05.004; JICHA DL, 1991, J EXP MED, V174, P1511, DOI 10.1084/jem.174.6.1511; Kilinc MO, 2009, J IMMUNOL, V183, P7656, DOI 10.4049/jimmunol.0902625; KOS FJ, 1993, J IMMUNOL, V150, P387; Lahat G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010105; Lai LJ, 2011, CANCER RES, V71, P61, DOI 10.1158/0008-5472.CAN-10-3198; Lake RA, 2005, NAT REV CANCER, V5, P397, DOI 10.1038/nrc1613; Le Saout C, 2008, P NATL ACAD SCI USA, V105, P19414, DOI 10.1073/pnas.0807743105; Levy Y, 2009, J CLIN INVEST, V119, P997, DOI 10.1172/JCI38052; Li B, 2007, CLIN IMMUNOL, V123, P155, DOI 10.1016/j.clim.2007.01.002; Liu SJ, 2007, INT IMMUNOL, V19, P1213, DOI 10.1093/intimm/dxm093; Mazzucchelli R, 2007, NAT REV IMMUNOL, V7, P144, DOI 10.1038/nri2023; MEHROTRA PT, 1995, J IMMUNOL, V154, P5093; MILLER AR, 1993, BLOOD, V82, P3686; Molino A, 1997, INT J CANCER, V74, P433, DOI 10.1002/(SICI)1097-0215(19970822)74:4<433::AID-IJC12>3.0.CO;2-A; Moller P, 1998, BRIT J CANCER, V77, P1907, DOI 10.1038/bjc.1998.317; MURPHY WJ, 1993, J CLIN INVEST, V92, P1918, DOI 10.1172/JCI116785; Overwijk WW, 2009, CLIN IMMUNOL, V132, P153, DOI 10.1016/j.clim.2009.03.512; Pellegrini M, 2009, NAT MED, V15, P528, DOI 10.1038/nm.1953; Ridolfi R, 2002, J CLIN ONCOL, V20, P1600, DOI 10.1200/JCO.20.6.1600; Rosenberg SA, 2006, J IMMUNOTHER, V29, P313, DOI 10.1097/01.cji.0000210386.55951.c2; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Sereti I, 2009, BLOOD, V113, P6304, DOI 10.1182/blood-2008-10-186601; Sharma S, 2003, HUM GENE THER, V14, P1511, DOI 10.1089/104303403322495025; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Sin JI, 2000, CLIN DIAGN LAB IMMUN, V7, P751, DOI 10.1128/CDLI.7.5.751-758.2000; Sportes C, 2008, J EXP MED, V205, P1701, DOI 10.1084/jem.20071681; Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356	45	37	38	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2014	9	1							e85789	10.1371/journal.pone.0085789	http://dx.doi.org/10.1371/journal.pone.0085789			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297GT	24465710	gold, Green Published, Green Submitted			2023-01-03	WOS:000330244500114
J	Gaillard, PJ; Appeldoorn, CCM; Dorland, R; van Kregten, J; Manca, F; Vugts, DJ; Windhorst, B; van Dongen, GAMS; de Vries, HE; Maussang, D; van Tellingen, O				Gaillard, Pieter J.; Appeldoorn, Chantal C. M.; Dorland, Rick; van Kregten, Joan; Manca, Francesca; Vugts, Danielle J.; Windhorst, Bert; van Dongen, Guus A. M. S.; de Vries, Helga E.; Maussang, David; van Tellingen, Olaf			Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101)	PLOS ONE			English	Article							MALIGNANT GLIOMA; CHEMOTHERAPY; TRANSPORT; BARRIER; CELLS; MODEL; BIODISTRIBUTION; ADRIAMYCIN; PACLITAXEL; METASTASES	Brain cancer is a devastating disease affecting many people worldwide. Effective treatment with chemotherapeutics is limited due to the presence of the blood-brain barrier (BBB) that tightly regulates the diffusion of endogenous molecules but also xenobiotics. Glutathione pegylated liposomal doxorubicin (2B3-101) is being developed as a new treatment option for patients with brain cancer. It is based on already marketed pegylated liposomal doxorubicin (Doxil (R)/Caelyx (R)), with an additional glutathione coating that safely enhances drug delivery across the BBB. Uptake of 2B3-101 by human brain capillary endothelial cells in vitro was time-, concentration-and temperature-dependent, while pegylated liposomal doxorubicin mainly remained bound to the cells. In vivo, 2B3-101 and pegylated liposomal doxorubicin had a comparable plasma exposure in mice, yet brain retention 4 days after administration was higher for 2B3-101. 2B3-101 was overall well tolerated by athymic FVB mice with experimental human glioblastoma (luciferase transfected U87MG). In 2 independent experiments a strong inhibition of brain tumor growth was observed for 2B3-101 as measured by bioluminescence intensity. The effect of weekly administration of 5 mg/kg 2B3-101 was more pronounced compared to pegylated liposomal doxorubicin (p<0.05) and saline (p<0.01). Two out of 9 animals receiving 2B3-101 showed a complete tumor regression. Twice-weekly injections of 5 mg/kg 2B3-101 again had a significant effect in inhibiting brain tumor growth (p<0.001) compared to pegylated liposomal doxorubicin and saline, and a complete regression was observed in 1 animal treated with 2B3-101. In addition, twice-weekly dosing of 2B3-101 significantly increased the median survival time by 38.5% (p<0.001) and 16.1% (p<0.05) compared to saline and pegylated liposomal doxorubicin, respectively. Overall, these data demonstrate that glutathione pegylated liposomal doxorubicin enhances the effective delivery of doxorubicin to brain tumors and could become a promising new therapeutic option for the treatment of brain malignancies.	[Gaillard, Pieter J.; Appeldoorn, Chantal C. M.; Dorland, Rick; van Kregten, Joan; Manca, Francesca; Maussang, David] To BBB Technol BV, Leiden, Netherlands; [Vugts, Danielle J.; Windhorst, Bert; van Dongen, Guus A. M. S.] Vrije Univ Amsterdam Med Ctr, Dept Radiol & Nucl Med, Amsterdam, Netherlands; [de Vries, Helga E.] Vrije Univ Amsterdam Med Ctr, Blood Brain Barrier Res Grp, Amsterdam, Netherlands; [van Tellingen, Olaf] Antoni van Leeuwenhoek Hosp NKI AvL, Netherlands Canc Inst, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Netherlands Cancer Institute	Gaillard, PJ (corresponding author), To BBB Technol BV, Leiden, Netherlands.	PieterGaillard@toBBB.com	Van Tellingen, Olaf/A-1344-2014	Van Tellingen, Olaf/0000-0002-1037-6269; de Vries, Helga/0000-0001-7904-7124; Windhorst, Albert/0000-0002-1250-7656; Vugts, Danielle/0000-0001-7068-8152	to-BBB technologies BV; to-BBB technologies	to-BBB technologies BV; to-BBB technologies	All of the work presented in this manuscript was supported by to-BBB technologies BV (http://www.tobbb.com/). DJ Vugts, B Windhorst, GAMS van Dongen, HE de Vries, and O van Tellingen have received research funding from to-BBB technologies for their part of the work. Other than through the scientific input of their participating employees, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal S, 2013, DRUG METAB DISPOS, V41, P33, DOI 10.1124/dmd.112.048322; Anders CK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061359; [Anonymous], 2012, Drug Discov Today Technol, V9, pe71, DOI 10.1016/j.ddtec.2011.12.002; Arnold RD, 2005, CLIN CANCER RES, V11, P8856, DOI 10.1158/1078-0432.CCR-05-1365; Aryal M, 2013, J CONTROL RELEASE, V169, P103, DOI 10.1016/j.jconrel.2013.04.007; Barenholz Y, 2012, J CONTROL RELEASE, V160, P117, DOI 10.1016/j.jconrel.2012.03.020; Block KI, 2008, INT J CANCER, V123, P1227, DOI 10.1002/ijc.23754; Che C, 2010, J MED CHEM, V53, P2814, DOI 10.1021/jm9016637; Dai HQ, 2003, J PHARMACOL EXP THER, V304, P1085, DOI 10.1124/jpet.102.045260; de Boer AG, 2007, ANNU REV PHARMACOL, V47, P323, DOI 10.1146/annurev.pharmtox.47.120505.105237; de Vries Nienke A, 2006, Expert Rev Neurother, V6, P1199, DOI 10.1586/14737175.6.8.1199; Fabel K, 2001, CANCER, V92, P1936, DOI 10.1002/1097-0142(20011001)92:7<1936::AID-CNCR1712>3.0.CO;2-H; Fidler IJ, 2011, SEMIN CANCER BIOL, V21, P107, DOI 10.1016/j.semcancer.2010.12.009; Gaillard PJ, 2012, J CONTROL RELEASE, V164, P364, DOI 10.1016/j.jconrel.2012.06.022; Gaillard PJ, 2013, DRUG DELIVERY BRAIN; Glas M, 2007, ONCOLOGY-BASEL, V72, P302, DOI 10.1159/000113052; Hau P, 2004, CANCER, V100, P1199, DOI 10.1002/cncr.20073; Joshi G, 2010, NEUROSCIENCE, V166, P796, DOI 10.1016/j.neuroscience.2010.01.021; Kannan R, 2000, BRAIN RES, V852, P374, DOI 10.1016/S0006-8993(99)02184-8; KANNAN R, 1990, J CLIN INVEST, V85, P2009, DOI 10.1172/JCI114666; Kemper EM, 2006, EUR J CANCER, V42, P3294, DOI 10.1016/j.ejca.2006.07.013; Klerk CPW, 2007, BIOTECHNIQUES, V43, P7, DOI 10.2144/000112515; Kurzrock R, 2009, MOL CANCER THER, V8, DOI 10.1158/1535-7163.TARG-09-B168; Kurzrock R, 2012, MOL CANCER THER, V11, P308, DOI 10.1158/1535-7163.MCT-11-0566; La Rocca RV, 2011, EXPERT OPIN PHARMACO, V12, P1325, DOI 10.1517/14656566.2011.580737; Laquintana V, 2009, EXPERT OPIN DRUG DEL, V6, P1017, DOI 10.1517/17425240903167942; Lesniak MS, 2005, ANTICANCER RES, V25, P3825; Liedtke C, 2010, BREAST CANCER RES TR, V121, P301, DOI 10.1007/s10549-009-0445-7; Lindqvist A, 2013, MOL PHARMACEUT, V10, P1533, DOI 10.1021/mp300272a; Lu-Emerson Christine, 2012, Continuum (Minneap Minn), V18, P295, DOI 10.1212/01.CON.0000413659.12304.a6; O'Brien MER, 2004, ANN ONCOL, V15, P440, DOI 10.1093/annonc/mdh097; Palmieri D, 2007, CLIN CANCER RES, V13, P1656, DOI 10.1158/1078-0432.CCR-06-2659; Pardridge WM, 2007, PHARM RES, V24, P1729, DOI 10.1007/s11095-007-9387-0; Perry J, 2007, Curr Oncol, V14, P189, DOI 10.3747/co.2007.147; Regina A, 2008, BRIT J PHARMACOL, V155, P185, DOI 10.1038/bjp.2008.260; Rip J, 2010, PHARM TOX BLOOD BRAI; SIEGAL T, 1995, J NEUROSURG, V83, P1029, DOI 10.3171/jns.1995.83.6.1029; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tardi PG, 1996, J DRUG TARGET, V4, P129, DOI 10.3109/10611869609015970; Tosoni A, 2008, CRIT REV ONCOL HEMAT, V68, P212, DOI 10.1016/j.critrevonc.2008.04.004; van Asperen J, 1998, J CHROMATOGR B, V712, P129, DOI 10.1016/S0378-4347(98)00165-0; VONHOLST H, 1990, ACTA NEUROCHIR, V104, P13, DOI 10.1007/BF01842886; Voulgaris S, 2002, AM J CLIN ONCOL-CANC, V25, P60, DOI 10.1097/00000421-200202000-00013; Walbert T, 2009, INT J CLIN ONCOL, V14, P299, DOI 10.1007/s10147-009-0916-1; Weksler BB, 2005, FASEB J, V19, P1872, DOI 10.1096/fj.04-3458fje; Whitaker G, 2010, J PHARMACEUT BIOMED, V53, P490, DOI 10.1016/j.jpba.2010.05.023; Wolff JEA, 1999, J CANCER RES CLIN, V125, P481, DOI 10.1007/s004320050305; ZLOKOVIC BV, 1994, BIOCHEM BIOPH RES CO, V201, P402, DOI 10.1006/bbrc.1994.1715	48	151	159	2	61	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2014	9	1							e82331	10.1371/journal.pone.0082331	http://dx.doi.org/10.1371/journal.pone.0082331			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	291WL	24416140	Green Published, Green Submitted, gold			2023-01-03	WOS:000329862500014
J	Belloni, V; Sorci, G; Paccagnini, E; Guerreiro, R; Bellenger, J; Faivre, B				Belloni, Virginia; Sorci, Gabriele; Paccagnini, Eugenio; Guerreiro, Romain; Bellenger, Jerome; Faivre, Bruno			Disrupting Immune Regulation Incurs Transient Costs in Male Reproductive Function	PLOS ONE			English	Article							SPERM PRODUCTION; TESTES SIZE; EVOLUTION; LIPOPOLYSACCHARIDE; IMMUNOPATHOLOGY; INFLAMMATION; COMPETITION; CYTOKINES; STRESS; CONSEQUENCES	Background: Immune protection against pathogenic organisms has been shown to incur costs. Previous studies investigating the cost of immunity have mostly focused on the metabolic requirements of immune maintenance and activation. In addition to these metabolic costs, the immune system can induce damage to the host if the immune response is mis-targeted or over-expressed. Given its non-specific nature, an over-expressed inflammatory response is often associated with substantial damage for the host. Here, we investigated the cost of an over-expressed inflammatory response in the reproductive function of male mice. Methodology/Principal Findings: We experimentally blocked the receptors of an anti-inflammatory cytokine (IL-10) in male mice exposed to a mild inflammatory challenge, with each treatment having an appropriate control group. The experiment was conducted on two age classes, young (3 month old) and old (15 month old) mice, to assess any age-related difference in the cost of a disrupted immune regulation. We found that the concomitant exposure to an inflammatory insult and the blockade of IL-10 induced a reduction in testis mass, compared to the three other groups. The frequency of abnormal sperm morphology was also higher in the group of mice exposed to the inflammatory challenge but did not depend on the blockade of the IL-10. Conclusions: Our results provide evidence that immune regulation confers protection against the risk of inflammation-induced infertility during infection. They also suggest that disruption of the effectors involved in the regulation of the inflammatory response can have serious fitness consequences even under mild inflammatory insult and benign environmental conditions.	[Belloni, Virginia; Sorci, Gabriele; Guerreiro, Romain; Faivre, Bruno] Univ Bourgogne, CNRS UMR 6282, Dijon, France; [Belloni, Virginia] Tulane Univ, Dept Trop Med, New Orleans, LA 70118 USA; [Paccagnini, Eugenio] Univ Siena, Dipartimento Biol Evolutiva, I-53100 Siena, Italy; [Bellenger, Jerome] Univ Bourgogne, INSERM, UMR 866, Dijon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Universite de Bourgogne; Tulane University; University of Siena; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Belloni, V (corresponding author), Univ Bourgogne, CNRS UMR 6282, Dijon, France.	vbelloni@tulane.edu	Guerreiro, Rita J L/A-1327-2011; BELLENGER, Jerome/AAC-9423-2022	BELLENGER, Jerome/0000-0001-8643-6195; Paccagnini, Eugenio/0000-0002-9784-2057; Belloni, Virginia/0000-0001-9807-1912; Sorci, Gabriele/0000-0002-0799-3995	Region Bourgogne; ANR - Project EVOREGIM	Region Bourgogne(Region Bourgogne-Franche-Comte); ANR - Project EVOREGIM(French National Research Agency (ANR))	Financial support was received from the Region Bourgogne and ANR - Project EVOREGIM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AMANN RP, 1970, FERTIL STERIL, V21, P662; Belloni V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012940; Bonneaud C, 2003, AM NAT, V161, P367, DOI 10.1086/346134; Bornstein SR, 2004, MOL CELL ENDOCRINOL, V215, P135, DOI 10.1016/j.mce.2003.11.022; Byrne PG, 2002, J EVOLUTION BIOL, V15, P347, DOI 10.1046/j.1420-9101.2002.00409.x; Day T, 2007, P ROY SOC B-BIOL SCI, V274, P2685, DOI 10.1098/rspb.2007.0809; Dejaco C, 2006, EXP GERONTOL, V41, P339, DOI 10.1016/j.exger.2006.01.008; Demas GE, 2004, HORM BEHAV, V45, P173, DOI 10.1016/j.yhbeh.2003.11.002; Eraud C, 2005, FUNCT ECOL, V19, P110, DOI 10.1111/j.0269-8463.2005.00934.x; Eraud C, 2009, EVOLUTION, V63, P1036, DOI 10.1111/j.1558-5646.2008.00540.x; Firman RC, 2008, J EVOLUTION BIOL, V21, P1524, DOI 10.1111/j.1420-9101.2008.01612.x; Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016; Freitak D, 2003, P ROY SOC B-BIOL SCI, V270, pS220, DOI 10.1098/rsbl.2003.0069; Gomez CR, 2008, EXP GERONTOL, V43, P718, DOI 10.1016/j.exger.2008.05.016; Graham AL, 2005, ANNU REV ECOL EVOL S, V36, P373, DOI 10.1146/annurev.ecolsys.36.102003.152622; Graham AL, 2002, Q REV BIOL, V77, P409, DOI 10.1086/344414; Graham AL, 2010, SCIENCE, V330, P662, DOI 10.1126/science.1194878; Guerreiro R, 2012, EVOLUTION, V66, P3615, DOI 10.1111/j.1558-5646.2012.01708.x; HARCOURT AH, 1995, FUNCT ECOL, V9, P468, DOI 10.2307/2390011; Hedger MP, 2003, J REPROD IMMUNOL, V58, P1, DOI 10.1016/S0165-0378(02)00060-8; JOUANNET P, 1988, INT J ANDROL, V11, P379, DOI 10.1111/j.1365-2605.1988.tb01011.x; Kawai Y, 2006, J REPROD DEVELOP, V52, P561, DOI 10.1262/jrd.18023; Kidd SA, 2001, FERTIL STERIL, V75, P237, DOI 10.1016/S0015-0282(00)01679-4; Licastro Federico, 2005, Immun Ageing, V2, P8; Liew SH, 2007, J ANDROL, V28, P176, DOI 10.2164/jandrol.106.000752; Linton PJ, 2004, NAT IMMUNOL, V5, P133, DOI 10.1038/ni1033; Long GH, 2011, TRENDS PARASITOL, V27, P300, DOI 10.1016/j.pt.2011.03.012; Long GH, 2011, EVOL APPL, V4, P278, DOI 10.1111/j.1752-4571.2010.00178.x; Long GH, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-128; Martin LB, 2003, P ROY SOC B-BIOL SCI, V270, P153, DOI 10.1098/rspb.2002.2185; Max EE, 2001, IMMUNOLOGY IMMUNOPAT; McElhaney JE, 2009, CURR OPIN IMMUNOL, V21, P418, DOI 10.1016/j.coi.2009.05.023; Meinhardt A, 2011, MOL CELL ENDOCRINOL, V335, P60, DOI 10.1016/j.mce.2010.03.022; Menkveld R, 2001, HUM REPROD, V16, P1165, DOI 10.1093/humrep/16.6.1165; Moret Y, 2000, SCIENCE, V290, P1166, DOI 10.1126/science.290.5494.1166; Nussey D, 2011, IMMUNOLOGY, V135, P30; O'Bryan MK, 2000, BIOL REPROD, V63, P1285, DOI 10.1095/biolreprod63.5.1285; O'Bryan MK, 2005, AM J PHYSIOL-REG I, V288, pR1744, DOI 10.1152/ajpregu.00651.2004; O'Bryan MK, 2000, ENDOCRINOLOGY, V141, P238, DOI 10.1210/en.141.1.238; Panda A, 2009, TRENDS IMMUNOL, V30, P325, DOI 10.1016/j.it.2009.05.004; Plas E, 2000, EXP GERONTOL, V35, P543, DOI 10.1016/S0531-5565(00)00120-0; Preston BT, 2003, P ROY SOC B-BIOL SCI, V270, P633, DOI 10.1098/rspb.2002.2268; Raberg L, 1998, P ROY SOC B-BIOL SCI, V265, P1637, DOI 10.1098/rspb.1998.0482; Raberg L, 2002, P ROY SOC B-BIOL SCI, V269, P817, DOI 10.1098/rspb.2001.1953; RATHJE TA, 1995, J ANIM SCI, V73, P2177; Sarkar D, 2006, CANCER LETT, V236, P13, DOI 10.1016/j.canlet.2005.04.009; Scharer L, 2007, EVOL ECOL, V21, P295, DOI 10.1007/s10682-006-9101-4; Schmid-Hempel P, 2003, P ROY SOC B-BIOL SCI, V270, P357, DOI 10.1098/rspb.2002.2265; Schradin C, 2009, BIOL REPROD, V81, P111, DOI 10.1095/biolreprod.108.075838; Sheldon BC, 1996, TRENDS ECOL EVOL, V11, P317, DOI 10.1016/0169-5347(96)10039-2; Singh T, 2011, AGEING RES REV, V10, P319, DOI 10.1016/j.arr.2010.11.002; Sorci G, 2009, PHILOS T R SOC B, V364, P71, DOI 10.1098/rstb.2008.0151; Svensson E, 1998, FUNCT ECOL, V12, P912, DOI 10.1046/j.1365-2435.1998.00271.x; Viney ME, 2005, TRENDS ECOL EVOL, V20, P665, DOI 10.1016/j.tree.2005.10.003; Winnall WR, 2011, J LEUKOCYTE BIOL, V90, P133, DOI 10.1189/jlb.1010557; Zhang M, 2012, POULTRY SCI, V91, P1997, DOI 10.3382/ps.2012-02236	56	7	7	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2014	9	1							e84606	10.1371/journal.pone.0084606	http://dx.doi.org/10.1371/journal.pone.0084606			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286IW	24400103	Green Published, Green Submitted, gold			2023-01-03	WOS:000329462700037
J	Maddocks, M; Halliday, V; Chauhan, A; Taylor, V; Nelson, A; Sampson, C; Byrne, A; Griffiths, G; Wilcock, A				Maddocks, Matthew; Halliday, Vanessa; Chauhan, Alpna; Taylor, Victoria; Nelson, Annmarie; Sampson, Cathy; Byrne, Anthony; Griffiths, Gareth; Wilcock, Andrew			Neuromuscular Electrical Stimulation of the Quadriceps in Patients with Non-Small Cell Lung Cancer Receiving Palliative Chemotherapy: A Randomized Phase II Study	PLOS ONE			English	Article							QUALITY-OF-LIFE; EXERCISE; THERAPY; MUSCLE; INTERVENTION; WEIGHT; MASS	Background: A reduced exercise capacity is associated with increased morbidity and mortality in patients with advanced non-small cell lung cancer (NSCLC). Therapeutic exercise can be beneficial and neuromuscular electrical stimulation (NMES) of the quadriceps muscles may represent a practical approach. The primary aim of this study was to determine the acceptability of NMES of the quadriceps to patients with NSCLC used alongside palliative chemotherapy. Secondary aims explored aspects of safety and efficacy of NMES in this setting. Methods: Patients with advanced NSCLC due to receive first-line palliative chemotherapy were randomized to usual care with or without NMES. They were asked to undertake 30 minute sessions of NMES, ideally daily, but as a minimum, three times weekly. For NMES to be considered acceptable, it was predetermined that >= 80% of patients should achieve this minimum level of adherence. Qualitative interviews were held with a subset of patients to explore factors influencing adherence. Safety was assessed according to the Common Terminology Criteria for Adverse Events. Quadriceps muscle strength, thigh lean mass, and physical activity level were assessed at baseline and after three cycles of chemotherapy. Results: 49 patients (28 male, median (IQR) age 69 (64-75) years) participated. Of 30 randomized to NMES, 18 were eligible for the primary endpoint, of whom 9 (50% [90% CI, 29 to 71]) met the minimum level of adherence. Adherence was enhanced by incorporating sessions into a daily routine and hindered by undesirable effects of chemotherapy. There were no serious adverse events related to NMES, nor significant differences in quadriceps muscle strength, thigh lean mass or physical activity level between groups. Conclusions: NMES is not acceptable in this setting, nor was there a suggestion of benefit. The need remains to explore NMES in patients with cancer in other settings.	[Maddocks, Matthew] Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabil, London WC2R 2LS, England; [Maddocks, Matthew; Taylor, Victoria; Wilcock, Andrew] Nottingham Univ Hosp Natl Hlth Serv Trust, Dept Palliat Med, Nottingham, England; [Halliday, Vanessa] Univ Nottingham, Sch Biosci, Nottingham NG7 2RD, England; [Chauhan, Alpna] Sherwood Forest Hosp Natl Hlth Serv Fdn Trust, Kings Mill Hosp, Sutton In Ashfield, Notts, England; [Nelson, Annmarie; Sampson, Cathy; Byrne, Anthony; Griffiths, Gareth] Cardiff Univ, Marie Curie Res Ctr, Cardiff CF10 3AX, S Glam, Wales; [Nelson, Annmarie; Sampson, Cathy; Byrne, Anthony; Griffiths, Gareth] Cardiff Univ, Wales Canc Trials Unit, Cardiff CF10 3AX, S Glam, Wales	University of London; King's College London; Nottingham University Hospital NHS Trust; University of Nottingham; Cardiff University; Cardiff University	Wilcock, A (corresponding author), Nottingham Univ Hosp Natl Hlth Serv Trust, Dept Palliat Med, Nottingham, England.	andrew.wilcock@nottingham.ac.uk	Nelson, Annmarie/AAD-2193-2020	Nelson, Annmarie/0000-0002-6075-8425; Wilcock, Andrew/0000-0002-3214-1188; Griffiths, Gareth/0000-0002-9579-8021; Maddocks, Matthew/0000-0002-0189-0952	National Cancer Research Institute Lung Cancer Supportive and Palliative Care Award [LCSuPaC35]; Cancer Research United Kingdom Wales Cancer Trial Unit programme grant; AN the Marie Curie Palliative Care Research Centre programme grant; National Institute for Health Research (NIHR) Post-Doctoral Fellowship award; Cancer Research UK [15954] Funding Source: researchfish; National Institute for Health Research [PDF-2011-04-048] Funding Source: researchfish	National Cancer Research Institute Lung Cancer Supportive and Palliative Care Award; Cancer Research United Kingdom Wales Cancer Trial Unit programme grant; AN the Marie Curie Palliative Care Research Centre programme grant; National Institute for Health Research (NIHR) Post-Doctoral Fellowship award(National Institute for Health Research (NIHR)); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	This research was supported by a National Cancer Research Institute Lung Cancer Supportive and Palliative Care Award (LCSuPaC35) who had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. GG and AB are funded by the Cancer Research United Kingdom Wales Cancer Trial Unit programme grant and AN the Marie Curie Palliative Care Research Centre programme grant. MM is funded by an National Institute for Health Research (NIHR) Post-Doctoral Fellowship award. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; BERGMAN B, 1994, EUR J CANCER, V30A, P635, DOI 10.1016/0959-8049(94)90535-5; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Fearon KCH, 2008, EUR J CANCER, V44, P1124, DOI 10.1016/j.ejca.2008.02.033; Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7; FLEMING TR, 1982, BIOMETRICS, V38, P143, DOI 10.2307/2530297; Gray C, 2011, CLIN NUTR, V30, P106, DOI 10.1016/j.clnu.2010.07.012; Hwang CL, 2012, SUPPORT CARE CANCER, V20, P3169, DOI 10.1007/s00520-012-1452-5; Jones LW, 2008, J THORAC ONCOL, V3, P194, DOI 10.1097/JTO.0b013e318160f36b; Jones LW, 2012, LUNG CANCER, V76, P248, DOI 10.1016/j.lungcan.2011.10.009; Jones LW, 2009, LANCET ONCOL, V10, P598, DOI 10.1016/S1470-2045(09)70031-2; Jones LW, 2012, CANCER, V116, P4825; Kasymjanova G, 2009, J THORAC ONCOL, V4, P602, DOI 10.1097/JTO.0b013e31819e77e8; Lakoski SG, 2012, NAT REV CLIN ONCOL, V9, P288, DOI 10.1038/nrclinonc.2012.27; Levine JA, 2000, J APPL PHYSIOL, V88, P452, DOI 10.1152/jappl.2000.88.2.452; Maddocks M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009419.pub2; Maddocks M, 2011, PSYCHO-ONCOLOGY, V20, P173, DOI 10.1002/pon.1720; Maddocks M, 2010, SUPPORT CARE CANCER, V18, P1539, DOI 10.1007/s00520-009-0776-2; Maddocks M, 2010, BRIT J SPORT MED, V44, P606, DOI 10.1136/bjsm.2008.051128; Maddocks M, 2009, J PAIN SYMPTOM MANAG, V38, P950, DOI 10.1016/j.jpainsymman.2009.05.011; Maddocks M, 2009, CANCER TREAT REV, V35, P383, DOI 10.1016/j.ctrv.2008.11.008; Maffiuletti NA, 2010, EUR J APPL PHYSIOL, V110, P223, DOI 10.1007/s00421-010-1502-y; Murphy RA, 2011, CANCER-AM CANCER SOC, V117, P1775, DOI 10.1002/cncr.25709; National Cancer Institute, 2009, NIH PUBLICATION; Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139; Prince SA, 2008, INT J BEHAV NUTR PHY, V5, DOI 10.1186/1479-5868-5-56; Purcell A, 2010, SUPPORT CARE CANCER, V18, P307, DOI 10.1007/s00520-009-0653-z; Quist M, 2012, LUNG CANCER, V75, P203, DOI 10.1016/j.lungcan.2011.07.006; Scott HR, 2002, BRIT J CANCER, V87, P264, DOI 10.1038/sj.bjc.6600466; Sillen MJH, 2009, CHEST, V136, P44, DOI 10.1378/chest.08-2481; Skipworth RJE, 2011, CLIN NUTR, V30, P812, DOI 10.1016/j.clnu.2011.05.010; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; Smets EMA, 1996, BRIT J CANCER, V73, P241, DOI 10.1038/bjc.1996.42; Temel JS, 2009, J THORAC ONCOL, V4, P595, DOI 10.1097/JTO.0b013e31819d18e5; Wilcock Andrew, 2008, BMC Palliat Care, V7, P3, DOI 10.1186/1472-684X-7-3	36	30	31	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2013	8	12							e86059	10.1371/journal.pone.0086059	http://dx.doi.org/10.1371/journal.pone.0086059			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282SX	24386491	Green Published, Green Accepted, gold			2023-01-03	WOS:000329194700148
J	Chang, D				Chang, Diane			Scut	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Montefiore Med Ctr, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Chang, D (corresponding author), Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA.	diachang@gmail.com						[Anonymous], 2013 US POV GUID; Benson B, 2013, CRAINS NEW YORK 0331; Bilton N, 2013, NY TIMES; College of Engineering at Georgia Tech, ROB COD LEARNS BATH; Hagman A, BESTIC EATING ASS DE; United States Department of Labor, 2014, OCC EMPL STAT OCC EM	6	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	2013	310	22					2399	2400		10.1001/jama.2013.282710	http://dx.doi.org/10.1001/jama.2013.282710			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266NN	24327036				2023-01-03	WOS:000328030900017
J	Konieczna, J; Garcia, AP; Sanchez, J; Palou, M; Palou, A; Pico, C				Konieczna, Jadwiga; Paula Garcia, Ana; Sanchez, Juana; Palou, Mariona; Palou, Andreu; Pico, Catalina			Oral Leptin Treatment in Suckling Rats Ameliorates Detrimental Effects in Hypothalamic Structure and Function Caused by Maternal Caloric Restriction during Gestation	PLOS ONE			English	Article							DIET-INDUCED OBESITY; ENERGY HOMEOSTASIS; PREVENTS OBESITY; FOOD PREFERENCES; ADIPOSE-TISSUE; INSULIN; LACTATION; NEURONS; UNDERNUTRITION; SUSCEPTIBILITY	A poor prenatal environment brings about perturbations in leptin surge and hypothalamic circuitry that program impaired ability to regulate energy homeostasis in adulthood. Here, using a rat model of moderate maternal caloric restriction during gestation, we aimed to investigate whether leptin supplementation with physiological doses throughout lactation is able to ameliorate the adverse developmental malprogramming effects exerted in offspring hypothalamus structure and function. Three groups of male and female rats were studied: the offspring of ad libitum fed dams (controls), the offspring of 20% calorie restricted dams during the first part of pregnancy (CR), and CR rats supplemented with physiological doses of leptin throughout lactation (CR-Leptin). Animals were sacrificed on postnatal day 25. Morphometric and immunohistochemical studies on arcuate (ARC) and paraventicular (PVN) nucleus were performed and hypothalamic expression levels of selected genes were determined. In CR males, leptin treatment restored, at least in part, the number of immunoreactive neuropeptide Y (NPY+) cells in ARC, the total number of cells in PVN, hypothalamic NPY, cocaine-and amphetamine-regulated transcript (CART) and suppressor of cytokine signalling-3 (SOCS-3) mRNA levels, and plasma leptin levels, which were decreased in CR animals. CR-Leptin males showed higher hypothalamic long-form leptin receptor (ObRb) mRNA levels, compared to control and CR animals. In CR females, leptin treatment reverted the increased number of cells in ARC and cell density in ARC and PVN, and reduced hypothalamic SOCS-3 mRNA expression to levels similar to controls. Leptin treatment also reverted the increased relative area of NPY+ fibers in the PVN occurring in CR animals. In conclusion, leptin supplementation throughout lactation is able to revert, at least partly, most of the developmental effects on hypothalamic structure and function caused by moderate maternal caloric restriction during gestation, and hence making this metabolic malprogramming reversible to some extent.	[Palou, Andreu] Univ Balearic Isl, Lab Mol Biol Nutr & Biotechnol Nutrigen, Palma de Mallorca, Spain; CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Palma de Mallorca, Spain	Universitat de les Illes Balears; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN	Palou, A (corresponding author), Univ Balearic Isl, Lab Mol Biol Nutr & Biotechnol Nutrigen, Palma de Mallorca, Spain.	andreu.palou@uib.es; cati.pico@uib.es	Palou, Mariona/H-9208-2015; Palou, Mariona/S-2098-2018; Palou, Andreu/K-9881-2014; Pico, Catalina/H-7115-2015; Sanchez, Juana/K-9675-2014	Palou, Mariona/0000-0001-9918-3764; Palou, Mariona/0000-0001-9918-3764; Palou, Andreu/0000-0002-0295-4452; Pico, Catalina/0000-0001-6759-5844; Sanchez, Juana/0000-0002-9176-8060	Spanish Government [AGL2009-11277]; European Union [244995]; Instituto de Salud Carlos III, Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, CIBERobn; "Direccio General d'Universitats, Recerca i Transferencia del Coneixement" of Regional Government (CAIB); FEDER funds (EU) [FP6-506360]	Spanish Government(Spanish GovernmentEuropean Commission); European Union(European Commission); Instituto de Salud Carlos III, Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, CIBERobn; "Direccio General d'Universitats, Recerca i Transferencia del Coneixement" of Regional Government (CAIB); FEDER funds (EU)(European Commission)	The research leading to these results was supported by the Spanish Government (grant AGL2009-11277), the European Union's Seventh Framework Programme FP7 2007-2013 under grant agreement n. 244995 (BIOCLAIMS Project), and the Instituto de Salud Carlos III, Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, CIBERobn. The Laboratory belongs to the Nutrigenomics-group, awarded as "Group of Excellence" of CAIB and supported by "Direccio General d'Universitats, Recerca i Transferencia del Coneixement" of Regional Government (CAIB) and FEDER funds (EU Contract: n. FP6-506360). Jadwiga Konieczna is granted with a PhD fellowship entitled "beca para la formacion de personal investigador, en el marco de un programa operativo cofinanciado por el Fondo Social Europeo". The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahima RS, 1998, J CLIN INVEST, V101, P1020, DOI 10.1172/JCI1176; Arora S, 2006, NEUROPEPTIDES, V40, P375, DOI 10.1016/j.npep.2006.07.001; Attig L, 2008, INT J OBESITY, V32, P1153, DOI 10.1038/ijo.2008.39; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Bouret SG, 2006, CLIN GENET, V70, P295, DOI 10.1111/j.1399-0004.2006.00684.x; Bouret SG, 2004, SCIENCE, V304, P108, DOI 10.1126/science.1095004; Casabiell X, 1997, J CLIN ENDOCR METAB, V82, P4270, DOI 10.1210/jc.82.12.4270; Cottrell EC, 2008, PHYSIOL BEHAV, V94, P17, DOI 10.1016/j.physbeh.2007.11.017; Minana-Solis MD, 2011, NUTR NEUROSCI, V14, P72, DOI 10.1179/1476830511Y.0000000003; Delahaye F, 2008, ENDOCRINOLOGY, V149, P470, DOI 10.1210/en.2007-1263; Djiane J, 2008, J PHYSIOL PHARMACOL, V59, P55; Garcia AP, 2010, DIABETES OBES METAB, V12, P403, DOI 10.1111/j.1463-1326.2009.01174.x; Grino M, 2005, AM J PHYSIOL-REG I, V289, pR1233, DOI 10.1152/ajpregu.00542.2005; Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Ikenasio-Thorpe BA, 2007, J ENDOCRINOL, V193, P31, DOI 10.1677/joe.1.07017; JONES AP, 1984, J NUTR, V114, P1484; JONES AP, 1982, SCIENCE, V215, P1518, DOI 10.1126/science.7063860; Loos RJF, 2003, J INTERN MED, V254, P401, DOI 10.1046/j.1365-2796.2003.01242.x; Oliver P, 2002, DEV DYNAM, V223, P148, DOI 10.1002/dvdy.1233; Palou A, 2009, APPETITE, V52, P249, DOI 10.1016/j.appet.2008.09.013; Palou M, 2012, J NUTR BIOCHEM, V23, P1627, DOI 10.1016/j.jnutbio.2011.11.005; Palou M, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-69; Palou M, 2010, ENDOCRINOLOGY, V151, P1030, DOI 10.1210/en.2009-0934; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pico C, 2007, INT J OBESITY, V31, P1199, DOI 10.1038/sj.ijo.0803585; Pico C, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00436; Pico C, 2011, AM J CLIN NUTR, V94, p1830S, DOI 10.3945/ajcn.110.000752; Plagemann A, 2000, J NUTR, V130, P2582, DOI 10.1093/jn/130.10.2582; Priego T, 2010, INT J OBESITY, V34, P809, DOI 10.1038/ijo.2010.18; Proulx K, 2002, ENDOCRINOLOGY, V143, P4683, DOI 10.1210/en.2002-220593; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; Sanchez J, 2005, ENDOCRINOLOGY, V146, P2575, DOI 10.1210/en.2005-0112; Sanchez J, 2008, ENDOCRINOLOGY, V149, P733, DOI 10.1210/en.2007-0630; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Spencer SJ, 2012, CURR DIABETES REV, V8, P55, DOI 10.2174/157339912798829214; Sullivan EL, 2010, FORUM NUTR, V63, P186, DOI 10.1159/000264406; Vickers Mark H, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P17, DOI 10.1097/MED.0b013e328013da48; Vickers MH, 2008, ENDOCRINOLOGY, V149, P1906, DOI 10.1210/en.2007-0981; Vickers MH, 2005, ENDOCRINOLOGY, V146, P4211, DOI 10.1210/en.2005-0581; Vickers MH, 2000, AM J PHYSIOL-ENDOC M, V279, pE83; Waterland RA, 1999, AM J CLIN NUTR, V69, P179; Yang ZY, 2013, MATERN CHILD NUTR, V9, P105, DOI 10.1111/mcn.12010	45	30	30	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2013	8	11							e81906	10.1371/journal.pone.0081906	http://dx.doi.org/10.1371/journal.pone.0081906			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261IJ	24312379	gold, Green Published, Green Submitted			2023-01-03	WOS:000327657900061
J	Gao, W; Gulliford, M; Bennett, MI; Murtagh, FEM; Higginson, IJ				Gao, Wei; Gulliford, Martin; Bennett, Michael I.; Murtagh, Fliss E. M.; Higginson, Irene J.			Managing Cancer Pain at the End of Life with Multiple Strong Opioids: A Population-Based Retrospective Cohort Study in Primary Care	PLOS ONE			English	Article							LAST 3 MONTHS; ADJUVANT ANALGESICS; PREVALENCE; MANAGEMENT	Background: End-of-life cancer patients commonly receive more than one type of strong opioid. The three-step analgesic ladder framework of the World Health Organisation (WHO) provides no guidance on multiple opioid prescribing and there is little epidemiological data available to inform practice. This study aims to investigate the time trend of such cases and the associated factors. Methods: Strong opioid prescribing in the last three months of life of cancer patients were extracted from the General Practice Research Database (GPRD). The outcome variable was the number of different types of prescribed non-rescue doses of opioids (1 vs 2-4, referred to as a complex case). Associated factors were evaluated using prevalence ratios (PR) derived from multivariate log-binomial model, adjusting for clustering effects and potential confounding variables. Results: Overall, 26.4% (95% CI: 25.6-27.1%) of 13,427 cancer patients (lung 41.7%, colorectal 19.1%, breast 18.6%, prostate 15.5%, head and neck 5.0%) were complex cases. Complex cases increased steadily over the study period (1.02% annually, 95% CI: 0.42-1.61%, p = 0.048) but with a small dip (7.5% reduction, 95% CI: -0.03 to 17.8%) around the period of the Shipman case, a British primary care doctor who murdered his patients with opioids. The dip significantly affected the correlation of the complex cases with persistent increasing background opioid prescribing (weighted correlation coefficients pre-, post-Shipman periods: 0.98(95% CI: 0.67-1.00), p = 0.011; 0.14 (95% CI: -0.85 to 0.91), p = 0.85). Multivariate adjusted analysis showed that the complex cases were predominantly associated with year of death (PRs vs 2000: 1.05-1.65), not other demographic and clinical factors except colorectal cancer (PR vs lung cancer: 1.24, 95% CI: 1.12-1.37). Conclusion: These findings suggest that prescribing behaviour, rather than patient factors, plays an important role in multiple opioid prescribing at the end of life; highlighting the need for training and education that goes beyond the well-recognised WHO approach for clinical practitioners.	[Gao, Wei; Murtagh, Fliss E. M.; Higginson, Irene J.] Kings Coll London, Sch Med, Dept Palliat Care Policy & Rehabil, London WC2R 2LS, England; [Gulliford, Martin] Kings Coll London, Sch Med, Dept Primary Care & Publ Hlth Sci, London WC2R 2LS, England; [Bennett, Michael I.] Univ Leeds, Leeds Inst Hlth Sci, Acad Unit Palliat Care, Leeds, W Yorkshire, England	University of London; King's College London; University of London; King's College London; University of Leeds	Gao, W (corresponding author), Kings Coll London, Sch Med, Dept Palliat Care Policy & Rehabil, London WC2R 2LS, England.	wei.gao@kcl.ac.uk	Bennett, Michael I/A-1620-2009; Gulliford, Martin C/I-8606-2018; Gao, Wei/G-8653-2011; Murtagh, Fliss E M/C-3216-2009; Higginson, Irene Julie/C-7309-2012	Bennett, Michael I/0000-0002-8369-8349; Gulliford, Martin C/0000-0003-1898-9075; Gao, Wei/0000-0001-8298-3415; Murtagh, Fliss E M/0000-0003-1289-3726; Higginson, Irene Julie/0000-0002-3687-1313	NCRI-NIHR COMPASS Collaborative (the UK National Cancer Research Institute Supportive and Palliative Care Research Collaborative); National Institute for Health Research [NF-SI-0611-10209] Funding Source: researchfish	NCRI-NIHR COMPASS Collaborative (the UK National Cancer Research Institute Supportive and Palliative Care Research Collaborative); National Institute for Health Research(National Institute for Health Research (NIHR))	This work is supported by the NCRI-NIHR COMPASS Collaborative (the UK National Cancer Research Institute Supportive and Palliative Care Research Collaborative). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bennett MI, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2806; Bennett Michael I, 2011, Curr Opin Support Palliat Care, V5, P20, DOI 10.1097/SPC.0b013e328342c607; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; Claseem A, 2008, ANN INTERN MED, V148, P141, DOI 10.7326/0003-4819-148-2-200801150-00009; Costantini M, 2009, ANN ONCOL, V20, P729, DOI 10.1093/annonc/mdn700; Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419; Droney J, 2012, CURR OPIN SUPPORT PA, V6, P10, DOI 10.1097/SPC.0b013e32834f6a07; Finch R, 2004, SHIPMAN HAS MADE GPS; Gao W, 2011, BRIT J CANCER, V104, P1704, DOI 10.1038/bjc.2011.150; Gardiner C, 2012, J PAIN SYMPTOM MANAG; Higginson IJ, 2012, J CLIN ONCOL; Jacobsen Ramune, 2007, J Opioid Manag, V3, P207; Khan NF, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-1; Lussier D, 2004, ONCOLOGIST, V9, P571, DOI 10.1634/theoncologist.9-5-571; Mercadante S, 2012, J PAIN SYMPTOM MANAG; Mercadante S, 2006, J PAIN SYMPTOM MANAG, V32, P413, DOI 10.1016/j.jpainsymman.2006.05.015; Mercadante S, 2012, J PALLIAT MED, V15, P347, DOI 10.1089/jpm.2011.0198; Mercadante S, 2011, PALLIATIVE MED, V25, P504, DOI 10.1177/0269216311406577; Mitra R, 2012, AM J HOSP PALLIAT ME, V29, P70, DOI 10.1177/1049909111413256; Moksnes K, 2012, EUR J CLIN PHARMACOL, V68, P1147, DOI 10.1007/s00228-012-1228-3; NICE, 2011, OP PALL CAR SAF EFF; Oldenmenger WH, 2009, EUR J CANCER, V45, P1370, DOI 10.1016/j.ejca.2009.01.007; Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5; Potter VT, 2003, PSYCHO-ONCOLOGY, V12, P153, DOI 10.1002/pon.627; Raijmakers NJ, 2012, SUPPORT CARE CANC; Rurup Mette L, 2010, BMC Palliat Care, V9, P23, DOI 10.1186/1472-684X-9-23; Skollerud LM, 2012, SUPPORT CARE CANC; Smith D J, 2004, REGULATION CONTROLLE; The Information Centre NHS, 2006, HOSP PRESCR 2005 ENG; Zeppetela G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub2	31	15	16	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2014	9	1							e79266	10.1371/journal.pone.0079266	http://dx.doi.org/10.1371/journal.pone.0079266			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301BI	24475016	gold, Green Published			2023-01-03	WOS:000330507300003
J	Kamerow, D				Kamerow, Douglas			Getting your "T" up	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									RTI Int, Res Triangle Pk, NC USA	Research Triangle Institute	Kamerow, D (corresponding author), RTI Int, Res Triangle Pk, NC USA.	dkamerow@rti.org		Kamerow, Douglas/0000-0001-7000-9957				Baillargeon J, 2013, JAMA INTERN MED, V173, P1465, DOI 10.1001/jamainternmed.2013.6895; Bhasin S, 2010, J CLIN ENDOCR METAB, V95, P2536, DOI 10.1210/jc.2009-2354; Schwartz LM, 2013, JAMA INTERN MED, V173, P1460, DOI 10.1001/jamainternmed.2013.7579; Singer N., 2013, NY TIMES	4	4	4	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 10	2014	348								g182	10.1136/bmj.g182	http://dx.doi.org/10.1136/bmj.g182			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KR	24412845				2023-01-03	WOS:000329611300020
J	Cahill, K; Stevens, S; Lancaster, T				Cahill, Kate; Stevens, Sarah; Lancaster, Tim			Pharmacological Treatments for Smoking Cessation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Cahill, Kate; Stevens, Sarah; Lancaster, Tim] Univ Oxford, Dept Primary Care Hlth Sci, Oxford OX2 6GG, England; [Cahill, Kate; Lancaster, Tim] Univ Oxford, Cochrane Tobacco Addict Grp, Oxford OX2 6GG, England	University of Oxford; University of Oxford	Cahill, K (corresponding author), Univ Oxford, Dept Primary Care Hlth Sci, New Radcliffe House, Oxford OX2 6GG, England.	kate.cahill@phc.ox.ac.uk		Lancaster, Timothy Ross/0000-0002-0580-1099; Lay-Flurrie, Sarah/0000-0003-1094-8455				Cahill K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009329.pub2, 10.1002/14651858.CD006103.pub6]; Cahill K, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006103.pub6; Centers for Disease Control and Prevention, SMOK TOB US CESS PRO; Fiore MC, 2008, AM J PREV MED, V35, P158, DOI 10.1016/j.amepre.2008.04.009; GlaxoSmithKline, ZYB 150 MG PROL REL; Hughes JR, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000031.pub3, 10.1002/14651858.CD000031.pub4]; Stead LF, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub4	7	120	123	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	2014	311	2					193	194		10.1001/jama.2013.283787	http://dx.doi.org/10.1001/jama.2013.283787			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284SA	24399558				2023-01-03	WOS:000329339400025
J	He, MH; Pan, H; Chang, RCC; So, KF; Brecha, NC; Pu, ML				He, Meihua; Pan, Hong; Chang, Raymond Chuen-Chung; So, Kwok-Fai; Brecha, Nicholas C.; Pu, Mingliang			Activation of the Nrf2/HO-1 Antioxidant Pathway Contributes to the Protective Effects of Lycium Barbarum Polysaccharides in the Rodent Retina after Ischemia-Reperfusion-Induced Damage	PLOS ONE			English	Article							INDUCED OXIDATIVE STRESS; HEME OXYGENASE-1; CAPILLARY DEGENERATION; GLUCOSE DEPRIVATION; GENE-EXPRESSION; CARBON-MONOXIDE; FREE-RADICALS; IN-VIVO; INJURY; CELLS	Lycium barbarum polysaccharides (LBP), extracts from the wolfberries, are protective to retina after ischemia-reperfusion (I/R). The antioxidant response element (ARE)-mediated antioxidant pathway plays an important role in maintaining the redox status of the retina. Heme oxygenase-1 (HO-1), combined with potent AREs in its promoter, is a highly effective therapeutic target for the protection against neurodegenerative diseases, including I/R-induced retinal damage. The aim of our present study was to investigate whether the protective effect of LBP after I/R damage was mediated via activation of the Nrf2/HO-1-antioxidant pathway in the retina. Retinal I/R was induced by an increase in intraocular pressure to 130 mm Hg for 60 minutes. Prior to the induction of ischemia, rats were orally treated with either vehicle (PBS) or LBP (1 mg/kg) once a day for 1 week. For specific experiments, zinc protoporphyrin (ZnPP, 20 mg/kg), an HO-1 inhibitor, was intraperitoneally administered at 24 h prior to ischemia. The protective effects of LBP were evaluated by quantifying ganglion cell and amacrine cell survival, and by measuring cell apoptosis in the retinal layers. In addition, HO-1 expression was examined using Western blotting and immunofluorescence analyses. Cytosolic and nuclear Nrf2 was measured using immunofluorescent staining. LBP treatment significantly increased Nrf2 nuclear accumulation and HO-1 expression in the retina after I/R injury. Increased apoptosis and a decrease in the number of viable cells were observed in the ganglion cell layer (GCL) and inner nuclear layer (INL) in the I/R retina, which were reversed by LBP treatment. The HO-1 inhibitor, ZnPP, diminished the LBP treatment-induced protective effects in the retina after I/R. Taken together, these results suggested that LBP partially exerted its beneficial neuroprotective effects via the activation of Nrf2 and an increase in HO-1 protein expression.	[He, Meihua; Pan, Hong; Pu, Mingliang] Peking Univ, Sch Basic Med Sci, Dept Anat Embryol, Beijing 100871, Peoples R China; [He, Meihua; Pan, Hong; Pu, Mingliang] Peking Univ, Minist Educ, Key Lab Machine Percept, Beijing 100871, Peoples R China; [He, Meihua; Pan, Hong; Pu, Mingliang] Peking Univ, Minist Educ, Key Lab Visual Impairment & Restorat, Beijing 100871, Peoples R China; [Chang, Raymond Chuen-Chung; So, Kwok-Fai] LKS Fac Med, Dept Anat, Pokfulam, Hong Kong, Peoples R China; [Chang, Raymond Chuen-Chung; So, Kwok-Fai] LKS Fac Med, Res Ctr Heart Brain Hormone & Hlth Aging, Pokfulam, Hong Kong, Peoples R China; [Chang, Raymond Chuen-Chung; So, Kwok-Fai] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Pokfulam, Hong Kong, Peoples R China; [So, Kwok-Fai] Jinan Univ, GHM Inst CNS Regenerat, Guangzhou, Guangdong, Peoples R China; [Brecha, Nicholas C.] Univ Hong Kong, Dept Ophthalmol, Pokfulam, Hong Kong, Peoples R China; [Brecha, Nicholas C.] Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med Los Angeles, CURE Digest Dis Res Ctr,Dept Neurobiol,Dept Med, Los Angeles, CA 90024 USA; [Brecha, Nicholas C.] Greater Los Angeles Hlth Syst, Vet Adm, Los Angeles, CA USA	Peking University; Peking University; Peking University; University of Hong Kong; University of Hong Kong; University of Hong Kong; Jinan University; University of Hong Kong; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pu, ML (corresponding author), Peking Univ, Sch Basic Med Sci, Dept Anat Embryol, Beijing 100871, Peoples R China.	mpu@hsc.pku.edu.cn	He, Meihua/D-4312-2017; Chang, Raymond Chuen-Chung/C-1107-2009	Chang, Raymond Chuen-Chung/0000-0001-8538-7993; So, Kwok-Fai/0000-0003-4039-4246	National Basic Research Program of China (973 Program) [2009CB320900, 2011CB510206]; National Science Foundation of China [30831160516, 81200691]; Ministry of Education of China [20090001120075]; Azalea Endowment Fund; Fundamental Research Fund for the Central Universities [21609101]; NIH [EY04067]; VA Merit Review; NATIONAL EYE INSTITUTE [R56EY004067, R01EY004067] Funding Source: NIH RePORTER	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China(Ministry of Education, China); Azalea Endowment Fund; Fundamental Research Fund for the Central Universities; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA Merit Review(US Department of Veterans Affairs); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This study was supported by grants obtained from the National Basic Research Program of China (973 Program, 2009CB320900 [MP] and 2011CB510206 [MP]), the National Science Foundation of China (30831160516 [MP] and 81200691 [MH]), the Ministry of Education of China (20090001120075 [MH]), Azalea (1972) Endowment Fund (KS & RC), and the Fundamental Research Fund for the Central Universities (21609101, KS), NIH EY04067 (NCB) and VA Merit Review (NB). NCB is a VA Career Research Scientist. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alam J, 2004, ANTIOXID REDOX SIGN, V6, P924, DOI 10.1089/1523086041798114; Amagase H, 2009, NUTR RES, V29, P19, DOI 10.1016/j.nutres.2008.11.005; Bonne C, 1998, GEN PHARMACOL, V30, P275, DOI 10.1016/S0306-3623(97)00357-1; Chang RCC, 2008, CELL MOL NEUROBIOL, V28, P643, DOI 10.1007/s10571-007-9181-x; Chao HM, 2013, J OCUL PHARMACOL TH, V29, P539, DOI 10.1089/jop.2012.0179; Cheng XH, 2011, ANTIOXID REDOX SIGN, V14, P469, DOI 10.1089/ars.2010.3283; Chiu Kin, 2009, J Ocul Biol Dis Infor, V2, P47; Danilov CA, 2009, GLIA, V57, P645, DOI 10.1002/glia.20793; Ghattas MH, 2002, INT J BIOCHEM CELL B, V34, P1619, DOI 10.1016/S1357-2725(02)00097-3; Goldblum D, 2002, VISION RES, V42, P471, DOI 10.1016/S0042-6989(01)00194-8; He M, 2011, NUTR METAB CARDIOVAS, V21, P277, DOI 10.1016/j.numecd.2009.12.008; Hornberg H, 2013, J NEUROSCI, V33, P10384, DOI 10.1523/JNEUROSCI.5858-12.2013; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jeong WS, 2006, ANTIOXID REDOX SIGN, V8, P99, DOI 10.1089/ars.2006.8.99; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Kwong JMK, 2011, INVEST OPHTH VIS SCI, V52, P9694, DOI 10.1167/iovs.11-7869; Lau BWM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033374; Li SY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016380; Li XM, 2007, INT J BIOL MACROMOL, V40, P461, DOI 10.1016/j.ijbiomac.2006.11.002; Li XM, 2007, J ETHNOPHARMACOL, V111, P504, DOI 10.1016/j.jep.2006.12.024; Liu XQ, 2013, J OCUL PHARMACOL TH, V29, P33, DOI 10.1089/jop.2012.0141; Lu SP, 2010, INT J BIOL MACROMOL, V47, P681, DOI 10.1016/j.ijbiomac.2010.08.016; Luo Q, 2009, J MED FOOD, V12, P695, DOI 10.1089/jmf.2008.1232; Mao F, 2011, MED ONCOL, V28, P121, DOI 10.1007/s12032-009-9415-5; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Mi XS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045469; Muller A, 1998, GEN PHARMACOL, V30, P315, DOI 10.1016/S0306-3623(97)00362-5; Niu AJ, 2008, INT J BIOL MACROMOL, V42, P447, DOI 10.1016/j.ijbiomac.2008.02.003; Osborne NN, 1999, SURV OPHTHALMOL, V43, pS102, DOI 10.1016/S0039-6257(99)00044-2; Panahian N, 1999, J NEUROCHEM, V72, P1187; Peng PH, 2011, CURR EYE RES, V36, P238, DOI 10.3109/02713683.2010.539760; rai-Gaun S, 2004, INVEST OPHTH VIS SCI, V45, P4226; Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005; Shah ZA, 2010, J CEREBR BLOOD F MET, V30, P1951, DOI 10.1038/jcbfm.2010.53; Shan XZ, 2011, INT J MOL SCI, V12, P1081, DOI 10.3390/ijms12021081; Shibuki H, 2000, INVEST OPHTH VIS SCI, V41, P3607; Siow RCM, 1999, CARDIOVASC RES, V41, P385, DOI 10.1016/S0008-6363(98)00278-8; Siow RCM, 2007, REDOX REP, V12, P11, DOI 10.1179/135100007X162167; Soane L, 2010, J NEUROSCI RES, V88, P1355, DOI 10.1002/jnr.22307; Sun MH, 2010, INVEST OPHTH VIS SCI, V51, P4798, DOI 10.1167/iovs.09-4086; Szabo ME, 2004, INVEST OPHTH VIS SCI, V45, P3727, DOI 10.1167/iovs.03-1324; Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P979, DOI 10.1167/iovs.04-1120; Varga B, 2013, J MOL NEUROSCI, V50, P558, DOI 10.1007/s12031-013-9998-3; Varga B, 2011, J MOL NEUROSCI, V43, P44, DOI 10.1007/s12031-010-9406-1; Wei YH, 2011, FREE RADICAL BIO MED, V51, P216, DOI 10.1016/j.freeradbiomed.2011.04.026; Wu HT, 2010, INT J BIOL MACROMOL, V46, P540, DOI 10.1016/j.ijbiomac.2010.02.010; Xiao J, 2012, J ETHNOPHARMACOL, V139, P462, DOI 10.1016/j.jep.2011.11.033; Xin YF, 2011, BIOL PHARM BULL, V34, P1523, DOI 10.1248/bpb.34.1523; Yang D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033596; Yu MS, 2005, EXP GERONTOL, V40, P716, DOI 10.1016/j.exger.2005.06.010; Zheng L, 2007, INVEST OPHTH VIS SCI, V48, P361, DOI 10.1167/iovs.06-0510	51	120	141	0	65	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2014	9	1							e84800	10.1371/journal.pone.0084800	http://dx.doi.org/10.1371/journal.pone.0084800			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286IW	24400114	Green Submitted, gold, Green Published			2023-01-03	WOS:000329462700048
J	de Quiros, YB; Seewald, JS; Sylva, SP; Greer, B; Niemeyer, M; Bogomolni, AL; Moore, MJ				de Quiros, Yara Bernaldo; Seewald, Jeffrey S.; Sylva, Sean P.; Greer, Bill; Niemeyer, Misty; Bogomolni, Andrea L.; Moore, Michael J.			Compositional Discrimination of Decompression and Decomposition Gas Bubbles in Bycaught Seals and Dolphins	PLOS ONE			English	Article							CETACEANS; EMBOLISM; LESIONS	Gas bubbles in marine mammals entangled and drowned in gillnets have been previously described by computed tomography, gross examination and histopathology. The absence of bacteria or autolytic changes in the tissues of those animals suggested that the gas was produced peri- or post-mortem by a fast decompression, probably by quickly hauling animals entangled in the net at depth to the surface. Gas composition analysis and gas scoring are two new diagnostic tools available to distinguish gas embolisms from putrefaction gases. With this goal, these methods have been successfully applied to pathological studies of marine mammals. In this study, we characterized the flux and composition of the gas bubbles from bycaught marine mammals in anchored sink gillnets and bottom otter trawls. We compared these data with marine mammals stranded on Cape Cod, MA, USA. Fresh animals or with moderate decomposition (decomposition scores of 2 and 3) were prioritized. Results showed that bycaught animals presented with significantly higher gas scores than stranded animals. Gas composition analyses indicate that gas was formed by decompression, confirming the decompression hypothesis.	[de Quiros, Yara Bernaldo; Bogomolni, Andrea L.; Moore, Michael J.] Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA; [Seewald, Jeffrey S.; Sylva, Sean P.] Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA; [Greer, Bill] Integrated Stat, Woods Hole, MA USA; [Greer, Bill] NOAA NMFS Northeast Fisheries, Woods Hole, MA USA; [Niemeyer, Misty] Int Fund Anim Welf, Yarmouth Port, MA USA; [Bogomolni, Andrea L.] Univ Connecticut, Dept Pathobiol & Vet Sci, Storrs, CT USA	Woods Hole Oceanographic Institution; Woods Hole Oceanographic Institution; University of Connecticut	de Quiros, YB (corresponding author), Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA.	ybernaldodequiros@whoi.edu	Sylva, Sean/D-4400-2014; Moore, Michael/E-1707-2015; de Quirós, Yara Bernaldo/A-3628-2015	Sylva, Sean/0000-0002-4727-440X; Moore, Michael/0000-0003-3074-6631; de Quirós, Yara Bernaldo/0000-0002-2611-0406	Woods Hole Oceanographic Institution Marine Mammal Center; Wick and Sloan Simmons	Woods Hole Oceanographic Institution Marine Mammal Center; Wick and Sloan Simmons	This study was funded by the Woods Hole Oceanographic Institution Marine Mammal Center, and Wick and Sloan Simmons. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armstrong HG, 1939, ANAL GAS EMBOLI ENG; Bernaldo de Quiros Y, 2011, THESIS U PALMAS GRAN; de Quiros YB, 2013, INT J LEGAL MED, V127, P437, DOI 10.1007/s00414-012-0783-6; de Quiros YB, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00177; Bernaldo de QuiruEs, 2012, PROTOCOL EXCHANGE, DOI 10.1038/protex.2012.002; Bert P., 1878, PRESSION BAROMETRIQU; BROWN CD, 1978, J FORENSIC SCI, V23, P511; Cole AJ, 2006, J CLIN PATHOL, V59, P489, DOI 10.1136/jcp.2005.031708; Cowan D, 1979, DIS FACTORS STENELLA; de Quiros YB, 2011, SCI REP-UK, V1, DOI 10.1038/srep00193; Dennison S, 2012, P ROY SOC B-BIOL SCI, V279, P1396, DOI 10.1098/rspb.2011.1754; EGGLETON P, 1945, J PHYSIOL-LONDON, V104, P129, DOI 10.1113/jphysiol.1945.sp004111; Fernandez A, 2005, VET PATHOL, V42, P446, DOI 10.1354/vp.42-4-446; Fernandez A, 2012, J MARINE SCI RES DEV, V2; Francis T. J. R., 2003, BENNETT ELLIOTTS PHY, P530; HARRIS M, 1945, J GEN PHYSIOL, V28, P225, DOI 10.1085/jgp.28.3.225; Heimesaat MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040758; Hutter CDD, 2000, MED HYPOTHESES, V54, P585, DOI 10.1054/mehy.1999.0901; ISHIYAMA A, 1983, Bulletin of Tokyo Medical and Dental University, V30, P25; Ishiyama A, 1981, 6 M PAN DIV PHYS TEC, P201; Jackowski C, 2005, FORENSIC SCI INT, V149, P11, DOI 10.1016/j.forsciint.2004.05.019; Jepson PD, 2003, NATURE, V425, P575, DOI 10.1038/425575a; Jepson PD, 2005, VET PATHOL, V42, P291, DOI 10.1354/vp.42-3-291; King J. M., 1989, NECROPSY BOOK; Knight B., 1996, FORENSIC PATHOLOGY, V2nd ed.; Kuiken T, 1991, NEWSLETTER; Lawrence C., 1997, SPUMS J, V27, P228; LEVER MJ, 1966, J PHYSIOL-LONDON, V184, P964, DOI 10.1113/jphysiol.1966.sp007960; LILLO RS, 1992, UNDERSEA BIOMED RES, V19, P375; Lorber B, 2000, PRINCIPLES PRACTICE; Moore MJ, 2009, VET PATHOL, V46, P536, DOI 10.1354/vp.08-VP-0065-M-FL; Moore MJ, 2004, SCIENCE, V306, P2215, DOI 10.1126/science.1105452; Pierucci G, 1968, Zacchia, V4, P347; ROMMEL SA, 1994, J COMP PHYSIOL B, V164, P130, DOI 10.1007/BF00301654; SHIM SS, 1967, CAN MED ASSOC J, V97, P1263	35	16	16	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2013	8	12							e83994	10.1371/journal.pone.0083994	http://dx.doi.org/10.1371/journal.pone.0083994			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276HY	24367623	gold, Green Submitted, Green Published			2023-01-03	WOS:000328741900027
J	Pepin, J; Abou Chakra, CN; Pepin, E; Nault, V				Pepin, Jacques; Abou Chakra, Claire Nour; Pepin, Eric; Nault, Vincent			Evolution of the Global Use of Unsafe Medical Injections, 2000-2010	PLOS ONE			English	Article								Objective: Since 1999, substantial efforts have been made by the international community to reduce the risks associated with unsafe injections, through ministries of health, international donors, the World Health Organization and the Safe Injection Global Network. The present study attempted to measure the progress, or lack thereof, made over the 2000-2010 decade in reducing unsafe injections in ten regions of the world corresponding to developing and transitional economies. Methods: Data about the number of injections per person per year and the proportion of re-use of syringes and needles were obtained for 2010, mainly from population surveys, and compared with previous estimates for 2000 which had used various sources of information including injection safety assessments, population surveys and published studies on injection practices. Results: From 2000 to 2010, in developing countries and transitional economies, the average number of injections per person per year decreased from 3.40 to 2.88, while the proportion of re-use of injection devices dropped from 39.8% to 5.5%. Combining both factors the number of unsafe injections per person per year decreased from 1.35 to 0.16. Even if substantial progress has been made, the Eastern Mediterranean region remains problematic, with 0.57 unsafe injections per person per year. In sub-Saharan Africa and Latin America, people now receive on average only 0.04-0.05 unsafe injections per year. Conclusion: Substantial progress has been made in reducing the number of unsafe injections in developing countries and transitional economies, essentially through a reduction in the re-use of injection devices. In some regions, elimination of unsafe injections might become a reasonable goal.	[Pepin, Jacques; Abou Chakra, Claire Nour; Pepin, Eric; Nault, Vincent] Univ Sherbrooke, Dept Microbiol & Infect Dis, Sherbrooke, PQ J1K 2R1, Canada	University of Sherbrooke	Pepin, J (corresponding author), Univ Sherbrooke, Dept Microbiol & Infect Dis, Sherbrooke, PQ J1K 2R1, Canada.	jacques.pepin@usherbrooke.ca			Safe Injection Global Network	Safe Injection Global Network	This work was supported by the Safe Injection Global Network which however had no role in data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed in this article are those of the authors only.	Altaf Arshad, 2006, J Coll Physicians Surg Pak, V16, P622; [Anonymous], INJ PRACT RAP ASS RE; Bhunia R, 2010, INDIAN PEDIATR, V47, P409, DOI 10.1007/s13312-010-0076-4; Fan CX, 2012, INT HEALTH, V4, P295, DOI 10.1016/j.inhe.2012.08.002; Hauri AM, 2004, INT J STD AIDS, V15, P7, DOI 10.1258/095646204322637182; Hauri AM., 2004, COMP QUANTIFICATION; Hutin YJF, 2003, BMJ-BRIT MED J, V327, P1075, DOI 10.1136/bmj.327.7423.1075; Logez S, 2004, AM J INFECT CONTROL, V32, P31, DOI 10.1016/j.ajic.2003.06.006; Measure DHS, 2013, DEMOGRAPHIC HLTH SUR; Measure DHS website, 2013, EG DEM HLTH SURV 200; Reeler AV, 2000, B WORLD HEALTH ORGAN, V78, P135; Talaat M, 2003, TROP MED INT HEALTH, V8, P234, DOI 10.1046/j.1365-3156.2003.01015.x; The SIGN Alliance website, 2013, SAF INJ GLOB NETW AD; The SIGN Alliance website, 2013, SUMM COUNTR INJ SAF; UNAIDS, 2010, UNAIDS REP GLOB AIDS; United Nations Department of Economic and Social Affairs website, 2013, WORLD POP PROSP 2010; World Health Organization, 2000, TOOL C ASS IN PRESS; Yan Y. W., 2007, SMJ Singapore Medical Journal, V48, P769	18	20	20	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2013	8	12							e80948	10.1371/journal.pone.0080948	http://dx.doi.org/10.1371/journal.pone.0080948			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	265KD	24324650	gold, Green Published			2023-01-03	WOS:000327949300062
J	Mao, P; Hever-Jardine, MP; Rahme, GJ; Yang, E; Tam, J; Kodali, A; Biswal, B; Fadul, CE; Gaur, A; Israel, MA; Spinella, MJ				Mao, Pingping; Hever-Jardine, Mary P.; Rahme, Gilbert J.; Yang, Eric; Tam, Janice; Kodali, Anita; Biswal, Bijesh; Fadul, Camilo E.; Gaur, Arti; Israel, Mark A.; Spinella, Michael J.			Serine/Threonine Kinase 17A Is a Novel Candidate for Therapeutic Targeting in Glioblastoma	PLOS ONE			English	Article							INTEGRATED GENOMIC ANALYSIS; GROWTH-FACTOR RECEPTOR; DAP-KINASE; PROTEIN-KINASE; GENE; CHEMOTHERAPY; SUBTYPES; MARKERS; GLIOMA; ROLES	STK17A is a relatively uncharacterized member of the death-associated protein family of serine/threonine kinases which have previously been associated with cell death and apoptosis. Our prior work established that STK17A is a novel p53 target gene that is induced by a variety of DNA damaging agents in a p53-dependent manner. In this study we have uncovered an additional, unanticipated role for STK17A as a candidate promoter of cell proliferation and survival in glioblastoma (GBM). Unexpectedly, it was found that STK17A is highly overexpressed in a grade-dependent manner in gliomas compared to normal brain and other cancer cell types with the highest level of expression in GBM. Knockdown of STK17A in GBM cells results in a dramatic alteration in cell shape that is associated with decreased proliferation, clonogenicity, migration, invasion and anchorage independent colony formation. STK17A knockdown also sensitizes GBM cells to genotoxic stress. STK17A overexpression is associated with a significant survival disadvantage among patients with glioma which is independent of age, molecular phenotype, IDH1 mutation, PTEN loss, and alterations in the p53 pathway and partially independent of grade. In summary, we demonstrate that STK17A provides a proliferative and survival advantage to GBM cells and is a potential target to be exploited therapeutically in patients with glioma.	[Mao, Pingping; Hever-Jardine, Mary P.; Yang, Eric; Tam, Janice; Kodali, Anita; Biswal, Bijesh; Spinella, Michael J.] Geisel Sch Med, Dept Pharmacol & Toxicol, Hanover, NH USA; [Rahme, Gilbert J.; Fadul, Camilo E.; Gaur, Arti; Israel, Mark A.] Geisel Sch Med, Hanover, NH USA; [Fadul, Camilo E.; Gaur, Arti; Israel, Mark A.] Norris Cotton Canc Ctr, Lebanon, NH USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Spinella, MJ (corresponding author), Geisel Sch Med, Dept Pharmacol & Toxicol, Hanover, NH USA.	michael.spinella@dartmouth.edu	Spinella, Michael/B-7210-2014	Biswal, Bijesh Kumar/0000-0002-5609-7660; Rahme, Gilbert/0000-0001-6060-1279	United States Department of Defense Investigator-Initiated Research Award [PR093629]; Prouty Developmental Award from Norris Cotton Cancer Center; NATIONAL CANCER INSTITUTE [R21CA177781] Funding Source: NIH RePORTER	United States Department of Defense Investigator-Initiated Research Award(United States Department of Defense); Prouty Developmental Award from Norris Cotton Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by United States Department of Defense Investigator-Initiated Research Award PR093629 (MJS) and a Prouty Developmental Award from the Norris Cotton Cancer Center (MJS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anton K, 2012, HEMATOL ONCOL CLIN N, V26, P825, DOI 10.1016/j.hoc.2012.04.006; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Beyrouthy MJ, 2009, CANCER RES, V69, P9360, DOI 10.1158/0008-5472.CAN-09-1490; Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; Bredel M, 2005, CANCER RES, V65, P8679, DOI 10.1158/0008-5472.CAN-05-1204; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; ENGLAND B, 2013, TUMOR BIOL IN PRESS; French PJ, 2005, CANCER RES, V65, P11335, DOI 10.1158/0008-5472.CAN-05-1886; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Giuliano CJ, 2005, BBA-GENE STRUCT EXPR, V1731, P48, DOI 10.1016/j.bbaexp.2005.08.006; GOODENGERGER ML, 2005, CANC GENET, V205, P613; Gozuacik D, 2006, AUTOPHAGY, V2, P74, DOI 10.4161/auto.2.2.2459; Gupta K, 2012, J CANCER RES CLIN, V138, P1971, DOI 10.1007/s00432-012-1323-y; Hegi ME, 2012, CURR OPIN NEUROL, V25, P774, DOI 10.1097/WCO.0b013e328359b0bc; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; Kuo JC, 2003, J CELL SCI, V116, P4777, DOI 10.1242/jcs.00794; Liang Y, 2005, P NATL ACAD SCI USA, V102, P5814, DOI 10.1073/pnas.0402870102; Lin Y, 2010, FEBS J, V277, P48, DOI 10.1111/j.1742-4658.2009.07411.x; Mao P, 2011, J BIOL CHEM, V286, P19381, DOI 10.1074/jbc.M111.218040; Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164; Neubueser D, 2010, MOL BIOL CELL, V21, P2869, DOI 10.1091/mbc.E10-04-0328; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Peller S, 1998, SEMIN CANCER BIOL, V8, P379, DOI 10.1006/scbi.1998.0100; Polivka J, 2012, ANTICANCER RES, V32, P2935; Robertson F, 2012, DEVELOPMENT, V139, P3432, DOI 10.1242/dev.080762; Robertson T, 2011, PATHOLOGY, V43, P88, DOI 10.1097/PAT.0b013e3283426e86; Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; TEMMERMAN K, 2013, FEBS J IN PRESS; Tran B, 2010, J CLIN NEUROSCI, V17, P417, DOI 10.1016/j.jocn.2009.09.004; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; Zalckvar E, 2009, AUTOPHAGY, V5, P720, DOI 10.4161/auto.5.5.8625	35	20	22	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2013	8	11							e81803	10.1371/journal.pone.0081803	http://dx.doi.org/10.1371/journal.pone.0081803			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261IJ	24312360	Green Published, gold, Green Submitted			2023-01-03	WOS:000327657900052
J	Xu, R; Han, QF; Zhu, TY; Ren, YP; Chen, JH; Zhao, HP; Chen, MH; Dong, J; Wang, Y; Hao, CM; Zhang, R; Zhang, XH; Wang, M; Tian, N; Wang, HY				Xu, Rong; Han, QingFeng; Zhu, TongYing; Ren, Yeping; Chen, JiangHua; Zhao, HuiPing; Chen, MengHua; Dong, Jie; Wang, Yue; Hao, ChuanMing; Zhang, Rui; Zhang, Xiaohui; Wang, Mei; Tian, Na; Wang, HaiYan			Diabetic Patients Could Do As Well as Non-Diabetic Patients without Inflammation on Peritoneal Dialysis	PLOS ONE			English	Article							RESIDUAL RENAL-FUNCTION; C-REACTIVE PROTEIN; GLYCATION END-PRODUCTS; CORONARY-HEART-DISEASE; LOW-GRADE INFLAMMATION; ENDOTHELIAL DYSFUNCTION; TECHNIQUE FAILURE; BLOOD-PRESSURE; RISK-FACTORS; MORTALITY	Background: Diabetic patients on peritoneal dialysis (PD) have lower survival and are more likely complicated with inflammation than their non-diabetic counterparts. Here, we explored the interaction effects between diabetes and inflammation on the survival of PD patients. Methods: Overall, 2,264 incident patients were enrolled from a retrospective cohort study in China. Patients were grouped according to the baseline levels of high-sensitive C-reactive protein (hsCRP, <= 3 mg/L or >3 mg/L) or serum albumin (SA, >= 38 g/L or <38 g/L). Then, several multivariable adjusted stratified Cox regsion models were constructed for these groups to explore the predicted role of diabetes on all-cause or cardiovascular death under inflammatory or non-inflammatory conditions. Results: Diabetics on PD were more likely to have inflammation than non-diabetics on PD, and they presented with elevated hsCRP (52.7% vs. 47.3%, P = 0.03) or decreased SA (77.9% vs. 62.7%, P < 0.001) levels. After stratification by size of center and controlling for confounding factors, diabetes was found to predict all-cause death in patients with hsCRP >3 mg/L or SA <38 g/L but not in patients with hsCRP <= 3 mg/L or SA >= 38 g/L. Similarly, the presence of diabetes was an indication of cardiovascular death in patients with hsCRP >3 mg/L or SA <38 g/L. However, if further adjusted by baseline cardiovascular disease, the predicted role of diabetes on death related to cardiovascular disease in patients with SA <38 g/L disappeared. Conclusion: Diabetic patients could do as well as non-diabetic patients without inflammation on peritoneal dialysis. Active strategies should be implemented to improve inflammation status in diabetic patients on PD.	[Xu, Rong; Dong, Jie; Wang, HaiYan] Peking Univ, Hosp 1, Key Lab Renal Dis, Renal Div,Dept Med,Inst Nephrol,Minist Hlth,Minis, Beijing 100871, Peoples R China; [Han, QingFeng; Wang, Yue] Peking Univ, Hosp 3, Dept Nephrol, Beijing 100871, Peoples R China; [Zhu, TongYing; Hao, ChuanMing] Fudan Univ, Huashan Hosp, Dept Nephrol, Shanghai 200433, Peoples R China; [Ren, Yeping; Zhang, Rui] Harbin Med Univ, Affiliated Hosp 2, Dept Nephrol, Heilongjiang, Peoples R China; [Chen, JiangHua; Zhang, Xiaohui] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Kidney Dis Ctr, Hangzhou 310003, Zhejiang, Peoples R China; [Zhao, HuiPing; Wang, Mei] Peking Univ, Dept Nephrol, Peoples Hosp, Beijing 100871, Peoples R China; [Chen, MengHua; Tian, Na] Ningxia Med Univ, Gen Hosp, Dept Nephrol, Ningxia, Peoples R China	Peking University; Peking University; Fudan University; Harbin Medical University; Zhejiang University; Peking University; Ningxia Medical University	Dong, J (corresponding author), Peking Univ, Hosp 1, Key Lab Renal Dis, Renal Div,Dept Med,Inst Nephrol,Minist Hlth,Minis, Beijing 100871, Peoples R China.	dongjie@medmail.com.cn	tian, na/GVR-9226-2022; Dong, Jie/AFM-0048-2022		Baxer Clinical Research Award of Baxter Corp; China and the ISN Research Award of ISN GO RP Committee	Baxer Clinical Research Award of Baxter Corp; China and the ISN Research Award of ISN GO RP Committee	This work is supported by grants from the Baxer Clinical Research Award of Baxter Corp, China and the ISN Research Award of ISN GO R&P Committee. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chae CU, 2001, HYPERTENSION, V38, P399, DOI 10.1161/01.HYP.38.3.399; CHOBANIAN AV, 2003, HYPERTENSION, V42, P1206, DOI [DOI 10.1161/01.HYP.0000107251.49515.c2, DOI 10.1161/01.HYP.0000107251.49515.C2]; Chung SH, 2010, NEPHROL DIAL TRANSPL, V25, P3742, DOI 10.1093/ndt/gfq233; Cotovio P, 2011, INT J NEPHROL, V2011, DOI 10.4061/2011/914849; Dalal P, 2012, CONTRIB NEPHROL, V178, P271, DOI 10.1159/000337890; Danesh J, 2000, BMJ-BRIT MED J, V321, P199, DOI 10.1136/bmj.321.7255.199; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; de Jager J, 2006, ARTERIOSCL THROM VAS, V26, P1086, DOI 10.1161/01.ATV.0000215951.36219.a4; de Mutsert R, 2009, J RENAL NUTR, V19, P127, DOI 10.1053/j.jrn.2008.08.003; Demirci MS, 2011, NEPHROL DIAL TRANSPL, V26, P1708, DOI 10.1093/ndt/gfq588; Engelstein E.D., 1998, HURSTS HEART, VVolume 9, P1081; ERA-EDTA Registry, 2012, ERA EDTA REG ANN REP; Fein PA, 2003, KIDNEY INT, V64, pS87, DOI 10.1046/j.1523-1755.64.s87.13.x; Fouque D, 2008, KIDNEY INT, V73, P391, DOI 10.1038/sj.ki.5002585; Herzig KA, 2001, J AM SOC NEPHROL, V12, P814, DOI 10.1681/ASN.V124814; Jain AK, 2012, J AM SOC NEPHROL, V23, P533, DOI 10.1681/ASN.2011060607; Kuriyama S, 2007, PERITON DIALYSIS INT, V27, pS190; Lambie M, 2013, J AM SOC NEPHROL; Liao CT, 2008, PERITON DIALYSIS INT, V28, pS191; Liao CT, 2009, NEPHROL DIAL TRANSPL, V24, P2909, DOI 10.1093/ndt/gfp056; Mehrotra R, 2007, J AM SOC NEPHROL, V18, P2781, DOI 10.1681/ASN.2006101130; Miguel A, 2002, NEPHRON, V90, P290, DOI 10.1159/000049065; Nowlin SY, 2012, J NUTR METAB, V2012, DOI 10.1155/2012/542698; Passadakis PS, 2010, SEMIN DIALYSIS, V23, P191, DOI 10.1111/j.1525-139X.2010.00707.x; Peduzzi P, 1995, J CLIN EPIDEMIOL, V48, P1503, DOI 10.1016/0895-4356(95)00048-8; Schaubel DE, 2001, KIDNEY INT, V60, P1517, DOI 10.1046/j.1523-1755.2001.00969.x; Smith SC, 2004, CIRCULATION, V109, P3112, DOI 10.1161/01.CIR.0000133427.35111.67; Stirban A, 2006, DIABETES CARE, V29, P2064, DOI 10.2337/dc06-0531; Utsunomiya K, 2012, VASC HEALTH RISK MAN, V8, P429, DOI 10.2147/VHRM.S32357; Vlassara H, 2009, SEMIN NEPHROL, V29, P594, DOI 10.1016/j.semnephrol.2009.07.013; Vlassara H, 2009, J CLIN ENDOCR METAB, V94, P4483, DOI 10.1210/jc.2009-0089; Wang AYM, 2011, SEMIN NEPHROL, V31, P159, DOI 10.1016/j.semnephrol.2011.01.005; Wang AYM, 2005, AM J KIDNEY DIS, V45, P715, DOI 10.1053/j.ajkd.2004.12.012; Wang AYM, 2003, J AM SOC NEPHROL, V14, P1871, DOI 10.1097/01.ASN.0000070071.57901.B3; Wang AYM, 2001, J AM SOC NEPHROL, V12, P1927, DOI 10.1681/ASN.V1291927; Whaley-Connell AT, 2012, AM J KIDNEY DIS, V59, pS1, DOI 10.1053/j.ajkd.2011.11.018; Xu R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050766; Yang X, 2013, DIABETES RES CLIN PR, V100, P354, DOI 10.1016/j.diabres.2013.03.030; Yeates K, 2012, NEPHROL DIAL TRANSPL, V27, P3568, DOI 10.1093/ndt/gfr674	39	6	7	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2013	8	11							e80486	10.1371/journal.pone.0080486	http://dx.doi.org/10.1371/journal.pone.0080486			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256KH	24260402	Green Published, gold, Green Submitted			2023-01-03	WOS:000327308500144
J	Drake, CG; Sharma, P; Gerritsen, W				Drake, C. G.; Sharma, P.; Gerritsen, W.			Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy	ONCOGENE			English	Review						androgen ablation; chemotherapy; immunotherapy; post-docetaxel; prostate cancer; radiotherapy	T-CELL RESPONSES; IMMUNE-RESPONSE; CTLA-4 BLOCKADE; INCREASED SURVIVAL; RECENT SUCCESSES; CLINICAL-TRIALS; LOCAL RADIATION; TUMOR-CELLS; OPEN-LABEL; PHASE-II	For the past decade, docetaxel has remained the global standard of care for frontline treatment of metastatic castration-resistant prostate cancer (mCRPC). Until recently, there were limited options for patients with mCRPC following docetaxel failure or resistance, but now the approved treatment choices for these patients have expanded to include abiraterone acetate, cabazitaxel and enzalutamide. Additionally, the radioactive therapeutic agent radium-223 dichloride has been recently approved in patients with CRPC with bone metastases. Although each of these agents has been shown to convey significant survival benefit as a monotherapy, preclinical findings suggest that combining such innovative strategies with traditional treatments may achieve additive or synergistic effects, further augmenting patient benefit. This review will discuss the transformation of the post-docetaxel space in mCRPC, highlighting the spectrum of newly approved agents in this setting in the USA and the European Union, as well as summarizing treatments with non-chemotherapeutic mechanisms of action that have demonstrated promising results in recent phase 3 trials. Lastly, this review will address the potential of combinatorial regimens in mCRPC, including the pairing of novel immunotherapeutic approaches with chemotherapy, radiotherapy or androgen ablation.	[Drake, C. G.] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, 1650 Orleans St CRB 410, Baltimore, MD 21231 USA; [Sharma, P.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Gerritsen, W.] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6525 ED Nijmegen, Netherlands	Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; UTMD Anderson Cancer Center; Radboud University Nijmegen	Drake, CG (corresponding author), Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, 1650 Orleans St CRB 410, Baltimore, MD 21231 USA.	cdrake@jhmi.edu	gerritsen, Winald/H-8031-2014		Bristol-Myers Squibb (BMS); NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER	Bristol-Myers Squibb (BMS)(Bristol-Myers Squibb); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Professional medical writing and editorial assistance was provided by Ami P. Modi, PhD, at StemScientific, and funded by Bristol-Myers Squibb (BMS).	Abdollah F, 2012, INT J UROL, V19, P836, DOI 10.1111/j.1442-2042.2012.03052.x; Angelergues A, 2013, J CLIN ONCOL, V31, p323s; [Anonymous], 2012, ZYT AB AC SUMM PROD; [Anonymous], 2013, US YERV IP PACK INS; [Anonymous], 2012, XTAND ENZ PACK INS; [Anonymous], PHAS 2 STUD AD PSA V; [Anonymous], 2012, ZYT AB AC PACK INS; [Anonymous], 2012, EU YERV IP PACK INS; [Anonymous], 2013, XOF RAD RA 223 DICHL; [Anonymous], 2013, XGEV DEN PACK INS; [Anonymous], 2011, PROV SIP T PACK INS; Antonarakis ES, 2012, CURR OPIN ONCOL, V24, P258, DOI 10.1097/CCO.0b013e32835205a0; Antonarakis ES, 2013, J CLIN ONCOL, V31, p312s; Aparicio A, 2012, CANC RES S8, V72; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Arlen PM, 2006, CLIN CANCER RES, V12, P1260, DOI 10.1158/1078-0432.CCR-05-2059; Berthold DR, 2008, J CLIN ONCOL, V26, P242, DOI 10.1200/JCO.2007.12.4008; Brown IE, 2006, J IMMUNOL, V177, P4521, DOI 10.4049/jimmunol.177.7.4521; Chakraborty M, 2004, CANCER RES, V64, P4328, DOI 10.1158/0008-5472.CAN-04-0073; Chakraborty M, 2003, J IMMUNOL, V170, P6338, DOI 10.4049/jimmunol.170.12.6338; *CLIN TRIALS, CONC VERS SEQ TREATM; *CLIN TRIALS, STUD DET SAF TOL ENZ; *CLIN TRIALS, SEQ SIP T ADT MEN NO; Clinical Trials.gov, PHAS 3 STUD IMM TREA; Clinical Trials.gov, STUD IMM TREAT ADV P; Clinical Trials.gov, IP ANDR DEPR THER; Clinical Trials.gov, IP COMB ANDR SUPPR T; Clinical Trials.gov, COMB IP AB ON AC PLU; Clinical Trials.gov NCT00450463, VACC THER PROSTVAC T; Clinical Trials.gov NCT01145508, DOC PREDN VACC THER; Clinical Trials.gov NCT01194271, NEOADJ IP PROST CANC; Clinical Trials.gov NCT01420965, SIP T CT 011 CYCL AD; Clinical Trials.gov NCT01436968, PHAS 3 STUD PROSTATA; Clinical Trials.gov NCT01696877, NEOADJ STUD ANDR ABL; Corn Paul G, 2012, Cancer Manag Res, V4, P183, DOI 10.2147/CMAR.S32839; Danila DC, 2011, CANCER J, V17, P438, DOI 10.1097/PPO.0b013e31823e69ac; Dayyani F, 2011, JNCI-J NATL CANCER I, V103, P1665, DOI 10.1093/jnci/djr362; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; Demaria S, 2005, CLIN CANCER RES, V11, P728; Dewan MZ, 2009, CLIN CANCER RES, V15, P5379, DOI 10.1158/1078-0432.CCR-09-0265; Dickinson M, 2010, INVEST NEW DRUG, V28, pS3, DOI 10.1007/s10637-010-9596-y; Drake CG, 2012, J CLIN ONCOL S, V30; Drake CG, 2010, NAT REV IMMUNOL, V10, P580, DOI 10.1038/nri2817; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Gao J, 2012, CANC RES S8, V72; Garnett CT, 2008, CLIN CANCER RES, V14, P3536, DOI 10.1158/1078-0432.CCR-07-4025; Gulley JL, 2005, CLIN CANCER RES, V11, P3353, DOI 10.1158/1078-0432.CCR-04-2062; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris TJ, 2008, PROSTATE, V68, P1319, DOI 10.1002/pros.20794; Higano D, 2009, 2009 GEN CANC S ORL; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoos A, 2010, SEMIN ONCOL, V37, P533, DOI 10.1053/j.seminoncol.2010.09.015; Horwich A, 2010, ANN ONCOL, V21, pv129, DOI 10.1093/annonc/mdq174; Huang X, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-35; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jure-Kunkel MN, 2008, J CLIN ONCOL S, V26, p144s; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kodumudi KN, 2010, CLIN CANCER RES, V16, P4583, DOI 10.1158/1078-0432.CCR-10-0733; Kuroda K, 2009, PROSTATE, V69, P1579, DOI 10.1002/pros.21004; Lebbe C, 2012, ANN ONCOL, V23, P363; Lee Francis, 2011, Ther Adv Med Oncol, V3, P11, DOI 10.1177/1758834010386402; Levy MY, 2009, J PHARMACOL EXP THER, V330, P596, DOI 10.1124/jpet.109.152603; Lugade AA, 2005, J IMMUNOL, V174, P7516, DOI 10.4049/jimmunol.174.12.7516; Ma YT, 2011, CANCER METAST REV, V30, P71, DOI 10.1007/s10555-011-9283-2; Madan RA, 2008, CLIN CANCER RES, V14, P4526, DOI 10.1158/1078-0432.CCR-07-5048; Madan RA, 2012, LANCET ONCOL, V13, P501, DOI 10.1016/S1470-2045(12)70006-2; Maio M, 2012, ANN ONCOL, V23, P367; Maluf FC, 2012, CLINICS, V67, P389, DOI 10.6061/clinics/2012(04)13; Marin-Aguilera M, 2012, MOL CANCER THER, V11, P329, DOI 10.1158/1535-7163.MCT-11-0289; McCourt CM, 2013, J CLIN PATHOL, V66, P58, DOI 10.1136/jclinpath-2012-201140; McDonnell AM, 2011, SEMIN IMMUNOPATHOL, V33, P353, DOI 10.1007/s00281-011-0246-z; Mercader M, 2001, P NATL ACAD SCI USA, V98, P14565, DOI 10.1073/pnas.251140998; Mokyr MB, 1998, CANCER RES, V58, P5301; NCCN Clinical Practice Guidelines in Oncology, 2012, NCCN CLIN PRACT GUID; Nilsson S, 2013, J CLIN ONCOL, V31, p317s; Nowak AK, 2003, CANCER RES, V63, P4490; Parker C, 2012, 2012 AM SOC CLIN ONC; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Pilones KA, 2009, CLIN CANCER RES, V15, P597, DOI 10.1158/1078-0432.CCR-08-1277; Prieto PA, 2012, CLIN CANCER RES, V18, P2039, DOI 10.1158/1078-0432.CCR-11-1823; Rathkopf DE, 2013, J CLIN ONCOL, V31, p310s; Risk Michael, 2009, Rev Urol, V11, P16; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Ross RW, 2008, CANCER-AM CANCER SOC, V112, P1247, DOI 10.1002/cncr.23304; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Sanda MG, 1999, UROLOGY, V53, P260, DOI 10.1016/S0090-4295(98)00539-1; Scher HI, 2013, J CLIN ONCOL, V31; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Sharma P, 2011, NAT REV CANCER, V11, P805, DOI 10.1038/nrc3153; Sheikh NA, 2013, CANCER IMMUNOL IMMUN, V62, P137, DOI 10.1007/s00262-012-1317-2; Shen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030815; Slovin SF, 2013, ANN ONCOL, V24, P1813, DOI 10.1093/annonc/mdt107; Slovin SR, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00043; Small E, 2006, J CLIN ONCOL S18, V24, P4609; Small EJ, 2013, J CLIN ONCOL, V31, p319s; Stevenson R, 2013, J CLIN ONCOL, V31; Sutherland JS, 2005, J IMMUNOL, V175, P2741, DOI 10.4049/jimmunol.175.4.2741; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Terry S, 2009, BRIT J CANCER, V101, P951, DOI 10.1038/sj.bjc.6605245; Tollefson MK, 2010, AM SOC CLIN ONC 2010; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; van den Eertwegh AJM, 2012, LANCET ONCOL, V13, P509, DOI 10.1016/S1470-2045(12)70007-4; Vanneman M, 2012, NAT REV CANCER, V12, P237, DOI 10.1038/nrc3237; Vicari AP, 2009, CANCER IMMUNOL IMMUN, V58, P615, DOI 10.1007/s00262-008-0586-2; Vogelzang NJ, 2013, J CLIN ONCOL, V31, p324s; Yuan JD, 2011, P NATL ACAD SCI USA, V108, P16723, DOI 10.1073/pnas.1110814108; Zitvogel L, 2008, J CLIN INVEST, V118, P1991, DOI 10.1172/JCI35180; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	110	34	37	1	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2014	33	43					5053	5064		10.1038/onc.2013.497	http://dx.doi.org/10.1038/onc.2013.497			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OF	24276248	Green Accepted			2023-01-03	WOS:000343768400001
J	Al-Chalabi, A				Al-Chalabi, Ammar			High-calorie diets in amyotrophic lateral sclerosis	LANCET			English	Editorial Material							DOUBLE-BLIND; TRIAL; DEXPRAMIPEXOLE; LITHIUM; PLACEBO		Kings Coll London, Inst Psychiat, London SE5 8AF, England	University of London; King's College London	Al-Chalabi, A (corresponding author), Kings Coll London, Inst Psychiat, London SE5 8AF, England.	ammar.al-chalabi@kcl.ac.uk	Al-Chalabi, Ammar/E-5361-2010	Al-Chalabi, Ammar/0000-0002-4924-7712	Medical Research Council [MR/L501529/1] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Allen C, 2013, LANCET NEUROL, V12, P339, DOI [10.1016/S1474-4422(13)70037-1, 10.1016/S1474-4422(13)700374]; Bouteloup C, 2009, J NEUROL, V256, P1236, DOI 10.1007/s00415-009-5100-z; Cudkowicz ME, 2013, LANCET NEUROL, V12, P1059, DOI 10.1016/S1474-4422(13)70221-7; Dupuis L, 2008, NEUROLOGY, V70, P1004, DOI 10.1212/01.wnl.0000285080.70324.27; Dupuis L, 2004, P NATL ACAD SCI USA, V101, P11159, DOI 10.1073/pnas.0402026101; Fang F, 2008, BRAIN, V131, P2729, DOI 10.1093/brain/awn161; Fornai F, 2008, P NATL ACAD SCI USA, V105, P2052, DOI 10.1073/pnas.0708022105; Johnston CA, 2006, J NEUROL, V253, P1642, DOI 10.1007/s00415-006-0195-y; Kasarskis EJ, 1996, AM J CLIN NUTR, V63, P130, DOI 10.1093/ajcn/63.1.130; Maessen M, 2010, J NEUROL, V257, P1192, DOI 10.1007/s00415-010-5474-y; Marin B, 2011, J NEUROL NEUROSUR PS, V82, P628, DOI 10.1136/jnnp.2010.211474; Rudnicki SA, 2013, AMYOTROPH LAT SCL FR, V14, P44, DOI 10.3109/17482968.2012.723723; Wicks P, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g368; Wills AM, 2014, LANCET	14	3	3	1	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2014	383	9934					2028	2030		10.1016/S0140-6736(14)60270-1	http://dx.doi.org/10.1016/S0140-6736(14)60270-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AI9VZ	24582470				2023-01-03	WOS:000337292400009
J	Vickers, AJ; Linde, K				Vickers, Andrew J.; Linde, Klaus			Acupuncture for Chronic Pain	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							OSTEOARTHRITIS	CLINICAL QUESTION Is acupuncture associated with reduced pain outcomes for patients with chronic pain compared with sham-acupuncture (placebo) or no-acupuncture control? BOTTOM LINE Acupuncture is associated with improved pain outcomes compared with sham-acupuncture and no-acupuncture control, with response rates of approximately 30% for no acupuncture, 42.5% for sham acupuncture, and 50% for acupuncture.	[Vickers, Andrew J.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; [Linde, Klaus] Tech Univ Munich, D-80290 Munich, Germany	Memorial Sloan Kettering Cancer Center; Technical University of Munich	Vickers, AJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 307 E 63rd St,Second Floor, New York, NY 10021 USA.	vickersa@mskcc.org		Linde, Klaus/0000-0002-2902-970X; Vickers, Andrew/0000-0003-1525-6503	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT004189] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT006794] Funding Source: NIH RePORTER; NCCIH NIH HHS [R21 AT004189I, R01 AT006794, R21 AT004189] Funding Source: Medline; NCI NIH HHS [P30 CA008748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		American Academy of Orthopaedic Surgeons, TREATMENT OF OSTEOAR; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Conaghan PG, 2008, BRIT MED J, V336, P502, DOI 10.1136/bmj.39490.608009.AD; Ezzo J, 2001, ARTHRITIS RHEUM, V44, P819, DOI 10.1002/1529-0131(200104)44:4<819::AID-ANR138>3.0.CO;2-P; Furlan AD, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001351.pub2; National Institute for Health and Clinical Excellence, HEADACHES; Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654	7	133	143	112	329	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	2014	311	9					955	956		10.1001/jama.2013.285478	http://dx.doi.org/10.1001/jama.2013.285478			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AC0FS	24595780	Green Accepted			2023-01-03	WOS:000332170800024
J	Donastorg, Y; Barrington, C; Perez, M; Kerrigan, D				Donastorg, Yeycy; Barrington, Clare; Perez, Martha; Kerrigan, Deanna			Abriendo Puertas: Baseline Findings from an Integrated Intervention to Promote Prevention, Treatment and Care among FSW Living with HIV in the Dominican Republic	PLOS ONE			English	Article							FEMALE SEX WORKERS; ANTIRETROVIRAL THERAPY; RISK BEHAVIOR; DEVELOPING-COUNTRIES; HIV/AIDS STIGMA; CONDOM USE; IMPACT; ADHERENCE; HEALTH; MEN	Female sex workers (FSW) are often the focus of primary HIV prevention efforts. However, little attention has been paid to the prevention, treatment, and care needs of FSW living with HIV. Based on formative research, we developed an integrated model to promote prevention and care for FSW living with HIV in Santo Domingo, Dominican Republic, including (1) individual counseling and education; (2) peer navigation; (3) clinical provider training; and (4) community mobilization. We enrolled 268 FSW living with HIV into the intervention and conducted socio-behavioral surveys, sexually transmitted infection (STI) testing, and viral load (VL) assessments. We used multivariate logistic regression to identify behavioral and socio-demographic factors associated with detectable VL (>50 copies/mL) and STI prevalence. Over half of all participants (51.9%) had a detectable VL, even though most received HIV-related care in the last 6 months (85.1%) and were currently on anti-retroviral treatment (ART) (72.4%). Factors positively associated with a detectable VL included being 18-35 years of age (Adjusted Odds Ratio [AOR] 2.46, 95% CI 1.31-4.60), having ever used drugs (AOR 2.34, 95% CI 1.14-4.79), and having ever interrupted ART (AOR 3.09, 95% CI 1.44-6.59). Factors protective against having a detectable VL included being single (AOR 0.45, 95% 0.20-0.98) and being currently on ART (AOR 0.17, 95% CI 0.07-0.41). Nearly one-quarter (23.1%) had an STI, which was associated with being single (AOR 3.21, 95% CI 1.27-8.11) and using drugs in the last 6 months (AOR 3.54, 95% CI 1.32-9.45). Being on ART was protective against STI (AOR 0.51, 95% CI 0.26-1.00). Baseline findings indicate significant barriers to VL suppression and STI prevention among FSW living with HIV and highlight gaps in the continuum of HIV care and treatment. These findings have important implications for both the individual health of FSW and population-level HIV transmission dynamics.	[Donastorg, Yeycy; Perez, Martha] Inst Dermatal & Cirugia Piel Dr Humberto Bogart D, HIV Vaccine Res Unit, Santo Domingo, Dominican Rep; [Barrington, Clare] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Behav, Chapel Hill, NC USA; [Kerrigan, Deanna] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD 21205 USA	University of North Carolina; University of North Carolina Chapel Hill; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Kerrigan, D (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD 21205 USA.	dkerriga@jhsph.edu	Barrington, Clare/AAM-4909-2021		U.S. Agency for International Development [GHH-I-00-07-00032-00]; President's Emergency Plan for AIDS Relief; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD050924] Funding Source: NIH RePORTER	U.S. Agency for International Development(United States Agency for International Development (USAID)); President's Emergency Plan for AIDS Relief(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The study was funded by the U.S. Agency for International Development (http://www. usaid. gov/) under Contract No. GHH-I-00-07-00032-00, beginning September 30, 2008, and supported by the President's Emergency Plan for AIDS Relief. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbas UL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000875; Amuri M, 2011, AIDS CARE, V23, P378, DOI 10.1080/09540121.2010.507739; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Baral S, 2012, LANCET INFECT DIS, V12, P538, DOI 10.1016/S1473-3099(12)70066-X; Baral S, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-36; Barrington C, 2009, SOC SCI MED, V68, P2037, DOI 10.1016/j.socscimed.2009.03.009; BASTOS FIP, 2009, PUBLIC HLTH ASPECTS, P629; Beattie TSH, 2012, J EPIDEMIOL COMMUN H, V66, pII42, DOI 10.1136/jech-2011-200475; Berger BE, 2001, RES NURS HEALTH, V24, P518, DOI 10.1002/nur.10011; Beyrer C, 2011, JAIDS-J ACQ IMM DEF, V57, pS96, DOI 10.1097/QAI.0b013e31821db944; Celum C, 2013, J INFECT DIS, V208, P189, DOI 10.1093/infdis/jit154; Chesney MA, 2000, CLIN INFECT DIS, V30, pS171, DOI 10.1086/313849; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; *COPRESIDA, 2008, LER ENC VIG COMP VIN; Cornish F, 2009, AM J COMMUN PSYCHOL, V44, P123, DOI 10.1007/s10464-009-9254-8; Desai K, 2008, AIDS, V22, P1829, DOI 10.1097/QAD.0b013e32830e00f5; Diabate S, 2011, WORLD J AIDS, V1, P94, DOI [10.4236/wja.2011.13014, DOI 10.4236/WJA.2011.13014]; *EMP WOM SHE, STRONG HIV POS; Forsyth AD, 2012, CURR OPIN HIV AIDS, V7, P111, DOI 10.1097/COH.0b013e32834fcff6; GHIMIRE L, 2009, GLOBAL J HLTH SCI, V1, pP12; Gupta GR, 2008, LANCET, V372, P764, DOI 10.1016/S0140-6736(08)60887-9; Hadland SE, 2012, AIDS PATIENT CARE ST, V26, P274, DOI 10.1089/apc.2011.0196; Halperin DT, 2009, JAIDS-J ACQ IMM DEF, V51, pS52, DOI 10.1097/QAI.0b013e3181a267e4; Hodgson I, 2012, AIDS CARE, V24, P1204, DOI 10.1080/09540121.2012.658755; Holtgrave DR, 2012, AIDS BEHAV, V16, P1085, DOI 10.1007/s10461-012-0186-1; Jana S, 2004, AIDS EDUC PREV, V16, P405, DOI 10.1521/aeap.16.5.405.48734; Kennedy C, 2007, AIDS CARE, V19, P707, DOI 10.1080/09540120701203261; Kennedy C., 2013, EXPLORING POSITIVE H; Kennedy CE, 2010, B WORLD HEALTH ORGAN, V88, P615, DOI 10.2471/BLT.09.068213; Kerrigan D, 2006, AM J PUBLIC HEALTH, V96, P120, DOI 10.2105/AJPH.2004.042200; Kerrigan D, 2013, DIR DEV, P1, DOI 10.1596/978-0-8213-9774-9; Kerrigan D., 2001, Culture, Health & Sexuality, V3, P221, DOI 10.1080/136910501750153049; KERRIGAN D, 2009, PUBLIC HLTH ASPECTS, P655; KERRIGAN D, 2013, LANCET; Kerrigan DL, 2013, AIDS BEHAV, V17, P1926, DOI 10.1007/s10461-013-0458-4; McClelland L, 2011, AIDS EDUC PREV, V23, P299, DOI 10.1521/aeap.2011.23.4.299; McClelland RS, 2010, AIDS, V24, P891, DOI 10.1097/QAD.0b013e32833616c7; Murray L, 2007, AIDS BEHAV, V11, P463, DOI 10.1007/s10461-006-9184-5; Nachega JB, 2009, JAIDS-J ACQ IMM DEF, V51, P65, DOI 10.1097/QAI.0b013e318199072e; Parker R, 2003, SOC SCI MED, V57, P13, DOI 10.1016/S0277-9536(02)00304-0; Reidpath DD, 2005, AIDS CARE, V17, P425, DOI 10.1080/09540120412331319769; Scambler G, 2008, SOC SCI MED, V66, P1848, DOI 10.1016/j.socscimed.2008.01.002; UNAIDS, 2009, UNAIDS GUID NOT HIV; *UNAIDS, 2002, UNAIDS TECHN UPD SEX; Wariki WMV, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005272.pub3; World Health Organization, 2011, PREV HIV SEX WORK SU; World Health Organization, 2004, WORLD HLTH REP 2004; Zelaya CE, 2008, AIDS BEHAV, V12, P781, DOI 10.1007/s10461-007-9331-7	48	40	40	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2014	9	2							e88157	10.1371/journal.pone.0088157	http://dx.doi.org/10.1371/journal.pone.0088157			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AA7IR	24551079	Green Published, gold			2023-01-03	WOS:000331271500030
J	Ottenbacher, KJ; Karmarkar, A; Graham, JE; Kuo, YF; Deutsch, A; Reistetter, TA; Al Snih, S; Granger, CV				Ottenbacher, Kenneth J.; Karmarkar, Amol; Graham, James E.; Kuo, Yong-Fang; Deutsch, Anne; Reistetter, Timothy A.; Al Snih, Soham; Granger, Carl V.			Thirty-Day Hospital Readmission Following Discharge From Postacute Rehabilitation in Fee-for-Service Medicare Patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FUNCTIONAL INDEPENDENCE MEASURE; QUALITY; PAYMENT; CARE; REHOSPITALIZATIONS; RELIABILITY; DISPARITIES; SYSTEM; RATES; COST	IMPORTANCE The Centers for Medicare & Medicaid Services recently identified 30-day readmission after discharge from inpatient rehabilitation facilities as a national quality indicator. Research is needed to determine the rates and factors related to readmission in this patient population. OBJECTIVE To determine 30-day readmission rates and factors related to readmission for patients receiving postacute inpatient rehabilitation. DESIGN, SETTING, AND PATIENTS Retrospective cohort study of records for 736 536 Medicare fee-for-service beneficiaries (mean age, 78.0 [SD, 7.3] years) discharged from 1365 inpatient rehabilitation facilities to the community in 2006 through 2011. Sixty-three percent of patients were women, and 85.1% were non-Hispanic white. MAIN OUTCOMES AND MEASURES Thirty-day readmission rates for the 6 largest diagnostic impairment categories receiving inpatient rehabilitation. These included stroke, lower extremity fracture, lower extremity joint replacement, debility, neurologic disorders, and brain dysfunction. RESULTS Mean rehabilitation length of stay was 12.4 (SD, 5.3) days. The overall 30-day readmission rate was 11.8%(95% CI, 11.7%-11.8%). Rates ranged from 5.8% (95% CI, 5.8%-5.9%) for patients with lower extremity joint replacement to 18.8% (95% CI, 18.8%-18.9%). for patients with debility. Rates were highest in men (13.0%[95% CI, 12.8%-13.1%], vs 11.0%[95% CI, 11.0%-11.1%] in women), non-Hispanic blacks (13.8% [95% CI, 13.5%-14.1%], vs 11.5%[95% CI, 11.5%-11.6%] in whites, 12.5%[95% CI, 12.1%-12.8%] in Hispanics, and 11.9%[95% CI, 11.4%-12.4%] in other races/ethnicities), beneficiaries with dual eligibility (15.1%[95% CI, 14.9%-15.4%], vs 11.1%[95% CI, 11.0%-11.2%] for no dual eligibility), and in patients with tier 1 comorbidities (25.6%[95% CI, 24.9%-26.3%], vs 18.9%[95% CI, 18.5%-19.3%] for tier 2, 15.1%[95% CI, 14.9%-15.3%] for tier 3, and 9.9% [95% CI, 9.9%-10.0%] for no tier comorbidities). Higher motor and cognitive functional status were associated with lower hospital readmission rates across the 6 impairment categories. Adjusted readmission rates by state ranged from 9.2% to 13.6%. Approximately 50% of patients rehospitalized within the 30-day period were readmitted within 11 days of discharge. Medicare Severity Diagnosis-Related Group codes for heart failure, urinary tract infection, pneumonia, septicemia, nutritional and metabolic disorders, esophagitis, gastroenteritis, and digestive disorders were common reasons for readmission. CONCLUSIONS AND RELEVANCE Among postacute rehabilitation facilities providing services to Medicare fee-for-service beneficiaries, 30-day readmission rates ranged from 5.8% to 18.8% for selected impairment groups. Further research is needed to understand the causes of readmission.	[Ottenbacher, Kenneth J.; Karmarkar, Amol; Graham, James E.; Al Snih, Soham] Univ Texas Med Branch UTMB, Div Rehabil Sci, Galveston, TX USA; [Kuo, Yong-Fang] UTMB, Dept Prevent Med & Community Hlth, Galveston, TX USA; [Deutsch, Anne] RTI Int, Washington, DC USA; [Deutsch, Anne] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Reistetter, Timothy A.] UTMB, Dept Occupat Therapy, Galveston, TX USA; [Granger, Carl V.] Uniform Data Syst Med Rehabil, Buffalo, NY USA; [Granger, Carl V.] SUNY Buffalo, Dept Med, Buffalo, NY 14260 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Research Triangle Institute; Shirley Ryan AbilityLab; University of Texas System; University of Texas Medical Branch Galveston; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ottenbacher, KJ (corresponding author), Univ Texas Med Branch, 301 Univ Blvd, Galveston, TX 77555 USA.	kottenba@utmb.edu	Deutsch, Anne/B-7530-2017; Al Snih, Soham/ABC-2882-2020; Karmarkar, Amol/E-6030-2011	Deutsch, Anne/0000-0003-2290-7757; Karmarkar, Amol/0000-0001-8355-1585; Ottenbacher, Kenneth/0000-0001-5990-3982; Al Snih, Soham/0000-0002-0681-4641	National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Center for Medical Rehabilitation Research [R24-HD065702, R01-HD069443, K01-HD068513]; National Center for Advancing Translational Sciences [UL1RR029876]; Agency for Healthcare Research and Quality [R24-HS022134]; National Institute on Disability and Rehabilitation Research, Department of Education [H133G080163]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R24HS022134] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K01HD068513, R24HD065702, R01HD069443] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR029876] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG024832] Funding Source: NIH RePORTER	National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Center for Medical Rehabilitation Research; National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Institute on Disability and Rehabilitation Research, Department of Education; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Center for Medical Rehabilitation Research (R24-HD065702, R01-HD069443, and K01-HD068513), by a Clinical and Translational Science Award from the National Center for Advancing Translational Sciences (UL1RR029876), by the Agency for Healthcare Research and Quality (R24-HS022134), and by the National Institute on Disability and Rehabilitation Research, Department of Education (H133G080163).	3MHealth Information Systems, 2013, THE IMPACT OF DISABI; American Hospital Association, 2010, TRENDWATCH MAXIMIZIN; American Hospital Association, 2013, ISSUE BRIEF MOVING T; [Anonymous], 2001, INPATIENT REHABILITA; [Anonymous], 2011, REPORT NO 76; Axon RN, 2011, JAMA-J AM MED ASSOC, V305, P504, DOI 10.1001/jama.2011.72; Brock J, 2013, JAMA-J AM MED ASSOC, V309, P381, DOI 10.1001/jama.2012.216607; Carter G, 2005, TR 201 CMS; Carter GM, 2003, HEALTH CARE FINANC R, V24, P25; Centers for Medicare & Medicaid Services, 2013, SPECIFICATIONS FOR T; Centers for Medicare & Medicaid Services (CMS) HHS, 2013, Fed Regist, V78, P47859; Chan L, 1997, NEW ENGL J MED, V337, P978, DOI 10.1056/NEJM199710023371406; Chandra A, 2013, HEALTH AFFAIR, V32, P864, DOI 10.1377/hlthaff.2012.1262; Chen LM, 2010, ARCH INTERN MED, V170, P340, DOI 10.1001/archinternmed.2009.511; DeJong G, 2010, PHYS THER, V90, P658, DOI 10.2522/ptj.2010.90.5.658; Deutsch A, 2012, REPORT 0212050; Fiscella K, 2000, JAMA-J AM MED ASSOC, V283, P2579, DOI 10.1001/jama.283.19.2579; Galloway RV, 2013, AM J PHYS MED REHAB, V92, P14, DOI 10.1097/PHM.0b013e31827441bc; Goodman D, 2013, THE REVOLVING DOOR A; Granger CV, 2007, AM J PHYS MED REHAB, V86, P883, DOI 10.1097/PHM.0b013e318152058a; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Hussey P, 2012, EVIDENCE REPORT TECH; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Joynt KE, 2013, NEW ENGL J MED, V368, P1175, DOI 10.1056/NEJMp1300122; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Krumholz HM, 2009, CIRC-CARDIOVASC QUAL, V2, P407, DOI 10.1161/CIRCOUTCOMES.109.883256; Li Y, 2011, AM J PUBLIC HEALTH, V101, P875, DOI 10.2105/AJPH.2010.300055; Lichtman JH, 2010, STROKE, V41, P2525, DOI 10.1161/STROKEAHA.110.599159; McNutt Robert, 2010, Qual Manag Health Care, V19, P17, DOI 10.1097/QMH.0b013e3181ccbd07; Mechanic R, 2012, NEW ENGL J MED, V367, P1873, DOI 10.1056/NEJMp1210823; Medicare Payment Advisory Comission (MedPAC), 2013, REPORT TO THE CONGRE; MedPAC, 2012, REPORT TO THE CONGRE; MedPAC, 2013, REPORT TO THE CONGRE; Newhouse JP, 2013, NEW ENGL J MED, V368, P1465, DOI 10.1056/NEJMp1302981; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Smedley BD, 2003, UNEQUAL TREATMENT CO, DOI [10.17226/12875, DOI 10.17226/12875]; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; van Walraven C, 2012, J CLIN EPIDEMIOL, V65, P126, DOI 10.1016/j.jclinepi.2011.08.002	39	114	114	0	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	2014	311	6					604	614		10.1001/jama.2014.8	http://dx.doi.org/10.1001/jama.2014.8			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AA2RE	24519300	Bronze, Green Accepted			2023-01-03	WOS:000330941000016
J	Zhou, PH; Shaffer, DR; Arias, DAA; Nakazaki, Y; Pos, W; Torres, AJ; Cremasco, V; Dougan, SK; Cowley, GS; Elpek, K; Brogdon, J; Lamb, J; Turley, SJ; Ploegh, HL; Root, DE; Love, JC; Dranoff, G; Hacohen, N; Cantor, H; Wucherpfennig, KW				Zhou, Penghui; Shaffer, Donald R.; Arias, Diana A. Alvarez; Nakazaki, Yukoh; Pos, Wouter; Torres, Alexis J.; Cremasco, Viviana; Dougan, Stephanie K.; Cowley, Glenn S.; Elpek, Kutlu; Brogdon, Jennifer; Lamb, John; Turley, Shannon J.; Ploegh, Hidde L.; Root, David E.; Love, J. Christopher; Dranoff, Glenn; Hacohen, Nir; Cantor, Harvey; Wucherpfennig, Kai W.			In vivo discovery of immunotherapy targets in the tumour microenvironment	NATURE			English	Article							CD8+ T-CELLS; PROGNOSTIC-FACTORS; IMMUNE CELLS; CANCER; MELANOMA; PHOSPHATASE; SUPPRESSORS; LYMPHOCYTES; PROTEINS; SURVIVAL	Recent clinical trials showed that targeting of inhibitory receptors on T cells induces durable responses in a subset of cancer patients, despite advanced disease. However, the regulatory switches controlling T-cell function in immunosuppressive tumours are not well understood. Here we show that such inhibitory mechanisms can be systematically discovered in the tumour microenvironment. We devised an in vivo pooled short hairpin RNA (shRNA) screen in which shRNAs targeting negative regulators became highly enriched in murine tumours by releasing a block on T-cell proliferation upon tumour antigen recognition. Such shRNAs were identified by deep sequencing of the shRNA cassette from T cells infiltrating tumour or control tissues. One of the target genes was Ppp2r2d, a regulatory subunit of the PP2A phosphatase family. In tumours, Ppp2r2d knockdown inhibited T-cell apoptosis and enhanced T-cell proliferation as well as cytokine production. Key regulators of immune function can therefore be discovered in relevant tissue microenvironments.	[Zhou, Penghui; Shaffer, Donald R.; Arias, Diana A. Alvarez; Nakazaki, Yukoh; Pos, Wouter; Cremasco, Viviana; Elpek, Kutlu; Turley, Shannon J.; Dranoff, Glenn; Cantor, Harvey; Wucherpfennig, Kai W.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Torres, Alexis J.; Love, J. Christopher] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02142 USA; [Dougan, Stephanie K.; Ploegh, Hidde L.] MIT, Whitehead Inst, Cambridge, MA 02142 USA; [Cowley, Glenn S.; Root, David E.; Hacohen, Nir] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Brogdon, Jennifer] Novartis Inst Biomed Res, Cambridge, MA 02139 USA; [Lamb, John] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA	Harvard University; Dana-Farber Cancer Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Novartis; Novartis	Wucherpfennig, KW (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.	kai_wucherpfennig@dfci.harvard.edu		zhou, penghui/0000-0003-0519-461X	National Institutes of Health [1R01CA173750]; Melanoma Research Alliance; DF/HCC-MIT Bridge Project; Lustgarten Foundation; Novartis Institutes of Biomedical Research; Koch Institute from the National Cancer Institute [P30-CA14051]; American Cancer Society; Terri Brodeur Breast Cancer Foundation; NIH [AI07386]; NATIONAL CANCER INSTITUTE [P30CA014051, R01CA173750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI045757, T32AI007386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [DP3DK097681] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Melanoma Research Alliance; DF/HCC-MIT Bridge Project; Lustgarten Foundation; Novartis Institutes of Biomedical Research; Koch Institute from the National Cancer Institute; American Cancer Society(American Cancer Society); Terri Brodeur Breast Cancer Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the National Institutes of Health (Transformative Research Award 1R01CA173750 to K.W.W.), the Melanoma Research Alliance (to K.W.W.), the DF/HCC-MIT Bridge Project and the Lustgarten Foundation (to K.W.W., J.C.L. and H.L.P.), Novartis Institutes of Biomedical Research (to K.W.W.), the Koch Institute Support Grant P30-CA14051 from the National Cancer Institute, the American Cancer Society John W. Thatcher, Jr Postdoctoral Fellowship in Melanoma Research (to D.R.S.), the Terri Brodeur Breast Cancer Foundation Postdoctoral Fellowship (to P.Z.) and a NIH T32 grant (AI07386 to D.A.A.A.).	Ashton JM, 2012, CELL STEM CELL, V11, P359, DOI 10.1016/j.stem.2012.05.024; Barr FA, 2011, J CELL SCI, V124, P2323, DOI 10.1242/jcs.087106; Bellone M, 2000, J IMMUNOL, V165, P2651, DOI 10.4049/jimmunol.165.5.2651; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brenner MK, 2010, CURR OPIN IMMUNOL, V22, P251, DOI 10.1016/j.coi.2010.01.020; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; Chuang E, 2000, IMMUNITY, V13, P313, DOI 10.1016/S1074-7613(00)00031-5; Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107; Doody KM, 2009, IMMUNOL REV, V228, P325, DOI 10.1111/j.1600-065X.2008.00743.x; DuPage M, 2012, NATURE, V482, P405, DOI 10.1038/nature10803; Eitelhuber AC, 2011, EMBO J, V30, P594, DOI 10.1038/emboj.2010.331; FIDLER IJ, 1975, CANCER RES, V35, P218; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gerber SA, 2003, P NATL ACAD SCI USA, V100, P6940, DOI 10.1073/pnas.0832254100; Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104; Han Q, 2010, LAB CHIP, V10, P1391, DOI 10.1039/b926849a; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Johnson LA, 2009, BLOOD, V114, P535, DOI 10.1182/blood-2009-03-211714; Kalos M, 2013, IMMUNITY, V39, P49, DOI 10.1016/j.immuni.2013.07.002; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; Mochida S, 2010, SCIENCE, V330, P1670, DOI 10.1126/science.1195689; Muranski P, 2008, BLOOD, V112, P362, DOI 10.1182/blood-2007-11-120998; Oble Darryl A, 2009, Cancer Immun, V9, P3; Overwijk WW, 2003, J EXP MED, V198, P569, DOI 10.1084/jem.20030590; Pages F, 2009, J CLIN ONCOL, V27, P5944, DOI 10.1200/JCO.2008.19.6147; Paolino M, 2010, SEMIN IMMUNOPATHOL, V32, P137, DOI 10.1007/s00281-010-0197-9; Restifo NP, 2012, NAT REV IMMUNOL, V12, P269, DOI 10.1038/nri3191; Rusakiewicz S, 2013, CANCER RES, V73, P3499, DOI 10.1158/0008-5472.CAN-13-0371; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Shiao SL, 2011, GENE DEV, V25, P2559, DOI 10.1101/gad.169029.111; Stumpf M, 2009, BRIT J CANCER, V101, P1513, DOI 10.1038/sj.bjc.6605274; Tamiya T, 2011, ARTERIOSCL THROM VAS, V31, P980, DOI 10.1161/ATVBAHA.110.207464; Tanchot C, 2013, CANCER MICROENVIRON, V6, P147, DOI 10.1007/s12307-012-0122-y; Tao J, 2007, EUR J IMMUNOL, V37, P818, DOI 10.1002/eji.200636726; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Torres AJ, 2013, LAB CHIP, V13, P90, DOI 10.1039/c2lc40869d; Turtle CJ, 2012, CURR OPIN IMMUNOL, V24, P633, DOI 10.1016/j.coi.2012.06.004; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061; Zheng Y, 2008, EMBO REP, V9, P50, DOI 10.1038/sj.embor.7401138	48	151	158	2	145	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 6	2014	506	7486					52	+		10.1038/nature12988	http://dx.doi.org/10.1038/nature12988			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BA	24476824	Green Accepted, Green Submitted			2023-01-03	WOS:000330648100029
J	Wan, GH; Wu, CL; Chen, YF; Huang, SH; Wang, YL; Chen, CW				Wan, Gwo-Hwa; Wu, Chieh-Liang; Chen, Yi-Fang; Huang, Sheng-Hsiu; Wang, Yu-Ling; Chen, Chun-Wan			Particle Size Concentration Distribution and Influences on Exhaled Breath Particles in Mechanically Ventilated Patients	PLOS ONE			English	Article								Humans produce exhaled breath particles (EBPs) during various breath activities, such as normal breathing, coughing, talking, and sneezing. Airborne transmission risk exists when EBPs have attached pathogens. Until recently, few investigations had evaluated the size and concentration distributions of EBPs from mechanically ventilated patients with different ventilation mode settings. This study thus broke new ground by not only evaluating the size concentration distributions of EBPs in mechanically ventilated patients, but also investigating the relationship between EBP level and positive expiratory end airway pressure (PEEP), tidal volume, and pneumonia. This investigation recruited mechanically ventilated patients, with and without pneumonia, aged 20 years old and above, from the respiratory intensive care unit of a medical center. Concentration distributions of EBPs from mechanically ventilated patients were analyzed with an optical particle analyzer. This study finds that EBP concentrations from mechanically ventilated patients during normal breathing were in the range 0.47-2,554.04 particles/breath (0.001-4.644 particles/mL). EBP concentrations did not differ significantly between the volume control and pressure control modes of the ventilation settings in the mechanically ventilated patients. The patient EBPs were sized below 5 mu m, and 80% of them ranged from 0.3 to 1.0 mu m. The EBPs concentrations in patients with high PEEP (> 5 cmH(2)O) clearly exceeded those in patients with low PEEP (<= 5 cmH(2)O). Additionally, a significant negative association existed between pneumonia duration and EBPs concentration. However, tidal volume was not related to EBPs concentration.	[Wan, Gwo-Hwa] Chang Gung Univ, Coll Med, Dept Resp Therapy, Tao Yuan, Taiwan; [Wu, Chieh-Liang] Taichung Vet Gen Hosp, Dept Internal Med, Chiayi Branch, Chiayi, Taiwan; [Chen, Yi-Fang] Chung Shan Med Univ Hosp, Dept Resp Therapy, Taichung, Taiwan; [Huang, Sheng-Hsiu] Natl Taiwan Univ, Coll Publ Hlth, Inst Occupat Med & Ind Hyg, Taipei 10764, Taiwan; [Wang, Yu-Ling] Taichung Vet Gen Hosp, Dept Resp Therapy, Taichung, Taiwan; [Chen, Chun-Wan] Council Labor Affairs, Inst Occupat Safety & Hlth, New Taipei City, Taiwan	Chang Gung University; Taichung Veterans General Hospital; Chung Shan Medical University; Chung Shan Medical University Hospital; National Taiwan University; Taichung Veterans General Hospital	Wan, GH (corresponding author), Chang Gung Univ, Coll Med, Dept Resp Therapy, Tao Yuan, Taiwan.	ghwan@mail.cgu.edu.tw		HUANG, SHENG-HSIU/0000-0003-1372-0480	Institute of Occupational Safety and Health of Taiwan [GMRPD1A0051, GMRPD1B0051]	Institute of Occupational Safety and Health of Taiwan	This study was supported by grants GMRPD1A0051 and GMRPD1B0051 from the Institute of Occupational Safety and Health of Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almstrand AC, 2010, J APPL PHYSIOL, V108, P584, DOI 10.1152/japplphysiol.00873.2009; Chao CYH, 2009, J AEROSOL SCI, V40, P122, DOI 10.1016/j.jaerosci.2008.10.003; Cheng CK, 2010, EDUC COMPET GLOB WOR, P1; DUGUID JP, 1946, J HYG-CAMBRIDGE, V44, P471, DOI 10.1017/S0022172400019288; Edward DA, 2006, INHALING CATIONIC AE; Edwards DA, 2004, P NATL ACAD SCI USA, V101, P17383, DOI 10.1073/pnas.0408159101; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Esteban A, 2000, AM J RESP CRIT CARE, V161, P1450, DOI 10.1164/ajrccm.161.5.9902018; Fabian P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002691; FAIRCHILD CI, 1987, AM IND HYG ASSOC J, V48, P948, DOI 10.1080/15298668791385868; Fennelly KP, 2004, AM J RESP CRIT CARE, V169, P604, DOI 10.1164/rccm.200308-1101OC; Holmgren H, 2013, RESP PHYSIOL NEUROBI, V185, P228, DOI 10.1016/j.resp.2012.10.010; Johnson GR, 2009, J AEROSOL MED PULM D, V22, P229, DOI 10.1089/jamp.2008.0720; Morawska L, 2009, J AEROSOL SCI, V40, P256, DOI 10.1016/j.jaerosci.2008.11.002; Papineni R S, 1997, J Aerosol Med, V10, P105, DOI 10.1089/jam.1997.10.105; Schwarz K, 2010, J AEROSOL MED PULM D, V23, P371, DOI 10.1089/jamp.2009.0809; Xie XJ, 2009, J R SOC INTERFACE, V6, pS703, DOI 10.1098/rsif.2009.0388.focus; Yang SH, 2007, J AEROSOL MED, V20, P484, DOI 10.1089/jam.2007.0610	18	19	22	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2014	9	1							e87088	10.1371/journal.pone.0087088	http://dx.doi.org/10.1371/journal.pone.0087088			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301BI	24475230	Green Published, Green Submitted, gold			2023-01-03	WOS:000330507300137
J	Xia, H; Wang, XJ; Zhou, Q; Shi, HZ; Tong, ZH				Xia, Huan; Wang, Xiao-Juan; Zhou, Qiong; Shi, Huan-Zhong; Tong, Zhao-Hui			Efficacy and Safety of Talc Pleurodesis for Malignant Pleural Effusion: A Meta-Analysis	PLOS ONE			English	Article							PROSPECTIVE RANDOMIZED-TRIAL; 1ST CHOICE MANAGEMENT; QUALITY-OF-LIFE; CHEMICAL PLEURODESIS; BREAST-CARCINOMA; BLEOMYCIN; SLURRY; CATHETER; TETRACYCLINE; POUDRAGE	Background: Talc pleurodesis has been widely used to control malignant pleural effusion; however, it is still not clear whether talc pleurodesis is more effective than other local therapies. We performed a meta-analysis to evaluate the efficacy and safety of talc pleurodesis in the management of malignant pleural effusion. Methods: PubMed, Embase, and Web of Science were searched for English-language studies of clinical controlled trials comparing talc pleurodesis with control therapies until August 8, 2013. Success rate and incidence of adverse events were evaluated. Relative risks were estimated using random-or fixed-effects model and statistical heterogeneity was assessed using I-2 test. Results: Twenty trials involving 1,525 patients with malignant pleural effusion were included. The success rate of talc pleurodesis was significantly higher than that of control therapies (relative risk, 1.21; 95% confidence interval, 1.01-1.45; p = 0.035) with similar adverse events. In addition, thoracoscopic talc poudrage was more effective than bedside talc slurry (relative risk, 1.12; 95% confidence interval, 1.01-1.23; p = 0.026). Conclusions: The current evidences suggested the benefit for talc pleurodesis in the treatment of malignant pleural effusion. Talc pleurodesis, especially thoracoscopic talc poudrage pleurodesis, should be performed in patients with malignant pleural effusion, especially those with life-expectancy longer than one month.	[Xia, Huan; Wang, Xiao-Juan; Shi, Huan-Zhong; Tong, Zhao-Hui] Capital Med Univ, Beijing Chaoyang Hosp, Beijing Inst Resp Med, Dept Resp & Crit Care Med, Beijing, Peoples R China; [Zhou, Qiong] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Resp & Crit Care Med, Wuhan 430074, Peoples R China; [Shi, Huan-Zhong] Capital Med Univ, Beijing Chaoyang Hosp, Med Res Ctr, Beijing, Peoples R China	Capital Medical University; Huazhong University of Science & Technology; Capital Medical University	Tong, ZH (corresponding author), Capital Med Univ, Beijing Chaoyang Hosp, Beijing Inst Resp Med, Dept Resp & Crit Care Med, Beijing, Peoples R China.	tongzhaohuicy@sina.com			Beijing High-Grade Talents Health Technology Fund [2011-2-06]; Beijing Municipal Science & Technology Commission [Z131107002213107]	Beijing High-Grade Talents Health Technology Fund; Beijing Municipal Science & Technology Commission(Beijing Municipal Science & Technology Commission)	This work was supported in part by a grant from the Beijing High-Grade Talents Health Technology Fund (NO. 2011-2-06) and in part by a grant from Beijing Municipal Science & Technology Commission (NO. Z131107002213107). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal R, 2011, RESPIROLOGY, V16, P1064, DOI 10.1111/j.1440-1843.2011.01999.x; Antony VB, 2000, AM J RESP CRIT CARE, V162, P1987, DOI 10.1164/ajrccm.162.5.ats8-00; Bernard A, 2002, ANN THORAC SURG, V74, P213, DOI 10.1016/S0003-4975(02)03599-3; Brega-Massone PP, 2004, SURG LAPARO ENDO PER, V14, P73, DOI 10.1097/00129689-200404000-00005; Brega-Massone PP, 2004, THORAC CARDIOV SURG, V52, P191, DOI 10.1055/s-2004-820869; Burrows CM, 2000, CHEST, V117, P73, DOI 10.1378/chest.117.1.73; Clarke MJ., 2001, SYSTEMATIC REV HLTH, P109; Crnjac A, 2004, EUR J CARDIO-THORAC, V26, P432, DOI 10.1016/j.ejcts.2004.03.010; Crnjac A, 2010, ZDR VESTN, V79, P272; Das Sibes Kumar, 2008, J Indian Med Assoc, V106, P589; Davies HE, 2012, JAMA-J AM MED ASSOC, V307, P2383, DOI 10.1001/jama.2012.5535; Demmy TL, 2012, J NATL COMPR CANC NE, V10, P975, DOI 10.6004/jnccn.2012.0102; Diacon AH, 2000, AM J RESP CRIT CARE, V162, P1445, DOI 10.1164/ajrccm.162.4.2002030; Diez-Porres L, 2008, PALLIATIVE MED, V22, P775, DOI 10.1177/0269216308095020; Dresler CM, 2005, CHEST, V127, P909, DOI 10.1378/chest.127.3.909; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; FENTIMAN IS, 1986, EUR J CANCER CLIN ON, V22, P1079, DOI 10.1016/0277-5379(86)90009-X; FENTIMAN IS, 1983, CANCER, V52, P737, DOI 10.1002/1097-0142(19830815)52:4<737::AID-CNCR2820520428>3.0.CO;2-8; Haddad FJ, 2004, WORLD J SURG, V28, P749, DOI 10.1007/s00268-004-7269-8; HAMED H, 1989, BRIT J SURG, V76, P1266, DOI 10.1002/bjs.1800761214; HARTMAN DL, 1993, J THORAC CARDIOV SUR, V105, P743; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Kastelik JA, 2013, LUNG, V191, P165, DOI 10.1007/s00408-012-9445-1; Khaleeq G, 2008, RESP MED, V102, P939, DOI 10.1016/j.rmed.2008.01.022; Kilic D, 2005, SURG TODAY, V35, P634, DOI 10.1007/s00595-005-2996-5; Kuzdzal Jaroslaw, 2003, Med Sci Monit, V9, pPI54; Lee P., 2012, CHEST, V142, P20; Lee P, 2012, CHEST, V142, P15, DOI 10.1378/chest.12-1085; Light RW, 2012, CHEST, V142, P17, DOI 10.1378/chest.12-1087; Light RW, 2000, AM J RESP CRIT CARE, V162, P2024, DOI 10.1164/ajrccm.162.6.pc09-00b; Lynch TJ, 1996, INT J ONCOL, V8, P183; Maceachern P, 2011, RESPIROLOGY, V16, P747, DOI 10.1111/j.1440-1843.2011.01986.x; Martinez-Moragon E, 1998, RESPIRATION, V65, P108, DOI 10.1159/000029240; Mohsen TA, 2011, EUR J CARDIO-THORAC, V40, P282, DOI 10.1016/j.ejcts.2010.09.005; Najmunnisa N, 2007, EUR RESPIR J, V29, P761, DOI 10.1183/09031936.00061606; Nasreen N, 2000, AM J RESP CRIT CARE, V161, P595, DOI 10.1164/ajrccm.161.2.9904123; Noppen M, 1997, ACTA CLIN BELG, V52, P258, DOI 10.1080/17843286.1997.11718587; Ohm C, 2003, AM SURGEON, V69, P198; Ong K C, 2000, Respirology, V5, P99, DOI 10.1046/j.1440-1843.2000.00235.x; Ozyurtkan MO, 2010, EUR J INTERN MED, V21, P30, DOI 10.1016/j.ejim.2009.09.012; Paschoalini MD, 2005, CHEST, V128, P684, DOI 10.1378/chest.128.2.684; Rehse DH, 1999, AM J SURG, V177, P437, DOI 10.1016/S0002-9610(99)00075-6; Roberts ME, 2010, THORAX, V65, P32, DOI 10.1136/thx.2010.136994; Rodriguez-Panadero F, 2012, RESPIRATION, V83, P91, DOI 10.1159/000335419; Saha SK, 2008, J INDIAN MED ASSOC, V106, P592; Shaw P, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002916.PUB2; SORENSEN PG, 1984, EUR J RESPIR DIS, V65, P131; Spiegler PA, 2003, CHEST, V123, P1895, DOI 10.1378/chest.123.6.1895; Stefani A, 2006, EUR J CARDIO-THORAC, V30, P827, DOI 10.1016/j.ejcts.2006.10.002; Su Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035629; Tan C, 2006, EUR J CARDIO-THORAC, V29, P829, DOI 10.1016/j.ejcts.2005.12.025; Terra RM, 2009, CHEST, V136, P361, DOI 10.1378/chest.08-2448; Tremblay A, 2006, CHEST, V129, P362, DOI 10.1378/chest.129.2.362; Ukale V, 2004, RESP MED, V98, P1166, DOI 10.1016/j.rmed.2004.04.008; Ukale V, 2004, LUNG CANCER-J IASLC, V43, P323, DOI 10.1016/j.lungcan.2003.09.014; Yim APC, 1996, ANN THORAC SURG, V62, P1655, DOI 10.1016/S0003-4975(96)00808-9; Zimmer PW, 1997, CHEST, V112, P430, DOI 10.1378/chest.112.2.430	57	63	66	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2014	9	1							e87060	10.1371/journal.pone.0087060	http://dx.doi.org/10.1371/journal.pone.0087060			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301BI	24475222	gold, Green Published, Green Submitted			2023-01-03	WOS:000330507300131
J	Zhang, H; Long, ZY; Ge, RY; Xu, LL; Jin, Z; Yao, L; Liu, YJ				Zhang, Hang; Long, Zhiying; Ge, Ruiyang; Xu, Lele; Jin, Zhen; Yao, Li; Liu, Yijun			Motor Imagery Learning Modulates Functional Connectivity of Multiple Brain Systems in Resting State	PLOS ONE			English	Article							NETWORKS; MRI; PLASTICITY; PRECUNEUS	Background: Learning motor skills involves subsequent modulation of resting-state functional connectivity in the sensory-motor system. This idea was mostly derived from the investigations on motor execution learning which mainly recruits the processing of sensory-motor information. Behavioral evidences demonstrated that motor skills in our daily lives could be learned through imagery procedures. However, it remains unclear whether the modulation of resting-state functional connectivity also exists in the sensory-motor system after motor imagery learning. Methodology/Principal Findings: We performed a fMRI investigation on motor imagery learning from resting state. Based on previous studies, we identified eight sensory and cognitive resting-state networks (RSNs) corresponding to the brain systems and further explored the functional connectivity of these RSNs through the assessments, connectivity and network strengths before and after the two-week consecutive learning. Two intriguing results were revealed: (1) The sensory RSNs, specifically sensory-motor and lateral visual networks exhibited greater connectivity strengths in precuneus and fusiform gyrus after learning; (2) Decreased network strength induced by learning was proved in the default mode network, a cognitive RSN. Conclusions/Significance: These results indicated that resting-state functional connectivity could be modulated by motor imagery learning in multiple brain systems, and such modulation displayed in the sensory-motor, visual and default brain systems may be associated with the establishment of motor schema and the regulation of introspective thought. These findings further revealed the neural substrates underlying motor skill learning and potentially provided new insights into the therapeutic benefits of motor imagery learning.	[Zhang, Hang; Ge, Ruiyang; Xu, Lele; Yao, Li] Beijing Normal Univ, Sch Informat Sci & Technol, Beijing 100875, Peoples R China; [Zhang, Hang; Liu, Yijun] Peking Univ, Dept Biomed Engn, Beijing 100871, Peoples R China; [Zhang, Hang] Chinese Acad Sci, C Lauterbur Res Ctr Biomed Imaging, Shenzhen Inst Adv Technol, Shenzhen, Peoples R China; [Long, Zhiying; Yao, Li] Beijing Normal Univ, Natl Key Lab Cognit Neurosci & Learning, Beijing 100875, Peoples R China; [Liu, Yijun] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Liu, Yijun] Univ Florida, McKnight Brain Inst, Gainesville, FL 32611 USA; [Jin, Zhen] PLA, Hosp 306, Lab Magnet Resonance Imaging, Beijing, Peoples R China	Beijing Normal University; Peking University; Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS; Beijing Normal University; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Yao, L (corresponding author), Beijing Normal Univ, Sch Informat Sci & Technol, Beijing 100875, Peoples R China.	yaoli@bnu.edu.cn; yjliufl@gmail.com	Xu, Le/HDN-9623-2022		National Key Basic Research Program of China (973 Program) [2012CB720704]; Key Program of National Natural Science Foundation of China [60931003, 61131003]	National Key Basic Research Program of China (973 Program)(National Basic Research Program of China); Key Program of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The National Key Basic Research Program of China (973 Program) (2012CB720704); The Key Program of National Natural Science Foundation of China (60931003 and 61131003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albert NB, 2009, CURR BIOL, V19, P1023, DOI 10.1016/j.cub.2009.04.028; BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129; Broyd SJ, 2009, NEUROSCI BIOBEHAV R, V33, P279, DOI 10.1016/j.neubiorev.2008.09.002; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Coynel D, 2010, NEUROIMAGE, V49, P759, DOI 10.1016/j.neuroimage.2009.08.048; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Dayan E, 2011, NEURON, V72, P443, DOI 10.1016/j.neuron.2011.10.008; de Lange FP, 2008, CORTEX, V44, P494, DOI 10.1016/j.cortex.2007.09.002; de Pasquale F, 2013, NEUROIMAGE, V69, P51, DOI 10.1016/j.neuroimage.2012.11.051; Doyon J, 2005, CURR OPIN NEUROBIOL, V15, P161, DOI 10.1016/j.conb.2005.03.004; Fair DA, 2008, P NATL ACAD SCI USA, V105, P4028, DOI 10.1073/pnas.0800376105; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2007, NEURON, V56, P171, DOI 10.1016/j.neuron.2007.08.023; Georgopoulos AP, 2000, CURR OPIN NEUROBIOL, V10, P238, DOI 10.1016/S0959-4388(00)00072-6; Hall C. R., 1997, J MENTAL IMAG, V21, P143, DOI DOI 10.1037/T07979-000; Isaac A.R., 1986, J MENT IMAG, V10, P23, DOI DOI 10.1037/T07980-000; KARNI A, 1995, NATURE, V377, P155; Lacourse MG, 2005, NEUROIMAGE, V27, P505, DOI 10.1016/j.neuroimage.2005.04.025; Lewisa CM, 2009, P NATL ACAD SCI USA, V106, P17558, DOI 10.1073/pnas.0902455106; Li R, 2011, NEUROIMAGE, V56, P1035, DOI 10.1016/j.neuroimage.2011.03.010; Ma LS, 2011, NEUROIMAGE, V58, P226, DOI 10.1016/j.neuroimage.2011.06.014; Ma LS, 2010, BRAIN RES, V1318, P64, DOI 10.1016/j.brainres.2009.12.073; Mantini D, 2007, P NATL ACAD SCI USA, V104, P13170, DOI 10.1073/pnas.0700668104; Mason MF, 2007, SCIENCE, V315, P393, DOI 10.1126/science.1131295; Miall RC, 2006, CURR BIOL, V16, pR998, DOI 10.1016/j.cub.2006.10.041; Munzert J, 2009, BRAIN RES REV, V60, P306, DOI 10.1016/j.brainresrev.2008.12.024; Northoff G, 2006, NEUROIMAGE, V31, P440, DOI 10.1016/j.neuroimage.2005.12.002; Nyberg L, 2006, NEUROPSYCHOLOGIA, V44, P711, DOI 10.1016/j.neuropsychologia.2005.08.006; Olsson CJ, 2008, FRONT HUM NEUROSCI, V2, DOI 10.3389/neuro.09.005.2008; Ostby Y, 2012, P NATL ACAD SCI USA, V109, P16800, DOI 10.1073/pnas.1210627109; Pearson K, 2000, CURR OPIN NEUROBIOL, V10, P649, DOI 10.1016/S0959-4388(00)00130-6; Rabin E, 2004, EXP BRAIN RES, V155, P362, DOI 10.1007/s00221-003-1736-6; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Rosazza C, 2011, NEUROL SCI, V32, P773, DOI 10.1007/s10072-011-0636-y; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Sharma N, 2006, STROKE, V37, P1941, DOI 10.1161/01.STR.0000226902.43357.fc; Shehzad Z, 2009, CEREB CORTEX, V19, P2209, DOI 10.1093/cercor/bhn256; Sommerville JA, 2006, PSYCHON B REV, V13, P179, DOI 10.3758/BF03193831; Taubert M, 2011, NEUROIMAGE, V57, P1492, DOI 10.1016/j.neuroimage.2011.05.078; Taylor JC, 2007, J NEUROPHYSIOL, V98, P1626, DOI 10.1152/jn.00012.2007; Taylor VA, 2013, SOC COGN AFFECT NEUR, V8, P4, DOI 10.1093/scan/nsr087; Vahdat S, 2011, J NEUROSCI, V31, P16907, DOI 10.1523/JNEUROSCI.2737-11.2011; Wallentin M, 2006, NEUROIMAGE, V32, P1850, DOI 10.1016/j.neuroimage.2006.05.002; Whitfield-Gabrieli S, 2012, ANNU REV CLIN PSYCHO, V8, P49, DOI 10.1146/annurev-clinpsy-032511-143049; Xiong JH, 2009, NEUROIMAGE, V45, P75, DOI 10.1016/j.neuroimage.2008.11.016; Zhang H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036052; Zhang H, 2011, BRAIN RES, V1407, P38, DOI 10.1016/j.brainres.2011.06.038	48	36	37	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2014	9	1							e85489	10.1371/journal.pone.0085489	http://dx.doi.org/10.1371/journal.pone.0085489			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297EA	24465577	Green Published, Green Submitted, gold			2023-01-03	WOS:000330237000039
J	DeRubeis, RJ; Cohen, ZD; Forand, NR; Fournier, JC; Gelfand, LA; Lorenzo-Luaces, L				DeRubeis, Robert J.; Cohen, Zachary D.; Forand, Nicholas R.; Fournier, Jay C.; Gelfand, Lois A.; Lorenzo-Luaces, Lorenzo			The Personalized Advantage Index: Translating Research on Prediction into Individualized Treatment Recommendations. A Demonstration	PLOS ONE			English	Article							RANDOMIZED CLINICAL-TRIALS; COGNITIVE THERAPY; SEVERE DEPRESSION; COVARIATE-INFORMATION; TREATMENT OUTCOMES; TREATMENT RESPONSE; MEDICINE; PHARMACOGENETICS; MEDICATIONS; MODERATE	Background: Advances in personalized medicine require the identification of variables that predict differential response to treatments as well as the development and refinement of methods to transform predictive information into actionable recommendations. Objective: To illustrate and test a new method for integrating predictive information to aid in treatment selection, using data from a randomized treatment comparison. Method: Data from a trial of antidepressant medications (N = 104) versus cognitive behavioral therapy (N = 50) for Major Depressive Disorder were used to produce predictions of post-treatment scores on the Hamilton Rating Scale for Depression (HRSD) in each of the two treatments for each of the 154 patients. The patient's own data were not used in the models that yielded these predictions. Five pre-randomization variables that predicted differential response (marital status, employment status, life events, comorbid personality disorder, and prior medication trials) were included in regression models, permitting the calculation of each patient's Personalized Advantage Index (PAI), in HRSD units. Results: For 60% of the sample a clinically meaningful advantage (PAI >= 3) was predicted for one of the treatments, relative to the other. When these patients were divided into those randomly assigned to their "Optimal" treatment versus those assigned to their "Non-optimal" treatment, outcomes in the former group were superior (d = 0.58, 95% CI .17-1.01). Conclusions: This approach to treatment selection, implemented in the context of two equally effective treatments, yielded effects that, if obtained prospectively, would rival those routinely observed in comparisons of active versus control treatments.	[DeRubeis, Robert J.; Cohen, Zachary D.; Gelfand, Lois A.; Lorenzo-Luaces, Lorenzo] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA; [Forand, Nicholas R.] Ohio State Univ, Dept Psychiat, Columbus, OH 43210 USA; [Fournier, Jay C.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA	University of Pennsylvania; University System of Ohio; Ohio State University; University of Pennsylvania	DeRubeis, RJ (corresponding author), Univ Penn, Dept Psychol, 3815 Walnut St, Philadelphia, PA 19104 USA.	derubeis@psych.upenn.edu	Cohen, Zachary/A-8946-2013; Fournier, Jay/AAG-8452-2019; Lorenzo-Luaces, Lorenzo/AAA-2070-2020	Cohen, Zachary/0000-0002-4883-1028; Fournier, Jay/0000-0001-8967-1668; Lorenzo-Luaces, Lorenzo/0000-0002-8882-0243; DeRubeis, Robert/0000-0003-3129-0277	NIMH [2-R01-MH-060998-06]; NATIONAL INSTITUTE OF MENTAL HEALTH [K23MH097889, R01MH060998] Funding Source: NIH RePORTER	NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Support provided by NIMH grant 2-R01-MH-060998-06, "Prevention of Recurrence in Depression with Drugs and CT" (http://www.nimh.nih.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdi H., 2010, ENCY RES DESIGN, P655; Arranz MJ, 2008, SCHIZOPHRENIA BULL, V34, P1130, DOI 10.1093/schbul/sbn114; Barber JP, 1996, J CONSULT CLIN PSYCH, V64, P951, DOI 10.1037/0022-006X.64.5.951; Baskaran A, 2012, NEUROPHARMACOLOGY, V63, P507, DOI 10.1016/j.neuropharm.2012.04.021; BYAR DP, 1985, STAT MED, V4, P255, DOI 10.1002/sim.4780040304; BYAR DP, 1977, J CHRON DIS, V30, P445, DOI 10.1016/0021-9681(77)90037-6; DAWES RM, 1989, SCIENCE, V243, P1668, DOI 10.1126/science.2648573; DeRubeis RJ, 2005, ARCH GEN PSYCHIAT, V62, P409, DOI 10.1001/archpsyc.62.4.409; DeRubeis RJ, 2008, NAT REV NEUROSCI, V9, P788, DOI 10.1038/nrn2345; Draper N.R., 2003, APPL REGRESSION ANAL; Dunlop BW, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-106; EFRON B, 1983, AM STAT, V37, P36, DOI 10.2307/2685844; Fournier JC, 2008, BRIT J PSYCHIAT, V192, P124, DOI 10.1192/bjp.bp.107.037234; Fournier JC, 2009, J CONSULT CLIN PSYCH, V77, P775, DOI 10.1037/a0015401; Gong QY, 2011, NEUROIMAGE, V55, P1497, DOI 10.1016/j.neuroimage.2010.11.079; Guo Y, 2008, HUM BRAIN MAPP, V29, P1092, DOI 10.1002/hbm.20450; Hamburg MA, 2010, NEW ENGL J MED, V363, P301, DOI 10.1056/NEJMp1006304; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hollon SD, 2005, ARCH GEN PSYCHIAT, V62, P417, DOI 10.1001/archpsyc.62.4.417; Hollon SD, 1986, PREDICTING OUTCOME V; Ising M, 2009, ARCH GEN PSYCHIAT, V66, P966, DOI 10.1001/archgenpsychiatry.2009.95; Jarrett RB, 1999, ARCH GEN PSYCHIAT, V56, P431, DOI 10.1001/archpsyc.56.5.431; Kirsch I, 2008, PLOS MED, V5, P260, DOI 10.1371/journal.pmed.0050045; Kraemer HC, 2004, INT J METH PSYCH RES, V13, P141, DOI 10.1002/mpr.170; Kraemer HC, 2002, ARCH GEN PSYCHIAT, V59, P877, DOI 10.1001/archpsyc.59.10.877; Kraemer HC, 2006, JAMA-J AM MED ASSOC, V296, P1286, DOI 10.1001/jama.296.10.1286; Leucht S, 2012, BRIT J PSYCHIAT, V200, P97, DOI 10.1192/bjp.bp.111.096594; Leykin Y, 2007, J CONSULT CLIN PSYCH, V75, P267, DOI 10.1037/0022-006X.75.2.267; Malhotra AK, 2012, MOL PSYCHIATR, V17, P760, DOI 10.1038/mp.2011.146; McClay JL, 2011, MOL PSYCHIATR, V16, P76, DOI 10.1038/mp.2009.89; McGrath CL, 2013, JAMA PSYCHIAT, V70, P821, DOI 10.1001/jamapsychiatry.2013.143; National Institute for Clinical Excellence, 2004, DEPR MAN DEPR PRIM S; Perlis RH, 2011, MOL PSYCHIATR, V16, P1076, DOI 10.1038/mp.2011.63; Schosser A, 2009, INT CLIN PSYCHOPHARM, V24, P277, DOI 10.1097/YIC.0b013e3283306a2f; Simon GE, 2010, AM J PSYCHIAT, V167, P1445, DOI 10.1176/appi.ajp.2010.09111680; Squassina A, 2010, PHARMACOGENOMICS, V11, P1149, DOI [10.2217/pgs.10.97, 10.2217/PGS.10.97]; Turner EH, 2008, NEW ENGL J MED, V358, P252, DOI 10.1056/NEJMsa065779; Uher R, 2011, HARVARD REV PSYCHIAT, V19, P109, DOI 10.3109/10673229.2011.586551; Uhr M, 2008, NEURON, V57, P203, DOI 10.1016/j.neuron.2007.11.017; YAKOVLEV AY, 1994, STAT MED, V13, P1575, DOI 10.1002/sim.4780131508; Zachary RA, 1991, W PSYCHOL SERVICES F	42	259	260	3	57	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2014	9	1							e83875	10.1371/journal.pone.0083875	http://dx.doi.org/10.1371/journal.pone.0083875			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	291WL	24416178	Green Accepted, Green Published, gold, Green Submitted			2023-01-03	WOS:000329862500081
J	Benzer, TI; Nejad, SH; Flood, JG				Benzer, Theodore I.; Nejad, Shamim H.; Flood, James G.			Case 40-2013: A 36-Year-Old Man with Agitation and Paranoia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIQUID-CHROMATOGRAPHY; DRUGS		[Benzer, Theodore I.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Nejad, Shamim H.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Flood, James G.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Benzer, Theodore I.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Nejad, Shamim H.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Flood, James G.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Benzer, TI (corresponding author), Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.							Alves E, 2009, NEUROSCIENCE, V158, P514, DOI 10.1016/j.neuroscience.2008.10.041; [Anonymous], 2012, SUBST CATH AKA BATH; Bell L., 1849, AM J INSANITY, V6, P97; Dal Cason T. A., 2007, MICROGRAM J, V5, P3; Fink M, 1999, Bipolar Disord, V1, P54, DOI 10.1034/j.1399-5618.1999.10112.x; Kao L, 2009, ROSENS EMERGENCY MED, P2440; Kelly JP, 2011, DRUG TEST ANAL, V3, P439, DOI 10.1002/dta.313; Menon DV, 2007, J AM COLL CARDIOL, V50, P626, DOI 10.1016/j.jacc.2007.03.060; Nelson LS, 2010, GOLDFRANKS TOXICOLOG, P33; PUOPOLO PR, 1991, CLIN CHEM, V37, P2124; Takahashi M, 2009, TALANTA, V77, P1245, DOI 10.1016/j.talanta.2008.07.062; Young R, 1998, PSYCHOPHARMACOLOGY, V140, P250, DOI 10.1007/s002130050765	12	16	16	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 26	2013	369	26					2536	2545		10.1056/NEJMcpc1304051	http://dx.doi.org/10.1056/NEJMcpc1304051			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278BT	24369079				2023-01-03	WOS:000328863700012
J	Prankerd, RJ; Nguyen, TH; Ibrahim, JP; Bischof, RJ; Nassta, GC; Olerile, LD; Russell, AS; Meiser, F; Parkington, HC; Coleman, HA; Morton, DAV; McIntosh, MP				Prankerd, Richard J.; Tri-Hung Nguyen; Ibrahim, Jibriil P.; Bischof, Robert J.; Nassta, Gemma C.; Olerile, Livesey D.; Russell, Adrian S.; Meiser, Felix; Parkington, Helena C.; Coleman, Harold A.; Morton, David A. V.; McIntosh, Michelle P.			Pulmonary Delivery of an Ultra-Fine Oxytocin Dry Powder Formulation: Potential for Treatment of Postpartum Haemorrhage in Developing Countries	PLOS ONE			English	Article							3RD STAGE; NONA-PEPTIDE; MISOPROSTOL; MANAGEMENT; LABOR; MYOMETRIUM; PREVENTION; EXPRESSION; RECEPTOR; PASSAGE	Oxytocin is recommended by the World Health Organisation as the most effective uterotonic for the prevention and treatment of postpartum haemorrhage. The requirement for parenteral administration by trained healthcare providers and the need for the drug solution to be maintained under cold-chain storage limit the use of oxytocin in the developing world. In this study, a spray-dried ultrafine formulation of oxytocin was developed with an optimal particle size diameter (1-5 mu m) to facilitate aerosolised delivery via the lungs. A powder formulation of oxytocin, using mannitol, glycine and leucine as carriers, was prepared with a volume-based median particle diameter of 1.9 mu m. Oxytocin content in the formulation was assayed using high-performance liquid chromatography-mass spectroscopy and was found to be unchanged after spray-drying. Ex vivo contractility studies utilising human and ovine uterine tissue indicated no difference in the bioactivity of oxytocin before and after spray-drying. Uterine electromyographic (EMG) activity in postpartum ewes following pulmonary (in vivo) administration of oxytocin closely mimicked that observed immediately postpartum (0-12 h following normal vaginal delivery of the lamb). In comparison to the intramuscular injection, pulmonary administration of an oxytocin dry powder formulation to postpartum ewes resulted in generally similar EMG responses, however a more rapid onset of uterine EMG activity was observed following pulmonary administration (129 +/- 18 s) than intramuscular injection (275 +/- 22 s). This is the first study to demonstrate the potential for oxytocin to elicit uterine activity after systemic absorption as an aerosolised powder from the lungs. Aerosolised oxytocin has the potential to provide a stable and easy to administer delivery system for effective prevention and treatment of postpartum haemorrhage in resource-poor settings in the developing world.	[Prankerd, Richard J.; Tri-Hung Nguyen; Ibrahim, Jibriil P.; Nassta, Gemma C.; Olerile, Livesey D.; Russell, Adrian S.; Morton, David A. V.; McIntosh, Michelle P.] Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic, Australia; [Ibrahim, Jibriil P.; Bischof, Robert J.] Monash Univ, Dept Physiol, Biotechnol Res Labs, Clayton, Vic 3168, Australia; [Meiser, Felix] Univ Western Australia, Ctr Microscopy Characterisat & Anal, Perth, WA 6009, Australia; [Parkington, Helena C.; Coleman, Harold A.] Monash Univ, Dept Physiol, Clayton, Vic 3168, Australia	Monash University; Monash University; University of Western Australia; Monash University	McIntosh, MP (corresponding author), Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic, Australia.	Michelle.McIntosh@monash.edu	Olerile, Dr. Livesey David/GPC-5176-2022	Olerile, Dr. Livesey David/0000-0002-3680-7530; McIntosh, Michelle Paula/0000-0002-1605-7226; Morton, David/0000-0002-1491-6517	Saving Lives at Birth Partners (United States Agency for International Development (USAID); Saving Lives at Birth Partners (Government of Norway); Saving Lives at Birth Partners (Bill and Melinda Gates Foundation); Saving Lives at Birth Partners (Grand Challenges of Canada); Saving Lives at Birth Partners (World Bank); Bill and Melinda Gates Foundation through a Grand Challenges Exploration grant	Saving Lives at Birth Partners (United States Agency for International Development (USAID)(United States Agency for International Development (USAID)); Saving Lives at Birth Partners (Government of Norway)(United States Agency for International Development (USAID)Bill & Melinda Gates Foundation); Saving Lives at Birth Partners (Bill and Melinda Gates Foundation)(United States Agency for International Development (USAID)Bill & Melinda Gates Foundation); Saving Lives at Birth Partners (Grand Challenges of Canada)(United States Agency for International Development (USAID)Bill & Melinda Gates Foundation); Saving Lives at Birth Partners (World Bank)(United States Agency for International Development (USAID)Bill & Melinda Gates Foundation); Bill and Melinda Gates Foundation through a Grand Challenges Exploration grant	This work was supported by a grant from the Saving Lives at Birth Partners (United States Agency for International Development (USAID), the Government of Norway, the Bill and Melinda Gates Foundation, Grand Challenges of Canada, and the World Bank). This work was also supported by the Bill and Melinda Gates Foundation through a Grand Challenges Exploration grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alfirevic Z, 2007, INT J GYNECOL OBSTET, V99, pS198, DOI 10.1016/j.ijgo.2007.09.012; Althabe F, 2011, INT J GYNECOL OBSTET, V114, P184, DOI 10.1016/j.ijgo.2011.05.003; Aronsson A, 2004, HUM REPROD, V19, P81, DOI 10.1093/humrep/deh005; Davis, 1999, Pharm Sci Technol Today, V2, P450, DOI 10.1016/S1461-5347(99)00199-6; DAVIS TV, 2004, LANCET, V363, P75, DOI DOI 10.1016/S0140-6736(03)15180-X; Deepak NN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062801; FOLKESSON HG, 1992, EXP LUNG RES, V18, P595, DOI 10.3109/01902149209031697; FOLKESSON HG, 1993, ACTA PHYSIOL SCAND, V147, P173, DOI 10.1111/j.1748-1716.1993.tb09486.x; Gulmezoglu AM, 2001, LANCET, V358, P689, DOI 10.1016/S0140-6736(01)05835-4; HASTINGS RH, 1992, J APPL PHYSIOL, V73, P1310, DOI 10.1152/jappl.1992.73.4.1310; Hawe A, 2009, PHARM RES-DORDR, V26, P1679, DOI 10.1007/s11095-009-9878-2; HOGERZEIL HV, 1994, BRIT MED J, V308, P59; Hogerzeil HV, 1996, EUR J OBSTET GYN R B, V69, P25, DOI 10.1016/0301-2115(95)02530-8; Irngartinger M, 2004, EUR J PHARM BIOPHARM, V58, P7, DOI 10.1016/j.ejpb.2004.03.016; Khan KS, 2006, LANCET, V367, P1066, DOI 10.1016/S0140-6736(06)68397-9; Kimura T, 1996, ENDOCRINOLOGY, V137, P780, DOI 10.1210/en.137.2.780; Labiris NR, 2003, BRIT J CLIN PHARMACO, V56, P588, DOI 10.1046/j.1365-2125.2003.01892.x; Lalonde A, 2012, INT J GYNECOL OBSTET, V117, P108, DOI 10.1016/j.ijgo.2012.03.001; Meeusen EN, 2009, DRUG DISCOV TODAY DI, V6, P101, DOI [DOI 10.1016/J.DDM0D.2009.12.002, 10.1016/j.ddmod.2009.12.002]; MIHALKO PJ, 1988, LIPOSOMES DRUG CARRI, P679; Oladapo OT, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009336.pub2; PARKINGTON HC, 1985, J PHYSIOL-LONDON, V359, P1, DOI 10.1113/jphysiol.1985.sp015571; PARKINGTON HC, 1988, J REPROD FERTIL, V82, P697, DOI 10.1530/jrf.0.0820697; Parkington HC, 1998, J PHYSIOL-LONDON, V507P, p68P; Patton JS, 1996, ADV DRUG DELIVER REV, V19, P3, DOI 10.1016/0169-409X(95)00113-L; PRENDIVILLE WJ, 1988, BMJ-BRIT MED J, V297, P1295, DOI 10.1136/bmj.297.6659.1295; Rogers J, 1998, LANCET, V351, P693, DOI 10.1016/S0140-6736(97)09409-9; RUIS H, 1981, BRIT MED J, V283, P340, DOI 10.1136/bmj.283.6287.340; Sou T, 2013, EUR J PHARM BIOPHARM, V83, P234, DOI 10.1016/j.ejpb.2012.10.015; Tsu VD, 2003, INT J GYNECOL OBSTET, V83, P103, DOI 10.1016/S0020-7292(03)00186-3; Tsu VD, 2009, MIDWIFERY, V25, P461, DOI 10.1016/j.midw.2007.10.010; Tuncalp O, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000494.pub4; Villar J, 2002, OBSTET GYNECOL, V100, P1301, DOI 10.1016/S0029-7844(02)02371-2; Weers JG, 2007, EXPERT OPIN DRUG DEL, V4, P297, DOI 10.1517/17425247.4.3.297; *WHO, 2011, WHO TRS; Winikoff B, 2010, LANCET, V375, P210, DOI 10.1016/S0140-6736(09)61924-3; World Health Organization, 2012, WHO REC PREV TREATM; Wu WX, 1996, ENDOCRINOLOGY, V137, P722, DOI 10.1210/en.137.2.722; YAMAHARA H, 1994, PHARMACEUT RES, V11, P1617, DOI 10.1023/A:1018918022865	39	15	15	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2013	8	12							e82965	10.1371/journal.pone.0082965	http://dx.doi.org/10.1371/journal.pone.0082965			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278IG	24376618	Green Published, gold, Green Submitted			2023-01-03	WOS:000328882000048
J	Calderon-Larranaga, A; Gimeno-Feliu, LA; Gonzalez-Rubio, F; Poblador-Plou, B; Lairla-San Jose, M; Abad-Diez, JM; Poncel-Falco, A; Prados-Torres, A				Calderon-Larranaga, Amaia; Gimeno-Feliu, Luis A.; Gonzalez-Rubio, Francisca; Poblador-Plou, Beatriz; Lairla-San Jose, Maria; Abad-Diez, Jose M.; Poncel-Falco, Antonio; Prados-Torres, Alexandra			Polypharmacy Patterns: Unravelling Systematic Associations between Prescribed Medications	PLOS ONE			English	Article							OPEN-ANGLE GLAUCOMA; RISK-FACTORS; THERAPY; DISEASE; COMORBIDITY; DEPRESSION; GUIDELINES; INHIBITORS; SYMPTOMS; IDENTIFY	Objectives: The aim of this study was to demonstrate the existence of systematic associations in drug prescription that lead to the establishment of patterns of polypharmacy, and the clinical interpretation of the associations found in each pattern. Methods: A cross-sectional study was conducted based on information obtained from electronic medical records and the primary care pharmacy database in 2008. An exploratory factor analysis of drug dispensing information regarding 79,089 adult patients was performed to identify the patterns of polypharmacy. The analysis was stratified by age and sex. Results: Seven patterns of polypharmacy were identified, which may be classified depending on the type of disease they are intended to treat: cardiovascular, depression-anxiety, acute respiratory infection (ARI), chronic obstructive pulmonary disease (COPD), rhinitis-asthma, pain, and menopause. Some of these patterns revealed a clear clinical consistency and included drugs that are prescribed together for the same clinical indication (i.e., AR! and COPD patterns). Other patterns were more complex but also clinically consistent: in the cardiovascular pattern, drugs for the treatment of known risk factors such as hypertension or dyslipidemia were combined with other medications for the treatment of diabetes or established cardiovascular pathology (e.g., antiplatelet agents). Almost all of the patterns included drugs for preventing or treating potential side effects of other drugs in the same pattern. Conclusions: The present study demonstrated the existence of non-random associations in drug prescription, resulting in patterns of polypharmacy that are sound from the pharmacological and clinical viewpoints and that exist in a significant proportion of the population. This finding necessitates future longitudinal studies to confirm some of the proposed causal associations. The information discovered would further the development and/or adaptation of clinical patient guidelines to patients with multimorbidity who are taking multiple drugs.	[Calderon-Larranaga, Amaia; Gimeno-Feliu, Luis A.; Gonzalez-Rubio, Francisca; Poblador-Plou, Beatriz; Lairla-San Jose, Maria; Abad-Diez, Jose M.; Poncel-Falco, Antonio; Prados-Torres, Alexandra] Miguel Servet Univ Hosp, IIS Aragon, Aragon Hlth Sci Inst IACS, EpiChron Res Grp Chron Dis, Zaragoza, Spain; [Calderon-Larranaga, Amaia; Abad-Diez, Jose M.; Prados-Torres, Alexandra] Univ Zaragoza, Dept Microbiol Prevent Med & Publ Hlth, Zaragoza, Spain; [Calderon-Larranaga, Amaia; Prados-Torres, Alexandra] Carlos III Hlth Inst, Red Invest Serv Salud Enfermedades Cron REDISSEC, Madrid, Spain; [Calderon-Larranaga, Amaia; Poblador-Plou, Beatriz; Prados-Torres, Alexandra] IIS Aragon, Aragon Hlth Sci Inst IACS, Teaching Unit Prevent Med & Publ Hlth, Zaragoza, Spain; [Gimeno-Feliu, Luis A.] San Pablo Hlth Ctr, Zaragoza, Spain; [Gonzalez-Rubio, Francisca] Delicias Sur Hlth Ctr, Zaragoza, Spain; [Gimeno-Feliu, Luis A.; Gonzalez-Rubio, Francisca] Univ Zaragoza, Dept Med Psychiat & Dermatol, Zaragoza, Spain; [Abad-Diez, Jose M.] Govt Aragon, Dept Hlth Wellbeing & Family, Zaragoza, Spain; [Poncel-Falco, Antonio] Aragon Hlth Serv, Primary Care Directorate, Zaragoza, Spain	Miguel Servet University Hospital; University of Zaragoza; University of Zaragoza	Calderon-Larranaga, A (corresponding author), Miguel Servet Univ Hosp, IIS Aragon, Aragon Hlth Sci Inst IACS, EpiChron Res Grp Chron Dis, Zaragoza, Spain.	acalderon.iacs@aragon.es	Rubio, Francisca Gonzalez/ABD-1444-2020; Gonzalez Rubio, Francisca/GPT-3556-2022; Calderón-Larrañaga, Amaia/ABC-6828-2021; Prados-Torres, Alexandra/P-5818-2017; Poblador-Plou, Beatriz/ABC-7915-2020; Gimeno-Feliu, Luis Andrés/E-5390-2016	Rubio, Francisca Gonzalez/0000-0001-5939-4436; Gonzalez Rubio, Francisca/0000-0001-5939-4436; Calderón-Larrañaga, Amaia/0000-0001-9064-9222; Prados-Torres, Alexandra/0000-0002-5704-6056; Poblador-Plou, Beatriz/0000-0002-5119-5093; Gimeno-Feliu, Luis Andrés/0000-0003-2928-6623; ABAD, JOSE MARIA/0000-0002-1510-7287	Carlos III Health Institute of the Spanish Ministry of Economy and Competitiveness [PI11/01126]	Carlos III Health Institute of the Spanish Ministry of Economy and Competitiveness(Spanish Government)	This study was funded by grant PI11/01126 from the Carlos III Health Institute of the Spanish Ministry of Economy and Competitiveness. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, EFPC RESP EU REFL CH; Benninger M, 2010, ANN ALLERG ASTHMA IM, V104, P13, DOI 10.1016/j.anai.2009.11.020; Bentsen SB, 2013, NURS HEALTH SCI, V15, P292, DOI 10.1111/nhs.12031; Benyamin R, 2008, PAIN PHYSICIAN, V11, pS105; Bhatt DL, 2008, AM J GASTROENTEROL, V103, P2890, DOI 10.1111/j.1572-0241.2008.02216.x; Bushardt RL, 2008, CLIN INTERV AGING, V3, P383, DOI 10.2147/CIA.S2468; Calderon-Larranaga A, 2010, BMC HEALTH SERV RES, V21, P10, DOI DOI 10.1186/1472-6963-10-S2-A22; Cano Parra J, 2005, Arch Soc Esp Oftalmol, V80, P137; Carville SF, 2008, ANN RHEUM DIS, V67, P536, DOI 10.1136/ard.2007.071522; Costello AB, 2005, PRACTICAL ASSESSMENT, V10, P1, DOI [DOI 10.7275/JYJ1-4868, DOI 10.1316/S0782-051X03024046-9]; D'Agostino RB, 2008, CIRCULATION, V117, P743, DOI 10.1161/CIRCULATIONAHA.107.699579; de Abajo FJ, 2008, ARCH GEN PSYCHIAT, V65, P795, DOI 10.1001/archpsyc.65.7.795; Echave-Susteeta JM, 2002, INF TER SIST NAC SAL, V26, P34; Feig DI, 2008, NEW ENGL J MED, V359, P1811, DOI 10.1056/NEJMra0800885; Fortin M, 2012, ANN FAM MED, V10, P142, DOI 10.1370/afm.1337; Franssen FME, 2011, INT J CHRONIC OBSTR, V6, P493, DOI 10.2147/COPD.S24443; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Gijsen R, 2001, J CLIN EPIDEMIOL, V54, P661, DOI 10.1016/S0895-4356(00)00363-2; Goldenberg DL, 2010, AM J MED, V123, P675, DOI 10.1016/j.amjmed.2010.01.014; Guglielmo R, 2012, CLIN NEUROPHARMACOL, V35, P45, DOI 10.1097/WNF.0b013e31823e669b; Gutierrez J, 2012, ARCH INTERN MED, V172, P909, DOI 10.1001/archinternmed.2012.2145; Heran BS, 2012, COCHRANE DB SYST REV, V4; Hoffmann F, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-190; Holdiness A, 2011, AM J MED, V124, P15, DOI 10.1016/j.amjmed.2010.07.021; Hull PR, 2005, DERMATOL CLIN, V23, P665, DOI 10.1016/j.det.2005.05.008; Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025-6196(11)60752-0; Lamkin S, 2009, J EMERG NURS, V35, P72, DOI 10.1016/j.jen.2008.10.014; Martin-Merino E, 2010, ALIMENT PHARM THER, V31, P1132, DOI 10.1111/j.1365-2036.2010.04280.x; Miglior S, 2007, AM J OPHTHALMOL, V144, P266, DOI 10.1016/j.ajo.2007.04.040; Muñoz Miguel A., 2006, Clínica y Salud, V17, P91; O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3; O'Driscoll BR, 2008, THORAX, V63, DOI 10.1136/thx.2008.102947; Pasquale LR, 2006, OPHTHALMOLOGY, V113, P1081, DOI 10.1016/j.ophtha.2006.01.066; Gil SP, 2010, REV CALID ASSIST, V25, P321, DOI 10.1016/j.cali.2010.03.008; Prados-Torres A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032190; Rotaeche del Campo R, 2008, GUIA PRACTICA CLIN D; Ruiz De Velasco Artaza E, 2002, Aten Primaria, V29, P414; Sauriyal DS, 2011, NEUROPEPTIDES, V45, P175, DOI 10.1016/j.npep.2010.12.004; Skerman HM, 2009, RES NURS HEALTH, V32, P345, DOI 10.1002/nur.20323; Tibaldi C, 2009, CLIN MICROBIOL INFEC, V15, P670, DOI 10.1111/j.1469-0691.2009.02842.x; Tinetti ME, 2011, NEW ENGL J MED, V364, P2478, DOI 10.1056/NEJMp1100535; Tinetti ME, 2004, NEW ENGL J MED, V351, P2870, DOI 10.1056/NEJMsb042458; Vaccarino V, 2011, CARDIOVASC RES, V90, P9, DOI 10.1093/cvr/cvq394; Vacheron-Trystram MN, 2004, ENCEPHALE, V30, P417; WHO Collaborating Centre for Drug Statistics Methodology Anatomical Chemical, 2008, CLASS IND DEF DAIL; Xu L, 2007, AM J OPHTHALMOL, V144, P461, DOI 10.1016/j.ajo.2007.05.013	46	36	36	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2013	8	12							e84967	10.1371/journal.pone.0084967	http://dx.doi.org/10.1371/journal.pone.0084967			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276IX	24376858	Green Published, Green Submitted, gold			2023-01-03	WOS:000328745100193
J	Holland, WL; Scherer, PE				Holland, William L.; Scherer, Philipp E.			Ronning After the Adiponectin Receptors	SCIENCE			English	Editorial Material							INSULIN ACTION; OBESITY; MICE		[Holland, William L.; Scherer, Philipp E.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Touchstone Diabet Ctr, Dallas, TX 75390 USA; [Scherer, Philipp E.] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Holland, WL (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Internal Med, Touchstone Diabet Ctr, Dallas, TX 75390 USA.	philipp.scherer@utsouthwestern.edu	Scherer, Philipp E/K-7819-2012	Scherer, Philipp E/0000-0003-0680-3392	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK088761, R01DK099110, R01DK055758] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK055758, P01 DK088761, R01 DK099110] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Combs TP, 2004, ENDOCRINOLOGY, V145, P367, DOI 10.1210/en.2003-1068; Ealey KN, 2008, EXP BIOL MED, V233, P1546, DOI 10.3181/0806-RM-192; Halberg N, 2009, DIABETES, V58, P1961, DOI 10.2337/db08-1750; Holland WL, 2013, CELL METAB, V17, P790, DOI 10.1016/j.cmet.2013.03.019; Holland WL, 2011, NAT MED, V17, P55, DOI 10.1038/nm.2277; Kim JY, 2007, J CLIN INVEST, V117, P2621, DOI 10.1172/JCI31021; Mancia F, 2004, STRUCTURE, V12, P1355, DOI 10.1016/j.str.2004.06.012; Okada-Iwabu M, 2013, NATURE, V503, P493, DOI 10.1038/nature12656; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Wei W, 2012, P NATL ACAD SCI USA, V109, P3143, DOI 10.1073/pnas.1200797109; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Ye RS, 2013, MOL METAB, V2, P133, DOI 10.1016/j.molmet.2013.04.001	15	57	58	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 20	2013	342	6165					1460	1461		10.1126/science.1249077	http://dx.doi.org/10.1126/science.1249077			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ZI	24357309	Green Accepted			2023-01-03	WOS:000328644300042
J	Cunningham, C; Srivastava, A; Collin, E; Grad, S; Alini, M; Pandit, A; Wall, JG				Cunningham, Claire; Srivastava, Akshay; Collin, Estelle; Grad, Sibylle; Alini, Mauro; Pandit, Abhay; Wall, J. Gerard			Isolation and Characterisation of a Recombinant Antibody Fragment That Binds NCAM1-Expressing Intervertebral Disc Cells	PLOS ONE			English	Article							HUMAN NUCLEUS PULPOSUS; DOMOIC ACID; PROTEIN; DEGENERATION; EXPRESSION; SINGLE; TISSUE; GENE; IMMOBILIZATION; REGENERATION	Degeneration of the intervertebral discs (IVD) is a leading cause of neck and low back pain. Degeneration begins in the central nucleus pulposus region, leading to loss of IVD osmotic properties. Regeneration approaches include administration of matrix-mimicking scaffolds, cells and/or therapeutic factors. Cell-targeting strategies are likely to improve delivery due to the low cell numbers in the IVD. Single-chain antibody fragments (scFvs) that bind IVD cells were isolated for potential delivery of therapeutics to degenerated IVD. The most cell-distal domain of neural cell adhesion molecule 1 (NCAM1) was cloned and expressed in Escherichia coli. Phage display technology was used to isolate a human scFv against the recombinant domain by panning a scFv library on the immobilised protein. The isolated scFv bound cultured rat astrocytes, as well as bovine nucleus pulposus and annulus fibrosus cells in immunocytochemical studies. The scFv also labelled cells in bovine spinal cord and six-month and two-year old bovine IVD sections by immunohistochemistry. Antibody fragments can provide cell-binding moieties at improved cost, time, yield and functionalisation potential over whole antibodies. The described scFv has potential application in delivery of therapeutics to NCAM1-expressing cells in degenerated IVD.	[Cunningham, Claire; Srivastava, Akshay; Wall, J. Gerard] Natl Univ Ireland, Network Excellence Funct Biomat NFB, Galway NUI Galway, Galway, Ireland; [Cunningham, Claire; Srivastava, Akshay; Collin, Estelle; Grad, Sibylle; Alini, Mauro; Pandit, Abhay; Wall, J. Gerard] NUI Galway, Galway, Ireland; [Grad, Sibylle; Alini, Mauro] AO Res Inst, Davos, Switzerland	Ollscoil na Gaillimhe-University of Galway	Wall, JG (corresponding author), Natl Univ Ireland, Network Excellence Funct Biomat NFB, Galway NUI Galway, Galway, Ireland.	gerard.wall@nuigalway.ie	Pandit, Abhay/B-6187-2008; Alini, Mauro/AAG-7961-2020	Pandit, Abhay/0000-0002-6292-4933; Srivastava, Akshay/0000-0001-5048-9420; Wall, Gerard/0000-0003-4603-4276	Science Foundation Ireland [07/SRC/B1163]	Science Foundation Ireland(Science Foundation IrelandEuropean Commission)	The work was supported by Science Foundation Ireland (www.sfi.ie) Grant No. 07/SRC/B1163 to the Network of Excellence for Functional Biomaterials at NUI Galway. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asgeirsdottir SA, 2010, J CONTROL RELEASE, V141, P241, DOI 10.1016/j.jconrel.2009.09.008; Boos N, 2002, SPINE, V27, P2631, DOI 10.1097/00007632-200212010-00002; Burton AK, 2006, EUR SPINE J, V15, pS136, DOI 10.1007/s00586-006-1070-3; Chang Ki-Hwan, 2012, Immune Netw, V12, P155, DOI 10.4110/in.2012.12.4.155; Collin EC, 2011, BIOMATERIALS, V32, P2862, DOI 10.1016/j.biomaterials.2011.01.018; Freemont T J, 2001, Expert Rev Mol Med, V2001, P1, DOI 10.1017/S1462399401002885; Frobin W, 2001, EUR RADIOL, V11, P263, DOI 10.1007/s003300000556; Gaetani P, 2008, TISSUE ENG PT A, V14, P1415, DOI 10.1089/ten.tea.2007.0330; Gruber HE, 2011, EXP MOL PATHOL, V91, P534, DOI 10.1016/j.yexmp.2011.06.001; Guarino V, 2012, POLYMERS-BASEL, V4, P1590, DOI 10.3390/polym4031590; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guterl CC, 2013, EUR CELLS MATER, V25, P1; Halloran DO, 2008, BIOMATERIALS, V29, P438, DOI 10.1016/j.biomaterials.2007.10.009; Hong H, 2012, ACS NANO, V6, P2361, DOI 10.1021/nn204625e; Hortiguela MJ, 2013, MAR DRUGS, V11, P881, DOI 10.3390/md11030881; Hu X., 2012, BIOL INTERACTIONS SU, P90; Hu XJ, 2005, J BIOTECHNOL, V120, P38, DOI 10.1016/j.jbiotec.2005.05.018; Hu XJ, 2007, PROTEIN EXPRES PURIF, V52, P194, DOI 10.1016/j.pep.2006.08.009; Hu XJ, 2006, J PHYS CHEM B, V110, P18703, DOI 10.1021/jp062423e; Hu XJ, 2013, BIOMACROMOLECULES, V14, P153, DOI 10.1021/bm301518p; Illien-Junger S, 2010, SPINE, V35, P1744, DOI 10.1097/BRS.0b013e3181c48019; Jendeberg L, 1997, J IMMUNOL METHODS, V201, P25, DOI 10.1016/S0022-1759(96)00215-3; Kepler CK, 2011, J AM ACAD ORTHOP SUR, V19, P543, DOI 10.5435/00124635-201109000-00005; LYONS G, 1981, BIOCHIM BIOPHYS ACTA, V673, P443, DOI 10.1016/0304-4165(81)90476-1; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MILLER JM, 1988, SYST BOT, V13, P173, DOI 10.1097/00007632-198802000-00008; Molloy PE, 1995, MOL BIOTECHNOL, V4, P239, DOI 10.1007/BF02779017; Newland B, 2013, ACS CHEM NEUROSCI, V4, P540, DOI 10.1021/cn4000023; O'Dwyer R, 2009, APPL BIOCHEM BIOTECH, V159, P178, DOI 10.1007/s12010-008-8379-9; Pansri P, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-6; Parolin M, 2010, Evid Based Spine Care J, V1, P67, DOI 10.1055/s-0028-1100919; Pattappa G, 2012, J ANAT, V221, P480, DOI 10.1111/j.1469-7580.2012.01521.x; Power KA, 2011, ARTHRITIS RHEUM-US, V63, P3876, DOI 10.1002/art.30607; Prasarn ML, 2012, J NEUROSURG-SPINE, V16, P172, DOI 10.3171/2011.10.SPINE11116; Richardson SM, 2008, BIOMATERIALS, V29, P85, DOI 10.1016/j.biomaterials.2007.09.018; Ronn LCB, 1998, EXP GERONTOL, V33, P853, DOI 10.1016/S0531-5565(98)00040-0; Roughley PJ, 2004, SPINE, V29, P2691, DOI 10.1097/01.brs.0000146101.53784.b1; Rutges J, 2010, OSTEOARTHR CARTILAGE, V18, P416, DOI 10.1016/j.joca.2009.09.009; Sakai D, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2226; Sakai D, 2009, SPINE, V34, P1448, DOI 10.1097/BRS.0b013e3181a55705; Spada S, 2002, EXTREMOPHILES, V6, P301, DOI 10.1007/s00792-001-0257-0; Strange DGT, 2012, J MECH BEHAV BIOMED, V11, P16, DOI 10.1016/j.jmbbm.2011.10.003; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Terpe K, 2003, APPL MICROBIOL BIOT, V60, P523, DOI 10.1007/s00253-002-1158-6; Thie Holger, 2009, V525, P309, DOI 10.1007/978-1-59745-554-1_16; Thomsen NK, 1996, NAT STRUCT BIOL, V3, P581, DOI 10.1038/nsb0796-581; Urban JPG, 2003, ARTHRITIS RES THER, V5, P120, DOI 10.1186/ar629; Yoon ST, 2003, SPINE, V28, P1773, DOI 10.1097/01.BRS.0000083204.44190.34; Zhang Y, 2007, SPINE, V32, P2515, DOI 10.1097/BRS.0b013e318158cc09	50	8	9	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2013	8	12							e83678	10.1371/journal.pone.0083678	http://dx.doi.org/10.1371/journal.pone.0083678			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276FP	24349544	Green Published, Green Submitted, gold			2023-01-03	WOS:000328734200098
J	Ho, LJ; Hung, LF; Liu, FC; Hou, TY; Lin, LC; Huang, CY; Lai, JH				Ho, Ling-Jun; Hung, Li-Feng; Liu, Feng-Cheng; Hou, Tsung-Yun; Lin, Leou-Chyr; Huang, Chuan-Yueh; Lai, Jenn-Haung			Ginkgo biloba Extract Individually Inhibits JNK Activation and Induces c-Jun Degradation in Human Chondrocytes: Potential Therapeutics for Osteoarthritis	PLOS ONE			English	Article							NF-KAPPA-B; NITRIC-OXIDE; ARTICULAR CHONDROCYTES; NEUROPSYCHIATRIC FEATURES; IN-VITRO; EXPRESSION; CARTILAGE; PATHWAY; PROTEIN-1; DISEASE	Osteoarthritis (OA) is a common joint disorder with varying degrees of inflammation. The ideal anti-OA drug should have immunomodulatory effects while at the same time having limited or no toxicity. We examined the anti-inflammatory effects of Ginkgo biloba extract (EGb) in interleukin-1 (IL-1)-stimulated human chondrocytes. Chondrocytes were prepared from cartilage specimens taken from patients with osteoarthritis who had received total hip or total knee replacement. The concentrations of chemokines and the degree of cell migration were determined by ELISA and chemotaxis assays, respectively. The activation of inducible nitric oxide synthase (iNOS), mitogen-activated protein kinases (MAPKs), activator protein-1 (AP-1), and nuclear factor-kappaB (NF-kappa B) was determined by immunoblotting, immunohistochemistry, and electrophoretic mobility shift assay. We found that EGb inhibited IL-1-induced production of chemokines, which in turn resulted in attenuation of THP-1 cell migration toward EGb-treated cell culture medium. EGb also suppressed IL-1-stimulated iNOS expression and release of nitric oxide (NO). The EGb-mediated suppression of the iNOS-NO pathway correlated with the attenuation of activator protein-1 (AP-1) but not nuclear factor-kappaB (NF-kappa B) DNA-binding activity. Of the mitogen-activated protein kinases (MAPKs), EGb inhibited only c-Jun N-terminal kinase (JNK). Unexpectedly, EGb selectively caused degradation of c-Jun protein. Further investigation revealed that EGb-mediated c-Jun degradation was preceded by ubiquitination of c-Jun and could be prevented by the proteosome inhibitor MG-132. The results imply that EGb protects against chondrocyte degeneration by inhibiting JNK activation and inducing ubiquitination-dependent c-Jun degradation. Although additional research is needed, our results suggest that EGb is a potential therapeutic agent for the treatment of OA.	[Ho, Ling-Jun; Hung, Li-Feng; Huang, Chuan-Yueh] Natl Hlth Res Inst, Inst Cellular & Syst Med, Zhunan, Taiwan; [Ho, Ling-Jun] China Med Univ, PhD Program Aging, Grad Inst Basic Med Sci, Taichung, Taiwan; [Liu, Feng-Cheng; Hou, Tsung-Yun] Tri Serv Gen Hosp, Natl Def Med Ctr, Dept Med, Taipei, Taiwan; [Lin, Leou-Chyr] Tri Serv Gen Hosp, Natl Def Med Ctr, Dept Orthopaed, Taipei, Taiwan; [Lai, Jenn-Haung] Natl Def Med Ctr, Grad Inst Med Sci, Taipei, Taiwan; [Lai, Jenn-Haung] Chang Gung Univ, Chang Gung Mem Hosp, Dept Internal Med, Div Allergy Immunol & Rheumatol, Tao Yuan, Taiwan	National Health Research Institutes - Taiwan; China Medical University Taiwan; National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; Chang Gung Memorial Hospital; Chang Gung University	Lai, JH (corresponding author), Natl Def Med Ctr, Grad Inst Med Sci, Taipei, Taiwan.	laiandho@gmail.com	Ho, Ling-Jun/B-1087-2010	Ho, Ling-Jun/0000-0003-3453-2913	National Health Research Institute [CS-102-PP-08]; National Science Council [NSC 101-2320-B-400-006-MY3, NSC 101-2314-B-182A-103-MY3]	National Health Research Institute(National Health Research Institutes - Taiwan); National Science Council(Ministry of Science and Technology, Taiwan)	The authors' work was supported in part by grants from National Health Research Institute (CS-102-PP-08) and National Science Council (NSC 101-2320-B-400-006-MY3 and NSC 101-2314-B-182A-103-MY3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abramson SB, 2008, OSTEOARTHR CARTILAGE, V16, pS15, DOI 10.1016/S1063-4584(08)60008-4; Abulencia JP, 2003, J BIOL CHEM, V278, P28388, DOI 10.1074/jbc.M301378200; Alaaeddine N, 2001, ARTHRITIS RHEUM-US, V44, P1633, DOI 10.1002/1529-0131(200107)44:7<1633::AID-ART286>3.0.CO;2-Z; Amieva H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052755; Arkin MR, 2009, CURR OPIN CHEM BIOL, V13, P284, DOI 10.1016/j.cbpa.2009.05.125; Borzi RM, 2000, ARTHRITIS RHEUM, V43, P1734, DOI 10.1002/1529-0131(200008)43:8<1734::AID-ANR9>3.0.CO;2-B; Cheng SM, 2003, BIOCHEM PHARMACOL, V66, P679, DOI 10.1016/S0006-2952(03)00388-5; Chu CR, 2004, AM J SPORT MED, V32, P191, DOI 10.1177/0363546503260743; Cybulska-Heinrich AK, 2012, MOL VIS, V18, P390; Fanning PJ, 2003, J BIOL CHEM, V278, P50940, DOI 10.1074/jbc.M305107200; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Hashimoto S, 1998, ARTHRITIS RHEUM-US, V41, P1266, DOI 10.1002/1529-0131(199807)41:7<1266::AID-ART18>3.0.CO;2-Y; Herrschaft H, 2012, J PSYCHIATR RES, V46, P716, DOI 10.1016/j.jpsychires.2012.03.003; Ho LJ, 2005, BIOCHEM PHARMACOL, V70, P200, DOI 10.1016/j.bcp.2005.04.039; Huang CY, 2009, EUR J CLIN INVEST, V39, P417, DOI 10.1111/j.1365-2362.2009.02106.x; Hung LF, 2008, IMMUNOL INVEST, V37, P675, DOI 10.1080/08820130802307237; Ishibashi Y, 2008, J CARD FAIL, V14, P724, DOI 10.1016/j.cardfail.2008.06.450; ISMAIEL S, 1992, BRIT J RHEUMATOL, V31, P369; Joshi-Barve S, 2003, HEPATOLOGY, V38, P1178, DOI 10.1053/jhep.2003.50470; Lim S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020301; Liu FC, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3127; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Melchiorri C, 1998, ARTHRITIS RHEUM-US, V41, P2165, DOI 10.1002/1529-0131(199812)41:12<2165::AID-ART11>3.3.CO;2-F; Mendes AF, 2002, INFLAMM RES, V51, P369, DOI 10.1007/PL00000317; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nakayama K, 2001, J IMMUNOL, V167, P1145, DOI 10.4049/jimmunol.167.3.1145; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Nishitani K, 2010, J CELL BIOCHEM, V109, P425, DOI 10.1002/jcb.22421; Ou HC, 2009, J APPL PHYSIOL, V106, P1674, DOI 10.1152/japplphysiol.91415.2008; Papachristou DJ, 2009, ARCH ORAL BIOL, V54, P1035, DOI 10.1016/j.archoralbio.2009.08.010; PELLETIER JP, 1993, AM J PATHOL, V142, P95; Pelletier JP, 2001, ARTHRITIS RHEUM-US, V44, P1237, DOI 10.1002/1529-0131(200106)44:6<1237::AID-ART214>3.0.CO;2-F; Peng SL, 2008, FRONT BIOSCI-LANDMRK, V13, P4218, DOI 10.2741/3001; Scanzello CR, 2011, ARTHRITIS RHEUM-US, V63, P391, DOI 10.1002/art.30137; Sohn DH, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3555; Weinmann S, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-14; Wolter S, 2008, MOL CELL BIOL, V28, P4407, DOI 10.1128/MCB.00535-07; Wu WL, 2009, EUR J IMMUNOL, V39, P3413, DOI 10.1002/eji.200939306; Yancheva S, 2009, AGING MENT HEALTH, V13, P183, DOI 10.1080/13607860902749057; Yuan GH, 2001, ARTHRITIS RHEUM-US, V44, P1056, DOI 10.1002/1529-0131(200105)44:5<1056::AID-ANR186>3.3.CO;2-L; Zadoyan G, 2012, EUR J CLIN PHARMACOL, V68, P553, DOI 10.1007/s00228-011-1174-5; Zenz R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2338	42	20	21	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2013	8	12							e82033	10.1371/journal.pone.0082033	http://dx.doi.org/10.1371/journal.pone.0082033			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276EG	24349175	Green Published, Green Submitted, gold			2023-01-03	WOS:000328730300071
J	Nakahara, S; Tomio, J; Takahashi, H; Ichikawa, M; Nishida, M; Morimura, N; Sakamoto, T				Nakahara, Shinji; Tomio, Jun; Takahashi, Hideto; Ichikawa, Masao; Nishida, Masamichi; Morimura, Naoto; Sakamoto, Tetsuya			Evaluation of pre-hospital administration of adrenaline (epinephrine) by emergency medical services for patients with out of hospital cardiac arrest in Japan: controlled propensity matched retrospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AMERICAN-HEART-ASSOCIATION; ADVANCED LIFE-SUPPORT; CARDIOPULMONARY-RESUSCITATION; CARDIOVASCULAR CARE; VENTRICULAR-FIBRILLATION; SURVIVAL; TRIAL; DEFIBRILLATION; HYPOTHERMIA; GUIDELINES	Objectives To evaluate the effectiveness of pre-hospital adrenaline (epinephrine) administered by emergency medical services to patients with out of hospital cardiac arrest. Design Controlled propensity matched retrospective cohort study, in which pairs of patients with or without (control) adrenaline were created with a sequential risk set matching based on time dependent propensity score. Setting Japan's nationwide registry database of patients with out of hospital cardiac arrest registered between January 2007 and December 2010. Participants Among patients aged 15-94 with out of hospital cardiac arrest witnessed by a bystander, we created 1990 pairs of patients with and without adrenaline with an initial rhythm of ventricular fibrillation or pulseless ventricular tachycardia (VF/VT) and 9058 pairs among those with non-VF/VT. Main outcome measures Overall and neurologically intact survival at one month or at discharge, whichever was earlier. Results After propensity matching, pre-hospital administration of adrenaline by emergency medical services was associated with a higher proportion of overall survival (17.0% v 13.4%; unadjusted odds ratio 1.34, 95% confidence interval 1.12 to 1.60) but not with neurologically intact survival (6.6% v 6.6%; 1.01, 0.78 to 1.30) among those with VF/VT; and higher proportions of overall survival (4.0% v 2.4%; odds ratio 1.72, 1.45 to 2.04) and neurologically intact survival (0.7% v 0.4%; 1.57, 1.04 to 2.37) among those with non-VF/VT. Conclusions Pre-hospital administration of adrenaline by emergency medical services improves the long term outcome in patients with out of hospital cardiac arrest, although the absolute increase of neurologically intact survival was minimal.	[Nakahara, Shinji] St Marianna Univ, Sch Med, Dept Epidemiol & Hlth Promot, Kawasaki, Kanagawa, Japan; [Tomio, Jun] Univ Tokyo, Dept Publ Hlth, Grad Sch Med, Tokyo, Japan; [Tomio, Jun] Tokyo Univ Hosp, Dept Disaster Med Management, Tokyo 113, Japan; [Takahashi, Hideto; Ichikawa, Masao] Univ Tsukuba, Fac Med, Tsukuba, Ibaraki, Japan; [Nishida, Masamichi] Toranomon Gen Hosp, Dept Emergency Med, Tokyo, Japan; [Morimura, Naoto] Yokohama City Univ, Grad Sch Med, Dept Emergency Med, Yokohama, Kanagawa 232, Japan; [Sakamoto, Tetsuya] Teikyo Univ, Sch Med, Dept Emergency Med, Tokyo 173, Japan	Saint Marianna University; University of Tokyo; University of Tokyo; University of Tsukuba; Toranomon Hospital; Yokohama City University; Teikyo University	Nakahara, S (corresponding author), Kanagawa Univ Human Serv, 1-10-1 Heiseicho, Yokosuka, Kanagawa 2388522, Japan.	snakahara-tky@umin.net		Nakahara, Shinji/0000-0001-7243-4797				Berg RA, 2010, CIRCULATION, V122, pS685, DOI 10.1161/CIRCULATIONAHA.110.970939; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bur A, 2001, INTENS CARE MED, V27, P1474, DOI 10.1007/s001340101045; Guo S, 2010, PROPENSITY SCORE ANA, P127; Hagihara A, 2012, JAMA-J AM MED ASSOC, V307, P1161, DOI 10.1001/jama.2012.294; Hayashi Y, 2012, CIRC J, V76, P1639, DOI 10.1253/circj.CJ-11-1433; HERLITZ J, 1995, RESUSCITATION, V29, P195, DOI 10.1016/0300-9572(94)00851-6; Holmberg M, 2002, RESUSCITATION, V54, P37, DOI 10.1016/S0300-9572(02)00048-5; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd, P339; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Jacobs IG, 2011, RESUSCITATION, V82, P1138, DOI 10.1016/j.resuscitation.2011.06.029; Kitamura T, 2010, NEW ENGL J MED, V362, P994, DOI 10.1056/NEJMoa0906644; Leuven E, PSMATCH2 STATA MODUL; Li YFP, 2001, J AM STAT ASSOC, V96, P870, DOI 10.1198/016214501753208573; Lu B, 2005, BIOMETRICS, V61, P721, DOI 10.1111/j.1541-0420.2005.00356.x; McQueen C, 2012, RESUSCITATION, V83, P921, DOI 10.1016/j.resuscitation.2012.06.001; Morrison LJ, 2010, CIRCULATION, V122, P8345, DOI 10.1161/CIRCULATIONAHA.110.971051; Nagao K, 2007, LANCET, V369, P920; Nakahara S, 2012, ACAD EMERG MED, V19, P782, DOI 10.1111/j.1553-2712.2012.01387.x; Olasveengen TM, 2012, RESUSCITATION, V83, P327, DOI 10.1016/j.resuscitation.2011.11.011; Olasveengen TM, 2009, JAMA-J AM MED ASSOC, V302, P2222, DOI 10.1001/jama.2009.1729; Ong MEH, 2007, ANN EMERG MED, V50, P635, DOI 10.1016/j.annemergmed.2007.03.028; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Shirako T, 2010, J JPN SOC EMERG MED, V13, P341; Stiell IG, 2004, NEW ENGL J MED, V351, P647, DOI 10.1056/NEJMoa040325; Tagami T, 2012, CIRCULATION, V126, P589, DOI 10.1161/CIRCULATIONAHA.111.086173; Tanigawa K, 2006, RESUSCITATION, V69, P365, DOI 10.1016/j.resuscitation.2006.04.001; Vandycke C, 2000, RESUSCITATION, V45, P161, DOI 10.1016/S0300-9572(00)00188-X	29	85	88	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 10	2013	347								f6829	10.1136/bmj.f6829	http://dx.doi.org/10.1136/bmj.f6829			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	273ZL	24326886	hybrid, Green Published			2023-01-03	WOS:000328574700001
J	Oeffinger, KC; Sklar, CA				Oeffinger, Kevin C.; Sklar, Charles A.			Childhood cancer, endocrine disorders, and cohort studies	LANCET			English	Editorial Material							LONG-TERM SURVIVORS; DIABETES-MELLITUS; RADIATION-THERAPY; RISK		[Oeffinger, Kevin C.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Sklar, Charles A.] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Oeffinger, KC (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA.	oeffingk@mskcc.org			NATIONAL CANCER INSTITUTE [K05CA160724] Funding Source: NIH RePORTER; NCI NIH HHS [K05 CA160724] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		de Fine Licht S, 2014, LANCET; de Vathaire F, 2012, LANCET ONCOL, V13, P1002, DOI 10.1016/S1470-2045(12)70323-6; FUKS Z, 1976, CANCER-AM CANCER SOC, V37, P1152, DOI 10.1002/1097-0142(197602)37:2+<1152::AID-CNCR2820370826>3.0.CO;2-T; Geenen MM, 2007, JAMA-J AM MED ASSOC, V297, P2705, DOI 10.1001/jama.297.24.2705; Kremer LCM, 2013, PEDIATR BLOOD CANCER, V60, P543, DOI 10.1002/pbc.24445; LUSHBAUGH CC, 1976, CANCER, V37, P1111, DOI 10.1002/1097-0142(197602)37:2+<1111::AID-CNCR2820370821>3.0.CO;2-E; Meacham LR, 2009, ARCH INTERN MED, V169, P1381, DOI 10.1001/archinternmed.2009.209; Oeffinger KC, 2007, JAMA-J AM MED ASSOC, V297, P2762, DOI 10.1001/jama.297.24.2762; Oeffinger KC, 2012, LANCET ONCOL, V13, P961, DOI 10.1016/S1470-2045(12)70340-6; SHALET SM, 1976, CANCER, V37, P1144, DOI 10.1002/1097-0142(197602)37:2+<1144::AID-CNCR2820370824>3.0.CO;2-U	10	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2014	383	9933					1950	1952		10.1016/S0140-6736(14)60114-8	http://dx.doi.org/10.1016/S0140-6736(14)60114-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AI4PV	24556021	Green Accepted			2023-01-03	WOS:000336848200006
J	Ecker, JL				Ecker, Jeffrey L.			NEW ENGLAND JOURNAL of MEDICINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								The case of Marlise Munoz, in which a Texas hospital was made to withdraw support from a pregnant woman who had been brain dead for 2 months, should underscore women's right to determine the course of their end-of-life care, whether or not they are pregnant. Marlise Munoz was 33 years old and the mother of a 15-month-old when she collapsed on November 26, 2013, from what was later determined to be a massive pulmonary embolism. Initially described as apneic but alive, she was brought to the county hospital where her family was soon told that she was brain dead. Ms. Munoz and her husband, both emergency medical technicians (EMTs), had discussed their feelings about such situations. So Erik Munoz felt confident in asserting that his wife would not want continued support. Her other family members agreed, and they requested withdrawal of ventilation and other measures ...	[Ecker, Jeffrey L.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA; [Ecker, Jeffrey L.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Ecker, JL (corresponding author), Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA.							Committee on Ethics, 2008, Obstet Gynecol, V111, P1021, DOI 10.1097/AOG.0b013e3181713d92; Feldman DM, 2000, OBSTET GYNECOL SURV, V55, P708, DOI 10.1097/00006254-200011000-00023	2	10	10	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 6	2014	370	10					889	891		10.1056/NEJMp1400969	http://dx.doi.org/10.1056/NEJMp1400969			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AC2EB	24499176				2023-01-03	WOS:000332309800003
J	Lee, TF; Chao, PJ; Ting, HM; Chang, LY; Huang, YJ; Wu, JM; Wang, HY; Horng, MF; Chang, CM; Lan, JH; Huang, YY; Fang, FM; Leung, SW				Lee, Tsair-Fwu; Chao, Pei-Ju; Ting, Hui-Min; Chang, Liyun; Huang, Yu-Jie; Wu, Jia-Ming; Wang, Hung-Yu; Horng, Mong-Fong; Chang, Chun-Ming; Lan, Jen-Hong; Huang, Ya-Yu; Fang, Fu-Min; Leung, Stephen Wan			Using Multivariate Regression Model with Least Absolute Shrinkage and Selection Operator (LASSO) to Predict the Incidence of Xerostomia after Intensity-Modulated Radiotherapy for Head and Neck Cancer	PLOS ONE			English	Article							QUALITY-OF-LIFE; 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; COMPLICATION PROBABILITY-MODELS; PATIENT-RATED XEROSTOMIA; NASOPHARYNGEAL CARCINOMA; CLINICAL FACTORS; STICKY SALIVA; NTCP MODELS; CONVENTIONAL RADIOTHERAPY; GLAND FUNCTION	Purpose: The aim of this study was to develop a multivariate logistic regression model with least absolute shrinkage and selection operator (LASSO) to make valid predictions about the incidence of moderate-to-severe patient-rated xerostomia among head and neck cancer (HNC) patients treated with IMRT. Methods and Materials: Quality of life questionnaire datasets from 206 patients with HNC were analyzed. The European Organization for Research and Treatment of Cancer QLQ-H&N35 and QLQ-C30 questionnaires were used as the endpoint evaluation. The primary endpoint (grade 3(+) xerostomia) was defined as moderate-to-severe xerostomia at 3 (XER3m) and 12 months (XER12m) after the completion of IMRT. Normal tissue complication probability (NTCP) models were developed. The optimal and suboptimal numbers of prognostic factors for a multivariate logistic regression model were determined using the LASSO with bootstrapping technique. Statistical analysis was performed using the scaled Brier score, Nagelkerke R-2, chi-squared test, Omnibus, Hosmer-Lemeshow test, and the AUC. Results: Eight prognostic factors were selected by LASSO for the 3-month time point: Dmean-c, Dmean-i, age, financial status, T stage, AJCC stage, smoking, and education. Nine prognostic factors were selected for the 12-month time point: Dmean-i, education, Dmean-c, smoking, T stage, baseline xerostomia, alcohol abuse, family history, and node classification. In the selection of the suboptimal number of prognostic factors by LASSO, three suboptimal prognostic factors were fine-tuned by Hosmer-Lemeshow test and AUC, i.e., Dmean-c, Dmean-i, and age for the 3-month time point. Five suboptimal prognostic factors were also selected for the 12-month time point, i.e., Dmean-i, education, Dmean-c, smoking, and T stage. The overall performance for both time points of the NTCP model in terms of scaled Brier score, Omnibus, and Nagelkerke R-2 was satisfactory and corresponded well with the expected values. Conclusions: Multivariate NTCP models with LASSO can be used to predict patient-rated xerostomia after IMRT.	[Lee, Tsair-Fwu; Chang, Chun-Ming] Natl Kaohsiung Univ Appl Sci, Med Phys & Informat Lab Elect Engn, Kaohsiung 807, Taiwan; [Chao, Pei-Ju; Ting, Hui-Min; Huang, Yu-Jie; Lan, Jen-Hong; Huang, Ya-Yu; Fang, Fu-Min] Kaohsiung Chang Gung Mem Hosp, Dept Radiat Oncol, Kaohsiung, Taiwan; [Chao, Pei-Ju; Ting, Hui-Min; Huang, Yu-Jie; Lan, Jen-Hong; Huang, Ya-Yu; Fang, Fu-Min] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Ting, Hui-Min; Wang, Hung-Yu; Horng, Mong-Fong; Lan, Jen-Hong] Natl Kaohsiung Univ Appl Sci, Dept Elect Engn, Kaohsiung 807, Taiwan; [Chang, Liyun] I Shou Univ, Dept Med Imaging & Radiol Sci, Kaohsiung, Taiwan; [Wu, Jia-Ming] E Da Hosp, Dept Radiat Oncol, Kaohsiung, Taiwan; [Leung, Stephen Wan] Kaohsiung Yuans Gen Hosp, Dept Radiat Oncol, Kaohsiung, Taiwan	National Kaohsiung University of Science & Technology; Chang Gung Memorial Hospital; Chang Gung University; National Kaohsiung University of Science & Technology; I Shou University; E-Da Hospital	Fang, FM (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Radiat Oncol, Kaohsiung, Taiwan.	fang2569@gmail.com; lwan@ms36.hinet.net	chao, P/GSD-8001-2022	Lee, Tsair-Fwu/0000-0002-3112-3594	National Science Council (NSC) of the Executive Yuan of the Republic of China [NSC-101-2221-E-151-007-MY3, NSC-102-2221-E-182A-002]	National Science Council (NSC) of the Executive Yuan of the Republic of China	This study was supported financially, in part, by grants from the National Science Council (NSC) of the Executive Yuan of the Republic of China, (NSC-101-2221-E-151-007-MY3, and NSC-102-2221-E-182A-002). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beetz I, 2013, ACTA ONCOL, P1; Beetz I, 2012, RADIOTHER ONCOL, V105, P101, DOI 10.1016/j.radonc.2012.03.004; Beetz I, 2012, RADIOTHER ONCOL, V105, P94, DOI 10.1016/j.radonc.2011.11.006; Beetz I, 2012, RADIOTHER ONCOL, V105, P86, DOI 10.1016/j.radonc.2011.05.010; Bjordal K, 1999, J CLIN ONCOL, V17, P1008, DOI 10.1200/JCO.1999.17.3.1008; Chen WC, 2009, ORAL ONCOL, V45, P505, DOI 10.1016/j.oraloncology.2008.07.002; Colombani C, 2013, J DAIRY SCI, V96, P575, DOI 10.3168/jds.2011-5225; Deasy JO, 2010, INT J RADIAT ONCOL, V76, pS58, DOI 10.1016/j.ijrobp.2009.06.090; Eisbruch A, 2001, INT J RADIAT ONCOL, V50, P695, DOI 10.1016/S0360-3016(01)01512-7; Eisbruch A, 1999, INT J RADIAT ONCOL, V45, P577, DOI 10.1016/S0360-3016(99)00247-3; El Naqa I, 2006, INT J RADIAT ONCOL, V64, P1275, DOI 10.1016/j.ijrobp.2005.11.022; Fang FM, 2010, RADIOTHER ONCOL, V97, P263, DOI 10.1016/j.radonc.2010.05.022; Fortin I, 2013, HEAD NECK J SCI SPEC; FRANZEN L, 1992, EUR J CANCER, V28A, P457, DOI 10.1016/S0959-8049(05)80076-0; Graff P, 2007, INT J RADIAT ONCOL, V67, P1309, DOI 10.1016/j.ijrobp.2006.11.012; Hastie T., 2005, ELEMENTS STAT LEARNI, V27, P83, DOI [10.1007/BF02985802, 10.1007/978-0-387-84858-7]; Henson BS, 2001, ORAL ONCOL, V37, P84, DOI 10.1016/S1368-8375(00)00063-4; Hsiung CY, 2006, INT J RADIAT ONCOL, V66, P454, DOI 10.1016/j.ijrobp.2006.04.033; Kaneko M, 1998, ORAL ONCOL, V34, P140, DOI 10.1016/S1368-8375(97)00087-0; Kwong DLW, 2004, CANCER, V101, P1584, DOI 10.1002/cncr.20552; Leal SC, 2010, GERODONTOLOGY, V27, P129, DOI 10.1111/j.1741-2358.2009.00293.x; Lee TF, 2012, CLIN ONCOL-UK, V24, P196, DOI 10.1016/j.clon.2011.06.006; Lee TF, 2013, RADIOTHER ONCOL, V106, P352, DOI 10.1016/j.radonc.2012.11.013; Leung SW, 2013, BMC CANCER, V5, p[9, 1]; Lim CH, 2012, STUD HEALTH TECHNOL, V176, P255, DOI 10.3233/978-1-61499-067-3-255; Moiseenko V, 2012, INT J RADIAT ONCOL, V82, P1108, DOI 10.1016/j.ijrobp.2011.04.020; Nutting CM, 2011, LANCET ONCOL, V12, P127, DOI 10.1016/S1470-2045(10)70290-4; Ogutu Joseph O, 2012, BMC Proc, V6 Suppl 2, pS10, DOI 10.1186/1753-6561-6-S2-S10; Rad M, 2013, J ORAL HEALTH ORAL E, V2, P28; Rasmussen MA, 2012, TUTORIAL LASSO APPRO; Skwarchuk MW, 2000, INT J RADIAT ONCOL, V47, P103, DOI 10.1016/S0360-3016(99)00560-X; Sturgis EM, 2004, SEMIN ONCOL, V31, P726, DOI 10.1053/j.seminoncol.2004.09.013; Sturgis EM, 2007, CANCER-AM CANCER SOC, V110, P1429, DOI 10.1002/cncr.22963; Teppola P, 2013, ANAL CHIM ACTA, V768, P57, DOI 10.1016/j.aca.2013.01.005; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Tribius S, 2013, STRAHLENTHER ONKOL, V189, P216, DOI 10.1007/s00066-012-0257-2; van de Water TA, 2009, RADIOTHER ONCOL, V93, P545, DOI 10.1016/j.radonc.2009.09.008; van der Schaaf A, 2012, RADIOTHER ONCOL, V105, P115, DOI 10.1016/j.radonc.2011.12.006; Xu CJ, 2012, INT J RADIAT ONCOL, V84, pE123, DOI 10.1016/j.ijrobp.2012.02.022; Xu CJ, 2012, INT J RADIAT ONCOL, V82, pE677, DOI 10.1016/j.ijrobp.2011.09.036; Xu J, 2013, IET COMPUT VIS, V7, P48, DOI 10.1049/iet-cvi.2011.0193	42	58	61	5	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2014	9	2							e89700	10.1371/journal.pone.0089700	http://dx.doi.org/10.1371/journal.pone.0089700			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC3DW	24586971	Green Submitted, Green Published, gold			2023-01-03	WOS:000332396200075
J	Wang, TJ; Chen, JR; Wang, WJ; Wang, YJ; Tseng, GF				Wang, Tsyr-Jiuan; Chen, Jeng-Rung; Wang, Wen-Jay; Wang, Yueh-Jan; Tseng, Guo-Fang			Genistein Partly Eases Aging and Estropause-Induced Primary Cortical Neuronal Changes in Rats	PLOS ONE			English	Article							ESTROGEN-RECEPTOR-ALPHA; DENDRITIC SPINE DENSITY; BETA MESSENGER-RNA; MIDDLE-AGED RATS; COGNITIVE FUNCTION; PREFRONTAL CORTEX; PYRAMIDAL NEURONS; ESTRADIOL REPLACEMENT; SPATIAL MEMORY; ER-BETA	Gonadal hormones can modulate brain morphology and behavior. Recent studies have shown that hypogonadism could result in cortical function deficits. To this end, hormone therapy has been used to ease associated symptoms but the risk may outweigh the benefits. Here we explored whether genistein, a phytoestrogen, is effective in restoring the cognitive and central neuronal changes in late middle age and surgically estropause female rats. Both animal groups showed poorer spatial learning than young adults. The dendritic arbors and spines of the somatosensory cortical and CA1 hippocampal pyramidal neurons were revealed with intracellular dye injection and analyzed. The results showed that dendritic spines on these neurons were significantly decreased. Remarkably, genistein treatment rescued spatial learning deficits and restored the spine density on all neurons in the surgically estropause young females. In late middle age females, genistein was as effective as estradiol in restoring spines; however, the recovery was less thorough than on young OHE rats. Neither genistein nor estradiol rectified the shortened dendritic arbors of the aging cortical pyramidal neurons suggesting that dendritic arbors and spines are differently modulated. Thus, genistein could work at central level to restore excitatory connectivity and appears to be potent alternative to estradiol for easing aging and menopausal syndromes.	[Wang, Tsyr-Jiuan] Natl Taichung Univ Sci & Technol, Dept Nursing, Taichung, Taiwan; [Chen, Jeng-Rung; Wang, Wen-Jay] Natl Chung Hsing Univ, Coll Vet Med, Dept Vet Med, Taichung 40227, Taiwan; [Wang, Yueh-Jan; Tseng, Guo-Fang] Tzu Chi Univ, Coll Med, Dept Anat, Hualien, Taiwan	National Taichung University of Science & Technology; National Chung Hsing University; Tzu Chi University	Wang, TJ (corresponding author), Natl Taichung Univ Sci & Technol, Dept Nursing, Taichung, Taiwan.	wtj@nutc.edu.tw; guofang@mail.tcu.edu.tw		Chen, Jeng-Rung/0000-0002-4429-283X	National Science Council of Taiwan [NSC102-2320-B-005-001-MY3, NSC100-2320-B-320-002, NSC100-2320-B-320-001]; NUTC [99T23308]; Tzu-Chi University [TCIRP98006]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); NUTC; Tzu-Chi University	This work was supported by research grants from the National Science Council of Taiwan to Chen, J-R (NSC102-2320-B-005-001-MY3); Wang, Y-J (NSC100-2320-B-320-002); and Tseng, G-F (NSC100-2320-B-320-001). This work was also supported by grants from the NUTC to Wang, T-J (99T23308) and Tzu-Chi University to Wang, Y-J and Tseng, G-F (TCIRP98006). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams M, 2001, IEEE COMMUN MAG, V39, P98, DOI 10.1109/35.925676; Adams MM, 2002, J NEUROSCI, V22, P3608; Adams MM, 2003, CEREB CORTEX, V13, P1271, DOI 10.1093/cercor/bhg078; Adlercreutz H, 1997, ANN MED, V29, P95, DOI 10.3109/07853899709113696; Akama KT, 2003, J NEUROSCI, V23, P2333; ANDREWS TJ, 1994, J NEUROSCI, V14, P3048; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Beeri R, 1997, J NEUROCHEM, V69, P2441; Bimonte-Nelson HA, 2006, EUR J NEUROSCI, V24, P229, DOI 10.1111/j.1460-9568.2006.04867.x; Bohacek J, 2009, J NEUROENDOCRINOL, V21, P640, DOI 10.1111/j.1365-2826.2009.01882.x; Burke SN, 2006, NAT REV NEUROSCI, V7, P30, DOI 10.1038/nrn1809; Cassidy A, 1999, CURR OPIN LIPIDOL, V10, P47, DOI 10.1097/00041433-199902000-00009; Chen JR, 2010, NEUROSCIENCE, V167, P414, DOI 10.1016/j.neuroscience.2010.02.028; Chen JR, 2009, NEUROSCIENCE, V161, P1104, DOI 10.1016/j.neuroscience.2009.04.022; Chen JR, 2013, BRAIN STRUCT FUNCT, V218, P1407, DOI 10.1007/s00429-012-0465-7; Chen JR, 2009, CEREB CORTEX, V19, P2719, DOI 10.1093/cercor/bhp048; Chen JR, 2004, J NEUROTRAUM, V21, P1640, DOI 10.1089/0897715042441729; Chen JR, 2003, J NEUROTRAUM, V20, P767, DOI 10.1089/089771503767869999; Choi JM, 2003, ENDOCRINOLOGY, V144, P4734, DOI 10.1210/en.2003-0216; Cooke BM, 2005, J NEUROBIOL, V64, P34, DOI 10.1002/neu.20143; Daniel JM, 2006, ENDOCRINOLOGY, V147, P607, DOI 10.1210/en.2005-0998; del Valle J, 2012, J ALZHEIMERS DIS, V32, P233, DOI 10.3233/JAD-2012-120718; Dickstein DL, 2012, NEUROSCIENCE, DOI [10.1016/j.neuroscience.2012.09.077, DOI 10.1016/J.NEUR0SCI-ENCE.2012.09.077]; Doumouchtsis KK, 2009, ENDOCR RES, V34, P90, DOI 10.1080/07435800903127598; FERRER I, 1990, ACTA NEUROPATHOL, V79, P680, DOI 10.1007/BF00294247; Filardo EJ, 2005, TRENDS ENDOCRIN MET, V16, P362, DOI 10.1016/j.tem.2005.08.005; Foster TC, 2005, FRONT NEUROENDOCRIN, V26, P51, DOI 10.1016/j.yfrne.2005.04.004; Foster TC, 2003, NEUROBIOL AGING, V24, P839, DOI 10.1016/S0197-4580(03)00014-9; Foster TC, 2012, HIPPOCAMPUS, V22, P656, DOI 10.1002/hipo.20935; Fowler CD, 2003, J NEUROBIOL, V57, P257, DOI 10.1002/neu.10273; FRANKFURT M, 1990, NEUROENDOCRINOLOGY, V51, P530, DOI 10.1159/000125387; GARCIASEGURA LM, 1986, BRAIN RES, V366, P131, DOI 10.1016/0006-8993(86)91287-4; Gibbs RB, 2010, ENDOCR REV, V31, P224, DOI 10.1210/er.2009-0036; GOULD E, 1990, J NEUROSCI, V10, P1286; Hao JD, 2006, J NEUROSCI, V26, P2571, DOI 10.1523/JNEUROSCI.3440-05.2006; Hart SA, 2001, J COMP NEUROL, V440, P144, DOI 10.1002/cne.1376; HORNER CH, 1993, PROG NEUROBIOL, V41, P281, DOI 10.1016/0301-0082(93)90002-A; Jelks KB, 2007, J NEUROSCI, V27, P6903, DOI 10.1523/JNEUROSCI.0909-07.2007; Kalita K, 2005, HIPPOCAMPUS, V15, P404, DOI 10.1002/hipo.20066; Knight DC, 1996, OBSTET GYNECOL, V87, P897; Kritzer MF, 2006, CEREB CORTEX, V16, P1181, DOI 10.1093/cercor/bhj059; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lee YB, 2005, J NUTR BIOCHEM, V16, P641, DOI 10.1016/j.jnutbio.2005.06.010; Lephart ED, 2002, NEUROTOXICOL TERATOL, V24, P5, DOI 10.1016/S0892-0362(01)00197-0; Lephart ED, 2005, BRAIN RES BULL, V65, P193, DOI 10.1016/j.brainresbull.2004.11.022; Lethaby A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003122.pub2; Luine V, 2006, BRAIN RES, V1126, P183, DOI 10.1016/j.brainres.2006.07.016; Luine V.N., 2011, CURR GERONTOL GERIAT, V2011, DOI DOI 10.1155/2011/316386; Ma CHE, 2010, CELL TISSUE RES, V339, P297, DOI 10.1007/s00441-009-0897-4; Markham JA, 2002, HORM BEHAV, V42, P284, DOI 10.1006/hbeh.2002.1819; Markowska AL, 2002, J NEUROSCI, V22, P10985; Mehra RD, 2005, BRAIN RES, V1056, P22, DOI 10.1016/j.brainres.2005.06.073; Milner TA, 2005, J COMP NEUROL, V491, P81, DOI 10.1002/cne.20724; Milner TA, 2001, J COMP NEUROL, V429, P355; Miranda P, 1999, J NEUROSCI, V19, P3316; MIYAKAWA M, 1987, BRAIN RES, V436, P184, DOI 10.1016/0006-8993(87)91574-5; Morissette M, 2008, J NEUROENDOCRINOL, V20, P1006, DOI 10.1111/j.1365-2826.2008.01754.x; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; PEGGS JF, 1992, AM FAM PHYSICIAN, V46, P1763; Perez SE, 2003, DEV BRAIN RES, V145, P117, DOI 10.1016/S0165-3806(03)00223-2; Rapp PR, 2003, J NEUROSCI, V23, P5708; Rodgers SP, 2010, ENDOCRINOLOGY, V151, P1194, DOI 10.1210/en.2009-1245; Ryan J, 2008, INT PSYCHOGERIATR, V20, P47, DOI 10.1017/S1041610207006485; Setchell KDR, 1999, J NUTR, V129, p758S, DOI 10.1093/jn/129.3.758S; Shughrue PJ, 2000, NEUROSCIENCE, V96, P41, DOI 10.1016/S0306-4522(99)00520-5; Smith Caroline C, 2009, Psychoneuroendocrinology, V34 Suppl 1, pS130, DOI 10.1016/j.psyneuen.2009.06.003; Talboom JS, 2008, NEUROBIOL LEARN MEM, V90, P155, DOI 10.1016/j.nlm.2008.04.002; Towart LA, 2003, J COMP NEUROL, V463, P390, DOI 10.1002/cne.10753; Tseng GF, 1996, J NEUROPHYSIOL, V75, P248, DOI 10.1152/jn.1996.75.1.248; Tseng GF, 1996, ACTA ANAT, V155, P184; Wallace M, 2006, BRAIN RES, V1126, P176, DOI 10.1016/j.brainres.2006.07.064; Wallace M, 2007, ANN NY ACAD SCI, V1097, P54, DOI 10.1196/annals.1379.026; Wang TJ, 2009, NEUROSCIENCE, V158, P776, DOI 10.1016/j.neuroscience.2008.10.025; Wang VC, 2011, NEUROTOXICOL TERATOL, V33, P405, DOI 10.1016/j.ntt.2011.01.003; Waters EM, 2011, BRAIN RES, V1379, P86, DOI 10.1016/j.brainres.2010.09.069; Westwood FR, 2008, TOXICOL PATHOL, V36, P375, DOI 10.1177/0192623308315665; Witty CF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051385; WOOLLEY CS, 1992, J NEUROSCI, V12, P2549; WOOLLEY CS, 1990, J NEUROSCI, V10, P4035, DOI 10.1523/JNEUROSCI.10-12-04035.1990; Woolley CS, 1998, EPILEPSIA, V39, pS2, DOI 10.1111/j.1528-1157.1998.tb02601.x; Wu WW, 2011, J NEUROSCI, V31, P2638, DOI 10.1523/JNEUROSCI.6081-10.2011; Xu J, 2007, J MOL NEUROSCI, V31, P101, DOI 10.1007/s12031-007-0010-y; Xu XH, 2007, PLANTA MED, V73, P1047, DOI 10.1055/s-2007-981564; Yamaguchi N, 2014, BRAIN RES, V1543, P49, DOI 10.1016/j.brainres.2013.11.010; Yamaguchi-Shima N, 2007, BRAIN RES, V1155, P34, DOI 10.1016/j.brainres.2007.04.016; Yamamoto H, 2007, J STEROID BIOCHEM, V107, P70, DOI 10.1016/j.jsbmb.2007.03.035; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yildirim M, 2008, NEUROSCIENCE, V152, P360, DOI 10.1016/j.neuroscience.2008.01.004; Yuen GS, 2011, BRAIN RES, V1379, P44, DOI 10.1016/j.brainres.2010.07.067	89	8	8	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2014	9	2							e89819	10.1371/journal.pone.0089819	http://dx.doi.org/10.1371/journal.pone.0089819			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC2ZX	24587060	Green Submitted, Green Published, gold			2023-01-03	WOS:000332385900088
J	Potuckova, E; Jansova, H; Machacek, M; Vavrova, A; Haskova, P; Tichotova, L; Richardson, V; Kalinowski, DS; Richardson, DR; Simunek, T				Potuckova, Eliska; Jansova, Hana; Machacek, Miloslav; Vavrova, Anna; Haskova, Pavlina; Tichotova, Lucie; Richardson, Vera; Kalinowski, Danuta S.; Richardson, Des R.; Simunek, Tomas			Quantitative Analysis of the Anti-Proliferative Activity of Combinations of Selected Iron-Chelating Agents and Clinically Used Anti-Neoplastic Drugs	PLOS ONE			English	Article							CELL-CYCLE ARREST; SALICYLALDEHYDE ISONICOTINOYL HYDRAZONE; BREAST-CANCER; ANTITUMOR-ACTIVITY; RIBONUCLEOTIDE REDUCTASE; OXIDATIVE STRESS; IN-VIVO; ANTHRACYCLINE CARDIOTOXICITY; METASTASIS SUPPRESSOR; IONIZING-RADIATION	Recent studies have demonstrated that several chelators possess marked potential as potent anti-neoplastic drugs and as agents that can ameliorate some of the adverse effects associated with standard chemotherapy. Anti-cancer treatment employs combinations of several drugs that have different mechanisms of action. However, data regarding the potential interactions between iron chelators and established chemotherapeutics are lacking. Using estrogen receptor-positive MCF-7 breast cancer cells, we explored the combined anti-proliferative potential of four iron chelators, namely: desferrioxamine (DFO), salicylaldehyde isonicotinoyl hydrazone (SIH), (E)-N'-[1-(2-hydroxy-5-nitrophenyl) ethyliden] isonicotinoyl hydrazone (NHAPI), and di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT), plus six selected anti-neoplastic drugs. These six agents are used for breast cancer treatment and include: paclitaxel, 5-fluorouracil, doxorubicin, methotrexate, tamoxifen and 4-hydroperoxycyclophosphamide (an active metabolite of cyclophosphamide). Our quantitative chelator-drug analyses were designed according to the Chou-Talalay method for drug combination assessment. All combinations of these agents yielded concentration-dependent, anti-proliferative effects. The hydrophilic siderophore, DFO, imposed antagonism when used in combination with all six anti-tumor agents and this antagonistic effect increased with increasing dose. Conversely, synergistic interactions were observed with combinations of the lipophilic chelators, NHAPI or Dp44mT, with doxorubicin and also the combinations of SIH, NHAPI or Dp44mT with tamoxifen. The combination of Dp44mT with anti-neoplastic agents was further enhanced following formation of its redox-active iron and especially copper complexes. The most potent combinations of Dp44mT and NHAPI with tamoxifen were confirmed as synergistic using another estrogen receptor-expressing breast cancer cell line, T47D, but not estrogen receptor-negative MDA-MB-231 cells. Furthermore, the synergy of NHAPI and tamoxifen was confirmed using MCF-7 cells by electrical impedance data, a mitochondrial inner membrane potential assay and cell cycle analyses. This is the first systematic investigation to quantitatively assess interactions between Fe chelators and standard chemotherapies using breast cancer cells. These studies are vital for their future clinical development.	[Potuckova, Eliska; Jansova, Hana; Machacek, Miloslav; Vavrova, Anna; Haskova, Pavlina; Tichotova, Lucie; Simunek, Tomas] Charles Univ Prague, Fac Pharm Hradec Kralove, Dept Biochem Sci, Prague, Czech Republic; [Richardson, Vera; Kalinowski, Danuta S.; Richardson, Des R.] Univ Sydney, Bosch Inst, Mol Pharmacol & Pathol Program, Sydney, NSW 2006, Australia; [Richardson, Vera; Kalinowski, Danuta S.; Richardson, Des R.] Univ Sydney, Dept Pathol, Sydney, NSW 2006, Australia	Charles University Prague; University of Sydney; University of Sydney	Richardson, DR (corresponding author), Univ Sydney, Bosch Inst, Mol Pharmacol & Pathol Program, Sydney, NSW 2006, Australia.	d.richardson@med.usyd.edu.au; Tomas.Simunek@faf.cuni.cz	Jirkovska, Anna/E-8419-2012; Hašková, Pavlína/ABC-6019-2021; Simunek, Tomas/A-3938-2008; Jansova, Hana/S-5847-2017; Machacek, Miloslav/T-3378-2017	Jirkovska, Anna/0000-0002-0131-6010; Simunek, Tomas/0000-0001-5464-4176; Jansova, Hana/0000-0002-5377-518X; Machacek, Miloslav/0000-0001-7221-5914; Haskova, Pavlina/0000-0002-1179-8885; Kalinowski, Danuta/0000-0002-9303-7405; Richardson, Des/0000-0002-5506-3274; Richardson, Des/0000-0003-0960-6415	Charles University [GAUK 299511, SW 267004]; European Social Fund; state budget of the Czech Republic (Operational Program) [CZ.1.07/2.3.00/30.0022]; National Health and Medical Research Council (NHMRC) [571123, 1048972];  [1021607];  [1021601]	Charles University; European Social Fund(European Social Fund (ESF)); state budget of the Czech Republic (Operational Program); National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); ; 	This study was supported by the Charles University (projects GAUK 299511, SW 267004) and the European Social Fund and the state budget of the Czech Republic (Operational Program CZ.1.07/2.3.00/30.0022). DRR thanks the National Health and Medical Research Council (NHMRC) for a Senior Principal Research Fellowship (571123) and Project Grants (1021607 and 1021601). DSK also thanks the NHMRC for a Project Grant (1048972). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abassi YA, 2009, CHEM BIOL, V16, P712, DOI 10.1016/j.chembiol.2009.05.011; BECTON DL, 1989, CANCER RES, V49, P4809; Bendova P, 2010, CHEM RES TOXICOL, V23, P1105, DOI 10.1021/tx100125t; Berndt C, 2010, BIOCHEM J, V432, P295, DOI 10.1042/BJ20100996; Buss JL, 2004, CURR TOP MED CHEM, V4, P1623, DOI 10.2174/1568026043387269; Buss JL, 2003, CURR MED CHEM, V10, P1021, DOI 10.2174/0929867033457638; CARMINE TC, 1995, CANCER LETT, V94, P219, DOI 10.1016/0304-3835(95)03852-N; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cooper CE, 1996, J BIOL CHEM, V271, P20291, DOI 10.1074/jbc.271.34.20291; Cui Y, 2007, CANCER EPIDEM BIOMAR, V16, P1682, DOI 10.1158/1055-9965.EPI-07-0187; DONFRANCESCO A, 1995, EUR J CANCER, V31A, P612, DOI 10.1016/0959-8049(95)00068-T; Doulias PT, 2003, FREE RADICAL BIO MED, V35, P719, DOI 10.1016/S0891-5849(03)00396-4; Durken M, 2000, FREE RADICAL BIO MED, V28, P887, DOI 10.1016/S0891-5849(00)00174-X; EDWARD JT, 1988, J CHEM ENG DATA, V33, P538, DOI 10.1021/je00054a044; Fisher B, 2005, JNCI-J NATL CANCER I, V97, P1652, DOI 10.1093/jnci/dji372; Fu D, 2007, BLOOD, V110, P752, DOI 10.1182/blood-2007-03-076737; Garner DL, 1999, MOL REPROD DEV, V53, P222, DOI 10.1002/(SICI)1098-2795(199906)53:2&lt;222::AID-MRD11&gt;3.0.CO;2-L; Gianni L, 2007, CARDIOVASC TOXICOL, V7, P67, DOI 10.1007/s12012-007-0013-5; Goldhirsch A, 2001, J CLIN ONCOL, V19, P3817, DOI 10.1200/JCO.2001.19.18.3817; Goodman L. S., 2008, GOODMAN GILMANS MANU; Haskova P, 2011, FREE RADICAL BIO MED, V50, P537, DOI 10.1016/j.freeradbiomed.2010.12.004; Hatcher HC, 2009, FUTURE MED CHEM, V1, P1643, DOI 10.4155/FMC.09.121; HERSHKO C, 1993, J LAB CLIN MED, V122, P245; Hosokawa Yuko, 2010, Gan To Kagaku Ryoho, V37, P1805; Hruskova K, 2011, CHEM RES TOXICOL, V24, P290, DOI 10.1021/tx100359t; Jansson PJ, 2010, J INORG BIOCHEM, V104, P1224, DOI 10.1016/j.jinorgbio.2010.07.012; Jiang XP, 2002, ANTICANCER RES, V22, P2685; Kabat GC, 2007, CANCER CAUSE CONTROL, V18, P1047, DOI 10.1007/s10552-007-9058-9; Kalinowski DS, 2005, PHARMACOL REV, V57, P547, DOI 10.1124/pr.57.4.2; Kovacevic Z, 2011, MOL PHARM; Kovacevic Z, 2008, BBA-MOL CELL RES, V1783, P1981, DOI 10.1016/j.bbamcr.2008.05.016; Kovacevic Z, 2011, MOL PHARMACOL, V80, P598, DOI 10.1124/mol.111.073627; Kovacevic Z, 2011, CURR TOP MED CHEM, V11, P483, DOI 10.2174/156802611794785190; Kwiatkowski JL, 2011, HEMATOL-AM SOC HEMAT, P451, DOI 10.1182/asheducation-2011.1.451; Lane DJR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057273; Lovejoy DB, 2012, J MED CHEM, V55, P7230, DOI 10.1021/jm300768u; Lovejoy DB, 2011, CANCER RES, V71, P5871, DOI 10.1158/0008-5472.CAN-11-1218; Mackova E, 2012, CHEM-BIOL INTERACT, V197, P69, DOI 10.1016/j.cbi.2012.03.010; Majewska U, 2007, PHYS MED BIOL, V52, P3895, DOI 10.1088/0031-9155/52/13/016; Merlot AM, 2013, ANTIOXID REDOX SIGN, V18, P973, DOI 10.1089/ars.2012.4540; MILLART H, 1993, ANTICANCER RES, V13, P779; Moller S, 2008, ACTA ONCOL, V47, P506, DOI 10.1080/02841860802059259; Napier I, 2005, BLOOD, V105, P1867, DOI 10.1182/blood-2004-10-3856; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Noulsri E, 2009, AM J HEMATOL, V84, P170, DOI 10.1002/ajh.21350; NYHOLM S, 1993, J BIOL CHEM, V268, P26200; Olivieri NF, 1997, BLOOD, V89, P739, DOI 10.1182/blood.V89.3.739; Pahl PMB, 2007, J EXP THER ONCOL, V6, P193; Pinnix ZK, 2010, SCI TRANSL MED, V2, DOI [10.1126/scitranslmed.3001127, 10.1126/scisignal.3001127]; PORTER K, 1973, J CELL BIOL, V57, P815, DOI 10.1083/jcb.57.3.815; Quach P, 2012, MOL PHARMACOL, V82, P105, DOI 10.1124/mol.112.078964; Rao VA, 2011, CANCER CHEMOTH PHARM, V68, P1125, DOI 10.1007/s00280-011-1587-y; REIZENSTEIN P, 1991, MED ONCOL TUMOR PHAR, V8, P229; Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75; RICHARDSON D, 1994, CANCER RES, V54, P685; Richardson DR, 2006, J MED CHEM, V49, P6510, DOI 10.1021/jm0606342; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; RICHARDSON DR, 1995, BLOOD, V86, P4295, DOI 10.1182/blood.V86.11.4295.bloodjournal86114295; Shpyleva SI, 2011, BREAST CANCER RES TR, V126, P63, DOI 10.1007/s10549-010-0849-4; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Simunek T, 2008, BRIT J PHARMACOL, V155, P138, DOI 10.1038/bjp.2008.236; Simunek T, 2009, PHARMACOL REP, V61, P154; Sterba M, 2013, ANTIOXID REDOX SIGN, V18, P899, DOI 10.1089/ars.2012.4795; Tanaka T, 1997, BBA-MOL CELL RES, V1357, P91, DOI 10.1016/S0167-4889(97)00016-5; Tantivejkul K, 2003, BREAST CANCER RES TR, V79, P301, DOI 10.1023/A:1024078415339; THELANDER L, 1983, J BIOL CHEM, V258, P4063; Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495; Toyokuni S, 1996, FREE RADICAL BIO MED, V20, P553, DOI 10.1016/0891-5849(95)02111-6; Turner J, 2005, BLOOD, V106, P3191, DOI 10.1182/blood-2005-03-1263; VANDEWALLE B, 1989, BIOCHEM BIOPH RES CO, V163, P149, DOI 10.1016/0006-291X(89)92112-8; Vyhlidal C, 2002, J MOL ENDOCRINOL, V29, P305, DOI 10.1677/jme.0.0290305; Wang G, 2004, BIOMETALS, V17, P15, DOI 10.1023/A:1024417309370; Wesierska-Gadek J, 2006, J CELL BIOCHEM, V98, P1367, DOI 10.1002/jcb.20960; Whitnall M, 2006, P NATL ACAD SCI USA, V103, P14901, DOI 10.1073/pnas.0604979103; Yin JY, 2011, CLIN CANCER RES, V17, P4600, DOI 10.1158/1078-0432.CCR-10-2591; Yu Y, 2012, BRIT J PHARMACOL, V165, P148, DOI 10.1111/j.1476-5381.2011.01526.x; Yu Y, 2007, CELL CYCLE, V6, P1982, DOI 10.4161/cc.6.16.4603; Yu Y, 2011, J BIOL CHEM, V286, P15413, DOI 10.1074/jbc.M111.225946; Yu Y, 2009, J MED CHEM, V52, P5271, DOI 10.1021/jm900552r; Yuan J, 2004, BLOOD, V104, P1450, DOI 10.1182/blood-2004-03-0868	81	16	16	1	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2014	9	2							e88754	10.1371/journal.pone.0088754	http://dx.doi.org/10.1371/journal.pone.0088754			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AB3UC	24586383	Green Published, Green Submitted, gold			2023-01-03	WOS:000331714700028
J	Mitome-Mishima, Y; Yamamoto, M; Yatomi, K; Nonaka, S; Miyamoto, N; Urabe, T; Arai, H; Oishi, H				Mitome-Mishima, Yumiko; Yamamoto, Munetaka; Yatomi, Kenji; Nonaka, Senshu; Miyamoto, Nobukazu; Urabe, Takao; Arai, Hajime; Oishi, Hidenori			Endothelial Cell Proliferation in Swine Experimental Aneurysm after Coil Embolization	PLOS ONE			English	Article							GUGLIELMI DETACHABLE COIL; RUPTURED INTRACRANIAL ANEURYSMS; CAROTID-ARTERY ANEURYSMS; ENDOVASCULAR TREATMENT; CEREBRAL ANEURYSMS; SACCULAR ANEURYSMS; PLATINUM COILS; TRIAL ISAT; PART I; MODEL	After coil embolization, recanalization in cerebral aneurysms adversely influences long-term prognosis. Proliferation of endothelial cells on the coil surface may reduce the incidence of recanalization and further improve outcomes after coil embolization. We aimed to map the expression of proliferating tissue over the aneurysmal orifice and define the temporal profile of tissue growth in a swine experimental aneurysm model. We compared the outcomes after spontaneous thrombosis with those of coil embolization using histological and morphological techniques. In aneurysms that we not coiled, spontaneous thrombosis was observed, and weak, easily detachable proliferating tissue was evident in the aneurysmal neck. In contrast, in the coil embolization group, histological analysis showed endothelial-like cells lining the aneurysmal opening. Moreover, immunohistochemical and morphological analysis suggested that these cells were immature endothelial cells. Our results indicated the existence of endothelial cell proliferation 1 week after coil embolization and showed immature endothelial cells in septal tissue between the systemic circulation and the aneurysm. These findings suggest that endothelial cells are lead to and proliferate in the former aneurysmal orifice. This is the first examination to evaluate the temporal change of proliferating tissue in a swine experimental aneurysm model.	[Mitome-Mishima, Yumiko; Yamamoto, Munetaka; Yatomi, Kenji; Arai, Hajime; Oishi, Hidenori] Juntendo Univ, Sch Med, Dept Neurosurg, Tokyo 113, Japan; [Oishi, Hidenori] Juntendo Univ, Sch Med, Dept Neuroendovasc Therapy, Tokyo, Japan; [Nonaka, Senshu] Juntendo Univ, Urayasu Hosp, Dept Neurosurg, Chiba, Japan; [Miyamoto, Nobukazu; Urabe, Takao] Juntendo Univ, Urayasu Hosp, Dept Neurol, Chiba, Japan	Juntendo University; Juntendo University; Juntendo University; Juntendo University	Mitome-Mishima, Y (corresponding author), Juntendo Univ, Sch Med, Dept Neurosurg, Tokyo 113, Japan.	ymishima@juntendo.ac.jp		Mitome-Mishima, Yumiko/0000-0001-8545-616X				Bouzeghrane F, 2010, AM J NEURORADIOL, V31, P418, DOI 10.3174/ajnr.A1853; Byrne JV, 1997, AM J NEURORADIOL, V18, P29; DAWSON RC, 1995, NEUROSURGERY, V36, P133, DOI 10.1227/00006123-199501000-00017; Dawson RC, 1996, AM J NEURORADIOL, V17, P853; Gallas S, 2009, AM J NEURORADIOL, V30, P1986, DOI 10.3174/ajnr.A1744; GERMAN WJ, 1954, NEW ENGL J MED, V250, P104, DOI 10.1056/NEJM195401212500303; GRAVES VB, 1992, AM J NEURORADIOL, V13, P189; GRAVES VB, 1993, AM J NEURORADIOL, V14, P787; GRAVES VB, 1990, AM J NEURORADIOL, V11, P249; GUGLIELMI G, 1991, J NEUROSURG, V75, P1, DOI 10.3171/jns.1991.75.1.0001; Hayakawa M, 2000, J NEUROSURG, V93, P561, DOI 10.3171/jns.2000.93.4.0561; Ishihara S, 2002, AJNR AM J NEURORADIO, V23; Johnston SC, 2001, STROKE, V32, P597, DOI 10.1161/01.STR.32.3.597; Kadirvel R, 2007, AM J NEURORADIOL, V28, P849; Lee D, 2007, J NEUROSURG, V107, P94, DOI 10.3171/JNS-07/07/0094; MASSOUD TF, 1994, NEURORADIOLOGY, V36, P537, DOI 10.1007/BF00593517; MAWAD ME, 1995, AM J NEURORADIOL, V16, P7; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5; Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8; Murayama Y, 1999, AM J NEURORADIOL, V20, P1986; Murayama Y, 1999, AM J NEURORADIOL, V20, P1992; Murayama Y, 1997, NEUROSURGERY, V40, P1233, DOI 10.1097/00006123-199706000-00024; Raymond J, 2003, STROKE, V34, P1398, DOI 10.1161/01.STR.0000073841.88563.E9; Szikora I, 1997, AM J NEURORADIOL, V18, P667; Tajiri N, 2012, CURR PHARM DESIGN, V18, P3663, DOI 10.2174/138161212802002724; Taylor RA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/746068; Walberer Maureen, 2010, Exp Transl Stroke Med, V2, P22, DOI 10.1186/2040-7378-2-22; Xia WL, 2010, CLIN EXP PHARMACOL P, V37, P253, DOI 10.1111/j.1440-1681.2009.05279.x; Yatomi K, 2012, J NEUROL SURG PART A, V73, P397, DOI 10.1055/s-0032-1322592	30	6	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2014	9	2							e89047	10.1371/journal.pone.0089047	http://dx.doi.org/10.1371/journal.pone.0089047			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7IR	24551215	Green Published, Green Submitted, gold			2023-01-03	WOS:000331271500094
J	Kloog, I; Nordio, F; Zanobetti, A; Coull, BA; Koutrakis, P; Schwartz, JD				Kloog, Itai; Nordio, Francesco; Zanobetti, Antonella; Coull, Brent A.; Koutrakis, Petros; Schwartz, Joel D.			Short Term Effects of Particle Exposure on Hospital Admissions in the Mid-Atlantic States: A Population Estimate	PLOS ONE			English	Article							PARTICULATE AIR-POLLUTION; CARDIOVASCULAR-DISEASE; ULTRAFINE PARTICLES; FINE; DETROIT; STROKE; RISK	Background: Many studies report significant associations between PM2.5 (particulate matter <2.5 micrometers) and hospital admissions. These studies mostly rely on a limited number of monitors which introduces exposure error, and excludes rural and suburban populations from locations where monitors are not available, reducing generalizability and potentially creating selection bias. Methods: Using prediction models developed by our group, daily PM2.5 exposure was estimated across the Mid-Atlantic (Washington D. C., and the states of Delaware, Maryland, New Jersey, Pennsylvania, Virginia, New York and West Virginia). We then investigated the short-term effects of PM2.5 exposures on emergency hospital admissions of the elderly in the Mid-Atlantic region. We performed case-crossover analysis for each admission type, matching on day of the week, month and year and defined the hazard period as lag01 (a moving average of day of admission exposure and previous day exposure). Results: We observed associations between short-term exposure to PM2.5 and hospitalization for all outcomes examined. For example, for every 10-mu g/m(3) increase in short-term PM2.5 there was a 2.2% increase in respiratory diseases admissions (95% CI = 1.9 to 2.6), and a 0.78% increase in cardiovascular disease (CVD) admission rate (95% CI = 0.5 to 1.0). We found differences in risk for CVD admissions between people living in rural and urban areas. For every10-mu g/m(3) increase in PM2.5 exposure in the 'rural' group there was a 1.0% increase (95% CI = 0.6 to 1.5), while for the 'urban' group the increase was 0.7% (95% CI = 0.4 to 1.0). Conclusions: Our findings showed that PM2.5 exposure was associated with hospital admissions for all respiratory, cardio vascular disease, stroke, ischemic heart disease and chronic obstructive pulmonary disease admissions. In addition, we demonstrate that our AOD (Aerosol Optical Depth) based exposure models can be successfully applied to epidemiological studies investigating the health effects of short-term exposures to PM2.5.	[Kloog, Itai] Ben Gurion Univ Negev, Dept Geog & Environm Dev, IL-84105 Beer Sheva, Israel; [Kloog, Itai; Nordio, Francesco; Zanobetti, Antonella; Koutrakis, Petros; Schwartz, Joel D.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Exposure Epidemiol & Risk Program, Boston, MA 02115 USA; [Coull, Brent A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Ben Gurion University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Kloog, I (corresponding author), Ben Gurion Univ Negev, Dept Geog & Environm Dev, IL-84105 Beer Sheva, Israel.	ikloog@bgu.ac.il			Harvard Environmental Protection Agency (EPA) Center Grant USEPA [RD-83479801]; NIEHS [ES-000002]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	Harvard Environmental Protection Agency (EPA) Center Grant USEPA; NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This study was supported by the Harvard Environmental Protection Agency (EPA) Center Grant USEPA grant RD-83479801 and NIEHS ES-000002. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ames B N, 1988, IARC Sci Publ, P407; Andersen ZJ, 2010, EUR HEART J, V31, P2034, DOI 10.1093/eurheartj/ehq188; Bell ML, 2009, AM J RESP CRIT CARE, V179, P1115, DOI 10.1164/rccm.200808-1240OC; Belleudi V, 2010, EPIDEMIOLOGY, V21, P414, DOI 10.1097/EDE.0b013e3181d5c021; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; Chudnovsky AA, 2013, ENVIRON POLLUT, V172, P131, DOI 10.1016/j.envpol.2012.08.016; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Fusco D, 2001, EUR RESPIR J, V17, P1143, DOI 10.1183/09031936.01.00005501; Ghio AJ, 1999, INHAL TOXICOL, V11, P293; Halonen JI, 2008, THORAX, V63, P635, DOI 10.1136/thx.2007.091371; Halonen JI, 2009, EPIDEMIOLOGY, V20, P143, DOI 10.1097/EDE.0b013e31818c7237; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kloog I, 2012, ENV SCI TECHNOL; Kloog I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034664; Kloog I, 2011, ATMOS ENVIRON, V45, P6267, DOI 10.1016/j.atmosenv.2011.08.066; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; NCDC, 2010, NAT CLIM DAT CTR DAT; Peacock JL, 2011, THORAX, V66, P591, DOI 10.1136/thx.2010.155358; Schwartz J, 2005, AM J RESP CRIT CARE, V171, P627, DOI 10.1164/rccm.200407-933OC; Schwartz J, 1996, EPIDEMIOLOGY, V7, P20, DOI 10.1097/00001648-199601000-00005; SCHWARTZ J, 1995, AM J EPIDEMIOL, V142, P23, DOI 10.1093/oxfordjournals.aje.a117541; SCHWARTZ J, 1994, AM J RESP CRIT CARE, V150, P648, DOI 10.1164/ajrccm.150.3.8087333; Schwartz J, 1997, EPIDEMIOLOGY, V8, P371, DOI 10.1097/00001648-199707000-00004; Seinfeld J.H., 2006, ATMOS CHEM PHYS, V2nd; SPENGLER JD, 1989, ENVIRON HEALTH PERSP, V79, P43; USCB, 2000, US CENS BUR 2000; Wellenius GA, 2005, STROKE, V36, P2549, DOI 10.1161/01.STR.0000189687.78760.47; Zanobetti A, 2005, ENVIRON HEALTH PERSP, V113, P978, DOI 10.1289/ehp.7550; Zanobetti A, 2000, ENVIRON HEALTH PERSP, V108, P1071, DOI 10.2307/3434961; Zanobetti A, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-58; Zeger SL, 2000, ENVIRON HEALTH PERSP, V108, P419, DOI 10.2307/3454382	31	65	71	2	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2014	9	2							e88578	10.1371/journal.pone.0088578	http://dx.doi.org/10.1371/journal.pone.0088578			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA1CR	24516670	gold, Green Published, Green Submitted			2023-01-03	WOS:000330834400077
J	Sorensen, CJ; Pedersen, OB; Petersen, MS; Sorensen, E; Kotze, S; Thorner, LW; Hjalgrim, H; Rigas, AS; Moller, B; Rostgaard, K; Riiskjaer, M; Ullum, H; Erikstrup, C				Sorensen, Cecilie J.; Pedersen, Ole B.; Petersen, Mikkel S.; Sorensen, Erik; Kotze, Sebastian; Thorner, Lise W.; Hjalgrim, Henrik; Rigas, Andreas S.; Moller, Bjarne; Rostgaard, Klaus; Riiskjaer, Mads; Ullum, Henrik; Erikstrup, Christian			Combined Oral Contraception and Obesity Are Strong Predictors of Low-Grade Inflammation in Healthy Individuals: Results from the Danish Blood Donor Study (DBDS)	PLOS ONE			English	Article							C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE; HORMONAL CONTRACEPTION; VENOUS THROMBOEMBOLISM; RISK; POPULATION; PLASMA; SERUM; CANCER; WOMEN	Background: C-reactive protein (CRP) is a well-established marker of inflammation. The level of CRP is affected by several lifestyle factors. A slightly increased CRP level, also known as low-grade inflammation (LGI), is associated with increased risk of several diseases, especially cardiovascular disease. The aim of this study was to identify predictors of increased CRP levels in healthy individuals. We therefore assessed CRP in a large cohort of blood donors. Methods: We measured plasma CRP levels in 15,684 participants from the Danish Blood Donor Study. CRP was measured by a commercial assay. Furthermore, all participants completed a standard questionnaire on smoking status, alcohol consumption, physical activity, diet, and various body measurements. Female participants also reported the use of contraception, childbirth, and menopausal status. The relationship between LGI (defined here as a plasma CRP level between 3 mg/L and 10 mg/L) and predictors was explored by multivariable logistic regression analysis. Results were presented as odds ratios (OR) with 95% confidence intervals (CI). Results: We found LGI in a total of 1,561 (10.0%) participants. LGI was more frequent in women using combined oral contraception (OC) (29.9%) than in men (6.1%) and women not using OC (7.9%). Among premenopausal women, OC was the strongest predictor of LGI (odds ratio = 8.98, p<0.001). Additionally, body mass index (BMI) and waist circumference were positively associated with LGI. Conclusion: High BMI and abdominal obesity strongly predicted LGI among healthy individuals. However, the most striking finding was the high prevalence of LGI among premenopausal women who used combined oral contraception. Although the significance of CRP as a marker of inflammation is well known, the role of CRP in pathogenesis is still uncertain. The impact of oral contraception on CRP levels should nevertheless be considered when CRP is used in risk assessment.	[Sorensen, Cecilie J.; Petersen, Mikkel S.; Kotze, Sebastian; Moller, Bjarne; Erikstrup, Christian] Aarhus Univ Hosp, Dept Clin Immunol, DK-8000 Aarhus, Denmark; [Pedersen, Ole B.] Naestved Sygehus, Dept Clin Immunol, Naestved, Denmark; [Sorensen, Erik; Thorner, Lise W.; Rigas, Andreas S.; Ullum, Henrik] Copenhagen Univ Hosp, Rigshosp, Dept Clin Immunol, Copenhagen, Denmark; [Hjalgrim, Henrik; Rostgaard, Klaus] Statens Serum Inst, DK-2300 Copenhagen, Denmark; [Riiskjaer, Mads] Aarhus Univ Hosp, Dept Obstet & Gynaecol, DK-8000 Aarhus, Denmark	Aarhus University; Naestved Hospital; Rigshospitalet; University of Copenhagen; Statens Serum Institut; Aarhus University	Sorensen, CJ (corresponding author), Aarhus Univ Hosp, Dept Clin Immunol, DK-8000 Aarhus, Denmark.	ceciliejuulsorensen@gmail.com	Pedersen, Ole Birger/W-8679-2019; Hjalgrim, Henrik/AAG-4973-2021; Sørensen, Erik/A-1783-2016	Pedersen, Ole Birger/0000-0003-2312-5976; Ullum, Henrik/0000-0001-7306-9058; Thorner, Lise Wegner/0000-0003-4391-4956; Rostgaard, Klaus/0000-0001-6220-9414; Erikstrup, Christian/0000-0001-6551-6647; Riiskjaer, Mads/0000-0001-7804-8782	Danish Council for Independent Research - Medical Sciences; Danish Administrative Regions; Bloddonorernes Forskningsfond og Fonden til laegevidenskabens fremme	Danish Council for Independent Research - Medical Sciences(Det Frie Forskningsrad (DFF)); Danish Administrative Regions; Bloddonorernes Forskningsfond og Fonden til laegevidenskabens fremme	This study was supported by grants from The Danish Council for Independent Research - Medical Sciences, The Danish Administrative Regions, Bloddonorernes Forskningsfond og Fonden til laegevidenskabens fremme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afzal S, 2013, CLIN CHEM, V59, P771, DOI 10.1373/clinchem.2012.201939; Allin KH, 2011, CRIT REV CL LAB SCI, V48, P155, DOI 10.3109/10408363.2011.599831; Atsma F, 2011, TRANSFUSION, V51, P412, DOI 10.1111/j.1537-2995.2010.02867.x; Buchbinder S, 2008, SCAND J CLIN LAB INV, V68, P140, DOI 10.1080/00365510701487727; Chenillot O, 2000, CLIN CHEM LAB MED, V38, P1003, DOI 10.1515/CCLM.2000.149; Cnattingius S, 2013, JAMA-J AM MED ASSOC, V309, P2362, DOI 10.1001/jama.2013.6295; Dawood MY, 2006, OBSTET GYNECOL, V108, P428, DOI 10.1097/01.AOG.0000230214.26638.0c; Dreon DM, 2003, LIFE SCI, V73, P1245, DOI 10.1016/S0024-3205(03)00425-9; Du Clos TW, 2000, ANN MED, V32, P274, DOI 10.3109/07853890009011772; Edgren G, 2007, TRANSFUSION, V47, P2017, DOI 10.1111/j.1537-2995.2007.01425.x; Fodevarestyrelsen, TIPS FISK; Grad E, 2013, BLOOD REV, V27, P23, DOI 10.1016/j.blre.2012.12.001; Hage FG, 2007, J AM COLL CARDIOL, V50, P1115, DOI 10.1016/j.jacc.2007.06.012; Hung J, 2008, AM J CARDIOL, V101, P193, DOI 10.1016/j.amjcard.2007.07.061; Hutchinson WL, 2000, CLIN CHEM, V46, P934; Imhof A, 2003, CLIN CHEM, V49, P669, DOI 10.1373/49.4.669; Janssen EB, 2013, HUM REPROD UPDATE, V19, P570, DOI 10.1093/humupd/dmt016; Kaptoge S., 2012, NEW ENGL J MED, V367, P1310, DOI [10.1056/nejmoa1107477, DOI 10.1056/NEJMOA1107477]; Kaptoge S, 2010, LANCET, V375, P132, DOI 10.1016/S0140-6736(09)61717-7; Kluft C, 2002, VASC PHARMACOL, V39, P99, DOI 10.1016/S1537-1891(02)00293-8; Koch MB, 2012, SOCIAL ULIGHED SUNDH; Koninckx PR, 1998, HUM REPROD UPDATE, V4, P741, DOI 10.1093/humupd/4.5.741; Krauss RM, 2000, STROKE, V31, P2751, DOI 10.1161/01.STR.31.11.2751; Ledue TB, 2001, CLIN CHEM LAB MED, V39, P1171, DOI 10.1515/CCLM.2001.185; Lee J, 2009, RESP MED, V103, P1286, DOI 10.1016/j.rmed.2009.04.003; Lidegaard O, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6423; Morin-Papunen L, 2008, AM J OBSTET GYNECOL, V199, DOI [10.1016/j.ajog.2008.04.013, DOI 10.1016/J.AJ0G.2008.04.013]; NHLBI Obesity Education Initiative Expert Panel on the Identification Evaluation and Treatment of Obesity in Adults (US), 1998, CLIN GUID ID EV TREA; Nielen MMJ, 2004, ARTHRITIS RHEUM-US, V50, P2423, DOI 10.1002/art.20431; Pedersen OB, 2012, VOX SANG, V102, P271, DOI 10.1111/j.1423-0410.2011.01553.x; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; Raitakari M, 2005, J INTERN MED, V258, P428, DOI 10.1111/j.1365-2796.2005.01563.x; Rhodes B, 2011, NAT REV RHEUMATOL, V7, P283, DOI 10.1038/nrrheum.2011.37; Ridker PM, 2001, CIRCULATION, V103, P1813, DOI 10.1161/01.CIR.103.13.1813; Rifai N, 2003, CLIN CHEM, V49, P666, DOI 10.1373/49.4.666; Saadeddin Salam M, 2002, Med Sci Monit, V8, pRA5; Salobir B, 2006, BLOOD COAGUL FIBRIN, V17, P551, DOI 10.1097/01.mbc.0000245298.64644.0a; Sesso HD, 2003, JAMA-J AM MED ASSOC, V290, P2945, DOI 10.1001/jama.290.22.2945; Shulman LP, 2011, AM J OBSTET GYNECOL, V205, pS9, DOI 10.1016/j.ajog.2011.06.057; Skouby SO, 2010, EUR J CONTRACEP REPR, V15, pS42, DOI 10.3109/13625187.2010.533002; Soska V, 2011, SCAND J CLIN LAB INV, V71, P94, DOI 10.3109/00365513.2011.553240; Tsilidis KK, 2008, INT J CANCER, V123, P1133, DOI 10.1002/ijc.23606; van Rooijen M, 2006, J THROMB HAEMOST, V4, P77, DOI 10.1111/j.1538-7836.2005.01690.x; VILLEGAS R, 2010, NUTR METAB CARDIOVAS; Waist Circumference and Waist-Hip Ratio, 2008, WHO EXP CONS GEN 8 1; Wilson NM, 2012, ACTA OBSTET GYN SCAN, V91, P810, DOI 10.1111/j.1600-0412.2012.01416.x	46	39	39	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2014	9	2							e88196	10.1371/journal.pone.0088196	http://dx.doi.org/10.1371/journal.pone.0088196			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA1BH	24516611	Green Published, gold, Green Submitted			2023-01-03	WOS:000330830700054
J	Shi, YH; Guo, R; Wang, XK; Yuan, DD; Zhang, SH; Wang, J; Yan, XB; Wang, CZ				Shi, Yinghua; Guo, Rui; Wang, Xianke; Yuan, Dedi; Zhang, Senhao; Wang, Jie; Yan, Xuebing; Wang, Chengzhang			The Regulation of Alfalfa Saponin Extract on Key Genes Involved in Hepatic Cholesterol Metabolism in Hyperlipidemic Rats	PLOS ONE			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-HEART-DISEASE; HMG-COA REDUCTASE; BILE-ACID SYNTHESIS; MESSENGER-RNA; ACYL-COENZYME; RECEPTOR; PLASMA; DIET; ACYLTRANSFERASE	To investigate the cholesterol-lowering effects of alfalfa saponin extract (ASE) and its regulation mechanism on some key genes involved in cholesterol metabolism, 40 healthy 7 weeks old male Sprague Dawley (SD) rats were randomly divided into four groups with 10 rats in each group: control group, hyperlipidemic group, ASE treatment group, ASE prevention group. The body weight gain, relative liver weight and serum lipid 1evels of rats were determined. Total cholesterol (TC) and total bile acids (TBA) levels in liver and feces were also measured. Furthermore, the activity and mRNA expressions of Hmgcr, Acat2, Cyp7a1 and Ldlr were investigated. The results showed the following: (1) The abnormal serum lipid levels in hyperlipidemic rats were ameliorated by ASE administration (both ASE prevention group and treatment group) (P<0.05). (2) Both ASE administration to hyperlipidemic rats significantly reduced liver TC and increased liver TBA level (P<0.05). TC and TBA levels in feces of hyperlipidemic rats were remarkably elevated by both ASE administration (P<0.05). (3) mRNA expressions of Hmgcr and Acat2 in the liver of hyperlipidemic rats were remarkably down-regulated (P<0.05), as well as mRNA expressions of Cyp7a1 and Ldlr were dramatically up-regulated by both ASE administration (P<0.05). The activities of these enzymes also paralleled the observed changes in mRNA levels. (4) There was no significant difference between ASE treatment and ASE prevention group for most parameters evaluated. Our present study indicated that ASE had cholesterol-lowering effects. The possible mechanism could be attributed to (1) the down-regulation of Hmgcr and Acat2, as well as up-regulation of Cyp7a1 and Ldlr in the liver of hyperlipidemic rats, which was involved in cholesterol biosynthesis, uptake, and efflux pathway; (2) the increase in excretion of cholesterol. The findings in our study suggested ASE had great potential usefulness as a natural agent for treating hyperlipidemia.	[Shi, Yinghua; Guo, Rui; Wang, Xianke; Yuan, Dedi; Zhang, Senhao; Wang, Jie; Yan, Xuebing; Wang, Chengzhang] Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou, Henan, Peoples R China	Henan Agricultural University	Shi, YH (corresponding author), Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou, Henan, Peoples R China.	annysyh@126.com; wangchengzhang@263.net		Zhang, Senhao/0000-0002-9231-9750	Earmarked Fund for Modern Agro-industry Technology Research System [CARS-35]; "Twelfth Five-year'' National Science and Technology Support Program [2011BAD17B04]	Earmarked Fund for Modern Agro-industry Technology Research System; "Twelfth Five-year'' National Science and Technology Support Program	Financial support for this research was provided by the Earmarked Fund for Modern Agro-industry Technology Research System (CARS-35), "Twelfth Five-year'' National Science and Technology Support Program (2011BAD17B04). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abidi P, 2005, ARTERIOSCL THROM VAS, V25, P2170, DOI 10.1161/01.ATV.0000181761.16341.2b; Alger HM, 2010, J BIOL CHEM, V285, P14267, DOI 10.1074/jbc.M110.118422; Arafa HMM, 2005, MED SCI MONITOR, V11, pBR228; Arsenault BJ, 2009, J AM COLL CARDIOL, V55, P35, DOI 10.1016/j.jacc.2009.07.057; BARNES D. K., 1995, AGRICULTURE, P205; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Cheeke P.R., 2000, J ANIM SCI, V77, P1, DOI DOI 10.2527/JAS2000.00218812007700ES0009X; Chiang JYL, 2004, J HEPATOL, V40, P539, DOI 10.1016/j.jhep.2003.11.006; Chiang MT, 1998, INT J VITAM NUTR RES, V68, P328; Choudhary MI, 2005, J ETHNOPHARMACOL, V98, P217, DOI 10.1016/j.jep.2005.01.013; Del Bas JM, 2005, FASEB J, V19, P479, DOI 10.1096/fj.04-3095fje; Durrington P, 2003, LANCET, V362, P717, DOI 10.1016/S0140-6736(03)14234-1; Gilardi F, 2007, PHARMACOL THERAPEUT, V116, P449, DOI 10.1016/j.pharmthera.2007.08.003; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Goldstein JL, 2001, SCIENCE, V292, P1310, DOI 10.1126/science.1061815; Gotto AM, 2004, J AM COLL CARDIOL, V43, P717, DOI 10.1016/j.jacc.2003.08.061; Guo J, 2011, J ETHNOPHARMACOL, V135, P299, DOI 10.1016/j.jep.2011.03.012; Jurevics H, 2000, J LIPID RES, V41, P1048; Kawakami Y, 2004, J AGR FOOD CHEM, V52, P1764, DOI 10.1021/jf0345898; Kwok CY, 2010, J FUNCT FOODS, V2, P179, DOI 10.1016/j.jff.2010.04.006; Lee MK, 2003, BIOORGAN MED CHEM, V11, P393, DOI 10.1016/S0968-0896(02)00441-8; Lee RG, 2005, J LIPID RES, V46, P1205, DOI 10.1194/jlr.M500018-JLR200; Lee RG, 2004, CIRC RES, V95, P998, DOI 10.1161/01.RES.0000147558.15554.67; Li Q, 2009, PLANTA MED, V75, P1203, DOI 10.1055/s-0029-1185539; MALINOW MR, 1977, STEROIDS, V29, P105, DOI 10.1016/0039-128X(77)90113-1; MALINOW MR, 1979, AM J CLIN NUTR, V32, P1810, DOI 10.1093/ajcn/32.9.1810; MALINOW MR, 1977, AM J CLIN NUTR, V30, P2061, DOI 10.1093/ajcn/30.12.2061; Matsuyama H, 2005, BBA-MOL CELL BIOL L, V1734, P136, DOI 10.1016/j.bbalip.2005.03.006; MILGATE J, 1995, NUTR RES, V15, P1223, DOI 10.1016/0271-5317(95)00081-S; [倪鸿昌 Ni Hongchang], 2004, [中国药理学通报, Chinese Pharmacological Bulletin], V20, P703; Pischon T, 2005, CIRCULATION, V112, P3375, DOI 10.1161/CIRCULATIONAHA.104.532499; Rao A V, 2000, Drug Metabol Drug Interact, V17, P211; Reena MB, 2011, J NUTR, V141, P24, DOI 10.3945/jn.110.127027; Rudel LL, 2002, J BIOL CHEM, V277, P31401, DOI 10.1074/jbc.M204106200; RUDLING M, 1992, J LIPID RES, V33, P493; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Sen S, 1998, J AGR FOOD CHEM, V46, P131, DOI 10.1021/jf970389i; SPADY DK, 1985, P NATL ACAD SCI USA, V82, P4526, DOI 10.1073/pnas.82.13.4526; SPADY DK, 1983, P NATL ACAD SCI-BIOL, V80, P3499, DOI 10.1073/pnas.80.11.3499; STORY JA, 1984, AM J CLIN NUTR, V39, P917, DOI 10.1093/ajcn/39.6.917; TOPPING DL, 1980, AM J CLIN NUTR, V33, P783, DOI 10.1093/ajcn/33.4.783; Wang ChengZhang, 2011, Acta Prataculturae Sinica, V20, P210; Whitney EJ, 2005, ANN INTERN MED, V142, P95, DOI 10.7326/0003-4819-142-2-200501180-00008; Wu H., 2009, J GERIATR CARDIOL, V6, P119; Wu JH, 2013, J FUNCT FOODS, V5, P1159, DOI 10.1016/j.jff.2013.03.013; Yan LP, 2006, LIFE SCI, V79, P324, DOI 10.1016/j.lfs.2006.01.016; Yuan DD, 2013, ACTA PRATACULT SINIC, V22, P294; 王先科, 2012, [江苏农业科学, Jiangsu Agricultural Sciences], V40, P182; 郭姣, 2009, [中药材, Journal of Chinese Medicinal Materials], V32, P582	51	25	31	1	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2014	9	2							e88282	10.1371/journal.pone.0088282	http://dx.doi.org/10.1371/journal.pone.0088282			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA1AT	24505463	Green Submitted, gold, Green Published			2023-01-03	WOS:000330829200165
J	Shushimita, S; de Bruijn, MJW; de Bruin, RWF; IJzermans, JNM; Hendriks, RW; Dor, FJMF				Shushimita, Shushimita; de Bruijn, Marjolein J. W.; de Bruin, Ron W. F.; IJzermans, Jan N. M.; Hendriks, Rudi W.; Dor, Frank J. M. F.			Dietary Restriction and Fasting Arrest B and T Cell Development and Increase Mature B and T Cell Numbers in Bone Marrow	PLOS ONE			English	Article							ISCHEMIA-REPERFUSION INJURY; PROLONGS LIFE-SPAN; CALORIE RESTRICTION; INFLUENZA INFECTION; AGED MICE; PROTECTION; ORGANISMS; LONGEVITY; SURVIVAL; RETARDS	Dietary restriction (DR) delays ageing and extends life span. Both long-and short-term DR, as well as short-term fasting provide robust protection against many "neuronal and surgery related damaging phenomena" such as Parkinson's disease and ischemia-reperfusion injury. The exact mechanism behind this phenomenon has not yet been elucidated. Its anti-inflammatory actions prompted us to thoroughly investigate the consequences of DR and fasting on B and T cell compartments in primary and secondary lymphoid organs of male C57Bl/6 mice. In BM we found that DR and fasting cause a decrease in the total B cell population and arrest early B cell development, while increasing the number of recirculating mature B cells. In the fasting group, a significant reduction in peripheral B cell counts was observed in both spleen and mesenteric lymph nodes (mLN). Thymopoiesis was arrested significantly at double negative DN2 stage due to fasting, whereas DR resulted in a partial arrest of thymocyte development at the DN4 stage. Mature CD3(+) T cell populations were increased in BM and decreased in both spleen and mLN. Thus, DR arrests B cell development in the BM but increases the number of recirculating mature B cells. DR also arrests maturation of T cells in thymus, resulting in depletion of mature T cells from spleen and mLN while recruiting them to the BM. The functional relevance in relation to protection against organ damage needs to be determined.	[Shushimita, Shushimita; de Bruin, Ron W. F.; IJzermans, Jan N. M.; Dor, Frank J. M. F.] Univ Med Ctr, Erasmus MC, Div Transplant Surg, Dept Surg, Rotterdam, Netherlands; [de Bruijn, Marjolein J. W.; Hendriks, Rudi W.] Univ Med Ctr, Erasmus MC, Dept Pulm Med, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Dor, FJMF (corresponding author), Univ Med Ctr, Erasmus MC, Div Transplant Surg, Dept Surg, Rotterdam, Netherlands.	f.dor@erasmusmc.nl			Erasmus MC fellowship grant	Erasmus MC fellowship grant	This study was supported by Erasmus MC fellowship grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Blagosklonny MV, 2010, CELL CYCLE, V9, P683, DOI 10.4161/cc.9.4.10766; Burne MJ, 2001, J CLIN INVEST, V108, P1283, DOI 10.1172/JCI200112080; Burne-Taney MJ, 2003, J IMMUNOL, V171, P3210, DOI 10.4049/jimmunol.171.6.3210; BUTCHER EC, 1982, J IMMUNOL, V129, P2698; Chen JC, 1998, J GERONTOL A-BIOL, V53, pB330, DOI 10.1093/gerona/53A.5.B330; Chung HY, 2001, ANN NY ACAD SCI, V928, P327; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Cox LS, 2009, AGING CELL, V8, P607, DOI 10.1111/j.1474-9726.2009.00509.x; EFFROS RB, 1991, J GERONTOL, V46, pB142, DOI 10.1093/geronj/46.4.B142; Eggenhofer E, 2013, J IMMUNOL, V191, P480, DOI 10.4049/jimmunol.1202975; FERNANDES G, 1992, J NUTR, V122, P716, DOI 10.1093/jn/122.suppl_3.716; Fontana L, 2006, JAMA-J AM MED ASSOC, V295, P1577, DOI 10.1001/jama.295.13.1577; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Fujita Y, 2012, CELL IMMUNOL, V273, P52, DOI 10.1016/j.cellimm.2011.11.007; Gardner EM, 2005, J GERONTOL A-BIOL, V60, P688, DOI 10.1093/gerona/60.6.688; GOODRICK CL, 1990, MECH AGEING DEV, V55, P69, DOI 10.1016/0047-6374(90)90107-Q; Greer EL, 2009, AGING CELL, V8, P113, DOI 10.1111/j.1474-9726.2009.00459.x; Heilbronn LK, 2006, JAMA-J AM MED ASSOC, V295, P1539, DOI 10.1001/jama.295.13.1539; Hochegger K, 2007, AM J PHYSIOL-RENAL, V293, pF741, DOI 10.1152/ajprenal.00486.2006; Jang HR, 2009, J MOL MED, V87, P859, DOI 10.1007/s00109-009-0491-y; Jiang JC, 2000, FASEB J, V14, P2135; Jolly CA, 2007, CURR OPIN LIPIDOL, V18, P53, DOI 10.1097/MOL.0b013e3280115416; Kemnitz JW, 2011, ILAR J, V52, P66, DOI 10.1093/ilar.52.1.66; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Lee C, 2011, ONCOGENE, V30, P3305, DOI 10.1038/onc.2011.91; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Liu YY, 2012, J IMMUNOL, V188, P2070, DOI 10.4049/jimmunol.1102835; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; Mair W, 2008, ANNU REV BIOCHEM, V77, P727, DOI 10.1146/annurev.biochem.77.061206.171059; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; Mitchell JR, 2010, AGING CELL, V9, P40, DOI 10.1111/j.1474-9726.2009.00532.x; Pahlavani MA, 2000, FRONT BIOSCI-LANDMRK, V5, pD580, DOI 10.2741/Pahlavani; Payne AM, 2003, J APPL PHYSIOL, V95, P2554, DOI 10.1152/japplphysiol.00758.2003; Rabb H, 2000, AM J PHYSIOL-RENAL, V279, pF525, DOI 10.1152/ajprenal.2000.279.3.F525; Ritz BW, 2008, J NUTR, V138, P2269, DOI 10.3945/jn.108.093633; Skorupa DA, 2008, AGING CELL, V7, P478, DOI 10.1111/j.1474-9726.2008.00400.x; Tanaka M, 2011, J NEUROSCI, V31, P8373, DOI 10.1523/JNEUROSCI.6562-10.2011; Valenzano DR, 2006, CURR BIOL, V16, P296, DOI 10.1016/j.cub.2005.12.038; van Ginhoven TM, 2010, TRANSPL INT, V23, P1171, DOI 10.1111/j.1432-2277.2010.01116.x; Yilmaz OH, 2012, NATURE, V486, P490, DOI 10.1038/nature11163; Zhang SL, 2011, BLOOD, V117, P1228, DOI 10.1182/blood-2010-05-287821	41	24	25	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2014	9	2							e87772	10.1371/journal.pone.0087772	http://dx.doi.org/10.1371/journal.pone.0087772			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VA	24504160	Green Published, Green Submitted, gold			2023-01-03	WOS:000330631800070
J	Chyau, CC; Ker, YB; Chang, CH; Huang, SH; Wang, HE; Peng, CC; Peng, RY				Chyau, Charng-Cherng; Ker, Yaw-Bee; Chang, Chi-Huang; Huang, Shiau-Huei; Wang, Hui-Er; Peng, Chiung-Chi; Peng, Robert Y.			Schisandra chinensis Peptidoglycan-Assisted Transmembrane Transport of Lignans Uniquely Altered the Pharmacokinetic and Pharmacodynamic Mechanisms in Human HepG2 Cell Model	PLOS ONE			English	Article							DIBENZOCYCLOOCTADIENE LIGNANS; GOMISIN N; HYALURONAN; BINDING; FRUIT; RATS; POLYSACCHARIDES; HEPATOTOXICITY; IDENTIFICATION; INHIBITORS	Schisandra chinensis (Turz Baill) (S. chinensis) (SC) fruit is a hepatoprotective herb containing many lignans and a large amount of polysaccharides. A novel polysaccharide (called SC-2) was isolated from SC of MW 841 kDa, which exhibited a protein-to-polysaccharide ratio of 0.4089, and showed a characteristic FTIR spectrum of a peptidoglycan. Powder X-ray diffraction revealed microcrystalline structures within SC-2. SC-2 contained 10 monosaccharides and 15 amino acids (essential amino acids of 78.12% w/w). In a HepG2 cell model, SC-2 was shown by MTT and TUNEL assay to be completely non-cytotoxic. A kinetic analysis and fluorescence-labeling technique revealed no intracellular disposition of SC-2. Combined treatment of lignans with SC-2 enhanced the intracellular transport of schisandrin B and deoxyschisandrin but decreased that of gomisin C, resulting in alteration of cell-killing bioactivity. The Second Law of Thermodynamics allows this type of unidirectional transport. Conclusively, SC-2 alters the transport and cell killing capability by a "Catcher-Pitcher Unidirectional Transport Mechanism".	[Chyau, Charng-Cherng; Chang, Chi-Huang; Huang, Shiau-Huei; Peng, Robert Y.] Hungkuang Univ, Biotechnol Res Inst, Taichung, Taiwan; [Ker, Yaw-Bee; Wang, Hui-Er] Hungkuang Univ, Dept Food & Appl Technol, Taichung, Taiwan; [Peng, Chiung-Chi] Taipei Med Univ, Grad Inst Clin Med, Taipei, Taiwan; [Peng, Robert Y.] Taipei Med Univ, Res Inst Med Sci, Taipei, Taiwan	Hungkuang University; Hungkuang University; Taipei Medical University; Taipei Medical University	Peng, CC (corresponding author), Taipei Med Univ, Grad Inst Clin Med, Taipei, Taiwan.	misspeng@ms2.hinet.net; ypeng@seed.net.tw			National Science Council of Taiwan [NSC-97-2313-B-241-002-MY3, NSC-100-2313-B-241-004]; Taipei Medical University [TMU101-AE1-B11, TMU102-SHH-11]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Taipei Medical University	This study was supported by grants from the National Science Council of Taiwan (NSC-97-2313-B-241-002-MY3 and NSC-100-2313-B-241-004). Additional support was received from Taipei Medical University (TMU101-AE1-B11 and TMU102-SHH-11). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Borisov AB, 2000, ANAT RECORD, V258, P305; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang CY, 2009, PHYTOTHER RES, V23, P251, DOI 10.1002/ptr.2602; Chen Y, 2012, INT J BIOL MACROMOL, V50, P844, DOI 10.1016/j.ijbiomac.2011.11.015; Chiu PY, 2007, BIOL PHARM BULL, V30, P1108, DOI 10.1248/bpb.30.1108; Cyong JC, 2000, AM J CHINESE MED, V28, P351, DOI 10.1142/S0192415X00000416; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FUJIHASHI T, 1995, ANTIMICROB AGENTS CH, V39, P2000, DOI 10.1128/AAC.39.9.2000; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gnabre J, 2010, J CHROMATOGR B, V878, P2693, DOI 10.1016/j.jchromb.2010.08.005; Ip SP, 1996, PHARMACOL TOXICOL, V78, P413, DOI 10.1111/j.1600-0773.1996.tb00228.x; Ip SP, 1997, BIOCHEM PHARMACOL, V54, P317, DOI 10.1016/S0006-2952(97)00164-0; Iwata H, 2004, DRUG METAB DISPOS, V32, P1351, DOI 10.1124/dmd.104.000646; Janes KA, 2001, ADV DRUG DELIVER REV, V47, P83, DOI 10.1016/S0169-409X(00)00123-X; Kaneo Y, 2000, INT J PHARM, V201, P59, DOI 10.1016/S0378-5173(00)00405-1; Ker YB, 2005, J AGR FOOD CHEM, V53, P7052, DOI 10.1021/jf0510034; Kim SR, 2004, J NEUROSCI RES, V76, P397, DOI 10.1002/jnr.20089; Kuang DM, 2007, BLOOD, V110, P587, DOI 10.1182/blood-2007-01-068031; La Torre GL, 2006, FOOD CHEM, V94, P640, DOI 10.1016/j.foodchem.2005.02.007; Lee IS, 1999, BIOL PHARM BULL, V22, P265, DOI 10.1248/bpb.22.265; Liu M, 2010, J ETHNOPHARMACOL, V127, P32, DOI 10.1016/j.jep.2009.09.055; Lu Y, 2009, J CHROMATOGR A, V1216, P1980, DOI 10.1016/j.chroma.2008.09.070; Ma WH, 2009, BIOORG MED CHEM LETT, V19, P4958, DOI 10.1016/j.bmcl.2009.07.078; Min HY, 2008, BIOORG MED CHEM LETT, V18, P523, DOI 10.1016/j.bmcl.2007.11.082; Oh SY, 2010, BIOSCI BIOTECH BIOCH, V74, P285, DOI 10.1271/bbb.90597; Opletal L, 2010, CESKA SLOV FARM, V50, P219; Opletal L, 2010, CESKA SLOV FARM, V50, P173; Peng CH, 2010, EUR J PHARM BIOPHARM, V75, P154, DOI 10.1016/j.ejpb.2010.03.004; Polyakov NE, 2010, NSTI NANOTECH, V3, P312; Shihorka V, 2001, J PHARM PHARM SCI, V4, P138; Tanaka T, 2004, INT J PHARM, V286, P9, DOI 10.1016/j.ijpharm.2004.07.031; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Victor R, 1999, INT J CANCER, V82, P77, DOI 10.1002/(SICI)1097-0215(19990702)82:1<77::AID-IJC14>3.0.CO;2-Q; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; Xie YA, 2010, J ETHNOPHARMACOL, V131, P290, DOI 10.1016/j.jep.2010.06.038; Yan F, 2009, PHYTOMEDICINE, V16, P805, DOI 10.1016/j.phymed.2009.02.004; Yim SY, 2009, MOL MED REP, V2, P725, DOI 10.3892/mmr_00000163; Yin FZ, 2010, ACTA CHROMATOGR, V22, P609, DOI 10.1556/AChrom.22.2010.4.10; Zhu M, 2000, PLANTA MED, V66, P521, DOI 10.1055/s-2000-11202	40	8	9	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2014	9	1							e85165	10.1371/journal.pone.0085165	http://dx.doi.org/10.1371/journal.pone.0085165			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301BI	24475039	Green Published, Green Submitted, gold			2023-01-03	WOS:000330507300018
J	Ruiz-Canela, M; Estruch, R; Corella, D; Salas-Salvado, J; Martinez-Gonzalez, MA				Ruiz-Canela, Miguel; Estruch, Ramon; Corella, Dolores; Salas-Salvado, Jordi; Martinez-Gonzalez, Miguel A.			Association of Mediterranean Diet With Peripheral Artery Disease: The PREDIMED Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							NUTRITION		[Ruiz-Canela, Miguel; Martinez-Gonzalez, Miguel A.] Univ Navarra, Dept Prevent Med & Publ Hlth, Pamplona 31008, Spain; [Estruch, Ramon] Inst Invest Biomed August Pi & Sunyer, Dept Internal Med, Barcelona, Spain; [Corella, Dolores] Univ Valencia, Dept Prevent Med, Valencia, Spain; [Salas-Salvado, Jordi] St Joan Hosp, Human Nutr Unit, Reus, Spain	University of Navarra; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Valencia	Martinez-Gonzalez, MA (corresponding author), Univ Navarra, Irunlarrea 1, Pamplona 31008, Spain.	mamartinez@unav.es	Salas-Salvado, Jordi/C-7229-2017; Martinez-Gonzalez, Miguel A./AAE-7669-2019; Ruiz-Canela, Miguel/I-7738-2016; Estruch, Ramon/AAZ-3723-2020	Salas-Salvado, Jordi/0000-0003-2700-7459; Ruiz-Canela, Miguel/0000-0002-7684-2787; Martinez-Gonzalez, Miguel A./0000-0002-3917-9808				Martinez-Gonzalez MA, 2012, INT J EPIDEMIOL, V41, P377, DOI 10.1093/ije/dyq250; Brostow DP, 2012, NAT REV CARDIOL, V9, P634, DOI 10.1038/nrcardio.2012.117; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Lane JS, 2008, J VASC SURG, V48, P897, DOI 10.1016/j.jvs.2008.05.014; Mente A, 2009, ARCH INTERN MED, V169, P659, DOI 10.1001/archinternmed.2009.38; Naqvi AZ, 2012, ATHEROSCLEROSIS, V222, P545, DOI 10.1016/j.atherosclerosis.2012.03.029	6	116	118	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	2014	311	4					415	417		10.1001/jama.2013.280618	http://dx.doi.org/10.1001/jama.2013.280618			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	292YT	24449321	Bronze, Green Published			2023-01-03	WOS:000329939300028
J	Zhou, L; Liu, L; Liu, XY; Chen, PY; Liu, L; Zhang, YQ; Wu, YZ; Pettigrew, JC; Cheng, DX; Yi, D				Zhou, Liang; Liu, Ling; Liu, Xiaoyu; Chen, Pinyi; Liu, Ling; Zhang, Yanqi; Wu, Yazhou; Pettigrew, Julia Christine; Cheng, Dixiang; Yi, Dong			Systematic Review and Meta-Analysis of the Clinical Efficacy and Adverse Effects of Chinese Herbal Decoction for the Treatment of Gout	PLOS ONE			English	Article							HYPERURICEMIA; PREVALENCE; DISEASE	Background: In East Asia, numerous reports describe the utilization of traditional Chinese herbal decoctions to treat gout. However, the reported clinical effects vary. Objectives: In this study, we reviewed and analyzed a large number of randomized controlled clinical trials to systematically assess the clinical efficacy and adverse reactions of Chinese herbal decoctions for treating gout. Methods: We performed a comprehensive search of databases, such as PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, Chinese biomedical literature database, et al. In addition, we manually searched the relevant meeting information in the library of the Third Military Medical University. Results: Finally, 17 randomized controlled trials with a sample size of 1,402 cases met the criteria and were included in the study. The results of the meta-analysis showed that when gout had progressed to the stage of acute arthritis, there was no significant difference in clinical efficacy between Chinese herbal decoctions and traditional Western medicine, as indicated based on the following parameters: serum uric acid (standardized mean difference (SMD): 0.35, 95% confidence interval (CI): 0.03 to 0.67), C reactive protein (SMD: 0.25, 95% CI: -0.18 to 0.69), erythrocyte sedimentation rate (SMD: 0.21, 95% CI: -0.02 to 0.45) and overall clinical response (relative risk (RR): 1.05, 95% CI: 1.01 to 1.10). However, the Chinese herbal decoction was significantly better than traditional Western medicine in controlling adverse drug reactions (RR: 0.06, 95% CI: 0.03 to 0.13). Conclusions: Through a systematic review of the clinical efficacy and safety of Chinese herbal decoctions and traditional Western medicine for the treatment of gout, we found that Chinese herbal decoction and traditional Western medicine led to similar clinical efficacy, but the Chinese herbal decoctions were superior to Western medicine in terms of controlling adverse drug reactions.	[Zhou, Liang; Liu, Ling; Liu, Xiaoyu; Chen, Pinyi; Liu, Ling; Zhang, Yanqi; Wu, Yazhou; Yi, Dong] Third Mil Med Univ, Dept Hlth Stat, Coll Prevent Med, Chongqing, Peoples R China; [Liu, Ling] Chongqing Univ Arts & Sci, PE Dept Phys Educ, Chongqing, Peoples R China; [Pettigrew, Julia Christine] Univ Washington, Sch Arts & Sci, Dept Biol Sci, Seattle, WA 98195 USA; [Pettigrew, Julia Christine] Univ Washington, Dept Asian Language & Literature, Seattle, WA 98195 USA; [Cheng, Dixiang] Chongqing Univ Posts & Telecommun, Sch Software Engn, Chongqing, Peoples R China	Army Medical University; Chongqing University of Arts & Sciences; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Chongqing University of Posts & Telecommunications	Yi, D (corresponding author), Third Mil Med Univ, Dept Hlth Stat, Coll Prevent Med, Chongqing, Peoples R China.	yd_house@hotmail.com			Natural Science Foundation of China [81172773, 30872184, 30901242]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The study was supported by three Natural Science Foundation of China (No. 81172773, No. 30872184 and No. 30901242). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Annemans L, 2008, ANN RHEUM DIS, V67, P960, DOI 10.1136/ard.2007.076232; Arroyo MP, 2004, BRIT J DERMATOL, V150, P581, DOI 10.1111/j.1365-2133.2004.05838.x; Banares R, 2002, HEPATOLOGY, V35, P609, DOI 10.1053/jhep.2002.31354; BARKER DJP, 1998, EPIDEMIOLOGY MED PRA; Choi HK, 2004, LANCET, V363, P1277, DOI 10.1016/S0140-6736(04)16000-5; Deveci OS, 2010, INT J CLIN PRACT, V64, P900, DOI 10.1111/j.1742-1241.2009.02263.x; Ding Y, 2011, J CHANGCHUN COLL TRA, V27, P436; Ding Y, 2006, CHINESE J PRIMARY ME, V13, P1085; Fan L, 2009, CHINA PHARMACIST, V9, P1360; Gianluca T, 2013, ANN RHEUM DIS, V72, P694; Han Y, 2011, INFORM TRADITIONAL C, V24, P102; Huang L, 2003, CLIN J ANHUI TRADITI, V15, P114; Huang YK, 2011, ACTA ACAD CPAPF, V20, P135; Huang Z, 2002, CHINESE MED, P461; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Ji B, 2010, LIAONING J TRADITION, V37, P147; Li G, 1992, TRADITIONAL CHINESE, P46; Li T, 2010, TRADITIONAL CHINESE; [李廷谦 LI Tingqian], 2007, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V7, P180; Li Y, 2004, HUNAN J TRADITIONAL, V20, P42; Lianqun Q, 2007, CHINA MED HERALD, V4, P87; Liming L, 2007, EPIDEMIOLOGY, P71; Liu M., 2011, LIAONING J TRADI CHI, V38, P675; Lu Y, 2008, CHINA PRACTICAL MED, V3, P102; Miao ZM, 2008, J RHEUMATOL, V35, P1859; Ogura T, 2004, METABOLISM, V53, P448, DOI 10.1016/j.metabol.2003.11.017; Ozdogu H, 2007, RHEUMATOL INT, V27, P763, DOI 10.1007/s00296-006-0285-2; Qin B, 2011, CHINA J EXPT TRADITI, V17, P279; Roddy E, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3199; Shin T, 1996, DIAGNOSIS THERAPY, V84, P905; Tang C, 2008, HEILONGJIANG J TRADI, V6, P12; The Chinese medical association, 2005, CLIN DIAGN TREATM GU, P321; The Ministry of Health of the People's Republic of China, 1995, CHIN HERB MED NEW ME, P179; Wallace KL, 2004, J RHEUMATOL, V31, P1582; WALLACE SL, 1977, ARTHRITIS RHEUM, V20, P895, DOI 10.1002/art.1780200320; Wang B, 2012, AM J CHINESE MED, V40, P25, DOI 10.1142/S0192415X12500036; Wang H, 2008, J EMERGENCY TRADITIO, V4, P187; Wang X. X., 2010, ZHEJIANG J TRADITION, V45, P430; Yang J, 2010, YUNNAN J TRADITIONAL, V31, P53; Ye Rengao, 2001, INTERNAL MED, P877; [余俊文 Yu Junwen], 2005, [中华流行病学杂志, Chinese Journal of Epidemiology], V26, P455; Yu Z, 2005, GOUT; Zhang, 2006, J PRACTICAL DIAGNOSI, V20, P505; Zhang XZ, 2011, J EMERGENCY TRADITIO, V20, P964; Zhang Y, 2000, CHINESE J TRADITIONA, V7, P50; Zhong B, 2007, J TRADITIONAL CHINES, V39, P645; 赵岭梅, 2007, [中医杂志, Journal of Traditional Chinese Medicine], V48, P533; 杨崇青, 2006, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V21, P474; 郑文洁, 2002, [中华医学杂志, National Medical Journal of China], V82, P716	50	22	26	1	45	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2014	9	1							e85008	10.1371/journal.pone.0085008	http://dx.doi.org/10.1371/journal.pone.0085008			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297GT	24465466	gold, Green Published, Green Submitted			2023-01-03	WOS:000330244500027
J	Williams, PS; Hoffman, RL; Clark, BC				Williams, Petra S.; Hoffman, Richard L.; Clark, Brian C.			Preliminary Evidence That Anodal Transcranial Direct Current Stimulation Enhances Time to Task Failure of a Sustained Submaximal Contraction	PLOS ONE			English	Article							HUMAN MOTOR CORTEX; NONINVASIVE BRAIN-STIMULATION; MAGNETIC STIMULATION; BICEPS-BRACHII; MUSCLE FATIGUE; ISOMETRIC CONTRACTION; CORTICAL EXCITABILITY; SUPRASPINAL FACTORS; ACTIVATION; PLASTICITY	The purpose of this study was to determine whether anodal transcranial direct current stimulation (tDCS) delivered while performing a sustained submaximal contraction would increase time to task failure (TTF) compared to sham stimulation. Healthy volunteers (n = 18) performed two fatiguing contractions at 20% of maximum strength with the elbow flexors on separate occasions. During fatigue task performance, either anodal or sham stimulation was delivered to the motor cortex for up to 20 minutes. Transcranial magnetic stimulation (TMS) was used to assess changes in cortical excitability during stimulation. There was no systematic effect of the anodal tDCS stimulation on TTF for the entire subject set (n = 18; p = 0.64). Accordingly, a posteriori subjects were divided into two tDCS-time groups: Full-Time (n = 8), where TTF occurred prior to the termination of tDCS, and Part-Time (n = 10), where TTF extended after tDCS terminated. The TTF for the Full-Time group was 31% longer with anodal tDCS compared to sham (p = 0.04), whereas TTF for the Part-Time group did not differ (p = 0.81). Therefore, the remainder of our analysis addressed the Full-Time group. With anodal tDCS, the amount of muscle fatigue was 6% greater at task failure (p = 0.05) and the amount of time the Full-Time group performed the task at an RPE between 8-10 ("very hard'') increased by 38% (p = 0.04) compared to sham. There was no difference in measures of cortical excitability between stimulation conditions (p = 0.90). That the targeted delivery of anodal tDCS during task performance both increased TTF and the amount of muscle fatigue in a subset of subjects suggests that augmenting cortical excitability with tDCS enhanced descending drive to the spinal motorpool to recruit more motor units. The results also suggest that the application of tDCS during performance of fatiguing activity has the potential to bolster the capacity to exercise under conditions required to derive benefits due to overload.	[Williams, Petra S.; Hoffman, Richard L.; Clark, Brian C.] Ohio Univ, Ohio Musculoskeletal & Neurol Inst, Athens, OH 45701 USA; [Williams, Petra S.] No Arizona Univ, Dept Phys Therapy & Athlet Training, Flagstaff, AZ 86011 USA; [Clark, Brian C.] Ohio Univ, Dept Biomed Sci, Athens, OH 45701 USA; [Clark, Brian C.] Ohio Univ, Dept Geriatr Med & Gerontol, Athens, OH 45701 USA	University System of Ohio; Ohio University; Northern Arizona University; University System of Ohio; Ohio University; University System of Ohio; Ohio University	Williams, PS (corresponding author), Ohio Univ, Ohio Musculoskeletal & Neurol Inst, Athens, OH 45701 USA.	petra.williams@nau.edu			National Institutes of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development [R15HD065552]; Research and Scholarly Affairs Committee at the Ohio University Heritage College of Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R15HD065552] Funding Source: NIH RePORTER	National Institutes of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Research and Scholarly Affairs Committee at the Ohio University Heritage College of Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported in part by grant R15HD065552 from the National Institutes of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development to B. C. Clark. Additionally, internal support for this work was provided by a grant from the Research and Scholarly Affairs Committee at the Ohio University Heritage College of Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; Barry BK, 2007, INTEGR COMP BIOL, V47, P465, DOI 10.1093/icb/icm047; Bastani A, 2012, CLIN NEUROPHYSIOL, V123, P644, DOI 10.1016/j.clinph.2011.08.029; BIGLANDRITCHIE B, 1982, J PHYSIOL-LONDON, V330, P265, DOI 10.1113/jphysiol.1982.sp014340; BIGLANDRITCHIE B, 1984, MUSCLE NERVE, V7, P691, DOI 10.1002/mus.880070902; Boggio PS, 2007, RESTOR NEUROL NEUROS, V25, P123; Bolognini N, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-8; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; BRASILNETO JP, 1992, J CLIN NEUROPHYSIOL, V9, P132, DOI 10.1097/00004691-199201000-00014; Brunoni AR, 2012, BRAIN STIMUL, V5, P175, DOI 10.1016/j.brs.2011.03.002; Cogiamanian F, 2007, EUR J NEUROSCI, V26, P242, DOI 10.1111/j.1460-9568.2007.05633.x; Damron LA, 2008, J NEUROSCI METH, V173, P121, DOI 10.1016/j.jneumeth.2008.06.001; DaSilva AF, 2011, JOVE-J VIS EXP, DOI 10.3791/2744; Docherty D, 2000, SPORTS MED, V30, P385, DOI 10.2165/00007256-200030060-00001; Duchateau J, 2002, J PHYSIOL-LONDON, V541, P959, DOI 10.1113/jphysiol.2002.016790; ENOKA RM, 1992, J APPL PHYSIOL, V72, P1631, DOI 10.1152/jappl.1992.72.5.1631; Enoka RM, 2012, J BIOMECH, V45, P427, DOI 10.1016/j.jbiomech.2011.11.047; Enoka RM, 2011, J ELECTROMYOGR KINES, V21, P208, DOI 10.1016/j.jelekin.2010.10.006; Fricke K, 2011, J NEUROPHYSIOL, V105, P1141, DOI 10.1152/jn.00608.2009; Gandevia SC, 2001, PHYSIOL REV, V81, P1725, DOI 10.1152/physrev.2001.81.4.1725; Gandevia SC, 1996, J PHYSIOL-LONDON, V490, P529, DOI 10.1113/jphysiol.1996.sp021164; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; GARLAND SJ, 1994, J APPL PHYSIOL, V76, P2411, DOI 10.1152/jappl.1994.76.6.2411; Hummel F, 2005, BRAIN, V128, P490, DOI 10.1093/brain/awh369; Hummel FC, 2006, LANCET NEUROL, V5, P708, DOI 10.1016/S1474-4422(06)70525-7; Hunter SK, 2003, J APPL PHYSIOL, V94, P108, DOI 10.1152/japplphysiol.00635.2002; Jones LA, 1995, ADV EXP MED BIOL, V384, P305; Kalmar JM, 2006, EXP BRAIN RES, V173, P446, DOI 10.1007/s00221-006-0383-0; Klass M, 2008, J NEUROPHYSIOL, V99, P1096, DOI 10.1152/jn.01252.2007; Lang N, 2004, EXP BRAIN RES, V156, P439, DOI 10.1007/s00221-003-1800-2; Lang N, 2005, EUR J NEUROSCI, V22, P495, DOI 10.1111/j.1460-9568.2005.04233.x; Lang N, 2011, J NEUROPHYSIOL, V105, P2802, DOI 10.1152/jn.00617.2010; Maluf KS, 2005, J APPL PHYSIOL, V99, P389, DOI 10.1152/japplphysiol.00207.2005; McGinley M, 2010, EXP GERONTOL, V45, P671, DOI 10.1016/j.exger.2010.04.005; McNeil CJ, 2011, J PHYSIOL-LONDON, V589, P3533, DOI 10.1113/jphysiol.2011.207191; McNeil CJ, 2009, J PHYSIOL-LONDON, V587, P5601, DOI 10.1113/jphysiol.2009.180968; McNeil CJ., 2011, PHYSL NEWS, V82, P29; Muthalib M, 2013, ADV EXP MED BIOL, V789, P73, DOI 10.1007/978-1-4614-7411-1_11; Nitsche MA, 2007, J NEUROPHYSIOL, V97, P3109, DOI 10.1152/jn.01312.2006; Nitsche MA, 2003, CLIN NEUROPHYSIOL, V114, P2220, DOI 10.1016/S1388-2457(03)00235-9; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2003, CLIN NEUROPHYSIOL, V114, P600, DOI 10.1016/S1388-2457(02)00412-1; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; Nitsche MA, 2005, J PHYSIOL-LONDON, V568, P291, DOI 10.1113/jphysiol.2005.092429; Nitsche MA, 2007, J NEUROSCI, V27, P3807, DOI 10.1523/JNEUROSCI.5348-06.2007; Nitsche MA, 2011, RESTOR NEUROL NEUROS, V29, P463, DOI 10.3233/RNN-2011-0618; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Peterchev AV, 2012, BRAIN STIMUL, V5, P435, DOI 10.1016/j.brs.2011.10.001; Place N, 2009, CLIN EXP PHARMACOL P, V36, P334, DOI 10.1111/j.1440-1681.2008.05021.x; Poortvliet PC, 2013, CLIN NEUROPHYSIOL, V124, P732, DOI 10.1016/j.clinph.2012.09.025; Priori A, 1998, NEUROREPORT, V9, P2257, DOI 10.1097/00001756-199807130-00020; Ratamess NA, 2009, MED SCI SPORT EXER, V41, P687, DOI 10.1249/MSS.0b013e3181915670; Reis J, 2008, J PHYSIOL-LONDON, V586, P325, DOI 10.1113/jphysiol.2007.144824; Reis J, 2011, CURR OPIN NEUROL, V24, P590, DOI 10.1097/WCO.0b013e32834c3db0; Reis J, 2008, BRAIN STIMUL, V1, P363, DOI 10.1016/j.brs.2008.08.001; Rothwell JC, 2009, J PHYSIOL-LONDON, V587, P5517, DOI 10.1113/jphysiol.2009.183475; Rothwell JC, 2010, FOLIA PHONIATR LOGO, V62, P153, DOI 10.1159/000314030; Sacco P, 1997, MUSCLE NERVE, V20, P1158, DOI 10.1002/(SICI)1097-4598(199709)20:9<1158::AID-MUS11>3.0.CO;2-P; Stagg CJ, 2011, NEUROSCIENTIST, V17, P37, DOI 10.1177/1073858410386614; Taylor JL, 2008, J APPL PHYSIOL, V104, P542, DOI 10.1152/japplphysiol.01053.2007; Taylor JL, 2006, CLIN EXP PHARMACOL P, V33, P400, DOI 10.1111/j.1440-1681.2006.04363.x; Taylor JL, 1997, EXP BRAIN RES, V117, P472, DOI 10.1007/s002210050243; Taylor JL, 1996, J PHYSIOL-LONDON, V490, P519, DOI 10.1113/jphysiol.1996.sp021163; Taylor JL, 2001, MUSCLE NERVE, V24, P18, DOI 10.1002/1097-4598(200101)24:1<18::AID-MUS2>3.3.CO;2-4; Thirugnanasambandam N, 2011, RESTOR NEUROL NEUROS, V29, P311, DOI 10.3233/RNN-2011-0601; Zijdewind I, 2006, EXP BRAIN RES, V175, P526, DOI 10.1007/s00221-006-0570-z	68	82	86	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2013	8	12							e81418	10.1371/journal.pone.0081418	http://dx.doi.org/10.1371/journal.pone.0081418			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275VD	24349067	Green Published, gold, Green Submitted			2023-01-03	WOS:000328705200027
J	Bajpe, PK; Prahallad, A; Horlings, H; Nagtegaal, I; Beijersbergen, R; Bernards, R				Bajpe, P. K.; Prahallad, A.; Horlings, H.; Nagtegaal, I.; Beijersbergen, R.; Bernards, R.			A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity	ONCOGENE			English	Article						SIRT2; drug resistance; chromatin modifiers; genetic screen	METASTATIC COLORECTAL-CANCER; FREQUENT MUTATIONS; CELL CARCINOMA; RAS MUTATIONS; BREAST-CANCER; CETUXIMAB; RESISTANCE; RECEPTOR; PATHWAY; MARKER	Resistance to targeted therapies is a major problem in cancer treatment. The epidermal growth factor receptor (EGFR) antibody drugs are effective in a subset of colorectal cancers, but the molecular mechanisms of resistance are understood poorly. Genes involved in epigenetic regulation are frequently deregulated in cancer, raising the possibility that such genes also contribute to drug resistance. Using a focused RNA interference library for genes involved in epigenetic regulation, we identify sirtuin2 (SIRT2), an NAD(+)-dependent deacetylase, as a modulator of the response to EGFR inhibitors in colon and lung cancer. SIRT2 loss also conferred resistance to BRAF and MEK inhibitors in BRAF mutant melanoma and KRAS mutant colon cancers, respectively. These results warrant further investigation into the potential role of SIRT2 in resistance to drugs that act in the receptor tyrosine kinase-RAS-RAF-MEK-ERK signaling pathway.	[Bajpe, P. K.; Prahallad, A.; Horlings, H.; Beijersbergen, R.; Bernards, R.] Netherlands Canc Inst, Div Mol Carcinogenesis, Canc Genom Ctr, NL-1066 CX Amsterdam, Netherlands; [Horlings, H.] Acad Medisch Cent, Dept Pathol, Amsterdam, Netherlands; [Nagtegaal, I.] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6525 ED Nijmegen, Netherlands	Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Radboud University Nijmegen	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Canc Genom Ctr, 121 Plesmanlaan, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl	Nagtegaal, Iris D/A-2448-2014	Nagtegaal, Iris D/0000-0003-0887-4127; Bernards, Rene/0000-0001-8677-3423; Beijersbergen, Roderick/0000-0003-0116-4130	Dutch Cancer Society (KWF); European Union [259015]	Dutch Cancer Society (KWF)(KWF Kankerbestrijding); European Union(European Commission)	We are grateful to Kees Punt, Sabine Tejpar, Josep Tabernero, Jose Jimenez, Adriana Lopez-Doriga Guerra, Ramon Salzar and Loredana Vecchione for providing clinical specimen of cetuximab-treated colon cancers. We thank Gerrit Hooiger and Marc van de Vijver (AMC, Amsterdam) for assistance in staining tissue microarrays and Alberto Bardelli for the kind gift of the Difi cells. We thank the NKI Genomics Core Facility, especially Iris de Rink, for support. We also thank Chong Sun and Sidong Huang for helpful discussions. This work was supported by grants from the Dutch Cancer Society (KWF) and the European Union Seventh Framework Program COLTHERES project, grant agreement 259015.	Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; Barber MF, 2012, NATURE, V487, P114, DOI 10.1038/nature11043; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Brummelkamp TR, 2006, NAT CHEM BIOL, V2, P202, DOI 10.1038/nchembio774; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Geutjes EJ, 2012, ONCOGENE, V31, P3827, DOI 10.1038/onc.2011.552; Glasspool RM, 2006, BRIT J CANCER, V94, P1087, DOI 10.1038/sj.bjc.6603024; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Huang SD, 2012, CELL, V151, P937, DOI 10.1016/j.cell.2012.10.035; Huang SD, 2009, CANCER CELL, V15, P328, DOI 10.1016/j.ccr.2009.02.023; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Liu H, 2009, CANCER BIOL THER, V8, P1204, DOI 10.4161/cbt.8.13.8924; Marschalek R, 2011, BRIT J HAEMATOL, V152, P141, DOI 10.1111/j.1365-2141.2010.08459.x; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Reisman DN, 2003, CANCER RES, V63, P560; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Samowitz WS, 2000, CANCER EPIDEM BIOMAR, V9, P1193; Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Yeung F, ONCOGENE	27	30	33	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					531	536		10.1038/onc.2013.588	http://dx.doi.org/10.1038/onc.2013.588			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469059				2023-01-03	WOS:000348451300014
J	Licht, SD; Winther, JF; Gudmundsdottir, T; Holmqvist, AS; Bonnesen, TG; Asdahl, PH; Tryggvadottir, L; Anderson, H; Wesenberg, F; Malila, N; Holm, K; Hasle, H; Olsen, JH				Licht, Sofie de Fine; Winther, Jeanette Falck; Gudmundsdottir, Thorgerdur; Holmqvist, Anna Sallfors; Bonnesen, Trine Gade; Asdahl, Peter Haubjerg; Tryggvadottir, Laufey; Anderson, Harald; Wesenberg, Finn; Malila, Nea; Holm, Kirsten; Hasle, Henrik; Olsen, Jorgen Helge		ALiCCS Study Grp	Hospital contacts for endocrine disorders in Adult Life after Childhood Cancer in Scandinavia (ALiCCS): a population-based cohort study	LANCET			English	Article							SURVIVORS; RADIATION; MENARCHE; THERAPY; TUMORS	Background The pattern of endocrine disorders in long-term survivors of childhood cancer has not been investigated comprehensively. Here, we aimed to assess the lifetime risk of these disorders in Nordic survivors of childhood cancer. Methods From the national cancer registries of Denmark, Finland, Iceland, Norway, and Sweden, we identified 31 723 1-year survivors of childhood cancer, notified since the start of registration in the 1940s and 1950s. From the national population registries, we randomly selected a comparison cohort of people matched by age, sex, and country. Study participants were linked to the national hospital registries, and observed numbers of first-time hospital contacts for endocrine disorders in survivors of childhood cancer were compared with the expected numbers derived from the population comparison cohort. We calculated the absolute excess risks attributable to status as a childhood cancer survivor and standardised hospitalisation rate ratios (SHRRs). Findings Of the childhood cancer survivors, 3292 had contact with a hospital for an endocrine disorder, yielding a SHRR of 4.8 (95% CI 4.6-5.0); the highest risks were in survivors of leukaemia (SHRR 7.3 [ 95% CI 6.7-7.9]), CNS tumours (6.6 [6.2-7.0]), and Hodgkin's lymphoma (6.2 [5.6-7.0]). The absolute excess risk for endocrine disorders was roughly 1000 per 100 000 person-years before 20 years of age, and 400 per 100 000 person-years during the remaining lifetime. For children with cancer diagnosed at 5-9 years of age, the cumulative risk for endocrine disorders was highest, and reached 43% at the age of 60 years. Diagnoses of pituitary hypofunction (SHRR 88.0), hypothyroidism (9.9), and testicular and ovarian dysfunction (42.5 and 4.7, respectively) together constituted 61% (655 of 1078) of all excess disease-induced and treatment-induced endocrine disorders in survivors of childhood cancer. Interpretation A cumulative risk for endocrine disorders at 60 years of age of above 40% in survivors of childhood cancer emphasises the importance of minimisation of damaging treatment, intensification of secondary prevention, and targeting of survivor follow-up throughout life. Since most long-term childhood cancer survivors are not followed in a specialised late-effect clinic, they are a growing challenge for the primary care physician and medical specialists working outside the late-effect area.	[Licht, Sofie de Fine; Winther, Jeanette Falck; Gudmundsdottir, Thorgerdur; Olsen, Jorgen Helge] Danish Canc Soc, Res Ctr, DK-2100 Copenhagen, Denmark; [Holmqvist, Anna Sallfors] Skane Univ Hosp, Div Paediat Oncol & Haematol, Lund, Sweden; [Holmqvist, Anna Sallfors] Lund Univ, Dept Clin Sci, Lund, Sweden; [Anderson, Harald] Lund Univ, Dept Canc Epidemiol, Lund, Sweden; [Bonnesen, Trine Gade; Asdahl, Peter Haubjerg; Hasle, Henrik] Aarhus Univ Hosp, Dept Paediat, DK-8000 Aarhus, Denmark; [Tryggvadottir, Laufey] Iceland Canc Registry, Reykjavik, Iceland; [Tryggvadottir, Laufey] Univ Iceland, Fac Med, Reykjavik, Iceland; [Wesenberg, Finn] Oslo Univ Hosp, Dept Paediat, Oslo, Norway; [Wesenberg, Finn] Univ Oslo, Fac Med, Oslo, Norway; [Wesenberg, Finn] Norwegian Canc Registry, Oslo, Norway; [Malila, Nea] Finnish Canc Registry, FIN-00170 Helsinki, Finland; [Holm, Kirsten] Hilleroed Hosp, Dept Paediat, Hillerod, Denmark	Danish Cancer Society; Lund University; Skane University Hospital; Lund University; Lund University; Aarhus University; University of Iceland; University of Oslo; University of Oslo; Finnish Cancer Registry; University of Copenhagen	Licht, SD (corresponding author), Danish Canc Soc, Res Ctr, Survivorship Unit, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.	sofielie@cancer.dk	Winther, Jeanette Falck/AAS-2754-2020	Winther, Jeanette Falck/0000-0002-3440-5108; Olsen, Jorgen Helge/0000-0001-9633-5662; Hasle, Henrik/0000-0003-3976-9231; Asdahl, Peter Haubjerg/0000-0002-5604-8578; Tryggvadottir, Laufey/0000-0001-8067-9030; de Fine Licht, Sofie/0000-0001-7855-4706	Danish Council for Strategic Research [09-066899]	Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF))	This study was funded by grant 09-066899 from the Danish Council for Strategic Research. We thank Andrea Bautz for her contribution to data management, Lasse Wegener Lund for helpful comments, and the ALiCCS board (Jorgen H Olsen, Finn Wesenberg, Catherine Rechnitzer, Kirsi Jahnukainen, Lars Hjorth, and Nea Malila), three of whom were coauthors, for their valuable help and guidance.	Armstrong GT, 2009, CANCER, V115, P2562, DOI 10.1002/cncr.24294; BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; Brabant G, 2012, INT J CANCER, V130, P1145, DOI 10.1002/ijc.26086; BROWN PD, 1995, ACTA PAEDIATR, V84, P316, DOI 10.1111/j.1651-2227.1995.tb13636.x; Chow EJ, 2008, PEDIATR BLOOD CANCER, V50, P854, DOI 10.1002/pbc.21316; CONSTINE LS, 1993, NEW ENGL J MED, V328, P87, DOI 10.1056/NEJM199301143280203; Gatta G, 2009, EUR J CANCER, V45, P992, DOI 10.1016/j.ejca.2008.11.042; Gjerstorff ML, 2011, SCAND J PUBLIC HEALT, V39, P42, DOI 10.1177/1403494810393562; Green DM, 2009, J CLIN ONCOL, V27, P2374, DOI 10.1200/JCO.2008.21.1839; Gurney JG, 2003, CANCER-AM CANCER SOC, V97, P663, DOI 10.1002/cncr.11095; HORNING SJ, 1981, NEW ENGL J MED, V304, P1377, DOI 10.1056/NEJM198106043042301; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Meacham Lillian, 2003, Curr Probl Pediatr Adolesc Health Care, V33, P217, DOI 10.1016/S1538-5442(03)00053-1; Nandagopal R, 2008, HORM RES, V69, P65, DOI 10.1159/000111809; Oberfield SE, 1996, ARCH PEDIAT ADOL MED, V150, P589, DOI 10.1001/archpedi.1996.02170310023003; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Punyko JA, 2005, PEDIATR BLOOD CANCER, V44, P643, DOI 10.1002/pbc.20310; Robison LL, 2009, J CLIN ONCOL, V27, P2308, DOI 10.1200/JCO.2009.22.3339; Robison LL, 2002, MED PEDIATR ONCOL, V38, P229, DOI 10.1002/mpo.1316; SHALET SM, 1976, CANCER, V37, P1144, DOI 10.1002/1097-0142(197602)37:2+<1144::AID-CNCR2820370824>3.0.CO;2-U; Sigurdardottir LG, 2012, ACTA ONCOL, V51, P880, DOI 10.3109/0284186X.2012.698751; Sklar C, 2000, J CLIN ENDOCR METAB, V85, P3227, DOI 10.1210/jc.85.9.3227; Teinturier C, 1998, BONE MARROW TRANSPL, V22, P989, DOI 10.1038/sj.bmt.1701483; Tulinius H, 1992, APMIS Suppl, V31, P1	25	54	55	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2014	383	9933					1981	1989		10.1016/S0140-6736(13)62564-7	http://dx.doi.org/10.1016/S0140-6736(13)62564-7			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AI4PV	24556022				2023-01-03	WOS:000336848200026
J	Gostin, LO				Gostin, Lawrence O.			Legal and Ethical Responsibilities Following Brain Death: The McMath and Munoz Cases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, Washington, DC 20001 USA	Georgetown University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu		Gostin, Lawrence/0000-0001-5286-4044				[Anonymous], 1968, JAMA, V205, P337; Fernandez M., 2014, NY TIMES, pA14; Fernandez See M., 2014, NEW YORK TIMES, pA1; MOLLARET P., 1959, REV NEUROL [PARIS], V101, P3; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1981, DEFINING DEATH A REP	5	29	30	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	2014	311	9					903	904		10.1001/jama.2014.660	http://dx.doi.org/10.1001/jama.2014.660			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AC0FS	24463988	Green Published			2023-01-03	WOS:000332170800012
J	Michon, AL; Jumas-Bilak, E; Chiron, R; Lamy, B; Marchandin, H				Michon, Anne-Laure; Jumas-Bilak, Estelle; Chiron, Raphael; Lamy, Brigitte; Marchandin, Helene			Advances toward the Elucidation of Hypertonic Saline Effects on Pseudomonas aeruginosa from Cystic Fibrosis Patients	PLOS ONE			English	Article							BIOFILM; CLEARANCE; NACL; PH	Objectives: Nebulized hypertonic saline (HTS) has beneficial effects including reducing pulmonary exacerbations in Cystic Fibrosis (CF) patients. Several mechanisms may explain these effects but antimicrobial activity of NaCl remains largely unexplored. We aimed to measure the antimicrobial effect of NaCl on Pseudomonas aeruginosa isolated from the respiratory tract in CF patients. Methods: NaCl minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) were determined for strains characterized for mucoidy, antimicrobial resistance, and ability to form biofilm using 0,9% to 15% NaCl solutions. NaCl effects on biofilm formation, preformed biofilm, and mobility were evaluated. Kinetics of antimicrobial effects was studied. Results: The growth of all isolates (n = 85) from 34 patients was inhibited by 6% NaCl solution. A 10% concentration had a bactericidal activity on 90% of the isolates. Mucoid and multidrug resistant (MDR) isolates displayed lower MICs compared to non-mucoid and to non-MDR isolates, respectively. Time-kill kinetics showed that NaCl exhibited a rapid, dose and growth phase dependent bactericidal effect. Three percent or more of NaCl inhibited biofilm formation for 69% of strongly adherent isolates. A dose-dependent decrease of preformed biofilm viability and an inhibitory activity on bacterial motility were observed. Conclusions: NaCl inhibited the growth of all isolates and killed 38% of tested isolates within concentration range currently used in therapeutics. Our results suggest that anti-pseudomonal activity is another mechanism of action of HTS to add to those already established. Clinical trials are needed to compare diverse HTS conditions of use (rhythm, dose and mode of delivery) to obtain efficient and optimized anti-P. aeruginosa effects. More generally, NaCl effect on other opportunistic pathogens as well as on global microbiotae recovered during polymicrobial diseases warrants further investigations.	[Michon, Anne-Laure; Jumas-Bilak, Estelle; Lamy, Brigitte; Marchandin, Helene] Univ Montpellier I, Equipe Pathogenes & Environm, UFR Sci Pharmaceut & Biol, UMR ECOSYM 5119, Montpellier, France; [Michon, Anne-Laure; Lamy, Brigitte; Marchandin, Helene] Ctr Hosp Reg Univ Montpellier, Hop Arnaud de Villeneuve, Bacteriol Lab, Montpellier, France; [Jumas-Bilak, Estelle] Ctr Hosp Reg Univ Montpellier, Lab Hyg Hosp, Montpellier, France; [Chiron, Raphael] Ctr Hosp Reg Univ Montpellier, Hop Arnaud de Villeneuve, Ctr Ressources & Competences Mucoviscidose, Montpellier, France	Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier	Michon, AL (corresponding author), Univ Montpellier I, Equipe Pathogenes & Environm, UFR Sci Pharmaceut & Biol, UMR ECOSYM 5119, Montpellier, France.	al-michon@chu-montpellier.fr	Lamy, Brigitte/A-8401-2015; MARCHANDIN, Hélène/AAM-8288-2021	Lamy, Brigitte/0000-0003-2370-8186; MARCHANDIN, Hélène/0000-0003-2130-6335	Ministere de l'enseignement superieur et de la recherche, France	Ministere de l'enseignement superieur et de la recherche, France	This work was supported by the Ministere de l'enseignement superieur et de la recherche, France. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelraouf K, 2011, J ANTIMICROB CHEMOTH, V66, P1311, DOI 10.1093/jac/dkr105; Ballmann Manfred, 2002, J Cyst Fibros, V1, P35, DOI 10.1016/S1569-1993(01)00009-1; Behrends V, 2010, MOL BIOSYST, V6, P562, DOI 10.1039/b918710c; Bergsson G, 2009, J IMMUNOL, V183, P543, DOI 10.4049/jimmunol.0803959; Boucher RC, 2007, J INTERN MED, V261, P5, DOI 10.1111/j.1365-2796.2006.01744.x; Bye PTP, 2007, PAEDIATR RESPIR REV, V8, P30, DOI 10.1016/j.prrv.2007.02.008; Clunes Mark T, 2007, Drug Discov Today Dis Mech, V4, P63, DOI 10.1016/j.ddmec.2007.09.001; Courvalin P., 2009, ANTIBIOGRAM; Cystic Fibrosis Foundation, 1994, MICR INF DIS CYST FI, V5, P1; Deligianni E, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-38; Dmello D, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2010-000019; Donaldson SH, 2006, NEW ENGL J MED, V354, P241, DOI 10.1056/NEJMoa043891; Elkins MR, 2006, NEW ENGL J MED, V354, P229, DOI 10.1056/NEJMoa043900; Emerson J, 2002, PEDIATR PULM, V34, P91, DOI 10.1002/ppul.10127; Eng PA, 1996, PEDIATR PULM, V21, P77, DOI 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M; Havasi V, 2008, J CYST FIBROS, V7, P267, DOI 10.1016/j.jcf.2007.11.009; O'Connell OJ, 2011, RESP CARE, V56, P771, DOI 10.4187/respcare.00866; O'Toole GA, 1998, MOL MICROBIOL, V30, P295, DOI 10.1046/j.1365-2958.1998.01062.x; Oguzhan N, 2012, RENAL FAILURE, V34, P181, DOI 10.3109/0886022X.2011.646884; Parmar JH, 2011, MOL BIOSYST, V7, P1138, DOI 10.1039/c0mb00224k; Patel JB, 2011, MANUAL CLIN MICROBIO, P1122, DOI DOI 10.1128/9781555816728.CH68; Peters BM, 2012, CLIN MICROBIOL REV, V25, P193, DOI 10.1128/CMR.00013-11; Pompilio A, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-145; Reeves EP, 2012, SCI WORLD J, DOI 10.1100/2012/465230; Robinson M, 1997, THORAX, V52, P900, DOI 10.1136/thx.52.10.900; Seo K, 2012, J FOOD PROTECT, V75, P533, DOI 10.4315/0362-028X.JFP-11-199; Shkilnyj P, 2007, J BACTERIOL, V189, P3115, DOI 10.1128/JB.01857-06; Sibley CD, 2006, FUTURE MICROBIOL, V1, P53, DOI 10.2217/17460913.1.1.53; Stepanovic S, 2000, J MICROBIOL METH, V40, P175, DOI 10.1016/S0167-7012(00)00122-6; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; van der Waal SV, 2011, INT ENDOD J, V44, P1110, DOI 10.1111/j.1365-2591.2011.01929.x; Wark P, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001506.pub3; Williams HD, 2010, FRONT MICROBIOL, V1, DOI 10.3389/fmicb.2010.00120; Williamson SJ, 2006, MICROB ECOL, V52, P217, DOI 10.1007/s00248-006-9113-1	34	26	26	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2014	9	2							e90164	10.1371/journal.pone.0090164	http://dx.doi.org/10.1371/journal.pone.0090164			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC3DW	24587256	Green Published, Green Submitted, gold			2023-01-03	WOS:000332396200140
J	Griva, K; Lai, AY; Lim, HA; Yu, ZL; Foo, MWY; Newman, SP				Griva, Konstadina; Lai, Alden Yuanhong; Lim, Haikel Asyraf; Yu, Zhenli; Foo, Marjorie Wai Yin; Newman, Stanton P.			Non-Adherence in Patients on Peritoneal Dialysis: A Systematic Review	PLOS ONE			English	Article							MEDICATION ADHERENCE; HEMODIALYSIS; PRESCRIPTION; CARE; NONCOMPLIANCE; CONSEQUENCES; EXCHANGES; CAPD; PREVALENCE; IMPACT	Background: It has been increasingly recognized that non-adherence is an important factor that determines the outcome of peritoneal dialysis (PD) therapy. There is therefore a need to establish the levels of non-adherence to different aspects of the PD regimen (dialysis procedures, medications, and dietary/fluid restrictions). Methods: A systematic review of peer-reviewed literature was performed in PubMed, PsycINFO and CINAHL databases using PRISMA guidelines in May 2013. Publications on non-adherence in PD were selected by two reviewers independently according to predefined inclusion and exclusion criteria. Relevant data on patient characteristics, measures, rates and factors associated with non-adherence were extracted. The quality of studies was also evaluated independently by two reviewers according to a revised version of the Effective Public Health Practice Project assessment tool. Results: The search retrieved 204 studies, of which a total of 25 studies met inclusion criteria. Reported rates of non-adherence varied across studies: 2.6-53% for dialysis exchanges, 3.9-85% for medication, and 14.4-67% for diet/fluid restrictions. Methodological differences in measurement and definition of non-adherence underlie the observed variation. Factors associated with non-adherence that showed a degree of consistency were mostly socio-demographical, such as age, employment status, ethnicity, sex, and time period on PD treatment. Conclusion: Non-adherence to different dimensions of the dialysis regimen appears to be prevalent in PD patients. There is a need for further, high-quality research to explore these factors in more detail, with the aim of informing intervention designs to facilitate adherence in this patient population.	[Griva, Konstadina; Lai, Alden Yuanhong; Lim, Haikel Asyraf] Natl Univ Singapore, Dept Psychol, Singapore 117548, Singapore; [Yu, Zhenli] Khoo Teck Puat Hosp, Dept Renal Med, Singapore, Singapore; [Foo, Marjorie Wai Yin] Singapore Gen Hosp, Peritoneal Dialysis Ctr, Dept Nephrol, Singapore, Singapore; [Griva, Konstadina; Newman, Stanton P.] UCL, Behav Med Unit, London, England; [Newman, Stanton P.] City Univ London, Hlth Serv Res Grp, London EC1V 0HB, England	National University of Singapore; Singapore General Hospital; University of London; University College London; City University London	Griva, K (corresponding author), Natl Univ Singapore, Dept Psychol, Singapore 117548, Singapore.	psygk@nus.edu.sg	Griva, Konstadina/A-6549-2018; Lim, Haikel A./C-7965-2014; Lai, Alden Yuanhong/ABA-5873-2020	Lim, Haikel A./0000-0002-9529-3517; /0000-0002-2416-2915; Newman, Stanton/0000-0001-6712-6079; GRIVA, KONSTADINA/0000-0001-8173-5663				Amici G, 1996, Perit Dial Int, V16 Suppl 1, pS176; Bane C, 2006, PATIENT EDUC COUNS, V60, P187, DOI 10.1016/j.pec.2005.01.003; Bender BG, 2004, CURR OPIN ALLERGY CL, V4, P191, DOI 10.1097/01.all.0000129449.73727.cf; Bender FH, 2006, KIDNEY INT, V70, pS44, DOI 10.1038/sj.ki.5001915; Bernardini J, 2000, AM J KIDNEY DIS, V35, P1104, DOI 10.1016/S0272-6386(00)70047-3; Bernardini J, 1997, PERITON DIALYSIS INT, V17, P338; Bernardini J, 1998, AM J KIDNEY DIS, V31, P101, DOI 10.1053/ajkd.1998.v31.pm9428459; Blake PG, 1999, PERITON DIALYSIS INT, V19, pS495; Blake PG, 2000, AM J KIDNEY DIS, V35, P506, DOI 10.1016/S0272-6386(00)70205-8; Bland RJ, 2008, DIALYSIS TRANSPLANT, V37, P174, DOI 10.1002/dat.20207; Chan MF, 2010, J CLIN NURS, V19, P649, DOI 10.1111/j.1365-2702.2009.03103.x; Chen W, 2006, J RENAL NUTR, V16, P132, DOI 10.1053/j.jrn.2006.01.009; Chua AN, 2011, PEDIATR NEPHROL, V26, P789, DOI 10.1007/s00467-011-1792-2; Denhaerynck K, 2005, TRANSPL INT, V18, P1121, DOI 10.1111/j.1432-2277.2005.00176.x; Denhaerynck K, 2009, TRANSPL INT, V22, P441, DOI 10.1111/j.1432-2277.2008.00820.x; Denhaerynd K, 2007, AM J CRIT CARE, V16, P222; DiMatteo MR, 2004, MED CARE, V42, P200, DOI 10.1097/01.mlr.0000114908.90348.f9; Effective Public Health Practice Project, 1998, QUAL ASS TOOL QUANT; Figueiredo Ana E, 2005, Adv Perit Dial, V21, P77; Fine A, 1997, PERITON DIALYSIS INT, V17, P343; Garcia-Llana H, 2013, PSICOTHEMA, V25, P79, DOI 10.7334/psicothema2012.96; Hailey B.J., 2000, PSYCHOL HEALTH MED, V5, P395, DOI [10.1080/713690222, DOI 10.1111/SDI.12123]; Hall Gayle, 2004, Nephrol Nurs J, V31, P149; Hirth RA, 2008, HEALTH AFFAIR, V27, P89, DOI 10.1377/hlthaff.27.1.89; Hollis JL, 2006, J RENAL CARE, V32, P202, DOI 10.1111/j.1755-6686.2006.tb00023.x; Hung KY, 2013, THER APHER DIAL, V17, P72, DOI 10.1111/j.1744-9987.2012.01098.x; Jain AK, 2012, J AM SOC NEPHROL, V23, P533, DOI 10.1681/ASN.2011060607; Juergensen Peter H, 2004, Adv Perit Dial, V20, P90; Kara B, 2007, J NURS SCHOLARSHIP, V39, P243, DOI 10.1111/j.1547-5069.2007.00175.x; Karamanidou C, 2008, BMC NEPHROL, V9, DOI 10.1186/1471-2369-9-2; Khalil Amani Anwar, 2010, Issues Ment Health Nurs, V31, P324, DOI 10.3109/01612840903384008; Kugler C, 2011, J NEPHROL, V24, P366, DOI 10.5301/JN.2010.5823; Kutner NG, 2002, NEPHROL DIAL TRANSPL, V17, P93, DOI 10.1093/ndt/17.1.93; Lam LW, 2010, J ADV NURS, V66, P763, DOI 10.1111/j.1365-2648.2009.05235.x; Lehane E, 2007, INT J NURS STUD, V44, P1468, DOI 10.1016/j.ijnurstu.2006.07.010; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lin Chiu-Chu, 1997, Kaohsiung Journal of Medical Sciences, V13, P243; Lindberg M, 2007, SCAND J UROL NEPHROL, V41, P546, DOI 10.1080/00365590701421363; Lulowsky L, 2013, CLIN J AM SOC NEPHRO, V8; Mawar S, 2012, INT UROL NEPHROL, V44, P1243, DOI 10.1007/s11255-011-0079-7; MORRIS LS, 1992, J CLIN PHARM THER, V17, P283, DOI 10.1111/j.1365-2710.1992.tb01306.x; National Kidney Foundation, 2012, DIAL; Neri L, 2002, ADV PERIT DIAL, V18; Pruthi R, 2013, UK RENAL REGISTRY 16; Quan L, 2006, PERITON DIALYSIS INT, V26, P95; Ricka R, 2002, INT J NURS STUD, V39, P329, DOI 10.1016/S0020-7489(01)00024-4; Rivetti M, 2002, EDTNA ERCA J, V28, P40; Rivetti M, 2002, EDTNA ERCA J, V28, P55; Russo R, 2006, KIDNEY INT, V70, pS127, DOI 10.1038/sj.ki.5001929; Sabat E, 2003, ADHERENCE LONG TERM; Schmid H, 2009, EUR J MED RES, V14, P185, DOI 10.1186/2047-783X-14-5-185; Sevick MA, 1999, PERITON DIALYSIS INT, V19, P23; Sokol MC, 2005, MED CARE, V43, P521, DOI 10.1097/01.mlr.0000163641.86870.af; Sunanda K, 2008, DIGEST DIS SCI, V53, P1020; Termorshuizen F, 2003, J AM SOC NEPHROL, V14, P2851, DOI 10.1097/01.ASN.0000091585.45723.9E; Vlaminck H, 2001, J CLIN NURS, V10, P707, DOI 10.1046/j.1365-2702.2001.00537.x; Vonesh E, 2004, KIDNEY INT, V66; WARREN PJ, 1994, J AM SOC NEPHROL, V4, P1627; Wazny LD, 2002, AM J KIDNEY DIS, V40, P623, DOI 10.1053/ajkd.2002.34925; Weed-Collins M, 1989, ANNA J, V16, P278; Wright M, 2004, NEPHROL DIAL TRANSPL, V19, P1581, DOI 10.1093/ndt/gfh227; Yu ZL, 2012, SINGAP MED J, V53, P474	62	55	60	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2014	9	2							e89001	10.1371/journal.pone.0089001	http://dx.doi.org/10.1371/journal.pone.0089001			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AC2ZX	24586478	gold, Green Published, Green Submitted, Green Accepted			2023-01-03	WOS:000332385900025
J	Kim, YR; Kim, HN; Ahn, SM; Choi, YH; Shin, HK; Choi, BT				Kim, Yu Ri; Kim, Ha Neui; Ahn, Sung Min; Choi, Yung Hyun; Shin, Hwa Kyoung; Choi, Byung Tae			Electroacupuncture Promotes Post-Stroke Functional Recovery via Enhancing Endogenous Neurogenesis in Mouse Focal Cerebral Ischemia	PLOS ONE			English	Article							NEURAL STEM-CELLS; ENDOTHELIAL GROWTH-FACTOR; NEUROTROPHIC FACTOR; SUBVENTRICULAR ZONE; ADULT NEUROGENESIS; STIMULATES NEUROGENESIS; PROGENITOR CELLS; IN-VITRO; BRAIN; STROKE	To investigate the question of whether electroacupuncture (EA) promotes functional recovery via enhancement of proliferation and differentiation of neuronal stem cells (NSCs) in ischemic stroke, EA stimulation with 2 Hz was applied at bilateral acupoints to Baihui (GV20) and Dazhui (GV14) in middle cerebral artery occlusion (MCAO) mice. EA stimulation improved neuromotor function and cognitive ability after ischemic stroke. EA stimulation resulted in an increase in the number of proliferated cells, especially in the subventricular zone (SVZ) of the ipsilateral hemisphere. Although a very limited number of NSCs survived and differentiated into neurons or astrocytes, EA treatment resulted in a significant increase in the number of proliferative cells and differentiated cells in the hippocampus and SVZ of the ipsilateral hemisphere compared to MCAO mice. EA stimulation resulted in significantly increased mRNA expression of brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF). Protein levels of these factors were confirmed in the ipsilateral hippocampus and SVZ by immunohistochemical and Western blotting analyses. Expression of phosphorylated phosphatidylinositol-3-kinase, BDNF, and VEGF-mediated down-stream were enhanced by EA stimulation in newly formed neuroblasts. These results indicate that EA treatment after ischemic stroke may promote post-stroke functional recovery by enhancement of proliferation and differentiation of NSCs via the BDNF and VEGF signaling pathway.	[Kim, Yu Ri; Kim, Ha Neui; Choi, Byung Tae] Pusan Natl Univ, Dept Korean Med Sci, Sch Korean Med, Yangsan, South Korea; [Ahn, Sung Min; Shin, Hwa Kyoung; Choi, Byung Tae] Pusan Natl Univ, Div Meridian & Struct Med, Sch Korean Med, Yangsan, South Korea; [Choi, Yung Hyun] Dong Eui Univ, Dept Biochem, Coll Oriental Med, Pusan, Yangjeong, South Korea	Pusan National University; Pusan National University; Dong-Eui University	Choi, BT (corresponding author), Pusan Natl Univ, Dept Korean Med Sci, Sch Korean Med, Yangsan, South Korea.	choibt@pusan.ac.kr		Kim, Haneui/0000-0002-5651-4727	Ministry of Education, Science and Technology [2013R1A1A2005824]; Basic Science Research Program through the National Research Foundation of Korea (NRF)	Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Basic Science Research Program through the National Research Foundation of Korea (NRF)(National Research Foundation of Korea)	This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2013R1A1A2005824). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe K, 2012, J CEREBR BLOOD F MET, V32, P1317, DOI 10.1038/jcbfm.2011.187; Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Benraiss A, 2001, J NEUROSCI, V21, P6718, DOI 10.1523/JNEUROSCI.21-17-06718.2001; Chang SH, 2004, J NEUROSCI, V24, P2277, DOI 10.1523/JNEUROSCI.4868-03.2004; Cheng SM, 2009, NEUROL RES, V31, P753, DOI 10.1179/174313209X382557; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Hong JC, 2013, INT J MOL MED, V31, P225, DOI 10.3892/ijmm.2012.1166; Hou SW, 2008, STROKE, V39, P2837, DOI 10.1161/STROKEAHA.107.510982; Iadecola C, 2011, NAT NEUROSCI, V14, P1363, DOI 10.1038/nn.2953; Iwai M, 2003, J CEREBR BLOOD F MET, V23, P331, DOI 10.1097/01.WCB.0000050060.57184.E7; Iwai M, 2002, J CEREBR BLOOD F MET, V22, P411, DOI 10.1097/00004647-200204000-00005; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Leker RR, 2007, STROKE, V38, P153, DOI 10.1161/01.STR.0000252156.65953.a9; Lichtenwalner RJ, 2006, J CEREBR BLOOD F MET, V26, P1, DOI 10.1038/sj.jcbfm.9600170; Lindvall O, 2011, STROKE, V42, P2369, DOI 10.1161/STROKEAHA.110.599654; Manni L, 2010, AUTON NEUROSCI-BASIC, V157, P9, DOI 10.1016/j.autneu.2010.03.020; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Ohira K, 2010, NAT NEUROSCI, V13, P173, DOI 10.1038/nn.2473; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Pencea V, 2001, J NEUROSCI, V21, P6706, DOI 10.1523/JNEUROSCI.21-17-06706.2001; Quirie A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044218; Schabitz WR, 2004, STROKE, V35, P992, DOI 10.1161/01.STR.0000119754.85848.0D; Schabitz WR, 2007, STROKE, V38, P2165, DOI 10.1161/STROKEAHA.106.477331; Schanzer A, 2004, BRAIN PATHOL, V14, P237; Seri B, 2006, CEREB CORTEX, V16, pI103, DOI 10.1093/cercor/bhk027; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Wang K, 2012, J NEUROSCI RES, V90, P1464, DOI 10.1002/jnr.23028; Wu P, 2010, STROKE, V41, pE171, DOI 10.1161/STROKEAHA.109.573576; Yamashita T, 2006, J NEUROSCI, V26, P6627, DOI 10.1523/JNEUROSCI.0149-06.2006; Yang ZJ, 2005, ACUPUNCTURE ELECTRO, V30, P185, DOI 10.3727/036012905815901244; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174; Yu JC, 2005, PHYSIOL BEHAV, V86, P434, DOI 10.1016/j.physbeh.2005.07.015; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004	40	68	78	2	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2014	9	2							e90000	10.1371/journal.pone.0090000	http://dx.doi.org/10.1371/journal.pone.0090000			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AB6EP	24587178	Green Published, Green Submitted, gold			2023-01-03	WOS:000331880700124
J	Tsai, YG; Lee, CY; Lin, TY; Lin, CY				Tsai, Yi-Giien; Lee, Chia-Ying; Lin, Tze-Yi; Lin, Ching-Yuang			CD8(+) Treg Cells Associated with Decreasing Disease Activity after Intravenous Methylprednisolone Pulse Therapy in Lupus Nephritis with Heavy Proteinuria	PLOS ONE			English	Article							REGULATORY T-CELLS; MEDIATED SUPPRESSION; GRANZYME-B; ERYTHEMATOSUS; INDUCTION; TOLERANCE; ACTIVATION; MECHANISMS; GENERATION; EXPRESSION	We focus on the role of CD8(+) Treg cell in Intravenous methyl-prednisolone (IVMP) pulse therapy in forty patients with active Class III/IV childhood lupus nephritis (LN) with heavy proteinuria. IVMP therapy for five days. From peripheral blood mononuclear cells (PBMCs) and renal tissues, we saw IVMP therapy definitely restoring both CD4(+)CD25(+)FoxP3(+) and CD8(+)CD25(+)Foxp3(+) Treg cell number plus greater expression with intracellular IL-10 and granzyme B in CD8(+)FoxP3(+) Treg from PBMCs. IVMP-treated CD8(+)CD25(+) Treg cells directly suppressed CD4(+) T proliferation and induced CD4(+) CD45RO(+) apoptosis. Histologically, CD4(+)FoxP3(+) as well as CD8(+)FoxP3(+) Treg cells appeared in renal tissue of LN patients before IVMP by double immunohistochemical stain. CD8(+)FoxP3(+) Treg cells increased in 10 follow-up renal biopsy specimens after IVMP. Reverse correlation of serum anti-C1q antibody and FoxP3(+) Treg cells in PBMNCs (r = -0.714, P<0.01). After IVMP, serum anti-C1q antibody decrease accompanied increase of CD4(+) FoxP3(+) Treg cells. CD8(+) Treg cells reduced interferon-r response in PBMCs to major peptide autoepitopes from nucleosomes after IVMP therapy; siRNA of FoxP3 suppressed granzyme B expression while decreasing CD8(+)CD25(+)Treg-induced CD4(+)CD45RO(+) apoptosis. Renal activity of LN by SLEDAI-2k in childhood LN was significantly higher than two weeks after IVMP (P<0.01). CD8(+)FoxP3(+) Treg cells return in post-IVMP therapy and exert crucial immune modulatory effect to control autoimmune response in LN.	[Tsai, Yi-Giien] Changhua Christian Hosp, Dept Pediat, Changhua, Taiwan; [Tsai, Yi-Giien] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Lee, Chia-Ying; Lin, Ching-Yuang] China Med Univ Hosp, Div Pediat Nephrol, Taichung, Taiwan; [Lin, Tze-Yi] China Med Univ Hosp, Dept Pathol, Taichung, Taiwan; [Lin, Ching-Yuang] China Med Univ Hosp, Clin Immunol Ctr, Taichung, Taiwan; [Lin, Ching-Yuang] China Med Univ, Coll Med, Taichung, Taiwan	Changhua Christian Hospital; Chung Shan Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan	Lin, CY (corresponding author), China Med Univ Hosp, Div Pediat Nephrol, Taichung, Taiwan.	cylin@mail.cmuh.org.tw			National Science Council, Taiwan [NSC 98-2314-B-039-006-MY3, 98-2314-B-371-001-MY2, NSC 100-2314-B-371 -005]; China Medium University Hospital [DMR-100-180]; Changhua Christian Hospital	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); China Medium University Hospital; Changhua Christian Hospital	This work was partially supported by grants from the National Science Council, Taiwan (NSC 98-2314-B-039-006-MY3, 98-2314-B-371-001-MY2, NSC 100-2314-B-371 -005); and China Medium University Hospital (DMR-100-180), Changhua Christian Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bisikirska B, 2005, J CLIN INVEST, V115, P2904, DOI 10.1172/JCI23961; Bovenschen HJ, 2011, J INVEST DERMATOL, V131, P1853, DOI 10.1038/jid.2011.139; Brimnes J, 2005, J IMMUNOL, V174, P5814, DOI 10.4049/jimmunol.174.9.5814; Brunner HI, 2002, ARTHRITIS RHEUM, V46, P436, DOI 10.1002/art.10072; Cao XF, 2007, IMMUNITY, V27, P635, DOI 10.1016/j.immuni.2007.08.014; Chaput N, 2009, GUT, V58, P520, DOI 10.1136/gut.2008.158824; Chen X, 2006, EUR J IMMUNOL, V36, P2139, DOI 10.1002/eji.200635873; Datta SK, 2005, J MOL MED, V83, P267, DOI 10.1007/s00109-004-0624-2; David S, 1997, NEPHROL DIAL TRANSPL, V12, P51, DOI 10.1093/ndt/12.1.51; DesaiMehta A, 1996, J CLIN INVEST, V97, P2063, DOI 10.1172/JCI118643; Endharti AT, 2011, J IMMUNOL, V186, P41, DOI 10.4049/jimmunol.1000800; Gladman DD, 2002, J RHEUMATOL, V29, P288; Gladman DD, 2000, J RHEUMATOL, V27, P377; Gondek DC, 2005, J IMMUNOL, V174, P1783, DOI 10.4049/jimmunol.174.4.1783; Hass C, 1998, J IMMUNOL, V160, P3173; HAY EM, 1993, Q J MED, V86, P447; Helmick CG, 2008, ARTHRITIS RHEUM-US, V58, P15, DOI 10.1002/art.23177; Joetham A, 2008, J IMMUNOL, V180, P7117, DOI 10.4049/jimmunol.180.11.7117; Kaliyaperumal A, 2002, J IMMUNOL, V168, P2530, DOI 10.4049/jimmunol.168.5.2530; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Keino H, 2006, INVEST OPHTH VIS SCI, V47, P1533, DOI 10.1167/iovs.04-1454; Kim HJ, 2010, NATURE, V467, P328, DOI 10.1038/nature09370; Kiniwa Y, 2007, CLIN CANCER RES, V13, P6947, DOI 10.1158/1078-0432.CCR-07-0842; Ling Y, 2007, EUR J HAEMATOL, V79, P310, DOI 10.1111/j.1600-0609.2007.00917.x; LINKERISRAELI M, 1990, ARTHRITIS RHEUM, V33, P1216; Lu LR, 2008, CELL MOL IMMUNOL, V5, P401, DOI 10.1038/cmi.2008.50; Mahic M, 2008, EUR J IMMUNOL, V38, P640, DOI 10.1002/eji.200737529; MOHAN C, 1993, J EXP MED, V177, P1367, DOI 10.1084/jem.177.5.1367; Nakatani K, 2004, KIDNEY INT, V65, P1290, DOI 10.1111/j.1523-1755.2004.00537.x; Navarro J, 2006, J NEUROIMMUNOL, V176, P153, DOI 10.1016/j.jneuroim.2006.03.022; Polcher M, 2010, CANCER IMMUNOL IMMUN, V59, P909, DOI 10.1007/s00262-010-0817-1; Rahman A, 2008, NEW ENGL J MED, V358, P929, DOI 10.1056/NEJMra071297; SERON D, 1991, NEPHROL DIAL TRANSPL, V6, P917, DOI 10.1093/ndt/6.12.917; Sharabi A, 2008, J IMMUNOL, V181, P3243, DOI 10.4049/jimmunol.181.5.3243; Siegmund K, 2009, J IMMUNOL, V182, P2124, DOI 10.4049/jimmunol.0802271; Skaggs BJ, 2008, HUM IMMUNOL, V69, P790, DOI 10.1016/j.humimm.2008.08.284; Smith TRF, 2008, TRENDS IMMUNOL, V29, P337, DOI 10.1016/j.it.2008.04.002; Strauss L, 2009, J IMMUNOL, V182, P1469, DOI 10.4049/jimmunol.182.3.1469; Suen JL, 2009, IMMUNOLOGY, V127, P196, DOI 10.1111/j.1365-2567.2008.02937.x; Tennakoon DK, 2006, J IMMUNOL, V176, P7119, DOI 10.4049/jimmunol.176.11.7119; Tower C, 2011, NAT REV RHEUMATOL, V7, P124, DOI 10.1038/nrrheum.2010.124; Tsai YG, 2010, J IMMUNOL, V184, P7229, DOI 10.4049/jimmunol.1000083; Tucci M, 2008, CLIN EXP IMMUNOL, V154, P247, DOI 10.1111/j.1365-2249.2008.03758.x; Valencia X, 2007, J IMMUNOL, V178, P2579, DOI 10.4049/jimmunol.178.4.2579; Wang RF, 2008, HUM IMMUNOL, V69, P811, DOI 10.1016/j.humimm.2008.08.276; Weening JJ, 2004, J AM SOC NEPHROL, V15, P241, DOI 10.1097/01.ASN.0000108969.21691.5D; Wu HY, 2008, J IMMUNOL, V181, P6038, DOI 10.4049/jimmunol.181.9.6038; Wu HY, 2004, LUPUS, V13, P192, DOI 10.1191/0961203303lu1002oa; Yamada A, 2009, J ALLERGY CLIN IMMUN, V123, P889, DOI 10.1016/j.jaci.2008.12.1115; Yan B, 2008, ARTHRITIS RHEUM-US, V58, P801, DOI 10.1002/art.23268; Zhang L, 2009, J IMMUNOL, V183, P6346, DOI 10.4049/jimmunol.0901773	51	15	17	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2014	9	1							e81344	10.1371/journal.pone.0081344	http://dx.doi.org/10.1371/journal.pone.0081344			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301BI	24475019	Green Published, Green Submitted, gold			2023-01-03	WOS:000330507300005
J	Gnjidic, D; Hilmer, SN; Hartikainen, S; Tolppanen, AM; Taipale, H; Koponen, M; Bell, JS				Gnjidic, Danijela; Hilmer, Sarah N.; Hartikainen, Sirpa; Tolppanen, Anna-Maija; Taipale, Heidi; Koponen, Marjaana; Bell, J. Simon			Impact of High Risk Drug Use on Hospitalization and Mortality in Older People with and without Alzheimer's Disease: A National Population Cohort Study	PLOS ONE			English	Article							BURDEN INDEX; ANTICHOLINERGIC DRUGS; FUNCTIONAL DECLINE; PHYSICAL FUNCTION; MEDICATION USE; CO-MORBIDITY; REGISTER; POLYPHARMACY; RESIDENTS; DEMENTIA	Background: Evidence is lacking about outcomes associated with the cumulative use of anticholinergic and sedative drugs in people with Alzheimer's disease (AD). This retrospective cohort study investigated the relationship between cumulative exposure to anticholinergic and sedative drugs and hospitalization and mortality in people with and without AD in Finland. Methods: Community-dwelling people aged 65 years and over, with AD on December 31st 2005 (n = 16,603) and individually matched (n = 16,603) comparison persons (age, sex, region of residence) were identified by the Social Insurance Institution of Finland. Drug utilization data were extracted from the Finnish National Prescription Register. Exposure to anticholinergic and sedative drugs was defined using the Drug Burden Index (DBI). Hospitalization and mortality data were extracted from national registers. Cox and zero-inflated negative binomial analyses were used to investigate the relationship between DBI and hospitalization and mortality over a one-year follow-up. Results: In total, 5.8% of people with AD and 3.7% without AD died during 2006. For every unit increase in DBI, the adjusted hazard ratio for mortality was 1.21 (95% confidence intervals [CI]: 1.09-1.33) among people with AD, and 1.37 (95% CI: 1.20-1.56) among people without AD. Overall, 44.3% of people with AD and 33.4% without AD were hospitalized. When using no DBI exposure as the reference group, the adjusted incidence rate ratio for length of hospital stay among high DBI group (>= 1) in people with AD was 1.15 (95% CI: 1.05-1.26) and 1.63 (95% CI: 1.41-1.88) in people without AD. Conclusion: There is a dose-response relationship between cumulative anticholinergic and sedative drug use and hospitalization and mortality in people with and without AD.	[Gnjidic, Danijela] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia; [Gnjidic, Danijela; Hilmer, Sarah N.] Royal N Shore Hosp, Dept Clin Pharmacol, Sydney, NSW, Australia; [Gnjidic, Danijela; Hilmer, Sarah N.] Royal N Shore Hosp, Dept Aged Care, Sydney, NSW, Australia; [Gnjidic, Danijela; Hilmer, Sarah N.] Royal N Shore Hosp, Kolling Inst Med Res, Sydney, NSW, Australia; [Gnjidic, Danijela; Hilmer, Sarah N.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia; [Gnjidic, Danijela] Ctr Educ & Res Ageing, Sydney, NSW, Australia; [Gnjidic, Danijela] Concord RG Hosp, Sydney, NSW, Australia; [Hartikainen, Sirpa; Taipale, Heidi; Koponen, Marjaana; Bell, J. Simon] Univ Eastern Finland, Sch Pharm, Kuopio Res Ctr Geriatr Care, Kuopio, Finland; [Tolppanen, Anna-Maija] Univ Eastern Finland, Dept Neurol, Kuopio, Finland; [Bell, J. Simon] Univ S Australia, Sch Pharm & Med Sci, Sansom Inst, Adelaide, SA 5001, Australia; [Bell, J. Simon] Monash Univ, Fac Pharm & Pharmaceut Sci, Ctr Med Use & Safety, Melbourne, Vic 3004, Australia	University of Sydney; Royal North Shore Hospital; University of Sydney; Royal North Shore Hospital; University of Sydney; Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; University of Sydney; Concord Repatriation General Hospital; University of Eastern Finland; University of Eastern Finland; University of South Australia; Monash University	Gnjidic, D (corresponding author), Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia.	danijela.gnjidic@sydney.edu.au	Hilmer, Sarah N/AAW-8554-2020	Hilmer, Sarah/0000-0002-5970-1501	Alzheimer's Australia Dementia Research Foundation; Australian National Health and Medical Research Council (NHMRC); University of Eastern Finland, Faculty of Health Sciences	Alzheimer's Australia Dementia Research Foundation; Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); University of Eastern Finland, Faculty of Health Sciences	This study was supported by the Alzheimer's Australia Dementia Research Foundation. The sponsor had no role in the study design, data collection, data analysis, data interpretation, writing of this report or the decision to submit for publication. Danijela Gnjidic is supported by the Australian National Health and Medical Research Council (NHMRC) Early Career Fellowship. Anna-Maija Tolppanen, Heidi Taipale, Marjaana Koponen and Sirpa Hartikainen acknowledge strategic funding received from the University of Eastern Finland, Faculty of Health Sciences.	Andersen F, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-58; Boudreau RM, 2009, PHARMACOEPIDEM DR S, V18, P916, DOI 10.1002/pds.1797; Daniel SB, 2011, NEW ENGL J MED, V365, P2002, DOI 10.1056/NEJMsa1103053; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Furu K, 2010, BASIC CLIN PHARMACOL, V106, P86, DOI 10.1111/j.1742-7843.2009.00494.x; Gnjidic D, 2012, CLIN PHARMACOL THER, V91, P521, DOI 10.1038/clpt.2011.258; Gnjidic D, 2012, FUNDAM CLIN PHARM; Gnjidic D, 2012, ANN MED, V44, P458, DOI 10.3109/07853890.2011.573499; Gnjidic D, 2012, NEW ENGL J MED, V366, P859, DOI 10.1056/NEJMc1114768; Gnjidic D, 2012, J CLIN PHARMACOL, V52, P258, DOI 10.1177/0091270010395591; Gray SL, 2006, J AM GERIATR SOC, V54, P224, DOI 10.1111/j.1532-5415.2005.00571.x; Hilmer SN, 2009, CLIN PHARMACOL THER, V85, P86, DOI 10.1038/clpt.2008.224; Hilmer SN, 2007, ARCH INTERN MED, V167, P781, DOI 10.1001/archinte.167.8.781; Hilmer SN, 2013, MED J AUSTRALIA, V198, P77, DOI 10.5694/mja12.11593; Hilmer SN, 2012, J GERONTOL A-BIOL, V67, P181, DOI 10.1093/gerona/glr066; Hilmer SN, 2009, AM J MED, V122, P1142, DOI 10.1016/j.amjmed.2009.02.021; Johnell K, 2008, DRUG AGING, V25, P871, DOI 10.2165/00002512-200825100-00006; JOST BC, 1995, J AM GERIATR SOC, V43, P1248, DOI 10.1111/j.1532-5415.1995.tb07401.x; Kripke DF, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000850; Kumpula EK, 2011, J CLIN PHARMACOL, V51, P256, DOI 10.1177/0091270010368410; Laitinen ML, 2011, INT PSYCHOGERIATR, V23, P1623, DOI 10.1017/S1041610211001621; Landi F, 2007, CLIN PHARMACOL THER, V81, P235, DOI 10.1038/sj.clpt.6100035; Lau DT, 2011, AM J ALZHEIMERS DIS, V26, P606, DOI 10.1177/1533317511432734; Lau DT, 2010, ALZ DIS ASSOC DIS, V24, P56, DOI 10.1097/WAD.0b013e31819d6ec9; Lieberman Joseph A 3rd, 2004, Prim Care Companion J Clin Psychiatry, V6, P20; Lonnroos E, 2013, J ALZHEIMERS DIS, V33, P157, DOI 10.3233/JAD-2012-120808; Lonnroos E, 2012, DRUG AGING, V29, P395, DOI 10.2165/11631420-000000000-00000; Lowry E, 2012, J CLIN PHARMACOL, V52, P1584, DOI 10.1177/0091270011421489; Lu CJ, 2003, AM J GERIAT PSYCHIAT, V11, P458, DOI 10.1176/appi.ajgp.11.4.458; Mangoni AA, 2013, AM J GERIAT PSYCHIAT, V21, P785, DOI 10.1016/j.jagp.2013.01.012; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; McLean AJ, 2004, PHARMACOL REV, V56, P163, DOI 10.1124/pr.56.2.4; Onder G, 2013, J GERONTOL A; Panula J, 2009, DRUG AGING, V26, P963, DOI 10.2165/11317660-000000000-00000; Runciman WB, 2003, INT J QUAL HEALTH C, V15, pI49, DOI 10.1093/intqhc/mzg085; Studenski S, 2011, JAMA-J AM MED ASSOC, V305, P50, DOI 10.1001/jama.2010.1923; Sund R, 2012, SCAND J PUBLIC HEALT, V40, P505, DOI 10.1177/1403494812456637; Taipale HT, 2012, J CLIN PSYCHOPHARM, V32, P218, DOI 10.1097/JCP.0b013e3182485802; Tjia J, 2010, J AM GERIATR SOC, V58, P880, DOI 10.1111/j.1532-5415.2010.02819.x; Wilson NM, 2012, DRUG AGING, V29, P157, DOI 10.2165/11598570-000000000-00000; Wolfson C, 2001, NEW ENGL J MED, V344, P1111, DOI 10.1056/NEJM200104123441501; Zilkens RR, 2009, NEUROEPIDEMIOLOGY, V32, P61, DOI 10.1159/000170908	42	70	71	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2014	9	1							e83224	10.1371/journal.pone.0083224	http://dx.doi.org/10.1371/journal.pone.0083224			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	292SL	24454696	Green Submitted, gold, Green Accepted, Green Published			2023-01-03	WOS:000329922500004
J	Aparicio, J; Garcia-Mora, C; Martin, M; Petriz, ML; Feliu, J; Sanchez-Santos, ME; Ayuso, JR; Fuster, D; Conill, C; Maurel, J				Aparicio, Jorge; Garcia-Mora, Carmen; Martin, Marta; Lourdes Petriz, Ma; Feliu, Jaime; Elena Sanchez-Santos, Ma; Ramon Ayuso, Juan; Fuster, David; Conill, Carlos; Maurel, Joan			A Phase I, Dose-Finding Study of Sorafenib in Combination with Gemcitabine and Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Grupo Espanol Multidisciplinario en Cancer Digestivo (GEMCAD) Study	PLOS ONE			English	Article							TRIAL; ACTIVATION; CHEMORADIOTHERAPY; CHEMOTHERAPY; CAPECITABINE; BEVACIZUMAB; PATHWAY; GROWTH	Purpose: Sorafenib, an oral inhibitor of B-raf, VEGFR2, and PDGFR2-beta, acts against pancreatic cancer in preclinical models. Due to the radio-sensitization activity of both sorafenib and gemcitabine, we designed a multicenter, phase I trial to evaluate the safety profile and the recommended dose of this combination used with concomitant radiation therapy. Methods: Patients with biopsy-proven, unresectable pancreatic adenocarcinoma (based on vascular invasion detected by computed tomography) were treated with gemcitabine (300 mg/m2 i.v. weekly 65 weeks) concurrently with radiation therapy (45 Gy in 25 fractions) and sorafenib (escalated doses in a 3+3 design, from 200 to 800 mg/day). Radiation portals included the primary tumor but not the regional lymph nodes. Patients with planning target volumes (PTV) over 500 cc were excluded. Cases not progressing during chemoradiation were allowed to continue with sorafenib until disease progression. Results: Twelve patients were included. Three patients received 200 mg/day, 6 received 400 mg/day, and 3 received 800 mg/day; PTVs ranged from 105 to 500 cc. No dose-limiting toxicities occurred. The most common grade 2 toxicities were fatigue, neutropenia, nausea, and raised serum transaminases. Treatment was discontinued in one patient because of a reversible posterior leukoencephalopathy. There were no treatment-related deaths. Conclusion: The addition of sorafenib to concurrent gemcitabine and radiation therapy showed a favorable safety profile in unresectable pancreatic adenocarcinoma. A dose of 800 mg/day is recommended for phase II evaluation.	[Aparicio, Jorge] Hosp Univ & Politecn La Fe, Dept Med Oncol, Valencia, Spain; [Garcia-Mora, Carmen] Hosp Univ & Politecn La Fe, Dept Radiat Oncol, Valencia, Spain; [Martin, Marta] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain; [Lourdes Petriz, Ma] Hosp Santa Creu & Sant Pau, Dept Radiat Oncol, Barcelona, Spain; [Feliu, Jaime] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain; [Elena Sanchez-Santos, Ma] Hosp Univ La Paz, Dept Radiat Oncol, Madrid, Spain; [Ramon Ayuso, Juan] Hosp Clin Barcelona, Dept Radiol, Barcelona, Spain; [Fuster, David] Hosp Clin Barcelona, Dept Nucl Med, Barcelona, Spain; [Conill, Carlos] Hosp Clin Barcelona, Dept Radiat Oncol, Barcelona, Spain; [Maurel, Joan] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain	Hospital Universitari i Politecnic La Fe; Hospital Universitari i Politecnic La Fe; Hospital of Santa Creu i Sant Pau; Hospital of Santa Creu i Sant Pau; Hospital Universitario La Paz; Hospital Universitario La Paz; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona	Maurel, J (corresponding author), Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain.	jmaurel@clinic.ub.es			Bayer	Bayer(Bayer AG)	This work was supported by Bayer (http://www.bayer.es/): 1200(sic)/patient included. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Corcoran RB, 2011, CANCER RES, V71, P5020, DOI 10.1158/0008-5472.CAN-11-0908; Dawson LA, 2012, I J RAD BIOL PHYS, V84, p3S; Goncalves A, 2012, ANN ONCOL, V23, P2799, DOI 10.1093/annonc/mds135; Huang SB, 2010, MOL CANCER THER, V9, P742, DOI 10.1158/1535-7163.MCT-09-1004; Huguet F, 2007, J CLIN ONCOL, V25, P326, DOI 10.1200/JCO.2006.07.5663; Kindler HL, 2011, LANCET ONCOL, V12, P256, DOI 10.1016/S1470-2045(11)70004-3; Kindler HL, 2010, J CLIN ONCOL, V28, P3617, DOI 10.1200/JCO.2010.28.1386; Lawrence TS, 1996, INT J RADIAT ONCOL, V34, P867, DOI 10.1016/0360-3016(95)02134-5; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; LoConte NK, 2013, INVEST NEW DRUG, V31, P943, DOI 10.1007/s10637-012-9916-5; Loehrer PJ, 2011, J CLIN ONCOL; Martin TD, 2011, CANCER RES, V71, P206, DOI 10.1158/0008-5472.CAN-10-1517; McGinn CJ, 2001, J CLIN ONCOL, V19, P4202, DOI 10.1200/JCO.2001.19.22.4202; Mukherjee S, 2013, LANCET ONCOL, V14, P317, DOI 10.1016/S1470-2045(13)70021-4; Plastaras JP, 2007, CANCER RES, V67, P9443, DOI 10.1158/0008-5472.CAN-07-1473; Scotti ML, 2010, CANCER RES, V70, P2064, DOI 10.1158/0008-5472.CAN-09-2684; Senan S, 2007, ONCOLOGIST, V12, P465, DOI 10.1634/theoncologist.12-4-465; Small W, 2011, INT J RADIAT ONCOL, V80, P476, DOI 10.1016/j.ijrobp.2010.02.030; Sultana A, 2007, J CLIN ONCOL, V25, P2607, DOI 10.1200/JCO.2006.09.2551; Ulivi P, 2009, J CELL PHYSIOL, V220, P214, DOI 10.1002/jcp.21753; Von Hoff DD, 2013, RANDOMIZED PHASE 3 S; Wahl RL, 2009, J NUCL MED, V50, p122S, DOI 10.2967/jnumed.108.057307; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Wolff RA, 2001, CLIN CANCER RES, V7, P2246	25	10	10	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2014	9	1							e82209	10.1371/journal.pone.0082209	http://dx.doi.org/10.1371/journal.pone.0082209			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	291XP	24416138	Green Published, gold, Green Submitted			2023-01-03	WOS:000329866300009
J	Altobelli, G; Bogdarina, IG; Stupka, E; Clark, AJL; Langley-Evans, S				Altobelli, Gioia; Bogdarina, Irina G.; Stupka, Elia; Clark, Adrian J. L.; Langley-Evans, Simon			Genome-Wide Methylation and Gene Expression Changes in Newborn Rats following Maternal Protein Restriction and Reversal by Folic Acid	PLOS ONE			English	Article							JUVENILE-PUBERTAL PERIOD; EMBRYONIC STEM-CELLS; DNA METHYLATION; PRENATAL EXPOSURE; BLOOD-PRESSURE; EPIGENETIC MODIFICATION; DEVELOPMENTAL ORIGINS; PREGNANT RATS; DIET; SUPPLEMENTATION	A large body of evidence from human and animal studies demonstrates that the maternal diet during pregnancy can programme physiological and metabolic functions in the developing fetus, effectively determining susceptibility to later disease. The mechanistic basis of such programming is unclear but may involve resetting of epigenetic marks and fetal gene expression. The aim of this study was to evaluate genome-wide DNA methylation and gene expression in the livers of newborn rats exposed to maternal protein restriction. On day one postnatally, there were 618 differentially expressed genes and 1183 differentially methylated regions (FDR 5%). The functional analysis of differentially expressed genes indicated a significant effect on DNA repair/cycle/maintenance functions and of lipid, amino acid metabolism and circadian functions. Enrichment for known biological functions was found to be associated with differentially methylated regions. Moreover, these epigenetically altered regions overlapped genetic loci associated with metabolic and cardiovascular diseases. Both expression changes and DNA methylation changes were largely reversed by supplementing the protein restricted diet with folic acid. Although the epigenetic and gene expression signatures appeared to underpin largely different biological processes, the gene expression profile of DNA methyl transferases was altered, providing a potential link between the two molecular signatures. The data showed that maternal protein restriction is associated with widespread differential gene expression and DNA methylation across the genome, and that folic acid is able to reset both molecular signatures.	[Altobelli, Gioia; Bogdarina, Irina G.; Clark, Adrian J. L.] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Ctr, Ctr Endocrinol, London, England; [Stupka, Elia] Queen Mary Univ London, Barts & London Sch Med & Dent, Inst Cell & Mol Biosci, London, England; [Langley-Evans, Simon] Univ Nottingham, Sch Biosci, Loughborough, Leics, England	University of London; Queen Mary University London; University of London; Queen Mary University London; University of Nottingham	Altobelli, G (corresponding author), UCL, Ctr Rheumatol Res, London, England.	g.altobelli@ucl.ac.uk	Langley-Evans, Simon C/F-3564-2012; Langley-Evans, Simon/AAR-4181-2020	Langley-Evans, Simon C/0000-0002-1969-8416; Altobelli, Gioia/0000-0001-9338-3466; Stupka, Elia/0000-0003-3154-4011	Medical Research Council (MRC) [G0801269]; Diabetes UK [12/0004456] Funding Source: researchfish; Medical Research Council [G0801269] Funding Source: researchfish; MRC [G0801269] Funding Source: UKRI	Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Diabetes UK(Diabetes UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by the Medical Research Council (MRC) under grant no. G0801269. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. MRC website: http://www.mrc.ac.uk/index.htm.	Barker DJP, 2006, HYPERTENSION, V48, P357, DOI 10.1161/01.HYP.0000236552.04251.42; Bell CG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014040; Bellinger L, 2006, INT J OBESITY, V30, P729, DOI 10.1038/sj.ijo.0803205; Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913; Blue GM, 2012, MED J AUSTRALIA, V197, P155, DOI 10.5694/mja12.10811; Bogdarina I, 2007, CIRC RES, V100, P520, DOI 10.1161/01.RES.0000258855.60637.58; Bogdarina I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009237; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Brinkman AB, 2010, METHODS, V52, P232, DOI 10.1016/j.ymeth.2010.06.012; Burdge GC, 2009, J NUTR, V139, P1054, DOI 10.3945/jn.109.104653; Carone BR, 2010, CELL, V143, P1084, DOI 10.1016/j.cell.2010.12.008; Chavez L, 2010, GENOME RES, V20, P1441, DOI 10.1101/gr.110114.110; Chen HA, 2009, GENE DEV, V23, P975, DOI 10.1101/gad.1742509; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Coelho D, 2008, NEW ENGL J MED, V358, P1454, DOI 10.1056/NEJMoa072200; Culhane AC, 2012, NUCLEIC ACIDS RES, V40, pD1060, DOI 10.1093/nar/gkr901; da Costa RMA, 2005, ONCOGENE, V24, P1359, DOI 10.1038/sj.onc.1208288; Delage B, 2008, ANNU REV NUTR, V28, P347, DOI 10.1146/annurev.nutr.28.061807.155354; Engeham SF, 2010, BRIT J NUTR, V103, P996, DOI 10.1017/S0007114509992662; Erhuma A, 2007, BRIT J NUTR, V98, P517, DOI 10.1017/S0007114507721505; Erhuma A, 2007, AM J PHYSIOL-ENDOC M, V292, pE1702, DOI 10.1152/ajpendo.00605.2006; Erhuma A, 2009, ENDOCRINE, V36, P333, DOI 10.1007/s12020-009-9225-8; Eriksson J, 2001, INT J OBESITY, V25, P735, DOI 10.1038/sj.ijo.0801602; Eriksson JG, 2007, J NUTR, V137, P1063, DOI 10.1093/jn/137.4.1063; Feinberg AP, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001262; Foundation BH, 2010, COR HEART DIS STAT 2; Gluckman PD, 2004, PEDIATR RES, V56, P311, DOI 10.1203/01.PDR.0000135998.08025.FB; Gluckman PD, 2007, P NATL ACAD SCI USA, V104, P12796, DOI 10.1073/pnas.0705667104; Godfrey KM, 2007, PEDIATR RES, V61, p5R, DOI 10.1203/pdr.0b013e318045bedb; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Jackson AA, 2002, CLIN SCI, V103, P633, DOI 10.1042/cs1030633; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Langley-Evans SC, 2009, J ANAT, V215, P36, DOI 10.1111/j.1469-7580.2008.00977.x; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lillycrop KA, 2005, J NUTR, V135, P1382, DOI 10.1093/jn/135.6.1382; Lillycrop KA, 2008, BRIT J NUTR, V100, P278, DOI 10.1017/S0007114507894438; Lillycrop KA, 2007, BRIT J NUTR, V97, P1064, DOI 10.1017/S000711450769196X; Lillycrop KA, 2011, J DEV ORIG HLTH DIS, V2, pS7; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Liu Y, 2013, NAT BIOTECHNOL, V31, P142, DOI 10.1038/nbt.2487; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; McMullen S, 2005, AM J PHYSIOL-REG I, V288, pR85, DOI 10.1152/ajpregu.00435.2004; McMullen S, 2004, BRIT J NUTR, V91, P133, DOI 10.1079/BJN20031029; McMullen S, 2012, MED HYPOTHESES, V78, P88, DOI 10.1016/j.mehy.2011.09.047; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nuytten M, 2008, ONCOGENE, V27, P1449, DOI 10.1038/sj.onc.1210774; Ouyang W, 2010, NAT IMMUNOL, V11, P618, DOI 10.1038/ni.1884; Rees WD, 2002, P NUTR SOC, V61, P71, DOI 10.1079/PNS2001137; Roychoudhuri R, 2013, NATURE; Sinclair KD, 2007, P NATL ACAD SCI USA, V104, P19351, DOI 10.1073/pnas.0707258104; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swali A, 2012, PLOS ONE IN PRESS; Swali A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023189; Torrens C, 2006, HYPERTENSION, V47, P982, DOI 10.1161/01.HYP.0000215580.43711.d1; Yu XP, 2009, INT J EXP PATHOL, V90, P638, DOI 10.1111/j.1365-2613.2009.00687.x; Zhang X, 2010, PROSTATE, V70, P765, DOI 10.1002/pros.21109; Zhou ZF, 2011, P NATL ACAD SCI USA, V108, P6626, DOI 10.1073/pnas.1018514108	58	41	41	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2013	8	12							e82989	10.1371/journal.pone.0082989	http://dx.doi.org/10.1371/journal.pone.0082989			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	284NF	24391732	Green Submitted, Green Published, gold			2023-01-03	WOS:000329325200029
J	Wang, CM; Li, TC; Jhan, YL; Weng, JH; Chou, CH				Wang, Chao-Min; Li, Tsai-Chi; Jhan, Yun-Lian; Weng, Jen-Hsien; Chou, Chang-Hung			The Impact of Microbial Biotransformation of Catechin in Enhancing the Allelopathic Effects of Rhododendron formosanum	PLOS ONE			English	Article							GREEN TEA EXTRACT; ALLELOCHEMICAL (+/-)-CATECHIN; CHLOROPHYLL FLUORESCENCE; BACTERIAL-DEGRADATION; LITTER DECOMPOSITION; ROOT EXUDATE; SOIL BIOTA; A-RING; PLANT; FLAVONOIDS	Rhododendron formosanum is distributed widely in the central mountains in Taiwan and the major allelopathic compound in the leaves has been identified as (-)-catechin, which is also a major allelochemical of an invasive spotted knapweed in North America. Soil microorganisms play key roles in ecosystems and influence various important processes, including allelopathy. However, no microorganism has been identified as an allelochemical mediator. This study focused on the role of microorganisms in the allelopathic effects of R. formosanum. The microorganism population in the rhizosphere of R. formosanum was investigated and genetic analysis revealed that the predominant genera of microorganisms in the rhizosphere of R. formosanum were Pseudomonas, Herbaspirillum, and Burkholderia. The dominant genera Pseudomonas utilized (-)-catechin as the carbon source and catalyzed the conversion of (-)-catechin into protocatechuic acid in vitro. The concentrations of allelochemicals in the soil were quantified by liquid chromatography-electrospray ionization/tandem mass spectrometry. The concentration of (-)-catechin in the soil increased significantly during the extreme rainfall in the summer season and suppressed total bacterial populations. Protocatechuic acid accumulation was observed while total bacterial populations increased abundantly in both laboratory and field studies. Allelopathic interactions were tested by evaluating the effects of different allelochemicals on the seed germination, radicle growth, and photosynthesis system II of lettuce. Protocatechuic acid exhibited higher phytotoxicity than (-)-catechin did and the effect of (-)-catechin on the inhibition of seed germination was enhanced by combining it with protocatechuic acid at a low concentration. This study revealed the significance of the allelopathic interactions between R. formosanum and microorganisms in the rhizosphere. These findings demonstrate that knowledge regarding the precise biotransformation process of (-)-catechin by microorganisms in the environment is necessary to increase our understanding of allelopathy.	[Wang, Chao-Min; Li, Tsai-Chi; Chou, Chang-Hung] China Med Univ, Res Ctr Biodivers, Taichung, Taiwan; [Jhan, Yun-Lian; Weng, Jen-Hsien; Chou, Chang-Hung] China Med Univ, Grad Inst Ecol & Evolutionary Biol, Taichung, Taiwan; [Chou, Chang-Hung] Natl Cheng Kung Univ, Dept Life Sci, Tainan 70101, Taiwan	China Medical University Taiwan; China Medical University Taiwan; National Cheng Kung University	Chou, CH (corresponding author), China Med Univ, Res Ctr Biodivers, Taichung, Taiwan.	choumasa@mail.cmu.edu.tw	Wang, Chao-Min/V-8680-2018	Wang, Chao-Min/0000-0002-8954-6151	National Science Council of Taiwan [NSC101-2811-B-039-013, NSC102-2811-B-039-005, NSC101-2621-B-039-001, NSC102-2313-B-039-001]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	This study was financially supported by grants from the National Science Council of Taiwan (NSC101-2811-B-039-013, NSC102-2811-B-039-005, NSC101-2621-B-039-001 and NSC102-2313-B-039-001) to C. H. Chou. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Araujo PI, 2012, OECOLOGIA, V168, P221, DOI 10.1007/s00442-011-2063-4; Arunachalam M, 2003, BBA-GEN SUBJECTS, V1621, P261, DOI 10.1016/S0304-4165(03)00077-1; Arunachalam M, 2003, MICROBIOL RES, V158, P37, DOI 10.1078/0944-5013-00174; Ashelford KE, 2005, APPL ENVIRON MICROB, V71, P7724, DOI 10.1128/AEM.71.12.7724-7736.2005; Bais HP, 2003, J AGR FOOD CHEM, V51, P897, DOI 10.1021/jf020978a; BAUCHOP T, 1960, J GEN MICROBIOL, V23, P457; Bever JD, 1997, J ECOL, V85, P561, DOI 10.2307/2960528; BJORKMAN O, 1987, PLANTA, V170, P489, DOI 10.1007/BF00402983; Blair AC, 2006, J CHEM ECOL, V32, P2327, DOI 10.1007/s10886-006-9168-y; Brennerova MV, 2009, ENVIRON MICROBIOL, V11, P2216, DOI 10.1111/j.1462-2920.2009.01943.x; Callaway RM, 2005, J ECOL, V93, P576, DOI 10.1111/j.1365-2745.2005.00994.x; Callaway RM, 2000, SCIENCE, V290, P521, DOI 10.1126/science.290.5491.521; Callaway RM, 2004, NATURE, V427, P731, DOI 10.1038/nature02322; Carando S, 2000, BASIC LIFE SCI, V66, P725; Chobot V, 2009, J CHEM ECOL, V35, P980, DOI 10.1007/s10886-009-9681-x; Chou C.H., 1999, RECENT ADV ALLELOPAT, V1, P3; Chou CH, 1999, CRIT REV PLANT SCI, V18, P609, DOI 10.1016/S0735-2689(99)00393-7; Chou SC, 2010, ALLELOPATHY J, V25, P73; Chou SC, 2009, NAT PROD COMMUN, V4, P1189; Dai CM, 2010, ENVIRON TOXICOL PHAR, V30, P284, DOI 10.1016/j.etap.2010.08.002; Das S, 2006, J NAT PROD, V69, P499, DOI 10.1021/np0504659; Donovan JL, 2006, FREE RADICAL RES, V40, P1029, DOI 10.1080/10715760600868545; Duke SO, 2009, J CHEM ECOL, V35, P141, DOI 10.1007/s10886-008-9587-z; Ferrazzano GF, 2011, J MED FOOD, V14, P907, DOI 10.1089/jmf.2010.0196; Fitter A, 2003, SCIENCE, V301, P1337, DOI 10.1126/science.1089291; Harrison KA, 2010, J ECOL, V98, P384, DOI 10.1111/j.1365-2745.2009.01614.x; Henning SM, 2003, NUTR CANCER, V45, P226, DOI 10.1207/S15327914NC4502_13; Hussain MI, 2011, PLANT PHYSIOL BIOCH, V49, P1290, DOI 10.1016/j.plaphy.2011.08.007; Inderjit, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002536; Inderjit, 2010, TRENDS ECOL EVOL, V25, P512, DOI 10.1016/j.tree.2010.06.006; JEFFREY AM, 1972, BIOCHEM J, V130, P383, DOI 10.1042/bj1300383; JEFFREY AM, 1972, BIOCHEM J, V130, P373, DOI 10.1042/bj1300373; Keswani J, 2001, INT J SYST EVOL MICR, V51, P667, DOI 10.1099/00207713-51-2-667; Kim YO, 2005, J CHEM ECOL, V31, P1175, DOI 10.1007/s10886-005-4255-z; Klironomos JN, 2002, NATURE, V417, P67, DOI 10.1038/417067a; Lin LC, 2011, MYCORRHIZA, V21, P331, DOI 10.1007/s00572-010-0342-2; Maxwell K, 2000, J EXP BOT, V51, P659, DOI 10.1093/jexbot/51.345.659; MULLER CH, 1966, B TORREY BOT CLUB, V93, P332, DOI 10.2307/2483447; Perez-Pantoja D, 2012, ENVIRON MICROBIOL, V14, P1091, DOI 10.1111/j.1462-2920.2011.02613.x; Perry LG, 2007, J CHEM ECOL, V33, P2337, DOI 10.1007/s10886-007-9383-1; Perry LG, 2005, J ECOL, V93, P1126, DOI 10.1111/j.1365-2745.2005.01044.x; Pollock JL, 2011, J CHEM ECOL, V37, P1044, DOI 10.1007/s10886-011-0005-6; Sakanaka S, 2000, J BIOSCI BIOENG, V90, P81, DOI 10.1016/S1389-1723(00)80038-9; Sanchez-Rabaneda F, 2003, J MASS SPECTROM, V38, P35, DOI 10.1002/jms.395; Sawada Y, 2009, PLANT CELL PHYSIOL, V50, P37, DOI 10.1093/pcp/pcn183; Schweizer HP, 1996, J BACTERIOL, V178, P5215, DOI 10.1128/jb.178.17.5215-5221.1996; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Taylor Peter W, 2005, Food Sci Technol Bull, V2, P71, DOI 10.1616/1476-2137.14184; Tharayil N, 2008, J AGR FOOD CHEM, V56, P3706, DOI 10.1021/jf073310a; Thorpe AS, 2009, J ECOL, V97, P641, DOI 10.1111/j.1365-2745.2009.01520.x; Valverde A, 2003, INT J SYST EVOL MICR, V53, P1979, DOI 10.1099/ijs.0.02677-0; van der Heijden MGA, 2008, ECOL LETT, V11, P296, DOI 10.1111/j.1461-0248.2007.01139.x; Van Der Putten WH, 2003, ECOLOGY, V84, P2269, DOI 10.1890/02-0284; Veluri R, 2004, J AGR FOOD CHEM, V52, P1077, DOI 10.1021/jf030653+; Vivanco L, 2008, J ECOL, V96, P727, DOI 10.1111/j.1365-2745.2008.01393.x; Wang CM, 2007, MICROB ECOL, V54, P1, DOI 10.1007/s00248-006-9139-4; Wardle DA, 2004, SCIENCE, V304, P1629, DOI 10.1126/science.1094875	57	37	43	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2013	8	12							e85162	10.1371/journal.pone.0085162	http://dx.doi.org/10.1371/journal.pone.0085162			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	284MV	24391991	gold, Green Published, Green Submitted			2023-01-03	WOS:000329323900134
J	Hennus, MP; van Vught, AJ; Brabander, M; Brus, F; Jansen, NJ; Bont, LJ				Hennus, Marije P.; van Vught, Adrianus J.; Brabander, Mark; Brus, Frank; Jansen, Nicolaas J.; Bont, Louis J.			Mechanical Ventilation Drives Inflammation in Severe Viral Bronchiolitis	PLOS ONE			English	Article							RESPIRATORY SYNCYTIAL VIRUS; DISEASE SEVERITY; DISTRESS-SYNDROME; HOSPITALIZED INFANTS; LUNG INFLAMMATION; TRACT INFECTION; CHILDREN; CYTOKINES; LOAD; NASOPHARYNGEAL	Introduction: Respiratory insufficiency due to severe respiratory syncytial virus (RSV) infection is the most frequent cause of paediatric intensive care unit admission in infants during the winter season. Previous studies have shown increased levels of inflammatory mediators in airways of mechanically ventilated children compared to spontaneous breathing children with viral bronchiolitis. In this prospective observational multi-center study we aimed to investigate whether this increase was related to disease severity or caused by mechanical ventilation. Materials and Methods: Nasopharyngeal aspirates were collected <1 hour before intubation and 24 hours later in RSV bronchiolitis patients with respiratory failure (n = 18) and non-ventilated RSV bronchiolitis controls (n = 18). Concentrations of the following cytokines were measured: interleukin (IL)-1 alpha, IL-1 beta, IL-6, monocyte chemotactic protein (MCP)-1 and macrophage inflammatory protein (MIP)-1 alpha. Results: Baseline cytokine levels were comparable between ventilated and non-ventilated infants. After 24 hours of mechanical ventilation mean cytokine levels, except for MIP-1 alpha, were elevated compared to non-ventilated infected controls: IL-1 alpha (159 versus 4 pg/ml, p<0.01), IL-1 beta (1068 versus 99 pg/ml, p<0.01), IL-6 (2343 versus 958 pg/ml, p<0.05) and MCP-1 (174 versus 26 pg/ml, p<0.05). Conclusions: Using pre-and post-intubation observations, this study suggests that endotracheal intubation and subsequent mechanical ventilation cause a robust pulmonary inflammation in infants with RSV bronchiolitis.	[Hennus, Marije P.; van Vught, Adrianus J.; Brabander, Mark; Jansen, Nicolaas J.] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Paediat Intens Care, Utrecht, Netherlands; [Brus, Frank] Locat Juliana Childrens Hosp, Dept Paediat, Haga Hosp, The Hague, Netherlands; [Bont, Louis J.] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Paediat Infect Dis, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Haga Hospital; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis	Hennus, MP (corresponding author), Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Paediat Intens Care, Utrecht, Netherlands.	m.p.hennus@umcutrecht.nl	Hennus, Marije/D-1643-2014	Hennus, Marije/0000-0003-1508-0456	Elisabeth von Freyburg Foundation (Catharijne Foundation)	Elisabeth von Freyburg Foundation (Catharijne Foundation)	This work was funded by a grant from the Elisabeth von Freyburg Foundation (Catharijne Foundation). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Behrendt CE, 1998, EUR J PEDIATR, V157, P215, DOI 10.1007/s004310050798; Belderbos ME, 2009, CLIN IMMUNOL, V133, P228, DOI 10.1016/j.clim.2009.07.003; Bem RA, 2009, AM J PHYSIOL-LUNG C, V296, pL46, DOI 10.1152/ajplung.00467.2007; Bennett BL, 2007, J INFECT DIS, V195, P1532, DOI 10.1086/515575; Bont L, 2001, J INFECT DIS, V184, P355, DOI 10.1086/322035; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Buckingham SC, 2000, PEDIATR INFECT DIS J, V19, P113, DOI 10.1097/00006454-200002000-00006; Chiumello D, 1999, AM J RESP CRIT CARE, V160, P109, DOI 10.1164/ajrccm.160.1.9803046; El Saleeby CM, 2011, J INFECT DIS, V204, P996, DOI 10.1093/infdis/jir494; Faber TE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034364; Fodha I, 2007, J MED VIROL, V79, P1951, DOI 10.1002/jmv.21026; Garcia C, 2012, PEDIATR INFECT DIS J, V31, P86, DOI 10.1097/INF.0b013e31822dc8c1; Garofalo RP, 2001, J INFECT DIS, V184, P393, DOI 10.1086/322788; Hennus MP, 2012, EUR RESPIR J, V40, P1508, DOI 10.1183/09031936.00177111; Hornsleth A, 2001, J CLIN VIROL, V21, P163, DOI 10.1016/S1386-6532(01)00159-7; Houben ML, 2010, J MED VIROL, V82, P1266, DOI 10.1002/jmv.21771; Joshi P, 1998, J ALLERGY CLIN IMMUN, V102, P618, DOI 10.1016/S0091-6749(98)70278-7; Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075; Lieberthal AS, 2006, PEDIATRICS, V118, P1774, DOI 10.1542/peds.2006-2223; McNamara PS, 2003, ARCH DIS CHILD, V88, P922, DOI 10.1136/adc.88.10.922; Plotz FB, 2002, INTENS CARE MED, V28, P486, DOI 10.1007/s00134-002-1216-7; Sheeran P, 1999, PEDIATR INFECT DIS J, V18, P115, DOI 10.1097/00006454-199902000-00007; Simoes EAF, 1999, LANCET, V354, P847, DOI 10.1016/S0140-6736(99)80040-3; Soilly AL, 2012, EPIDEMIOL INFECT, V140, P608, DOI 10.1017/S0950268811001208; Thorburn K, 2006, THORAX, V61, P611, DOI 10.1136/thx.2005.048397; Tremblay LN, 2006, INTENS CARE MED, V32, P24, DOI 10.1007/s00134-005-2817-8; Welliver TP, 2007, J INFECT DIS, V195, P1126, DOI 10.1086/512615; Wright M, 2011, PEDIATR PULM, V46, P324, DOI 10.1002/ppul.21377; Zosky GR, 2009, J APPL PHYSIOL, V107, P1472, DOI 10.1152/japplphysiol.00393.2009	30	11	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2013	8	12							e83035	10.1371/journal.pone.0083035	http://dx.doi.org/10.1371/journal.pone.0083035			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276EG	24349427	Green Submitted, Green Published, gold			2023-01-03	WOS:000328730300125
J	Lloyd, DA; Abrahamyan, A; Harris, JA				Lloyd, David A.; Abrahamyan, Arman; Harris, Justin A.			Brain-Stimulation Induced Blindsight: Unconscious Vision or Response Bias?	PLOS ONE			English	Article							STRIATE CORTEX; AREA MT; ABSENCE; V1	A dissociation between visual awareness and visual discrimination is referred to as "blindsight". Blindsight results from loss of function of the primary visual cortex (V1) which can occur due to cerebrovascular accidents (i.e. stroke-related lesions). There are also numerous reports of similar, though reversible, effects on vision induced by transcranial Magnetic Stimulation (TMS) to early visual cortex. These effects point to V1 as the "gate" of visual awareness and have strong implications for understanding the neurological underpinnings of consciousness. It has been argued that evidence for the dissociation between awareness of, and responses to, visual stimuli can be a measurement artifact of the use of a high response criterion under yes-no measures of visual awareness when compared with the criterion free forced-choice responses. This difference between yes-no and forced-choice measures suggests that evidence for a dissociation may actually be normal near-threshold conscious vision. Here we describe three experiments that tested visual performance in normal subjects when their visual awareness was suppressed by applying TMS to the occipital pole. The nature of subjects' performance whilst undergoing occipital TMS was then verified by use of a psychophysical measure (d') that is independent of response criteria. This showed that there was no genuine dissociation in visual sensitivity measured by yes-no and forced-choice responses. These results highlight that evidence for visual sensitivity in the absence of awareness must be analysed using a bias-free psychophysical measure, such as d', In order to confirm whether or not visual performance is truly unconscious.	[Lloyd, David A.; Abrahamyan, Arman; Harris, Justin A.] Univ Sydney, Sch Psychol, Sydney, NSW 2006, Australia	University of Sydney	Lloyd, DA (corresponding author), Univ Sydney, Sch Psychol, Sydney, NSW 2006, Australia.	dllo2792@uni.sydney.edu.au		Harris, Justin/0000-0003-3865-8097	Australian Research Council [DP0986137]	Australian Research Council(Australian Research Council)	This research was funded by the Australian Research Council Grant DP0986137. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrahamyan A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022342; Alexander I, 2010, CONSCIOUS COGN, V19, P520, DOI 10.1016/j.concog.2010.01.008; Azzopardi P, 1998, CONSCIOUS COGN, V7, P292, DOI 10.1006/ccog.1998.0358; Azzopardi P, 1997, P NATL ACAD SCI USA, V94, P14190, DOI 10.1073/pnas.94.25.14190; BARBUR JL, 1980, BRAIN, V103, P905, DOI 10.1093/brain/103.4.905; BLYTHE IM, 1987, BRAIN, V110, P887, DOI 10.1093/brain/110.4.887; Boyer JL, 2005, P NATL ACAD SCI USA, V102, P16875, DOI 10.1073/pnas.0505332102; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; CAMPION J, 1983, BEHAV BRAIN SCI, V6, P423, DOI 10.1017/S0140525X00016861; Christensen MS, 2008, P NATL ACAD SCI USA, V105, P1353, DOI 10.1073/pnas.0705858105; de Gelder B, 1999, NEUROREPORT, V10, P3759, DOI 10.1097/00001756-199912160-00007; GROSS CG, 1991, NEUROPSYCHOLOGIA, V29, P497, DOI 10.1016/0028-3932(91)90007-U; Harris JA, 2008, J COGNITIVE NEUROSCI, V20, P734, DOI 10.1162/jocn.2008.20048; HOLMES G, 1945, PROC R SOC SER B-BIO, V132, P348, DOI 10.1098/rspb.1945.0002; Jolij J, 2005, P NATL ACAD SCI USA, V102, P10747, DOI 10.1073/pnas.0500834102; Ko Y, 2012, PHILOS T R SOC B, V367, P1401, DOI 10.1098/rstb.2011.0380; Kontsevich LL, 1999, VISION RES, V39, P2729, DOI 10.1016/S0042-6989(98)00285-5; Lamme VAF, 2006, TRENDS COGN SCI, V10, P193, DOI 10.1016/j.tics.2006.03.002; McNicol D., 1972, PRIMER SIGNAL DETECT; Milner D., 2006, VISUAL BRAIN ACTION, V27; Morgan MJ, 1997, NATURE, V385, P401, DOI 10.1038/385401b0; Overgaard M, 2004, J CONSCIOUSNESS STUD, V11, P77; Overgaard M, 2004, BRAIN COGNITION, V54, P58, DOI 10.1016/S0278-2626(03)00260-4; Overgaard M, 2012, PHILOS T R SOC B, V367, P1287, DOI 10.1098/rstb.2011.0425; Overgaard M, 2011, EXP BRAIN RES, V209, P473, DOI 10.1007/s00221-011-2578-2; Overgaard M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003028; Persaud N, 2008, CONSCIOUS COGN, V17, P1046, DOI 10.1016/j.concog.2007.10.001; Pinker Steven, 2007, Time, V169, P58; POPPEL E, 1973, NATURE, V243, P295, DOI 10.1038/243295a0; Radoeva PD, 2008, J COGNITIVE NEUROSCI, V20, P1927, DOI 10.1162/jocn.2008.20139; Ramsy T. Z., 2004, PHENOMENOL COGN SCI, V3, P1, DOI [10.1023/b:phen.0000041900.30172.e8, DOI 10.1023/B:PHEN.0000041900.30172.E8, 10.1023/B:PHEN.0000041900.30172.e8]; Ro T, 2004, P NATL ACAD SCI USA, V101, P9933, DOI 10.1073/pnas.0403061101; RODMAN HR, 1989, J NEUROSCI, V9, P2033; SANDERS MD, 1974, LANCET, V1, P707; Schiller PH, 2001, PROG BRAIN RES, V134, P127; Stoerig P, 2010, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.074.2009; Trevethan CT, 2007, NEUROPSYCHOLOGIA, V45, P2092, DOI 10.1016/j.neuropsychologia.2007.01.022; Weiskrantz L., 1986, BLINDSIGHT CASE STUD; Weiskrantz L, 2009, EXP BRAIN RES, V192, P413, DOI 10.1007/s00221-008-1388-7	39	24	24	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 6	2013	8	12							e82828	10.1371/journal.pone.0082828	http://dx.doi.org/10.1371/journal.pone.0082828			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	273WJ	24324837	gold, Green Published, Green Submitted			2023-01-03	WOS:000328566700116
J	Zhang, RW; Wang, YL; Li, JX; Jin, HL; Song, SJ; Huang, CS				Zhang, Ruowen; Wang, Yulei; Li, Jingxia; Jin, Honglei; Song, Shaojiang; Huang, Chuanshu			The Chinese Herb Isolate Yuanhuacine (YHL-14) Induces G(2)/M Arrest in Human Cancer Cells by Up-regulating p21 Protein Expression through an p53 Protein-independent Cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						Anticancer Drug; Cell Growth; p38; MAPK; Protein Stability; Sp1; p21; Yuanhuacine	STRESS-ACTIVATED CHECKPOINT; POTENT INHIBITORY-ACTIVITY; DAPHNANE DITERPENE ESTERS; NF-KAPPA-B; CYCLE ARREST; TUMOR-GROWTH; DNA-DAMAGE; P38 MAPK; APOPTOSIS; PHOSPHORYLATION	Background: The potential mechanism of YHL-14 against cancer cells has not been explored. Results: YHL-14 induces G(2)/M phase arrest and inhibition of cancer cell growth by up-regulation of p21 transcription and protein expression via modulation of Sp1 protein stability. Conclusion: YHL-14 inhibits bladder and colon cancer cell growth through up-regulation of p21 expression. Significance: This study identifies a novel mechanism underlying the anticancer effect of YHL-14. Yuanhuacine (YHL-14), the major component of daphnane diterpene ester isolated from the flower buds of Daphne genkwa, has been reported to have activity against cell proliferation in various cancer cell lines. Nevertheless, the potential mechanism has not been explored yet. Here we demonstrate that YHL-14 inhibits bladder and colon cancer cell growth through up-regulation of p21 expression in an Sp1-dependent manner. We found that YHL-14 treatment resulted in up-regulation of p21 expression and a significant G(2)/M phase arrest in T24T and HCT116 cells without affecting p53 protein expression and activation. Further studies indicate that p21 induction by YHL-14 occurs at the transcriptional level via up-regulation of Sp1 protein expression. Moreover, our results show that p38 is essential for YHL-14-mediated Sp1 protein stabilization, G(2)/M growth arrest induction, and anchorage-independent growth inhibition of cancer cells. Taken together, our studies demonstrate a novel mechanism of YHL-14 against cancer cell growth in bladder and colon cancer cell lines, which provides valuable information for the design and synthesis of other new conformation-constrained derivatives on the basis of the structure of YHL-14 for cancer therapy.	[Zhang, Ruowen; Wang, Yulei; Li, Jingxia; Jin, Honglei; Huang, Chuanshu] NYU, Nelson Inst Environm Med, Sch Med, Tuxedo Pk, NY 10987 USA; [Zhang, Ruowen; Song, Shaojiang] Shenyang Pharmaceut Univ, Sch Tradit Chinese Mat Med, Key Lab Struct Based Drug Design & Discovery, Shenyang 110016, Peoples R China	New York University; Shenyang Pharmaceutical University	Song, SJ (corresponding author), Shenyang Pharmaceut Univ, Sch Tradit Chinese Mat Med, Key Lab Struct Based Drug Design & Discovery, Shenyang 110016, Peoples R China.	songsj99@gmail.com; chuanshu.huang@nyumc.org	WANG, YULEI/HJG-7151-2022	Zhang, Ruowen/0000-0003-1403-2356; Huang, Chuanshu/0000-0003-4133-5096	NCI, National Institutes of Health [CA177665, CA165980, CA112557]; National Institutes of Health [NSFC81229002, LR2012034]; NATIONAL CANCER INSTITUTE [R01CA177665, R01CA112557, P01CA165980, P30CA016087] Funding Source: NIH RePORTER	NCI, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by NCI, National Institutes of Health Grants CA177665, CA165980, and CA112557 and National Institutes of Health Grants NSFC81229002 and LR2012034.	Bhandurge P., 2013, ASIAN J BIOMED PHARM, V3, P1; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Cai T, 2011, CURR CANCER DRUG TAR, V11, P548, DOI 10.2174/156800911795656001; Chadalapaka G, 2012, CARCINOGENESIS, V33, P886, DOI 10.1093/carcin/bgs102; Chintharlapalli S, 2007, CANCER RES, V67, P2816, DOI 10.1158/0008-5472.CAN-06-3735; Chuang JY, 2008, MOL BIOL CELL, V19, P1139, DOI 10.1091/mbc.E07-09-0881; Cummins Jordan M., 2004, Cancer Research, V64, P3006; D'Addario M, 2006, GENE, V379, P51, DOI 10.1016/j.gene.2006.04.012; De Souza CPC, 2007, EUKARYOT CELL, V6, P1521, DOI 10.1128/EC.00178-07; Ding J, 2006, J BIOL CHEM, V281, P24405, DOI 10.1074/jbc.M600751200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eom HJ, 2010, ENVIRON SCI TECHNOL, V44, P8337, DOI 10.1021/es1020668; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gartel AL, 2000, ONCOGENE, V19, P5182, DOI 10.1038/sj.onc.1203900; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; HALL IH, 1986, EUR J CANCER CLIN ON, V22, P45, DOI 10.1016/0277-5379(86)90341-X; Harding MA, 2010, EUR J CANCER, V46, P1252, DOI 10.1016/j.ejca.2010.02.025; HARPER JW, 1993, CELL, V75, P805; Hong JY, 2011, J NAT PROD, V74, P2102, DOI 10.1021/np2003512; Hong JY, 2010, CHEM PHARM BULL, V58, P234, DOI 10.1248/cpb.58.234; Hopkins Maton A., 1997, CELLS BUILDING BLOCK, P76; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jutooru I, 2010, J BIOL CHEM, V285, P25332, DOI 10.1074/jbc.M109.095240; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Liu JY, 2010, J BIOL CHEM, V285, P26058, DOI 10.1074/jbc.M110.100271; Luo WJ, 2008, J BIOL CHEM, V283, P8624, DOI 10.1074/jbc.M707860200; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mikhailov A, 2005, CELL CYCLE, V4, P57, DOI 10.4161/cc.4.1.1357; Mikhailov A, 2007, CURR BIOL, V17, P2162, DOI 10.1016/j.cub.2007.11.028; Park BY, 2007, J ETHNOPHARMACOL, V111, P496, DOI 10.1016/j.jep.2006.12.023; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Sisodiya D., 2012, IJAPBC, V1, P138; Tan NY, 2009, MOL CELL BIOL, V29, P2483, DOI 10.1128/MCB.01828-08; Vinay K. M., 2004, ROBBINS COTRAN PATHO, P331; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; WHO, 2009, WHO TECH REP SER, V958, P1; WHO Library Cataloguing-in-Publication Data, 2010, WHOHRHHPN103, P18; Wood CD, 2009, INT J BIOL SCI, V5, P428; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zhan ZJ, 2005, BIOORGAN MED CHEM, V13, P645, DOI 10.1016/j.bmc.2004.10.054; Zhang DY, 2006, J BIOL CHEM, V281, P34113, DOI 10.1074/jbc.M602821200; Zhang DY, 2010, CANCER RES, V70, P813, DOI 10.1158/0008-5472.CAN-09-0448; Zhang SX, 2006, BIOORGAN MED CHEM, V14, P3888, DOI 10.1016/j.bmc.2006.01.055; Zhang SX, 2009, J DRUG TARGET, V17, P286, DOI 10.1080/10611860902737912; Zhou J. J., 2013, ENCY TRADITIONAL CHI, V5, P227	49	28	30	1	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2014	289	10					6394	6403		10.1074/jbc.M113.513960	http://dx.doi.org/10.1074/jbc.M113.513960			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	AC3BG	24451377	Green Published, hybrid			2023-01-03	WOS:000332389400008
J	Shi, SH; Cai, YP; Cai, XJ; Zheng, XY; Cao, DS; Ye, FQ; Xiang, Z				Shi, Shao-hua; Cai, Yue-piao; Cai, Xiao-jun; Zheng, Xiao-yong; Cao, Dong-sheng; Ye, Fa-qing; Xiang, Zheng			A Network Pharmacology Approach to Understanding the Mechanisms of Action of Traditional Medicine: Bushenhuoxue Formula for Treatment of Chronic Kidney Disease	PLOS ONE			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; UNILATERAL URETERAL OBSTRUCTION; ANGIOTENSIN-ALDOSTERONE SYSTEM; SALVIAE-MILTIORRHIZAE RADIX; INSULIN SIGNALING PATHWAY; TANSHINONE IIA; DIABETIC-NEPHROPATHY; MASS-SPECTROMETRY; TGF-BETA; GENE-EXPRESSION	Traditional Chinese medicine (TCM) has unique therapeutic effects for complex chronic diseases. However, for the lack of an effective systematic approach, the research progress on the effective substances and pharmacological mechanism of action has been very slow. In this paper, by incorporating network biology, bioinformatics and chemoinformatics methods, an integrated approach was proposed to systematically investigate and explain the pharmacological mechanism of action and effective substances of TCM. This approach includes the following main steps: First, based on the known drug targets, network biology was used to screen out putative drug targets; Second, the molecular docking method was used to calculate whether the molecules from TCM and drug targets related to chronic kidney diseases (CKD) interact or not; Third, according to the result of molecular docking, natural product-target network, main component-target network and compound-target network were constructed; Finally, through analysis of network characteristics and literature mining, potential effective multi-components and their synergistic mechanism were putatively identified and uncovered. Bu-shen-Huo-xue formula (BSHX) which was frequently used for treating CKD, was used as the case to demonstrate reliability of our proposed approach. The results show that BSHX has the therapeutic effect by using multi-channel network regulation, such as regulating the coagulation and fibrinolytic balance, and the expression of inflammatory factors, inhibiting abnormal ECM accumulation. Tanshinone IIA, rhein, curcumin, calycosin and quercetin may be potential effective ingredients of BSHX. This research shows that the integration approach can be an effective means for discovering active substances and revealing their pharmacological mechanisms of TCM.	[Shi, Shao-hua; Cai, Yue-piao; Cai, Xiao-jun; Zheng, Xiao-yong; Ye, Fa-qing; Xiang, Zheng] Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou, Peoples R China; [Cao, Dong-sheng] Cent S Univ, Sch Pharmaceut Sci, Changsha, Hunan, Peoples R China	Wenzhou Medical University; Central South University	Ye, FQ (corresponding author), Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou, Peoples R China.	yfq664340@163.com; XZH0077@126.com			National Natural Science Foundation of China [81001614]; Nature Foundation Committee of Zhejiang Province, China [Y2100317, LQ13H280001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Nature Foundation Committee of Zhejiang Province, China	The authors acknowledge financial support from the National Natural Science Foundation of China (No. 81001614) and the Nature Foundation Committee of Zhejiang Province, China (Y2100317 and LQ13H280001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbasian N, 2012, NEPHROL DIAL TRANSPL, V27, P241; Abdel-Rahman E, 2009, SEMIN DIALYSIS, V22, P532, DOI 10.1111/j.1525-139X.2009.00634.x; Agarwal SK, 2001, J SCI IND RES INDIA, V60, P1; Ahn YM, 2010, PHYTOTHER RES, V24, P1886, DOI 10.1002/ptr.3347; Akgul T, 2011, KAOHSIUNG J MED SCI, V27, P15, DOI 10.1016/j.kjms.2010.03.001; Alasbahi RH, 2012, PHARMAZIE, V67, P5, DOI 10.1691/ph.2012.1642; [Anonymous], KIDNEY INT, V73, P269; Azuaje FJ, 2011, SCI REP-UK, V1, DOI 10.1038/srep00052; Bailey JL, 2002, J AM SOC NEPHROL, V13, p522A; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Becker KG, 2004, NAT GENET, V36, P431, DOI 10.1038/ng0504-431; Berger SI, 2009, BIOINFORMATICS, V25, P2466, DOI 10.1093/bioinformatics/btp465; Berman H, 2007, NUCLEIC ACIDS RES, V35, pD301, DOI 10.1093/nar/gkl971; Biggar PH, 2011, PEDIATR NEPHROL, V26, P7, DOI 10.1007/s00467-010-1526-x; Brandes U, 2001, J MATH SOCIOL, V25, P163, DOI 10.1080/0022250X.2001.9990249; Brophy D, 2009, AM J KIDNEY DIS, V53, pA30; Cao J, 2008, BIOMED CHROMATOGR, V22, P164, DOI 10.1002/bmc.911; Chea E, 2007, BMC BIOINFORMATICS, V8; Chen XH, 2012, J CHROMATOGR A, V1263, P34, DOI 10.1016/j.chroma.2012.09.074; Chen XM, 2011, J CHROMATOGR B, V879, P2339, DOI 10.1016/j.jchromb.2011.06.019; [陈修平 CHEN Xiu-ping], 2010, [中草药, Chinese Traditional and Herbal Drugs], V41, P1; Chevalier RL, 1999, J UROLOGY, V161, P309, DOI 10.1016/S0022-5347(01)62137-2; Cho DY, 2012, PLOS COMPUTATIONAL B, V8; Choi ME, 2012, SEMIN NEPHROL, V32, P244, DOI 10.1016/j.semnephrol.2012.04.003; Chuang CC, 2010, AM J CLIN NUTR, V92, P1511, DOI 10.3945/ajcn.2010.29807; Chuang PY, 2010, KIDNEY INT, V78, P231, DOI 10.1038/ki.2010.158; CHUNG HY, 1988, CHEM PHARM BULL, V36, P274; Coca SG, 2012, KIDNEY INT, V81, P442, DOI 10.1038/ki.2011.379; Coresh J, 2007, JAMA-J AM MED ASSOC, V298, P2038, DOI 10.1001/jama.298.17.2038; Draghici S, 2007, GENOME RES, V17, P1537, DOI 10.1101/gr.6202607; Dubey RK, 1999, HYPERTENSION, V33, P177, DOI 10.1161/01.HYP.33.1.177; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Eybl V, 2008, HUM EXP TOXICOL, V27, P347, DOI 10.1177/0960327108094508; Fernand VE, 2011, CHEM-BIOL INTERACT, V192, P220, DOI 10.1016/j.cbi.2011.03.013; Fujimoto H, 1998, CHEM PHARM BULL, V46, P1506; Gaedeke J, 2004, KIDNEY INT, V66, P112, DOI 10.1111/j.1523-1755.2004.00713.x; Gao S, 2012, ATHEROSCLEROSIS, V220, P3, DOI 10.1016/j.atherosclerosis.2011.06.041; Gao ZhiQing, 2010, China Journal of Traditional Chinese Medicine and Pharmacy, V25, P296; Garcia-Mediavilla V, 2007, EUR J PHARMACOL, V557, P221, DOI 10.1016/j.ejphar.2006.11.014; Gold MR, 2000, IMMUNOL REV, V176, P47; Gong ZW, 2009, ENDOCRINOLOGY, V150, P104, DOI 10.1210/en.2008-0322; Gonzalez-Salazar A, 2011, CARDIOVASC TOXICOL, V11, P357, DOI 10.1007/s12012-011-9128-9; Greenbaum D, 2003, GENOME BIOL, V4; Griffin TJ, 2002, MOL CELL PROTEOMICS, V1, P323, DOI 10.1074/mcp.M200001-MCP200; Guan XH, 2009, TRANSPL INT, V22, P232, DOI 10.1111/j.1432-2277.2008.00770.x; Ha MK, 2011, BIOL PHARM BULL, V34, P1432, DOI 10.1248/bpb.34.1432; Hamosh A, 2005, NUCLEIC ACIDS RES, V33, pD514; He DY, 2011, BIOL PHARM BULL, V34, P1219, DOI 10.1248/bpb.34.1219; Heyman SN, 2008, AM J NEPHROL, V28, P998, DOI 10.1159/000146075; Hong JY, 2006, J FOOD SCI, V71, pS626, DOI 10.1111/j.1750-3841.2006.00194.x; Hsieh CL, 2013, J AGR FOOD CHEM, V61, P7258, DOI 10.1021/jf304595p; Hu YB, 2012, ACTA PHYS-CHIM SIN, V28, P1257, DOI 10.3866/PKU.WHXB201202212; Hu Y, 2010, AM J NEPHROL, V31, P332, DOI 10.1159/000287230; Huang LM, 2006, ACTA PHARMACOL SIN, V27, P321; Huang XZ, 2008, CANCER BIOL THER, V7, P468, DOI 10.4161/cbt.7.3.5457; Hwang JS, 2005, ARCH PHARM RES, V28, P190, DOI 10.1007/BF02977714; Hwang WC, 2008, CLIN PHARMACOL THER, V84, P563, DOI 10.1038/clpt.2008.129; Hwang W, 2006, ALGORITHM MOL BIOL, V1, DOI 10.1186/1748-7188-1-24; Iqbal M, 2009, MOL CELL BIOCHEM, V324, P157, DOI 10.1007/s11010-008-9994-z; Jariyawat S, 2009, J NAT MED-TOKYO, V63, P430, DOI 10.1007/s11418-009-0345-5; Jha V, 2010, NEPHROLOGY, V15, P10, DOI 10.1111/j.1440-1797.2010.01305.x; Jia J, 2009, NAT REV DRUG DISCOV, V8, P111, DOI 10.1038/nrd2683; Jin RF, 2011, INT J QUANTUM CHEM, V111, P1064, DOI 10.1002/qua.22466; Joy MP, 2005, J BIOMED BIOTECHNOL, P96, DOI 10.1155/JBB.2005.96; Kang DG, 2002, AM J CHINESE MED, V30, P87, DOI 10.1142/S0192415X02000107; Keiser MJ, 2009, NATURE, V462, P175, DOI 10.1038/nature08506; Khan SS, 2012, AM J KIDNEY DIS, V59, pA47; Khorsandi L, 2008, DARU, V16, P155; Kim SK, 2009, BIOL PHARM BULL, V32, P220, DOI 10.1248/bpb.32.220; Kim W, 2006, NY TIMES BK REV, P1; Knox C, 2011, NUCLEIC ACIDS RES, V39, pD1035, DOI 10.1093/nar/gkq1126; Ko JC, 2011, BIOCHEM PHARMACOL, V81, P680, DOI 10.1016/j.bcp.2010.12.008; Kong LD, 2004, J ETHNOPHARMACOL, V91, P351, DOI 10.1016/j.jep.2004.01.013; Koyama J, 2007, J CHROMATOGR A, V1145, P183, DOI 10.1016/j.chroma.2007.01.076; KUPPUSAMY UR, 1994, BIOCHEM PHARMACOL, V47, P521, DOI 10.1016/0006-2952(94)90184-8; Lai PB, 2012, RENAL FAILURE, V34, P83, DOI 10.3109/0886022X.2011.623564; Lee KJ, 2012, PHARM BIOL, V50, P591; Lee S, 2009, EXPERT OPIN DRUG DIS, V4, P1177, DOI 10.1517/17460440903322234; Lee W, 2012, BMB REP, V45, P141, DOI 10.5483/BMBRep.2012.45.3.141; Letavernier E, 2005, J AM SOC NEPHROL, V16, P2395, DOI 10.1681/ASN.2004090802; Li BH, 2012, INT J MOL SCI, V13, P13501, DOI 10.3390/ijms131013501; Li FM, 2010, HYPERTENSION, V56, pE123; Li JH, 2002, J AM SOC NEPHROL, V13, p287A; Li JX, 2005, CHINESE J PHYSIOL, V48, P101; Li LS, 1996, NEPHROLOGY, V2, pS146, DOI 10.1111/j.1440-1797.1996.tb00160.x; Li M, 2013, J ETHNOPHARMACOL, V146, P614, DOI 10.1016/j.jep.2013.01.038; Li R, 2011, FOOD CHEM, V126, P1890, DOI 10.1016/j.foodchem.2010.12.014; Li S, 2006, J ASIAN NAT PROD RES, V8, P281, DOI 10.1080/10286020412331286434; Li Shao, 2011, Zhongguo Zhong Yao Za Zhi, V36, P2017; Li SG, 2009, CARBOHYD POLYM, V78, P343, DOI 10.1016/j.carbpol.2009.04.013; Li XM, 2005, ADV CHRONIC KIDNEY D, V12, P276, DOI 10.1016/j.ackd.2005.03.007; Li YG, 2009, J CHROMATOGR A, V1216, P1941, DOI 10.1016/j.chroma.2008.12.032; Li YS, 2009, J HUAZHONG U SCI-MED, V29, P476, DOI 10.1007/s11596-009-0417-5; Lin SL, 2011, AM J PATHOL, V178, P911, DOI 10.1016/j.ajpath.2010.10.012; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; Liu F, 2012, KIDNEY BLOOD PRESS R, V35, P182, DOI 10.1159/000331054; Liu Y, 2010, J PHARMACEUT BIOMED, V53, P698, DOI 10.1016/j.jpba.2010.03.041; Luyckx VA, 2012, ADV CHRONIC KIDNEY D, V19, P129, DOI 10.1053/j.ackd.2012.04.005; Lv ZM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022806; Ma QL, 2009, J NEUROSCI, V29, P9078, DOI 10.1523/JNEUROSCI.1071-09.2009; Martin A, 2010, BMC BIOINFORMATICS, V11; Matsuura S, 2011, J HISTOCHEM CYTOCHEM, V59, P864, DOI 10.1369/0022155411413929; Mencher Simon K, 2005, BMC Clin Pharmacol, V5, P3, DOI 10.1186/1472-6904-5-3; Morphy R, 2007, DRUG DISCOV TODAY, V12, P156, DOI 10.1016/j.drudis.2006.12.006; Nabavi SM, 2012, RENAL FAILURE, V34, P901, DOI 10.3109/0886022X.2012.687347; Nagao S, 2008, KIDNEY INT, V73, P269, DOI 10.1038/sj.ki.5002629; Nagler EV, 2012, NEPHROL DIAL TRANSPL, V27, P3736, DOI 10.1093/ndt/gfs295; Navab KD, 2011, CURR PHARM DESIGN, V17, P17; Navaneethan SD, 2008, BMC NEPHROL, V9, DOI 10.1186/1471-2369-9-3; Ozturk M, 2007, FOOD CHEM, V103, P623, DOI 10.1016/j.foodchem.2006.09.005; PALYA A, 2008, AM J KIDNEY DIS, V51, pA77; Pan HJ, 2005, J ETHNOPHARMACOL, V99, P99, DOI 10.1016/j.jep.2005.02.007; Pei LX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057414; Qi LW, 2009, J CHROMATOGR A, V1216, P2087, DOI 10.1016/j.chroma.2008.02.095; Qin Y, 2011, AM J PATHOL, V179, P2766, DOI 10.1016/j.ajpath.2011.08.025; Remuzzi G, 2005, KIDNEY INT, V68, P57; Sheng BW, 2005, CHINESE MED J-PEKING, V118, P43; Shi CS, 2007, THROMB RES, V119, P769, DOI 10.1016/j.thromres.2006.06.008; Siragy HM, 2010, AM J NEPHROL, V31, P541, DOI 10.1159/000313363; Skupien J, 2009, DIABETES, V58, pA219; Soetikno V, 2011, NUTR METAB, V8; Stinghen AEM, 2010, BLOOD PURIFICAT, V29, P114, DOI 10.1159/000245636; Stone R, 2008, SCIENCE, V319, P709, DOI 10.1126/science.319.5864.709; Tang FT, 2011, EUR J PHARMACOL, V650, P275, DOI 10.1016/j.ejphar.2010.07.038; Tang JL, 2008, LANCET, V372, P1938, DOI 10.1016/S0140-6736(08)61354-9; Tang JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011822; Tang JH, 2008, J HUAZHONG U SCI-MED, V28, P539, DOI 10.1007/s11596-008-0511-0; Tang SCW, 2006, J AM SOC NEPHROL, V17, P1633, DOI 10.1681/ASN.2005101113; Tapmeier TT, 2008, KIDNEY INT, V73, P885, DOI 10.1038/sj.ki.5002797; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Tsukiyama F, 2006, BIOCHEM BIOPH RES CO, V351, P234, DOI 10.1016/j.bbrc.2006.10.025; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang D, 2006, J SEP SCI, V29, P2012, DOI 10.1002/jssc.200500486; Wang H, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008000.pub2; Wang JX, 2012, IEEE ACM T COMPUT BI, V9, P1070, DOI 10.1109/TCBB.2011.147; Wang JP, 2006, EUR J PHARMACOL, V553, P297, DOI 10.1016/j.ejphar.2006.08.087; Wang R, 2007, LIFE SCI, V80, P2481, DOI 10.1016/j.lfs.2007.04.010; Wang SP, 2010, RAPID COMMUN MASS SP, V24, P1641, DOI 10.1002/rcm.4561; Wang YJ, 2012, J ETHNOPHARMACOL, V139, P757, DOI 10.1016/j.jep.2011.12.009; Wasserman RL, 2012, J CLIN IMMUNOL, V32, P1153, DOI 10.1007/s10875-012-9740-x; Wichitnithad W, 2009, PHYTOCHEM ANALYSIS, V20, P314, DOI 10.1002/pca.1129; Wu LC, 2012, ACTA PHARMACOL SIN, V33, P1254, DOI 10.1038/aps.2012.84; Wu XL, 2012, PLANTA MED, V78, P866, DOI 10.1055/s-0031-1298487; Xavier S, 2012, EUR J PHARMACOL, V687, P14, DOI 10.1016/j.ejphar.2012.02.050; Xiang Z, 2011, PHYTOCHEM ANALYSIS, V22, P411, DOI 10.1002/pca.1296; Xiao HB, 2004, J CHROMATOGR A, V1032, P117, DOI 10.1016/j.chroma.2003.09.032; Xiao-hong D, 2011, CHIN J INTEGR TRAD W, V31, P765; Yang FQ, 2006, J CHROMATOGR A, V1134, P226, DOI 10.1016/j.chroma.2006.09.048; Yang JX, 2008, J ETHNOPHARMACOL, V119, P166, DOI 10.1016/j.jep.2008.06.027; Yang KY, 2007, J CHROMATOGR B, V853, P183, DOI 10.1016/j.jchromb.2007.03.010; Ye M, 2005, RAPID COMMUN MASS SP, V19, P1469, DOI 10.1002/rcm.1944; Yon JM, 2011, REPROD TOXICOL, V31, P513, DOI 10.1016/j.reprotox.2011.02.011; Yongzheng H., 2011, COMPREHENSIVE NATURA; Zhang G, 1996, NEPHROL DIAL TRANSPL, V11, P186, DOI 10.1093/oxfordjournals.ndt.a027039; Zhang HX, 2004, J CHROMATOGR B, V812, P175, DOI 10.1016/j.jchromb.2004.08.010; ZHANG JH, 1992, KIDNEY INT, V42, P498; Zhang LX, 2012, LANCET, V379, P815, DOI 10.1016/S0140-6736(12)60033-6; Zhang P, 2008, PHYSICA A, V387, P6869, DOI 10.1016/j.physa.2008.09.006; Zhang Q, 2012, EXP BIOL MED, V237, P903, DOI 10.1258/ebm.2012.012032; Zhang X, 2007, ANAL CHIM ACTA, V602, P252, DOI 10.1016/j.aca.2007.09.033; Zhao YL, 2011, FOOD CHEM TOXICOL, V49, P1705, DOI 10.1016/j.fct.2011.04.011; Zhong F, 2011, BIOL PHARM BULL, V34, P226, DOI 10.1248/bpb.34.226; Zhu B, 2011, MOL MED REP, V4, P505, DOI 10.3892/mmr.2011.444; Zhu M, 2009, J DRUG TARGET, V17, P524, DOI 10.1080/10611860903046610; Zuo C, 2009, J ZHEJIANG UNIV-SC B, V10, P380, DOI 10.1631/jzus.B0820230	166	70	73	4	97	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2014	9	3							e89123	10.1371/journal.pone.0089123	http://dx.doi.org/10.1371/journal.pone.0089123			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC4GP	24598793	Green Published, Green Submitted, gold			2023-01-03	WOS:000332479400008
J	Rogers, MAM; Micic, D; Blumberg, N; Young, VB; Aronoff, DM				Rogers, Mary A. M.; Micic, Dejan; Blumberg, Neil; Young, Vincent B.; Aronoff, David M.			Storage Duration of Red Blood Cell Transfusion and Clostridium difficile Infection: A Within Person Comparison	PLOS ONE			English	Article							PROLONGED STORAGE; CARDIAC-SURGERY; CRITICALLY-ILL; IMMUNE; IMPACT; TRIAL; TIME	Objective: Randomized controlled trials demonstrated that red blood cell (RBC) transfusion elevates the risk of infection, and trials are underway to evaluate whether RBC storage affects outcomes. We previously reported that transfusion predicts Clostridium difficile infection (CDI) and, therefore, planned an investigation to examine this further using a more robust design. Design: Within-person case-crossover study. Hospitalizations in which CDI developed (n = 406) were compared to hospitalizations for the same individuals in which CDI did not occur (n = 949). Transfusion volume and storage duration were assessed prior to the onset of CDI. Setting: University of Michigan Health System. Patients: Participants were individuals with a diagnosis of CDI from July 2009 through June 2012. Measurements and Main Results: During the hospitalizations when CDI occurred, 34.7% of the patients received allogeneic RBC transfusions (mean volume, 688 ml) compared to 19.0% of patients in hospitalizations without CDI (mean volume, 180 ml). The odds of healthcare-associated CDI increased by 76% (95% CI 1.39-2.23) for every liter of RBCs transfused and was elevated in both nonsurgical (OR = 1.90) and surgical (OR = 1.86) hospitalizations. In patients who received RBC transfusions, the odds of developing CDI increased by 6% for every additional day of RBC stored and by 53% for every week of additional storage (P = 0.002). Conclusions: Hospitalizations in which a patient received a greater volume of RBC transfusions were more likely to be associated with the development of CDI. RBC units stored for a longer duration were associated with the development of healthcare-associated CDI after adjustment for RBC volume.	[Rogers, Mary A. M.; Micic, Dejan; Young, Vincent B.; Aronoff, David M.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Blumberg, Neil] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA; [Young, Vincent B.; Aronoff, David M.] Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; [Aronoff, David M.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA	University of Michigan System; University of Michigan; University of Rochester; University of Michigan System; University of Michigan; Vanderbilt University	Rogers, MAM (corresponding author), Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.	maryroge@umich.edu	Young, Vincent B/B-3179-2009; Young, Vincent Bensan/M-9916-2019	Young, Vincent B/0000-0003-3687-2364; Young, Vincent Bensan/0000-0003-3687-2364; Rogers, Mary/0000-0001-5519-3223; Aronoff, David/0000-0003-4587-6121	National Institute of Allergy and Infectious Diseases [5U19AI090871-02]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI090871] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project was funded by a grant from the National Institute of Allergy and Infectious Diseases (grant number 5U19AI090871-02). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguilar I, 2011, ARCH INTERN MED, V171, P1385, DOI 10.1001/archinternmed.2011.231; Bennett-Guerrero E, 2007, P NATL ACAD SCI USA, V104, P17063, DOI 10.1073/pnas.0708160104; Bernard A, 2010, J TRAUMA, V69, P320, DOI 10.1097/TA.0b013e3181e401f0; BLUMBERG N, 1989, ARCH PATHOL LAB MED, V113, P246; Butler M, 2011, COMP EFFECTIVENESS R; Carson JL, 2012, ANN INTERN MED, V157, P49, DOI 10.7326/0003-4819-157-1-201206190-00429; Carson JL, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002042.pub3; Crabtree T, 2007, ANN THORAC SURG, V83, P1396, DOI 10.1016/j.athoracsur.2006.10.067; Dubberke E, 2012, J HOSP MED, V7, pS1, DOI 10.1002/jhm.1916; Fergusson DA, 2012, JAMA-J AM MED ASSOC, V308, P1443, DOI 10.1001/2012.jama.11953; Glynn SA, 2013, TRANSFUSION, V53, P438, DOI 10.1111/j.1537-2995.2012.03742.x; Hebert PC, 2005, ANESTH ANALG, V100, P1433, DOI 10.1213/01.ANE.0000148690.48803.27; Hess JR, 2010, TRANSFUS APHER SCI, V43, P51, DOI 10.1016/j.transci.2010.05.009; Hod EA, 2010, BLOOD, V115, P4284, DOI 10.1182/blood-2009-10-245001; Horvath KA, 2013, ANN THORAC SURG, V95, P2194, DOI 10.1016/j.athoracsur.2012.11.078; Hoyert DL, 2012, NATL VITAL STAT REPO, V2012, P6; Koch C, 2013, RED CELL STORAGE DUR; Kor DJ, 2012, AM J RESP CRIT CARE, V185, P842, DOI 10.1164/rccm.201107-1332OC; La Gamma EF, 2012, SEMIN PERINATOL, V36, P294, DOI 10.1053/j.semperi.2012.04.011; Lacroix J, 2011, TRANSFUS MED REV, V25, P197, DOI 10.1016/j.tmrv.2011.03.001; Lannan KL, 2013, BLOOD CELL MOL DIS, V50, P61, DOI 10.1016/j.bcmd.2012.08.009; Marik PE, 2008, CRIT CARE MED, V36, P2667, DOI 10.1097/CCM.0b013e3181844677; Muszynski J, 2012, TRANSFUSION, V52, P794, DOI 10.1111/j.1537-2995.2011.03348.x; Mynster T, 2001, TRANSFUS APHER SCI, V25, P17, DOI 10.1016/S1473-0502(01)00081-7; Rogers MAM, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-37; Sommer F, 2013, NAT REV MICROBIOL, V11, P227, DOI 10.1038/nrmicro2974; Spinella PC, 2011, TRANSFUSION, V51, P894, DOI 10.1111/j.1537-2995.2011.03103.x; Steiner ME, 2010, TRANSFUS APHER SCI, V43, P107, DOI 10.1016/j.transci.2010.05.014; US Department of Health and Human Services, 2009, NAT ACT PLAN PREV HE; Van Spall HGC, 2007, JAMA-J AM MED ASSOC, V297, P1233, DOI 10.1001/jama.297.11.1233; Walsh TS, 2004, CRIT CARE MED, V32, P364, DOI 10.1097/01.CCM.0000108878.23703.E0	31	7	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2014	9	2							e89332	10.1371/journal.pone.0089332	http://dx.doi.org/10.1371/journal.pone.0089332			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AB3VI	24586694	gold, Green Published, Green Submitted			2023-01-03	WOS:000331717900081
J	Wu, CY; Hu, HY; Huang, N; Fang, YT; Chou, YJ; Li, CP				Wu, Chen-Yi; Hu, Hsiao-Yun; Huang, Nicole; Fang, Yi-Ting; Chou, Yiing-Jeng; Li, Chung-Pin			Determinants of Long-Term Care Services among the Elderly: A Population-Based Study in Taiwan	PLOS ONE			English	Article							PHYSICAL-DISABILITY; RISK-FACTORS; HOME-CARE; PEOPLE; HEALTH; COMMUNITY; INSURANCE; TRENDS	Objectives: The aim of the study was to investigate determinants of long-term care use and to clarify the differing characteristics of home/community-based and institution-based services users. Design: Cross-sectional, population-based study. Setting: Utilizing data from the 2005 National Health Interview Survey conducted in Taiwan. Participants: A national sample of 2,608 people (1,312 men, 1,296 women) aged 65 and older. Measurements: The utilization of long-term care services (both home/community- and institution-based services) was measured. A chi(2) analysis tested differences in baseline characteristics between home/community-based and institution-based long-term care users. The multiple-logistic model was adopted with a hierarchical approach adding the Andersen model's predisposing, enabling, and need factors sequentially. Multiple logistic models further stratified data by gender and age. Results: Compared with users of home/community-based care, those using institution-based care had less education (p = 0.019), greater likelihood of being single (p = 0.001), fewer family members (p = 0.002), higher prevalence of stool incontinence (p = 0.011) and dementia (P =.025), and greater disability (p = 0.016). After adjustment, age (compared with 65-69 years; 75-79 years, odds ratio [OR] = 2.08, p = 0.044; age >= 80, OR = 3.30, p = 0.002), being single (OR = 2.16, p = 0.006), urban living (OR = 1.68, p = 0.037), stroke (OR = 2.08, p = 0.015), dementia (OR = 2.32, p = 0.007), 1-3 items of activities of daily living (ADL) disability (OR = 5.56, p<0.001), and 4-6 items of ADL disability (OR = 21.57, p<0.001) were significantly associated with long-term care use. Conclusion: Age, single marital status, stroke, dementia, and ADL disability are predictive factors for long-term care use. The utilization was directly proportional to the level of disability.	[Wu, Chen-Yi; Hu, Hsiao-Yun; Chou, Yiing-Jeng] Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan; [Wu, Chen-Yi] Taipei City Hosp, Dept Dermatol, Heping Fuyou Branch, Taipei, Taiwan; [Hu, Hsiao-Yun; Huang, Nicole] Taipei City Hosp, Dept Educ & Res, Taipei, Taiwan; [Huang, Nicole] Natl Yang Ming Univ, Inst Hosp & Hlth Care Adm, Taipei 112, Taiwan; [Fang, Yi-Ting] Natl Yang Ming Univ, Inst Hlth & Welf Policy, Taipei 112, Taiwan; [Fang, Yi-Ting] Universal Eye Ctr, Taoyuan Branch, Tao Yuan, Taiwan; [Li, Chung-Pin] Taipei Vet Gen Hosp, Div Gastroenterol, Dept Med, Taipei, Taiwan; [Li, Chung-Pin] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; Taipei City Hospital; Taipei City Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University	Chou, YJ (corresponding author), Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan.	yjchou@ym.edu.tw; cpli@vghtpe.gov.tw		Huang, Nicole/0000-0002-6629-1176	Taiwan Ministry of Education; Taiwan's National Science Council [98-2314-B-010-015-MY2]	Taiwan Ministry of Education(Ministry of Education, Taiwan); Taiwan's National Science Council	This study was supported by the Taiwan Ministry of Education through its "Aim for the Top University Plan,'' and by Taiwan's National Science Council through Grant 98-2314-B-010-015-MY2. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; Bonsang E, 2009, J HEALTH ECON, V28, P143, DOI 10.1016/j.jhealeco.2008.09.002; Chang HT, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-274; Cheng TM, 2003, HEALTH AFFAIR, V22, P61, DOI 10.1377/hlthaff.22.3.61; Cigolle CT, 2007, ANN INTERN MED, V147, P156, DOI 10.7326/0003-4819-147-3-200708070-00004; de Meijer C, 2011, J HEALTH ECON, V30, P425, DOI 10.1016/j.jhealeco.2010.12.010; de Meijer CAM, 2009, MED CARE, V47, P1156, DOI 10.1097/MLR.0b013e3181b69fa8; Freedman VA, 2002, JAMA-J AM MED ASSOC, V288, P3137, DOI 10.1001/jama.288.24.3137; Gaugler Joseph E, 2007, BMC Geriatr, V7, P13, DOI 10.1186/1471-2318-7-13; Honda A, 2013, GERIATR GERONTOL INT; Kashiwagi M, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-1; Kato Gohei, 2009, BMC Geriatr, V9, P58, DOI 10.1186/1471-2318-9-58; KATZ S, 1976, INT J HEALTH SERV, V6, P493, DOI 10.2190/UURL-2RYU-WRYD-EY3K; Katz SJ, 2000, JAMA-J AM MED ASSOC, V284, P3022, DOI 10.1001/jama.284.23.3022; Knol HR, 2003, DISABIL REHABIL, V25, P845, DOI 10.1080/0963828031000090542; Kosloski K, 1994, J Aging Health, V6, P17, DOI 10.1177/089826439400600102; Ku LJE, 2013, ARCH GERONTOL GERIAT, V56, P370, DOI 10.1016/j.archger.2012.11.005; Lafortune L, 2009, MED CARE, V47, P286, DOI 10.1097/MLR.0b013e3181894293; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; Li IC, 2011, ARCH GERONTOL GERIAT, V53, P303, DOI 10.1016/j.archger.2010.11.009; Luppa M, 2010, AGE AGEING, V39, P31, DOI 10.1093/ageing/afp202; Manton KG, 2008, ANNU REV PUBL HEALTH, V29, P91, DOI 10.1146/annurev.publhealth.29.020907.090812; Murtagh KN, 2004, AM J PUBLIC HEALTH, V94, P1406, DOI 10.2105/AJPH.94.8.1406; Olivares-Tirado P, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-103; Oman D, 1999, AM J EPIDEMIOL, V150, P834; Stuck AE, 1999, SOC SCI MED, V48, P445, DOI 10.1016/S0277-9536(98)00370-0; Tang Z, 1999, ARCH GERONTOL GERIAT, V29, P115, DOI 10.1016/S0167-4943(99)00026-6; Tsai ACH, 2011, ARCH GERONTOL GERIAT, V53, P298, DOI 10.1016/j.archger.2010.12.003; van Campen C, 2005, HEALTH SOC CARE COMM, V13, P287, DOI 10.1111/j.1365-2524.2005.00546.x; Weaver F, 2009, HEALTH ECON, V18, P867, DOI 10.1002/hec.1409	30	39	42	0	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2014	9	2							e89213	10.1371/journal.pone.0089213	http://dx.doi.org/10.1371/journal.pone.0089213			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AB3TA	24586602	gold, Green Published, Green Submitted			2023-01-03	WOS:000331711900108
J	Mao, Y; Fang, LQ; Ai, L; Li, CY; Wang, ZB; Wu, JR; Bai, J; Li, FQ				Mao, Ying; Fang, Liaoqiong; Ai, Liang; Li, Chongyan; Wang, Zhibiao; Wu, Junru; Bai, Jin; Li, Faqi			An In Vivo Study of the Effects on Serum Glucose, Amylase and Histopathology of the Feline Pancreatic Tissue Treated by Focused Ultrasound	PLOS ONE			English	Article							CANCER STATISTICS; GEMCITABINE; PRINCIPLES; RADIATION; ABLATION; THERAPY	Pancreatic cancer is one of the most malignant neoplasms originating in the digestive system. Focused ultrasound (FUS) treatment instead of the surgery operation has been used to treat Pancreatic cancer noninvasively in clinical trials. The endocrine and exocrine glands in pancreas provide the two unique functions for a person to be healthy. It is critically important to find out if the FUS treatment can still keep the normal functions of the two glands. The goal of this study is to examine and analyze changes in histopathology and serum glucose and amylase levels of the targeted in-vivo felines after the FUS treatment. Various percentage volumes of pancreas of felines were insonified. The FUS treatment (7.5 MHz of central frequency; 5 W of acoustical power; transducer f-number = 0.33; 6 s insonification time per point) effectively generated coagulative necrosis at the insonified site while leaving tissue outside the insonified site intact. It was also observed that all felines endured well with the FUS treatment; changes introduced to pancreatic tissue after up to 50% of a pancreas by volume was insonified by the FUS procedure did not affect its normal endocrine and exocrine functions.	[Mao, Ying; Fang, Liaoqiong; Ai, Liang; Wang, Zhibiao; Bai, Jin; Li, Faqi] Chongqing Med Univ, Coll Biomed Engn, State Key Lab Ultrasound Engn Med, Chongqing & Minist Sci & Technol, Chongqing, Peoples R China; [Li, Chongyan] Natl Engn Res Ctr Ultrasound Med, Chongqing, Peoples R China; [Wu, Junru] Univ Vermont, Dept Phys, Burlington, VT 05405 USA	Chongqing Medical University; University of Vermont	Bai, J (corresponding author), Chongqing Med Univ, Coll Biomed Engn, State Key Lab Ultrasound Engn Med, Chongqing & Minist Sci & Technol, Chongqing, Peoples R China.	sajinbai@haifu.com.cn; lifaqi70@163.com			National Basic Research Program 973 of China [2012CB722402, 2011CB707900]; National Natural Science Foundation of China [81127901, 30830040, 11274404, 30970827]; HAS fund of the University of Vermont	National Basic Research Program 973 of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); HAS fund of the University of Vermont	This work is supported in part by the National Basic Research Program 973 of China (Grant No. 2012CB722402 and Grant No. 2011CB707900) and funded by National Natural Science Foundation of China (Grant No. 81127901, 30830040, 11274404 and 30970827). JW has been supported partially by HAS fund of the University of Vermont. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Buchler M, 1987, ACUTE PANCREATITIS, P143; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; CLAVIEN PA, 1989, BRIT J SURG, V76, P1234, DOI 10.1002/bjs.1800761205; CRAMP DG, 1967, J CLIN PATHOL, V20, P910, DOI 10.1136/jcp.20.6.910; DIMAGNO EP, 1973, NEW ENGL J MED, V288, P813, DOI 10.1056/NEJM197304192881603; Hwang JH, 2009, ULTRASOUND MED BIOL, V35, P967, DOI 10.1016/j.ultrasmedbio.2008.12.006; Iovanne J, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00006; Johung K, 2012, INT J RADIAT ONCOL, V82, P508, DOI 10.1016/j.ijrobp.2011.08.008; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Nakakura E. K., 2007, SURG LIVER BILIARY T, P849; Orsi F, 2010, J CANCER RES THER, V6, P414, DOI 10.4103/0973-1482.77064; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; PIERRE KJ, 1976, CLIN CHEM, V22, P1219; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; STEINBERG WM, 1985, ANN INTERN MED, V102, P576, DOI 10.7326/0003-4819-102-5-576; Sung HY, 2011, PANCREAS, V40, P1080, DOI 10.1097/MPA.0b013e31821fde24; Ter Haar G, 2007, INT J HYPERTHER, V23, P89, DOI 10.1080/02656730601186138; Wilkowski R, 2005, J PANCREAS, V6, P216; Wu F, 2005, RADIOLOGY, V236, P1034, DOI 10.1148/radiol.2362041105; Wu J, 2008, ADV DRUG DELIVER REV, V60, P1103, DOI 10.1016/j.addr.2008.03.009; Xie BA, 2011, INT J MED SCI, V8, P9, DOI 10.7150/ijms.8.9; Xiong LL, 2009, J PANCREAS, V10, P123; Yeo CJ, 2005, CANC PRINCIPLES PRAC; [张樯 Zhang Qiang], 2011, [中国超声医学杂志, Chinese Journal of Ultrasonic in Medical], V27, P571; Zhao H, 2010, ANTI-CANCER DRUG, V21, P447, DOI 10.1097/CAD.0b013e32833641a7	25	2	3	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2014	9	2							e88815	10.1371/journal.pone.0088815	http://dx.doi.org/10.1371/journal.pone.0088815			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AB3RA	24558434	Green Published, Green Submitted, gold			2023-01-03	WOS:000331706700080
J	Rius, B; Titos, E; Moran-Salvador, E; Lopez-Vicario, C; Garcia-Alonso, V; Gonzalez-Periz, A; Arroyo, V; Claria, J				Rius, Bibiana; Titos, Esther; Moran-Salvador, Eva; Lopez-Vicario, Cristina; Garcia-Alonso, Veronica; Gonzalez-Periz, Ana; Arroyo, Vicente; Claria, Joan			Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis	FASEB JOURNAL			English	Article						inflammation; anti-inflammatory mediators; macrophages; NAFLD; weight loss	FATTY LIVER-DISEASE; LIPID MEDIATORS; WEIGHT-LOSS; METABOLIC SYNDROME; INFLAMMATION; OMEGA-3-FATTY-ACIDS; MECHANISMS; MICRORNAS; THERAPY; PROMOTE	Insulin resistance and nonalcoholic steatohepatitis (NASH), characterized by hepatic steatosis combined with inflammation, are major sequelae of obesity. Currently, lifestyle modification (i.e., weight loss) is the first-line therapy for NASH. However, weight loss resolves steatosis but not inflammation. In this study, we tested the ability of resolvin D1 (RvD1), an anti-inflammatory and proresolving molecule, to promote the resolution initiated by calorie restriction in obese mice with NASH. Calorie restriction reduced adipose and liver weight (-56 and -13%, respectively; P<0.001), serum leptin and resistin levels, hepatic steatosis, and insulin resistance. In addition to these, mice receiving RvD1 during the dietary intervention showed increased adiponectin expression at both the mRNA and protein levels and reduced liver macrophage infiltration (-15%, P<0.01). Moreover, RvD1 skewed macrophages from an M1- to an M2-like anti-inflammatory phenotype, induced a specific hepatic miRNA signature (i.e., miR-219-5p and miR-199a-5p), and reduced inflammatory adipokine mRNA and protein expression and macrophage innate immune response. In precision-cut liver slices (PCLSs), which override the influence of circulating factors, RvD1 attenuated hypoxia-induced mRNA and protein expression of COX-2, IL-1, IL-6, and CCR7. Of note, RvD1 anti-inflammatory actions were absent in macrophage-depleted PCLSs. In summary, RvD1 acts as a facilitator of the hepatic resolution process by reducing the inflammatory component of obesity-induced NASH.Rius, B., Titos, E., Moran-Salvador, E., Lopez-Vicario, C., Garcia-Alonso, V., Gonzalez-Periz, A., Arroyo, V., Claria, J. Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis.	[Rius, Bibiana; Titos, Esther; Moran-Salvador, Eva; Lopez-Vicario, Cristina; Garcia-Alonso, Veronica; Gonzalez-Periz, Ana; Claria, Joan] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Esther Koplowitz Ctr, Dept Biochem & Mol Genet, E-08036 Barcelona, Spain; [Arroyo, Vicente] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Esther Koplowitz Ctr, Liver Unit, Barcelona 08036, Spain; [Titos, Esther; Gonzalez-Periz, Ana; Arroyo, Vicente; Claria, Joan] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain; [Claria, Joan] Univ Barcelona, Dept Physiol Sci 1, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Barcelona	Claria, J (corresponding author), Hosp Clin Barcelona, Dept Biochem & Mol Genet, Villarroel 170, E-08036 Barcelona, Spain.	jclaria@clinic.ub.es	Arroyo, Vicente/F-9189-2015; Titos, Esther/AAA-5394-2019; Claria, Joan/M-7772-2019	Arroyo, Vicente/0000-0002-2728-1848; Titos, Esther/0000-0002-2543-2243; Lopez-Vicario, Cristina/0000-0002-6609-8501; Claria, Joan/0000-0003-4333-7749	Ministerio de Economia y Competitividad [SAF 12/32789]; Instituto de Salud Carlos III; Ministerio de Ciencia e Innovacion (MICINN) [AP2007-02004, BES-2010-034193]; CIBERehd; IDIBAPS	Ministerio de Economia y Competitividad(Spanish Government); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Ministerio de Ciencia e Innovacion (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); CIBERehd; IDIBAPS	The authors thank the Bioinformatics Unit of the Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS) for technical help. This work was supported by Ministerio de Economia y Competitividad (SAF 12/32789). Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd) is funded by the Instituto de Salud Carlos III. The authors' laboratory is a Consolidated Research Group recognized by the Generalitat de Catalunya (2009SGR1484). This study was conducted at the Esther Koplowitz Center (Barcelona, Spain) and was supported by Ministerio de Ciencia e Innovacion (MICINN) grants AP2007-02004 (to E. M-S.) and BES-2010-034193 (to V. G.-A). E. T. and A. G.-P. had contracts with CIBERehd. C. L.-V. was supported by IDIBAPS.	Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80; Aron-Wisnewsky J, 2012, J HEPATOL, V56, P225, DOI 10.1016/j.jhep.2011.04.022; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Capristo E, 2005, Eur Rev Med Pharmacol Sci, V9, P265; Claria J, 2013, AM J PHYSIOL-CELL PH, V304, pC1141, DOI 10.1152/ajpcell.00351.2012; Claria J, 2012, J IMMUNOL, V189, P2597, DOI 10.4049/jimmunol.1201272; Fredman G, 2012, SCI REP-UK, V2, DOI 10.1038/srep00639; Gonsalves CS, 2010, J IMMUNOL, V184, P3878, DOI 10.4049/jimmunol.0902594; Gonzalez-Periz A, 2006, FASEB J, V20, P2537, DOI 10.1096/fj.06-6250fje; Gonzalez-Periz A, 2009, FASEB J, V23, P1946, DOI 10.1096/fj.08-125674; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Harrison SA, 2007, GUT, V56, P1760, DOI 10.1136/gut.2006.112094; Hellmann J, 2011, FASEB J, V25, P2399, DOI 10.1096/fj.10-178657; Huang MA, 2005, AM J GASTROENTEROL, V100, P1072, DOI 10.1111/j.1572-0241.2005.41334.x; Hudert CA, 2006, P NATL ACAD SCI USA, V103, P11276, DOI 10.1073/pnas.0601280103; Jou J, 2008, SEMIN LIVER DIS, V28, P370, DOI 10.1055/s-0028-1091981; Klassen LW, 2008, BIOCHEM PHARMACOL, V76, P426, DOI 10.1016/j.bcp.2008.05.012; Kosteli A, 2010, J CLIN INVEST, V120, P3466, DOI 10.1172/JCI42845; Li PP, 2010, J BIOL CHEM, V285, P15333, DOI 10.1074/jbc.M110.100263; Lopez-Vicario C., 2013, GUT, DOI 10.1136/gutjnl-2012-303179; Mantovani A, 2010, CURR MOL MED, V10, P369, DOI 10.2174/156652410791316968; Masterton GS, 2010, ALIMENT PHARM THER, V31, P679, DOI 10.1111/j.1365-2036.2010.04230.x; Parker HM, 2012, J HEPATOL, V56, P944, DOI 10.1016/j.jhep.2011.08.018; Promrat K, 2010, HEPATOLOGY, V51, P121, DOI 10.1002/hep.23276; Recchiuti A, 2011, FASEB J, V25, P544, DOI 10.1096/fj.10-169599; Rius B, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00257; Roderburg C, 2011, HEPATOLOGY, V53, P209, DOI 10.1002/hep.23922; Sackmann-Sala L, 2012, OBESITY, V20, P101, DOI 10.1038/oby.2011.235; Sanyal AJ, 2005, NAT CLIN PRACT GASTR, V2, P46, DOI 10.1038/ncpgasthep0084; Schnitger AKD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027435; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2010, AM J PATHOL, V177, P1576, DOI 10.2353/ajpath.2010.100322; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Sun YP, 2007, J BIOL CHEM, V282, P9323, DOI 10.1074/jbc.M609212200; Szabo G, 2012, J HEPATOL, V57, P462, DOI 10.1016/j.jhep.2012.01.030; Tilg H, 2006, GASTROENTEROLOGY, V131, P934, DOI 10.1053/j.gastro.2006.05.054; Tilg H, 2010, HEPATOLOGY, V52, P1836, DOI 10.1002/hep.24001; Titos E, 2011, J IMMUNOL, V187, P5408, DOI 10.4049/jimmunol.1100225; Torres DM, 2008, GASTROENTEROLOGY, V134, P1682, DOI 10.1053/j.gastro.2008.02.077; Xydakis AM, 2004, J CLIN ENDOCR METAB, V89, P2697, DOI 10.1210/jc.2003-031826; Zelber-Sagi S, 2012, J HEPATOL, V56, P1145, DOI 10.1016/j.jhep.2011.12.011; Zivkovic AM, 2007, AM J CLIN NUTR, V86, P285, DOI 10.1093/ajcn/86.2.285	42	69	71	0	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2014	28	2					836	848		10.1096/fj.13-235614	http://dx.doi.org/10.1096/fj.13-235614			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AA4NG	24249635				2023-01-03	WOS:000331072200029
J	Gelir, E; Budak, MT; Ardic, S				Gelir, Ethem; Budak, Murat Timur; Ardic, Sadik			The Relationship between CPAP Usage and Corneal Thickness	PLOS ONE			English	Article							OBSTRUCTIVE SLEEP-APNEA; REM-SLEEP; HEALTHY-SUBJECTS; HYPOXIA; DENSITY; WEAR	The purpose of this study was to determine whether there is a correlation between CPAP usage and corneal thickness in patients with sleep disordered breathing. Full-night polysomnography (PSG) recordings were collected. Ten patients had undergone PSG recordings with continuous positive airway pressure (CPAP), and seven patients had undergone PSG recordings without CPAP. We measured corneal thickness by ultrasonic pachymeter before sleep and ten minutes after waking. We also measured visual acuity with a routine ophthalmologic eye chart before and after sleep. We asked patients to fill out a post-sleep questionnaire to get their subjective opinions. In the without-CPAP group, corneal thickness increased significantly during sleep in both eyes (left, p = 0.0025; right, p<0.0001). In the with-CPAP group, corneal thickness did not increase significantly (p>0.05 for both left and right cornea). There was no significant difference in visual acuity tests (p>0.05 for both left and right eye) between the two groups. According to our results, there is a significant increase in corneal thickness in the without-CPAP group. Our data show that a low percentage of Rapid Eye Movement (REM) sleep may cause an increase in corneal thickness, which can indicate poor corneal oxygenation. In fact, many sleep-disordered breathing (SDB) patients have low REM. Since a contact lens may cause low corneal oxygenation, SDB patients with contact lenses should be monitored carefully for their corneal thickness.	[Gelir, Ethem; Budak, Murat Timur] Hacettepe Univ, Sch Med, Dept Physiol, Ankara, Turkey; [Ardic, Sadik] SGK Ankara Educ Hosp, Sleep Lab, Dept Pulm Med, Ankara, Turkey	Hacettepe University; Ankara Training & Research Hospital	Gelir, E (corresponding author), Hacettepe Univ, Sch Med, Dept Physiol, Ankara, Turkey.	egelir@hacettepe.edu.tr						Aloia M S, 2001, Sleep Breath, V5, P13, DOI 10.1007/s11325-001-0013-9; ANTONIOLI M, 1981, SLEEP, V4, P221, DOI 10.1093/sleep/4.2.221; BONNET M, 1993, SLEEP, V16, P748; Bornstein SK., 1982, SLEEPING WAKING DISO, P183; Buchanan P, 2011, PRINCIPLES PRACTICE, V5th, P1233; Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477; Congdon NG, 2006, AM J OPHTHALMOL, V141, P868, DOI 10.1016/j.ajo.2005.12.007; du Toit R, 2003, CORNEA, V22, P205, DOI 10.1097/00003226-200304000-00004; Faulkner W, 1997, CORNEA FUNDAMENTALS, P279; Feige B, 2002, NEUROPSYCHOPHARMACOL, V26, P246, DOI 10.1016/S0893-133X(01)00314-1; Feng PF, 2001, SLEEP, V24, P645, DOI 10.1093/sleep/24.6.645; Ferini-Strambi L, 2003, BRAIN RES BULL, V61, P87, DOI 10.1016/S0361-9230(03)00068-6; Ferini-Strambi L, 2013, INT J PSYCHOPHYSIOL; FISHER C, 1965, ARCH GEN PSYCHIAT, V12, P29; HAJAK G, 1994, SLEEP, V17, P11, DOI 10.1093/sleep/17.1.11; HEDBYS BO, 1966, EXP EYE RES, V5, P221, DOI 10.1016/S0014-4835(66)80010-6; Heller H, 1988, CLIN PHYSL SLEEP, P145; HOHAGEN F, 1993, NEUROPSYCHOPHARMACOL, V9, P225, DOI 10.1038/npp.1993.58; HOLDEN BA, 1985, INVEST OPHTH VIS SCI, V26, P1489; Horner RL, 1998, SLEEP, V21, P847; Jalbert I, 2009, EYE, V23, P1282, DOI 10.1038/eye.2008.307; JOHNSON MH, 1985, AM J OPTOM PHYS OPT, V62, P768; Karacan I, 1965, THESIS NEW YORK U BR; KING D, 1981, PSYCHIAT RES, V5, P267, DOI 10.1016/0165-1781(81)90073-1; Kleitman N., 1963, SLEEP WAKEFULNESS; KLYCE SD, 1981, J PHYSIOL-LONDON, V321, P49, DOI 10.1113/jphysiol.1981.sp013971; Kohlhaas M, 2006, ARCH OPHTHALMOL-CHIC, V124, P471, DOI 10.1001/archopht.124.4.471; Kryger MH, 2011, PRINCIPLES PRACTICE, P431, DOI [DOI 10.1016/13978-1-4160-6645-3.00037-2, DOI 10.1016/B978-1-4160-6645-3.00037-2]; Maurice DM, 1998, EXP EYE RES, V66, P139, DOI 10.1006/exer.1997.0444; Moezzi AM, 2011, EYE CONTACT LENS, V37, P61, DOI 10.1097/ICL.0b013e31820e0bc3; Moghimi S, 2013, SLEEP MED, V14, P53, DOI 10.1016/j.sleep.2012.07.004; PESSAH MA, 1972, SCIENCE, V178, P773, DOI 10.1126/science.178.4062.773; POLSE KA, 1970, ARCH OPHTHALMOL-CHIC, V84, P505; Rechtschaffen A., 1968, MANUAL STANDARDIZED; SALZ JJ, 1983, OPHTHALMIC SURG LAS, V14, P750; Tai LY, 2013, CORNEA, V32, P766, DOI 10.1097/ICO.0b013e318269938d; Wellman A, 2011, PRINCIPLES PRACTICE, P1140	37	4	4	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2014	9	1							e87274	10.1371/journal.pone.0087274	http://dx.doi.org/10.1371/journal.pone.0087274			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298QQ	24475261	Green Published, Green Submitted, gold			2023-01-03	WOS:000330339800092
J	McIntyre, CW; Burton, JO				McIntyre, Christopher W.; Burton, James O.			ABC of Kidney Disease, 2nd Edition Dialysis	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HEMODIALYSIS		[McIntyre, Christopher W.] Derby City Hosp, Dept Renal Med, Derby, England; [Burton, James O.] Univ Leicester, Sch Med & Biol Sci, Dept Infect Immun & Inflammat, Leicester, Leics, England	University of Nottingham; University of Leicester	McIntyre, CW (corresponding author), Derby City Hosp, Dept Renal Med, Derby, England.		Burton, James O/AAQ-7361-2021	Burton, James O/0000-0003-1176-7592				Bender FH, 2006, KIDNEY INT, V70, pS44, DOI 10.1038/sj.ki.5001915; Greneche Sylvie, 2005, Nephrol Ther, V1, P213, DOI 10.1016/j.nephro.2005.01.009; Hayashi R, 2006, NAT CLIN PRACT NEPHR, V2, P504, DOI 10.1038/ncpneph0239; Light P, 2006, CURR HYPERTENS REP, V8, P413, DOI 10.1007/s11906-006-0088-6; RABINDRANATH KS, 2006, COCHRANE DB SYST REV, V18	5	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 23	2014	348								g2	10.1136/bmj.g2	http://dx.doi.org/10.1136/bmj.g2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298BE	24384463				2023-01-03	WOS:000330298100007
J	Zilverstand, A; Sorger, B; Zimmermann, J; Kaas, A; Goebel, R				Zilverstand, Anna; Sorger, Bettina; Zimmermann, Jan; Kaas, Amanda; Goebel, Rainer			Windowed Correlation: A Suitable Tool for Providing Dynamic fMRI-Based Functional Connectivity Neurofeedback on Task Difficulty	PLOS ONE			English	Article							REAL-TIME FMRI; MOOD-REGULATING CIRCUIT; RESTING-STATE; PHYSIOLOGICAL NOISE; BRAIN ACTIVATION; MOTOR CORTEX; NETWORK; MODULATION; DEMAND; FUTURE	The goal of neurofeedback training is to provide participants with relevant information on their ongoing brain processes in order to enable them to change these processes in a meaningful way. Under the assumption of an intrinsic brain-behavior link, neurofeedback can be a tool to guide a participant towards a desired behavioral state, such as a healthier state in the case of patients. Current research in clinical neuroscience regarding the most robust indicators of pathological brain processes in psychiatric and neurological disorders indicates that fMRI-based functional connectivity measures may be among the most important biomarkers of disease. The present study therefore investigated the general potential of providing fMRI neurofeedback based on functional correlations, computed from short-window time course data at the level of single task periods. The ability to detect subtle changes in task performance with block-wise functional connectivity measures was evaluated based on imaging data from healthy participants performing a simple motor task, which was systematically varied along two task dimensions representing two different aspects of task difficulty. The results demonstrate that fMRI-based functional connectivity measures may provide a better indicator for an increase in overall ( motor) task difficulty than activation level-based measures. Windowed functional correlations thus seem to provide relevant and unique information regarding ongoing brain processes, which is not captured equally well by standard activation level-based neurofeedback measures. Functional connectivity markers, therefore, may indeed provide a valuable tool to enhance and monitor learning within an fMRI neurofeedback setup.	[Zilverstand, Anna; Sorger, Bettina; Zimmermann, Jan; Kaas, Amanda; Goebel, Rainer] Maastricht Univ, Fac Psychol & Neurosci, Dept Cognit Neurosci, Maastricht, Netherlands; [Goebel, Rainer] Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, Dept Neuroimaging & Neuromodeling, Amsterdam, Netherlands	Maastricht University; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Zilverstand, A (corresponding author), Maastricht Univ, Fac Psychol & Neurosci, Dept Cognit Neurosci, Maastricht, Netherlands.	anna.zilverstand@maastrichtuniversity.nl	Zilverstand, Anna/AFR-0554-2022	Zilverstand, Anna/0000-0002-4889-9700; Goebel, Rainer/0000-0003-1780-2467; Kaas, Amanda/0000-0002-2847-8167; Sorger, Bettina/0000-0003-1393-3144; Zimmermann, Jan/0000-0003-3345-6074	Netherlands Ministry of Economic Affairs; Netherlands Ministry of Education, Culture and Science [SSM06011]	Netherlands Ministry of Economic Affairs(Ministry of Economic Affairs, Netherlands); Netherlands Ministry of Education, Culture and Science	The authors gratefully acknowledge the support of the BrainGain Smart Mix Programme of The Netherlands Ministry of Economic Affairs and The Netherlands Ministry of Education, Culture and Science (grant number: SSM06011). http://www.government.nl/ministries/ocw. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anand A, 2005, NEUROPSYCHOPHARMACOL, V30, P1334, DOI 10.1038/sj.npp.1300725; Anand A, 2007, J NEUROPSYCH CLIN N, V19, P274, DOI 10.1176/appi.neuropsych.19.3.274; Birn RM, 2012, NEUROIMAGE, V62, P864, DOI 10.1016/j.neuroimage.2012.01.016; Birn RM, 2009, NEUROIMAGE, V47, P1092, DOI 10.1016/j.neuroimage.2009.05.030; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Bullmore ET, 2012, NEUROIMAGE, V62, P1267, DOI 10.1016/j.neuroimage.2012.01.026; Coynel D, 2010, NEUROIMAGE, V49, P759, DOI 10.1016/j.neuroimage.2009.08.048; deCharms RC, 2005, P NATL ACAD SCI USA, V102, P18626, DOI 10.1073/pnas.0505210102; Engstrom M, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00140; Esposito F, 2003, NEUROIMAGE, V20, P2209, DOI 10.1016/j.neuroimage.2003.08.012; Fall S, 2008, BIOL CYBERN, V98, P101, DOI 10.1007/s00422-007-0198-5; Feinberg DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015710; Friston KJ, 2011, BRAIN CONNECT, V1, P13, DOI 10.1089/brain.2011.0008; Fu CHY, 2006, NEUROIMAGE, V30, P266, DOI 10.1016/j.neuroimage.2005.09.035; Goebel R., 2010, IMAGING MED, V2, P407; Grefkes C, 2008, NEUROIMAGE, V41, P1382, DOI 10.1016/j.neuroimage.2008.03.048; Guo CC, 2012, NEUROIMAGE, V61, P1471, DOI 10.1016/j.neuroimage.2012.03.027; Haller S, 2010, EUR RADIOL, V20, P696, DOI 10.1007/s00330-009-1595-z; Hampson M, 2004, NEUROREPORT, V15, P1315, DOI 10.1097/01.wnr.0000129997.95055.15; Hutton C, 2011, NEUROIMAGE, V57, P101, DOI 10.1016/j.neuroimage.2011.04.018; Jiang TZ, 2004, HUM BRAIN MAPP, V22, P63, DOI 10.1002/hbm.20012; Jo HJ, 2010, NEUROIMAGE, V52, P571, DOI 10.1016/j.neuroimage.2010.04.246; Joel SE, 2011, MAGN RESON MED, V66, P644, DOI 10.1002/mrm.22818; Kim MJ, 2011, BEHAV BRAIN RES, V223, P403, DOI 10.1016/j.bbr.2011.04.025; Konrad K, 2010, HUM BRAIN MAPP, V31, P904, DOI 10.1002/hbm.21058; Koush Y, 2013, NEUROIMAGE, V81, P422, DOI 10.1016/j.neuroimage.2013.05.010; Koush Y, 2012, NEUROIMAGE, V59, P478, DOI 10.1016/j.neuroimage.2011.07.076; LaConte SM, 2011, NEUROIMAGE, V56, P440, DOI 10.1016/j.neuroimage.2010.06.052; Leech R, 2011, J NEUROSCI, V31, P3217, DOI 10.1523/JNEUROSCI.5626-10.2011; Linden DEJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038115; Ma LS, 2011, NEUROIMAGE, V58, P226, DOI 10.1016/j.neuroimage.2011.06.014; Minshew NJ, 2010, CURR OPIN NEUROL, V23, P124, DOI 10.1097/WCO.0b013e32833782d4; Nagel IE, 2011, J COGNITIVE NEUROSCI, V23, P2030, DOI 10.1162/jocn.2010.21560; Newton AT, 2007, HUM BRAIN MAPP, V28, P663, DOI 10.1002/hbm.20294; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pizzagalli DA, 2011, NEUROPSYCHOPHARMACOL, V36, P183, DOI 10.1038/npp.2010.166; Posse S, 2001, HUM BRAIN MAPP, V12, P25, DOI 10.1002/1097-0193(200101)12:1<25::AID-HBM30>3.0.CO;2-H; Posse S, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00479; Poston KL, 2012, NEUROIMAGE, V62, P2261, DOI 10.1016/j.neuroimage.2011.12.021; Rao SM, 1996, J CEREBR BLOOD F MET, V16, P1250, DOI 10.1097/00004647-199611000-00020; Riecker A, 2003, NEUROIMAGE, V18, P731, DOI 10.1016/S1053-8119(03)00003-X; Rogers BP, 2007, MAGN RESON IMAGING, V25, P1347, DOI 10.1016/j.mri.2007.03.007; Rogers BP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003708; Rubia K, 2009, NEUROPHARMACOLOGY, V57, P640, DOI 10.1016/j.neuropharm.2009.08.013; Ruiz Sergio, 2013, Front Psychiatry, V4, P17, DOI 10.3389/fpsyt.2013.00017; Sitaram Ranganatha, 2007, Comput Intell Neurosci, P25487, DOI 10.1155/2007/25487; Smith SM, 2012, NEUROIMAGE, V62, P1257, DOI 10.1016/j.neuroimage.2012.01.022; Smith SM, 2011, NEUROIMAGE, V54, P875, DOI 10.1016/j.neuroimage.2010.08.063; Sorger B, 2012, CURR BIOL, V22, P1333, DOI 10.1016/j.cub.2012.05.022; Stephan KE, 2006, BIOL PSYCHIAT, V59, P929, DOI 10.1016/j.biopsych.2005.10.005; Subramanian L, 2011, J NEUROSCI, V31, P16309, DOI 10.1523/JNEUROSCI.3498-11.2011; Sulzer J, 2013, NEUROIMAGE, V76, P386, DOI 10.1016/j.neuroimage.2013.03.033; Sun FT, 2007, CEREB CORTEX, V17, P1227, DOI 10.1093/cercor/bhl033; Sun FT, 2004, NEUROIMAGE, V21, P647, DOI 10.1016/j.neuroimage.2003.09.056; Swinnen SP, 2004, TRENDS COGN SCI, V8, P18, DOI 10.1016/j.tics.2003.10.017; Talairach G, 1988, COPLANAR STEREOTAXIC; Weiskopf N, 2004, J PHYSIOL-PARIS, V98, P357, DOI 10.1016/j.jphysparis.2005.09.019; Weiskopf N., 2011, NEUROIMAGE; Weissenbacher A, 2009, NEUROIMAGE, V47, P1408, DOI 10.1016/j.neuroimage.2009.05.005; Witt ST, 2008, NEUROIMAGE, V42, P343, DOI 10.1016/j.neuroimage.2008.04.025; Yoo K, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00049; Zaitsev M, 2006, NEUROIMAGE, V31, P1038, DOI 10.1016/j.neuroimage.2006.01.039	62	38	38	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2014	9	1							e85929	10.1371/journal.pone.0085929	http://dx.doi.org/10.1371/journal.pone.0085929			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297FH	24465794	gold, Green Published			2023-01-03	WOS:000330240500090
J	Rose, S; Prevoteau, A; Elziere, P; Hourdet, D; Marcellan, A; Leibler, L				Rose, Severine; Prevoteau, Alexandre; Elziere, Paul; Hourdet, Dominique; Marcellan, Alba; Leibler, Ludwik			Nanoparticle solutions as adhesives for gels and biological tissues	NATURE			English	Article							POLY(ETHYLENE GLYCOL); HYDROGELS; ADSORPTION; COMPLEXITY; CHEMISTRY; POLYMERS; LAYERS	Adhesives are made of polymers(1) because, unlike other materials, polymers ensure good contact between surfaces by covering asperities, and retard the fracture of adhesive joints by dissipating energy under stress(2,3). But using polymers to 'glue' together polymer gels is difficult, requiring chemical reactions, heating, pH changes, ultraviolet irradiation or an electric field(4-7). Here we show that strong, rapid adhesion between two hydrogels can be achieved at room temperature by spreading a droplet of a nanoparticle solution on one gel's surface and then bringing the other gel into contact with it. The method relies on the nanoparticles' ability to adsorb onto polymer gels and to act as connectors between polymer chains, and on the ability of polymer chains to reorganize and dissipate energy under stress when adsorbed onto nanoparticles. We demonstrate this approach by pressing together pieces of hydrogels, for approximately 30 seconds, that have the same or different chemical properties or rigidities, using various solutions of silica nanoparticles, to achieve a strong bond. Furthermore, we show that carbon nanotubes and cellulose nanocrystals that do not bond hydrogels together become adhesive when their surface chemistry is modified. To illustrate the promise of the method for biological tissues, we also glued together two cut pieces of calf's liver using a solution of silica nanoparticles. As a rapid, simple and efficient way to assemble gels or tissues, this method is desirable for many emerging technological and medical applications such as microfluidics, actuation, tissue engineering and surgery.	[Rose, Severine; Elziere, Paul; Hourdet, Dominique; Marcellan, Alba] Univ Paris 06, Ecole Super Phys & Chim Ind, CNRS, Physicochim Polymeres & Milieux Disperses UMR7615, F-75005 Paris, France; [Prevoteau, Alexandre; Marcellan, Alba; Leibler, Ludwik] Ecole Super Phys & Chim Ind Ville Paris, CNRS, Matiere Molle & Chim UMR 7167, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Leibler, L (corresponding author), Ecole Super Phys & Chim Ind Ville Paris, CNRS, Matiere Molle & Chim UMR 7167, 10 Rue Vauquelin, F-75005 Paris, France.	alba.marcellan@espci.fr; ludwik.leibler@espci.fr			ED397, UPMC, Paris France; CNRS; ESPCI; UPMC	ED397, UPMC, Paris France; CNRS(Centre National de la Recherche Scientifique (CNRS)); ESPCI; UPMC	We thank D. Montero and L. Olanier for technical assistance with electron microscopy and tensile test equipment, respectively. We also thank L. Alison and L. Negre for help with experiments and A. Legrand for synthesis of silica AL-30 particles. We thank A. Johner for discussions on adsorption and M. Cloitre, J. Lewiner, A. Maggs, R. Nicolay and F. Tournilhac for encouragements and discussions. S.R. and A.P. acknowledge PhD fellowship funding from ED397, UPMC, Paris France. The financial support of the CNRS, the ESPCI and the UPMC is acknowledged.	Bondeson D, 2006, CELLULOSE, V13, P171, DOI 10.1007/s10570-006-9061-4; Carlsson L, 2010, SOFT MATTER, V6, P3619, DOI 10.1039/c0sm00009d; Cordier P, 2008, NATURE, V451, P977, DOI 10.1038/nature06669; deGennes PG, 1996, LANGMUIR, V12, P4497, DOI 10.1021/la950886y; Duarte AP, 2012, PROG POLYM SCI, V37, P1031, DOI 10.1016/j.progpolymsci.2011.12.003; Gaharwar AK, 2011, ACTA BIOMATER, V7, P4139, DOI 10.1016/j.actbio.2011.07.023; Gent AN, 2003, J ADHESION, V79, P905, DOI 10.1080/714906144; Gong JP, 2006, SOFT MATTER, V2, P544, DOI 10.1039/b603209p; Greensmith H.W., 1963, J APPL POLYM SCI, V7, P993, DOI [10.1002/app.1963.070070316, DOI 10.1002/APP.1963.070070316]; GRIOT O, 1965, T FARADAY SOC, V61, P1026, DOI 10.1039/tf9656101026; Harada A, 2011, NAT CHEM, V3, P34, DOI [10.1038/nchem.893, 10.1038/NCHEM.893]; Haraguchi K, 2011, MACROMOL RAPID COMM, V32, P1253, DOI 10.1002/marc.201100248; Hourdet D, 2010, MACROMOL SYMP, V291-292, P144, DOI 10.1002/masy.201050518; JOHNER A, 1992, J CHEM PHYS, V96, P6257, DOI 10.1063/1.462617; KENDALL K, 1975, J ADHESION, V7, P137, DOI 10.1080/00218467508075045; Kendall K., 2001, MOLECULAR ADHESION A; LAKE GJ, 1967, PROC R SOC LON SER-A, V300, P108, DOI 10.1098/rspa.1967.0160; Montarnal D, 2011, SCIENCE, V334, P965, DOI 10.1126/science.1212648; Nah C, 2012, POLYM TEST, V31, P248, DOI 10.1016/j.polymertesting.2011.11.007; Netz RR, 2003, PHYS REP, V380, P1, DOI 10.1016/S0370-1573(03)00118-2; Nicolay R, 2010, MACROMOLECULES, V43, P4355, DOI 10.1021/ma100378r; Prevoteau A, 2012, J AM CHEM SOC, V134, P19961, DOI 10.1021/ja309029n; Reutenauer P, 2009, CHEM-EUR J, V15, P1893, DOI 10.1002/chem.200802145; Sahlin JJ, 1997, J BIOMAT SCI-POLYM E, V8, P421, DOI 10.1163/156856297X00362; Saito J, 2011, POLYM CHEM-UK, V2, P575, DOI 10.1039/c0py00272k; Santore MM, 2005, CURR OPIN COLLOID IN, V10, P176, DOI 10.1016/j.cocis.2005.05.005; STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021-9797(68)90272-5; Tamagawa H, 2008, MATER CHEM PHYS, V107, P164, DOI 10.1016/j.matchemphys.2007.06.063; Techawanitchai P, 2012, SOFT MATTER, V8, P2844, DOI 10.1039/c2sm07277g; Wang Q, 2010, NATURE, V463, P339, DOI 10.1038/nature08693	30	532	550	67	1534	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 16	2014	505	7483					382	+		10.1038/nature12806	http://dx.doi.org/10.1038/nature12806			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288OR	24336207				2023-01-03	WOS:000329621800038
J	Hernandez-Bule, ML; Trillo, MA; Ubeda, A				Luisa Hernandez-Bule, Maria; Angeles Trillo, Maria; Ubeda, Alejandro			Molecular Mechanisms Underlying Antiproliferative and Differentiating Responses of Hepatocarcinoma Cells to Subthermal Electric Stimulation	PLOS ONE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; RADIOFREQUENCY-OUTPUT POWER; PLUS REGIONAL HYPERTHERMIA; HUMAN NEUROBLASTOMA-CELLS; HEPATOCYTE GROWTH-FACTOR; HZ MAGNETIC-FIELD; C-MET; ELECTROMAGNETIC-FIELDS; LUNG-CANCER; P53	Capacitive Resistive Electric Transfer (CRET) therapy applies currents of 0.4-0.6 MHz to treatment of inflammatory and musculoskeletal injuries. Previous studies have shown that intermittent exposure to CRET currents at subthermal doses exert cytotoxic or antiproliferative effects in human neuroblastoma or hepatocarcinoma cells, respectively. It has been proposed that such effects would be mediated by cell cycle arrest and by changes in the expression of cyclins and cyclin-dependent kinase inhibitors. The present work focuses on the study of the molecular mechanisms involved in CRET-induced cytostasis and investigates the possibility that the cellular response to the treatment extends to other phenomena, including induction of apoptosis and/or of changes in the differentiation stage of hepatocarcinoma cells. The obtained results show that the reported antiproliferative action of intermittent stimulation (5 m On/4 h Off) with 0.57 MHz, sine wave signal at a current density of 50 mu A/mm(2), could be mediated by significant increase of the apoptotic rate as well as significant changes in the expression of proteins p53 and Bcl-2. The results also revealed a significantly decreased expression of alpha-fetoprotein in the treated samples, which, together with an increased concentration of albumin released into the medium by the stimulated cells, can be interpreted as evidence of a transient cytodifferentiating response elicited by the current. The fact that this type of electrical stimulation is capable of promoting both, differentiation and cell cycle arrest in human cancer cells, is of potential interest for a possible extension of the applications of CRET therapy towards the field of oncology.	[Luisa Hernandez-Bule, Maria; Angeles Trillo, Maria; Ubeda, Alejandro] Ramon y Cajal Univ Hosp, Ramon y Cajal Inst Med Res, Bioelectromagnet Serv, Madrid, Spain		Hernandez-Bule, ML (corresponding author), Ramon y Cajal Univ Hosp, Ramon y Cajal Inst Med Res, Bioelectromagnet Serv, Madrid, Spain.	mluisa.hernandez@hrc.es	Hernandez-Bule, Maria Luisa/AAE-4403-2022; Hernandez-Bule, Maria Luisa/A-5010-2019	Hernandez-Bule, Maria Luisa/0000-0002-1437-3452; Hernandez-Bule, Maria Luisa/0000-0002-1437-3452	Fundacion para la Investigacion Biomedica del Hospital Ramon y Cajal, through Project FiBio-HRC [2006/0158]	Fundacion para la Investigacion Biomedica del Hospital Ramon y Cajal, through Project FiBio-HRC	This work was financially supported by Fundacion para la Investigacion Biomedica del Hospital Ramon y Cajal, through Project FiBio-HRC No. 2006/0158. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cid MA, 2012, CELL PHYSIOL BIOCHEM, V30, P1502, DOI 10.1159/000343338; Martinez MA, 2012, CELL PHYSIOL BIOCHEM, V29, P675, DOI 10.1159/000178457; Barbault A, 2009, J EXP CLIN CANC RES, V14, P28; Beerheide W, 2000, BIOCHEM BIOPH RES CO, V273, P54, DOI 10.1006/bbrc.2000.2891; BOIX L, 1994, HEPATOLOGY, V19, P88, DOI 10.1016/0270-9139(94)90057-4; Brown L, 2007, CRIT REV EUKAR GENE, V17, P73, DOI 10.1615/CritRevEukarGeneExpr.v17.i1.50; Caldon CE, 2010, CELL CYCLE, V9, P1918, DOI 10.4161/cc.9.10.11474; Carvajal LA, 2013, EMBO REP, V14, P414, DOI 10.1038/embor.2013.25; Chen H, 2012, J INT MED RES, V40, P85, DOI 10.1177/147323001204000109; Cheuk W, 2004, INT J SURG PATHOL, V12, P185, DOI 10.1177/106689690401200301; Coffman FD, 1999, EXP CELL RES, V248, P58, DOI 10.1006/excr.1999.4457; Costa FP, 2011, BRIT J CANCER, V105, P640, DOI 10.1038/bjc.2011.292; Costin GE, 2012, CURR MOL MED, V12, P14, DOI 10.2174/156652412798376143; Grimnes S., 2000, BIOIMPEDANCE BIOELEC, P71; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Guo LF, 2011, ELECTROMAGN BIOL MED, V30, P21, DOI 10.3109/15368378.2011.566775; Heiser D, 2004, EXP GERONTOL, V39, P1125, DOI 10.1016/j.exger.2004.04.011; Hemann MT, 2006, CELL DEATH DIFFER, V13, P1256, DOI 10.1038/sj.cdd.4401962; Hernandez-Bule ML, 2004, NEUROCIRUGIA, V15, P366; Hernandez-Bule ML, 2007, INT J ONCOLOGY, V30, P583; Huang HP, 2010, J BIOL CHEM, V285, P33510, DOI 10.1074/jbc.M110.122093; Iseki K, 2000, INT J ONCOL, V16, P1141; Issels RD, 2010, LANCET ONCOL, V11, P561, DOI 10.1016/S1470-2045(10)70071-1; Kato S, 2011, CYTOTECHNOLOGY, V63, P425, DOI 10.1007/s10616-011-9363-8; Kong N, 2013, ASIAN PAC J CANCER P, V14, P747, DOI 10.7314/APJCP.2013.14.2.747; Kotnik T, 2000, BIOELECTROMAGNETICS, V21, P385, DOI 10.1002/1521-186X(200007)21:5<385::AID-BEM7>3.0.CO;2-F; Lee KH, 2008, CLIN EXP METASTAS, V25, P89, DOI 10.1007/s10585-007-9106-6; Li P, 2011, WORLD J GASTROENTERO, V17, P4563, DOI 10.3748/wjg.v17.i41.4563; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; Hernandez-Bule ML, 2012, INT J ONCOL, V41, P1251, DOI 10.3892/ijo.2012.1569; Hernandez-Bule ML, 2010, INT J ONCOL, V37, P1399, DOI 10.3892/ijo_00000791; Malmlof M, 2007, J BIOL CHEM, V282, P2288, DOI 10.1074/jbc.M604953200; Moon SD, 2011, LUNG CANCER, V71, P338, DOI 10.1016/j.lungcan.2010.06.007; O'Brate A, 2003, DRUG RESIST UPDATE, V6, P313, DOI 10.1016/j.drup.2003.10.004; Ohguri T, 2012, LUNG CANCER, V77, P140, DOI 10.1016/j.lungcan.2012.02.018; Ohguri T, 2011, INT J HYPERTHER, V27, P20, DOI 10.3109/02656736.2010.500644; Ohguri T, 2009, INT J RADIAT ONCOL, V73, P128, DOI 10.1016/j.ijrobp.2008.03.059; Ren W, 2011, APOPTOSIS, V16, P382, DOI 10.1007/s10495-010-0572-y; San BH, 2013, INT J HYPERTHER, V29, P99, DOI 10.3109/02656736.2012.760137; Sheikh AQ, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.0548; STECK KD, 1995, CYTOMETRY, V20, P154, DOI 10.1002/cyto.990200208; SUZUKI K, 1994, HEPATOLOGY, V20, P1231; Takahashi K, 2004, J PHYS THER SCI, V11, P45, DOI [DOI 10.1589/JPTS.11.45, 10.1589/jpts.11.45]; Takahashi M, 1999, J HEPATOL, V31, P315, DOI 10.1016/S0168-8278(99)80230-X; Takehara T, 2001, HEPATOLOGY, V34, P55, DOI 10.1053/jhep.2001.25387; Tomek M, 2012, J PHARM PHARMACOL, V64, P1695, DOI 10.1111/j.2042-7158.2012.01526.x; Wang SY, 2004, J HEPATOL, V41, P267, DOI 10.1016/j.jhep.2004.04.013; Yao DF, 2007, HEPATOB PANCREAT DIS, V6, P241	48	20	23	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2014	9	1							e84636	10.1371/journal.pone.0084636	http://dx.doi.org/10.1371/journal.pone.0084636			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	291WL	24416255	Green Published, gold, Green Submitted			2023-01-03	WOS:000329862500143
J	La Marca, M; Beffy, P; Pugliese, A; Longo, V				La Marca, Margherita; Beffy, Pascale; Pugliese, Annalisa; Longo, Vincenzo			Fermented Wheat Powder Induces the Antioxidant and Detoxifying System in Primary Rat Hepatocytes	PLOS ONE			English	Article							ALPHA-LIPOIC ACID; NF-KAPPA-B; HEME OXYGENASE-1 GENE; OXIDATIVE STRESS; LISOSAN-G; CHEMOPREVENTIVE COMPOUNDS; ENDOTHELIAL-CELLS; FREE-RADICALS; UP-REGULATION; WHOLE GRAINS	Many plants exhibit antioxidant properties which may be useful in the prevention of oxidative stress reactions, such as those mediated by the formation of free radical species in different pathological situations. In recent years a number of studies have shown that whole grain products in particular have strong antioxidant activity. Primary cultures of rat hepatocytes were used to investigate whether and how a fermented powder of wheat (Lisosan G) is able to modulate antioxidant and detoxifying enzymes, and whether or not it can activate Nrf2 transcription factor or inhibit NF-kB activation. All of the antioxidant and detoxifying enzymes studied were significantly up-regulated by 0.7 mg/ml Lisosan G treatment. In particular, NAD(P) H: quinone oxidoreductase and heme oxygenase-1 were induced, although to different degrees, at the transcriptional, protein and/or activity levels by the treatment. As for the Nrf2 transcription factor, a partial translocation of its protein from the cytosol to the nucleus after 1 h of Lisosan G treatment was revealed by immunoblotting. Lisosan G was also observed to decrease H2O2-induced toxicity Taken together, these results show that this powder of wheat is an effective inducer of ARE/Nrf2-regulated antioxidant and detoxifying genes and has the potential to inhibit the translocation of NF-kB into the nucleus.	[La Marca, Margherita; Pugliese, Annalisa; Longo, Vincenzo] CNR, Ist Biol & Biotecnol Agr, I-56100 Pisa, Italy; [Beffy, Pascale] CNR, Ist Fisiol Clin, I-56100 Pisa, Italy	Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR)	Longo, V (corresponding author), CNR, Ist Biol & Biotecnol Agr, I-56100 Pisa, Italy.	v.longo@ibba.cnr.it	Longo, Vincenzo/K-3695-2018	Longo, Vincenzo/0000-0001-8972-8564				Alam J, 2000, J BIOL CHEM, V275, P27694; Balogun E, 2003, BIOCHEM J, V371, P887, DOI 10.1042/BJ20021619; Bao W, 2010, J ETHNOPHARMACOL, V128, P549, DOI 10.1016/j.jep.2010.01.029; Baublis AJ, 2000, J AM COLL NUTR, V19, p308S, DOI 10.1080/07315724.2000.10718965; Beken S, 1998, Methods Mol Biol, V107, P303; BENSON AM, 1980, P NATL ACAD SCI-BIOL, V77, P5216, DOI 10.1073/pnas.77.9.5216; Buckley BJ, 2003, BIOCHEM BIOPH RES CO, V307, P973, DOI 10.1016/S0006-291X(03)01308-1; Cao ZX, 2002, BIOCHEM BIOPH RES CO, V292, P50, DOI 10.1006/bbrc.2002.6614; Chen C, 2004, FREE RADICAL BIO MED, V36, P1505, DOI 10.1016/j.freeradbiomed.2004.03.015; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; De Oliveira SQ, 2003, FREE RADICAL RES, V37, P555, DOI 10.1080/1071576031000076259; De Smet K, 1998, Methods Mol Biol, V107, P295; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; DUNN JCY, 1991, BIOTECHNOL PROGR, V7, P237, DOI 10.1021/bp00009a007; Elangovan S, 2008, INT J ONCOL, V33, P833, DOI 10.3892/ijo_00000071; Flight I, 2006, EUR J CLIN NUTR, V60, P1145, DOI 10.1038/sj.ejcn.1602435; Gaesser GA, 2007, J AM DIET ASSOC, V107, P1768, DOI 10.1016/j.jada.2007.07.011; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HALLIWELL B, 1995, FOOD CHEM TOXICOL, V33, P601, DOI 10.1016/0278-6915(95)00024-V; Heiss E, 2001, J BIOL CHEM, V276, P32008, DOI 10.1074/jbc.M104794200; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jeong WS, 2005, J BIOCHEM MOL BIOL, V38, P167; Jia ZQ, 2008, NEUROCHEM RES, V33, P790, DOI 10.1007/s11064-007-9496-5; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Karuri AR, 2006, J PHARMACOL EXP THER, V317, P61, DOI 10.1124/jpet.105.096396; Kim HS, 2007, EXP MOL MED, V39, P106, DOI 10.1038/emm.2007.12; Kuhnt K, 2012, EUR J LIPID SCI TECH, V114, P153, DOI 10.1002/ejlt.201100008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laus MN, 2013, MED WETER, V69, P235; Lee SH, 2006, EUR J PHARMACOL, V532, P178, DOI 10.1016/j.ejphar.2006.01.005; Lii CK, 2010, J NUTR, V140, P885, DOI 10.3945/jn.110.121418; Liu YC, 2007, LIFE SCI, V80, P1420, DOI 10.1016/j.lfs.2006.12.040; Longo V, 2011, FOOD CHEM TOXICOL, V49, P233, DOI 10.1016/j.fct.2010.10.021; Longo V, 2007, BIOTECHNOL LETT, V29, P1155, DOI 10.1007/s10529-007-9378-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lubrano V, 2012, INDIAN J MED RES, V136, P82; Masella R, 2005, J NUTR BIOCHEM, V16, P577, DOI 10.1016/j.jnutbio.2005.05.013; McKeown NM, 2002, AM J CLIN NUTR, V76, P390, DOI 10.1093/ajcn/76.2.390; Naughton P, 2002, J BIOL CHEM, V277, P40666, DOI 10.1074/jbc.M203863200; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Ogborne RM, 2005, ARTERIOSCL THROM VAS, V25, P2100, DOI 10.1161/01.ATV.0000183745.37161.6e; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; Pal M, 2012, FOOD CHEM TOXICOL, V50, P1066, DOI 10.1016/j.fct.2011.12.042; Pastore A, 2003, CLIN CHIM ACTA, V333, P19, DOI 10.1016/S0009-8981(03)00200-6; Payen L, 2001, BIOCHEM BIOPH RES CO, V282, P257, DOI 10.1006/bbrc.2001.4531; Prawan A, 2009, CHEM-BIOL INTERACT, V179, P202, DOI 10.1016/j.cbi.2008.12.014; Randi G, 2010, NUTR REV, V68, P389, DOI 10.1111/j.1753-4887.2010.00299.x; Russo GL, 2009, BIOCHEM PHARMACOL, V77, P937, DOI 10.1016/j.bcp.2008.10.020; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Saw Constance Lay-Lay, 2010, Chin Med, V5, P37, DOI 10.1186/1749-8546-5-37; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; Slavin J, 2004, NUTR RES REV, V17, P99, DOI 10.1079/NRR200374; Slavin JL, 2001, J AM DIET ASSOC, V101, P780, DOI 10.1016/S0002-8223(01)00194-8; STACEY NH, 1980, TOXICOL APPL PHARM, V53, P470, DOI 10.1016/0041-008X(80)90359-2; Steffen LM, 2003, AM J CLIN NUTR, V78, P383, DOI 10.1093/ajcn/78.3.383; Storz Peter, 2006, Sci STKE, V2006, pre3, DOI 10.1126/stke.3322006re3; Swift B, 2010, DRUG METAB REV, V42, P446, DOI 10.3109/03602530903491881; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; VENN B, 2012, J NUTR METABOLISM, V2012, P1; VONJAGOW R, 1965, N-S ARCH EX PATH PH, V251, P73, DOI 10.1007/BF00245731; Wakabayashi N, 2010, ANTIOXID REDOX SIGN, V13, P1649, DOI 10.1089/ars.2010.3216; Weisburger JH, 1999, FOOD CHEM TOXICOL, V37, P943, DOI 10.1016/S0278-6915(99)00086-1; Wu X, 2009, ACTA PHARMACOL SIN, V30, P501, DOI 10.1038/aps.2009.50	68	31	31	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2013	8	12							e83538	10.1371/journal.pone.0083538	http://dx.doi.org/10.1371/journal.pone.0083538			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	284NF	24391783	Green Submitted, Green Published, gold			2023-01-03	WOS:000329325200080
J	Siddharth, J; Holway, N; Parkinson, SJ				Siddharth, Jay; Holway, Nicholas; Parkinson, Scott J.			A Western Diet Ecological Module Identified from the 'Humanized' Mouse Microbiota Predicts Diet in Adults and Formula Feeding in Children	PLOS ONE			English	Article							GUT	The interplay between diet and the microbiota has been implicated in the growing frequency of chronic diseases associated with the Western lifestyle. However, the complexity and variability of microbial ecology in humans and preclinical models has hampered identification of the molecular mechanisms underlying the association of the microbiota in this context. We sought to address two key questions. Can the microbial ecology of preclinical models predict human populations? And can we identify underlying principles that surpass the plasticity of microbial ecology in humans? To do this, we focused our study on diet; perhaps the most influential factor determining the composition of the gut microbiota. Beginning with a study in 'humanized' mice we identified an interactive module of 9 genera allied with Western diet intake. This module was applied to a controlled dietary study in humans. The abundance of the Western ecological module correctly predicted the dietary intake of 19/21 top and 21/21 of the bottom quartile samples inclusive of all 5 Western and 'low-fat' diet subjects, respectively. In 98 volunteers the abundance of the Western module correlated appropriately with dietary intake of saturated fatty acids, fat-soluble vitamins and fiber. Furthermore, it correlated with the geographical location and dietary habits of healthy adults from the Western, developing and third world. The module was also coupled to dietary intake in children (and piglets) correlating with formula (vs breast) feeding and associated with a precipitous development of the ecological module in young children. Our study provides a conceptual platform to translate microbial ecology from preclinical models to humans and identifies an ecological network module underlying the association of the gut microbiota with Western dietary habits.	[Siddharth, Jay; Parkinson, Scott J.] Novartis Inst Biomed Res, Host Commensal Hub, Basel, Switzerland; [Holway, Nicholas] Novartis Inst Biomed Res, NIBR IT, Basel, Switzerland	Novartis; Novartis	Parkinson, SJ (corresponding author), Novartis Inst Biomed Res, Host Commensal Hub, Basel, Switzerland.	scott.parkinson@novartis.com		Siddharth, Jay/0000-0003-3288-400X; Holway, Nicholas/0000-0002-2126-5118				[Anonymous], 2003, DIET NUTR PREV CHRON; Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944; Brenna JT, 2007, AM J CLIN NUTR, V85, P1457, DOI 10.1093/ajcn/85.6.1457; Cummings JH, 1997, JPEN-PARENTER ENTER, V21, P357, DOI 10.1177/0148607197021006357; Fewtrell M, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c5955; GIBSON RA, 1981, AM J CLIN NUTR, V34, P252, DOI 10.1093/ajcn/34.2.252; Goodman AL, 2011, P NATL ACAD SCI USA, V108, P6252, DOI 10.1073/pnas.1102938108; Gordon JI, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004347; Hvistendahl M, 2012, SCIENCE, V336, P1250, DOI 10.1126/science.336.6086.1250; Koletzko B, 2009, ADV EXP MED BIOL, V646, P15, DOI 10.1007/978-1-4020-9173-5_2; Little AEF, 2008, ANNU REV MICROBIOL, V62, P375, DOI 10.1146/annurev.micro.030608.101423; McCance R, 2002, MCCANCE WIDDOWSONS C, P131; Poroyko V, 2011, NUTR HOSP, V26, P1283, DOI [10.3305/nh.2011.26.6.5362, 10.1590/S0212-16112011000600015]; Schloss PD, 2011, APPL ENVIRON MICROB, V77, P3219, DOI 10.1128/AEM.02810-10; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Scientific Advisory Committee on Nutrition Subgroup on Maternal and Child Nutrition (SMCN), 2011, INFL MAT FET CHILD N; Smith P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030273; Strom SL, 2008, SCIENCE, V320, P1043, DOI 10.1126/science.1153527; UNICEF, 2007, UNICEF PUBL; Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053	21	13	13	0	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2013	8	12							e83689	10.1371/journal.pone.0083689	http://dx.doi.org/10.1371/journal.pone.0083689			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	284NF	24391809	Green Submitted, Green Published, Green Accepted, gold			2023-01-03	WOS:000329325200107
J	Madec, Y; Leroy, S; Rey-Cuille, MA; Huber, F; Calmy, A				Madec, Yoann; Leroy, Sandrine; Rey-Cuille, Marie-Anne; Huber, Florence; Calmy, Alexandra			Persistent Difficulties in Switching to Second-Line ART in Sub-Saharan Africa - A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							1ST-LINE ANTIRETROVIRAL TREATMENT; RESOURCE-LIMITED SETTINGS; HIV-1 DRUG-RESISTANCE; TREATMENT FAILURE; IMMUNOLOGICAL CRITERIA; VIROLOGICAL FAILURE; THERAPEUTIC OPTIONS; RURAL DISTRICT; PREDICTORS; OUTCOMES	Objectives: Switching to second-line antiretroviral therapy (ART) largely depends on careful clinical assessment and access to biological measurements. We performed a systematic review and meta-analysis to estimate the incidence of switching to second-line ART in sub-Saharan Africa and its main programmatic determinants. Methods: We searched 2 databases for studies reporting the incidence rate of switching to second-line ART in adults living in sub-Saharan Africa. Data on the incidence rate of switching were pooled, and random-effect models were used to evaluate the effect of factors measured at the programme level on this incidence rate. Results: Nine studies (157,340 patients) in 21 countries were included in the meta-analysis. All studies considered patients under first-line ART and conditions to initiate ART were similar across studies. Overall, 3,736 (2.4%) patients switched to second-line ART. Incidence rate of switch was in mean 2.65 per 100 person-years (PY) (95% confidence interval: 2.01-3.30); it ranged from 0.42 to 4.88 per 100 PY and from 0 to 4.80 per 100 PY in programmes with and without viral load monitoring, respectively. No factors measured at the programme level were associated with the incidence rate of switching to second-line ART. Conclusion: The low incidence rate of switching to second-line ART suggests that the monitoring of patients under ART is challenging and that access to second-line ART is ineffective; efforts should be made to increase access to second-line ART to those in need by providing monitoring tools, education and training, as well as a more convenient regimen.	[Madec, Yoann; Leroy, Sandrine; Rey-Cuille, Marie-Anne] Inst Pasteur, Emerging Dis Epidemiol Unit, Paris, France; [Huber, Florence] SOLTHIS, Paris, France; [Calmy, Alexandra] Univ Hosp Geneva, Dept Internal Med, HIV Unit, Geneva, Switzerland	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Geneva	Madec, Y (corresponding author), Inst Pasteur, Emerging Dis Epidemiol Unit, Paris, France.	yoann.madec@pasteur.fr	Leroy, Sandrine/I-9136-2014	Leroy, Sandrine/0000-0002-2964-2002; Huber, Florence/0000-0002-4340-0106; Madec, Yoann/0000-0002-6201-1261				Ajose O, 2012, AIDS, V26, P929, DOI 10.1097/QAD.0b013e328351f5b2; [Anonymous], 2012, WHO HIV DRUG RES REP; [Anonymous], 2009, SYST REV CRDS GUID U; [Anonymous], 2013, CONSOLIDATED GUIDELI; [Anonymous], 2012, UNDETECTABLE VIRAL L; [Anonymous], 2013, GUID US ANT AG HIV 1; [Anonymous], 2010, ANTIRETROVIRAL THERA; Auld AF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018453; Barth RE, 2012, ANTIVIR THER, V17, P377, DOI 10.3851/IMP2010; Dagnra AY, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-30; De Luca A, 2012, JAIDS-J ACQ IMM DEF, V59, P236, DOI 10.1097/QAI.0b013e31824276e9; Ferradini L, 2006, LANCET, V367, P1335, DOI 10.1016/S0140-6736(06)68580-2; Fox MP, 2012, JAIDS-J ACQ IMM DEF, V60, P428, DOI 10.1097/QAI.0b013e3182557785; Hamers RL, 2012, CLIN INFECT DIS, V54, P1660, DOI 10.1093/cid/cis254; Hosseinipour MC, 2010, HIV MED, V11, P510, DOI 10.1111/j.1468-1293.2010.00825.x; Hosseinipour MC, 2009, AIDS, V23, P1127, DOI 10.1097/QAD.0b013e32832ac34e; Keiser O, 2011, AIDS, V25, P1761, DOI 10.1097/QAD.0b013e328349822f; Keiser O, 2010, TROP MED INT HEALTH, V15, P251, DOI 10.1111/j.1365-3156.2009.02445.x; Keiser O, 2009, AIDS, V23, P1867, DOI 10.1097/QAD.0b013e32832e05b2; Keiser O, 2009, TROP MED INT HEALTH, V14, P1220, DOI 10.1111/j.1365-3156.2009.02338.x; Landier J, 2011, AIDS CARE, V23, P75, DOI 10.1080/09540121.2010.498867; Laurent C, 2011, LANCET INFECT DIS, V11, P825, DOI 10.1016/S1473-3099(11)70168-2; Levison JH, 2011, ANTIVIR THER, V16, P853, DOI 10.3851/IMP1819; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Mugyenyi P, 2010, LANCET, V375, P123, DOI 10.1016/S0140-6736(09)62067-5; Orrell C, 2007, ANTIVIR THER, V12, P83; Palombi L, 2009, CLIN INFECT DIS, V48, P115, DOI 10.1086/593312; Petersen ML, 2008, AIDS, V22, P2097, DOI 10.1097/QAD.0b013e32830f97e2; Pujades-Rodriguez M, 2008, AIDS, V22, P1305, DOI 10.1097/QAD.0b013e3282fa75b9; Pujades-Rodriguez M, 2010, JAMA-J AM MED ASSOC, V304, P303, DOI 10.1001/jama.2010.980; Ramadhani HO, 2007, CLIN INFECT DIS, V45, P1492, DOI 10.1086/522991; Rawizza HE, 2011, CLIN INFECT DIS, V53, P1283, DOI 10.1093/cid/cir729; Reynolds SJ, 2009, AIDS, V23, P697, DOI 10.1097/QAD.0b013e3283262a78; Sanne IM, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-38; Schoffelen AF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058526; Sigaloff KCE, 2012, J INFECT DIS, V205, P1739, DOI 10.1093/infdis/jis261; Sigaloff KCE, 2012, AIDS RES HUM RETROV, V28, P171, DOI 10.1089/aid.2011.0136; Srasuebkul Preeyaporn, 2007, AIDS Res Ther, V4, P18, DOI 10.1186/1742-6405-4-18; Stadeli KM, 2013, ANTIVIR THER, V18, P115, DOI 10.3851/IMP2437; van Oosterhout JJG, 2009, TROP MED INT HEALTH, V14, P856, DOI 10.1111/j.1365-3156.2009.02309.x; van Zyl GU, 2011, J MED VIROL, V83, P1764, DOI 10.1002/jmv.22189; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X	42	34	34	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2013	8	12							e82724	10.1371/journal.pone.0082724	http://dx.doi.org/10.1371/journal.pone.0082724			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278IG	24376570	Green Submitted, Green Published, gold			2023-01-03	WOS:000328882000024
J	Shuryak, I; Smilenov, LB; Kleiman, NJ; Brenner, DJ				Shuryak, Igor; Smilenov, Lubomir B.; Kleiman, Norman J.; Brenner, David J.			Potential Reduction of Contralateral Second Breast-Cancer Risks by Prophylactic Mammary Irradiation: Validation in a Breast-Cancer-Prone Mouse Model	PLOS ONE			English	Article							LOCAL RECURRENCE; RADIOTHERAPY; RADIATION; INDUCTION; TAMOXIFEN; TUMORS	Background: Long-term breast-cancer survivors have a highly elevated risk (1 in 6 at 20 years) of contralateral second breast cancer. This high risk is associated with the presence of multiple pre-malignant cell clones in the contralateral breast at the time of primary breast cancer diagnosis. Mechanistic analyses suggest that a moderate dose of X-rays to the contralateral breast can kill these pre-malignant clones such that, at an appropriate Prophylactic Mammary Irradiation (PMI) dose, the long-term contralateral breast cancer risk in breast cancer survivors would be considerably decreased. Aims: To test the predicted relationship between PMI dose and cancer risk in mammary glands that have a high risk of developing malignancies. Methods: We tested the PMI concept using MMTV-PyVT mammary-tumor-prone mice. Mammary glands on one side of each mouse were irradiated with X-rays, while those on the other side were shielded from radiation. The unshielded mammary glands received doses of 0, 4, 8, 12 and 16 Gy in 4-Gy fractions. Results: In high-risk mammary glands exposed to radiation doses designed for PMI (12 and 16 Gy), tumor incidence rates were respectively decreased by a factor of 2.2 (95% CI, 1.1-5.0) at 12 Gy, and a factor of 3.1 (95% CI, 1.3-8.3) at 16 Gy, compared to those in the shielded glands that were exposed to very low radiation doses. The same pattern was seen for PMI-exposed mammary glands relative to zero-dose controls. Conclusions: The pattern of cancer risk reduction by PMI was consistent with mechanistic predictions. Contralateral breast PMI may thus have promise as a spatially targeted breast-conserving option for reducing the current high risk of contralateral second breast cancers. For estrogen-receptor positive primary tumors, PMI might optimally be used concomitantly with systemically delivered chemopreventive drugs such as tamoxifen or aromatase inhibitors, while for estrogen-receptor negative tumors, PMI might be used alone.	[Shuryak, Igor; Smilenov, Lubomir B.; Kleiman, Norman J.; Brenner, David J.] Columbia Univ, Med Ctr, Ctr Radiol Res, New York, NY 10027 USA	Columbia University	Shuryak, I (corresponding author), Columbia Univ, Med Ctr, Ctr Radiol Res, New York, NY 10027 USA.	is144@columbia.edu	Kleiman, Norman/B-9745-2008	Kleiman, Norman/0000-0002-4725-998X	Irving Institute for Clinical and Translational Research, Columbia University; NIAID [U19 AI67773]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI067773] Funding Source: NIH RePORTER	Irving Institute for Clinical and Translational Research, Columbia University; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by a Pilot Study Award Grant from the Irving Institute for Clinical and Translational Research, Columbia University, and by NIAID grant U19 AI67773. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abramson Joseph H, 2004, Epidemiol Perspect Innov, V1, P6, DOI 10.1186/1742-5573-1-6; American Cancer Society Inc, 2011, BREAST CANC FACTS FI; Anastasiadis Panagiotis G., 2000, Breast J, V6, P178, DOI 10.1046/j.1524-4741.2000.99081.x; Arrington AK, 2009, ANN SURG ONCOL, V16, P2697, DOI 10.1245/s10434-009-0641-z; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Bartstra RW, 1998, RADIAT RES, V150, P442, DOI 10.2307/3579664; Bhatnagar AK, 2006, BREAST CANCER RES TR, V96, P41, DOI 10.1007/s10549-005-9032-8; BOICE JD, 1992, NEW ENGL J MED, V326, P781, DOI 10.1056/NEJM199203193261201; Boice JD, 2001, MED PEDIATR ONCOL, V36, P508, DOI 10.1002/mpo.1122; Brenner DJ, 2007, J CLIN ONCOL, V25, P4868, DOI 10.1200/JCO.2007.11.0379; Breslow NE, 1987, DESIGN ANAL COHORT S, P1; Chai Yunfei, 2009, Acta Medica Nagasakiensia, V53, P65; Chiang HC, 2012, EXP HEMATOL ONCOL, V1, DOI 10.1186/2162-3619-1-31; Curtis RE, 2006, NIH PUBLICATION, P1973; Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Freedman GM, 2005, INT J RADIAT ONCOL, V61, P1328, DOI 10.1016/j.ijrobp.2004.08.026; Gao X, 2003, INT J RADIAT ONCOL, V56, P1038, DOI 10.1016/S0360-3016(03)00203-7; Gujral DM, 2011, INT J RADIAT ONCOL, V79, P19, DOI 10.1016/j.ijrobp.2009.10.074; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; International Agency for Research on Cancer, 1980, STAT METHODS CANC RE; King TA, 2011, J CLIN ONCOL, V29, P2158, DOI 10.1200/JCO.2010.29.4041; Lam JBB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004968; Preston DL, 2002, RADIAT RES, V158, P220, DOI 10.1667/0033-7587(2002)158[0220:REOBCR]2.0.CO;2; Ramaseshan R, 2004, PHYS MED BIOL, V49, P4031, DOI 10.1088/0031-9155/49/17/014; Sandberg MEC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046535; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Stucky CCH, 2010, ANN SURG ONCOL, V17, pS330, DOI 10.1245/s10434-010-1259-x; Taggart F, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-238; Uray IP, 2011, RECENT RESULTS CANC, V188, P147, DOI 10.1007/978-3-642-10858-7_13; Veronesi U, 2013, LANCET ONCOL, V14, P1269, DOI 10.1016/S1470-2045(13)70497-2; William WN, 2009, NAT REV DRUG DISCOV, V8, P213, DOI 10.1038/nrd2663; Williams N, 2008, LANCET ONCOL, V9, P45, DOI 10.1016/S1470-2045(07)70385-6; Yi M, 2011, ANN SURG, V253, P572, DOI 10.1097/SLA.0b013e318208fc2a	34	13	13	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2013	8	12							e85795	10.1371/journal.pone.0085795	http://dx.doi.org/10.1371/journal.pone.0085795			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276IX	24376895	Green Published, Green Submitted, gold			2023-01-03	WOS:000328745100209
J	Schattner, A				Schattner, Ami			Review: Strength training, with or without flexibility and aerobic training, reduces pain in lower limb osteoarthritis	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Nuffield Orthopaed Ctr, Oxford OX3 7LD, England	Nuffield Orthopaedic Centre	Schattner, A (corresponding author), Nuffield Orthopaed Ctr, Oxford OX3 7LD, England.		Schattner, Ami/ABI-1894-2020	Schattner, Ami/0000-0002-1413-8858				Baker KR, 2001, J RHEUMATOL, V28, P1655; Jansen JP, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-159	2	3	3	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 17	2013	159	12							JC7	10.7326/0003-4819-159-12-201312170-02007	http://dx.doi.org/10.7326/0003-4819-159-12-201312170-02007			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290ED	24343412				2023-01-03	WOS:000329735300006
J	Glinskii, OV; Huxley, VH; Glinskii, VV; Rubin, LJ; Glinsky, VV				Glinskii, Olga V.; Huxley, Virginia H.; Glinskii, Vladimir V.; Rubin, Leona J.; Glinsky, Vladislav V.			Pulsed Estrogen Therapy Prevents Post-OVX Porcine Dura Mater Microvascular Network Weakening via a PDGF-BB-Dependent Mechanism	PLOS ONE			English	Article							CEREBROSPINAL-FLUID; BETA-RECEPTOR; ARTERIOVENOUS-MALFORMATION; INTRACRANIAL ANEURYSMS; POSTMENOPAUSAL WOMEN; RISK-FACTORS; MAST-CELLS; MICE; ACTIVATION; DEFICIENT	In postmenopausal women, estrogen (E2) deficiencies are frequently associated with higher risk of intracranial hemorrhage, increased incidence of stroke, cerebral aneurysm, and decline in cognitive abilities. In younger postpartum women and those using oral contraceptives, perturbations in E2 are associated with higher risk of cerebral venous thrombosis. A number of serious intracranial pathologic conditions linked to E2 deficiencies, such as dural sinus thrombosis, dural fistulae, non-parenchymal intracranial hemorrhages, migraines, and spontaneous cerebrospinal fluid leaks, involve the vessels not of the brain itself, but of the outer fibrous membrane of the brain, the dura mater (DM). The pathogenesis of these disorders remains mysterious and how estrogen regulates structural and functional integrity of DM vasculature is largely unknown. Here, we demonstrate that post ovariectomy (OVX) DM vascular remodeling is manifested by microvessel destabilization, capillary rarefaction, increased vascular permeability, and aberrant angio-architecture, and is the result of disrupted E2-regulated PDGF-BB signaling within dura microvasculature. These changes, associated with the reduction in systemic PDGF-BB levels, are not corrected by a flat-dose E2 hormone replacement therapy (HRT), but are largely prevented using HRT schedules mimicking physiological E2 fluctuations. We demonstrate that 1) E2 regulates PDGF-BB production by endothelial cells in a dose-dependent manner and 2) optimization of PDGF-BB levels and induction of robust PDGF-mediated endothelial cell-vascular pericyte interactions require high (estrous) E2 concentrations. We conclude that high (estrous) levels of E2 are important in controlling PDGF-mediated crosstalk between endothelial cells and pericytes, a fundamental mechanism governing microvessel stability and essential for preserving intracranial homeostasis.	[Glinskii, Olga V.; Glinsky, Vladislav V.] Harry S Truman Mem Vet Hosp, Res Serv, Columbia, MO 65201 USA; [Glinskii, Olga V.; Huxley, Virginia H.] Univ Missouri, Dept Med Pharmacol & Physiol, Columbia, MO USA; [Glinsky, Vladislav V.] Univ Missouri, Dept Pathol & Anat Sci, Columbia, MO USA; [Rubin, Leona J.] Univ Missouri, Dept Biomed Sci, Columbia, MO USA; [Glinskii, Olga V.; Huxley, Virginia H.; Rubin, Leona J.; Glinsky, Vladislav V.] Univ Missouri, Ctr Gender Physiol & Environm Adaptat, Columbia, MO USA; [Glinskii, Vladimir V.] Yale Univ, Sch Med, New Haven, CT USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harry S. Truman Memorial Veterans' Hospital; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; Yale University	Glinsky, VV (corresponding author), Harry S Truman Mem Vet Hosp, Res Serv, Columbia, MO 65201 USA.	glinskiivl@health.missouri.edu	Huxley, Virginia H/R-5030-2019	Glinsky, Vladislav/0000-0003-0893-4388	American Heart Association [SDG 0830287N]; Biomedical Laboratory Research & Development Service of the VA Office of Research and Development [1I01BX000609]; National Cancer Institute of the National Institutes of Health [R01CA160461]; NATIONAL CANCER INSTITUTE [R01CA160461] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078816] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); Biomedical Laboratory Research & Development Service of the VA Office of Research and Development; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by the American Heart Association National SDG 0830287N (OVG), Award Number 1I01BX000609 from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development (VVG), National Cancer Institute of the National Institutes of Health Award R01CA160461 (VVG). The content is solely the responsibility of the authors and does not necessarily represent the official views of the American Heart Association, National Institutes of Health, or VA Office of Research and Development. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aboian MS, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.8.FOCUS09161; Boes T, 2012, CEPHALALGIA, V32, P924, DOI 10.1177/0333102412454947; Brass LM, 2004, STROKE, V35, P2644, DOI 10.1161/01.STR.0000143218.20061.ac; Clarke M, 2008, NEURORADIOLOGY, V50, P653, DOI 10.1007/s00234-008-0411-9; COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014; Cognard C, 1998, J NEUROL NEUROSUR PS, V65, P308, DOI 10.1136/jnnp.65.3.308; Crosby JR, 1998, NAT GENET, V18, P385, DOI 10.1038/ng0498-385; Ellamushi HE, 2001, J NEUROSURG, V94, P728, DOI 10.3171/jns.2001.94.5.0728; ELLIS EF, 1979, AM J PHYSIOL, V237, pH381, DOI 10.1152/ajpheart.1979.237.3.H381; Eng E, 2005, KIDNEY INT, V68, P695, DOI 10.1111/j.1523-1755.2005.00448.x; Fox RJ, 1996, NEUROSURGERY, V39, P84, DOI 10.1097/00006123-199607000-00017; Glinskii OV, 2008, CELL CYCLE, V7, P1385, DOI 10.4161/cc.7.10.5819; Glinskii OV, 2007, AM J PHYSIOL-HEART C, V293, pH1131, DOI 10.1152/ajpheart.01156.2006; Glinskii OV, 2004, J PHYSIOL-LONDON, V554, P89, DOI 10.1113/jphysiol.2003.054783; Glinskii OV, 2003, CLIN EXP METASTAS, V20, P451, DOI 10.1023/A:1025449031136; Glinskii VV, 2006, J VASC RES, V43, P43; Gordon N, 2009, DEV MED CHILD NEUROL, V51, P932, DOI 10.1111/j.1469-8749.2009.03514.x; GREENE AS, 1989, AM J PHYSIOL, V256, pH126, DOI 10.1152/ajpheart.1989.256.1.H126; Gupta Ak, 2009, Indian J Radiol Imaging, V19, P43, DOI 10.4103/0971-3026.45344; Harrod CG, 2006, MED HYPOTHESES, V66, P736, DOI 10.1016/j.mehy.2005.09.051; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298; HOUSER OW, 1979, MAYO CLIN PROC, V54, P651; Johnston KD, 2007, J NEUROSURG, V107, P841, DOI 10.3171/JNS-07/10/0841; Kandere-Grzybowska K, 2003, BRAIN RES, V980, P213, DOI 10.1016/S0006-8993(03)02975-5; Klinghoffer RA, 2001, MOL CELL, V7, P343, DOI 10.1016/S1097-2765(01)00182-4; KOSTELJANETZ M, 1987, ACTA NEUROL SCAND, V75, P1; Kurata A, 1999, NEUROL RES, V21, P631, DOI 10.1080/01616412.1999.11740988; KURATA A, 1994, J NEUROSURG, V80, P552, DOI 10.3171/jns.1994.80.3.0552; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Lindahl P, 1998, DEVELOPMENT, V125, P3313; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Lloyd KM, 2008, RADIOLOGY, V248, P725, DOI 10.1148/radiol.2483070362; Mack J, 2009, PEDIATR RADIOL, V39, P200, DOI 10.1007/s00247-008-1084-6; MARKOWITZ S, 1989, BRAIN RES, V477, P157, DOI 10.1016/0006-8993(89)91403-0; Nishimura H, 2001, PROSTAG OTH LIPID M, V66, P1, DOI 10.1016/S0090-6980(01)00115-0; Ohlsson R, 1999, DEV BIOL, V212, P124, DOI 10.1006/dbio.1999.9306; Pae CU, 2008, NEUROENDOCRINOL LETT, V29, P500; Papanek PE, 1998, AM J HYPERTENS, V11, P998, DOI 10.1016/S0895-7061(98)00114-9; PRASAD A, 1995, J HYPERTENS, V13, P265; Rajkumar VS, 2006, AM J PATHOL, V169, P2254, DOI 10.2353/ajpath.2006.060196; Saposnik G, 2011, STROKE, V42, P1158, DOI 10.1161/STR.0b013e31820a8364; Scallan J, 2010, FLUID EXCHANGE REGUL; SHAPIRO K, 1985, J NEUROSURG, V63, P76, DOI 10.3171/jns.1985.63.1.0076; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Tallquist MD, 2000, GENE DEV, V14, P3179, DOI 10.1101/gad.844700; Uranishi R, 1999, J NEUROSURG, V91, P781, DOI 10.3171/jns.1999.91.5.0781; Vaghela V, 2011, NEUROL INDIA, V59, P17, DOI 10.4103/0028-3886.84328; Winkler EA, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-32; WOODWARD DF, 1993, EUR J PHARMACOL, V230, P327, DOI 10.1016/0014-2999(93)90569-4; Zhang XC, 2007, J PHARMACOL EXP THER, V322, P806, DOI 10.1124/jpet.107.123745	52	15	15	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2013	8	12							e82900	10.1371/journal.pone.0082900	http://dx.doi.org/10.1371/journal.pone.0082900			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275VD	24349391	Green Submitted, Green Published, gold			2023-01-03	WOS:000328705200111
J	McCartney, M				McCartney, Margaret			How many new cancers are diagnosed after emergency admission?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				[Anonymous], 2012, DAILY EXPRESS   0921; [Anonymous], 2012, BBC NEWS; Baughan P, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X606591; Borland S, 2012, DAILY MAIL; Elliss-Brookes L, 2012, BRIT J CANCER, V107, P1220, DOI 10.1038/bjc.2012.408; Jones R, 2007, BMJ-BRIT MED J, V334, P1040, DOI 10.1136/bmj.39171.637106.AE; Lyratzopoulos G, 2012, LANCET ONCOL, V13, P353, DOI 10.1016/S1470-2045(12)70041-4; National Cancer Intelligence Network, 2013, ROUT DIAGN EXPL EM A; North West Cancer Intelligence Service, 2013, ROUT DIAGN INV DIFF; Teenage Cancer Trust, 2013, YOUNG CANC PAT 3 TIM; Teenage Cancer Trust, 2013, IMPR DIAGN REP; Tsang C, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-308	12	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	2013	347								f6857	10.1136/bmj.f6857	http://dx.doi.org/10.1136/bmj.f6857			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258KF	24259328				2023-01-03	WOS:000327457400009
J	Nacher, M; Basurko, C; Adenis, A; Gaubert-Marechal, E; Mosnier, E; Edouard, S; Vantilcke, V; Sivapregassam, S; Tressieres, B; Cabie, A; Couppie, P				Nacher, Mathieu; Basurko, Celia; Adenis, Antoine; Gaubert-Marechal, Emilie; Mosnier, Emilie; Edouard, Sophie; Vantilcke, Vincent; Sivapregassam, Sindou; Tressieres, Benoit; Cabie, Andre; Couppie, Pierre			Predictive Factors of Herpes Zoster HIV-Infected Patients: Another Adverse Effect of Crack Cocaine	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; RISK-FACTORS; AIDS; COHORT; PROGRESSION; VARICELLA; DISEASE; ERA	A retrospective cohort study was conducted on 1541 HIV-infected patients to determine variables associated with the incidence of herpes zoster. A single failure Cox model showed that herpes zoster incidence increased following the first 6 months of antiretroviral treatment adjusted hazard ratio (AHR)=5 (95%CI=2.6-9.2), P<0.001; in the >60 years age group AHR=2 (95%CI=1-4), P=0.04; in patients in the top CD8 quartile AHR=2.1 (95%CI=1.3-3.6), P<0.001; and in patients previously reported to use crack cocaine AHR=5.9, (95%CI=1.4-25), P=0.02. Herpes zoster incidence increased in patients with CD4 counts<500 per mm(3) and gradually declined since 1992-1996, with AHR=0.3 (95%CI=0.2-0.5), P<0.001 for the 1997-2002 period and AHR=0.24 (95%CI=0.14-0.4), P<0.001 for the 2002-2008 period. Contrary to what has been described elsewhere, there was no specific effect of protease inhibitors on herpes zoster incidence. The present study is the first to suggest that crack cocaine is associated with an increased incidence of herpes zoster. The neurological or immunological effects of crack are discussed.	[Nacher, Mathieu; Basurko, Celia; Adenis, Antoine; Sivapregassam, Sindou] Ctr Hosp Cayenne, Ctr Invest Clin Epidemiol Clin Antilles Guyane IN, DGOS CIE 802, Cayenne, French Guiana; [Nacher, Mathieu] Univ Antilles Guyane, EA 3593, Cayenne, French Guiana; [Nacher, Mathieu] COREVIH Guyane, Cayenne, French Guiana; [Nacher, Mathieu; Gaubert-Marechal, Emilie] Ctr Hosp Cayenne, Cayenne, French Guiana; [Mosnier, Emilie; Couppie, Pierre] Ctr Hosp Cayenne, Serv Dermatol Venereol, Cayenne, French Guiana; [Vantilcke, Vincent] Ctr Hosp Franck Ouest Guyanais, Med Serv, St Laurent Du Maroni, French Guiana; [Tressieres, Benoit] Ctr Hosp Univ Martinique, Ctr Invest Clin Epidemiol Clin Antilles Guyane IN, DGOS CIE 802, Fort De France, Martinique, France; [Cabie, Andre] Ctr Hosp Univ Martinique, Serv Malad Infect & Trop, Fort De France, Martinique, France	CHU Martinique; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Martinique	Nacher, M (corresponding author), Ctr Hosp Cayenne, Ctr Invest Clin Epidemiol Clin Antilles Guyane IN, DGOS CIE 802, Cayenne, French Guiana.	mathieu.nacher@ch-cayenne.fr	nacher, mathieu/AAH-4796-2021; Basurko, Célia/AAM-8297-2021; MOSNIER, Emilie/GXV-4053-2022; TRESSIERES, Benoit/ABH-1085-2020	nacher, mathieu/0000-0001-9397-3204; MOSNIER, Emilie/0000-0002-6004-3323; Cabie, Andre/0000-0003-0117-3061; adenis, antoine/0000-0003-4000-4981; Couppie, Pierre/0000-0002-4213-2867				Aldeen T, 1998, AIDS, V12, P1719; Alliegro MB, 1996, CLIN INFECT DIS, V23, P990, DOI 10.1093/clinids/23.5.990; Blank LJ, J ACQ IMMUN DEF SYND, V61, P203, DOI [10.1097/QAI.0b013e318266cd3c, DOI 10.1097/QAI.0B013E318266CD3C.PUBMED:22766968]; BUCHBINDER SP, 1992, J INFECT DIS, V166, P1153, DOI 10.1093/infdis/166.5.1153; Cabral GA, 2006, J NEUROIMMUNE PHARM, V1, P280, DOI 10.1007/s11481-006-9023-5; Carr A, 1996, J ACQ IMMUN DEF SYND, V13, P320, DOI 10.1097/00042560-199612010-00004; CAUDA R, 1987, J IMMUNOL, V138, P1229; Domingo P, 2001, AM J MED, V110, P605, DOI 10.1016/S0002-9343(01)00703-3; Engels EA, 1999, J INFECT DIS, V180, P1784, DOI 10.1086/315146; Gebo KA, 2005, JAIDS-J ACQ IMM DEF, V40, P169, DOI 10.1097/01.qai.0000178408.62675.b0; GLESBY MJ, 1993, J INFECT DIS, V168, P1264, DOI 10.1093/infdis/168.5.1264; MAHALINGAM R, 1990, NEW ENGL J MED, V323, P627, DOI 10.1056/NEJM199009063231002; Martinez E, 1998, CLIN INFECT DIS, V27, P1510, DOI 10.1086/515019; Moanna A, 2013, CLIN INFECT DIS, V57, P122, DOI 10.1093/cid/cit165; Molton J, 2010, J INFECTION, V61, P73, DOI 10.1016/j.jinf.2010.04.004; Murdoch DM, 2008, AIDS, V22, P1689, DOI 10.1097/QAD.0b013e328308de33; Nacher M, 2009, AIDS, V23, P2223, DOI 10.1097/QAD.0b013e32833147c2; Ratnam I, 2006, CLIN INFECT DIS, V42, P418, DOI 10.1086/499356; ROGUES AM, 1993, J INFECT DIS, V168, P245, DOI 10.1093/infdis/168.1.245; VEENSTRA J, 1995, AIDS, V9, P1153, DOI 10.1097/00002030-199510000-00006; Wood SM, 2008, PEDIATRICS, V121, pE150, DOI 10.1542/peds.2007-0564	21	3	3	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2013	8	11							e80187	10.1371/journal.pone.0080187	http://dx.doi.org/10.1371/journal.pone.0080187			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255EG	24244647	Green Published, gold			2023-01-03	WOS:000327221600190
J	Ghosh, S; Wanders, D; Stone, KP; Van, NT; Cortez, CC; Gettys, TW				Ghosh, Sujoy; Wanders, Desiree; Stone, Kirsten P.; Van, Nancy T.; Cortez, Cory C.; Gettys, Thomas W.			A systems biology analysis of the unique and overlapping transcriptional responses to caloric restriction and dietary methionine restriction in rats	FASEB JOURNAL			English	Article						obesity; animal models; insulin sensitivity; amino acid sensing	AMINO-ACID STARVATION; ADIPOSE-TISSUE; GENE-EXPRESSION; EXTRACELLULAR-MATRIX; ACTIN CYTOSKELETON; SIGNAL TRANSDUCER; OXIDATIVE STRESS; INFLAMMATION; ADIPOGENESIS; METABOLISM	Dietary methionine restriction (MR) and calorie restriction (CR) each improve metabolic health and extend life span. We used comprehensive transcriptome profiling and systems biology analysis to interrogate the unique and overlapping molecular responses in rats provided these dietary regimens for 20 mo after weaning. Microarray analysis was conducted on inguinal white adipose (IWAT), brown adipose tissue (BAT), liver, and skeletal muscle. Compared to controls, CR-induced transcriptomic responses (absolute fold change >= 1.5 and P <= 0.05) were comparable in IWAT, BAT, and liver (similar to 800 genes). MR-induced effects were largely restricted to IWAT and liver (similar to 2400 genes). Pathway enrichment and gene-coexpression analyses showed that induction of fatty acid synthesis in IWAT was common to CR and MR, whereas immunity and proinflammatory signaling pathways were specifically down-regulated in MR-treated IWAT and liver (FDR <= 0.07-0.3). BAT demonstrated consistent down-regulation of PPAR-signaling under CR and MR, whereas muscle was largely unaffected. Interactome analysis identified CR-specific down-regulation of cytoskeletal matrix components in IWAT and MR-specific up-regulation of ribosomal genes in liver (FDR <= 0.001). Transcriptomic down-regulation of inflammation genes by MR in IWAT was consistent with upstream inhibition of STAT3. Together, these results provide an integrated picture of the breadth of transcriptional responses to MR and CR among key metabolic tissues.	[Ghosh, Sujoy; Gettys, Thomas W.] Pennington Biomed Res Ctr, Lab Computat Biol, Baton Rouge, LA 70808 USA; [Ghosh, Sujoy; Wanders, Desiree; Stone, Kirsten P.; Van, Nancy T.; Cortez, Cory C.; Gettys, Thomas W.] Pennington Biomed Res Ctr, Lab Nutrient Sensing & Adipocyte Signaling, Baton Rouge, LA 70808 USA; [Ghosh, Sujoy] Duke Natl Univ Singapore, Grad Sch Med, Cardiovasc & Metab Disorders Res Program, Singapore, Singapore	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; National University of Singapore	Gettys, TW (corresponding author), Pennington Biomed Res Ctr, Lab Nutrient Sensing & Adipocyte Signaling, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	gettystw@pbrc.edu	Gettys, Thomas W/N-1964-2017; Ghosh, Sujoy/I-3729-2017; Stone, Kirsten/AAB-3804-2019	Gettys, Thomas W/0000-0001-7125-7995; Ghosh, Sujoy/0000-0002-7601-165X; Stone, Kirsten/0000-0001-5511-1638; Wanders, Desiree/0000-0003-2638-3954	American Diabetes Association (ADA) [1-12-BS-58]; U.S. National Institutes of Health (NIH) [DK-096311]; ADA [7-13-MI-05]; NIH [1F32DK098918-01, P20-GM103528, P30 DK072476]; Mouse Metabolic Phenotyping Center Consortium (NIH) [U24DK076169]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK098918, R01DK096311, U24DK076169, P30DK072476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103528] Funding Source: NIH RePORTER	American Diabetes Association (ADA)(American Diabetes Association); U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ADA(American Diabetes Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mouse Metabolic Phenotyping Center Consortium (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by American Diabetes Association (ADA) grant 1-12-BS-58 (T.W.G.), U.S. National Institutes of Health (NIH) grant DK-096311 (T.W.G.), ADA grant 7-13-MI-05 (T.W.G.), NIH grant 1F32DK098918-01 (D.W.), and the Mouse Metabolic Phenotyping Center Consortium (NIH grant U24DK076169). This work also made use of the Genomics and the Cell Biology and Bioimaging core facilities at the Pennington Biomedical Research Center, supported by NIH grants P20-GM103528 (T.W.G.) and P30 DK072476. The authors acknowledge the excellent technical assistance of Kelly Dille and Mollye Baker, and the clerical support of Cindi Tramonte.	Aggarwal BB, 2009, ANN NY ACAD SCI, V1171, P59, DOI 10.1111/j.1749-6632.2009.04911.x; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Barzilai N, 2001, J NUTR, V131, p903S, DOI 10.1093/jn/131.3.903S; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Cernkovich ER, 2008, ENDOCRINOLOGY, V149, P1581, DOI 10.1210/en.2007-1148; Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018; Curtis JM, 2010, DIABETES, V59, P1132, DOI 10.2337/db09-1105; Deyl Z, 1975, Adv Exp Med Biol, V53, P359; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI21625, 10.1172/JCI20042162S]; Gaccioli F, 2006, J BIOL CHEM, V281, P17929, DOI 10.1074/jbc.M600341200; Hasek BE, 2013, DIABETES, V62, P3362, DOI 10.2337/db13-0501; Hasek BE, 2010, AM J PHYSIOL-REG I, V299, pR728, DOI 10.1152/ajpregu.00837.2009; Henegar C, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-r14; Higami Y, 2006, J NUTR, V136, P343, DOI 10.1093/jn/136.2.343; HITOMI Y, 1993, BIOSCI BIOTECH BIOCH, V57, P1216, DOI 10.1271/bbb.57.1216; Huang HY, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002691; Huffman DM, 2010, INTERD T GERONT GERI, V37, P1, DOI 10.1159/000319991; Huffman DM, 2009, BBA-GEN SUBJECTS, V1790, P1117, DOI 10.1016/j.bbagen.2009.01.008; Ishii K, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-37; Jhun JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078843; Kawaguchi N, 2003, J CELL SCI, V116, P3893, DOI 10.1242/jcs.00699; Kemnitz JW, 2011, ILAR J, V52, P66, DOI 10.1093/ilar.52.1.66; Kimball SR, 2002, J NUTR, V132, P883; MAGER WH, 1988, BIOCHIM BIOPHYS ACTA, V949, P1, DOI 10.1016/0167-4781(88)90048-6; Malloy VL, 2006, AGING CELL, V5, P305, DOI 10.1111/j.1474-9726.2006.00220.x; MCCAY CM, 1989, NUTRITION, V5, P155; MCGOWN E, 1973, J NUTR, V103, P109, DOI 10.1093/jn/103.1.109; Muzumdar R, 2008, AGING CELL, V7, P438, DOI 10.1111/j.1474-9726.2008.00391.x; Newman MEJ, 2006, P NATL ACAD SCI USA, V103, P8577, DOI 10.1073/pnas.0601602103; O'Sullivan K. E., 2013, J GASTROINTEST CANC; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Omodei D, 2011, FEBS LETT, V585, P1537, DOI 10.1016/j.febslet.2011.03.015; ORENTREICH N, 1993, J NUTR, V123, P269; Petrovic V, 2006, COMP BIOCHEM PHYS C, V142, P60, DOI 10.1016/j.cbpc.2005.10.004; Priceman SJ, 2013, P NATL ACAD SCI USA, V110, P13079, DOI 10.1073/pnas.1311557110; Prifti E, 2010, BIOINFORMATICS, V26, P3083, DOI 10.1093/bioinformatics/btq591; Przanowski P, 2014, J MOL MED, V92, P239, DOI 10.1007/s00109-013-1090-5; Richard AJ, 2014, BBA-MOL BASIS DIS, V1842, P431, DOI 10.1016/j.bbadis.2013.05.030; RICHIE JP, 1994, FASEB J, V8, P1302, DOI 10.1096/fasebj.8.15.8001743; Schiller ZA, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt230; Simon R, 2007, CANCER INFORM, V3, P11; Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675; Stewart WC, 1999, BBA-MOL CELL RES, V1452, P188, DOI 10.1016/S0167-4889(99)00129-9; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Svensson PA, 2011, INT J MOL MED, V27, P227, DOI 10.3892/ijmm.2010.566; Swindell WR, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-585; Wanders D, 2014, BIOFACTORS, V40, P13, DOI 10.1002/biof.1111; Weindruch R, 2001, J NUTR, V131, p918S, DOI 10.1093/jn/131.3.918S; Wu GM, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-5-r53; Yang WL, 2014, HUM MOL GENET, V23, P502, DOI 10.1093/hmg/ddt444; Ye JP, 2010, AGING-US, V2, P361, DOI 10.18632/aging.100155; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhou Z, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-109	53	33	33	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2577	2590		10.1096/fj.14-249458	http://dx.doi.org/10.1096/fj.14-249458			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24571921	Green Published			2023-01-03	WOS:000339883600017
J	Latham, NK; Harris, BA; Bean, JF; Heeren, T; Goodyear, C; Zawacki, S; Heislein, DM; Mustafa, J; Pardasaney, P; Giorgetti, M; Holt, N; Goehring, L; Jette, AM				Latham, Nancy K.; Harris, Bette Ann; Bean, Jonathan F.; Heeren, Timothy; Goodyear, Christine; Zawacki, Stacey; Heislein, Diane M.; Mustafa, Jabed; Pardasaney, Poonam; Giorgetti, Marie; Holt, Nicole; Goehring, Lori; Jette, Alan M.			Effect of a Home-Based Exercise Program on Functional Recovery Following Rehabilitation After Hip Fracture A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOWER-EXTREMITY FUNCTION; OUTPATIENT REHABILITATION; PHYSICAL FUNCTION; MORTALITY; BALANCE; RELIABILITY; VELOCITY; EFFICACY; SCALE; RISK	IMPORTANCE For many older people, long-term functional limitations persist after a hip fracture. The efficacy of a home exercise program with minimal supervision after formal hip fracture rehabilitation ends has not been established. OBJECTIVE To determine whether a home exercise program with minimal contact with a physical therapist improved function after formal hip fracture rehabilitation ended. DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial conducted from September 2008 to October 2012 in the homes of 232 functionally limited older adults who had completed traditional rehabilitation after a hip fracture. INTERVENTIONS The intervention group (n = 120) received functionally oriented exercises (such as standing from a chair, climbing a step) taught by a physical therapist and performed independently by the participants in their homes for 6 months. The attention control group (n = 112) received in-home and telephone-based cardiovascular nutrition education. MAIN OUTCOMES AND MEASURES Physical function assessed at baseline, 6 months (ie, at completion of the intervention), and 9 months by blinded assessors. The primary outcome was change in function at 6 months measured by the Short Physical Performance Battery (SPPB; range 0-12, higher score indicates better function) and the Activity Measure for Post-Acute Care (AM-PAC) mobility and daily activity (range, 23-85 and 9-101, higher score indicates better function). RESULTS Among the 232 randomized patients, 195 were followed up at 6 months and included in the primary analysis. The intervention group (n=100) showed significant improvement relative to the control group (n=95) in functional mobility (mean SPPB scores for intervention group: 6.2 [SD, 2.7] at baseline, 7.2 [SD, 3] at 6 months; control group: 6.0 [SD, 2.8] at baseline, 6.2 [SD, 3] at 6 months; and between-group differences: 0.8 [95% CI, 0.4 to 1.2], P < .001; mean AM-PAC mobility scores for intervention group: 56.2 [SD, 7.3] at baseline, 58.1 [SD, 7.9] at 6 months; control group: 56 [SD, 7.1] at baseline, 56.6 [SD, 8.1] at 6 months; and between-group difference, 1.3 [95% CI, 0.2 to 2.4], P = .03; and mean AM-PAC daily activity scores for intervention group: 57.4 [SD, 13.7] at baseline, 61.3 [SD, 15.7] at 6 months; control group: 58.2 [SD, 15.2] at baseline, 58.6 [SD, 15.3] at 6 months; and between-group difference, 3.5 [95% CI, 0.9 to 6.0], P = .03). In multiple imputation analyses, between-group differences remained significant for SPPB and AM-PAC daily activity, but not for mobility. Significant between-group differences persisted at 9 months for all functional measures with and without imputation. CONCLUSIONS AND RELEVANCE Among patients who had completed standard rehabilitation after hip fracture, the use of a home-based functionally oriented exercise program resulted in modest improvement in physical function at 6 months after randomization. The clinical importance of these findings remains to be determined.	[Latham, Nancy K.; Heeren, Timothy; Zawacki, Stacey; Heislein, Diane M.; Mustafa, Jabed; Goehring, Lori; Jette, Alan M.] Boston Univ, Boston, MA 02118 USA; [Harris, Bette Ann; Giorgetti, Marie] MGH Inst Hlth Profess, Boston, MA USA; [Bean, Jonathan F.] Harvard Univ, Sch Med, Boston, MA USA; [Bean, Jonathan F.; Holt, Nicole] Spaulding Cambridge Outpatient Ctr, Cambridge, MA USA; [Goodyear, Christine] Spaulding Rehabil Network, Boston, MA USA; [Pardasaney, Poonam] RTI Int, Boston, MA USA	Boston University; Harvard University; Harvard Medical School; Research Triangle Institute	Latham, NK (corresponding author), Boston Univ, Sch Publ Hlth, Hlth & Disabil Res Inst, 715 Albany St,5TW, Boston, MA 02118 USA.	nlatham@bu.edu	Bean, Jonathan F/F-5798-2017	Bean, Jonathan F/0000-0001-8385-8210	National Institute of Nursing Research [5R01NR010815]; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR010815] Funding Source: NIH RePORTER	National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	This study was funded by grant 5R01NR010815 from the National Institute of Nursing Research. All Thera-Band products were donated by Thera-Band.	Akamigbo A, 2012, MANDATED REPORT IMPR; Auais MA, 2012, PHYS THER, V92, P1437, DOI 10.2522/ptj.20110274; Bean JF, 2004, J AM GERIATR SOC, V52, P799, DOI 10.1111/j.1532-5415.2004.52222.x; BERG K, 1995, SCAND J REHABIL MED, V27, P27; BERG KO, 1992, CAN J PUBLIC HEALTH, V83, pS7; BERG KO, 1992, ARCH PHYS MED REHAB, V73, P1073; Binder EF, 2004, JAMA-J AM MED ASSOC, V292, P837, DOI 10.1001/jama.292.7.837; Braithwaite RS, 2003, J AM GERIATR SOC, V51, P364, DOI 10.1046/j.1532-5415.2003.51110.x; Brauer CA, 2009, JAMA-J AM MED ASSOC, V302, P1573, DOI 10.1001/jama.2009.1462; Chandra A, 2013, HEALTH AFFAIR, V32, P864, DOI 10.1377/hlthaff.2012.1262; Fransen M, 2002, J AM GERIATR SOC, V50, P685, DOI 10.1046/j.1532-5415.2002.50163.x; Fritz JM, 2011, PHYS THER, V91, P330, DOI 10.2522/ptj.20090290; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Haley SM, 2004, MED CARE, V42, P49, DOI 10.1097/01.mlr.0000103520.43902.6c; Handoll HHG, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001704.pub4; Hill KD, 1996, ARCH PHYS MED REHAB, V77, P1025, DOI 10.1016/S0003-9993(96)90063-5; Jette AM, 2007, PHYS THER, V87, P385, DOI 10.2522/ptj.20060121; Jette AM, 1999, AM J PUBLIC HEALTH, V89, P66, DOI 10.2105/AJPH.89.1.66; Jette AM, 1996, J AM GERIATR SOC, V44, P644, DOI 10.1111/j.1532-5415.1996.tb01825.x; Kammerlander C, 2011, ARCH ORTHOP TRAUM SU, V131, P1435, DOI 10.1007/s00402-011-1313-6; Kwon S, 2009, J NUTR HEALTH AGING, V13, P538, DOI 10.1007/s12603-009-0104-z; Latham NK, 2008, ARCH PHYS MED REHAB, V89, P2146, DOI 10.1016/j.apmr.2008.04.016; Latham NK, 2008, ARCH PHYS MED REHAB, V89, P807, DOI 10.1016/j.apmr.2008.02.010; Lord SR, 2003, PHYS THER, V83, P237, DOI 10.1093/ptj/83.3.237; Magaziner J, 2000, J GERONTOL A-BIOL, V55, pM498, DOI 10.1093/gerona/55.9.M498; Orwig DL, 2011, ARCH INTERN MED, V171, P323, DOI 10.1001/archinternmed.2011.15; Resnick B, 2000, NURS RES, V49, P154, DOI 10.1097/00006199-200005000-00007; Resnick B, 2000, J GERONTOL B-PSYCHOL, V55, pS352, DOI 10.1093/geronb/55.6.S352; Sherrington C, 2004, ARCH PHYS MED REHAB, V85, P710, DOI 10.1016/S0003-9993(03)00620-8; Sherrington C, 1997, ARCH PHYS MED REHAB, V78, P208, DOI 10.1016/S0003-9993(97)90265-3; Stevens JA, 2013, OSTEOPOROSIS INT, V24, P2725, DOI 10.1007/s00198-013-2375-9; TINETTI ME, 1990, J GERONTOL, V45, pP239, DOI 10.1093/geronj/45.6.P239; US Department of Health and Human Services and US Department of Agriculture, 2005, DIET GUID AM	34	122	123	0	39	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	2014	311	7					700	708		10.1001/jama.2014.469	http://dx.doi.org/10.1001/jama.2014.469			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AA8ZO	24549550	Green Accepted			2023-01-03	WOS:000331383700022
J	Suksomboon, N; Poolsup, N; Nge, YL				Suksomboon, Naeti; Poolsup, Nalinee; Nge, Yuu Lay			Impact of Phone Call Intervention on Glycemic Control in Diabetes Patients: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials	PLOS ONE			English	Article							AFRICAN-AMERICAN WOMEN; IMPROVE SELF-CARE; NURSE FOLLOW-UP; DELIVERED INTERVENTION; AUTOMATED CALLS; GLUCOSE CONTROL; CASE-MANAGEMENT; OUTCOMES; ADHERENCE; SUPPORT	Background: Telephone-delivered intervention can provide many supports in diabetes self-management to improve glycemic control. Several trials showed that telephone intervention was positively associated with glycemic outcomes in diabetes. The objective of this meta-analysis was to assess the impact of telephone contact intervention (intervention group) on glycemic control compared with standard clinical care (control group). Methods: Randomized control studies of telephone intervention in diabetes were searched on Medline (Pubmed), the Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science (ISI), and Scopus. Electronic search was done from inception to April 2013. The following MeSH terms were used: diabetes mellitus, randomized control trials and telemedicine, together with keywords including phone intervention, diabetes, and glycemic control. Historical search was also conducted on the references of relevant articles. The quality of the trials was assessed using Maastricht-Amsterdam scale. Treatment effect was estimated with mean difference in the change of hemoglobin A1c (HbA1c) from baseline between the intervention and control groups. Results: A total of 203 articles were examined. Five trials involving 953 patients met the inclusion criteria and contributed to the meta-analysis. Telephone contact intervention was no more effective than standard clinical care in improving glycemic control (pooled mean difference in HbA1c 20.38%, 95% CI - 0.91 to 0.16%). Conclusions: This meta-analysis showed that the phone contact intervention was no more effective than standard clinical care in improving glycemic control in diabetes. However, telephone intervention may still have potential benefits especially for low-and middle-income countries; thus further large sample size and well-controlled studies are needed to evaluate the impact of the intervention.	[Suksomboon, Naeti; Nge, Yuu Lay] Mahidol Univ, Dept Pharm, Fac Pharm, Bangkok 10700, Thailand; [Poolsup, Nalinee] Silpakorn Univ, Dept Pharm, Fac Pharm, Nakhon Pathom, Thailand	Mahidol University; Silpakorn University	Poolsup, N (corresponding author), Silpakorn Univ, Dept Pharm, Fac Pharm, Nakhon Pathom, Thailand.	npoolsup@hotmail.com						Adwan Mezyed A, 2013, Glob J Health Sci, V5, P213, DOI 10.5539/gjhs.v5n2p213; Aubert RE, 1998, ANN INTERN MED, V129, P605, DOI 10.7326/0003-4819-129-8-199810150-00004; Bogner HR, 2012, ANN FAM MED, V10, P15, DOI 10.1370/afm.1344; Crowley MJ, 2013, AM HEART J, V166, P179, DOI 10.1016/j.ahj.2013.04.004; Dale J, 2009, PATIENT EDUC COUNS, V75, P91, DOI 10.1016/j.pec.2008.09.014; Eakin EG, 2013, ANN BEHAV MED, V46, P193, DOI 10.1007/s12160-013-9498-2; Free C, 2013, PLOS MED, V10, DOI [10.1371/journal.pmed.1001363, 10.1371/journal.pmed.1001362]; Furlan AD, 2009, SPINE, V34, P1929, DOI 10.1097/BRS.0b013e3181b1c99f; Graziano Judith A, 2009, ANS Adv Nurs Sci, V32, pE42, DOI 10.1097/ANS.0b013e3181b117a9; Higgins Julian PT, 2011, COCHRANE HDB SYSTEMA, P649; Holtz B, 2012, TELEMED E-HEALTH, V18, P175, DOI 10.1089/tmj.2011.0119; Howe Carol J, 2005, J Pediatr Nurs, V20, P83, DOI 10.1016/j.pedn.2004.12.010; Howells L, 2002, DIABETIC MED, V19, P643, DOI 10.1046/j.1464-5491.2002.00791.x; Institute of Medicine, 1996, TEL GUID ASS TEL HLT; International Diabetes Federation, 2013, IDF DIABETES ATLAS, Vsixth; International Telecommunication Union, 2013, STAT AGGR DAT; Jaana M, 2007, J EVAL CLIN PRACT, V13, P242, DOI 10.1111/j.1365-2753.2006.00686.x; Jarab AS, 2012, J MANAGE CARE PHARM, V18, P516, DOI 10.18553/jmcp.2012.18.7.516; Keogh KM, 2011, AM J MANAG CARE, V17, P105; Keyserling TC, 2002, DIABETES CARE, V25, P1576, DOI 10.2337/diacare.25.9.1576; Khattab M, 2010, J DIABETES COMPLICAT, V24, P84, DOI 10.1016/j.jdiacomp.2008.12.008; Kim HS, 2003, J ADV NURS, V44, P256, DOI 10.1046/j.1365-2648.2003.02800.x; Krein SL, 2004, AM J MED, V116, P732, DOI 10.1016/j.amjmed.2003.11.028; Krishna Santosh, 2008, J Diabetes Sci Technol, V2, P509; Liang X, 2011, DIABETIC MED, V28, P455, DOI 10.1111/j.1464-5491.2010.03180.x; Maljanian Rose, 2005, Dis Manag, V8, P15, DOI 10.1089/dis.2005.8.15; Minet L, 2010, PATIENT EDUC COUNS, V80, P29, DOI 10.1016/j.pec.2009.09.033; Moriyama M, 2009, JPN J NURS SCI, V6, P51, DOI 10.1111/j.1742-7924.2009.00120.x; Naik AD, 2012, BMC GERIATR, V12, DOI 10.1186/1471-2318-12-37; Nesari M, 2010, JPN J NURS SCI, V7, P121, DOI 10.1111/j.1742-7924.2010.00146.x; Norris AC, 2002, ESSENTIALS TELEMEDIC; Nunn E, 2006, PEDIATR DIABETES, V7, P254, DOI 10.1111/j.1399-5448.2006.00200.x; Oh JA, 2003, YONSEI MED J, V44, P1, DOI 10.3349/ymj.2003.44.1.1; Piette JD, 2000, AM J MED, V108, P20, DOI 10.1016/S0002-9343(99)00298-3; Piette JD, 2001, DIABETES CARE, V24, P202, DOI 10.2337/diacare.24.2.202; Piette JD, 2011, MED CARE, V49, P641, DOI 10.1097/MLR.0b013e318215d0c9; Polisena J, 2009, DIABETES OBES METAB, V11, P913, DOI 10.1111/j.1463-1326.2009.01057.x; Samuel-Hodge Carmen D, 2006, Prev Chronic Dis, V3, pA93; Skelly AH, 2009, NURS RES, V58, P410, DOI 10.1097/NNR.0b013e3181bee597; Song MS, 2007, J CLIN NURS, V16, P1367, DOI 10.1111/j.1365-2702.2007.01800.x; Taylor CB, 2003, DIABETES CARE, V26, P1058, DOI 10.2337/diacare.26.4.1058; Thom DH, 2013, ANN FAM MED, V11, P137, DOI 10.1370/afm.1443; Thompson DM, 1999, CAN MED ASSOC J, V161, P959; Walker EA, 2011, DIABETES CARE, V34, P2, DOI 10.2337/dc10-1005; Whittemore R, 2004, DIABETES EDUCATOR, V30, P795, DOI 10.1177/014572170403000515; Williams ED, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-602; Young RJ, 2005, DIABETES CARE, V28, P278, DOI 10.2337/diacare.28.2.278	47	30	31	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2014	9	2							e89207	10.1371/journal.pone.0089207	http://dx.doi.org/10.1371/journal.pone.0089207			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AB3TA	24586596	Green Published, Green Submitted, gold			2023-01-03	WOS:000331711900104
J	Parr, EB; Camera, DM; Areta, JL; Burke, LM; Phillips, SM; Hawley, JA; Coffey, VG				Parr, Evelyn B.; Camera, Donny M.; Areta, Jose L.; Burke, Louise M.; Phillips, Stuart M.; Hawley, John A.; Coffey, Vernon G.			Alcohol Ingestion Impairs Maximal Post-Exercise Rates of Myofibrillar Protein Synthesis following a Single Bout of Concurrent Training	PLOS ONE			English	Article							HUMAN SKELETAL-MUSCLE; NEW-ZEALAND SPORTSPEOPLE; RESISTANCE EXERCISE; HAZARDOUS DRINKING; GENE-EXPRESSION; MESSENGER-RNA; RAG GTPASES; AMINO-ACIDS; MTOR; PHOSPHORYLATION	Introduction: The culture in many team sports involves consumption of large amounts of alcohol after training/ competition. The effect of such a practice on recovery processes underlying protein turnover in human skeletal muscle are unknown. We determined the effect of alcohol intake on rates of myofibrillar protein synthesis (MPS) following strenuous exercise with carbohydrate (CHO) or protein ingestion. Methods: In a randomized cross-over design, 8 physically active males completed three experimental trials comprising resistance exercise (865 reps leg extension, 80% 1 repetition maximum) followed by continuous (30 min, 63% peak power output (PPO)) and high intensity interval (10x30 s, 110% PPO) cycling. Immediately, and 4 h post-exercise, subjects consumed either 500 mL of whey protein (25 g; PRO), alcohol (1.5 g center dot kg body mass(-1), 12 +/- 2 standard drinks) co-ingested with protein (ALC-PRO), or an energy-matched quantity of carbohydrate also with alcohol (25 g maltodextrin; ALC-CHO). Subjects also consumed a CHO meal (1.5 g CHO center dot kg body mass(-1)) 2 h post-exercise. Muscle biopsies were taken at rest, 2 and 8 h post-exercise. Results: Blood alcohol concentration was elevated above baseline with ALC-CHO and ALC-PRO throughout recovery (P<0.05). Phosphorylation of mTOR(Sper2448) 2 h after exercise was higher with PRO compared to ALC-PRO and ALC-CHO (P<0.05), while p70S6K phosphorylation was higher 2 h post-exercise with ALC-PRO and PRO compared to ALC-CHO (P<0.05). Rates of MPS increased above rest for all conditions (similar to 29-109%, P<0.05). However, compared to PRO, there was a hierarchical reduction in MPS with ALC-PRO (24%, P<0.05) and with ALC-CHO (37%, P, 0.05). Conclusion: We provide novel data demonstrating that alcohol consumption reduces rates of MPS following a bout of concurrent exercise, even when co-ingested with protein. We conclude that alcohol ingestion suppresses the anabolic response in skeletal muscle and may therefore impair recovery and adaptation to training and/or subsequent performance.	[Parr, Evelyn B.; Camera, Donny M.; Areta, Jose L.] RMIT Univ, Sch Med Sci, Exercise & Nutr Res Grp, Bundoora, Vic, Australia; [Burke, Louise M.] Australian Inst Sport, Dept Sports Nutr, Canberra, ACT, Australia; [Phillips, Stuart M.] McMaster Univ, Dept Kinesiol, Exercise Metab Res Grp, Hamilton, ON, Canada; [Hawley, John A.] Australian Catholic Univ, Sch Exercise Sci, Exercise & Nutr Res Grp, Fitzroy, Vic, Australia; [Hawley, John A.] Liverpool John Moores Univ, Res Inst Sport & Exercise Sci, Liverpool L3 5UX, Merseyside, England; [Coffey, Vernon G.] Queensland Univ Technol, Sch Exercise & Nutr Sci, Kelvin Grove, Qld, Australia; [Coffey, Vernon G.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Kelvin Grove, Qld, Australia	Royal Melbourne Institute of Technology (RMIT); Australian Institute of Sport; McMaster University; Australian Catholic University; Liverpool John Moores University; Queensland University of Technology (QUT); Queensland University of Technology (QUT)	Hawley, JA (corresponding author), Australian Catholic Univ, Sch Exercise Sci, Exercise & Nutr Res Grp, Fitzroy, Vic, Australia.	john.hawley@acu.edu.au	Burke, Louise/X-3127-2019; Hawley, John A/U-3814-2018; Burke, Louise/ABC-5691-2020; Camera, Donny/J-1571-2018; Phillips, Stuart/B-2343-2009; Parr, Evelyn/J-1576-2018; Areta, José L/H-8216-2019	Burke, Louise/0000-0001-8866-5637; Hawley, John A/0000-0002-0886-9881; Camera, Donny/0000-0002-6494-9472; Phillips, Stuart/0000-0002-1956-4098; Parr, Evelyn/0000-0003-1710-6381; Areta, José L/0000-0001-6918-1223	Australian Sports Commission	Australian Sports Commission	This study was, in part, funded by a grant from the Australian Sports Commission to LMB. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. No additional external funding was received for this study.	Areta JL, 2013, J PHYSIOL-LONDON, V591, P2319, DOI 10.1113/jphysiol.2012.244897; ASP S, 1995, J PHYSIOL-LONDON, V482, P705, DOI 10.1113/jphysiol.1995.sp020553; Atherton PJ, 2010, AM J CLIN NUTR, V92, P1080, DOI 10.3945/ajcn.2010.29819; Baar K, 1999, AM J PHYSIOL-CELL PH, V276, pC120, DOI 10.1152/ajpcell.1999.276.1.C120; Barnes MJ, 2011, EUR J APPL PHYSIOL, V111, P725, DOI 10.1007/s00421-010-1655-8; Barnes MJ, 2010, EUR J APPL PHYSIOL, V108, P1009, DOI 10.1007/s00421-009-1311-3; Burd NA, 2012, METABOLISM, V61, P931, DOI 10.1016/j.metabol.2011.11.004; Burd NA, 2010, J PHYSIOL-LONDON, V588, P3119, DOI 10.1113/jphysiol.2010.192856; Burke LM, 2003, J APPL PHYSIOL, V95, P983, DOI 10.1152/japplphysiol.00115.2003; BURKE LM, 1988, CAN J SPORT SCI, V13, P15; Burke LM, 2011, J SPORT SCI, V29, pS17, DOI 10.1080/02640414.2011.585473; Camera DM, 2012, J APPL PHYSIOL, V113, P206, DOI 10.1152/japplphysiol.00395.2012; Coffey VG, 2011, EUR J APPL PHYSIOL, V111, P1473, DOI 10.1007/s00421-010-1768-0; Coffey VG, 2009, AM J PHYSIOL-REG I, V297, pR1441, DOI 10.1152/ajpregu.00351.2009; Deldicque L, 2012, EXERC SPORT SCI REV, V40, P43, DOI 10.1097/JES.0b013e3182355e8c; Dreyer HC, 2008, AM J PHYSIOL-ENDOC M, V294, pE392, DOI 10.1152/ajpendo.00582.2007; Fernandez-Sola J, 2007, ALCOHOL CLIN EXP RES, V31, P1953, DOI 10.1111/j.1530-0277.2007.00530.x; Fry CS, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-11; HAWLEY JA, 1992, EUR J APPL PHYSIOL, V65, P79, DOI 10.1007/BF01466278; Hawley JA, 2011, J APPL PHYSIOL, V110, P834, DOI 10.1152/japplphysiol.00949.2010; Kim E, 2008, NAT CELL BIOL, V10, P935, DOI 10.1038/ncb1753; Koopman R, 2007, SPORTS MED, V37, P895, DOI 10.2165/00007256-200737100-00005; Kumar V, 2002, AM J PHYSIOL-ENDOC M, V283, pE917, DOI 10.1152/ajpendo.00181.2002; Kumar V, 2009, J PHYSIOL-LONDON, V587, P211, DOI 10.1113/jphysiol.2008.164483; Lang CH, 1999, AM J PHYSIOL-ENDOC M, V277, pE268, DOI 10.1152/ajpendo.1999.277.2.E268; Lang CH, 2000, ALCOHOL CLIN EXP RES, V24, P322, DOI 10.1111/j.1530-0277.2000.tb04614.x; Lang CH, 2004, ALCOHOL CLIN EXP RES, V28, P1758, DOI 10.1097/01.ALC.0000145787.66405.59; Lang CH, 2004, AM J PHYSIOL-ENDOC M, V286, pE916, DOI 10.1152/ajpendo.00554.2003; Lang CH, 2003, AM J PHYSIOL-ENDOC M, V285, pE1205, DOI 10.1152/ajpendo.00177.2003; Lang CH, 2008, ALCOHOL CLIN EXP RES, V32, P796, DOI 10.1111/j.1530-0277.2008.00637.x; Lang CH, 2009, NUTR METAB, V6, DOI 10.1186/1743-7075-6-4; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Louis E, 2007, J APPL PHYSIOL, V103, P1744, DOI 10.1152/japplphysiol.00679.2007; Martens MP, 2006, J SUBST ABUSE TREAT, V31, P305, DOI 10.1016/j.jsat.2006.05.004; Miyazaki M, 2009, AM J PHYSIOL-CELL PH, V296, pC583, DOI 10.1152/ajpcell.00464.2008; Moore DR, 2009, J PHYSIOL-LONDON, V587, P897, DOI 10.1113/jphysiol.2008.164087; O'Brien KS, 2007, ALCOHOL ALCOHOLISM, V42, P376, DOI 10.1093/alcalc/agm035; O'Brien KS, 2005, ALCOHOL ALCOHOLISM, V40, P239, DOI 10.1093/alcalc/agh145; O'Neil TK, 2009, J PHYSIOL-LONDON, V587, P3691, DOI 10.1113/jphysiol.2009.173609; OBRIEN CP, 1993, SPORTS MED, V15, P71, DOI 10.2165/00007256-199315020-00001; Phillips SM, 1997, AM J PHYSIOL-ENDOC M, V273, pE99, DOI 10.1152/ajpendo.1997.273.1.E99; Phillips SM, 2006, APPL PHYSIOL NUTR ME, V31, P647, DOI 10.1139/h06-035; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Stellingwerff T, 2011, J SPORT SCI, V29, pS79, DOI 10.1080/02640414.2011.589469; Vary TC, 2008, AM J PHYSIOL-REG I, V294, pR1777, DOI 10.1152/ajpregu.00056.2008; Wang XM, 2005, MOL CELL BIOL, V25, P2558, DOI 10.1128/MCB.25.7.2558-2572.2005; Watten RG, 1995, SCAND J MED SCI SPOR, V5, P364; West DWD, 2011, AM J CLIN NUTR, V94, P795, DOI 10.3945/ajcn.111.013722; Yang YF, 2006, J APPL PHYSIOL, V101, P1442, DOI 10.1152/japplphysiol.00438.2006; Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056	50	58	58	0	51	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2014	9	2							e88384	10.1371/journal.pone.0088384	http://dx.doi.org/10.1371/journal.pone.0088384			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7FJ	24533082	Green Published, gold, Green Submitted			2023-01-03	WOS:000331262600040
J	Deere, JD; Kauffman, RC; Cannavo, E; Higgins, J; Villalobos, A; Adamson, L; Schinazi, RF; Luciw, PA; North, TW				Deere, Jesse D.; Kauffman, Robert C.; Cannavo, Elda; Higgins, Joanne; Villalobos, Andradi; Adamson, Lourdes; Schinazi, Raymond F.; Luciw, Paul A.; North, Thomas W.			Analysis of Multiply Spliced Transcripts in Lymphoid Tissue Reservoirs of Rhesus Macaques Infected with RT-SHIV during HAART	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; CD4(+) T-CELLS; TYPE-1 REVERSE-TRANSCRIPTASE; VIRAL MESSENGER-RNA; TRANSACTIVATOR GENE; HIV-1 INFECTION; HTLV-III; PRODUCTIVE INFECTION; ANTIVIRAL THERAPY	Highly active antiretroviral therapy (HAART) can reduce levels of human immunodeficiency virus type 1 (HIV-1) to undetectable levels in infected individuals, but the virus is not eradicated. The mechanisms of viral persistence during HAART are poorly defined, but some reservoirs have been identified, such as latently infected resting memory CD4(+) T cells. During latency, in addition to blocks at the initiation and elongation steps of viral transcription, there is a block in the export of viral RNA (vRNA), leading to the accumulation of multiply-spliced transcripts in the nucleus. Two of the genes encoded by the multiply-spliced transcripts are Tat and Rev, which are essential early in the viral replication cycle and might indicate the state of infection in a given population of cells. Here, the levels of multiply-spliced transcripts were compared to the levels of gag-containing RNA in tissue samples from RT-SHIV-infected rhesus macaques treated with HAART. Splice site sequence variation was identified during development of a TaqMan PCR assay. Multiply-spliced transcripts were detected in gastrointestinal and lymphatic tissues, but not the thymus. Levels of multiply-spliced transcripts were lower than levels of gag RNA, and both correlated with plasma virus loads. The ratio of multiply-spliced to gag RNA was greatest in the gastrointestinal samples from macaques with plasma virus loads <50 vRNA copies per mL at necropsy. Levels of gag RNA and multiply-spliced mRNA in tissues from RT-SHIV-infected macaques correlate with plasma virus load.	[Deere, Jesse D.; Kauffman, Robert C.; Cannavo, Elda; Higgins, Joanne; Villalobos, Andradi; Adamson, Lourdes; Luciw, Paul A.; North, Thomas W.] Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; [Schinazi, Raymond F.] Emory Univ, Vet Affairs Med Ctr, Sch Med, Ctr AIDS Res,Lab Biochem Pharmacol,Dept Pediat, Atlanta, GA USA; [Luciw, Paul A.] Univ Calif Davis, Sch Med, Dept Pathol, Davis, CA 95616 USA; [North, Thomas W.] Univ Calif Davis, Dept Vet Mol Biosci, Davis, CA 95616 USA	University of California System; University of California Davis; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; University of California System; University of California Davis; University of California System; University of California Davis	North, TW (corresponding author), Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA.	tnorth@emory.edu	Deere, Jesse Dee/ABH-7940-2020; Schinazi, Raymond F/B-6777-2017	Deere, Jesse/0000-0002-2539-0338	NIH [P01-AI058708, 1R01-RR-025996, 1RO1-MH10099, T32-AI60555]; Emory Centers for AIDS Research NIH [2P30-AI-050409]; Department of Veterans Affairs; California HIV/AIDS Research Program [D09-D-310]; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR025996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI058708, P30AI050409, T32AI060555] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Emory Centers for AIDS Research NIH; Department of Veterans Affairs(US Department of Veterans Affairs); California HIV/AIDS Research Program; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported in part by NIH program project grant P01-AI058708, NIH grant 1R01-RR-025996 (TWN and RFS) and 1RO1-MH10099 (RFS). It was also supported by the Emory Centers for AIDS Research NIH grant 2P30-AI-050409 and the Department of Veterans Affairs. J.D. Deere was supported in part by NIH training grant T32-AI60555. R.C. Kauffman was funded by the California HIV/AIDS Research Program grant D09-D-310. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAMS M, 1994, P NATL ACAD SCI USA, V91, P3862, DOI 10.1073/pnas.91.9.3862; Ambrose Z, 2004, J VIROL, V78, P13553, DOI 10.1128/JVI.78.24.13553-13561.2004; Ambrose Z, 2007, J VIROL, V81, P12145, DOI 10.1128/JVI.01301-07; Baumgarth N, 2004, AM J PATHOL, V165, P707, DOI 10.1016/S0002-9440(10)63334-2; BEDNARIK DP, 1987, J VIROL, V61, P1253, DOI 10.1128/JVI.61.4.1253-1257.1987; Brady T, 2009, AIDS, V23, P1461, DOI 10.1097/QAD.0b013e32832caf28; Chun TW, 2005, J CLIN INVEST, V115, P3250, DOI 10.1172/JCI26197; Chun TW, 2000, NAT MED, V6, P757, DOI 10.1038/77481; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Deere JD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011640; Dinoso JB, 2009, J VIROL, V83, P9247, DOI 10.1128/JVI.00840-09; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; Gavegnano Christina, 2009, Antiviral Chemistry & Chemotherapy, V20, P63, DOI 10.3851/IMP1374; Gunthard HF, 1999, J VIROL, V73, P9404; Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001; Hatziioannou T, 2009, P NATL ACAD SCI USA, V106, P4425, DOI 10.1073/pnas.0812587106; Havlir DV, 2001, JAMA-J AM MED ASSOC, V286, P171, DOI 10.1001/jama.286.2.171; Havlir DV, 2003, J VIROL, V77, P11212, DOI 10.1128/JVI.77.20.11212-11219.2003; Hofman MJ, 2004, ANTIMICROB AGENTS CH, V48, P3483, DOI 10.1128/AAC.48.9.3483-3490.2004; Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188; Jordan A, 2001, EMBO J, V20, P1726, DOI 10.1093/emboj/20.7.1726; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KODAMA T, 1989, J VIROL, V63, P4709, DOI 10.1128/JVI.63.11.4709-4714.1989; Lassen K, 2004, TRENDS MOL MED, V10, P525, DOI 10.1016/j.molmed.2004.09.006; Lassen KG, 2006, PLOS PATHOG, V2, P650, DOI 10.1371/journal.ppat.0020068; Lassen KG, 2004, J VIROL, V78, P9105, DOI 10.1128/JVI.78.17.9105-9114.2004; Lee C, 2006, J BIOTECHNOL, V123, P273, DOI 10.1016/j.jbiotec.2005.11.014; Leutenegger CM, 2001, AIDS RES HUM RETROV, V17, P243, DOI 10.1089/088922201750063160; Lewin SR, 1999, J VIROL, V73, P6099, DOI 10.1128/JVI.73.7.6099-6103.1999; Lin X, 2003, J VIROL, V77, P8227, DOI 10.1128/JVI.77.15.8227-8236.2003; Maldarelli F, 2007, PLOS PATHOG, V3, P484, DOI 10.1371/journal.ppat.0030046; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Mok HP, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-228; North TW, 2010, J VIROL, V84, P2913, DOI 10.1128/JVI.02356-09; North TW, 2005, J VIROL, V79, P7349, DOI 10.1128/JVI.79.12.7349-7354.2005; Palmer S, 2003, J CLIN MICROBIOL, V41, P4531, DOI 10.1128/JCM.41.10.4531-4536.2003; Palmer S, 2008, P NATL ACAD SCI USA, V105, P3879, DOI 10.1073/pnas.0800050105; PARK IW, 1991, J VIROL, V65, P2987, DOI 10.1128/JVI.65.6.2987-2992.1991; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; Poles MA, 2006, JAIDS-J ACQ IMM DEF, V43, P65, DOI 10.1097/01.qai.0000230524.71717.14; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577; REGIER DA, 1990, AIDS RES HUM RETROV, V6, P1221, DOI 10.1089/aid.1990.6.1221; Reinhart TA, 1996, VIROLOGY, V224, P338, DOI 10.1006/viro.1996.0539; Reinhart TA, 1997, NAT MED, V3, P218, DOI 10.1038/nm0297-218; SCHULZEFORSTER K, 1990, BIOCHEM BIOPH RES CO, V168, P141, DOI 10.1016/0006-291X(90)91685-L; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; Shen AD, 2003, J VIROL, V77, P4938, DOI 10.1128/JVI.77.8.4938-4949.2003; Soderberg K, 2002, J VIROL, V76, P5803, DOI 10.1128/JVI.76.11.5803-5806.2002; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; Tobin NH, 2005, J VIROL, V79, P9625, DOI 10.1128/JVI.79.15.9625-9634.2005; UBERLA K, 1995, P NATL ACAD SCI USA, V92, P8210, DOI 10.1073/pnas.92.18.8210; UNGER RE, 1991, VIROLOGY, V182, P177, DOI 10.1016/0042-6822(91)90661-T; Van Rompay KKA, 2004, ANTIMICROB AGENTS CH, V48, P1469, DOI 10.1128/AAC.48.5.1469-1487.2004; VIGLIANTI GA, 1988, J VIROL, V62, P4523, DOI 10.1128/JVI.62.12.4523-4532.1988; VIGLIANTI GA, 1990, J VIROL, V64, P4207, DOI 10.1128/JVI.64.9.4207-4216.1990; Yukl SA, 2010, J INFECT DIS, V202, P1553, DOI 10.1086/656722; Yukl SA, 2010, AIDS, V24, P2450, DOI 10.1097/QAD.0b013e32833ef7bb; Zhang LQ, 2000, J CLIN INVEST, V106, P839, DOI 10.1172/JCI10565	67	14	14	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2014	9	2							e87914	10.1371/journal.pone.0087914	http://dx.doi.org/10.1371/journal.pone.0087914			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA1AT	24505331	Green Published, gold, Green Submitted			2023-01-03	WOS:000330829200085
J	Qiu, SL; Chen, J; Qin, T; Hu, YL; Wang, DY; Fan, Q; Zhang, CS; Chen, XY; Chen, XL; Liu, C; Gao, ZZ; Li, XP				Qiu, Shulei; Chen, Jin; Qin, Tao; Hu, Yuanliang; Wang, Deyun; Fan, Qiang; Zhang, Cunshuai; Chen, Xingying; Chen, Xiaolan; Liu, Cui; Gao, Zhenzhen; Li, Xiuping			Effects of Selenylation Modification on Immune-Enhancing Activity of Garlic Polysaccharide	PLOS ONE			English	Article							CHINESE; ADJUVANTICITY	The garlic polysaccharide was modified by HNO3-Na2SeO3 method according to orthogonal design L-9(3(4)) to obtain nine selenizing garlic polysaccharides, sGPS(1)-sGPS(9). Their effects on chicken peripheral lymphocytes proliferation in vitro were compared by MTT assay. The results showed that sGPSs could significantly promote lymphocytes proliferation, sGPS(3), sGPS(5) and sGPS(6) presented stronger efficacy. In vivo experiment, 14-day-old chickens were injected respectively with sGPS(3), sGPS(5) and sGPS(6) when they were vaccinated with ND vaccine taking unmodified GPS as control. The results showed that three sGPSs could significantly promote lymphocyte proliferation, enhance serum antibody titer, IFN-gamma and IL-2 contents. These results indicated that selenylation modification could significantly enhance the immune-enhancing activity of GPS, sGPS(6) possessed the best efficacy and could be as a candidate drug of immunoenhancer. Its optimal modification conditions were 400 mg of sodium selenite for 500 mg of GPS, reaction temperature of 70 degrees C and reaction time of 6 h.	[Qiu, Shulei; Qin, Tao; Hu, Yuanliang; Wang, Deyun; Chen, Xingying; Chen, Xiaolan; Liu, Cui; Gao, Zhenzhen; Li, Xiuping] Nanjing Agr Univ, Coll Vet Med, Inst Tradit Chinese Vet Med, Nanjing, Jiangsu, Peoples R China; [Chen, Jin] Jiangsu Acad Agr Sci, Natl Res Ctr Vet Biol Engn & Technol, Nanjing, Jiangsu, Peoples R China; [Fan, Qiang; Zhang, Cunshuai] China Inst Vet Drug Control, Beijing, Peoples R China	Nanjing Agricultural University; Jiangsu Academy of Agricultural Sciences; China Institute of Veterinary Drug Control	Hu, YL (corresponding author), Nanjing Agr Univ, Coll Vet Med, Inst Tradit Chinese Vet Med, Nanjing, Jiangsu, Peoples R China.	ylhu@njau.edu.cn			National Natural Science Foundation of China [31272596]; National Technological Supporting Program of China [2011BAD34B02]; Priority Academic Program Development of Jiangsu Higher Education Institutions	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Technological Supporting Program of China; Priority Academic Program Development of Jiangsu Higher Education Institutions	The project was supported by National Natural Science Foundation of China (31272596), National Technological Supporting Program of China (2011BAD34B02), and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abula S, 2011, CARBOHYD POLYM, V85, P687, DOI 10.1016/j.carbpol.2011.03.032; ADETUMBI MA, 1983, MED HYPOTHESES, V12, P227, DOI 10.1016/0306-9877(83)90040-3; Basinski TM, 2009, J ALLERGY CLIN IMMUN, V124, P74, DOI 10.1016/j.jaci.2009.04.019; Cao J., 2010, CHINESE FOLK MED, V19, P61; Cui Q, 2003, CHINESE J BIOCH PHAR, V24, P155; Decker T, 2005, NAT REV IMMUNOL, V19, P1; [高建忠 GAO Jianzhong], 2006, [分析科学学报, Journal of Analytical Science], V22, P157; Gong X, 1997, J SHENZHEN U, V14, P68; Guichard E, 2000, FOOD CHEM, V71, P301, DOI 10.1016/S0308-8146(00)00181-3; Guo LW, 2012, INT J BIOL MACROMOL, V50, P512, DOI 10.1016/j.ijbiomac.2012.01.002; Hu Q, 2001, J CHINESE MARINE DRU, V5, P20; Irie T, 2003, DEV COMP IMMUNOL, V27, P413, DOI 10.1016/S0145-305X(02)00137-4; Koch H. P., 1996, GARLIC SCI THERAPEUT, P1; Kong XF, 2004, INT IMMUNOPHARMACOL, V4, P975, DOI 10.1016/j.intimp.2004.03.008; LAU BHS, 1983, NUTR RES, V3, P119, DOI 10.1016/S0271-5317(83)80128-6; Li CR, 2007, CELL IMMUNOL, V250, P40, DOI 10.1016/j.cellimm.2008.01.003; [李公斌 Li Gongbin], 2008, [东北林业大学学报, Journal of North-East Forestry University], V36, P66; Li X., 2008, HUBEI J NATL I NATUR, V26, P456; Li X, 2006, CHINESE HERBAL MED, V37, P7; Liang L.J., 2008, THESIS NANCHANG U; Liu J, 2003, BEVE FAST FROZEN FOO, V9, P27; Liu J, 2013, J NUTR, V35, P36; Lu ZQ, 2013, CARBOHYD POLYM, V96, P131, DOI 10.1016/j.carbpol.2013.03.063; Piraprez G, 1998, FOOD CHEM, V61, P119, DOI 10.1016/S0308-8146(97)00120-9; Qin T, 2013, CARBOHYD POLYM, V95, P183, DOI 10.1016/j.carbpol.2013.02.072; Qin T, 2013, CARBOHYD POLYM, V92, P645, DOI 10.1016/j.carbpol.2012.08.097; [邱妍 QIU Yan], 2007, [畜牧兽医学报, Acta Veterinaria et Zootechnica Sinica], V38, P723; Staaf M, 2000, CARBOHYD RES, V326, P113, DOI 10.1016/S0008-6215(00)00027-6; Tang J, 1988, BIOCH BIOPHYSICS, V20, P259; Thekisoe MMO, 2004, VET MICROBIOL, V101, P23, DOI 10.1016/j.vetmic.2004.03.011; Veterinary Pharmacopoeia Commission of the People's Republic of China, 2010, VET PHARM PEOPL RE 1, V72-73; Wang DY, 2005, VACCINE, V23, P3704, DOI 10.1016/j.vaccine.2005.02.011; [王红连 WANG Hong-lian], 2009, [食品科学, Food Science], V30, P316; Wang Y., 2009, ANIMAL HUSBANDRY VET, V41, P71; Yang H C, 1997, ANIMAL IMMUNOLOGY, P129; Yang J., 2009, CHINESE PATENT MED, V32, P1065; Yu W., 2009, FOOD SCI TECHNOLOGY, V10, P262; Yu W., 2009, J FOOD SCI TECH MYS, V10, P256; Zhang X., 2000, OCEANOLOGY LIMNOLOGY, V31, P643; Zheng M, 2003, J XIANNING COLL, V17, P85; Zimmermann M, 2011, J ALLERGY CLIN IMMUN, V127, P200, DOI 10.1016/j.jaci.2010.11.005	41	33	41	3	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2014	9	1							e86377	10.1371/journal.pone.0086377	http://dx.doi.org/10.1371/journal.pone.0086377			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302PJ	24497946	Green Submitted, gold, Green Published			2023-01-03	WOS:000330617100014
J	Chen, XH; Yin, SY; Hu, C; Chen, XM; Jiang, K; Ye, SM; Feng, XW; Fan, SF; Xie, HY; Zhou, L; Zheng, SS				Chen, Xinhua; Yin, Shengyong; Hu, Chen; Chen, Xinmei; Jiang, Kai; Ye, Shuming; Feng, Xiaowen; Fan, Shifeng; Xie, Haiyang; Zhou, Lin; Zheng, Shusen			Comparative Study of Nanosecond Electric Fields In Vitro and In Vivo on Hepatocellular Carcinoma Indicate Macrophage Infiltration Contribute to Tumor Ablation In Vivo	PLOS ONE			English	Article							SELF-DESTRUCT; MELANOMAS; NANOELECTROABLATION; THERAPY; MODEL	Background and Aim: Recurrence and metastasis are associated with poor prognosis in hepatocellular carcinoma even in the patients who have undergone radical resection. Therefore, effective treatment is urgently needed for improvement of patients' survival. Previously, we reported that nanosecond pulse electric fields (nsPEFs) can ablate melanoma by induction of apoptosis and inhibition of angiogenesis. This study aims to investigate the in vivo ablation strategy by comparing the dose effect of nanosecond electric fields in vitro and in vivo on hepatocellular carcinoma. Materials and Methods: Four hepatocellular carcinoma cell lines HepG2, SMMC7721, Hep1-6, and HCCLM3 were pulsed to test the anti-proliferation and anti-migration ability of 100 ns nsPEFs in vitro. The animal model of human subdermal xenograft HCCLM3 cells into BALB/c nude mouse was used to test the anti-tumor growth and macrophage infiltration in vivo. Results: In vitro assays showed anti-tumor effect of nsPEFs is dose-dependant. But the in vivo study showed the strategy of low dose and multiple treatments is superior to high dose single treatment. The macrophages infiltration significantly increased in the tumors which were treated by multiple low dose nsPEFs. Conclusion: The low dose multiple nsPEFs application is more efficient than high dose single treatment in inhibiting the tumor volume in vivo, which is quite different from the dose-effect relationship in vitro. Beside the electric field strength, the macrophage involvement must be considered to account for effect variability and toxicology in vivo.	[Chen, Xinhua; Yin, Shengyong; Hu, Chen; Feng, Xiaowen; Xie, Haiyang; Zhou, Lin; Zheng, Shusen] Zhejiang Univ, Sch Med, Affiliated Hosp 1,Key Lab Combined Multiorgan Tra, Minist Publ Hlth,Dept Hepatobiliary & Pancreat Su, Hangzhou 310003, Zhejiang, Peoples R China; [Chen, Xinmei] Shandong Tradit Chinese Med Univ, Dept Pharm, Jinan, Shandong, Peoples R China; [Jiang, Kai; Ye, Shuming] Zhejiang Univ, Coll Biomed Engn, Hangzhou 310003, Zhejiang, Peoples R China; [Jiang, Kai; Ye, Shuming] Zhejiang Univ, Coll Instrument Sci, Hangzhou 310003, Zhejiang, Peoples R China; [Fan, Shifeng] Xinjiang Nanosecond Pulse Technol Inst, Urumqi, Xinjiang, Peoples R China	Zhejiang University; Shandong University of Traditional Chinese Medicine; Zhejiang University; Zhejiang University	Zheng, SS (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 1,Key Lab Combined Multiorgan Tra, Minist Publ Hlth,Dept Hepatobiliary & Pancreat Su, Hangzhou 310003, Zhejiang, Peoples R China.	shusenzheng@zju.edu.cn		Chen, Xinmei/0000-0001-7549-7793	National Natural Science Foundation of China [3070078, 81372425, 81000962]; National ST Major Project [2012ZX10002017]; National Basic Research Program of China (973 Program) [2009CB522403]; Zhejiang Medical Research Funding [2008B079, LY13H180003]; SRF for ROCS, SEM [J20120279]; Xinjiang Science and Technology Bureau Project [2013911131]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National ST Major Project; National Basic Research Program of China (973 Program)(National Basic Research Program of China); Zhejiang Medical Research Funding; SRF for ROCS, SEM(Scientific Research Foundation for the Returned Overseas Chinese Scholars); Xinjiang Science and Technology Bureau Project	The research is supported by National Natural Science Foundation of China (No. 3070078, 81372425, 81000962), National S&T Major Project (No. 2012ZX10002017), National Basic Research Program of China (973 Program No. 2009CB522403), Zhejiang Medical Research Funding (No. 2008B079, No. LY13H180003). SRF for ROCS, SEM (No. J20120279) and Xinjiang Science and Technology Bureau Project (No. 2013911131). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bakiri L, 2013, MOL ONCOL, V7, P206, DOI 10.1016/j.molonc.2013.01.005; Beebe SJ, 2003, DNA CELL BIOL, V22, P785, DOI 10.1089/104454903322624993; Beebe SJ, 2011, IEEE ENG MED BIO, P6861, DOI 10.1109/IEMBS.2011.6091692; Chen X, 2012, TECHNOL CANCER RES T, V11, P83, DOI 10.7785/tcrt.2012.500237; Chen XH, 2011, IN VIVO, V25, P23; Chen XH, 2010, PIGM CELL MELANOMA R, V23, P554, DOI 10.1111/j.1755-148X.2010.00704.x; Chen XH, 2009, MELANOMA RES, V19, P361, DOI 10.1097/CMR.0b013e32832f1558; Kwon S, 2013, BIOMED OPT EXPRESS, V4, P967, DOI 10.1364/BOE.4.000967; Nuccitelli R, 2006, BIOCHEM BIOPH RES CO, V343, P351, DOI 10.1016/j.bbrc.2006.02.181; Nuccitelli R, 2013, INT J CANCER, V132, P1933, DOI 10.1002/ijc.27860; Nuccitelli R, 2012, PIGM CELL MELANOMA R, V25, P618, DOI 10.1111/j.1755-148X.2012.01027.x; Nuccitelli R, 2012, BIOCHEM BIOPH RES CO, V424, P446, DOI 10.1016/j.bbrc.2012.06.129; Nuccitelli R, 2010, INT J CANCER, V127, P1727, DOI 10.1002/ijc.25364; Pakhomov AG, 2007, ARCH BIOCHEM BIOPHYS, V465, P109, DOI 10.1016/j.abb.2007.05.003; Schoenbach KH, 2001, BIOELECTROMAGNETICS, V22, P440, DOI 10.1002/bem.71; Wang J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043213	16	19	23	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2014	9	1							e86421	10.1371/journal.pone.0086421	http://dx.doi.org/10.1371/journal.pone.0086421			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301BI	24475118	Green Submitted, Green Published, gold			2023-01-03	WOS:000330507300064
J	Mathew, M; Subramanian, S				Mathew, Maya; Subramanian, Sarada			In Vitro Screening for Anti-Cholinesterase and Antioxidant Activity of Methanolic Extracts of Ayurvedic Medicinal Plants Used for Cognitive Disorders	PLOS ONE			English	Article							ALZHEIMERS-DISEASE; INHIBITORY-ACTIVITY; POMEGRANATE JUICE; ACETYLCHOLINESTERASE; MEMORY	Inhibition of Acetylcholinesterase (AChE) is still considered as the main therapeutic strategy against Alzheimer's disease (AD). Many plant derived phytochemicals have shown AChE inhibitory activity in addition to the currently approved drugs for AD. In the present study, methanolic extracts of 20 plants used in Indian Ayurvedic system of medicine for improving cognitive function were screened for acetylcholinesterase inhibitory activity by Ellman's microplate colorimetric method. Out of 20 extracts, Emblica officinalis, Nardostachys jatamansi, Nelumbo nucifera, Punica granatum and Raulfia Serpentina showed IC50 values <100 mu g/ml for acetylcholinesterase inhibitory activity. Antioxidant activities of these plants were assessed by DPPH scavenging assay. Among the extracts used, antioxidant activity was highest for Terminalia chebula and Emblica officinalis with IC50 values <10 mu g/ml. Considering the complex multifactorial etiology of AD, these plant extracts will be safer and better candidates for the future disease modifying therapies against this devastating disease.	[Mathew, Maya; Subramanian, Sarada] Natl Inst Mental Hlth & Neurosci, Dept Neurochem, Bangalore 560029, Karnataka, India	National Institute of Mental Health & Neurosciences - India	Subramanian, S (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Neurochem, Bangalore 560029, Karnataka, India.	sarada@nimhans.kar.nic.in			Department of Science & Technology, New Delhi, India [SR/SO/BB-27/2009, SR/WOS-A/LS-102/2008]	Department of Science & Technology, New Delhi, India(Department of Science & Technology (India))	This study was supported by funding to SS (grant no. SR/SO/BB-27/2009) and MM (grant no. SR/WOS-A/LS-102/2008) from Department of Science & Technology, New Delhi, India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arya U, 2009, EXP GERONTOL, V44, P462, DOI 10.1016/j.exger.2009.02.010; Atoui AK, 2005, FOOD CHEM, V89, P27, DOI 10.1016/j.foodchem.2004.01.075; Bolognesi ML, 2009, CURR OPIN CHEM BIOL, V13, P303, DOI 10.1016/j.cbpa.2009.04.619; Capurro V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056870; DAVIES P, 1976, LANCET, V2, P1403; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Ferreira A, 2006, J ETHNOPHARMACOL, V108, P31, DOI 10.1016/j.jep.2006.04.010; Gil MI, 2000, J AGR FOOD CHEM, V48, P4581, DOI 10.1021/jf000404a; Gutzmann H, 1998, J NEURAL TRANSM-SUPP, P301; Hartman RE, 2006, NEUROBIOL DIS, V24, P506, DOI 10.1016/j.nbd.2006.08.006; Ingkaninan K, 2003, J ETHNOPHARMACOL, V89, P261, DOI 10.1016/j.jep.2003.08.008; Itoh A, 2005, J NAT PROD, V68, P848, DOI 10.1021/np058007n; Joshi H, 2006, J MED FOOD, V9, P113, DOI 10.1089/jmf.2006.9.113; Jung HA, 2010, LIFE SCI, V87, P420, DOI 10.1016/j.lfs.2010.08.005; Karkada Gloria, 2012, J Nat Sci Biol Med, V3, P125, DOI 10.4103/0976-9668.101879; Kwak HM, 2005, ARCH PHARM RES, V28, P1328, DOI 10.1007/BF02977896; Ling ZQ, 2005, J AGR FOOD CHEM, V53, P2441, DOI 10.1021/jf040325p; Mangialasche F, 2010, LANCET NEUROL, V9, P702, DOI 10.1016/S1474-4422(10)70119-8; Manyam BV, 1999, J ALTERN COMPLEM MED, V5, P81, DOI 10.1089/acm.1999.5.81; Mathew M, 2013, INT J PHARM SCI RES, V4, P4691, DOI 10.13040/IJPSR.0975-8232.4(12).4685-91; Mathew M, 2012, INT J PHARM SCI RES, V3, P4276, DOI 10.13040/IJPSR.0975-8232.3(11).4281-84; Mehta M, 2012, INT J ALZHEIMERS DIS; Mukherjee PK, 2007, PHYTOTHER RES, V21, P1142, DOI 10.1002/ptr.2224; Mukherjee PK, 2007, PHYTOMEDICINE, V14, P289, DOI 10.1016/j.phymed.2007.02.002; Naik GH, 2005, PHYTOTHER RES, V19, P582, DOI 10.1002/ptr.1515; Nordberg A, 1998, DRUG SAFETY, V19, P465, DOI 10.2165/00002018-199819060-00004; Oh MH, 2004, PHYTOMEDICINE, V11, P544, DOI 10.1016/j.phymed.2004.03.001; Orhan I, 2004, J ETHNOPHARMACOL, V91, P57, DOI 10.1016/j.jep.2003.11.016; Murray AP, 2013, CURR NEUROPHARMACOL, V11, P388, DOI 10.2174/1570159X11311040004; Peckels C.M., 2013, CURR ENZ INHIBITION, V9, P67; Rao RV, 2012, ALZHEIMERS RES THER, V4, DOI 10.1186/alzrt125; RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9; Tepe B, 2005, FOOD CHEM, V90, P333, DOI 10.1016/j.foodchem.2003.09.013; Vasudevan M, 2007, PHYSIOL BEHAV, V91, P46, DOI 10.1016/j.physbeh.2007.01.016; Vina J, 2011, CURR PHARM DESIGN, V17, P3861, DOI 10.2174/138161211798357755; Warrier P.K., 1993, INDIAN MED PLANTS CO, VVolume 5; Yang ZD, 2012, NAT PROD RES, V26, P387, DOI 10.1080/14786419.2010.487188	37	119	128	2	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2014	9	1							e86804	10.1371/journal.pone.0086804	http://dx.doi.org/10.1371/journal.pone.0086804			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297XI	24466247	gold, Green Submitted, Green Published			2023-01-03	WOS:000330288000145
J	Strollo, PJ; Soose, RJ; Maurer, JT; de Vries, N; Cornelius, J; Froymovich, O; Hanson, RD; Padhya, TA; Steward, DL; Gillespie, MB; Woodson, BT; Van de Heyning, PH; Goetting, MG; Vanderveken, OM; Feldman, N; Knaack, L; Strohl, KP				Strollo, Patrick J., Jr.; Soose, Ryan J.; Maurer, Joachim T.; de Vries, Nico; Cornelius, Jason; Froymovich, Oleg; Hanson, Ronald D.; Padhya, Tapan A.; Steward, David L.; Gillespie, M. Boyd; Woodson, B. Tucker; Van de Heyning, Paul H.; Goetting, Mark G.; Vanderveken, Oliver M.; Feldman, Neil; Knaack, Lennart; Strohl, Kingman P.		STAR Trial Grp	Upper-Airway Stimulation for Obstructive Sleep Apnea	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPOGLOSSAL NERVE-STIMULATION; ELECTRICAL-STIMULATION; PRESSURE THERAPY; ADHERENCE; HYPOPNEA; FAILURE	BACKGROUND Obstructive sleep apnea is associated with considerable health risks. Although continuous positive airway pressure (CPAP) can mitigate these risks, effectiveness can be reduced by inadequate adherence to treatment. We evaluated the clinical safety and effectiveness of upper-airway stimulation at 12 months for the treatment of moderate-to-severe obstructive sleep apnea. METHODS Using a multicenter, prospective, single-group, cohort design, we surgically implanted an upper-airway stimulation device in patients with obstructive sleep apnea who had difficulty either accepting or adhering to CPAP therapy. The primary outcome measures were the apnea-hypopnea index (AHI; the number of apnea or -hypopnea events per hour, with a score of >= 15 indicating moderate-to-severe apnea) and the oxygen desaturation index (ODI; the number of times per hour of sleep that the blood oxygen level drops by >= 4 percentage points from baseline). Secondary outcome measures were the Epworth Sleepiness Scale, the Functional Outcomes of Sleep Questionnaire (FOSQ), and the percentage of sleep time with the oxygen saturation less than 90%. Consecutive participants with a response were included in a randomized, controlled therapy-withdrawal trial. RESULTS The study included 126 participants; 83% were men. The mean age was 54.5 years, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 28.4. The median AHI score at 12 months decreased 68%, from 29.3 events per hour to 9.0 events per hour (P<0.001); the ODI score decreased 70%, from 25.4 events per hour to 7.4 events per hour (P<0.001). Secondary outcome measures showed a reduction in the effects of sleep apnea and improved quality of life. In the randomized phase, the mean AHI score did not differ significantly from the 12-month score in the nonrandomized phase among the 23 participants in the therapy-maintenance group (8.9 and 7.2 events per hour, respectively); the AHI score was significantly higher (indicating more severe apnea) among the 23 participants in the therapy-withdrawal group (25.8 vs. 7.6 events per hour, P<0.001). The ODI results followed a similar pattern. The rate of procedure-related serious adverse events was less than 2%. CONCLUSIONS In this uncontrolled cohort study, upper-airway stimulation led to significant improvements in objective and subjective measurements of the severity of obstructive sleep apnea. (Funded by Inspire Medical Systems; STAR ClinicalTrials.gov number, NCT01161420.)	[Strollo, Patrick J., Jr.] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA; [Soose, Ryan J.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15213 USA; [Maurer, Joachim T.] Univ Hosp Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Sleep Disorders Ctr, Mannheim, Germany; [Knaack, Lennart] Intersom Koln, Cologne, Germany; [de Vries, Nico] Sint Lucas Hosp, Dept Otolaryngol, Amsterdam, Netherlands; [Cornelius, Jason] North Mem Sleep Hlth Ctr, Maple Grove, MN USA; [Froymovich, Oleg] Paparella Ear Head & Neck Inst, Minneapolis, MN USA; [Hanson, Ronald D.] St Cloud Ear Nose & Throat, St Cloud, MN USA; [Padhya, Tapan A.] Univ S Florida, Coll Med, Dept Otolaryngol Head & Neck Surg, Tampa, FL USA; [Feldman, Neil] St Petersburg Sleep Disorders Ctr, St Petersburg, FL USA; [Steward, David L.] Univ Cincinnati, Dept Otolaryngol Head & Neck Surg, Acad Hlth Ctr, Cincinnati, OH USA; [Gillespie, M. Boyd] Med Coll South Carolina, Dept Otolaryngol, Charleston, SC USA; [Woodson, B. Tucker] Med Coll Wisconsin, Dept Otolaryngol & Human Commun, Milwaukee, WI 53226 USA; [Van de Heyning, Paul H.; Vanderveken, Oliver M.] Univ Antwerp Hosp, Dept Otorhinolaryngol & Head & Neck Surg, Edegem, Belgium; [Van de Heyning, Paul H.; Vanderveken, Oliver M.] Univ Antwerp, Fac Med & Hlth Sci, B-2020 Antwerp, Belgium; [Goetting, Mark G.] Borgess Med Ctr, Sleep Disorders Ctr, Kalamazoo, MI USA; [Strohl, Kingman P.] Case Western Reserve Univ, Louis Stokes Cleveland Vet Affairs Med Ctr, Div Pulm Crit Care & Sleep Med, Cleveland, OH 44106 USA; [Strohl, Kingman P.] Case Western Reserve Univ, Case Med Ctr, Cleveland, OH 44106 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Ruprecht Karls University Heidelberg; Sint Lucas Andreas Hospital; State University System of Florida; University of South Florida; University System of Ohio; University of Cincinnati; Medical College of Wisconsin; University of Antwerp; University of Antwerp; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University	Strollo, PJ (corresponding author), Univ Pittsburgh, Montefiore Med Ctr, Suite S639-11,3459 Fifth Ave, Pittsburgh, PA 15213 USA.	strollopj@upmc.edu	VANDERVEKEN, Olivier/K-8549-2014; Dieltjens, Marijke/P-7049-2014; Skovlund, Soren/AAK-3058-2020; Heyning, Paul H Vande/I-8278-2017; Woodson, B Tucker/K-2266-2019; Strollo, Patrick J/L-7062-2016	VANDERVEKEN, Olivier/0000-0002-4088-4213; Dieltjens, Marijke/0000-0002-5822-1960; Skovlund, Soren/0000-0003-3464-0885; Heyning, Paul H Vande/0000-0002-8424-3717; 	Inspire Medical Systems	Inspire Medical Systems	Supported by Inspire Medical Systems.	American Academy of Sleep Medicine, 2007, AASM MANUAL SCORING; Caples SM, 2010, SLEEP, V33, P1396, DOI 10.1093/sleep/33.10.1396; Durgan DJ, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.111.000091; Eastwood PR, 2011, SLEEP, V34, P1479, DOI 10.5665/sleep.1380; Elshaug AG, 2007, SLEEP, V30, P461, DOI 10.1093/sleep/30.4.461; Goding GS, 2012, OTOLARYNG HEAD NECK, V146, P1017, DOI 10.1177/0194599812436472; Gottlieb DJ, 2010, CIRCULATION, V122, P352, DOI 10.1161/CIRCULATIONAHA.109.901801; Johns MW, 2000, J SLEEP RES, V9, P5, DOI 10.1046/j.1365-2869.2000.00177.x; Kohler M, 2011, AM J RESP CRIT CARE, V184, P1192, DOI 10.1164/rccm.201106-0964OC; Lim J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004435.pub3; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; Maurer JT, 2012, OPERATIVE TECHNIQUES, V23, P227, DOI [DOI 10.1016/J.0T0T.2012.07.002, 10.1016/j.otot.2012.07.002]; Mwenge GB, 2013, EUR RESPIR J, V41, P360, DOI 10.1183/09031936.00042412; Oliven A, 2003, J APPL PHYSIOL, V95, P2023, DOI 10.1152/japplphysiol.00203.2003; Punjabi NM, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000132; Punjabi NM, 2004, AM J EPIDEMIOL, V160, P521, DOI 10.1093/aje/kwh261; Ravesloot MJL, 2011, SLEEP, V34, P105, DOI 10.1093/sleep/34.1.105; Redline S, 2010, AM J RESP CRIT CARE, V182, P269, DOI 10.1164/rccm.200911-1746OC; REMMERS JE, 1990, J APPL PHYSIOL, V68, P1286, DOI 10.1152/jappl.1990.68.3.1286; Sawyer AM, 2011, SLEEP MED REV, V15, P343, DOI 10.1016/j.smrv.2011.01.003; Schwartz AR, 2012, AM J RESP CRIT CARE, V185, P420, DOI 10.1164/rccm.201109-1614OC; Schwartz AR, 2001, ARCH OTOLARYNGOL, V127, P1216, DOI 10.1001/archotol.127.10.1216; SCHWARTZ AR, 1993, AM REV RESPIR DIS, V147, P1144, DOI 10.1164/ajrccm/147.5.1144; Seicean S, 2008, DIABETES CARE, V31, P1001, DOI 10.2337/dc07-2003; STROHL KP, 1978, NEW ENGL J MED, V299, P969, DOI 10.1056/NEJM197811022991801; Strollo PJ, 1996, NEW ENGL J MED, V334, P99, DOI 10.1056/NEJM199601113340207; Sundaram S, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001004.pub2; Van de Heyning PH, 2012, LARYNGOSCOPE, V122, P1626, DOI 10.1002/lary.23301; Vanderveken OM, 2008, AM J RESP CRIT CARE, V178, P197, DOI 10.1164/rccm.200701-114OC; Vanderveken OM, 2013, J CLIN SLEEP MED, V9, P433, DOI 10.5664/jcsm.2658; Weaver Terri E, 2008, Proc Am Thorac Soc, V5, P173, DOI 10.1513/pats.200708-119MG; Weaver TE, 2007, SLEEP, V30, P711, DOI 10.1093/sleep/30.6.711	32	627	644	4	134	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 9	2014	370	2					139	149		10.1056/NEJMoa1308659	http://dx.doi.org/10.1056/NEJMoa1308659			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AH4TA	24401051				2023-01-03	WOS:000336119800009
J	Nathanson, DA; Gini, B; Mottahedeh, J; Visnyei, K; Koga, T; Gomez, G; Eskin, A; Hwang, K; Wang, J; Masui, K; Paucar, A; Yang, HJ; Ohashi, M; Zhu, SJ; Wykosky, J; Reed, R; Nelson, SF; Cloughesy, TF; James, CD; Rao, PN; Kornblum, HI; Heath, JR; Cavenee, WK; Furnari, FB; Mischel, PS				Nathanson, David A.; Gini, Beatrice; Mottahedeh, Jack; Visnyei, Koppany; Koga, Tomoyuki; Gomez, German; Eskin, Ascia; Hwang, Kiwook; Wang, Jun; Masui, Kenta; Paucar, Andres; Yang, Huijun; Ohashi, Minori; Zhu, Shaojun; Wykosky, Jill; Reed, Rachel; Nelson, Stanley F.; Cloughesy, Timothy F.; James, C. David; Rao, P. Nagesh; Kornblum, Harley I.; Heath, James R.; Cavenee, Webster K.; Furnari, Frank B.; Mischel, Paul S.			Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA	SCIENCE			English	Article							GROWTH-FACTOR-RECEPTOR; DOUBLE-MINUTE CHROMOSOMES; HOMOGENEOUSLY STAINING REGIONS; DRUG-RESISTANCE; CELL-LINES; GLIOBLASTOMA-MULTIFORME; KINASE INHIBITORS; GENE; AMPLIFICATION; TUMORIGENICITY	Intratumoral heterogeneity contributes to cancer drug resistance, but the underlying mechanisms are not understood. Single-cell analyses of patient-derived models and clinical samples from glioblastoma patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) demonstrate that tumor cells reversibly up-regulate or suppress mutant EGFR expression, conferring distinct cellular phenotypes to reach an optimal equilibrium for growth. Resistance to EGFR TKIs is shown to occur by elimination of mutant EGFR from extrachromosomal DNA. After drug withdrawal, reemergence of clonal EGFR mutations on extrachromosomal DNA follows. These results indicate a highly specific, dynamic, and adaptive route by which cancers can evade therapies that target oncogenes maintained on extrachromosomal DNA.	[Gini, Beatrice; Koga, Tomoyuki; Gomez, German; Masui, Kenta; Yang, Huijun; Zhu, Shaojun; Wykosky, Jill; Reed, Rachel; Cavenee, Webster K.; Furnari, Frank B.; Mischel, Paul S.] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; [Nathanson, David A.; Paucar, Andres; Ohashi, Minori; Kornblum, Harley I.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Hwang, Kiwook; Wang, Jun; Heath, James R.] CALTECH, NanoSyst Biol Canc Ctr, Pasadena, CA 91030 USA; [Hwang, Kiwook; Wang, Jun; Heath, James R.] CALTECH, Div Chem & Chem Engn, Pasadena, CA 91030 USA; [Mottahedeh, Jack; Visnyei, Koppany; Paucar, Andres; Kornblum, Harley I.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Neuropsychiat Inst, Los Angeles, CA 90095 USA; [James, C. David] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Cloughesy, Timothy F.; Kornblum, Harley I.] Univ Calif Los Angeles, David Geffen Sch Med, Henry Singleton Brain Tumor Program, Los Angeles, CA 90095 USA; [Cloughesy, Timothy F.; Kornblum, Harley I.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Cloughesy, Timothy F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Eskin, Ascia; Nelson, Stanley F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA; [Cavenee, Webster K.; Furnari, Frank B.; Mischel, Paul S.] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; California Institute of Technology; California Institute of Technology; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Diego	Mischel, PS (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.	pmischel@ucsd.edu	Cloughesy, Timothy Francis/AGV-1013-2022; Wang, Jun/A-8216-2015; Nelson, Stanley F/D-4771-2009	Nelson, Stanley F/0000-0002-2082-3114; Koga, Tomoyuki/0000-0002-8330-117X; Furnari, Frank/0000-0003-1909-4361; Mischel, Paul/0000-0002-4560-2211	Ben and Catherine Ivy Foundation; National Institutes of Health (NIH) [NS73831, U54 CA151819, P01-CA95616, R01-NS080939, NINDS R01 NS052563]; Ziering Family Foundation; Art of the Brain Fund; James S. McDonnell Foundation; European Commission [PIOF-GA-2010-271819]; Ruth L. Kirschstein Institutional National Research Service Award [T32 CA009056]; UCLA Scholars in Oncologic Molecular Imaging (SOMI) Program; NATIONAL CANCER INSTITUTE [U54CA151819, U54CA119347, P30CA023100, T32CA009056, P01CA095616] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073831, R01NS052563, R01NS080939] Funding Source: NIH RePORTER	Ben and Catherine Ivy Foundation; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ziering Family Foundation; Art of the Brain Fund; James S. McDonnell Foundation; European Commission(European CommissionEuropean Commission Joint Research Centre); Ruth L. Kirschstein Institutional National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UCLA Scholars in Oncologic Molecular Imaging (SOMI) Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the Ben and Catherine Ivy Foundation Fund (P. S. M., J.R.H., and T. F. C.); by National Institutes of Health (NIH) grants NS73831 (P. S. M.), U54 CA151819 (P. S. M. and J.R.H., principal investigator), P01-CA95616 (W. K. C. and F. B. F.), R01-NS080939 (F. B. F.), and NINDS R01 NS052563 (H. I. K.); and by the Ziering Family Foundation in memory of Sigi Ziering (T. F. C. and P. S. M.), the Art of the Brain Fund (T. F. C.), the James S. McDonnell Foundation (to F. B. F.), the European Commission PIOF-GA-2010-271819 (B. G.), Ruth L. Kirschstein Institutional National Research Service Award T32 CA009056 (D.A.N.), and the UCLA Scholars in Oncologic Molecular Imaging (SOMI) Program (D.A.N.). W. K. C. is a Fellow of the National Foundation for Cancer Research. We thank R. Kolodner for careful reading of the manuscript and helpful suggestions. We also thank W. Yong and the UCLA Brain Tumor Translational Resource.	Aldape KD, 2004, J NEUROPATH EXP NEUR, V63, P700, DOI 10.1093/jnen/63.7.700; BENNER SE, 1991, ANTI-CANCER DRUG, V2, P11, DOI 10.1097/00001813-199102000-00002; BIGNER SH, 1990, CANCER RES, V50, P8017; Bonavia R, 2011, CANCER RES, V71, P4055, DOI 10.1158/0008-5472.CAN-11-0153; Brandes AA, 2008, CLIN CANCER RES, V14, P957, DOI 10.1158/1078-0432.CCR-07-1810; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Del Vecchio CA, 2013, ONCOGENE, V32, P2670, DOI 10.1038/onc.2012.280; Ercan D, 2010, ONCOGENE, V29, P2346, DOI 10.1038/onc.2009.526; Frederick L, 2000, CANCER RES, V60, P1383; Garraway LA, 2012, CANCER DISCOV, V2, P214, DOI 10.1158/2159-8290.CD-12-0012; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Glickman MS, 2012, CELL, V148, P1089, DOI 10.1016/j.cell.2012.02.015; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; HABER DA, 1981, CELL, V26, P355, DOI 10.1016/0092-8674(81)90204-X; Heimberger AB, 2005, CLIN CANCER RES, V11, P1462, DOI 10.1158/1078-0432.CCR-04-1737; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Jeuken J, 2009, BRAIN PATHOL, V19, P661, DOI 10.1111/j.1750-3639.2009.00320.x; KAUFMAN RJ, 1981, MOL CELL BIOL, V1, P1084, DOI 10.1128/MCB.1.12.1084; KURPAD SN, 1995, GLIA, V15, P244, DOI 10.1002/glia.440150306; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Nishikawa Ryo, 2004, Brain Tumor Pathol, V21, P53, DOI 10.1007/BF02484510; Sanborn JZ, 2013, CANCER RES, V73, P6036, DOI 10.1158/0008-5472.CAN-13-0186; Sarkaria JN, 2007, MOL CANCER THER, V6, P1167, DOI 10.1158/1535-7163.MCT-06-0691; SCHIMKE RT, 1978, SCIENCE, V202, P1051, DOI 10.1126/science.715457; Shimizu N, 2009, CYTOGENET GENOME RES, V124, P312, DOI 10.1159/000218135; Sun J, 2010, CANCER RES, V70, P6128, DOI 10.1158/0008-5472.CAN-10-0076; Vivanco I, 2012, CANCER DISCOV, V2, P458, DOI 10.1158/2159-8290.CD-11-0284; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Vogt N, 2004, P NATL ACAD SCI USA, V101, P11368, DOI 10.1073/pnas.0402979101; VONHOFF DD, 1992, P NATL ACAD SCI USA, V89, P8165, DOI 10.1073/pnas.89.17.8165	34	328	351	7	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 3	2014	343	6166					72	76		10.1126/science.1241328	http://dx.doi.org/10.1126/science.1241328			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282HR	24310612	Green Accepted			2023-01-03	WOS:000329162000050
J	Salter, C; McDaid, L; Bhattacharya, D; Holland, R; Marshall, T; Howe, A				Salter, Charlotte; McDaid, Lisa; Bhattacharya, Debi; Holland, Richard; Marshall, Tarnya; Howe, Amanda			Abandoned Acid? Understanding Adherence to Bisphosphonate Medications for the Prevention of Osteoporosis among Older Women: A Qualitative Longitudinal Study	PLOS ONE			English	Article							PHARMACEUTICAL-INDUSTRY; EXPERIENCE; MEDICINES; DIAGNOSIS	Background: There is significant morbidity and mortality caused by the complications of osteoporosis, for which ageing is the greatest epidemiological risk factor. Preventive medications to delay osteoporosis are available, but little is known about motivators to adhere to these in the context of a symptomless condition with evidence based on screening results. Aim: To describe key perceptions that influence older women's adherence and persistence with prescribed medication when identified to be at a higher than average risk of fracture. Design of Study: A longitudinal qualitative study embedded within a multi-centre trial exploring the effectiveness of screening for prevention of fractures. Setting: Primary care, Norfolk. United Kingdom Methods: Thirty older women aged 70-85 years of age who were offered preventive medication for osteoporosis and agreed to undertake two interviews at 6 and 24 months post-first prescription. Results: There were no overall predictors of adherence which varied markedly over time. Participants' perceptions and motivations to persist with medication were influenced by six core themes: understanding adherence and non-adherence, motivations and self-care, appraising and prioritising risk, anticipating and managing side effects, problems of understanding, and decision making around medication. Those engaged with supportive professionals could better tolerate and overcome barriers such as side-effects. Conclusions: Many issues are raised following screening in a cohort of women who have not previously sought advice about their bone health. Adherence to preventive medication for osteoporosis is complex and multifaceted. Individual participant understanding, choice, risk and perceived need all interact to produce unpredictable patterns of usage and acceptability. There are clear implications for practice and health professionals should not assume adherence in any older women prescribed medication for the prevention of osteoporosis. The beliefs and motivations of participants and their healthcare providers regarding the need to establish acceptable medication regimes is key to promoting and sustaining adherence.	[Salter, Charlotte; McDaid, Lisa; Holland, Richard; Howe, Amanda] Univ E Anglia, Fac Med & Hlth Sci, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England; [Bhattacharya, Debi] Univ E Anglia, Sch Pharm & Chem, Norwich NR4 7TJ, Norfolk, England; [Marshall, Tarnya] Norfolk & Norwich Univ Fdn Trust Hosp, Dept Rheumatol, Norwich, Norfolk, England	University of East Anglia; University of East Anglia	Salter, C (corresponding author), Univ E Anglia, Fac Med & Hlth Sci, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England.	c.salter@uea.ac.uk	Bhattacharya, Debi/F-8400-2011	Bhattacharya, Debi/0000-0003-3024-7453; Holland, Richard/0000-0002-4663-6923; McDaid, Lisa/0000-0001-5032-2380	Research for Patient Benefit Programme National Institute for Health Research [PG-PB-0807-14068]; ESRC [ES/J022497/1] Funding Source: UKRI; Economic and Social Research Council [ES/J022497/1] Funding Source: researchfish; National Institute for Health Research [PB-PG-0807-14068] Funding Source: researchfish	Research for Patient Benefit Programme National Institute for Health Research; ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); National Institute for Health Research(National Institute for Health Research (NIHR))	Funding came from Research for Patient Benefit Programme National Institute for Health Research PG-PB-0807-14068. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, OST ASS RISK FRAG FR; Britten N, 2004, SOC SCI MED, V59, P1495, DOI 10.1016/j.socscimed.2004.01.019; Brookhart MA, 2007, AM J MED, V120, P251, DOI 10.1016/j.amjmed.2006.03.029; Brown P, 2012, HEALTH-LONDON, V16, P57, DOI 10.1177/1363459309360783; Cohen D, 2001, HEALTH-LONDON, V5, P441, DOI 10.1177/136345930100500403; Hodgetts D, 2011, HEALTH PLACE, V17, P353, DOI 10.1016/j.healthplace.2010.11.015; International Osteoporosis Foundation (IOF), 2005, ADH GAP WHY OST PAT; Kanis JA, 2000, OSTEOPOROSIS INT, V11, P192, DOI 10.1007/s001980050281; Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140-6736(02)08761-5; Marshall IJ WC, 2012, BRIT MED J, V345; Mirand AL, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-15; Moynihan R, 2002, BRIT MED J, V324, P886, DOI 10.1136/bmj.324.7342.886; Moynihan R DJ, 2012, BRIT MED J, V244; Murdoch J, MISUNDERSTANDINGS CO; Murdoch J, 2013, SOCIOL HEALTH ILL, V35, P449, DOI 10.1111/j.1467-9566.2012.01499.x; Pickney CS, 2005, OSTEOPOROSIS INT, V16, P1156, DOI 10.1007/s00198-004-1818-8; Poole Kenneth ES, 2006, BMJ, V333; Pound P, 2005, SOC SCI MED, V61, P133, DOI 10.1016/j.socscimed.2004.11.063; Recker RR, 2005, MAYO CLIN PROC, V80, P856, DOI 10.4065/80.7.856; Ritchie J., 2003, GUIDE SOCIAL SCI STU, V1, P77; Rossini M BG, 2006, OSTEOPOROSIS INT, V17, P941; Salter C, 2007, BMJ-BRIT MED J, V334, P1101, DOI 10.1136/bmj.39171.577106.55; Salter CI, 2011, SOC SCI MED, V73, P808, DOI 10.1016/j.socscimed.2011.06.030; Shepstone L, 2012, OSTEOPOROSIS INT, V23, P2507, DOI 10.1007/s00198-011-1876-7; Shoemaker SJ, 2011, PATIENT EDUC COUNS, V83, P443, DOI 10.1016/j.pec.2011.02.007; (SIGN) SIGN, 2003, MAN OST RISK; Solomon DH, 2005, ARCH INTERN MED, V165, P2414, DOI 10.1001/archinte.165.20.2414; Verdijk NA, 2009, BRIT J GEN PRACT, V59, P256, DOI 10.3399/bjgp09X420338; Williams SJ CM, 2008, SOCIOL HLTH ILL, V16; World Health Organization, 2003, PREV MAN OST	30	19	19	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 2	2014	9	1							e83552	10.1371/journal.pone.0083552	http://dx.doi.org/10.1371/journal.pone.0083552			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	286ID	24392086	Green Accepted, Green Submitted, Green Published, gold			2023-01-03	WOS:000329460100010
J	Nespoulet, H; Rupp, T; Bachasson, D; Tamisier, R; Wuyam, B; Levy, P; Verges, S				Nespoulet, Hugo; Rupp, Thomas; Bachasson, Damien; Tamisier, Renaud; Wuyam, Bernard; Levy, Patrick; Verges, Samuel			Positive Expiratory Pressure Improves Oxygenation in Healthy Subjects Exposed to Hypoxia	PLOS ONE			English	Article							ACUTE MOUNTAIN-SICKNESS; NEAR-INFRARED SPECTROSCOPY; ALTITUDE PULMONARY-EDEMA; AIRWAY PRESSURE; BREATHING PATTERN; CARDIAC-OUTPUT; EXERCISE; ILLNESS; VENTILATION; DYSPNEA	Introduction: Positive end-expiratory pressure (PEEP) is commonly used in critical care medicine to improve gas exchange. Altitude sickness is associated with exaggerated reduction in arterial oxygenation. We assessed the effect of PEEP and pursed lips breathing (PLB) on arterial and tissue oxygenation under normobaric and hypobaric hypoxic conditions. Methods: Sixteen healthy volunteers were exposed to acute normobaric hypoxia (Laboratory study, FiO(2)=0.12). The protocol consisted in 3-min phases with PEEPs of 0, 5 or 10 cmH(2)O, PLB or similar ventilation than with PEEP-10, interspaced with 3-min phases of free breathing. Arterial (pulse oximetry) and quadriceps (near-infrared spectroscopy) oxygenation, ventilation, cardiac function, esophageal and gastric pressures and subjects' subjective perceptions were recorded continuously. In addition, the effect of PEEP on arterial oxygenation was tested at 4,350 m of altitude in 9 volunteers breathing for 20 min with PEEP-10 (Field study). Results: During the laboratory study, PEEP-10 increased arterial and quadriceps oxygenation (arterial oxygen saturation +5.6 +/- 5.0% and quadriceps oxyhemoglobin +58 +/- 73 mu mol. cm compared to free breathing; p<0.05). Conversely, PLB did not increase oxygenation. Oxygenation improvement with PEEP-10 was accompanied by an increase in expiratory esophageal and gastric pressures (esophageal pressure swing +5.4 +/- 3.2 cmH(2)O, p<0.05) but no change in minute ventilation, breathing pattern, end-tidal CO2 or cardiac function (all p>0.05) compared to PEEP-0. During the field study, PEEP-10 increased arterial oxygen saturation by +6.7 +/- 6.0% after the 3rd minute with PEEP-10 without further significant increase until the 20th minute with PEEP-10. Subjects did not report any significant discomfort with PEEP. Conclusions: These data indicate that 10-cmH(2)O PEEP significantly improves arterial and muscle oxygenation under both normobaric and hypobaric hypoxic conditions in healthy subjects. PEEP-10 could be an attractive non-pharmacological tool to limit blood oxygen desaturation and possibly symptoms at altitude.	[Nespoulet, Hugo; Rupp, Thomas; Bachasson, Damien; Tamisier, Renaud; Wuyam, Bernard; Levy, Patrick; Verges, Samuel] INSERM, U1042, Grenoble, France; [Nespoulet, Hugo; Rupp, Thomas; Bachasson, Damien; Tamisier, Renaud; Wuyam, Bernard; Levy, Patrick; Verges, Samuel] Univ Grenoble Alpes, Hypoxia Physiopathol Lab HP2, Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Verges, S (corresponding author), INSERM, U1042, Grenoble, France.	sverges@chu-grenoble.fr	Bachasson, Damien/U-4233-2019; LEVY, Patrick/AAX-2802-2020; wuyam, bernard MF/M-7438-2014; Tamisier, Renaud/M-6858-2014; Verges, Samuel/M-7040-2014; Bachasson, Damien/ABC-1705-2020	LEVY, Patrick/0000-0003-3174-7935; Tamisier, Renaud/0000-0003-1128-6529; Verges, Samuel/0000-0002-0831-9222; Bachasson, Damien/0000-0001-6335-9916	scientific council of AGIRadom	scientific council of AGIRadom	The present study was funded by the scientific council of AGIRadom (http://www.agiradom.com/spip.php?article35). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agostoni P, 2010, EUR HEART J, V31, P457, DOI 10.1093/eurheartj/ehp472; Aguilaniu B, 2008, EUR RESPIR J, V31, P1091, DOI 10.1183/09031936.00063207; Bouzat P, 2013, RESP PHYSIOL NEUROBI, V186, P16, DOI 10.1016/j.resp.2012.12.009; Burtscher M, 2004, HIGH ALT MED BIOL, V5, P335, DOI 10.1089/ham.2004.5.335; Charloux A, 2000, EUR J APPL PHYSIOL, V82, P313, DOI 10.1007/s004210000226; Da Costa NP, 2011, CRIT CARE MED, V39, P2283, DOI 10.1097/CCM.0b013e3182227fce; Di Marco F, 2010, CRIT CARE MED, V38, P127, DOI 10.1097/CCM.0b013e3181b4a7e7; Dongelmans DA, 2012, MINERVA ANESTESIOL, V78, P790; Ferrari M, 2004, CAN J APPL PHYSIOL, V29, P463, DOI 10.1139/h04-031; Ferrari M, 2011, PHILOS T R SOC A, V369, P4577, DOI 10.1098/rsta.2011.0230; Hackett PH, 2001, NEW ENGL J MED, V345, P107, DOI 10.1056/NEJM200107123450206; LARSON EB, 1985, LANCET, V1, P371; Launay JC, 2004, SCAND J WORK ENV HEA, V30, P322, DOI 10.5271/sjweh.801; Luecke T, 2005, CRIT CARE, V9, P607, DOI 10.1186/cc3877; Millet GP, 2012, J APPL PHYSIOL, V112, P1783, DOI 10.1152/japplphysiol.00067.2012; MUELLER RE, 1970, J APPL PHYSIOL, V28, P784, DOI 10.1152/jappl.1970.28.6.784; Nespoulet H, 2012, EUR RESPIR J, V40, P673, DOI 10.1183/09031936.00073111; Nield MA, 2007, J CARDIOPULM REHABIL, V27, P237; Reissmann HK, 2000, INTENS CARE MED, V26, P1764, DOI 10.1007/s001340000725; Richalet JP, 2012, AM J RESP CRIT CARE, V185, P192, DOI 10.1164/rccm.201108-1396OC; ROACH RC, 1993, HYPOXIA AND MOLECULAR MEDICINE, P272; Savourey G, 1998, EUR J APPL PHYSIOL O, V77, P32; Savourey G, 2001, AVIAT SPACE ENVIR MD, V72, P21; SCHOENE RB, 1985, CHEST, V87, P330, DOI 10.1378/chest.87.3.330; Spahija J, 2005, CHEST, V128, P640, DOI 10.1378/chest.128.2.640; Tannheimer M, 2009, SLEEP BREATH, V13, P195, DOI 10.1007/s11325-008-0237-z; Ugalde V, 2000, ARCH PHYS MED REHAB, V81, P472, DOI 10.1053/mr.2000.3790; Yasuma F, 2004, CHEST, V125, P683, DOI 10.1378/chest.125.2.683	28	8	8	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2013	8	12							e85219	10.1371/journal.pone.0085219	http://dx.doi.org/10.1371/journal.pone.0085219			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278IG	24376872	gold, Green Published, Green Submitted			2023-01-03	WOS:000328882000180
J	Donze, J; Lipsitz, S; Bates, DW; Schnipper, JL				Donze, Jacques; Lipsitz, Stuart; Bates, David W.; Schnipper, Jeffrey L.			Causes and patterns of readmissions in patients with common comorbidities: retrospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; PHARMACIST INTERVENTION; HOSPITAL READMISSIONS; EXACERBATIONS; VALIDATION; DISCHARGE; DISEASE	Objective To evaluate the primary diagnoses and patterns of 30 day readmissions and potentially avoidable readmissions in medical patients with each of the most common comorbidities. Design Retrospective cohort study. Setting Academic tertiary medical centre in Boston, 2009-10. Participants 10 731 consecutive adult discharges from a medical department. Main outcome measures Primary readmission diagnoses of readmissions within 30 days of discharge and potentially avoidable 30 day readmissions to the index hospital or two other hospitals in its network. Results Among 10 731 discharges, 2398 (22.3%) were followed by a 30 day readmission, of which 858 (8.0%) were identified as potentially avoidable. Overall, infection, neoplasm, heart failure, gastrointestinal disorder, and liver disorder were the most frequent primary diagnoses of potentially avoidable readmissions. Almost all of the top five diagnoses of potentially avoidable readmissions for each comorbidity were possible direct or indirect complications of that comorbidity. In patients with a comorbidity of heart failure, diabetes, ischemic heart disease, atrial fibrillation, or chronic kidney disease, the most common diagnosis of potentially avoidable readmission was acute heart failure. Patients with neoplasm, heart failure, and chronic kidney disease had a higher risk of potentially avoidable readmissions than did those without those comorbidities. Conclusions The five most common primary diagnoses of potentially avoidable readmissions were usually possible complications of an underlying comorbidity. Post-discharge care should focus attention not just on the primary index admission diagnosis but also on the comorbidities patients have.	[Donze, Jacques; Lipsitz, Stuart; Bates, David W.; Schnipper, Jeffrey L.] Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, Boston, MA 02120 USA; [Donze, Jacques; Lipsitz, Stuart; Bates, David W.; Schnipper, Jeffrey L.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Donze, Jacques] Univ Hosp Bern, Div Gen Internal Med, CH-3010 Bern, Switzerland; [Bates, David W.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Schnipper, Jeffrey L.] Brigham & Womens Hosp, BWH Hospitalist Serv, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Bern; University Hospital of Bern; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Donze, J (corresponding author), Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, Boston, MA 02120 USA.	donze.author@gmail.com	Bates, David/AAE-7283-2019		Swiss National Science Foundation; Swiss Foundation for Medical-Biological Scholarships	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Foundation for Medical-Biological Scholarships	JD was supported by the Swiss National Science Foundation and the Swiss Foundation for Medical-Biological Scholarships. The Swiss Science National Foundation and the Swiss Foundation for Medical-Biological Scholarships had no role in the design and conduct of this study, the analysis or interpretation of the data, or the preparation of this manuscript.	[Anonymous], 2013, POT AV READM; Chu LW, 1999, GERONTOLOGY, V45, P220, DOI 10.1159/000022091; Dharmarajan K, 2013, JAMA-J AM MED ASSOC, V309, P355, DOI 10.1001/jama.2012.216476; Donze J, 2013, JAMA INTERN MED, V173, P632, DOI 10.1001/jamainternmed.2013.3023; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Gunen H, 2010, EUR RESPIR J, V35, P1243, DOI 10.1183/09031936.00120909; Halfon P, 2002, J CLIN EPIDEMIOL, V55, P573, DOI 10.1016/S0895-4356(01)00521-2; Halfon P, 2006, MED CARE, V44, P972, DOI 10.1097/01.mlr.0000228002.43688.c2; Jasti H, 2008, CLIN INFECT DIS, V46, P550, DOI 10.1086/526526; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Kripalani S, 2012, ANN INTERN MED, V157, P1, DOI 10.7326/0003-4819-157-1-201207030-00003; Krumholz HM, 2013, NEW ENGL J MED, V368, P100, DOI 10.1056/NEJMp1212324; Librero J, 1999, J CLIN EPIDEMIOL, V52, P171, DOI 10.1016/S0895-4356(98)00160-7; Maldonado F, 2010, CHEST, V138, P1295, DOI 10.1378/chest.09-2567; Naeije Robert, 2005, Proc Am Thorac Soc, V2, P20, DOI 10.1513/pats.200407-037MS; Schnipper JL, 2010, CIRC-CARDIOVASC QUAL, V3, P212, DOI 10.1161/CIRCOUTCOMES.109.921833; Sethi S, 2008, NEW ENGL J MED, V359, P2355, DOI 10.1056/NEJMra0800353; Shetty R, 2008, J THROMB THROMBOLYS, V26, P35, DOI 10.1007/s11239-007-0157-y; van Walraven C, 2011, CAN MED ASSOC J, V183, pE391, DOI 10.1503/cmaj.101860; van Walraven C, 2010, CAN MED ASSOC J, V182, P551, DOI 10.1503/cmaj.091117; Wells JM, 2012, NEW ENGL J MED, V367, P913, DOI 10.1056/NEJMoa1203830; Williams M, ACAD MED IN PRESS; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; Zekry D, 2012, J AM MED DIR ASSOC, V13, P272, DOI 10.1016/j.jamda.2010.11.011; Zvezdin B, 2009, CHEST, V136, P376, DOI 10.1378/chest.08-2918	25	133	134	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 16	2013	347								f7171	10.1136/bmj.f7171	http://dx.doi.org/10.1136/bmj.f7171			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277LV	24342737	hybrid, Green Published			2023-01-03	WOS:000328821800002
J	Yusop, NBM; Mun, CY; Shariff, ZM; Huat, CB				Yusop, Nor Baizura Md; Mun, Chan Yoke; Shariff, Zalilah Mohd; Huat, Choo Beng			Factors Associated with Quality of Life among Hemodialysis Patients in Malaysia	PLOS ONE			English	Article							SUBJECTIVE GLOBAL ASSESSMENT; NUTRITIONAL-STATUS; KIDNEY-DISEASE; RENAL-FAILURE; BODY-FAT; MAINTENANCE HEMODIALYSIS; DIALYSIS ADEQUACY; DIABETIC-PATIENTS; DIETARY-INTAKE; MENTAL-HEALTH	Although hemodialysis treatment has greatly increased the life expectancy of end stage renal disease patients, low quality of life among hemodialysis patients is frequently reported. This cross-sectional study aimed to determine the relationship between medical history, hemodialysis treatment and nutritional status with the mental and physical components of quality of life in hemodialysis patients. Respondents (n=90) were recruited from Hospital Kuala Lumpur and dialysis centres of the National Kidney Foundation of Malaysia. Data obtained included socio-demography, medical history, hemodialysis treatment and nutritional status. Mental and physical quality of life were measured using the Mental Composite Summary (MCS) and Physical Composite Summary (PCS) of the Short-Form Health Survey 36-items, a generic core of the Kidney Disease Quality of Life Short Form. Two summary measures and total SF-36 was scored as 0-100, with a higher score indicating better quality of life. Approximately 26 (30%) of respondents achieved the body mass index (24 kg/m(2)) and more than 80% (n=77) achieved serum albumin level (>35.0 mg/dL) recommended for hemodialysis patients. The majority of respondents did not meet the energy (n=72, 80%) and protein (n=68,75%) recommendations. The total score of SF-36 was 54.1 +/- 19.2, while the score for the mental and physical components were 45.0 +/- 8.6 and 39.6 +/- 8.6, respectively. Factors associated with a higher MCS score were absence of diabetes mellitus (p=0.000) and lower serum calcium (p=0.004), while higher blood flow (p=0.000), higher serum creatinine (p=0.000) and lower protein intake (p= 0.006) were associated with a higher PCS score. To improve the overall quality of life of hemodialysis patients, a multidisciplinary intervention that includes medical, dietetic and psychosocial strategies that address factors associated with mental and physical quality of life are warranted to reduce further health complications and to improve quality of life.	[Yusop, Nor Baizura Md; Mun, Chan Yoke; Shariff, Zalilah Mohd] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Nutr & Dietet, Serdang 43400, Selangor, Malaysia; [Huat, Choo Beng] Manipal Med Collage, Dept Med, Melaka, Malaysia	Universiti Putra Malaysia	Shariff, ZM (corresponding author), Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Nutr & Dietet, Serdang 43400, Selangor, Malaysia.	zalilahms@upm.edu.my						Abbas Tarek M, 2005, Hemodial Int, V9, P153, DOI 10.1111/j.1492-7535.2005.01126.x; Abu Bakar A, 2000, TOTAL QUAL MANAGE, V11, pS788; Agarwal SK, 2005, NEPHROL DIAL TRANSPL, V20, P1638, DOI 10.1093/ndt/gfh855; Allen KL, 2002, J RENAL NUTR, V12, P160, DOI 10.1053/jren.2002.33512; Anees M, 2011, IRAN J KIDNEY DIS, V5, P9; [Anonymous], 2006, DIAL REG PAK 2005 20; Borzou SR, 2009, SAUDI J KIDNEY DIS T, V20, P639; Bossola M, 2005, J RENAL NUTR, V15, P244, DOI 10.1053/j.jrn.2005.01.004; BROZEK J, 1951, BRIT J NUTR, V5, P194, DOI 10.1079/BJN19510025; Buckner S, 2003, J RENAL NUTR, V13, P295, DOI 10.1016/S1051-2276(03)00119-5; Chiang CK, 2004, BLOOD PURIFICAT, V22, P490, DOI 10.1159/000081730; DETSKY AS, 1987, JPEN-PARENTER ENTER, V11, P8, DOI 10.1177/014860718701100108; DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060; Durose CL, 2004, J AM DIET ASSOC, V104, P35, DOI 10.1016/j.jada.2003.10.016; Eknoyan G, 2004, KIDNEY INT, V66, P1310, DOI 10.1111/j.1523-1755.2004.00894.x; FAO/WHO/UNU, 2004, FOOD NUTR TECHN REP FOOD NUTR TECHN REP; Germin-Petrovic D, 2011, COLLEGIUM ANTROPOL, V35, P687; Gibson RS, 2005, PRINCIPLES NUTR ASSE, P290; GOLDBERG GR, 1991, EUR J CLIN NUTR, V45, P569; HAYS RD, 1994, QUAL LIFE RES, V3, P329, DOI 10.1007/BF00451725; Hooi L S, 2006, Med J Malaysia, V61, P513; International Diabetes Federation, 2011, IDF DIABETES ATLAS; Ishimura E, 2001, J AM SOC NEPHROL, V12, P1921, DOI 10.1681/ASN.V1291921; Ismail A, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-39; Johansen KL, 2003, AM J CLIN NUTR, V77, P842, DOI 10.1093/ajcn/77.4.842; Jones CH, 2004, J RENAL NUTR, V14, P26, DOI 10.1053/j.jrn.2003.09.006; Kalantar-Zadeh K, 2001, J AM SOC NEPHROL, V12, P2797, DOI 10.1681/ASN.V12122797; Kalantar-Zadeh K, 2003, AM J KIDNEY DIS, V42, P864, DOI 10.1016/j.ajkd.2003.07.016; Kalantar-Zadeh K, 2006, AM J CLIN NUTR, V83, P202; Kloppenburg WD, 1999, KIDNEY INT, V55, P1961, DOI 10.1046/j.1523-1755.1999.00412.x; Kovesdy CP, 2010, CLIN J AM SOC NEPHRO, V5, P468, DOI 10.2215/CJN.06040809; Kugler C, 2005, J NURS SCHOLARSHIP, V37, P25, DOI 10.1111/j.1547-5069.2005.00009.x; Lim YN, 2005, 13 MAL DIAL TRANSP R; Lim YN, 2011, 18 MAL DIAL TRANSP; Lim YN, 2004, 11 MAL DIAL TRANSP; Liu W J, 2006, Med J Malaysia, V61, P540; Lou LM, 2007, NEFROLOGIA, V27, P38; Manns BJ, 2002, ASAIO J, V48, P565, DOI 10.1097/00002480-200209000-00021; Medical Nutrition Therapy Guidelines for Chronic, 2005, KIDN DIS; Mehrotra R, 2002, AM J KIDNEY DIS, V40, P133, DOI 10.1053/ajkd.2002.33922; Miller JE, 2010, AM J NEPHROL, V32, P403, DOI 10.1159/000319861; Morais Alvaro A. C., 2005, Clinics, V60, P185, DOI 10.1590/S1807-59322005000300002; Morsch CM, 2006, J CLIN NURS, V15, P498, DOI 10.1111/j.1365-2702.2006.01349.x; National Kidney Foundation, 2000, AM J KIDNEY DIS, V35; Neves KR, 2004, KIDNEY INT, V66, P2237, DOI 10.1111/j.1523-1755.2004.66013.x; Ohkawa S, 2005, NEPHROL DIAL TRANSPL, V20, P945, DOI 10.1093/ndt/gfh643; Ohri-Vachaspati P, 1999, J Ren Nutr, V9, P9; Piperi C, 2004, MOL CELL BIOCHEM, V265, P57, DOI 10.1023/B:MCBI.0000044315.74038.78; Pupim LB, 2002, AM J KIDNEY DIS, V40, P143, DOI 10.1053/ajkd.2002.33923; Pyram R, 2012, MATURITAS, V71, P94, DOI 10.1016/j.maturitas.2011.11.009; Rutledge C, 2000, NEPHROLOGY, V5, P27, DOI 10.1046/j.1440-1797.2000.00510.x; Sararaks S, 2001, Med J Malaysia, V56, P350; Slinin Y, 2005, J AM SOC NEPHROL, V16, P1788, DOI 10.1681/ASN.2004040275; Sorensen VR, 2007, DIABETOLOGIA, V50, P2254, DOI 10.1007/s00125-007-0810-1; Streja E, 2011, CLIN J AM SOC NEPHRO, V6, P1463, DOI 10.2215/CJN.09131010; Suzana S, 2002, ATLAS FOOD EXCHANGES; Tanaka M, 2007, NEPHROL DIAL TRANSPL, V22, P1658, DOI 10.1093/ndt/gfm008; Valderrabano F, 2001, AM J KIDNEY DIS, V38, P443, DOI 10.1053/ajkd.2001.26824; Wang VV, 2012, INT J ARTIF ORGANS, V35, P217, DOI 10.5301/ijao.5000014; Wee HL, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-93; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Wong J S, 2005, Med J Malaysia, V60, P146; Wu AW, 2004, J AM SOC NEPHROL, V15, P743, DOI 10.1097/01.ASN.0000113315.81448.CA; Wu AYT, 2005, DIABETOLOGIA, V48, P17, DOI 10.1007/s00125-004-1599-9; Zyga S, 2005, J RENAL CARE, V31, P24, DOI 10.1111/j.1755-6686.2005.tb00385.x	65	32	33	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2013	8	12							e84152	10.1371/journal.pone.0084152	http://dx.doi.org/10.1371/journal.pone.0084152			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	276GD	24358336	gold, Green Published, Green Accepted, Green Submitted			2023-01-03	WOS:000328735700153
J	Campbell, J; Colvin, LA				Campbell, James; Colvin, Lesley A.			ABC of Pain Management of Low Back Pain	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Campbell, James] Royal Infirm Edinburgh NHS Trust, Dept Orthopaed, Edinburgh, Midlothian, Scotland; [Colvin, Lesley A.] Univ Edinburgh, Western Gen Hosp, Dept Anaesthesia Crit Care & Pain Med, Edinburgh, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	Campbell, J (corresponding author), Royal Infirm Edinburgh NHS Trust, Dept Orthopaed, Edinburgh, Midlothian, Scotland.			Colvin, Lesley/0000-0002-1563-8600				[Anonymous], 2009, ABS SPINAL DISORDERS; Battie MC, 2004, SPINE, V29, P2679, DOI 10.1097/01.brs.0000146457.83240.eb; Cochrane Back Review Group, FREQ UPD REV EV BACK; Eubanks JD, 2007, SPINE, V32, P2058, DOI 10.1097/BRS.0b013e318145a3a9; Gibson JNA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001350.pub4; Koes BW, 2001, SPINE, V26, P2504, DOI 10.1097/00007632-200111150-00022; Staal JB, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001824.pub3; [No title captured]	8	2	2	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	2013	347								f3148	10.1136/bmj.f3148	http://dx.doi.org/10.1136/bmj.f3148			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268DX	24308922				2023-01-03	WOS:000328150000001
J	Derrett, S; Wilson, S; Samaranayaka, A; Langley, J; Wyeth, E; Ameratunga, S; Lilley, R; Davie, G; Mauiliu, M				Derrett, Sarah; Wilson, Suzanne; Samaranayaka, Ari; Langley, John; Wyeth, Emma; Ameratunga, Shanthi; Lilley, Rebbecca; Davie, Gabrielle; Mauiliu, Melbourne			Prevalence and Predictors of Disability 24-Months after Injury for Hospitalised and Non-Hospitalised Participants: Results from a Longitudinal Cohort Study in New Zealand	PLOS ONE			English	Article							OF-LIFE OUTCOMES; FUNCTIONAL CONSEQUENCES; MAJOR TRAUMA; HEALTH; QUALITY; DISPARITIES; BURDEN; WOMEN; CARE	Introduction: Most studies investigating disability outcomes following injury have examined hospitalised patients. It is not known whether variables associated with disability outcomes are similar for injured people who are not hospitalised. Aims: This paper compares the prevalence of disability 24 months after injury for participants in the Prospective Outcomes of Injury Study who were hospitalised and those non-hospitalised, and also seeks to identify pre-injury and injury-related predictors of disability among hospitalised and non-hospitalised participants. Methods: Participants, aged 18-64 years, were recruited from an injury claims register managed by New Zealand's no-fault injury compensation insurer after referral by health care professionals. A wide range of pre-injury socio-demographic, health and psychosocial characteristics were collected, as well as injury-related characteristics; outcome is assessed using the WHODAS. Multivariable models estimating relative risks of disability for hospitalised and non-hospitalised participants were developed using Poisson regression methods. Results: Of 2856 participants, analyses were restricted to 2184 (76%) participants for whom both pre-injury and 24 month WHODAS data were available. Of these, 25% were hospitalised. In both hospitalised and non-hospitalised groups, 13% experience disability (WHODAS >= 10) 24 months after injury; higher than pre-injury (5%). Of 28 predictor variables, seven independently placed injured participants in the hospitalised group at increased risk of disability 24 months after injury; eight in the non-hospitalised. Only four predictors (pre-injury disability, two or more pre-injury chronic conditions, pre-injury BMI>30 and trouble accessing healthcare services) were common to both the hospitalised and non-hospitalised groups. There is some evidence to suggest that among the hospitalised group, Maori ori have higher risk of disability relative to nonMaori. Conclusions: At 24 months considerable disability is borne, equally, by hospitalised and non-hospitalised groups. However, predictors of disability are not necessarily consistent between the hospitalised and non-hospitalised groups, suggesting caution in generalising results from one group to the other.	[Derrett, Sarah; Wilson, Suzanne; Samaranayaka, Ari; Langley, John; Lilley, Rebbecca; Davie, Gabrielle; Mauiliu, Melbourne] Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Injury Prevent Res Unit, Dunedin, New Zealand; [Wyeth, Emma] Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Ngai Tahu Maori Hlth Res Unit, Dunedin, New Zealand; [Ameratunga, Shanthi] Univ Auckland, Fac Med & Hlth Sci, Sch Populat Hlth, Auckland 1, New Zealand; [Derrett, Sarah] Massey Univ, Coll Hlth, Sch Hlth & Social Serv, Palmerston North, New Zealand	University of Otago; University of Otago; University of Auckland; Massey University	Derrett, S (corresponding author), Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Injury Prevent Res Unit, Dunedin, New Zealand.	s.l.derrett@massey.ac.nz	Wyeth, Emma/GLU-8874-2022	Davie, Gabrielle/0000-0001-5466-5364; Wyeth, Emma/0000-0002-6869-5190; Derrett, Sarah/0000-0003-2867-0498; Ameratunga, Shanthi/0000-0001-8042-2251	Health Research Council of New Zealand; Accident Compensation Corporation, New Zealand	Health Research Council of New Zealand(Health Research Council of New Zealand); Accident Compensation Corporation, New Zealand	This study is funded by the Health Research Council of New Zealand (2007-2013), and was co-funded by the Accident Compensation Corporation, New Zealand (2007-2010). The views and conclusions expressed herein are the authors and may not reflect those of the funders. The Accident Compensation Corporation sent out invitations to eligible potential participants on the research team's behalf, and also provided, following participants' consent, information from the electronic record about participants' injuries. The funders had no role in study design, analysis, decision to publish, or preparation of the manuscript.	Accident Compensation Corporation, 2010, ANNUAL REPORT 2010; American Psychiatric Association Committee of Nomenclature and Statistics, 1980, DIAGNOSTIC AND STATI; Andrews G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008343; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Black JA, 2011, J TRAUMA, V71, P1003, DOI 10.1097/TA.0b013e3182238833; Bradley KA, 2007, ALCOHOL CLIN EXP RES, V31, P1208, DOI 10.1111/j.1530-0277.2007.00403.x; Delaibatiki Cammock R, 2012, AUSTRALAS EPIDEMIOL, V19, P17; Derrett S, 2009, INJURY PREV, V15, DOI [10.1136/ip.2009.022558, 10.1136/ip.2009.022558a]; Derrett S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044909; Derrett S, 2011, INJURY PREV, V17, P415, DOI 10.1136/injuryprev-2011-040044; Fingerhut LA, 2006, INJURY PREV, V12, P24, DOI 10.1136/ip.2005.009076; Gabbe BJ, 2010, J TRAUMA, V69, P532, DOI 10.1097/TA.0b013e3181e5125b; Holbrook TL, 2004, J TRAUMA, V56, P284, DOI 10.1097/01.TA.0000109758.75406.F8; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Kendrick D, 2013, INJURY PREV, V19, P370, DOI 10.1136/injuryprev-2012-040658; Langley JD, 2013, INJURY PREV, V19, P428, DOI 10.1136/injuryprev-2012-040685; Malm Sigrun, 2008, Ann Adv Automot Med, V52, P93; Mauri Ora Associates, 2010, ORI EXPERIENCE OF AC; Ministry of Health, 2012, TUPU OLA MOUI PACIFI; Ministry of Health, 2010, TATAU KAHUKURA MA OR; Ministry of Health, 2008, PORTRAIT HLTH KEY RE; Ministry of Social Development, 2000, DIRECT MEASUREMENT O; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Overgaard M, 2011, J TRAUMA, V71, P435, DOI 10.1097/TA.0b013e31820e7ec3; Peterman AH, 2002, ANN BEHAV MED, V24, P49, DOI 10.1207/S15324796ABM2401_06; Polinder S, 2012, BRIT J SURG, V99, P114, DOI 10.1002/bjs.7708; Polinder S, 2012, EPIDEMIOL REV, V34, P17, DOI 10.1093/epirev/mxr022; Portney KE, 1997, AM BEHAV SCI, V40, P632, DOI 10.1177/0002764297040005009; Ratima K, 2007, HAUORA MA ORI STANDA; Robroek SJW, 2013, SCANDANAVIAN JOURNAL, DOI [10.5271/ sjweh. 3354., DOI 10.5271/SJWEH.3354.]; RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.1093/biomet/63.3.581; Rumball-Smith JML, 2009, NEW ZEAL MED J, V122, P68; SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063, DOI 10.1037/0022-3514.67.6.1063; Schwarzer R., 1995, MEASURES HLTH PSYCHO, P35, DOI DOI 10.1037/T00393-000; Seaman SR, 2013, STAT METHODS MED RES, V22, P278, DOI 10.1177/0962280210395740; Smith DL, 2008, DISABIL HEALTH J, V1, P79, DOI 10.1016/j.dhjo.2008.01.001; Soberg HL, 2012, ARCH PHYS MED REHAB, V93, P765, DOI 10.1016/j.apmr.2011.08.050; Soberg HL, 2007, J TRAUMA, V62, P461, DOI 10.1097/01.ta.0000222916.30253.ea; Sport and Recreation New Zealand, 2004, THE NEW ZEALAND PHYS; StataCorp, 2011, STATA RELEASE 12 STA; Statistics New Zealand, 2007, QUICKSTATS ABOUT MA; Statistics New Zealand, 2006, 2006 CENSUS OF POPUL; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; T Ustun, 2010, MEASURING HEALTH AND; Toien K, 2012, INJURY, V43, P1606, DOI 10.1016/j.injury.2011.03.038; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; Ware J, 2000, SF 36H HEALTH SURVEY; Wilson R, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-68; World Health Organization (WHO), 2011, BMI CLASSIFICATION; Wyeth EH, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-120; Wyeth EH, 2010, ETHNIC HEALTH, V15, P303, DOI 10.1080/13557851003721194; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	52	36	36	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2013	8	11							e80194	10.1371/journal.pone.0080194	http://dx.doi.org/10.1371/journal.pone.0080194			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259PW	24278258	Green Published, gold			2023-01-03	WOS:000327539800063
J	Abubakar, A; Van Baar, A; Fischer, R; Bomu, G; Gona, JK; Newton, CR				Abubakar, Amina; Van Baar, Anneloes; Fischer, Ronald; Bomu, Grace; Gona, Joseph K.; Newton, Charles R.			Socio-Cultural Determinants of Health-Seeking Behaviour on the Kenyan Coast: A Qualitative Study	PLOS ONE			English	Article							EPILEPSY TREATMENT; CHILDHOOD ILLNESSES; TRADITIONAL HEALERS; CARE-SEEKING; MALARIA; COMMUNITY; NUTRITION; CHILDREN	Background: Severe childhood illnesses present a major public health challenge for Africa, which is aggravated by a suboptimal response to the child's health problems with reference to the health-seeking behaviour of the parents or guardians. We examined the health-seeking behaviour of parents at the Kenyan coast because understanding impediments to optimal health-seeking behaviour could greatly contribute to reducing the impact of severe illness on children's growth and development. Methods and Results: Health-seeking behaviour, and the factors influencing this behaviour, were examined in two traditional communities. We held in-depth interviews with 53 mothers, fathers and caregivers from two rural clinics at the Kenyan Coast. Biomedical medicine (from health facilities and purchased over the counter) was found to be the most popular first point of treatment. However, traditional healing still plays a salient role in the health care within these two communities. Traditional healers were consulted for various reasons: a) attribution of causation of ill-health to supernatural sources, b) chronic illness (inability of modern medicine to cure the problem) and c) as prevention against possible ill-health. In developing an explanatory model of decision-making, we observed that this was a complex process involving consultation at various levels, with elders, but also between both parents, depending on the perceived nature and chronicity of the illness. However, it was reported that fathers were the ultimate decision makers in relation to decisions concerning where the child would be taken for treatment. Conclusions: Health systems need to see traditional healing as a complementary system in order to ensure adequate access to health care. Importantly, fathers also need to be addressed in intervention and education programs.	[Abubakar, Amina; Van Baar, Anneloes] Univ Utrecht, Utrecht, Netherlands; [Abubakar, Amina; Bomu, Grace; Gona, Joseph K.; Newton, Charles R.] KEMRI, Ctr Geog Med Res Coast, Kilifi, Kenya; [Abubakar, Amina] Tilburg Univ, NL-5000 LE Tilburg, Netherlands; [Fischer, Ronald] Victoria Univ Wellington, Wellington, New Zealand; [Newton, Charles R.] Univ Oxford, Oxford, England	Utrecht University; Tilburg University; Victoria University Wellington; University of Oxford	Abubakar, A (corresponding author), Univ Utrecht, Utrecht, Netherlands.	A.AbubakarAli@uvt.nl	van Baar, Anneloes/L-8236-2013; Newton, Charles RJC/B-7578-2014; Fischer, Ronald/G-6447-2017; Newton, Charles/V-7872-2019; Abubakar, Amina/F-1479-2017	van Baar, Anneloes/0000-0002-3498-9019; Newton, Charles RJC/0000-0002-6999-5507; Fischer, Ronald/0000-0002-3055-3955; Newton, Charles/0000-0002-6999-5507; Abubakar, Amina/0000-0002-3686-7904	Utrecht University	Utrecht University	The study was funded by an internal grant by Utrecht University to Amina Abubakar and Anneloes Van Baar. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abubakar A, 2011, RURAL REMOTE HEALTH, V11; Beiersmann C, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-106; Carter JA, 2012, EPILEPSY BEHAV, V25, P614, DOI 10.1016/j.yebeh.2012.07.009; Chibwana AI, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-219; Corbin J., 1998, BASICS QUALITATIVE R; Dillip A, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-113; Feyisetan B J, 1997, Health Transit Rev, V7, P221; Goodman CA, 2006, HEALTH POLICY PLANN, V21, P275, DOI 10.1093/heapol/czl011; Government of Kenya, 2009, MSAMBW DISTR DEV PLA; Government of Kenya, 2001, POV ER STRAT PAP KIL; Grantham-McGregor S, 2007, LANCET, V369, P60, DOI 10.1016/S0140-6736(07)60032-4; Kendall-Taylor NH, 2009, RURAL REMOTE HEALTH, V9; Kendall-Taylor N, 2008, EPILEPSIA, V49, P1638, DOI 10.1111/j.1528-1167.2008.01580_1.x; Maitland K, 2006, PLOS MED, V3, P2431, DOI 10.1371/journal.pmed.0030500; Marsh VM, 2004, TROP MED INT HEALTH, V9, P451, DOI 10.1111/j.1365-3156.2004.01223.x; Ministry of Planning and National Development, 2005, KIL DISTR STRAT PLAN; Muthaura CN, 2007, J ETHNOPHARMACOL, V114, P377, DOI 10.1016/j.jep.2007.08.033; Mwangome M, 2010, J HEALTH POPUL NUTR, V28, P167; Mwenesi H, 1995, SOCIAL SCI MED, V40; Oberlander L, 2000, B WORLD HEALTH ORGAN, V78, P1352; Ogunjuyigbe P. O., 2004, DEM RES, V11, P43, DOI DOI 10.4054/DEMRES.2004.11.2; Sabuni LP, 2007, QUAL HEALTH RES, V17, P1280, DOI 10.1177/1049732307307864; Silverman D., 2010, DOING QUALITATIVE RE, V3; Solarsh G, 2006, DISEASE AND MORTALITY IN SUB-SAHARAN AFRICA, 2ND EDITION, P125; Taffa N, 2005, TROP MED INT HEALTH, V10, P240, DOI 10.1111/j.1365-3156.2004.01381.x; Tinuade O, 2010, J PAEDIATR CHILD H, V46, P238, DOI 10.1111/j.1440-1754.2009.01677.x; Winkler AS, 2010, EPILEPSY BEHAV, V19, P596, DOI 10.1016/j.yebeh.2010.09.023; World Health Organization, 2002, WHO TRAD MED STRAT 2; World Health Organization, 2007, MILL DEV GOALS REP 2; Wreford J, 2005, SOC DYNAMICS, V31, P55, DOI 10.1080/02533950508628708	30	53	53	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2013	8	11							e71998	10.1371/journal.pone.0071998	http://dx.doi.org/10.1371/journal.pone.0071998			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256KH	24260094	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000327308500002
J	Xu, HY; Yang, NW; Wan, FH				Xu, Hai-Yun; Yang, Nian-Wan; Wan, Fang-Hao			Competitive Interactions between Parasitoids Provide New Insight into Host Suppression	PLOS ONE			English	Article							TABACI BIOTYPE-B; BEMISIA-TABACI; INTRINSIC COMPETITION; ENCARSIA-FORMOSA; LETHAL INTERFERENCE; LARVAL PARASITOIDS; 2 ENDOPARASITOIDS; ERETMOCERUS; DISCRIMINATION; HYMENOPTERA	Understanding the dynamics of potential inter- and intraspecific competition in parasitoid communities is crucial in the screening of efficient parasitoid species and for utilization of the best parasitoid species combinations. In this respect, the host-parasitoid systems, Bemisia tabaci and two parasitoids, Eretmocerus hayati (exotic) and Encarsia sophia (existing) were studied under laboratory conditions to investigate whether interference competition between the exotic and existing species occurs as well as the influence of potential interference competition on the suppression of the host B. tabaci. Studies on interspecific-, intraspecific- and self-interference competition in two parasitoid species were conducted under both rich and limited host resource conditions. Results showed that (1) both parasitoid species negatively affect the progeny production of the other under both rich and limited host resource conditions; (2) both parasitoid species interfered intraspecifically on conspecific parasitized hosts when the available hosts are scarce and; 3) the mortality of B. tabaci induced by parasitoids via parasitism, host-feeding or both parasitism and host-feeding together varied among treatments under different host resource conditions, but showed promise for optimizing control strategies. As a result of our current findings, we suggest a need to investigate the interactions between the two parasitoids on continuous generations.	[Xu, Hai-Yun; Yang, Nian-Wan; Wan, Fang-Hao] Chinese Acad Agr Sci, Inst Plant Protect, State Key Lab Biol Plant Dis & Insect Pests, Beijing 100193, Peoples R China	Chinese Academy of Agricultural Sciences; Institute of Plant Protection, CAAS	Wan, FH (corresponding author), Chinese Acad Agr Sci, Inst Plant Protect, State Key Lab Biol Plant Dis & Insect Pests, Beijing 100193, Peoples R China.	wanfanghao@caas.cn	Yang, Nianwan/AAH-7371-2019	Yang, Nianwan/0000-0002-6014-3383; Tang, Shihuan/0000-0003-0589-4499	National Natural Science Foundation [30930062]; National Basic Research and Development Program of China [2009CB119200]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); National Basic Research and Development Program of China(National Basic Research Program of China)	The research was financially supported by the National Natural Science Foundation (30930062) and the National Basic Research and Development Program of China (2009CB119200). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ardeh MJ, 2005, BIOL CONTROL, V33, P74, DOI 10.1016/j.biocontrol.2005.01.006; Bogran CE, 2002, ECOLOGY, V83, P653, DOI 10.1890/0012-9658(2002)083[0653:ICAIPF]2.0.CO;2; BROWN JK, 1995, ANNU REV ENTOMOL, V40, P511, DOI 10.1146/annurev.en.40.010195.002455; Collier T, 2002, BIOL CONTROL, V23, P254, DOI 10.1006/bcon.2001.1007; Collier TR, 2007, ECOL ENTOMOL, V32, P70, DOI 10.1111/j.1365-2311.2006.00844.x; Collier TR, 2001, OECOLOGIA, V129, P147, DOI 10.1007/s004420100706; COLLIER TR, 1995, ANN ENTOMOL SOC AM, V88, P206, DOI 10.1093/aesa/88.2.206; De Barro PJ, 2011, ANNU REV ENTOMOL, V56, P1, DOI 10.1146/annurev-ento-112408-085504; De Moraes CM, 2005, ECOL ENTOMOL, V30, P564, DOI 10.1111/j.0307-6946.2005.00723.x; De Moraes CM, 1999, ECOL ENTOMOL, V24, P402, DOI 10.1046/j.1365-2311.1999.00212.x; De Vis RMJ, 2003, J INSECT BEHAV, V16, P117, DOI 10.1023/A:1022805529942; FORCE DC, 1985, AM NAT, V126, P440, DOI 10.1086/284430; FORCE DC, 1974, SCIENCE, V184, P624, DOI 10.1126/science.184.4137.624; Giron D, 2002, FUNCT ECOL, V16, P750, DOI 10.1046/j.1365-2435.2002.00679.x; Godfray H. C. J., 1994, PARASITOIDS BEHAV EV, DOI 10.1515/9780691207025; Goolsby J, 2005, 2 INT S BIOL CONTR A; Goolsby JA, 2005, BIOL CONTROL, V32, P70, DOI 10.1016/j.biocontrol.2004.07.012; Goolsby John A., 2008, V4, P179; Gould Juli, 2008, V4, P191, DOI 10.1007/978-1-4020-6740-2_12; Harvey JA, 2013, ANNU REV ENTOMOL, V58, P333, DOI 10.1146/annurev-ento-120811-153622; Harvey JA, 2009, ENTOMOL EXP APPL, V132, P155, DOI 10.1111/j.1570-7458.2009.00882.x; Huang Jian, 2000, Entomological Journal of East China, V9, P29; Hunter MS, 2001, ANNU REV ENTOMOL, V46, P251, DOI 10.1146/annurev.ento.46.1.251; Hunter MS, 1998, ENTOMOL EXP APPL, V89, P249, DOI 10.1023/A:1003555607725; JERVIS MA, 1986, BIOL REV, V61, P395, DOI 10.1111/j.1469-185X.1986.tb00660.x; [冀禄禄 Ji Lulu], 2012, [中国生物防治学报, Chinese Journal of Biological Control], V28, P303; Khafagi WE, 2008, BIOCONTROL, V53, P427, DOI 10.1007/s10526-007-9078-0; Liu SS, 2007, SCIENCE, V318, P1769, DOI 10.1126/science.1149887; Luo Chen, 2002, Acta Entomologica Sinica, V45, P759; MACKAUER M, 1990, CRITICAL ISSUES IN BIOLOGICAL CONTROL, P41; Moretti R, 2008, ENTOMOL EXP APPL, V129, P44, DOI 10.1111/j.1570-7458.2008.00745.x; Mucheru OM, 2009, ENTOMOL EXP APPL, V130, P10, DOI 10.1111/j.1570-7458.2008.00788.x; Murdoch WW, 1998, INSECT POPULATIONS IN THEORY AND IN PRACTICE, P167; Oliveira MRV, 2001, CROP PROT, V20, P709, DOI 10.1016/S0261-2194(01)00108-9; Pedata PA, 2002, B ENTOMOL RES, V92, P521, DOI 10.1079/BER2002203; Perring Thomas M., 1996, P3; Polis GA, 1996, AM NAT, V147, P813, DOI 10.1086/285880; PRICE PW, 1972, ECOLOGY, V53, P190, DOI 10.2307/1935729; PRICE PW, 1988, AM NAT, V131, P544, DOI 10.1086/284805; Qio Bao-Li, 2004, Entomological Knowledge, V41, P333; TILLMAN PG, 1992, ENTOMOPHAGA, V37, P439, DOI 10.1007/BF02373117; WALTER GH, 1983, BIOL J LINN SOC, V19, P63, DOI 10.1111/j.1095-8312.1983.tb00777.x; Wan FH, 2009, SCI CHINA SER C, V52, P88, DOI 10.1007/s11427-008-0135-4; Yang NW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041189; Yang NW, 2011, BIOL CONTROL, V59, P313, DOI 10.1016/j.biocontrol.2011.07.019; Zang LS, 2008, ENTOMOL EXP APPL, V127, P55, DOI 10.1111/j.1570-7458.2008.00667.x; Zolnerowich G, 1998, P ENTOMOL SOC WASH, V100, P310	47	43	50	2	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2013	8	11							e82003	10.1371/journal.pone.0082003	http://dx.doi.org/10.1371/journal.pone.0082003			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261IJ	24339904	Green Published, Green Submitted, gold			2023-01-03	WOS:000327657900066
J	Ghosh, A; Sarkar, S; Mandal, AK; Das, N				Ghosh, Aparajita; Sarkar, Sibani; Mandal, Ardhendu K.; Das, Nirmalendu			Neuroprotective Role of Nanoencapsulated Quercetin in Combating Ischemia-Reperfusion Induced Neuronal Damage in Young and Aged Rats	PLOS ONE			English	Article							DRUG-DELIVERY; NITRIC-OXIDE; LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; BRAIN; DEATH; FLAVONOIDS; NANOPARTICLES; ANTIOXIDANTS; MEMBRANE	Cerebral stroke is the leading cause of death and permanent disability among elderly people. In both humans and animals, cerebral ischemia damages the nerve cells in vulnerable regions of the brain, viz., hippocampus, cerebral cortex, cerebellum, and hypothalamus. The present study was conducted to evaluate the therapeutic efficacy of nanoencapsulated quercetin (QC) in combating ischemia-reperfusion-induced neuronal damage in young and aged Swiss Albino rats. Cerebral ischemia was induced by occlusion of the common carotid arteries of both young and aged rats followed by reperfusion. Nanoencapsulated quercetin (2.7 mg/kg b wt) was administered to both groups of animals via oral gavage two hours prior to ischemic insults as well as post-operation till day 3. Cerebral ischemia and 30 min consecutive reperfusion caused a substantial increase in lipid peroxidation, decreased antioxidant enzyme activities and tissue osmolality in different brain regions of both groups of animals. It also decreased mitochondrial membrane microviscosity and increased reactive oxygen species (ROS) generation in different brain regions of young and aged rats. Among the brain regions studied, the hippocampus appeared to be the worst affected region showing increased upregulation of iNOS and caspase-3 activity with decreased neuronal count in the CA1 and CA3 subfields of both young and aged rats. Furthermore, three days of continuous reperfusion after ischemia caused massive damage to neuronal cells. However, it was observed that oral treatment of nanoencapsulated quercetin (2.7 mg/kg b wt) resulted in downregulation of iNOS and caspase-3 activities and improved neuronal count in the hippocampal subfields even 3 days after reperfusion. Moreover, the nanoformulation imparted a significant level of protection in the antioxidant status in different brain regions, thus contributing to a better understanding of the given pathophysiological processes causing ischemic neuronal damage.	[Ghosh, Aparajita; Sarkar, Sibani; Mandal, Ardhendu K.; Das, Nirmalendu] Indian Inst Chem Biol, Biomembrane Div, Kolkata, W Bengal, India; [Ghosh, Aparajita] Bose Inst, Div Mol Med, Kolkata, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); Department of Science & Technology (India); Bose Institute	Das, N (corresponding author), Indian Inst Chem Biol, Biomembrane Div, Kolkata, W Bengal, India.	dasnirmalendu@hotmail.com	; Jabgunde, Amit/I-8155-2018; Ghosh, Sougata/GOH-0726-2022; Mandal, Ardhendu Kumar/R-3694-2018; Pardesi, Karishma/D-5827-2012; Ghosh, Sougata/C-6409-2018	Dhavale, Dilip/0000-0001-8221-6347; Jabgunde, Amit/0000-0002-9324-8552; Jagtap, Soham/0000-0002-8687-7326; Ghosh, Sougata/0000-0001-8631-0357; Mandal, Ardhendu Kumar/0000-0001-8336-1220; Shinde, Vaishali/0000-0001-8800-7247; Patil, Ajay B./0000-0003-0509-4926; Pardesi, Karishma/0000-0001-7535-6317; Ghosh, Sougata/0000-0003-0077-1318	Indian Council of Medical Research (ICMR), Government of India [58/17/2003-BMS]; Council of Scientific and Industrial Research (CSIR), Government of India, New Delhi	Indian Council of Medical Research (ICMR), Government of India(Indian Council of Medical Research (ICMR)); Council of Scientific and Industrial Research (CSIR), Government of India, New Delhi(Council of Scientific & Industrial Research (CSIR) - India)	This work was supported by the Indian Council of Medical Research (ICMR), Adhoc Project number 58/17/2003-BMS, Government of India, and the Council of Scientific and Industrial Research (CSIR), Government of India, New Delhi. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABE K, 1995, STROKE, V26, P1478, DOI 10.1161/01.STR.26.8.1478; Aebi H, 1984, Methods Enzymol, V105, P121; Almeida A, 1999, BRAIN RES, V816, P580, DOI 10.1016/S0006-8993(98)01240-2; Bala I, 2004, CRIT REV THER DRUG, V21, P387, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20; Batandier C, 2002, J CELL MOL MED, V6, P175, DOI 10.1111/j.1582-4934.2002.tb00185.x; BORS W, 1990, METHOD ENZYMOL, V186, P343; Brouns R, 2009, CLIN NEUROL NEUROSUR, V111, P483, DOI 10.1016/j.clineuro.2009.04.001; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Changtam C, 2010, EUR J MED CHEM, V45, P941, DOI 10.1016/j.ejmech.2009.11.035; Chen J, 1997, J NEUROCHEM, V69, P232; Chrissobolis S, 2008, TRENDS MOL MED, V14, P495, DOI 10.1016/j.molmed.2008.09.003; DAVIES DC, 1992, ACTA NEUROPATHOL, V83, P510, DOI 10.1007/BF00310028; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; DogruAbbasoglu S, 1997, MECH AGEING DEV, V98, P177, DOI 10.1016/S0047-6374(97)00082-1; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; GINSBERG MD, 1994, ANN NEUROL, V36, P553, DOI 10.1002/ana.410360402; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Hariharan S, 2006, PHARM RES-DORDR, V23, P184, DOI 10.1007/s11095-005-8418-y; Harry GJ, 2003, NEUROTOXICOLOGY, V24, P343, DOI 10.1016/S0161-813X(03)00039-1; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; HAVSTEEN B, 1983, BIOCHEM PHARMACOL, V32, P1141, DOI 10.1016/0006-2952(83)90262-9; HORN M, 1992, ACTA NEUROPATHOL, V85, P79, DOI 10.1007/BF00304636; ISSA AM, 1990, J NEUROSCI, V10, P3247; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Kong LD, 2000, CELL MOL LIFE SCI, V57, P500, DOI 10.1007/PL00000710; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; Lee H, 2004, J NEUROSCI RES, V77, P892, DOI 10.1002/jnr.20193; Lee JC, 2003, EXP CELL RES, V291, P386, DOI 10.1016/S0014-4827(03)00410-5; Lockman PR, 2002, DRUG DEV IND PHARM, V28, P1, DOI 10.1081/DDC-120001481; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANIATIS T, 1975, P NATL ACAD SCI USA, V72, P1184, DOI 10.1073/pnas.72.3.1184; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; McCracken E, 2000, J CEREBR BLOOD F MET, V20, P1529, DOI 10.1097/00004647-200011000-00002; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; Moghimi SM, 2001, PHARMACOL REV, V53, P283; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Olivier Jean-Christophe, 2005, NeuroRx, V2, P108, DOI 10.1007/BF03206647; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; RAPOPORT SI, 1978, J THEOR BIOL, V74, P439, DOI 10.1016/0022-5193(78)90224-2; RECKNAGEL RO, 1984, METHOD ENZYMOL, V105, P331; Rodriguez RJ, 2001, FOOD CHEM TOXICOL, V39, P437, DOI 10.1016/S0278-6915(00)00159-9; Ruozi B, 2007, TALANTA, V73, P12, DOI 10.1016/j.talanta.2007.03.031; Sarkar A, 1995, CANCER BIOCHEM BIOPH, V15, P111; Sarkar S, 2002, J DRUG TARGET, V10, P573, DOI 10.1080/106118021000072681; Silva GA, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S3-S4; Squire L.R., 2002, NEUROPSYCHOLOGY MEMO; Taylor CP, 1999, J NEUROSCI, V19, P619; Vergoni AV, 2009, NANOMED-NANOTECHNOL, V5, P369, DOI 10.1016/j.nano.2009.02.005; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; Zhu DH, 2005, J CELL SCI, V118, P3695, DOI 10.1242/jcs.02507	52	114	119	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2013	8	4							e57735	10.1371/journal.pone.0057735	http://dx.doi.org/10.1371/journal.pone.0057735			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130JA	24367520	gold, Green Published, Green Submitted			2023-01-03	WOS:000317909500001
J	Wang, Q; Tikhonenko, M; Bozack, SN; Lydic, TA; Yan, L; Panchy, NL; Mcsorley, KM; Faber, MS; Yan, YQ; Boulton, ME; Grant, MB; Busik, JV				Wang, Qi; Tikhonenko, Maria; Bozack, Svetlana N.; Lydic, Todd A.; Yan, Lily; Panchy, Nicholas L.; Mcsorley, Kelly M.; Faber, Matthew S.; Yan, Yuanqing; Boulton, Michael E.; Grant, Maria B.; Busik, Julia V.			Changes in the Daily Rhythm of Lipid Metabolism in the Diabetic Retina	PLOS ONE			English	Article							CLOCK GENE-EXPRESSION; CIRCADIAN CLOCK; MOLECULAR CLOCKS; LIVER; MOUSE; TIME; MELATONIN; INSULIN; PROTEIN-1; SYSTEM	Disruption of circadian regulation was recently shown to cause diabetes and metabolic disease. We have previously demonstrated that retinal lipid metabolism contributed to the development of diabetic retinopathy. The goal of this study was to determine the effect of diabetes on circadian regulation of clock genes and lipid metabolism genes in the retina and retinal endothelial cells (REC). Diabetes had a pronounced inhibitory effect on the negative clock arm with lower amplitude of the period (per) 1 in the retina; lower amplitude and a phase shift of per2 in the liver; and a loss of cryptochrome (cry) 2 rhythmic pattern in suprachiasmatic nucleus (SCN). The positive clock arm was increased by diabetes with higher amplitude of circadian locomotor output cycles kaput (CLOCK) and brain and muscle aryl-hydrocarbon receptor nuclear translocator-like 1 (bmal1) and phase shift in bmal1 rhythmic oscillations in the retina; and higher bmal1 amplitude in the SCN. Peroxisome proliferator-activated receptor (PPAR) alpha exhibited rhythmic oscillation in retina and liver; PPAR gamma had lower amplitude in diabetic liver; sterol regulatory element-binding protein (srebp) 1c had higher amplitude in the retina but lower in the liver in STZ-induced diabetic animals. Both of Elongase (Elovl) 2 and Elovl4 had a rhythmic oscillation pattern in the control retina. Diabetic retinas lost Elovl4 rhythmic oscillation and had lower amplitude of Elovl2 oscillations. In line with the in vivo data, circadian expression levels of CLOCK, bmal1 and srebp1c had higher amplitude in rat REC (rREC) isolated from diabetic rats compared with control rats, while PPAR gamma and Elovl2 had lower amplitude in diabetic rREC. In conclusion, diabetes causes dysregulation of circadian expression of clock genes and the genes controlling lipid metabolism in the retina with potential implications for the development of diabetic retinopathy.	[Wang, Qi; Bozack, Svetlana N.; Mcsorley, Kelly M.; Faber, Matthew S.; Busik, Julia V.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; [Tikhonenko, Maria; Panchy, Nicholas L.] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; [Lydic, Todd A.] Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; [Yan, Lily] Michigan State Univ, Dept Psychol Social Sci, E Lansing, MI 48824 USA; [Yan, Yuanqing; Grant, Maria B.] Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL USA; [Boulton, Michael E.] Indiana Univ, Dept Ophthalmol, Indianapolis, IN 46204 USA	Michigan State University; Michigan State University; Michigan State University; Michigan State University; State University System of Florida; University of Florida; Indiana University System; Indiana University-Purdue University Indianapolis	Busik, JV (corresponding author), Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA.	busik@msu.edu	Busik, Julia V/A-2698-2010; Lydic, Todd A./ADB-0177-2022	Busik, Julia V/0000-0003-3453-7124; Yan, Lily/0000-0002-6261-2542; Faber, Matthew/0000-0002-5583-5115	National Institutes of Health (NIH) [EY016077]; MEAS [MICL02163, EY07739, EY12601, EY021626, DK090730]; NATIONAL EYE INSTITUTE [R01EY016077, R01EY007739, R01EY012601, R21EY021626, R29EY007739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK090730, P30DK020572] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MEAS; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institutes of Health (NIH) Grants EY016077; and MEAS grant MICL02163 to JVB, EY07739 and EY12601 to MBG, EY021626 to MEB and DK090730 to MBG and JVB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akhtar RA, 2002, CURR BIOL, V12, P540, DOI 10.1016/S0960-9822(02)00759-5; Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Ando H, 2009, DIABETOLOGIA, V52, P329, DOI 10.1007/s00125-008-1194-6; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Bhatwadekar AD, 2013, DIABETES, V62, P273, DOI 10.2337/db12-0172; Botolin D, 2003, J BIOL CHEM, V278, P6959, DOI 10.1074/jbc.M212846200; Brewer M, 2005, J BIOL RHYTHM, V20, P195, DOI 10.1177/0748730405275952; Bugianesi E, 2005, HEPATOLOGY, V42, P987, DOI 10.1002/hep.20920; Busik J, 2009, DIABETES, V58, pA229; Busik JV, 2008, DIABETES, V57, P1952, DOI 10.2337/db07-1520; Busik JV, 2009, J EXP MED, V206, P2897, DOI 10.1084/jem.20090889; Canaple L, 2006, MOL ENDOCRINOL, V20, P1715, DOI 10.1210/me.2006-0052; Deng X, 2007, J BIOL CHEM, V282, P17517, DOI 10.1074/jbc.M702228200; Dibner C, 2010, ANNU REV PHYSIOL, V72, P517, DOI 10.1146/annurev-physiol-021909-135821; Dinet V, 2007, J PINEAL RES, V42, P83, DOI 10.1111/j.1600-079X.2006.00387.x; Grace MS, 1996, BRAIN RES, V735, P93; Herichova I, 2005, MOL CELL BIOCHEM, V270, P223, DOI 10.1007/s11010-005-5323-y; Hirota T, 2002, J BIOL CHEM, V277, P44244, DOI 10.1074/jbc.M206233200; Hofmann K, 2013, HORM METAB RES, V45, P629, DOI 10.1055/s-0033-1343462; Iuvone PM, 2005, PROG RETIN EYE RES, V24, P433, DOI 10.1016/j.preteyeres.2005.01.003; Kohsaka A, 2007, TRENDS ENDOCRIN MET, V18, P4, DOI 10.1016/j.tem.2006.11.005; Kudo T, 2004, DIABETOLOGIA, V47, P1425, DOI 10.1007/s00125-004-1461-0; Kuriyama K, 2004, FEBS LETT, V572, P206, DOI 10.1016/j.febslet.2004.07.036; Lemberger T, 1996, J BIOL CHEM, V271, P1764, DOI 10.1074/jbc.271.3.1764; Lowden A, 2010, SCAND J WORK ENV HEA, V36, P150, DOI 10.5271/sjweh.2898; Maeda A, 2006, INVEST OPHTH VIS SCI, V47, P4050, DOI 10.1167/iovs.06-0183; Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; Matsumoto E, 2010, J BIOL CHEM, V285, P33028, DOI 10.1074/jbc.M109.089391; Maywood ES, 2003, J NEUROENDOCRINOL, V15, P329, DOI 10.1046/j.1365-2826.2003.00971.x; Monteleone P, 2008, NEUROSCI LETT, V435, P30, DOI 10.1016/j.neulet.2008.02.003; Mulligan JD, 2008, EXP GERONTOL, V43, P146, DOI 10.1016/j.exger.2007.10.011; Nagoshi E, 2004, CELL, V119, P693, DOI 10.1016/j.cell.2004.11.015; Oishi K, 2006, FEBS LETT, V580, P127, DOI 10.1016/j.febslet.2005.11.063; Oishi K, 2005, BIOCHEM J, V386, P575, DOI 10.1042/BJ20041150; Oishi K, 2004, BIOCHEM BIOPH RES CO, V317, P330, DOI 10.1016/j.bbrc.2004.03.055; Organisciak DT, 2000, INVEST OPHTH VIS SCI, V41, P3694; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Pavan B, 2006, BIOCHEM BIOPH RES CO, V350, P169, DOI 10.1016/j.bbrc.2006.09.015; Paxinos G, 1999, CHEMOARCHITECTONIC A; Peirson SN, 2006, BIOCHEM BIOPH RES CO, V351, P800, DOI 10.1016/j.bbrc.2006.10.118; Peschke E, 2008, J PINEAL RES, V45, P439, DOI 10.1111/j.1600-079X.2008.00612.x; Prasai MJ, 2008, DIABETES VASC DIS RE, V5, P89, DOI 10.3132/dvdr.2008.015; Reick M, 2001, SCIENCE, V293, P506, DOI 10.1126/science.1060699; Rudic RD, 2004, PLOS BIOL, V2, P1893, DOI 10.1371/journal.pbio.0020377; Sakamoto K, 2000, NEUROREPORT, V11, P3995, DOI 10.1097/00001756-200012180-00018; Scott EM, 2008, INT J OBESITY, V32, P658, DOI 10.1038/sj.ijo.0803778; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Sookoian S, 2008, AM J CLIN NUTR, V87, P1606, DOI 10.1093/ajcn/87.6.1606; Stamenkovic JA, 2012, METABOLISM, V61, P978, DOI 10.1016/j.metabol.2011.11.013; Storch KF, 2007, CELL, V130, P730, DOI 10.1016/j.cell.2007.06.045; Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744; Straume M, 2004, METHOD ENZYMOL, V383, P149; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; Wang NN, 2008, CELL METAB, V8, P482, DOI 10.1016/j.cmet.2008.10.009; Xue JF, 2010, FITOTERAPIA, V81, P173, DOI 10.1016/j.fitote.2009.08.020; Yamazaki S, 1999, J BIOL RHYTHM, V14, P197, DOI 10.1177/074873099129000605; Yang GR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038117; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101	61	24	25	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2014	9	4							e95028	10.1371/journal.pone.0095028	http://dx.doi.org/10.1371/journal.pone.0095028			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI5PW	24736612	Green Published, Green Submitted, gold			2023-01-03	WOS:000336922600131
J	Shen, Y; Honma, N; Kobayashi, K; Jia, LN; Hosono, T; Shindo, K; Ariga, T; Seki, T				Shen, Yan; Honma, Natsumi; Kobayashi, Katsuya; Jia, Liu Nan; Hosono, Takashi; Shindo, Kazutoshi; Ariga, Toyohiko; Seki, Taiichiro			Cinnamon Extract Enhances Glucose Uptake in 3T3-L1 Adipocytes and C2C12 Myocytes by Inducing LKB1-AMP-Activated Protein Kinase Signaling	PLOS ONE			English	Article							HUMAN HEPG2 CELLS; INSULIN SENSITIVITY; DIABETES-MELLITUS; MUSCLE-CELLS; IN-VIVO; ACTIVATION; TYPE-2; METFORMIN; LKB1; AMPK	We previously demonstrated that cinnamon extract (CE) ameliorates type 1 diabetes induced by streptozotocin in rats through the up-regulation of glucose transporter 4 (GLUT4) translocation in both muscle and adipose tissues. This present study was aimed at clarifying the detailed mechanism(s) with which CE increases the glucose uptake in vivo and in cell culture systems using 3T3-L1 adipocytes and C2C12 myotubes in vitro. Specific inhibitors of key enzymes in insulin signaling and AMP-activated protein kinase (AMPK) signaling pathways, as well as small interference RNA, were used to examine the role of these kinases in the CE-induced glucose uptake. The results showed that CE stimulated the phosphorylation of AMPK and acetyl-CoA carboxylase. An AMPK inhibitor and LKB1 siRNA blocked the CE-induced glucose uptake. We also found for the first time that insulin suppressed AMPK activation in the adipocyte. To investigate the effect of CE on type 2 diabetes in vivo, we further performed oral glucose tolerance tests and insulin tolerance tests in type 2 diabetes model rats administered with CE. The CE improved glucose tolerance in oral glucose tolerance tests, but not insulin sensitivity in insulin tolerance test. In summary, these results indicate that CE ameliorates type 2 diabetes by inducing GLUT4 translocation via the AMPK signaling pathway. We also found insulin antagonistically regulates the activation of AMPK.	[Shen, Yan; Honma, Natsumi; Kobayashi, Katsuya; Hosono, Takashi; Ariga, Toyohiko; Seki, Taiichiro] Nihon Univ, Coll Bioresource Sci, Grad Sch Bioresource Sci, Dept Chem & Life Sci, Fujisawa, Kanagawa, Japan; [Jia, Liu Nan] Nihon Univ, Sch Pharm, Chiba, Japan; [Shindo, Kazutoshi] Japan Womens Univ, Dept Food & Nutr, Tokyo 112, Japan	Nihon University; Nihon University; Japan Womens University	Hosono, T (corresponding author), Nihon Univ, Coll Bioresource Sci, Grad Sch Bioresource Sci, Dept Chem & Life Sci, Fujisawa, Kanagawa, Japan.	hosono.takashi@nihon-u.ac.jp			Nihon University; Japan Science and Technology Agency (JST) A-STEP program; Ministry of Education, Culture, Sports, Science, and Technology of Japan	Nihon University; Japan Science and Technology Agency (JST) A-STEP program; Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by grants from the Nihon University individual research grant program (to T. S.). This work was also supported by grants from the Japan Science and Technology Agency (JST) A-STEP program (to T. H.). Y.S. is supported by a Fellowship from the Academic Frontier Project from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Amitani H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053913; Anderson RA, 2004, J AGR FOOD CHEM, V52, P65, DOI 10.1021/jf034916b; Babu PS, 2007, PHYTOMEDICINE, V14, P15, DOI 10.1016/j.phymed.2006.11.005; Beauloye C, 2001, FEBS LETT, V505, P348, DOI 10.1016/S0014-5793(01)02788-0; BERRIO LF, 1992, HORM RES, V37, P225, DOI 10.1159/000182317; Blevins SM, 2007, DIABETES CARE, V30, P2236, DOI 10.2337/dc07-0098; Cao HP, 2007, ARCH BIOCHEM BIOPHYS, V459, P214, DOI 10.1016/j.abb.2006.12.034; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Cheng BC., 1983, ZHONG CAO YAO, V14, P134; Cheng Z, 2006, BBA-GEN SUBJECTS, V1760, P1682, DOI 10.1016/j.bbagen.2006.09.007; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Gamble J, 1997, METABOLISM, V46, P1270, DOI 10.1016/S0026-0495(97)90229-8; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Hwang YP, 2013, J NUTR BIOCHEM, V24, P1469, DOI 10.1016/j.jnutbio.2012.12.006; Hwang YP, 2013, MOL NUTR FOOD RES, V57, P471, DOI 10.1002/mnfr.201200529; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kannappan S., 2006, SMJ Singapore Medical Journal, V47, P858; Kim SH, 2006, J ETHNOPHARMACOL, V104, P119, DOI 10.1016/j.jep.2005.08.059; Lee YS, 2006, DIABETES, V55, P2256, DOI 10.2337/db06-0006; Leverve XM, 2003, DIABETES METAB, V29, pS88; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Mang B, 2006, EUR J CLIN INVEST, V36, P340, DOI 10.1111/j.1365-2362.2006.01629.x; Nawrocki AR, 2006, J BIOL CHEM, V281, P2654, DOI 10.1074/jbc.M505311200; Nishiumi S, 2007, BIOSCI BIOTECH BIOCH, V71, P2343, DOI 10.1271/bbb.70342; Onderoglu S, 1999, J PHARM PHARMACOL, V51, P1305, DOI 10.1211/0022357991776886; Pham AQ, 2007, PHARMACOTHERAPY, V27, P595, DOI 10.1592/phco.27.4.595; Qin B, 2004, HORM METAB RES, V36, P119, DOI 10.1055/s-2004-814223; Qin BL, 2003, DIABETES RES CLIN PR, V62, P139, DOI 10.1016/S0168-8227(03)00173-6; Ragolia L, 1997, ENDOCRINOLOGY, V138, P2398, DOI 10.1210/en.138.6.2398; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; Riddle MC, 1999, AM FAM PHYSICIAN, V60, P2613; Russell RR, 1999, AM J PHYSIOL-HEART C, V277, pH643, DOI 10.1152/ajpheart.1999.277.2.H643; Sakamoto K, 2005, EMBO J, V24, P1810, DOI 10.1038/sj.emboj.7600667; Seki T, 2001, J CELL PHYSIOL, V189, P72, DOI 10.1002/jcp.1140; Sewter C, 2002, DIABETES OBES METAB, V4, P239, DOI 10.1046/j.1463-1326.2002.00187.x; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shen Y, 2010, BIOSCI BIOTECH BIOCH, V74, P2418, DOI 10.1271/bbb.100453; Suppapitiporn S, 2006, J MED ASS THAI S3, V89, pS200; Vanschoonbeek K, 2006, J NUTR, V136, P977, DOI 10.1093/jn/136.4.977; Verspohl EJ, 2005, PHYTOTHER RES, V19, P203, DOI 10.1002/ptr.1643; Wang JG, 2007, FERTIL STERIL, V88, P240, DOI 10.1016/j.fertnstert.2006.11.082; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005	50	82	86	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2014	9	2							e87894	10.1371/journal.pone.0087894	http://dx.doi.org/10.1371/journal.pone.0087894			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AA7IR	24551069	Green Submitted, gold, Green Published			2023-01-03	WOS:000331271500023
J	Knowles, SE; Toms, G; Sanders, C; Bee, P; Lovell, K; Rennick-Egglestone, S; Coyle, D; Kennedy, CM; Littlewood, E; Kessler, D; Gilbody, S; Bower, P				Knowles, Sarah E.; Toms, Gill; Sanders, Caroline; Bee, Penny; Lovell, Karina; Rennick-Egglestone, Stefan; Coyle, David; Kennedy, Catriona M.; Littlewood, Elizabeth; Kessler, David; Gilbody, Simon; Bower, Peter			Qualitative Meta-Synthesis of User Experience of Computerised Therapy for Depression and Anxiety	PLOS ONE			English	Article							COGNITIVE-BEHAVIORAL THERAPY; STEPPED CARE; SELF-HELP; ACCEPTABILITY; ETHNOGRAPHY; MANAGEMENT; BARRIERS; SYSTEM; AGENTS	Objective: Computerised therapies play an integral role in efforts to improve access to psychological treatment for patients with depression and anxiety. However, despite recognised problems with uptake, there has been a lack of investigation into the barriers and facilitators of engagement. We aimed to systematically review and synthesise findings from qualitative studies of computerised therapies, in order to identify factors impacting on engagement. Method: Systematic review and meta-synthesis of qualitative studies of user experiences of computer delivered therapy for depression and/or anxiety. Results: 8 studies were included in the review. All except one were of desktop based cognitive behavioural treatments. Black and minority ethnic and older participants were underrepresented, and only one study addressed users with a comorbid physical health problem. Through synthesis, we identified two key overarching concepts, regarding the need for treatments to be sensitive to the individual, and the dialectal nature of user experience, with different degrees of support and anonymity experienced as both positive and negative. We propose that these factors can be conceptually understood as the 'non-specific' or 'common' factors of computerised therapy, analogous to but distinct from the common factors of traditional face-to-face therapies. Conclusion: Experience of computerised therapy could be improved through personalisation and sensitisation of content to individual users, recognising the need for users to experience a sense of 'self' in the treatment which is currently absent. Exploiting the common factors of computerised therapy, through enhancing perceived connection and collaboration, could offer a way of reconciling tensions due to the dialectal nature of user experience. Future research should explore whether the findings are generalisable to other patient groups, to other delivery formats (such as mobile technology) and other treatment modalities beyond cognitive behaviour therapy. The proposed model could aid the development of enhancements to current packages to improve uptake and support engagement.	[Knowles, Sarah E.; Toms, Gill; Sanders, Caroline; Bower, Peter] Univ Manchester, NIHR Sch Primary Care Res, Ctr Primary Care, Manchester, Lancs, England; [Bee, Penny; Lovell, Karina] Univ Manchester, Sch Nursing Midwifery & Social Work, Manchester, Lancs, England; [Rennick-Egglestone, Stefan] Univ Nottingham, Mixed Real Lab, Sch Comp Sci, Nottingham NG7 2RD, England; [Coyle, David] Univ Bristol, Dept Comp Sci, Bristol, Avon, England; [Kennedy, Catriona M.] Univ Birmingham, Sch Comp Sci, Birmingham B15 2TT, W Midlands, England; [Littlewood, Elizabeth; Gilbody, Simon] Univ York, Mental Hlth & Addict Res Grp, York YO10 5DD, N Yorkshire, England; [Kessler, David] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England	University of Manchester; University of Manchester; University of Nottingham; University of Bristol; University of Birmingham; University of York - UK; University of Bristol	Knowles, SE (corresponding author), Univ Manchester, NIHR Sch Primary Care Res, Ctr Primary Care, Manchester, Lancs, England.	sarah.knowles@manchester.ac.uk	Lovell, Karina S E/E-6410-2012; Lonsdale, Chris/T-8710-2017; Coyle, David/P-3920-2019; Sanders, Taren/N-9511-2018; Gilbody, Simon/AAY-3720-2021; Kessler, david/ABB-6489-2021; Bower, Peter/A-1508-2011; Bee, Penny E/O-8822-2014; Sanders, Caroline/G-8021-2014	Lovell, Karina S E/0000-0001-8821-895X; Lonsdale, Chris/0000-0002-2523-5565; Coyle, David/0000-0002-5103-0379; Sanders, Taren/0000-0002-4504-6008; Gilbody, Simon/0000-0002-8236-6983; Bower, Peter/0000-0001-9558-3349; Bee, Penny E/0000-0002-5600-0400; Sanders, Caroline/0000-0002-0539-928X; Kennedy, Catriona/0000-0003-3510-9113; Rennick-Egglestone, Stefan/0000-0003-4187-011X; Knowles, Sarah/0000-0002-0863-5866; Cliff, Dylan/0000-0001-6863-3996	UK National Institute of Health Research (NIHR) School for Primary Care Research; Medical Research Council [G0401181] Funding Source: researchfish; National Institute for Health Research [SPCR-040, 06/43/05, 06/43/504] Funding Source: researchfish	UK National Institute of Health Research (NIHR) School for Primary Care Research; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	The study was funded as part of the UK National Institute of Health Research (NIHR) School for Primary Care Research. The research team were independent from the funding agency. The views expressed in this publication are those of the authors and not necessarily those of the NHS, NIHR, or Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Advocat J, 2010, SOC SCI MED, V70, P485, DOI 10.1016/j.socscimed.2009.10.051; [Anonymous], 1994, QUAL HEALTH RES, DOI [10.1177/104973239400400102, DOI 10.1177/104973239400400102]; Atkins S, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-21; Bate P., 2007, J APPL BEHAV SCI, V43, P41, DOI [10.1177/0021886306297014, DOI 10.1177/0021886306297014]; Bickmore T, 2010, HARVARD REV PSYCHIAT, V18, P119, DOI 10.3109/10673221003707538; Bower P, 2005, BRIT J PSYCHIAT, V186, P11, DOI 10.1192/bjp.186.1.11; Bradley KL., 2012, INT J MENT HEALTH PR, V14, P23, DOI [10.1080/14623730.2012.665337, DOI 10.1080/14623730.2012.665337]; Carlbring P, 2011, BEHAV RES THER, V49, P18, DOI 10.1016/j.brat.2010.10.002; Cavanagh Kate, 2009, Cognitive Behaviour Therapy, V38, P235, DOI 10.1080/16506070802561256; Chambers DA, 2013, GEN HOSP PSYCHIAT, V35, P329, DOI 10.1016/j.genhosppsych.2013.03.006; Coyle D, 2007, INTERACT COMPUT, V19, P545, DOI 10.1016/j.intcom.2007.02.001; Coyle D, 2008, ONTORACT 2008: FIRST INTERNATIONAL WORKSHOP ON ONTOLOGIES IN INTERACTIVE SYSTEMS, PROCEEDINGS, P18, DOI 10.1109/ONTORACT.2008.12; Dehn DM, 2000, INT J HUM-COMPUT ST, V52, P1, DOI 10.1006/ijhc.1999.0325; Dixon-Woods Mary, 2006, BMC Med Res Methodol, V6, P35, DOI 10.1186/1471-2288-6-35; Doherty G., 2012, P 2012 ACM ANN C HUM, P1421, DOI [DOI 10.1145/2207676.2208602, 10.1145/2207676.2208602]; Farzanfar R, 2007, COMPUT HUM BEHAV, V23, P1167, DOI 10.1016/j.chb.2004.11.015; Gerhards SAH, 2011, J AFFECT DISORDERS, V129, P117, DOI 10.1016/j.jad.2010.09.012; Green KE, 2009, PROF PSYCHOL-RES PR, V40, P96, DOI 10.1037/a0012847; Helgadottir FD, 2009, BEHAV CHANGE, V26, P245, DOI 10.1375/bech.26.4.245; Hind D, 2010, PSYCHOL HEALTH, V25, P699, DOI 10.1080/08870440902842739; Iloabachie C, 2011, GEN HOSP PSYCHIAT, V33, P543, DOI 10.1016/j.genhosppsych.2011.08.004; Kaltenthaler E, 2008, PSYCHOL MED, V38, P1521, DOI 10.1017/S0033291707002607; Klein B, 2008, J APPL PSYCHOL, V4; Knowles SE, 2012, 2012 C PRIM CAR MENT; Lambert MJ, 2005, J CLIN PSYCHOL, V61, P855, DOI 10.1002/jclp.20130; Layard R, 2006, DEPRESSION REPORT; Malpass A, 2009, SOC SCI MED, V68, P154, DOI 10.1016/j.socscimed.2008.09.068; Marks I, 2009, ANNU REV CLIN PSYCHO, V5, P121, DOI 10.1146/annurev.clinpsy.032408.153538; Mitchell J., 2005, PRIMARY CARE MENTAL, V3, P27; Mitchell N, 2007, COUNS PSYCHOTHER RES, V7, P144, DOI 10.1080/14733140701565987; NHS Confederation Mental Health Network, 2013, E MENT HLTH WHATS AL; NICE, 2009, DEPR AD UPD NICE CLI; Noblit G.W., 1988, METAETHNOGRAPHY SYNT; Peck DF, 2010, CLIN PSYCHOL PSYCHOT, V17, P147, DOI 10.1002/cpp.669; Pilgrim D, 2009, HEALTH-LONDON, V13, P235, DOI 10.1177/1363459308099686; Prevost S., 2000, EMBODIED CONVERSATIO, DOI DOI 10.7551/MITPRESS/2697.001.0001; Reeves B., 1996, CSLI PUBLICATIONS ST; Richards DA, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-3; Rosser BA, 2009, J TELEMED TELECARE, V15, P327, DOI 10.1258/jtt.2009.090116; Ryan RM, 2011, COUNS PSYCHOL, V39, P193, DOI 10.1177/0011000009359313; Sanders C, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-220; Schneider J, 2012, COMPUTERISED CBT COM; Simon GE, 2009, LANCET, V374, P594, DOI 10.1016/S0140-6736(09)61415-X; Smith LK, 2005, LANCET, V366, P825, DOI 10.1016/S0140-6736(05)67030-4; STRUPP H, 1978, HDB PSYCHOTHERAPY BE; The King's Fund, 2011, PAT CTR CAR KINGS FU; Timmermans S, 2003, SOCIOL HEALTH ILL, V25, P97, DOI 10.1111/1467-9566.00342; Titov N, 2010, COMPUTER DELIVERED C; Tong A, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-181; Waller R, 2009, PSYCHOL MED, V39, P705, DOI 10.1017/S0033291708004224; Watkins DC, 2011, J TELEMED TELECARE, V17, P378, DOI 10.1258/jtt.2011.110105	51	143	148	0	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2014	9	1							e84323	10.1371/journal.pone.0084323	http://dx.doi.org/10.1371/journal.pone.0084323			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	297EA	24643129	Green Published, gold, Green Submitted			2023-01-03	WOS:000330237000012
J	Song, Y; Garg, S; Girotra, M; Maddox, C; von Rosenvinge, EC; Dutta, A; Dutta, S; Fricke, WF				Song, Yang; Garg, Shashank; Girotra, Mohit; Maddox, Cynthia; von Rosenvinge, Erik C.; Dutta, Anand; Dutta, Sudhir; Fricke, W. Florian			Microbiota Dynamics in Patients Treated with Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection	PLOS ONE			English	Article							GUT MICROBIOTA; INTESTINAL MICROBIOTA; SEQUENCE-ANALYSIS; DISEASE; THERAPY; VANCOMYCIN; COLITIS; DIARRHEA; COMBINATION; SENSITIVITY	Clostridium difficile causes antibiotic-associated diarrhea and pseudomembraneous colitis and is responsible for a large and increasing fraction of hospital-acquired infections. Fecal microbiota transplantation (FMT) is an alternate treatment option for recurrent C. difficile infection (RCDI) refractory to antibiotic therapy. It has recently been discussed favorably in the clinical and scientific communities and is receiving increasing public attention. However, short-and long-term health consequences of FMT remain a concern, as the effects of the transplanted microbiota on the patient remain unknown. To shed light on microbial events associated with RCDI and treatment by FMT, we performed fecal microbiota analysis by 16S rRNA gene amplicon pyrosequencing of 14 pairs of healthy donors and RCDI patients treated successfully by FMT. Post-FMT patient and healthy donor samples collected up to one year after FMT were studied longitudinally, including one post-FMT patient with antibiotic-associated relapse three months after FMT. This analysis allowed us not only to confirm prior reports that RCDI is associated with reduced diversity and compositional changes in the fecal microbiota, but also to characterize previously undocumented post-FMT microbiota dynamics. Members of the Streptococcaceae, Enterococcaceae, or Enterobacteriaceae were significantly increased and putative butyrate producers, such as Lachnospiraceae and Ruminococcaceae were significantly reduced in samples from RCDI patients before FMT as compared to post-FMT patient and healthy donor samples. RCDI patient samples showed more case-specific variations than post-FMT patient and healthy donor samples. However, none of the bacterial groups were invariably associated with RCDI or successful treatment by FMT. Overall microbiota compositions in post-FMT patients, specifically abundances of the above-mentioned Firmicutes, continued to change for at least 16 weeks after FMT, suggesting that full microbiota recovery from RCDI may take much longer than expected based on the disappearance of diarrheal symptoms immediately after FMT.	[Song, Yang; Maddox, Cynthia; Fricke, W. Florian] Univ Maryland, Sch Med, Inst Genome Sci, Baltimore, MD 21201 USA; [Garg, Shashank; Girotra, Mohit; Dutta, Anand; Dutta, Sudhir] Sinai Hosp, Div Gastroenterol, Baltimore, MD 21215 USA; [von Rosenvinge, Erik C.] Univ Maryland, Sch Med, Div Gastroenterol & Hepatol, Baltimore, MD 21201 USA; [Dutta, Sudhir] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; Sinai Hospital of Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Fricke, WF (corresponding author), Univ Maryland, Sch Med, Inst Genome Sci, Baltimore, MD 21201 USA.	wffricke@som.umaryland.edu	song, yang/P-1033-2015	Garg, Shashank/0000-0001-9917-3021; Song, Haengseok/0000-0002-5027-7310; Fricke, W. Florian/0000-0003-1586-0962; von Rosenvinge, Erik C./0000-0002-1862-7288	Institute for Genome Sciences (IGS), University of Maryland School of Medicine, Baltimore, MD; Division of Gastroenterology, Department of Medicine, Sinai Hospital of Baltimore, Baltimore, MD	Institute for Genome Sciences (IGS), University of Maryland School of Medicine, Baltimore, MD; Division of Gastroenterology, Department of Medicine, Sinai Hospital of Baltimore, Baltimore, MD	This study or parts thereof were funded by the Institute for Genome Sciences (IGS), University of Maryland School of Medicine, Baltimore, MD and Gastroenterology Research Funds from the Division of Gastroenterology, Department of Medicine, Sinai Hospital of Baltimore, Baltimore, MD. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aas J, 2003, CLIN INFECT DIS, V36, P580, DOI 10.1086/367657; Anderson JL, 2012, ALIMENT PHARM THER, V36, P503, DOI 10.1111/j.1365-2036.2012.05220.x; Angiuoli SV, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-356; [Anonymous], 2013, GRID EN STOR; Antharam VC, 2013, J CLIN MICROBIOL, V51, P2884, DOI 10.1128/JCM.00845-13; Bakken JS, 2011, CLIN GASTROENTEROL H, V9, P1044, DOI 10.1016/j.cgh.2011.08.014; Bartlett JG, 2002, NEW ENGL J MED, V346, P334, DOI 10.1056/NEJMcp011603; Belzer C, 2012, ISME J, V6, P1449, DOI 10.1038/ismej.2012.6; Berman AL, 2007, J CLIN GASTROENTEROL, V41, P932, DOI 10.1097/01.mcg.0000225685.37465.e7; Borody Thomas J, 2013, Curr Gastroenterol Rep, V15, P337, DOI 10.1007/s11894-013-0337-1; Borody TJ, 2012, NAT REV GASTRO HEPAT, V9, P88, DOI 10.1038/nrgastro.2011.244; Brandt LJ, 2012, AM J GASTROENTEROL, V107, P1079, DOI 10.1038/ajg.2012.60; BUGGY BP, 1987, J CLIN GASTROENTEROL, V9, P155, DOI 10.1097/00004836-198704000-00009; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Daneman N, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001268; Derrien M, 2004, INT J SYST EVOL MICR, V54, P1469, DOI 10.1099/ijs.0.02873-0; Dethlefsen L, 2011, P NATL ACAD SCI USA, V108, P4554, DOI 10.1073/pnas.1000087107; Dutta SK, 2013, GASTROENTEROLO UNPUB; Ebenman B, 2005, TRENDS ECOL EVOL, V20, P568, DOI 10.1016/j.tree.2005.06.011; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Forster AJ, 2012, CAN MED ASSOC J, V184, P37, DOI 10.1503/cmaj.110543; Garey KW, 2009, J CLIN GASTROENTEROL, V43, P91, DOI 10.1097/MCG.0b013e31814a4e97; Gorkiewicz G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055817; Gough E, 2011, CLIN INFECT DIS, V53, P994, DOI 10.1093/cid/cir632; Hajishengallis G, 2011, CELL HOST MICROBE, V10, P497, DOI 10.1016/j.chom.2011.10.006; Hamilton MJ, 2013, GUT MICROBES, V4, P125, DOI 10.4161/gmic.23571; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; James White WFF, 2011, NATURE PRECEDINGS; Jangi S, 2010, J PEDIATR GASTR NUTR, V51, P2, DOI 10.1097/MPG.0b013e3181d29767; JOBE BA, 1995, AM J SURG, V169, P480, DOI 10.1016/S0002-9610(99)80199-8; Johnson S, 2007, CLIN INFECT DIS, V44, P846, DOI 10.1086/511870; Johnson S, 2009, ANAEROBE, V15, P290, DOI 10.1016/j.anaerobe.2009.08.004; Kelly Ciaran P, 2008, N Engl J Med, V359, P1932, DOI 10.1056/NEJMra0707500; Khoruts A, 2010, J CLIN GASTROENTEROL, V44, P354, DOI 10.1097/MCG.0b013e3181c87e02; KORUDA MJ, 1990, AM J CLIN NUTR, V51, P685, DOI 10.1093/ajcn/51.4.685; Kump PK, 2013, INFLAMM BOWEL DIS, V19, P2155, DOI 10.1097/MIB.0b013e31829ea325; Lawley B, 2012, GASTROENTEROL CLIN N, V41, P855, DOI 10.1016/j.gtc.2012.08.010; Lawley TD, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002995; Lawley TD, 2009, INFECT IMMUN, V77, P3661, DOI 10.1128/IAI.00558-09; Ludwig W, 2009, BERGEYS MANUAL SYSTE, V3, P1, DOI DOI 10.1007/978-0-387-68489-5_; Lund-Tonnesen Stein, 1998, Tidsskrift for den Norske Laegeforening, V118, P1027; Maroo S, 2006, GASTROENTEROLOGY, V130, P1311, DOI 10.1053/j.gastro.2006.02.044; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; McDonald LC, 2005, NEW ENGL J MED, V353, P2433, DOI 10.1056/NEJMoa051590; McFarland LV, 2002, AM J GASTROENTEROL, V97, P1769, DOI 10.1111/j.1572-0241.2002.05839.x; Miller BA, 2011, INFECT CONT HOSP EP, V32, P387, DOI 10.1086/659156; Musa S, 2010, SCAND J GASTROENTERO, V45, P261, DOI 10.3109/00365520903497098; Musher DM, 2007, J ANTIMICROB CHEMOTH, V59, P705, DOI 10.1093/jac/dkl553; Navaneethan U, 2010, WORLD J GASTROENTERO, V16, P4892, DOI 10.3748/wjg.v16.i39.4892; O'Keefe SJD, 2010, WORLD J GASTROENTERO, V16, P139, DOI 10.3748/wjg.v16.i2.139; Peng LY, 2007, PEDIATR RES, V61, P37, DOI 10.1203/01.pdr.0000250014.92242.f3; Pepin J, 2006, CLIN INFECT DIS, V42, P758, DOI 10.1086/501126; Petrof EO, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-3; Pohl JF, 2012, CURR OPIN PEDIATR, V24, P627, DOI 10.1097/MOP.0b013e328355a3e1; Power ME, 1996, BIOSCIENCE, V46, P609, DOI 10.2307/1312990; Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490; Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107; Reeves AE, 2012, INFECT IMMUN, V80, P3786, DOI 10.1128/IAI.00647-12; Rivera Emmanuel V, 2003, J Gend Specif Med, V6, P27; ROEDIGER WEW, 1982, GASTROENTEROLOGY, V83, P424; Sartor RB, 2008, GASTROENTEROLOGY, V134, P577, DOI 10.1053/j.gastro.2007.11.059; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Shahinas D, 2012, MBIO, V3, DOI 10.1128/mBio.00338-12; Skraban J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058005; Surawicz CM, 2000, CLIN INFECT DIS, V31, P1012, DOI 10.1086/318130; Vrieze A, 2013, BEST PRACT RES CL GA, V27, P127, DOI 10.1016/j.bpg.2013.03.003; Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Wettstein A, 2007, 15 GUT UN EUR GAS S1, V39, pA303; White JR, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000352	70	140	172	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 26	2013	8	11							e81330	10.1371/journal.pone.0081330	http://dx.doi.org/10.1371/journal.pone.0081330			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259SK	24069443	Green Published, Green Submitted, gold			2023-01-03	WOS:000327546400060
J	Wang, X; Xu, Z; Miao, CH				Wang, Xin; Xu, Zheng; Miao, Chang-Hong			Current Clinical Evidence on the Effect of General Anesthesia on Neurodevelopment in Children: An Updated Systematic Review with Meta-Regression	PLOS ONE			English	Review							EARLY EXPOSURE; DEVELOPMENTAL DISORDERS; CHILDHOOD EXPOSURE; SURGERY	Background: Several epidemiological studies have been conducted to address the later effect of anesthesia on neurodevelopment in children. However, the results are still inconclusive. Methods: We here conducted a systematic review and meta-analysis to summarize the currently available clinical and epidemiologic evidence on the association of anesthesia/surgery with neurodevelopmental outcomes in children by searching PubMed, EMBASE, and Web of Science database (from January-1 2000 to February-1, 2013). The evaluation of neurodevelopment includes language and learning disabilities, cognition, behavioral development, and academic performance. Both retrospective and prospective studies were included. Data were abstracted from seven eligible studies. We estimated the synthesized hazard ratios (HR) and 95% confidence interval (CI) according to inter-study heterogeneity. Results: The pooled HR for the association of anesthesia/surgery with an adverse behavioral or developmental outcome was 1.25 (95% CI, 1.13-1.38, P, 0.001; random-effects model) in children undergoing the first anesthesia before the age of 4-year. Then we analyzed the factors for this association using meta-regression method. It showed that it was the number of times of exposure (HR = 1.75, 95% CI 1.31-2.33; P<0.001) rather than the time at exposure before 4-year (HR = 1.08, 95% CI 0.87-1.34 for the effect of per 1-year early exposure; P = 0.47) is a risk factor for neurodevelopmental impairment. Conclusion: The current clinical evidence suggests modestly elevated risk of adverse neurodevelopmental outcomes in children who were exposed to anesthesia/surgery during early childhood, especially for those with multiple times of exposure. Due to limitation of retrospective studies, prospective investigations are needed to determine whether anesthesia/surgery is causative.	[Wang, Xin] Fudan Univ, Dept Anesthesiol, Shanghai Canc Ctr, Shanghai Med Coll, Shanghai 200433, Peoples R China; Fudan Univ, Shanghai Med Coll, Inst Canc, Shanghai 200433, Peoples R China	Fudan University; Fudan University	Wang, X (corresponding author), Fudan Univ, Dept Anesthesiol, Shanghai Canc Ctr, Shanghai Med Coll, Shanghai 200433, Peoples R China.	xinwang79@gmail.com; miaochh@yahoo.com.cn	Cammeraat, Erik L.H./G-2863-2010; Kalbitz, Karsten/A-9641-2013	Cammeraat, Erik L.H./0000-0003-4398-206X; 				Bartels M, 2009, TWIN RES HUM GENET, V12, P246, DOI 10.1375/twin.12.3.246; BERLIN JA, 1993, EPIDEMIOLOGY, V4, P218, DOI 10.1097/00001648-199305000-00005; DiMaggio C, 2012, J NEUROSURG ANESTH, V24, P376, DOI 10.1097/ANA.0b013e31826a038d; DiMaggio C, 2011, ANESTH ANALG, V113, P1143, DOI 10.1213/ANE.0b013e3182147f42; DiMaggio C, 2009, J NEUROSURG ANESTH, V21, P286, DOI 10.1097/ANA.0b013e3181a71f11; Flick RP, 2011, PEDIATRICS, V128, pE1053, DOI 10.1542/peds.2011-0351; GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237; Guerra GG, 2011, PEDIATR ANESTH, V21, P932, DOI 10.1111/j.1460-9592.2011.03581.x; Hansen TG, 2011, ANESTHESIOLOGY, V114, P1076, DOI 10.1097/ALN.0b013e31820e77a0; HATTORI R, 1991, LANCET, V337, P1357, DOI 10.1016/0140-6736(91)93045-B; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Ing C, 2012, PEDIATRICS, V130, pE476, DOI 10.1542/peds.2011-3822; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Kalkman CJ, 2009, ANESTHESIOLOGY, V110, P805, DOI 10.1097/ALN.0b013e31819c7124; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Neugebauer R, 1999, JAMA-J AM MED ASSOC, V282, P455, DOI 10.1001/jama.282.5.455; Paule MG, 2011, NEUROTOXICOL TERATOL, V33, P220, DOI 10.1016/j.ntt.2011.01.001; Roze JC, 2008, ARCH PEDIAT ADOL MED, V162, P728, DOI 10.1001/archpedi.162.8.728; Satomoto M, 2009, ANESTHESIOLOGY, V110, P628, DOI 10.1097/ALN.0b013e3181974fa2; Wilder RT, 2009, ANESTHESIOLOGY, V110, P796, DOI 10.1097/01.anes.0000344728.34332.5d	21	241	245	14	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2014	9	1							e85760	10.1371/journal.pone.0085760	http://dx.doi.org/10.1371/journal.pone.0085760			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297FH	24802350	Green Submitted, gold, Green Published			2023-01-03	WOS:000330240500070
J	Wang, J; Bian, YJ; Wang, ZR; Li, D; Wang, CM; Li, QZ; Gao, XJ				Wang, Jie; Bian, Yanjie; Wang, Zhuoran; Li, Dan; Wang, Chunmei; Li, Qingzhang; Gao, Xuejun			MicroRNA-152 Regulates DNA Methyltransferase 1 and Is Involved in the Development and Lactation of Mammary Glands in Dairy Cows	PLOS ONE			English	Article							GENE-EXPRESSION; METHYLATION; MILK; TARGETS; CANCER; CELLS; DNMT1; GROWTH; RNAS; 3B	MicroRNAs (miRNAs) are a class of small non-coding, endogenous regulatory RNAs that function by controlling gene expression at the post-transcriptional level. Using small RNA sequencing and qRT-PCR techniques, we found that the expression of miR-152 was significantly increased during lactation in the mammary glands of dairy cows producing high quality milk compared with that in cows producing low quality milk. Furthermore, DNA methyltransferase 1 (DNMT1), which is a target of miR-152, was inversely correlated with the expression levels of miR-152 in the mammary glands of dairy cows. Dairy cow mammary epithelial cells (DCMECs) were used as in vitro cell models to study the function of miR-152. The forced expression of miR-152 in DCMECs resulted in a marked reduction of DNMT1 at both mRNA and protein levels. This in turn led to a decrease in global DNA methylation and increased the expression of two lactation-related genes, serine/threonine protein kinase Akt (Akt) and peroxisome proliferator-activated receptor gamma (Ppar gamma). In contrast, inhibition of miR-152 showed the opposite results. By using an electronic Coulter counter (CASY-TT) and flow cytometer, we discovered that miR-152 enhanced the viability and multiplication capacity of DCMECs. In conclusion, miR-152 plays an important role in the development and lactation processes in the mammary glands of dairy cows. Our data provide insights into dairy cow mammary gland development and lactation.	[Wang, Jie; Bian, Yanjie; Wang, Zhuoran; Li, Dan; Wang, Chunmei; Li, Qingzhang; Gao, Xuejun] Northeast Agr Univ, Educ Minist, Key Lab Dairy Sci, Harbin, Heilongjiang, Peoples R China	Northeast Agricultural University - China	Wang, CM (corresponding author), Northeast Agr Univ, Educ Minist, Key Lab Dairy Sci, Harbin, Heilongjiang, Peoples R China.	wangcm-1@163.com		Bose, Shambunath/0000-0003-0737-5713; Wang, jing-hua/0000-0002-2034-7429; HONG, SEUNGUG/0000-0002-6228-3312	Major State Basic Research Development Program of China (973 Program) [2011CB100804]; Heilongjiang Department of Education Project Program [1154z1004]	Major State Basic Research Development Program of China (973 Program)(National Basic Research Program of China); Heilongjiang Department of Education Project Program	This study was supported by Major State Basic Research Development Program of China (973 Program, No. 2011CB100804); Heilongjiang Department of Education Project Program, No. 1154z1004. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803; Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; Anderson SM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1653; Bionaz M, 2011, BIOINFORM BIOL INSIG, V5, P83, DOI 10.4137/BBI.S7003; Bionaz M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-366; Boutinaud M, 2004, REPROD NUTR DEV, V44, P499, DOI 10.1051/rnd:2004054; Boxer RB, 2006, CELL METAB, V4, P475, DOI 10.1016/j.cmet.2006.10.011; Braconi C, 2010, HEPATOLOGY, V51, P881, DOI 10.1002/hep.23381; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Chiam K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025634; Cui W, 2011, MOL CELL BIOCHEM, V355, P17, DOI 10.1007/s11010-011-0834-1; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Fan GP, 2005, DEVELOPMENT, V132, P3345, DOI 10.1242/dev.01912; Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589; Gerlach D, 2009, NUCLEIC ACIDS RES, V37, pD111, DOI 10.1093/nar/gkn707; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hassler MR, 2012, BIOCHIMIE, V94, P2297, DOI 10.1016/j.biochi.2012.05.029; Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1; Hu H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007636; Huang JF, 2010, HEPATOLOGY, V52, P60, DOI 10.1002/hep.23660; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Ji WD, 2013, CARCINOGENESIS, V34, P446, DOI 10.1093/carcin/bgs343; Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732; Lee JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061658; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li HM, 2012, MOLECULES, V17, P12037, DOI 10.3390/molecules171012037; Liu XF, 2012, IN VITRO CELL DEV-AN, V48, P554, DOI 10.1007/s11626-012-9545-5; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Neville MC, 2002, J MAMMARY GLAND BIOL, V7, P49, DOI 10.1023/A:1015770423167; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Schwertfeger KL, 2003, J LIPID RES, V44, P1100, DOI 10.1194/jlr.M300045-JLR200; Sethupathy P, 2006, NAT METHODS, V3, P881, DOI 10.1038/NMETH954; Tanaka T, 2009, DIFFERENTIATION, V77, P181, DOI 10.1016/j.diff.2008.10.001; Vanselow J, 2006, J MOL ENDOCRINOL, V37, P463, DOI 10.1677/jme.1.02131; Wan YH, 2007, GENE DEV, V21, P1895, DOI 10.1101/gad.1567207; Wang Chunmei, 2007, Journal of Genetics and Genomics, V34, P966, DOI 10.1016/S1673-8527(07)60109-X; Wang H, 2011, CARCINOGENESIS, V32, P1033, DOI 10.1093/carcin/bgr081; Xiang Y, 2013, ONCOGENE; Xu Q, 2013, J MOL CELL BIOL, V5, P3, DOI 10.1093/jmcb/mjs049; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028	41	90	100	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2014	9	7							e101358	10.1371/journal.pone.0101358	http://dx.doi.org/10.1371/journal.pone.0101358			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO5BA	24475077	Green Submitted, Green Published, gold			2023-01-03	WOS:000341354100077
J	Dong, J; Han, QF; Zhu, TY; Ren, YP; Chen, JH; Zhao, HP; Chen, MH; Xu, R; Wang, Y; Hao, CM; Zhang, R; Zhang, XH; Wang, M; Tian, N; Wang, HY				Dong, Jie; Han, Qing-Feng; Zhu, Tong-Ying; Ren, Ye-Ping; Chen, Jiang-Hua; Zhao, Hui-Ping; Chen, Meng-Hua; Xu, Rong; Wang, Yue; Hao, Chuan-Ming; Zhang, Rui; Zhang, Xiao-Hui; Wang, Mei; Tian, Na; Wang, Hai-Yan			The Associations of Uric Acid, Cardiovascular and All-Cause Mortality in Peritoneal Dialysis Patients	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; CORONARY-HEART-DISEASE; RENAL-FUNCTION DECLINE; HIGH BLOOD-PRESSURE; HEMODIALYSIS-PATIENTS; RISK-FACTOR; ENDOTHELIAL DYSFUNCTION; ATHEROSCLEROSIS RISK; LOWERING THERAPY; ARTERY-DISEASE	Aims: To investigate whether uric acid (UA) is an independent predictor of cardiovascular (CV) and all-cause mortality in peritoneal dialysis (PD) patients after controlling for recognized CV risk factors. Methods: A total of 2264 patients on chronic PD were collected from seven centers affiliated with the Socioeconomic Status on the Outcome of Peritoneal Dialysis (SSOP) Study. All demographic and laboratory data were recorded at baseline. Multivariate Cox regression was used to calculate the hazard ratio (HR) of CV and all-cause mortality with adjustments for recognized traditional and uremia-related CV factors. Results: There were no significant differences in baseline characteristics between patients with (n = 2193) and without (n = 71) UA measured. Each 1 mg/dL of increase in UA was associated with higher all-cause mortality with 1.05(1.00 similar to 1.10) of HR and higher CV mortality with 1.12 (1.05 similar to 1.20) of HR after adjusting for age, gender and center size. The highest gender-specific tertile of UA predicted higher all-cause mortality with 1.23(1.00 similar to 1.52) of HR and higher CV mortality with 1.69 (1.21 similar to 2.38) of HR after adjusting for age, gender and center size. The predictive value of UA was stronger in patients younger than 65 years without CV disease or diabetes at baseline. The prognostic value of UA as both continuous and categorical variable weakened or disappeared after further adjusted for uremia-related and traditional CV risk factors. Conclusions: The prognostic value of UA in CV and all-cause mortality was weak in PD patients generally, which was confounded by uremia-related and traditional CV risk factors.	[Dong, Jie; Xu, Rong; Wang, Hai-Yan] Peking Univ, Dept Med, Div Renal, Hosp 1, Beijing 100871, Peoples R China; [Dong, Jie; Xu, Rong; Wang, Hai-Yan] Peking Univ, Inst Nephrol, Beijing 100871, Peoples R China; [Dong, Jie; Xu, Rong; Wang, Hai-Yan] Minist Hlth, Key Lab Renal Dis, Beijing, Peoples R China; [Dong, Jie; Xu, Rong; Wang, Hai-Yan] Minist Educ, Key Lab Renal Dis, Beijing, Peoples R China; [Han, Qing-Feng; Wang, Yue] Peking Univ, Hosp 3, Dept Nephrol, Beijing 100871, Peoples R China; [Zhu, Tong-Ying] Fudan Univ, Dept Nephrol, Huashan Hosp, Shanghai 200433, Peoples R China; [Ren, Ye-Ping; Zhang, Rui] Harbin Med Univ, Dept Nephrol, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China; [Zhang, Xiao-Hui] Zhejiang Univ, Affiliated Hosp 1, Kidney Dis Ctr, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China; [Wang, Mei] Peking Univ, Peoples Hosp, Dept Nephrol, Beijing 100871, Peoples R China; [Chen, Meng-Hua; Tian, Na] Ningxia Med Univ, Gen Hosp, Dept Nephrol, Ningxia, Peoples R China	Peking University; Peking University; Peking University; Fudan University; Harbin Medical University; Zhejiang University; Peking University; Ningxia Medical University	Dong, J (corresponding author), Peking Univ, Dept Med, Div Renal, Hosp 1, Beijing 100871, Peoples R China.	dongjie@medmail.com.cn	Dong, Jie/AFM-0048-2022; tian, na/GVR-9226-2022; Dong, Jinwei/C-4949-2009	Biradar, Chandrashekhar/0000-0002-9532-9452; Xiao, Xiangming/0000-0003-0956-7428; Dong, Jinwei/0000-0001-5687-803X	Education Department, China; Baxer Clinical Research Award from Baxter Corp, China; ISN Research Award from the ISN GO RP Committee	Education Department, China; Baxer Clinical Research Award from Baxter Corp, China; ISN Research Award from the ISN GO RP Committee	This study is supported in part by New Century Excellent Talents from The Education Department, China, Baxer Clinical Research Award from Baxter Corp, China, and an ISN Research Award from the ISN GO R&P Committee. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALEXANDER RW, 1994, NEW ENGL J MED, V331, P468, DOI 10.1056/NEJM199408183310709; Badve SV, 2011, NAT REV NEPHROL, V7, P295, DOI 10.1038/nrneph.2010.186; Caravaca F, 2005, NEFROLOGIA, V25, P645; Chen J, 2012, AM J CARDIOL, V110, P136, DOI 10.1016/j.amjcard.2012.02.061; Chen YM, 2011, AM J NEPHROL, V33, P97, DOI 10.1159/000322966; CHOBANIAN AV, 2003, HYPERTENSION, V42, P1206, DOI [DOI 10.1161/01.HYP.0000107251.49515.c2, DOI 10.1161/01.HYP.0000107251.49515.C2]; Culleton BF, 1999, ANN INTERN MED, V131, P7, DOI 10.7326/0003-4819-131-1-199907060-00003; Elsayed EF, 2007, ARCH INTERN MED, V167, P1130, DOI 10.1001/archinte.167.11.1130; Garg JP, 2005, ARTHRITIS RHEUM-US, V52, P290, DOI 10.1002/art.20781; Hsu SP, 2004, NEPHROL DIAL TRANSPL, V19, P457, DOI 10.1093/ndt/gfg563; Iuliano L, 2001, LIPIDS, V36, pS41, DOI 10.1007/s11745-001-0680-1; Johnson RJ, 2003, HYPERTENSION, V41, P1183, DOI 10.1161/01.HYP.0000069700.62727.C5; Jonasson T, 2005, CLIN CHEM LAB MED, V43, P628, DOI 10.1515/CCLM.2005.108; Jun M, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008176.pub2; Kanbay M, 2012, AM J NEPHROL, V36, P324, DOI 10.1159/000342390; Kanbay M, 2011, AM J NEPHROL, V33, P298, DOI 10.1159/000324847; Khosla UM, 2005, KIDNEY INT, V67, P1739, DOI 10.1111/j.1523-1755.2005.00273.x; Kuo CF, 2013, RHEUMATOLOGY, V52, P127, DOI 10.1093/rheumatology/kes223; Latif W, 2011, CLIN J AM SOC NEPHRO, V6, P2470, DOI 10.2215/CJN.00670111; Lee SMK, 2009, AM J NEPHROL, V29, P79, DOI 10.1159/000151292; Liu WC, 2012, CLIN J AM SOC NEPHRO, V7, P541, DOI 10.2215/CJN.09420911; Madero M, 2009, AM J KIDNEY DIS, V53, P796, DOI 10.1053/j.ajkd.2008.12.021; Melendez-Ramirez G, 2012, ENDOCR RES, V37, P1, DOI 10.3109/07435800.2011.566235; Moriarity JT, 2000, ANN EPIDEMIOL, V10, P136, DOI 10.1016/S1047-2797(99)00037-X; Muntner P, 2005, J AM SOC NEPHROL, V16, P529, DOI 10.1681/ASN.2004080656; Navaneethan SD, 2009, NEPHROL DIAL TRANSPL, V24, P1260, DOI 10.1093/ndt/gfn621; Navaneethan SD, 2009, COCHRANE DATABASE SY; Nieto FJ, 2000, ATHEROSCLEROSIS, V148, P131, DOI 10.1016/S0021-9150(99)00214-2; Niskanen LK, 2004, ARCH INTERN MED, V164, P1546, DOI 10.1001/archinte.164.14.1546; Palmer SC, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001436; Pan Y, 2012, BRIT J NUTR, V108, P400, DOI 10.1017/S0007114511007033; Park JT, 2009, NEPHROL DIAL TRANSPL, V24, P3520, DOI 10.1093/ndt/gfp272; Sarnak MJ, 2003, HYPERTENSION, V42, P1050, DOI 10.1161/01.HYP.0000102971.85504.7c; Smith SC, 2004, CIRCULATION, V109, P3112, DOI 10.1161/01.CIR.0000133427.35111.67; Stenvinkel P, 2008, CLIN J AM SOC NEPHRO, V3, P505, DOI 10.2215/CJN.03670807; Suliman ME, 2006, AM J KIDNEY DIS, V48, P761, DOI 10.1053/j.ajkd.2006.08.019; Suzuki T, 2007, NITRIC OXIDE-BIOL CH, V16, P266, DOI 10.1016/j.niox.2006.10.008; Tangri N, 2010, AM J KIDNEY DIS, V56, P247, DOI 10.1053/j.ajkd.2010.06.004; Wang AYM, 2007, PERITON DIALYSIS INT, V27, pS228; Wannamethee SG, 1997, HEART, V78, P147, DOI 10.1136/hrt.78.2.147; Wen CP, 2010, AM J KIDNEY DIS, V56, P273, DOI 10.1053/j.ajkd.2010.01.024; Xu R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050766; Zhang LX, 2012, NEPHROL DIAL TRANSPL, V27, P1836, DOI 10.1093/ndt/gfr597	43	62	69	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2014	9	1							e82342	10.1371/journal.pone.0082342	http://dx.doi.org/10.1371/journal.pone.0082342			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	291WL	24465714	Green Published, Green Submitted, gold			2023-01-03	WOS:000329862500015
J	Shin, H; Song, H; Suh, CS; Lim, HJ				Shin, Hyejin; Song, Haengseok; Suh, Chang Suk; Lim, Hyunjung Jade			The Formin Protein mDia2 Serves as a Marker of Spindle Pole Dynamics in Vitrified-Warmed Mouse Oocytes	PLOS ONE			English	Article							POLARIZED-LIGHT MICROSCOPY; LIVING HUMAN OOCYTES; MEIOTIC SPINDLE; DEVELOPMENTAL COMPETENCE; THAWED OOCYTES; GAMMA-TUBULIN; CRYOPRESERVATION; VITRIFICATION; MICROTUBULES; ORGANIZATION	The mouse diaphanous 2 (mDia2) protein belongs to the formin family and has been shown to nucleate actin filaments and stabilize microtubules, thus indicating a role in cytoskeleton organization. Our previous study, which showed that mDia2 specifically localizes to spindle poles of metaphase I mouse oocytes and NIH3T3 cells, provided the first evidence of its spindle pole-associated cellular function. In the present study, we aim to determine whether spindle pole proteins, such as mDia2 and pericentrin, can be used to monitor the status of spindle poles in cryopreserved mouse oocytes. We show herein that mDia2 exhibits an overlapping distribution with pericentrin, which is a crucial component of centrosomes and microtubule organizing centers (MTOCs). In vitrified-warmed oocytes, the overlapping distribution of mDia2 and pericentrin was immediately detected after thawing, thereby suggesting that mDia2 maintains a tight association with the spindle pole machinery. Interestingly, we observed that microtubules extend from mDia2 clusters in cytoplasmic MTOCs after thawing. This result suggests that mDia2 is a major MTOC component that is closely associated with pericentrin and that it plays a role in microtubule growth from MTOCs. Collectively, our results provide evidence that mDia2 is a novel marker of spindle pole dynamics before and after cryopreservation.	[Shin, Hyejin; Lim, Hyunjung Jade] Konkuk Univ, Inst Biomed Sci & Technol, Dept Biomed Sci & Technol, Seoul, South Korea; [Song, Haengseok] CHA Univ, Dept Biomed Sci, Coll Life Sci, Seoul, South Korea; [Suh, Chang Suk] Seoul Natl Univ, Dept Obstet & Gynecol, Bundang Hosp, Songnam, South Korea	Konkuk University; Pochon Cha University; Seoul National University (SNU)	Lim, HJ (corresponding author), Konkuk Univ, Inst Biomed Sci & Technol, Dept Biomed Sci & Technol, Seoul, South Korea.	hlim@konkuk.ac.kr	song, yang/P-1033-2015	Garg, Shashank/0000-0001-9917-3021; Song, Haengseok/0000-0002-5027-7310; Fricke, W. Florian/0000-0003-1586-0962; von Rosenvinge, Erik C./0000-0002-1862-7288	Ministry of Health & Welfare, Republic of Korea [HI12C0055]	Ministry of Health & Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	This study was supported by a grant from the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI12C0055) (https://www.htdream.kr/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Azoury J, 2008, CURR BIOL, V18, P1514, DOI 10.1016/j.cub.2008.08.044; Bartolini F, 2008, J CELL BIOL, V181, P523, DOI 10.1083/jcb.200709029; Block J, 2008, J MICROSC-OXFORD, V231, P506, DOI 10.1111/j.1365-2818.2008.02063.x; Bromfield JJ, 2009, HUM REPROD, V24, P2114, DOI 10.1093/humrep/dep182; Carabatsos MJ, 2000, MICROSC RES TECHNIQ, V49, P435, DOI 10.1002/(SICI)1097-0029(20000601)49:5<435::AID-JEMT5>3.0.CO;2-H; Cha Soo Kyung, 2011, Clin Exp Reprod Med, V38, P24, DOI 10.5653/cerm.2011.38.1.24; CHEN C, 1986, LANCET, V1, P884, DOI 10.1016/S0140-6736(86)90989-X; Chen CK, 2004, FERTIL STERIL, V82, P666, DOI 10.1016/j.fertnstert.2003.12.053; Ciotti PM, 2009, FERTIL STERIL, V91, P2399, DOI 10.1016/j.fertnstert.2008.03.013; Compton DA, 2000, ANNU REV BIOCHEM, V69, P95, DOI 10.1146/annurev.biochem.69.1.95; Courtois A, 2012, J CELL BIOL, V198, P357, DOI 10.1083/jcb.201202135; Cui XS, 2013, REPROD FERT DEVELOP, V25, P691, DOI 10.1071/RD12138; DIDION BA, 1990, J ANIM SCI, V68, P2803; Gaillard J, 2011, MOL BIOL CELL, V22, P4575, DOI 10.1091/mbc.E11-07-0616; George MA, 1996, MOL HUM REPROD, V2, P445, DOI 10.1093/molehr/2.6.445; Gomes CM, 2008, FERTIL STERIL, V90, P1396, DOI 10.1016/j.fertnstert.2007.08.025; GUETHHALLONET C, 1993, J CELL SCI, V105, P157; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; Higgs HN, 2005, TRENDS BIOCHEM SCI, V30, P342, DOI 10.1016/j.tibs.2005.04.014; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Jo JW, 2011, FERTIL STERIL, V96, P1239, DOI 10.1016/j.fertnstert.2011.08.023; Kwon Sojung, 2011, Clin Exp Reprod Med, V38, P1, DOI 10.5653/cerm.2011.38.1.1; Kwon S, 2011, MOL HUM REPROD, V17, P317, DOI 10.1093/molehr/gaq088; Lammers M, 2008, J BIOL CHEM, V283, P35236, DOI 10.1074/jbc.M805634200; LANZENDORF SE, 1990, BIOL REPROD, V42, P703, DOI 10.1095/biolreprod42.4.703; Leader B, 2002, NAT CELL BIOL, V4, P921, DOI 10.1038/ncb880; Li HB, 2008, NAT CELL BIOL, V10, P1301, DOI 10.1038/ncb1788; MANDELBAUM J, 1988, HUM REPROD, V3, P117, DOI 10.1093/oxfordjournals.humrep.a136642; Moon JH, 2005, HUM REPROD, V20, P2207, DOI 10.1093/humrep/dei044; Moon JH, 2003, HUM REPROD, V18, P817, DOI 10.1093/humrep/deg165; Otoi T, 1997, CRYOBIOLOGY, V34, P36, DOI 10.1006/cryo.1996.1988; Pellegrin S, 2005, CURR BIOL, V15, P129, DOI 10.1016/j.cub.2005.01.011; Schuh M, 2007, CELL, V130, P484, DOI 10.1016/j.cell.2007.06.025; Schuh M, 2008, CURR BIOL, V18, P1986, DOI 10.1016/j.cub.2008.11.022; Sereni E, 2009, REPROD BIOMED ONLINE, V19, P191, DOI 10.1016/S1472-6483(10)60071-5; Wang WH, 2001, HUM REPROD, V16, P2374, DOI 10.1093/humrep/16.11.2374; WHITTINGHAM DG, 1977, J REPROD FERTIL, V49, P89, DOI 10.1530/jrf.0.0490089; Zimmerman WC, 2004, MOL BIOL CELL, V15, P3642, DOI 10.1091/mbc.E03-11-0796	39	140	172	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2013	8	9							e75729	10.1371/journal.pone.0075729	http://dx.doi.org/10.1371/journal.pone.0075729			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223BC	24069443	Green Submitted, gold, Green Published			2023-01-03	WOS:000324777300094
J	Kawaza, K; Machen, HE; Brown, J; Mwanza, Z; Iniguez, S; Gest, A; Smith, EO; Oden, M; Richards-Kortum, RR; Molyneux, E				Kawaza, Kondwani; Machen, Heather E.; Brown, Jocelyn; Mwanza, Zondiwe; Iniguez, Suzanne; Gest, Al; Smith, E. O'Brian; Oden, Maria; Richards-Kortum, Rebecca R.; Molyneux, Elizabeth			Efficacy of a Low-Cost Bubble CPAP System in Treatment of Respiratory Distress in a Neonatal Ward in Malawi	PLOS ONE			English	Article							POSITIVE AIRWAY PRESSURE; PRETERM INFANTS; BIRTH; SUPPORT; CARE; INTUBATION	Background: Respiratory failure is a leading cause of neonatal mortality in the developing world. Bubble continuous positive airway pressure (bCPAP) is a safe, effective intervention for infants with respiratory distress and is widely used in developed countries. Because of its high cost, bCPAP is not widely utilized in low-resource settings. We evaluated the performance of a new bCPAP system to treat severe respiratory distress in a low resource setting, comparing it to nasal oxygen therapy, the current standard of care. Methods: We conducted a non-randomized convenience sample study to test the efficacy of a low-cost bCPAP system treating newborns with severe respiratory distress in the neonatal ward of Queen Elizabeth Central Hospital, in Blantyre, Malawi. Neonates weighing >1,000 g and presenting with severe respiratory distress who fulfilled inclusion criteria received nasal bCPAP if a device was available; if not, they received standard care. Clinical assessments were made during treatment and outcomes compared for the two groups. Findings: 87 neonates (62 bCPAP, 25 controls) were recruited. Survival rate for neonates receiving bCPAP was 71.0% (44/62) compared with 44.0% (11/25) for controls. 65.5% (19/29) of very low birth weight neonates receiving bCPAP survived to discharge compared to 15.4% (1/13) of controls. 64.6% (31/48) of neonates with respiratory distress syndrome (RDS) receiving bCPAP survived to discharge, compared to 23.5% (4/17) of controls. 61.5% (16/26) of neonates with sepsis receiving bCPAP survived to discharge, while none of the seven neonates with sepsis in the control group survived. Interpretation: Use of a low-cost bCPAP system to treat neonatal respiratory distress resulted in 27% absolute improvement in survival. The beneficial effect was greater for neonates with very low birth weight, RDS, or sepsis. Implementing appropriate bCPAP devices could reduce neonatal mortality in developing countries.	[Kawaza, Kondwani; Mwanza, Zondiwe; Molyneux, Elizabeth] Queen Elizabeth Cent Hosp, Dept Pediat, Coll Med, Blantyre, Malawi; [Machen, Heather E.; Smith, E. O'Brian] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Brown, Jocelyn; Oden, Maria; Richards-Kortum, Rebecca R.] Rice Univ, Dept Bioengn, Houston, TX 77251 USA; [Iniguez, Suzanne] Texas Childrens Hosp, Dept Resp Care, Houston, TX 77030 USA	University of Malawi; Baylor College of Medicine; Rice University; Baylor College of Medicine	Richards-Kortum, RR (corresponding author), Rice Univ, Dept Bioengn, Houston, TX 77251 USA.	rkortum@rice.edu	Richards-Kortum, Rebecca R/P-4074-2014	Richards-Kortum, Rebecca R/0000-0003-2347-9467	United States Agency for International Development (USAID); Government of Norway; Bill & Melinda Gates Foundation; Grand Challenges Canada; World Bank; African Network for Drugs and Diagnostics Innovation (ANDI); USAID [AID-OAA-A-13-00014]	United States Agency for International Development (USAID)(United States Agency for International Development (USAID)CGIAR); Government of Norway; Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Grand Challenges Canada(CGIAR); World Bank(The World Bank India); African Network for Drugs and Diagnostics Innovation (ANDI); USAID(United States Agency for International Development (USAID))	This work was made possible through the generous support of the Saving Lives at Birth partners: the United States Agency for International Development (USAID), the Government of Norway, the Bill & Melinda Gates Foundation, Grand Challenges Canada, and the World Bank. It was prepared by William Marsh Rice University and does not necessarily reflect the views of the Saving Lives at Birth Partners. Funding was also provided by the African Network for Drugs and Diagnostics Innovation (ANDI). 1. USAID Cooperative Agreement Award No. AID-OAA-A-13-00014, www.usaid.gov 2. African Network for Drugs and Diagnostics Innovation (ANDI), www.andi-africa.org. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4; Blencowe H, 2009, J TROP PEDIATRICS, V55, P244, DOI 10.1093/tropej/fmn116; Brown J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053622; Buckmaster AG, 2007, PEDIATRICS, V120, P509, DOI 10.1542/peds.2007-0775; Clair CS, 2008, AM J PERINAT, V25, P473, DOI 10.1055/s-0028-1085066; Courtney SE, 2001, PEDIATRICS, V107, P304, DOI 10.1542/peds.107.2.304; De Klerk AM, 2001, J PAEDIATR CHILD H, V37, P161, DOI 10.1046/j.1440-1754.2001.00624.x; DiBlasi RM, 2009, RESP CARE, V54, P1209; Duke T, 2005, ARCH DIS CHILD-FETAL, V90, P211, DOI 10.1136/adc.2003.048108; Finer NN, 2010, NEW ENGL J MED, V362, P1970, DOI 10.1056/NEJMoa0911783; Gittermann MK, 1997, EUR J PEDIATR, V156, P384, DOI 10.1007/s004310050620; Gnanaratnem J, 2000, CURR OPIN PEDIATR, V12, P227, DOI 10.1097/00008480-200006000-00009; Kamath BD, 2011, PEDIATRICS, V127, P1139, DOI 10.1542/peds.2010-3212; Koti J, 2010, INDIAN PEDIATR, V47, P139, DOI 10.1007/s13312-010-0021-6; Koyamaibole L, 2006, J TROP PEDIATRICS, V52, P249, DOI 10.1093/tropej/fmi109; Lawn JE, 2009, BJOG-INT J OBSTET GY, V116, P49, DOI 10.1111/j.1471-0528.2009.02328.x; Lawn JE, 2010, SEMIN PERINATOL, V34, P371, DOI 10.1053/j.semperi.2010.09.011; Malik K., 2013, HUMAN DEV REPORT 201; Morley CJ, 2008, NEW ENGL J MED, V358, P700, DOI 10.1056/NEJMoa072788; Nowadzky T, 2009, PEDIATRICS, V123, P1534, DOI 10.1542/peds.2008-1279; Pieper CH, 2003, J TROP PEDIATRICS, V49, P148, DOI 10.1093/tropej/49.3.148; Rehan V K, 2001, J Perinatol, V21, P521, DOI 10.1038/sj.jp.7210587; Schmolzer GM, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5980; Sweet D, 2007, J PERINAT MED, V35, P175, DOI 10.1515/JPM.2007.048; Tagare A, 2010, J TROP PEDIATRICS, V56, P191, DOI 10.1093/tropej/fmp092; Urs PS, 2009, INDIAN PEDIATR, V46, P409; Van den Heuvel M, 2011, ANN TROP PAEDIATR, V31, P59, DOI 10.1179/1465328110Y.0000000001; Wilson PT, 2012, J PEDIAT; Zupan J, 2006, NEONATAL PERINATAL M, Viv	29	93	95	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2014	9	1							e86327	10.1371/journal.pone.0086327	http://dx.doi.org/10.1371/journal.pone.0086327			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301ZC	27895847	Green Published, gold			2023-01-03	WOS:000330570000033
J	Sanders, T; Cliff, DP; Lonsdale, C				Sanders, Taren; Cliff, Dylan P.; Lonsdale, Chris			Measuring Adolescent Boys' Physical Activity: Bout Length and the Influence of Accelerometer Epoch Length	PLOS ONE			English	Article							ACTIVITY PATTERNS; CHILDREN; HEALTH; LEVEL	Objectives: Accurate, objective measurement is important for understanding adolescents' physical activity (PA) behaviour. When using accelerometry to objectively measure PA, a decision must be made regarding how frequently data is recorded (i.e., epoch length). The purpose of this study was to examine i) PA bout length, and ii) the effect of variations in accelerometer epoch length on PA estimates during physical education (PE) and leisure time in adolescent boys. Design: Cross-sectional study. Methods: Year 9 boys (N = 133; mean age +/- SD = 14.36 +/- 0.48 years) wore accelerometers during two PE lessons, and for a period of seven consecutive days. Data were reintegrated from 1s into longer periods of 2, 5, 10, 30, and 60 seconds. ANOVAs were used to test for differences in PA estimates between epochs in leisure time and PE. Results: The mean length of vigorous PA (VPA) bouts was 3.5 +/- 2.0 seconds for PE and 2.5 +/- 1.7 seconds for leisure time, and mean length of moderate PA (MPA) bouts was 2.3 +/- 0.5 seconds for PE and 2.9 +/- 0.5 seconds for leisure time. During PE, estimates of MVPA, MPA, and light PA (LPA) increased as epoch increased from 1 second to 60 seconds, while VPA and sedentary behaviour estimates decreased. During leisure time, estimates of all PA intensities decreased as epoch increased from 1 second to 60 seconds, with the exception of sedentary behaviour, which increased as epoch length increased. Conclusion: The context in which PA occurs can influence PA bout length measurement and the effect of variations in epoch length on PA estimates. Researchers measuring PA with accelerometry should be conscious of the possible influence of context on PA estimates.	[Sanders, Taren; Lonsdale, Chris] Univ Western Sydney, Sch Sci & Hlth, Penrith, NSW 1797, Australia; [Cliff, Dylan P.] Univ Wollongong, Interdisciplinary Educ Res Inst, Sch Educ, Wollongong, NSW, Australia	Western Sydney University; University of Wollongong	Lonsdale, C (corresponding author), Univ Western Sydney, Sch Sci & Hlth, Penrith, NSW 1797, Australia.	c.lonsdale@uws.edu.au	Lovell, Karina S E/E-6410-2012; Lonsdale, Chris/T-8710-2017; Coyle, David/P-3920-2019; Sanders, Taren/N-9511-2018; Gilbody, Simon/AAY-3720-2021; Kessler, david/ABB-6489-2021; Bower, Peter/A-1508-2011; Bee, Penny E/O-8822-2014; Sanders, Caroline/G-8021-2014	Lovell, Karina S E/0000-0001-8821-895X; Lonsdale, Chris/0000-0002-2523-5565; Coyle, David/0000-0002-5103-0379; Sanders, Taren/0000-0002-4504-6008; Gilbody, Simon/0000-0002-8236-6983; Bower, Peter/0000-0001-9558-3349; Bee, Penny E/0000-0002-5600-0400; Sanders, Caroline/0000-0002-0539-928X; Kennedy, Catriona/0000-0003-3510-9113; Rennick-Egglestone, Stefan/0000-0003-4187-011X; Knowles, Sarah/0000-0002-0863-5866; Cliff, Dylan/0000-0001-6863-3996	University of Western Sydney; National Heart Foundation of Australia [PH 11S 6025]; Medical Research Council [G0401181] Funding Source: researchfish; National Institute for Health Research [SPCR-040, 06/43/05, 06/43/504] Funding Source: researchfish	University of Western Sydney; National Heart Foundation of Australia(National Heart Foundation of Australia); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This study was funded by the University of Western Sydney's support for Bachelor of Health Science (Honours) research projects. Dylan Cliff is funded by a National Heart Foundation of Australia Postdoctoral Research Fellowship (PH 11S 6025). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ActiGraph Software Department, 2012, ACT 6 US MAN; Andersen RE, 1998, JAMA-J AM MED ASSOC, V279, P938, DOI 10.1001/jama.279.12.938; BAILEY RC, 1995, MED SCI SPORT EXER, V27, P1033, DOI 10.1249/00005768-199507000-00012; Baquet G, 2007, PREV MED, V44, P143, DOI 10.1016/j.ypmed.2006.10.004; Berman N, 1998, AM J HUM BIOL, V10, P289, DOI 10.1002/(SICI)1520-6300(1998)10:3<289::AID-AJHB4>3.0.CO;2-E; Blaes A, 2011, AM J HUM BIOL, V23, P353, DOI 10.1002/ajhb.21142; Carson V, 2014, INT J OBESITY, V38, P16, DOI 10.1038/ijo.2013.135; Cohen J., 2013, STAT POWER ANAL BEHA; Dencker M, 2012, J SPORT MED PHYS FIT, V52, P115; Edwardson CL, 2010, MED SCI SPORT EXER, V42, P928, DOI 10.1249/MSS.0b013e3181c301f5; Esliger D.W., 2005, J PHYS ACT HEALTH, V2, P366, DOI [https://doi.org/10.1123/jpah.2.3.366, DOI 10.1123/JPAH.2.3.366, DOI 10.1186/1479-5868-8-62]; Freedson P, 2005, MED SCI SPORT EXER, V37, pS523, DOI 10.1249/01.mss.0000185658.28284.ba; Freedson P.S., 1997, MED SCI SPORT EXER S, V29, P45, DOI DOI 10.1097/00005768-199705001-00256; Freedson PS, 2000, RES Q EXERCISE SPORT, V71, pS21, DOI 10.1080/02701367.2000.11082782; Gabriel KP, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-53; Gutin B, 2008, OBESITY, V16, P2193, DOI 10.1038/oby.2008.348; Holman RM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025733; Janssen I, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-40; Matthews CE, 2012, MED SCI SPORT EXER, V44, pS68, DOI 10.1249/MSS.0b013e3182399e5b; Mcclain JJ, 2008, MED SCI SPORT EXER, V40, P2080, DOI 10.1249/MSS.0b013e3181824d98; Nader PR, 2008, JAMA-J AM MED ASSOC, V300, P295, DOI 10.1001/jama.300.3.295; Nilsson A, 2002, PEDIATR EXERC SCI, V14, P87, DOI 10.1123/pes.14.1.87; Obeid J, 2011, APPL PHYSIOL NUTR ME, V36, P291, DOI [10.1139/h11-002, 10.1139/H11-002]; Rowls AV., 2006, CITESEER, V4, P52; Sallis JF, 2000, MED SCI SPORT EXER, V32, P963, DOI 10.1097/00005768-200009000-00012; Sayers A, 2011, J CLIN ENDOCR METAB, V96, pE793, DOI 10.1210/jc.2010-2550; Sirard JR, 2009, J PHYS ACT HEALTH, V6, pS148, DOI 10.1123/jpah.6.s1.s148; Strong WB, 2005, J PEDIATR-US, V146, P732, DOI 10.1016/j.jpeds.2005.01.055; Tabachnick B. G., 2007, USING MULTIVARIATE S, Vfifth; Troiano RP, 2008, MED SCI SPORT EXER, V40, P181, DOI 10.1249/mss.0b013e31815a51b3; Trost SG, 2005, MED SCI SPORT EXER, V37, pS531, DOI 10.1249/01.mss.0000185657.86065.98; Trost SG, 2007, AM J LIFESTYLE MED, V1, P299, DOI 10.1177/1559827607301686; Trost SG, 2011, MED SCI SPORT EXER, V43, P1360, DOI 10.1249/MSS.0b013e318206476e; Vale S, 2009, PEDIATR EXERC SCI, V21, P413, DOI 10.1123/pes.21.4.413; Vanhelst J, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-26; Ward DS, 2005, MED SCI SPORT EXER, V37, pS582, DOI 10.1249/01.mss.0000185292.71933.91; Welk GJ, 2000, RES Q EXERCISE SPORT, V71, pS59, DOI 10.1080/02701367.2000.11082788	37	143	148	0	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2014	9	3							e92040	10.1371/journal.pone.0092040	http://dx.doi.org/10.1371/journal.pone.0092040			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD4ZE	24643129	Green Published, gold, Green Submitted			2023-01-03	WOS:000333259900069
J	Wang, X; Cammeraat, ELH; Romeijn, P; Kalbitz, K				Wang, Xiang; Cammeraat, Erik L. H.; Romeijn, Paul; Kalbitz, Karsten			Soil Organic Carbon Redistribution by Water Erosion-The Role of CO2 Emissions for the Carbon Budget	PLOS ONE			English	Article							DIOXIDE EVOLUTION; VARIABLE RAINFALL; INTERRILL EROSION; ENRICHMENT RATIO; MATTER; RUNOFF; DEPOSITION; FRACTIONS; STABILITY; SEDIMENT	A better process understanding of how water erosion influences the redistribution of soil organic carbon (SOC) is sorely needed to unravel the role of soil erosion for the carbon (C) budget from local to global scales. The main objective of this study was to determine SOC redistribution and the complete C budget of a loess soil affected by water erosion. We measured fluxes of SOC, dissolved organic C (DOC) and CO2 in a pseudo-replicated rainfall-simulation experiment. We characterized different C fractions in soils and redistributed sediments using density fractionation and determined C enrichment ratios (CER) in the transported sediments. Erosion, transport and subsequent deposition resulted in significantly higher CER of the sediments exported ranging between 1.3 and 4.0. In the exported sediments, C contents (mg per g soil) of particulate organic C (POC, C not bound to soil minerals) and mineral-associated organic C (MOC) were both significantly higher than those of non-eroded soils indicating that water erosion resulted in losses of C-enriched material both in forms of POC and MOC. The averaged SOC fluxes as particles (4.7 g C m(-2) yr(-1)) were 18 times larger than DOC fluxes. Cumulative emission of soil CO2 slightly decreased at the erosion zone while increased by 56% and 27% at the transport and depositional zone, respectively, in comparison to non-eroded soil. Overall, CO2 emission is the predominant form of C loss contributing to about 90.5% of total erosion-induced C losses in our 4-month experiment, which were equal to 18 g C m(-2). Nevertheless, only 1.5% of the total redistributed C was mineralized to CO2 indicating a large stabilization after deposition. Our study also underlines the importance of C losses by particles and as DOC for understanding the effects of water erosion on the C balance at the interface of terrestrial and aquatic ecosystems.	[Wang, Xiang; Cammeraat, Erik L. H.; Romeijn, Paul; Kalbitz, Karsten] Univ Amsterdam, Inst Biodivers & Ecosyst Dynam, Amsterdam, Netherlands	University of Amsterdam	Wang, X (corresponding author), Univ Amsterdam, Inst Biodivers & Ecosyst Dynam, Amsterdam, Netherlands.	X.Wang@uva.nl	Cammeraat, Erik L.H./G-2863-2010; Kalbitz, Karsten/A-9641-2013	Cammeraat, Erik L.H./0000-0003-4398-206X; 	China Scholarship Council (CSC); University of Amsterdam (UvA)	China Scholarship Council (CSC)(China Scholarship Council); University of Amsterdam (UvA)	This work was supported by China Scholarship Council (CSC) and University of Amsterdam (UvA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allison SD, 2006, SOIL BIOL BIOCHEM, V38, P3245, DOI 10.1016/j.soilbio.2006.04.011; Berhe AA, 2012, J GEOPHYS RES-BIOGEO, V117, DOI 10.1029/2011JG001790; Bianchi TS, 2011, P NATL ACAD SCI USA, V108, P19473, DOI 10.1073/pnas.1017982108; Blake G.R., 1986, METHODS SOIL ANAL PA, P363, DOI 1.10.2136/sssabookser5.1.2-d.c13; Borselli L, 2001, EARTH SURF PROC LAND, V26, P329, DOI [10.1002/1096-9837(200103)26:3<329::AID-ESP177>3.0.CO;2-Y, 10.1002/1096-9837(200103)26:3&lt;329::AID-ESP177&gt;3.0.CO;2-Y]; Bremenfeld S, 2013, CATENA, V104, P14, DOI 10.1016/j.catena.2012.12.011; Buishand TA, 1980, EXTREME NEERSLAGHOEV, P104; Casals P, 2009, SOIL BIOL BIOCHEM, V41, P1915, DOI 10.1016/j.soilbio.2009.06.015; Cerli C, 2012, GEODERMA, V170, P403, DOI 10.1016/j.geoderma.2011.10.009; Chapin FS, 2009, J ECOL, V97, P840, DOI 10.1111/j.1365-2745.2009.01529.x; Chen FS, 2010, APPL SOIL ECOL, V44, P42, DOI 10.1016/j.apsoil.2009.09.003; Cole JJ, 2007, ECOSYSTEMS, V10, P171, DOI 10.1007/s10021-006-9013-8; Creed IF, 2013, BIOGEOCHEMISTRY, V112, P149, DOI 10.1007/s10533-012-9713-4; Denef K, 2001, SOIL BIOL BIOCHEM, V33, P1599, DOI 10.1016/S0038-0717(01)00076-1; Denef K, 2001, SOIL BIOL BIOCHEM, V33, P2145, DOI 10.1016/S0038-0717(01)00153-5; Doetterl S, 2012, GLOBAL CHANGE BIOL, V18, P2218, DOI 10.1111/j.1365-2486.2012.02680.x; Feng WT, 2014, SOIL BIOL BIOCHEM, V69, P398, DOI 10.1016/j.soilbio.2013.11.024; Fontaine S, 2007, NATURE, V450, P277, DOI 10.1038/nature06275; Franzluebbers AJ, 1999, SOIL BIOL BIOCHEM, V31, P1083, DOI 10.1016/S0038-0717(99)00022-X; GHADIRI H, 1993, J ENVIRON MANAGE, V37, P37, DOI 10.1006/jema.1993.1003; GHADIRI H, 1991, J ENVIRON QUAL, V20, P634, DOI 10.2134/jeq1991.00472425002000030021x; GOLCHIN A, 1994, AUST J SOIL RES, V32, P285, DOI 10.1071/SR9940285; Gregorich EG, 1998, SOIL TILL RES, V47, P291, DOI 10.1016/S0167-1987(98)00117-2; Harden JW, 1999, GLOBAL BIOGEOCHEM CY, V13, P885, DOI 10.1029/1999GB900061; HEIMOVAARA TJ, 1990, WATER RESOUR RES, V26, P2311, DOI 10.1029/90WR01239; Huxman TE, 2004, OECOLOGIA, V141, P254, DOI 10.1007/s00442-004-1682-4; IPCC, 2007, IPCC CLIMATE CHANGE; Jacinthe PA, 2002, SOIL TILL RES, V66, P23, DOI 10.1016/S0167-1987(02)00010-7; Jacinthe PA, 2001, LAND DEGRAD DEV, V12, P329, DOI 10.1002/ldr.454; Kaiser K, 2003, EUR J SOIL SCI, V54, P219, DOI 10.1046/j.1365-2389.2003.00544.x; Kuhn NJ, 2007, EARTH SURF PROC LAND, V32, P794, DOI 10.1002/esp.1486; KWAAD FJPM, 1994, CATENA, V23, P253, DOI 10.1016/0341-8162(94)90071-X; Kwaad FJPM, 2006, SOIL EROSION EUROPE; Lal R, 2004, SCIENCE, V304, P1623, DOI 10.1126/science.1097396; Lal R, 2003, ENVIRON INT, V29, P437, DOI 10.1016/S0160-4120(02)00192-7; Nadeu E, 2012, BIOGEOSCIENCES, V9, P1099, DOI 10.5194/bg-9-1099-2012; Palis RG, 1997, AUST J SOIL RES, V35, P891, DOI 10.1071/S92060; Polyakov VO, 2008, GEODERMA, V143, P216, DOI 10.1016/j.geoderma.2007.11.005; Schiettecatte W, 2008, SOIL SCI SOC AM J, V72, P50, DOI 10.2136/sssaj2007.0201; Six J, 1998, SOIL SCI SOC AM J, V62, P1367, DOI 10.2136/sssaj1998.03615995006200050032x; Smith SV, 2005, ECOL APPL, V15, P1929, DOI 10.1890/05-0073; Smith SV, 2001, GLOBAL BIOGEOCHEM CY, V15, P697, DOI 10.1029/2000GB001341; Stallard RF, 1998, GLOBAL BIOGEOCHEM CY, V12, P231, DOI 10.1029/98GB00741; Strickland TC, 2005, J SOIL WATER CONSERV, V60, P142; Truman CC, 2007, J ENVIRON QUAL, V36, P1495, DOI 10.2134/jeq2006.0018; Van Hemelryck H, 2010, BIOGEOSCIENCES, V7, P3971, DOI 10.5194/bg-7-3971-2010; Van Hemelryck H, 2011, EARTH SURF PROC LAND, V36, P427, DOI 10.1002/esp.2055; Van Oost K, 2007, SCIENCE, V318, P626, DOI 10.1126/science.1145724; Wan Y, 1998, J ENVIRON QUAL, V27, P132, DOI 10.2134/jeq1998.00472425002700010019x; Wang X, 2013, EUR J SOIL SCI, V64, P219, DOI 10.1111/ejss.12018; Wang ZG, 2010, GEOMORPHOLOGY, V124, P65, DOI 10.1016/j.geomorph.2010.08.010; WRB, 2015, WORLD REF BAS SOIL R, DOI 10.1017/S0014479706394902; Zhang JH, 2006, GLOBAL CHANGE BIOL, V12, P1834, DOI 10.1111/j.1365-2486.2006.01206.x	53	241	245	14	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2014	9	5							e96299	10.1371/journal.pone.0096299	http://dx.doi.org/10.1371/journal.pone.0096299			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AJ9KS	24802350	gold, Green Published, Green Submitted			2023-01-03	WOS:000338029800051
J	Miller, CT; Fraser, SF; Levinger, I; Straznicky, NE; Dixon, JB; Reynolds, J; Selig, SE				Miller, Clint T.; Fraser, Steve F.; Levinger, Itamar; Straznicky, Nora E.; Dixon, John B.; Reynolds, John; Selig, Steve E.			The Effects of Exercise Training in Addition to Energy Restriction on Functional Capacities and Body Composition in Obese Adults during Weight Loss: A Systematic Review	PLOS ONE			English	Review							FAT-FREE MASS; PHYSICAL-ACTIVITY; MUSCLE STRENGTH; POSTMENOPAUSAL WOMEN; CALORIC RESTRICTION; SKELETAL-MUSCLE; OLDER PERSONS; ABDOMINAL FAT; RISK-FACTORS; HIGH-PROTEIN	Background: Obesity is associated with impairments of physical function, cardiovascular fitness, muscle strength and the capacity to perform activities of daily living. This review examines the specific effects of exercise training in relation to body composition and physical function demonstrated by changes in cardiovascular fitness, and muscle strength when obese adults undergo energy restriction. Methods: Electronic databases were searched for randomised controlled trials comparing energy restriction plus exercise training to energy restriction alone. Studies published to May 2013 were included if they used multi-component methods for analysing body composition and assessed measures of fitness in obese adults. Results: Fourteen RCTs met the inclusion criteria. Heterogeneity of study characteristics prevented meta-analysis. Energy restriction plus exercise training was more effective than energy restriction alone for improving cardiovascular fitness, muscle strength, and increasing fat mass loss and preserving lean body mass, depending on the type of exercise training. Conclusion: Adding exercise training to energy restriction for obese middle-aged and older individuals results in favourable changes to fitness and body composition. Whilst weight loss should be encouraged for obese individuals, exercise training should be included in lifestyle interventions as it offers additional benefits.	[Miller, Clint T.; Fraser, Steve F.; Selig, Steve E.] Deakin Univ, Sch Exercise & Nutr Sci, Ctr Exercise & Sports Sci, Melbourne, Vic, Australia; [Levinger, Itamar] Victoria Univ, Sch Sport & Exercise Sci, Inst Sport Exercise & Act Living, Melbourne, Vic 8001, Australia; [Straznicky, Nora E.] Baker IDI Heart & Diabet Inst, Human Neurotransmitters Lab, Melbourne, Vic, Australia; [Dixon, John B.] Baker IDI Heart & Diabet Inst, Clin Obes Res Lab, Melbourne, Vic, Australia; [Reynolds, John] Deakin Univ, Fac Hlth, Biostat Unit, Melbourne, Vic, Australia	Deakin University; Victoria University; Baker Heart and Diabetes Institute; Baker Heart and Diabetes Institute; Deakin University	Selig, SE (corresponding author), Deakin Univ, Sch Exercise & Nutr Sci, Ctr Exercise & Sports Sci, Melbourne, Vic, Australia.	steve.selig@deakin.edu.au	Wrighton, Kelly C/ABD-6621-2021; Dixon, John B/A-5318-2011; Reynolds, John/D-2591-2013	Wrighton, Kelly C/0000-0003-0434-4217; Dixon, John B/0000-0001-5391-4082; Reynolds, John/0000-0002-8825-8625; Fraser, Steve F/0000-0003-0202-9619; Banfield, Jill/0000-0001-8203-8771; Miller, Christopher/0000-0002-9448-8144; Miller, Clint/0000-0001-7743-6986; Handley, Kim/0000-0003-0531-3009; Levinger, Itamar/0000-0001-9194-2033	Heart Foundation [G11M5892]; Diabetes Australia Millennium Grant	Heart Foundation; Diabetes Australia Millennium Grant	Dr. Itamar Levinger is a Heart Foundation Research Fellow (PR 11M 6086 and Prof John Dixon is an NHMRC Senior Research Fellow. Dr. Nora Straznicky is funded by a Heart Foundation Grant-in-Aid (G11M5892) and a Diabetes Australia Millennium Grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allison DB, 1999, INT J OBESITY, V23, P603, DOI 10.1038/sj.ijo.0800875; Alvarez VP, 2007, OBES SURG, V17, P211, DOI 10.1007/s11695-007-9032-3; Amati F, 2008, J APPL PHYSIOL, V105, P825, DOI 10.1152/japplphysiol.90384.2008; Anandacoomarasamy A, 2009, CURR OPIN RHEUMATOL, V21, P71, DOI 10.1097/BOR.0b013e32831bc0d7; Beavers KM, 2011, AM J CLIN NUTR, V94, P767, DOI 10.3945/ajcn.110.004895; Beckman LM, 2010, J AM DIET ASSOC, V110, P571, DOI 10.1016/j.jada.2009.12.023; Blazer DG, 2006, J AM GERIATR SOC, V54, P502, DOI 10.1111/j.1532-5415.2005.00607.x; Bouchard DR, 2011, METAB SYNDR RELAT D, V9, P225, DOI 10.1089/met.2010.0101; Bouchard DR, 2009, MENOPAUSE, V16, P66, DOI 10.1097/gme.0b013e31817dacf7; BRAY GA, 1988, WESTERN J MED, V149, P429; Byrne NM, 2003, AM J CLIN NUTR, V77, P1368, DOI 10.1093/ajcn/77.6.1368; Campbell KL, 2012, J CLIN ONCOL, V30, P2314, DOI 10.1200/JCO.2011.37.9792; Capodaglio P, 2010, INT J OCCUP SAF ERGO, V16, P507, DOI 10.1080/10803548.2010.11076863; Chaston TB, 2007, INT J OBESITY, V31, P743, DOI 10.1038/sj.ijo.0803483; Chmelo E, 2012, J PHYS ACT HEALTH; Clemes SA, 2010, OCCUP MED-OXFORD, V60, P101, DOI 10.1093/occmed/kqp127; Coulson JC, 2008, INT J WORKPLACE HEAL, V1, P176, DOI 10.1108/17538350810926534; Craig BN, 2006, AM J IND MED, V49, P249, DOI 10.1002/ajim.20290; Daly RM, 2005, OSTEOPOROSIS INT, V16, P1703, DOI 10.1007/s00198-005-1906-4; Das SK, 2005, CURR OPIN CLIN NUTR, V8, P602, DOI 10.1097/01.mco.0000171122.60665.5f; DEMPSTER P, 1995, MED SCI SPORT EXER, V27, P1692; Dishman RK, 2006, OBESITY, V14, P345, DOI 10.1038/oby.2006.46; Dixon JB, 2010, MOL CELL ENDOCRINOL, V316, P104, DOI 10.1016/j.mce.2009.07.008; Donnelly JE, 2009, MED SCI SPORT EXER, V41, P459, DOI 10.1249/MSS.0b013e3181949333; Duvigneaud N, 2008, J SPORT MED PHYS FIT, V48, P201; Fields DA, 2005, CURR OPIN CLIN NUTR, V8, P624, DOI 10.1097/01.mco.0000171127.44525.07; Formiguera X, 2004, BEST PRACT RES CL GA, V18, P1125, DOI [10.1016/S1521-6918(04)00091-5, 10.1016/j.bpg.2004.06.030]; Foster-Schubert KE, 2012, OBESITY, V20, P1628, DOI 10.1038/oby.2011.76; Frimel TN, 2008, MED SCI SPORT EXER, V40, P1213, DOI 10.1249/MSS.0b013e31816a85ce; Fruhbeck G, 2004, NEW ENGL J MED, V350, P308, DOI 10.1056/NEJM200401153500323; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; GARROW JS, 1995, EUR J CLIN NUTR, V49, P1; GENAIDY AM, 1992, ERGONOMICS, V35, P1081, DOI 10.1080/00140139208967384; Glasziou P.P., 2001, SYSTEMATIC REV HLTH, DOI DOI 10.1017/CBO9780511543500; GOING SB, 1993, AM J CLIN NUTR, V57, P845, DOI 10.1093/ajcn/57.6.845; Guyenet SJ, 2012, J CLIN ENDOCR METAB, V97, P745, DOI 10.1210/jc.2011-2525; Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1; He XXZ, 2004, AM J PUBLIC HEALTH, V94, P1567, DOI 10.2105/AJPH.94.9.1567; Hills A P, 2002, Obes Rev, V3, P35, DOI 10.1046/j.1467-789X.2002.00054.x; Himes CL, 2000, DEMOGRAPHY, V37, P73, DOI 10.2307/2648097; Hulens M, 2003, SCAND J MED SCI SPOR, V13, P98, DOI 10.1034/j.1600-0838.2003.10273.x; Hulens M, 2001, INT J OBESITY, V25, P676, DOI 10.1038/sj.ijo.0801560; Ismail I, 2012, OBES REV, V13, P68, DOI 10.1111/j.1467-789X.2011.00931.x; Janssen I, 1999, INT J OBESITY, V23, P1035, DOI 10.1038/sj.ijo.0801038; Janssen I, 2002, DIABETES CARE, V25, P431, DOI 10.2337/diacare.25.3.431; Janssen I, 2011, J OBES, V2011, DOI 10.1155/2011/531403; Jebb SA, 1999, MED SCI SPORT EXER, V31, pS534, DOI 10.1097/00005768-199911001-00008; Kaila B, 2008, CAN J GASTROENTEROL, V22, P61, DOI 10.1155/2008/609039; Kraemer WJ, 2001, MED SCI SPORT EXER, V33, P1011, DOI 10.1097/00005768-200106000-00022; Larrieu S, 2004, INT J OBESITY, V28, P1555, DOI 10.1038/sj.ijo.0802755; Leone N, 2011, OBESITY; Maffiuletti NA, 2007, EUR J APPL PHYSIOL, V101, P51, DOI 10.1007/s00421-007-0471-2; Manini TM, 2010, OBESITY, V18, P1168, DOI 10.1038/oby.2009.317; Marks BL, 1996, SPORTS MED, V22, P273, DOI 10.2165/00007256-199622050-00001; Messier V, 2010, J SPORT SCI, V28, P83, DOI 10.1080/02640410903390105; Miller GD, 2006, OBESITY, V14, P1219, DOI 10.1038/oby.2006.139; Miller SL, 2008, J NUTR HEALTH AGING, V12, P487, DOI 10.1007/BF02982710; Monteiro Maria Silvia, 2011, Rev. esc. enferm. USP, V45, P1177; Nicklas BJ, 2009, AM J CLIN NUTR, V89, P1043, DOI 10.3945/ajcn.2008.26938; Payne RW, 2011, GUIDE GENSTAT RELEAS; Peppard PE, 2000, JAMA-J AM MED ASSOC, V284, P3015, DOI 10.1001/jama.284.23.3015; Rantanen T, 1999, JAMA-J AM MED ASSOC, V281, P558, DOI 10.1001/jama.281.6.558; Rantanen T, 1999, ARCH PHYS MED REHAB, V80, P130, DOI 10.1016/S0003-9993(99)90109-0; Ratamess NA, 2009, MED SCI SPORT EXER, V41, P687, DOI 10.1249/MSS.0b013e3181915670; Rice B, 1999, DIABETES CARE, V22, P684, DOI 10.2337/diacare.22.5.684; Ruiz JR, 2010, J PEDIATR-US, V157, P917, DOI 10.1016/j.jpeds.2010.06.026; Stenholm S, 2009, INT J OBESITY, V33, P635, DOI 10.1038/ijo.2009.62; Stenholm S, 2013, J GERONTOL A, P1079; Straznicky NE, 2010, DIABETES, V59, P71, DOI 10.2337/db09-0934; Toledo FGS, 2008, DIABETES, V57, P987, DOI 10.2337/db07-1429; Vargas CB, 2013, OBES SURG, V23, P1590, DOI 10.1007/s11695-013-0924-0; Vaynman S, 2006, J NEUROSCI RES, V84, P699, DOI 10.1002/jnr.20979; Vieira ER, 2008, INT J IND ERGONOM, V38, P143, DOI 10.1016/j.ergon.2006.02.001; Villareal DT, 2011, NEW ENGL J MED, V364, P1218, DOI 10.1056/NEJMoa1008234; Vingard E, 2009, WORK, V34, P339, DOI 10.3233/WOR-2009-0932; WEBSTER JD, 1984, HUM NUTR-CLIN NUTR, V38C, P299; Weinheimer EM, 2010, NUTR REV, V68, P375, DOI 10.1111/j.1753-4887.2010.00298.x; Weiss EP, 2007, J APPL PHYSIOL, V102, P634, DOI 10.1152/japplphysiol.00853.2006; Wilson JM, 2012, J STRENGTH COND RES, V26, P2293, DOI 10.1519/JSC.0b013e31823a3e2d; Woodrow G, 2007, PERITON DIALYSIS INT, V27, pS245; Wycherley TP, 2012, AM J CLIN NUTR, V96, P1281, DOI 10.3945/ajcn.112.044321; Wycherley TP, 2010, DIABETES CARE, V33, P969, DOI 10.2337/dc09-1974	82	194	199	5	113	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 25	2013	8	11							e81692	10.1371/journal.pone.0081692	http://dx.doi.org/10.1371/journal.pone.0081692			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	259RH	23405248	gold, Green Published, Green Accepted			2023-01-03	WOS:000327543500119
J	Miller, CS; Handley, KM; Wrighton, KC; Frischkorn, KR; Thomas, BC; Banfield, JF				Miller, Christopher S.; Handley, Kim M.; Wrighton, Kelly C.; Frischkorn, Kyle R.; Thomas, Brian C.; Banfield, Jillian F.			Short-Read Assembly of Full-Length 16S Amplicons Reveals Bacterial Diversity in Subsurface Sediments	PLOS ONE			English	Article							RIBOSOMAL-RNA GENE; MICROBIAL DIVERSITY; RARE BIOSPHERE; ENVIRONMENTAL SURVEYS; SPECIES RICHNESS; BODY HABITATS; DEEP-SEA; SEQUENCE; COMMUNITIES; URANIUM	In microbial ecology, a fundamental question relates to how community diversity and composition change in response to perturbation. Most studies have had limited ability to deeply sample community structure (e.g. Sanger-sequenced 16S rRNA libraries), or have had limited taxonomic resolution (e. g. studies based on 16S rRNA hypervariable region sequencing). Here, we combine the higher taxonomic resolution of near-full-length 16S rRNA gene amplicons with the economics and sensitivity of short-read sequencing to assay the abundance and identity of organisms that represent as little as 0.01% of sediment bacterial communities. We used a new version of EMIRGE optimized for large data size to reconstruct near-full-length 16S rRNA genes from amplicons sheared and sequenced with Illumina technology. The approach allowed us to differentiate the community composition among samples acquired before perturbation, after acetate amendment shifted the predominant metabolism to iron reduction, and once sulfate reduction began. Results were highly reproducible across technical replicates, and identified specific taxa that responded to the perturbation. All samples contain very high alpha diversity and abundant organisms from phyla without cultivated representatives. Surprisingly, at the time points measured, there was no strong loss of evenness, despite the selective pressure of acetate amendment and change in the terminal electron accepting process. However, community membership was altered significantly. The method allows for sensitive, accurate profiling of the "long tail'' of low abundance organisms that exist in many microbial communities, and can resolve population dynamics in response to environmental change.	[Miller, Christopher S.; Handley, Kim M.; Wrighton, Kelly C.; Frischkorn, Kyle R.; Thomas, Brian C.; Banfield, Jillian F.] Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Miller, CS (corresponding author), Univ Colorado, Dept Integrat Biol, Denver, CO 80202 USA.	christopher.s.miller@ucdenver.edu	Wrighton, Kelly C/ABD-6621-2021; Dixon, John B/A-5318-2011; Reynolds, John/D-2591-2013	Wrighton, Kelly C/0000-0003-0434-4217; Dixon, John B/0000-0001-5391-4082; Reynolds, John/0000-0002-8825-8625; Fraser, Steve F/0000-0003-0202-9619; Banfield, Jill/0000-0001-8203-8771; Miller, Christopher/0000-0002-9448-8144; Miller, Clint/0000-0001-7743-6986; Handley, Kim/0000-0003-0531-3009; Levinger, Itamar/0000-0001-9194-2033	IFRC, Subsurface Biogeochemical Research Program; Office of Science, Biological and Environmental Research, US Department of Energy (DOE) [DE-AC02-05CH11231]	IFRC, Subsurface Biogeochemical Research Program; Office of Science, Biological and Environmental Research, US Department of Energy (DOE)	Funding was provided by the IFRC, Subsurface Biogeochemical Research Program and the Knowledgebase Program (DE-AC02-05CH11231), Office of Science, Biological and Environmental Research, US Department of Energy ( DOE). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aklujkar M, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-490; Anderson RT, 2003, APPL ENVIRON MICROB, V69, P5884, DOI 10.1128/AEM.69.10.5884-5891.2003; Angenent LT, 2005, P NATL ACAD SCI USA, V102, P4860, DOI 10.1073/pnas.0501235102; Bartram AK, 2011, APPL ENVIRON MICROB, V77, P3846, DOI 10.1128/AEM.02772-10; Beman JM, 2012, LIMNOL OCEANOGR, V57, P711, DOI 10.4319/lo.2012.57.3.0711; Caporaso JG, 2012, ISME J, V6, P1621, DOI 10.1038/ismej.2012.8; Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Caporaso JG, 2010, BIOINFORMATICS, V26, P266, DOI 10.1093/bioinformatics/btp636; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; Degnan PH, 2012, ISME J, V6, P183, DOI 10.1038/ismej.2011.74; Denef VJ, 2010, P NATL ACAD SCI USA, V107, P2383, DOI 10.1073/pnas.0907041107; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Dethlefsen L, 2008, PLOS BIOL, V6, P2383, DOI 10.1371/journal.pbio.0060280; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Engelbrektson A, 2010, ISME J, V4, P642, DOI 10.1038/ismej.2009.153; Gloor GB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015406; Goltsman DSA, 2009, APPL ENVIRON MICROB, V75, P4599, DOI 10.1128/AEM.02943-08; Handley KM, 2012, FEMS MICROBIOL ECOL, V81, P188, DOI 10.1111/j.1574-6941.2012.01363.x; Harismendy O, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r32; Harismendy O, 2009, BIOTECHNIQUES, V46, P229, DOI 10.2144/000113082; Hazen TC, 2010, SCIENCE, V330, P204, DOI 10.1126/science.1195979; Holmes DE, 2007, ISME J, V1, P663, DOI 10.1038/ismej.2007.85; Huse SM, 2010, ENVIRON MICROBIOL, V12, P1889, DOI 10.1111/j.1462-2920.2010.02193.x; Huse SM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000255; Jeraldo P, 2011, ENVIRON MICROBIOL, V13, P3000, DOI 10.1111/j.1462-2920.2011.02577.x; Kauserud H, 2012, MYCORRHIZA, V22, P309, DOI 10.1007/s00572-011-0403-1; Kembel SW, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002743; Knights D, 2011, NAT METHODS, V8, P761, DOI 10.1038/nmeth.1650; Kunin V, 2010, ENVIRON MICROBIOL, V12, P118, DOI 10.1111/j.1462-2920.2009.02051.x; Lane DJ., 1991, NUCL ACID TECHNIQUES, P115; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r134; Lazarevic V, 2009, J MICROBIOL METH, V79, P266, DOI 10.1016/j.mimet.2009.09.012; Li L, 2010, J CONTAM HYDROL, V112, P45, DOI 10.1016/j.jconhyd.2009.10.006; Liu ZZ, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm541; Liu ZZ, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn491; Lo I, 2007, NATURE, V446, P537, DOI 10.1038/nature05624; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Marchetti A, 2012, P NATL ACAD SCI USA, V109, pE317, DOI 10.1073/pnas.1118408109; Miller CS, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-5-r44; Morowitz MJ, 2011, P NATL ACAD SCI USA, V108, P1128, DOI 10.1073/pnas.1010992108; Mueller RS, 2011, ENVIRON MICROBIOL, V13, P2279, DOI 10.1111/j.1462-2920.2011.02486.x; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490; Pruesse E, 2007, NUCLEIC ACIDS RES, V35, P7188, DOI 10.1093/nar/gkm864; Quince C, 2009, NAT METHODS, V6, P639, DOI [10.1038/NMETH.1361, 10.1038/nmeth.1361]; Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107; Sharpton TJ, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001061; Shrestha PM, 2007, ENVIRON MICROBIOL, V9, P2464, DOI 10.1111/j.1462-2920.2007.01364.x; Sogin ML, 2006, P NATL ACAD SCI USA, V103, P12115, DOI 10.1073/pnas.0605127103; Spring S, 2009, STAND GENOMIC SCI, V1, P242, DOI 10.4056/sigs.39508; Stewart FJ, 2012, ENVIRON MICROBIOL, V14, P23, DOI 10.1111/j.1462-2920.2010.02400.x; Tringe SG, 2008, CURR OPIN MICROBIOL, V11, P442, DOI 10.1016/j.mib.2008.09.011; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Vrionis HA, 2005, APPL ENVIRON MICROB, V71, P6308, DOI 10.1128/AEM.71.10.6308-6318.2005; Walters WA, 2011, BIOINFORMATICS, V27, P1159, DOI 10.1093/bioinformatics/btr087; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Werner JJ, 2012, ISME J, V6, P1273, DOI 10.1038/ismej.2011.186; Werner JJ, 2012, ISME J, V6, P94, DOI 10.1038/ismej.2011.82; Whitman WB, 1998, P NATL ACAD SCI USA, V95, P6578, DOI 10.1073/pnas.95.12.6578; Wilkins MJ, 2009, APPL ENVIRON MICROB, V75, P6591, DOI 10.1128/AEM.01064-09; Williams KH, 2011, GEOMICROBIOL J, V28, P519, DOI 10.1080/01490451.2010.520074; Wrighton KC, 2012, SCIENCE, V337, P1661, DOI 10.1126/science.1224041; Youssef N, 2009, APPL ENVIRON MICROB, V75, P5227, DOI 10.1128/AEM.00592-09; Zhou HW, 2011, ISME J, V5, P741, DOI 10.1038/ismej.2010.160; Zhou JZ, 2011, ISME J, V5, P1303, DOI 10.1038/ismej.2011.11	67	194	199	5	113	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2013	8	2							e56018	10.1371/journal.pone.0056018	http://dx.doi.org/10.1371/journal.pone.0056018			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092WJ	23405248	gold, Green Published, Green Submitted			2023-01-03	WOS:000315153400193
